<SEC-DOCUMENT>0001193125-25-035754.txt : 20250226
<SEC-HEADER>0001193125-25-035754.hdr.sgml : 20250226
<ACCEPTANCE-DATETIME>20250226062151
ACCESSION NUMBER:		0001193125-25-035754
CONFORMED SUBMISSION TYPE:	S-1/A
PUBLIC DOCUMENT COUNT:		24
FILED AS OF DATE:		20250226
DATE AS OF CHANGE:		20250226

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KESTRA MEDICAL TECHNOLOGIES, LTD.
		CENTRAL INDEX KEY:			0001877184
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			D0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-284807
		FILM NUMBER:		25665995

	BUSINESS ADDRESS:	
		STREET 1:		3933 LAKE WASHINGTON BLVD NE
		STREET 2:		SUITE 200
		CITY:			KIRKLAND
		STATE:			WA
		ZIP:			98033
		BUSINESS PHONE:		(425) 279-8002

	MAIL ADDRESS:	
		STREET 1:		3933 LAKE WASHINGTON BLVD NE
		STREET 2:		SUITE 200
		CITY:			KIRKLAND
		STATE:			WA
		ZIP:			98033
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1/A
<SEQUENCE>1
<FILENAME>d744414ds1a.htm
<DESCRIPTION>S-1/A
<TEXT>
<HTML><HEAD>
<TITLE>S-1/A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>As filed with the U.S. Securities and Exchange Commission on February&nbsp;26, 2025
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right"><B>Registration No. 333-284807 </B></P>  <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES
AND EXCHANGE COMMISSION </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:20%">&nbsp;</P></center>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>Amendment
No.&nbsp;1 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>to </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT STYLE="white-space:nowrap">S-1</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>UNDER </I></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>THE
SECURITIES ACT OF 1933 </I></B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:20%">&nbsp;</P></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:22pt; font-family:Times New Roman" ALIGN="center"><B>Kestra Medical Technologies, Ltd. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:20%">&nbsp;</P></center> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top" ALIGN="center"><B>Bermuda</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>3841</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Not Applicable</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Primary Standard Industrial</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Classification Code Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification Number)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>3933 Lake Washington Blvd NE, Suite 200 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Kirkland, Washington 98033 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>(425) <FONT STYLE="white-space:nowrap">279-8002</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address, including zip code, and telephone number, including </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>area code, of registrant&#146;s principal executive offices) </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:20%">&nbsp;</P></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Brian Webster </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Chief
Executive Officer </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>3933 Lake Washington Blvd NE, Suite 200 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Kirkland, Washington 98033 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>(425) <FONT STYLE="white-space:nowrap">279-8002</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Name, address, including zip code, and telephone number, including </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>area code, of agent for service) </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:20%">&nbsp;</P></center> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B><I>Copies to:
</I></B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Sophia Hudson, P.C.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Christie W.S. Mok</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Kirkland&nbsp;&amp; Ellis LLP</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>601 Lexington Avenue</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>New York, New York 10022</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Telephone: (212) <FONT STYLE="white-space:nowrap">446-4800</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Traci S. Umberger</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>General Counsel and</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Chief Administrative Officer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>3933 Lake Washington Blvd NE, Suite 200</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Kirkland, Washington 98033</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Telephone: (425) <FONT STYLE="white-space:nowrap">279-8002</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Ilir Mujalovic</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Allen Overy Shearman Sterling US LLP</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>599 Lexington Avenue</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>New York, New York 10022</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Telephone: (212) <FONT STYLE="white-space:nowrap">848-4000</FONT></B></P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:20%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:8pt; font-family:Times New Roman">Approximate date of commencement of proposed sale to the public:<B> As soon as practicable after this Registration Statement is declared
effective.</B> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:20%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:8pt; font-family:Times New Roman">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the
Securities Act of 1933, check the following box.&#8194;&#9744; </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:8%; font-size:8pt; font-family:Times New Roman">If this Form is filed to register additional securities for an offering
pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#8194;&#9744; </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:8%; font-size:8pt; font-family:Times New Roman">If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering.&#8194;&#9744; </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:8%; font-size:8pt; font-family:Times New Roman">If this
Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration number of the earlier effective registration statement for the same offering.&#8194;&#9744;
</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:8%; font-size:8pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
<FONT STYLE="white-space:nowrap">non-accelerated</FONT> filer, a smaller reporting company or an emerging growth company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer,&#148; &#147;smaller reporting
company&#148; and &#147;emerging growth company&#148; in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Exchange Act. </P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">Large&nbsp;accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">Non-accelerated</FONT> filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">Emerging&nbsp;growth&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:8%; font-size:8pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended
transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;7(a)(2)(B) of the Securities Act.&#8194;&#9744; </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:20%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:8pt; font-family:Times New Roman"><B>The registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the
registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act of 1933, as amended, or until this Registration
Statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section&nbsp;8(a), may determine. </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <DIV STYLE="position:relative; overflow:visible; width:628pt; height:30pt; transform-origin:bottom left; transform: rotate(-90deg) translate(-100%, 100%) translateX(30pt);">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#c21128">The information in this preliminary prospectus is not complete and may be changed. We may not sell these securities until the
registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and it is not soliciting offers to buy these securities in any jurisdiction where the offer
or sale is not permitted. </FONT></P></DIV><DIV STYLE="position:relative; overflow:visible; margin-left:48pt; margin-right:48pt; transform: translateY(-30pt);"> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#c21128">Subject to Completion, </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#c21128">Preliminary Prospectus dated February&nbsp;26, 2025 </FONT></P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>PROSPECTUS<B></B> </U></P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>10,000,000
Shares </B></P>  <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g744414g62z73.jpg" ALT="LOGO" STYLE="width:4.55963in;height:1.2554in;">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Shares </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:20%">&nbsp;</P></center>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:9pt; font-family:Times New Roman">This is the
initial public offering of Kestra Medical Technologies, Ltd. We are selling 10,000,000 common shares. We expect the public offering price to be between $14.00 and $16.00 per common share. Currently, no public market exists for the common shares. We
have applied to list our common shares on The Nasdaq Global Select Market under the symbol &#147;KMTS.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:9pt; font-family:Times New Roman">Upon the closing of this
offering, an investment fund advised by affiliates of Bain Capital, L.P. will own approximately 52.8% of our common shares (or 51.2% of our outstanding common shares if the underwriters exercise in full their over-allotment option). As a result, we
will be a &#147;controlled company&#148; within the meaning of the applicable listing rules of the Nasdaq Global Select Market. See &#147;Management&#151;Controlled Company Exception&#148; and &#147;Principal Shareholders.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:9pt; font-family:Times New Roman">We are an &#147;emerging growth company&#148; and a &#147;smaller reporting company&#148; as defined under the federal securities laws and,
under applicable Securities and Exchange Commission (&#147;SEC&#148;) rules, we have elected to comply with certain reduced public company reporting and disclosure requirements.<B> </B>See &#147;Prospectus Summary&#151;Implications of Being an
Emerging Growth Company and a Smaller Reporting Company.&#148; </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:11pt; font-family:Times New Roman"><B>Investing in our common shares involves risks that are described in
the &#147;<A HREF="#rom744414_2">Risk&nbsp;Factors</A>&#148; section beginning on page&nbsp;23 of this prospectus. </B></P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:20%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="19%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Per&nbsp;Share</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Underwriting discount (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Proceeds, before expenses, to us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">We refer you to the section titled &#147;Underwriting&#148; for additional information regarding underwriter
compensation. </P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:9pt; font-family:Times New Roman">We have granted the underwriters an over-allotment option for a period of 30 days from the date of
this prospectus to purchase up to 1,500,000 additional common shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:9pt; font-family:Times New Roman">At our request, the underwriters have reserved up to 5% of the
common shares offered hereby, for sale at the initial public offering price through a reserved shares program to our officers, directors, team members and certain of their friends or family. See &#147;Underwriting&#151;Reserved Shares.&#148; </P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:9pt; font-family:Times New Roman"><B>Neither the SEC nor any other regulatory body has approved or disapproved of these securities or passed upon the adequacy or accuracy
of this prospectus. Any representation to the contrary is a criminal offense. </B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:9pt; font-family:Times New Roman">The Bermuda Monetary Authority has given general
permission under the Exchange Control Act 1972 (and its related regulations) for the issue and transfer of our common shares that are the subject of this offering to and between residents and <FONT STYLE="white-space:nowrap">non-residents</FONT> of
Bermuda, for exchange control purposes, provided our shares remain listed on an appointed stock exchange, which includes the Nasdaq Global Select Market. In granting such general permission, the Bermuda Monetary Authority does not accept any
responsibility for our financial soundness or the correctness of any of the statements made or opinions expressed in this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:9pt; font-family:Times New Roman">The
common shares will be ready for delivery on or about &#8195;&#8195;&#8195;&#8195;&#8195;, 2025. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:20%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:14pt" ALIGN="center">


<TR>

<TD WIDTH="26%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:14pt">
<TD VALIGN="top" NOWRAP><B>BofA&nbsp;Securities</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><B>Goldman&nbsp;Sachs&nbsp;&amp;&nbsp;Co.&nbsp;LLC</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="right"><B>Piper&nbsp;Sandler</B></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:14pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:14pt">
<TD VALIGN="top" NOWRAP><B>Wells&nbsp;Fargo&nbsp;Securities</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="right"><B>Stifel</B></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" ALIGN="center">


<TR>

<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:14pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><B>Wolfe&nbsp;|&nbsp;Nomura&nbsp;Alliance</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:20%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">The date of this prospectus is &#8195;&#8195;&#8195;&#8195; , 2025 </P></DIV> <p STYLE="clear:both; font-size:1pt; height:0">&nbsp;</p>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="96%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom744414_1">PROSPECTUS SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom744414_2">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom744414_3">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom744414_4">ORGANIZATIONAL TRANSACTIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom744414_5">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom744414_6">DIVIDEND POLICY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom744414_7">CAPITALIZATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom744414_8">DILUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom744414_9">MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
 OF OPERATIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom744414_10">BUSINESS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom744414_11">MANAGEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">165</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom744414_12">EXECUTIVE COMPENSATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom744414_13">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom744414_14">PRINCIPAL SHAREHOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">182</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom744414_15">DESCRIPTION OF CERTAIN INDEBTEDNESS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom744414_16">DESCRIPTION OF SHARE CAPITAL</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom744414_17">SHARES ELIGIBLE FOR FUTURE SALE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom744414_18">BERMUDA COMPANY CONSIDERATIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom744414_19">MATERIAL BERMUDA, IRISH AND U.S. FEDERAL INCOME TAX
CONSIDERATIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">209</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom744414_20">UNDERWRITING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">219</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom744414_21">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">228</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom744414_22">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">228</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom744414_23">WHERE YOU CAN FIND ADDITIONAL INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">228</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom744414_24">EXCHANGE CONTROLS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">228</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom744414_25">ENFORCEMENT OF CIVIL LIABILITIES UNDER U.S. FEDERAL SECURITIES
LAWS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">229</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom744414_26">INDEX TO FINANCIAL STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are responsible for the information contained in this prospectus and in any free writing prospectus we
prepare or authorize. We have not, and the underwriters have not, authorized anyone to provide you with different information, and we and the underwriters take no responsibility for any other information others may give you. We are not, and the
underwriters are not, making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. You should not assume that the information contained in this prospectus is accurate as of any date other than the date on
the cover of this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Persons who come into possession of this prospectus and any applicable free writing prospectus in
jurisdictions outside the United States are required to inform themselves about and to observe any restrictions as to this offering and the distribution of this prospectus and any such free writing prospectus applicable to that jurisdiction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BASIS OF PRESENTATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Kestra Medical Technologies, Ltd., the issuer in this offering, was incorporated on May&nbsp;20, 2021 in connection with this offering to
serve as a holding company for its subsidiaries, and it has not engaged in any business or other activities other than those incidental to its formation, the organizational transactions described herein and the preparation of this prospectus and the
registration statement of which this prospectus forms a part. Following this offering and the consummation of the organizational transactions, Kestra Medical Technologies, Ltd. will remain a holding company, and it will operate and control all of
the business and affairs and consolidate the financial results of West Affum Intermediate Holdings Corp., a Cayman Islands exempted company (&#147;West Affum Intermediate Holdings&#148;), and its subsidiaries, which will operate our business. Unless
stated otherwise or the context otherwise requires, all information in this prospectus reflects the consummation of the organizational transactions described herein, which we refer to collectively as the &#147;Organizational Transactions.&#148; See
&#147;Organizational Transactions&#148; for a description of the Organizational Transactions and diagrams depicting both our existing structure prior to giving pro forma effect to the Organizational Transactions and our anticipated structure after
giving pro forma effect to the Organizational Transactions and this offering. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">West Affum Intermediate Holdings was incorporated on
August&nbsp;6, 2020 as a holding company for our principal operating subsidiary, West Affum Holdings Corp. (&#147;West Affum Holdings&#148;). The condensed consolidated financial statements as of and for the six months ended October&nbsp;31, 2024
and 2023, and the consolidated financial statements as of and for the fiscal years ended April&nbsp;30, 2024 and 2023 included elsewhere in this prospectus represent the consolidated assets and liabilities and operations of West Affum Intermediate
Holdings and its consolidated subsidiaries. Following the consummation of the Organizational Transactions and this offering, Kestra Medical Technologies, Ltd. will be our top holding company and its consolidated financial statements will be included
in our reports filed with the SEC, and West Affum Intermediate Holdings will be the predecessor for financial reporting purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Certain monetary amounts, percentages, and other figures included elsewhere in this prospectus have been subject to rounding adjustments.
Accordingly, figures shown as totals in certain tables or charts may not be the arithmetic aggregation of the figures that precede them, and figures expressed as percentages in the text may not total 100% or, as applicable, when aggregated may not
be the arithmetic aggregation of the percentages that precede them. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Unless stated otherwise or the context otherwise requires the terms
&#147;we,&#148; &#147;us,&#148; &#147;our,&#148; &#147;our business,&#148; &#147;our company,&#148; the &#147;Company&#148; and similar references refer: (1)&nbsp;prior to the consummation of the Organizational Transactions, to West Affum
Intermediate Holdings and its consolidated subsidiaries and (2)&nbsp;at or following the consummation of the Organizational Transactions, to Kestra Medical Technologies, Ltd. and its consolidated subsidiaries. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INDUSTRY AND MARKET DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Certain industry data and market data included in this prospectus were obtained from independent third-party surveys, market research,
publicly available information, reports of governmental agencies and industry publications and surveys. Management&#146;s estimates presented herein are based upon management&#146;s analysis of internally compiled data, independent third-party
surveys and industry publications prepared by a number of sources and other publicly available information. We obtained the industry and market data set forth in this prospectus from our own internal estimates and research, as well as from academic
and industry publications, research, surveys and studies conducted by third parties. Internal estimates are derived from publicly available information released by industry analysts and third-party sources, our internal research and our industry
experience, and are based on assumptions made by us based on our knowledge of the industry and market, which we believe to be reasonable. We believe that the information from academic and industry publications, research, surveys and studies
conducted by third parties included in this prospectus is reliable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Additionally, our estimated total addressable market is based on
epidemiology data regarding cardiac patient populations with low ejection fractions, payor data on WCD reimbursement rates, the average initial prescription duration for our ASSURE WCD and our estimates of the industry average initial prescription
duration for WCDs generally. Our total addressable market in the United States is based on epidemiology data from third-party sources including the American Heart Association and the Heart Failure Society of America and the Medicare reimbursement
rate for WCDs as of January 2024 as published in the Centers for Medicare and Medicaid Services DMEPOS Fee Schedule. Our estimated total addressable market outside the United States is based on estimated average reimbursement rates and initial
prescription durations for WCDs derived from internally collected data from industry sources and market participants and our internal estimates based on such data, as well as epidemiology data from third-party sources including PubMed, UptoDate,
Statistica and the European Society of Cardiology in the following select international markets: Japan, Germany, United Kingdom, France, Italy, Spain, Canada, Poland, Australia, Romania, Netherlands, Belgium, Czech Republic, Sweden, Hungary,
Austria, Switzerland and Denmark. These international markets were selected because they have already adopted WCD therapy or have a history of ICD utilization. See &#147;Risk Factors&#151;Risks Related to Our Business&#151;The estimates of our
market and forecasts of market growth included in this prospectus are based on a number of complex assumptions and estimates that may prove to be inaccurate, and even if the markets in which we compete achieve the forecasted growth, our business may
not increase at similar rates, if at all.&#148; The industry in which we operate and the data related thereto are subject to a high degree of uncertainty and risk due to a variety of factors, including those described in the sections titled
&#147;Risk Factors&#148; and &#147;Special Note Regarding Forward-Looking Statements.&#148; These and other factors could cause results to differ materially from those expressed in the estimates, publications and reports made by the independent
parties and by us. Forecasts and other forward-looking information with respect to the industry, business, market, and other data included in this prospectus are subject to the same qualifications and additional uncertainties regarding the other
forward-looking statements in this prospectus. See &#147;Special Note Regarding Forward-Looking Statements.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Certain information in
the text of this prospectus is contained in independent industry publications. The source of these independent industry publications is provided below. These independent industry publications do not form part of this prospectus and are not
incorporated by reference herein. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The New England Journal of Medicine, Wearable Cardioverter-Defibrillator after Myocardial Infarction, September
2018 (the &#147;New England Journal of Medicine Study&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">American Heart Association, Abstract 4141304: Clinical Impact of Ventricular and Supraventricular Arrhythmia
Detection with a Novel Wearable Cardioverter Defibrillator, November 2024; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">American Heart Association, Abstract 4141488: Initial Real-World Experience with a Novel Wearable Cardioverter
Defibrillator, November 2024; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">iii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">American Heart Association, Heart Disease and Stroke Statistics &#150; 2023 Update: A Report From the American
Heart Association, February 2023; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">American Heart Association, Left Ventricular Ejection Fraction Assessment Among Patients with Acute Myocardial
Infarction and Its Association with Hospital Quality of Care and Evidence-Based Therapy Use, September 2012; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">American Heart Association, Trends in Hospitalizations and Survival of Acute Decompensated Heart Failure in Four
US Communities (2005-2014), July 2018; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">American Heart Association, 2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the
American Heart Association, February 2024; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">European Heart Journal, 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure,
May 2016; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Heart Failure Society of America, HF Stats 2024: Heart Failure Epidemiology and Outcomes Statistics, September
2024; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">JAMA, Heart Failure with Reduced Ejection Fraction&#151;A Review, August 2020; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Journal of Cardiovascular Electrophysiology, Impact of Wearable Cardioverter-Defibrillator Compliance on Outcomes
in the VEST Trial: <FONT STYLE="white-space:nowrap">As-Treated</FONT> and <FONT STYLE="white-space:nowrap">Per-Protocol</FONT> Analyses, February 2020; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Journal of Cardiovascular Electrophysiology, A Wearable Cardioverter Defibrillator with a Low False Alarm Rate,
January 2022; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">American Journal of Cardiology, The Sudden Death Following Hospitalization for Heart Failure with Reduced
Ejection Fraction (From the Everest Trial), July 2018 (the &#147;American Journal of Cardiology Study&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Journal of Interventional Cardiac Electrophysiology, A Novel Artificial Intelligence Based Algorithm to Reduce
Wearable Cardioverter-Defibrillator Alarms, February 2023 (the &#147;Journal of Interventional Cardiac Electrophysiology Study&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Journal of Cardiac Failure, HF STATS 2024: Heart Failure Epidemiology and Outcomes Statistics An Updated 2024
Report from the Heart Failure Society of America, September 2024; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Nature Reviews Cardiology, Epidemiology of Heart Failure with Preserved Ejection Fraction, May 2017; and
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">PLOS ONE, Defibrillation effectiveness and safety of the shock waveform used in a contemporary wearable
cardioverter defibrillator: Results from animal and human studies, March 14, 2023. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">iv </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SERVICE MARKS, TRADEMARKS AND TRADE NAMES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This prospectus includes references to trademarks and service marks for which we have obtained or applied for registration, such as ASSURE,
ASSURE ASSIST, CARDIAC RECOVERY SYSTEM, KESTRA and KESTRA CARESTATION. This prospectus also contains trade names, trademarks and service marks of other companies, which are the property of their respective owners. This prospectus contains additional
trade names, trademarks and service marks of other companies that are the property of their respective owners. We do not intend our use or display of other companies&#146; trade names, trademarks or service marks to imply a relationship with, or
endorsement or sponsorship of us by, these other companies. Solely for convenience, trademarks and trade names referred to in this prospectus may appear without the <SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> or <SUP
STYLE="font-size:75%; vertical-align:top">&#153;</SUP> symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensor to
these trademarks and trade names. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">v </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom744414_1"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>This summary highlights information contained elsewhere in this prospectus and does not contain all of the information that you should
consider in making your investment decision. Before investing in our common shares, you should carefully read this entire prospectus, including our consolidated financial statements, our condensed consolidated financial statements and the related
notes thereto included elsewhere in this prospectus and the information set forth in the sections titled &#147;Risk Factors&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations.&#148; This
summary contains forward-looking statements that involve risks and uncertainties. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular
disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates
monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator
(&#147;WCD&#148;) used to protect patients at an elevated risk of sudden cardiac arrest (&#147;SCA&#148;), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S. The ASSURE WCD automatically
monitors elevated risk patients and, if needed, delivers a defibrillation shock to return the patient&#146;s heart to normal rhythm. The ASSURE WCD was purpose-built to enhance patient comfort and compliance and directly address the key barriers to
adoption associated with the only other commercially available WCD. We believe the ASSURE WCD offers significant clinical and functional advantages, including greater patient compliance as a result of a major reduction in false alarms and enhanced
comfort and wearability. In addition to the ASSURE WCD, our Cardiac Recovery System platform includes a comprehensive suite of fully integrated digital solutions and services that enable enhanced patient and provider engagement and oversight, with
the objective of improving patient outcomes. We believe our Cardiac Recovery System platform addresses serious unmet needs in the cardiac patient population and has the potential to disrupt and grow the market which has been limited to a single
solution for more than 20 years. As of January&nbsp;31, 2025, our system is actively being prescribed by more than 550 hospitals across the U.S., representing approximately 20% of WCD prescribing hospitals in the U.S., and has been worn by over
17,000 patients since it was fully commercially launched. In our top 50 hospitals, we believe we have successfully captured approximately 45% of the currently available prescriptions based on company-sourced data on all hospitals that we serve in
the U.S. and the percentage of WCD filled prescriptions at those hospitals that are for our ASSURE WCD. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">SCA is a life-threatening
emergency characterized by the abrupt cessation of the heartbeat caused by an electrical malfunction in the heart. This is typically triggered by ventricular arrhythmias, such as ventricular fibrillation (&#147;VF&#148;), and leads to a loss of
consciousness and potentially death within minutes if not promptly treated. The American Heart Association (&#147;AHA&#148;) estimates that SCA causes approximately 436,000 deaths per year, making it the third leading cause of death in the U.S.
Defibrillation, or an electrical shock, is the only way to restore a fibrillating heart to a normal rhythm. Each minute of delay in restoring the heart to a normal rhythm reduces a patient&#146;s chance of survival by 7% to 10%. The average time for
Emergency Medical Services (&#147;EMS&#148;) arrival is 7 minutes from the time of a 911 call, and often longer in rural communities. The most common location of a SCA in adults is at a home or residence, representing approximately 73% of SCAs. In
addition, approximately 50% of all SCAs are unwitnessed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A WCD is a wearable, <FONT STYLE="white-space:nowrap">non-invasive</FONT>
miniaturized automated external defibrillator and is worn underneath regular clothing. The device continuously monitors a patient&#146;s heart rhythm and is capable of delivering a defibrillation shock. Wires connect electrodes inside the garment to
the monitor, which is carried in </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
a small pack or shoulder bag. The electrodes continuously acquire a patient&#146;s heart rate and rhythm for evaluation by the automated external defibrillator. If the monitor detects a
potentially life-threatening arrhythmia, the WCD first alerts the patient via an audible alarm and then administers a shock, if needed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For over 20 years, WCDs have been used to protect patients at elevated risk of SCA. However, until the ASSURE WCD received Food and Drug
Administration (&#147;FDA&#148;) approval in July of 2021, the market was limited to a single solution. Since the approval of the first WCD in 2001, global WCD revenues have grown to $1.3&nbsp;billion in 2023, with approximately 85% of the revenues
generated in the U.S based on our analysis of third-party claims data and estimated average WCD wear prescription lengths and average reimbursement rates in the U.S. and in select international markets derived from industry data and internal
estimates. The volume of patients prescribed a WCD in the U.S. grew at roughly 6% annually between 2021 and 2023, and we expect WCD revenues to continue growing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Despite being proven as safe and effective in treating dangerous cardiac rhythms when worn, WCD therapy remains underutilized, reaching just
14% of the eligible U.S. patient population in 2023 based on data on patients indicated for a WCD and WCD prescription data from industry sources. We believe that the low penetration of WCD therapy is largely due to the limitations of&nbsp;the
incumbent commercially available device. In feedback we have collected through directly engaging with patients and providers and customer feedback on public platforms, commonly cited reasons for patients or providers failing to use the competitor
device include high false alarm frequency, poor wearability and patient discomfort, a unisex-only garment, low utility data and limited connectivity with patients. In the U.S., we estimate that there are approximately 800,000 cardiac patients each
year who have experienced a myocardial infarction (&#147;MI&#148;) or are diagnosed with heart failure and have low Left Ventricular Ejection Fraction (&#147;LVEF&#148;), therefore making them eligible for WCD therapy. Additionally, approximately
50,000 patients each year either have documented ventricular tachycardia (&#147;VT&#148;) or VF, an inherited genetic condition, or have had their implantable cardioverter defibrillators (&#147;ICD&#148;) temporarily explanted, and are also
indicated for WCDs. Based on an average WCD wear prescription length of 3.4 months per patient and an average Medicare reimbursement rate of $3,436 per patient per month, we believe this represents an approximately $10&nbsp;billion annual
addressable market. In select international markets, we estimate based on patient population data collected by various third-party industry sources that there are approximately 3.7 million people each year who experience an MI, are diagnosed with
heart failure, have documented VT or VF, have an inherited genetic condition, or have had their ICD temporarily explanted. Among these patients, based on the same third-party industry sources, we estimate that approximately 1.8 million patients meet
the indications for WCD therapy. Based on estimated average WCD wear prescription length in these international markets of 2.5 months per patient and estimated average reimbursement rate of $3,000 per patient per month derived from industry data and
internal estimates, we believe this represents an approximately $14&nbsp;billion total annual market opportunity outside the U.S. For a description of the international markets covered by this estimated market opportunity, see &#147;Industry and
Market Data.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The ASSURE WCD is the next generation of WCD therapy, delivering a safe and effective solution for patients with a
design that enhances patient comfort and compliance. In addition to the ASSURE WCD, the various digital solutions and services of our Cardiac Recovery System platform include the ASSURE patient application, Kestra CareStation remote patient data
platform, Heart Alert Services, and ASSURE Assist services. The ASSURE patient application engages patients with real-time mobile updates to promote compliance, while the Kestra CareStation remote patient data platform equips healthcare providers
with actionable insights to support timely and informed care decisions. Heart Alert Services and ASSURE Assist services work together to enhance safety and are designed to provide critical alerts to healthcare providers for significant arrhythmias
and notify emergency services when therapy is administered. This post-therapy EMS support is critical as a range of injuries, such as head injuries, soft tissue damage and bone fractures, can result from falling down after a SCA. In addition, the
ASSURE wearable ECG as part of our Cardiac Recovery System platform provides monitoring and connectivity for patients no longer indicated for a WCD but who still require ongoing support while their </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
heart continues to remodel. We believe we offer the most comprehensive and cohesive platform, with digital solutions and services that are seamlessly integrated with our ASSURE WCD, meaningfully
differentiating our Cardiac Recovery System platform from the only other commercially available WCD. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are building a body of clinical
evidence supporting the safety, efficacy, and benefits of the ASSURE WCD, with six publications completed to date. This growing portfolio includes our pivotal trials&#151;the ASSURE WCD Clinical Evaluation&#151;Detection and Safety Study <FONT
STYLE="white-space:nowrap">(&#147;ACE-DETECT&#148;)</FONT> and the ASSURE WCD Clinical Evaluation&#151;Conversion Efficacy Study <FONT STYLE="white-space:nowrap">(&#147;ACE-CONVERT&#148;)&#151;which</FONT> served as the basis for our premarket
approval (&#147;PMA&#148;). In addition, we are conducting the ASSURE WCD Clinical Evaluation&#151;Post Approval Study <FONT STYLE="white-space:nowrap">(&#147;ACE-PAS&#148;)</FONT> as part of a broader ongoing ASSURE Patient Registry. All patients
prescribed the ASSURE WCD in the United States after August 5, 2022 are included in the Registry. As of January&nbsp;31, 2025, our ongoing registry has enrolled over 17,000 patients, and its findings further validate the results of <FONT
STYLE="white-space:nowrap">ACE-DETECT</FONT> and <FONT STYLE="white-space:nowrap">ACE-CONVERT.</FONT> Our most recent FDA submission from <FONT STYLE="white-space:nowrap">ACE-PAS</FONT> from July 2024, which includes data from 5,929 patients,
reported first shock conversion efficacy of approximately 96%, a low false alarm rate with only 6% of our patients experiencing a false alarm, compared to 46% for the competitor&#146;s device, and a median daily use of 23.2&nbsp;hours. These results
underscore the ASSURE WCD&#146;s competitive advantages in wearability, usability, and patient compliance, providing strong support for continued adoption. We believe this collection of real-world evidence will generate additional publications,
continue to increase awareness of WCDs as a proven therapy for elevated risk cardiac patients and further demonstrate the clinical differentiation of our ASSURE WCD. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have made material investments in infrastructure to support rapid growth and scalability, specifically in our commercial organization,
distribution and supply chain capabilities, as well as revenue cycle management capabilities. In the U.S., we have built a commercial sales team of approximately 70 direct sales representatives and more than 40 sales and clinical support
professionals with deep expertise in cardiac rhythm management and established relationships in the cardiology and electrophysiology fields. This team is responsible for developing sales territory business plans, targeting and opening new accounts,
and processing prescriptions of our ASSURE WCD. Our direct sales team is supported by a contracted team of over 250 ASSURE Patient Specialists (&#147;APSs&#148;) who assist patients with fitting and training. At fitting, we deliver our ASSURE WCD
from our distribution network to the patient. We utilize a lease business model, and when a patient&#146;s wear time has concluded, the device is returned for reprocessing and reintroduction into the distribution network. To support our growth, we
have developed a highly scalable supply chain in collaboration with experienced, <FONT STYLE="white-space:nowrap">top-tier</FONT> medical technology suppliers. Our substantial investment in a fleet of devices, each with a capacity for approximately
three patient wears per year, are reprocessed through efficient reconditioning, which enables the business to scale with an attractive unit economic profile. Finally, our revenue cycle management capabilities streamline reimbursement processes by
ensuring claims are accurately prepared and submitted according to individual payor requirements, facilitating timely collections. These capabilities are a critical asset in driving operational efficiency and supporting both patient and prescriber
satisfaction. We believe our significant investments in infrastructure create a high barrier to entry that will help us protect and grow our market share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have experienced rapid growth since our full commercial launch, expanding our headcount from 66&nbsp;team members in October 2020 to over
300 team members as of January&nbsp;31, 2025. We generated revenue of $27.5 million for the six months ended October 31, 2024, compared to revenue of $9.5 million for the six&nbsp;months ended October 31, 2023, representing 190% quarter-over-quarter
growth. For the fiscal year ended April 30, 2024, we generated revenue of $27.8 million, compared to revenue of $7.6 million for the fiscal year ended April 30, 2023, representing 265% year-over-year growth. In the six months ended October 31, 2024,
we recognized a net loss of $40.9 million, compared to a net loss of $50.2 million for the six months ended October&nbsp;31, 2023. For the fiscal year ended April 30, 2024, we recognized a net loss of $94.1 million, compared to a net loss of $84.2
million </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
for the fiscal year ended April 30, 2023. As of October 31, 2024, April 30, 2024 and April&nbsp;30, 2023, we had an accumulated deficit of $446.7 million, $406.4 million and $312.3 million,
respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Market Overview and Opportunity </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Overview of Sudden Cardiac Arrest </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">SCA is a major public health problem and accounts for approximately 50% of all cardiovascular deaths in the U.S. and commonly occurs in
individuals with heart disease or those experiencing cardiac events. Several research studies indicate that low LVEF may be a sign of heart disease and is one of the greatest risk factors for SCA. Normal LVEF is typically between 50% and 70%. This
means that during each heartbeat, 50% to 70% of the blood in the left ventricle is pumped out to the body. Low LVEF is typically considered 40% or less. According to the New England Journal of Medicine Study, patients with an LVEF of 30% or less
were two times more likely to suffer from SCA compared to patients with an LVEF of more than 40%. The American Journal of Cardiology Study showed that the absolute risk of SCA is highest during the early period following a cardiac event, especially
within the first 30 days. In this same study, each 5% decrease in LVEF was associated with a 21% increase in the risk of SCA during the first 30 days after an MI. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>WCD Therapy for Patients at Risk of SCA </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">There are three main types of defibrillators: implantable cardioverter defibrillators (&#147;ICD&#148;), external defibrillators (both manual
and automated), and WCDs.&nbsp;An ICD is a small battery-powered device surgically placed in the chest that continuously checks the heartbeat and delivers electric shocks, when needed, to restore a regular heart rhythm. An external defibrillator is
a portable device that uses two adhesive pads placed on the patient&#146;s skin by a trained professional or a bystander to deliver an electric shock through the chest to the heart to restore a normal rhythm. An automated external defibrillator
automatically detects a patient&#146;s heart rhythm and delivers a shock while a manual external defibrillator requires the user to select a specific shock energy to be delivered to the patient. A WCD is an external wearable device that continuously
monitors a patient&#146;s heart rhythm. If it detects a potentially life-threatening arrhythmia, the WCD alerts the patient and, if necessary, automatically delivers a defibrillation shock to restore a normal heart rhythm. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">WCDs are typically prescribed to patients immediately following an MI or heart failure diagnosis and serve as a bridge to recovery between the
cardiac event and a longer-term treatment regimen. During this period, healthcare providers will optimize the patient&#146;s medical therapy while also waiting to see if the patient&#146;s LVEF improves. The expected wear duration of the WCD varies
based on the patient indication, with the majority of our patients being prescribed the WCD for three months or longer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Limitations of the Legacy,
Commercially Available WCD </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The WCD is indicated for use in patients who are at risk for SCA and are not candidates for, or
refuse, an ICD. However, limitations of the only other commercially available WCD, such as patient comfort and false alarm rate, as well as gaps in awareness by healthcare providers of its broader diagnostic utility have led to underutilization of
the therapy. Many indicated patients do not receive a prescription and some choose not to wear a WCD. Patients who choose not to wear a WCD are often left reliant on first responders or EMS in the event of a SCA. This reliance poses a significant
risk, as only 16% of sudden cardiac events occur in public places where an automated external defibrillator might be available according to the American Heart Association. Based on data from the American Medical Association, the average time for EMS
arrival is 7 minutes from the time of a 911 call, and often longer in rural communities. During this critical time, survival rates decline by 7% to 10% for every minute that passes. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our Market Opportunity </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Since the approval of the first WCD in 2001, global WCD revenues have grown significantly, reaching over $1.3&nbsp;billion in 2023, with
approximately 85% of the revenues coming from the U.S. based on our analysis of third-party claims data and estimated average WCD wear prescription lengths and average reimbursement rates in the U.S. and in select international markets derived from
industry data and internal estimates. Between 2021 and 2023, the volume of patients prescribed a WCD in the U.S. grew roughly 6% annually. We expect further penetration and growth of the WCD market, driven by increased awareness and education about
WCD therapy, the expanded launch of our innovative and comprehensive solution, and the rapidly growing heart failure population, which will likely expand the number of patients at elevated risk of SCA and indicated for a WCD. Despite being available
for over 20 years and proven effective in treating dangerous cardiac rhythms when worn by patients, the therapy has reached just 14% of eligible U.S. patients in 2023 based on data on patients indicated for a WCD and WCD prescription data from
industry sources, highlighting a significant opportunity for growth. We attribute this low penetration to poor patient compliance, driven by the limitations of our competitor&#146;s device. The ASSURE WCD, as part of our broader Cardiac Recovery
System platform, is designed to prioritize patient comfort and compliance, addressing common barriers to acceptance experienced by the only other commercially available WCD. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The WCD is indicated for use in patients who are at risk for SCA and are not candidates for, or refuse, an ICD. Medical guidelines recommend
WCD use in those patients with a low LVEF and a recent MI, recent revascularization procedure or newly diagnosed nonischemic cardiomyopathy with heart failure symptoms. In addition, patients with documented VT/VF or an inherited genetic condition
that places them at high risk for SCA, or patients who have had their ICD temporarily explanted are also indicated for WCDs. According to the AHA, approximately 1.8 million people in the U.S. each year experience a serious cardiac event, such as an
MI, or are diagnosed with heart failure. Among these patients, around 800,000 patients have low LVEF, placing them at an elevated risk of SCA. Additionally, approximately 50,000 patients each year either have documented VT or VF, an inherited
genetic condition, or have had their ICD temporarily explanted. Based on the foregoing annual incidences, the current Medicare reimbursement rates of $3,436 per patient per month as published in the Centers for Medicare and Medicaid Services
(&#147;CMS&#148;) DMEPOS Fee Schedule, and our average initial WCD prescription length of 3.4 months, we believe the total, annual addressable market in the U.S. for the ASSURE WCD is approximately $10 billion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">While our current commercial focus is on the U.S., approximately 15% of the global WCD revenues in 2023 were generated internationally,
representing approximately $200&nbsp;million, and that has primarily been concentrated in western Europe where the market has been most developed, as well as in Japan. In select international markets, we estimate based on patient population data
collected by various third-party industry sources that there are approximately 3.7 million people each year who experience an MI, are diagnosed with heart failure, have documented VT or VF, have an inherited genetic condition, or have had their ICD
temporarily explanted. Among these patients, based on the same third-party industry sources, we estimate that approximately 1.8 million patients meet the indications for WCD therapy. Based on estimated average WCD wear prescription length in these
international markets of 2.5&nbsp;months per patient and estimated average reimbursement rate of $3,000 per patient per month derived from industry data and internal estimates, we believe this represents an approximately $14 billion total annual
market opportunity outside the U.S. For a description of the international markets covered by this estimated market opportunity, see &#147;Industry and Market Data.&#148; As of the date of this prospectus, we have not received any regulatory
approvals to commercialize our products outside of the U.S. and have not submitted any applications to obtain such regulatory approvals. However, we are currently planning to pursue CE Mark approval in Europe and, in the future, intend to
strategically commercialize in selected international countries. We anticipate Western Europe to be our initial focus due to favorable market dynamics and our goal is to obtain regulatory approvals to begin distributing our ASSURE WCD in certain
markets in Western Europe within the next three years. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Solution </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The ASSURE WCD is the cornerstone of our Cardiac Recovery System platform, a robust and extensible system integrating therapy, monitoring, and
digital health solutions that represents the future of cardiac care. As a next generation of WCD therapy, the ASSURE WCD delivers a safe and effective solution for patients and was intentionally designed to enhance patient comfort and compliance and
successfully resolve the key barriers to adoption associated with the only other commercially available WCD. The ASSURE WCD received FDA approval on July&nbsp;27, 2021 for adult patients at elevated risk of SCA who are not candidates for, or
decline, an ICD. As of January&nbsp;31, 2025, the ASSURE WCD is actively being prescribed by more than 550 hospitals and has been worn by over 17,000 patients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition to the ASSURE WCD, our Cardiac Recovery System platform includes fully integrated digital solutions and services such as the
ASSURE patient application, Kestra CareStation remote patient data platform, Heart Alert Services, and ASSURE Assist services, as well as the recently launched ASSURE wearable ECG. Cleared by the FDA on May&nbsp;7, 2024, the ASSURE wearable ECG
provides extended monitoring and valuable insights into a patient&#146;s heart function after they are no longer indicated for a WCD. This <FONT STYLE="white-space:nowrap">non-therapeutic</FONT> platform supports cardiac recovery monitoring using
many of the same familiar features as the ASSURE WCD, ensuring continuity and ease of use for both patients and clinicians. </P> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>  <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g744414g89x91.jpg" ALT="LOGO" STYLE="width:6.25in;height:1.36186in;">
 </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Key Benefits of Our Solution </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our Cardiac Recovery System platform offers notable benefits and an improved user-experience that differentiates it from the only other
commercially available WCD. These benefits include: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Modern and advanced design to improve comfort, performance and maximize wearability.</I></B> The design of
our garments incorporates advancements in electronics, mobile technology, signal processing techniques, and fabrics. The garments were developed with an athletic and sportswear designer and are tailored for body inclusivity, offering two styles and
a wide range of sizes. We believe that having separate, gender-specific designs is particularly important given women make up approximately 40% of SCA patients.<B><I> </I></B>Overall wearability is further supported by the results of our
post-approval study which demonstrates a median wear time of greater than 23 hours per day. In addition to improving comfort and wearability, our unique garment design incorporates cushioned electrodes that are embedded in the fabric to improve
electrode contact and, ultimately, improve electrocardiogram (&#147;ECG&#148;) signal quality. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>High fidelity ECG leading to fewer false alarms.</I></B> The ASSURE WCD is designed to minimize false
alarms. The overall level of noise is reduced through use of resistive ECG electrodes that are cushioned and securely bonded to the fabric, custom shielded cables, and isolation circuitry. The ASSURE WCD also utilizes four channels of high-quality
ECG, combined with Adaptive Patient Intelligence (&#147;API&#148;), a proprietary technology that adapts to the patient heart rhythm to filter out artifacts and improve performance even in a noisy environment. According to the Journal of
</P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
Interventional Cardiac Electrophysiology Study, as a result of these features, only 6% of our patients experience a false alarm, compared to 46% for the competitor&#146;s device. Reduction in
false alarms may lead to lower patient anxiety, improved patient satisfaction and increased patient compliance. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Product innovations and integrated digital solutions and services supporting the patient throughout the
cardiac care continuum. </I></B>Our Cardiac Recovery System platform represents a comprehensive suite of proprietary wearable and fully integrated digital solutions and services for monitoring, diagnosing, and protecting patients through their
cardiac recovery journey. We believe our Cardiac Recovery System platform represents a competitive advantage, with the goal of ultimately improving the prescriber and patient experience, maximizing patient comfort and compliance, and increasing
adoption of our system. In addition, our Cardiac Recovery System platform&#146;s capabilities allow healthcare providers to identify other clinically significant arrhythmias. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Improved energy delivery to enhance efficacy and safety.</I></B> The ASSURE WCD delivers a 170 joule shock
to better serve patients with higher defibrillation thresholds, compared to the competitor device which delivers a 150 joule shock.&nbsp;In addition, our system has a minimum defibrillation capacity of 25 shocks, providing a significant safety
buffer for patients experiencing multiple cardiac events within a short time period, such as a VT storm, where a patient experiences multiple episodes of sustained VT within a short period of time. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Success Factors </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We believe the
continued growth of our company will be driven by the following success factors: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Large, growing, and underpenetrated WCD market with a single competitor;</P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Highly innovative Cardiac Recovery System platform designed to protect patients from SCA and improve patient
compliance and healthcare provider adoption; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Comprehensive and fully integrated suite of mission critical digital solutions and services for driving patient
and healthcare provider engagement; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Material investments in infrastructure to support rapid growth and scale; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Established reimbursement and favorable payor coverage; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Strong and compelling body of clinical evidence; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Broad research and development capabilities and a robust intellectual property portfolio; and
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Highly experienced management team and board with proven commercial growth success. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Growth Strategies </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">To fully achieve
our mission of providing innovative, intuitive medical technologies to protect and support at-risk patients, we intend to pursue the following growth strategies: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Continue to capture share of the current WCD prescriptions in the U.S.; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Expand adoption of our Cardiac Recovery System platform in the U.S. to increase the penetration of the U.S. total
addressable WCD market; </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Build upon our strong base of clinical evidence; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Continue our payor engagement to broaden coverage and increase reimbursement; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Innovate our system and bolster our digital healthcare platform and data management capabilities;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Drive gross margin expansion and operating leverage; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Pursue expansion in international markets; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Strategically pursue adjacent markets with new products offerings and differentiated services.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Recent Developments </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Preliminary estimated selected financial results as of and for the three months ended January&nbsp;31, 2025 </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Included below are certain preliminary estimated selected unaudited financial results of West Affum Intermediate Holdings as of and for the
three months ended January&nbsp;31, 2025 and actual unaudited financial results for the three months ended January&nbsp;31, 2024. The results as of and for the three months ended January&nbsp;31, 2025 are preliminary and subject to change, and there
is a possibility that our actual results may differ from these preliminary estimates. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The preliminary financial data included in this
prospectus has been prepared by, and is the responsibility of, our management. PricewaterhouseCoopers LLP has not audited, reviewed, examined, compiled, nor applied agreed-upon procedures with respect to the preliminary financial data. Accordingly,
PricewaterhouseCoopers LLP does not express an opinion or any other form of assurance with respect thereto. These preliminary estimated results should not be viewed as a substitute for financial statements prepared in accordance with U.S. generally
accepted accounting principles. Moreover, this data has been prepared solely on the basis of currently available information by, and are the responsibility of, management. It is possible that we or our independent registered public accounting firm
may identify items that would require us to make adjustments to the preliminary estimates set forth below as we complete our financial statements and that our actual results may differ from these preliminary estimates. Accordingly, we have provided
ranges, rather than specific amounts, for the preliminary estimated results described below. Except as required by law, we undertake no obligation to update or supplement the preliminary estimated results below until we release our results of
operations as of and for the three months ended January 31, 2025, which will not occur until after this offering is completed. These preliminary estimates are not necessarily indicative of any future period and should be read together with
&#147;Risk Factors,&#148; &#147;Special Note Regarding Forward-Looking Statements,&#148; &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations,&#148; our consolidated financial statements, and our condensed
consolidated financial statements and related notes thereto included elsewhere in this prospectus. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Three Months Ended
January&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Estimated 2025</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Actual&nbsp;2024</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2025&nbsp;(Low)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2025&nbsp;(High)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands, except percentages)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Selected Statement of Operations and Comprehensive Loss Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,277</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross margin</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">880</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross margin (as a percentage of revenue)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(20,800</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(20,400</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(19,946</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Revenue </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For the three months ended January&nbsp;31, 2025, we expect preliminary unaudited revenue to be between $14.5&nbsp;million and
$15.5&nbsp;million, compared to revenue of $8.3&nbsp;million for the three months ended January&nbsp;31, 2024, an increase of 75% to 87%. The estimated increase in revenue was primarily driven by an increase in the number of patients using our
product and continued increase in reimbursement realization, while reimbursement rates remained largely flat. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Gross margin </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For the three months ended January&nbsp;31, 2025, we expect preliminary unaudited gross margin to be between $6.2&nbsp;million and
$6.8&nbsp;million, compared to gross margin of $0.9&nbsp;million for the three months ended January 31, 2024, an increase of 602% to 667%. The estimated increase in gross margin was primarily due to growth in revenue driven by the increase in number
of patients and reimbursement realization and continued decrease in cost per patient due to further improvements in the utilization of our rental pool of medical equipment and lower disposable costs driven by volume and manufacturing cost
improvement programs. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Gross margin as a percentage of revenue </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For the three months ended January&nbsp;31, 2025, we expect gross margin as a percentage of revenue to be between 42.6% and 43.5%, compared to
gross margin as a percentage of revenue of 10.6% for the three months ended January&nbsp;31, 2024. The estimated improvement in gross margin as a percentage of revenue was primarily due to growth in revenue driven by the increase in number of
patients and reimbursement realization and continued decrease in cost per patient driven by further improvements in the utilization of our rental pool of medical equipment and lower disposable costs driven by volume and manufacturing cost
improvement programs. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Loss from operations </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For the three months ended January&nbsp;31, 2025, we expect loss from operations to be between $20.4&nbsp;million and $20.8&nbsp;million,
compared to loss from operations of $19.9&nbsp;million for the three months ended January&nbsp;31, 2024, an increase between 2% and 4%. The estimated change in loss from operations was relatively flat. While revenue grew between 75% and 87%, this
increase was offset by increases in costs related to additional employee headcount to expand the commercial organization and support functions and expenses related to legal and professional services in connection with this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cash and cash equivalents, and long-term debt, net </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of January&nbsp;31, 2025, we expect cash and cash equivalents to be approximately $54.4&nbsp;million and
<FONT STYLE="white-space:nowrap">long-term</FONT> debt, net to be approximately $43.7&nbsp;million. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Risk Factors Summary </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">An investment in our common shares involves substantial risks and uncertainties that may adversely affect our business, financial condition,
results of operations and prospects. Before deciding to invest in our common shares, you should carefully consider all of the risks, uncertainties and challenges described in the section of this prospectus captioned &#147;Risk Factors&#148; and all
of the other information in this prospectus. These risks, uncertainties and challenges include, but are not limited to, the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we have a limited operating history, which may make it difficult for you to evaluate our current business and its
likelihood of success and viability. If we are unable to manage our business and any fluctuations in our business effectively, our business and growth prospects could be materially and adversely affected; </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we have a history of net losses, and there is no assurance as to when we will achieve profitability, if at all,
even as we continue to grow and scale our business. As part of such continued growth, we may need to raise equity or debt financing in the future; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our recurring losses from operations and financial condition raise substantial doubt about our ability to
continue as a going concern; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we generate revenue primarily from the lease of our ASSURE WCD as part of our Cardiac Recovery System platform,
and we are therefore highly dependent on our ASSURE WCD for our continued success; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our business is dependent upon healthcare providers, hospitals and patients adopting our solutions, and if we
fail to obtain and maintain broad adoption, our business would be adversely affected; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the estimates of our market and forecasts of market growth included in this prospectus are based on a number of
complex assumptions and estimates that may prove to be inaccurate, and even if the markets in which we compete achieve the forecasted growth, our business may not increase at similar rates, if at all; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our commercial success depends in part on the extent to which governmental authorities and health insurers
provide coverage and adequate reimbursement levels. Failure to obtain and maintain coverage and adequate reimbursement for our products could limit our ability to market those products and make it difficult for us to operate profitably;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if we are unable to manage the anticipated growth of our business, our future revenue and operating results may
be harmed; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our clinical study initiatives may be complex, lengthy, expensive and carry uncertain outcomes. Future trials and
studies by us or others may fail to replicate positive results observed to date; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we depend on a limited number of third-party suppliers and contract manufacturers to manufacture and recondition
our ASSURE WCD and its components, which could make us vulnerable to supply shortages and price fluctuations that could harm our business; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">billing for our products is complex, and we must dedicate substantial time and resources to the billing process;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if our competitors are able to develop or market products and services that are more effective, or gain greater
acceptance in the marketplace, than any products and services we develop, our commercial opportunities will be reduced or eliminated; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we have identified material weaknesses in our internal control over financial reporting, and may identify
additional material weaknesses. If our remediation of material weaknesses in our internal control over financial reporting is not effective, or we fail to develop and maintain effective internal control over financial reporting, our ability to
produce timely and accurate financial statements could be impaired, which could harm our business and negatively impact the value of our common shares; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">third parties may assert that we are employing their intellectual property and other proprietary technology
without authorization, and we may become a party to litigation or administrative proceedings related to intellectual property that could be costly, time-consuming, or unsuccessful and could hinder our ability to commercialize our existing or future
products; </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our efforts to obtain intellectual property protection and the intellectual property rights we obtain may be
inadequate, and our business may be adversely affected as a result; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be subject to claims challenging the inventorship of our patents and other intellectual property;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in the regulatory environment may make it more difficult and costly for us to manufacture, market or
distribute our products, or to obtain approval for any future products; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if we fail to comply with healthcare and other governmental regulations, we could face substantial penalties and
our business, results of operations and financial condition could be adversely affected; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Bain Capital controls us, and its interests may conflict with ours or yours. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">See &#147;Risk Factors&#148; for a discussion of these and other factors you should consider before making an investment in our common shares.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Organizational Transactions Summary </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We intend to consummate the following organizational transactions prior to or concurrently with (unless otherwise stated) this offering: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">West Affum Holdings, L.P. will contribute all its equity interests, including preferred shares, in West Affum
Intermediate Holdings to Kestra Medical Technologies, Ltd., the issuer in this offering in exchange for common shares of Kestra Medical Technologies, Ltd., thereby making Kestra Medical Technologies, Ltd. the top parent company of West Affum
Intermediate Holdings and all of its subsidiaries; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Kestra Medical Technologies, Ltd. will deliver 37,651,467 newly-issued common shares with a par value of $1.00
per share to the holders of West Affum Holdings, L.P. Class&nbsp;A common units and incentive units (including a third-party investor who will receive Class&nbsp;A common units in West Affum Holdings, L.P. immediately prior to the distribution in
exchange for its equity interests in West Affum Holdings Designated Activity Company), including 10,997 common shares of Kestra Medical Technologies, Ltd. that will be subject to vesting conditions, in consideration for the exchange of such
holders&#146; interests in West Affum Holdings, L.P; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Kestra Medical Technologies, Ltd. will issue new warrants in consideration of the cancellation of certain
warrants issued by West Affum Holdings, L.P. (see &#147;Organizational Transactions&#151;Warrant Transactions&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">West Affum Holdings, L.P. will continue to hold common shares of Kestra Medical Technologies, Ltd. for the
benefit of the holders of common units in West Affum Holdings, L.P., including an affiliate of Bain Capital, until such time that such common shares are distributed by West Affum Holdings, L.P. to the remaining partners of West Affum Holdings, L.P.,
which is currently expected to occur approximately nine months after the consummation of this offering (the &#147;Post-IPO Distribution&#148;). The allocation of the number of common shares of Kestra Medical Technologies, Ltd. held by West Affum
Holdings, L.P. among the holders of common units in West Affum Holdings, L.P. in the Post-IPO Distribution will be determined in reference to the liquidation value of West Affum Holdings, L.P. at the time of such Post-IPO Distribution; and
</P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Following the Organizational Transactions, at the West Affum Intermediate Holdings level, pre-existing preferred
interests as well as noncontrolling interests of its subsidiaries, will be converted into common shares, which will all be wholly owned by Kestra Medical Technologies, Ltd. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The 100&nbsp;shares of Kestra Medical Technologies, Ltd. common stock outstanding as of October&nbsp;31, 2024, owned by West Affum Holdings,
L.P., will continue to be owned by West Affum Holdings, L.P. following the consummation of the Organizational Transactions. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We refer
to the above transactions, as well as the transactions incidental to or in connection therewith, collectively as the &#147;Organizational Transactions.&#148; See the sections titled &#147;Basis of Presentation&#148; and &#147;Organizational
Transactions&#148; included elsewhere in this prospectus for more information. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following chart shows our simplified organizational structure immediately following
the consummation of the Organizational Transactions and this offering, after giving effect to the sale of 10,000,000&nbsp;common shares in this offering and assuming an initial public offering price of $15.00&nbsp;per share (the midpoint of the
price range set forth on the cover page of this prospectus) and assuming no exercise of the underwriters&#146; over-allotment option. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g744414g16a16.jpg" ALT="LOGO" STYLE="width:4.83529in;height:7.39027in;">
 </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Implications of Being an Emerging Growth Company and a Smaller Reporting Company </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">We qualify as an &#147;emerging growth company&#148; as defined in the Jumpstart Our Business Startups Act of 2012, as amended (the &#147;JOBS
Act&#148;). For so long as we remain an emerging growth company, we may rely on the following provisions of the JOBS Act that contain exceptions from disclosure and other requirements that otherwise are applicable to companies that conduct initial
public offerings and file periodic reports with the SEC. These provisions include, but are not limited to: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">being permitted to present only two years of audited financial statements and only two years of related
&#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; in this prospectus; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">not being required to comply with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley
Act of 2002, as amended (the &#147;Sarbanes-Oxley Act&#148;), in the assessment of our internal control over financial reporting; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delayed adoption of new or revised accounting standards until those standards apply to private companies;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced disclosure obligations regarding executive compensation in our periodic reports, proxy statements and
registration statements, including in this prospectus; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">not being required to comply with the requirement of the Public Company Accounting Oversight Board regarding the
communication of critical audit matters in the auditor&#146;s report on financial statements; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder
approval of any golden parachute payments not previously approved. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We will remain an emerging growth company until the
earliest to occur of (i)&nbsp;the last day of the fiscal year that follows the fifth anniversary of the completion of this offering; (ii)&nbsp;the last day of the fiscal year in which we have total annual gross revenue of at least
$1.235&nbsp;billion; (iii)&nbsp;the last day of the fiscal year in which we are deemed to be a &#147;large accelerated filer,&#148; as defined in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> under the Securities Exchange Act of 1934, as
amended (the &#147;Exchange Act&#148;), which will occur when the market value of our common shares held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> exceeds $700.0&nbsp;million as of the most recently completed second quarter; and
(iv)&nbsp;the date on which we have issued more than $1&nbsp;billion in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt over a three-year period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have elected to take advantage of certain of the reduced disclosure obligations in this prospectus and may elect to take advantage of other
reduced reporting requirements in our future filings with the SEC. As a result, the information that we provide to our shareholders may be different than what you might receive from other public reporting companies in which you hold equity
interests. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have elected to avail ourselves of the provision of the JOBS Act that permits emerging growth companies to take advantage
of an extended transition period to comply with new or revised accounting standards applicable to public companies. As a result, we will not be subject to new or revised accounting standards at the same time as other public companies that are not
emerging growth companies. As a result of these elections, our financial statements may not be comparable to those of public companies that comply with such new or revised accounting standards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are also a &#147;smaller reporting company,&#148; as such term is defined in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> under the
Exchange Act. We may continue to be a smaller reporting company for so long as either (1)&nbsp;the market value of our </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
common shares held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $250.0&nbsp;million as of the last business day of our most recently completed second fiscal quarter or
(2)&nbsp;our annual revenue was less than $100.0&nbsp;million during the most recently completed fiscal year and the market value of our common shares held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $700.0&nbsp;million as
of the last business day of our most recently completed second quarter. Any loss of our status as a smaller reporting company takes effect in the first quarter after the fiscal year in which we cease to qualify as a smaller reporting company. To the
extent that we continue to qualify as a smaller reporting company at the time we cease to qualify as an emerging growth company, we will continue to be permitted to make certain reduced disclosures in our periodic reports and other documents that we
file with the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For additional information, see the section titled &#147;Risk Factors&#151;Risks Related to this Offering&#151;We are
an emerging growth company and a smaller reporting company, and our compliance with the reduced reporting and disclosure requirements applicable to emerging growth companies and smaller reporting companies could make our common shares less
attractive to investors.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Principal Shareholder; Controlled Company </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Upon the closing of this offering, Bain Charger Holdings, L.P. (&#147;Bain Charger&#148;), an investment fund advised by Bain Capital, will
beneficially own approximately 52.8% of our common shares (or 51.2% if the underwriters exercise in full their over-allotment option). As a result, we will be a &#147;controlled company&#148; within the meaning of the applicable listing rules of the
Nasdaq Global Select Market. See &#147;Risk Factors&#151;Risks Related to this Offering&#151;Upon listing of our shares on the Nasdaq Global Select Market, we will be a &#147;controlled company&#148; within the meaning of the rules and, as a result,
we will qualify for exemptions from certain corporate governance requirements. You will not have the same protections as those afforded to shareholders of companies that are subject to such governance requirements.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Bain Capital </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Founded in 1984,
Bain Capital, L.P. is one of the world&#146;s leading private investment firms. Bain Capital, L.P. is committed to creating lasting impact for its investors, teams, businesses, and the communities in which we live. As a private partnership, Bain
Capital, L.P. leads with conviction and a culture of collaboration, advantages that enable it to innovate investment approaches, unlock opportunities, and create exceptional outcomes. Bain Capital, L.P.&#146;s global platform invests across five
focus areas: Private Equity, Growth&nbsp;&amp; Venture, Capital Solutions, Credit&nbsp;&amp; Capital Markets, and Real Assets. In these focus areas, Bain Capital, L.P. brings deep sector expertise and wide-ranging capabilities. Bain Capital, L.P.
has 25 offices on four continents, more than 1,850 employees, and approximately $185&nbsp;billion in assets under management. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Bain
Capital Private Equity, L.P. and Bain Capital Life Sciences, L.P., each an affiliate of Bain Capital, L.P. (collectively with Bain Charger, &#147;Bain Capital&#148;), have made nearly 1,000 investments in a variety of industries around the world.
Bain Capital has a long and successful history of investing in healthcare businesses and has a dedicated group of investment professionals focused on the sector. Bain Capital has helped to build and scale many leading companies in the healthcare
industry, including Aveanna Healthcare, Cerevel Therapeutics, Grupo NotreDame Intermedica, Gynesonics, Imperative Care, HCA, IQVIA, JenaValve, Physio-Control, QuVa Pharma, STADA, Surgery Partners, US Renal Care, Waystar, HeartFlow, Affera and Zelis.
</P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Kestra
Medical Technologies, Ltd. was incorporated as a Bermuda exempted company on May&nbsp;20, 2021 in anticipation of this offering and has not engaged in any business or other activities to date other than those incidental to its formation, the
Organizational Transactions and the preparation of the prospectus and the registration statement of which this prospectus forms a part. Our principal office is located at 3933 Lake </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Washington Blvd NE, Suite 200, Kirkland, Washington 98033, and our registered office is located in Bermuda at Cumberland House, 7th Floor, 1 Victoria Street, Hamilton HM 11, Bermuda. Our
telephone number is <FONT STYLE="white-space:nowrap">(425)&nbsp;279-8002.</FONT> Our website address is https://www.kestramedical.com. Following the consummation of this offering, Kestra Medical Technologies, Ltd. will become a tax resident of
Ireland. The information contained on, or accessible through, our website is not incorporated by reference into this prospectus, and you should not consider any information contained on, or that can be accessed through, our website as part of this
prospectus or in deciding whether to purchase our common shares. We are a holding company and all of our business operations are conducted through our subsidiaries. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE OFFERING </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Common Shares Offere</B><B>d by Us </B> </P></TD>
<TD>10,000,000 common shares. </TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Over-allotment Option</B> </P></TD>
<TD>We have granted the underwriters an over-allotment option for a period of 30 days from the date of this prospectus to purchase up to 1,500,000 additional common shares at the public offering price, less the underwriting discount.
</TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Common Shares to be Outstanding Immediately After this Offering</B> </P></TD>
<TD>47,651,467 common shares (or 49,151,467 common shares if the underwriters exercise in full their over-allotment option). </TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Use of Proceeds</B> </P></TD>
<TD>We estimate that the net proceeds from our issuance and sale of common shares in this offering will be approximately $133.3&nbsp;million, or approximately $154.2 million if the underwriters exercise in full their over-allotment option, based on
an assumed initial public offering price of $15.00 per common share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting estimated underwriting discounts and commissions and estimated offering
expenses incurred by us. We intend to use the net proceeds from this offering to scale up our commercial organization through the hiring of additional sales representatives, sales team leadership and clinical care specialists, as well as through
investments in our fleet of devices, supply chain and revenue cycle management capabilities; and to fund the research and development of continued innovation in our products and to fund trials to build upon our strong base of clinical evidence. We
intend to use the remainder for working capital and general corporate purposes. </TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">See &#147;Use of Proceeds&#148; for more information. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Controlled Company</B> </P></TD>
<TD>After this offering, assuming an offering size as set forth in this section, we expect to be a &#147;controlled company&#148; within the meaning of the applicable listing rules of the Nasdaq Global Select Market. See
&#147;Management&#151;Controlled Company Exception.&#148; </TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Dividend Policy</B> </P></TD>
<TD>We have not historically declared or paid any dividends on our common shares.<SUP STYLE="font-size:75%; vertical-align:top"> </SUP>We anticipate that we will retain all of our future earnings, if any, for use in the operation and expansion of
our business and do not anticipate paying cash dividends in the foreseeable future. Any decision to declare and pay dividends in the future will be made at the sole discretion of our board of directors (the &#147;Board of Directors&#148;) and will
depend on, among other things, our results of operations, cash requirements, financial condition, contractual restrictions and other factors that our Board of Directors may deem relevant. We are not obligated to pay dividends on our common shares.
See &#147;Dividend Policy&#148; for more information. </TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B>Risk Factors </B> </P></TD>
<TD>Investing in our common shares involves a high degree of risk. You should read the section titled &#147;Risk Factors&#148; for a discussion of factors to consider carefully before deciding to invest in our common shares. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Material Bermuda, Irish and U.S. Federal Income Tax Considerations </B></P></TD>
<TD>For a discussion of material Bermuda, Irish and U.S. federal income tax consequences, see the section titled &#147;Material Bermuda, Irish and U.S. Federal Income Tax Considerations.&#148; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Proposed Trading Symbol </B> </P></TD>
<TD>&#147;KMTS.&#148; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Reserved Shares Program </B> </P></TD>
<TD>At our request, the underwriters have reserved up to 5% of the common shares offered hereby, for sale at the initial public offering price to our officers, directors, team members and certain of their friends or family. The sales will be made to
certain entities and individuals identified by management through a reserved shares program. If these persons purchase reserved common shares, it will reduce the number of common shares available for sale to the general public. Any reserved common
shares that are not so purchased will be offered by the underwriters to the general public on the same terms as the other common shares offered hereby. For further information regarding our reserved shares program, see
&#147;Underwriting&#151;Reserved Shares.&#148; </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The number of common shares that will be outstanding immediately after this
offering is based on 37,651,467 common shares issued as of October 31, 2024, after giving pro forma effect to the Organizational Transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Except as otherwise indicated herein, all information in this prospectus, including the number of common shares that will be outstanding after
this offering, assumes or gives effect to: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the completion of the Organizational Transactions, as described under the section titled &#147;Organizational
Transactions,&#148; including the issuance of common shares in connection with the Organizational Transactions that are subject to certain vesting conditions; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an assumed initial public offering price of $15.00 per share, which is the midpoint of the price range set forth
on the cover page of this prospectus; </P></TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effectiveness of our amended and restated <FONT STYLE="white-space:nowrap">bye-laws</FONT> upon the closing
of this offering; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no exercise by the underwriters of their over-allotment option. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Except as otherwise indicated herein, in this prospectus the number of common shares that will be outstanding after this offering excludes:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">4,728,033 common shares underlying stock options to be granted to our NEOs and certain other employees
immediately following the determination of the initial public offering price for this offering, with an exercise price equal to the initial public offering price; </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">12,680,000 common shares expected to be reserved for issuance under our new equity incentive plan (which number
of reserved common shares will be subject to adjustment depending on the number of shares offered in this offering); and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">438,936 common shares issuable upon the exercise of warrants issued by Kestra Medical Technologies, Ltd., with
warrants with respect to 62,901, 47,176 and 328,859 common shares having exercise prices of $17.64, $20.46 and $11.44, respectively. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The number of common shares underlying the stock options to be granted to our NEOs and certain other employees immediately following the
determination of the initial public offering price for this offering will be determined by reference to the initial public offering price. A $1.00 increase in the assumed initial public offering price of $15.00 per common share, which is the
midpoint of the price range set forth on the cover page of this prospectus, will result in the number of common shares for which such options are exercisable being 107,177 options lower. A $1.00 decrease in the assumed initial public offering price
of $15.00 per common share, which is the midpoint of the price range set forth on the cover page of this prospectus, will result in the number of common shares for which such options are exercisable being 75,424 options higher. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The number of common shares underlying the warrants described above and exercise price thereof will be determined by reference to the initial
public offering price. A $1.00 increase in the assumed initial public offering price of $15.00 per common share, which is the midpoint of the price range set forth on the cover page of this prospectus, will result in the issuance of warrants
exercisable for 62,626, 46,969 and 327,417 common shares, with exercise prices of $17.72, $20.55 and $11.49, respectively. A $1.00 decrease in the assumed initial public offering price of $15.00 per common share, which is the midpoint of the price
range set forth on the cover page of this prospectus, will result in the issuance of warrants exercisable for 63,198, 47,399 and 330,412 common shares, with exercise prices of $17.56, $20.36 and $11.38, respectively. For more information on the
warrants, see &#147;Organizational Transactions&#151;Warrant Transactions.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The number of common shares issued in connection with
the Organizational Transactions that are subject to vesting conditions versus the number of common shares issued in connection with the Organizational Transactions that are not subject to vesting conditions will be determined by reference to the
initial public offering price. However, the total number of common shares issued in connection with the Organizational Transactions will remain the same. Assuming an initial public offering price of $15.00&nbsp;per common share, which is the
midpoint of the price range set forth on the cover page of this prospectus, 10,997 common shares subject to vesting conditions will be issued in connection with the Organizational Transactions. A $1.00&nbsp;increase in the assumed initial public
offering price of $15.00&nbsp;per common share, which is the midpoint of the price range set forth on the cover page of this prospectus, will result in the issuance of 10,310&nbsp;common shares subject to vesting conditions in connection with the
Organizational Transactions. A $1.00&nbsp;decrease in the assumed initial public offering price of $15.00&nbsp;per common share, which is the midpoint of the price range set forth on the cover page of this prospectus, will result in the issuance of
11,783&nbsp;common shares subject to vesting conditions in connection with the Organizational Transactions. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SUMMARY CONSOLIDATED FINANCIAL DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following tables set forth our summary condensed consolidated financial data for the six months ended October 31, 2024 and 2023, and our
summary consolidated financial data for the fiscal years ended April&nbsp;30, 2024 and 2023. We derived the consolidated statements of operations and comprehensive loss data for the fiscal years ended April 30, 2024 and 2023 and the consolidated
balance sheet data as of April&nbsp;30, 2024 and 2023 from the audited consolidated financial statements of West Affum Intermediate Holdings and its consolidated subsidiaries included elsewhere in this prospectus. We derived the condensed
consolidated statements of operations and comprehensive loss data for the six months ended October&nbsp;31, 2024 and 2023 and the condensed consolidated balance sheet data as of October&nbsp;31, 2024 from the unaudited condensed consolidated
financial statements of West Affum Intermediate Holdings and its consolidated subsidiaries included elsewhere in this prospectus. We have prepared the unaudited condensed consolidated financial statements on the same basis as the audited
consolidated financial statements and have included all adjustments, consisting only of normal recurring adjustments, which in our opinion are necessary to state fairly the financial information set forth in those statements. See &#147;Basis of
Presentation.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Kestra Medical Technologies, Ltd. was incorporated as a Bermuda exempted company on May&nbsp;20, 2021, in
anticipation of this offering and has not engaged in any business or other activities to date other than those incidental to its formation, the Organizational Transactions and the preparation of the prospectus and the registration statement of which
this prospectus forms a part. As such, summary consolidated financial data for Kestra Medical Technologies, Ltd. has not been provided. The balance sheets of Kestra Medical Technologies, Ltd. as of October&nbsp;31, 2024, April 30, 2024 and
April&nbsp;30, 2023 are included elsewhere in this prospectus for reference purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our historical results are not necessarily
indicative of the results to be expected in the future. You should read the summary consolidated financial data and the summary condensed consolidated financial data set forth below in conjunction with our consolidated financial statements, our
condensed consolidated financial statements and related notes thereto included elsewhere in this prospectus, as well as the sections titled &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and
&#147;Capitalization.&#148; Our fiscal year ends on April&nbsp;30. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Statements of Operations Data </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Six Months Ended</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>October 31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Fiscal Year Ended</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>April 30,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in thousands, except share and per share amounts)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2024</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2024</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Consolidated Statements of Operations and Comprehensive Loss </B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27,492</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,483</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27,814</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Costs of revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,462</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,398</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,452</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,281</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross margin</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,915</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">362</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,651</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating expenses:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,913</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,934</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,490</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,756</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,682</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,919</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69,935</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total operating expenses </B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,595</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,853</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85,425</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69,770</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(37,565</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(44,768</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(85,063</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(80,421</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other expense:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,276</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,644</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,629</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense (income)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,768</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,803</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,827</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss before provision for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(40,929</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(50,180</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(94,096</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(84,223</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="57%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Six Months Ended</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>October 31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Fiscal Year Ended</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>April 30,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in thousands, except share and per share amounts)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2024</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2024</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision for income taxes (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss and comprehensive loss </B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(40,944</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(50,217</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(94,120</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(84,238</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to non-controlling interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(692</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss attributable to West Affum Intermediate Holdings Corp.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(40,252</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(50,217</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(94,120</TD>
<TD NOWRAP VALIGN="bottom">)&#8194;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(84,238</TD>
<TD NOWRAP VALIGN="bottom">)&#8194;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Undeclared preferred stock dividends</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,706</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,915</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,721</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,499</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common stockholder, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(45,958</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(53,132</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(100,841</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(86,737</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to common stockholder, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(434</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(502</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(953</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(820</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares of common stock, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105,808</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105,808</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105,808</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105,808</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss per share attributable to common shareholders, basic and diluted
(1)(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1.09</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2.65</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma weighted-average common shares, basic and diluted (1)(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,640,470</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,640,470</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Following the Organizational Transactions and this offering, Kestra Medical Technologies, Ltd. will report on
its consolidated financial statements U.S. federal income taxes, in addition to state and local taxes, because it will own 100% of Kestra Medical Technologies, Inc. and its subsidiaries, which are subject to U.S. federal (and state and local) income
taxes. As we have historically generated losses, and on a pro forma basis, will continue to have losses following the Organizational Transactions and this offering, the pro forma net loss per share attributable to common shareholders, basic and
diluted, in our unaudited pro forma consolidated statements of operations does not reflect adjustments to our provision for income taxes as it has been determined that it is more likely than not that our net operating loss will not be realized.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The unaudited pro forma net loss per share and pro forma weighted-average shares information represent that of
Kestra Medical Technologies, Ltd. and give pro forma effect to the Organizational Transactions (assuming an initial public offering price of $15.00 per common share, which is the midpoint of the price range set forth on the cover page of this
prospectus), as described in the section titled &#147;Organizational Transactions&#148; included elsewhere in this prospectus, and excludes 10,997 unvested common shares which are not considered outstanding for calculating unaudited pro forma net
loss per share. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#8201;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The following table summarizes our unaudited pro forma net loss per share for the six months ended
October&nbsp;31, 2024 and year ended April&nbsp;30, 2024. The pro forma adjustment to our net loss attributable to common stockholder, basic and diluted, for the six months ended October&nbsp;31, 2024 include the removal of (1)&nbsp;net loss
attributable to non-controlling interest of $0.7&nbsp;million and (2)&nbsp;undeclared preferred stock dividends of $5.7&nbsp;million. The pro forma adjustment to our net loss attributable to common stockholder, basic and diluted, for the year ended
April&nbsp;30, 2024 include (1) the removal of undeclared preferred stock dividends of $6.7&nbsp;million, (2) the recognition of estimated offering and reorganization costs of $2.6&nbsp;million and (3)&nbsp;recognition of accelerated stock-based
compensation expense of $2.8&nbsp;million based on the unrecognized stock-based compensation expense as of October&nbsp;31, 2024. The pro forma adjustment to our weighted-average shares used in computing pro forma net loss per share attributable to
common shareholders, basic and diluted, includes (1)&nbsp;the issuance of 37,651,467 shares of Kestra Medical Technologies, Ltd. common stock, less (2)&nbsp;10,997 shares of unvested common stock and (3) net of 105,808
</P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
historical weighted-average shares as of October&nbsp;31, 2024 and April&nbsp;30, 2024 as described in the section entitled &#147;Organizational Transactions&#148;. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Six&nbsp;Months&nbsp;Ended<BR>October&nbsp;31,&nbsp;2024</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Year&nbsp;Ended<BR>April&nbsp;30,&nbsp;2024</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center">(in thousands, except share and<BR>per&nbsp;share amounts)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common stockholder, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(45,958</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(100,841</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma adjustment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,248</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss attributable to common shareholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(40,944</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(99,593</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares used in computing net loss per share attributable to common stockholder,
basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105,808</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105,808</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma adjustment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,534,662</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,534,662</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma weighted-average shares used in computing pro forma net loss per share attributable to
common shareholders, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,640,470</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,640,470</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss per share attributable to common shareholders basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.09</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.65</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Balance Sheet Data </B></P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="57%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>As of October&nbsp;31,
2024</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in thousands)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Actual</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Pro&nbsp;Forma&nbsp;(1)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Pro&nbsp;Forma&nbsp;As</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Adjusted&nbsp;(2) </B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Consolidated Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">76,918</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">76,918</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">210,190</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">121,454</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">121,454</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">254,725</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term debt, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77,489</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77,489</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77,489</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(446,687</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(449,520</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(452,160</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total shareholders&#146; equity (deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(236,545</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,964</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">177,236</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The unaudited pro forma consolidated balance sheet data give (1)&nbsp;the Organizational Transactions (assuming
an initial public offering price of $15.00 per common share, which is the midpoint of the price range set forth on the cover page of this prospectus), and (2)&nbsp;the effectiveness of our amended and restated
<FONT STYLE="white-space:nowrap">bye-laws</FONT> as if they had occurred on October&nbsp;31, 2024. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The pro forma as adjusted consolidated balance sheet data give further effect to (i)&nbsp;our issuance and sale
of 10,000,000 common shares in this offering at an assumed initial public offering price of $15.00 per common share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting estimated underwriting
discounts, commissions and offering and reorganization costs incurred by us, and (ii)&nbsp;the receipt of the net proceeds therefrom as described in the section titled &#147;Use of Proceeds&#148; included elsewhere in this prospectus. The pro forma
as adjusted information discussed above is illustrative only and will change based on the actual initial public offering price and other terms of this offering determined at pricing. Each $1.00 increase or decrease in the assumed initial public
offering price of $15.00 per common share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting estimated underwriting discounts, commissions and offering and reorganization costs incurred by us,
would increase or decrease, as applicable, each of cash and cash equivalents, total assets and total shareholders&#146; equity on a pro forma as adjusted basis by approximately $9.3&nbsp;million, assuming that the number of shares offered by us, as
set forth on the cover page of this prospectus, remains the same. Each increase or decrease of one million in the number of common shares we are offering at the assumed initial public offering price of $15.00 per common share, which is the midpoint
of the price range set forth on the cover page of this prospectus, after deducting estimated underwriting discounts, commissions and offering and reorganization costs incurred by us, would increase or decrease, as applicable, each of cash and cash
equivalents, total assets and total shareholders&#146; equity on a pro forma as adjusted basis by approximately $14.0&nbsp;million. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom744414_2"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Investing in our common shares involves a high degree of risk. You should consider carefully the risks and uncertainties described below,
together with all of the other information in this prospectus, including the section titled &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and our consolidated financial statements and the
related notes thereto, before deciding to invest in our common shares. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties that we are unaware of, or that we currently believe are not
material, may also become important factors that affect us. If any of the following risks occur, our business, financial condition, results of operations and prospects could be materially and adversely affected. In that event, the market price of
our common shares could decline, and you could lose all or part of your investment. Please also see &#147;Special Note Regarding Forward-Looking Statements&#148; and &#147;Industry and Market Data.&#148; </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Business </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have a limited
operating history, which may make it difficult for you to evaluate our current business and its likelihood of success and viability. If we are unable to manage our business and any fluctuations in our business effectively, our business and growth
prospects could be materially and adversely affected. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are a commercial-stage, wearable medical device and digital healthcare
company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery
System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the
ASSURE WCD. We completed clinical trials for our ASSURE WCD in March 2020, received our PMA for our ASSURE WCD on July&nbsp;27, 2021 and fully commercially launched our ASSURE WCD in August 2022. Until the ASSURE WCD was approved by the U.S. FDA,
the WCD market was served by a single competitor, which was providing the only other commercially available WCD for over 20 years and as a result, has a significantly longer commercial track record than our company. We are continuing to develop the
capabilities and infrastructure to increase our commercial organization, distribution, supply chain and revenue cycle management capabilities to further strengthen our market penetration. However, there is no assurance as to the extent to which we
will be able to continue to scale our business and expand our market penetration. Consequently, any predictions you make about our future success or viability may not be as accurate as they could be if we had a longer operating history. We may be
unsuccessful for a number of reasons, including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">responses of our primary competitor, and other <FONT STYLE="white-space:nowrap">start-up</FONT> or large
companies that are emerging or may emerge as competitors in the future, who have or may develop more technologically advanced products, stronger relationships with healthcare providers, and greater capital, marketing and other resources than our
company; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">limitations on our ability to demonstrate the differentiation and advantages of our ASSURE WCD or other products
we may develop in the future and their relative safety, efficacy and ease of use over other products in the market; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the limited size and geographic scope of our sales and marketing capabilities as compared to our competitors and
the learning curve required for our direct sales force personnel to become effective in processing prescriptions of our products and capturing market share; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to continue to provide products that are clinically effective, meet our desired product profile and
are capable of being supplied at quantities and at a cost that addresses the clinical needs and commercial opportunities we target; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to obtain sufficient and timely supplies of components necessary to manufacture our products or
secure second source suppliers if our primary suppliers are unable to fulfill our orders; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to timely make improvements to our products in response to feedback from patients or from the
medical community; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">insufficient financial or other resources to support our commercialization efforts; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the introduction and market acceptance of new, more effective or less expensive competing products and
technologies. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, as a company with a limited operating history, we may encounter unforeseen expenses,
difficulties, complications, delays and other known and unknown factors. The challenges we face in managing our evolving business place significant demands on our management, financial, operational, manufacturing, technological and other resources.
In particular, rapid and continued growth increases the challenges involved in a number of areas, including recruiting and retaining sufficient skilled personnel, maintaining consistent and high-quality products and customer service to meet
increased demand for our products, developing revenue cycle management, inventory management, payor contracting, supply chain and information technology infrastructure that can support the growing scale of our business and ensuring our compliance
with the laws and regulations of new markets we may enter into. We are continuing to transition from a company with a research and development focus to a company with increasingly significant commercial activities. As we continue to grow, we may
also need to invest significant resources to improve and expand our portfolio of technologies and solutions, scale up our manufacturing capabilities through our third-party suppliers and expand our distribution resources, including our network of
APSs, which we may not be able to do so in a cost-effective manner or at all. We cannot assure you that any changes in scale, related quality or compliance assurance will be successfully implemented or that appropriate personnel will be available to
facilitate the management of and changes to our business. If we do not adequately address these risks and difficulties, our ability to support and further grow our current commercial activities may be negatively impacted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, our business is affected by general macroeconomic and business conditions worldwide, including the impacts of inflation,
increased interest rates, market instability and evolving regulation. If we do not effectively manage our business through the various challenges we face, we may not be able to execute on our business plan, respond to competitive pressures, take
advantage of market opportunities, satisfy patient requirements or maintain high-quality products, which could have a material adverse effect on our business, financial condition, results of operations and prospects. We expect our financial
condition and results of operations to continue to fluctuate significantly from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. Accordingly, you should not rely upon the results of any quarterly
or annual periods as indications of future operating performance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have a history of net losses, and there is no assurance as to when we will
achieve profitability, if at all, even as we continue to grow and scale our business. As part of such continued growth, we may need to raise equity or debt financing in the future. If we are unable to raise capital when needed, we may be forced to
delay or scale back our growth plans, which could materially and adversely affect our results of operations and prospects. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The
development, manufacturing and distribution of medical technologies is capital intensive. From our inception in 2014 through the full commercial launch of our ASSURE WCD in August 2022, we made significant investments in research and development
efforts, developing and running clinical trials to obtain regulatory approval for our ASSURE WCD, and enabling manufacturing activities in support of our product development efforts to prepare for the commercialization of our ASSURE WCD. Since the
commercial launch of our ASSURE WCD, we have incurred, and expect to continue to incur, significant expenses related to our sales, marketing, product manufacturing and distribution functions and processes and establishing the infrastructure,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
including revenue cycle management capabilities, necessary to continue to support its commercialization. We have incurred net losses since our inception in 2014 largely due to these expenses. We
had net losses of $40.9&nbsp;million and $50.2 million for the six months ended October 31, 2024 and 2023, respectively, and as of October 31, 2024, we had an accumulated deficit of $446.7 million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In order to achieve profitability, we will need to continue to make investments to successfully grow and scale our business while managing our
expenses. We expect to continue to incur losses for the next several years and there is no assurance as to when we will achieve profitability, if at all, or whether we will be able to maintain profitability, if achieved, in the future. Factors that
have impacted, and that we expect will continue to impact, our ability to achieve profitability and our capital requirements include: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our continued investments in recruiting, training and retaining our direct sales force and supporting our
commercial infrastructure as our operations continue to grow; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to manage the costs of manufacturing and distributing our ASSURE WCD and increase our gross margins
through supply chain efficiencies and manufacturing process improvements; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in reimbursement rates for WCDs, including as a result of improved market access and shifts in patient
mix towards patients with longer wear duration; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the availability of reimbursement from payors, including Medicare, Medicaid and private payors, to cover the cost
of our products; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effectiveness of our revenue cycle management infrastructure and our ability to timely and accurately collect
payments from payors, which may be impacted by seasonality due to the resetting of patient healthcare insurance plan deductibles at certain times of the year; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to establish and maintain collaborations with technology, commercial and clinical partners on
favorable terms, if at all; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope, prioritization and number of our research and development initiatives. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We expect our expenses to continue to increase as our business grows, including as a result of our ongoing efforts to grow our sales and
commercial organization, increase our brand awareness through programmatic and industry-specific advertising, conduct clinical studies to expand the clinical evidence supporting the efficacy of our ASSURE WCD and our broader Cardiac Recovery System
platform and engage in research and development initiatives to enhance and broaden our suite of solutions. Our efforts to continue to grow and scale our business may not be successful or may prove more expensive than we currently anticipate, and we
may not succeed in increasing our revenue sufficiently to offset these higher expenses or at all. In addition, as a public company, we will incur significant additional expenses that we did not incur as a private company, including expenses related
to audit, legal, regulatory, compliance, director and officer insurance, investor and public relations, and <FONT STYLE="white-space:nowrap">tax-related</FONT> services associated with maintaining compliance with the rules and regulations of the SEC
and standards applicable to companies listed on a national securities exchange. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">While we believe that our existing cash and cash
equivalents (including the net proceeds from this offering) will be sufficient to fund our operating and capital needs for at least the next 12 months, we may need additional funding, which may include future equity and debt financing. We may not
have accurately anticipated how much we will accomplish with the net proceeds from this offering, or we may experience lower than expected cash generated from operating activities or greater than expected capital expenditures, cost of revenue or
operating expenses, and we may require additional funding in the future to further our growth plans. Any additional fundraising efforts may divert our management from their
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities, which may adversely </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
affect our ability to further commercialize our ASSURE WCD. Any disruptions in the financial markets or other adverse macroeconomic conditions may make equity and debt financing more difficult to
obtain and may have a material adverse effect on our ability to meet our fundraising needs. We cannot guarantee that future financing will be available in sufficient amounts or on terms favorable to us, if at all. Moreover, the terms of any
financing may adversely affect the holdings or the rights of our shareholders and the issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of our shares to decline. The
sale of additional equity or convertible securities would dilute all of our shareholders. The incurrence of indebtedness would result in increased fixed payment obligations, and we may be required to agree to certain restrictive covenants, such as
limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. We could also
be required to seek funds through arrangements with collaborators or otherwise at an earlier stage than otherwise would be desirable, and we may be required to relinquish rights to some of our technologies or current or future products or otherwise
agree to terms unfavorable to us, any of which may have a material adverse effect on our business, financial condition, results of operations and prospects. Additionally, if we are capital constrained and unable to raise capital when needed, we may
not be able to meet our obligations, which may limit or halt our ability to continue operations, or we may be forced to delay or scale back our growth plans, including our initiatives to increase market adoption of our ASSURE WCD and further our
market penetration, which could materially and adversely affect our results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our recurring losses from operations and
financial condition raise substantial doubt about our ability to continue as a going concern. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In Note&nbsp;1 to our condensed
consolidated financial statements for the six months ended October 31, 2024 and 2023 and Note 1 to our consolidated financial statements for the fiscal years ended April&nbsp;30, 2024 and 2023 included elsewhere in this prospectus, we concluded that
our history of continued operating losses and accumulated deficit raise substantial doubt about our ability to continue as a going concern. Similarly, our independent registered public accounting firm included an explanatory paragraph in its report
on our consolidated financial statements as of and for the fiscal years ended April&nbsp;30, 2024 and 2023, describing the existence of substantial doubt about our ability to continue as a going concern. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our future viability is dependent on our ability to generate cash from our operating activities or to raise additional capital to finance our
operations. There is no assurance that we will succeed in obtaining sufficient funding on terms acceptable to us to fund continuing operations, if at all. The perception that we might be unable to continue as a going concern may also make it more
difficult to obtain financing for the continuation of our operations on terms that are favorable to us, or at all, and could result in the loss of confidence by investors, suppliers and employees. Our consolidated financial statements do not include
any adjustments that might result from the outcome of this uncertainty. If we are unable to continue as a going concern, we may have to liquidate our assets and may receive less than the value at which those assets are carried on our consolidated
financial statements, and it is likely that our investors will lose all or a part of their investment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We generate revenue primarily from the lease
of our ASSURE WCD as part of our Cardiac Recovery System platform, and we are therefore highly dependent on our ASSURE WCD for our continued success. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We generate revenue primarily by leasing our ASSURE WCD to patients for a fixed amount on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">month-to-month</FONT></FONT> basis as part of our Cardiac Recovery System platform. We expect that revenues from our ASSURE WCD and associated products and services delivered as part of our Cardiac Recovery System platform
will continue to account for nearly all of our revenue for the foreseeable future. Our ability to execute our growth strategy and become profitable will significantly depend upon educating healthcare providers on the clinical efficacy and diagnostic
utility of WCD therapy, broadening healthcare providers&#146; awareness of <FONT STYLE="white-space:nowrap">WCD-eligible</FONT> populations, advancing the adoption of our ASSURE WCD and increasing our brand awareness, including through <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">peer-to-peer</FONT></FONT> education and effectively engaging with payors to educate them of the benefits of our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Cardiac Recovery System platform and optimize reimbursement. We may incur significant expenses in our efforts to engage with healthcare providers to broaden awareness of the benefits of our
ASSURE WCD, and there is no assurance that such efforts will lead to increased adoption of our ASSURE WCD or that we will generate sufficient revenue to offset the expenses incurred in connection with such efforts. In addition, some healthcare
providers may have a preference for other treatment options or may be reluctant to alter their practice patterns and undergo the training and other transition processes, including updating billing procedures, required to enable them to prescribe our
ASSURE WCD to their patients. Additionally, patients may decide to not utilize, and some payors may decide not to provide reimbursement for, our ASSURE WCD if, among other potential reasons, they believe our pricing is too high or that alternative
devices are either more clinically efficacious, cost-effective or more comfortable to use than our product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We derive nearly all our
revenue from the direct billing of various third-party payors, including Medicare, Medicaid, private payors and other healthcare-related organizations, for the lease of our ASSURE WCD to patients as part of our Cardiac Recovery System platform. We
also bill patients for <FONT STYLE="white-space:nowrap">co-insurance</FONT> payments and deductibles. As such, our cash flows and our ability to generate revenue depend on our ability to obtain and maintain broad
<FONT STYLE="white-space:nowrap">in-network</FONT> payor coverage of and optimize reimbursement for our ASSURE WCD. Patients are unlikely to use our product unless coverage is provided and reimbursement is adequate to cover a significant portion of
the cost. As a result, healthcare providers may be reluctant to adopt our product for patients covered by <FONT STYLE="white-space:nowrap">non-contracted</FONT> insurance policies because of the uncertainty surrounding reimbursement. Our gross
margin is also affected by payors&#146; reimbursement rates for our ASSURE WCD, as well as our ability to increase our reimbursement realization. Although reimbursement rates for WCDs have generally increased in recent years, there is no assurance
that they will remain at or increase from historical levels. A decrease in reimbursement rates for our ASSURE WCD, or the introduction of other limitations to payors&#146; coverage for our ASSURE WCD, could adversely affect our results of operations
and financial condition. For more information on factors that may affect our reimbursement rates, see also &#147;&#151;Our commercial success depends in part on the extent to which governmental authorities and health insurers provide coverage and
adequate reimbursement levels. Failure to obtain and maintain coverage and adequate reimbursement for our products could limit our ability to market those products and make it difficult for us to operate profitably.&#148; Additionally, as we
continue to scale our business, our ability to achieve profitability will depend on our efforts to increase our reimbursement realization for our ASSURE WCD, including through achieving manufacturing process improvements and supply chain
efficiencies. If we are unable to achieve such efficiencies, including as a result of increased costs of manufacturing and distributing our products such as increased pricing of materials and electronics components, labor rates, shipping rates and
inflation, our ability to grow our business could be adversely affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our business is dependent upon healthcare providers, hospitals and
patients adopting our solutions, and if we fail to obtain and maintain broad adoption, our business would be adversely affected. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our ability to execute our growth strategy and become profitable will depend on our ability to educate healthcare providers, hospitals and
patients on the benefits of our ASSURE WCD and associated products and services delivered as part of our Cardiac Recovery System platform over the existing product and services in the market. There is no assurance that the products and solutions we
offer through our Cardiac Recovery System platform or other potential products we may develop in the future will achieve and maintain widespread market adoption over the long term or at all. Market acceptance of the solutions and services we provide
through our Cardiac Recovery System platform or other potential products we may develop may be negatively impacted if healthcare providers, hospitals and patients do not perceive WCDs, including our ASSURE WCD, to be useful, safe, effective,
reliable and trustworthy or do not perceive the advantages of ASSURE WCD over our main competitor, or if we are unable to provide adequate customer service and sufficient training to patients or effectively harmonize our products with healthcare
providers and processes in which we operate. We are currently engaged in a post-approval study of our ASSURE WCD and may in the future engage in additional clinical trials and other clinical initiatives to support additional indications and stronger
guideline recommendations for WCD therapy and to obtain regulatory approvals to market our products in new markets. Any studies we, or third parties that we sponsor, may conduct may be expensive, time consuming and may not
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
yield positive results. Negative clinical research results from past, current or future clinical studies or negative publicity or an adverse change to published or unpublished guidelines or
recommendations from third parties (including, without limitation, key opinion leaders, medical societies and clinical advisory boards) relating to the use, clinical benefit or risk profile of WCDs in general, including our ASSURE WCD, generally
could result in negative perception of the efficiency and safety of our products and affect our brand and reputation. Healthcare providers play a significant role in determining the course of a patient&#146;s treatment and, as a result, the type of
product that will be used to treat a patient. If we are not successful in convincing healthcare providers of the merits of our ASSURE WCD, they may not prescribe it or recommend it to other healthcare providers and we may be unable to increase
revenue, sustain our growth or achieve profitability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Furthermore, we believe healthcare providers may not adopt our ASSURE WCD unless
they determine, based on their personal experience, recommendations from other healthcare providers, available clinical data and published peer-reviewed journal articles, that our ASSURE WCD is an attractive alternative to our competitors&#146;
products. Healthcare providers may be hesitant to adopt or switch to our ASSURE WCD for the following reasons, among others: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">long-standing relationships with competitors and distributors that sell other products and their competitive
responses and negative selling efforts aimed at our product; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">lack of experience with our products and concerns that we are relatively new to the WCD industry, or concerns
that our competitors have greater resources than our company; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reluctance to change to or use new products; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">perceived liability risk generally associated with the use of new products; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adverse clinical evidence regarding the clinical benefits of our ASSURE WCD and WCDs in general;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">perception that the clinical evidence for our products is not sufficient or that our products are unproven or
experimental; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the time commitment that may be required to gain familiarity with and establish the infrastructure, including
billing processes, required to adopt our products. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, the medical device industry&#146;s relationship with
healthcare providers is under increasing scrutiny by federal, state and other foreign and domestic government agencies. In recent years, Congress, the Department of Justice (the &#147;DOJ&#148;), the Office of the Inspector General (the
&#147;OIG&#148;) of the Department of Health and Human Services (the &#147;HHS&#148;) and the state attorneys general have issued subpoenas and other requests for information to, as well as initiated enforcement actions against and entered into
settlements with, medical device manufacturers, primarily related to financial arrangements with healthcare providers, regulatory compliance and marketing and product promotional practices. Furthermore, the federal government and certain state
governments have enacted legislation to limit and/or increase the transparency of interactions between medical device manufacturers and healthcare providers, pursuant to which we are or may be required by law to disclose certain payments and other
transfers of value to healthcare providers or marketing expenditures both nationally and those licensed by certain states. Our failure to comply with laws, rules and regulations governing our relationships with healthcare providers, or an
investigation into our compliance by the DOJ, the HHS OIG, state attorneys general or other government agencies, could significantly harm our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Additionally, adoption of our products may be directly influenced by a number of financial factors, including the extent to which our products
have broad coverage from third-party payors and have well-established reimbursement codes and adequate reimbursement rates. The efficacy, safety, performance, patient compliance </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
benefits and cost-effectiveness of our solutions, on a stand-alone basis and relative to competing products and/or services will determine the availability and level of reimbursement received by
us. There is no assurance that we will be able to obtain and maintain adequate levels of coverage and reimbursement for our products. In particular, as we seek to expand into new markets in the future, including select international markets, we may
be subject to different, and potentially conflicting requirements, to obtain the necessary coverage and reimbursement for our products. Complying with various coverage and reimbursement requirements in each jurisdiction in which we distribute our
products may be costly, and we may face difficulty in adequately adjusting our business to comply with any diverging requirements, which could hinder our ability to expand our market reach or launch new products. In order to generate revenue, we
will need to target potential prescribers of our products, such as hospitalists, cardiologists and other healthcare providers, as well as potential <FONT STYLE="white-space:nowrap">end-users</FONT> of our products with whom we have had little
contact, which may require significant marketing and sales efforts. Even if we succeed in increasing adoption of our products by healthcare providers and hospitals, maintaining and creating new relationships with third-party payors and developing
and commercializing new features or indications for our products we may be unable to generate sufficient revenue to achieve or sustain profitability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The revenue we generate from distributing our ASSURE WCDs also varies, in part, based on the wear time of patients who are prescribed our
ASSURE WCD. We bill third-party payors for patient use of our ASSURE WCDs based on their wear time. Although we have designed our ASSURE WCD to enhance the comfort of patients and allow for more extended wear times as part of their longer-term
cardiac care, the actual wear time of our ASURE WCDs can vary due to a number of factors, many of which are beyond our control. The emergence of new medical technologies, therapies and other medical advances may reduce the need to wear a WCD for an
extended period. Patients may shorten their wear time due to any inconvenience or discomfort from wearing a WCD or because they do not perceive the need to wear a WCD for an extended period of time and are willing to take on the heightened risk of
experiencing a SCA from not wearing a WCD. Additionally, healthcare providers may elect to prescribe our ASSURE WCD for a more limited period of time because of concerns of reduced patient compliance with longer wear times, difficulties with
obtaining reimbursement from third-party payors for extended wear times, changes in medical guidelines on recommended wear times or other clinical factors that result in the need to shorten or terminate the use of a WCD, such as a patient requiring
an ICD sooner than anticipated. If the average wear time of our ASSURE WCD does not increase or is reduced over time, this may limit the revenue we generate, which may negatively impact our results of operations, cash flows and the growth of our
business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our commercial success depends in part on the extent to which governmental authorities and health insurers provide coverage and adequate
reimbursement levels. Failure to obtain and maintain coverage and adequate reimbursement for our products could limit our ability to market those products and make it difficult for us to operate profitably. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the United States and in other countries, patients who are prescribed medical treatment generally rely on third-party payors to reimburse
all or part of the costs associated with their treatment. In the United States, third-party payors include government healthcare programs such as Medicare, Medicaid, TRICARE and the Veterans Administration and private payors. Coverage and adequate
reimbursement from payors are critical to new product acceptance. As we expand our business and enter into new markets, we will need to enter into new payor contracts with national, state, regional and international payors. There is no assurance
that we will be able to enter into new payor contracts, or renew our existing payor contracts upon their expiration, on terms acceptable to us, or at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Government healthcare programs and other third-party payors may change their coverage and reimbursement policies, as well as payment amounts,
in a way that could prevent or limit reimbursement for our products, which would significantly harm our business. Coverage and reimbursement by a third-party payor may depend upon a number of factors, including macro-economic developments, as well
as the third-party payor&#146;s determination that use of a product is: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a covered benefit under its health plan; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">safe, effective and medically necessary; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">cost-effective; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">supported by peer-reviewed publications and key opinion leaders; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">appropriate for the specific patient; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">neither experimental nor investigational. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors. Therefore, coverage and
reimbursement for our products can differ significantly from payor to payor. As a result, obtaining coverage and reimbursement approval of a product from a government or other third-party payor is a time-consuming and costly process that typically
requires us to provide supporting scientific, clinical and cost-effectiveness data for the use of our products with no assurance that coverage and adequate reimbursement will be obtained. Even if we obtain coverage for a given product, the resulting
reimbursement payment rates might not be adequate for us to achieve or sustain profitability or may require <FONT STYLE="white-space:nowrap">co-payments</FONT> that patients find unacceptably high. There is no assurance that we will be able to
maintain adequate coverage and reimbursement for our ASSURE WCD in each of the markets it is distributed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Market adoption of our products
also depends on whether we are able to obtain reimbursement codes so that our products are eligible for reimbursement by payors such as Medicare and Medicaid. Our ASSURE WCD is currently reimbursable under the Healthcare Common Procedure Coding
System (&#147;HCPCS&#148;) code K0606, which is well-established. HCPCS is a standardized system used by all U.S. insurance payors to provide descriptions of healthcare equipment, supplies and services. HCPCS codes are used by payors to identify
what services are being billed and to assign payment rates to those specific services. HCPCS codes for durable medical equipment are assigned and managed by the CMS and a Medicare contractor responsible for Pricing, Data Analysis and Coding
(&#147;PDAC&#148;). New products and product revisions must go through a coding verification process to confirm the products meet the requested HCPCS definitions. CMS or its contractor can also review and revise coding assignments if they believe a
product no longer meets the assigned HCPCS definition. If the PDAC contractor determines one of our products does not meet the current HCPCS definition, it could remove all coding or assign a different&nbsp;HCPCS&nbsp;code&nbsp;with a lesser payment
rate. This could have an adverse impact on our reimbursement rates, results of operations and cash flows. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We were issued a Medicare
Provider Number by the CMS, which enables us to bill Medicare for reimbursement for our ASSURE WCD as an accredited DME supplier to the extent the claim meets medical necessity and coverage requirements set forth by Medicare. Determinations of which
products or services will be reimbursed under Medicare can be developed at the national level through a national coverage determination (&#147;NCD&#148;), by CMS, or at the local level through a local coverage determination (&#147;LCD&#148;), by one
or more of the regional Medicare Administrative Contractors (&#147;MACs&#148;), which are private contractors that process and pay claims on behalf of CMS for different regions. In the absence of an NCD, the MAC with jurisdiction over a specific
geographic region will have the discretion to make an LCD and determine the fee schedule and reimbursement rate within the region, and regional LCDs may not always be consistent in their determinations. Currently, no NCD has been issued with respect
to products reimbursed pursuant to HCPCS Code K0606, so reimbursement for our ASSURE WCD will depend on the medical necessity and coverage requirements set forth with respect to K0606 in the relevant LCD. Reductions in reimbursement rates, if
enacted, could have a material adverse effect on our business. Further, a reduction in coverage by Medicare could cause some commercial <FONT STYLE="white-space:nowrap">third-party</FONT> payors to implement similar reductions in their coverage or
level of reimbursement of our products. Given the evolving nature of the healthcare industry and <FONT STYLE="white-space:nowrap">on-going</FONT> healthcare cost reforms, we may be subject to changes in the level of coverage for our products by
government healthcare programs, once approved for commercial sales, and unfavorable coverage determinations at the national or local level could adversely affect our business and results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Additionally, healthcare reform legislation or regulation may be proposed or enacted in the
future that may adversely affect such policies and amounts. Changes in the healthcare industry directed at controlling healthcare costs or perceived over-utilization of cardiac monitoring products and services in ambulatory care environments could
reduce the volume of demand for our products. If more healthcare cost controls are broadly instituted throughout the healthcare industry, the volume of cardiac monitoring solutions prescribed could decrease, resulting in pricing pressure and
declining demand for our products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our quarterly and annual results may fluctuate significantly and may not fully reflect the underlying
performance of our business. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our quarterly and annual results of operations, including our revenue, profitability and cash flow,
may vary significantly in the future and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">period-to-period</FONT></FONT> comparisons of our operating results may not be meaningful. Accordingly, the results of any one quarter or
period should not be relied upon as an indication of future performance. Our quarterly and annual financial results may fluctuate as a result of a variety of factors, many of which are outside our control and, as a result, may not fully reflect the
underlying performance of our business. Fluctuation in quarterly and annual results may decrease the value of our common shares. Factors that may cause fluctuations in our quarterly and annual results include, without limitation: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">market acceptance of our ASSURE WCD and other products and solutions we may develop in the future;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain marketing approval for our ASSURE WCD in international markets we enter in the future or
for other products and solutions we may develop in the future, and the timing and scope of any such approvals we may receive; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the availability of reimbursement for our ASSURE WCD or any future product candidates at acceptable reimbursement
rates; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the availability of reimbursement for our products and solutions through government healthcare programs at
acceptable reimbursement rates; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of manufacturing our ASSURE WCD or any future product candidates, which may vary depending on the
quantity of production and the terms of our agreements with manufacturers and other vendors; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to attract, hire, train and retain qualified personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the amount and timing of costs and expenses related to the maintenance and expansion of our business and
operations; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in our future pricing policies or those of our competitors; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the level of demand for our ASSURE WCD or any future product candidates that receive necessary marketing and
other regulatory approvals, which may vary significantly; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">general economic, industry and market conditions or extraordinary external events, such as a recession;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in our regulatory environment; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expenses associated with unforeseen product quality issues; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and success or failure of clinical trials or post-approval studies for our ASSURE WCD or any future
product candidates or competing product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other change in the competitive landscape of our industry, including consolidation amongst our competitors or
partners; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">litigation or other claims against us for intellectual property infringement or otherwise; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expenses associated with indemnification obligations to third parties that are subject to litigation or claims,
including in relation to intellectual property infringement, or incur other losses as a result of their use of our products; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain additional financing as necessary; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">advances and trends in new technologies and industry standards. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, our revenue is subject to seasonality as our billings and collections efforts during January and February tend to be lower
because of resetting annual patient healthcare insurance plan deductibles. In addition, as our sales grow in the United States and any international markets we may enter into in the future, we may experience seasonality based on holidays, vacations
and other factors. The cumulative effects of these factors could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">period-to-period</FONT></FONT> basis may not be meaningful. This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If
our revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if the forecasts we provide to the market are below the expectations of analysts or investors, the price of
our common shares could decline substantially. Such a share price decline could occur even if we meet any previously publicly-stated guidance we may have provided. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to manage the anticipated growth of our business, our future revenue and operating results may be harmed. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Any growth that we experience in the future could provide challenges to our organization, requiring us to expand our sales personnel and
general and administrative infrastructure. In addition to the need to establish effective sales, marketing, patient support and clinical operations capabilities, our future growth will impose significant added responsibilities on our management,
including the need to identify, recruit, train and integrate additional employees. Rapid expansion in personnel could mean that less experienced people market and offer our products, which could result in inefficiencies, unanticipated costs and
cause disruptions to our operations. Additionally, rapid and significant growth may strain our administrative and operational infrastructure. Our ability to manage our business and growth will require us to continue to improve our operational,
financial and management controls, reporting systems and procedures. The time and resources required to optimize these systems and procedures are uncertain, and failure to complete optimization in a timely and efficient manner could adversely affect
our operations. If we are unable to manage our growth effectively, it may be difficult for us to execute our business strategy and our business could be harmed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our clinical study initiatives may be complex, lengthy, expensive and carry uncertain outcomes. Future trials and studies by us or others may fail to
replicate positive results observed to date. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In order to support the continued adoption of our products, we will need to continue
to invest in clinical study initiatives to grow the body of clinical evidence supporting the safety, efficacy and benefits of our products and solutions. We conduct our own clinical studies and provide support for third party-initiated trials that
evaluate different aspects of the ASSURE WCD. As of the date of this prospectus, we have one ongoing active surveillance post-approval study, the <FONT STYLE="white-space:nowrap">ACE-PAS,</FONT> which is continuing to enroll patients. There is no
assurance of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
whether we will be able to complete patient enrollment for our <FONT STYLE="white-space:nowrap">ACE-PAS</FONT> study or other clinical trials we may conduct in the future and delays in completing
patient enrollment may result in increased costs or affect the timing or outcome of our ongoing and planned clinical trials. If we are unable to timely complete our clinical studies, our ability to continue to develop a sufficient body of clinical
evidence to support the safety, efficacy and benefits of our products may be adversely affected, which may negatively impact adoption rates for our products. Clinical trials are difficult to design and implement, can take many years, can be
expensive and carry uncertain outcomes. The results of preclinical studies and clinical trials of our products conducted to date and ongoing or future studies and trials of our current, planned, or future products may not be predictive of the
results of later clinical trials or real-world performance, and interim results of a clinical trial do not necessarily predict final results. Additionally, clinical trials may produce different results depending on the type of statistical analysis
used to report data results, such as per protocol analyses and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">intent-to-treat</FONT></FONT> analyses. Results produced under one type of statistical analysis may not be consistent
with or may not be as favorable as results produced under alternative types of statistical analysis. For example, in the VEST study published in 2018, initial
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">intention-to-treat</FONT></FONT> analysis of WCD therapy did not indicate a statistically significantly lower rate in sudden arrhythmic death when compared to treatment through GDMT
alone, whereas the <FONT STYLE="white-space:nowrap">as-treated</FONT> analysis showed that a significantly lower percentage of patients died when they were wearing the WCD than when they were not. If any studies conducted by third parties on any of
our products produce results that are not as favorable as the findings in the clinical trials we conduct, the adoption of our products could be impeded and our reputation in the medical community may be damaged, which could have a material adverse
effect on our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Additionally, failure to establish the safety and
efficacy of any additional products we may develop in the future would prevent receipt of regulatory clearance or approval and, ultimately, the commercialization of that product or indication for use. Even after any products are cleared or approved
in the United States, commercialization of our products in foreign countries would require clearance, certification or approval by regulatory authorities in those countries. Clearance, certification or approval procedures vary among jurisdictions
and can involve requirements and administrative review periods different from, and greater than, those in the United States, including additional <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies or clinical trials. Adjusting our clinical
trial procedures to satisfy the clearance, certification or approval requirements of different foreign jurisdictions may be costly and may result in delays in our ability to complete our clinical trials and commence the commercialization of our
products in such jurisdictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The initiation and completion of any of our clinical trials or investigations may be prevented, delayed
or halted for numerous reasons. We may experience delays in future clinical trials or investigations for a number of reasons, which could adversely affect the costs, timing or successful completion of our clinical trials, including related to the
following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be required to submit an Investigational Device Exemption (&#147;IDE&#148;) application to FDA, which must
become effective prior to commencing certain human clinical trials of medical devices, and FDA may reject our IDE application and notify us that we may not begin clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulators and other comparable foreign regulatory authorities may disagree as to the design or implementation of
our clinical trials or investigations; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulators and/or institutional review boards (&#147;IRB&#148;) or other reviewing bodies may not authorize us or
our investigators to commence a clinical trial or investigation, or to conduct or continue a clinical trial or investigation at a prospective or specific trial site; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not reach agreement on acceptable terms with prospective contract research organizations, or CROs, and
clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical trials or investigations may produce negative or inconclusive results, and we may decide, or regulators
may require us, to conduct additional clinical trials or investigations or abandon product development programs; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of subjects or patients required for clinical trials or investigations may be larger than we
anticipate, enrollment in these clinical trials may be insufficient or slower than we anticipate, and the number of clinical trials or investigations being conducted at any given time may be high and result in fewer available patients for any given
clinical trial or investigation, or patients may drop out of these clinical trials at a higher rate than we anticipate; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our third-party contractors, including those manufacturing products or conducting clinical trials or
investigations on our behalf, may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we might have to suspend or terminate clinical trials or investigations for various reasons, including a finding
that the subjects are being exposed to unacceptable health risks; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may have to amend clinical trial protocols or conduct additional studies to reflect changes in regulatory
requirements or guidance, which we may be required to submit to an IRB and/or regulatory authorities for <FONT STYLE="white-space:nowrap">re-examination;</FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulators, IRBs, other reviewing bodies or other parties may require or recommend that we or our investigators
suspend or terminate clinical research for various reasons, including safety signals or noncompliance with regulatory requirements; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of clinical trials or investigations may be greater than we anticipate; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical sites may not adhere to our clinical protocol or may drop out of a clinical trial;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be unable to recruit a sufficient number of clinical trial sites; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulators, IRBs, or other reviewing bodies may fail to approve or subsequently find fault with the manufacturing
processes or facilities of third-party manufacturers with which we enter into agreement for clinical and commercial supplies, the supply of devices or other materials necessary to conduct clinical trials may be insufficient, inadequate or not
available at an acceptable cost, or we may experience interruptions in supply; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approval policies or regulations of FDA or applicable foreign regulatory agencies may change in a manner
rendering our clinical data insufficient for approval; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our current or future products may have undesirable side effects or other unexpected characteristics.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Any of these occurrences may significantly harm our business, financial condition, results of operations and prospects.
In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials or investigations may also ultimately lead to the denial of regulatory approval of any future product candidates. Clinical trials
and investigations must be conducted in accordance with the laws and regulations of the FDA and other applicable regulatory authorities&#146; legal requirements, regulations or guidelines, and are subject to oversight by these governmental agencies
and IRBs or other regulatory bodies at the medical institutions where the clinical trials or investigations are conducted. In addition, clinical trials and investigations must be conducted with supplies of our devices produced under current good
manufacturing practice, or cGMP, requirements and other regulations. Furthermore, we may rely on CROs, and clinical trial sites to ensure the proper and timely conduct of our clinical trials and we may have limited influence over their actual
performance. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
We depend on our collaborators and on medical institutions and CROs to conduct our clinical trials in compliance with good clinical practice, or GCP, requirements. To the extent our collaborators
or the CROs fail to enroll participants for our clinical trials, fail to conduct the study to GCP standards or are delayed for a significant time in the execution of trials, including achieving full enrollment, we may be affected by increased costs,
program delays or both. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have limited experience supplying our ASSURE WCD in quantities and providing services on a broad scale that is both
commercially successful and meets clinical needs, and production or service delays or shortfalls may occur, which could adversely affect our business. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As we fully commercially launched our ASSURE WCD in August 2022, we have limited experience in supplying our ASSURE WCD in commercial
quantities and providing services on a broad scale that is both commercially successful and meets clinical needs. As a result, we may encounter production or service delays or shortfalls. Such production or service delays or shortfalls may be caused
by many factors, including the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to develop and maintain the infrastructure necessary to drive our operational efficiency and support
our growth; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">key components of our ASSURE WCD are provided by a limited number of suppliers, and we do not currently maintain
large inventory levels of these components; if we experience a shortage of or quality issues in any of these components, we would need to identify and qualify new supply sources, which could increase our expenses and result in manufacturing delays;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our current suppliers and service providers may not be able to provide adequate coverage for new markets we
intend to distribute our products to, and there is no assurance that we will be able to engage with new suppliers to cover such new markets on terms acceptable to us, or at all; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we and our manufacturing partners are subject to state and federal regulations, including the FDA&#146;s Quality
System Regulation (the &#147;QSR&#148;), for both the manufacture of our products and provision of our services, <FONT STYLE="white-space:nowrap">non-compliance</FONT> with which could cause an interruption in our ability to manufacture and deliver
our products and services; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to increase our revenue significantly and scale our services, we will be required to attract, hire, train and
retain qualified personnel. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If we are unable to keep up with demand for our products, including our ASSURE WCD, our
revenue could be negatively impacted, market adoption of our products could be harmed and we may not be able to compete against our current or future competitors. We utilize a lease business model, whereby when a patient&#146;s indicated wear time
has concluded, our ASSURE WCDs are returned for reprocessing and reintroduction into the distribution network. Patients are typically prescribed our ASSURE WCDs for 40 to 90 days, during which time the patient wears the ASSURE WCD primarily at home.
Upon conclusion of the prescription period, the patient must return our ASSURE WCD so that we can refurbish and recondition the equipment. We rely on a third-party manufacturer to recondition our used ASSURE WCDs. If our patients fail to return
their equipment on time or at all or if the equipment is severely damaged requiring extensive repairs and we are unable to timely deploy the equipment for the next customer&#146;s use, then our business, financial condition, results of operations
and prospects could be adversely affected. Although historically we have not experienced any material losses due to damaged or unreturned equipment, there is no assurance that we will not be adversely affected by such losses in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The manufacturing facilities and processes of our third-party suppliers are subject to unannounced FDA and state regulatory inspections for
compliance with the QSR. Developing and maintaining a compliant quality system is time consuming and expensive. Failure to maintain compliance with, or not fully complying with the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
requirements of the FDA and state regulators could result in enforcement actions against us or our third-party suppliers, which could include the issuance of warning letters, seizures,
prohibitions on product sales, recalls and civil and criminal penalties. Additionally, our third-party suppliers have in the past and may in the future receive 483 letters or warning letters from the FDA for violations of the FDA&#146;s
requirements. If our third-party suppliers fail to adequately rectify any such violations, they may be subject to fines or penalties, which could significantly impact our manufacturing supply and provision of services and impair our reputation and
financial results. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We depend on a limited number of third-party suppliers and contract manufacturers to manufacture and recondition our ASSURE WCD
and its components, which could make us vulnerable to supply shortages and price fluctuations that could harm our business. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We
outsource the manufacturing of our ASSURE WCD and all of its components to third-party suppliers, including contract manufacturers that manufacture garments, chargers, monitors, batteries, cables and various accessories for our ASSURE WCD. We also
rely on a third-party manufacturing partner to recondition our ASSURE WCDs for use by subsequent patients. As a result, we depend on our third-party suppliers and contract manufacturers to provide us with materials and services in a timely manner
that meet our quality, quantity and cost requirements. These suppliers and contract manufacturers may encounter problems during manufacturing for a variety of reasons, any of which could delay or impede their ability to meet demand for our products.
Our reliance on third-party suppliers subjects us to a number of risks, including, but not limited to: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">inability to obtain sufficient quantities of components used in our products in a timely manner or on
commercially acceptable terms, including shortages of <FONT STYLE="white-space:nowrap">off-the</FONT> shelf commercial components; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in the reconditioning of our ASSURE WCDs, which impacts the fleet of devices available to be deployed to
new patients; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">supply interruptions resulting from disruptions or changes to, or discontinuations of, a supplier&#146;s
operations; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">production delays related to the evaluation and testing of products from alternative suppliers and corresponding
regulatory qualifications; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inability of the manufacturer or supplier to comply with the QSR and other relevant state or federal
regulations; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in product shipments resulting from uncorrected defects, reliability issues or a supplier&#146;s failure
to consistently produce quality components; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">third party litigation or other claims for intellectual property infringement based on key components provided by
suppliers; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays or increased costs due to the inability of a manufacturer or supplier to provide or import components due
to injunctions or import bans; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays or increased costs due to the need to secure components from alternative manufacturers or suppliers in
order to secure appropriate intellectual property licenses or equivalent rights; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">price fluctuations due to a lack of long-term supply arrangements with our suppliers for key components;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">inability to control the quality of components manufactured by our third-party suppliers; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">trade protection measures, laws and business practices that favor local companies, tariffs, and other duties,
especially in light of trade disputes between the United States and several foreign countries, that may impact the supply and costs of certain components that our third-party suppliers source from foreign countries; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exchange controls, currency restrictions, and fluctuations in currency values; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">political, social, and economic instability; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">difficulties in the protection of intellectual property; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the outbreak of contagious diseases; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">inflation and/or deflation; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential adverse tax consequences; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">labor disputes, terrorism, vandalism, cyberattacks, infrastructure failures, natural disasters, severe weather or
work stoppages; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in delivery by our suppliers due to changes in demand from us or their other customers and consequently,
our inability to fulfill our contractual obligations to deliver our products to our <FONT STYLE="white-space:nowrap">end-users.</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, our suppliers and contract manufacturers may cease producing the components we purchase from them or otherwise decide to cease
doing business with us. Further, we maintain limited volumes of inventory from most of our suppliers and contract manufacturers. If we inaccurately forecast demand for finished products, we may be unable to meet customer demand, which could harm our
competitive position and reputation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, if we fail to effectively manage our relationships with our suppliers and contract
manufacturers, we may be required to change suppliers or contract manufacturers. While we believe replacement suppliers exist for all materials, components and services necessary to manufacture our ASSURE WCD, establishing additional or replacement
suppliers for any of these materials, components or services, if required, could be time-consuming and expensive, and may result in interruptions in our operations and product delivery. Even if we are able to find replacement suppliers, we will be
required to verify that the new supplier maintains facilities, procedures and operations that comply with our quality expectations and applicable regulatory requirements. Any of these events could require that we obtain regulatory authority approval
before we implement the change, which could result in further delay and which may not be obtained at all. If our third-party suppliers fail to deliver the required commercial quantities of materials on a timely basis and at commercially reasonable
prices, and we are unable to find one or more replacement suppliers capable of production at a substantially equivalent cost in substantially equivalent volumes and quality on a timely basis, the continued commercialization of our ASSURE WCD, the
supply of our products to customers and the development of any future products will be delayed, limited or prevented, which could have material adverse effect on our business, financial condition, results of operations and prospects. Pandemics, such
as the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, other health crises, adverse weather conditions, natural disasters and accidents have in the past and may in the future result in supply chain disruptions that adversely affect our
contract manufacturing partners&#146; ability to provide the supplies we require on a timely basis. Any significant delays or interruption in the supply of components and materials necessary for our products, or our inability to obtain substitute
components or materials from alternate sources at acceptable terms and in a timely manner could impair our ability to meet demand for our products, fulfill our contractual obligations to deliver our products and harm our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If our suppliers&#146; manufacturing facilities become damaged or inoperable, or if they are required
to vacate a facility, they may be unable to manufacture our products or we may experience delays in production or an increase in costs, which could adversely affect our results of operations. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Facilities and equipment of our suppliers could be harmed or rendered inoperable by natural or
<FONT STYLE="white-space:nowrap">man-made</FONT> disasters, including fire, earthquake, terrorism, flooding, cyberattacks, power outages and other infrastructure failures. Any of these may render it difficult or impossible for our suppliers to
manufacture products for some period of time. If our suppliers&#146; manufacturing facilities are inoperable for even a short period of time, the inability to manufacture our ASSURE WCD may result in harm to our reputation and our ability to achieve
profitability. Our research and development facilities are subject to similar risks, and inability to access such facilities may result in interruptions to our research and development efforts for other products we are developing. Additionally, it
may be costly and time-consuming to repair or replace our facilities and the equipment we use to conduct our research and development activities and manufacture our products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Performance issues, service interruptions or price increases by our shipping carriers could adversely affect our business and harm our reputation and
ability to provide our services on a timely basis. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Expedited, reliable shipping is essential to our operations. We rely heavily
on providers of transport services for reliable and secure <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-to-point</FONT></FONT> transport of our ASSURE WCD to our customers and for tracking of these shipments. In
particular, this is because we employ a lease model whereby at the end of a prescription, each patient ships our ASSURE WCD back to our third-party manufacturing partner, who then reconditions the ASSURE WCD before it is redistributed to the next
patient. Delays in the transport of our ASSURE WCDs to and from our suppliers could cause shortages in our inventory of ASSURE WCDs and adversely affect our ability to respond to customer demands. Should a carrier encounter delivery performance
issues such as loss, damage or destruction of any ASSURE WCDs or components thereof, it would be costly to replace such systems or components in a timely manner and such occurrences may damage our reputation and lead to decreased demand for our
products and increased cost and expense to our business. In addition, any significant increase in shipping rates could adversely affect our operating margins and results of operations. Similarly, strikes, severe weather, natural disasters or other
service interruptions affecting delivery services we use would adversely affect our ability to process orders for our products on a timely basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to support demand for our current or future products or services, our business could suffer. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As we continue to commercialize our products and demand for our ASSURE WCD and associated products and services delivered as part of our
Cardiac Recovery System platform or any future products or services increases, we will need to continue to expand our customer service, billing and systems processes and enhance our internal quality assurance program. Additionally, we will need to
ensure that our third-party suppliers and service providers, including the third-party suppliers we rely on to manufacture and recondition our ASSURE WCDs, are able to provide adequate supplies and services to support increasing demand for our
products. We cannot assure you that any increases in scale, related improvements and quality assurance will be successfully implemented or that appropriate personnel will be available to facilitate growth of our business. Failure to implement
necessary procedures, transition to new processes or hire the necessary personnel could result in higher costs of processing data or inability to meet increased demand. There can be no assurance that we will be able to analyze data regarding
patients&#146; clinically relevant health events on a timely basis at a level consistent with demand, quality standards and healthcare provider expectations. If we encounter difficulty meeting market demand, quality standards or healthcare provider
expectations, our reputation could be harmed and our prospects and business could suffer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to successfully expand our sales and customer service resources, including hiring and
retaining relevant personnel, and adequately address our customers&#146; needs, it could negatively impact our profitability and market acceptance of our ASSURE WCD and other products we may develop in the future. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our commercial team is comprised of approximately 70 direct sales representatives as well as more than 40 sales and clinical support
professionals. Once a healthcare provider prescribes our ASSURE WCD to a patient, our direct sales team is supported by a contracted team of over 250 APSs who assist patients with fitting and training. As we continue to commercialize our products,
we will need to grow and optimize the size and geographic scope of our sales and marketing capabilities, as well as our network of APSs, in order to develop broad brand awareness and increase market penetration. There is significant competition for
qualified and experienced sales force personnel, as well as healthcare personnel who are able to assist with <FONT STYLE="white-space:nowrap">WCD-related</FONT> training and patient fittings. Identifying and recruiting qualified personnel and
training them in the application of our solutions, on relevant federal and state laws and regulations and on our internal policies and procedures require significant time, expense and attention. New hires require training and take time to achieve
full productivity. If we fail to train new hires adequately, or if we experience high turnover in our sales force or network of APSs in the future, new hires may not become as productive as may be necessary to maintain or increase our sales. Upon
completion of the training, our direct sales force personnel will require lead time in the markets in which they operate to grow their network of accounts and achieve the productivity levels we expect them to attain. Newly-contracted APSs may also
require lead time before they are able to complete patient fittings at the levels of quality and efficiency we expect them to attain. In addition, in order to attract and maintain qualified personnel, we will need to offer competitive compensation
and benefits packages to current and prospective employees. Our business may be harmed if our efforts to expand and train our sales force and grow our network of APSs do not generate a corresponding increase in revenue. In particular, we have in the
past and expect in the future to enter into compensation arrangements with our commercial team that may include minimum guaranteed commissions, which may increase our compensation costs without a commensurate increase in revenue if our sales
personnel do not operate as efficiently as expected. In particular, if we are unable to attract, hire, develop and retain talented sales personnel and APSs or if new sales personnel or APSs are unable to achieve desired productivity levels in a
reasonable period of time, we may not be able to realize the expected benefits of this investment or increase our revenue. Moreover, to the extent we would consider hiring sales or marketing personnel from our competitors, we may be required to wait
until applicable <FONT STYLE="white-space:nowrap">non-competition</FONT> provisions have expired before deploying such personnel in restricted territories or incur costs to relocate personnel outside of such territories. We also may partner with
technology, commercial and clinical partners to market and distribute our products and grow our brand. We have executed one distribution agreement with a DME supplier in order to facilitate billing and collections related to the distribution of our
ASSURE WCD. We may also consider entering into other arrangements with third parties to perform certain sales, marketing, patient support and distribution services. There is no assurance of whether we will be successful in entering into arrangements
with third parties to sell and market our ASSURE WCD or any future product candidates on terms that are favorable to us, if at all. We may have little control over such third parties, and any of them may fail to devote the necessary resources and
attention to sell and market our ASSURE WCD or any future product candidates effectively. If we do not establish sales and marketing capabilities successfully, either on our own or in collaboration with third parties, in a cost-effective manner, we
may not be able to maintain or grow sales of our ASSURE WCD or commercialize any future product candidates and our revenue may be materially adversely affected. In addition, since we have a limited history as a direct sales organization, we may not
be as effective or efficient in utilizing our sales personnel as other companies with longer histories utilizing a direct sales organization. As a result, we may be required to restructure our sales organization to utilize our sales personnel more
effectively and efficiently, which would be costly, may divert attention from management, and lead to both planned and unplanned turnover. If we are unable to expand our sales and marketing capabilities and our product-related educational
initiatives domestically and internationally, we may be unable to effectively commercialize our products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, our future
revenues will also be impacted by our ability to provide high-quality customer service to address our customers&#146; needs. We may be unable to attract and retain sufficient personnel to maintain </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
an effective customer service force and adequately train our personnel to ensure consistently high-quality customer service. If we are unable to adequately address our customers&#146; needs, it
could negatively impact revenues generated by and market acceptance of our ASSURE WCD and other products we may develop in the future, and we may not generate sufficient revenue to achieve or sustain profitability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If the ASSURE WCD is not effective or if we or our competitors receive negative publicity about the effectiveness of WCDs, then our brand and reputation
could suffer and our business could be adversely impacted. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the course of conducting our business, we must adequately address
quality issues that may arise with our products, as well as defects in third-party components included in our products. We employ a rigorous manufacturing and supplier partner assessment, qualification, and selection process to target partners that
meet the requirements of the FDA and the International Organization for Standardization, as well as quality standards supported by internal policies and procedures. While our quality assurance program monitors and maintains manufacturing and
supplier partner performance through qualification and periodic reviews and audits, we may be unable to eliminate or mitigate quality control issues and associated liabilities. Lasting harm to our brand may be caused by actual or perceived quality
issues even if we are able to subsequently address such issues. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Additionally, if our products or similar products offered by our
competitors are involved in an instance of patient harm, even if it is through misuse of such products, it could result in decreased demand for our products and damage to our reputation. For example, our competitor has been subject to negative
publicity from the media and medical journals relating to false alarms and inappropriate shocks delivered by their WCDs. Reports of device failures or other instances of patient harm relating to our products or similar products offered by our
competitor could negatively impact demand and adoption rates for our ASSURE WCD or WCDs more generally, which could adversely affect our results of operations. This adverse impact may occur whether or not we are directly related to, or otherwise
control, such events and even the mere perception of our involvement could dilute, tarnish or otherwise adversely affect our reputation and brand. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The rising popularity of social media and other consumer-oriented technologies has increased the speed and accessibility of information
dissemination and given users the ability to organize collective actions more effectively, such as boycotts and other brand-damaging events. Many, if not all, social media platforms immediately publish their participants&#146; posts, often without
filters or checks on the accuracy of the content posted. Any failure to respond quickly and effectively to negative or potentially damaging social media content about our products or our affiliates, regardless of the content&#146;s accuracy, could
damage our reputation, which in turn could harm our business, prospects, financial condition and results of operations. The harm may be immediate without affording us an opportunity for redress or correction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Billing for our products is complex, and we must dedicate substantial time and resources to the billing process. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Billing for medical devices and durable medical equipment is complex, time consuming and expensive. In connection with the distribution of our
ASSURE WCD, we currently bill, and expect to continue to bill, several types of payors, including Medicare, Medicaid, private payors and other healthcare-related organizations, each of whom have different billing requirements, procedures and
expectations. We are also required to bill patients for <FONT STYLE="white-space:nowrap">co-insurance</FONT> payments and deductibles. As our business expands and we distribute our products into new markets, we may need to obtain new reimbursement
codes, adapt our billing processes to more payors and invest additional resources into our billing infrastructure to ensure that claims are timely and accurately prepared and submitted according to the individual requirements of each payor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Healthcare providers in the U.S. generally rely on third-party payors, principally Medicare, Medicaid and private payors, to cover and
reimburse all or part of the cost of our ASSURE WCD. The revenue we can generate from the lease of our ASSURE WCD depends in large part on the availability of reimbursement from such payors. These payors may deny reimbursement if they determine that
our ASSURE WCD was not medically necessary for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the patient or was not used in accordance with the payor&#146;s coverage policy. A significant component of our operational efforts includes working with private payors to ensure positive
coverage decisions for our product and investing in our revenue cycle management infrastructure to collect cash from payors. Additionally, we are reimbursed for the use of our ASSURE WCD based on patient wear time and are therefore dependent, to an
extent, on patients complying with their prescriptions and wearing our ASSURE WCD for the time periods prescribed by their healthcare providers. Lack of patient compliance with prescribed wear times may also result in healthcare providers becoming
less likely to prescribe our ASSURE WCDs at the same volumes we have experienced in the past, or at all, which would adversely impact our revenues and the growth of our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Additionally, as part of our collection efforts, we may face potential write-offs of doubtful accounts and long collection cycles, which could
in turn adversely affect our profitability and financial condition. Factors that may render our billing and collection processes more uncertain or costly include: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">differences between the submitted price for our products and the reimbursement rates of payors;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compliance with applicable federal and state regulations related to billing government healthcare programs;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">differences in coverage among payors and the effect of patient
<FONT STYLE="white-space:nowrap">co-payments,</FONT> <FONT STYLE="white-space:nowrap">co-insurance</FONT> and deductibles; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">incorrect or missing patient history, indications or billing information. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Further, our billing activities require us to implement compliance procedures and oversee, train and monitor our employees and undertake
internal review procedures to evaluate compliance with applicable laws, regulations and internal policies. We have made significant investments in our revenue cycle management processes and have partnered with a third-party DME supplier to perform
certain billing and collection services. However, as our business continues to grow, we may face increasing billing complexities, and the potential uncertainties in obtaining payments for our products, could negatively affect our revenue and cash
flow, our ability to achieve profitability, and the consistency and comparability of our results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Federal and state
governments have contracted with private entities to audit and recover revenue resulting from payments made in excess of those permitted by government healthcare program rules. These entities include, but are not limited to, Recovery Audit
Contractors that are responsible for auditing Medicare claims, Unified Program Integrity Contractors that are responsible for the identification of suspected fraud through medical record review and Medicaid Integrity Contractors, that are
responsible for auditing Medicaid claims. We believe audits, inquiries, and investigations from these contractors and others will occur from time to time in the ordinary course of our business. We also may be subject to increased audits from
commercial payors. Our efforts to be responsive to these audits, inquiries, and investigations may result in substantial costs and divert management&#146;s time and attention away from the operation of our business. Moreover, an adverse outcome with
respect to any audit, inquiry or investigation may result in damage to our reputation, or in fines, penalties or other sanctions imposed on us. Such pending or future audits, inquiries, or investigations, or the public disclosure of such matters,
could have a material adverse effect on our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In many instances, there
are only limited publicly-available guidelines and methodologies for determining errors with certain payor audits. As a result, there can be a significant lack of clarity regarding required documentation and audit methodology. The clarity and
completeness of each patient medical file, some of which is the work product of healthcare providers not employed by us, is essential to successfully challenging any payment denials. For example, certain provisions under CMS guidance manuals, local
coverage determinations, and the Durable Medical Equipment Medicare Administrative Contractor (&#147;DME MAC&#148;) Supplier Manuals provide that clinical information from the &#147;patient&#146;s medical record&#148; is required to justify the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
initial and ongoing medical necessity for the provision of DMEPOS. Some DME MACs, CMS staff and other government contractors have taken the position, that the &#147;patient&#146;s medical
record&#148; refers not to documentation maintained by the DMEPOS supplier but instead to documentation maintained by the patient&#146;s healthcare providers and hospitals, and that clinical information created by the DMEPOS supplier&#146;s
personnel and confirmed by the patient&#146;s healthcare provider is not sufficient to establish medical necessity. If treating healthcare providers do not adequately document, among other things, their diagnoses and plans of care, the risks that
the Company will be subject to audits and payment denials are likely to increase. Moreover, auditors&#146; interpretations of these policies are inconsistent and subject to individual interpretation, leading to significant increases in individual
supplier and industry-wide perceived error rates. High error rates could lead to further audit activity and regulatory burdens, and could result in our making significant refunds and other payments to Medicare and other government programs.
Accordingly, our future revenue and cash flows from government healthcare programs may be reduced. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Commercial payors also may conduct
audits and may take legal action to recover alleged overpayments. We could be adversely affected in some of the markets in which we operate if the auditing payor alleges substantial overpayments were made to us due to coding errors or lack of
documentation to support medical necessity determinations. We cannot currently predict the adverse impact these measures might have on our financial condition and results of operations, but such impact could be material. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If our competitors are able to develop or market products and services that are more effective, or gain greater acceptance in the marketplace, than any
products and services we develop, our commercial opportunities will be reduced or eliminated. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We operate in a competitive
business environment that is evolving. Historically, the WCD market has been served by a single incumbent commercial product, the LifeVest WCD, marketed by ZOLL Medical Corporation (&#147;ZOLL&#148;), our primary competitor. As we continue to scale
our business, ZOLL may take competitive actions against us, including competitive pricing actions and litigation challenges, such as intellectual property challenges. In the future, we may also face competition from new market entrants. For example,
we are aware of one privately-held potential new entrant which is developing an adhesive-based external defibrillator that has yet to receive FDA approval. The development of new or more effective drug candidates could also negatively impact the
adoption and average wear time of our WCD system. Healthcare providers who are accustomed to using the products of our primary competitor may be reluctant to try new products from a source with which they are less familiar. Larger medical device
companies may also acquire, invest in or form alliances with smaller companies to diversify their product offerings and enhance their competitive position in the competitive business environment, including the WCD industry and industries for other
related products and services. Other potential competitors are publicly traded, or are divisions of publicly traded, major medical device or technology companies that enjoy significant competitive advantages and may be able to deploy larger or more
effective sales and marketing resources than we currently have. We may also face challenges in overcoming the long-standing preferences of healthcare providers for using the products of larger, more established companies. Competition with these
companies could result in price-cutting, reduced profit margins and loss of market share, any of which would harm our business, financial condition, results of operations and prospects. Our competitors may also enjoy other competitive advantages
such as: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">greater financial and other resources than us which enable them to market and discount their products more
effectively than us; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">large and established sales, marketing and worldwide distribution channels that have greater reach in both
domestic and international markets; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">greater brand recognition in the medical community; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">established business and financial relationships with a more expansive network of healthcare providers, hospitals
and medical schools; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">greater collaborations with key opinion leaders, medical societies and clinical advisory boards;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">greater market share in the cardiac monitoring products market; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">greater resources devoted to research and development of competing products and greater capacity to allocate
additional resources; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">greater experience in obtaining and maintaining regulatory clearances and approvals for new products and product
enhancements and commercializing new products; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">larger patent portfolios and other intellectual property rights. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Medical innovation is accelerating and the market for WCD products and services is becoming increasingly competitive. Our planned innovation
pipeline includes apparel, hardware, software and service solutions to remotely and securely monitor and manage patients in an ambulatory care environment. We compete with a variety of companies offering alternative products and services for
ambulatory cardiac solutions. Our ability to compete effectively depends on our ability to distinguish our company and our products from our competitors and their products, and includes such factors as: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product safety and effectiveness; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">detection algorithm sensitivity, specificity and false alarm rate; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patient physical and psychological comfort and ease of use; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patient compliance; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ability to integrate within the patient monitoring ecosystem; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">quality, breadth and ongoing generation of clinical evidence; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">technological innovation, product enhancements and speed of innovation; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">capital required to achieve PMA approval as well as to facilitate post-commercial initial inventory; and
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory status and speed to market. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Additionally, our ability to commercially compete in the WCD market will be impacted by factors such as: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patient and healthcare provider connectivity and engagement; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">post-event monitoring and emergency support; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">effective marketing to and education of patients, physicians, other healthcare providers and hospitals;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">company, product and brand recognition; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">device reusability and durability; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reimbursement and payor coverage; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">complexity in building up the remote cardiac monitoring (&#147;RCM&#148;) capabilities and logistics to support
broad-based commercialization and service levels; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recruitment and retention of a qualified and experienced sales force. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If our competitors and potential competitors are better able to develop WCDs and related products than us or introduce more effective, more
comfortable or less expensive WCDs and related products before we are able to introduce and commercialize our products, the products and services we offer may be rendered obsolete or <FONT STYLE="white-space:nowrap">non-competitive.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our marketing and sales practices, as well as our interactions with healthcare providers, may entail risks that could result in significant liability,
require us to change our business practices and restrict our operations in the future. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are subject to numerous domestic
(federal, state and local) and foreign laws addressing fraud and abuse in the healthcare industry, including the federal False Claims Act, the Federal Anti-Kickback Statute, self-referral laws, the Foreign Corrupt Practices Act, the U.K. Bribery
Act, FDA promotional restrictions, the federal Physician Payment Sunshine Act and state marketing and disclosure laws. Violations of these laws are punishable by criminal or civil sanctions, including substantial fines, imprisonment of responsible
corporate officers, and exclusion from participation in government healthcare programs such as Medicare and Medicaid as well as health programs outside the U.S., and even alleged violations can result in the imposition of corporate integrity
agreements or deferred prosecution agreements that could severely restrict or limit our business practices. These laws and regulations are complex and subject to changing interpretation and application, which could restrict our sales or marketing
practices. Even minor and inadvertent irregularities could potentially give rise to a charge that the law has been violated. Although we believe we have implemented and will maintain an appropriate healthcare compliance program we cannot be certain
that the program will adequately detect or prevent violations and/or the relevant regulatory authorities may disagree with our interpretation. Additionally, if there is a change in law, regulation or administrative or judicial interpretations, we
may have to change one or more of our business practices to be in compliance with these laws. Required changes could be costly and time consuming. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If our business practices or operations are found to be in violation of these laws or any other government regulations that apply to us, we
may be subject to penalties, including, without limitation, civil and criminal penalties, damages, fines, imprisonment of responsible corporate officers, the curtailment or restructuring of our operations, or exclusion from government healthcare
programs including Medicare and Medicaid, any of which could have a material adverse effect on our business, results of operations, financial condition and cash flows. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our ability to compete depends on our ability to innovate successfully. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The market for medical devices, including the WCD market, is marked by technological development and product innovation. Demand for our ASSURE
WCD and associated products and services delivered as part of our Cardiac Recovery System platform, or other products and services that we are developing or may develop in the future could be diminished by equivalent or superior products and
technologies offered by our competitors. If we are unable to innovate successfully, our products and services could become obsolete, and as a result, we may not be able to achieve profitability as customers purchase our competitors&#146; products
and services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In order to remain competitive, we must continue to enhance our existing products and services and develop new product
offerings. We will need to ensure that our Cardiac Recovery System platform and other products we develop in the future can support extensions and enhancements in response to evolving patient needs. We can provide no assurance that we will be
successful in monetizing our medical technologies, including our ASSURE WCD, developing new products or commercializing them in ways that achieve broad market acceptance. In addition, if we develop new products, the distribution of those products
may reduce revenue </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
generated from our existing products. Maintaining adequate research and development personnel and resources to meet the demands of the market is essential. If we are unable to develop new
products, applications or features or improve our algorithms due to constraints, such as insufficient cash resources, high employee turnover, inability to hire personnel with sufficient technical skills or a lack of other research and development
resources, we may not be able to maintain our competitive position compared to other companies. Furthermore, our competitors may devote a considerably greater amount of funds to their research and development programs than we do, and those that do
not may be acquired by larger companies that would allocate greater resources to research and development programs. Our failure or inability to devote adequate research and development resources or compete effectively with the research and
development programs of our competitors could harm our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Due to the significant resources required for the development of our products, we
may expend our limited resources to pursue the development and commercialization of select products and fail to capitalize on other products that may be more profitable or for which there is a greater likelihood of success. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The initial focus of our Cardiac Recovery System platform is to serve high-acuity patients who require both continuous monitoring and therapy.
We fully commercially launched our ASSURE WCD, the cornerstone of our Cardiac Recovery System platform, in August 2022 and have introduced various updates and complementary technologies and services related to our Cardiac Recovery System platform
since then. We also recently launched our ASSURE wearable ECG as part of our efforts to expand into providing monitoring and connectivity solutions to patients who longer indicated for a WCD but who still require ongoing support. As of the date of
this prospectus, we are also in various stages of research and development for other potential solutions and new indications for our technology. We seek to maintain a process of prioritization and resource allocation among our various research and
development efforts to maintain a balance between advancing our ASSURE WCD and developing other current and any future cardiovascular solutions. Our decisions concerning the allocation of research, development, collaboration, management and
financial resources toward particular products or therapeutic areas may not maximize our ability to generate potential profits, may not lead to the development of any viable commercial product and may divert resources away from other products and
solutions tailored to other therapeutic areas that later prove to have greater commercial potential or a greater likelihood of success. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable
market opportunities. If we do not accurately evaluate the commercial potential or target market for a particular product, we may relinquish valuable rights to that product through future collaboration, licensing or other royalty arrangements in
cases in which it would have been more advantageous for us to retain sole development and commercialization rights. In addition, if we make incorrect determinations regarding the viability or market potential of any of our products and solutions or
misread trends in cardiovascular care and the wearable healthcare technology industry, our business, financial condition, results of operations and prospects could be materially and adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our outstanding debt may affect our ability to operate our business and secure additional financing in the future. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of October 31, 2024, we had an aggregate principal amount of $45.0&nbsp;million outstanding under the Credit Agreement and Guaranty, dated
as of September&nbsp;29, 2023 (as amended from time to time, the &#147;Term Loan&#148;), among Perceptive Credit Holdings IV, LP, as administrative agent and as a lender, the other lenders party thereto, West Affum Holdings and Kestra Medical
Technologies, Inc., as borrowers, and the guarantors party thereto. We must make significant quarterly interest payments under the loan agreement, which will divert resources from other activities. Our outstanding debt under the Term Loan is
collateralized by substantially all of our assets and contains customary financial and operating covenants limiting our ability to, among other things, dispose of assets, undergo a change in control, merge or consolidate, enter into certain
transactions with affiliates, make acquisitions, incur debt, incur liens, pay dividends, repurchase stock and make investments, in each case subject to certain exceptions. The covenants in the Term Loan, as well as in any future financing agreements
into which we may enter, may restrict our ability to finance our operations and engage in, expand or otherwise pursue our business activities and strategies. The Term Loan also contains a minimum liquidity
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
covenant, and a minimum revenue covenant which increases on a quarterly basis through maturity of the Term Loan. Additionally, there are certain non-financial covenants. See &#147;Description of
Certain Indebtedness&#148; and Note&nbsp;7, &#147;<I>Long Term Debt</I>&#148; to the consolidated financial statements included elsewhere in this prospectus. Our ability to comply with these covenants may be affected by a number of events, some of
which may be beyond our control and future breaches of any of these covenants could result in a default under the loan agreement. If not waived, future defaults could cause all of the outstanding indebtedness under the loan agreement to become
immediately due and payable and terminate commitments to extend further credit. If we do not have or are unable to generate sufficient cash available to repay our debt obligations when they become due and payable, either upon maturity or in the
event of a default, we may not be able to obtain additional debt or equity financing on favorable terms, if at all, which may negatively impact our ability to operate and continue our business. See the section titled &#147;Description of Certain
Indebtedness&#148; for more information on the Term Loan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We may be able to incur significant additional indebtedness in the future.
Although the Term Loan limits our ability and the ability of our present and future subsidiaries to incur additional indebtedness, the terms of the Term Loan permit us to incur significant additional indebtedness. In addition, the Term Loan does not
prohibit us from incurring obligations that do not constitute indebtedness as defined therein. To the extent that we incur additional indebtedness or such other obligations, the risk associated with our substantial indebtedness described above,
including our potential inability to service our debt, will increase. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If there were an event of default under the Term Loan relating to
our outstanding indebtedness, the holders of the defaulted debt could cause all amounts outstanding with respect to that debt to be due and payable immediately. We cannot guarantee that our assets or cash flow would be sufficient to fully repay
borrowings under our outstanding debt instruments if accelerated upon an event of default. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Further, if we are unable to repay, refinance
or restructure our indebtedness under our secured debt, the holders of such debt could proceed against the collateral securing that indebtedness. In addition, any event of default or declaration of acceleration under one debt instrument could also
result in an event of default under one or more of our other debt instruments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As a result, any default by us on our indebtedness could
have a material adverse effect on our business, results of operations and financial condition.<B> </B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We depend on our senior management team and
the loss of one or more key employees or an inability to attract and retain highly skilled employees could harm our business. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our
success depends largely on the continued services of key members of our executive management team and others in key management positions, as well as our ability to attract, motivate, develop and retain a sufficient number of other highly skilled
personnel. Our senior management team has extensive experience in the medical device industry, and we believe that the depth of their experience is instrumental to our continued success. For example, the services and expertise provided by Brian
Webster, our President and Chief Executive Officer, are critical to our overall management, as well as the continued development of our solutions, our culture, our strategic direction, our innovation and our operations. Our employees may terminate
their employment with us at any time. If we lose one or more key employees, we may experience difficulties in competing effectively, developing our technologies and implementing our business strategy. We do not currently maintain key person life
insurance policies on these or any of our employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, our research and development programs depend on our ability to attract
and retain highly skilled engineers. We may not be able to attract or retain qualified engineers in the future due to the competition for qualified personnel. We have from time to time experienced, and we expect to continue to experience, difficulty
in hiring and retaining employees with appropriate qualifications. Many of the companies with which we compete for experienced personnel have greater resources than us. If we hire employees from competitors or other companies, their former employers
may attempt to assert that these employees or we have breached legal </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
obligations, resulting in a diversion of our time and resources and, potentially, damages. In addition, job candidates and existing employees often consider the value of the share awards they
receive in connection with their employment. If the perceived value of our share awards declines, either because we are a public company or otherwise, it may harm our ability to recruit and retain highly skilled employees. Additionally, maintaining
a positive company culture is necessary to enable us to retain and hire key talent and have a cohesive, aligned employee base. Our ability to maintain this culture will directly affect the continued growth and success of our company. Our culture
could face sustainability challenges as we continue to grow and scale our business. Potential obstacles include reduced adoption of our culture by new employees, limited ability to maintain consistency of culture within business teams, and failure
to attract and retain leaders who support our culture and business plans. If we fail to attract new personnel or fail to retain and motivate our current personnel, our business, financial condition, results of operations and prospects could be
materially adversely affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Security breaches, loss of data, unauthorized uses or disclosures, and other disruptions involving our systems,
products or data could compromise sensitive information related to our business or patients, result in operational disruption, or prevent us from accessing critical information, exposing us to liability, and adversely affecting our business,
financial condition, results of operation and prospects. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the ordinary course of our business, we, and certain of our vendors
on our behalf, collect, transfer, process and store sensitive data, including legally-protected personally identifiable health information about patients. We also collect, transfer, process and store, and use additional third parties to collect,
transfer, process and store on our behalf, sensitive confidential information, including intellectual property, other proprietary business information, and preclinical and clinical trial data, including that of our customers, payors and
collaborative partners. We employ administrative, technical and physical controls to secure personally identifiable health information, and we maintain our applications and data utilizing a combination of public cloud platforms and <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">software-as-a-service</FONT></FONT></FONT> providers.&nbsp;These applications and data encompass a wide variety of critical information, including patient
data collected and processed through the digital solutions and services offered as part of our Cardiac Recovery System platform, clinical evidence collected through our ASSURE Patient Registry, other research and development information, commercial
information and business and financial information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are highly dependent on information technology networks and systems, including the
internet, to securely process, transmit and store this critical information to ensure the effective operation of our business and the timely delivery of our solutions and services. For example, we rely on information technology networks to ensure
that our digital solutions, such as our Heart Alert Services and ASSURE Assist services, are able to deliver timely critical alerts to healthcare providers and notify emergency services when therapy is administered to patients. Our third-party
information technology systems may not remain available on terms acceptable to us and may require replacement, which could result in substantial operational expense, diversion of our resources, and reduced efficiency, any of which could result in
any a material adverse effect on our business, financial condition, results of operations and prospects. Security breaches of our information technology infrastructure, including physical or electronic
<FONT STYLE="white-space:nowrap">break-ins,</FONT> computer viruses, attacks by hackers and similar breaches, can create system disruptions, shutdowns or unauthorized disclosure, access, use or modifications of confidential information, including
patient information and trade secrets. The secure collection, use, processing, storage, maintenance, protection and transmission of this critical information are vital to our operations and business strategy, and we devote significant resources to
protecting such information. Data security-related incidents and fraudulent activity are increasing in frequency, sophistication, and variety, and can originate from many sources, including third-party suppliers and nation-state actors. Our
information technology and infrastructure, and those of our vendors, has been and will continue to be vulnerable to attacks by hackers or viruses or breaches due to employee error, malfeasance or other disruptions. While we have taken steps to
identify critical and high-risk vulnerabilities to and protect our infrastructure and sensitive information from unauthorized access, disclosure, or other activity, and while we have implemented compliance measures along those lines, we continue to
develop our policies and procedures for protecting such information, and there can be no assurance that these will prevent, detect, or mitigate such issues given the unpredictability of the timing, nature, and scope of data
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
security-related incidents and fraudulent activity. Furthermore, some confidential and protected health information is transmitted to us by third parties, who may not implement adequate security
and privacy measures. Our third-party vendors and other business partners may also experience breaches to their information technology systems that could lead to disruptions to our business and ability to deliver our solutions and services. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As part of the delivery of our digital solutions and services through our Cardiac Recovery System platform, we collect, process and analyze a
substantial amount of patient data, including through our ASSURE Patient Registry. A security breach or privacy violation that results in a business interruption or leads to disclosure or modification of, or prevents or interferes with access to,
patient information, including protected health information, could harm our reputation, compel us to comply with disparate U.S. state and other international breach notification laws, require us to verify the correctness of database contents and
otherwise subject us to liability under laws that protect personal data, resulting in increased costs or loss of revenue. If we are unable to prevent such security breaches or privacy violations or implement satisfactory remedial measures, our
operations could be disrupted and we may suffer loss of reputation, financial loss and other regulatory penalties because of lost or misappropriated information, including sensitive patient data. The loss of patient data and other information
critical to our solutions and services as a result of data breaches could also impair our ability to grow our clinical evidence to support the continued development of our products. In addition, these breaches and other inappropriate access can be
difficult to detect, and any delay in identifying them may lead to increased harm. We do not currently maintain cyber insurance, which could help to mitigate certain losses related to security events that may occur, and we have no assurance that we
will be able to obtain such coverage in the future. Therefore, any breach or cyber incident may expose us to certain potential losses, damages or penalization with fines in an amount exceeding our resources. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Any such breach or interruption of our systems, or those of any of our third-party information technology partners, could compromise our
networks or data security processes and sensitive information could be inaccessible or could be accessed by unauthorized parties, publicly disclosed, lost or stolen. Any such interruption in access, improper access, disclosure or other loss of
information could result in legal claims or proceedings (such as class actions), liability under laws that protect the privacy of patient information, such as the federal Health Insurance Portability and Accountability Act of 1996
(&#147;HIPAA&#148;) and regulatory penalties (such as state data breach laws). Unauthorized access, loss or dissemination could also disrupt our operations, including our ability to perform our services, bill payors or patients, process claims and
appeals, provide customer assistance services, conduct research and development activities, collect, process and prepare company financial information, provide information about our current and future solutions and engage in other patient and
healthcare provider education and outreach efforts. Any such breach could also result in the compromise of our trade secrets and other proprietary information, which could adversely affect our business and competitive position. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, the individually identifiable health information we collect, receive, store, access, transfer, process and use from patients and
covered entity healthcare providers may be subject to limitations on use and disclosure, and may require us to obtain HIPAA-compliant authorizations or other consents from patients for such uses and disclosures, including use of patient information
in connection with the ASSURE Patient Registry. To the extent we fail to collect necessary authorizations or consents to use or disclose such information, or to the extent our uses or disclosures of such information violate applicable laws that
protect the privacy of patient information, including HIPAA, we may be subject to liability, legal claims or proceedings (such as class actions), fines, or penalties pursuant to such laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our existing general liability and cybersecurity liability insurance policies may not cover, or may cover only a portion of, any potential
claims related to security breaches to which we are exposed or may not be adequate to indemnify us for all or any portion of liabilities that may be imposed. We also cannot be certain that our existing insurance coverage will continue to be
available on acceptable terms or in amounts sufficient to cover the potentially significant losses that may result from a security incident or breach or that the insurer will not deny coverage of any future claim. Accordingly, if our cybersecurity
measures, and those of our customers </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and service providers, fail to protect against unauthorized access, attacks (which may include sophisticated cyberattacks), and the mishandling of data, then our reputation, business, financial
condition, results of operations and prospects could be materially and adversely affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are subject to complex and rapidly evolving laws,
regulations, rules, and standards relating to data privacy and security, and our failure to comply with such laws, regulations, rules and standards could adversely affect our business, financial condition, results of operations and prospects.
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Numerous federal and state laws, including state security breach notification laws, state health information privacy laws and
federal and state consumer protection laws, as well as HIPAA, govern the collection, use and disclosure of personal information. For example, the California Consumer Privacy Act of 2018, as amended (&#147;CCPA&#148;), went into operation on
January&nbsp;1, 2020 and broadly defines personal information, affords California residents expanded privacy rights and protections and provides for civil penalties for violations and a private right of action related to certain data security
breaches. These protections were expanded by the California Privacy Rights Act (&#147;CPRA&#148;), which was approved by California voters in November 2020 and became operational in most key respects on January&nbsp;1, 2023. In addition, the My
Health My Data Act of 2023 (&#147;MHMD&#148;) went into effect in Washington state on April 27, 2023 and protects personal health data that falls outside the ambit of HIPAA. Several states have enacted similar types of privacy laws and there are
similar legislative proposals being advanced in other states, as well as in Congress. Our business is also subject to the Bermuda Personal Information Protection 2016 Act, and other international laws, such as the General Data Protection Regulation,
which could also apply to our operations as we expand internationally. Failure to provide adequate privacy protections and maintain compliance with applicable privacy laws could result in significant penalties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The interpretation and application of data protection laws, rules and regulations in the United States and elsewhere are often uncertain,
contradictory and in flux, with new laws passing or entering into force on a regular basis. It is possible that these laws, rules and regulations may be interpreted and applied in a manner that is inconsistent with our practices or those of our
distributors and partners. If we or these third parties are found to have violated such laws, rules or regulations, it could result in government-imposed fines, orders requiring that we or these third parties change our or their practices, or
criminal charges, which could adversely affect our business. Complying with these various laws could cause us to incur substantial costs or require us to change our business practices, systems and compliance procedures in a manner adverse to our
business. In addition, certain of these laws, such as the CCPA, may provide for a private right of action with respect to certain data breaches. This private right of action may increase the likelihood of, or the risks arising from, data breach
litigation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to fines, penalties, or injunctions if we are determined to be promoting the use of our products for unapproved or <FONT
STYLE="white-space:nowrap">&#147;off-label&#148;</FONT> uses, resulting in damage to our reputation and our business. Further, the use, misuse or <FONT STYLE="white-space:nowrap">off-label</FONT> use of our products may harm our reputation in the
marketplace, result in injuries that lead to product liability suits or result in costly investigations, fines or sanctions by regulatory bodies if we are deemed to have engaged in the promotion of these uses, any of which could be costly to our
business. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our business exposes us to potential product liability claims that are inherent in the provision of medical devices for
cardiovascular support. Furthermore, if our customers are not sufficiently trained in the use of our products, they may misuse or ineffectively use our products, which may result in unsatisfactory patient outcomes or patient injury. Similarly, if we
are unable to sufficiently train APSs who assist with customer fittings, our ASSURE WCD may be ineffective, or may result in patient discomfort, injury or unsatisfactory patient outcomes. Our ASSURE WCD has been approved by FDA for use in adult
patients who are at risk for SCA and are not candidates for, or refuse, an ICD. However, we cannot prevent a healthcare provider from prescribing our devices <FONT STYLE="white-space:nowrap">off-label</FONT> when they deem it appropriate. The use,
misuse or <FONT STYLE="white-space:nowrap">off-label</FONT> use of our products, including our ASSURE WCD, may in the future result in outcomes and complications potentially leading to product liability claims and harm to our reputation. If our
products are defectively designed, manufactured or labeled, contains defective components or is misused, we may become subject to costly litigation initiated by healthcare providers, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the hospitals and clinics where healthcare providers prescribing our products work or their patients and reputational harm. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If our devices are misused or used with improper technique, we may become subject to costly litigation by our customers or their patients. As
described above, product liability claims could divert management&#146;s attention from our core business, be expensive to defend, and result in sizeable damage awards against us that may not be covered by insurance, all of which would have a
material adverse effect on our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Product liability claims are
especially prevalent in the medical device industry, and regardless of the merit or eventual outcome, may result in: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">decreased demand for our products; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injury to our reputation; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">significant litigation costs; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">substantial monetary awards to or costly settlements with patients; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product recalls; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">material defense costs; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">loss of revenue; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inability to commercialize new products; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">diversion of management attention from pursuing our business strategy. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Although we maintain product liability insurance, we may not have sufficient insurance coverage for future product liability claims. We may
not be able to obtain insurance in amounts or scope sufficient to provide us with adequate coverage against all potential liabilities. Any product liability claims brought against us, with or without merit, could increase our product liability
insurance rates or prevent us from securing continuing coverage, harm our reputation, significantly increase our expenses and reduce our revenues. Product liability claims in excess of our insurance coverage would be paid out of cash reserves,
harming our financial condition and operating results. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If the FDA determines that our promotional materials, sales practices or training
constitute improper promotion of an <FONT STYLE="white-space:nowrap">off-label</FONT> use, they could request that we modify our training, sales practices or promotional materials or subject us to regulatory or enforcement actions, including the
issuance or imposition of an untitled letter, warning letter, injunction, seizure, civil fine or criminal penalties. These types of enforcement actions could have a material adverse impact on our business, revenues and financial results. It is also
possible that other federal or state enforcement authorities might take action under other regulatory authority, such as false claims laws, if they consider our business activities to constitute promotion of an
<FONT STYLE="white-space:nowrap">off-label</FONT> use, which could result in significant penalties, including, but not limited to, criminal, civil and administrative penalties, damages, fines, disgorgement, exclusion from participation in government
healthcare programs and the curtailment of our operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We bear the risk of warranty claims on our products. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We bear the risk of warranty claims on our products. We may not be successful in claiming recovery under any warranty or indemnity provided to
us by our suppliers or vendors in the event of a successful warranty </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
claim against us by a customer or any recovery from such vendor or supplier may not be sufficient to cover our losses. In addition, warranty claims brought by our customers related to third-party
components may arise after our ability to bring corresponding warranty claims against such suppliers expires, which could result in our inability to recover any costs incurred by us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may acquire other companies or technologies, which could divert our management&#146;s attention, result in additional dilution to our shareholders
and otherwise disrupt our operations and harm our operating results. The failure to effectively manage acquisitions, investments, licenses or other strategic alliances, or the failure to integrate them with our existing business, could have a
material adverse effect on our operating results, increase our debt or cause us to incur significant expense. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our success depends
on our ability to continually enhance and broaden our product offerings in response to changing customer demands, competitive pressures, technologies and market pressures. Accordingly, from time to time we may consider opportunities to acquire, make
investments in or <FONT STYLE="white-space:nowrap">in-license</FONT> other technologies, products and businesses that may enhance our capabilities, complement our current products or expand the breadth of our markets or customer base. Potential and
completed acquisitions, strategic investments, licenses and other alliances involve numerous risks, including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">difficulty assimilating or integrating acquired or licensed technologies, products or business operations;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issues maintaining uniform standards, procedures, controls and policies; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unanticipated costs associated with acquisitions or strategic alliances, including the assumption of unknown or
contingent liabilities and the incurrence of debt or future write-offs of intangible assets or goodwill; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unanticipated problems or liabilities with the businesses or products acquired; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">diversion of management&#146;s attention from our core business and disruption of ongoing operations;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adverse effects on existing business relationships with suppliers and customers; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">risks associated with entering new markets in which we have limited or no experience; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential losses related to investments in other companies; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential loss of key employees of acquired businesses; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">increased legal and accounting compliance costs. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The pursuit of potential acquisitions may divert the attention of management and cause us to incur various costs and expenses in identifying,
investigating and pursuing suitable acquisitions, whether or not they are consummated. We may not be able to identify desirable acquisition targets or be successful in entering into an agreement with any particular target or obtain the expected
benefits of any acquisition or investment. To date, the growth of our operations has been largely organic, and we have limited experience in acquiring other businesses or technologies. We may not be able to successfully integrate acquired personnel,
operations and technologies, or effectively manage the combined business following an acquisition. Acquisitions could also result in dilutive issuances of equity securities, the use of our available cash, or the incurrence of debt, which could harm
our operating results. In addition, if an acquired business fails to meet our expectations, our operating results, business and financial condition may suffer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Consolidation among commercial payors could result in payors eliminating coverage or demanding price
concessions, which may affect our ability to offer our products at prices necessary to support our current business strategies. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The commercial payor industry is undergoing significant consolidation. In recent years, a number of health insurers have merged or increased
efforts to consolidate with other commercial payors. Insurers are also increasingly pursuing alignment initiatives with healthcare providers. Consolidation within the health insurance industry may result in insurers having increased negotiating
leverage and competitive advantages, such as greater access to performance and pricing data. Our ability to negotiate prices and favorable terms with health insurers in certain markets could be affected negatively as a result of this consolidation.
When payors combine their operations, the combined company may elect to reimburse our products at the lowest rate paid by any of the participants in the consolidation or use its increased size to negotiate reduced rates. If one of the payors
participating in the consolidation does not provide reimbursement for our products, or provides reimbursement at reduced rates, the combined company may elect not to provide reimbursement for our products, or provide such reimbursement at reduced
rates, which would adversely affect our operating results. In addition, the shift toward value-based payment models could be accelerated if larger insurers, including those engaging in consolidation activities, find these models to be financially
beneficial. There can be no assurance that we will be able to negotiate favorable terms with payors and otherwise respond effectively to the impact of increased consolidation in the payor industry or vertical integration efforts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our management team has limited experience managing a public company. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Most members of our management team have limited experience managing a publicly traded company, interacting with public company investors and
complying with the increasingly complex laws pertaining to public companies. Our management team may not successfully or efficiently manage us as a public company that is subject to significant regulatory oversight and reporting obligations under
the federal securities laws and the continuous scrutiny of securities analysts and investors. These new obligations and constituents require significant attention from our senior management and could divert their attention away from <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">the&nbsp;day-to-day&nbsp;management</FONT></FONT> of our business, which could adversely affect our business, results of operations, financial condition and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have identified material weaknesses in our internal control over financial reporting, and may identify additional material weaknesses. If our
remediation of the material weaknesses is not effective, or we fail to develop and maintain effective internal control over financial reporting, our ability to produce timely and accurate financial statements could be impaired, which could harm our
business and negatively impact the value of our common shares. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Prior to completion of this offering, we have been a private
company with limited accounting personnel to address our internal control over financial reporting. This lack of adequate accounting resources contributed to audit adjustments to our financial statements in the past. In connection with the
preparation of our consolidated financial statements, we identified material weaknesses in our internal control over financial reporting. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial
reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim consolidated financial statements will not be prevented or detected on a timely basis. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We did not design and maintain an effective control environment commensurate with our financial reporting
requirements. Specifically, we lacked a sufficient complement of resources in the accounting, finance and IT functions to appropriately analyze, record and disclose accounting matters timely and accurately. This material weakness contributed to the
following additional material weaknesses. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We did not design and maintain effective controls to ensure the financial statements were properly presented and
classified for certain <FONT STYLE="white-space:nowrap">non-routine</FONT> or complex transactions. Specifically, we did not </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
design and maintain controls to appropriately account for the classification of selling, general and administrative expenses,
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">paid-in-kind</FONT></FONT> interest, restricted cash, right of use lease assets, and the cash flow presentation of leases. This material weakness resulted in immaterial audit
adjustments to the aforementioned accounts, which were recorded in previous years, prior to the issuance of the consolidated financial statements. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We did not design and maintain effective controls to verify personnel would not have the ability to prepare and
post manual journal entries or review account reconciliations without an independent review by someone without the ability to prepare and post manual journal entries. This material weakness did not result in adjustments to the consolidated financial
statements. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Additionally, these material weaknesses could result in a misstatement of substantially all of the
financial statement accounts and disclosures that would result in a material misstatement to our annual or interim consolidated financial statements that would not be prevented or detected. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We did not design and maintain effective controls over IT general controls for information systems that are
relevant to the preparation of our consolidated financial statements. Specifically, we did not design and maintain: (i)&nbsp;program change management controls to ensure that IT program and data changes affecting financial IT applications and
underlying accounting records are identified, tested, authorized and implemented appropriately; (ii)&nbsp;user access controls to ensure appropriate segregation of duties and that adequately restrict user and privileged access to financial
applications, programs, and data to appropriate Company personnel; (iii)&nbsp;computer operations controls to ensure that data backups are authorized and monitored; and (iv)&nbsp;testing and approval controls for program development to ensure that
new software development is aligned with business and IT requirements. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">These IT deficiencies did not result in
adjustments to our consolidated financial statements; however, the deficiencies, when aggregated, could impact maintaining effective segregation of duties, as well as the effectiveness of <FONT STYLE="white-space:nowrap">IT-dependent</FONT> controls
(such as automated controls that address the risk of material misstatement to one or more assertions, along with the IT controls and underlying data that support the effectiveness of system-generated data and reports) that could result in
misstatements potentially impacting all financial statement accounts and disclosures that would not be prevented or detected. Accordingly, we have determined these deficiencies in the aggregate constitute a material weakness. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have begun implementation of a plan to remediate these material weaknesses. These remediation measures are ongoing as of the date of this
prospectus and include: hiring additional personnel, such as financial planning and accounting, compliance, information technology, and other professionals with appropriate levels of knowledge and experience; engaging a third parties to assist with
technical accounting and in designing and implementing controls related to <FONT STYLE="white-space:nowrap">period-end</FONT> financial reporting, segregation of duties and IT general controls; designing and implementing controls to properly present
and classify <FONT STYLE="white-space:nowrap">non-routine</FONT> or complex transactions; and enhancing IT governance processes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We
intend to evaluate current and projected resource needs on a regular basis and hire additional qualified resources as needed. Our ability to maintain qualified and adequate resources to support the Company and our projected growth will be a critical
component of our internal control environment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are working to remediate the material weaknesses as efficiently and effectively as
possible and expect full remediation could go beyond the fiscal year ended April&nbsp;30, 2025. At this time, we cannot provide an estimate of costs expected to be incurred in connection with implementing this remediation plan; however, these
remediation measures will be time consuming, incur significant costs, and place significant demands on our financial and operational resources. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We cannot assure you that the measures we have taken to date, and actions we may take in the
future, will be sufficient to remediate the material weaknesses in our internal control over financial reporting or that they will prevent or avoid potential future material weaknesses. If we are unable to successfully remediate our existing or any
future material weaknesses in our internal control over financial reporting, or identify any additional material weaknesses, the accuracy and timing of our financial reporting may be negatively impacted, we may be unable to maintain compliance with
securities law requirements in addition to applicable stock exchange listing requirements, investors may lose confidence in our financial reporting, and our common share price may decline as a result. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are subject to risks from legal and arbitration proceedings that may prevent us from pursuing our business activities or require us to incur
additional costs in defending against claims or paying damages. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We may become subject to legal disputes and regulatory
proceedings in connection with our business activities involving, among other things, product liability, product defects, intellectual property infringement, employment matters, and/or alleged violations of other applicable laws in various
jurisdictions. We may not be insured against all potential damages that may arise out of any claims to which we may be party in the ordinary course of our business. A negative outcome of these proceedings may prevent us from pursuing certain
activities and/or require us to incur additional costs in order to do so and pay damages. In addition, securities class action litigation has often been instituted against companies following periods of volatility in the market price of a
company&#146;s securities. This type of litigation, if instituted, could result in substantial costs and a diversion of management&#146;s attention and resources, which would harm our business, financial condition, results of operations and
prospects. Additionally, the significant increase in the cost of directors&#146; and officers&#146; liability insurance may cause us to opt for lower overall policy limits or to forgo insurance that we may otherwise rely on to cover significant
defense costs, settlements, and damages awarded to plaintiffs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The outcome of pending or potential future legal and arbitration
proceedings is difficult to predict with certainty. In the event of a negative outcome of any material legal or arbitration proceeding, whether based on a judgment or a settlement agreement, we could be obligated to make substantial payments, which
could have a material adverse effect on our business, financial condition, results of operations and prospects. In addition, the costs related to litigation and arbitration proceedings may be significant, and any legal or arbitration proceedings
could have a material adverse effect on our business, financial condition, results of operations and prospects, even if ultimately resolved in our favor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The estimates of our market and forecasts of market growth included in this prospectus are based on a number of complex assumptions and estimates that
may prove to be inaccurate, and even if the markets in which we compete achieve the forecasted growth, our business may not increase at similar rates, if at all. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The estimates and forecasts in this prospectus relating to, among other things, our total addressable market, our near-term achievable market
and the expected growth in the WCD market are subject to significant uncertainty and may prove to be inaccurate. In particular, our estimates of our total addressable markets in the U.S. and outside the U.S. are based on a number of internal and
third-party estimates and assumptions relating to, amongst other things, the number of patients who are at risk of suffering a SCA, are not immediately eligible for an ICD and are either currently using or may in the future use WCDs; the
reimbursement rates for WCDs by Medicare and private payors in the U.S. and payors outside the U.S.; the average WCD patient wear time; and the use of WCDs over alternative treatments such as ICDs. In addition, our estimates of our total addressable
markets in the U.S. and outside the U.S. both reflect the opportunities available to all current and potential participants in the market, and we cannot predict with precision our ability to address the potential demand for WCDs or the extent of
market adoption of our ASSURE WCD over solutions offered by our current or future competitors. While we believe that our assumptions and the data underlying our estimates for our total addressable markets in the U.S. and outside the U.S. are
reasonable, they may not be correct and the conditions supporting our assumptions or estimates may change at any time, thereby reducing the predictive accuracy of such underlying factors. Our estimated addressable markets in the U.S. and outside the
U.S. may not materialize </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
for many years, if ever. Accordingly, the forecasts of market growth included in this prospectus should not be taken as indicative of our future growth. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Macroeconomic conditions could materially adversely affect our business, financial condition, results of operations and prospects. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Macroeconomic conditions, such as high inflationary pressure, changes to monetary policy, high interest rates, volatile currency exchange
rates, credit and debt concerns, decreasing consumer confidence and spending, including capital spending, concerns about the stability and liquidity of certain financial institutions, the introduction of or changes in tariffs or trade barriers, and
global recessions can adversely impact demand for our products, which could negatively impact our business, financial condition, results of operations and prospects. Recent macroeconomic conditions have been adversely impacted by geopolitical
instability and military hostilities in multiple geographies and monetary and financial uncertainties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The impacts of these macroeconomic
conditions, and the actions taken by governments, central banks, companies, and consumers in response, have resulted in, and may continue to result in, higher inflation in the United States and globally, which is likely, in turn, to lead to an
increase in costs and may cause changes in fiscal and monetary policy, including additional increases in interest rates. Although reimbursement rates for WCDs, including our ASSURE WCD, have increased in recent years, adverse macroeconomic
conditions could result in payors reducing reimbursement rates, which could negatively impact our profitability and cash flows. Such conditions could also reduce demand for our ASSURE WCD if they adversely affect insured customers&#146; ability to
pay insurance deductibles and uninsured customers&#146; ability to lease our device. Other adverse impacts of recent macroeconomic conditions have been, and may continue to be, supply chain constraints, logistics challenges, liquidity concerns in
the broader financial services industry, and fluctuations in labor availability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In a higher inflationary environment, we may be unable
to raise the prices of our products sufficiently to keep up with the rate of inflation. A higher inflationary environment can also negatively impact raw material, component, and logistics costs that, in turn, may increase the costs of producing and
distributing our products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We may in the future experience supply chain constraints, including difficulties obtaining a sufficient supply
or increased prices of component materials used in our products. Increased interest rates may make access to credit more difficult, which may result in the insolvency of key suppliers, which would exacerbate supply chain challenges. Such supply
chain constraints could cause us to fail to meet product demand or maintain our margins. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our annual effective income tax rate can change materially
as a result of changes in our mix of U.S. and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> earnings and other factors, including changes in tax laws and changes made by regulatory authorities. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our overall effective income tax rate is equal to our total tax expense as a percentage of total earnings before tax. However, income tax
expense and benefits are not recognized on a global basis but rather on a jurisdictional or legal entity basis. Losses in one jurisdiction may not be used to offset profits in other jurisdictions and may cause an increase in our tax rate. Changes in
the mix of earnings (or losses) between jurisdictions and assumptions used in the calculation of income taxes, among other factors, could have a significant effect on our overall effective income tax rate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to additional taxes if our transfer pricing arrangements are challenged or we fail to establish tax residency in Ireland. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have entered into transfer pricing arrangements that establish prices for our intercompany operations. However, our transfer pricing
procedures are not binding on the applicable taxing authorities. No official authority in any jurisdiction has made a determination as to whether or not we are operating in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
compliance with such authority&#146;s transfer pricing laws. Accordingly, a taxing authority could challenge our transfer prices and require us to adjust them to reallocate our income. Any change
to the allocation of our income as a result of review by a taxing authority could have a negative effect on our results of operations and financial condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, while, as described below, we intend for Kestra Medical Technologies, Ltd. to become a company resident in Ireland for Irish
corporation tax purposes, if we fail to establish such residency in a timely manner, U.S. withholding taxes may apply to royalty payments paid by Kestra Medical Technologies, Inc. and its subsidiaries to West Affum Holdings Designated Activity
Company. Such U.S. withholding taxes, if they were to apply, could have a significant effect on our effective tax rate and a negative effect on our results of operations and financial condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Taxing authorities may disagree with and may challenge our tax positions. If our tax positions are not sustained in the event of such
challenge, we could be required to pay additional taxes, interest, penalties or other costs which could impact our results of operations and financial condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are subject to taxation in Ireland and multiple other jurisdictions. As a result, any adverse development in the tax laws of Ireland or any of these
jurisdictions or any disagreement with our tax positions could have a material adverse effect on our business, consolidated financial condition or results of operations. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">West Affum Holdings Designated Activity Company is, and each of Kestra Medical Technologies, Ltd., West Affum Intermediate Holdings Corp. and
West Affum Holdings Corp. intends to become, a company resident in Ireland for Irish corporation tax purposes. We believe that, as Irish tax resident entities, our status should improve our ability to maintain a competitive worldwide effective
corporate tax rate; however, we cannot give any assurance as to what our effective tax rate will be because of, among other things, uncertainty regarding the tax policies of the jurisdictions where we operate. In general, under current Irish
legislation, a company is regarded as resident for tax purposes in Ireland if it is incorporated in Ireland (unless broadly this is displaced by the terms of a double taxation treaty that Ireland has entered into) or it is centrally managed and
controlled in Ireland. Trading income (active business income) of an Irish resident company is generally taxable at the Irish corporation tax rate of 12.5% (provided that the company is not part of a consolidated multinational group with more than
EUR750&nbsp;million of annual consolidated revenue in which case the company may be subject to Irish corporation tax at 15%). <FONT STYLE="white-space:nowrap">Non-trading</FONT> income of an Irish resident company is taxable at a rate of 25% and
capital gains at a rate of 33%. It is possible that in the future, whether as a result of a change in law or the practice of any relevant tax authority or as a result of any change in the conduct of our affairs, those companies could become, or be
regarded as having become, tax resident in a jurisdiction other than Ireland. Should any of those companies cease to be Irish tax resident, they may be subject to a charge to Irish capital gains tax as a result of a deemed disposal of their assets.
Our actual effective tax rate may vary from our expectation and that variance may be material. Additionally, the tax laws of Ireland, the United States and other jurisdictions could change in the future, and such changes could cause a material
change in our effective tax rate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A number of factors may increase our future effective tax rates, including: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the jurisdictions in which profits are determined to be earned and taxed; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the resolution of issues arising from tax audits with various tax authorities; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">loss of tax treaty benefits in one or more jurisdictions; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in the valuation of our deferred tax assets and liabilities; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">increases in expense not deductible for tax purposes, including transaction costs and impairments of goodwill in
connection with acquisitions; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in available tax credits; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in share-based compensation; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in tax laws or the interpretation of such tax laws, and changes in generally accepted accounting
principles; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">challenges to the transfer pricing policies related to our structure. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Ireland is a Member State of the European Union (the &#147;EU&#148;). The EU has become increasingly active in the area of direct taxation in
recent years, in some cases on foot of wider international tax initiatives such as the OECD BEPS (Base Erosion and Profit Shifting) initiative and in other cases unilaterally. A number of EU legislative tax measures have been implemented in recent
years such as the <FONT STYLE="white-space:nowrap">Anti-tax</FONT> Avoidance Directive, the EU Mandatory Disclosure Regime DAC6 requiring the reporting of certain cross-border arrangements, and the EU Global Minimum Tax Directive. There are also a
number of proposed EU legislative tax measures such as the Business in Europe: Framework for Income Taxation (&#147;BEFIT&#148;) which proposes a new legislative framework for corporate taxation in the EU. Additionally, the EU Commission has carried
out a number of investigations concerning unlawful EU State Aid involving tax measures in Member States, most notably in the European Court case of <I>European Commission v Ireland and Apple Sales International </I>(Case <FONT
STYLE="white-space:nowrap">C-465/20</FONT> P) which was held in favor of the European Commission. State Aid is any aid granted by an EU Member State or through EU Member State resources in any form whatsoever which distorts or threatens to distort
competition by favoring certain undertakings or the production of certain goods. Any of these proposed or actual legislative measures or EU law related actions could impact our tax treatment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our tax position could be adversely impacted by changes in tax rates generally, tax laws, tax treaties or tax regulations or changes in the
interpretation of such laws, treaties or regulations by the tax authorities in Ireland, the United States and other jurisdictions. In addition, the tax authorities in any applicable jurisdiction may disagree with the positions we have taken or
intend to take regarding the tax treatment or characterization of any of our transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Failure to manage the risks associated with
such changes, or misinterpretation of the laws relating to taxation, could result in increased charges, financial loss, including penalties, and reputational damage and materially and adversely affect our results, financial condition and prospects.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are required to reclassify independent contractors as employees, we may incur additional costs and taxes which could adversely affect our
business, financial condition, results of operations and prospects. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We engage independent contractors in our operations for whom
we do not pay or withhold any federal, state or other employment tax. There are a number of different tests used in determining whether an individual is an employee, or an independent contractor and such tests generally take into account multiple
factors. There can be no assurance that legislative, judicial, or regulatory (including tax) authorities will not introduce proposals or assert interpretations of existing rules and regulations that would change, or at least challenge, the
classification of our independent contractors. Although we believe we have properly classified our independent contractors, the U.S. Internal Revenue Service or other U.S. federal or state authorities or similar authorities of a foreign government
may determine that we have misclassified our independent contractors for employment tax or other purposes and, as a result, seek additional taxes from us or attempt to impose fines and penalties. If we are required to pay employer or withholding
taxes with respect to prior periods with respect to or on behalf of our independent contractors, our operating costs will increase, which could adversely impact our business, financial condition, results of operations and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Intellectual Property </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Third parties may assert that we are employing their intellectual property and other proprietary technology without authorization, and we may become a
party to litigation or administrative proceedings related to intellectual property that could be costly, time-consuming, or unsuccessful and could hinder our ability to commercialize our existing or future products. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The medical device industry has been characterized by extensive litigation regarding patents, trademarks, trade secrets, copyrights and other
intellectual property rights, and companies in the industry have used intellectual property litigation to gain a competitive advantage. It is possible that U.S. and foreign patents and pending patent applications, trademarks, copyright registrations
or other intellectual property controlled by third parties may be alleged to cover our products or services, or components of our products or services, or that we may be accused of misappropriating third parties&#146; trade secrets. Additionally,
our products include hardware and software components and other elements that we purchase or license from vendors and other third parties, and may include design components (including open-source components) or other elements that are outside of our
direct control and could become unavailable on terms acceptable to us or be found or alleged to infringe, misappropriate or otherwise violate the intellectual property rights of third parties. Our direct or indirect competitors, many of which have
substantially greater resources and have made substantial investments in patent portfolios, trade secrets, trademarks, copyright registrations, and other intellectual property rights and competing technologies, may have applied for or obtained, or
may in the future apply for or obtain, patents or trademarks that will prevent, limit or otherwise interfere with our ability to make, have made, use, sell, offer to sell, and/or import our products and services (or components thereof) or to use
product names. Moreover, patent applications in the United States and many international jurisdictions are typically not published until 18 months after the filing of certain priority documents (or, in some cases, are not published until they issue
as patents) and publications in the scientific literature often lag behind actual discoveries. Thus, we cannot be certain that others have not filed patent applications directed to our products or technology similar to ours. Any such patent
application may have priority over our patent applications or patents, which could further require us to obtain rights, if available, to any resulting third-party patents directed to such technologies. Given the number of patents directed toward the
medical device industry or otherwise applicable to technologies utilized in the medical device industry, we cannot be certain that we do not infringe existing patents or that we will not infringe patents that may be granted in the future. If a
patent holder believes our Cardiac Recovery System platform, any components thereof including the ASSURE WCD, any other products or any future product candidates infringe its patent, the patent holder may sue us even if we have received patent
protection. Our Cardiac Recovery System platform, including existing products and any future products that we commercialize, could be alleged to infringe patent rights and other proprietary rights of third parties. Any lawsuits resulting from such
allegations, if we are not successful, could subject us to significant liability for damages. Any potential intellectual property litigation also could force us to do one or more of the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">stop making, having made, selling, offering to sell, importing or using products or technologies that allegedly
infringe or violate the asserted intellectual property; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">incur significant legal expenses; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pay substantial damages or royalties to the party whose intellectual property rights we may be found to be
infringing or violating, including enhanced damages if we are found to be willfully infringing or violating such intellectual property rights; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pay the attorneys&#146; fees and costs of litigation to the party whose intellectual property rights we may be
found to be infringing or violating; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">redesign those products that contain the allegedly infringing or violating intellectual property or replace
components thereof that contain the allegedly infringing or violating intellectual property, which could be costly, disruptive, infeasible, or require further FDA approval; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">attempt to obtain a license to the relevant intellectual property from third parties, which may not be available
on reasonable terms or at all, or from third parties who may attempt to license rights that they do not have. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Any
litigation or claim against us, even those without merit or that we are able to successfully defend, may cause us to incur substantial costs, and could place a significant strain on our financial resources, divert the attention of management from
our core business and harm our reputation. The defense and prosecution of these matters are both costly and time-consuming. Vendors and other parties from which we purchase or license hardware, software or other intellectual property may not
indemnify us in the event that such hardware or software is accused of infringing a third party&#146;s patent or trademark or of misappropriating a third party&#146;s trade secret or otherwise violating a third party&#146;s intellectual property
rights. There can be no assurance with respect to the outcome of any litigation brought against us, and even if any litigation is resolved in our favor, the outcome of any such litigation could have a material adverse impact on our business,
operating results and financial condition. Litigation is inherently unpredictable and outcomes are uncertain. Further, as the costs and outcome of these types of claims and proceedings can vary significantly, it is difficult to estimate potential
losses that may occur. Accordingly, we are unable at this time to estimate the effects of these potential future lawsuits on our financial condition, operations or cash flows. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>In the event of a successful claim against us for infringement, misappropriation or other violation of third-party intellectual property rights, we may
have to pay substantial damages. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If patents, trademarks, trade secrets, or other intellectual property rights are successfully
asserted against us, this may harm our business and result in injunctions preventing us from selling our products, license fees, damages and the payment of attorney fees and court costs. A finding of infringement could prevent us from continuing to
sell our Cardiac Recovery System platform or any components thereof including the ASSURE WCD, or prevent us from commercializing any future product candidates or force us to cease some or all of our business operations, which could materially harm
our business. In addition, if we are found to have willfully infringed third party patents or trademarks, or to have willfully misappropriated trade secrets or otherwise violated other intellectual property rights of others, we could be required to
pay enhanced damages in addition to other penalties, including attorneys&#146; fees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, we may have to obtain one or more
licenses from third parties to continue developing and marketing our products and technology, pay royalties and/or redesign our products or technologies, which may be impossible or require substantial time and monetary expenditure. Although patent,
trademark, trade secret and other intellectual property disputes in the medical device area sometimes may be settled through licensing or similar arrangements, we may not be able to obtain such arrangements at all and if we do, costs associated with
such arrangements may be substantial and could include ongoing royalties that materially adversely impact our revenue. We may be unable to obtain necessary licenses on satisfactory terms and one or more third parties may refuse to grant necessary
licenses. Some licenses from third parties may include access to technologies for use by us on defined terms. Other licenses from third parties may not provide access to any additional technologies and may be limited to granting permission for us to
utilize existing or future technology in exchange for additional fees. If we do not obtain necessary licenses, we may not be able to redesign our products to avoid infringement, which could result in a material adverse effect on our business. Even
if we were able to obtain such licenses, then it could be granted on <FONT STYLE="white-space:nowrap">non-exclusive</FONT> terms, thereby providing our competitors and other third parties access to any technologies licensed to us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to claims challenging the inventorship of our patents and other intellectual property. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We may be subject to claims that current or former employees, partners or other third parties have an interest in our patents or other
intellectual property as an inventor or <FONT STYLE="white-space:nowrap">co-inventor.</FONT> The failure to name the proper inventors on a patent application can result in the patents issuing thereon being unenforceable. Inventorship disputes may
arise from conflicting views regarding the contributions of different individuals named as </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
inventors, the effects of foreign laws where foreign nationals are involved in the development of the subject matter of the patent, conflicting obligations of third parties involved in developing
our pipeline assets or as a result of questions regarding <FONT STYLE="white-space:nowrap">co-ownership</FONT> of potential joint inventions. Litigation may be necessary to resolve these and other claims challenging inventorship and/or ownership.
Alternatively, or additionally, we may enter into agreements to clarify the scope of our rights in such intellectual property. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual
property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could
result in substantial costs and be a distraction to management and other employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Similarly, interference or derivation proceedings
provoked by third parties or brought by the U.S. Patent and Trademark Office (&#147;USPTO&#148;) or other jurisdictional bodies may be necessary to determine priority or originality with respect to our patents or patent applications. We may also
become involved in other proceedings, such as reexamination, <I>inter partes</I> review, post-grant reviews, cancellations, derivation or opposition proceedings before the USPTO or other jurisdictional bodies relating to our intellectual property
rights or the intellectual property rights of others. Adverse determinations in a judicial or administrative proceeding or failure to obtain necessary licenses could prevent us from manufacturing and selling our products or using product names,
which would have a significant adverse impact on our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may become involved in litigation or administrative proceedings related to
intellectual property, including litigation to protect, enforce or defend the validity of our intellectual property. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We may need
to commence proceedings or assert counterclaims against others to enforce our patents, trademarks or other intellectual property, to protect our trade secrets or <FONT STYLE="white-space:nowrap">know-how</FONT> or to determine the enforceability,
scope and validity of the proprietary rights of others when we determine that a successful outcome may lead to an increase in the value of the intellectual property. If we choose to enforce our patent rights against a party, then that individual or
company has the right to ask the court to rule that such patents are invalid or should not be enforced. Additionally, the validity of our patents and the patents we have licensed may be challenged if a petition for post-grant proceedings, such as
<I>inter partes</I> review and post-grant review, is filed within the statutorily applicable time with the USPTO. Proceedings to challenge patents are also available internationally, including for example, opposition proceedings and nullity actions.
In patent litigation in the United States, counterclaims alleging invalidity and/or unenforceability and U.S. Patent Trial and Appeal Board (&#147;PTAB&#148;) challenges are commonplace. Grounds for a validity challenge could be an alleged failure
to meet any of several statutory requirements, including lack of novelty, obviousness or <FONT STYLE="white-space:nowrap">non-enablement.</FONT> Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution
of the patent intentionally withheld material information from the USPTO, or made a misleading statement, during prosecution. Third parties also may raise similar claims before the PTAB, even outside the context of litigation. These proceedings
would result in substantial expense to us and significant diversion of effort by our technical and management personnel. There is also the risk that, even if the validity or enforceability of such patents is upheld, a court or jury may find that the
other party&#146;s products or services do not infringe our patents. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. We may not be able to stop a competitor
from marketing and selling products that are the same or similar to our products and services or from using product or service names that are the same or similar to ours, and our business may be materially harmed as a result. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our ability to enforce our patent rights depends on our ability to detect infringement by third parties. It may be difficult to detect
infringers that do not advertise the components or methodologies that are used in their products. Moreover, it may be difficult or impossible to obtain evidence of infringement in a competitor&#146;s or potential competitor&#146;s product. We may
not prevail in any lawsuits that we initiate and the damages or other remedies awarded if we were to prevail may not be commercially meaningful. Adverse proceedings can be expensive, time-consuming and may divert the efforts of our technical and
managerial personnel, which could in turn harm our business, whether or not we receive a determination favorable to us. In addition, a court or other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
judicial body may decide that the patent we seek to enforce is not patentable, invalid or unenforceable. Additionally, a court or other judicial body may refuse to stop the other party from using
the technology at issue on the grounds that the patent in question does not cover the allegedly infringing technology in question or otherwise refuse to enjoin a party found to have infringed a patent. An adverse result in any proceeding could put
one or more of our patents at risk of being found not patentable, invalidated or interpreted narrowly. Some of our competitors may be able to devote significantly more resources to intellectual property proceedings, and may have significantly larger
intellectual property portfolios to assert against us if we assert our rights against them. Further, because of the substantial discovery required in connection with intellectual property litigation, there is a risk that some of our confidential
information could be disclosed or otherwise compromised. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">From time to time, we may be subject to legal proceedings and claims in the
ordinary course of business with respect to intellectual property or issues, which proceedings and claims may also include claims related indirectly to our intellectual property such as breach of contract, antitrust, or unfair competition. In
addition, we generally indemnify our customers and distributors with respect to infringement by our products of the proprietary rights of third parties. Third parties may assert infringement claims against our customers, distributors or suppliers.
These claims may require us to initiate or defend protracted and costly litigation on behalf of our customers, distributors or suppliers, regardless of the merits of these claims. If any of these claims succeeds or settles, we may be forced to pay
damages or settlement payments on behalf of our customers, distributors or suppliers or may be required to obtain licenses for the products they use or produce for us. If we cannot obtain all necessary licenses on commercially reasonable terms, our
customers may be forced to stop purchasing and using our products, which could expose us to substantial losses or liability and otherwise have an adverse effect on our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our efforts to obtain intellectual property protection and the intellectual property rights we obtain may be inadequate, and our business may be
adversely affected as a result. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As part of our competitive strategy, we have and will continue to develop, maintain, enforce and
protect the proprietary aspects of our technologies. We rely on a combination of patents, copyrights, trademarks, trade secret laws and confidentiality and invention assignment agreements with employees and third parties to protect our intellectual
property rights. These legal measures afford only limited protection. As of the date of this prospectus, we have rights to 225 issued U.S. and foreign patents, consisting of 193 issued patents in the U.S., 16 issued patents in the European Union, 7
issued patents in Japan, 4 issued patents in Australia and 5 issued patents in China. Additionally, as of the date of this prospectus, we had 141 pending published and unpublished U.S. and foreign patent applications, consisting of 128 pending
published and unpublished patent applications in the U.S., 5 pending published patent applications in the European Union, 3 pending published patent applications in Japan, 2 pending published patent applications in Australia and 3 pending published
patent applications in China. Assuming all required fees and other charges are paid, the earliest expiry date for issued patents owned or used and maintained by us is in July 2025. We rely, in part, on our ability to obtain and maintain patent
protection for our proprietary products and processes. The process of applying for and obtaining a patent is expensive, time-consuming and complex, and we may not be able to file, prosecute, maintain, enforce or license all necessary or desirable
patent applications at a reasonable cost, in a timely manner, or in all jurisdictions where protection may be commercially advantageous, or we may not be able to protect our proprietary rights at all. Despite our efforts to protect our proprietary
rights, unauthorized parties may be able to obtain and use information that we regard as proprietary. We cannot be certain that our or our licensors&#146; claims in U.S. pending and corresponding international or foreign patent applications will be
considered patentable. In addition, the issuance of a patent does not ensure that it is valid or enforceable, so even if we obtain patents, they may not be valid or enforceable against third parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our patent applications may not result in issued patents and our patents may not be sufficiently broad to protect our products or technology.
Furthermore, the issuance of a patent does not give us the right to make, have made, use, offer to sell, sell or import the patented invention. Other parties may have developed technologies that may be related or competitive to our products, may
have filed or may file patent applications and may have </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
received or may receive patents that overlap or conflict with our patents or patent applications, either by claiming the same methods or devices or by claiming subject matter that could dominate
our patent position. The patent positions of medical device companies, including our patent position, may involve complex legal and factual questions, and, therefore, the scope, validity and enforceability of any patent claims that we or others have
or may obtain cannot be predicted with certainty. Third parties may have blocking patents that could prevent us from manufacturing, marketing or distributing our own products and making, using, offering to sell, selling, or importing the Cardiac
Recovery System platform, one or more products or components thereof, or existing or future products or components. Alternatively, third parties may seek approval to market their own products similar to or otherwise competitive with our products. In
these circumstances, we may need to defend and/or assert our patents and other intellectual property rights, including by filing lawsuits or asserting counterclaims alleging patent infringement, misappropriation and other violations of intellectual
property. In any of these types of proceedings, a court or agency with jurisdiction may find our patents invalid or unenforceable; competitors may then be able to market and sell products and use manufacturing and analytical processes that are
substantially similar to ours. In addition, such proceedings may be costly. Even if we have valid and enforceable patents, these patents still may not provide protection against competing products or processes sufficient to achieve our business
objectives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We may not be able to protect our intellectual property rights throughout the world. Filing, prosecuting and defending
patents in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some
foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. The legal systems of certain countries may not favor the enforcement of patents and other intellectual property
protection, particularly those relating to medical devices, and some jurisdictions, such as Europe, Japan, and China, may have a higher standard for patentability than in the United States. Consequently, we may not be able to prevent third parties
from making, having made, using, selling, offering to sell, or importing in all countries outside of the United States, or from making, having made, using, selling offering to sell, or importing products incorporating our inventions in and into the
United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have
patent protection, but where enforcement is not as strong as that in the United States. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from
competing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We may not be able to correctly estimate or control our future operating expenses in relation to obtaining intellectual
property, enforcing intellectual property and/or defending intellectual property, which could affect operating expenses. Our operating expenses may fluctuate significantly in the future as a result of a variety of factors, including the costs of
preparing, filing, prosecuting, defending, and enforcing patent and trademark claims and other intellectual property-related costs, including adverse proceedings (such as litigation) costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">To the extent our intellectual property protection is incomplete, we are exposed to a greater risk of direct competition. A third party could,
without authorization, copy or otherwise obtain and use our products or technology, or develop similar technology. Our competitors could purchase our products and attempt to replicate some or all of the competitive advantages we derive from our
development efforts or design around our protected technology. Our failure to secure, protect, maintain and enforce our intellectual property rights could substantially harm the value of our products, brand and business. The theft or unauthorized
use or publication of our trade secrets and other confidential business information could reduce the differentiation of our products and harm our business, the value of our investment in development or business acquisitions could be reduced and
third parties might make claims against us related to losses of their confidential or proprietary information. Any of the foregoing could materially and adversely affect our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to protect the confidentiality of our trade secrets and other proprietary
information, our business and competitive position may be harmed. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We rely heavily on trade secrets and confidentiality agreements
to protect our unpatented <FONT STYLE="white-space:nowrap">know-how,</FONT> technology, proprietary information, including parts of our Cardiac Recovery System platform, including the ASSURE WCD, and to maintain our competitive position. However,
trade secrets and <FONT STYLE="white-space:nowrap">know-how</FONT> can be difficult to protect. In particular, we anticipate that with respect to our technologies, these trade secrets and <FONT STYLE="white-space:nowrap">know-how</FONT> will over
time be disseminated within the industry through independent development, the publication of journal articles describing the methodology and movement of personnel, including from academic to industry scientific positions. In addition to pursuing
patents on our products and technology, we take steps to protect our intellectual property and proprietary technology by entering into agreements, including confidentiality agreements, <FONT STYLE="white-space:nowrap">non-disclosure</FONT>
agreements and intellectual property assignment agreements, with parties who have access to them, such as our employees, consultants and other third parties. We may not be able to prevent the unauthorized disclosure or use of our technical knowledge
or other trade secrets by consultants, vendors or former or current employees, despite the existence generally of these confidentiality agreements and other restrictions. These agreements may not provide meaningful protection for our trade secrets, <FONT
STYLE="white-space:nowrap">know-how</FONT> or other proprietary information in the event of any unauthorized use, misappropriation or disclosure of such trade secrets, <FONT STYLE="white-space:nowrap">know-how</FONT> or other proprietary
information. We may not be able to execute assignment agreements with each relevant party and such agreements may be unenforceable or not self-executing. There can be no assurance that employees, consultants, vendors, clients and others with access
to the confidential and proprietary information have executed such agreements or have not breached or will not breach their agreements with us, that we will have adequate remedies for any breach, or that our trade secrets will not otherwise become
known or independently developed by competitors. Despite the protections we do place on our intellectual property, monitoring unauthorized use and disclosure of our intellectual property is difficult, and we do not know whether the steps we have
taken to protect our intellectual property will be adequate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">While we use commonly accepted security measures, trade secret violations
are often a combination of federal and state law in the United States, and the criteria for protection of trade secrets can vary among different jurisdictions. If the steps we have taken to maintain our trade secrets are deemed inadequate, we may
have insufficient recourse against third parties for misappropriating the trade secret. In addition, the laws of many foreign countries will not protect our intellectual property rights to the same extent as the laws of the United States and there
can be no assurance that we have sufficiently protected our intellectual property in every foreign country in which our products may be sold. Consequently, we may be unable to prevent our proprietary technology from being exploited abroad, which
could affect our ability to expand to international markets or require costly efforts to protect our technology. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, while it is
our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement
with each party who in fact conceives or develops intellectual property that we regard as our own. Our assignment agreements may not be self-executing or may be breached, and we may be forced to bring claims against third parties, or defend claims
they may bring against us, to determine the ownership of what we regard as our intellectual property. We may be subject to claims challenging the inventorship or ownership of our intellectual property. We also may be subject to claims that former
employees, collaborators or other third parties have an ownership interest in our patents or other intellectual property. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we fail in
defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims,
litigation could result in substantial costs and distraction to management and other employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Further, it is possible that others
independently will develop the same or similar technology or otherwise obtain access to our unpatented technology, and in such cases we could not assert any trade secret rights against </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such parties. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our trade secret rights and related confidentiality and nondisclosure provisions. If we
fail to obtain or maintain trade secret protection, or if our competitors obtain our trade secrets or independently develop technology similar to ours or competing technologies, our competitive market position could be materially adversely affected.
In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets and agreement terms that address <FONT STYLE="white-space:nowrap">non-competition</FONT> are difficult to enforce in many
jurisdictions and might not be enforceable in certain cases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to claims that our employees, consultants or independent contractors
have wrongfully used or disclosed confidential information or alleged trade secrets of third parties or competitors or are in breach of <FONT STYLE="white-space:nowrap">non-competition</FONT> or
<FONT STYLE="white-space:nowrap">non-solicitation</FONT> agreements with our competitors or their former employers. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We also may
employ or otherwise engage personnel who were previously or are concurrently employed or engaged at research institutions or other medical device companies, including our competitors or potential competitors. We may be subject to claims that these
personnel, or we, have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former or concurrent employers, or that patents and applications we have filed to protect inventions of these personnel, even
those related to one or more of our products, are rightfully owned by their former or concurrent employer. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could
result in substantial costs and be a distraction to management. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If our trademarks and trade names are not adequately protected, we may not be able
to build name recognition in our markets and our business may be adversely affected. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We rely on trademarks, service marks, trade
names and brand names, such as our registered trademarks ASSURE, ASSURE ASSIST, KESTRA and KESTRA CARESTATION, to distinguish our products from the products of our competitors, and have registered or applied to register these trademarks. We cannot
assure you that we have applied for all the marks in the jurisdictions and classes of goods and services that are or will be material to our business or, where we have applied, that our trademark applications will be approved. During trademark
registration proceedings, we may receive rejections. Although we are given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in proceedings before the USPTO or equivalent institutions in other
jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings have and may be filed against our trademarks, and our trademarks may
not survive such proceedings. In the event that our trademarks are successfully challenged, we could be forced to rebrand our products, which could result in loss of brand recognition and could require us to devote resources towards advertising and
marketing new brands. Moreover, any name we propose to use with our ASSURE WCD or any future medical device product candidates in the United States must be approved by the FDA, regardless of whether we have registered it, or applied to register it,
as a trademark. The FDA typically conducts a review of proposed medical device names, including an evaluation of potential for confusion with other medical device names. If the FDA objects to any of our proposed proprietary medical device names, we
may be required to expend significant additional resources in an effort to identify a suitable substitute name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Further, we cannot assure you that competitors will not infringe our trademarks or that we will have adequate resources to enforce our
trademarks. We also face risks in connection with our international expansion, including in countries that may have less protection for our trademarks than the United States. There is a risk that our trademarks may not be adequate to protect our
brand or may conflict with the trademarks of other companies, both domestically and abroad, which may require us to rebrand our products, obtain costly licenses, defend against third-party claims, or substantially change our product or service
offerings. Should such risks manifest, we may be required to expend considerable resources and divert the attention of our management, which could have an adverse effect on our business and results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If we do not adequately protect our trademarks and trade names, then we may not be able to
build name recognition in our markets of interest and our business may be adversely affected. Our registered or unregistered trademarks may be challenged, infringed, circumvented, declared to be descriptive, declared generic or conflict with
third-party rights. We may not be able to protect our rights to these trademarks, which we need to build name recognition by potential partners or customers in our markets of interest. In addition, third parties may file first for our trademarks in
certain countries. If they succeed in registering such trademarks, and if we are not successful in challenging such third-party rights, we may not be able to use these trademarks to market our products in those countries. In such cases, over the
long term, if we are unable to establish name recognition based on our trademarks and trade names, then our marketing abilities may be impacted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes in U.S. or foreign patent law or their interpretations could diminish the value of patents in general, thereby impairing our ability to protect
our existing and future products. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As is the case with other medical device and medical technology companies, our success is
heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the medical device and medical technology industries involve both technological and legal complexity and is therefore costly, time-consuming and
inherently uncertain, due in part to ongoing changes in patent laws. Depending on decisions by Congress, the federal courts and the USPTO and equivalent institutions in other jurisdictions, the laws and regulations governing patents, and
interpretation thereof, could change in unpredictable ways that could weaken our ability to obtain new patents or to enforce existing or future patents. For example, in recent years the U.S. Supreme Court has ruled on several patent cases that have
been interpreted to have either narrowed the scope of patent protection or weakened the rights of patent owners in certain situations. In addition, patent reform legislation or regulation, such as the Patent Eligibility Restoration Act of 2023 which
was introduced to the U.S. Senate on June&nbsp;22, 2023, may be proposed or enacted in the future that may impact our ability to obtain patents in the future. Therefore, there is increased uncertainty with regard to our ability to obtain patents in
the future, as well as uncertainty with respect to the value of patents once obtained. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Patent reform legislation or changes to USPTO
regulations or fees could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. Assuming that other requirements for patentability are met, prior to March 2013, in
the United States, the first to invent the claimed invention was entitled to the patent, while outside the United States, the first to file a patent application was entitled to the patent. After March 2013, under the Leahy-Smith America Invents Act
enacted in September 2011 (the &#147;Leahy-Smith Act&#148;), the United States transitioned to a first inventor to file system in which, assuming that other requirements for patentability are met, the first inventor to file a patent application will
be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. The Leahy-Smith Act also includes a number of significant changes that affect the way patent applications are prosecuted and
may also affect patent litigation. These include allowing third party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO-administered post-grant proceedings, including
post-grant review, <I>inter partes</I> review and derivation proceedings. The USPTO has developed new regulations and procedures to govern administration of the Leahy-Smith Act, and many of the substantive changes to patent law associated with the
Leahy-Smith Act, particularly the first <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">inventor-to-file</FONT></FONT> provisions. Accordingly, it is not clear what, if any, impact the Leahy-Smith Act will have on the operation of
our business. However, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could harm our
business, financial condition, results of operations and prospects. We cannot predict future changes in the interpretation of patent laws or changes to patent laws that might be enacted into law. Those changes may materially affect our patents or
patent applications and our ability to obtain additional patent protection in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Additionally, as of June 2023, the
Company&#146;s <FONT STYLE="white-space:nowrap">EPO-registered</FONT> patents are subject to the jurisdiction of the European Unitary Patent system and the European Unified Patent Court (&#147;UPC&#148;). It will be several years before we will
understand the scope of patent rights that will be recognized and the strength of patent remedies that will be provided by the UPC. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Even if our patents are determined by a court to be valid and enforceable, courts may not
interpret them sufficiently broadly to prevent others from marketing products similar to ours or designing around our patents. For example, third parties may be able to make product that are similar to ours but that are not covered by the claims of
our patents. Third parties may assert that were not the first to make the inventions covered by our issued patents. The claims of our issued patents or patent applications when issued may not cover our proposed commercial technologies or the future
products that we develop. We may not have freedom to commercialize our products unimpeded by the patent rights of others. Third parties may have dominating, blocking, or other patents relevant to our technology of which we are not aware. There may
be prior public disclosures or art that could be deemed to invalidate one or more of our patent claims. Further, we may not develop additional proprietary technologies in the future, and, if we do, they may not be patentable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Patent law can be highly uncertain and involve complex legal and factual questions for which important principles remain unresolved. In the
United States and in many international jurisdictions, policy regarding the breadth of claims allowed in patents can be inconsistent. The U.S. Supreme Court and the Court of Appeals for the Federal Circuit have made, and will likely continue to
make, changes in how they interpret the patent laws of the United States. Similarly, international courts have made, and will likely continue to make, changes in how they interpret the patent laws in their respective jurisdictions. We cannot predict
future changes in the interpretation of patent laws or changes to patent laws that might be enacted into law by U.S. and international legislative bodies. Those changes may materially affect our patent rights and our ability to obtain issued
patents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other
requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated if we fail to comply with these requirements. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The patent prosecution process is also expensive and time-consuming, and we may not be able to file, prosecute, maintain, protect, defend,
enforce or license all necessary or desirable patents or patent applications, as applicable, at a reasonable cost, in a timely manner, in all potentially relevant jurisdictions, or at all. It is possible that defects as to form in the preparation or
filing of our patents or patent applications may exist, or may arise in the future, for example with respect to proper priority claims, inventorship, claim scope, or requests for patent term adjustments. It is also possible that we will fail to
identify patentable aspects of our research and development output in time to obtain patent protection. If we delay filing a patent application, and a competitor files a patent application on the same or similar invention before we do, our ability
to secure patent rights may be limited and we may not be able to patent the invention at all. Even if we can patent the invention, we may be able to patent only a limited scope of the invention, and the limited scope may be inadequate to protect our
assets and technologies, or to block competitor&#146;s products and technologies that are similar or adjacent to ours. There are also uncertainties or limitations in our ability to properly protect and defend patents covering our products, which
could have a material adverse effect on our business, financial condition, results of operations and prospects. Our earliest patents and patent filings are public. A competitor may review our published patent filings and arrive at the same or
similar technology advances for our assets as we developed. If the competitor files a patent application on such an advance before we do, then we may no longer be able to protect that aspect of our assets and technologies and we may require a
license from the competitor, which may not be available on commercially viable terms or at all. Moreover, we may not develop additional proprietary products, methods and technologies that are patentable. We also rely to a certain extent on trade
secrets, <FONT STYLE="white-space:nowrap">know-how,</FONT> and technology, that are not protected by patents, to maintain our competitive position. If any trade secret, <FONT STYLE="white-space:nowrap">know-how</FONT> or other technology not
protected by a patent were to be disclosed to or independently developed by a competitor, our business and financial condition could be materially and adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Periodic maintenance fees, renewal fees, annuity fees and various other government fees on any issued patents and certain pending patent
applications are required to be paid to the USPTO or foreign patent agencies in several stages over the lifetime of a patent. The USPTO and various foreign patent agencies also require compliance with a number of procedural, documentary, fee payment
and other similar requirements during the patent application and prosecution process. Noncompliance events that could result in abandonment or lapse of a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
patent or patent application include failure to respond to official communications within prescribed time <FONT STYLE="white-space:nowrap">limits,&nbsp;non-payment&nbsp;of</FONT> fees and failure
to properly legalize and submit formal documents. While an inadvertent lapse in many cases can be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in
<FONT STYLE="white-space:nowrap">which&nbsp;non-compliance</FONT> can result in irrevocable abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. If we fail to
maintain the patents and patent applications directed to our Cardiac Recovery System platform, any components thereof including the ASSURE WCD, other products or any future product candidates, our competitors might be able to enter the market with
similar or identical products or technology, which would harm our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In
addition, patent expiration dates may be affected by a number of factors. For example, patent terms may be shortened or lengthened by terminal disclaimers, patent term adjustments, supplemental protection certificates, and patent term extensions.
Patent term extensions and supplemental protection certificates, and the like, may be impacted by the regulatory process and may not significantly lengthen patent term. <FONT STYLE="white-space:nowrap">Non-payment</FONT> or delay in payment of
patent fees or annuities, delay in patent filings or delay in extension filing (including any patent term extension or adjustment filing), whether intentional or unintentional, may also result in the loss of patent rights important to our business.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Intellectual property rights do not necessarily address all potential threats. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have
limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">others may be able to make products that are similar to any existing products or product candidates we may
develop or utilize similar technology but that are not covered by the claims of the patents that we own or license now or in the future; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we might not have been the first to make the inventions covered by the issued patent or pending patent
application that we own now or in the future; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we might not have been the first to file patent applications directed to certain of our or their inventions;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">others may independently develop similar or alternative technologies or duplicate any of our technologies without
infringing our owned or licensed intellectual property rights; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it is possible that our pending held or licensed patent applications or those that we may file or license in the
future will not lead to issued patents; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issued patents to which we hold rights may be held invalid or unenforceable, including as a result of legal
challenges by other persons; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our competitors might conduct research and development activities in the United States under <FONT
STYLE="white-space:nowrap">FDA-related</FONT> safe harbor patent infringement exemptions and/or in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for
distribution in our major commercial markets; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not develop additional proprietary technologies or products that are patentable; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the patents or pending patent applications of others may harm our business; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may choose not to file a patent in order to maintain certain trade secrets
<FONT STYLE="white-space:nowrap">or&nbsp;know-how,&nbsp;and</FONT> a third party may subsequently file a patent covering such intellectual property; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we cannot assure that any of our patents, or any of our pending patent applications, if issued, will include
claims having a scope sufficient to protect our products; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not be able to successfully commercialize our products on a substantial scale, if approved, before our
relevant patents expire; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we cannot assure that our commercial activities or products will not infringe the intellectual property rights of
others; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we cannot assure any patents issued to us will provide a basis for an exclusive market for our commercially
viable products, will provide us with any competitive advantages or will not be challenged by third parties. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Should any
of these events occur, they could harm our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We include technology in our
products that is licensed to us by third parties. Any loss of our rights to this technology could prevent us from selling our products. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We hold certain intellectual property and technology licenses under which we license intellectual property and technology from third parties
that we use in our products or other parts of our business. We do not own the intellectual property that underlies these licenses. Our rights to use the licensed intellectual property is subject to the continuation of and compliance with the terms
of the licenses, including terms that may restrict our ability to expand our use of such intellectual property into other fields. We expect that we may need to enter into additional license agreements in the future. Our business could suffer, for
example, if any current or future licenses terminates, if the licensors fail to abide by the terms of the license, if the licensed patents or other rights are found to be invalid or unenforceable, or if we are unable to enter into necessary licenses
on acceptable terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As we have done previously, we may need or may choose to obtain patent or other licenses from third parties to
advance our research or allow commercialization of our current or future products. We cannot provide any assurances that third-party patents do not exist that might be enforced against our current or future products in the absence of such a license.
We may fail to obtain any of these licenses on commercially reasonable terms, if at all. Even if we are able to obtain a license, it may not be exclusive. In that event, we may be required to expend significant time and resources to develop or
license replacement technology. If we are unable to do so, we may be unable to develop or commercialize the affected products, which could materially harm our business and the third parties owning such intellectual property rights could seek either
an injunction prohibiting the commercialization of our products or an obligation on our part to pay royalties and/or other forms of compensation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Disputes may arise in the future between us and our licensors regarding intellectual property subject to a license agreement, including: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope of rights granted under the license agreement and other interpretation-related issues;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether and the extent to which our technology and processes infringe or violate intellectual property rights of
the licensor that is not subject to the licensing agreement; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our right to enlist third party vendors or contractors to manufacture or assemble components under the scope of
the license agreement; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our right to sublicense patent and other rights to third parties under collaborative development relationships;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">royalty calculations, including our obligation to disclose proprietary manufacturing information, determining
products included or excluded from royalty obligations, and compliance with audit rights; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">disclosure of terms of existing license agreements to third parties based on confidentiality obligations included
in the license agreements; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">mergers, acquisition, dissolutions, or other business entity transactions that can affect the ownership of
intellectual property rights subject to the license agreement or obligations under the license agreement; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our diligence obligations with respect to the use of the licensed technology in relation to our development and
commercialization of our products, and what activities satisfy those diligence obligations; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ownership of inventions and <FONT STYLE="white-space:nowrap">know-how</FONT> resulting from the joint
creation or use of intellectual property by our licensors and us and our partners. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Disputes regarding our current
licensing arrangements may have an adverse effect on our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition to agreements pursuant to which we <FONT
STYLE="white-space:nowrap">in-license</FONT> intellectual property, we have granted in the past, and will continue to grant in the future licenses under our intellectual property. Like our <FONT STYLE="white-space:nowrap">in-bound</FONT> licenses,
our <FONT STYLE="white-space:nowrap">out-bound</FONT> licenses are complex and disputes may arise between us and our licensees, such as the types of disputes described above. Moreover, our licensees may breach their obligations, or we may be exposed
to liability due to our failure or alleged failure to satisfy our obligations. Any such an occurrence could have an adverse effect on our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Government Regulation </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes in
the regulatory environment may make it more difficult and costly for us to manufacture, market or distribute our products, or to obtain approval for any future products. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Healthcare laws and regulations change frequently and may change significantly in the future. We may not be able to adapt our operations to
address every new regulation, and new regulations may adversely affect our business. We cannot assure you that a review of our business by courts or regulatory authorities would not result in a determination that adversely affects our revenue and
operating results, or that the healthcare regulatory environment will not change in a way that restricts our operations. In addition, there is risk that the U.S. Congress may implement changes in laws and regulations governing providers of
healthcare services and products, including measures to control costs, or reductions in reimbursement levels, which may adversely affect our business and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Government payors, such as Medicare, as well as private payors, have increased their efforts to control the cost, utilization and delivery of
healthcare services and products. From time to time, the U.S. Congress has considered and implemented changes in the Medicare fee schedules in conjunction with budgetary legislation. For example, The Budget Control Act, as amended, resulted in the
imposition of 2% reductions in Medicare (but not Medicaid) payments to providers in 2013 and will remain in effect through 2030. Any significant spending reductions affecting Medicare, Medicaid or other publicly funded or subsidized health programs
that may be implemented and/or any significant taxes or fees that may be imposed on us could have an adverse impact on our results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Further reductions of reimbursement by Medicare for services or changes in policy regarding
coverage of tests or other requirements for payment, such as prior authorization or a healthcare provider or qualified practitioner&#146;s signature on test requisitions, may be implemented from time to time. Reductions in the reimbursement rates
and changes in payment policies of other third-party payors may occur as well. Similar changes in the past have resulted in reduced payments as well as added costs and have added more complex regulatory and administrative requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The FDA and other regulatory agencies that impact our operations may also change their policies or take other actions, including as a result
of legal challenges against such agencies, which may increase the cost of compliance and prevent or delay marketing authorization of our future products under development or impact our ability to enhance products for which we have already obtained
marketing authorizations on a timely basis or at all. The U.S. Supreme Court&#146;s June 2024 decision in <I>Loper Bright Enterprises v. Raimondo</I> (the &#147;Loper decision&#148;) overturned the longstanding Chevron doctrine, under which courts
were required to give deference to regulatory agencies&#146; reasonable interpretations of ambiguous federal statutes. The Loper decision could result in additional legal challenges to regulations and guidance issued by federal agencies applicable
to our business, including those of the FDA, the USPTO, the Federal Trade Commission (&#147;FTC&#148;) and the International Trade Commission. Any such legal challenges, if successful, could have a material impact on our business. Additionally, the
Loper decision may result in increased regulatory uncertainty, inconsistent judicial interpretations, and other impacts to the agency rulemaking process, any of which could adversely impact our business and operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to comply with healthcare and other governmental regulations, we could face substantial penalties and our business, results of operations and
financial condition could be adversely affected. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The products and services we offer are highly regulated, and there can be no
assurance that the regulatory environment in which we operate will not change significantly and adversely in the future. Our business practices, distribution and billing arrangements with third-party DME providers, and other arrangements with
healthcare providers, hospitals, and patients may expose us to scrutiny under broadly applicable fraud and abuse and other laws and regulations that may restrict the financial arrangements and relationships through which we market, sell and
distribute our products and services. U.S. federal and state healthcare laws and regulations that may affect our ability to conduct business, include, without limitation: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">federal and state laws and regulations regarding billing and claims payment applicable to our products and
regulatory agencies enforcing those laws and regulations; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal Anti-Kickback Statute, which prohibits, among other things, any person from knowingly and willfully
offering, soliciting, receiving or providing remuneration, directly or indirectly, in cash or in kind, in exchange for or to induce either the referral of an individual for, or the furnishing, purchase, order or recommendation of, any good or
service for which payment may be made under government healthcare programs, such as the Medicare and Medicaid programs. In addition, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it to have
committed a violation; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal civil and criminal false claims laws and civil monetary penalties laws, including the federal False
Claims Act, which prohibits, among other things, individuals or entities from knowingly presenting, or causing to be presented, false claims, or knowingly using false statements, to obtain payment from the government, healthcare programs. Moreover,
the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act; the federal Civil Monetary
Penalties Law, which prohibits, among other things, offering or transferring remuneration to a federal healthcare beneficiary that a person knows or should know is likely to influence the beneficiary&#146;s decision to order or receive items or
services reimbursable by the government from a particular provider or supplier; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal Physician Payment Sunshine Act (&#147;Open Payments&#148;), created under the Affordable Care Act (as
defined below), and its implementing regulations, which requires manufacturers of drugs, medical devices, biologicals and medical supplies for which payment is available under Medicare, Medicaid or the Children&#146;s Health Insurance Program to
report annually to CMS information related to payments or other transfers of value made to licensed physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. Additionally,
beginning in 2022, applicable manufacturers are also required to report certain payments and other transfers of value made during the previous year to physician assistants, nurse practitioners, clinical nurse specialists, anesthesiologist
assistants, certified registered nurse anesthetists, anesthesiology assistants and certified nurse midwives; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, and its implementing
regulations, which impose certain requirements relating to the privacy, security and transmission of individually identifiable health information upon &#147;covered entities&#148; (health plans, healthcare clearinghouses and certain healthcare
providers), and their respective business associates, individuals or entities that create, receive, maintain or transmit protected health information in connection with providing a service for or on behalf of a covered entity. HIPAA mandates the
reporting of certain breaches of health information to the HHS Office of Civil Rights, affected individuals, and, if the breach is large enough, the media. Entities that are covered by HIPAA (e.g., covered entities and business associates) found to
be in violation of HIPAA as the result of a breach of unsecured protected health information, a complaint about privacy practices or an audit by the HHS, may be subject to significant civil, criminal and administrative fines and penalties and/or
additional reporting and oversight obligations if required to enter into a resolution agreement and corrective action plan with the HHS to settle allegations of HIPAA <FONT STYLE="white-space:nowrap">non-compliance.</FONT> HIPAA also created
criminal liability for executing a scheme to defraud any healthcare benefit program and making false statements relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge
of the statute or specific intent to violate it to have committed a violation. Additionally, the FTC also has authority to initiate enforcement actions against entities for, amongst other things, misleading customers about HIPAA compliance, making
deceptive statements about privacy and data sharing in privacy policies, failing to limit third-party use of personal health information, failing to implement policies to protect personal health information, or engaging in other unfair practices
that harm customers or that may violate Section&nbsp;5 of the FTC Act; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Federal Food, Drug and Cosmetic Act, which regulates the manufacturing, labeling, marketing and sale of
medical devices and prohibits, among other things, the adulteration or misbranding of drugs, biologics and medical devices; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">U.S. federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and
activities that potentially harm customers; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal physician self-referral prohibition, commonly known as the Stark Law; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may
apply to items or services reimbursed by any third party payor, including commercial insurers, state-mandated disclosures of payments or other transfers of value to healthcare providers or marketing expenditures, state laws related to insurance
fraud in the case of claims involving private insurers, and state and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not
preempted by HIPAA, thus complicating compliance efforts. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">These laws and regulations, among other things, constrain our
business, marketing, sales, distribution and other promotional and research activities by limiting the kinds of financial arrangements that we may have </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with hospitals, healthcare providers or other potential referral sources for our products, as well as our arrangements with other third parties for the purchase, sale, billing, and distribution
of our products. In particular, these laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs, and other business arrangements, as well as
interactions with healthcare providers through consultant arrangements, product training, sponsorships, or other activities. Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare and other laws
and regulations will involve substantial costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Because of the breadth of these laws and the narrowness of available statutory and
regulatory exemptions, governmental authorities may possibly conclude that our business practices may not comply with healthcare laws and regulations. To enforce compliance with the healthcare regulatory laws, certain enforcement bodies have
recently increased their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. Any action brought against us
for violations of these laws or regulations, even successfully defended, could cause us to incur significant legal expenses and divert our management&#146;s attention from the operation of our business. We may be subject to private &#147;qui
tam&#148; actions brought by individual whistleblowers on behalf of the federal or state governments, with potential liability under the federal False Claims Act including mandatory treble damages and significant
<FONT STYLE="white-space:nowrap">per-claim</FONT> penalties. Additionally, as a result of these investigations and qui tam actions, we may have to agree to additional compliance and reporting requirements as part of a consent decree, deferred
prosecution or corporate integrity agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have implemented a corporate compliance program designed to actively identify, prevent
and mitigate risk through the implementation of compliance policies, training, auditing and monitoring. We expect to devote substantial resources to implement, maintain, administer and expand the compliance program as necessary. Our company is a
member of AdvaMed and complies with the AdvaMed Code. We cannot be certain, however, that our compliance program will ensure compliance with the various complex laws and regulations to which we are subject now or in the future. The risk of our being
found in violation of these or other laws and regulations is further increased by the fact that many have not been fully interpreted by the regulatory authorities or the courts, and their provisions are open to a variety of interpretations. Any
action brought against us for violation of these or other laws or regulations, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#146;s attention from the operation of our
business. If our operations are found to be in violation of any of the federal and state laws described above or any other current or future fraud and abuse or other healthcare laws and regulations that apply to us, we may be subject to penalties,
including significant criminal, civil, and administrative penalties, damages, fines, imprisonment, for individuals, exclusion from participation in government healthcare programs, such as Medicare and Medicaid, or oversight if we become subject to a
consent decree, deferred prosecution or corporate integrity agreement, and we could be required to curtail or cease our operations. Any of the foregoing consequences could materially adversely affect our business, financial condition, results of
operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our team members, consultants and commercial partners may engage without our awareness in misconduct or other
improper activities, including <FONT STYLE="white-space:nowrap">non-compliance</FONT> with regulatory standards and requirements despite any policies we may have in place to prevent such misconduct, and we may be found liable for their actions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our products and operations are subject to extensive government regulation and oversight. If we fail to obtain and maintain necessary regulatory
clearances or approvals for our products, or if clearances or approvals for future products and indications are delayed or not issued, or if we fail to comply with post-marketing regulatory requirements, our commercial operations would be harmed.
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our products are subject to extensive regulation by the FDA. Government regulations specific to medical devices are wide ranging
and govern, among other things: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product design, development and manufacture; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">laboratory, <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical testing, labeling, packaging,
storage and distribution; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">premarketing clearance and approval; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">record keeping; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishment registration and device listing; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product marketing, promotion, advertising, sales and distribution; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">post-marketing surveillance, including reporting of deaths or serious injuries, recalls, corrections and
removals. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Before a new medical device or service, or a new intended use for an existing product or service, can be
marketed in the United States, a company must first submit and receive either 510(k) clearance or premarketing approval from the FDA, unless an exemption applies. Either process can be expensive, lengthy and unpredictable. The FDA&#146;s 510(k)
clearance process usually takes from three to 12 months, but can last longer. The process of obtaining a PMA is much more costly and uncertain than the 510(k) clearance process and generally takes from one to three years, or even longer, from the
time the application is submitted to the FDA. In addition, a PMA generally requires the performance of one or more clinical trials. We may not be able to obtain the necessary clearances or approvals or may be unduly delayed in doing so, which could
harm our business. Furthermore, even if we are granted regulatory clearances or approvals, they may include significant limitations on the indicated uses for the product, which may limit the market for the product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The FDA can delay, limit or deny clearance or approval of a device for many reasons, including: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to demonstrate to the satisfaction of the FDA or the applicable regulatory entity or notified body
that our products are safe or effective for their intended uses; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the disagreement of the FDA or the applicable foreign regulatory body with the design or implementation of
clinical trials or the interpretation of data from <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies or clinical trials of our products; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">serious and unexpected adverse device effects experienced by participants in clinical trials of our products;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the data from <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies and clinical trials of our products
may be insufficient to support clearance or approval, where required; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to demonstrate that the clinical and other benefits of the device outweigh the risks;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the manufacturing process or facilities we use may not meet applicable requirements; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential for approval policies or regulations of the FDA or applicable foreign regulatory bodies to change
significantly, including as a result of changes in administration, in a manner resulting in delays in the approval process or rendering our performance testing and clinical data or regulatory filings insufficient for clearance or approval.
</P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Although we have obtained FDA approval to market our ASSURE WCD, we are subject to ongoing and pervasive
post-marketing regulatory requirements governing, among other things, the manufacture, marketing, advertising, medical device reporting, sale, promotion, registration, and listing of devices. For example, we are required to file various reports with
the FDA, including reports required by the medical device reporting regulations (&#147;MDRs&#148;) that require that we report to the regulatory authorities if our products may have caused or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
contributed to a death or serious injury or malfunctioned in a way that would likely cause or contribute to a death or serious injury if the malfunction were to recur. If these reports are not
filed in a timely manner, regulators may impose sanctions and we may be subject to product liability or regulatory enforcement actions, all of which could harm our business. In addition, our PMA for our ASSURE WCD was subject to several conditions
of approval, including labeling, useful life restrictions, the commencement of a post-approval registry and post-market study requirements. Though we believe we have complied with these conditions to date, any failure to comply with the conditions
of approval could result in the withdrawal of our PMA and the inability to continue to market our ASSURE WCD. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If we initiate a correction
or removal for any of our products to reduce a risk to health posed by any such products, we would be required to submit a publicly available Correction and Removal report to the FDA and, in many cases, similar reports to other regulatory agencies.
This report could be classified by the FDA as a device recall which could lead to increased scrutiny by the FDA and our customers regarding the quality and safety of our products. Furthermore, the submission of these reports could be used by
competitors against us and cause healthcare providers to delay or cancel prescriptions, which could harm our reputation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The FDA and the
FTC also regulate the advertising and promotion of our products and services to ensure that the claims we make are consistent with our regulatory approvals and clearances, that there is adequate and reasonable data to substantiate the claims and
that our promotional labeling and advertising is neither false nor misleading. If the FDA or FTC determines that any of our advertising or promotional claims are misleading, not substantiated or not permissible, we may be subject to enforcement
actions, including warning letters, and we may be required to revise our promotional claims and make other corrections or restitutions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The FDA and state authorities have broad enforcement powers. Our failure to comply with applicable regulatory requirements could result in
enforcement action by the FDA or state agencies, which may include any of the following sanctions: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adverse publicity, untitled letters, warning letters, fines, injunctions, consent decrees and civil penalties;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">repair, replacement, refunds, recall or seizure of our products; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">operating restrictions, partial suspension or total shutdown of production; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays or denial of our requests for 510(k) clearance or premarket approval of new products or services, new
intended uses or modifications to existing products or services; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">withdrawal of 510(k) clearance or premarket approvals that have already been granted; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">criminal prosecution. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If any of these events were to occur, our business, financial condition, results of operations and prospects could be materially adverse
affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Material modifications to our ASSURE WCD or any future products may require new PMAs, 510(k) clearances, CE Marks or other premarket
approvals or may require us to recall or cease marketing our products and services until clearances are obtained. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Material
modifications to the intended use or technological characteristics of our products will require new PMA or 510(k) clearances or CE Mark grants or require us to recall or cease marketing the modified devices until these clearances or approvals are
obtained. Based on FDA published guidelines, the FDA requires device manufacturers to initially make and document a determination of whether or not a modification requires a new </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
approval, supplement or clearance; however, the FDA can review a manufacturer&#146;s decision. Any modification to an FDA cleared device or service that would significantly affect its safety or
efficacy or that would constitute a major change in its intended use would require a new PMA or 510(k) clearance. We may not be able to obtain additional PMA or 510(k) clearances for new products or for modifications to, or additional indications
for, our products in a timely fashion, or at all. Delays in obtaining future clearances would adversely affect our ability to introduce new or enhanced products in a timely manner, which in turn would have an adverse effect on our business,
financial condition, results of operations and prospects. For device modifications that we conclude do not require a new regulatory clearance or approval, we may be required to recall and to stop marketing the modified devices if the government
agency disagrees with our conclusion and requires new clearances or approvals for the modifications. This could have an adverse effect on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we or our suppliers fail to comply with the federal, state and international regulations, our operations could be delayed or shut down and our
revenue could suffer. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The manufacturing processes of our third-party suppliers are required to comply with the FDA&#146;s QSR,
which covers procedures and documentation of the design, testing, production, control, quality assurance, labeling, packaging, storage and shipping of our products. We are also subject to similar state requirements and licenses, and to ongoing ISO
13485 and ISO 14971 compliance in all operations, including design and service. In addition, we must engage in extensive recordkeeping and reporting and must make available our facilities and records for periodic unannounced inspections by
governmental agencies, including the FDA and state authorities. If we or our third-party suppliers fail a regulatory inspection, our operations could be disrupted and manufacturing interrupted. Failure to take adequate corrective action in response
to an adverse regulatory inspection could result in, among other things, a shutdown of our third-party suppliers&#146; manufacturing operations, our product distribution operations, significant fines, suspension of marketing clearances and
approvals, seizures or recalls of our device, operating restrictions and criminal prosecutions, any of which would cause our business to suffer. Furthermore, our key component suppliers may not currently be or may not continue to be in compliance
with applicable regulatory requirements, which may result in manufacturing delays for our products and cause our revenue to decline. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The
FDA has broad post-market and regulatory enforcement powers. We and our third-party suppliers are subject to unannounced inspections by the FDA to determine our compliance with the QSR and other regulations at both our design and third-party
manufacturing facilities, and these inspections may include the manufacturing facilities of our suppliers. We can provide no assurance that we will continue to remain in compliance with the QSR. If the FDA inspect any of our facilities or our
third-party suppliers&#146; facilities and discover compliance problems, we may have to cease manufacturing and product distribution until we can take the appropriate remedial steps to correct the audit findings. Taking corrective action may be
expensive, time consuming and a distraction for management, which may have an adverse impact on our ability to continue with our research and development projects and implement our business growth plans. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If our products cause or contribute to a death or serious injury, or malfunction in a way that would likely cause or contribute to a death or serious
injury, we will be subject to medical device reporting regulations and other applicable laws, and may need to initiate voluntary or mandatory corrective actions, such as the recall of our healthcare products. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under the FDA&#146;s medical device reporting regulations, we are required to report to the FDA when we receive or become aware of information
that reasonably suggests that one or more of our products may have caused or contributed to a death or serious injury or in which a product of ours malfunctioned and, if the malfunction were to recur, would be likely to cause or contribute to death
or serious injury. Other countries we may market our products to in the future will similarly have regulatory agencies requiring us to report any incident in which our products cause or contribute to a death or serious injury, or malfunction in a
way that would likely cause or contribute to a death or serious injury. The timing of our obligation to report is triggered by </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the date we become aware of the adverse event as well as the nature of the event. We may fail to report adverse events of which we become aware within the prescribed timeframe. We may also fail
to recognize that we have become aware of a reportable adverse event, especially if it is not reported to us as an adverse event or if it is an adverse event that is unexpected or removed in time from the use of the product. If we fail to comply
with our reporting obligations, including when the FDA may disagree with our determination that an event was not reportable, the FDA or other governmental authorities could take action, including warning letters, untitled letters, administrative
actions, criminal prosecution, imposition of civil monetary penalties, revocation of our device clearance, seizure of our products or delay in clearance of future products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The FDA and similar foreign regulatory authorities have the authority to require the recall of our products in the event of material
deficiencies or defects in, for example, design, labeling or manufacture. The FDA must find that there is a reasonable probability that the device would cause serious adverse health consequences or death in order to require a recall. The standard
for recalling deficient products may be different in foreign jurisdictions. Manufacturers may, under their own initiative, recall a product if any material deficiency is found in a device or they become aware of a safety issue involving a marketed
product. A government-mandated or voluntary recall by us could occur as a result of component failures, manufacturing errors, design or labeling defects or other deficiencies and issues. Any correction or removal initiated by us to reduce a health
risk posed by our device, or to remedy a violation of the Federal Food, Drug, and Cosmetic Act or other regulations caused by our product that may present a risk to health, must be reported to the FDA. If the FDA subsequently determines that a
report was required for a correction or removal of our products that we did not believe required a report, we could be subject to enforcement actions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Any recalls or corrections of our products or enforcement actions would divert managerial and financial resources and could have an adverse
effect on our financial condition and results of operations. Depending on the corrective action we take to redress a product&#146;s deficiencies or defects, the FDA may require, or we may decide, that we will need to obtain new clearances or
approvals for the device before we may market or distribute the corrected device. Seeking such clearances or approvals may delay our ability to replace the recalled devices in a timely manner. Moreover, if we do not adequately address problems
associated with our devices, we may face additional regulatory enforcement action, including FDA warning letters, product seizure, injunctions, administrative penalties or civil or criminal fines. In addition, given our dependence upon healthcare
provider and consumer perceptions, any negative publicity associated with any recalls could materially and adversely affect our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We may also be required to maintain certain records of recalls and corrections, even if they are not reportable to the FDA. We may initiate
voluntary withdrawals or corrections for our products in the future that we determine do not require notification of the FDA. If the FDA disagrees with our determinations, it could require us to report those actions as recalls and we may be subject
to enforcement action. A future recall announcement could harm our reputation with customers, potentially lead to product liability claims against us, and negatively affect our revenues, in addition to the FDA enforcement actions. Any corrective
action, voluntary or involuntary, as well as defending ourselves in a lawsuit, will require the dedication of our time and capital, attention of our management, and may harm our reputation, business, financial condition, results of operations and
prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we do not obtain international regulatory registrations, clearances, certifications or approvals for our products, we will be unable
to market and offer our products outside of the United States. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Any future distribution of our products outside of the United
States is subject to foreign regulatory requirements that we have limited experience with and that may vary widely from country to country. As of the date of this prospectus, we have not received any regulatory approvals to commercialize our
products outside of the U.S. and have not submitted any applications to obtain such regulatory approvals. However, we are currently planning to pursue CE Mark approval in Europe and, in the future, intend to strategically commercialize in selected
international markets. We anticipate Western Europe to be our initial focus due to favorable market </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
dynamics and our goal is to obtain regulatory approvals to begin distributing our ASSURE WCD in certain markets in Western Europe within the next three years. There is no assurance of when we
will successfully obtain the CE Mark, if at all. In addition, as a result of the United Kingdom leaving the European Union, since January&nbsp;1, 2021, the regulatory framework and regimes for medical devices in the United Kingdom and the European
Union have diverged. As such, we may need to invest additional time and resources to obtain the relevant approvals if we intend to distribute our products in both the European Union and in the United Kingdom. We may incur significant costs in our
efforts to obtain foreign regulatory approvals and there is no assurance that we will generate sufficient revenues to offset such costs. In addition, the FDA regulates exports of medical devices from the United States. While the regulations of some
countries may not impose barriers to marketing and selling our products or only require notification, others require that we obtain the clearance, certification or approval of a specified regulatory body. Moreover, clinical studies or manufacturing
processes conducted in one country may not be accepted by regulatory authorities in other countries. Complying with foreign regulatory requirements, including obtaining registrations, clearances, certifications or approvals, can be expensive and
time-consuming, and we may not receive regulatory clearances, certifications or approvals in each country in which we plan to market our products or we may be unable to do so on a timely basis. The time required to obtain registrations, clearances,
certifications or approvals, if required by other countries, may be longer than that required for FDA clearance or approval, and requirements for such registrations, clearances, certifications or approvals may significantly differ from FDA
requirements. If we modify our products, we may need to apply for regulatory clearances or approvals before we are permitted to sell the modified product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Regulatory clearance or approval by the FDA does not ensure registration, clearance, certification or approval by regulatory authorities in
other countries, and registration, clearance, certification or approval by one or more foreign regulatory authorities does not ensure registration, clearance, certification or approval by regulatory authorities in other foreign countries or by the
FDA. However, a failure or delay in obtaining registration or regulatory clearance, certification or approval in one country may have a negative effect on the regulatory process in others. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Healthcare reform measures could hinder or prevent the commercialization of our products and our ability to achieve profitability. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">There have been, and we expect there will continue to be, a number of legislative and regulatory changes to the healthcare system that could
harm our future revenue and profitability. Federal and state lawmakers regularly propose and, at times, enact legislation that would result in significant changes to the healthcare system, some of which are intended to contain or reduce the costs of
medical products and services. For example, the Affordable Care Act contains a number of provisions, including those governing enrollment in government healthcare programs, reimbursement changes and fraud and abuse measures, all of which will impact
existing government healthcare programs and will result in the development of new programs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under the prior Trump administration, there
were ongoing efforts to modify or repeal all or certain provisions of the Affordable Care Act. For example, tax reform legislation was enacted at the end of 2017 that eliminated the tax penalty established under Affordable Care Act for individuals
who do not maintain mandated health insurance coverage beginning in 2019. The Affordable Care Act has also been subject to judicial challenge. The case <I>Texas v. Azar</I>, which challenges the constitutionality of the Affordable Care Act,
including provisions that are unrelated to healthcare reform but were enacted as part of the Affordable Care Act, was argued before the Supreme Court in November 2020. The Supreme Court determined the Affordable Care Act would remain in place. The
nature and scope of healthcare reform in the wake of the transition from the Biden administration to the new Trump administration remains uncertain. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">There likely will continue to be legislative and regulatory proposals at the federal and state levels directed at containing or lowering the
cost of healthcare, particularly in light of the new Trump administration which has stated its intent to make some changes to the regulatory landscape overseen by the HHS, including the FDA. We cannot predict the initiatives that may be adopted in
the future or their full impact. The continuing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare may harm: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to set a price that we believe is fair for our products; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to generate revenue and achieve or maintain profitability; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the availability of capital. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, FDA regulations and guidance are often revised or reinterpreted by the FDA in ways that may significantly affect our business and
our products. Any new statutes, regulations or revisions or reinterpretations of existing regulations may make it more difficult and costly to manufacture, market, or distribute our commercialized products, or may impose additional costs, lengthen
regulatory application and approval review times, or make it more difficult to obtain marketing authorizations for any future products we develop. If we are slow or unable to adapt to changes in existing requirements or the adoption of new
requirements or policies, or if we are not able to maintain regulatory compliance, we may be subject to enforcement action and we may not achieve or sustain profitability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to maintain required licenses, certifications, or accreditation, or if we do not fully comply with requirements to provide notice to or
obtain approval from regulatory authorities due to changes in our ownership structure or operation, it could adversely impact our operations. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are required to maintain state and/or federal licenses and certifications for our operations and facilities. From time to time, we may
become subject to new or different licensing requirements due to legislative or regulatory requirements or the development of or changes to our business. We are subject to periodic inspection by governmental and other authorities to assure continued
compliance with the various standards necessary for licensing and certifications, some of which are complex and may be unclear or subject to varying interpretation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Accurate licensure is also a critical threshold issue for Medicare enrollment as a DMEPOS Supplier, which is required in order to bill
Medicare for products provided to Medicare beneficiaries. In addition, many private payors and Medicaid agencies require DMEPOS suppliers to maintain Medicare enrollment, and we are required to comply with the Medicare DMEPOS Supplier Standard in
order to maintain such Medicare enrollment. Although we believe we have the right systems in place to monitor licensure and certification, our failure to obtain and maintain appropriate licensure or certification for our operations, facilities, and
healthcare providers could result in interruptions in our operations and our ability to service patients, refunds to state and/or federal payors, and the imposition of sanctions or fines, which could have an adverse and material impact on our
business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Accreditation is required by most commercial payors and is a
mandatory requirement for all Medicare DMEPOS suppliers. Our company has received DME accreditation via a virtual inspection and a confirmatory onsite visit. CMS has also issued a Medicare <FONT STYLE="white-space:nowrap">P-TAN</FONT> number to our
company as a Medicare DMEPOS supplier. If we fail to maintain our accreditation or Medicare <FONT STYLE="white-space:nowrap">P-TAN</FONT> number, or lose our accreditation or Medicare <FONT STYLE="white-space:nowrap">P-TAN</FONT> number, it could
have a material adverse effect on our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The requirements for licensure
and certification may include notification or approval in the event of a transfer or change of ownership or certain other changes. Government healthcare programs or commercial payors with which we intend to enter into contracts may have similar
requirements and some of those processes may be complex. Failure to provide required notifications or obtain the requisite approvals could result in the delay or inability to complete an acquisition or transfer, loss of licensure, lapses in
reimbursement or other penalties. While we make reasonable efforts to substantially comply with these requirements, if we are found to have failed to comply in some material respect, it could have an adverse or material impact on our business and
our financial conditions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Compliance with environmental laws and regulations could be expensive, and failure to comply with
these laws and regulations could subject us to significant liability. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our research and development operations involve the use of
hazardous substances and are subject to a variety of federal, state, local and foreign environmental laws and regulations relating to the storage, use, discharge, disposal, remediation of, and human exposure to, hazardous substances and the sale,
labeling, collection, recycling, treatment and disposal of products containing hazardous substances. Liability under environmental laws and regulations can be joint and several and without regard to fault or negligence. Compliance with environmental
laws and regulations may be expensive and noncompliance could result in substantial liabilities, fines and penalties, personal injury and third-party property damage claims and substantial investigation and remediation costs. Environmental laws and
regulations could become more stringent over time, imposing greater compliance costs and increasing risks and penalties associated with violations. We cannot assure you that violations of these laws and regulations will not occur in the future as a
result of human error, accidents, equipment failure or other causes. The expense associated with environmental regulation and remediation could materially adversely affect our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our products contain third-party open source software components and failure to comply with the terms of the underlying open source software licenses
could restrict our ability to sell our products, affect our ability to protect our proprietary information and subject us to possible litigation. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our products contain software tools licensed by third parties under open source software licenses. Use and distribution of open source
software may entail greater risks than use of third-party commercial software, as open source software licenses generally do not provide warranties or other contractual protections regarding infringement claims or the quality of the code and have
not been interpreted by United States courts. We may be subject to suits by third parties claiming ownership of what we believe to be open source software, or claiming non-compliance with the applicable open source licensing terms. If we are held to
have breached the terms of an open source software license, we could be required to seek licenses from third parties to continue offering our solutions on terms that are not economically feasible, to re-engineer our products, services or technology,
to discontinue the sale of our products, services or technology if re-engineering could not be accomplished on a timely basis, to pay statutory or other damages to the license holder or to make generally available, in source code form, our
proprietary code, any of which could materially adversely affect our business, financial condition, results of operations and prospects. Use of open source software may also present additional security risks because the public availability of such
software may make it easier for hackers and other third parties to compromise or attempt to compromise our technology platform and systems. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks
Related to This Offering </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Bain Capital controls us, and its interests may conflict with ours or yours. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Immediately following this offering, Bain Capital will own approximately 52.8% of our common shares, or 51.2% if the underwriters exercise in
full their over-allotment option, which means that, based on its percentage voting power held after this offering, Bain Capital will control the vote of all matters submitted to a vote of our shareholders, which will enable it to control the
election of the members of our Board of Directors and other corporate decisions. Even when Bain Capital ceases to own a portion of our shares representing a majority of the total voting power, for so long as Bain Capital continues to own a
significant percentage of our shares, Bain Capital will still be able to significantly influence actions relating to the composition of our Board of Directors, new issuances of equity, including to our employees under equity incentive plans,
amendments of our organizational documents and approval of any merger, amalgamation, sale of assets or other major corporate transaction. Accordingly, for such period of time, Bain Capital will have substantial influence with respect to our
management, business plans and policies. In particular, for so long as Bain Capital continues to own a significant </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
percentage of our shares, Bain Capital will be able to cause or prevent a change of control of us or a change in the composition of our Board of Directors and could preclude any unsolicited
acquisition of us. The concentration of ownership could deprive you of an opportunity to receive a premium for your common shares as part of a sale of us and ultimately might affect the market price of our common shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Bain Capital and its affiliates engage in a broad spectrum of activities, including investments in the healthcare industry generally. In the
ordinary course of its business activities Bain Capital and its affiliates may engage in activities where their respective interests conflict with our interests or those of our other shareholders, such as investing in or advising businesses that
directly or indirectly compete with certain portions of our business or are suppliers or customers of ours. Bain Capital also may pursue acquisition opportunities that may be complementary to our business, and, as a result, those acquisition
opportunities may not be available to us. In addition, Bain Capital may have an interest in pursuing acquisitions, divestitures and other transactions that, in its judgment, could enhance its investment, even though such transactions might involve
risks to you. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our amended and restated bye-laws to be in effect upon the closing of this offering will provide that the Company will
renounce to the fullest extent permitted by applicable law any interest or expectancy in, or in being offered an opportunity to participate in, any business opportunity that may from time to time be presented to Bain Charger and its affiliates, and
that may be a business opportunity for such parties, even if the opportunity is one that the Company might reasonably have pursued or had the ability or desire to pursue if granted the opportunity to do so. In addition, to the fullest extent
permitted by applicable law, Bain Charger and its affiliates will not be liable to the Company for breach of any fiduciary or other duty by reason of the fact that Bain Charger pursues or acquires any such business opportunity, directs any such
business opportunity to another person or fails to present any such business opportunity, or information regarding any such business opportunity, to us. Bain Charger and its affiliates do not have any duty to refrain from engaging directly or
indirectly in the same or similar business activities or lines of business as the Company or any of its subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Upon listing of our shares on
the Nasdaq Global Select Market, we will be a &#147;controlled company&#148; within the meaning of the Nasdaq rules and, as a result, we will qualify for exemptions from certain corporate governance requirements. You will not have the same
protections as those afforded to shareholders of companies that are subject to such governance requirements. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">After the completion
of this offering, Bain Capital will continue to control a majority of the voting power of our outstanding common shares. As a result, we will be a &#147;controlled company&#148; within the meaning of the corporate governance standards of the Nasdaq
Global Select Market. However, depending on the price of the shares offered and the number of common shares offered by us, as set forth on the cover page of this prospectus, Bain Charger may not continue to own a majority of the voting power of our
outstanding common shares eligible to vote in the election of our directors. As a result, we may not be a &#147;controlled company&#148; within the meaning of the corporate governance standards of the Nasdaq Global Select Market. Under these
&#147;controlled company&#148; rules, a company of which more than 50% of the voting power for the election of directors is held by an individual, group or another company is a &#147;controlled company&#148; and may elect not to comply with certain
corporate governance requirements, including: </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the requirement that a majority of our Board of Directors consist of independent directors;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the requirement that we have a nominating and corporate governance committee that is composed entirely of
independent directors with a written charter addressing the committee&#146;s purpose and responsibilities; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the requirement that we have a compensation committee that is composed entirely of independent directors with a
written charter addressing the committee&#146;s purpose and responsibilities; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the requirement for an annual performance evaluation of the nominating and corporate governance and compensation
committees. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Following this offering, we may elect to utilize one or more of these exemptions.
Accordingly, you will not have the same protections afforded to shareholders of companies that are subject to all of the corporate governance requirements of the Nasdaq Global Select Market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are an emerging growth company and a smaller reporting company, and our compliance with the reduced reporting and disclosure requirements applicable
to emerging growth companies and smaller reporting companies could make our common shares less attractive to investors. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are an
&#147;emerging growth company,&#148; as defined in the JOBS Act, and may remain an emerging growth company for up to five years. For as long as we are an emerging growth company, we will not be required to comply with certain requirements that are
applicable to other public companies that are not emerging growth companies, including the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act, and may also take advantage of the reduced disclosure obligations regarding
executive compensation in our periodic reports, proxy statements and registration statements and the exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and obtaining shareholder approval of any golden
parachute payments not previously approved. As a result, the information we provide shareholders will be different than the information that is available with respect to other public companies. In this prospectus, we have not included all of the
executive compensation related information that would be required if we were not an emerging growth company and we have provided only two years of audited financial statements and only two years of related &#147;Management&#146;s Discussion and
Analysis of Financial Condition and Results of Operations.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, under the JOBS Act, emerging growth companies can delay
adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. We have elected to avail ourselves of the provision of the JOBS Act that permits emerging
growth companies to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies. As a result, we will not be subject to new or revised accounting standards at the same time as
other public companies that are not emerging growth companies. As a result of these elections, our financial statements may not be comparable to those of public companies that comply with such new or revised accounting standards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are also a &#147;smaller reporting company,&#148; as such term is defined in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> under the
Exchange Act. We may continue to be a smaller reporting company for so long as either (1)&nbsp;the market value of our common shares held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $250.0&nbsp;million as of the last
business day of our most recently completed second fiscal quarter or (2)&nbsp;our annual revenue was less than $100.0&nbsp;million during the most recently completed fiscal year and the market value of our common shares held by <FONT
STYLE="white-space:nowrap">non-affiliates</FONT> is less than $700.0&nbsp;million as of the last business day of our most recently completed second quarter. Any loss of our status as a smaller reporting company takes effect in the first quarter
after the fiscal year in which we cease to qualify as a smaller reporting company. To the extent that we continue to qualify as a smaller reporting company at the time we cease to qualify as an emerging growth company, we will continue to be
permitted to make certain reduced disclosures in our periodic reports and other documents that we file with the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>An active, liquid trading
market for our common shares may not develop, which may limit your ability to sell your shares. </I></B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Prior to this offering, there
was no public market for our common shares. We have applied to list our common shares on The Nasdaq Global Select Market under the symbol &#147;KMTS.&#148; However, an active trading market for our shares may never develop or be sustained following
this offering. The initial public offering price will be determined by negotiations among us and the representatives of the underwriters and may not be indicative of market prices of our common shares that will prevail in the open market after the
offering. A public trading market having the desirable characteristics of depth, liquidity and orderliness depends upon the existence of willing buyers and sellers at any given time, such existence being dependent upon the individual decisions of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
buyers and sellers over which neither we nor any market maker has control. The failure of an active and liquid trading market to develop and continue would likely have a material adverse effect
on the value of our common shares. The market price of our common shares may decline below the initial public offering price, and you may not be able to sell your shares at or above the price you paid in this offering, or at all. An inactive market
may also impair our ability to raise capital to continue to fund operations by selling shares and may impair our ability to acquire other technologies related to our business by using our shares as consideration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our share price may be volatile, and you may be unable to resell your shares at or above the initial public offering price. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The market price of our common shares may be highly volatile and may fluctuate or decline substantially as a result of a variety of factors.
In addition, securities markets worldwide have experienced, and are likely to continue to experience, significant price and volume fluctuations. This market volatility, as well as general economic, market or political conditions, could subject the
market price of our shares to wide price fluctuations regardless of our operating performance. We and the underwriters have negotiated the initial public offering price. You may not be able to resell your shares at or above the initial public
offering price or at all. The public trading price for our common shares after this offering will be affected by a number of factors, including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in analysts&#146; estimates, investors&#146; perceptions, recommendations by securities analysts or our
failure to achieve analysts&#146; estimates; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">quarterly variations in our or our competitors&#146; results of operations; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">periodic fluctuations in our revenue; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the financial projections we may provide to the public, any changes in these projections or our failure to meet
these projections; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">general market conditions and other factors unrelated to our operating performance or the operating performance
of our competitors; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in reimbursement by potential payors; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in operating performance and stock market valuations of other technology companies generally, or those in
the medical device industry in particular; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">actual or anticipated changes in regulatory oversight of our products; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the results of our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the loss of key personnel, including changes in our Board of Directors and management; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">legislation or regulation of our market; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">lawsuits threatened or filed against us; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the announcement of new products or product enhancements by us or our competitors; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announced or completed acquisitions of businesses or technologies by us or our competitors;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcements related to patents issued to us or our competitors and related litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">general economic conditions and trends; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">effects of public health crises; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developments in our industry. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">These and other factors, many of which are beyond our control, may cause our results of operations and the market price and demand for our
shares to fluctuate substantially. In addition, the share prices of many companies in the medical device industry have experienced wide fluctuations that have often been unrelated to the operating performance of those companies. While we believe
that results of operations for any particular quarter are not necessarily a meaningful indication of future results, fluctuations in our quarterly results of operations could limit or prevent investors from readily selling their shares and may
otherwise negatively affect the market price and liquidity of our shares. In addition, in the past, when the market price of a stock has been volatile, holders of that stock have sometimes instituted securities class action litigation against the
company that issued the stock. If any of our shareholders brought a lawsuit against us, we could incur substantial costs defending the lawsuit. Such a lawsuit could also divert the time and attention of our management from our business, which could
significantly harm our profitability and reputation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be a passive foreign investment company, which could result in adverse U.S. federal
income tax consequences to United States Holders. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under the United States Internal Revenue Code of 1986, as amended (the
&#147;Code&#148;), a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> corporation (such as ourselves) will be classified as a passive foreign investment company (a &#147;PFIC&#148;) for any taxable year if, for such year after the application of
certain look-through rules with respect to subsidiaries, either (1)&nbsp;at least 75% of our gross income for the year is &#147;passive income&#148; (as described below), or (2)&nbsp;the average percentage of our assets (determined at the end of
each quarter) during the taxable year which produce &#147;passive income&#148; or which are held for the production of &#147;passive income&#148; is at least 50%. &#147;Passive income&#148; generally includes dividends, interest, rents, royalties
(other than rents or royalties derived from the active conduct of a trade or business) and gains from the disposition of passive assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If it is determined that we are a PFIC for any taxable year (or portion thereof) that is included in the holding period of a U.S. Holder (as
defined in &#147;Material Bermuda, Irish and U.S. Federal Income Tax Considerations&#151;U.S. Federal Income Tax Consequences for U.S. Holders&#148;), such U.S. Holder may be subject to increased U.S. federal income tax liability and may be subject
to additional reporting requirements. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Based on the nature of our business, our financial statements, our expectations about the
nature and amount of our income, assets and activities and the expected price of our common shares in this offering, we do not expect to be a PFIC for U.S. federal income tax purposes for the current taxable year or in the foreseeable future.
However, whether we will be a PFIC in the current year or any future year is a factual determination that must be made annually at the close of each taxable year, and, thus, is subject to significant uncertainty. Among other things, a determination
of whether we are a PFIC will depend on the composition of our income and assets and the market value of our assets from time to time. Accordingly, there can be no assurance that we will not be a PFIC in the current year or any future taxable year.
</P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If we are a PFIC for any taxable year during which a U.S. Holder holds our common shares, we generally would continue to be treated
as a PFIC with respect to that U.S. Holder for all succeeding years during which the U.S. Holder holds our common shares even if we ceased to meet the threshold requirements for PFIC status, unless certain exceptions apply. Such a U.S. Holder may be
subject to adverse U.S. federal income tax consequences, including (i)&nbsp;the treatment of all or a portion of any gain on disposition as ordinary income, (ii)&nbsp;the application of a deferred interest charge on such gain and the receipt of
certain dividends and (iii)&nbsp;compliance with certain reporting requirements. We do not currently expect to provide information that would allow a U.S. Holder to make a &#147;qualifying electing fund&#148; election (a &#147;QEF Election&#148;) in
the event that we are classified as a PFIC and, therefore, U.S. Holders should assume such election would not be available. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For a more detailed discussion of the application of the PFIC rules to us and the
consequences to U.S. Holders if we were determined to be a PFIC, see &#147;Material Bermuda, Irish and U.S. Federal Income Taxation&#151;U.S. Federal Income Tax Consequences for U.S. Holders&#151;Passive Foreign Investment Company.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>A sale of a substantial number of shares of our common shares may cause the price of our common shares to decline. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If our existing shareholders sell, or indicate an intention to sell, substantial amounts of our common shares in the public market after the
lapse of <FONT STYLE="white-space:nowrap">lock-up</FONT> and other legal restrictions on resale discussed in this prospectus, the trading price of our common shares could decline. Based on shares outstanding as of October 31, 2024, following the
Organizational Transactions and upon completion of this offering, we will have outstanding a total of 47,651,467 common shares. Of these shares, all of the common shares sold in this offering will be freely tradable, without restriction, in the
public market immediately after the offering, other than the shares purchased by certain of our existing investors, which will be subject to <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements, as described below. Each of our directors and
officers and substantially all of our other shareholders have entered into a <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement with the underwriters that restricts their ability to sell or transfer their shares. The <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreements pertaining to this offering will expire 180 days from the date of this prospectus. BofA Securities, Inc., Goldman Sachs &amp; Co. LLC and Piper Sandler &amp; Co., however, may, in their sole
discretion, waive the contractual <FONT STYLE="white-space:nowrap">lock-up</FONT> prior to the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements. After the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements expire,
based on shares outstanding as of October 31, 2024, 37,651,467 common shares, plus any shares purchased in this offering by our existing investors, will be eligible for sale in the public market, of which 25,463,914 shares, plus any shares purchased
in this offering by certain of our existing investors, will be held by directors, executive officers and other affiliates and will be subject to volume limitations under Rule 144 under the Securities Act, and various vesting agreements. After this
offering, the holders of an aggregate of 37,022,259 shares of our outstanding common shares as of October 31, 2024, will have rights, subject to some conditions, to require us to file registration statements covering their shares or to include their
shares in registration statements that we may file for ourselves or our shareholders. In addition, upon the consummation of this offering, there will be 4,728,033&nbsp;common shares underlying outstanding stock options to be granted to our NEOs and
certain other employees immediately following the determination of the initial public offering price for this offering, with an exercise price equal to the initial public offering price. Such common shares will become eligible for sale in the public
market to the extent permitted by the provisions of various vesting agreements, the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements and Rules 144 and 701 under the Securities Act. Additionally, 12,680,000 common shares are expected to be
reserved for issuance under our new equity incentive plan (which number of reserved common shares will be subject to adjustment depending on the number of shares offered in this offering). We intend to file a registration statement on Form <FONT
STYLE="white-space:nowrap">S-8</FONT> under the Securities Act covering all of the common shares subject to options outstanding and reserved for issuance under our share plans. This registration statement will become effective immediately upon
filing, and shares covered by this registration statement will be eligible for sale in the public markets, subject to Rule 144 limitations applicable to affiliates and any <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described above.
If these additional shares are sold, or if it is perceived that they will be sold, in the public market, the trading price of our common shares could decline. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will have broad discretion in the use of net proceeds from this offering. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our management will have broad discretion over the use and investment of the net proceeds of this offering. We intend to use the majority of
the net proceeds from this offering to scale up our commercial operations, including through investments in our commercial organization by the hiring of additional sales representatives, sales team leadership and clinical care specialists, as well
as through investments in our fleet of devices, supply chain and revenue cycle management capabilities. We also expect to use proceeds of this offering to fund the research and development of continued innovation in our products and to fund trials
to build upon our strong base of clinical evidence. Additionally, a portion of the proceeds of this offering will be used to fund offering and reorganization costs incurred by us as part of this offering. The proceeds will also be used for working
capital and general corporate purposes. However, this expected use of the net proceeds from this offering represents our intentions based upon our current plans and business conditions, which could change in the future as our plans and business
conditions evolve. Accordingly, investors in this offering will need to rely </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
upon the judgment of our management with respect to the use of proceeds with only limited information concerning management&#146;s specific intentions. See &#147;Use of Proceeds&#148; for
additional information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are a Bermuda company, and it may be difficult for you to enforce judgments against us or our directors and executive
officers. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are a Bermuda exempted company limited by shares. As a result, the rights of our shareholders are governed by
Bermuda law, our memorandum of association and the amended and restated <FONT STYLE="white-space:nowrap">bye-laws</FONT> to be in effect upon the closing of this offering. The rights of shareholders under Bermuda law may differ from the rights of
shareholders of companies incorporated in another jurisdiction. It may be difficult for investors to effect service of process on concerned persons not resident in the United States or to enforce in the U.S. judgments obtained in U.S. courts against
us based on the civil liability provisions of the U.S. securities laws. It is doubtful whether courts in Bermuda will enforce judgments obtained in other jurisdictions, including the United States, against us or our directors or officers under the
securities laws of those jurisdictions or entertain actions in Bermuda against us or our directors or officers under the securities laws of other jurisdictions. See &#147;Enforcement of Civil Liabilities under U.S. Federal Securities Laws&#148; for
additional information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Bermuda law differs from the laws in effect in the United States and may afford less protection to our shareholders.
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are incorporated under the laws of Bermuda. As a result, our corporate affairs are governed by the Bermuda Companies Act 1981,
as amended (the &#147;Companies Act&#148;), which differs in some material respects from laws typically applicable to U.S. corporations and shareholders, including the provisions relating to interested directors, amalgamations, mergers and
acquisitions, takeovers, shareholder lawsuits and indemnification of directors. Generally, the duties of directors and officers of a Bermuda company are owed to the company only. Shareholders of Bermuda companies typically do not have rights to take
action against directors or officers of the company and may only do so in limited circumstances. Shareholder class actions are not available under Bermuda law in the same way they are under the laws of the United States. The circumstances in which
shareholder derivative actions may be available under Bermuda law are substantially more proscribed and less clear than they would be to shareholders of U.S. corporations. The Bermuda courts, however, would ordinarily be expected to permit a
shareholder to commence an action in the name of a company to remedy a wrong to the company where the act complained of is alleged to be ultra vires or illegal, or would result in the violation of the company&#146;s memorandum of association or <FONT
STYLE="white-space:nowrap">bye-laws.</FONT> Furthermore, consideration would be given by a Bermuda court to acts that are alleged to constitute a fraud against the minority shareholders or, for instance, where an act requires the approval of a
greater percentage of the company&#146;s shareholders than those who actually approved it. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">When the affairs of a company are being
conducted in a manner that is oppressive or prejudicial to the interests of some shareholders, one or more shareholders may apply to the Supreme Court of Bermuda, which may make such order as it sees fit, including an order regulating the conduct of
the company&#146;s affairs in the future or ordering the purchase of the shares of any shareholders by other shareholders or by the company. Additionally, under our amended and restated <FONT STYLE="white-space:nowrap">bye-laws</FONT> to be in
effect upon the closing of this offering and as permitted by Bermuda law, each shareholder will waive any claim or right of action against our directors or officers for any action taken by directors or officers in the performance of their duties,
except for actions involving fraud or dishonesty or any claims of violations of the Securities Act or the Exchange Act. In addition, the rights of our shareholders and the fiduciary responsibilities of our directors under Bermuda law are not as
clearly established as under statutes or judicial precedent in existence in jurisdictions in the United States, particularly the State of Delaware. Therefore, our shareholders may have more difficulty protecting their interests than would
shareholders of a corporation incorporated in a jurisdiction within the United States. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>There are regulatory limitations on the ownership and
transfer of our common shares. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Common shares may be offered or sold in Bermuda only in compliance with the provisions of the
Companies Act and the Bermuda Investment Business Act 2003 as amended, which regulates the sale of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">85 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
securities in Bermuda. In addition, the Bermuda Monetary Authority must approve all issues and transfers of shares of a Bermuda exempted company. However, the Bermuda Monetary Authority has,
pursuant to its notice to the public of June&nbsp;1, 2005, given its general permission under the Exchange Control Act 1972 and related regulations for the issue and free transfer of our common shares that are the subject of this offering to and
among persons who are <FONT STYLE="white-space:nowrap">non-residents</FONT> of Bermuda for exchange control purposes as long as the shares are listed on an appointed stock exchange, which includes the Nasdaq Global Select Market. The general
permission would cease to apply if we were to cease to be listed on the Nasdaq Global Select Market or another appointed stock exchange. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We
have&nbsp;anti-takeover&nbsp;provisions&nbsp;in our amended and restated <FONT STYLE="white-space:nowrap">bye-laws</FONT> that may discourage a change of control, even if an acquisition would be beneficial to our shareholders, and may prevent
attempts by our shareholders to replace or remove our current management. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our amended and restated
<FONT STYLE="white-space:nowrap">bye-laws</FONT> to be in effect upon the closing of this offering contain provisions that could make it more difficult for a third party to acquire us without the consent of our Board of Directors. These provisions
provide for: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a classified Board of Directors with staggered three-year terms until the seventh annual general meeting of
shareholders after the completion of this offering (the &#147;Triggering Annual Meeting&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">directors only to be removed for cause and only with a resolution passed by holders of at least 66&nbsp;2/3% of
all issued shares entitled to vote, from and after the date that Bain Charger and its affiliates cease to beneficially own at least 50% of the issued common shares of our company (the &#147;Trigger Event&#148;); </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">from and after the Trigger Event, amendments to our amended and restated
<FONT STYLE="white-space:nowrap">bye-laws</FONT> and memorandum of association will require the approval of our Board of Directors and a resolution passed by holders of at least 66 2/3% of all issued shares entitled to vote; </P></TD></TR></TABLE>
 <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">from and after the Trigger Event, only permit shareholder action by written consent when it is unanimously
approved by our shareholders; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on the time period in which directors may be nominated; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">limitations on our shareholders&#146; ability to call special general meetings; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability of our Board of Directors to determine the powers, preferences and rights of preference shares and to
cause us to issue the preference shares without shareholder approval. </P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, although the Companies Act does
not contain specific provisions regarding &#147;business combinations&#148; between companies organized under the laws of Bermuda and &#147;interested shareholders,&#148; we will include these provisions in our amended and restated bye-laws to be in
effect upon the closing of this offering. Specifically, our amended and restated bye-laws to be in effect upon the closing of this offering will contain provisions which prohibit us, subject to certain exceptions, from engaging in business
combinations and other specified transactions with persons (excluding Bain Charger and its affiliates) for a period of three years after the time of the transaction in which the person acquired 15% or more of our issued voting shares. See
&#147;Description of Share Capital&#151;Business Combinations.&#148; </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">These anti-takeover defenses could discourage, delay or prevent
a transaction involving a change of control of our company and may prevent our shareholders from receiving the benefit from any premium to the market price of our common shares offered by a bidder in a takeover context. Even in the absence of a
takeover attempt, the existence of these provisions may adversely affect the prevailing market price of our common shares if the provisions are viewed as discouraging takeover attempts in the future. These provisions could also
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">86 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
discourage proxy contests, make it more difficult for our shareholders to elect directors of their choosing and cause us to take corporate actions other than those our shareholders desire. See
&#147;Description of Share Capital.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our amended and restated <FONT STYLE="white-space:nowrap">bye-laws</FONT> will provide that the Supreme
Court of Bermuda or the federal district courts of the United States will be the exclusive forum for certain types of lawsuits and this may have the effect of discouraging lawsuits against our directors and officers. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our amended and restated <FONT STYLE="white-space:nowrap">bye-laws</FONT> will provide that, unless we, in writing, select or consent to the
selection of an alternate forum, the Supreme Court of Bermuda shall be the exclusive forum for any dispute that arises under the Companies Act or out of or in connection with our amended and restated <FONT STYLE="white-space:nowrap">bye-laws,</FONT>
including any question regarding the existence, validity, application, enforceability or scope of any <FONT STYLE="white-space:nowrap">bye-law</FONT> and/or whether there has been any breach of the Companies Act or our amended and restated <FONT
STYLE="white-space:nowrap">bye-laws</FONT> or any breach of a duty (including any fiduciary duty) by, or other wrongdoing by, a current or former officer, director, employee, agent or shareholder of the Company to the Company or its shareholders
(whether or not such a claim is brought in the name of a shareholder or in the name of the Company). Further, unless we select or consent to the selection of an alternative forum, to the fullest extent permitted by applicable law, the federal
district courts of the United States shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act against the Company or any director, officer, employee or agent of the Company.
Notwithstanding the foregoing, these provisions in our amended and restated <FONT STYLE="white-space:nowrap">bye-laws</FONT> will not apply to suits brought to enforce any liability or duty created by the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Any person or entity purchasing or otherwise acquiring or holding any interest in our common shares shall be deemed to have notice of and to
have consented to the forum selection provisions described in our amended and restated <FONT STYLE="white-space:nowrap">bye-laws.</FONT> These exclusive forum provisions may limit a shareholder&#146;s ability to bring a claim in a judicial forum
that it finds favorable for disputes with us or any of our directors, officers, or shareholders, which may discourage lawsuits with respect to such claims. Our shareholders will not be deemed to have waived our compliance with the federal securities
laws and the rules and regulations thereunder as a result of our exclusive forum provisions. Further, in the event a court finds the exclusive forum provisions contained in our amended and restated <FONT STYLE="white-space:nowrap">bye-laws</FONT> to
be unenforceable or inapplicable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business, operating results and financial condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have historically not paid cash dividends and do not expect to pay cash dividends in the foreseeable future, and, as a result, any return on
investment may be limited to the value of our shares. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have historically not paid cash dividends and do not anticipate paying
cash dividends in the foreseeable future. The payment of cash dividends will depend on our earnings, capital requirements, financial condition, prospects and other factors our Board of Directors may deem relevant. Our Term Loan limits our ability
to, among other things, pay dividends or make other distributions or payments on account of our common shares, in each case, subject to certain exceptions. In addition, pursuant to Bermuda law, we cannot declare or pay dividends, or make
distributions out of our contributed surplus, if there are reasonable grounds for believing that (1)&nbsp;our Company is, or would after the payment be, unable to pay our liabilities as they become due or (2)&nbsp;the realizable value of our assets
would thereby be less than our liabilities. Our ability to pay dividends is also restricted by covenants in our Term Loan. Additionally, because we are a holding company with no material direct operations, we are financially dependent on loans,
dividends and other payments from our operating subsidiaries. To the extent that we decide to pay dividends on our common shares in the future, we will be dependent on our operating subsidiaries to make funds available to us for the payment of any
such dividends. See &#147;Dividend Policy&#148; for more information. If we do not pay dividends, our shares may be less valuable because a return on your investment will only occur if you sell our common shares after our share price appreciates.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>New investors purchasing our common shares will experience immediate and substantial dilution.
</I></B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The initial public offering price of our common shares is expected to be substantially higher than the pro forma net tangible
book value (deficit) per share of our common shares. Therefore, if you purchase shares of our common shares in this offering, you will pay a price per share that substantially exceeds our pro forma as adjusted net tangible book value (deficit) per
share after this offering. You will experience immediate dilution of $11.36 per share, representing the difference between our pro forma as adjusted net tangible book value (deficit) per share after giving pro forma effect to this offering and the
assumed initial public offering price. In addition, purchasers of common shares in this offering will have contributed 23.2% of the aggregate price paid by all purchasers of our shares but will own only approximately 21.0% of our common shares
issued after this offering. See &#147;Dilution.&#148; In connection with this offering, the Existing KLIM Warrants and the Existing Perceptive Warrants will be canceled and Kestra Medical Technologies, Ltd. will issue new warrants to purchase an
aggregate of 438,936 common shares of Kestra Medical Technologies, Ltd. pursuant to the Warrants, assuming an initial public offering price of $15.00 per share, the midpoint of the price range set forth on the cover page of this prospectus. Any
exercise of warrants issued under the Warrant Agreements could result in further dilution to our shareholders. See the section titled &#147;Organizational Transactions&#151;Warrants.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General Risk Factors </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will incur increased
costs as a result of operating as a public company, and our management will be required to devote substantial time to compliance with our public company responsibilities and corporate governance practices. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As a public company, and particularly after we are no longer an &#147;emerging growth company&#148; or &#147;smaller reporting company,&#148;
we will incur significant legal, accounting and other expenses that we did not incur as a private company. The Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of the Nasdaq Global Select
Market, and other applicable securities rules and regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. We expect that
we will need to hire additional accounting, finance and other personnel in connection with our becoming, and our efforts to comply with the requirements of being, a public company, and our management and other personnel will need to devote a
substantial amount of time toward maintaining compliance with these requirements. Our management and other personnel will also need to devote a substantial amount of time toward compliance with the additional reporting requirements of the Exchange
Act. These requirements will increase our legal and financial compliance costs and will make some activities more time-consuming and costly. For example, we expect that the rules and regulations applicable to us as a public company may make it more
difficult and more expensive for us to obtain director and officer liability insurance. We are currently evaluating these rules and regulations and cannot predict or estimate the amount of additional costs we may incur or the timing of such costs.
These rules and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing
bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to implement and maintain effective internal control over financial reporting, investors may lose confidence in the accuracy and
completeness of our reported financial information, and the market price of our common shares may be negatively affected. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are
not currently required to comply with the SEC&#146;s rules implementing Section&nbsp;404 of the Sarbanes-Oxley Act and are therefore not required to make a formal assessment of the effectiveness of our internal control over financial reporting for
that purpose.&nbsp;As a public company, we will be required to evaluate and determine the effectiveness of our internal control over financial reporting and, beginning with our second annual report after the completion of this offering, provide a
management report on the effectiveness of our internal control over financial reporting. In connection with the preparation of our consolidated financial </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">88 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
statements, we identified material weaknesses in our internal control over financial reporting as of April&nbsp;30, 2024. For more information, see &#147;&#151;Risks Related to Our
Business&#151;We have identified material weaknesses in our internal control over financial reporting, and may identify additional material weaknesses. If our remediation of the material weaknesses is not effective, or we fail to develop and
maintain effective internal control over financial reporting, our ability to produce timely and accurate financial statements could be impaired, which could harm our business and negatively impact the value of our common shares.&#148; Future
evaluations by us of our internal control over financial reporting as a public company may identify additional material weaknesses. The identification of a material weakness in our internal control over financial reporting or the failure to
remediate existing material weaknesses in our internal control over financial reporting may cause us to be unable to report our financial information on a timely basis and thereby subject us to adverse regulatory consequences, including sanctions by
the SEC or violations of Nasdaq Global Select Market rules. Ensuring that we have adequate internal financial and accounting controls and procedures in place so that we can produce accurate financial statements on a timely basis may be a costly and
time-consuming effort that will need to be evaluated frequently. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Moreover, when we are no longer an emerging growth company, our
independent registered public accounting firm will be required to issue an audit report on the effectiveness of our internal control over financial reporting. An independent assessment of the effectiveness of our internal control over financial
reporting could detect problems that our management&#146;s assessment might not.&nbsp;If we are unable to conclude that our internal control over financial reporting is effective, or when we are no longer an emerging growth company, if our auditors
were to express an adverse opinion on the effectiveness of our internal control over financial reporting because we had one or more material weaknesses, investors could lose confidence in the accuracy and completeness of our financial disclosures,
which could cause the price of our common shares to decline. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If securities or industry analysts do not publish research or reports about our
business, or publish negative reports about our business, our share price and trading volume could decline. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The trading market
for our shares will be influenced, in part, by the research and reports that industry or securities analysts publish about us or our business. We do not have any control over these analysts. Securities and industry analysts do not currently, and may
never, publish research on our company. If no securities or industry analysts commence coverage of our company, the trading price of our shares would likely be negatively impacted. In the event securities or industry analysts initiated coverage, and
one or more of these analysts cease coverage of our company or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our share price or trading volume to decline. Moreover, if one or
more of the analysts who cover us downgrade our shares, or if our results of operations do not meet their expectations, our share price could decline. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom744414_3"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This prospectus contains forward-looking statements that involve substantial risks and uncertainties. The forward-looking statements are
contained principally in the sections titled &#147;Prospectus Summary,&#148; &#147;Risk Factors,&#148; &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and &#147;Business,&#148; but are also
contained elsewhere in this prospectus. In some cases, you can identify forward-looking statements by the words &#147;anticipate,&#148; &#147;believe,&#148; &#147;continue,&#148; &#147;could,&#148; &#147;estimate,&#148; &#147;expect,&#148;
&#147;intend,&#148; &#147;may,&#148; &#147;might,&#148; &#147;objective,&#148; &#147;ongoing,&#148; &#147;plan,&#148; &#147;potential,&#148; &#147;predict,&#148; &#147;project,&#148; &#147;should,&#148; &#147;will&#148; and &#147;would,&#148; or the
negative of these terms, or other comparable terminology intended to identify statements about the future. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity,
performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this
prospectus, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. Forward-looking statements include statements about: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to continue to expand the commercialization of our ASSURE WCD, including associated products and
services as part of our Cardiac Recovery System platform, or to commercialize any future product candidates and begin generating revenue; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to maintain regulatory approvals for our ASSURE WCD and to obtain new regulatory approvals necessary
to distribute our ASSURE WCD in new markets or to distribute additional products we develop in the future; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rate and degree of market acceptance of our ASSURE WCD or any future product candidates that receive the
necessary marketing and other regulatory approvals; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the availability of reimbursement for our products; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to scale the manufacturing of our ASSURE WCD, obtain sufficient and timely supplies of components
necessary to manufacture our ASSURE WCD and effectively manage inventory and distribution; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to hire and retain qualified personnel, including senior management and sales professionals;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">estimates of our total addressable market and near-term achievable market for our products;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing or likelihood of regulatory filings and approvals or clearances; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding the use of proceeds from this offering; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our growth plans, including our plans to enter into new markets; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to establish and maintain intellectual property protection for our products or defend ourselves
against claims of infringement; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the progress, timing, costs and results of our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes and developments relating to our regulatory landscape; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our financial performance and our expectations about market trends; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">90 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the increased expenses associated with being a public company; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developments and projections relating to our competitors and our industry. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">You should refer to the section titled &#147;Risk Factors&#148; for a discussion of important factors that may cause our actual results to
differ materially from those expressed or implied by our forward-looking statements. As a result of these factors, we cannot assure you that the forward-looking statements in this prospectus will prove to be accurate. Furthermore, if our
forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any
other person that we will achieve our objectives and plans in any specified time frame, or at all. Any forward-looking statement that we make in this prospectus speaks only as of the date of such statement. We undertake no obligation to publicly
update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In
addition, statements that &#147;we believe&#148; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this prospectus, and while we believe
such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially
available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">You should read this prospectus and the documents that we reference in this prospectus and have filed as exhibits to the registration
statement, of which this prospectus is a part, completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">91 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom744414_4"></A>ORGANIZATIONAL TRANSACTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We intend to consummate the following organizational transactions prior to or concurrently with (unless otherwise stated) this offering: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">West Affum Holdings, L.P. will contribute all its equity interests, including preferred shares, in West Affum
Intermediate Holdings to Kestra Medical Technologies, Ltd., the issuer in this offering, in exchange for common shares of Kestra Medical Technologies, Ltd., thereby making Kestra Medical Technologies, Ltd. the top parent company of West Affum
Intermediate Holdings and all of its subsidiaries; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Kestra Medical Technologies, Ltd. will deliver 37,651,467 newly-issued common shares with a par value of $1.00
per share to the holders of West Affum Holdings, L.P. Class&nbsp;A common units and incentive units (including a third-party investor who will receive Class&nbsp;A common units in West Affum Holdings, L.P. immediately prior to the distribution in
exchange for its equity interests in West Affum Holdings Designated Activity Company) including 10,997 common shares of Kestra Medical Technologies, Ltd. that will be subject to vesting conditions, in consideration for the exchange of such
holders&#146; interests in West Affum Holdings, L.P; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Kestra Medical Technologies, Ltd. will issue new warrants in consideration of the cancellation of certain
warrants issued by West Affum Holdings, L.P. (see &#147;&#151;Warrant Transactions&#148; below); </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">West Affum Holdings, L.P. will continue to hold common shares of Kestra Medical Technologies, Ltd. for the
benefit of the holders of common units in West Affum Holdings, L.P., including an affiliate of Bain Capital, until such time that such common shares are distributed by West Affum Holdings, L.P. to the remaining partners of West Affum Holdings, L.P.,
which is currently expected to occur approximately nine months after the consummation of this offering. The allocation of the number of common shares of Kestra Medical Technologies, Ltd. held by West Affum Holdings, L.P. among the holders of common
units in West Affum Holdings, L.P. in the Post-IPO Distribution will be determined in reference to the liquidation value of West Affum Holdings, L.P. at the time of such Post-IPO Distribution; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Following the Organizational Transactions, at the West Affum Intermediate Holdings level, pre-existing preferred
interests as well as noncontrolling interests of its subsidiaries, will be converted into common shares, which will all be wholly owned by Kestra Medical Technologies, Ltd. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The 100 shares of Kestra Medical Technologies, Ltd. common stock outstanding as of October 31, 2024, owned by West Affum Holdings, L.P., will
continue to be owned by West Affum Holdings, L.P. following the consummation of the Organizational Transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Organizational
Transactions impact the equity and do not impact the total assets or total liabilities of Kestra Medical Technologies, Ltd. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The
allocation of the Kestra Medical Technologies, Ltd. common shares that will be delivered to unitholders of West Affum Holdings, L.P. among such unitholders will depend on the initial public offering price per common share, specifically the
allocation between the holders of incentive units and the holders of Class A Common Units and common units. The percentage shareholdings in this prospectus reflect an assumed initial public offering price of $15.00 per common share, which is the
midpoint of the price range set forth on the cover page of this prospectus. A $1.00 increase in the initial public offering price would result in the holders of incentive units being allocated 163,833 more common shares and the holders of Class A
Common Units and common units the converse. A $1.00 decrease in the initial public offering price would result in the holders of incentive units being allocated 176,292 fewer common shares and the holders of Class A Common Units and common units the
converse. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">92 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Additionally, the number of common shares issued in connection with the Organizational
Transactions that are subject to vesting conditions versus the number of common shares issued in connection with the Organizational Transactions that are not subject to vesting conditions will be determined by reference to the initial public
offering price. However, the total number of common shares issued in connection with the Organizational Transactions will remain the same. Assuming an initial public offering price of $15.00 per common share, which is the midpoint of the price range
set forth on the cover page of this prospectus, 10,997&nbsp;common shares subject to vesting conditions will be issued in connection with the Organizational Transactions. A $1.00 increase in the assumed initial public offering price of $15.00 per
common share, which is the midpoint of the price range set forth on the cover page of this prospectus, will result in the issuance of 10,310&nbsp;common shares subject to vesting conditions in connection with the Organizational Transactions. A
$1.00&nbsp;decrease in the assumed initial public offering price of $15.00 per common share, which is the midpoint of the price range set forth on the cover page of this prospectus, will result in the issuance of 11,783 common shares subject to
vesting conditions in connection with the Organizational Transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Warrant Transactions </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In connection with this offering, warrants issued by West Affum Holdings, L.P. to Kennedy Lewis Capital Partners Master Fund II LP (the
&#147;Existing KLIM Warrants&#148;) will be canceled and Kestra Medical Technologies, Ltd. will issue new warrants to purchase common shares (the &#147;KLIM Warrants&#148;). The number of common shares underlying the KLIM Warrants and exercise
prices thereof will be determined based on the initial public offering price. Based on an assumed initial public offering price of $15.00 per share, the midpoint of the price range on the cover of this prospectus, we will issue warrants exercisable
for 62,901 and 47,176&nbsp;shares, with exercise prices of $17.64 and $20.46, respectively. The warrants will expire on December&nbsp;28, 2030 and March&nbsp;7, 2032, respectively. A $1.00 increase in the assumed initial public offering price will
result in the issuance of KLIM Warrants exercisable for 62,626 and 46,969 common shares with exercise prices of $17.72 and $20.55, respectively. A $1.00 decrease in the assumed initial public offering price will result in the issuance of KLIM
Warrants exercisable for 63,198 and 47,399 common shares with exercise prices of $17.56 and $20.36, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Also in connection with
this offering, warrants issued by West Affum Holdings, L.P. to Perceptive Credit Holdings IV, LP (the &#147;Existing Perceptive Warrants&#148;) will be canceled and Kestra Medical Technologies, Ltd. will issue new warrants to purchase common shares
of the Company (the &#147;Perceptive Warrants&#148;, and together with the KLIM Warrants, the &#147;Warrants&#148;). The number of common shares underlying the Perceptive Warrants and exercise price thereof will be determined based on the initial
public offering price. Based on an assumed initial public offering price of $15.00 per share, the midpoint of the price range set forth on the cover page of this prospectus, we will issue warrants exercisable for 328,859&nbsp;shares, with an
exercise price of $11.44. The warrants will expire on September&nbsp;29, 2033. A $1.00 increase in the assumed initial public offering price will result in the issuance of Perceptive Warrants exercisable for 327,417 common shares with an exercise
price of $11.49. A $1.00 decrease in the assumed initial public offering price will result in the issuance of Perceptive Warrants exercisable for 330,412 common shares, with an exercise price of $11.38. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For information regarding the beneficial ownership of our common shares before and after this offering, and after giving pro forma effect to
the Organizational Transactions, see &#147;Principal Shareholders.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">93 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following chart shows our simplified organizational structure prior to the consummation
of the Organizational Transactions and this offering: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g744414g34h43.jpg" ALT="LOGO" STYLE="width:4.97624in;height:5.72117in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following chart shows our simplified organizational structure immediately following the consummation of
the Organizational Transactions and this offering, after giving effect to the sale of 10,000,000&nbsp;common shares in this offering, assuming an initial public offering price of $15.00 per share (the midpoint of the price range set forth on the
cover page of this prospectus) and assuming no exercise of the underwriters&#146; over-allotment option. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Following the consummation
of the Organizational Transactions and this offering, Kestra Medical Technologies, Ltd. will be our top holding company and its consolidated financial statements will be included in our reports filed with the SEC, and West Affum Intermediate
Holdings will be the predecessor for financial reporting purposes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">94 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Kestra Medical Technologies, Ltd. has not engaged in any business or other activities other
than those incidental to its formation, the Organizational Transactions and the preparation of this prospectus and the registration statement of which this prospectus forms a part. Following the consummation of the Organizational Transactions and
this offering, Kestra Medical Technologies, Ltd. will remain a holding company, and it will operate and control all of the business and affairs and consolidate the financial results of its subsidiaries. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>  <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g744414g16a16.jpg" ALT="LOGO" STYLE="width:4.83529in;height:7.39027in;">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">95 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom744414_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We estimate that the net proceeds from our issuance and sale of common shares in this offering will be approximately $133.3&nbsp;million, or
approximately $154.2&nbsp;million if the underwriters exercise in full their over-allotment option, based upon an assumed initial public offering price of $15.00 per common share, which is the midpoint of the price range set forth on the cover page
of this prospectus, after deducting estimated underwriting discounts and commissions and estimated offering expenses incurred by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Each
$1.00 increase or decrease in the assumed initial public offering price of $15.00 per common share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting estimated underwriting discounts,
commissions and offering expenses incurred by us, would increase or decrease, as applicable, the net proceeds to us from this offering by approximately $9.3&nbsp;million, assuming that the number of common shares offered by us, as set forth on the
cover page of this prospectus, remains the same. We may also increase or decrease the number of common shares we are offering. Each increase or decrease of one million in the number of common shares we are offering at the assumed initial public
offering price of $15.00 per common share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting estimated underwriting discounts, commissions and offering expenses incurred by us, would increase or
decrease, as applicable, the net proceeds to us from this offering by approximately $14.0&nbsp;million, assuming the assumed initial public offering price stays the same. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We intend to use the net proceeds from this offering, together with our existing cash, as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approximately $80.0&nbsp;million to scale up our commercial organization through the hiring of additional sales
representatives, sales team leadership and clinical care specialists, as well as through investments in our fleet of devices, supply chain and revenue cycle management capabilities; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approximately $15.0&nbsp;million to fund the research and development of continued innovation in our products and
to fund trials to build upon our strong base of clinical evidence; and </P></TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the remainder for working capital and general corporate purposes. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Net proceeds from our issuance and sale of common shares in this offering include deductions of approximately $6.2&nbsp;million to fund
estimated offering and reorganization costs incurred by us as part of this offering, of which approximately $3.6&nbsp;million and $2.6&nbsp;million will be capitalized and expensed, respectively, in connection with this offering and the
reorganization transactions. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This expected use of the net proceeds from this offering represents our intentions based upon our
current plans and business conditions, which could change in the future as our plans and business conditions evolve. The amounts and timing of our actual expenditures may vary significantly depending on numerous factors, including our success in
scaling up our commercial operations, the continued innovation in our products and achieving a strong base of clinical evidence. We may find it necessary or advisable to use the net proceeds for other purposes, and we will have broad discretion in
the application of the net proceeds. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We plan to invest the net proceeds from this offering that are not used as described above (or
that are pending their use) in short-term, interest-bearing obligations, investment-grade instruments, certificates of deposit or direct or guaranteed obligations of the U.S. government. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">96 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom744414_6"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have not historically declared or paid any dividends on our common shares. We anticipate that we will retain all of our future earnings, if
any, for use in the operation and expansion of our business and do not anticipate paying cash dividends in the foreseeable future. Any decision to declare and pay dividends in the future will be made at the sole discretion of our Board of Directors
and will depend on, among other things, our results of operations, cash requirements, financial condition, contractual restrictions and other factors that our Board of Directors may deem relevant. Our Term Loan limits our ability to, among other
things, pay dividends or make other distributions or payments on account of our common shares, in each case, subject to certain exceptions. In addition, pursuant to Bermuda law, a company may not declare or pay dividends, or make distributions out
of contributed surplus, if there are reasonable grounds for believing that (1)&nbsp;the company is, or would after the payment be, unable to pay its liabilities as they become due or (2)&nbsp;the realizable value of its assets would thereby be less
than its liabilities. &#147;Contributed surplus&#148; is defined for purposes of Section&nbsp;54 of the Companies Act to include the proceeds arising from donated shares, credits resulting from the redemption or conversion of shares at less than the
amount set up as nominal capital and donations of cash and other assets to the company. Additionally, as a holding company with no material direct operations, our ability to pay dividends on our common shares is dependent on the earnings and
distributions of funds from our operating subsidiaries. We are not obligated to pay dividends on our common shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For additional
information on the restrictions on our ability to pay dividends, see &#147;Description of Certain Indebtedness&#148; and &#147;Risk Factors&#151;Risks Related to This Offering&#151;We have historically not paid cash dividends and do not expect to
pay cash dividends in the foreseeable future, and, as a result, any return on investment may be limited to the value of our shares.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">97 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom744414_7"></A>CAPITALIZATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table sets forth the cash and cash equivalents and capitalization as of October 31, 2024 for: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">West Affum Intermediate Holdings and its consolidated subsidiaries on an actual basis; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Kestra Medical Technologies, Ltd. and its consolidated subsidiaries on a pro forma basis to give effect to
(1)&nbsp;the Organizational Transactions described in the section titled &#147;Organizational Transactions&#148; included elsewhere in this prospectus assuming an initial public offering price of $15.00 per common share, which is the midpoint of the
price range set forth on the cover page of this prospectus) and (2)&nbsp;the effectiveness of our amended and restated <FONT STYLE="white-space:nowrap">bye-laws</FONT> upon the closing of this offering; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Kestra Medical Technologies, Ltd. and its consolidated subsidiaries on a pro forma as adjusted basis to give
effect to the issuance and sale of common shares in this offering at an assumed initial public offering price of $15.00 per common share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting
estimated underwriting discounts, commissions and offering and reorganization costs incurred by us, and the receipt of the net proceeds therefrom. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma and pro forma as adjusted information set forth in the table below is illustrative only and will change based on the
actual initial public offering price and other terms of this offering determined at pricing. You should read this table together with the sections titled &#147;Use of Proceeds,&#148; &#147;Management&#146;s Discussion and Analysis of Financial
Condition and Results of Operations&#148; and our consolidated financial statements, condensed consolidated financial statements and the related notes included elsewhere in this prospectus. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>As of October&nbsp;31,
2024</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>West
Affum<BR>Intermediate<BR>Holdings</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Kestra<BR>Medical<BR>Technologies,<BR>Ltd.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Kestra<BR>Medical<BR>Technologies,<BR>Ltd.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>(in thousands, except share and per share amounts)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Actual</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Pro Forma</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Pro&nbsp;Forma&nbsp;As<BR>Adjusted</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">76,918</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">76,918</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">210,190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term debt, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">43,343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">43,343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">43,343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable preferred stock, $0.01 par value; 5,000,000&nbsp;shares authorized, 280,510&nbsp;shares
Issued and outstanding, actual</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">280,510</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shareholders&#146; equity (deficit):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.01 par value; 5,000,000 shares authorized; 105,808 shares issued and outstanding,
actual</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common shares, $1.00 par value; 100,000,000 shares authorized; 37,651,467 shares issued and
outstanding, pro forma; 47,651,467 shares issued and outstanding, pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,651</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,651</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">193,733</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">455,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">581,745</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(446,687</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(449,520</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(452,160</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Non-controlling interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total shareholders&#146; equity (deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(236,545</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,964</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">177,236</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total capitalization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">87,308</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">87,307</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">220,579</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">98 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In accordance with U.S. GAAP, the Organizational Transactions will be treated as a
common control transaction with West Affum Intermediate Holdings as the transferring entity and Kestra Medical Technologies, Ltd. as the receiving entity as set forth below, assuming the Organizational Transactions closed on October&nbsp;31, 2024
for the purpose of the pro forma and pro forma, as adjusted columns in the table above. With respect to the pro forma adjusted amounts presented above: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All assets and liabilities of West Affum Intermediate Holdings will become the assets and liabilities of Kestra
Medical Technologies, Ltd. on a historical book value basis; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The adjustments to additional paid-in capital are comprised of the (i) elimination of the historical carrying
values of West Affum Intermediate Holdings redeemable preferred stock and common stock, (ii) the elimination of the historical carrying values of West Affum Intermediate Holdings noncontrolling interests, (iii) $2.8&nbsp;million of share-based
payment costs as a result of accelerated vesting of incentive units contemporaneously with the consummation of the Organizational Transactions (&#147;Equity Award Acceleration&#148;), partially offset by (iv) the issuance of $37.7&nbsp;million par
value of Kestra Medical Technologies, Ltd. common stock as described in the section entitled &#147;Organizational Transactions&#148;; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The warrants of West Affum Holdings, L.P. are assumed to be carried by Kestra Medical Technologies, Ltd. at
West Affum Intermediate Holdings&#146; historical carrying value; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The adjustment to accumulated deficit represents $2.8&nbsp;million of share-based payment costs related to the
Equity Award Acceleration. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The number of common shares to be outstanding after this offering is based on 37,651,467
common shares issued as of October 31, 2024, after giving pro forma effect to the Organizational Transactions, and excludes 4,728,033 common shares underlying stock options to be granted to our NEOs and certain other employees immediately following
the determination of the initial public offering price for this offering, with an exercise price equal to the initial public offering price; 12,680,000 common shares expected to be reserved for issuance under our new equity incentive plan (which
number of reserved common shares will be subject to adjustment depending on the number of shares offered in this offering); and 438,936 common shares underlying the Warrants. The number of authorized common shares presented above reflects the
increase in our authorized share capital approved by our Board and sole shareholder of the Company in connection with this offering. See &#147;Description of Share Capital.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, the information presented above assumes or includes : </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an assumed initial public offering price of $15.00 per share, which is the midpoint of the price range set forth
on the cover page of this prospectus; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">common shares issued in connection with the Organizational Transactions that are subject to certain vesting
conditions; </P></TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effectiveness of our amended and restated <FONT STYLE="white-space:nowrap">bye-laws</FONT> upon the closing
of this offering; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no exercise by the underwriters of their over-allotment option. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Each $1.00 increase or decrease in the assumed initial public offering price of $15.00 per common share, which is the midpoint of the price
range set forth on the cover page of this prospectus, after deducting estimated underwriting discounts, commissions and offering and reorganization costs incurred by us, would increase or decrease, as applicable, each of cash and cash equivalents,
additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital, total shareholder&#146;s equity and total capitalization on a pro forma as adjusted basis by approximately $9.3&nbsp;million, assuming that the number of shares offered by us, as
set forth on the cover page of this prospectus, remains the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">99 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
same. Each increase or decrease of one million in the number of common shares we are offering at the assumed initial public offering price of $15.00 per common share, which is the midpoint of the
price range set forth on the cover page of this prospectus, after deducting estimated underwriting discounts, commissions and offering and reorganization costs incurred by us, would increase or decrease, as applicable, each of cash and cash
equivalents, additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital, total shareholders equity and total capitalization on a pro forma as adjusted basis by approximately $14.0&nbsp;million. The pro forma as adjusted information is
illustrative only of our capitalization following the closing of this offering and will change based on the actual initial public offering price and other terms of this offering determined at pricing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">100 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom744414_8"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If you invest in our common shares in this offering, your investment will be immediately diluted to the extent of the difference between the
initial public offering price per common share and the pro forma as adjusted net tangible book value (deficit) per common share after this offering. Dilution results from the fact that the per share offering price of the common shares is
substantially in excess of the pro forma as adjusted net tangible book value (deficit) per share attributable to our existing shareholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our historical net tangible book value (deficit) as of October&nbsp;31, 2024 was approximately $(240.5)&nbsp;million, or $(2,273.11) per
common share. Historical net tangible book value (deficit) represents the amount of total tangible assets less total liabilities and redeemable preferred stock. Total tangible assets represent total assets less prepaid expenses, unamortized debt
issuance costs, deferred offering cost, and other intangible assets. Historical net tangible book value (deficit) per common share represents historical net tangible book value (deficit) divided by the number of common shares issued as of
October&nbsp;31, 2024. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our pro forma net tangible book value (deficit) as of October&nbsp;31, 2024 was approximately $40.0&nbsp;million,
or $1.06 per common share. Pro forma net tangible book value (deficit) represents the amount of total tangible assets less total liabilities, and pro forma net tangible book value (deficit) per common share represents net tangible book value
(deficit) divided by 37,651,467 common shares issued as of October 31, 2024 after giving effect to the Organizational Transactions described in the section titled &#147;Organizational Transactions&#148; included elsewhere in this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">After giving pro forma effect to (1)&nbsp;the issuance and sale of 10,000,000 common shares by us in this offering at an assumed initial
public offering price of $15.00 per share (the midpoint of the price range set forth on the cover page of this prospectus), after deducting estimated underwriting discounts, commissions and offering and reorganization costs incurred by us, and
(2)&nbsp;the receipt of the net proceeds from this offering, our pro forma as adjusted net tangible book value (deficit) as of October&nbsp;31, 2024 would have been $173.3 million, or $3.64 per common share. This represents an immediate increase in
pro forma as adjusted net tangible book value (or a decrease in net tangible book deficit) of $2.58 per common share to our existing shareholders and an immediate dilution in pro forma as adjusted net tangible book value (deficit) of $11.36&nbsp;per
common share to investors in this offering. Dilution in pro forma as adjusted net tangible book value (deficit) per common share to investors in this offering represents the difference between the initial public offering price of $15.00 per share
(the midpoint of the price range set forth on the cover page of this prospectus), and the pro forma as adjusted net tangible book value per common share after giving effect to this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table illustrates this dilution on a per common share basis: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="93%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assumed initial offering price per common share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15.00</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net tangible book value (deficit) per common share as of October&nbsp;31, 2024 after
giving effect to the Organizational Transactions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.06</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in pro forma net tangible book value (deficit) per common share attributable to investors
participating in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma as adjusted net tangible book value (deficit) per common share after giving effect to
the offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution in pro forma as adjusted net tangible book value (deficit) per common share to investors
in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If the underwriters exercise their over-allotment option in full, our pro forma as adjusted net
tangible book value (deficit) per share after giving pro forma effect to this offering would be $3.95 per common share. This represents an increase in pro forma as adjusted net tangible book value (deficit) of $2.89&nbsp;per common share to existing
shareholders and dilution in pro forma as adjusted net tangible book value (deficit) of $11.05 per common share to new investors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">101 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Each $1.00 increase (decrease) in the assumed initial public offering price of $15.00
per common share (the midpoint of the price range set forth on the cover page of this prospectus) would increase (decrease) our pro forma as adjusted net tangible book value (deficit) as of October 31, 2024 by $0.20 per common share, and would
increase (decrease) dilution to investors in this offering by $0.80 per common share, assuming that the number of common shares offered by us, as set forth on the cover page of this prospectus, remains the same, and after deducting estimated
underwriting discounts, commissions and offering and reorganization costs incurred by us. Similarly, each increase of one million in the number of common shares offered by us would increase our pro forma as adjusted net tangible book value (deficit)
per common share after this offering by $0.21 per common share and decrease the dilution to new investors by $0.21&nbsp;per common share, assuming that the assumed initial public offering price of $15.00&nbsp;per common share remains the same, and
after deducting estimated underwriting discounts, commissions and offering and reorganization costs incurred by us. A decrease of one million in the number of common shares offered by us would decrease our pro forma as adjusted net tangible book
value (deficit) per common share after this offering by $0.22 per common share and increase the dilution to new investors by $0.22 per common share, assuming that the assumed initial public offering price of $15.00 per common share remains the same,
and after deducting estimated underwriting discounts, commissions and offering and reorganization costs incurred by us. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The
following table summarizes, on the same pro forma as adjusted basis described above, as of October 31, 2024, the total number of common shares purchased from us, the total cash consideration paid to us and the average price per common share paid by
our existing shareholders and by new investors purchasing common shares in this offering. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Shares Purchased</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Total&nbsp;Consideration</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Average&nbsp;Price</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Per Share</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Percent</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Amount</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Percent</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Existing shareholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,651,467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">497,757,128</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investors in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">150,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,651,467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">647,757,128</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Each $1.00 increase (decrease) in the assumed initial public offering price of $15.00 per common
share would increase (decrease) the total consideration paid by new investors by $9.3 million and increase (decrease) the percentage of total consideration paid by new investors to 24.2%, assuming no change to the number of common shares offered by
us, as set forth on the cover page of this prospectus, and after deducting estimated underwriting discounts, commissions and offering and reorganization costs incurred by us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The number of common shares to be outstanding after this offering is based on 37,651,467 common shares issued as of October&nbsp;31, 2024,
after giving pro forma effect to the Organizational Transactions, and excludes 4,728,033 common shares underlying stock options to be granted to our NEOs and certain other employees immediately following the determination of the initial public
offering price for this offering, with an exercise price equal to the initial public offering price; 12,680,000 common shares expected to be reserved for issuance under our new equity incentive plan (which number of reserved common shares will be
subject to adjustment depending on the number of shares offered in this offering); and 438,936 common shares underlying the Warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The
number of common shares underlying the stock options to be granted to our NEOs and certain other employees immediately following the determination of the initial public offering price for this offering will be determined by reference to the initial
public offering price. A $1.00 increase in the assumed initial public offering price of $15.00&nbsp;per common share, which is the midpoint of the price range set forth on the cover page of this prospectus, will result in the number of common shares
for which such options are exercisable being 107,177 options lower. A $1.00 decrease in the assumed initial public offering price of $15.00&nbsp;per common share, which is the midpoint of the price range set forth on the cover page of this
prospectus, will result in the number of common shares for which such options are exercisable being 75,424 options higher. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The number of
common shares underlying the warrants described above and exercise price thereof will be determined by reference to the initial public offering price. A $1.00 increase in the assumed initial public </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">102 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
offering price of $15.00&nbsp;per common share, which is the midpoint of the price range set forth on the cover page of this prospectus, will result in the issuance of warrants exercisable for
62,626, 46,969 and 327,417 common shares, with exercise prices of $17.72, $20.55 and $11.49, respectively. A $1.00 decrease in the assumed initial public offering price of $15.00&nbsp;per common share, which is the midpoint of the price range set
forth on the cover page of this prospectus, will result in the issuance of warrants exercisable for 63,198, 47,399 and 330,412 common shares, with exercise prices of $17.56, $20.36 and $11.38, respectively. For more information on the Warrants, see
&#147;Organizational Transactions&#151;Warrant Transactions.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Any exercise of options or similar rights or of the Warrants could
result in further dilution to our shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Additionally, the number of common shares issued in connection with the Organizational
Transactions that are subject to vesting conditions versus the number of common shares issued in connection with the Organizational Transactions that are not subject to vesting conditions will be determined by reference to the initial public
offering price. However, the total number of common shares issued in connection with the Organizational Transactions will remain the same. Assuming an initial public offering price of $15.00 per common share, which is the midpoint of the price range
set forth on the cover page of this prospectus, 10,997 common shares subject to vesting conditions will be issued in connection with the Organizational Transactions. A $1.00 increase in the assumed initial public offering price of $15.00 per common
share, which is the midpoint of the price range set forth on the cover page of this prospectus, will result in the issuance of 10,310 common shares subject to vesting conditions in connection with the Organizational Transactions. A $1.00 decrease in
the assumed initial public offering price of $15.00 per common share, which is the midpoint of the price range set forth on the cover page of this prospectus, will result in the issuance of 11,783 common shares subject to vesting conditions in
connection with the Organizational Transactions. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The dilution information above is for illustrative purposes only. Our pro forma as
adjusted net tangible book value (deficit) following the consummation of this offering is subject to adjustment based on the actual initial public offering price of our common shares and other terms of this offering determined at pricing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">103 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom744414_9"></A>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AND RESULTS OF OPERATIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>This Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the
sections of this prospectus captioned &#147;Prospectus Summary&#151;Summary Consolidated Financial Data,&#148; &#147;Business&#148; and our consolidated financial statements, condensed consolidated financial statements and the related notes thereto
included elsewhere in this prospectus. In addition to the historical financial information, the following discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results and timing of
selected events may differ materially from those anticipated in these forward-looking statements as a result of many factors, including those discussed under the sections of this prospectus captioned &#147;Special Note Regarding Forward-Looking
Statements&#148; and &#147;Risk Factors.&#148; </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular
disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates
monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation WCD used to protect patients at an elevated
risk of SCA. The ASSURE WCD automatically monitors elevated risk patients and, if needed, delivers a defibrillation shock to return the patient&#146;s heart to normal rhythm. We believe the ASSURE WCD offers significant clinical and functional
advantages, including greater patient compliance as a result of a major reduction in false alarms, enhanced comfort and improved wearability. In addition to the ASSURE WCD, our Cardiac Recovery System platform includes a comprehensive suite of fully
integrated digital solutions and services that enable enhanced patient and provider engagement and oversight, with the objective of improving patient outcomes. We believe our Cardiac Recovery System platform has the potential to disrupt the large
existing market and grow the underpenetrated addressable market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have been issued a Medicare Provider Number by the CMS, which enables
us to bill Medicare for reimbursement for our ASSURE WCD as an accredited supplier to the extent the claim meets Medicare medical necessity and coverage requirements. We derive nearly all our revenue from the direct billing of various third-party
payors, including Medicare, Medicaid, private payors and other healthcare-related organizations, for the lease of our ASSURE WCD to patients. We also bill patients for <FONT STYLE="white-space:nowrap">co-insurance</FONT> payments and deductibles. As
WCD therapy has existed for over 20 years in the United States, reimbursement codes are well-established, and WCDs are covered by Medicare, Medicaid and many private payors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We outsource the manufacturing of our ASSURE WCD and all of its components to third-party suppliers, including contract manufacturers that
manufacture garments, chargers, monitors, batteries, cables and various accessories for our ASSURE WCD. We believe that our contract manufacturing partners are recognized in their field for their competency to manufacture the respective components
of our&nbsp;ASSURE WCD and have established quality systems that meet FDA requirements. We believe the manufacturers we currently utilize have sufficient capacity to meet our expansion requirements and can scale up their capacity to meet anticipated
demand for our products for the foreseeable future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Since our inception, we have devoted substantially all of our efforts to research and
development, undertaking clinical trials, enabling manufacturing activities in support of our product development efforts, hiring personnel, organizing and staffing our company, performing business planning, establishing our intellectual property
portfolio, building and expanding a commercial team to market our Cardiac Recovery System platform in the United States, and raising capital to support and expand such activities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">104 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our fiscal year ends on April&nbsp;30 of each year. We incurred net losses of
$40.9&nbsp;million and $50.2&nbsp;million for the six months ended October 31, 2024 and 2023, respectively. We incurred net losses of $94.1&nbsp;million and $84.2&nbsp;million for the fiscal years ended April&nbsp;30, 2024 and 2023, respectively. We
generated revenue of $27.5&nbsp;million and gross margin of $10.0&nbsp;million for the six months ended October&nbsp;31, 2024, compared to revenue of $9.5 million and gross margin of $(1.9)&nbsp;million for the six months ended October&nbsp;31,
2023. For the fiscal year ended April&nbsp;30, 2024, we generated revenue of $27.8&nbsp;million, with a gross margin of $0.4&nbsp;million, compared to revenue of $7.6&nbsp;million, with a gross margin of $(10.7)&nbsp;million, for the fiscal year
ended April&nbsp;30, 2023. As of October&nbsp;31, 2024, we had cash and cash equivalents balances of $76.9&nbsp;million, and an accumulated deficit of $446.7&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Since our inception, our operations have primarily been funded by proceeds from our capital contributions made by West Affum Holdings, L.P.,
our direct parent prior to the Organizational Transactions, in the form of common stock and redeemable preferred stock, and borrowings under our Term Loan (as defined below), as well as borrowings under our Term Loan 2020 (as defined below) prior to
its repayment in September of 2023. For more information, see &#147;&#151;Liquidity and Capital Resources&#151;Sources of Liquidity&#148; and Note 10, <I>&#147;Redeemable Preferred Stock,&#148;</I> to our consolidated financial statements included
elsewhere in this prospectus. We have invested heavily in developing and commercializing our Cardiac Recovery System platform. We have also made significant investments in clinical studies to demonstrate the safety and effectiveness of our ASSURE
WCD and to support applications for regulatory approvals. We have made and will continue to make significant investments to build our sales and marketing organization, and we intend to continue to increase the size of our commercial team to market
our product in the United States. While we believe that our existing cash and cash equivalents (including the net proceeds from this offering) will be sufficient to fund our operating and capital needs for at least the next 12 months, we may require
additional funding to execute on our growth plans, which may include future equity and debt financings. Adequate funding may not be available to us on acceptable terms or at all. Our failure to obtain sufficient funds on acceptable terms when needed
could have a material and adverse effect on our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Key Factors Affecting Our Results
of Operations and Performance </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Factors that have impacted, and that we expect will continue to impact, our operating performance and
results of operations include: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Commercial Organization</I></B>. We have made and continue to make significant investments in recruiting,
training and retaining our direct sales force and supporting commercial infrastructure. Successfully recruiting and training additional commercial team members is required to achieve growth. As of January 2025, we had approximately 70 territory
managers in the United States. We have in the past and expect in the future to enter into compensation arrangements with our commercial team that may include minimum guaranteed commissions. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Gross Margin</I></B>. Our results of operations will depend, in part, on our ability to increase our gross
margins by more effectively managing our costs to build and deliver our ASSURE WCD and obtaining higher reimbursement realization due to improved market access and shifts in patient mix towards patients with longer wear duration. We expect supply
chain efficiencies to result from higher volume purchases of components, and continued manufacturing process improvements. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Payor Coverage and Revenue Cycle Management</I></B>. Healthcare providers in the United States generally
rely on third-party payors, principally Medicare, Medicaid and private payors, to cover and reimburse all or part of the cost of our product. The revenue we can generate from the lease of our ASSURE WCD depends in large part on the availability of
reimbursement from such payors. A significant component of our operational efforts includes working with private payors to ensure positive coverage decisions for our product and investing in our revenue cycle management infrastructure to collect
cash from payors. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">105 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Seasonality</I></B>. Our billings and collections efforts during January and February tend to be lower
because of resetting annual patient healthcare insurance plan deductibles. In addition, as our business grows in the United States and any international markets we may enter into in the future, we may experience seasonality based on holidays,
vacations and other factors. <B><I></I></B><B><I></I></B> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Key Components of Our Results of Operations </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following discussion describes certain key components of our consolidated statement of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We received FDA approval
for the commercialization of our ASSURE WCD on July&nbsp;27, 2021 and fully commercially launched our ASSURE WCD in August 2022. We generate revenue by leasing our ASSURE WCD to patients for a fixed amount on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">month-to-month</FONT></FONT> basis. The lease payments generally consist of the contracted amounts based on reimbursement arrangements with third-party payors, comprising Medicare, Medicaid, private payors and other
healthcare-related organizations, and patient payments. The patient has the right to cancel the lease at any time during the lease period. We recognize lease revenue over the term of the lease when collectability is probable. If collectability of
the lease payments is not deemed to be probable, the lease revenue is limited to the lesser of the income that would have been recognized if collectability was probable or the lease payments collected. If the lease payments are not deemed to be
probable at inception, lease revenue is recognized when cash payments are received. We expect that our revenue will continue to increase as the number of patients that use our product increases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Costs of Revenue </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Costs of
revenue consist of direct material, labor and indirect costs related to the lease performance of our ASSURE WCD such as the cost of disposable WCD device components, depreciation expense of reusable medical rental equipment components, shipping and
order fulfillment costs, as well as other indirect costs incurred to support the manufacture and medical rental equipment delivery to and ongoing support for the patient incurred in connection with providing our ASSURE WCD to patients. Overall
expenditures for disposable components and reprocessing costs will increase as the number of patients receiving our ASSURE WCD increases and to a lesser extent, depreciation expense will increase as additional reusable ASSURE WCD components are
purchased. However, depreciation expense as a percentage of costs of revenue is expected to decrease in the long run through economies of scale as we continue to grow our business. For additional information on how depreciation impacts our financial
results, see Note 2, &#147;<I>Significant Accounting Policies</I>,&#148; to our consolidated financial statements included elsewhere in this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Gross Margin </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We calculate gross
margin as revenue less costs of revenue. We expect our gross margin to increase as reimbursement realization increases due to improved market access and shifts in patient mix towards patients with longer wear duration, as well as supply chain
efficiencies from higher volume purchases of components and manufacturing process improvements. In addition, as the number of patients we serve continues to increase, we expect the cost of fitting per patient to continue to decrease. However, gross
margin may be negatively impacted by a number of factors, including increases in prices of materials and electronics components, labor rates, shipping rates, and inflation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Costs </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Research and development expenses consist of personnel expenses, including salaries, benefits and stock-based compensation expense for product
development personnel, prototype materials and other expenses related to the development of new products. We expense research and development costs as they are incurred, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">106 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
although advanced payments that we make for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses and expensed as the
related goods are delivered or the services are performed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We expect our research and development costs to decrease as a percentage of
revenue for the foreseeable future as our revenue increases. We will continue to invest in research and development activities related to developing new products and services, further enhancing our products and services through introducing new
extensions and enhancements, conducting clinical trials as necessary and preparing any new products and services for commercialization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Selling,
General and Administrative Expenses </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Selling expenses consist primarily of personnel expenses, including salaries, commissions,
bonuses, benefits, travel, and stock-based compensation expense for sales, marketing and field clinical personnel, as well as investments in marketing initiatives to increase market awareness of our technology, including expenses related to travel,
conferences, trade shows and consulting services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">General and administrative expenses consist primarily of personnel expenses, including
salaries, benefits and stock-based compensation expense for personnel in executive, finance, accounting, commercial operations, distribution costs, revenue cycle management, legal, human resources, IT and administrative functions. General and
administrative expenses also include direct or allocated expenses for rent and maintenance of facilities and insurance, not otherwise included in research and development expenses, selling expenses, or costs of revenue, as well as professional fees
for legal, patent and consulting services. We expect expenses related to revenue cycle management to increase at higher rates than other types of general and administrative expenses as this function will continue to grow as the volume increases.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We expect that our overall selling, general and administrative expenses will increase in the foreseeable future as we increase our
headcount to support the continued growth of our business. We also anticipate incurring additional expenses associated with operating as a public company, including increased expenses related to audit, legal, regulatory, compliance, director and
officer insurance, investor and public relations, and <FONT STYLE="white-space:nowrap">tax-related</FONT> services associated with maintaining compliance with the rules and regulations of the SEC and standards applicable to companies listed on a
national securities exchange. These expenses may further increase when we no longer qualify as an &#147;emerging growth company&#148; under the JOBS Act, which will require us to comply with certain reporting requirements from which we are currently
exempt. However, we expect overall general and administrative expenses to decrease as a percentage of revenue primarily as, and to the extent, our revenue grows. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interest and Other Expense (Income) </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Interest and other expense (income) consists of cash and <FONT STYLE="white-space:nowrap">non-cash</FONT> components. The cash component of
interest expense is attributable to borrowings under our Term Loan and a portion of loss on extinguishment of debt. The <FONT STYLE="white-space:nowrap">non-cash</FONT> component consists of interest expense recognized from the amortization of debt
discounts and debt issuance costs. Loss on extinguishment of debt is part of other expense (income). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Provision for Income Taxes </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">To date, we have recorded a limited amount of United States federal and state income state expense. As of April&nbsp;30, 2024, significant
deferred tax assets include net operating loss carryforwards of $34.6&nbsp;million, intangible assets of $35.4&nbsp;million, interest carryforwards of $5.8&nbsp;million and United States research and development credits of $5.1&nbsp;million. In
assessing the realizability of deferred tax assets, we consider whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the
generation of future taxable income during periods in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">107 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
which those temporary differences become deductible. We consider the scheduled reversal of deferred tax liabilities, projected future taxable income, carryback opportunities and tax planning
strategies in making the assessment. We believe it is more likely than not that we will not realize the benefits of these deductible differences and have applied a full valuation allowance against them. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of Operations for the Six Months Ended October 31, 2024 and 2023 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table sets forth our results of operations for the six months ended October 31, 2024 and 2023. We have derived the data for the
six months ended October 31, 2024 and 2023 from our condensed consolidated financial statements included elsewhere in this prospectus. This information should be read in conjunction with our condensed consolidated financial statements and related
notes included elsewhere in this prospectus. The results for historical periods are not necessarily indicative of the results of operations for any future period, and our interim results are not necessarily indicative of the results to be expected
for the full year. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Six Months Ended</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>October 31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2024</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>$</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Change</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>%</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Change</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27,492</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,483</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,009</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">190</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Costs of revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,462</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,398</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,064</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross margin</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,915</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,945</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">624</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,913</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,934</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,021</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,682</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,919</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,763</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,595</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,853</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,742</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(37,565</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(44,768</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,276</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,644</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">632</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,768</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,680</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(97</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss before provision for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(40,929</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(50,180</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,251</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision (benefit) for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(59</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(40,944</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(50,217</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,273</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to non-controlling interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(692</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(692</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss attributable to West Affum Intermediate Holdings Corp.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(40,252</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(50,217</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,965</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Undeclared preferred stock dividends</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,706</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,915</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,791</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common shareholders, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(45,958</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(53,132</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comparison of the Six Months Ended October 31, 2024 and 2023 </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Revenue increased by
$18.0&nbsp;million, or 190%, to $27.5&nbsp;million for the six months ended October 31, 2024, compared to $9.5&nbsp;million for the six months ended October 31, 2023, primarily driven by an increase in the number of patients using our products and
an increase in reimbursement realization while reimbursement rates remained largely flat. There was a 166% increase in the number of patients using our product, along with a 9% increase in reimbursement realization due to additional payor contracts
and a 12% increase in the size of our revenue cycle management team to improve collection efforts. For further information on our revenue recognition policy and estimates, see Note 2 to our condensed consolidated financial statements included
elsewhere in this prospectus and below under &#147;&#151;Critical Accounting Policies and Significant Management Estimates.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">108 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Costs of Revenue </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Costs of revenue increased by $6.1&nbsp;million, or 53%, to $17.5&nbsp;million for the six months ended October&nbsp;31, 2024, compared to
$11.4&nbsp;million for the six months ended October 31, 2023. The increase in cost of revenue was primarily driven by an increase of $6.7&nbsp;million in the cost of disposable medical equipment supplies, equipment reconditioning and other supplier
costs, which were directly attributable to an increase in the number of patients using our product, partially offset by a $0.4&nbsp;million decrease in depreciation expense and a $0.2 million decrease in other supplier costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Gross Margin </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Gross margin
increased by $11.9&nbsp;million to $10.0&nbsp;million for the six months ended October 31, 2024, compared to $(1.9) million for the six months ended October 31, 2023. The increase in gross margin as compared to the six months ended October 31, 2023
was primarily due to growth in both our total revenue, which was driven by the increased number of patients using our product, as well as an increase in revenue per patient as a result of an increase of 9% in reimbursement realization due to an
increased number of payor contracts resulting in a higher percentage of patients having greater in-network coverage through their insurance providers and improved collection efforts driven by further increases in the size of our revenue cycle
management team. The increase in gross margin was also driven by a decrease in cost of revenues per patient by 42%, compared to the six months ended October 31, 2023, due to further improvements in the utilization of our rental pool of medical
equipment and lower disposable costs driven by volume and manufacturing cost improvement programs we implemented during the six months ended October&nbsp;31, 2024, including a therapy cable repair program approved by the FDA in May 2024. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Costs </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Research and development costs decreased by $1.0&nbsp;million, or 13%, to $6.9 million for the six months ended October 31, 2024, compared to
$7.9 million for the six months ended October 31, 2023. The decrease was primarily driven by a $0.7 million decrease in contractor costs and a $0.3 million decrease in cost of materials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Selling, General and Administrative Expenses </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Selling, general and administrative expenses increased by $5.8&nbsp;million, or 17%, to $40.7&nbsp;million in the six months ended October 31,
2024, compared to $34.9&nbsp;million for the six months ended October 31, 2023. The increase was primarily driven by a $5.9&nbsp;million increase in personnel expenses such as salaries, benefits and stock-based compensation, resulting from an
increase in headcount, and a $0.5&nbsp;million increase in travel expenses, offset by a $0.4 million decrease in legal expenses and a net $0.2&nbsp;million decrease in other selling, general and administrative expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interest and Other Expense </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Interest expense increased by $0.6&nbsp;million, or 24%, to $3.3&nbsp;million in the six months ended October 31, 2024, compared to
$2.7&nbsp;million for the six months ended October 31, 2023. The increase was attributable to interest expense and amortization of debt discounts and debt issuance costs related to borrowings under our Term Loan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Other expense decreased by $2.7 million, or 97%, to less than $0.1 million in the six months ended October 31, 2024, compared to $2.8 million
for the six months ended October 31, 2023. The decrease was attributable to an early loan termination fee and a loss on debt extinguishment totaling $2.7 million related to our Term Loan 2020 (as defined below) that occurred in September 2023. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">109 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Provision for Income Taxes </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For each of the six months ended October 31, 2024 and 2023, the tax provision was less than $0.1&nbsp;million, which was primarily related to
state tax liabilities in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of Operations for the Fiscal Years Ended April&nbsp;30, 2024 and 2023 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table sets forth our results of operations for the fiscal years ended April&nbsp;30, 2024 and 2023. We have derived the data for
the fiscal years ended April&nbsp;30, 2024 and 2023 from our consolidated financial statements included elsewhere in this prospectus. This information should be read in conjunction with our consolidated financial statements and related notes
included elsewhere in this prospectus. The results for historical periods are not necessarily indicative of the results of operations for any future period. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Fiscal Year Ended</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>April&nbsp;30,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2024</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>$</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Change</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>%</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Change</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27,814</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">265</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Costs of revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,452</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,281</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross margin</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">362</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,651</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,013</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">103</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,490</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,756</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(266</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69,935</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,921</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85,425</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69,770</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,655</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(85,063</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(80,421</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,642</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense (income):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,629</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">601</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense (income)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,803</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,827</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">253</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss before provision for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(94,096</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(84,223</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,873</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(94,120</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(84,238</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,882</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Undeclared preferred stock dividends</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,721</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,499</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">169</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common shareholders, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(100,841</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(86,737</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(14,104</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comparison of the Fiscal Years Ended April&nbsp;30, 2024 and 2023 </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Revenue increased by
$20.2&nbsp;million, or 265%, to $27.8&nbsp;million for the fiscal year ended April&nbsp;30, 2024, from $7.6&nbsp;million for the fiscal year ended April&nbsp;30, 2023, primarily driven by an increase in the number of patients using our products and
an increase in reimbursement realization while reimbursement rates remained largely flat. There was a 72% increase in the number of patients using our product, along with an increase in reimbursement realization due to additional payor contracts and
a 37% increase in the size of our revenue cycle management team to improve collection efforts. For further information on our revenue recognition policy and estimates, see Note 2 to our consolidated financial statements included elsewhere in this
prospectus and below under &#147;&#151;Critical Accounting Policies and Significant Management Estimates.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">110 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Costs of Revenue </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Costs of revenue increased by $9.2&nbsp;million, or 50%, to $27.5&nbsp;million for the fiscal year ended April&nbsp;30, 2024, from
$18.3&nbsp;million for the fiscal year ended April&nbsp;30, 2023. The increase in cost of revenue was primarily driven by an increase of $12.5&nbsp;million in the cost of disposable medical equipment supplies, equipment reconditioning and other
supplier costs, which were directly attributable to an increase in the number of patients using our product, partially offset by $3.3&nbsp;million in savings generated from volume purchases of reusable and disposable components and continued
manufacturing process improvements to reduce labor and material costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Gross Margin </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Gross margin increased by $11.0&nbsp;million to $0.4&nbsp;million for the fiscal year ended April&nbsp;30, 2024, from $(10.6) million for the
fiscal year ended April&nbsp;30, 2023. The increase in gross margin as compared to the fiscal year ended April 30, 2023 was primarily due to growth in our revenue, which was driven by the increased number of patients using our product and an
increase of 111% in reimbursement realization due to increased number of payor contracts and improved collection efforts driven by an increase in the size of our revenue cycle management team. The increase in gross margin was also partly
attributable to a decrease in cost of revenues per patient by 13% due to our improved utilization of the rental pool of medical equipment and lower disposable costs driven by volume and manufacturing cost improvement programs, including a focus of
supply chain management to improve efficiency to timely inspect, test, recertify and deliver our ASSURE WCDs to patients at a faster rate and minimize product idle time between patients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Costs </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Research and development costs were largely flat at $15.5&nbsp;million in the fiscal year ended April&nbsp;30, 2024, compared to
$15.8&nbsp;million in the fiscal year ended April&nbsp;30, 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Selling, General and Administrative Expenses </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Selling, general and administrative expenses increased by $15.9&nbsp;million, or 29%, to $69.9&nbsp;million in the fiscal year ended
April&nbsp;30, 2024, from $54.0&nbsp;million for the fiscal year ended April&nbsp;30, 2023. The increase was primarily driven by a $9.8&nbsp;million increase in personnel expenses such as salaries, benefits and stock-based compensation, resulting
from an increase in headcount, $2.0&nbsp;million increase in commissions and bonuses driven by an increase in revenue, $0.9&nbsp;million increase in sales and marketing expense, $0.8&nbsp;million increase in software license fees, and a net
$2.4&nbsp;million increase in other selling, general and administrative expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interest and Other Expense (Income) </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Interest expense increased by $0.6&nbsp;million, or 11%, to $6.2&nbsp;million in the fiscal year ended April&nbsp;30, 2024, from
$5.6&nbsp;million for the fiscal year ended April&nbsp;30, 2023. The increase was attributable to interest expense and amortization of debt discounts and debt issuance costs related to borrowings under our Term Loan (as defined below). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Other expense incurred during the fiscal year ended April&nbsp;30, 2024, primarily included an early loan termination fee and a loss on debt
extinguishment totaling $2.7&nbsp;million related to our Term Loan 2020 (as defined below), along with $0.1&nbsp;million related to other expenses. Other income generated during the fiscal year ended April&nbsp;30, 2023 primarily consisted of a tax
refund of $1.8&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Provision for Income Taxes </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For each of the fiscal years ended April&nbsp;30, 2024 and 2023, the tax provision was less than $0.1&nbsp;million, which was primarily
related to state tax liabilities in the United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">111 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Quarterly Results of Operations Data </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table sets forth unaudited quarterly results of operations for each of the four fiscal quarters ended April&nbsp;30, 2024 and
the fiscal quarters ended July&nbsp;31, 2024 and October&nbsp;31, 2024. The information for each of these quarters has been prepared in accordance with U.S. generally accepted accounting principles (&#147;GAAP&#148;), on the same basis as our
consolidated financial statements included elsewhere in this prospectus. This information should be read in conjunction with our consolidated financial statements and related notes included elsewhere in this prospectus. The results for historical
quarterly periods are not necessarily indicative of the results of operations for any future period. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="22" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Three Months Ended</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>July&nbsp;31,</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>October&nbsp;31,</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>January&nbsp;31,</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2024</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>April&nbsp;30,</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2024</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>July&nbsp;31,</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2024</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>October&nbsp;31,</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2024</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,464</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,277</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,054</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,782</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Costs of revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,623</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,775</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,397</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,657</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,880</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross margin</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(159</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,756</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">880</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,397</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,830</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,735</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,735</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,821</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,404</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,509</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,816</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,091</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,925</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,455</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,302</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,826</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,746</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,631</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,964</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20,710</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24,058</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,946</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20,349</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,431</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,134</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense (income):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,254</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,390</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,651</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,935</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,837</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,439</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense (income)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,717</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss before provision for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,015</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(28,165</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21,605</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,311</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20,316</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20,613</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision (benefit) for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,032</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(28,185</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21,619</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,284</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20,323</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20,621</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to <FONT STYLE="white-space:nowrap">non-controlling</FONT> interest</P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(439</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(253</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss attributable to West Affum Intermediate Holdings Corp.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,032</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(28,185</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21,619</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,284</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,884</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20,368</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Undeclared preferred stock dividends</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,326</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,589</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,812</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,994</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,383</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,323</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common shareholders, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(23,358</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(29,774</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(23,431</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(24,278</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(22,267</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(23,691</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Quarterly Trends </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Revenue increased
sequentially in each of the periods presented primarily driven by an increase in number of patients using our product, an increase in reimbursement realization due to an increase in the number of payor contracts, and expansion of the revenue cycle
management team to improve collection efforts. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">112 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Costs of Revenue </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Costs of revenue increased sequentially in each of the periods presented primarily due to an increase in cost of disposable medical equipment
supplies, equipment reconditioning and other supplier costs, which were directly attributable to an increase in the number of patients using our product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Gross Margin </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Gross margin
increased sequentially in each of the periods presented primarily due to growth in our revenue due to the increased number of patients using our product and increased reimbursement realization due to increased number of payor contracts and improved
collection efforts driven by an increase in size of the revenue cycle management team. The increase in gross margin was also a result of savings generated from volume purchases of reusable and disposable components and continued focus on
manufacturing process improvements within cost of revenues, including a focus of supply chain management to improve efficiency to timely inspect, test, recertify, and deliver our ASSURE WCDs to patients at a faster rate and minimize product idle
time between patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Costs </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Research and development costs were largely flat in each of the periods presented. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Selling, General and Administrative Expenses </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Selling, general and administrative expenses increased gradually in each of the periods presented primarily due to increase in personnel
expenses such as salaries, benefits and stock-based compensation, resulting from an increase in headcount and other related expenses to support the growth of our business and related infrastructure. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interest and Other Expense (Income) </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Interest expense was largely flat in each of the periods presented. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Other expense (income) was largely flat in each of the periods presented except for the three months ended October&nbsp;31, 2023 due to an
early loan termination fee and a loss on debt extinguishment totaling $2.7&nbsp;million related to our Term Loan 2020 (as defined below) that occurred in September 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Provision (Benefit) for Income Taxes </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For each of the periods presented, the tax provision (benefit) was less than $0.1&nbsp;million, which was primarily related to state tax
liabilities in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity and Capital Resources </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Going Concern </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Since inception,
we have devoted substantially all our efforts to research and development, undertaking clinical trials, enabling manufacturing activities in support of our product development efforts, hiring personnel, organizing and staffing our company,
performing business planning, establishing our intellectual property portfolio, building and expanding a commercial team to market our Cardiac Recovery System platform in the United States, and raising capital to support and expand such activities.
We have incurred net losses in each year since inception and expect to continue to incur net losses in the foreseeable future. Our net loss and comprehensive loss were $40.9 million and $50.2 million for the six months ended October 31, 2024 and
2023, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">113 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
respectively. Our net loss and comprehensive loss were $94.1 million and $84.2 million for the fiscal years ended April 30, 2024 and 2023, respectively. As of October 31, 2024, we had an
accumulated deficit of $446.7&nbsp;million. For the six months ended October 31, 2024 and 2023, we generated negative operating cash flows of $35.5&nbsp;million and $41.5 million, respectively. For the fiscal years ended April&nbsp;30, 2024 and
2023, we generated negative operating cash flows of $72.2 million and $69.6 million, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have concluded that our history of
continued operating losses and accumulated deficit raise substantial doubt about our ability to continue as a going concern. See Note 1 to our consolidated financial statements for the fiscal years ended April 30, 2024 and 2023 included elsewhere in
this prospectus for additional information on our assessment. Similarly, our independent registered public accounting firm included an explanatory paragraph in its report on our consolidated financial statements as of and for the fiscal years ended
April&nbsp;30, 2024 and 2023 included elsewhere in this prospectus, describing the existence of substantial doubt about our ability to continue as a going concern. We believe that the actions presently being taken to further implement our business
plan, generate revenues, and raise additional capital provide the opportunity for us to continue as a going concern. While we believe in the viability of our strategy to generate revenues and in our ability to raise additional funds, there can be no
assurances that we will be successful in these efforts and the substantial doubt will be alleviated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Funding Requirements and Contractual
Obligations </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have incurred significant operating losses and negative cash flows driven by substantial research and development
costs as well as our large investment in our fleet of ASSURE WCDs and building our commercial organization. Our operations have focused on developing products, establishing our intellectual property portfolio, marketing our product and staffing the
Company to support continued growth. Our primary use of cash has been to fund operating expenses, which comprise research and development costs, and costs of building the commercial team and necessary infrastructure to support our growth. Cash used
to fund our operating expenses is impacted by the timing of when we pay for such expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We obtained the PMA for our ASSURE WCD from
the FDA on July&nbsp;27, 2021 and fully commercially launched our ASSURE WCD in August 2022. We will continue to scale the business and therefore expect operating losses to continue. While we believe that our existing cash and cash equivalents
(including the net proceeds from this offering) will be sufficient to fund our operating and capital needs for at least the next 12&nbsp;months, we may require additional funding to execute on our growth plans, which may include future equity and
debt financings. Our assessment of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement and involves risks and uncertainties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our future obligations primarily consist of our debt obligations. From our inception, our operations have primarily been funded by proceeds
from our capital contributions made by West Affum Holdings, L.P., our direct parent prior to the Organizational Transactions, borrowings under our Term Loan and, prior to its repayment in September of 2023, our Term Loan 2020, and our revenues. We
expect our cash generation from operations and future ability to refinance or secure additional equity or financing to be sufficient to repay our outstanding debt obligations. As of October&nbsp;31, 2024, the outstanding principal amount under the
Term Loan, which is further described in the section titled &#147;Description of Certain Indebtedness.&#148; was approximately $45.0&nbsp;million. The Term Loan 2020 was repaid in full in September 2023. For further information, see Note 7,
&#147;<I>Long-Term Debt</I>,&#148; to our consolidated financial statements included elsewhere in this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sources of Liquidity
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the six months ended October 31, 2024 and 2023, we received $103.4&nbsp;million and $50.0&nbsp;million, respectively, in cash
from West Affum Holdings, L.P. in return for the issuance of redeemable preferred stock as described in Note 10, &#147;<I>Redeemable Preferred Stock</I>,&#148; to our consolidated financial statements included elsewhere in this prospectus.
Additionally, in July 2024, one of our subsidiaries received $17.1&nbsp;million from a third-party </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">114 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
investor in return for redeemable shares of the subsidiary. As of October 31, 2024, we had cash and cash equivalents and restricted cash balances of $77.3 million and an accumulated deficit of
$446.7&nbsp;million. In the fiscal years ended April 30, 2024 and 2023, we received $75.0&nbsp;million and $102.1&nbsp;million, respectively, in cash from West Affum Holdings, L.P. in return for the issuance of redeemable preferred stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On September&nbsp;24, 2020, we entered into the Loan and Security Agreement with a lender providing for aggregate borrowings of up to
$50.0&nbsp;million (as amended, the &#147;Term Loan 2020&#148;). Available commitments under our Term Loan 2020 were able to be drawn in up to three tranches, which were subject to the Company achieving certain funding, regulatory or revenue
milestones, with $20.0&nbsp;million available in the first tranche and $15.0&nbsp;million available in each of the second and third tranches. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On December&nbsp;28, 2020, we drew the first tranche of the Term Loan 2020 in the amount of $20.0&nbsp;million. In conjunction with the draw
on the first tranche, West Affum Holdings, L.P. issued a warrant to the lender to purchase up to 49,044 shares of West Affum Holdings, L.P.&#146;s common units at an exercise price of $22.63 per unit. The fair value of the warrant is
$0.3&nbsp;million and is recognized as a debt discount and as a capital contribution, and the debt discount is amortized over the term of the loan to interest expense. On January&nbsp;21, 2022, we drew on the second tranche of the Term Loan 2020 in
the amount of $15.0&nbsp;million. In conjunction with the draw of the second tranche, West Affum Holdings, L.P. issued a warrant to the lender to purchase up to 36,783 shares of West Affum Holdings, L.P.&#146;s common units at an exercise price of
$26.24 per unit. The fair value of the warrant is $0.4&nbsp;million and is recognized as a debt discount and as a capital contribution, and the debt discount is amortized over the term of the loan to interest expense. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On September 29, 2023, we repaid our Term Loan 2020 in full using a portion of our borrowings under the Term Loan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On September&nbsp;29, 2023, we entered into a credit agreement with Perceptive Credit Holdings IV, LP, as administrative agent, which provides
for a senior secured delayed draw term loan facility in an aggregate principal amount of up to $60.0&nbsp;million. The Term Loan matures on September&nbsp;29, 2028. Borrowings under the Term Loan are made available in up to three tranches, the first
of which is available upon closing of the Term Loan and two <FONT STYLE="white-space:nowrap">follow-on</FONT> tranches of $7.5&nbsp;million which become available before November&nbsp;1, 2024 and February&nbsp;1, 2025 and are dependent upon
achievement of revenue milestones of trailing twelve month revenues of $50.0&nbsp;million and $70.0&nbsp;million, respectively. We did not meet the revenue milestone required to draw on the November&nbsp;1, 2024
<FONT STYLE="white-space:nowrap">follow-on</FONT> tranche of the Term Loan. As of October 31, 2024, we determined it is not likely that we will meet the revenue milestone required to draw on the February 1, 2025 follow-on tranche of the Term Loan.
As a result, we expensed the asset related to debt issuance costs and facility fees in the amount of $0.5&nbsp;million. The Term Loan bears interest on outstanding balances of Term SOFR plus a margin of 7.25% per annum. On or prior to March&nbsp;31,
2025, up to 2.00% of the margin can be <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">paid-in-kind,</FONT></FONT> accrued and added to the principal balance and compounded quarterly. All interest is due and payable quarterly in
arrears. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On September&nbsp;29, 2023, we drew the initial $45.0&nbsp;million under the Term Loan. In conjunction with the draw of the
first tranche, West Affum Holdings, L.P. issued a warrant to the lender to purchase up to 256,410 shares of West Affum Holdings, L.P.&#146;s common units at an exercise price of $17.55 per share. The fair value of the warrant is $1.6&nbsp;million
and is recognized as a debt discount and as a capital contribution, and the debt discount is amortized over the term of the loan to interest expense. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In February of 2025, we amended the Term Loan pursuant to the Second Amendment (as defined below) to adjust the revenue milestones set forth
in the Term Loan and to amend our ability to draw on additional funds. Pursuant to the Second Amendment, if this offering is not completed by July&nbsp;31, 2025, the revenue milestones will revert to the revenue milestones set forth in the Term Loan
prior to the Second Amendment. Further, upon the completion of this offering and the achievement of $60.0&nbsp;million of revenue on a 12-month trailing basis, an additional $15.0&nbsp;million term loan draw is available to us through July&nbsp;31,
2026. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">115 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For further information, see Note 7, &#147;<I>Long-Term Debt</I>,&#148; to our condensed
consolidated financial statements for the six months ended October 31, 2024 and 2023, and consolidated financial statements for the fiscal years ended April&nbsp;30, 2024 and 2023 included elsewhere in this prospectus and under &#147;Description of
Certain Indebtedness.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash Flows </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table presents a summary of our cash flows from operating activities, investing activities and financing activities for the
periods indicated: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Six Months Ended </B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>October 31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2024</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(35,525</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(41,491</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,484</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,105</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">115,678</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,592</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in cash, cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">68,669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Fiscal Year Ended</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>April&nbsp;30,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2024</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(72,235</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(69,642</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,229</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,461</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77,725</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96,106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase (decrease) in cash, cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,739</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,003</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:10pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Cash Flows from Operating Activities </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For the six months ended October 31, 2024, cash used in operating activities was $35.5 million, which primarily consisted of a net loss of
$40.9 million and a net decrease of $2.9&nbsp;million in operating assets and liabilities, offset by a net increase of $8.3 million in non-cash charges. The non-cash charges primarily consisted of depreciation and amortization of $4.2 million,
stock-based compensation expense of $1.5 million, interest paid-in-kind of $0.5&nbsp;million related to the Term Loan, loss on disposal of property and equipment of $1.0&nbsp;million, non-cash lease expense of $0.2 million and amortization of debt
discounts and issuance costs of $0.9 million. The net change in our operating assets and liabilities consisted of changes in accrued liabilities of $1.8 million driven by increases in accrued compensation due to increased headcount, prepaid expenses
and other current assets of $0.2&nbsp;million related to prepayments for commercial materials and software licenses and fees, and operating lease liabilities of $0.1 million, partially offset by changes in account receivables of $3.4 million,
disposable medical equipment supplies of $1.0&nbsp;million and accounts payable of $0.5 million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For the six months ended October 31,
2023, cash used in operating activities was $41.5 million, which primarily consisted of a net loss of $50.2 million, offset by a net increase of $0.2 million in operating assets and liabilities and $8.5 million in non-cash charges. The non-cash
charges primarily consisted of depreciation and amortization of $4.7 million, stock-based compensation expense of $0.7 million, interest paid-in-kind of $0.6&nbsp;million related to the Term Loan and the Term Loan 2020, loss on disposal of property
and equipment of $0.8 million, non-cash loss on extinguishment of debt related to the Term Loan 2020 of $0.9 million, non-cash lease expense of $0.6 million and amortization of debt discounts and issuance costs of $0.2 million. The net change in our
operating assets and liabilities consisted of changes in accounts payable of $4.2 million and prepaid expenses and other current assets of $0.3 million related to prepayments for commercial materials and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">116 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
software licenses and fees, partially offset by changes in disposable medical equipment supplies of $2.3 million, accrued liabilities of $1.3&nbsp;million driven by increases in accrued
compensation due to increased headcount and operating lease liabilities of $0.7 million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For the fiscal year ended April&nbsp;30, 2024,
cash used in operating activities was $72.2&nbsp;million, which primarily consisted of a net loss of $94.1&nbsp;million, offset by a net increase of $4.4&nbsp;million in operating assets and liabilities and $17.5&nbsp;million in <FONT
STYLE="white-space:nowrap">non-cash</FONT> charges. The <FONT STYLE="white-space:nowrap">non-cash</FONT> charges primarily consisted of depreciation and amortization of $11.6&nbsp;million, stock-based compensation expense of $1.5&nbsp;million,
interest <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">paid-in-kind</FONT></FONT> of $1.1&nbsp;million related to the Term Loan and the Term Loan 2020, loss on disposal of property and equipment of $1.1&nbsp;million, <FONT
STYLE="white-space:nowrap">non-cash</FONT> loss on extinguishment of debt related to the Term Loan 2020 of $0.9&nbsp;million, <FONT STYLE="white-space:nowrap">non-cash</FONT> lease expense of $0.7&nbsp;million and amortization of debt discounts and
issuance costs of $0.6&nbsp;million. The net change in our operating assets and liabilities consisted of changes in accounts payable of $7.4&nbsp;million, accrued liabilities of $0.4&nbsp;million driven by increases in accrued compensation due to
increased headcount, and prepaid expenses and other current assets of $0.3&nbsp;million related to prepayments for commercial materials and software licenses and fees, partially offset by changes in account receivables of $2.0&nbsp;million,
disposable medical equipment supplies of $1.2&nbsp;million, and operating lease liabilities of $0.5&nbsp;million. </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For the fiscal year
ended April&nbsp;30, 2023, cash used in operating activities was $69.6&nbsp;million, which primarily consisted of a net loss of $84.2&nbsp;million offset by a net increase of $1.3&nbsp;million in operating assets and liabilities, and
$13.3&nbsp;million in <FONT STYLE="white-space:nowrap">non-cash</FONT> charges. The <FONT STYLE="white-space:nowrap">non-cash</FONT> charges primarily consisted of interest
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">paid-in-kind</FONT></FONT> of $5.2&nbsp;million related to the Term Loan 2020, $4.8&nbsp;million of depreciation and amortization expense, stock-based compensation expense of
$1.2&nbsp;million, <FONT STYLE="white-space:nowrap">non-cash</FONT> lease expense of $1.1&nbsp;million, loss on disposal of property and equipment of $0.6&nbsp;million, amortization of debt discounts and issuance costs of $0.4&nbsp;million. The net
increase in our operating assets and liabilities was primarily due to changes in accounts payable of $2.1&nbsp;million and accrued liabilities of $1.3&nbsp;million largely attributable to an increase in commissions and bonuses payable, partially
offset by changes in operating lease liabilities of $1.1&nbsp;million attributable to operating lease repayments, disposable medical equipment supplies of $0.7&nbsp;million, and prepaid expenses and other current assets of $0.3&nbsp;million. </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Cash Flows from Investing Activities </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For the six months ended October 31, 2024, cash used in investing activities was $11.5 million, which primarily consisted of purchases of
property and equipment, such as medical rental equipment, computer hardware, test equipment and other research and development activities, and leasehold improvements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For the six months ended October 31, 2023, cash used in investing activities was $3.1 million, which primarily consisted of $3.2 million of
cash used for purchases of property and equipment, such as medical rental equipment, computer hardware, test equipment and other research and development activities, leasehold improvements, and $0.1 million of cash used for deposits for medical
rental equipment, partially offset by $0.2&nbsp;million of cash received from refund of deposits for medical rental equipment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For the
fiscal year ended April&nbsp;30, 2024, cash used in investing activities was $12.2&nbsp;million, which primarily consisted of $12.2&nbsp;million cash used for purchases of property and equipment such as medical rental equipment, computer hardware,
test equipment and other research and development activities, and leasehold improvements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For the fiscal year ended April&nbsp;30, 2023,
cash used in investing activities was $15.5&nbsp;million, which primarily consisted of $13.9&nbsp;million of cash used for purchases of property and equipment such as medical rental equipment, computer hardware, test equipment and other research and
development activities, leasehold improvements, and $1.6&nbsp;million of cash used for deposits for medical rental equipment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Cash
Flows from Financing Activities </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For the six months ended October 31, 2024, cash provided by financing activities was $115.7 million,
which primarily consisted of $103.4 million in proceeds from the issuance of redeemable preferred stock and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">117 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
$17.1&nbsp;million in proceeds from the issuance of stock to non-controlling interest. The increase in cash provided by financing activities was offset by payments of equity issuance costs of
$3.2 million and deemed dividend payments of $1.6 million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For the six months ended October 31, 2023, cash provided by financing
activities was $53.6 million, which primarily consisted of $50.0 million in proceeds from the issuance of redeemable preferred stock and $45.0 million in proceeds from the initial draw on the Term Loan in September 2023. The increase in cash
provided by financing activities was offset by re-payments of long-term debt of $39.1 million, debt issuance costs of $1.9 million and deemed dividend payments of $0.4 million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For the fiscal year ended April&nbsp;30, 2024, cash provided by financing activities was $77.7&nbsp;million, which primarily consisted of
$75.0&nbsp;million in proceeds from the issuance of redeemable preferred stock and $45.0&nbsp;million in proceeds from the initial draw on the Term Loan in September 2023. The increase in cash provided by financing activities was offset by <FONT
STYLE="white-space:nowrap">re-payments</FONT> of long-term debt of $39.1&nbsp;million, debt issuance costs of $2.4&nbsp;million and deemed dividend payments of $0.8&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For the fiscal year ended April&nbsp;30, 2023, cash provided by financing activities was $96.1&nbsp;million, which primarily consisted of
proceeds from the issuance of redeemable preferred stock of $102.1&nbsp;million, which were partially offset by <FONT STYLE="white-space:nowrap">re-payments</FONT> of long-term debt of $5.3&nbsp;million and deemed dividend payments of
$0.7&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Off-Balance&nbsp;Sheet</FONT> Arrangements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of October 31, 2024, we had two irrevocable standby letters of credit issued by Silicon Valley Bank, a division of First Citizens Bank,
that total $0.1&nbsp;million related to our office leases and Cash Pledge Agreement of $0.2&nbsp;million as collateral for the Company credit card program. We did not have any other obligations, assets or liabilities that would be considered <FONT
STYLE="white-space:nowrap">off-balance</FONT> sheet arrangements. We do not participate in transactions that create relationships with unconsolidated entities or financial partnerships, often referred to as variable interest entities, which would
have been established for the purpose of facilitating <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet arrangements. We have not entered into any <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet financing arrangements, established
any special purpose entities, guaranteed any debt or commitments of other entities, or entered into any <FONT STYLE="white-space:nowrap">non-financial</FONT> agreements involving assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical Accounting Policies and Significant Management Estimates </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our management&#146;s discussion and analysis of our financial condition and results of operations are based on our consolidated financial
statements, which have been prepared in accordance with United States generally accepted accounting principles. The preparation of our consolidated financial statements and related disclosures requires us to make estimates and assumptions that
affect the reported amounts of assets, liabilities, costs and expenses and related disclosures. We base our estimates on historical experience, known trends and events and various other assumptions that we believe to be reasonable under the
circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual
results may differ from these estimates under different assumptions or conditions, could have a material impact on the Company&#146;s business, financial condition, results of operations and prospects. While our significant accounting policies are
described in more detail in Note 2 of our consolidated financial statements included elsewhere in this prospectus, we believe that the accounting policies discussed below are critical to understanding our historical and future performance, as these
policies relate to the more significant areas involving management&#146;s judgments and estimates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We generate revenue from the leases of our ASSURE WCD, which are classified as operating leases at lease commencement in accordance with
Accounting Standards Codification Topic 842, <I>Leases </I>(&#147;ASC Topic 842&#148;). Under ASC Topic 842, we recognize lease revenue for fixed lease payments on operating leases on a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">118 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
straight-line basis over the contractual lease term, when collectability of the lease payments is deemed to be probable. Variable lease payments are recognized into revenue in the period in which
the changes in facts and circumstances on which those payments are based occur. The lease term begins on the date the device is made available to the patient. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If collectability of the lease payments is not probable, then lease income is limited to the lesser of the income that would have been
recognized if collectability was probable, or the lease payments collected. Collectability of all lease payments, which includes amounts reimbursed by third-party payors or amounts covered by the patient, is assessed for each type of contract upon
lease commencement and is subject to subsequent reassessment throughout the lease term, as necessary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have elected the practical
expedient provided under ASC Topic 842 to combine the lease of our ASSURE WCD with the <FONT STYLE="white-space:nowrap">non-lease</FONT> components of our Cardiac Recovery System platform, which include the digital healthcare platform. Our ASSURE
WCD is the predominant component and, as a result, we account for the combined components under ASC Topic 842. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Due to the nature of the
industry and the reimbursement environment in which we operate, we evaluate the need to record a general reserve under Accounting Standards Codification Topic 450, <I>Contingencies</I>, for a portfolio of operating lease receivables that are
probable of collection. Inherent in the reserve estimates is the risk that they will have to be revised or updated as additional information becomes available. Specifically, the complexity of many third-party billing arrangements and the uncertainty
of reimbursement amounts for certain services from certain payors may result in adjustments to amounts originally recorded. Such adjustments are expected to be identified and recorded at the point of cash application or claim denial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Property and Equipment </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Property
and equipment consist of medical rental equipment, test equipment, computer software and equipment, and leasehold improvements. Medical rental equipment used in the delivery of our ASSURE WCD system consists of therapy cables, batteries, battery
chargers, assistants, and WCD monitors, all of which have different useful lives. Upon completion of use by a patient, medical rental equipment is returned to our third-party manufacturing and supply partner and inspected, tested and recertified for
use by another patient. We are exposed to risks of patients failing to return the medical rental equipment on time or at all, as well as risks that the medical rental equipment may be severely damaged upon return and require extensive repair. We
record reserves for damaged components that are beyond repair and return failures. The charges recorded were $1.1&nbsp;million and $0.6&nbsp;million for the years ended April&nbsp;30, 2024, and 2023, respectively and $1.0&nbsp;million and
$0.8&nbsp;million for the six months ended October&nbsp;31, 2024 and 2023, respectively. When medical rental equipment is not in use by patients, it resides with our third-party manufacturing and supply partner, at other third-party warehouses or
with the Company&#146;s territory managers. Physical counts of medical rental equipment components are conducted at least annually at our third-party manufacturing and supply partner locations and at least quarterly at all other locations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Property and equipment are stated at cost less accumulated depreciation. Depreciation of medical rental equipment commences at the date when
it becomes available for service, which represents the date that the asset is ready for intended use by the patients and continues through the estimated useful life of the asset. Expenditures for major renewals and betterments that extend the useful
lives of property and equipment are capitalized. Expenditures for maintenance and repairs, including planned major maintenance activities, are expensed as incurred. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">119 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Property and equipment are depreciated using the straight-line method based on the following
estimated useful lives: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Asset Classification </B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Estimated&nbsp;Useful&nbsp;Lives
</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computer software and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">3.0 years</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Test equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">5.0 years</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Lesser&nbsp;of&nbsp;useful&nbsp;life&nbsp;or&nbsp;lease-term</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Medical rental equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2.0&nbsp;-&nbsp;8.0 years</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">When assets are retired, lost, or otherwise disposed of, the cost and related accumulated depreciation are
removed from the accounts, and any resulting gain or loss is recognized in the consolidated statements of operations and comprehensive loss for the appropriate period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Impairment of Long-Lived Assets </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company&#146;s long-lived assets consist of property and equipment, which includes leasehold improvements and <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets. The Company does not have long-lived assets held for sale. Long-lived assets are reviewed for potential impairment at such time that events or changes in
circumstances indicate that the carrying amount of an asset may not be recoverable. When evaluating long-lived assets for potential impairment, the Company will first compare the carrying amount of the assets to estimated future net undiscounted
cash flows expected to result from the use of the assets, including cash flows from disposition. If the estimated future cash flows are less than the carrying amounts of the assets, an impairment loss is recognized and measured based upon the excess
of the carrying value of the asset over its estimated fair value. There were no impairments of long-lived assets during the fiscal years ended April&nbsp;30, 2024 and 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Valuation of Equity </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Prior to the
completion of this offering, the fair value of the common shares underlying our stock-based awards was determined by the Board of Directors. The valuations of our common shares prior to the completion of this offering were determined in accordance
with the guidelines outlined in the American Institute of Certified Public Accountants Practice Aid, <I>Valuation of Privately-Held-Company Equity Securities Issued as Compensation</I>. In the absence of a public trading market, the Board of
Directors, with input from management, exercised significant judgment and considered numerous objective and subjective factors to determine the fair value of our common shares as of the date of each option grant, including the following factors:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our stage of development; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our history and the timing of the introduction of new technology; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our actual operating results and performance and financial condition, including our levels of available capital
resources; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">current business conditions and projections; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the prices, rights, preferences, and privileges of our redeemable preferred stock relative to those of our common
stock; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">market and economic conditions; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">conditions of the medical device industry; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the stock price performance, volatility, and valuation multiples of comparable publicly-traded companies;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">120 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the likelihood and timing of achieving a liquidity event, such as an initial public offering, given prevailing
market conditions; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the prices of redeemable preferred stock sold by us to third-party investors in arms-length transactions;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recent stock transactions in shares of our preferred and common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">relevant mergers and acquisitions in targeted industries; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the lack of marketability of our common stock; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">contemporaneous valuations performed by third-party valuation firms. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We determined that the Probability-Weighted Expected Returns Method (&#147;PWERM&#148;) approach is the most appropriate method for estimating
our enterprise value. This method considers various exit scenarios including an initial public offering (the &#147;IPO Scenario&#148;), potential merger or acquisition (the &#147;M&amp;A Scenario&#148;), or staying private, and assigns a probability
weight to each scenario. Using the PWERM, the enterprise value under each potential exit scenario and the timing of each scenario were weighted based on our estimated probability of occurrence for such scenario. Our equity values under the IPO
Scenario and M&amp;A Scenario were each estimated using the market approach based on the valuation of comparable public companies. We then allocated the equity value to our outstanding common stock based on the estimated timing, valuation and
probability of each scenario. The stay private scenario estimated our equity value using an income approach based on our financial projections. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The scenario-specific values were probability-weighted and discounted to present value to arrive at an overall estimated equity value. After
the equity value was determined, we applied a discount for lack of marketability to reflect the lack of marketability associated with our common stock, which is not traded on public exchanges. For financial reporting purposes, we considered the
amount of time between the valuation date and the grant date of any stock options to determine whether to use the latest common stock valuation or a straight-line interpolation between the latest valuation date and the grant date. This determination
included an evaluation of whether any significant events or changes had occurred between the previous valuation date and the grant date that could materially change our equity value determined at the latest valuation date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For valuations after the completion of this offering, the fair value of each share of underlying common stock will be based on the closing
price of our common stock as reported on the date of grant on the primary stock exchange on which our common stock is traded. </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock-Based
Compensation </I></B></P> <P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense related to equity incentive units of West Affum Holdings, L.P., which is allocated
to us, is measured at the grant date based on the fair value of the award and is recognized as stock-based compensation expense based on employees&#146; continued services. The Company historically used either the Black-Scholes option pricing model
or the probability-weighted expected return method (&#147;PWERM&#148;) to determine the fair value of incentive units. Forfeitures are recognized as they occur. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Black-Scholes option pricing model requires the use of subjective assumptions to determine the fair value of stock-based awards. These
assumptions include: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Fair value of common shares. </I>The fair value of common units is determined by the Board of Directors as of
the date of award grant, with input from management, considering contemporaneous independent third-party valuations of common units, and the Board of Directors&#146; assessment of additional objective and subjective factors that it believed were
relevant and which may have changed from the date of the most recent valuation through the date of the grant. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">121 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Expected term. </I>Expected term represents the period that stock-based awards are expected to be outstanding.
The expected term for incentive units is the expected time to liquidity. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Expected volatility. </I>Since we have been a privately held company and do not have any trading history for
our common units, the expected volatility is estimated based on the average volatility for comparable publicly traded medical technology companies over a period equal to the expected term. The comparable companies were chosen based on their similar
size, stage in the life cycle or area of specialty. We will continue to apply this process until a sufficient amount of historical information regarding the volatility of our own share price becomes available. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Expected dividend. </I>We have never paid dividends on our common shares and have no plans to pay dividends on
our common units. Therefore, we used an expected dividend yield of zero. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Discount for lack of marketability. </I>We applied a discount for lack of marketability (&#147;DLOM&#148;)
based on two widely accepted models: the 2012 Finnerty Model and the Asian Put. The DLOM was assessed by applying a low range based on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">time-to-liquidity</FONT></FONT> assumption of
0.50 years and a volatility assumption of 70.0%, and a high range based on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">time-to-liquidity</FONT></FONT> assumption of 1.50 years and a volatility assumption of 90.0%. After
evaluating the results from both models, we selected a DLOM range and selected a final DLOM at the low end of the selected range. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company determined that the PWERM approach is the most appropriate method for estimating our enterprise value. This method considers
various exit scenarios including an initial public offering (the &#147;IPO Scenario&#148;), potential merger or acquisition (the &#147;M&amp;A Scenario&#148;), or staying private, and assigns a probability weight to each scenario. Using the PWERM,
the enterprise value under each potential exit scenario and the timing of each scenario were weighted based on our estimated probability of occurrence for such scenario. Our equity values under the IPO Scenario and M&amp;A Scenario were each
estimated using the market approach based on the valuation of comparable public companies. The Company then allocated the equity value to our outstanding common stock based on the estimated timing, valuation and probability of each scenario. The
stay private scenario estimated our equity value using an income approach based on our financial projections. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The scenario-specific
values were probability-weighted and discounted to present value to arrive at an overall estimated equity value. After the equity value was determined, we applied a discount for lack of marketability to reflect the lack of marketability associated
with our common stock, which is not traded on public exchanges. For financial reporting purposes, we considered the amount of time between the valuation date and the grant date of any stock options to determine whether to use the latest common stock
valuation or a straight- line interpolation between the latest valuation date and the grant date. This determination included an evaluation of whether any significant events or changes had occurred between the previous valuation date and the grant
date that could materially change our equity value determined at the latest valuation date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income Taxes </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We account for income taxes using the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax
consequences attributable to differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and
liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences representing future deductible amounts are expected to be recovered or settled. The effect on deferred tax assets
and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances are provided if, based upon the weight of available evidence, it is more likely than not that some or all of the
net deferred tax assets will not be realized. As a result of the valuation allowances, our net deferred tax position has historically been immaterial. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">122 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We recognize the effect of income tax positions only if those positions are more likely than
not of being sustained upon an audit. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being recognized. Changes in recognition or measurement are reflected in the period in which the change in
judgement occurs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Quantitative and Qualitative Disclosures about Market Risk </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are exposed to market risk in the ordinary course of our business. Market risk represents the risk of loss that may impact our financial
position due to adverse changes in financial market prices and rates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interest Rate Risk </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We had cash, cash equivalents and restricted cash balances of $77.3&nbsp;million as of October 31, 2024. We had cash, cash equivalents and
restricted cash balances of $8.6 million and $15.3 million as of April 30, 2024 and 2023, respectively. Cash consists of deposits with financial institutions. Interest income is sensitive to changes in the general level of interest rates. However,
our exposure to interest rate risk as a result of our cash deposits with financial institutions is not significant, and a hypothetical 10% change in interest rates during any of the periods presented would not have had a material impact on our
consolidated financial statements included elsewhere in this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We also are subject to interest rate risk under the Term Loan.
All amounts outstanding under the Term Loan accrue interest at an annual rate equal to the greater of (a)&nbsp;forward-looking <FONT STYLE="white-space:nowrap">one-month</FONT> term SOFR as posted by the CME group and (b) 4.75% per annum, plus an
applicable margin of 7.25% of which up to 2.00% may be <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">paid-in-kind</FONT></FONT> through March of 2025. However, our exposure to interest rate risk is not significant, and a
hypothetical 10% change in interest rates during any of the periods presented would not have had a material impact on our consolidated financial statements included elsewhere in this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We do not currently engage in nor do we plan to enter into investments for trading or speculative purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Concentrations of Credit Risk </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We
are subject to credit risk from cash balances we maintain that are in excess of federal depository insurance limits of $250,000 and certain cash balances in accounts located in the Cayman Islands and Ireland which are not insured. As of October 31,
2024, we maintained cash, cash equivalents and restricted cash balances of $77.3&nbsp;million, $0.3&nbsp;million of which was in accounts located in the Cayman Islands. As of April 30, 2024, we maintained cash, cash equivalents and restricted cash
balances of $8.6 million, $0.3 million of which was in accounts located in the Cayman Islands. As of April&nbsp;30, 2023, we maintained cash, cash equivalents and restricted cash balances of $15.3&nbsp;million, with $2.7&nbsp;million in accounts
located in the Cayman Islands. Cash, cash equivalents and restricted cash balances as of October 31, 2024, and April 2024 and 2023 were in excess of federal depository insurance limits. We have not experienced any losses in such accounts as of the
date of this prospectus, and we believe that we are not exposed to significant credit risk on our cash balances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Inflation Risk </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our consolidated results of operations and financial condition are presented based on historical cost. While it is difficult to accurately
measure the impact of inflation due to the imprecise nature of the estimates required, we believe the effects of inflation, if any, on our results of operations and financial condition have been immaterial. There can be no assurance that future
inflation will not have an adverse impact on our results of operations and financial condition. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">123 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Emerging Growth Company and Smaller Reporting Company Status </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth company&#148; as defined in Section&nbsp;2(a) of the Securities Act. We will remain an emerging growth company
until the earliest to occur of (i)&nbsp;the last day of the fiscal year that follows the fifth anniversary of the completion of this offering; (ii)&nbsp;the last day of the fiscal year in which we have total annual gross revenue of at least
$1.235&nbsp;billion; (iii)&nbsp;the last day of the fiscal year in which we are deemed to be a &#147;large accelerated filer,&#148; as defined in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> under the Exchange Act, which will occur when the
market value of our common shares held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> exceeds $700.0&nbsp;million as of the most recently completed second quarter; and (iv)&nbsp;the date on which we have issued more than $1&nbsp;billion
in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt over a three-year period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pursuant to the JOBS Act, an emerging growth
company is provided the option to adopt new or revised accounting standards that may be issued by the Financial Accounting Standards Board or the SEC either (i)&nbsp;within the same periods as those otherwise applicable to <FONT
STYLE="white-space:nowrap">non-emerging</FONT> growth companies or (ii)&nbsp;within the same time periods as private companies. We have elected to take advantage of the exemption for complying with new or revised accounting standards within the same
time periods as private companies. Accordingly, the information contained herein may be different than the information you receive from other public companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We also intend to take advantage of some of the reduced regulatory and reporting requirements of emerging growth companies pursuant to the
JOBS Act so long as we qualify as an emerging growth company, including, but not limited to, not being required to comply with the auditor attestation requirements of Section&nbsp;404(b) of the Sarbanes-Oxley Act, and reduced disclosure obligations
regarding executive compensation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are also a &#147;smaller reporting company,&#148; as such term is defined in Rule <FONT
STYLE="white-space:nowrap">12b-2</FONT> under the Exchange Act. We may continue to be a smaller reporting company for so long as either (1)&nbsp;the market value of our common shares held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is
less than $250.0&nbsp;million as of the last business day of our most recently completed second fiscal quarter or (2)&nbsp;our annual revenue was less than $100.0&nbsp;million during the most recently completed fiscal year and the market value of
our common shares held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $700.0&nbsp;million as of the last business day of our most recently completed second quarter. Any loss of our status as a smaller reporting company takes
effect in the first quarter after the fiscal year in which we cease to qualify as a smaller reporting company. To the extent that we continue to qualify as a smaller reporting company at the time we cease to qualify as an emerging growth company, we
will continue to be permitted to make certain reduced disclosures in our periodic reports and other documents that we file with the SEC. Specifically, as a smaller reporting company, we may choose to present only the two most recent fiscal years of
audited financial statements in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Accounting Pronouncements </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A
discussion of recently-adopted and recently-issued accounting pronouncements applicable to our company is provided in Note 2, &#147;<I>Significant Accounting Policies</I>,&#148; to our consolidated financial statements for the fiscal years ended
April 30, 2024 and 2023, and our condensed consolidated financial statements for the six&nbsp;months ended October 31, 2024 and 2023 included elsewhere in this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">124 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom744414_10"></A>BUSINESS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are a commercial-stage,
wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed
and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our
Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (&#147;WCD&#148;) used to protect patients at an elevated risk of sudden cardiac arrest (&#147;SCA&#148;), a major public health problem that
accounts for approximately 50% of all cardiovascular deaths in the U.S. The ASSURE WCD automatically monitors elevated risk patients and, if needed, delivers a defibrillation shock to return the patient&#146;s heart to normal rhythm. The ASSURE WCD
was purpose-built to enhance patient comfort and compliance and directly address the key barriers to adoption associated with the only other commercially available WCD. We believe the ASSURE WCD offers significant clinical and functional advantages,
including greater patient compliance as a result of a major reduction in false alarms and enhanced comfort and wearability. In addition to the ASSURE WCD, our Cardiac Recovery System platform includes a comprehensive suite of fully integrated
digital solutions and services that enable enhanced patient and provider engagement and oversight, with the objective of improving patient outcomes. We believe our Cardiac Recovery System platform addresses serious unmet needs in the cardiac patient
population and has the potential to disrupt and grow the market which has been limited to a single solution for more than 20 years. As of January&nbsp;31, 2025, our system is actively being prescribed by more than 550 hospitals across the U.S.,
representing approximately 20% of WCD prescribing hospitals in the U.S. Active prescriptions represent hospitals that have prescribed the ASSURE WCD within the last six months. Additionally, our ASSURE WCD has been worn by over 17,000 patients since
it was fully commercially launched. In our top 50 hospitals, we believe we have successfully captured approximately&nbsp;45% of the currently available prescriptions based on company-sourced data on all hospitals that we serve in the U.S. and the
percentage of WCD filled prescriptions at those hospitals that are for our ASSURE WCD. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">SCA is a life-threatening emergency characterized
by the abrupt cessation of the heartbeat caused by an electrical malfunction in the heart. This is typically triggered by ventricular arrhythmias, such as ventricular fibrillation (&#147;VF&#148;), and leads to a loss of consciousness and
potentially death within minutes if not promptly treated. The American Heart Association (&#147;AHA&#148;) estimates that SCA causes approximately 436,000 deaths per year, making it the third leading cause of death in the U.S. Defibrillation, or an
electrical shock, is the only way to restore a fibrillating heart to a normal rhythm. Each minute of delay in restoring the heart to a normal rhythm reduces a patient&#146;s chance of survival by 7% to 10%. The average time for Emergency Medical
Services (&#147;EMS&#148;) arrival is 7 minutes from the time of a 911 call, and often longer in rural communities. The most common location of a SCA in adults is at a home or residence, representing approximately 73% of SCAs. In addition,
approximately 50% of all SCAs are unwitnessed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A WCD is a wearable, <FONT STYLE="white-space:nowrap">non-invasive</FONT> miniaturized
automated external defibrillator and is worn underneath regular clothing. The device continuously monitors a patient&#146;s heart rhythm and is capable of delivering a defibrillation shock. Wires connect electrodes inside the garment to the monitor,
which is carried in a small pack or shoulder bag. The electrodes continuously acquire a patient&#146;s heart rate and rhythm for evaluation by the automated external defibrillator. If the monitor detects a potentially life-threatening arrhythmia,
the WCD first alerts the patient via an audible alarm and then administers a shock, if needed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The WCD is indicated for use in patients
who are at risk for SCA and are not candidates for, or refuse, an ICD. WCDs are typically prescribed to patients immediately following an MI or heart failure diagnosis and serve as a bridge to recovery between the cardiac event and a longer-term
treatment regimen. During this period, healthcare providers will adjust the medications prescribed for the patient and observe whether the patient&#146;s LVEF improves. The expected wear duration of the WCD varies based on the patient&#146;s
indication, with the majority of our patients being prescribed the WCD for three months or longer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">125 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For over 20 years, WCDs have been used to protect patients at elevated risk of SCA. However,
until the ASSURE WCD received Food and Drug Administration (&#147;FDA&#148;) approval in July of 2021, the market was limited to a single solution. Since the approval of the first WCD in 2001, global WCD revenues have grown to $1.3&nbsp;billion in
2023, with approximately 85% of the revenues generated in the U.S. based on our analysis of third-party claims data and estimated average WCD wear prescription lengths and average reimbursement rates in the U.S. and in select international markets
derived from industry data and internal estimates. The volume of patients prescribed a WCD in the U.S. grew at roughly 6% annually between 2021 and 2023, and we expect WCD revenues to continue growing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Despite being proven as safe and effective in treating dangerous cardiac rhythms when worn, WCD therapy remains underutilized, reaching just
14% of the eligible U.S. patient population in 2023 based on data on patients indicated for a WCD and WCD prescription data from industry sources. We believe that the low penetration of WCD therapy is largely due to the limitations of the incumbent
commercially available device. In feedback we have collected through directly engaging with patients and providers and customer feedback on public platforms, commonly cited reasons for patients or providers failing to use the competitor device
include high false alarm frequency, poor wearability and patient discomfort, a unisex-only garment, low utility data and limited connectivity with patients. In the U.S., we estimate that there are approximately 800,000 cardiac patients each year who
have experienced an MI or are diagnosed with heart failure and have low LVEF, therefore making them eligible for WCD therapy. Additionally, approximately 50,000 patients each year either have documented VT or VF, an inherited genetic condition, or
have had their ICD temporarily explanted, and are also indicated for WCDs. Based on an average WCD wear prescription length of 3.4 months per patient and an average Medicare reimbursement rate of $3,436 per patient per month, we believe this
represents an approximately $10&nbsp;billion annual addressable market. In select international markets, we estimate based on patient population data collected by various <FONT STYLE="white-space:nowrap">third-party</FONT> industry sources that
there are approximately 3.7&nbsp;million people each year who experience an MI, are diagnosed with heart failure, have documented VT or VF, have an inherited genetic condition, or have had their ICD temporarily explanted. Among these patients, based
on the same <FONT STYLE="white-space:nowrap">third-party</FONT> industry sources, we estimate that approximately 1.8 million patients meet the indications for WCD therapy. Based on estimated average WCD wear prescription length in these
international markets of 2.5 months per patient and estimated average reimbursement rate of $3,000 per patient per month derived from industry data and internal estimates, we believe this represents an approximately $14 billion total annual market
opportunity outside the U.S. For a description of the international markets covered by this estimated market opportunity, see &#147;Industry and Market Data.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The ASSURE WCD is the next generation of WCD therapy, delivering a safe and effective solution for patients with a design that enhances
patient comfort and compliance. In addition to the ASSURE WCD, the various digital solutions and services of our Cardiac Recovery System platform include the ASSURE patient application, Kestra CareStation remote patient data platform, Heart Alert
Services, and ASSURE Assist services. The ASSURE patient application engages patients with real-time mobile updates to promote compliance, while the Kestra CareStation remote patient data platform equips healthcare providers with actionable insights
to support timely and informed care decisions. Heart Alert Services and ASSURE Assist services work together to enhance safety and are designed to provide critical alerts to healthcare providers for significant arrhythmias and notify emergency
services when therapy is administered. This post-therapy EMS support is critical as a range of injuries, such as head injuries, soft tissue damage and bone fractures, can result from falling down after a SCA. In addition, the ASSURE wearable ECG as
part of our Cardiac Recovery System platform provides monitoring and connectivity for patients no longer indicated for a WCD but who still require ongoing support while their heart continues to remodel. We believe we offer the most comprehensive and
cohesive platform, with digital solutions and services that are seamlessly integrated with our ASSURE WCD, meaningfully differentiating our Cardiac Recovery System platform from the only other commercially available WCD and offering the following
benefits: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Modern and advanced design improves comfort, performance and maximizes wearability.</I></B> The garments
were developed with an athletic and sportswear designer and are tailored for body inclusivity, offering two styles and a wide range of sizes. We believe that having separate, gender-specific designs is particularly important given women make up
approximately 40% of SCA patients.<B><I> </I></B>Overall wearability is further supported by the results of our active surveillance post-</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">126 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
approval study, <FONT STYLE="white-space:nowrap">ACE-PAS,</FONT> which demonstrate a median wear time of greater than 23 hours per day. In addition to improving comfort and wearability, our
unique garment design incorporates cushioned electrodes that are embedded in the fabric to improve electrode contact and, ultimately, improve electrocardiogram (&#147;ECG&#148;) signal quality. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>High fidelity ECG leading to</I></B><B><I> </I></B><B><I>fewer</I></B><B><I>
</I></B><B><I>false</I></B><B><I> </I></B><B><I>alarms.</I></B> The ASSURE WCD is designed to minimize false alarms. The overall level of noise is reduced through use of resistive ECG electrodes that are cushioned and securely bonded to the fabric,
custom shielded cables, and isolation circuitry. The ASSURE WCD also utilizes four channels of high-quality ECG, combined with Adaptive Patient Intelligence (&#147;API&#148;), a proprietary technology that adapts to the patient heart rhythm to
filter out artifacts and improve performance even in a noisy environment. According to the Journal of Interventional Cardiac Electrophysiology Study, as a result of these features, only 6% of our patients experience a false alarm, compared to 46%
for the competitor&#146;s device. Reduction in false alarms may lead to lower patient anxiety, improved patient satisfaction and increased patient compliance. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Product innovations and integrated digital solutions and services supporting the patient throughout the
cardiac care continuum. </I></B>Our Cardiac Recovery System platform is a comprehensive suite of proprietary wearable and fully integrated digital solutions and services for monitoring, diagnosing, and protecting patients through their cardiac
recovery journey. We believe our Cardiac Recovery System platform represents a competitive advantage, with the goal of ultimately improving the prescriber and patient experience, maximizing patient comfort and compliance, and increasing adoption of
our system. In addition, our Cardiac Recovery System platform&#146;s capabilities allow healthcare providers to identify other clinically significant arrhythmias. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Improved energy delivery to enhance efficacy and safety.</I></B> The ASSURE WCD delivers a 170 joule shock
to better serve patients with higher defibrillation thresholds, compared to the competitor device which delivers a 150 joule shock. In addition, our system has a minimum defibrillation capacity of 25 shocks, providing a significant safety buffer for
patients experiencing multiple cardiac events within a short time period, such as a VT storm, where a patient experiences multiple episodes of sustained VT within a short period of time. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are building a body of clinical evidence supporting the safety, efficacy, and benefits of the ASSURE WCD, with six publications completed
to date. This growing portfolio includes our pivotal trials&#151;the ASSURE WCD Clinical Evaluation&#151;Detection and Safety Study <FONT STYLE="white-space:nowrap">(&#147;ACE-DETECT&#148;)</FONT> and the ASSURE WCD Clinical
Evaluation&#151;Conversion Efficacy Study <FONT STYLE="white-space:nowrap">(&#147;ACE-CONVERT&#148;)&#151;which</FONT> served as the basis for our premarket approval (&#147;PMA&#148;). In addition, we are conducting the <FONT
STYLE="white-space:nowrap">ACE-PAS</FONT> as part of a broader ongoing ASSURE Patient Registry. All patients prescribed the ASSURE WCD in the United States after August&nbsp;5, 2022 are included in the Registry. As of January&nbsp;31, 2025, our
ongoing registry has enrolled over 17,000 patients, and its findings further validate the results of <FONT STYLE="white-space:nowrap">ACE-DETECT</FONT> and <FONT STYLE="white-space:nowrap">ACE-CONVERT.</FONT> Our most recent FDA submission from <FONT
STYLE="white-space:nowrap">ACE-PAS</FONT> from July 2024, which includes data from 5,929 patients, reported first shock conversion efficacy of approximately 96%, a low false alarm rate with only 6% of our patients experiencing a false alarm,
compared to 46% for the competitor&#146;s device, and a median daily use of 23.2 hours. These results underscore the ASSURE WCD&#146;s competitive advantages in wearability, usability, and patient compliance, providing strong support for continued
adoption. We believe this collection of real-world evidence will generate additional publications, continue to increase awareness of WCDs as a proven therapy for elevated risk cardiac patients and further demonstrate the clinical differentiation of
our ASSURE WCD. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have made material investments in infrastructure to support rapid growth and scalability, specifically in our
commercial organization, distribution and supply chain capabilities, as well as revenue cycle management capabilities. In the U.S., we have built a commercial sales team of approximately 70 direct sales representatives and more than 40 sales and
clinical support professionals with deep expertise in cardiac rhythm management and established relationships in the cardiology and electrophysiology fields. This team is </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">127 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
responsible for developing sales territory business plans, targeting and opening new accounts, and processing prescriptions of our ASSURE WCD. Our direct sales team is supported by a contracted
team of over 250 APSs who assist patients with fitting and training. At fitting, we deliver our ASSURE WCD from our distribution network to the patient. We utilize a lease business model, and when a patient&#146;s wear time has concluded, the device
is returned for reprocessing and reintroduction into the distribution network. To support our growth, we have developed a highly scalable supply chain in collaboration with experienced, <FONT STYLE="white-space:nowrap">top-tier</FONT> medical
technology suppliers. Our substantial investment in a fleet of devices, each with a capacity for approximately three patient wears per year, are reprocessed through efficient reconditioning, which enables the business to scale with an attractive
unit economic profile. Finally, our revenue cycle management capabilities streamline reimbursement processes by ensuring claims are accurately prepared and submitted according to individual payor requirements, facilitating timely collections. These
capabilities are a critical asset in driving operational efficiency and supporting both patient and prescriber satisfaction. We believe our significant investments in infrastructure create a high barrier to entry that will help us protect and grow
our market share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Over a decade of investment in our research and development capabilities has resulted in a highly experienced and
capable innovation engine. Designed to be scalable, our Cardiac Recovery System platform supports future extensions and enhancements, enabling the integration of new therapeutic and diagnostic capabilities to support our existing fleet of ASSURE
WCDs. The platform also enables data collection from patients that we believe will support training of future automated algorithms to detect and predict clinically relevant events. Moreover, we have a robust patent and trade secrets portfolio, with
more than 365 pending and issued patents worldwide. We believe the combination of our intellectual property portfolio and upgradeable product design creates significant opportunities for efficient innovation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">WCD therapy in the U.S. has well-defined reimbursement codes, steadily increasing Medicare payment rates and broad coverage from major U.S.
payors. Reimbursement rates continue to rise, reflecting growing recognition and support for this life-saving therapy. Strong prescriber demand and patient preference for the ASSURE WCD have driven broad payor coverage for the ASSURE WCD, with over
285&nbsp;million U.S. lives being currently covered via insurance contracts, representing approximately 90% of the total available lives, including traditional Medicare, select state Medicaid programs, and national commercial insurers. Based on
feedback from our payors, we believe that this reflects payors&#146; desire for a second choice to the competitor product, our solution addressing an unmet need with a female-specific garment and the overall patient compliance benefits of the ASSURE
WCD. Our established payor relationships reduce our administrative burden in authorization and billing for our ASSURE WCD. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have
experienced rapid growth since our full commercial launch, expanding our headcount from 66&nbsp;team members in October 2020 to over 300 team members as of January&nbsp;31, 2025. We generated revenue of $27.5&nbsp;million for the six months ended
October 31, 2024, compared to revenue of $9.5 million for the six&nbsp;months ended October 31, 2023, representing 190% quarter-over-quarter growth. For the fiscal year ended April&nbsp;30, 2024, we generated revenue of $27.8 million, compared to
revenue of $7.6 million for the fiscal year ended April&nbsp;30, 2023, representing 265% year-over-year growth. In the six months ended October 31, 2024, we recognized a net loss of $40.9 million, compared to a net loss of $50.2 million for the six
months ended October&nbsp;31, 2023. For the fiscal year ended April 30, 2024, we recognized a net loss of $94.1 million, compared to a net loss of $84.2&nbsp;million for the fiscal year ended April 30, 2023. As of October 31, 2024, April 30, 2024
and April&nbsp;30, 2023, we had an accumulated deficit of $446.7 million, $406.4 million and $312.3 million, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Success Factors
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We believe the continued growth of our company will be driven by the following success factors: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Large, growing, and underpenetrated WCD market with a single competitor.</I></B><B><I></I></B>&nbsp;For
over 20 years, WCDs have been used to protect patients at an elevated risk of SCA. However, until the ASSURE WCD received FDA approval in July of 2021, the market was served by a single supplier. Since the
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">128 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
approval of the first WCD in 2001, global WCD revenues have grown to $1.3&nbsp;billion in 2023, with approximately 85% of the revenues generated in the U.S. based on our analysis of third-party
claims data and estimated average WCD wear prescription lengths and average reimbursement rates in the U.S. and in select international markets derived from industry data and internal estimates. The volume of patients prescribed a WCD in the U.S.
grew at roughly 6% annually between 2021 and 2023, and we expect WCD revenues to continue growing. Despite being proven as safe and effective in treating dangerous cardiac rhythms when worn, WCD therapy remains underutilized, reaching just 14% of
the eligible U.S. patient population in 2023 based on data on patients indicated for a WCD and WCD prescription data from industry sources. This low penetration is attributed largely to poor patient compliance, a challenge stemming from the
limitations of the competitor device. As a next-generation WCD therapy, our ASSURE WCD, as part of our broader comprehensive Cardiac Recovery System platform, is aiming to solve this issue by providing a solution that is intended to enhance patient
comfort and compliance. In the U.S., we estimate that there are approximately 800,000 cardiac patients each year who have experienced an MI or are diagnosed with heart failure and have low LVEF, therefore making them eligible for WCD therapy.
Additionally, approximately 50,000 patients each year either have documented VT or VF, an inherited genetic condition, or have had their ICD temporarily explanted, and are also indicated for WCDs. Based on an average WCD wear prescription length 3.4
months per patient and an average Medicare reimbursement rate of $3,436 per patient per month, we believe this represents an approximately $10&nbsp;billion annual addressable market. While our current commercial efforts are focused on the U.S.,
international markets represented approximately 15% of global WCD revenues in 2023, primarily concentrated in several large countries in western Europe. In select international markets, we estimate based on patient population data collected by
various third-party industry sources that there are approximately 3.7&nbsp;million people each year who experience an MI, are diagnosed with heart failure, have documented VT or VF, have an inherited genetic condition, or have had their ICD
temporarily explanted. Among these patients, based on the same <FONT STYLE="white-space:nowrap">third-party</FONT> industry sources, we estimate that approximately 1.8&nbsp;million patients meet the indications for WCD therapy. Based on estimated
average WCD wear prescription length in these international markets of 2.5 months per patient and estimated average reimbursement rate of $3,000 per patient per month derived from industry data and internal estimates, we believe this represents an
approximately $14&nbsp;billion total annual market opportunity outside the U.S. For a description of the international markets covered by this estimated market opportunity, see &#147;Industry and Market Data.&#148; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Highly innovative Cardiac Recovery System platform designed to protect patients from SCA and improve
patient compliance and healthcare provider adoption.</I></B><B><I></I></B><B><I>&nbsp;</I></B>With improved patient compliance and superior clinical efficacy as our main objectives,<B><I> </I></B>we purpose-built our ASSURE WCD from the ground
up.<B><I> </I></B>The ASSURE WCD is the cornerstone of our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified
solution. The ASSURE WCD directly addresses known barriers by prioritizing comfort, usability, and diagnostic utility, positioning it to drive broader adoption and improve outcomes for elevated risk cardiac patients. The wearable
garments&#151;developed with an athletic and sportswear designer&#151;incorporate advanced electronics, mobile technology, signal processing and performance fabrics to deliver superior wearability. Available in gender-specific styles and a wide
range of sizes, the garments feature cushioned integrated sensors, ensuring comfort and body inclusivity. This design is proven out by results from our post-approval study, which demonstrate a median wear time of over 23 hours per day. The ASSURE
WCD minimizes false alarms using advanced, custom electrical engineering techniques to reduce motion-induced noise. The ASSURE WCD utilizes four channels of high-quality ECG, combined with API, a proprietary technology that adapts to the patient
heart rhythm, to filter out artifacts and improve performance even in a noisy environment. According to the Journal of Interventional Cardiac Electrophysiology Study, as a result of these features, only 6% of our patients experience a false alarm,
compared to 46% for the competitor&#146;s device. This reduction lowers patient anxiety and improves satisfaction. With a patient-</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">129 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
centered design, advanced ECG fidelity, and integrated digital platform, the ASSURE WCD is a differentiated solution that protects patients, empowers healthcare providers with actionable
insights, and improves outcomes across the cardiac care continuum. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Comprehensive and fully integrated suite of mission critical digital solutions and services for driving
patient and healthcare provider engagement. </I></B>Designed to enhance both patient and provider experiences, our Cardiac Recovery System platform is a unified, patient-centered solution that addresses known barriers to adoption and improves
patient care. The various digital solutions and services of the Cardiac Recovery System platform include the ASSURE patient application, Kestra CareStation remote patient data platform, Heart Alert Services, and ASSURE Assist services. The ASSURE
patient application engages patients with real-time mobile updates to promote compliance, while the Kestra CareStation remote patient data platform equips healthcare providers with actionable insights to support timely and informed care decisions.
Heart Alert Services and ASSURE Assist services work together to enhance safety and are designed to provide critical alerts to healthcare providers for significant arrhythmias and notify emergency services when therapy is administered. We believe we
offer the most comprehensive and cohesive platform, with digital solutions and services that are seamlessly integrated with our ASSURE WCD, meaningfully differentiating our Cardiac Recovery System platform. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Material investments in infrastructure to support rapid growth and scale.</I></B><B><I></I></B>&nbsp;We
have made material investments in infrastructure to support rapid growth and scalability, specifically in our commercial organization, distribution and supply chain capabilities, and revenue cycle management capabilities. In the U.S., we have built
a commercial sales team of approximately 70 direct sales representatives and more than 40 sales and clinical support professionals with deep expertise in cardiac rhythm management and established relationships in the cardiology and electrophysiology
fields. Our team is further supported by a contracted network of over 250 patient specialists who assist with onboarding, fitting, and training patients, ensuring a scalable and seamless adoption process. Our commercial team has been successful at
processing prescriptions of the ASSURE WCD, with more than&nbsp;550 hospitals actively prescribing our system as of January&nbsp;31, 2025. To support our growth, we have developed a highly scalable supply chain in collaboration with experienced, <FONT
STYLE="white-space:nowrap">top-tier</FONT> medical technology suppliers. Our substantial investment in a fleet of devices, each with a capacity for approximately three patient wears per year, are reprocessed through efficient reconditioning, which
enables the business to scale with an attractive unit economic profile. Finally, our revenue cycle management capabilities streamline reimbursement processes by ensuring claims are accurately prepared and submitted according to individual payor
requirements, facilitating timely collections. These capabilities are a critical asset in driving operational efficiency and supporting both patient and prescriber satisfaction. We believe our significant investments in infrastructure create a high
barrier to entry that will help us protect and grow our market share. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Established reimbursement and favorable payor coverage.</I></B><B><I></I></B>&nbsp;WCD therapy in the U.S.
has well-defined reimbursement codes, steadily increasing Medicare payment rates and broad coverage from major U.S. payors. Reimbursement rates continue to rise, reflecting growing recognition and support for this life-saving therapy. From 2021 to
2024, published Medicare reimbursement rates have increased at a CAGR of 5.4%. Strong prescriber demand and patient preference for the ASSURE WCD have driven broad payor coverage for the ASSURE WCD, with over 285&nbsp;million U.S. lives being
currently covered via insurance contracts, representing approximately 90% of the total available lives, including traditional Medicare, select state Medicaid programs, and national commercial insurers. Based on feedback from our payors, we believe
that this rapid payor coverage adoption reflects payors&#146; desire for a second choice to the competitor product, our solution addressing an unmet need with a female-specific garment and the overall patient compliance benefits of the ASSURE WCD.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">130 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Strong and compelling body of clinical evidence.</I></B><B><I></I></B>&nbsp;We are building a body of
clinical evidence supporting the safety, efficacy, and benefits of the ASSURE WCD, with six publications completed to date. This growing portfolio includes our pivotal trials&#151;ACE-DETECT and
<FONT STYLE="white-space:nowrap">ACE-CONVERT&#151;which</FONT> served as the basis for our PMA approval. <FONT STYLE="white-space:nowrap">ACE-DETECT</FONT> confirmed detection of arrhythmias and demonstrated a significantly lower false-positive
shock alarm rate compared to the existing commercial device with no missed events, low patient-reported discomfort, and no serious adverse events over a <FONT STYLE="white-space:nowrap">30-day</FONT> wear period in ambulatory patients at elevated
risk of SCA.<B> </B><FONT STYLE="white-space:nowrap">ACE-CONVERT</FONT> showed a cumulative first- and second-shock conversion efficacy of 100% for induced VT/VF, highlighting the system&#146;s reliability in life-threatening scenarios. In addition,
we are continuing our active enrollment of patients in <FONT STYLE="white-space:nowrap">ACE-PAS,</FONT> our real-world post-approval patient registry. All patients prescribed the ASSURE WCD in the United States after August&nbsp;5, 2022 are included
in the Registry. As of January&nbsp;31, 2025, our ongoing registry has enrolled over 17,000 patients, and its findings further validate the results of <FONT STYLE="white-space:nowrap">ACE-DETECT</FONT> and
<FONT STYLE="white-space:nowrap">ACE-CONVERT.</FONT> Our most recent FDA submission from <FONT STYLE="white-space:nowrap">ACE-PAS</FONT> from July 2024, which includes data from 5,929 patients, reported first shock conversion efficacy of
approximately 96%, a low false alarm rate with only 6% of our patients experiencing a false alarm, compared to 46% for the competitor&#146;s device, and a median daily use of 23.2 hours. These results underscore the ASSURE WCD&#146;s competitive
advantages in wearability, usability, and patient compliance, providing strong support for continued adoption. Looking ahead, we remain committed to expanding our clinical data and evidence to reinforce the value of our solutions, drive further
market adoption, and strengthen evidence of the system&#146;s clinical utility. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Broad research and development capabilities and a robust intellectual property
portfolio.</I></B><B><I></I></B>&nbsp;Over a decade of investment in our research and development capabilities has resulted in a highly experienced and capable innovation engine. Designed to be scalable, our Cardiac Recovery System platform supports
future extensions and enhancements, enabling the integration of new therapeutic and diagnostic capabilities to support our existing fleet of ASSURE WCDs. The platform also enables data collection from patients that will support training of future
automated algorithms to detect and predict clinically relevant events. Moreover, we have a robust patent and trade secrets portfolio, with more than 365 pending and issued patents worldwide. We believe the combination of our IP portfolio and
upgradeable product design create significant opportunities for future innovation. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Highly experienced management team and board with proven commercial growth success. </I></B>Our leadership
team brings over 350 years of combined experience spanning enterprise strategy, finance, operations, research and development, and regulatory affairs. Our team also has deep experience and expertise in external defibrillation technologies. With a
proven track record of successfully scaling medical technology businesses, the team guided the ASSURE WCD from concept through commercial launch. This expertise is further bolstered by an experienced board and world-class investors with deep
industry knowledge and recognized leadership in healthcare, medical technology, and adjacent, relevant industries. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Growth
Strategies </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">To fully achieve our mission of providing innovative, intuitive medical technologies to protect and support at-risk
patients, we intend to pursue the following growth strategies: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Continue to capture share of the current WCD prescriptions in the U.S. </I></B>In 2023, approximately
120,000 U.S. patients received a WCD, generating over $1&nbsp;billion in revenues. As of January&nbsp;31, 2025, the ASSURE WCD is actively being prescribed by more than 550&nbsp;hospitals and, since its full commercial launch in August 2022, has
been worn by more than 17,000 patients, demonstrating its potential to address unmet clinical needs and disrupt the market. To build on this momentum, we are expanding our commercial organization, currently comprised of approximately 130 team
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">131 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
members, including regional sales leaders, territory managers, associate sales representatives, and clinical care specialists. This strategic expansion will enhance territory coverage, accelerate
entry into new markets, and strengthen our ability to reach more patients. We see additional opportunities to drive compliance by prioritizing patient comfort and leveraging greater connectivity to prevent lapses in usage. To further advance
utilization, we are responsibly fostering advocacy through collaborations with key opinion leaders, medical societies, and clinical advisory boards. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Peer-to-peer</FONT></FONT>
education, supported by our medical consultants, plays a critical role in ensuring the ASSURE WCD&#146;s unique benefits are widely recognized and embraced within the medical community. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Expand adoption of our Cardiac Recovery System platform in the U.S. to</I></B><B><I> increase the
penetration of the U.S. total addressable WCD market.</I></B> Despite its established efficacy, WCD therapy remains underutilized in the U.S., primarily due to the limitations of the legacy device and gaps in awareness by healthcare providers of its
broader diagnostic utility. As a result, many indicated patients do not receive a prescription and some choose not to wear the device. Additionally, many healthcare providers&#151;even those familiar with WCD therapy&#151;may not fully recognize the
breadth of patients who could benefit from this life-saving technology. This underutilization highlights significant opportunities to expand awareness and adoption. To close this gap, we are implementing a targeted market-shaping strategy to
emphasize the differentiated, clinically meaningful advantages of our Cardiac Recovery System platform. A key focus is educating healthcare providers on the benefits of WCD therapy for newly diagnosed heart failure patients in parallel to receiving
guideline-directed medical therapy (&#147;GDMT&#148;). These efforts include direct engagement with healthcare providers to broaden awareness of eligible patient populations and position WCDs as integral to comprehensive, longer-term cardiac care.
We are further advancing adoption through conference and tradeshow participation, developing key opinion leader partnerships to build advocacy, and increasing brand awareness with programmatic and industry-specific advertising.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Build upon our strong base of clinical evidence. </I></B>We are committed to building upon our strong
foundation of clinical evidence demonstrating the efficacy of our ASSURE WCD and our broader Cardiac Recovery System platform. The ASSURE Patient Registry serves as a cornerstone for generating real-world evidence on our ASSURE WCD&#146;s
performance, and we anticipate that it will support a robust cadence of publications. For example, a recent Cleveland Clinic study, presented through two abstracts at the American Heart Association Scientific Sessions 2024, highlighted the ASSURE
WCD&#146;s clinical efficacy and diagnostic utility, including its ability to detect clinically significant arrhythmias such as asymptomatic atrial fibrillation. These findings demonstrated the system&#146;s high success rate in terminating
life-threatening ventricular arrhythmias with minimal false alarms, reinforcing its value as both a trusted therapy and a diagnostic tool. We believe our ongoing clinical initiatives will further validate the benefits of our system and may support
stronger guideline recommendations for WCD therapy. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Continue our payor engagement to broaden coverage and increase reimbursement.</I></B> After successfully
contracting with national payors, we are now focusing on state and smaller regional plans. Using historical data, we are identifying health plans with the highest volume of
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-network</FONT></FONT> referrals and patient fittings, prioritizing those with the greatest potential to increase our <FONT STYLE="white-space:nowrap">in-network</FONT> coverage
in the geographies that we serve. This targeted approach aims to shift a larger proportion of our business to <FONT STYLE="white-space:nowrap">in-network</FONT> fittings, driving greater efficiency and accessibility for patients and providers. We
are also engaging with payors to educate them of the benefits of our Cardiac Recovery System platform and to optimize reimbursement. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Innovate our system and bolster our digital healthcare platform and data management capabilities.</I></B>
Our research and development initiatives are focused on introducing </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">132 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
enhancements, new features, and improvements to our ASSURE WCD as well as our broader suite of digital solutions. We are continuously innovating to improve our WCD in order to expand utility to
broader patient populations and to ensure greater reliability and patient confidence. From a regulatory perspective, our digital healthcare platform is separate from the ASSURE WCD and is treated as an FDA Class&nbsp;I 510(k)-exempt device, which
allows us to rapidly innovate and upgrade the digital capabilities of our Cardiac Recovery System platform. As a robust digital health platform, our system is designed to provide data transparency, diagnostic flexibility, and workflow efficiencies.
With features like configurable notifications and <FONT STYLE="white-space:nowrap">on-demand</FONT> reporting, our system empowers healthcare providers to deliver more informed care. Through the ASSURE Patient Registry, we are maximizing the utility
of this system to collect and leverage aggregated, <FONT STYLE="white-space:nowrap">de-identified</FONT> data to build clinical evidence and support innovations in prediction, prevention, and therapy. For example, we seek to identify opportunities
to develop advanced capabilities to deliver personalized clinical decision support. Our efforts to continuously innovate reflect our vision of leveraging our unique capabilities to deliver smarter, more effective solutions for cardiac patients.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Drive gross margin expansion and operating leverage.</I></B><B> </B>Our gross margin has expanded
significantly through our commercial launch with improvements in realized <FONT STYLE="white-space:nowrap">per-patient</FONT> reimbursement and a lower cost per patient due to the increased number of patients we served. Rapid commercial payor
contracting uptake has resulted in increased reimbursement from a higher mix of <FONT STYLE="white-space:nowrap">in-network</FONT> patients. The reduction in cost of revenues per patient has come from volume increases in the number of fittings, <FONT
STYLE="white-space:nowrap">re-use</FONT> of our WCD fleet, our preventative maintenance program and manufacturing process enhancements. As the number of patients we serve increased, the cost of fitting per patient has decreased. In addition to
improving gross margins, we believe our business model enables us to drive operating leverage.&nbsp;The operating cost to commercialize and service the ASSURE WCD is highly efficient with case coverage support and streamlined provider referral
processes, including direct electronic medical record (&#147;EMR&#148;) selection of the ASSURE WCD. We believe that this, coupled with expected gross margin expansion, will enable us to drive profitability as the company grows.<I> </I>
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Pursue expansion in international markets.</I></B> While our current commercial focus remains on the U.S.,
international markets accounted for approximately 15% of the global $1.3&nbsp;billion in WCD revenues in 2023. In select international markets, we estimate based on patient population data collected by various third-party industry sources that there
are approximately 3.7&nbsp;million people each year who experience an MI, are diagnosed with heart failure, have documented VT or VF, have an inherited genetic condition, or have had their ICD temporarily explanted. Among these patients, based on
the same <FONT STYLE="white-space:nowrap">third-party</FONT> industry sources, we estimate that approximately 1.8&nbsp;million patients meet the indications for WCD therapy. Based on estimated average WCD wear prescription length in these
international markets of 2.5 months per patient and estimated average reimbursement rate of $3,000 per patient per month derived from industry data and internal estimates, we believe this represents an approximately $14&nbsp;billion total annual
market opportunity outside the U.S. For a description of the international markets covered by this estimated market opportunity, see &#147;Industry and Market Data.&#148; As of the date of this prospectus, we have not received any regulatory
approvals to commercialize our products outside of the U.S. and have not submitted any applications to obtain such regulatory approvals. However, we are currently planning to pursue CE Mark approval in Europe and, in the future, intend to
strategically commercialize in select international countries. We anticipate Western Europe to be our initial focus due to favorable market dynamics and our goal is to obtain regulatory approvals to begin distributing our ASSURE WCD in certain
markets in Western Europe within the next three years. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Strategically pursue adjacent markets with new products offerings and differentiated services.</I></B> The
initial focus of our Cardiac Recovery System platform is to serve high-acuity patients who require both continuous monitoring and therapy. Beyond this, we are strategically positioned to
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">133 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
expand our offerings to address a broader spectrum of cardiac patients, including those with atrial fibrillation, advanced hypertension, and other conditions, many of whom may remain undiagnosed
without advanced monitoring solutions. Our long-term vision is to enable seamless transitions in monitoring, diagnostics, and therapy as patients&#146; health conditions evolve. The launch of our ASSURE wearable ECG marks the first step in this
expansion, providing monitoring and connectivity for patients no longer indicated for a WCD but who still require ongoing support. We received FDA approval for our ASSURE wearable ECG in May 2024 and began its limited commercial launch in September
of 2024 in certain strategic U.S. markets. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Market Overview </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our Market Opportunity </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">SCA is a
major public health problem and accounts for approximately 50% of all cardiovascular deaths in the U.S. For more than two decades, healthcare providers have prescribed WCDs to protect their patients at an elevated risk of SCA. Until the ASSURE WCD
was approved by the FDA in July of 2021, the WCD market was served by a single competitor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Since the approval of the first WCD in 2001,
global WCD revenues have grown significantly, reaching over $1.3&nbsp;billion in 2023, with approximately 85% of the revenues coming from the U.S. based on our analysis of third-party claims data and estimated average WCD wear prescription lengths
and average reimbursement rates in the U.S. and in select international markets derived from industry data and internal estimates. Between 2021 and 2023, the volume of patients prescribed a WCD in the U.S. grew roughly 6% annually. We expect further
penetration and growth of the WCD market, driven by increased awareness and education about WCD therapy, the expanded launch of our innovative and comprehensive solution, and the rapidly growing heart failure population, which will likely expand the
number of patients at elevated risk of SCA and indicated for a WCD. Despite being available for over 20 years and proven effective in treating dangerous cardiac rhythms when worn by patients, the therapy has reached just 14% of eligible U.S.
patients in 2023 based on data on patients indicated for a WCD and WCD prescription data from industry sources, highlighting a significant opportunity for growth. We attribute this low penetration to poor patient compliance, driven by the
limitations of our competitor&#146;s device. The ASSURE WCD, as part of our broader Cardiac Recovery System platform, is designed to prioritize patient comfort and compliance, addressing common barriers to acceptance experienced by the only other
commercially available WCD. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The WCD is indicated for use in patients who are at risk for SCA and are not candidates for, or refuse, an
ICD. Medical guidelines recommend WCD use in those patients with a low LVEF and a recent MI, recent revascularization procedure or newly diagnosed nonischemic cardiomyopathy with heart failure symptoms. In addition, patients with documented VT or VF
or an inherited genetic condition that places them at high risk for SCA, or patients who have had their ICD temporarily explanted are also indicated for WCDs. According to the AHA, approximately 1.8 million people in the U.S. each year experience a
serious cardiac event, such as an MI, or are diagnosed with heart failure. Among these patients, around 800,000 patients have low LVEF, placing them at an elevated risk of SCA. Additionally, approximately 50,000 patients each year either have
documented VT or VF, an inherited genetic condition, or have had their ICD temporarily explanted. Based on the foregoing annual incidences, the current Medicare reimbursement rates of $3,436 per patient per month as published in the CMS DMEPOS Fee
Schedule, and our average initial WCD prescription length of 3.4 months, we believe the total, annual addressable market in the U.S. for the ASSURE WCD is approximately $10 billion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">While our current commercial focus is on the U.S., approximately 15% of the global WCD revenues in 2023 were generated internationally,
representing approximately $200&nbsp;million, and that has primarily been concentrated in western Europe where the market has been most developed, as well as in Japan. In select international markets, we estimate based on patient population data
collected by various third-party industry sources that there are approximately 3.7 million people each year who experience an MI, are diagnosed with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">134 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
heart failure, have documented VT or VF, have an inherited genetic condition, or have had their ICD temporarily explanted. Among these patients, based on the same
<FONT STYLE="white-space:nowrap">third-party</FONT> industry sources, we estimate that approximately 1.8&nbsp;million patients meet the indications for WCD therapy. Based on estimated average WCD wear prescription length in these international
markets of 2.5 months per patient and estimated average reimbursement rate of $3,000 per patient per month derived from industry data and internal estimates, we believe this represents an approximately $14&nbsp;billion total annual market
opportunity outside the U.S. For a description of the international markets covered by this estimated market opportunity, see &#147;Industry and Market Data.&#148; As of the date of this prospectus, we have not received any regulatory approvals to
commercialize our products outside of the U.S. and have not submitted any applications to obtain such regulatory approvals. However, we are currently planning to pursue CE Mark approval in Europe and, in the future, intend to strategically
commercialize in selected international countries. We anticipate Western Europe to be our initial focus due to favorable market dynamics and our goal is to obtain regulatory approvals to begin distributing our ASSURE WCD in certain markets in
Western Europe within the next three years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Overview of Sudden Cardiac Arrest and Arrhythmias </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">SCA is a life-threatening emergency characterized by the abrupt cessation of the heartbeat caused by an electrical malfunction in the heart.
This is typically triggered by ventricular arrhythmias, such as ventricular fibrillation, and leads to a loss of consciousness and potentially death within minutes if not promptly treated. The AHA estimates that SCA causes approximately 436,000
deaths per year, making it the third leading cause of death in the U.S. Defibrillation, or an electrical shock, is the only way to restore a fibrillating heart to a normal rhythm. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">There are three main types of defibrillators: ICDs, external defibrillators (both manual and automated), and WCDs. An ICD is a small
battery-powered device surgically placed in the chest that continuously checks the heartbeat and delivers electric shocks, when needed, to restore a regular heart rhythm. An external defibrillator is a portable device that uses two adhesive pads
placed on the patient&#146;s skin by a trained professional or a bystander to deliver an electric shock through the chest to the heart to restore a normal rhythm. An automated external defibrillator automatically detects a patient&#146;s heart
rhythm and delivers a shock while a manual external defibrillator requires the user to select a specific shock energy to be delivered to the patient. A WCD is an external wearable device that continuously monitors a patient&#146;s heart rhythm. If
it detects a potentially life-threatening arrhythmia, the WCD alerts the patient and, if necessary, automatically delivers a defibrillation shock to restore a normal heart rhythm. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Each minute of delay in restoring the heart to a normal rhythm reduces a patient&#146;s chance of survival by 7% to 10%. Based on data from
the American Medical Association, the average time for EMS arrival is 7&nbsp;minutes from the time of a 911 call, and often longer in rural communities. The most common location of a SCA in adults is at a home or residence, representing
approximately 73% of SCAs. In addition, approximately 50% of all SCAs are unwitnessed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">135 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Chances of Survival Post Onset of Sudden Cardiac Arrest </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>  <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g744414g10t05.jpg" ALT="LOGO" STYLE="width:5.87362in;height:2.5903in;">
 </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">SCA commonly occurs in individuals with heart disease or those experiencing cardiac events. Several
research studies indicate that low LVEF may be a sign of heart disease and is one of the greatest risk factors for SCA. Normal LVEF is typically between 50% and 70%. This means that during each heartbeat, 50% to 70% of the blood in the left
ventricle is pumped out to the body. Low LVEF is typically considered 40% or less. According to the New England Journal of Medicine Study, patients with an LVEF of 30% or less were two times more likely to suffer from SCA compared to patients with
an LVEF of more than 40%. The American Journal of Cardiology Study showed that the absolute risk of SCA is highest during the early period following a cardiac event, especially within the first 30 days. In this same study, each 5% decrease in LVEF
was associated with a 21% increase in the risk of SCA during the first 30 days after a MI. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Overview of Arrhythmias </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The normal human heart has four chambers, consisting of two atria and two ventricles, which on average expand and contract over 100,000 times
each day. The walls of the atria and the ventricles are made up of cardiac muscle, which contracts rhythmically when stimulated by an electrical current. Normally, the heartbeat starts in the right atrium when a specialized group of cells that serve
as the heart&#146;s natural pacemaker send an electrical signal. This signal spreads through the atria and then moves to the ventricles, causing the atria to contract a fraction of a second before the ventricles. This pattern allows the heart to
pump blood to the lungs and the rest of the body. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Arrhythmias are abnormal rhythms of the heart that can disrupt normal blood flow. The
heart may beat too fast, too slow or beat irregularly. Arrhythmias may be caused by a number of factors, including, certain cardiac disease or cardiac events, congenital heart problems, side effects of medications and lifestyle choices. The two main
types of arrhythmias causing SCA are ventricular fibrillation and ventricular tachycardia. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Ventricular Fibrillation</I></B><I>. </I>VF is a condition in which disorganized electrical activity causes
the ventricles to contract in a rapid and uncoordinated fashion, resulting in an insufficient amount of blood being pumped from the heart. Ventricular fibrillation is the most common type of arrhythmia thought to cause SCA and often occurs without
warning. The only accepted treatment for ventricular fibrillation is defibrillation, in which electrical current is delivered to the heart to stop the fibrillation and permit the return of coordinated cardiac contractions. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Ventricular Tachycardia</I></B><I>.</I> VT is a fast heart rate that starts in the heart&#146;s lower
chambers. This type of arrhythmia may be life- threatening, requiring immediate diagnosis and treatment. In cases of </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">136 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
ventricular tachycardia, electrical signals in the heart&#146;s lower chambers fire abnormally, resulting in a faster than normal heart rate. This rapid heartbeat keeps the heart&#146;s chambers
from filling completely between contractions, which compromises blood flow to the rest of the body. VT may self-terminate; however, prolonged VT can result in SCA unless treated by defibrillation. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>WCD Therapy for Patients at Elevated Risk of SCA </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A WCD is a wearable, <FONT STYLE="white-space:nowrap">non-invasive</FONT> monitor and miniaturized automated external defibrillator intended
to perform the same tasks as an ICD without the need for an invasive surgical procedure. WCDs can automatically detect SCA and, if needed, safely deliver a defibrillation shock to return the patient&#146;s heart rhythm to normal, even when a patient
is alone. A WCD is composed of a garment that is worn underneath regular clothing and a portable miniaturized automated defibrillator. Wires connect electrodes inside the garment to the monitor, which is carried in a small pack or shoulder bag. The
electrodes continuously acquire a patient&#146;s heart rate and rhythm for evaluation by the automated defibrillator. If the monitor detects a potentially life-threatening arrhythmia, the WCD first alerts the patient via an audible alarm and then
administers a shock, if needed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">WCDs are proven to work when worn. The Vest Prevention of Early Sudden Death (&#147;VEST&#148;) trial, a
randomized controlled trial sponsored by the National Institutes of Health and ZOLL, evaluated the survival benefit of WCD therapy in <FONT STYLE="white-space:nowrap">post-MI</FONT> patients with an LVEF of 35% or less. This trial compared the
competitor WCD with GDMT versus GDMT alone. Although the initial <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">intention-to-treat</FONT></FONT> analysis of the WCD therapy in the VEST study published in 2018 did not indicate a
statistically significantly lower rate in sudden arrhythmic death when compared to GDMT alone, the <FONT STYLE="white-space:nowrap">as-treated</FONT> analysis showed a significantly lower percentage of patients died when they were wearing the WCD
than when they were not. This suggested that poor patient compliance with wearing the WCD was a primary driver of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">intention-to-treat-results</FONT></FONT> in which 75% percent of
patients were not wearing the WCD at time of death. In addition, to assess the impact of early discontinuation of the WCD, investigators performed a subsequent <FONT STYLE="white-space:nowrap">per-protocol</FONT> analysis which censored patients
after they stopped wearing the WCD. This <FONT STYLE="white-space:nowrap">per-protocol</FONT> analysis published in 2020 demonstrated a significant reduction in arrhythmic death (62%, p=0.02) and <FONT STYLE="white-space:nowrap">all-cause</FONT>
death (75%, p&lt;0.001) when comparing those patients who wore the WCD with those who did not wear the WCD. Similarly, registry studies have shown a survival rate of over 90% for SCA patients wearing a WCD after an appropriate shock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">WCDs are typically prescribed to patients immediately following an MI or heart failure diagnosis and serve as a bridge to recovery between the
cardiac event and a longer-term treatment regimen. During this period, healthcare providers will optimize the patient&#146;s medical therapy while also waiting to see if the patient&#146;s LVEF improves. The expected wear duration of the WCD varies
based on the patient indication, with the majority of our patients being prescribed the WCD for three months or longer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The average age
of our patients prescribed a WCD is 65 years. The population of patients indicated and eligible for receiving WCDs can be split into three main groups: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Newly diagnosed heart failure with low LVEF. </I></B>These patients represent approximately 56% of the
addressable market at elevated risk for SCA. Current guidelines require a waiting period of three months before this patient population is eligible to be evaluated for an ICD.&nbsp;During this period, patients are typically treated with GDMT, which
consists of a combination of up to four main drug classes. After three months, the patient&#146;s LVEF should be reassessed.&nbsp;If the patient&#146;s LVEF improves above 35%, neither the WCD nor an ICD is indicated.&nbsp;If the patient&#146;s LVEF
remains&nbsp;at or below 35%, the patient may receive an ICD (per the current guidelines), or their healthcare provider may decide to continue with GDMT and the WCD while their heart continues to remodel.&nbsp;The expected WCD wear duration for
patients in this population is three months or greater. According to the Heart Failure Society of America, approximately 6.7&nbsp;million Americans over 20 years of age have heart failure, and the prevalence is expected to continue to rise.&nbsp;Of
the newly diagnosed heart failure patients each year, approximately 50% have a low LVEF. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">137 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Post MI with low LVEF. </I></B>These patients represent approximately 38% of the addressable market at
elevated risk for SCA. Current guidelines require an ICD waiting period of 40 days post MI or 90&nbsp;days post coronary revascularization.&nbsp;Coronary revascularization includes procedures such as percutaneous coronary intervention, which is a
minimally invasive procedure that restores blood flow from the inside using balloon catheters or stents, or coronary artery bypass grafting, which is a surgery where a provider creates a bypass around a blocked section of an artery.&nbsp;The
expected WCD wear duration for patients in this population is 40 days or greater. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Other.</I></B><B><I></I></B>&nbsp;These patients represent approximately 6% of the addressable market and
include patients with documented VT/VF, those indicated for an ICD but who have a contraindication to immediate placement, such as an infection or extraction, and patients with an inherited genetic condition.&nbsp;As there is no waiting period
mandated by current guidelines for these indications, the expected WCD wear duration for patients in this population is variable, but likely less than 60 days. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Limitations of the Legacy, Commercially Available WCD </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The WCD is indicated for use in patients who are at risk for SCA and are not candidates for, or refuse, an ICD. However, limitations of the
only other commercially available WCD, such as patient comfort and false alarm rate, as well as gaps in awareness by healthcare providers of its broader diagnostic utility have led to underutilization of the therapy. Many indicated patients do not
receive a prescription and some choose not to wear a WCD. Patients who&nbsp;choose not to wear a WCD are often left reliant on first responders or EMS in the event of a SCA. This reliance poses a significant risk, as only 16% of sudden cardiac
events occur in public places where an automated external defibrillator might be available according to the American Heart Association. Based on data from the American Medical Association, the average time for EMS arrival is 7 minutes from the time
of a 911 call, and often longer in rural communities. During this critical time, survival rates decline by 7% to 10% for every minute that passes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This underutilization is reflected in the findings of the VEST trial, where 34% of patients had a median daily wear time of zero
hours&#151;indicating patients fully opted out of potentially life-saving therapy rather than wear the product. These results highlight the critical impact of patient compliance on WCD therapy and underscore the need for solutions that address the
barriers preventing consistent wear. In feedback we have collected through directly engaging with patients and providers and customer feedback on public platforms, commonly cited reasons for patients or providers failing to use the LifeVest WCD on a
consistent basis include: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>High frequency of false positive shock alarms.</I></B> Prior to delivering a therapeutic shock, a WCD
sounds an alarm that alerts the patient that a shock is about to be delivered. A false positive shock alarm occurs when the device detects a signal and mistakenly classifies it as a shockable rhythm. For the LifeVest WCD, this may occur due to noisy
ECG channels resulting from a poor fit or from very fast <FONT STYLE="white-space:nowrap">non-shockable</FONT> rhythms. False alarms are common with the LifeVest WCD and typically contribute to added anxiety for patients, sleep disturbances and
restriction of daily routines. High false alarms also lead to patient frustration that may result in unnecessary calls to the prescribing provider. Even after recent algorithm design updates, the competitor reported that 46% of patients wearing
their WCD still experienced false alarms. In addition, we believe that the interface of the LifeVest WCD is cumbersome, requiring the user to locate the monitor and press two buttons simultaneously to divert a shock during a false alarm event.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Discomfort and unisex-only garment. </I></B>The LifeVest WCD only comes in one style, intended to fit both
genders, which has been reported to cause significant discomfort, especially for women given many must wear a bra over the garment, based on feedback we have collected through directly engaging with patients and providers and customer feedback on
public platforms. Additionally, poorly fitting garments combined with ECG sensors attached by Velcro fasteners can lead to the electrodes digging into the patient&#146;s skin or flipping over, exacerbating discomfort and poor ECG contact.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">138 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>ECG noise and low utility data. </I></B>Poor fit and ECG contact with only two channels may result in noisy
ECG data, which in turn may contribute to false alarms and may limit the diagnostic utility of the LifeVest WCD remote monitoring functionality. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Limited connectivity with patient.</I></B> Patient connectivity is critical because it fosters ongoing
engagement with the patient to improve compliance and ensures clinically-actionable data is transferred to healthcare providers in a consistent, timely, and easy manner. According to the LifeVest 5100 WCD operating manual, although the monitor
contains a cell phone module for data transmission, patient data is generally only uploaded once per day, potentially reducing the diagnostic utility of patient data. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Solution </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The ASSURE WCD is the
cornerstone of our Cardiac Recovery System platform, a robust and extensible system integrating therapy, monitoring, and digital health solutions that represents the future of cardiac care. As a next generation of WCD therapy, the ASSURE WCD
delivers a safe and effective solution for patients and was intentionally designed to enhance patient comfort and compliance and successfully resolve the key barriers to adoption associated with the only other commercially available WCD. The ASSURE
WCD received FDA approval on July&nbsp;27, 2021 for adult patients at elevated risk of SCA who are not candidates for, or decline, an ICD. As of January&nbsp;31, 2025, the ASSURE WCD is actively being prescribed by more than 550 hospitals and has
been worn by over 17,000 patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition to the ASSURE WCD, our Cardiac Recovery System platform includes fully integrated digital
solutions and services such as the ASSURE patient application, Kestra CareStation remote patient data platform, Heart Alert Services, and ASSURE Assist services, as well as the recently launched ASSURE wearable ECG. Cleared by the FDA on May&nbsp;7,
2024, the ASSURE wearable ECG provides extended monitoring and valuable insights into a patient&#146;s heart function after they are no longer indicated for a WCD. This <FONT STYLE="white-space:nowrap">non-therapeutic</FONT> platform supports
cardiac recovery monitoring using many of the same familiar features as the ASSURE WCD, ensuring continuity and ease of use for both patients and clinicians. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following paragraphs describe the several components of the ASSURE WCD, ASSURE wearable ECG and digital solutions and services that are
all integrated and included as part of our Cardiac Recovery System platform. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Wearable Components </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>SensorFit</I></B><B><I></I></B><B><I> Garment. </I></B>A breathable, lightweight fabric garment with
embedded, <FONT STYLE="white-space:nowrap">non-adhesive,</FONT> cushioned ECG sensors designed to move with the patient and capture high fidelity ECG signals. The SensorFit Garment was developed with an athletic and sportswear designer and is
available in two styles and multiple sizes, intentionally designed to fit different gender and body types.&nbsp;The SensorFit Garment can be worn with both the ASSURE WCD and the ASSURE wearable ECG. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Monitor. </I></B>The primary electronic component that controls overall system operation and delivers 170J
biphasic defibrillation therapy. The monitor leverages four channels of high-fidelity ECG signals&#151;an industry first&#151;to detect heart arrhythmia and, if needed, quickly and autonomously deliver appropriate electric defibrillation therapy to
restore normal heart rhythm. It is powered by a rechargeable <FONT STYLE="white-space:nowrap">lithium-ion</FONT> battery pack with two batteries, each having a minimum runtime of 24 hours. The ASSURE wearable ECG includes a separate compact monitor
that fits into the existing SensorFit Garment. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Therapy Cable.</I></B> The ASSURE WCD includes a custom reusable cable that securely connects the garment
to the monitor. This cable facilitates the integration of three defibrillation pads, which </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">139 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
snap into conductive mesh pockets in the garment and release a defibrillation gel onto the patient&#146;s skin to prepare for the delivery of a defibrillation shock. Additionally, the system
features the HeartPoint Alert Button, which attaches to the left or right shoulder strap of the garment. This button provides both tactile and audible feedback, allowing patients to check device status or divert a shock from an ergonomic location.
Patients can also use the button to trigger a recording of their heart rhythm when experiencing symptoms like VT induced rapid heartrate, with the data becoming accessible to their care teams via the Kestra CareStation remote patient data platform.
The ASSURE wearable ECG is equipped with a separate cable that connects the ECG front-end monitor to the portable battery pack. Both components fit seamlessly into the existing pockets of the SensorFit Garment, ensuring ease of integration and
usability. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Accessories for the Patient </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Charger. </I></B><FONT STYLE="white-space:nowrap">Table-top</FONT> charging station for the monitor&#146;s <FONT
STYLE="white-space:nowrap">lithium-ion</FONT> batteries. Also includes a USB port and a stand for charging mobile devices. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Carry Pack.</I></B> A wearable case designed to hold the monitor that can be worn easily clipped to a belt,
around the waist, or over the shoulder to adapt to the patient&#146;s lifestyle. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Provider and Patient Care Specialist Tools
</I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Programming Tablet. </I></B>Used by our patient care specialist during the fitting and training process to
program our ASSURE WCD for patient use. Wirelessly connects to the monitor to configure the system according to the patient&#146;s prescription and receives patient physiological data collected by the ECG electrodes to assess real-time electrode
contact. This technology is a key tool used to ensure proper patient application during the fitting process. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Integrated Digital
Solutions and Services </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Downloadable ASSURE</I></B><B><I> </I></B><B><I>Patient App. </I></B>Transmits key patient data to the
Company and care teams automatically and enables patients to track their physical activity and usage, record symptoms, watch educational videos, and access troubleshooting assistance.<B>&nbsp;</B> </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Kestra CareStation Remote Patient Data Platform. </I></B>Available to healthcare professionals who follow
patients wearing our ASSURE WCD and ASSURE wearable ECG. The Kestra CareStation remote patient data platform is a cloud-based monitoring platform that summarizes relevant patient data for healthcare providers, enabling them to conveniently track
patient progress, receive configured alerts and notifications, and to bill Remote Physiologic Monitoring CPT codes. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>ASSURE Assist Services. </I></B>Provides additional support for patients who experience a life-threatening
heart rhythm by sending an alert via the ASSURE patient application to an EMS operator after a defibrillation shock or a high-rate heart event. The EMS operator attempts to contact the patient to determine if additional help is required and, if
needed, may dispatch EMS to the patient&#146;s location. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Heart Alert Services. </I></B>Remote cardiac patient monitoring that enables timely identification of
clinically significant arrhythmias, physiologic trends and other device alerts that may warrant intervention.&nbsp;This service is administered by a team of our cardiac device specialists utilizing the Kestra CareStation remote patient data
platform. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">140 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>  <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g744414g89x91.jpg" ALT="LOGO" STYLE="width:6.25in;height:1.36186in;">
 </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Key Benefits of Our Solution </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our Cardiac Recovery System platform offers notable benefits and an improved user-experience that differentiates it from the only other
commercially available WCD. These benefits include: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Modern and advanced design to improve comfort, performance and maximize wearability.</I></B> The design of
our garments incorporates advancements in electronics, mobile technology, signal processing techniques, and fabrics. The garments were developed with an athletic and sportswear designer and are tailored for body inclusivity, offering two styles and
a wide range of sizes. We believe that having separate, gender-specific designs is particularly important given women make up approximately 40% of SCA patients.<B><I> </I></B>Overall wearability is further supported by the results of our
post-approval study which demonstrates a median wear time of greater than 23 hours per day. In addition to improving comfort and wearability, our unique garment design incorporates cushioned electrodes that are embedded in the fabric to improve
electrode contact and, ultimately, improve ECG signal quality. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>High fidelity ECG leading to</I></B><B><I> </I></B><B><I>fewer</I></B><B><I>
</I></B><B><I>false</I></B><B><I> </I></B><B><I>alarms.</I></B> The ASSURE WCD is designed to minimize false alarms. The overall level of noise is reduced through use of resistive ECG electrodes that arrhythmias are cushioned and securely bonded to
the fabric, custom shielded cables, and isolation circuitry. The ASSURE WCD also utilizes four channels of high-quality ECG, combined with API, a proprietary technology that adapts to the patient heart rhythm to filter out artifacts and improve
performance even in a noisy environment. According to the Journal of Interventional Cardiac Electrophysiology Study, as a result of these features, only 6% of our patients experience a false alarm, compared to 46% for the competitor&#146;s device.
Reduction in false alarms may lead to lower patient anxiety, improved patient satisfaction and increased patient compliance. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Product innovations and integrated digital solutions and services supporting the patient throughout the
cardiac care continuum. </I></B>Our Cardiac Recovery System platform represents a comprehensive suite of proprietary wearable and fully integrated digital solutions and services for monitoring, diagnosing, and protecting patients through their
cardiac recovery journey. We believe our Cardiac Recovery System platform represents a competitive advantage, with the goal of ultimately improving the prescriber and patient experience, maximizing patient comfort and compliance, and increasing
adoption of our system. In addition, our Cardiac Recovery System platform&#146;s capabilities allow healthcare providers to identify other clinically significant arrhythmias. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Improved energy delivery to enhance efficacy and safety.</I></B> The ASSURE WCD delivers a 170 joule shock
to better serve patients with higher defibrillation thresholds, compared to the competitor device which delivers a 150 joule shock.&nbsp;In addition, our system has a minimum defibrillation capacity of 25 shocks, providing a significant safety
buffer for patients experiencing multiple cardiac events within a short time period, such as a VT storm, where a patient experiences multiple episodes of sustained VT within a short period of time. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">141 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Treatment with the ASSURE WCD </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">WCDs are generally prescribed by a general cardiologist, interventional cardiologist, cardiac electrophysiologist, cardiothoracic surgeon,
hospitalist, nurse practitioner or physician&#146;s assistant. The healthcare provider determines the prescription length of a WCD. Once prescribed, we are responsible for the product delivery and can support fitting and training of the patient
within 24 hours of the prescription. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The ASSURE WCD is intended to be continuously worn (except when bathing or showering), and can be
easily removed and put back on by the patient. Patients receive two batteries for the monitor with a minimum runtime of approximately 24 hours. Patients are instructed to always charge one battery, replacing the monitor&#146;s battery at the end of
each day. The patient is also typically provided two SensorFit Garments so they can remain protected while washing one of the garments. Our ASSURE WCD is designed to detect life-threatening rapid heart rhythms, specifically VF and VT, above a heart
rate threshold programmable by the clinician. If the system determines a shock is needed to correct a heart rhythm, it will first vibrate and emit an audible alert notifying the patient they are about to receive a shock. If the patient does not
respond by pressing the HeartPoint Alert Button, gel is released from the defibrillation pads onto the patient&#146;s back and chest, and a shock is delivered to restore a normal heart rhythm without further interaction required from the patient or
bystander. The ASSURE WCD will continue to analyze the patient&#146;s heart rhythm and administer additional shocks, if needed. After a shock is delivered, we offer an additional layer of support for the patient through our ASSURE Assist services,
which enables us to connect with the patient, a designated caregiver, or 911 emergency services. Our ASSURE WCD also analyzes the patient&#146;s heart rate for very slow rhythms. When certain <FONT STYLE="white-space:nowrap">non-shockable</FONT>
rhythms are detected, the rhythm is recorded, and an alert sequence is initiated to attract bystander attention, instructing them to call 911 and perform cardiopulmonary resuscitation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">At the conclusion of the wear period, the patient returns all components of the ASSURE WCD in a
<FONT STYLE="white-space:nowrap">pre-paid</FONT> shipping box that we supply. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Clinical Results and Studies </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are committed to generating clinical evidence to support the safety, efficacy and benefits of the ASSURE WCD, and we will continue to
invest in developing clinical evidence to further demonstrate the advantages of our system. Preclinical and human clinical safety and effectiveness data provided the basis for PMA approval of the ASSURE WCD on July&nbsp;27, 2021. The evidence
included an extensive series of engineering verification tests and statistically robust animal studies, followed by two investigational device exemption (&#147;IDE&#148;) human trials, <FONT STYLE="white-space:nowrap">ACE-DETECT</FONT> and <FONT
STYLE="white-space:nowrap">ACE-CONVERT.</FONT> These combined studies evaluated 143 elevated risk SCA patients in the U.S. Currently, we are conducting the <FONT STYLE="white-space:nowrap">ACE-PAS</FONT> as part of a broader <FONT
STYLE="white-space:nowrap">on-going</FONT> ASSURE Patient Registry. The real-world evidence in connection with ACE-PAS is collected by demographic and clinical characteristics being abstracted from medical history records provided with the Durable
Medical Equipment order for the ASSURE WCD. The detected arrhythmias are automatically stored by the ASSURE WCD and then adjudicated by clinical experts in electrophysiology to assess rhythm and shock efficacy, if applicable. Device usage, which is
measured by minutes worn, is automatically stored by the ASSURE WCD. We believe this collection of real-world evidence will generate additional publications, continue to increase awareness of WCDs as a proven therapy for elevated risk cardiac
patients and further demonstrate the clinical differentiation of our ASSURE WCD. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Overview of Our Sponsored Clinical Trials </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U><FONT STYLE="white-space:nowrap">ACE-DETECT</FONT> Trial </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The ASSURE WCD Clinical Evaluation&#151;DETECTion and Safety Study <FONT STYLE="white-space:nowrap">(ACE-DETECT&#151;NCT03887052)</FONT> was a
multi-center, prospective, nonrandomized study at 10 sites across the U.S. The study&#146;s primary purpose was to evaluate the false positive shock alarm rate in patients at elevated risk for SCA. Eligible patients were adults (&#8805;18 years old)
with LVEF &#8804;40% and an active ICD. Complete study design and results of <FONT STYLE="white-space:nowrap">ACE-DETECT</FONT> were published by Poole et al. in the Journal of Cardiovascular Electrophysiology (2022), <I>A </I><I>Wearable
Cardioverter Defibrillator</I><I> with a </I><I>Low False Alarm Rate</I><I>.</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">142 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A total of 130 patients were enrolled in the
<FONT STYLE="white-space:nowrap">ACE-DETECT</FONT> study. The mean age was 61.2 &plusmn; 11.4 years and a majority were male (69%). All patients had been diagnosed with a cardiomyopathy, most having severely reduced LVEF. A history of atrial
fibrillation, atrial flutter or atrial tachycardia was present in nearly half of the patients and approximately half of the patients had VF/VT previously detected by their ICD. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">WCD shock therapy and shock alarms were disabled, but shock alarm markers were recorded. WCD parameters were programmed to nominal settings
and ICD parameters were left to the discretion of the investigator. Patients were asked to wear the ASSURE WCD as much as possible for 30 days with exceptions allowed for showering or bathing. Clinical
<FONT STYLE="white-space:nowrap">follow-ups</FONT> were conducted weekly via phone; patients returned for final <FONT STYLE="white-space:nowrap">follow-ups</FONT> at the end of the <FONT STYLE="white-space:nowrap">30-day</FONT> period. Both the WCD
and ICD were interrogated to collect all stored arrhythmia episodes. WCD data also captured minutes of wear per day. Patients separately reported their perceived discomfort for eight anatomical regions on the torso at baseline and final <FONT
STYLE="white-space:nowrap">follow-up.</FONT> Relative comfort and ease of use were assessed after wear by patients who had prior experience wearing the LifeVest WCD. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The primary endpoint was the false positive alarm rate compared to a <FONT STYLE="white-space:nowrap">pre-specified</FONT> objective
performance goal of 0.29 per <FONT STYLE="white-space:nowrap">patient-day.</FONT> False positive alarms were defined as a WCD shock alarm event marker associated with a rhythm other than VF/VT. Other outcome measures included a summary of WCD and
ICD detected episodes, patient use compliance and adverse events determined to be at least possibly related to the device. Other detected episode types included true positive alarms, true positive detections and missed events. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Results </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The primary
endpoint performance goal was achieved. Three false positive alarms occurred in the cohort of 130 patients over a total of 3,501 patient-days, or 9.6 years, of device exposure. The observed false positive alarm rate was 0.00075 per <FONT
STYLE="white-space:nowrap">patient-day</FONT> or one false positive alarm every 1,333 days. This was well below the <FONT STYLE="white-space:nowrap">pre-specified</FONT> performance goal of 0.29 per
<FONT STYLE="white-space:nowrap">patient-day</FONT> (p&lt;0.001), equivalent to one false positive alarm every 3.5 days. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A total of 163
WCD episodes were recorded in 18 patients. Four of these episodes in three patients were adjudicated as VF/VT, true positive detections, and were also detected by the ICD. The remaining 159 WCD episodes in 17 patients were adjudicated as other
rhythm with noise, uncertain rhythm with noise or atrial flutter without noise. Of the 159 WCD episodes, 156 closed before a shock alarm event marker was recorded because the noise was resolved, or the rhythm was determined to be <FONT
STYLE="white-space:nowrap">non-shockable.</FONT> In the remaining three episodes, a shock alarm event marker (false positive alarm) was recorded. Two of these episodes occurred during a ventricular paced rhythm in one patient and one during a sinus
rhythm in another patient. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The ICDs detected a total of 106 episodes in 51 patients that were adjudicated as rhythm type VF/VT. These
include the four WCD true positive detections discussed above, of which three received ICD therapy. The remaining 102 episodes were not detected by the WCD as they either did not have a duration of at least 20 seconds, or the rate was less than 170
bpm, which was below the programmed detection criteria. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Compliance </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Patients were asked to wear our ASSURE WCD for a period of 30 days. Due to some patients returning our ASSURE WCD after the required <FONT
STYLE="white-space:nowrap">30-day</FONT> period, patients wore our ASSURE WCD for a median of 31 days with a median daily use of 23 hours. Approximately 95% of patients had a median daily wear time of at least 22&nbsp;hours. No significant
differences were found in use by age or by sex. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Safety </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">None of the observed adverse events were classified as serious or unanticipated adverse effects. The most frequently reported events were mild
skin irritation, followed by musculoskeletal-related complaints, such as muscle strain related to carrying the monitor. One patient reported severe musculoskeletal pain related to wearing the ASSURE WCD. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">143 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Comfort </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Of the 130 patients enrolled, 127 completed the comfort survey at both the outset of the study, and at end of wear for eight anatomical
regions on the torso. Of these 127, 89.0% reported no or slight discomfort at baseline, and 83.5% reported no or slight discomfort at end of wear. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Twenty-one</FONT> of the 130 patients who participated in our
<FONT STYLE="white-space:nowrap">ACE-DETECT</FONT> clinical trial had previously worn the LifeVest WCD. <FONT STYLE="white-space:nowrap">Seventy-six</FONT> percent (76%) of these patients reported that our ASSURE WCD was easier to use and more
comfortable than the LifeVest WCD. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U><FONT STYLE="white-space:nowrap">ACE-CONVERT</FONT> Trial </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The ASSURE WCD Clinical Evaluation &#150; Conversion Efficacy Study <FONT STYLE="white-space:nowrap">(ACE-CONVERT-</FONT> NCT04132466) was a
prospective, nonrandomized study at two sites across the U.S. The trial was designed to evaluate shock conversion efficacy of the ASSURE WCD defibrillation waveform in humans. Eligible patients were adults (&#8805;18 years old) undergoing
electrophysiology procedures with planned induction of ventricular arrhythmias. Complete study design and results for <FONT STYLE="white-space:nowrap">ACE-CONVERT</FONT> were published by Gleva et al. in the PLOS ONE journal (2023),
<I>Defibrillation</I><I> effectiveness and safety of the shock waveform used in a contemporary wearable cardioverter defibrillator: Results from animal and human studies. </I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A total of 13 patients were enrolled in the <FONT STYLE="white-space:nowrap">ACE-CONVERT</FONT> trial. The mean age was 55.3 &plusmn; 11.3
years and a majority were male (54%). All enrolled patients underwent new ICD implant or ICD replacement. Additionally, the enrolled patients had a mix of primary etiologies of cardiovascular disease, and all had comorbidities. The mean LVEF of
enrolled patients was 46.8%. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">VF was induced and the ASSURE WCD defibrillation shock was delivered on physician command. If the first
shock was not successful, a second shock from the ASSURE WCD was delivered. If this second shock was not successful, the commercial external defibrillator was to be used to deliver a rescue shock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The primary endpoint was cumulative first and second shock conversion rate with a performance goal of &#8805; 94% based on prior studies.
Other outcome measures included the first shock conversion rate and a summary of adverse events. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Results </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The primary endpoint of cumulative first and second shock efficacy for conversion of ventricular fibrillation was 100%, exceeding the 94% <FONT
STYLE="white-space:nowrap">pre-specified</FONT> performance goal. On an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">intention-to-treat</FONT></FONT> analysis, the first shock efficacy was 84.6%. A total of 15 shocks were
delivered from the ASSURE WCD in 13 patients. No patient required rescue defibrillation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Safety </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Three adverse events occurred in three subjects (23.1%). All events were mild skin irritation from the adhesive defibrillation pads and all
events resolved without further sequelae. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>ASSURE Patient Registry and <FONT STYLE="white-space:nowrap">ACE-PAS</FONT> </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The ASSURE Patient Registry was established to enroll patients fitted with the ASSURE WCD after PMA approval. The primary goal of the registry
was to cultivate a database to support endpoint analysis for our post-approval study, <FONT STYLE="white-space:nowrap">ACE-PAS</FONT> <FONT STYLE="white-space:nowrap">(ACE-PAS,</FONT> NCT05135403). The secondary goal of the registry was to provide
data for observational studies and real-world evidence specifically related to performance of our ASSURE WCD under its intended use. All patients prescribed the ASSURE WCD in the United States after August 5, 2022 are included in the Registry. As of
January&nbsp;31, 2025, our ongoing registry has enrolled over 17,000 patients, and its findings further validate the results of <FONT STYLE="white-space:nowrap">ACE-DETECT</FONT> and <FONT STYLE="white-space:nowrap">ACE-CONVERT.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">144 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our latest FDA submission for ACE-PAS in July 2024 included 5,929 patients, of which 33%
were female and the average age was 65. This real-world evidence demonstrated greater than 95% first-shock conversion efficacy. The percentage of patients experiencing one or more false positive alarms was only 6% (compared to 46% for the
competitor&#146;s device) and median daily usage (excluding first and last wear day) was 23.2 hours per day. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Select Independent Group Studies
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Cleveland Clinic presented two abstracts at the AHA Scientific Sessions in November 2024. The abstracts are summarized below.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Abstract #1 Initial Real-World Experience with a Novel Wearable Cardioverter Defibrillator (Tanaka-Esposito et al.) </U></I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The first abstract evaluated patient compliance and efficacy in a cohort with balanced gender representation, as well as performance of the
ASSURE WCD in minimizing noise artifact leading to false alarms and unnecessary shocks. The data was gathered through a medical chart review of 55 patients prescribed the ASSURE WCD at the Cleveland Clinic between January 2023 and April 2024 as part
of a retrospective analysis. All device-detected arrhythmia episodes were manually adjudicated by a Board-Certified Electrophysiologist. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The median daily wear time was 22 hours per day. Female representation was 49%, significantly greater than prior reports of competitive WCD
usage. Four episodes of sustained VF/VT were detected in four patients. A single shock terminated VF/VT in two, while asymptomatic VT was diverted by the other two patients who were only aware because of the device alerting of an imminent shock. One
shock for hemodynamically unstable atrial fibrillation with heart rate &gt;200bpm was delivered and deemed necessary. There were no unnecessary shocks and no deaths occurred while wearing the ASSURE WCD. A total of 10 patients experienced a median
of one alarm during the WCD wear period. Nearly 97% of the alarms were associated with a significant tachyarrhythmia, with only 3% due to noise artifact. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Patient compliance with the ASSURE WCD was high in this real-world observational study with equal representation of both sexes. The ASSURE WCD
effectively terminated sustained hemodynamically significant tachyarrhythmias, emitted few false alarms due to noise, and resulted in no unnecessary shocks. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Abstract #2 Clinical Impact of Ventricular and Supraventricular Arrhythmia Detection with a Novel Wearable Cardioverter Defibrillator (Tanaka-Esposito
et al.) </U></I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The second abstract evaluated the occurrence of ventricular and atrial arrhythmia detected by the ASSURE WCD and the
clinical consequences of these diagnoses. The data was gathered through a medical chart review of 55 patients prescribed the ASSURE WCD at the Cleveland Clinic between January 2023 and April 2024 as part of a retrospective analysis. Rhythm
classification of all device-detected and patient-initiated episodes displayed with four independent ECG channels was manually adjudicated by a Board-Certified Electrophysiologist. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Four patients (7%) had sustained VF/VT detected by the ASSURE WCD and all received a secondary prevention ICD. Notably, two patients were
asymptomatic and became aware of their condition only after the device alerted them to an imminent shock. Both patients showed significant recovery of EF &gt;35% during the wear period. Moreover, had sustained VF/VT not been detected by the ASSURE
WCD for these patients, neither would have met the indication for a preventative ICD. Additionally, six patients (11%) had AF/AFL recorded by the ASSURE WCD. In three patients, AF/AFL manifested in a paroxysmal pattern, which was a new diagnosis for
each of them. All were at an elevated risk for stroke with median CHADS-VaSC &#8805;4. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The authors concluded that in addition to its
primary utility for preventing SCA, the ASSURE WCD can detect unnoticed yet clinically-significant arrhythmia. The detection of sustained ventricular arrhythmias in asymptomatic, elevated risk patients enabled secondary prevention of SCA. Similarly,
documenting AF/AFL in high-risk patients could significantly reduce their risk. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">145 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sales and Marketing </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We generate revenue primarily from the lease of our ASSURE WCD as part of our Cardiac Recovery System platform. Patients are prescribed our
ASSURE WCD by a healthcare provider for a specific length of time. Once an order is made, we fit the patient for the WCD in a hospital, clinic or home setting. We directly bill various third-party payors for the lease of our product for the duration
of its use by patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our commercial strategy and our direct sales force primarily target general cardiologists, interventional
cardiologists, cardiac electrophysiologists, and advanced practice providers within hospitals and clinics in the U.S., as these represent the primary healthcare providers managing the care of patients at elevated risk of SCA and who typically make
decisions regarding WCD prescriptions. Our sales, marketing and product education efforts are focused on capturing market share and driving adoption by offering healthcare providers an innovative, safe and effective WCD alternative. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our commercial team is comprised of approximately 70 direct sales representatives as well as more than 40 sales and clinical support
professionals as of January&nbsp;31, 2025 with deep expertise in cardiac rhythm management as well as established relationships in the cardiology and electrophysiology fields. This team is responsible for developing sales territory business plans,
targeting and opening new accounts, and driving adoption of our Cardiac Recovery System platform. Once a healthcare provider prescribes our ASSURE WCD to a patient, our direct sales team is supported by a contracted team of over 250 APSs who assist
patients with fitting and training. These specialists assist with fitting patients with the appropriate size and gender-specific option of the ASSURE WCD and provide training on its proper wear and use. At fitting, we deliver our ASSURE WCD from our
distribution network to the patient. When a patient&#146;s wear time has concluded, the device is returned for reprocessing and reintroduction into the distribution network. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Based on data from Definitive Healthcare and our internal estimates, we estimate that there are approximately 2,700 hospitals in the U.S. that
actively prescribe WCDs as of November&nbsp;30, 2024. We further estimate based on our internal analysis of the same data, that approximately 80% of U.S. WCD prescription volume is generated by approximately 30% of these hospitals. We have initially
focused on establishing key customer accounts and expansion into high <FONT STYLE="white-space:nowrap">WCD-volume</FONT> areas. We plan to continue to further scale our commercial team to reach a wider range of healthcare providers across the entire
U.S. Our commercial team has been successful at driving adoption of the ASSURE WCD, with more than 550 hospitals, ranging from top academic medical centers to community hospitals, actively prescribing our system as of January&nbsp;31, 2025. As
healthcare providers gain experience with our ASSURE WCD, we expect to capture more volume and further establish the WCD as the standard of care protection for patients at elevated risk of SCA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Having established our commercial presence in the U.S., one of our future initiatives is to expand internationally where similar unmet patient
needs remain. The prevalence of single payor health systems outside of the U.S. provides an opportunity to efficiently penetrate large pools of net new eligible lives. As of the date of this prospectus, we have not received any regulatory approvals
to commercialize our products outside of the U.S. and have not submitted any applications to obtain such regulatory approvals. However, we are currently planning to pursue CE Mark approval in Europe and, in the future, intend to strategically
commercialize in select international countries. We anticipate Western Europe to be our initial focus due to favorable market dynamics and our goal is to obtain regulatory approvals to begin distributing our ASSURE WCD in certain markets in Western
Europe within the next three years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Third Party Coverage, Reimbursement and Payor Relations </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We derive nearly all our revenue from the direct billing of various third-party payors, including Medicare, Medicaid, private payors and other
healthcare-related organizations, for the lease of our ASSURE WCD to patients as part of our Cardiac Recovery System platform. Additionally, any costs associated with our solution that are not covered by third-party payors, such as <FONT
STYLE="white-space:nowrap">co-payments,</FONT> are billed directly to the patient by our team. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">146 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have strong, established payor relationships, including some of the largest private
payors in the U.S. Based on our estimates, we are contracted or enrolled as an <FONT STYLE="white-space:nowrap">in-network</FONT> healthcare provider with payors currently covering over 285&nbsp;million lives. These contracts allow us to be an <FONT
STYLE="white-space:nowrap">in-network</FONT> healthcare provider for patients, enabling them to access our system at a competitive rate and copay. These established payor relationships reduce our administrative burden in authorization and billing
for our ASSURE WCD. Our payor relationships are supported by our revenue cycle management platform, which streamlines reimbursement processes by ensuring claims are accurately prepared and submitted according to individual payor requirements,
facilitating timely collections. These capabilities are an important element in our strategy to increase operational efficiency and support both patient and healthcare provider satisfaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">WCDs are reimbursed as Durable Medical Equipment under the DMEPOS Fee Schedule and our ASSURE WCD is eligible for payment under the existing
HCPCS code K0606. The ASSURE WCD is the only WCD officially code-verified by the Medicare PDAC. Code K0606 falls under the Capped Rental monthly reimbursement rate for lease payments. K0606 is a valid 2024 HCPCS code defined as an automated
defibrillator, with integrated ECG analysis, garment type. The Medicare allowable for code K0606 is approximately $3,436 per month as of January 2024, while the maximum Medicare allowable over the course of their lease is approximately $34,360. The
standard patient <FONT STYLE="white-space:nowrap">co-insurance</FONT> is 20%. We have been issued a Medicare Provider Number by the CMS, which enables us to bill Medicare for reimbursement for our ASSURE WCD. Reimbursement rates for WCDs have shown
favorable trends, with published Medicare reimbursement rates having increased at a CAGR of 5.4% from 2021 to 2024. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Private payor
reimbursement rates are generally in line with Medicare rates and vary based on several factors, including but are not limited to, the payor, geographic location, and contract terms. Most large, national payors have established coverage policies in
place to cover WCD therapy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Outside the U.S., reimbursement levels vary by country and by region. Some countries or regions may require
us to gather additional clinical data before granting coverage and reimbursement for our ASSURE WCD. We intend to work with payors to obtain coverage and reimbursement approval in countries and regions we intend to enter in the future, including
select countries in Western Europe such as Germany and France. We estimate that these two countries include approximately 600,000 <FONT STYLE="white-space:nowrap">WCD-indicated</FONT> patients, representing a sizeable opportunity for our
international expansion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Research&nbsp;&amp; Development </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are committed to investing in research and development activities to advance our Cardiac Recovery System platform as well as develop and
commercialize next-generation products. Over a decade of investment in our research and development capabilities has resulted in a highly experienced and capable innovation engine. Designed as a scalable platform, our Cardiac Recovery System
platform supports future extensions and enhancements, enabling the integration of new therapeutic and diagnostic capabilities to support our existing fleet of ASSURE WCDs. The platform also enables data collection from patients that will support
training of automated algorithms to detect and predict clinically relevant events. We also intend to leverage the Class&nbsp;I nature of our broader suite of digital solutions to continually enhance the digital capabilities of our Cardiac Recovery
System platform, offering greater data transparency, diagnostic flexibility, and workflow efficiency. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Through the ASSURE Patient
Registry, we are maximizing the utility of this system to collect and leverage aggregated, <FONT STYLE="white-space:nowrap">de-identified</FONT> data to build clinical evidence and support innovations in prediction, prevention, and therapy. For
example, we aim to develop advanced capabilities to deliver personalized clinical decision support. Our efforts to continuously innovate reflect our vision of leveraging our unique capabilities to deliver smarter, more effective solutions for
cardiac patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition to serving high-acuity patient populations, we believe we are positioned to expand our offerings to a
broader range of cardiac patients, including those with previously undiagnosed atrial fibrillation, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">147 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
advanced hypertension, and other cardiac conditions. Our long-term vision is to deliver a comprehensive and cohesive ecosystem of monitoring, diagnostics, and therapy that seamlessly supports
patients as their health conditions evolve. The launch of our ASSURE wearable ECG is the first step in this effort, designed for patients no longer indicated for a WCD but who still require monitoring, patient support, and connectivity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have established a tenured and dedicated research and development team comprised of highly skilled engineers and program managers with
extensive experience in external and implantable defibrillation, as well as more than a decade of experience creating our next generation wearable medical device. In addition, we have strong software development resources capable of innovating
advanced algorithms, user interfaces, and connectivity solutions to enhance the functionality and user experience of our Cardiac Recovery System platform. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For the six months ended October 31, 2024 and 2023, our research and development expenses were $6.9&nbsp;million and $7.9 million,
respectively. For the fiscal years ended April&nbsp;30, 2024 and 2023, our research and development expenses were $15.5&nbsp;million and $15.8&nbsp;million, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Manufacturing and Supply </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We utilize
third-party manufacturing and supply partners to manufacture our ASSURE WCD and its components. We believe outsourcing the manufacture of our ASSURE WCD provides the expertise and capacity required to effectively and efficiently scale production
based on the demand. We select our third-party partners to ensure that our ASSURE WCD and its components are of the highest quality and adhere to all applicable regulations. We employ a rigorous manufacturing and supplier partner assessment,
qualification, and selection process to target partners that meet the requirements of the FDA and the International Organization for Standardization, as well as quality standards supported by internal policies and procedures. Our quality assurance
program monitors and maintains manufacturing and supplier partner performance through qualification and periodic reviews and audits. Our tier one third-party manufacturing and supplier partners, which supply our SensorFit Garment and assemble our
ASSURE WCD, are also independently audited by the FDA. We rely on a single or limited number of suppliers for certain components of our ASSURE WCD. We seek to manage single-source supplier risk by regularly assessing the quality and capacity of our
partners, as well as by qualifying alternative partners and developing contingency plans for responding to disruptions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our third-party
manufacturing and supplier partners inspect, test, and assemble our ASSURE WCD and its components under strict manufacturing processes supported by internal policies and procedures. Our third-party partners are all in compliance with current Good
Manufacturing Practice regulations applicable to our ASSURE WCD. Both of our <FONT STYLE="white-space:nowrap">tier-one</FONT> third-party manufacturing and supplier partners are headquartered in the U.S. and provide products from their facilities
based in the U.S. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We utilize a lease business model where certain components of our ASSURE WCD are reused for multiple patients. At the
end of a prescription, the patient ships our ASSURE WCD back to our third-party manufacturing partner, who disposes of the <FONT STYLE="white-space:nowrap">single-use</FONT> items, such as our SensorFit Garment, and then inspects, tests, and
recertifies the other components for use by another patient. The reusable nature of our ASSURE WCD allows each device to be deployed multiple times, thereby reducing the ongoing demand for new inventory. These reconditioning processes are validated
and FDA approved. We also have preventative maintenance and repair processes that can further extend the life each ASSURE WCD. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We
utilize an inventory distribution strategy where we <FONT STYLE="white-space:nowrap">pre-emptively</FONT> deploy our ASSURE WCD and its components to a central distribution location, as well as 14 additional strategically-located third-party
warehouses across the U.S. This is done to ensure our ASSURE WCD is available for immediate use no matter where a patient is located. Inventory stock is allocated based on historical ASSURE WCD utilization in that territory, as well as sales
forecasting to account for growing demand. Using this strategy, ASSURE WCD components are typically replenished within a <FONT STYLE="white-space:nowrap">24-hour</FONT> window. We believe this distribution model optimizes the availability of our
ASSURE WCD inventory, supports growth, and minimizes the impact of localized weather, transportation delays, or other disruptions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">148 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our <FONT STYLE="white-space:nowrap">tier-one</FONT> third-party manufacturing and supplier
partners also operate facilities in Asia and Europe, equipped with localized manufacturing and reconditioning capabilities. These facilities can leverage our proven systems and processes in the U.S. to support our future international needs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Competition </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We believe that our Cardiac
Recovery System platform, including our ASSURE WCD and wearable ECG, provide us with an advantage relative to other competing solutions. However, our currently marketed products and any future products we commercialize will be subject to
competition. The WCD market has historically been served by a single incumbent commercial product, the LifeVest WCD marketed by ZOLL Medical Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are aware of one privately-held potential new entrant which is developing an adhesive-based external defibrillator that has yet to receive
FDA approval. We remain confident that our Cardiac Recovery System platform will continue to be advantaged in the market due to our differentiated and integrated features enabling superior patient comfort, compliance, connectivity and support. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We believe that the primary factors in developing a competitive WCD include: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product safety and effectiveness; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">detection algorithm sensitivity, specificity and false alarm rate; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patient physical and psychological comfort and ease of use; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ability to integrate within the patient monitoring ecosystem; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">quality, breadth and ongoing generation of clinical evidence; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">technological innovation, product enhancements and speed of innovation; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">capital required to achieve PMA approval as well as to facilitate post-commercial initial inventory; and
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory status and speed to market. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Additionally, we believe that the following factors are required to commercially compete in the WCD market: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patient and healthcare provider connectivity and engagement; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">post-event monitoring and emergency support; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">effective marketing to and education of patients, physicians, other healthcare providers and hospitals;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">company, product and brand recognition; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">device reusability and durability; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reimbursement and payor coverage; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">complexity in building up the RCM capabilities and logistics to support broad-based; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">149 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">commercialization and service levels; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recruitment and retention of a qualified and experienced sales force. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Intellectual Property </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In order to
remain competitive, we must develop and maintain protection for the proprietary aspects of our technologies. We rely on a combination of patent, copyright, trademark and trade secret laws, and confidentiality and invention assignment agreements to
protect our intellectual property rights. The protection of intellectual property has been and remains a priority for us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We rely on
utility patent, design patent or other similar protection and registration mechanisms through various jurisdictions that relate to our ASSURE WCD. As of the date of this prospectus, we have rights to 225 issued U.S. and foreign patents, consisting
of 193 issued patents in the U.S., 16 issued patents in the European Union, 7&nbsp;issued patents in Japan, 4 issued patents in Australia and 5 issued patents in China. Additionally, as of the date of this prospectus, we had 141 pending published
and unpublished U.S. and foreign patent applications, consisting of 128 pending published and unpublished patent applications in the U.S., 5 pending published patent applications in the European Union, 3 pending published patent applications in
Japan, 2 pending published patent applications in Australia and 3 pending published patent applications in China. Assuming all required fees and other charges are paid, the earliest expiry date for issued patents owned or used by us is in July 2025.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We rely on trademarks, service marks, trade names and brand names, such as our registered or applied for trademarks for the marks ASSURE,
CARDIAC RECOVERY SYSTEM, KESTRA and KESTRA CARESTATION to distinguish our products from the products of our competitors. We have registered or applied for the ASSURE mark in the United States and selected locations internationally, but we may be
unable to obtain, maintain, protect or enforce our trademarks in the markets where we currently or may in the future operate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We also
rely upon trade secrets, <FONT STYLE="white-space:nowrap">know-how,</FONT> continuing technological innovation, and licensing opportunities, to develop and maintain our competitive position. However, trade secrets and know how may be difficult to
protect. We protect our proprietary rights through a variety of methods, including confidentiality agreements and proprietary information agreements with third party contract manufacturers, suppliers, employees, consultants and others who may have
access to proprietary information that we own or license for use. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">There is no active litigation involving any of our patents or other
intellectual property rights and we have not received any notices of patent infringement. We may be required to enforce or defend our intellectual property rights against third parties in the future. For additional information regarding these and
other risks related to our intellectual property portfolio and their potential effect on us, see &#147;Risk Factors&#151;Risks Related to Our Intellectual Property.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Government Regulation </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our products and
our operations are subject to extensive and ongoing regulation by the FDA, the CMS and other federal and state authorities in the United States. Regulations cover virtually every critical aspect of a medical device company&#146;s business
operations, including research activities, product development, quality and risk management, contracting, reimbursement, medical communications, and sales and marketing. In addition, we are subject to regulation by CMS, state law, and private payor
requirements as a DME supplier with respect to our product leasing and payor billing operations. In the United States, the Federal Food, Drug and Cosmetic Act (the &#147;FDCA&#148;) and the implementing regulations of the FDA govern, among other
things, product design and development, <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical testing, premarket notifications and clearance or approval, investigational device exemption, establishment registration and device listing,
product manufacturing, quality systems, import </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">150 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and export, product labeling, product storage, medical device reporting, recalls and field safety corrective actions, advertising and promotion, revenues and distribution, and post-market
surveillance (including complaint handling and adverse event reporting). Our business is subject to various federal, state and local regulations, including, but not limited to, ISO 13485, ISO 14971 and the FDA&#146;s QSR contained in 21 CFR Parts
801, 803, 807, 812, 814, and 820. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>FDA Premarket Clearance and Approval Requirements </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Unless an exemption applies, each medical device commercially distributed in the United States requires either FDA clearance of a premarket
notification under Section&nbsp;510(k) of the FDCA or a PMA. Under the FDCA, medical devices are classified into one of three classes&#151;Class&nbsp;I, Class&nbsp;II or Class&nbsp;III&#151;depending on the degree of risk associated with each
medical device and the extent of manufacturer and regulatory control needed to ensure its safety and effectiveness. Class&nbsp;I includes devices with the lowest risk to the patient and are those for which safety and effectiveness can be assured by
adherence to the FDA&#146;s General Controls for medical devices, which include compliance with the applicable portions of the QSR, establishment registration and product listing, reporting of adverse events, and truthful and <FONT
STYLE="white-space:nowrap">non-misleading</FONT> labeling, advertising and promotional materials. Class&nbsp;II devices are subject to the FDA&#146;s General Controls, and special controls as deemed necessary by the FDA to ensure the safety and
effectiveness of the device. These special controls can include performance standards, special labeling requirements, post-market surveillance, patient registries and FDA product-specific guidance documents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">While most Class&nbsp;I devices are exempt from the 510(k) premarket notification requirement, manufacturers of most Class&nbsp;II devices are
required to submit to the FDA a premarket notification under Section&nbsp;510(k) of the FDCA requesting permission to commercially distribute the device. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Devices deemed by the FDA to pose the greatest risks, such as life-sustaining or life-supporting devices, those that are of substantial
importance in preventing impairment of human health, or which present a potential unreasonable risk of illness or injury, are placed in Class&nbsp;III, requiring approval of PMA. The PMA process is more stringent, time-consuming and expensive than
the 510(k) clearance process. Some <FONT STYLE="white-space:nowrap">pre-amendment</FONT> devices are unclassified, but are subject to the FDA&#146;s premarket notification and clearance process in order to be commercially distributed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our ASSURE WCD is a Class&nbsp;III device that has received a PMA. For the purpose of our PMA, our digital health platform is separate from
our ASSURE WCD and is treated as a FDA Class&nbsp;I 510(k)&#151;exempt device. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>510(k) Clearance Marketing Pathway </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The FDA&#146;s permission to commercially distribute a device subject to a 510(k) premarket notification is generally known as 510(k)
clearance. Under the 510(k) clearance process, the manufacturer must submit to the FDA a premarket notification demonstrating that the device is &#147;substantially equivalent&#148; to either a device that was legally marketed prior to May&nbsp;28,
1976, the date upon which the Medical Device Amendments of 1976 were enacted, and for which a PMA is not required, a device that has been reclassified from Class&nbsp;III to Class&nbsp;II or I, or another commercially available device that was
cleared through the 510(k) process. The FDA&#146;s 510(k) clearance process usually takes from three to twelve months but may take longer. The FDA may require additional information, including clinical data, to make a determination regarding
substantial equivalence. FDA collects user fees for certain medical device submission and annual fees and for medical device establishments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If the FDA agrees that the device is substantially equivalent to a predicate device currently on the market, it will grant 510(k) clearance to
commercially market the device. If the FDA determines that the device is not &#147;substantially equivalent&#148; to a previously cleared device, the device is automatically designated as a Class&nbsp;III device. The device sponsor must then fulfill
more rigorous PMA requirement as described below. After </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">151 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
a device receives 510(k) clearance or <I>de novo </I>classification, any modification that could significantly affect its safety or effectiveness, or that would constitute a major change or
modification in its intended use, will require a new 510(k) clearance or, depending on the modification, PMA approval or <I>de novo </I>classification. The FDA requires each manufacturer to determine whether the proposed change requires submission
of a 510(k), <I>de novo </I>request or a PMA in the first instance, but the FDA can review any such decision and disagree with a manufacturer&#146;s determination. If the FDA disagrees with a manufacturer&#146;s determination, the FDA can require
the manufacturer to cease marketing and/or request the recall of the modified device until 510(k) marketing clearance or PMA approval is obtained or a <I>de novo </I>request is granted. In these circumstances, the manufacturer may be subject to
significant regulatory fines or penalties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>De Novo Classification Process </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Medical device types that the FDA has not previously classified as Class&nbsp;I, II, or III are automatically classified into Class&nbsp;III
regardless of the level of risk they pose. The Food and Drug Administration Modernization Act of 1997 established a route to market for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">low-to-moderate</FONT></FONT> risk medical
devices that are automatically placed into Class&nbsp;III due to the absence of a predicate device, called the &#147;Request for Evaluation of Automatic Class&nbsp;III Designation,&#148; or the <I>de novo </I>classification procedure. This procedure
allows a manufacturer whose novel device is automatically classified into Class&nbsp;III to request down-classification of its medical device into Class&nbsp;I or Class&nbsp;II on the basis that the device presents low or moderate risk, rather than
requiring the submission and approval of a PMA application. Pursuant to the Food and Drug Administration Safety and Innovation Act (the &#147;FDASIA&#148;) manufacturers may request <I>de novo </I>classification directly without first submitting a
510(k) <FONT STYLE="white-space:nowrap">pre-market</FONT> notification to the FDA and receiving a <FONT STYLE="white-space:nowrap">not-substantially-equivalent</FONT> determination. <I>De novo </I>classification requests are subject to the payment
of user fees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under FDASIA, FDA is required to classify the device within 120 days following receipt of the <I>de novo </I>request,
although the process may take significantly longer. If the manufacturer seeks reclassification into Class&nbsp;II, the manufacturer must include a draft proposal for special controls that are necessary to provide a reasonable assurance of the safety
and effectiveness of the medical device. If FDA grants the <I>de novo </I>request, the device may be legally marketed in the United States. However, the FDA may reject the request if the FDA identifies a legally marketed predicate device that would
be appropriate for a 510(k) notification, determines that the device is not <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">low-to-moderate</FONT></FONT> risk, or determines that General Controls would be inadequate to control the
risks and/or special controls cannot be developed. After a device receives <I>de novo </I>classification, any modification that could significantly affect its safety or efficacy, or that would constitute a major change or modification in its
intended use, will require a new 510(k) clearance or, depending on the modification, another <I>de novo </I>request or even PMA approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>PMA
Pathway </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Class&nbsp;III devices require a PMA before they can be marketed, although some
<FONT STYLE="white-space:nowrap">pre-amendment</FONT> Class&nbsp;III devices for which the FDA has not yet required a PMA are cleared through the 510(k) process. The PMA process is more demanding than the 510(k) premarket notification process. In a
PMA application, the applicant must demonstrate that the device is safe and effective, and the PMA application must be supported by extensive data, including data from <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies and human clinical
trials. The PMA application must also contain a full description of the device and its components, a full description of the methods, facilities and controls used for manufacturing, and proposed labeling. The PMA process is burdensome, and in
practice, the FDA&#146;s review of a PMA application may take up to several years following initial application. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Following receipt of a
PMA application, the FDA determines whether the application is sufficiently complete to permit a substantive review. If the FDA accepts the application for review, it has 180 days under the FDCA to complete its review of a PMA application, although
in practice, the FDA&#146;s review often takes significantly longer, and can take up to several years. During this review period, the FDA may request additional </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">152 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
information or clarification of information already provided. The FDA can delay, limit or deny approval of a PMA application for many reasons, including: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the device may not be safe, effective, reliable or accurate to the FDA&#146;s satisfaction;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the data from <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies and clinical trials may be
insufficient to support approval; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the manufacturing process or facilities may not meet applicable requirements; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in FDA approval policies or adoption of new regulations may require additional data.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">An advisory panel of experts from outside the FDA may be convened to review and evaluate the application and provide
recommendations to the FDA as to the approvability of the device. The FDA may or may not accept the panel&#146;s recommendation. In addition, the FDA will generally conduct a preapproval inspection of the applicant, its clinical trial data and
clinical sites, as well as its third-party manufacturers&#146; or suppliers&#146; manufacturing facility or facilities to ensure compliance with FDA requirements, including the Quality System Regulation, or QSR. PMA applications are also subject to
the payment of user fees, which for fiscal year 2021 includes a standard application fee of $365,657. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The FDA will approve the new device
for commercial distribution if it determines that the data and information in the PMA application constitute valid scientific evidence and that there is reasonable assurance that the device is safe and effective for its intended use(s). The FDA may
approve a PMA application with post-approval conditions intended to ensure the safety and effectiveness of the device, including, among other things, restrictions on labeling, promotion, sale and distribution, and collection of long-term <FONT
STYLE="white-space:nowrap">follow-up</FONT> data from patients in the clinical study that supported a PMA or requirements to conduct additional clinical studies post-approval. The FDA may condition a PMA on some form of post-market surveillance when
deemed necessary to protect the public health or to provide additional safety and efficacy data for the device in a larger population or for a longer period of use. In such cases, the manufacturer might be required to follow certain patient groups
for a number of years and to make periodic reports to the FDA on the clinical status of those patients. Failure to comply with the conditions of approval can result in material adverse enforcement action, including withdrawal of the approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Certain changes to an approved device, such as changes in manufacturing facilities, methods, or quality control procedures, or changes in the
design performance specifications, which affect the safety or effectiveness of the device, require submission of a PMA supplement. PMA supplements often require submission of the same type of information as a PMA application, except that the
supplement is limited to information needed to support any changes from the device covered by the original PMA application and may not require as extensive clinical data or the convening of an advisory panel. Certain other changes to an approved
device require the submission of a new PMA, such as when the design change causes a different intended use, mode of operation, and technical basis of operation, or when the design change is so significant that a new generation of the device will be
developed, and the data that were submitted with the original PMA application are not applicable for the change in demonstrating a reasonable assurance of safety and effectiveness. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Clinical Trials </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Clinical trials
are almost always required to support a PMA application and are sometimes required to support a 510(k) submission. We completed clinical trials for our ASSURE WCD in March 2020 and received our PMA for our ASSURE WCD on July&nbsp;27, 2021 We are
currently engaged in a post-approval clinical study of our ASSURE WCD and may in the future engage in additional clinical trials and other clinical initiatives to support additional indications and stronger guideline recommendations for WCD therapy
and to obtain regulatory approvals to market our products in new markets. All clinical investigations of investigational devices to determine safety and effectiveness must be conducted in accordance with the FDA&#146;s IDE regulations which govern
investigational device labeling, prohibit promotion of the investigational device, and specify an array of recordkeeping, reporting and monitoring responsibilities of study sponsors and study investigators. If the device presents a &#147;significant
risk&#148; to human health, as defined by the FDA, the FDA requires the device sponsor to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">153 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
submit an IDE application to the FDA, which must become effective prior to commencing human clinical trials. If the device under evaluation does not present a significant risk to human health,
then the device sponsor is not required to submit an IDE application to the FDA before initiating human clinical trials, but must still comply with abbreviated IDE requirements and obtain Institutional Review Board, or IRB approval when conducting
such trials. A significant risk device is one that presents a potential for serious risk to the health, safety or welfare of a patient and either is implanted, used in supporting or sustaining human life, substantially important in diagnosing,
curing, mitigating or treating disease or otherwise preventing impairment of human health, or otherwise presents a potential for serious risk to a subject. An IDE application must be supported by appropriate data, such as animal and laboratory test
results, showing that it is safe to test the device in humans and that the testing protocol is scientifically sound. The IDE will automatically become effective 30 days after receipt by the FDA unless the FDA notifies the company that the
investigation may not begin. If the FDA determines that there are deficiencies or other concerns with an IDE for which it requires modification, the FDA may permit a clinical trial to proceed under a conditional approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, regardless of the degree of risk presented by the medical device, clinical studies must be approved by, and conducted under the
oversight of, an IRB for each clinical site. The IRB is responsible for the initial and continuing review of the IDE, and may pose additional requirements for the conduct of the study. If an IDE application is approved by the FDA and one or more
IRBs, human clinical trials may begin at a specific number of investigational sites with a specific number of patients, as approved by the FDA. If the device presents a <FONT STYLE="white-space:nowrap">non-significant</FONT> risk to the patient and
does not require an IDE application, a sponsor may begin the clinical trial after obtaining approval for the trial by one or more IRBs without separate approval from the FDA, but must still follow abbreviated IDE requirements, such as monitoring the
investigation, ensuring that the investigators obtain informed consent, and labeling and record-keeping requirements. The FDA&#146;s approval of an IDE application allows clinical testing to go forward, but it does not bind the FDA to accept the
results of the trial as sufficient to prove the product&#146;s safety and efficacy, even if the trial meets its intended success criteria. All clinical trials must be conducted in accordance with applicable FDA regulations including for example
those that govern good clinical practices, IRB review, investigational device labeling, prohibitions on promotion, and recordkeeping, reporting and monitoring responsibilities of study sponsors and study investigators. Required records and reports
are subject to inspection by the FDA. The results of clinical testing may be unfavorable or, even if the intended safety and efficacy success criteria are achieved, may not be considered sufficient for the FDA to grant approval or clearance of a
product. Clinical trials that meet certain requirements must be entered into the clinical trials registry at clinicaltrials.gov. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The
commencement or completion of any clinical trial may be delayed or halted, or be inadequate to support approval of a PMA application, for numerous reasons, including, but not limited to, the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA or other regulatory authorities do not approve a clinical trial protocol or a clinical trial, or place a
clinical trial on hold; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patients do not enroll in clinical trials at the rate expected; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patients, sponsor or study sites do not comply with trial protocols; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patient <FONT STYLE="white-space:nowrap">follow-up</FONT> is not at the rate expected; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patients experience adverse side effects; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patients die during a clinical trial, even though their death may not be related to the products that are part of
our trial; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">IRBs and third-party clinical investigators may delay or reject the trial protocol; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">154 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">third-party clinical investigators decline to participate in a trial or do not perform a trial on the anticipated
schedule or consistent with the clinical trial protocol, good clinical practices or other FDA requirements; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the sponsor or third-party organizations do not perform data collection, monitoring and analysis in a timely or
accurate manner or consistent with the clinical trial protocol or investigational or statistical plans; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">third-party clinical investigators have significant financial interests related to the sponsor or the study that
the FDA deems to make the study results unreliable, or the company or investigators fail to disclose such interests; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory inspections of our clinical trials, which may, among other things, require us to undertake corrective
action or suspend or terminate our clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in governmental regulations or administrative actions; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the interim or final results of the clinical trial are inconclusive or unfavorable as to safety or efficacy; and
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA concludes that our trial design is inadequate to demonstrate safety and efficacy. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Post-market Regulation </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">After a
device is cleared or approved for marketing, numerous and pervasive regulatory requirements continue to apply. These include: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishment registration and device listing with the FDA; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">QSR requirements, which require manufacturers, including third-party manufacturers and suppliers, to follow
stringent design, testing, control, documentation and other quality assurance procedures during all aspects of the design and manufacturing process, as well as maintain various records; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">labeling and marketing regulations, which require that promotion is truthful, not misleading, fairly balanced and
provide adequate directions for use and that all claims are substantiated, and also prohibit the promotion of products for uncleared, unapproved or <FONT STYLE="white-space:nowrap">&#147;off-label&#148;</FONT> uses and impose other restrictions on
labeling; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">requirements related to promotional activities; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">FDA guidance on <FONT STYLE="white-space:nowrap">off-label</FONT> dissemination of information and responding to
unsolicited requests for information; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clearance or approval of product modifications to 510(k)-cleared devices that could significantly affect safety
or effectiveness or that would constitute a major change in intended use of one of our cleared devices, or approval of a supplement for certain modifications to PMA devices; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">medical device reporting regulations, which require that a manufacturer report to the FDA if a device it markets
may have caused or contributed to a death or serious injury, or has malfunctioned and the device or a similar device that it markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">155 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">correction, removal and recall reporting regulations, which require that manufacturers report to the FDA field
corrections and product recalls or removals if undertaken to reduce a risk to health posed by the device or to remedy a violation of the FDCA that may present a risk to health; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">complying with the federal law and regulations requiring Unique Device Identifiers (&#147;UDI&#148;) on devices
and also requiring the submission of certain information about each device to the FDA&#146;s Global Unique Device Identification Database (&#147;GUDID&#148;); </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA&#146;s recall authority, whereby the agency can order device manufacturers to recall from the market a
product that is in violation of governing laws and regulations; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">post-market surveillance activities and regulations, which apply when deemed by the FDA to be necessary to
protect the public health or to provide additional safety and effectiveness data for the device. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Additionally, the FDA
may require us to conduct post-market surveillance studies or establish and maintain a system for tracking our products through the chain of distribution to the patient level. The FDA enforces regulatory requirements by conducting periodic,
unannounced inspections and market surveillance. Inspections may include the manufacturing facilities of our subcontractors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The FDA has
broad regulatory compliance and enforcement powers. Failure to comply with applicable regulatory requirements can result in enforcement actions by the FDA and other regulatory agencies. These may include any of the following sanctions or
consequences: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">warning letters or untitled letters that require corrective action; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fines and civil penalties; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unanticipated expenditures; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in approving or refusal to approve future products; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">suspension or withdrawal of FDA 510(k) clearance or PMAs that have already been granted; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product recall, withdrawal, administrative detention or seizure; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">interruption of production, including partial suspension or total shutdown; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">operating restrictions, including refusal to grant export approvals for devices being shipped to foreign markets;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injunctions, consent decrees; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">criminal prosecution. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We and our contract manufacturers, specification developers and some suppliers of components of our products, are also required to comply with
current good manufacturing practice requirements set forth in the QSR. The QSR requires a quality system for the design, manufacture, packaging, labeling, storage, installation and servicing of marketed devices, and it includes extensive
requirements with respect to quality management and organization, device design, buildings, equipment, purchase and handling of components or services, production and process controls, packaging and labeling controls, device evaluation,
distribution, installation, complaint handling, servicing, and record keeping. The FDA evaluates compliance with the QSR through </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">156 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
periodic unannounced inspections that may include the manufacturing facilities of our subcontractors. If the FDA believes that we or any of our contract manufacturers or regulated suppliers are
not in compliance with these requirements, it can shut down such manufacturing operations, require recall of our products, refuse to approve new marketing applications, institute legal proceedings to detain or seize products, enjoin future
violations or assess civil and criminal penalties against us or our officers or other employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fraud and Abuse Laws </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition to FDA restrictions, there are numerous federal and state laws pertaining to healthcare fraud and abuse, including anti-kickback
laws and physician self-referral laws. Our relationships with healthcare providers and other third parties are subject to scrutiny under these laws. Violations of these laws are punishable by criminal and civil sanctions, including, in some
instances, imprisonment and exclusion from participation in federal and state healthcare programs, including the Medicare, Medicaid and Veterans Administration health programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Federal Anti-Kickback and Self-Referral Laws </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The federal Anti-Kickback Statute prohibits persons from knowingly and willfully soliciting, receiving, offering or providing remuneration
(including any kickback, bribe or rebate), directly or indirectly, overtly or covertly, to induce either the referral of an individual, or the furnishing, recommending, or arranging of a good or service, for which payment may be made under a federal
healthcare program such as Medicare and Medicaid or other federal healthcare programs. The term &#147;remuneration&#148; has been broadly interpreted to include anything of value, including such items as gifts, discounts, the furnishing of supplies
or equipment, credit arrangements, waiver of payments and providing anything at less than its fair market value. Although there are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution, the
exceptions and safe harbors are drawn narrowly. Practices that involve remuneration that may be alleged to be intended to induce prescribing, purchases or recommendations may be subject to scrutiny if they do not qualify for an exception or safe
harbor. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the Anti-Kickback Statute. Instead, the legality of the arrangement will be
evaluated on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis based on a review of all its relevant facts and circumstances. Several courts have interpreted the statute&#146;s intent requirement to
mean that if any one purpose of an arrangement involving remuneration is to induce referrals of (or purchases, or recommendations related to) federal healthcare covered business, the Anti-Kickback Statute has been implicated and potentially
violated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The penalties for violating the federal Anti-Kickback Statute include imprisonment for up to five years, fines of up to $25,000
per violation and possible exclusion from federal healthcare programs such as Medicare and Medicaid. Many states have adopted prohibitions similar to the federal Anti-Kickback Statute, some of which do not have the same exceptions and apply to the
referral of patients for healthcare services reimbursed by any source, not only by the Medicare and Medicaid programs. Further, the Anti-Kickback Statute was amended by the Patient Protection and Affordable Care Act (&#147;PPACA&#148;).
Specifically, under the Anti-Kickback Statute, the government must prove the defendant acted &#147;knowingly&#148; to prove a violation occurred. The PPACA added a provision to clarify that with respect to violations of the Anti-Kickback Statute,
&#147;a person need not have actual knowledge&#148; of the statute or specific intent to commit a violation of the statute. This change effectively overturns case law interpretations that set a higher standard under which prosecutors had to prove
the specific intent to violate the law. In addition, the PPACA codified case law that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the
federal civil False Claims Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We plan to provide the initial training to providers and patients necessary for appropriate use of our
ASSURE WCD through training and educating patients, cardiologists, cardiac electrophysiologists, key opinion leaders from these disciplines and medical societies. We may hire or contract with a network of patient care specialists to assist with
fitting and training patients and such specialists will be reimbursed for their services at fair market value. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">157 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Noncompliance with the federal Anti-Kickback Statute could result in our exclusion from
Medicare, Medicaid or other governmental programs, restrictions on our ability to operate in certain jurisdictions, and civil and criminal penalties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Federal law also includes a provision commonly known as the &#147;Stark Law,&#148; which prohibits a physician from referring Medicare or
Medicaid patients to an entity providing &#147;designated health services,&#148; including a company that furnishes durable medical equipment, in which the physician has an ownership or investment interest or with which the physician has entered
into a compensation arrangement. Violation of the Stark Law could result in denial of payment, disgorgement of reimbursements received under a noncompliant arrangement, civil penalties, and exclusion from Medicare, Medicaid or other governmental
programs. We believe that we have structured our provider arrangements to comply with current Stark Law requirements. Nevertheless, a determination of liability under such laws could result in fines and penalties and restrictions on our ability to
operate in these jurisdictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Federal False Claims Act </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Federal False Claims Act provides, in part, that the federal government may bring a lawsuit against any person whom it believes has
knowingly presented, or caused to be presented, a false or fraudulent request for payment from the federal government, or who has made a false statement or used a false record to get a claim approved. In addition, amendments in 1986 to the Federal
False Claims Act have made it easier for private parties to bring &#147;qui tam&#148; whistleblower lawsuits against companies under the Federal False Claims Act. Penalties include fines ranging from $5,500 to $11,000 for each false claim, plus
three times the amount of damages that the federal government sustained because of the act of that person. Qui tam actions have increased significantly in recent years, causing greater numbers of healthcare companies to have to defend a false claim
action, pay fines or be excluded from Medicare, Medicaid or other federal or state healthcare programs as a result of an investigation arising out of such action. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">There are other federal anti-fraud laws that that prohibit, among other actions, knowingly and willfully executing, or attempting to execute,
a scheme to defraud any healthcare benefit program, including private <FONT STYLE="white-space:nowrap">third-party</FONT> payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal
investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare
benefits, items or services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Additionally, HIPAA established two federal crimes in related to healthcare fraud and false statements
relating to healthcare matters. The healthcare fraud statute prohibits knowingly and willfully executing a scheme to defraud any healthcare benefit program, including private payors. A violation of this statute is a felony and may result in fines,
imprisonment or exclusion from government sponsored programs. The false statements statute prohibits knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in
connection with the delivery of or payment for healthcare benefits, items or services. A violation of this statute is a felony and may result in fines or imprisonment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Civil Monetary Penalties Law </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In
addition to the Anti-Kickback Statute and the civil and criminal False Claims Acts, the federal government has the authority to seek civil monetary penalties (&#147;CMPs&#148;), assessments, and exclusion against an individual or entity based on a
wide variety of prohibited conduct. For example, the Civil Monetary Penalties Law authorizes the imposition of substantial CMPs against an entity that engages in activities including, but not limited to: (1)&nbsp;knowingly presenting or causing to
be presented, a claim for services not provided as claimed or which is otherwise false or fraudulent in any way; (2)&nbsp;knowingly giving or causing to be given false or misleading information reasonably expected to influence the decision to
discharge a patient; (3)&nbsp;offering or giving remuneration to any beneficiary of a federal healthcare program likely to influence the receipt of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">158 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reimbursable items or services; (4)&nbsp;arranging for reimbursable services with an entity which is excluded from participation from a federal healthcare program; (5)&nbsp;knowingly or willfully
soliciting or receiving remuneration for a referral of a federal healthcare program beneficiary; or (6)&nbsp;using a payment intended for a federal health care program beneficiary for another use. Noncompliance can result in civil money penalties of
up to $10,000 for each wrongful act, assessment of three times the amount claimed for each item or service and exclusion from the federal healthcare programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>State Fraud and Abuse Provisions </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Many states have also adopted some form of anti-kickback and anti-referral laws and a false claims act. We believe that we are in compliance
with such laws. Violations of state fraud and abuse laws may be punishable by criminal and civil sanctions, including fines and civil monetary penalties, the possibility of exclusion from state healthcare programs, disgorgement, and corporate
integrity agreements, which impose, among other things, rigorous operational and monitoring requirements on companies. Similar sanctions and penalties, as well as imprisonment, also can be imposed upon executive officers and employees of such
companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Physician Payment Sunshine Act </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Transparency laws regarding payments or other items of value provided to healthcare providers and teaching hospitals may also impact our
business practices. The federal Physician Payment Sunshine Act requires most medical device manufacturers to report annually to the Secretary of Human Health Services financial arrangements, payments, or other transfers of value made by that entity
to physicians and teaching hospitals. The payment information is made publicly available in a searchable format on a CMS website. We will need to dedicate significant resources to establish and maintain systems and processes in order to comply with
these regulations. Failure to comply with the reporting requirements can result in significant civil monetary penalties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Data Privacy and Security
Laws </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We may also be subject to data privacy and security regulation by both the federal government and the states in which we
conduct our business. The HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (&#147;HITECH&#148;), and their respective implementing regulations, imposes specified requirements relating to the privacy,
security and transmission of individually identifiable health information, applicable to health plans, healthcare clearinghouses and certain health care providers, referred to as covered entities, and the business associates with whom such covered
entities contract for services. Among other things, HITECH makes HIPAA&#146;s security standards directly applicable to business associates, defined as service providers of covered entities that create, receive, maintain or transmit protected health
information in connection with providing a service for or on behalf of a covered entity. In performing our activities as a DME supplier, we are a covered entity under HIPAA, and as a result, must implement a HIPAA privacy and security program in
accordance with HIPAA requirements. In addition, we are a business associate with respect to our billing distribution partnership with a third-party DME provider, to which we will provide assistance with preparing and reviewing claims to be
submitted to payors, and as a result, must comply with the HIPAA privacy and security requirements set forth in our business associate agreement. With regard to our other operations, we are not a covered entity or a business associate, though we may
be subject to certain HIPAA requirements in our collection of individually identifiable health information from patients. HITECH also created four new tiers of civil monetary penalties and gave state attorneys general new authority to file civil
actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#146; fees and costs associated with pursuing federal civil actions. In addition, many state laws govern the privacy and security of health
information in certain circumstances, many of which differ from HIPAA and each other in significant ways and may not have the same effect. At the state level, the California Consumer Privacy Act, as amended by the California Privacy Rights Act, for
example, affords California residents expended privacy rights and provides for civil penalties for violations and a private right of action related to certain data security breaches; and Washington&#146;s My Health My Data Act (&#147;MHMDA&#148;)
extends privacy protections for Washington residents for health data beyond what HIPAA covers, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">159 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
granting Washington residents with more control over their health data by allowing them to access, delete, and restrict its use. Similar legislations have been advanced in other states as well as
in Congress. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Federal Trade Commission (the &#147;FTC&#148;) also has authority to initiate enforcement actions against entities that
mislead customers about HIPAA compliance, make deceptive statements about privacy and data sharing in privacy policies, fail to limit third-party use of personal health information, fail to implement policies to protect personal health information,
or engage in other unfair practices that harm customers or that may violate Section&nbsp;5 of the FTC Act. Even when HIPAA does not apply, failing to take appropriate steps to keep consumers&#146; personal information secure may constitute unfair
acts or practices in or affecting commerce under the FTC Act. The FTC expects a company&#146;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity
of its business and the cost of available tools to improve security and reduce vulnerabilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our business is also subject to the
Bermuda Personal Information Protection 2016 Act (&#147;PIPA&#148;). The PIPA regulates how any organization in Bermuda may use personal information. PIPA will be brought fully into effect on January&nbsp;1, 2025. After this date, organizations in
Bermuda will be required to comply with a combination of principle based and prescriptive rules. Prescriptive rules for in scope organizations (i.e., those that use personal information, noting &#147;use&#148; is broadly defined) include a
requirement to only use personal information where a legal condition applies, a requirement to appoint a data privacy officer, a requirement to provide all individuals with a privacy notice that must contain at a minimum certain required information
and requirement to understand and comply with individual rights around access, rectification and erasure. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Although we work to comply with
applicable laws, regulations and standards, our contractual obligations, research protocols, and other obligations, any actual or perceived failure by us or our employees, representatives, contractors, consultants, or other third parties to comply
with such requirements or adequately address data privacy and security concerns, even if unfounded, could result in, among other adverse impacts, damage to our reputation, loss of customer confidence in our security measures, withdrawal or
withholding of customer consent for using patient data, government investigations, and enforcement actions and litigation and claims by third parties, any of which could have a material adverse effect on our business, financial condition, results of
operations, and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>U.S. Foreign Corrupt Practices Act </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The U.S. Foreign Corrupt Practices Act (the &#147;FCPA&#148;) prohibits U.S. corporations and their representatives from offering, promising,
authorizing or making corrupt payments, gifts or transfers to any foreign government official, government staff member, political party or political candidate in an attempt to obtain or retain business abroad. The FCPA also obligates companies whose
securities are listed in the United States to comply with accounting provisions requiring the company to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to
devise and maintain an adequate system of internal accounting controls for international operations. Activities that violate the FCPA, even if they occur wholly outside the United States, can result in criminal and civil fines, imprisonment,
disgorgement, oversight, and debarment from government contracts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Centers for Medicare and Medicaid Services; Coverage and Reimbursement </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the United States, our commercial success depends in part on the extent to which governmental authorities, private health insurers and
other third-party payors provide coverage for and establish adequate reimbursement levels for our products and related services. Medicare is a federal program administered by CMS through fiscal intermediaries and carriers. Available to individuals
aged 65 or over, and certain other individuals, the Medicare program provides, among other things, healthcare benefits that cover, within prescribed limits, the major costs of most medically necessary care for such individuals, subject to certain
deductibles and copayments. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">160 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">CMS has established guidelines for the coverage and reimbursement of certain products,
supplies and services. In general, in order to be reimbursed by Medicare, a healthcare product or service furnished to a Medicare beneficiary must be reasonable and necessary for the diagnosis or treatment of an illness or injury, or to improve the
functioning of a malformed body part. The methodology for determining coverage status and the amount of Medicare reimbursement varies based upon, among other factors, the setting in which a Medicare beneficiary received healthcare products and
services. Any changes in federal legislation, regulations and policy affecting Medicare coverage and reimbursement relative to our products could have a material effect on our performance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">CMS also administers the Medicaid program, a cooperative federal/state program that provides medical assistance benefits to qualifying low
income and medically needy persons. State participation in Medicaid is optional, and each state is given discretion in developing and administering its own Medicaid program, subject to certain federal requirements pertaining to payment levels,
eligibility criteria and minimum categories of services. The coverage, method and level of reimbursement varies from state to state and is subject to each state&#146;s budget restraints. Changes to the coverage, method or level of reimbursement for
our products may affect future revenue negatively if reimbursement amounts are decreased or discontinued. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">All CMS programs are subject to
statutory and regulatory changes, retroactive and prospective rate adjustments, administrative rulings, interpretations of policy, intermediary determinations, and government funding restrictions, all of which may materially increase or decrease the
rate of program payments to healthcare facilities and other healthcare providers, including those paid for our products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Significant
uncertainty exists as to the coverage and reimbursement status of any product candidates for which we may seek regulatory approval by the FDA or other government authorities. Patients who are prescribed treatments for their conditions and providers
performing the prescribed services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. Patients are unlikely to use any product candidates we may develop unless coverage is provided and reimbursement is
adequate to cover a significant portion of the cost of such product candidates. With respect to our ASSURE WCD, and any other product candidates we may develop, to the extent they are approved, the distribution of our ASSURE WCD and other future
product candidates will depend, in part, on the extent to which third-party payors, including government health programs such as Medicare and Medicaid, commercial health insurers, and managed care organizations, provide coverage, and establish
adequate reimbursement levels for, such product candidates. The process for determining whether a payor will provide coverage for a product may be separate from the process for setting the price or reimbursement rate that the payor will pay for the
product once coverage is approved. Third-party payors are increasingly challenging the prices charged, examining the medical necessity, and reviewing the accuracy of claims and overall cost-effectiveness of medical products and services and imposing
controls to manage costs. Third-party payors may limit coverage to specific products on an approved list, also known as a formulary, which might not include all of the approved products for a particular indication. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In order to secure coverage and reimbursement for any product that might be approved for sale, a company may need to conduct expensive
clinical studies in order to demonstrate the medical necessity and cost-effectiveness of the product, in addition to the costs required to obtain FDA or other comparable marketing approvals. Nonetheless, product candidates may not be considered
medically necessary or cost effective. A&nbsp;decision by a third-party payor not to cover any product candidates we may develop could reduce physician utilization of such product candidates once approved and have a material adverse effect on our
revenues, results of operations and financial condition. Additionally, a payor&#146;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Further, one payor&#146;s determination to provide
coverage for a product does not assure that other payors will also provide coverage and reimbursement for the product, and the level of coverage and reimbursement can differ significantly from payor to payor. Third-party reimbursement and coverage
may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">161 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Coverage policies and third-party reimbursement rates may change at any time. Even if
favorable coverage and reimbursement status is attained for one or more products for which a company or its collaborators receive marketing approval, less favorable coverage policies and reimbursement rates may be implemented in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Healthcare Reform </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">There have
been and continue to be proposals by the federal government, state governments, regulators and third-party payors to control or manage the increased costs of healthcare and, more generally, to reform the U.S. healthcare system. Adoption of price
controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit a company&#146;s revenue generated from the sale of any approved products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For example, in March 2010, the Affordable Care Act (the &#147;ACA&#148;) was enacted in the United States. The ACA contains a number of
significant provisions, including those governing enrollment in federal healthcare programs, reimbursement changes and fraud and abuse measures, all of which will impact existing government healthcare programs and will result in the development of
new programs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Some of the provisions of the ACA have yet to be fully implemented, while certain provisions have been subject to judicial
and Congressional challenges. Congress has considered legislation that would repeal or repeal and replace all or part of the ACA. While Congress has not passed comprehensive repeal legislation, two bills affecting the implementation of certain taxes
under the ACA have been signed into law. The Tax Act includes a provision that decreased the <FONT STYLE="white-space:nowrap">tax-based</FONT> shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying
health coverage for all or part of a year, commonly referred to as the &#147;individual mandate,&#148; to $0, effective January&nbsp;1, 2019. On December&nbsp;14, 2018, a federal district court in Texas ruled the individual mandate is a critical and
inseverable feature of the ACA, and therefore, because it was repealed as part of the Tax Act, the remaining provisions of the ACA are invalid as well. On December&nbsp;18, 2019, the Fifth Circuit U.S. Court of Appeals held that the individual
mandate is unconstitutional, and remanded the case to the lower court to reconsider its earlier invalidation of the full ACA. On March&nbsp;2, 2020, the United States Supreme Court granted the petitions for writs of certiorari to review this case,
and held oral arguments on November&nbsp;10, 2020. On June&nbsp;17, 2021, the United States Supreme Court dismissed this challenge to the ACA without specifically ruling on its constitutionality. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On January&nbsp;22, 2018, former President Trump signed a continuing resolution on appropriations for fiscal year 2018 that delayed the
implementation of certain ACA -mandated fees, including the <FONT STYLE="white-space:nowrap">so-called</FONT> &#147;Cadillac&#148; tax on certain high cost employer-sponsored insurance plans, the annual fee imposed on certain health insurance
providers based on market share, and the medical device excise tax on <FONT STYLE="white-space:nowrap">non-exempt</FONT> medical devices; however, on December&nbsp;20, 2019, former President Trump signed into law the Further Consolidated
Appropriations Act (H.R. 1865), which repealed the Cadillac tax, the health insurance provider tax, and the medical device excise tax. Other legislative changes have been proposed and adopted in the United States since the Affordable Care Act was
enacted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In December 2018, CMS published a final rule permitting further collections and payments to and from certain ACA qualified
health plans and health insurance issuers under the Affordable Care Act risk adjustment program in response to the outcome of the federal district court litigation regarding the method CMS uses to determine this risk adjustment. Since then, the ACA
risk adjustment program payment parameters have been updated annually. In addition, CMS published a final rule that would give states greater flexibility, starting in 2020, in setting benchmarks for insurers in the individual and small group
marketplaces, which may have the effect of relaxing the essential health benefits required under the ACA for plans sold through such marketplaces. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, other legislative changes have been proposed and adopted since the ACA was enacted. On August&nbsp;2, 2011, the Budget Control
Act of 2011 was signed into law, which, among other things, includes reductions to Medicare payments to providers of 2% per fiscal year, which went into effect on April&nbsp;1, 2013 and, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">162 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
due to subsequent legislative amendments to the statute, including the BBA, will remain in effect through 2030 unless additional Congressional action is taken. On January&nbsp;2, 2013, the
American Taxpayer Relief Act of 2012 was signed into law, which, among other things, reduced Medicare payments to several providers, including hospitals, and increased the statute of limitations period for the government to recover overpayments to
providers from three to five years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We expect additional state and federal healthcare reform measures to be adopted in the future,
particularly in light of the new Trump administration which has stated its intent to make some changes to the regulatory landscape overseen by, for example, the HHS, including the FDA, any of which could, among others, change product approval
pathways, or limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our products or additional pricing pressures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cost Containment Measures </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our
products are directly distributed by our sales personnel to our healthcare provider customers. We may be directly reimbursed by third-party payors, including Medicare, Medicaid, private payors and other healthcare-related organizations, for the
lease of our devices. There have been and continue to be proposals by the federal government, state governments, regulators and third-party payors to control or manage the increased costs of healthcare and, more generally, to reform the U.S.
healthcare system. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit a company&#146;s revenue generated from the sale of any
approved products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On August&nbsp;2, 2011, the Budget Control Act of 2011 was signed into law, which, among other things, includes
reductions to Medicare payments to providers of 2% per fiscal year, which went into effect on April&nbsp;1, 2013 and, due to subsequent legislative amendments to the statute, including the BBA, will remain in effect through 2030 unless additional
Congressional action is taken. However, pursuant to the Coronavirus Aid, Relief and Economic Security Act, or CARES Act, and subsequent legislation, these Medicare sequester reductions are suspended from May&nbsp;1, 2020 through March&nbsp;31, 2021
due to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. On April&nbsp;14, 2021, the Act to Prevent <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Across-the-Board</FONT></FONT> Direct Spending Cuts, and for Other
Purposes, extended the sequestration suspension from April&nbsp;1, 2021 to December&nbsp;31, 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On January&nbsp;2, 2013, the American
Taxpayer Relief Act of 2012 was signed into law, which, among other things, reduced Medicare payments to several providers, including hospitals, and increased the statute of limitations period for the government to recover overpayments to providers
from three to five years. Further, recently, under the former Trump administration, there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several U.S.
Congressional inquiries and proposed, and enacted federal and state legislation designed to bring transparency to product pricing and reduce the cost of products and services under government healthcare programs. At this time, it is unclear whether
the current administration will continue to pursue legislative and/or administrative measures to control product costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Additionally,
regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what products to purchase and which suppliers will be included in their healthcare programs. CMS also continues to implement a
competitive bidding program (&#147;CBP&#148;) enacted under the Medicare Prescription Drug, Improvement and Modernization Act of 2003 that applies to certain suppliers of durable medical equipment, prosthetics, orthotics and supplies. Under the CBP,
suppliers that operate in a designated bidding area are required to submit electronic bids for certain products; CMS awards contracts to suppliers that offer the best price and meet applicable quality and financial standards. At this time, it is
unclear whether the CBP will have an impact on the pricing or the commercialization of our current or future products. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">163 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Team Members and Human Capital Resources </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of January&nbsp;31, 2025 we had over 300 team members, all of which were located in the United States. None of our team members is subject
to a collective bargaining agreement or represented by a trade or labor union, and we have not experienced any material work stoppages to date. We consider our relationship with our team members to be good, and we are committed to inclusion and
policies and procedures to maintain a safe work environment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our human capital resources objectives include, as applicable, identifying,
recruiting, retaining, incentivizing and integrating our team members. We believe our success depends on our ability to attract, retain, develop and motivate diverse highly skilled personnel. In particular, we depend upon the personal efforts and
abilities of the principal members of our senior management to partner effectively as a team, and who provide strategic direction, develop our business, manage our operations and maintain a cohesive and stable work environment. We also rely on
qualified sales managers and other skilled employees, who possess technical expertise in operations, scientific knowledge, engineering and quality management experience, in order to operate our business successfully. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our compensation program is designed to retain, motivate and, as needed, attract highly qualified executives. Accordingly, we use a mix of
competitive base salary, cash-based annual incentive compensation, performance-based equity compensation awards and other employee benefits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Facilities </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our principal office is
located at 3933 Lake Washington Blvd Northeast, Suite 200, Kirkland, Washington 98033, where we lease approximately 16,700 square feet of office space. We lease this space under a lease that terminates on April&nbsp;30, 2029. We intend to add new
facilities as we expand, and we believe that suitable additional or substitute space will be available as needed to accommodate any such expansion of our operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">164 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom744414_11"></A>MANAGEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table sets forth the names, ages and positions of our executive officers and directors: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="63%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Age</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Position</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Executive Officers</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Brian Webster</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">President,&nbsp;Chief&nbsp;Executive&nbsp;Officer,&nbsp;and&nbsp;Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vaseem Mahboob</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Financial Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Traci S. Umberger</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">General Counsel, Chief Administrative Officer, and Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Al Ford</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Commercial Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Additional Officers</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Phillip D. Foshee, Jr.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Senior Vice President of Research&nbsp;&amp; Development</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jeffrey Laub</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Senior Vice President of Supply Chain Operations</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Debra Schotz</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Senior Vice President of Marketing</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Non-Employee Directors</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jeffrey Schwartz</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director, Chairman of the Board of Directors</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Toby AuWerter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Maxwell Bikoff</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Raymond W. Cohen</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christopher Gordon</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mary Kay Ladone</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kevin Reilly</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Officers </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B><I>Brian Webster</I></B> is our Founder, President and Chief Executive Officer and is a member of our Board of Directors. Mr.&nbsp;Webster
has served in these roles at Kestra Medical Technologies, Ltd. since 2021 and at West Affum Intermediate Holdings, West Affum Holdings and Kestra Medical Technologies, Inc. since 2020, 2018 and 2016, respectively. Mr.&nbsp;Webster has over 32 years
in the medical device industry, including 10 years as President and Chief Executive Officer of Physio-Control, Inc. Mr.&nbsp;Webster was a founder of our company and has been building the company since 2014, when the predecessor company,
Physio-Control Development Corporation became fully independent from Physio Control Inc. Mr.&nbsp;Webster previously held executive positions including Vice President roles in operations, sales, and marketing at Physio-Control. Mr.&nbsp;Webster
brings broad knowledge of emergency medicine, the cardiac field, and the external defibrillation industry. Mr.&nbsp;Webster received his Bachelor of Arts in Business from the University of Puget Sound and his M.B.A. from Seattle University. We
believe Mr.&nbsp;Webster is qualified to serve on our Board of Directors based on his knowledge of our company through his role as our President and Chief Executive Officer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B><I>Vaseem Mahboob</I></B> is our Chief Financial Officer. Mr.&nbsp;Mahboob has served in this role at Kestra Medical Technologies, Ltd.
since 2021. Mr.&nbsp;Mahboob has over 23 years of finance leadership experience. Prior to joining our company, Mr.&nbsp;Mahboob served as the Executive Vice President, Chief Financial Officer and Chief Operations Officer of DIH Technology Ltd. from
2020 to 2021. From 2015 to 2020, Mr.&nbsp;Mahboob served as the Chief Financial Officer of ENDOLOGIX Inc. ENDOLOGIX Inc. filed for Chapter 11 bankruptcy protection with the United States Bankruptcy Court for the Northern District of Texas in July
2020. Mr.&nbsp;Mahboob was also a member of the board of directors and the audit committee chair for INSYS Therapeutics from 2018 to 2019. Prior to ENDOLOGIX Inc., Mr.&nbsp;Mahboob held various positions at GE Healthcare, including as the Chief
Financial Officer of the Global Magnetic Resonance Business from 2006 to 2010, as Chief Financial Officer of the Global Ultrasound Business from 2010 to 2012, as Chief Financial Officer of the Eastern and African Growth Markets from 2013 to 2015 and
as Chief Financial Officer of GE Healthcare IT from June 2015 to September 2015. Mr.&nbsp;Mahboob received his M.B.A. in Financial Markets and Institutions and Information Systems from the Jacobs School of Management at the State University of New
York. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B><I>Traci S. Umberger</I></B> is our <FONT STYLE="white-space:nowrap">Co-Founder,</FONT> General Counsel and Chief Administrative
Officer and is a member of our Board of Directors. Ms.&nbsp;Umberger has served in these roles at Kestra Medical Technologies, Ltd. since 2021 and at </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">165 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Kestra Medical Technologies, Inc. since 2016. Ms.&nbsp;Umberger has responsibility for the company&#146;s Legal, Compliance, and Human Resources functions. Ms.&nbsp;Umberger has over 34 years of
life sciences representation, including 10 years as General Counsel and Chief Administrative Officer at Physio-Control, Inc. Prior to going <FONT STYLE="white-space:nowrap">in-house,</FONT> Ms.&nbsp;Umberger practiced in the areas of commercial and
healthcare litigation, representing physicians and hospitals. Ms.&nbsp;Umberger received her Bachelor of Arts in Psychology/English from the University of British Columbia and her J.D. from the University of British Columbia. We believe
Ms.&nbsp;Umberger is qualified to serve on our Board of Directors based on her extensive legal career to date and knowledge of our company through her role as our General Counsel and Chief Administrative Officer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B><I>Al Ford</I></B><I> </I>has been appointed as our Chief Commercial Officer and will begin serving in this role prior to the consummation
of this offering. Mr.&nbsp;Ford has 20 years of experience driving global strategic sales, marketing, business development, product development, and commercial operations primarily within the medical device industry. Mr. Ford served as Chief
Commercial Officer of Axonics, Inc. (Nasdaq: AXNX), a medical device company with implantable technologies to treat bladder and bowel disorders, from 2017 to 2025, Chief Commercial Officer, General Manager and Senior Vice President of Global Sales
&amp; Marketing at Cardiac Science Corporation from 2015 to 2017. Mr. Ford received his B.S. in Marketing and his M.S. in International Business from Saint Joseph&#146;s University. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Additional Officers </B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B><I>Phillip
D. Foshee, Jr. </I></B>is our Senior Vice President of Research&nbsp;&amp; Development. Mr.&nbsp;Foshee has served in this role at Kestra Medical Technologies, Inc. since 2016. Mr.&nbsp;Foshee has over 40 years of research and development
experience. Twenty-eight of those years were in leadership roles at medical device companies. Prior roles include serving as general manager from 1998 to 2010 of Boston Scientific&#146;s Redmond, Washington design center and leading product
development of the Metrix implantable atrial defibrillator from 1991 to 1998 as the Vice President of Research&nbsp;&amp; Development at InControl. Mr.&nbsp;Foshee received his B.S. in Electrical Engineering and his M.S. in Mechanical Engineering
from Auburn University, Alabama. </P>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B><I>Jeffrey Laub </I></B>is our Senior Vice President of Supply Chain Operations.
Mr.&nbsp;Laub has served in this role at Kestra Medical Technologies, Ltd. since 2020. Mr.&nbsp;Laub has spent over 26 years as a commercial, operations, supply chain, quality, regulatory and services executive in the medical device industry. Prior
to joining our company, Mr.&nbsp;Laub served as President and Chief Operating Officer of Ventec Life Systems, Inc. from 2019 to 2020, and was also a member of their board of directors. Prior to joining Ventec Life Systems, Inc., Mr.&nbsp;Laub served
in multiple capacities at Physio-Control, Inc. from 2003 to 2019, including most recently as their Vice President and General Manager, Commercial Operations and ProCare, from 2018 to 2019. Mr.&nbsp;Laub is also a retired Naval Officer. Mr.&nbsp;Laub
received his B.S. in Business Management from the University of Phoenix and his M.B.A. from Washington State University. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B><I>Debra
Schotz </I></B>is our Senior Vice President of Marketing. Ms.&nbsp;Schotz has served in this role at Kestra Medical Technologies, Ltd. since 2023. Since 2022, Ms.&nbsp;Schotz has been the vice chairman of the board of directors Swedish Hospital
(part of Endeavor Health) and was a member of the board of directors of Swedish Hospital from 2017 to 2022. From 2022 to 2023, Ms.&nbsp;Schotz was the chief operating officer of Musculo, a post-seed startup. Prior to that, Ms.&nbsp;Schotz was a Vice
President and General Manager at Baxter International Inc. from 2021 to 2022. From 2018 to 2021, Ms.&nbsp;Schotz held various roles at <FONT STYLE="white-space:nowrap">Hill-Rom</FONT> Holdings, Inc (&#147;Hillrom&#148;), including as Vice President
of global marketing and business development from 2020 to 2021 and as Vice President of global marketing for patient support systems from 2018 to 2020. Ms.&nbsp;Schotz has over 30 years in the medical device industry, primarily in high volume
consumable and capital products, with roles in marketing, business development and general management. Ms. Schotz has extensive experience in new product development and commercialization. Ms.&nbsp;Schotz received her B.S. in Marketing from Indiana
University Bloomington and her M.B.A. from DePaul University. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">166 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Non-Executive Directors </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B><I>Jeffrey Schwartz </I></B>is a member of our Board of Directors and has served in such role since 2023. He is also the Chairman of our
Board of Directors. Mr.&nbsp;Schwartz joined Bain Capital in 2004 and is the Chief Operating Officer of Bain Capital&#146;s Global Private Equity business. Prior to his current role, Mr. Schwartz co-founded and was a partner of its Life Sciences
team from 2016-2023. Prior to that, Mr. Schwartz was a member of Bain Capital&#146;s Private Equity team from 2004 to 2016, where he focused on healthcare investments. Mr.&nbsp;Schwartz previously served as an equity research analyst at Lehman
Brothers, where he was focused on the aerospace and defense industries working in both New York and London. Mr.&nbsp;Schwartz has over 20 years of investing experience. Mr.&nbsp;Schwartz currently serves on the board of directors of Rapid Micro
Biosystems, Inc. (Nasdaq: RPID). Mr.&nbsp;Schwartz previously served on the board of directors of BCLS Acquisition Corp. (a special purpose acquisition company) and SpringWorks Therapeutics, Inc. (Nasdaq: SWTX). Mr.&nbsp;Schwartz graduated from Yale
University where he majored in economics and received his M.B.A. from The Wharton School at the University of Pennsylvania, where he was a Palmer Scholar. We believe Mr.&nbsp;Schwartz is qualified to serve on our Board of Directors based on his
experience in advising and supporting the growth and development of companies in the healthcare industry. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B><I>Toby AuWerter
</I></B>is a member of the Board of Directors of our subsidiary, Kestra Medical Technologies, Inc., and has served in such role since 2022. Mr. AuWerter has been a member of our Board of Directors since 2025. Mr. AuWerter has been an investment
director of Endeavour Vision since 2020. Mr. AuWerter focuses on medical technology and digital health and has more than fifteen years of experience working with medical technology companies across corporate, commercial, and research and development
strategy. Previously, Mr. AuWerter served as an engagement manager at McKinsey &amp; Company from 2017 to 2020 specializing in therapeutic areas including cardiovascular products. Mr. AuWerter currently serves on the board of directors of Nalu
Medical, Inc and is a board observer at Healthjoy, LLC. Mr. AuWerter received his BSE in Biomedical Engineering from Duke University and his M.B.A. in Health Care Management from The Wharton School at the University of Pennsylvania. We believe Mr.
AuWerter is qualified to serve on our Board of Directors based on his extensive experience working with medical technologies companies and experience as a director of a number of healthcare companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B><I>Maxwell Bikoff </I></B>is a member of the Board of Directors of our subsidiary, Kestra Medical Technologies, Inc., and has served in
such role since 2024. Mr. Bikoff has been a member of our Board of Directors since 2025. Mr. Bikoff is a managing director at Longitude Capital, which he joined in 2016. Mr. Bikoff currently serves on the board of Polares Medical and is a board
observer at Bolt Medical and FIRE1. Mr. Bikoff previously served as a board observer at Amphora (which has since been acquired), Ceribell (Nasdaq: CBLL), Eargo (Nasdaq: EAR), Endogenex, LimFlow (which has since been acquired), Nalu Medical, and
RxSight (Nasdaq: RXST), and was also actively involved in Longitude Capital&#146;s investments in Axonics Modulation Technologies (Nasdaq: AXNX) and PROCEPT BioRobotics (Nasdaq: PRCT). Mr. Bikoff held a series of strategy, finance, and operating
roles at Cardinal Health from 2010 to 2016, including director of Marketing, North America for a portfolio of cardiovascular devices from 2014 to 2016. Mr. Bikoff began his career in Deloitte Consulting&#146;s Life Sciences Strategy practice and
holds a BSE in Biomedical Engineering from Duke University. We believe Mr.&nbsp;Bikoff is qualified to serve on our Board of Directors based on his background in biomedical engineering and prior experience as a director of a number of healthcare
companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B><I>Raymond W. Cohen </I></B>is a member of the Board of Directors of our subsidiary, Kestra Medical Technologies, Inc., and
has served in such role since 2024. Mr. Cohen has been a member of our Board of Directors since 2025. Prior to joining the Company, from 2013 to 2024, Mr.&nbsp;Cohen served as the Chief Executive Officer and a member of the board of directors of
Axonics, Inc. (Nasdaq: AXNX), a medical device company with implantable technologies to treat bladder and bowel disorders. Mr.&nbsp;Cohen currently serves as a venture advisor to&nbsp;Andera Partners and serves as the chairman of the board of
directors of SoniVie Ltd. Previously, Mr.&nbsp;Cohen served as chairman of BioLife Solutions Inc. (Nasdaq: BLFS) and BiVACOR, Inc., and served on the board of directors of Spectrum Pharmaceuticals Inc. (Nasdaq: SPPI) and Axonics, Inc. (Nasdaq:
AXNX). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">167 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Mr.&nbsp;Cohen received his B.S. in Business Management from Binghamton University. We believe Mr.&nbsp;Cohen is qualified to serve on our Board of Directors based on his management experience of
a medical device company and prior experience as a director of a number of healthcare companies. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B><I>Christopher Gordon </I></B>is
a member of our Board of Directors and has served in such role since 2016. Mr.&nbsp;Gordon <FONT STYLE="white-space:nowrap">co-heads</FONT> Bain Capital Private Equity&#146;s Global and North American private equity businesses and leads Bain Capital
Private Equity&#146;s healthcare team. Mr.&nbsp;Gordon has been actively involved in and served on the boards of a wide spectrum of healthcare companies in which the firm has made investments in and currently serves on the board of directors of
Aveanna Healthcare Holdings Inc. (Nasdaq: AVAH). Mr.&nbsp;Gordon previously served on the board of directors of Cerevel Therapeutics Holdings, Inc. (Nasdaq: CERE), Grupo NotreDame Interm&eacute;dica, Surgery Partners, Inc. (Nasdaq: SGRY), IQVIA
Holdings Inc. f/k/a Quintiles Transnational Holdings Inc. (NYSE: IQV), HCA Healthcare, Inc. (NYSE: HCA), and Acadia Healthcare Company, Inc. (Nasdaq: ACHC). Mr.&nbsp;Gordon is also a founding director of the Healthcare Private Equity Association.
Mr.&nbsp;Gordon received his A.B. in Economics from Harvard College and his M.B.A. from Harvard Business School where he was a Baker Scholar. We believe Mr.&nbsp;Gordon is qualified to serve on our Board of Directors based on his expertise and prior
experience as a director of a number of healthcare companies. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B><I>Mary Kay Ladone </I></B>is a member of the Board of Directors of
our subsidiary, Kestra Medical Technologies, Inc., and has served in such role since 2022. Ms. Ladone has been a member of our Board of Directors since 2025. Ms.&nbsp;Ladone previously served as senior vice president of corporate development,
strategy and investor relations at <FONT STYLE="white-space:nowrap">Hill-Rom</FONT> Holdings, Inc. from 2018 to 2022, and vice president of investor relations at Hillrom from 2016 to 2018. Prior to Hillrom, Ms. Ladone served as senior vice president
and corporate officer, investor relations of Baxalta, Inc., a global biopharmaceutical company, from 2015 to 2016. Ms. Ladone began her career in finance at Baxter International, Inc., and served in several progressive financial, operational and
communication roles at Baxter International, Inc. from 1988 to 2015. Ms.&nbsp;Ladone currently serves on the board of directors of Novanta Inc., Bioventus LLC and Inogen, Inc. Ms.&nbsp;Ladone is an accomplished executive with over 30 years of
experience serving large global healthcare companies. Ms.&nbsp;Ladone received her B.B.A. degree in Finance and Business Economics, cum laude, from the University of Notre Dame. We believe Ms.&nbsp;Ladone is qualified to serve on our Board of
Directors based on her extensive experience working with large global healthcare companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B><I>Kevin Reilly </I></B>is a member of the
Board of Directors of our subsidiary, Kestra Medical Technologies, Inc., and has served in such role since 2024. Mr. Reilly has been a member of our Board of Directors since 2025. Mr. Reilly joined Ally Bridge Group in 2021 and since 2021, has been
a managing director and head of medtech for the private equity strategy focused on transactions across healthcare subsectors. Before joining Ally Bridge Group, from 2014 to 2021, Mr. Reilly was a principal at CRG, a healthcare investment management
firm providing growth capital to companies through the form of long-term debt and equity. Mr. Reilly began his career in the Healthcare Investment Banking Group at Stifel. Mr. Reilly holds a B.S. in Finance and Information Systems from the
University of Maryland. We believe Mr. Reilly is qualified to serve on our Board of Directors based on his experience investing in healthcare companies and prior experience as a director of a number of healthcare companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Composition and Director Independence </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our business and affairs are managed under the direction of our Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Following the completion of this offering, our Board of Directors will be composed of&nbsp;nine directors. In accordance with our amended and
restated <FONT STYLE="white-space:nowrap">bye-laws</FONT> to be in effect upon the closing of this offering, prior to the Triggering Annual Meeting, our directors will be divided into three classes serving staggered three-year terms. Prior to the
Triggering Annual Meeting, at each annual meeting of shareholders, our directors will be elected to succeed the class of directors whose terms have expired. From and after the Triggering Annual Meeting, our Board of Directors will be declassified
and our directors will be elected to hold office for a one-year term </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">168 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
expiring at the next annual general meeting of shareholders. Our current board of directors will be divided among the three classes as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Class&nbsp;I directors will consist of Christopher Gordon, Toby AuWerter and Maxwell Bikoff, and their terms
will expire at the first annual general meeting of shareholders occurring after this offering; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Class&nbsp;II directors will consist of Raymond W. Cohen, Kevin Reilly and Traci S. Umberger, and their terms
will expire at the second annual general meeting of shareholders occurring after this offering; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Class&nbsp;III directors will consist of Mary Kay Ladone, Brian Webster and Jeffrey Schwartz, and their terms
will expire at the third annual general meeting of shareholders occurring after this offering. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Directors in a
particular class will be elected for three-year terms at the annual general meeting of shareholders in the year in which their terms expire. As a result, prior to the Triggering Annual Meeting, only one class of directors will be elected at each
annual general meeting of our shareholders, with the other classes continuing for the remainder of their respective three-year terms. Each director&#146;s term continues until the election and qualification of his or her successor, or his or her
earlier death, resignation, retirement, disqualification or removal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The classification of our Board of Directors prior to the Triggering
Annual Meeting, together with the ability of the shareholders to remove our directors only for cause from and after the Trigger Event and the limitations on our shareholders&#146; ability to call special general meetings, may have the effect of
delaying or preventing a change of control or management. See the section titled &#147;Description of Share Capital&#151;Anti-Takeover Provisions&#148; for a discussion of other anti-takeover provisions that are included in our memorandum of
association and amended and restated <FONT STYLE="white-space:nowrap">bye-laws</FONT> to be in effect upon the closing of this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In connection with this offering, our Board of Directors has undertaken a review of the independence of each director. As a result of this
review, our Board of Directors determined that Jeffrey Schwartz, Christopher Gordon, Mary Kay Ladone, Raymond W. Cohen, Maxwell Bikoff, Kevin Reilly and Toby AuWerter are &#147;independent directors&#148; as defined under the applicable rules and
regulations of the SEC and the listing requirements and rules of the Nasdaq Global Select Market, representing seven of our nine directors. In making these determinations, our Board of Directors reviewed and discussed information provided by the
directors and us with regard to each director&#146;s business and personal activities and current and prior relationships, including personal relationships, as they may relate to us and our management. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Family Relationships </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">There are no
family relationships between our Board of Directors and our executive officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Controlled Company Exception </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Upon the closing of this offering, an investment fund advised by affiliates of Bain Capital will own approximately 52.8% of our common shares
(or 51.2% of our outstanding common shares if the underwriters exercise in full their over-allotment option). As a result, we will be a &#147;controlled company&#148; within the meaning of the applicable listing rules of the Nasdaq Global Select
Market. Under these corporate governance standards, a company of which more than 50% of the voting power is beneficially owned by an individual, group or other company is a &#147;controlled company&#148; and may elect not to comply with certain
corporate governance standards, including the requirements (1)&nbsp;that a majority of its board of directors consist of independent directors, (2)&nbsp;that its board of directors have a compensation committee that is composed entirely of
independent directors with a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">169 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
written charter addressing the committee&#146;s purpose and responsibilities and (3)&nbsp;that its board of directors have a nominating and corporate governance committee that is composed
entirely of independent directors with a written charter addressing the committee&#146;s purpose and responsibilities. Accordingly, you will not have the same protections afforded to shareholders of companies that are subject to all of these
corporate governance requirements. In the event that we cease to be a &#147;controlled company&#148; and our common shares continues to be listed on the Nasdaq Global Select Market, we will be required to comply with these provisions within the
applicable transition periods. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">These exemptions do not modify the independence requirements for our audit committee, and we expect to
satisfy the member independence requirement for the audit committee prior to the end of the transition period provided under the Nasdaq Global Select Market&#146;s listing standards and SEC rules and regulations for companies completing their
initial public offering. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Committees </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We anticipate that, prior to the completion of this offering, our Board of Directors will establish an audit committee, a compensation
committee and a nominating and corporate governance committee. The composition and responsibilities of each committee are described below. Our Board of Directors may also establish from time to time any other committees that it deems necessary or
desirable. Members serve on these committees until their resignation or until otherwise determined by our Board of Directors. Each of the committees operates under its own written charter adopted by the Board of Directors, each of which will be
available on our website upon the completion of this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Audit Committee </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our Board of Directors will establish, effective upon the consummation of this offering, an audit committee which is responsible for, among
other matters: (1)&nbsp;appointing, compensating, retaining, evaluating, terminating and overseeing our independent registered public accounting firm; (2)&nbsp;discussing with our independent registered public accounting firm its independence from
us; (3)&nbsp;reviewing with our independent registered public accounting firm the matters required to be reviewed by applicable auditing requirements; (4)&nbsp;approving all audit and permissible <FONT STYLE="white-space:nowrap">non-audit</FONT>
services to be performed by our independent registered public accounting firm; (5)&nbsp;overseeing the financial reporting process and discussing with management and our independent registered public accounting firm the interim and annual financial
statements that we file with the SEC; (6)&nbsp;reviewing and monitoring our internal controls, disclosure controls and procedures and compliance with legal and regulatory requirements; (7)&nbsp;establishing procedures for the confidential anonymous
submission of concerns regarding questionable accounting, internal controls, auditing and federal securities law matters; and (8)&nbsp;reviewing and approving related person transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our audit committee will consist of Mary Kay Ladone, Raymond W. Cohen and Maxwell Bikoff, with Mary Kay Ladone serving as chairperson. Rule <FONT
STYLE="white-space:nowrap">10A-3</FONT> of the Exchange Act and the Nasdaq Global Select Market rules require us to have one independent audit committee member upon the listing of our common shares on the Nasdaq Global Select Market, a majority of
independent directors within 90 days of the date of listing and all independent audit committee members within one year of the date of listing. We intend to comply with the independence requirements within the time periods specified. Our Board of
Directors has determined that Mary Kay Ladone is an &#147;audit committee financial expert&#148; as defined by applicable SEC rules. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Compensation
Committee </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our Board of Directors will establish, effective upon the consummation of this offering, a compensation committee which is
responsible for, among other matters: (1)&nbsp;reviewing officer and executive compensation goals, policies, plans and programs; (2)&nbsp;reviewing and approving or recommending to our Board of Directors or the independent directors, as applicable,
the compensation of our directors, Chief Executive Officer and other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">170 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
executive officers; (3)&nbsp;reviewing and approving employment agreements and other similar arrangements between us and our officers and other key executives; and (4)&nbsp;appointing and
overseeing any compensation consultants. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our compensation committee will consist of Raymond W. Cohen, Jeffrey Schwartz and Kevin
Reilly, with Raymond W. Cohen serving as chairperson. Our Board of Directors has determined that each member of the compensation committee is independent under the Nasdaq Global Select Market listing standards and
<FONT STYLE="white-space:nowrap">a&nbsp;&#147;non-employee</FONT> director&#148; as defined in <FONT STYLE="white-space:nowrap">Rule&nbsp;16b-3&nbsp;promulgated</FONT> under the&nbsp;Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Nominating and Corporate Governance Committee </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our Board of Directors will establish, effective upon the consummation of this offering, a nominating and corporate governance committee that
is responsible for, among other matters: (1)&nbsp;identifying individuals qualified to become members of our Board of Directors, consistent with criteria approved by our Board of Directors; (2)&nbsp;overseeing the organization of our Board of
Directors to discharge the board&#146;s duties and responsibilities properly and efficiently; and (3)&nbsp;developing and recommending to our Board of Directors a set of corporate governance guidelines and principles. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our nominating and corporate governance committee will consist of Jeffrey Schwartz, Mary Kay Ladone and Toby AuWerter, with Jeffrey Schwartz
serving as chairperson. Our Board of Directors has determined that each member of the nominating and corporate governance committee is independent under the Nasdaq Global Select Market listing standards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Oversight of Risk Management </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Management is responsible for the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> management of
risks our company faces. Our full Board of Directors has ultimate oversight responsibility for the risk management process, and, through its committees, oversees risk in certain specified areas. In particular, our audit committee oversees management
of enterprise risks as well as financial risks and is responsible for overseeing the review and approval of related party transactions. Our compensation committee is responsible for overseeing the management of risks relating to our executive
compensation plans and arrangements and the incentives created by the compensation awards it administers. Our nominating and corporate governance committee oversees risks associated with corporate governance, business conduct and ethics. Pursuant to
our Board of Directors&#146; instruction, management regularly reports on applicable risks to the relevant committee or our full Board of Directors, as appropriate, with additional review or reporting on risks conducted as needed or as requested by
our Board of Directors and its committees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Code of Ethics </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our Board of Directors has adopted a code of ethics that will apply to all of our employees, officers and directors, including our executive
and senior financial officers. The full text of our code of ethics will be posted on the investor relations page of our website prior to completion of this offering. The information contained on, or accessible through, our website is not
incorporated by reference into this prospectus. We intend to disclose any amendments to our code of ethics, or waivers of its requirements, on our website or in filings under the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Compensation Committee Interlocks and Insider Participation </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">None of our executive officers has served as a member of a compensation committee (or if no committee performs that function, the board of
directors) of any other entity that has an executive officer serving as a member of our Board<B> </B>of Directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">171 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom744414_12"></A>EXECUTIVE COMPENSATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are currently considered an &#147;emerging growth company,&#148; as defined in Section&nbsp;2(a)(19) of the Securities Act, for purposes of
the SEC&#146;s executive compensation disclosure rules. In accordance with such rules, we are required to provide a Summary Compensation Table and an Outstanding Equity Awards at Fiscal Year End Table, as well as limited narrative disclosures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This section provides information about the material elements of compensation that are paid, awarded to, or earned by, our named executive
officers for fiscal year 2024 (whom we collectively refer to as our &#147;NEOs&#148;), who consist of any individual who served as our principal executive officer during fiscal year 2024, and our two most highly compensated executive officers who
were serving at the end of fiscal year 2024 other than our principal executive officer. For fiscal year 2024, our NEOs and their respective positions were: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Brian Webster, our Principal Executive Officer and President, Chief Executive Officer and Director;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Vaseem Mahboob, our Principal Financial Officer; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Traci S. Umberger, our General Counsel, Chief Administrative Officer and Director. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The objective of our executive compensation program is to provide a total compensation package to each of our NEOs that will enable us to
attract, motivate and retain outstanding individuals, align the interests of our NEOs with those of our shareholders, encourage individual and collective contributions to the successful execution of our short- and long-term business strategies and
reward our NEOs for the attainment of specified performance goals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Fiscal Year 2024 Summary Compensation Table </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table sets forth information regarding compensation earned during the fiscal year ended April&nbsp;30, 2024 by our named
executive officers. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="49%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Officer</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>FY</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Salary<BR>($)
(1)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B><FONT
STYLE="white-space:nowrap">Non-Equity</FONT><BR>Incentive Plan<BR>Compensation<BR>($) (2)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>All
Other<BR>Compensation<BR>($) (3)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Total<BR>Compensation<BR>($)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Brian Webster</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>President, Chief Executive Officer &amp; Director</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>&nbsp;</B></TD>
<TD VALIGN="top" ALIGN="right"><B>2024</B></TD>
<TD NOWRAP VALIGN="top"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">522,535</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">195,951</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">39,078</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">757,564</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Vaseem Mahboob</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Financial Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>&nbsp;</B></TD>
<TD VALIGN="top" ALIGN="right"><B>2024</B></TD>
<TD NOWRAP VALIGN="top"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">397,515</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">119,255</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">13,406</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">530,176</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Traci S. Umberger</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>General Counsel&nbsp;&amp; Chief Administrative Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>&nbsp;</B></TD>
<TD VALIGN="top" ALIGN="right"><B>2024</B></TD>
<TD NOWRAP VALIGN="top"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">364,395</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">109,319</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">24,575</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">498,289</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amounts reported represent the base salary paid to each of our named executive officers during the fiscal
year ended April&nbsp;30, 2024. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amounts in this column represent annual performance-based cash bonuses earned by our NEOs in the applicable
fiscal year and paid in the subsequent fiscal year. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amounts reflected in &#147;All Other Compensation&#148; consist of, for fiscal year 2024, the following
perquisites received by our NEOs in the amounts set forth in the following table: (a)&nbsp;a business allowance for monthly automobile use expenses, (b)&nbsp;an employer matching contribution to the 401(k) plan, (c)&nbsp;payments for the cost of
premiums for a term life insurance policy paid by us, and (d)&nbsp;an annual executive physical with a designated physician, as well as certain additional medical, cardio, and lab tests.<SUP STYLE="font-size:75%; vertical-align:top"> </SUP>
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">172 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Officer</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Business<BR>Allowance<BR>($)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>401(k)<BR>Company<BR>Match<BR>($)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Life<BR>Insurance<BR>Premiums<BR>($)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Physical<BR>Program<BR>($)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Total
&#147;All<BR>Other<BR>Compensation&#148;<BR>($)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Brian Webster</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,536</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,079</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Vaseem Mahboob</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Traci S. Umberger</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,471</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Outstanding Equity Awards Table at Fiscal 2024 Year End </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table provides information about outstanding equity awards held by each of our named executive officers as of April&nbsp;30,
2024. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="8" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Option
Awards&nbsp;(1)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Officer</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Grant<BR>Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Number
of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options (#)<BR>Exercisable&nbsp;(2)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Number
of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options (#)<BR>Unexercisable&nbsp;(2)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Equity<BR>Incentive<BR>Plan<BR>Awards:<BR>Number
of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Unearned<BR>Options&nbsp;(#)&nbsp;(2)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Brian Webster</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>10/21/14</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">132,702.19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0.00</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">132,702.19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>10/17/16</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84,855.64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0.00</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84,855.64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>3/26/18</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">173,069.79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0.00</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">173,069.79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>11/26/19</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,499.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0.00</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,499.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>12/20/20</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">284,633.54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0.00</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">284,633.54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Vaseem Mahboob</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>10/18/21</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,500.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">38,500.00</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77,000.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>11/10/22</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,850.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">11,550.00</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,400.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Traci S. Umberger</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>10/21/14</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,177.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0.00</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,177.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>10/26/16</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,157.23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0.00</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,157.23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>3/20/18</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,711.70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0.00</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,711.70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>11/26/19</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,010.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0.00</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,010.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>12/8/20</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78,728.42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0.00</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78,728.42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This table reflects information regarding incentive units granted to our named executive officers that were
outstanding as of April&nbsp;30, 2024. For more information on these incentive units, see the &#147;Equity Incentive Compensation&#148; section below. The incentive units are not traditional options, and therefore, there is no exercise price, but
rather the incentive units participate in distributions attributable to the appreciation in the fair market value of West Affum Holdings, L.P., or profits of West Affum Holdings, L.P., after their respective dates of grant. The incentive units have
no expiration date. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All incentive units granted to our named executive officers that were outstanding as of April&nbsp;30, 2024
vest based on the achievement of specified phases of the Company&#146;s development program (all of which were achieved as of July 2021), subject to continued employment through each applicable date, other than (i)&nbsp;the December 2020 grants to
Mr.&nbsp;Webster and Ms.&nbsp;Umberger, which are subject to time-based vesting and vest in three equal installments on July&nbsp;1, 2021, July&nbsp;1, 2022 and July&nbsp;1, 2023, (ii) Mr.&nbsp;Mahboob&#146;s October 2021 grant, which is subject to
time-based vesting and vests in four equal installments on each of October&nbsp;18, 2022, October&nbsp;18, 2023, October&nbsp;18, 2024 and October&nbsp;18, 2025, and (iii)&nbsp;Mr.&nbsp;Mahboob&#146;s November 2022 grant, which is subject to
time-based vesting and vests in four equal installments on each of November&nbsp;10, 2023, November&nbsp;10, 2024, November&nbsp;10, 2025 and November&nbsp;10, 2026. See &#147;Equity Incentive Compensation&#151;Incentive Units&#151;Vesting&#151;Upon
Consummation of this Offering&#148; for information regarding the vesting and conversion of these incentive units into our common shares upon the consummation of this offering. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">173 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Employment Agreements </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On October&nbsp;17, 2016, Kestra Medical Technologies, Inc. entered into an employment agreement with Mr.&nbsp;Webster to serve as the Chief
Executive Officer of Kestra Medical Technologies, Inc. and our principal executive officer. The initial term of his employment agreement expired on December&nbsp;31, 2020; however, the employment agreement provides for automatic successive <FONT
STYLE="white-space:nowrap">one-year</FONT> renewals unless either party provides 90 days&#146; prior written notice. Mr.&nbsp;Webster&#146;s employment agreement provides for an initial annual base salary of $400,000 (which is subject to review by
the Board at least annually for possible increase), as well as eligibility for Mr.&nbsp;Webster to earn an annual cash bonus with a target bonus opportunity equal to a specified percentage of base salary as described below in the <FONT
STYLE="white-space:nowrap">&#147;Non-Equity</FONT> Incentive Plan Compensation&#148; section. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On September&nbsp;10, 2021, Kestra Medical
Technologies, Inc. entered into an employment agreement with Mr.&nbsp;Mahboob to serve as the Chief Financial Officer of Kestra Medical Technologies, Inc. The initial term of his employment agreement expires on April&nbsp;30, 2025, and the
employment agreement provides for automatic successive <FONT STYLE="white-space:nowrap">one-year</FONT> renewals unless either party provides 90 days&#146; prior written notice. Mr.&nbsp;Mahboob&#146;s employment agreement provides for an initial
annual base salary of $375,000 (which is subject to review by the Board at least annually for possible increase), as well as eligibility for Mr.&nbsp;Mahboob to earn an annual cash bonus with a target bonus opportunity equal to a specified
percentage of base salary as described below in the <FONT STYLE="white-space:nowrap">&#147;Non-Equity</FONT> Incentive Plan Compensation&#148; section. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On October&nbsp;26, 2016, Kestra Medical Technologies, Inc. entered into an employment agreement with Ms.&nbsp;Umberger to serve as the
General Counsel, Chief Administrative Officer of Kestra Medical Technologies, Inc. The initial term of her employment agreement expired on December&nbsp;31, 2020; however, the employment agreement provides for automatic successive <FONT
STYLE="white-space:nowrap">one-year</FONT> renewals unless either party provides 90 days&#146; prior written notice. Ms.&nbsp;Umberger&#146;s employment agreement provides for an initial annual base salary of $260,000 (which is subject to review by
the Board at least annually for possible increase), as well as eligibility for Ms.&nbsp;Umberger to earn a target bonus opportunity equal to a specified percentage of base salary as described below in the
<FONT STYLE="white-space:nowrap">&#147;Non-Equity</FONT> Incentive Plan Compensation&#148; section. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Upon a termination due to death or
disability Mr.&nbsp;Webster, Mr.&nbsp;Mahboob, and Ms.&nbsp;Umberger are entitled to receive a pro rata portion of their respective annual cash bonus for the calendar year of termination, based on actual achievement. Upon a termination by Kestra
Medical Technologies, Inc. without Cause, resignation by the NEO for Good Reason (each as defined in the employment agreement), or <FONT STYLE="white-space:nowrap">non-renewal</FONT> of the employment agreement term by Kestra Medical Technologies,
Inc., subject to the NEO&#146;s timely execution and <FONT STYLE="white-space:nowrap">non-revocation</FONT> of a release of claims in Kestra Medical Technologies, Inc.&#146;s favor and their continued compliance with the restrictive covenants set
forth in the employment agreement (as described below), Mr.&nbsp;Webster, Mr.&nbsp;Mahboob, and Ms.&nbsp;Umberger respectively are entitled to receive (i)&nbsp;a cash payment equal to two times (or for Mr.&nbsp;Mahboob, one times) the sum of their
respective current (x)&nbsp;base salary and (y)&nbsp;target bonus, payable in equal monthly installments for a period of 12 months following termination, and (ii)&nbsp;continued participation in Kestra Medical Technologies, Inc.&#146;s group health
plan for 12 months (or for Mr.&nbsp;Mahboob, six months) following termination. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Each NEO&#146;s employment agreement provides for
the following restrictive covenants: <FONT STYLE="white-space:nowrap">(i)&nbsp;non-competition,</FONT> and <FONT STYLE="white-space:nowrap">non-solicitation</FONT> and <FONT STYLE="white-space:nowrap">non-hire</FONT> of employees (and for
Mr.&nbsp;Webster and Ms.&nbsp;Umberger only, or service providers), in each case, during employment and for two years following termination (except for Mr.&nbsp;Mahboob, who has only one year), (ii)&nbsp;perpetual mutual <FONT
STYLE="white-space:nowrap">non-disparagement,</FONT> (iii)&nbsp;perpetual <FONT STYLE="white-space:nowrap">non-disclosure</FONT> of confidential information, and (iv)&nbsp;assignment of intellectual property. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Benefit Plans and Policies </B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Each of
the NEOs participates in the Kestra Medical Technologies, Inc.&#146;s Executive Benefits Policy, which provides for a matching employer contribution under the Company&#146;s 401(k) plan, and medical, vision, dental, life and accidental death and
dismemberment insurance, disability and a flexible savings account. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">174 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-Equity</FONT> Incentive Plan Compensation </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Webster, Mr.&nbsp;Mahboob, and Ms.&nbsp;Umberger are each eligible to receive an annual cash bonus during each fiscal year, with a
target annual bonus opportunity equal to 50%, 40% and 40% of the annual base salary, respectively. The performance goals for all Kestra Medical Technologies, Ltd. employees (including our NEOs) are defined for each quarter, based on the performance
of the overall company (and the applicable division of the company) and the applicable individual. Any annual bonus payable to Mr.&nbsp;Webster, Mr.&nbsp;Mahboob, and Ms.&nbsp;Umberger are paid following completion of the fiscal year to which
performance relates, subject to the Board of Directors&#146; determination of achievement of the applicable performance goals. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Equity Incentive
Compensation </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Incentive Units </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">West Affum Holdings, L.P. has granted incentive units to certain employees and service providers of Kestra Medical Technologies, Ltd.&#146;s,
which are governed by the terms of the individual award agreement documenting the grant and the Partnership Agreement. The incentive units are intended to qualify as &#147;profits interests&#148; for federal income tax purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Vesting </I></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Unless otherwise provided
in an individual award agreement, grants of incentive units (in the form of Restricted Common Units) vest either based on the achievement of specified performance goals or based on service. The performance-based incentive units generally vest based
on the achievement of specified phases of Kestra Medical Technologies, Ltd.&#146;s development program, subject to continued employment through each applicable date. The time-based incentive units generally vest 25% on the first four anniversaries
of the applicable grant date, subject to continued employment through each such date, other than the time-based incentive units for Mr.&nbsp;Webster and Ms.&nbsp;Umberger which vested in three equal installments on July&nbsp;1, 2021, July&nbsp;1,
2022, and July&nbsp;1, 2023. Further information with respect to our named executive officers&#146; equity awards is set forth above in the Outstanding Equity Awards Table. All unvested incentive units accelerate and vest upon the occurrence of a
Sale of the Partnership (as defined in the Partnership Agreement). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Upon Consummation of this Offering </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Upon the consummation of this offering, the Board will accelerate the unvested incentive units of each participant and all vested incentive
units will then be converted into shares of our common stock, which conversion will be based on the <FONT STYLE="white-space:nowrap">per-share</FONT> price to the public in this offering. For more information, see the section titled
&#147;Organizational Transactions.&#148; </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Restrictive Covenants </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Incentive unit holders are generally subject to the following restrictive covenants, which are included in the applicable award agreement, <FONT
STYLE="white-space:nowrap">(i)&nbsp;non-competition,</FONT> and <FONT STYLE="white-space:nowrap">non-solicitation</FONT> and <FONT STYLE="white-space:nowrap">non-hire</FONT> of employees or service providers, in each case, during employment and for
one year following termination, (ii)&nbsp;perpetual mutual <FONT STYLE="white-space:nowrap">non-disparagement,</FONT> (iii)&nbsp;perpetual <FONT STYLE="white-space:nowrap">non-disclosure</FONT> of confidential information and (iv)&nbsp;assignment of
intellectual property. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Compensation Programs Following This Offering </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In connection with the consummation of this offering, the Board has adopted, and our shareholders have approved, the 2025 Omnibus Incentive
Plan (the &#147;2025 Plan&#148;), pursuant to which employees, consultants and directors of our company and our affiliates performing services for us, including our executive officers, will be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">175 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
eligible to receive awards. The 2025 Plan provides for the grant of share options, share appreciation rights, restricted shares, restricted share units, bonus shares, dividend equivalents, other
share-based awards, substitute awards, annual incentive awards and performance awards intended to align the interests of participants with those of our shareholders. The following description of the 2025 Plan is qualified in its entirety by
reference to the 2025 Plan, a copy of which in substantially final form is filed as an exhibit to the registration statement of which this prospectus is a part. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Summary of the 2025 Omnibus Incentive Plan </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Share Reserve </I></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In connection with
its approval by the Board and adoption by our shareholders, we have reserved common shares for issuance under the 2025 Plan. In addition, the following common shares will again be available for grant or issuance under the 2025 Plan: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">shares subject to awards granted under the 2025 Plan that are subsequently forfeited or cancelled;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">shares subject to awards granted under the 2025 Plan that otherwise terminate without shares being issued;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">shares surrendered, cancelled or exchanged for cash; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">shares surrendered to pay the exercise price or withholding taxes associated with the award.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Administration </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The 2025 Plan will be administered by our Compensation Committee. The Compensation Committee has the authority to construe and interpret the
2025 Plan, grant awards and make all other determinations necessary or advisable for the administration of the 2025 Plan. Awards under the 2025 Plan may be made subject to &#147;performance conditions&#148; and other terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Eligibility </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our employees, consultants
and directors, and the employees, consultants and directors of our affiliates, will be eligible to receive awards under the 2025 Plan. The Compensation Committee will determine who will receive awards and the terms and conditions associated with
such awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Term </I></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The 2025
Plan will terminate 10 years from the date our Board approved the plan, unless it is terminated earlier by our Board. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Award Forms and Limitations
</I></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The 2025 Plan authorizes the award of share awards, performance awards and other cash-based awards. An aggregate of 12,680,000
common shares (which number of common shares will be subject to adjustment depending on the number of shares offered in this offering) are expected to be available for issuance under awards granted pursuant to the 2025 Plan. For share options that
are intended to qualify as incentive stock options (&#147;ISOs&#148;) under Section&nbsp;422 of the Code, the maximum number of shares subject to ISO awards is expected to be 12,680,000 common shares (which number of common shares will be subject to
adjustment depending on the number of shares offered in this offering). </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Share Options </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The 2025 Plan provides for the grant of ISOs only to our employees. Nonqualified stock options may be granted to our employees, directors and
consultants. The exercise price of each option to purchase ordinary </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">176 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
shares must be at least equal to the fair market value of our common shares on the date of grant. The exercise price of ISOs granted to 10% or more shareholders must be at least equal to 110% of
that value. Options granted under the 2025 Plan may be exercisable at such times and subject to such terms and conditions as the Compensation Committee determines. The maximum term of options granted under the 2025 Plan is 10 years (five years in
the case of ISOs granted to 10% or more shareholders). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Share Appreciation Rights </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Share appreciation rights provide for a payment, or payments, in cash or common shares, to the holder based upon the difference between the
fair market value of our common shares on the date of exercise and the stated exercise price of the share appreciation right. The exercise price must be at least equal to the fair market value of our common shares on the date the share appreciation
right is granted. Share appreciation rights may vest based on time or achievement of performance conditions, as determined by the Compensation Committee in its discretion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Restricted Shares </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Compensation
Committee may grant awards consisting of common shares subject to restrictions on sale and transfer. The price (if any) paid by a participant for a restricted share award will be determined by the Compensation Committee. Unless otherwise determined
by the Compensation Committee at the time of award, vesting will cease on the date the participant no longer provides services to us and unvested shares will be forfeited to or repurchased by us. The Compensation Committee may condition the grant or
vesting of restricted shares on the achievement of performance conditions and/or the satisfaction of a time-based vesting schedule. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Performance Awards
</I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A performance award is an award that becomes payable upon the attainment of specific performance goals. A performance award may
become payable in cash or in common shares. These awards are subject to forfeiture prior to settlement due to termination of a participant&#146;s employment or failure to achieve the performance conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Other Cash-Based Awards </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The
Compensation Committee may grant other cash-based awards to participants in amounts and on terms and conditions determined by them in their discretion. Cash-based awards may be granted subject to vesting conditions or awarded without being subject
to conditions or restrictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Additional Provisions </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Awards granted under the 2025 Plan may not be transferred in any manner other than by will or by the laws of descent and distribution, or as
determined by the Compensation Committee. Unless otherwise restricted by our Compensation Committee, awards that are <FONT STYLE="white-space:nowrap">non-ISOs</FONT> or SARs may be exercised during the lifetime of the participant only by the
participant, the participant&#146;s guardian or legal representative or a family member of the participant who has acquired the <FONT STYLE="white-space:nowrap">non-ISOs</FONT> or SARs by a permitted transfer. Awards that are ISOs may be exercised
during the lifetime of the participant only by the participant or the participant&#146;s guardian or legal representative. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the event
of a change of control (as defined in the 2025 Plan), the Compensation Committee may, in its discretion, provide for any or all of the following actions: (i)&nbsp;awards may be continued, assumed or substituted with new rights, (ii)&nbsp;awards may
be purchased for cash equal to the excess (if any) of the price per common share paid in the change in control transaction over the aggregate exercise price of such awards, (iii)&nbsp;outstanding and unexercised share options and share appreciation
rights may be terminated prior to the change in control (in which case holders of such unvested awards would be given notice and the opportunity to exercise such awards), or (iv)&nbsp;vesting or lapse of restrictions may be accelerated. All awards
will be equitably adjusted in the case of the division of shares and similar transactions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">177 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Grants in Connection with This Offering </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Upon the pricing of this offering, our Board of Directors expects to make a <FONT STYLE="white-space:nowrap">one-time</FONT> grant of stock
options to our NEOs and certain other employees. The options granted will typically vest over two years, with an initial one-year cliff and monthly vesting thereafter, except that sixty percent of the options granted to our Chief Executive Officer
and to our General Counsel and Chief Administrative Officer will be fully vested upon grant, in each case generally subject to the holder&#146;s continued employment through the applicable vesting date and the terms and conditions of the relevant
award agreement. Each stock option granted as of the pricing of this offering will have an exercise price equal to the initial public offering price in this offering. The number of options to be granted is as follows, assuming the initial public
offering price is $15.00, the midpoint of the price range on the cover of this prospectus. Because the number of options to be granted in connection with this offering will be determined by reference to the initial public offering price, a change in
the initial public offering price would have a corresponding impact on the number of options granted. A $1.00 increase in the assumed initial public offering price of $15.00 per common share, which is the midpoint of the price range set forth on the
cover page of this prospectus, will result in the number of options to be granted in connection with this offering being decreased by 101,177 options. A $1.00 decrease in the assumed initial public offering price of $15.00 per common share, which is
the midpoint of the price range set forth on the cover page of this prospectus, will result in the number of options to be granted in connection with this offering being increased by 75,424 options. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="55.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="63%"></TD>

<TD VALIGN="bottom" WIDTH="20%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Option Recipient</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Number&nbsp;of&nbsp;Stock&nbsp;Options</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Brian Webster</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,796,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vaseem Mahboob</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">161,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Traci Umberger</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">546,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Al Ford</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">133,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other employees in the aggregate</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,091,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Changes to Employment Agreements in Connection with This Offering </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Upon the consummation of this offering, we will increase the base salary of our NEOs. Each of our NEOs&#146; base salary will be increased as
follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="55.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="27%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Named Executive Officer</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Base&nbsp;Salary&nbsp;Upon&nbsp;Offering</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Brian Webster</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">765,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vaseem Mahboob</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">470,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Traci Umberger</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Compensation </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">None of the Company&#146;s <FONT STYLE="white-space:nowrap">non-employee</FONT> directors (which included Mr. Gordon, Mr. Schwartz, Ms. Mishan
and Mr. Chilazi) received compensation in respect of their service on the Board for fiscal year 2024. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Following the 2024 fiscal year in
November 2024, Ms.&nbsp;Mishan entered into an individual director compensation agreement under which she is entitled to receive (i)&nbsp;a $40,000 annual cash retainer for her service as a member of the Board, and (ii)&nbsp;an initial grant of
10,224.95 incentive units (in the form of Class&nbsp;A Common Units) intended to qualify as &#147;profits interests&#148; for federal income tax purposes. This award also vests in three equal installments on the three anniversaries following the
date of grant, subject to Ms.&nbsp;Mishan&#146;s continued service through each applicable vesting date. All unvested incentive units subject to the award accelerate and vest upon the occurrence of a Sale of the Partnership (as defined in the
Partnership Agreement). The director compensation agreement also subjects Ms. Mishan to the following restrictive covenants: (i)&nbsp;non-competition (for the longer of (a)&nbsp;12 months or (b)&nbsp;through such period that severance is being paid
by West Affum Holdings, L.P. or its affiliates to the director); (ii)&nbsp;non-solicitation and non-hire of employees or service providers of West Affum Holdings, L.P., in each case, while the director is providing services and for one year
following </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">178 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
termination; (iii)&nbsp;perpetual non-disparagement; and (iv)&nbsp;perpetual non-disclosure of confidential information. Ms.&nbsp;Mishan resigned from the Board on February&nbsp;10, 2025. </P>
  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Director Compensation Table </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As discussed above, we did not have any nonemployee directors who received compensation for their service on our board of directors and
committees of our board of directors during 2024. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="55.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Fees&nbsp;earned&nbsp;or<BR>paid
in cash<BR>($)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Total<BR>($)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christopher Gordon</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jeffrey Schwartz</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Orly Mishan (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">JP Chilazi (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Ms.&nbsp;Mishan resigned from the Board on February&nbsp;10, 2025 and Mr.&nbsp;Chilazi resigned from the Board
on February&nbsp;4, 2025. </P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In connection with the consummation of the offering, the Board has approved a director
compensation policy for non-employee directors and executive directors of the company. Under the policy, the non-executive chair of the Board will receive an annual retainer in the amount of $120,000, each other non-employee director will receive an
annual retainer of $60,000 and each executive director will receive an annual retainer of $50,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition to annual fees,
non-employee directors serving on standing committees of the Board will be paid as follows: an additional $12,000 for Audit Committee members (or $25,000 for the Chair of the Audit Committee); an additional $9,000 for Compensation Committee members
(or $18,000 for the Chair of the Compensation Committee); and an additional $6,000 for Governance Committee members (or $12,000 for the Chair of the Governance Committee). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition to the fees above, each non-employee director who (i) serves on the Board as of the date of the annual meeting of the stockholders
and (ii) will continue to serve as a non-employee director immediately following such annual meeting will receive annual grant of restricted stock units pursuant to the 2025 Plan with a grant date value equal to $185,000 with one-year cliff vesting.
Upon a termination of a non-employee director&#146;s service on the Board for any reason, all unvested RSUs will be forfeited. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our
directors will be reimbursed for travel, food, lodging and other expenses directly related to their activities as directors. Our directors are also entitled to the protection provided by the indemnification provisions in our amended and restated
bye-laws to be in effect upon the closing of this offering. Our board of directors may revise the compensation arrangements for our directors from time to time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">179 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom744414_13"></A>CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Certain agreements described in this section, or forms of such agreements as they will be in effect at the time of this offering, are filed
as exhibits to the registration statement of which this prospectus forms a part, and the following descriptions are qualified by reference thereto. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following is a description of transactions, other than compensation arrangements, since May&nbsp;1, 2022 to which we have been a
participant or will be a participant and in which (1)&nbsp;the amount involved exceeded or will exceed $120,000 and (2)&nbsp;any of our directors, executive officers or holders of more than 5% of our share capital, or any members of their immediate
family, had or will have a direct or indirect material interest. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Organizational Transactions </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pursuant to the Organizational Transactions, West Affum Holdings, L.P. will deliver our common shares to existing holders of Class&nbsp;A
common units and incentive units in West Affum Holdings, L.P. in exchange for such holders&#146; units as described in the section titled &#147;Organizational Transactions&#148; included elsewhere in this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights Agreement </B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In
connection with this offering, West Affum Holdings, L.P. intends to assign, and we intend to assume, all rights and obligations of West Affum Holdings, L.P. under a registration rights agreement (the &#147;Registration Rights Agreement&#148;) with
certain of our beneficial shareholders, including Bain Charger. The Registration Rights Agreement provides such shareholders certain rights with respect to the registration of our common shares under the Securities Act that may be exercised at any
time following this offering and the expiration of any related lock-up period. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain Relationships </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Affiliates of Bain Capital have ownership interests in a broad range of companies. From time to time, we collaborate with Bain Capital and/or
its affiliates to source and outsource certain goods and services and enter into other commercial transactions in the ordinary course of our business. We believe that all such arrangements have been entered into in the ordinary course of business
and have been negotiated on commercially reasonable terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Indemnification Agreements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In connection with this offering, we will enter into indemnification agreements with each of our directors and executive officers, among
others. These indemnification agreements will provide the directors and executive officers with contractual rights to indemnification to the fullest extent permitted by applicable law, subject to certain exceptions and procedures. See the section
titled &#147;Description of Share Capital&#151;Indemnification of Directors and Officers&#148; for additional information regarding indemnification under Bermuda law and our amended and restated <FONT STYLE="white-space:nowrap">bye-laws</FONT> to be
in effect upon the closing of this offering. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Reserved Share Program </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">At our request, the underwriters have reserved up to&nbsp;5% of the common shares offered hereby, for sale at the initial public offering
price to our officers, directors, team members and certain of their friends or family. See &#147;Underwriting&#151;Reserved Shares.&#148; </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Related
Party Transactions Policy </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our Board of Directors will adopt a policy, effective upon the completion of this offering, that our
executive officers, directors, nominees for election as a director, beneficial owners of more than 5% of any class </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">180 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of our common shares and any members of the immediate family of any of the foregoing persons are not permitted to enter into a related person transaction with us without the prior consent of our
audit committee. Any request for us to enter into a transaction with an executive officer, director, nominee for election as a director, beneficial owner of more than 5% of any class of our common shares or any member of the immediate family of any
of the foregoing persons in which the amount involved exceeds $120,000 and such person would have a direct or indirect interest must first be presented to our audit committee for review, consideration and approval. In approving or rejecting any such
proposal, our audit committee is to consider the material facts of the transaction, including, but not limited to, whether the transaction is on terms no less favorable than terms generally available to an unaffiliated third party under the same or
similar circumstances and the extent of the related person&#146;s interest in the transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We did not have a formal review and
approval policy for related party transactions at the time of any of the transactions described above. However, all of the transactions described above were entered into after presentation, consideration and approval by our Board of Directors and/or
our audit committee. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">181 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom744414_14"></A>PRINCIPAL SHAREHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The following table sets forth the beneficial ownership of our common shares as of October 31, 2024, and as adjusted to reflect the sale of
common shares offered by us in this offering, by: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each person, or group of affiliated persons, who is known by us to beneficially own more than 5% of our common
shares; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of our named executive officers; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of our current directors; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all of our executive officers and directors as a group. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Information regarding shares beneficially owned before this offering is based on the partnership interests in West Affum Holdings, L.P. held
by the persons named herein immediately before this offering and gives pro forma effect to the Organizational Transactions (assuming an initial public offering price of $15.00 per common share, which is the midpoint of the price range set forth on
the cover page of this prospectus) and the effectiveness of our amended and restated <FONT STYLE="white-space:nowrap">bye-laws</FONT> to be in effect upon the closing of this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The percentage ownership information before the offering is based upon 37,651,467 common shares issued as of October 31, 2024, after giving
pro forma effect to the Organizational Transactions (assuming an initial public offering price of $15.00 per common share, which is the midpoint of the price range set forth on the cover page of this prospectus) and the effectiveness of our amended
and restated <FONT STYLE="white-space:nowrap">bye-laws</FONT> to be in effect upon the closing of this offering. Each shareholder&#146;s percentage ownership after the offering is based on common shares issued immediately after the completion of
this offering. We have also granted the underwriters an over-allotment option to purchase up to 1,500,000 additional common shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have determined beneficial ownership in accordance with the rules of the SEC. These rules generally provide that a person is the beneficial
owner of securities if such person has or shares the power to vote or direct the voting thereof, or to dispose or direct the disposition thereof or has the right to acquire such powers within 60 days. Common shares subject to options that are
currently exercisable or exercisable within 60 days of October 31, 2024 are deemed to be outstanding and beneficially owned by the person holding the options. These shares, however, are not deemed outstanding for the purposes of computing the
percentage ownership of any other person. Except as disclosed in the footnotes to this table and subject to applicable community property laws, we believe that each shareholder identified in the table possesses sole voting and investment power over
all common shares shown as beneficially owned by the shareholder. Additionally, the table below assumes no purchase of our common shares by the beneficial owners identified therein through our reserved shares program. If any shares are purchased by
these persons or entities, the number and percentage of shares of our common shares beneficially owned by them after this offering will differ from the amounts set forth in the table below. See &#147;Underwriting&#151;Reserved Shares.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">182 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Except as otherwise noted below, the address for persons or entities listed in the table is
c/o Kestra Medical Technologies, Ltd., 3933 Lake Washington Blvd NE, Suite 200, Kirkland, Washington 98033. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>SHARES</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>BENEFICIALLY</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>OWNED</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>BEFORE THIS</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>OFFERING</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>SHARES</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>BENEFICIALLY</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>OWNED
AFTER</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>THIS</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>OFFERING</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(WITHOUT</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>OPTION)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>SHARES</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>BENEFICIALLY</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>OWNED
AFTER</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>THIS</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>OFFERING</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(WITH</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>OPTION)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>NAME OF BENEFICIAL OWNER</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>NUMBER</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>&#8195;%</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>NUMBER</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>&#8195;%</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>NUMBER</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>&#8195;%</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B></B><B><I>5% Shareholder</I></B><B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Affiliate of Bain Capital (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,180,519</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,180,519</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,180,519</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Affiliates of Endeavour Entities (2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,671,370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,671,370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,671,370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B></B><B><I>Directors and Named Executive Officers </I></B><B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Brian Webster (3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,266,621</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,266,621</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,266,621</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vaseem Mahboob (4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,484</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,484</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,484</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Traci S. Umberger (5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">391,410</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">391,410</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">391,410</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jeffrey Schwartz (6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Toby AuWerter (7)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Maxwell Bikoff (8)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Raymond W. Cohen</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christopher Gordon (9)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mary Kay Ladone (10)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,080</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,080</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,080</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kevin Reilly (11)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All executive officers and directors as a group (11&nbsp;persons)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">421,974</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">421,974</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">421,974</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents beneficial ownership of less than one percent. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 18,004,835 shares held directly by Bain Charger and 7,175,684 shares indirectly held by Bain Charger
Holdings, L.P. through West Affum Holdings, L.P., which Bain Charger is entitled to receive in connection with the Post-IPO Distribution, which final number will be calculated by reference to the liquidation value of West Affum Holdings, L.P.
immediately following this offering. Bain Capital Investors, LLC (&#147;BCI&#148;) is the general partner of Bain Charger Holdings, L.P. (&#147;Bain Entity&#148;). As a result, BCI may be deemed to exercise voting and dispositive power with respect
to the shares held by the Bain Entity. Voting and investment decisions with respect to securities held by the Bain Entity are made by the partners of BCI, of whom there are three or more and none of whom individually has the power to direct such
decisions. The address of BCI and the Bain Entity is c/o Bain Capital Private Equity, LP, 200 Clarendon Street, Boston, Massachusetts 02116. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 1,643,075 shares held directly by Endeavour Medtech Growth II LP and 981,064 shares indirectly held by
Endeavour Medtech Growth II LP through West Affum Holdings, L.P., which Endeavour Medtech Growth II LP is entitled to receive in connection with the Post-IPO Distribution, which final number will be calculated by reference to the liquidation value
of West Affum Holdings, L.P. immediately following this offering; and 29,572 shares held directly by Endeavour Medtech Growth II Parallel LP and 17,659 shares indirectly held by Endeavour Medtech Growth II Parallel LP through West Affum Holdings,
L.P., which Endeavour Medtech Growth II Parallel LP is entitled to receive in connection with the Post-IPO Distribution based on the liquidation value of West Affum Holdings, L.P. immediately following this offering. Endeavour Medtech II GP Limited
is the general partner of Endeavour Medtech Growth II LP and Endeavour Medtech Growth II Parallel LP (collectively, the &#147;Endeavour Entities&#148;). As a result, Endeavour Medtech GP Limited may be deemed to exercise voting and dispositive power
with respect to the shares held by Endeavour Medtech Growth II LP and Endeavour Medtech Growth II Parallel LP. Voting and investment decisions with respect to securities held by Endeavour Medtech Growth II LP and Endeavour Medtech Growth II Parallel
LP are made by the directors of Endeavour Medtech II GP Limited, of whom </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">183 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
there are three or more and none of whom individually has the power to direct such decisions. The principal business address of the Endeavour Entities is c/o Endeavour Medtech Growth II LP, P.O.
Box 656, East Wing Trafalgar Court, Les Banques, St Peter Port, Guernesy GY1 3PP. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 157,984 shares held directly by Mr. Webster, 1,077,600 shares underlying vested options directly held
by Mr. Webster and 31,037 shares indirectly held by Mr. Webster through West Affum Holdings, L.P., which Mr. Webster is entitled to receive in connection with the Post-IPO Distribution, which final number will be calculated by reference to the
liquidation value of West Affum Holdings, L.P. immediately following this offering. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 9,124 shares held directly by Mr. Mahboob and 5,360 shares indirectly held by Mr. Mahboob, which Mr.
Mahboob is entitled to receive in connection with the Post-IPO Distribution, which final number will be calculated by reference to the liquidation value of West Affum Holdings, L.P. immediately following this offering. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 49,638 shares held directly by Ms. Umberger, 327,600 shares underlying vested options directly held by
Ms. Umberger and 14,172 shares indirectly held by Ms. Umberger, which Ms. Umberger is entitled to receive in connection with the Post-IPO Distribution, which final number will be calculated by reference to the liquidation value of West Affum
Holdings, L.P. immediately following this offering. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The address of Mr. Schwartz is c/o Bain Capital Private Equity, LP, 200 Clarendon Street, Boston, Massachusetts
02116. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The address of Mr. AuWerter is c/o Endeavour Medtech Growth II LP, P.O. Box 656, East Wing Trafalgar Court, Les
Banques, St Peter Port, Guernesy GY1 3PP. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The address of Mr. Bikoff is c/o 2740 Sand Hill Road, 2nd Floor, Menlo Park, CA 94025. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The address of Mr. Gordon is c/o Bain Capital Private Equity, LP, 200 Clarendon Street, Boston, Massachusetts
02116. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 16,080 shares indirectly held by Ms. Ladone, which Ms. Ladone is entitled to receive in connection
with the Post-IPO Distribution, which final number will be calculated by reference to the liquidation value of West Affum Holdings, L.P. immediately following this offering. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The address of Mr. Reilly is c/o 430 Park Avenue, Floor 12, New York, NY 10022. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">184 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom744414_15"></A>DESCRIPTION OF CERTAIN INDEBTEDNESS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:9.5pt; font-family:Times New Roman"><I>The following is a summary of certain provisions of the instruments evidencing our material indebtedness. This summary does not purport to
be complete and is subject to, and is qualified in its entirety by reference to, all of the provisions of the definitive documentation with respect to such indebtedness, including the definitions of certain terms therein that are not otherwise
defined in this prospectus. </I></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:9.5pt; font-family:Times New Roman">On September&nbsp;29, 2023, West Affum Holdings and Kestra Medical Technologies, Inc. (together with
West Affum Holdings, individually and collectively, jointly and severally, &#147;Borrower&#148;) entered into a credit agreement (as amended by the consent and first amendment to the credit agreement and guaranty, dated as of July&nbsp;12, 2024, and
as amended by the second amendment (the &#147;Second Amendment&#148;) to credit agreement and guaranty, dated as of February&nbsp;25, 2025, the &#147;Credit Agreement&#148;) among Perceptive Credit Holdings IV, LP, a Delaware limited partnership, as
administrative agent (in such capacity, together with its successors and assigns in such capacity, &#147;Administrative Agent&#148;), the lenders party thereto from time to time, the Borrower and each guarantor party thereto from time to time. The
Credit Agreement provides for a senior secured delayed draw term loan facility in an aggregate principal amount of up to $60.0&nbsp;million. The funding of the Term Loan is available in up to two tranches. The first tranche of $45.0&nbsp;million was
funded in September 2023. The second tranche is available through July&nbsp;31, 2026 and has not been drawn and is subject to the Company generating $60.0&nbsp;million of revenue on a 12-month trailing basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:9.5pt; font-family:Times New Roman">The Term Loan bears interest on outstanding balances of Term SOFR plus a margin of 7.25% per annum. On or prior to March&nbsp;31, 2025, up to
2.00% of the margin can be <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">paid-in-kind,</FONT></FONT> accrued and added to the principal balance and compounded quarterly. All interest is due and payable quarterly in arrears. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:9.5pt; font-family:Times New Roman">The Term Loan will mature on September&nbsp;29, 2028. The Term Loan is not subject to amortization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:9.5pt; font-family:Times New Roman">The Term Loan may be prepaid in whole or in part at any time for any reason at the option of the Borrower and is required to be mandatorily
prepaid upon certain casualty events, incurrence of <FONT STYLE="white-space:nowrap">non-permitted</FONT> indebtedness and asset sale or upon any acceleration of the Term Loan. Voluntary prepayment of the Term Loan, or mandatory prepayment of the
Term Loan resulting from the incurrence of <FONT STYLE="white-space:nowrap">non-permitted</FONT> indebtedness or asset sale, or upon acceleration of the Term Loan are subject to the payment of a prepayment premium. The prepayment premium is 10% on
or prior to September&nbsp;29, 2024, which declines to 9%, 8%, 6% and 4% every 12&nbsp;months thereafter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:9.5pt; font-family:Times New Roman">The Term Loan is guaranteed by
certain subsidiaries of the Borrower and secured by substantially all assets of the Borrower and the guarantors, subject to certain customary exceptions and limitations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:9.5pt; font-family:Times New Roman">The Term Loan includes a number of negative covenants imposing certain restrictions on our business, including, among other things,
restrictions on our ability to incur indebtedness, prepay certain indebtedness, incur liens, make certain fundamental changes including mergers or dissolutions, pay dividends and make other payments, repurchases and redemptions in respect of capital
stock, make loans and investments, sell assets, change our lines of business, enter into transactions with affiliates and certain other corporate actions. Such negative covenants are subject to customary and other agreed-upon exceptions. The Term
Loan also includes customary affirmative covenants. The Term Loan contains certain financial covenants relating to minimum liquidity and minimum revenue. Additionally, there are certain non-financial covenants. As of the date of this prospectus, the
Borrower is in compliance with all financial and non-financial covenants under the Term Loan. We expect to enter into an amendment to the Credit Agreement prior the consummation of this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:9.5pt; font-family:Times New Roman">The Term Loan contains a number of customary events of default. If an event of default occurs, subject to varying cure periods and rights for
certain events of default, the Administrative Agent and the majority lenders will be entitled to take various actions, including the acceleration of amounts due thereunder, the termination of loan commitments in respect of the Term Loan and/or other
actions permitted to be taken by a secured creditor. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:9.5pt; font-family:Times New Roman">For further information, see Note 7, &#147;<I>Long-Term Debt</I>&#148; and Note
17, &#147;<I>Subsequent Events</I>&#148; to our consolidated financial statements included elsewhere in this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">185 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom744414_16"></A>DESCRIPTION OF SHARE CAPITAL </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>The following description of our share capital and provisions of our memorandum of association and amended and restated <FONT
STYLE="white-space:nowrap">bye-laws</FONT> are summaries. You should also refer to the memorandum of association and the amended and restated <FONT STYLE="white-space:nowrap">bye-laws,</FONT> which are filed as exhibits to the registration statement
of which this prospectus is part. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are an exempted company limited by shares incorporated under the laws of Bermuda. We are registered with the Registrar of Companies in
Bermuda under registration number 56682. We were incorporated on May&nbsp;20, 2021 under the name Kestra Medical Technologies, Ltd. Our principal office is located at 3933 Lake Washington Blvd NE, Suite 200, Kirkland, Washington 98033, and our
registered office is located in Cumberland House, 7th Floor, 1 Victoria Street, Hamilton HM 11, Bermuda. Following the consummation of this offering, Kestra Medical Technologies, Ltd. will become a tax resident of Ireland. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The objects of our business are unrestricted, and Kestra Medical Technologies, Ltd. has the capacity of a natural person. We can therefore
undertake activities without restriction on our capacity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Since our incorporation, there have been no material changes to our share
capital, mergers, amalgamations or consolidations of us or any of our subsidiaries, no material changes in the mode of conducting our business and no material changes in the types of products produced or services rendered. There have been no
bankruptcy, receivership or similar proceedings with respect to us or our subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">There have been no public takeover offers by
third parties for our shares nor any public takeover offers by us for the shares of another company that have occurred during the last or current financial years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Initial settlement of our common shares will take place on the closing date of this offering through The Depository Trust Company
(&#147;DTC&#148;), in accordance with its customary settlement procedures for equity securities registered through DTC&#146;s book-entry transfer system. Each person beneficially owning common shares registered through DTC must rely on the
procedures thereof and on institutions that have accounts therewith to exercise any rights of a holder of the common shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Share Capital </B></P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In connection with this offering, our Board and sole shareholder of the Company have approved an increase in our authorized share capital
and a redesignation of our ordinary shares into common shares, as a result of which our authorized share capital is US$100,000,000 divided into 100,000,000 common shares of par value of US$1.00 each. Such increase in our authorized share capital
will be filed prior to the consummation of this offering with the Registrar of Companies of Bermuda who will issue a Certificate of Deposit of Memorandum of Increase of Share Capital. After the consummation of the Organizational Transactions, we
expect to have 37,651,467 common shares issued. After the consummation of the Organizational Transactions, this offering and the use of the net proceeds therefrom as described under the section titled &#147;Use of Proceeds,&#148; we expect to have
47,651,467 common shares issued, assuming no exercise by the underwriters of their over-allotment option, or 49,151,467 common shares if the underwriters exercise their over-allotment option in full. Pursuant to our amended and restated <FONT
STYLE="white-space:nowrap">bye-laws</FONT> to be in effect upon the closing of this offering, subject to the requirements of the Nasdaq Global Select Market, and to any resolution of the shareholders to the contrary, our Board of Directors is
authorized to issue any of our authorized but unissued shares. There are no limitations on the right of <FONT STYLE="white-space:nowrap">non-Bermudians</FONT> or <FONT STYLE="white-space:nowrap">non-residents</FONT> of Bermuda to hold or vote our
shares provided our common shares remain listed on an appointed stock exchange, which includes the Nasdaq Global Select Market. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">186 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Shares </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dividend Rights </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under Bermuda
law, a company may not declare or pay dividends, or make distributions out of contributed surplus, if there are reasonable grounds for believing that (1)&nbsp;the company is, or would after the payment be, unable to pay its liabilities as they
become due; or (2)&nbsp;the realizable value of its assets would thereby be less than its liabilities. &#147;Contributed surplus&#148; is defined for purposes of Section&nbsp;54 of the Companies Act to include the proceeds arising from donated
shares, credits resulting from the redemption or conversion of shares at less than the amount set up as nominal capital and donations of cash and other assets to the company. Under our amended and restated
<FONT STYLE="white-space:nowrap">bye-laws</FONT> to be in effect upon the closing of this offering, each common share is entitled to dividends if, as and when dividends are declared by our Board of Directors, subject to any preferred dividend right
of the holders of any preference shares. We do not anticipate paying cash dividends in the foreseeable future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Voting Rights </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Holders of common shares are entitled to one vote per share on all matters submitted to a vote of holders of common shares. Unless a different
majority is required by law or by our amended and restated <FONT STYLE="white-space:nowrap">bye-laws</FONT> to be in effect upon the closing of this offering, ordinary resolutions to be approved by holders of common shares require approval by a
simple majority of votes cast by shareholders entitled to vote at a quorate meeting or by written resolution. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Majority shareholders
do not generally owe any duties to other shareholders to refrain from exercising all of the votes attached to their shares. There are no deadlines in the Companies Act relating to the time when votes must be exercised. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The key powers of our shareholders include the power to alter the terms of our memorandum of association and to approve and thereby make
effective any alterations to our amended and restated <FONT STYLE="white-space:nowrap">bye-laws</FONT> to be in effect upon the closing of this offering made by the Board of Directors. Pursuant to Bermuda law, dissenting shareholders holding 20% of
our issued share capital may apply to the court to annul or vary an alteration to our memorandum of association. A majority vote against an alteration to our amended and restated <FONT STYLE="white-space:nowrap">bye-laws</FONT> to be in effect upon
the closing of this offering made by the Board of Directors will prevent the alteration from becoming effective. Other key powers are to approve the alteration of our capital, including a reduction in share capital, to approve the removal of a
director, to resolve that we will be wound up or discontinued from Bermuda to another jurisdiction or to enter into an amalgamation, merger or winding up. Under the Companies Act, all of the foregoing corporate actions require approval by an
ordinary resolution (a simple majority of votes cast), unless our amended and restated <FONT STYLE="white-space:nowrap">bye-laws</FONT> to be in effect upon the closing of this offering provide otherwise, which our
<FONT STYLE="white-space:nowrap">bye-laws</FONT> will. Our amended and restated <FONT STYLE="white-space:nowrap">bye-laws</FONT> to be in effect upon the closing of this offering will provide that the Board of Directors may, with the sanction of a
resolution passed by shareholders holding at least a majority of the issued shares entitled to vote and present in person or by proxy at a general meeting with the necessary quorum for such meeting of two persons at least holding or representing a
majority of our issued shares entitled to vote at such meeting (provided that if the Company has only one shareholder, one shareholder present in person or by proxy will be a quorum for such meeting), amalgamate or merge us with another company. In
addition, our amended and restated <FONT STYLE="white-space:nowrap">bye-laws</FONT> to be in effect upon the closing of this offering will permit us to reduce our issued share capital with the authority of an ordinary resolution of the shareholders.
Not less than ten days&#146; prior written notice of any resolution to reduce our issued share capital and a copy of such resolution shall be circulated to all shareholders who would be entitled to vote on the resolution at a general meeting at
which the resolution could have been considered.&#8195; </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Companies Act provides that a company shall not be bound to take notice
of any trust or other interest in its shares. There is a presumption that all the rights attaching to shares are held by, and are exercisable by, the registered holder, by virtue of being registered as a member of the company. Our relationship is
with the registered holder of our shares. If the registered holder of the shares holds the shares for someone else (the beneficial owner), then the beneficial owner is entitled to the shares and may give instructions to the registered holder on how
to vote the shares. The Companies Act provides that the registered holder may appoint more than </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">187 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
one proxy to attend a shareholder meeting, and consequently where rights to shares are held in a chain the registered holder may appoint the beneficial owner as the registered holder&#146;s
proxy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Pre-emptive</FONT> or Conversion Rights </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Companies Act does not, and our amended and restated <FONT STYLE="white-space:nowrap">bye-laws</FONT> to be in effect upon the closing of
this offering will not, confer any <FONT STYLE="white-space:nowrap">pre-emptive</FONT> or sinking fund rights attached to our common shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Redemption, Repurchase and Surrender of Shares </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Subject to certain balance sheet restrictions, the Companies Act permits a company to purchase its own shares if it is able to do so without
becoming cash flow insolvent as a result. Where a company purchases its own shares, such shares may be cancelled (in which event, the company&#146;s issued, but not its authorized, capital will be diminished accordingly) or held as treasury shares.
The restrictions are that the par value of the share must be charged against the company&#146;s issued share capital account or a company fund which is available for dividend or distribution or be paid for out of the proceeds of a fresh issue of
shares. Any premium paid on the repurchase of shares must be charged to the company&#146;s current share premium account or charged to a company fund which is available for dividend or distribution. The Companies Act does not impose any requirement
that the directors shall make a general offer to all shareholders to purchase their shares pro rata to their respective shareholdings. Our amended and restated <FONT STYLE="white-space:nowrap">bye-laws</FONT> to be in effect upon the closing of this
offering will not contain any specific rules regarding the procedures to be followed by us when purchasing our common shares, and consequently the primary source of our obligations to shareholders when we tender for our common shares will be the
rules of the listing exchanges on which our common shares are listed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidation Rights </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the event of our liquidation, dissolution or winding up, the holders of common shares are entitled to share in our assets, if any,
remaining after the payment of all of our debts and liabilities, subject to any liquidation preference on any outstanding preference shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preference Shares </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pursuant to Bermuda
law and our amended and restated <FONT STYLE="white-space:nowrap">bye-laws</FONT> to be in effect upon the closing of this offering, our Board of Directors may, by resolution, establish one or more series of preference shares having such number of
shares, designations, dividend rates, relative voting rights, conversion or exchange rights, redemption rights, liquidation rights and other relative participation, optional or other special rights, qualifications, limitations or restrictions as may
be fixed by our Board of Directors without any further shareholder approval. Such rights, preferences, powers and limitations, as may be established, could have the effect of discouraging an attempt to obtain control of our company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Warrants </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In connection with this
offering, the Existing KLIM Warrants will be canceled and Kestra Medical Technologies, Ltd. will issue new KLIM Warrants to purchase common shares. The number of common shares underlying the KLIM Warrants and exercise prices thereof will be
determined based on the initial public offering price. Based on an assumed initial public offering price of $15.00 per share, the midpoint of the price range on the cover of this prospectus, we will issue warrants exercisable for 62,901 and 47,176
shares, with exercise prices of $17.64 and $20.46, respectively. The warrants will expire on December&nbsp;28, 2030 and March&nbsp;7, 2032, respectively. A $1.00 increase in the assumed initial public offering price will result in the issuance of
KLIM Warrants exercisable for 62,626 and 46,969 common shares with exercise prices of $17.72 and $20.55, respectively. A $1.00 decrease in the assumed initial public offering price will result in the issuance of KLIM Warrants exercisable for 63,198
and 47,399 common shares with exercise prices of $17.56 and $20.36, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">188 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Also in connection with this offering, the Existing Perceptive Warrants will be canceled
and Kestra Medical Technologies, Ltd. will issue new Perceptive Warrants to purchase common shares of the Company. The number of common shares underlying the Perceptive Warrants and exercise price thereof will be determined based on the initial
public offering price. Based on an assumed initial public offering price of $15.00&nbsp;per share, the midpoint of the price range on the cover of this prospectus, we will issue warrants exercisable for 328,859&nbsp;shares, with an exercise price of
$11.44. The warrants will expire on September&nbsp;29, 2033. A $1.00 increase in the assumed initial public offering price will result in the issuance of Perceptive Warrants exercisable for 327,417 common shares with an exercise price of $11.49. A
$1.00 decrease in the assumed initial public offering price will result in the issuance of Perceptive Warrants exercisable for 330,412 common shares, with an exercise price of $11.38. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Variation of Rights </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If at any time we
have more than one class of shares, the rights attaching to any class, unless otherwise provided for by the terms of issue of the relevant class, may be varied either: (1)&nbsp;with the consent in writing of the holders of 75% of the issued shares
of that class; or (2)&nbsp;with the sanction of a resolution passed by a simple majority of the votes cast at a general meeting of the relevant class of shareholders at which a quorum of two or more persons holding (or representing by proxy) at
least <FONT STYLE="white-space:nowrap">one-third</FONT> of the issued shares of the applicable class is present. Our amended and restated <FONT STYLE="white-space:nowrap">bye-laws</FONT> to be in effect upon the closing of this offering will specify
that the creation or issue of shares ranking equally with existing preference shares will not, unless expressly provided by the terms of issue of existing preference shares, vary the rights attached to existing preference shares. In addition, the
creation or issue of preference shares ranking prior to common shares will not be deemed to vary the rights attached to common shares or, subject to the terms of any other class or series of preference shares, to vary the rights attached to any
other class or series of preference shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer of Shares </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our Board of Directors may, in its absolute discretion and without assigning any reason, refuse to register the transfer of a share on the
basis that it is not fully paid. Our Board of Directors may also refuse to recognize an instrument of transfer of a share unless it is accompanied by the relevant share certificate and such other evidence of the transferor&#146;s right to make the
transfer as our Board of Directors shall reasonably require and must refuse to register the transfer unless all applicable consents, authorizations and permissions of any governmental agency or body in Bermuda have been obtained. Subject to these
restrictions, a holder of common shares may transfer the title to all or any of his common shares by completing a form of transfer in such common form as our Board of Directors may accept. If required, the instrument of transfer must be signed by
the transferor and transferee, although in the case of a fully paid share our Board of Directors may accept the instrument signed only by the transferor. Our common shares may also be transferred without a written instrument if transferred by an
appointed agent or otherwise in accordance with the Companies Act. Notwithstanding the foregoing, shares that are listed may be transferred in accordance with the rules and regulations of the exchange on which the shares are listed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Meetings of Shareholders </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under Bermuda
law, a company is required to convene an annual general meeting of shareholders each calendar year (the &#147;annual general meeting&#148;). However, the shareholders may by resolution waive this requirement, either for a specific year or period of
time, or indefinitely. When the requirement has been so waived, any shareholder may, on notice to the company, terminate the waiver no more than three months before the end of the year, in which case an annual general meeting must be called. We have
chosen not to waive the convening of an annual general meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Bermuda law provides that a special general meeting of shareholders may
be called by the board of directors of a company and must be called upon the request of shareholders holding not less than 10% of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">189 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<FONT STYLE="white-space:nowrap">paid-up</FONT> capital of the company carrying the right to vote at general meetings. Bermuda law also requires that shareholders be given at least five
days&#146; advance notice of a general meeting, but the accidental omission to give notice to any person entitled to receive notice does not invalidate the proceedings at a meeting. Our amended and restated
<FONT STYLE="white-space:nowrap">bye-laws</FONT> to be in effect upon the closing of this offering will provide that at least ten days but not more than sixty days advance notice be given to shareholders entitled to receive notice of the annual
general meeting and of any special general meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our amended and restated <FONT STYLE="white-space:nowrap">bye-laws</FONT> will
establish advance notice procedures with respect to shareholder proposals and the nomination of candidates for election as directors. In order for any matter to be &#147;properly brought&#148; before a meeting, a shareholder will have to comply with
advance notice requirements and provide us with certain information. Our amended and restated <FONT STYLE="white-space:nowrap">bye-laws</FONT> allow the chairperson of the meeting of shareholders to adopt rules and regulations for the conduct of
meetings which may have the effect of precluding the conduct of certain business at a meeting if the rules and regulations are not followed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">These provisions may defer, delay or discourage a potential acquirer from conducting a solicitation of proxies to elect the acquirer&#146;s
own slate of directors or otherwise attempting to obtain control of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Access to Books and Records and Dissemination of Information </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Members of the general public have a right to inspect the public documents of a company available at the office of the Registrar of Companies
in Bermuda. These documents include a company&#146;s memorandum of association, including its objects and powers, and certain alterations to the memorandum of association. The shareholders have the additional right to inspect the <FONT
STYLE="white-space:nowrap">bye-laws</FONT> of the company, minutes of general meetings and the company&#146;s audited financial statements, which must be presented in the annual general meeting (unless all the shareholders and all of the directors
agree to dispense with this requirement). The register of members of a company is also open to inspection by shareholders and by members of the general public without charge. The register of members is required to be open for inspection for not less
than two hours in any business day (subject to the ability of a company to close the register of members for not more than thirty days in a year). A company is required to maintain its share register in Bermuda but may, subject to the provisions of
the Companies Act, establish a branch register outside of Bermuda. A company is required to keep at its registered office a register of directors and officers that is open for inspection for not less than two hours in any business day by members of
the public without charge. Bermuda law does not, however, provide a general right for shareholders to inspect or obtain copies of any other corporate records. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Election and Removal of Directors </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our amended and restated <FONT STYLE="white-space:nowrap">bye-laws</FONT> to be in effect upon the closing of this offering will provide that,
except in relation to the right of the holders of any series of preference shares to elect additional directors, our Board of Directors shall be a minimum number of six directors and a maximum number of eleven directors, or such number in excess
thereof as the Company may from time to time determine by resolution of the Board of Directors. Upon the closing of this offering and until the Triggering Annual Meeting, our Board of Directors will consist of three classes of directors (other than
those directors elected by the holders of any series of preference shares, voting separately as a series or together with one or more other such series, as the case may be). Prior to the Triggering Annual Meeting, each director will serve a
three-year term. From and after the Triggering Annual Meeting, our Board of Directors will be declassified and our directors will be elected to hold office for a one-year term expiring at the next annual general meeting of shareholders. See
&#147;Management&#151;Board Composition and Director Independence.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">To be elected, directors must receive a majority of the votes
cast by shareholders who are entitled to vote at the applicable shareholder meeting; provided that where the number of persons validly proposed for re-election or election as a director is greater than the number of directors to be elected, the
persons receiving the most votes (up to the number of directors to be elected) will be elected as directors, and an absolute majority of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">190 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the votes cast shall not be a prerequisite to the election of such directors. Any one or more vacancies on the Board of Directors not filled at any general meeting, and any new vacancy created by
the Board of Directors as a result of increasing the size of the Board of Directors, can be filled by the Board. Prior to the Triggering Annual Meeting, a director so appointed shall hold office for a term that shall coincide with the remaining term
of its class of directors. From and after the Triggering Annual Meeting, a director so appointed will hold office until the next election of directors and until his or her successor will be elected and qualified, subject to prior death, resignation,
retirement, disqualification or removal from office. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Subject to the rights of the holders of any series of preferred shares, a director
may be removed by the shareholders with or without cause with the affirmative vote of the holders of a majority of the issued shares entitled to vote; provided that from and after the Trigger Event, a director may be removed, only with cause, by a
resolution passed by shareholders holding at least 66 2/3% of the issued shares entitled to vote. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Proceedings of Board of Directors </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our amended and restated <FONT STYLE="white-space:nowrap">bye-laws</FONT> to be in effect upon the closing of this offering will provide that
our business is to be managed and conducted by our Board of Directors. Bermuda law permits individual and corporate directors and there will be no requirement in our amended and restated <FONT STYLE="white-space:nowrap">bye-laws</FONT> to be in
effect upon the closing of this offering or Bermuda law that directors hold any of our shares. There will also be no requirement in our amended and restated <FONT STYLE="white-space:nowrap">bye-laws</FONT> to be in effect upon the closing of this
offering or Bermuda law that our directors must retire at a certain age. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The quorum necessary for the transaction of business at a
meeting of the Board of Directors shall be the presence of a majority of the total number of directors then in office. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The
compensation of our directors will be determined by the Board of Directors, and there is no requirement that a specified number or percentage of &#147;independent&#148; directors must approve any such determination. Our directors may also be paid
all travel, hotel and other reasonable <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses properly incurred by them in connection with our business or their duties as directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A director who discloses a direct or indirect interest (an &#147;Interested Director&#148;) in any contract or arrangement with us shall
declare the nature of such interest as required by the Companies Act; provided that no such declaration will be required to be made by a non-employee director in respect of such non-employee director being involved in any business opportunity which
may be a corporate opportunity for the non-employee director and the Company or any of its affiliates. Following such declaration, the Interested Director shall not be disqualified from participating in the discussion or voting on the matter in
which such director is interested unless the chairperson of the meeting determines that such Interested Director shall be disqualified as such. In the event the chairperson of the meeting is the Interested Director, the determination as to whether
or not he should be disqualified may be made by a majority of the votes cast by the directors not having such interest. In addition, an Interested Director may, but shall not be required to, recuse himself from the discussion or voting on any
particular matter because of possible conflict or for any other reason disclosed to the other directors. Any Interested Director that is so disqualified or that elects to be recused shall nevertheless be counted toward a quorum for the meeting. </P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The chairperson of our Board of Directors will chair all meetings of the Board of Directors at which such individual is present. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Indemnification of Directors and Officers </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Section&nbsp;98 of the Companies Act provides generally that a Bermuda company may indemnify its directors, officers and auditors against any
liability which by virtue of any rule of law would otherwise be imposed on them in respect of any negligence, default, breach of duty or breach of trust, except in cases where </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">191 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such liability arises from fraud or dishonesty of which such director, officer or auditor may be guilty in relation to the company. Section&nbsp;98 further provides that a Bermuda company may
indemnify its directors, officers and auditors against any liability incurred by them in defending any proceedings, whether civil or criminal, in which judgment is awarded in their favor or in which they are acquitted or granted relief by the
Supreme Court of Bermuda pursuant to Section&nbsp;281 of the Companies Act. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our amended and restated bye-laws to be in effect upon
the closing of this offering will provide that we shall indemnify our directors and any officers appointed by our Board of Directors to the fullest extent permitted by applicable law; provided, however, that if a director or an officer is a party to
an indemnification agreement with us, then the terms of the indemnification agreement shall apply instead of the provisions in our amended and restated bye-laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Amendment of memorandum of association and <FONT STYLE="white-space:nowrap">Bye-laws</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Bermuda law provides that the memorandum of association of a company may be amended by a resolution passed at a general meeting of
shareholders. Our amended and restated <FONT STYLE="white-space:nowrap">bye-laws</FONT> to be in effect upon the closing of this offering will generally provide that no <FONT STYLE="white-space:nowrap">bye-law</FONT> shall be rescinded, altered or
amended, and no new <FONT STYLE="white-space:nowrap">bye-law</FONT> shall be made, nor shall our memorandum of association be altered or amended, save in accordance with the Companies Act and unless such change has been approved by a resolution of
our Board of Directors and by a resolution of our shareholders. However, from and after the Trigger Event, no <FONT STYLE="white-space:nowrap">bye-law</FONT> shall be rescinded, altered or amended, and no new
<FONT STYLE="white-space:nowrap">bye-law</FONT> shall be made, nor shall our memorandum of association be altered or amended, save in accordance with the Companies Act and unless such change has been approved by a resolution of our Board of
Directors and a resolution passed by shareholders holding at least 66 2/3% of all issued shares entitled to vote thereon. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under
Bermuda law, the holders of an aggregate of not less than 20% in par value of a company&#146;s issued share capital or any class thereof have the right to apply to the Supreme Court of Bermuda for an annulment of any amendment of the memorandum of
association adopted by shareholders at any general meeting, other than an amendment that alters or reduces a company&#146;s share capital as provided in the Companies Act. Where such an application is made, the amendment becomes effective only to
the extent that it is confirmed by the Supreme Court of Bermuda. An application for an annulment of an amendment of the memorandum of association must be made within 21 days after the date on which the resolution altering the company&#146;s
memorandum of association is passed and may be made on behalf of persons entitled to make the application by one or more of their number as they may appoint in writing for the purpose. No application may be made by shareholders voting in favor of
the amendment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Amalgamations and Mergers </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The amalgamation or merger of a Bermuda company with another company or corporation (other than certain affiliated companies) requires the
amalgamation or merger agreement to be approved by the company&#146;s board of directors and by its shareholders. Unless the company&#146;s <FONT STYLE="white-space:nowrap">bye-laws</FONT> provide otherwise, the approval of at least 75% of the
shareholders voting at such meeting is required to approve the amalgamation or merger agreement, and the quorum for such meeting must be two or more persons holding or representing more than <FONT STYLE="white-space:nowrap">one-third</FONT> of the
issued shares of the company. Our amended and restated <FONT STYLE="white-space:nowrap">bye-laws</FONT> to be in effect upon the closing of this offering will provide that the approval of the amalgamation or merger agreement by at least a majority
of the issued shares entitled to vote and present in person or by proxy at the applicable meeting shall be sufficient (other than in respect of any amalgamation or merger constituting a &#147;business combination&#148;), and the quorum for such
meeting shall be two or more persons holding or representing at least a majority of the issued shares entitled to vote; provided that if the company shall at any time have only one shareholder, one shareholder present in person or by proxy shall
form a quorum for such meeting. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under Bermuda law, in the event of an amalgamation or merger of a Bermuda company with another
company or corporation, a shareholder of the Bermuda company who did not vote in favor of the amalgamation </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">192 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or merger and who is not satisfied that fair value has been offered for such shareholder&#146;s shares may, within one month of the giving of the notice of the shareholders meeting, apply to the
Supreme Court of Bermuda to appraise the fair value of those shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Business Combinations </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Although the Companies Act does not contain specific provisions regarding &#147;business combinations&#148; between companies organized under
the laws of Bermuda and &#147;interested shareholders,&#148; we will include these provisions in our amended and restated <FONT STYLE="white-space:nowrap">bye-laws</FONT> to be in effect upon the closing of this offering. Specifically, our amended
and restated <FONT STYLE="white-space:nowrap">bye-laws</FONT> to be in effect upon the closing of this offering will contain provisions which prohibit us from engaging in a business combination with an interested shareholder for a period of three
years after the time of the transaction in which the person became an interested shareholder, unless: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">prior to the time that the shareholder became an interested shareholder, our Board of Directors approved either
the business combination or the transaction that resulted in the shareholder becoming an interested shareholder; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">upon consummation of the transaction that resulted in the shareholder becoming an interested shareholder, the
interested shareholder owned at least 85% of our issued voting shares outstanding at the time the transaction commenced; or </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">after the time of the transaction that resulted in the shareholder becoming an interested shareholder, the
business combination is approved by our Board of Directors and authorized at an annual general meeting or special general meeting of shareholders by the affirmative vote of at least 66 2/3% of our issued shares entitled to vote that are not owned by
the interested shareholder. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For purposes of these provisions, a &#147;business combination&#148; includes mergers,
amalgamations, consolidations, exchanges, asset sales, leases, issues or transfers of shares or other securities and certain other transactions resulting in a financial benefit to the interested shareholder. An &#147;interested shareholder&#148; is
any person or entity that beneficially owns 15% or more of our issued and outstanding voting shares (other than Bain Charger and its affiliates) and any affiliate or associate of that person or entity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Shareholder Suits and Choice of Forum </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Shareholder class&nbsp;actions and derivative actions are generally not available to shareholders under Bermuda law in the same way that they
are under the laws in the United States. The Bermuda courts, however, would ordinarily be expected to permit a shareholder to commence an action in the name of a company to remedy a wrong to the company where the act complained of is alleged to be
ultra vires or illegal, or would result in the violation of the company&#146;s memorandum of association or <FONT STYLE="white-space:nowrap">bye-laws.</FONT> Furthermore, consideration would be given by a Bermuda court to acts that are alleged to
constitute a fraud against the minority shareholders or, for instance, where an act requires the approval of a greater percentage of the company&#146;s shareholders than that which actually approved it. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">When the affairs of a company are being conducted in a manner that is oppressive or prejudicial to the interests of some part of the
shareholders, one or more shareholders may apply to the Supreme Court of Bermuda, which may make such order as it sees fit, including an order regulating the conduct of the company&#146;s affairs in the future or ordering the purchase of the shares
of any shareholders by other shareholders or by the company. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our amended and restated
<FONT STYLE="white-space:nowrap">bye-laws</FONT> will provide that, unless we, in writing, select or consent to the selection of an alternate forum, the Supreme Court of Bermuda shall be the exclusive forum for any dispute that arises under the
Companies Act or out of or in connection with our amended and restated <FONT STYLE="white-space:nowrap">bye-laws,</FONT> including any question regarding the existence, validity, application, enforceability or scope of any <FONT
STYLE="white-space:nowrap">bye-law</FONT> and/or whether </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">193 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
there has been any breach of the Companies Act or our amended and restated <FONT STYLE="white-space:nowrap">bye-laws</FONT> or any breach of a duty (including any fiduciary duty) by, or other
wrongdoing by, a current or former officer, director, employee, agent or shareholder of the Company to the Company or its shareholders (whether or not such a claim is brought in the name of a shareholder or in the name of the Company). Further,
unless we select or consent to the selection of an alternative forum, to the fullest extent permitted by applicable law, the federal district courts of the United States shall be the exclusive forum for the resolution of any complaint asserting a
cause of action arising under the Securities Act against the Company or any director, officer, employee or agent of the Company. Notwithstanding the foregoing, the provisions of this paragraph will not apply to suits brought to enforce any liability
or duty created by the Exchange Act. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Investors cannot waive compliance with the federal securities laws and the rules and
regulations thereunder. Any person or entity purchasing or otherwise acquiring an interest in any of our common shares shall be deemed to have notice of and to have consented to the forum provisions in our amended and restated <FONT
STYLE="white-space:nowrap">bye-laws.</FONT> It is possible that, in connection with one or more actions or proceedings described above, a court could rule that this provision in our amended and restated
<FONT STYLE="white-space:nowrap">bye-laws</FONT> is inapplicable or unenforceable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Capitalization of Profits and Reserves </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pursuant to our amended and restated <FONT STYLE="white-space:nowrap">bye-laws</FONT> to be in effect upon the closing of this offering, our
Board of Directors may (1)&nbsp;capitalize any part of the amount of our share premium or other reserve accounts or any amount credited to our profit and loss account or otherwise available for distribution by applying such sum in paying up unissued
shares to be allotted as fully paid bonus shares pro rata (except in connection with the conversion of shares) to the shareholders; or (2)&nbsp;capitalize any sum standing to the credit of a reserve account or sums otherwise available for dividend
or distribution by paying up in full, partly paid or nil paid shares of those shareholders who would have been entitled to such sums if they were distributed by way of dividend or distribution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Untraced Shareholders </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our amended and
restated <FONT STYLE="white-space:nowrap">bye-laws</FONT> to be in effect upon the closing of this offering will provide that our Board of Directors may forfeit any dividend or other monies payable in respect of any shares that remain unclaimed for
six years from the date when such monies became due for payment and as such will cease to remain owing by the Company. In addition, we are entitled to cease sending dividend warrants and checks by post or otherwise to a shareholder if such
instruments have been returned undelivered to, or left uncashed by, such shareholder on at least two consecutive occasions or, following one such occasion, reasonable enquires have failed to establish the shareholder&#146;s new address. This
entitlement ceases if the shareholder claims a dividend or cashes a dividend check or a warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain Provisions of Bermuda Law </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have been designated by the Bermuda Monetary Authority as a <FONT STYLE="white-space:nowrap">non-resident</FONT> for Bermuda exchange
control purposes. This designation allows us to engage in transactions in currencies other than the Euro, and there are no restrictions on our ability to transfer funds (other than funds denominated in Euros) in and out of Ireland or to pay
dividends to U.S. residents who are holders of our common shares. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Bermuda Monetary Authority has given its general permission for
the issue and free transferability of all of the common shares that are the subject of this offering to and between residents and <FONT STYLE="white-space:nowrap">non-residents</FONT> of Bermuda for exchange control purposes, provided our shares
remain listed on an appointed stock exchange, which includes the Nasdaq Global Select Market. Approvals or permissions given by the Bermuda Monetary Authority do not constitute a guarantee by the Bermuda Monetary Authority as to our performance or
our creditworthiness. Accordingly, in giving such consent or permissions, the Bermuda Monetary Authority shall not be liable for the financial soundness, performance or default of our business or for the correctness of any opinions or statements
expressed in this prospectus. Certain issues and transfers of common shares involving persons deemed resident in Bermuda for exchange control purposes require the specific consent of the Bermuda Monetary Authority. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">194 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In accordance with Bermuda law, share certificates are only issued in the names of
companies, partnerships or individuals. In the case of a shareholder acting in a special capacity (for example as a trustee), certificates may, at the request of the shareholder, record the capacity in which the shareholder is acting.
Notwithstanding such recording of any special capacity, we are not bound to investigate or see to the execution of any such trust. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Economic
Substance Act </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Bermuda&#146;s economic substance laws are contained in the Economic Substance Act 2018, as amended, and the
Economic Substance Regulations 2018, as amended (together the &#147;ESA&#148;). The ESA was enacted to demonstrate Bermuda&#146;s commitment to comply with international standards with respect to cooperation for tax purposes and to ensure that
Bermuda does not facilitate the use of structures which attract profits, but which do not reflect real economic activity within Bermuda. The ESA provides that a registered entity other than an entity which is resident for tax purposes in certain
jurisdictions outside Bermuda <FONT STYLE="white-space:nowrap">(&#147;non-resident</FONT> entity&#148;) that carries on as a business any one or more of the &#147;relevant activities&#148; referred to in the ESA must comply with economic substance
requirements. The list of &#147;relevant activities&#148; includes carrying on any one or more of the following activities: banking, insurance, fund management, financing, leasing, headquarters, shipping, distribution and service center,
intellectual property and holding entities. Under the ESA, if an entity is engaged in one or more &#147;relevant activities,&#148; it is required to maintain a substantial economic presence in Bermuda and to comply with the economic substance
requirements set forth in the ESA. An entity will comply with those economic substance requirements if it: (a)&nbsp;is managed and directed in Bermuda; (b)&nbsp;undertakes &#147;core income generating activities&#148; (as may be prescribed under the
ESA) in Bermuda in respect of the relevant activity; (c)&nbsp;maintains adequate physical presence in Bermuda; (d)&nbsp;has adequate senior executives, employees or other persons in Bermuda with suitable qualifications; and (e)&nbsp;incurs adequate
operating expenditure in Bermuda in relation to the relevant activity undertaken by it. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The ESA requires entities subject to it to make
annual filings with the Bermuda Registrar of Companies to demonstrate the economic substance of the entity&#146;s activities and business in Bermuda. The Company does not currently file any ESA declarations as it does not conduct a relevant activity
for the purposes of the ESA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights Agreement </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Following the completion of this offering certain of our shareholders, including Bain Capital and certain of our executive officers, will be
entitled to rights with respect to the registration of our common shares under the Securities Act. These registration rights are contained in a Registration Rights Agreement with such shareholders that West Affum Holdings, L.P. intends to assign to
us and we intend to assume in connection with this offering. See &#147;Certain Relationships and Related Party Transactions&#151;Registration Rights Agreement.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Opportunities </B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our amended
and restated <FONT STYLE="white-space:nowrap">bye-laws</FONT> to be in effect upon the closing of this offering will provide that, to the fullest extent permitted by applicable law, we renounce any interest or expectancy in, or in being offered an
opportunity to participate in, any business opportunity that may from time to time be presented to Bain Charger, members of our Board of Directors who are not our employees <FONT STYLE="white-space:nowrap">(&#147;Non-Employee</FONT>
Directors&#148;), and their respective affiliates (collectively, the &#147;Identified Persons&#148;), and that may be a business opportunity for such parties, even if the opportunity is one that we might reasonably have pursued or had the ability or
desire to pursue if granted the opportunity to do so. No Identified Person will be liable to us, to the fullest extent permitted by applicable law, for breach of any fiduciary or other duty, as a shareholder, director or officer, by reason of the
fact that such person pursues or acquires any such business opportunity, directs any such business opportunity to another person or fails to present any such business opportunity, or information regarding any such business opportunity, to us unless,
in the case of any <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors, any such business opportunity is expressly offered to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">195 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such person in writing solely in his or her capacity as our director. No Identified Person has any duty to refrain from engaging directly or indirectly in the same or similar business activities
or lines of business as us or any of our subsidiaries. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anti-Takeover Provisions </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our memorandum of association and our amended and restated <FONT STYLE="white-space:nowrap">bye-laws</FONT> to be in effect upon the closing
of this offering will contain provisions that may delay, defer or discourage another party from acquiring control of us. We expect that these provisions will discourage coercive takeover practices or inadequate takeover bids. These provisions are
also designed to encourage persons seeking to acquire control of us to first negotiate with the Board of Directors, which we believe may result in an improvement of the terms of any such acquisition in favor of our shareholders. However, they may
also discourage acquisitions that some shareholders may favor. These provisions include: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a classified Board of Directors with staggered three-year terms until the Triggering Annual Meeting;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">directors only to be removed for cause and only with a resolution passed by holders of at least 66&nbsp;2/3% of
all issued shares entitled to vote, from and after the Trigger Event; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">from and after the Trigger Event, amendments to our amended and restated
<FONT STYLE="white-space:nowrap">bye-laws</FONT> and memorandum of association will require the approval of our Board of Directors and a resolution passed by holders of at least 66 2/3% of all issued shares entitled to vote; </P></TD></TR></TABLE>
 <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">from and after the Trigger Event, only permit shareholder action by written consent when it is unanimously
approved by our shareholders; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on the time period in which directors may be nominated; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">limitations on our shareholders&#146; ability to call special general meetings; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability of our Board of Directors to determine the powers, preferences and rights of preference shares and to
cause us to issue the preference shares without shareholder approval. </P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, our amended and restated
bye-laws to be in effect upon the closing of this offering will contain provisions which prohibit us, subject to certain exceptions, from engaging in business combinations and other specified transactions with persons (excluding Bain Charger and its
affiliates) for a period of three years after the time of the transaction in which the person acquired 15% of more of our issued voting shares. See &#147;&#151;Business Combinations.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar </B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A
register of holders of the common shares will be maintained by Maples Corporate Services (Bermuda) Limited in Bermuda, and a branch register will be maintained in the United States by Computershare Trust Company, N.A., which will also serve as
transfer agent. The transfer agent&#146;s address is 150 Royall Street, Canton, Massachusetts 02021. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Listing </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have applied to list our common shares on The Nasdaq Global Select Market under the symbol &#147;KMTS.&#148;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">196 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom744414_17"></A>SHARES ELIGIBLE FOR FUTURE SALE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Prior to this offering, no public market existed for our common shares. Future sales of our common shares in the public market after this
offering, or the perception that these sales could occur, could adversely affect prevailing market prices for our common shares and could impair our future ability to raise equity capital. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Based on the number of common shares issued as of October 31, 2024, upon the closing of this offering and assuming no exercise by the
underwriters of their over-allotment option to purchase up to 1,500,000 additional common shares, 47,651,467 common shares will be outstanding. All of the common shares sold in this offering will be freely tradable without restrictions or further
registration under the Securities Act, except for any shares sold to our affiliates, as defined in Rule 144 under the Securities Act. The remaining common shares held by existing shareholders are restricted securities, as that term is defined in
Rule 144 under the Securities Act. Restricted securities may be sold in the public market only if registered or if their resale qualifies for exemption from registration described below under Rule 144 promulgated under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As a result of contractual restrictions described below and the provisions of Rules 144 and 701, the common shares sold in this offering and
the restricted securities will be available for sale in the public market as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all the common shares sold in this offering will be eligible for immediate sale upon the closing of this
offering; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an additional 37,651,467 common shares will be eligible for sale in the public market upon expiration of <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreements 180 days after the date of this prospectus, subject in certain circumstances to the volume, manner of sale and other limitations under Rule 144 and Rule 701. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule 144 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In general, persons who have
beneficially owned our common shares for at least six months, and any affiliate of the company who owns our common shares, are entitled to sell their securities without registration with the SEC under an exemption from registration provided by Rule
144 under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Non-Affiliates</FONT> </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Any person who is not deemed to have been one of our affiliates at the time of, or at any time during the three months preceding, a sale may
sell an unlimited number of common shares under Rule 144 if: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the common shares have been held for at least six months, including the holding period of any prior owner other
than one of our affiliates; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we have been subject to the Exchange Act periodic reporting requirements for at least 90 days before the sale;
and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we are current in our Exchange Act reporting at the time of sale. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Any person who is not deemed to have been an affiliate of ours at the time of, or at any time during the three months preceding, a sale and
has held the common shares for at least one year, including the holding period of any prior owner other than one of our affiliates, will be entitled to sell an unlimited number of common shares without regard to the length of time we have been
subject to Exchange Act periodic reporting or whether we are current in our Exchange Act reporting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">197 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Affiliates </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Persons seeking to sell restricted securities who are our affiliates at the time of, or any time during the three months preceding, a sale,
would be subject to the restrictions described above. They are also subject to additional restrictions, by which such person would be required to comply with the manner of sale and notice provisions of Rule 144 and would be entitled to sell within
any three-month period only that number of securities that does not exceed the greater of either of the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1% of the number of our common shares then outstanding, which will equal approximately 476,515&nbsp;shares
immediately after the closing of this offering based on the number of shares outstanding as of October 31, 2024, or </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the average weekly trading volume of our common shares on the Nasdaq Global Select Market during the four
calendar weeks preceding the filing of a notice on Form 144 with respect to the sale. </P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Additionally, persons who
are our affiliates at the time of, or any time during the three months preceding, a sale may sell unrestricted securities under the requirements of Rule 144 described above, without regard to the <FONT STYLE="white-space:nowrap">six-month</FONT>
holding period of Rule 144, which does not apply to sales of unrestricted securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule 701 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Rule 701 under the Securities Act, as in effect on the date of this prospectus, permits resales of shares in reliance upon Rule 144 but
without compliance with certain restrictions of Rule 144, including the holding period requirement. Our employees, executive officers or directors who purchase shares under a written compensatory plan or contract will be entitled to rely on the
resale provisions of Rule 701, but any holders of Rule 701 shares will be required to wait until 90 days after the date of this prospectus before selling their shares. However, all our Rule 701 shares are subject to
<FONT STYLE="white-space:nowrap">lock-up</FONT> agreements as described below and in the section titled &#147;Underwriting&#148; and will become eligible for sale only upon the expiration of the restrictions set forth in those agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Equity Incentive Plans </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As soon as
practicable after the closing of this offering, we intend to file with the SEC one or more registration statements on Form <FONT STYLE="white-space:nowrap">S-8</FONT> under the Securities Act to register our common shares that are subject to
outstanding options and awards issuable pursuant to our equity incentive plans. Shares covered by these registration statements will then be eligible for sale in the public markets, subject to vesting restrictions, any applicable <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreements described below and Rule 144 limitations applicable to affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We and the holders of substantially all of our common shares issued on the date of this prospectus, including each of our executive officers
and directors, have entered into <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements with the underwriters or otherwise agreed, subject to certain exceptions, that we and they will not, directly or indirectly, offer, pledge, sell, contract to
sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any common shares or any securities
convertible into or exercisable or exchangeable for common shares; file any registration statement with the SEC relating to the offering of any common shares or any securities convertible into or exercisable or exchangeable for common shares; enter
into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of common shares; or make any demand for, or exercise any right with respect to, the registration of any common shares
of or any security convertible into or exercisable or exchangeable for common shares, without the prior written consent of BofA Securities, Inc., Goldman Sachs &amp; Co. LLC and Piper Sandler &amp; Co. for a period of 180 days from the date of this
prospectus. See the section titled &#147;Underwriting&#151;No Sales of Similar Securities&#148; for more information on the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">198 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Subject to the <FONT STYLE="white-space:nowrap">lock-up</FONT> restrictions described above, following this offering, certain holders of our
common shares may demand (subject to certain conditions set forth in the Registration Rights Agreement) that we register the sale of their shares under the Securities Act or, if we file another registration statement under the Securities Act other
than a Form <FONT STYLE="white-space:nowrap">S-8</FONT> covering securities issuable under our equity plans or on Form <FONT STYLE="white-space:nowrap">S-4,</FONT> may elect to include their common shares in such registration. Following such
registered sales, the shares will be freely tradable without restriction under the Securities Act, unless held by our affiliates. See &#147;Certain Relationships and Related Party Transactions&#151;Registration Rights Agreement.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">199 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom744414_18"></A>BERMUDA COMPANY CONSIDERATIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our corporate affairs are governed by our memorandum of association and amended and restated <FONT STYLE="white-space:nowrap">bye-laws</FONT>
to be in effect upon the closing of this offering and by the laws of Bermuda. The provisions of the Companies Act, which applies to us, differ in certain material respects from laws generally applicable to U.S. companies incorporated in the State of
Delaware and their shareholders. The following is a summary of significant differences between the Companies Act (including modifications to be adopted pursuant to our amended and restated <FONT STYLE="white-space:nowrap">bye-laws</FONT> to be in
effect upon the closing of this offering) and Bermuda common law applicable to us and our shareholders and the provisions of the Delaware General Corporation Law (&#147;DGCL&#148;) applicable to U.S. companies organized under the laws of Delaware
and their shareholders. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Bermuda</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Delaware</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B><I>Shareholder Meetings</I></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;A special
general meeting may be called by the board of directors and must be called upon the request of shareholders holding not less than 10% of the <FONT STYLE="white-space:nowrap">paid-up</FONT> capital of the company carrying the right to vote at general
meetings.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;May be
held at such time or place as designated in the certificate of incorporation or the <FONT STYLE="white-space:nowrap">bye-laws,</FONT> or if not so designated, as determined by the board of directors.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;May be
held in or outside Bermuda.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;May be
held in or outside of Delaware.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Notice:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Notice:</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:3.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Shareholders must be given at least five days&#146; advance notice of a general meeting, but the
unintentional failure to give notice to any person does not invalidate the proceedings at a meeting.</P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2"> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Written notice shall be given not less than ten nor more than 60 days before the meeting.</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:3.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Whenever shareholders are
required to take any action at a meeting, a written notice of the meeting shall be given which shall state the place, if any, date and hour of the meeting, and the means of remote communication, if any.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Notice of
general meetings must specify the place, the day and hour of the meeting and in the case of special general meetings, the general nature of the business to be considered.</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:3.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Our amended and restated <FONT STYLE="white-space:nowrap">bye-laws</FONT> to be in effect upon the
closing of this offering will provide that at least ten days but not more than 60 days advance notice be provided to shareholders entitled to receive notice for any annual general meeting and of any special general meeting.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B><I>Shareholders&#146; Voting Rights</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Under
Bermuda law, shareholders may act by written consent to elect directors. However, shareholders may not act by written consent to remove a director or auditor. Our amended and restated <FONT STYLE="white-space:nowrap">bye-laws</FONT> will generally
allow shareholder action by written consent. However, from and after the Trigger Event, any shareholder action by written</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Under the
DGCL, unless otherwise specified in a corporation&#146;s certificate of incorporation, stockholders may take action permitted to be taken at an annual or special meeting, without a meeting, notice or a vote, if consents, in writing, setting forth
the action, are signed by stockholders with not less than the minimum</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">200 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Bermuda</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Delaware</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman">consent will require the unanimous approval of our shareholders.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman">number of votes that would be necessary to authorize the action at a meeting. All consents must be dated and are only
effective if the requisite signatures are collected within 60 days of the earliest dated consent delivered.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Generally,
except as otherwise provided in the <FONT STYLE="white-space:nowrap">bye-laws,</FONT> or the Companies Act, any action or resolution requiring approval of the shareholders may be passed by a simple majority of votes cast. Any person authorized to
vote may authorize another person or persons to act for him or her by proxy.</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Our amended and restated <FONT STYLE="white-space:nowrap">bye-laws</FONT> will generally provide
that no <FONT STYLE="white-space:nowrap">bye-law</FONT> shall be rescinded, altered or amended, and no new <FONT STYLE="white-space:nowrap">bye-law</FONT> shall be made, nor shall our memorandum of association be altered or amended, save in
accordance with the Companies Act and unless such change has been approved by a resolution of our Board of Directors and by a resolution of our shareholders. However, from and after the Trigger Event, no
<FONT STYLE="white-space:nowrap">bye-law</FONT> shall be rescinded, altered or amended, and no new <FONT STYLE="white-space:nowrap">bye-law</FONT> shall be made, nor shall our memorandum of association be altered or amended, save in accordance with
the Companies Act and unless such change has been approved by a resolution of our Board of Directors and a resolution passed by holders of at least 66 2/3% of all issued shares entitled to vote.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;In matters
other than the election of directors, with the exception of special voting requirements related to extraordinary transactions, and unless otherwise provided in a company&#146;s certificate of incorporation or bylaws, the affirmative vote of a
majority of shares present in person or represented by proxy and entitled to vote at a meeting in which a quorum is present is required for shareholder action.</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Any person authorized to vote may authorize another person or persons to act for him or her by
proxy.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Under
Bermuda law, the voting rights of shareholders are regulated by a company&#146;s <FONT STYLE="white-space:nowrap">bye-laws</FONT> and, in certain circumstances, by the Companies Act. The <FONT STYLE="white-space:nowrap">bye-laws</FONT> may specify
the number to constitute a quorum and if the <FONT STYLE="white-space:nowrap">bye-laws</FONT> permit, a general meeting of the shareholders of a company may be held with only one individual present if the requirement for a quorum is
satisfied.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;For stock
corporations, the certificate of incorporation or <FONT STYLE="white-space:nowrap">bye-laws</FONT> may specify the number to constitute a quorum, but in no event shall a quorum consist of less than <FONT STYLE="white-space:nowrap">one-third</FONT>
of shares entitled to vote at a meeting. In the absence of such specifications, a majority of shares entitled to vote shall constitute a quorum.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Our
amended and restated <FONT STYLE="white-space:nowrap">bye-laws</FONT> to be in effect upon the closing of this offering will provide that the quorum required for a general meeting of shareholders is two or more persons present in person at the start
of the meeting and representing in person or by proxy in excess of 50% of all issued shares that are entitled to vote at the meeting provided that if the company shall at any time have only one shareholder, one shareholder present in person or by
proxy shall form a quorum for the transaction of business at any general meeting held during such time.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">201 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Bermuda</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Delaware</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Under Bermuda law, the <FONT STYLE="white-space:nowrap">bye-laws</FONT> may
provide for cumulative voting, although our amended and restated <FONT STYLE="white-space:nowrap">bye-laws</FONT> to be in effect upon the closing of this offering will not.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;The certificate of incorporation may provide for cumulative
voting.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;The
amalgamation or merger of a Bermuda company with another company or corporation (other than certain affiliated companies) requires the amalgamation or merger agreement to be approved by the company&#146;s board of directors and by its shareholders.
Unless the company&#146;s <FONT STYLE="white-space:nowrap">bye-laws</FONT> provide otherwise, the approval of at least 75% of the shareholders voting at such meeting is required to approve the amalgamation or merger agreement, and the quorum for
such meeting must be two or more persons holding or representing more than <FONT STYLE="white-space:nowrap">one-third</FONT> of the issued shares of the company. Our amended and restated <FONT STYLE="white-space:nowrap">bye-laws</FONT> to be in
effect upon the closing of this offering will provide that the approval of the amalgamation or merger agreement by at least a majority of the issued shares entitled to vote and present in person or by proxy at the applicable meeting (other than in
respect of any amalgamation or merger constituting a &#147;business combination&#148;), and the quorum for such meeting shall be two or more persons holding or representing at least a majority of the issued shares entitled to vote; provided that if
the Company shall at any time have only one shareholder, one shareholder present in person or by proxy shall form a quorum for such meeting.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Any two or
more corporations existing under the laws of the state may merge into a single corporation pursuant to a board resolution and upon the majority vote by shareholders of each constituent corporation at an annual or special meeting.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Every
company may at any meeting of its board of directors sell, lease or exchange all or substantially all of its property and assets as its board of directors deems expedient and in the best interests of the company to do so when authorized by a
resolution adopted by the holders of a majority of issued shares of a company entitled to vote.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Every
corporation may at any meeting of the board sell, lease or exchange all or substantially all of its property and assets as its board deems expedient and for the best interests of the corporation when so authorized by a resolution adopted by the
holders of a majority of the outstanding stock of a corporation entitled to vote.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Any
company that is the wholly owned subsidiary of a holding company, or one or more companies which are wholly owned subsidiaries of the same holding company, may amalgamate or merge with holding company or with each other without the vote or consent
of shareholders provided that the approval of the board of directors is obtained and that a director or officer of each such company signs a statutory solvency declaration in respect of the relevant company.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Any
corporation owning at least 90% of the outstanding shares of each class of another corporation (subject to certain exceptions) may merge the other corporation into itself and assume all of its obligations without the vote or consent of shareholders;
however, in case the parent corporation is not the surviving corporation, the proposed merger shall be approved by a majority of the outstanding stock of the parent corporation entitled to vote at a duly called stockholder
meeting.</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">202 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Bermuda</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Delaware</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Any mortgage or pledge of a corporation&#146;s property and assets may be
authorized without the vote or consent of shareholders, except to the extent that the certificate of incorporation otherwise provides.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Any
mortgage, charge or pledge of a company&#146;s property and assets may be authorized without the consent of shareholders subject to any restrictions under the <FONT STYLE="white-space:nowrap">bye-laws.</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B><I>Directors</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Under
Bermuda law, the board of directors must consist of at least one director. Following the completion of this offering, our Board of Directors will be composed of nine directors. In accordance with our amended and restated bye-laws, until the
Triggering Annual Meeting our directors will be divided into three classes serving staggered three-year terms. From and after the Triggering Annual Meeting, our Board of Directors will be declassified and our directors will be elected to hold office
for a one-year term expiring at the next annual general meeting of shareholders.</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;The number of directors is fixed by the bye-laws, and any changes to such number must be approved
by the board of directors and/or the shareholders in accordance with the company&#146;s bye-laws. Our amended and restated bye-laws will provide that, except in relation to the right of the holders of any series of preference shares to elect
additional directors, our Board of Directors shall be a minimum number of six directors and a maximum number of eleven directors, or such number in excess thereof as the Company may from time to time determine by resolution of the Board of
Directors.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;The board
of directors must consist of at least one member.</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Number of board members shall be fixed by the bye-laws, unless the certificate of incorporation
fixes the number of directors, in which case a change in the number shall be made only by amendment of the certificate of incorporation.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B><I>Appointment</I></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Our amended and restated bye-laws will provide that to be elected, directors
must receive a majority of the votes cast by shareholders who are entitled to vote at the applicable shareholder meeting; provided that where the number of persons validly proposed for re-election or election as a director is greater than the number
of directors to be elected, the persons receiving the most votes (up to the number of directors to be elected) will be elected as directors, and an absolute majority of the votes cast shall not be a prerequisite to the election of such directors.
Any one or more vacancies on the Board of</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Pursuant to the DGCL, unless otherwise provided in a company&#146;s
certificate of incorporation or bylaws, directors are elected by a plurality of the votes of the shares present in person or represented by proxy at the meeting and entitled to vote on the election of directors. Vacancies and newly created
directorships resulting from any increase in the authorized number of directors elected by all of the stockholders having the right to vote as a single class may be filled by a majority of the directors then in office,
although</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">203 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Bermuda</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Delaware</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman">Directors not filled at any general meeting, and any new vacancy created by the Board of Directors as a result of
increasing the size of the Board of Directors, can be filled by the Board. Prior to the Triggering Annual Meeting, a director so appointed shall hold office for a term that shall coincide with the remaining term of its class of directors. From and
after the Triggering Annual Meeting, a director so appointed will hold office until the next election of directors and until his or her successor will be duly elected and qualified, subject to prior death, resignation, retirement, disqualification
or removal from office.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman">less than a quorum, or by a sole remaining director.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Removal</I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Under our amended and
restated <FONT STYLE="white-space:nowrap">bye-laws</FONT> to be in effect upon the closing of this offering, subject to the rights of the holders of any series of preferred shares, a director may be removed by the shareholders with or without cause
with the affirmative vote of the holders of a majority of the issued shares; provided that from and after the Trigger Event, a director may be removed, only with cause, by a resolution passed by shareholders holding at least 66 2/3% of the issued
shares entitled to vote.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Any
director or the entire board of directors may be removed, with or without cause, by the holders of a majority of the shares then entitled to vote at an election of directors, except as follows:</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Unless the certificate of
incorporation otherwise provides, in the case of a corporation whose board is classified, stockholders may effect such removal only for cause; or</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:3.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;In the case of a corporation having cumulative voting, if less than the entire board is to be
removed, no director may be removed without cause if the votes cast against such director&#146;s removal would be sufficient to elect such director if then cumulatively voted at an election of the entire board of directors, or, if there be classes
of directors, at an election of the class of directors of which such director is a part.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B><I>Duties of Directors</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;The
Companies Act authorizes the directors of a company, subject to its <FONT STYLE="white-space:nowrap">bye-laws,</FONT> to exercise all powers of the company except those that are required by the Companies Act or the company&#146;s <FONT
STYLE="white-space:nowrap">bye-laws</FONT> to be exercised by the shareholders of the company. Our amended and restated <FONT STYLE="white-space:nowrap">bye-laws</FONT> to be in effect upon the closing of this offering will provide that our business
is to be managed and conducted by our Board of Directors. At common law, members of a board of directors owe a fiduciary duty to the company to act in good faith in their dealings with or on behalf of the company and exercise their powers and
fulfill the duties of their</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Under
Delaware law, the business and affairs of a corporation are managed by or under the direction of its board of directors. In exercising their powers, directors are charged with a fiduciary duty of care to protect the interests of the corporation and
a fiduciary duty of loyalty to act in the best interests of its shareholders. The duty of care requires that a director act in good faith, with the care that an ordinarily prudent person would exercise under similar circumstances. Under this duty, a
director must inform himself of, and disclose to shareholders, all material information reasonably available regarding a significant transaction. The duty of</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">204 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Bermuda</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Delaware</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman">office honestly. This duty includes the following essential elements:</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;a duty to act in good faith
in the best interests of the company;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;a duty not to make a personal profit from opportunities that arise from the office of
director;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;a duty to
avoid conflicts of interest; and</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:3.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;a duty to exercise powers for the purpose for which such powers were intended.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman">loyalty requires that a director act in a manner he reasonably believes to be in the best interests of the corporation.
He must not use his corporate position for personal gain or advantage. This duty prohibits self-dealing by a director and mandates that the best interest of the corporation and its shareholders take precedence over any interest possessed by a
director, officer or controlling shareholder and not shared by the shareholders generally.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;The
Companies Act imposes a duty on directors and officers of a Bermuda company:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;to act honestly and in good faith with a view to the best interests of the company;</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;to exercise the care,
diligence and skill that a reasonably prudent person would exercise in comparable circumstances; and</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;to comply with the Companies Act, the regulations and the
<FONT STYLE="white-space:nowrap">bye-laws</FONT> of the company.</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;The Companies Act also imposes various duties on directors and officers of a company with respect
to certain matters of management and administration of the company. Under Bermuda law, directors and officers generally owe fiduciary duties to the company itself, not to the company&#146;s individual shareholders, creditors or any class thereof.
Our shareholders may not have a direct cause of action against our directors.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;In
general, actions of a director are presumed to have been made on an informed basis, in good faith and in the honest belief that the action taken was in the best interests of the corporation. However, this presumption may be rebutted by evidence of a
breach of one of the fiduciary duties. Should such evidence be presented concerning a transaction by a director, a director must prove the procedural fairness of the transaction, and that the transaction was of fair value to the
corporation.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B><I>Takeovers</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;An
acquiring party is generally able to acquire compulsorily the common shares of minority holders of a company in the following ways:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;By a procedure under the Companies Act known as a &#147;scheme of arrangement.&#148; A scheme of
arrangement could be effected by obtaining the agreement of the company and of holders of common shares, representing in the aggregate a majority in number and at least 75% in value of the common shareholders present and voting at a court ordered
meeting held to consider the scheme of arrangement. The scheme of arrangement must then</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Delaware
law provides that a parent corporation, by resolution of its board of directors and without any stockholder vote, may merge with any subsidiary of which it owns at least 90% of each class of its capital stock. Upon any such merger, and in the event
the parent corporate does not own all of the stock of the subsidiary, dissenting shareholders of the subsidiary are entitled to certain appraisal rights.</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Delaware law also provides, subject to certain exceptions, that if a person acquires 15% of voting
stock of a company, the person is an</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">205 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Bermuda</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Delaware</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman">be sanctioned by the Bermuda Supreme Court. If a scheme of arrangement receives all necessary agreements and sanctions,
upon the filing of the court order with the Registrar of Companies in Bermuda, all holders of common shares could be compelled to sell their shares under the terms of the scheme of arrangement.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman">&#147;interested stockholder&#148; and may not engage in &#147;business combinations&#148; with the company for a
period of three years from the time the person acquired 15% or more of voting stock.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Where the
acquiring party or parties hold not less than 95% of the shares or a class of shares of the company, by acquiring, pursuant to a notice given to the remaining shareholders or class of shareholders, the shares of such remaining shareholders or class
of shareholders. When this notice is given, the acquiring party is entitled and bound to acquire the shares of the remaining shareholders on the terms set out in the notice, unless a remaining shareholder, within one month of receiving such notice,
applies to the Supreme Court of Bermuda for an appraisal of the value of their shares. This provision only applies where the acquiring party offers the same terms to all holders of shares whose shares are being acquired.</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;By acquiring pursuant to a
tender offer 90% of the shares or class of shares not already owned by, or by a nominee for, the acquiring party (the offeror), or any of its subsidiaries. If an offeror has, within four months after the making of an offer for all the shares or
class of shares not owned by, or by a nominee for, the offeror, or any of its subsidiaries, obtained the approval of the holders of 90% or more of all the shares to which the offer relates, the offeror may, at any time within two months beginning
with the date on which the approval was obtained, by notice compulsorily acquire the shares of any nontendering shareholder on the same terms as the original offer unless the Supreme Court of Bermuda (on application made within a <FONT
STYLE="white-space:nowrap">one-month</FONT> period from the date of the offeror&#146;s notice of its intention to acquire such shares) orders otherwise.</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;The Companies Act does not contain specific provisions regarding &#147;business combinations&#148;
between companies organized under the laws of Bermuda and &#147;interested shareholders.&#148; However, we will include these provisions in our amended and restated bye-laws to be in effect upon the closing of this offering. Specifically, our
amended and restated bye-laws to be in effect upon the closing of this offering will contain provisions which prohibit us, subject to certain exceptions, from engaging in business combinations and other specified</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">206 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Bermuda</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Delaware</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman">transactions with persons (excluding Bain Charger and its affiliates) for a period of three years after the time of the
transaction in which the person acquired 15% of more of our issued voting shares.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B><I>Dissenter&#146;s Rights of Appraisal</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;A
dissenting shareholder (that did not vote in favor of the amalgamation or merger) of a Bermuda exempted company is entitled to be paid the fair value of his or her shares in an amalgamation or merger.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;With
limited exceptions, appraisal rights shall be available for the shares of any class or series of stock of a corporation in a merger or consolidation.</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Stockholders of a Delaware corporation participating in certain mergers and other transactions
may, depending on the form of consideration the stockholder would receive in the transaction, be entitled to appraisal rights pursuant to which the stockholder would receive, in lieu of the consideration the stockholder would otherwise receive for
its shares in the transaction, cash in an amount equal to the fair value of its shares as determined by the Delaware Court of Chancery.</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;The certificate of incorporation may provide that appraisal rights are available for shares as a
result of an amendment to the certificate of incorporation, any merger or consolidation or the sale of all or substantially all of the assets.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B><I>Dissolution</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Under
Bermuda law, a solvent company may be wound up by way of a shareholders&#146; voluntary liquidation. Prior to the company entering liquidation, a majority of the directors shall each make a statutory declaration, which states that the directors have
made a full enquiry into the affairs of the company and have formed the opinion that the company will be able to pay its debts within a period of 12 months of the commencement of the winding up and must file the statutory declaration with the
Registrar of Companies in Bermuda. The general meeting will be convened primarily for the purposes of passing a resolution that the company be wound up voluntarily and appointing a liquidator. The winding up of the company is deemed to commence at
the time of the passing of the resolution.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Under
Delaware law, a corporation may voluntarily dissolve (1)&nbsp;if a majority of the board of directors adopts a resolution to that effect and the holders of a majority of the issued and outstanding shares entitled to vote thereon vote for such
dissolution; or (2)&nbsp;if all shareholders entitled to vote thereon consent in writing to such dissolution.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B><I>Shareholders&#146; Derivative Actions</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Shareholder class&nbsp;actions and derivative actions are generally not available to shareholders
under Bermuda law in the same way as under the laws of</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;In any
derivative suit instituted by a stockholder of a corporation, it shall be averred in the complaint that the plaintiff was a stockholder of</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">207 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Bermuda</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Delaware</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman">the United States. Bermuda courts, however, would ordinarily be expected to permit a shareholder to commence an action in
the name of a company to remedy a wrong to the company where the act complained of is alleged to be beyond the corporate power of the company or illegal, or would result in the violation of the company&#146;s memorandum of association or <FONT
STYLE="white-space:nowrap">bye-laws.</FONT> Furthermore, consideration would be given by a Bermuda court to acts that are alleged to constitute a fraud against the minority shareholders or, for instance, where an act requires the approval of a
greater percentage of the company&#146;s shareholders than that which actually approved it.</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Under our amended and restated bye-laws to be in effect upon the closing of this offering and as
permitted by Bermuda law, each shareholder will waive any claim or right of action against our directors or officers for any action taken by directors or officers in the performance of their duties, except for actions involving fraud or dishonesty
or any claims of violations of the Securities Act or the Exchange Act. Additionally, to the fullest extent permitted by applicable law, a director or officer of the Company will not be liable to the Company or its shareholders for breach of
fiduciary duty as a director or officer.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.50em; font-size:10pt; font-family:Times New Roman">the corporation at the time of the transaction of which he complains or that such stockholder&#146;s stock thereafter
devolved upon such stockholder by operation of law.</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;The DGCL authorizes corporations to limit or eliminate the personal liability of directors and
certain officers to corporations and their stockholders for monetary damages for breaches of directors&#146; fiduciary duties, subject to certain exceptions. Currently, the DGCL does not permit exculpation of liability for: (i) a director or officer
for any breach of the director&#146;s or officer&#146;s duty of loyalty to a corporation or its stockholders; (ii) a director or officer for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law;
(iii) a director for unlawful payment of dividends or unlawful stock repurchases or redemptions, as provided under Section 174 of the DGCL; (iv) a director or officer for any transaction from which the director or officer derived an improper
personal benefit; or (v) an officer in any action by or in the right of the corporation.</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">208 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom744414_19"></A>MATERIAL BERMUDA, IRISH AND U.S. FEDERAL INCOME TAX
CONSIDERATIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following is a discussion of the material Bermuda, Irish and U.S. federal income tax considerations that may be
relevant to an investment decision by a potential investor with respect to our common shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Bermuda Tax Considerations </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under current law, we are not subject to tax on income or profits tax, withholding tax, capital gains tax, capital transfer tax, estate duty
or inheritance tax payable by us or by our shareholders in respect of our common shares. Furthermore, we have obtained an assurance from the Minister of Finance of Bermuda under the Exempted Undertakings Tax Protection Act 1966 (the &#147;EUTP
Act&#148;) that, in the event that any legislation is enacted in Bermuda imposing any tax computed on profits or income, or computed on any capital asset, gain or appreciation or any tax in the nature of estate duty or inheritance tax, such tax
shall not, until March&nbsp;31, 2035, be applicable to us or to any of our operations or to our shares, debentures or other obligations except insofar as such tax applies to persons ordinarily resident in Bermuda or is payable by us in respect of
real property owned or leased by us in Bermuda. As a result of changes made to the EUTP Act by the CIT Act (as defined below), this assurance has been made subject to the application of any taxes pursuant to the CIT Act, as described further below.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On December&nbsp;20, 2021, the OECD published the Pillar Two / Global Minimum Tax Rules which are aimed at ensuring that large
multinational enterprises will be subject to a global minimum 15% tax rate (&#147;Pillar Two&#148;). The European Union Council Directive (EU) 2022/2523, adopted on December&nbsp;15, 2022, requires that E.U. Member States implement the Pillar Two
rules into domestic law by December&nbsp;31, 2023. The Bermuda Government has responded to the Pillar Two initiative passing the Corporate Income Tax Act 2023 (the &#147;CIT Act&#148;), on December&nbsp;27, 2023, to introduce a corporate income tax
on certain Bermuda entities with effect from January&nbsp;1, 2025. As a result of changes made to the EUTP Act by the CIT Act, this assurance has been made subject to the application of any taxes pursuant to the CIT Act, as described further below.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the 2023 Budget, the Bermuda Government announced the formation of an International Tax Working Group consisting of specialists in
international tax matters and representatives of various bodies whose members may be directly impacted by such to examine how Bermuda can appropriately implement the Pillar Two initiative. The Working Group reported its findings and provided
recommendations to the Bermuda Government in July 2023. The Bermuda Government subsequently issued three public consultation papers as part of its considerations on the introduction of a corporate income tax in Bermuda, on August&nbsp;8, 2023,
October&nbsp;5, 2023 and November&nbsp;10, 2023. On December&nbsp;15, 2023, Bermuda passed the CIT Act, which became fully operative with respect to the imposition of corporate income tax on January&nbsp;1, 2025. The Corporate Income Tax Act 2023
Amendment Regulations 2024 (the &#147;Regulations&#148;) amending the CIT Act were made on 20&nbsp;December 2024 by the Minister of Finance in Bermuda. (For the purposes of this summary, references to CIT Act are to the CIT Act, as amended by the
Regulations.) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Ministry of Finance in Bermuda has issued guidance in the form of Frequently Asked Questions (FAQs) with respect to the
CIT Act (mostly recently dated November&nbsp;18, 2024) and intends to develop further FAQs in response to developments in the application of the law, and in international tax laws and practices in other jurisdictions, and which may impact the
application of the CIT Act in practice, and further changes may apply. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A primary stated objective in developing the corporate income tax
is to ensure to the greatest extent possible that it is not a material incremental expense by ensuring that the Bermuda corporate income tax qualifies as a Covered Tax for the purposes of the GloBE Rules and thereby reduce the amount, if any, of
top-up tax payable to other jurisdictions and prevent the double taxation of profits earned in Bermuda. A second stated objective is the desire to remain aligned so far as practicable with the GloBE Rules. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">209 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under the CIT Act, Bermuda corporate income tax will be chargeable in respect of fiscal
years beginning on or after January&nbsp;1, 2025 and will apply only to Bermuda Constituent Entities (as defined in the CIT Act) of an In Scope MNE Group (as defined in the CIT Act). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A &#145;Bermuda Constituent Entity&#146; is a Bermuda Tax Resident Entity or a Bermuda Permanent Establishment (each as defined in the CIT
Act). A &#145;Bermuda Tax Resident Entity&#146; means an entity that is incorporated, formed or organised in Bermuda unless the entity is tax resident in another jurisdiction under the laws of that jurisdiction based on its location of management
and control. A &#145;Bermuda Permanent Establishment&#146; means A fixed place of business in Bermuda through which the business of an entity which is not a Bermuda Tax Resident Entity is wholly or partly carried on as determined in accordance with
Article&nbsp;5 of the OECD Model Tax Convention. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">An In Scope MNE Group for these purposes is a group which meets the relevant revenue
threshold (EUR&nbsp;750&nbsp;million or more in annual revenues in at least two of the four fiscal years immediately preceding the fiscal year in question) and is a MNE Group (being a group (as defined in the CIT Act) comprising of an ultimate
parent entity and one or more entities (which includes permanent establishments) located in another jurisdiction). For MNE Groups that meet the revenue threshold, corporate income tax will generally apply to each Bermuda Tax Resident Entity and
Bermuda Permanent Establishment that is a constituent entity of such MNE Group. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We note that, following the consummation of this
offering and on the assumption that Kestra Medical Technologies, Ltd. will become tax resident in Ireland based under the laws of Ireland based on its location of management and control (as described in the section titled &#147;Organizational
Transactions&#148;). Based on this and the assumption that Kestra Medical Technologies, Ltd. will not be a Bermuda Permanent Establishment (as defined in the CIT Act), we anticipate that Kestra Medical Technologies, Ltd. will not be a Bermuda
Constituent Entity Group for purposes of the CIT Act and that it will not be considered in scope for the purposes of the CIT Act. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Irish Tax
Considerations </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following is a general summary of the main Irish tax considerations that will become applicable to certain
investors who are the owners of our common shares following the establishment of the Company&#146;s tax residency in Ireland following the consummation of this offering. It is based on existing Irish law and our understanding of the practices of the
Irish Revenue Commissioners on the date of this document. Legislative, administrative or judicial changes may modify the tax consequences described below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The statements do not constitute tax advice and are intended only as a general guide. Furthermore, this information applies only to our shares
that are held as capital assets and does not apply to all categories of shareholders, such as dealers in securities, trustees, insurance companies, collective investment schemes or shareholders who have, or who are deemed to have, acquired their
shares by virtue of an office or employment. This summary is not exhaustive and shareholders should consult their own tax advisers as to the tax consequences in Ireland, or other relevant jurisdictions of this offering, including the acquisition,
ownership and disposition of our shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Tax on Chargeable Gains </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A disposal of our shares by a shareholder who is not resident or ordinarily resident for tax purposes in Ireland should not give rise to Irish
tax on any chargeable gain realized on such disposal unless such shares are used, held or acquired for the purposes of a trade or business carried on by such shareholder through a branch or agency in Ireland. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A disposal of our shares by an Irish resident or ordinarily resident shareholder may, depending on the circumstances (including the
availability of exemptions and reliefs), give rise to a chargeable gain or allowable loss for that shareholder. The rate of capital gains tax in Ireland is currently 33%. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">210 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A holder of our shares who is an individual and who is temporarily <FONT
STYLE="white-space:nowrap">non-resident</FONT> in Ireland may, under Irish anti-avoidance legislation, be liable to Irish tax on any chargeable gain realized on a disposal during the period in which such individual is
<FONT STYLE="white-space:nowrap">non-resident.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dividend Withholding Tax </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Dividend withholding tax, or DWT, (currently at a rate of 25%) may arise in respect of dividends or distributions from an Irish tax resident
company, such as the Company when it establishes tax residence in Ireland unless an exemption applies. Where DWT does arise in respect of dividends, the company is responsible for deducting DWT at source and forwarding the relevant payment to the
Irish Revenue Commissioners. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Certain shareholders are entitled to an exemption from DWT. In particular, dividends to a <FONT
STYLE="white-space:nowrap">non-Irish</FONT> resident shareholder should not be subject to DWT if the shareholder is beneficially entitled to the dividend and is: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">an individual shareholder resident for tax purposes in a &#147;relevant territory&#148; and the individual is
neither resident nor ordinarily resident in Ireland; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a corporate shareholder resident for tax purposes in a &#147;relevant territory&#148; provided that the
corporate shareholder is not under the control, whether directly or indirectly, of a person or persons who is or are resident in Ireland; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a corporate shareholder that is not resident for tax purposes in Ireland and which is ultimately controlled,
directly or indirectly, by persons resident in a &#147;relevant territory&#148;; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a corporate shareholder that is not resident for tax purposes in Ireland and whose principal class of shares
(or those of its 75% parent) is substantially and regularly traded on a stock exchange in Ireland, a recognized stock exchange in a &#147;relevant territory&#148; or on such other stock exchange approved by the Irish Minister for Finance; or
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a corporate shareholder that is not resident for tax purposes in Ireland and is wholly owned, directly or
indirectly, by two or more companies where the principal class of shares of each of such companies is substantially and regularly traded on a stock exchange in Ireland, a recognized stock exchange in a &#147;relevant territory&#148; or on such other
stock exchange approved by the Irish Minister for Finance, and provided that, in all cases noted above (but subject to the exception in the paragraph below regarding &#147;U.S. Resident Shareholders&#148;), the shareholder has provided a relevant
Irish DWT declaration form to his or her broker before the record date for the dividend (in the case of shares held through DTC), and the relevant information is further transmitted to the Company (in the case of shares held through DTC) or to our
transfer agent (in the case of shares held outside of DTC). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A list of &#147;relevant territories&#148; for the purposes
of DWT is set forth below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="29%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.40em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Albania</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.40em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Iceland</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.40em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Russia</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.40em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Armenia</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.40em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;India</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.40em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Saudi Arabia</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.40em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Australia</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.40em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Israel</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.40em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Serbia</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.40em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Austria</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.40em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Italy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.40em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Singapore</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.40em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Bahrain</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.40em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Japan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.40em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Slovak&nbsp;Republic</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.40em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Belarus</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.40em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Kazakhstan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.40em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Slovenia</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.40em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Belgium</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.40em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Kosovo</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.40em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;South Africa</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.40em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Bosnia&nbsp;&amp; Herzegovina</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.40em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Kuwait</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.40em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Spain</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.40em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Botswana</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.40em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Latvia</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.40em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Sweden</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">211 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="29%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.40em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Bulgaria</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.40em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Lithuania</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.40em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Switzerland</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.40em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Canada</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.40em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Luxembourg</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.40em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Thailand</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.40em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Chile</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.40em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Macedonia</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.40em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;The&nbsp;Republic&nbsp;of&nbsp;Korea</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.40em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;China</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.40em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Malaysia</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.40em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;The&nbsp;Republic&nbsp;of&nbsp;Turkey</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.40em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Croatia</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.40em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Malta</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.40em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Ukraine</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.40em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Cyprus</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.40em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Mexico</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.40em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;United Arab Emirates</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.40em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Czech Republic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.40em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Moldova</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.40em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;United Kingdom</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.40em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Denmark</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.40em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Montenegro</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.40em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;United States</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.40em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Egypt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.40em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Morocco</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.40em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Uzbekistan</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.40em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Estonia</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.40em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Netherlands</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.40em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Vietnam</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.40em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Ethiopia</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.40em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;New Zealand</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.40em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Zambia</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.40em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Finland</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.40em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Norway</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.40em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;France</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.40em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Pakistan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.40em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Georgia</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.40em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Panama</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.40em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Germany</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.40em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Poland</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Prior to paying any dividend, the Company intends to put in place an agreement with an entity which is
recognized by the Irish Revenue Commissioners as a &#147;qualifying intermediary&#148; which satisfies one of the Irish requirements for dividends to be paid free of DWT to certain shareholders who hold their shares through DTC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>U.S. Resident Shareholders </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Dividends paid in respect of shares in an Irish resident company that are owned by residents of the United States and held through DTC will
not be subject to DWT provided that the address of the beneficial owner of the shares in the records of the broker is in the United States. We strongly recommend that such shareholders ensure that their information has been properly recorded by
their brokers (so that such brokers can provide the relevant information to a qualifying intermediary appointed by us). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Dividends paid in
respect of shares in an Irish resident company that are owned by residents of the United States and held outside of DTC will not be subject to DWT provided that the shareholder has completed the relevant Irish DWT declaration form and this
declaration form remains valid. Such shareholders must provide the relevant Irish DWT declaration form to our transfer agent at least seven business days before the record date for the first dividend payment to which they are entitled. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If a U.S resident shareholder receives a dividend subject to DWT, that shareholder should generally be able to make an application for a
refund of DWT from the Irish Revenue Commissioners subject to certain time limits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Residents of &#147;Relevant Territories&#148; other than the
United States </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Shareholders who are residents of &#147;relevant territories&#148; other than the United States (regardless of when
such shareholders acquired their shares) must complete the appropriate Irish DWT declaration form in order to receive dividends without DWT. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Shareholders must provide the appropriate Irish DWT declaration form to their brokers (so that such brokers can provide the relevant
information to a qualifying intermediary appointed by us) before the record date for the first dividend to which they are entitled (in the case of shares held through DTC), or to our transfer agent at least seven business days before such record
date (in the case of shares held outside of DTC). We strongly recommend that such shareholders complete the appropriate Irish DWT declaration form and provide them to their brokers or our transfer agent as soon as possible. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">212 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If a shareholder who is resident in a &#147;relevant territory&#148; and entitled to an
exemption from our DWT receives a dividend subject to DWT, that shareholder should generally be able to make an application for a refund of DWT from the Irish Revenue Commissioners subject to certain time limits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Irish Resident Shareholders </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Irish tax resident or ordinarily resident shareholders will generally be subject to DWT in respect of dividends or distributions received from
an Irish resident company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Irish tax resident or ordinarily resident shareholders that are entitled to receive dividends without DWT must
complete the relevant Irish DWT declaration form and provide the declaration form to their brokers (so that such brokers can provide the relevant information to a qualifying intermediary appointed by us) before the record date for the first dividend
to which they are entitled (in the case of shares held through DTC), or to our transfer agent at least seven business days before such record date (in the case of shares held outside of DTC). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Irish tax resident or ordinarily resident shareholders who are not entitled to an exemption from DWT and who are subject to Irish tax should
consult their own tax adviser. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Persons </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Shareholders that do not fall within one of the categories mentioned above may fall within other exemptions from DWT. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If a shareholder is exempt from DWT but receives a dividend subject to DWT, that shareholder may be able to claim a refund of DWT from the
Irish Revenue Commissioners subject to certain time limits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income Tax on Dividends </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-Irish</FONT> Resident Shareholders. A shareholder who is not resident or ordinarily resident for tax
purposes in Ireland and who is entitled to an exemption from DWT, generally has no liability to Irish income tax or income charges on a dividend from an Irish resident company unless that shareholder holds the shares through a branch or agency which
carries on a trade in Ireland. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A shareholder who is not resident or ordinarily resident for tax purposes in Ireland and who is not
entitled to an exemption from DWT, generally has no additional liability to Irish income tax or income charges unless that shareholder holds the shares through a branch or agency which carries on a trade in Ireland. The shareholder&#146;s liability
to tax is effectively limited to the amount of DWT already deducted by the company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Irish Resident Shareholders. Irish resident or
ordinarily resident individual shareholders may be subject to Irish income tax and income charges such as pay related social insurance (PRSI) and the Universal Social Charge (USC) on dividends received from us. Such shareholders should consult their
own tax adviser. Irish resident corporate shareholders should not be subject to tax on dividends from us on the basis that the dividend is not in respect of preference shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stamp Duty </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Irish stamp duty
should not be payable in respect of transfers of our common shares for cash. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Capital Acquisitions Tax </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Irish capital acquisitions tax comprises principally gift tax and inheritance tax on property situated in Ireland for capital acquisitions tax
purposes or otherwise within the territorial scope of capital acquisitions tax by virtue of the Irish tax residence, ordinary tax residence or domicile of the donor or donee of the gift or inheritance. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">213 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">It is considered that the common shares are not Irish situate property for the purposes of
Irish capital acquisitions tax. As such a gift or inheritance of our common shares should not be within the charge to Irish capital acquisitions tax if both the donor and the donee are not tax resident or ordinarily resident in Ireland at the
relevant date of the gift or inheritance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If either a donor or donee of our common shares is resident or ordinarily resident in Ireland
at the time of the gift or inheritance they may be within the charge to Irish capital acquisitions tax and they should consult their own tax advisers as to the Irish tax consequences. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Federal Income Tax Consequences for U.S. Holders </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following discussion is a summary of material U.S. federal income tax consequences to a U.S. Holder (as defined below), under current law,
of the purchase, ownership, and disposition of our common shares acquired pursuant to this offering. It does not describe all tax considerations that may be relevant to a particular person&#146;s decision to acquire our common shares. This
discussion applies only to a U.S. Holder that holds our common shares as a capital asset for U.S. federal income tax purposes (generally, property held for investment) within the meaning of Section&nbsp;1221 of the Code, and this discussion applies
only such common shares. This discussion is general in nature and it does not describe all of the U.S. federal income tax consequences that may be relevant in light of the U.S. Holder&#146;s particular circumstances, including the potential
application of the Medicare contribution tax, estate or gift tax consequences, any tax consequences other than U.S. federal income tax consequences, and tax consequences applicable to U.S. Holders in special tax situations, such as: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">banks; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain financial institutions; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">insurance companies; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulated investment companies; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">real estate investment trusts or real estate mortgage investment conduits; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;controlled foreign corporations,&#148; and &#147;passive foreign investment companies,&#148; each as
defined in the Code, corporations that accumulate earnings to avoid U.S. federal income tax, or expatriated entities subject to Section&nbsp;7874 of the Code; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">brokers or dealers in stocks and securities, or currencies; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons who use or are required to use a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> method of accounting; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain former citizens or residents of the United States subject to Section&nbsp;877 of the Code;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">entities subject to the U.S. anti-inversion rules or the base erosion and anti-abuse tax; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">non-U.S.</FONT> persons or entities; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">tax-exempt</FONT> organizations and entities, including an &#147;individual
retirement account&#148; as defined in the Code or a &#147;Roth IRA&#148;; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons subject to the alternative minimum tax provisions of the Code; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons who are subject to Section&nbsp;451(b) of the Code; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">214 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons whose functional currency for U.S. federal income tax purposes is not the U.S. dollar;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons holding common shares as part of a straddle, hedging, conversion or integrated transaction or persons
entering into a constructive sale with respect to common shares; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons holding common shares through a bank, financial institution or other entity, or a branch thereof,
located, organized or resident outside the United States; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons who hold or receive our common shares pursuant to the exercise of an employee stock option or otherwise
as compensation; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">tax qualified retirement plans; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons that actually or constructively own 10% or more (by vote or value) of our common shares; or
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">entities classified as partnerships or other pass-through entities (including S corporations), or persons holding
common shares through such entities. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If a partnership (including an entity or arrangement classified as a partnership
for U.S. federal income tax purposes) holds common shares, the U.S. federal income tax treatment of a partner in the partnership generally will depend upon the status of the partner and the activities of the partner and the partnership. A
partnership holding our common shares, or a partner in such a partnership, should consult its tax advisors regarding the tax consequences of investing in and holding the common shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This discussion is based on the federal income tax laws of the United States as of the date of this prospectus, including the Code, existing
and proposed Treasury Regulations promulgated thereunder, judicial authority, published administrative positions of the U.S. Internal Revenue Service (&#147;IRS&#148;) and other applicable authorities. All of the foregoing authorities are subject to
change or differing interpretations, possibly with retroactive effect and could significantly affect the tax consequences described below. We have not sought, and do not intend to seek, any ruling from the IRS with respect to the statements made and
the conclusions reached in the following discussion and there can be no assurance that the IRS or a court will not take a contrary position to the tax consequences discussed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">THIS SUMMARY OF CERTAIN U.S. FEDERAL INCOME TAX CONSIDERATIONS IS FOR GENERAL INFORMATION ONLY AND IS NOT TAX ADVICE. YOU SHOULD CONSULT YOUR
TAX ADVISOR WITH RESPECT TO THE APPLICATION OF U.S. FEDERAL INCOME TAX LAWS TO YOUR PARTICULAR SITUATION AS WELL AS ANY TAX CONSEQUENCES OF THE PURCHASE, OWNERSHIP, AND DISPOSITION OF THE COMMON SHARES ARISING UNDER U.S. FEDERAL ESTATE OR GIFT TAX
RULES OR UNDER THE LAWS OF ANY STATE, LOCAL, <FONT STYLE="white-space:nowrap">NON-U.S.</FONT> OR ANY OTHER TAXING JURISDICTION OR UNDER ANY APPLICABLE TAX TREATY. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For purposes of the discussion below, a &#147;U.S. Holder&#148; is a beneficial owner of our common shares that is, for U.S. federal income
tax purposes: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an individual who is a citizen or resident of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a corporation (or other entity treated as a corporation for U.S. federal income tax purposes) created or
organized in or under the laws of the United States, any state thereof or the District of Columbia; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an estate, the income of which is subject to U.S. federal income taxation regardless of its source; or
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">215 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a trust, if either&nbsp;(i) a court within the United States is able to exercise primary jurisdiction over its
administration and one or more U.S. persons have the authority to control all of its substantial decisions or (ii)&nbsp;the trust has a valid election in effect under applicable Treasury regulations to treat such trust as a domestic trust.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dividends and Other Distributions on the Common Shares </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Subject to the PFIC rules discussed below, the gross amount of any distribution that we make to U.S. Holders with respect to our common shares
(including the amount of any tax withheld) generally will be taxable as a dividend, to the extent paid out of our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. Such income generally will be
includable in gross income in the year actually or constructively received. To the extent the amount of the distribution exceeds our current and accumulated earnings and profits, such excess amount generally will be treated first as a <FONT
STYLE="white-space:nowrap">tax-free</FONT> return of tax basis in the common shares, and then, to the extent such excess amount exceeds the holder&#146;s tax basis in the common shares, as capital gain and will be treated as described below in the
section relating to the disposition of our common shares. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Dividends received by corporate U.S. Holders generally will not be eligible
for the dividends-received deduction available to U.S. corporations under the Code. Subject to applicable limitations, including conditions relating to holding period, dividends received by certain
<FONT STYLE="white-space:nowrap">non-corporate</FONT> U.S. Holders may be eligible for taxation as &#147;qualified dividend income&#148; if we are a &#147;qualified foreign corporation&#148; and other conditions discussed below are met. A <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> corporation is treated as a qualified foreign corporation (i)&nbsp;with respect to dividends paid by that corporation on shares that are readily tradable on an established securities market in the United
States (such as Nasdaq) or (ii)&nbsp;if such <FONT STYLE="white-space:nowrap">non-U.S.</FONT> corporation is eligible for the benefits of a qualifying income tax treaty with the United States that the IRS determines is satisfactory and includes an
exchange of information program. However, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> corporation will not be treated as a qualified foreign corporation if it is a PFIC in the taxable year in which the dividend is paid or the preceding
taxable year. Therefore, subject to applicable limitations, dividends paid to certain <FONT STYLE="white-space:nowrap">non-corporate</FONT> U.S. Holders may be taxable at rates not in excess of the long-term capital gain rate applicable to such U.S.
Holder. U.S. Holders should consult their tax advisors regarding the availability of such lower rate for any dividends paid with respect to our common shares. The amount of a dividend will include any amounts withheld by us in respect of any <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> taxes. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Subject to the PFIC rules described below, the amount of a dividend generally will
be treated as foreign-source dividend. The amount of any dividend income paid in a functional currency other than the U.S. dollar will be the U.S. dollar amount calculated by reference to the exchange rate in effect on the date of actual or
constructive receipt, regardless of whether the payment is in fact converted into U.S. dollars at that time. If the dividend is converted into U.S. dollars on the date of receipt, a U.S. Holder should not be required to recognize foreign currency
gain or loss in respect of the dividend income. A U.S. Holder may have foreign currency gain or loss if the dividend is converted into U.S. dollars after the date of receipt. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Subject to applicable limitations, some of which vary depending upon the U.S. Holder&#146;s particular circumstances, <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> income taxes withheld from dividends on our common shares may be creditable against the U.S. Holder&#146;s U.S. federal income tax liability. The rules governing foreign tax credits are complex, and U.S.
Holders should consult their tax advisors regarding the creditability of any <FONT STYLE="white-space:nowrap">non-U.S.</FONT> taxes based on their particular circumstances. In lieu of claiming a foreign tax credit, U.S. Holders may, at their
election, deduct <FONT STYLE="white-space:nowrap">non-U.S.</FONT> taxes in computing their taxable income, subject to generally applicable limitations under U.S. law. An election to deduct <FONT STYLE="white-space:nowrap">non-U.S.</FONT> taxes
instead of claiming foreign tax credits applies to all foreign taxes paid or accrued in the taxable year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sale, Exchange, or Other Taxable
Disposition of the Common Shares </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Subject to the PFIC rules described below, U.S. Holders generally will recognize gain or loss on
a sale, exchange or other taxable disposition of common shares in an amount equal to the difference between the amount </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">216 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
realized for U.S. federal income tax purposes on the sale, exchange or other taxable disposition and the holder&#146;s adjusted tax basis in the common shares. Such gain or loss generally will be
capital gain or loss and will be long-term capital gain or loss if the U.S. Holder held the common shares disposed of for more than one year. Any gain or loss recognized by U.S. Holders on a disposition of our common shares generally will be treated
as U.S.-source income or loss for foreign tax credit limitation purposes. The deductibility of capital losses is subject to various limitations. U.S. Holders are urged to consult their tax advisors regarding the proper treatment of gain or loss, as
well as the availability of a foreign tax credit, based on their particular circumstances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Passive Foreign Investment Company </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under the Code, we may be a PFIC for any taxable year in which, after the application of certain &#147;look-through&#148; rules with respect
to subsidiaries, either (i) 75% or more of our gross income consists of &#147;passive income,&#148; or (ii) 50% or more of the average quarterly value of our assets consist of assets that produce, or are held for the production of, &#147;passive
income.&#148; For purposes of the above calculations, we will be treated as if we hold our proportionate share of the assets of, and receive directly our proportionate share of the income of, any other corporation in which we directly or indirectly
own at least 25%, by value, of the shares of such corporation. Passive income generally includes dividends, interest, rents, certain <FONT STYLE="white-space:nowrap">non-active</FONT> royalties and capital gains. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Based on the nature of our business, our financial statements, our expectations about the nature and amount of our income, assets and
activities and the expected price of our common shares in this offering, we do not expect to be a PFIC for U.S. federal income tax purposes for the current taxable year or in the foreseeable future. However, whether we will be a PFIC in the current
year or any future year is a factual determination that must be made annually at the close of each taxable year, and, thus, is subject to significant uncertainty. Among other things, a determination of whether we are PFIC will depend on the
composition of our income and assets and the market value of our assets from time to time. Accordingly, there can be no assurance that we will not be a PFIC in the current year or any future taxable year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If we are a PFIC for any year during which a U.S. Holder holds or is deemed to hold common shares, we generally would continue to be treated
as a PFIC with respect to that U.S. Holder for all succeeding years during which the U.S. Holder holds or is deemed to hold common shares, even if we ceased to meet the threshold requirements for PFIC status, unless under certain circumstances the
U.S. Holder makes a valid deemed sale or deemed dividend election under the applicable Treasury regulations with respect to its common shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Generally, if we were a PFIC for any taxable year during which a U.S. Holder held or is deemed to have held common shares, gain recognized by
a U.S. Holder on a sale or other disposition (including certain pledges) of such common shares, would be allocated ratably over the U.S. Holder&#146;s holding period for such common shares. The amounts allocated to the taxable year of the sale or
other disposition and to any year before we became a PFIC would be taxed as ordinary income. The amount allocated to each other taxable year would be subject to tax at the highest rate in effect for individuals or corporations, as appropriate, for
that taxable year, and an interest charge would be imposed on the amount allocated to that taxable year. Further, to the extent that any distribution received by a U.S. Holder with respect to its common shares exceeds 125% of the average of the
annual distributions on the common shares received during the preceding three years or the U.S. Holder&#146;s holding period, whichever is shorter, that distribution would be subject to taxation in the same manner as gain, described immediately
above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A U.S. Holder can avoid certain of the adverse rules described above by making a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election with respect to its common shares, provided that the common shares are &#147;marketable.&#148; Common shares generally will be marketable if they are &#147;regularly traded&#148; on a
&#147;qualified exchange&#148; or other market within the meaning of applicable Treasury Regulations. If a U.S. Holder makes the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election, it generally
will recognize as ordinary income any excess of the fair market value of the common shares at the end of each taxable year over their adjusted tax basis, and will recognize an ordinary loss in respect of any excess of the adjusted tax basis of the
common shares over their fair market value at the end of the taxable year (but only to the extent of the net amount of income previously included as a result of the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election). If a U.S. Holder makes the election, the U.S. Holder&#146;s tax basis in the common shares will be adjusted to reflect the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">217 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
income or loss amounts recognized. Any gain recognized on the sale or other disposition of common shares, as applicable, in a year when we are a PFIC will be treated as ordinary income and any
loss will be treated as an ordinary loss (but only to the extent of the net amount of income previously included as a result of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election). U.S.
Holders should consult their tax advisers regarding the availability and advisability of making a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election based on their particular circumstances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, a U.S. Holder can avoid certain of the adverse rules described above by making a QEF Election with respect to such PFIC, and each
PFIC in which the PFIC holds equity interests, if the PFIC provides the information necessary for such election to be made. We do not currently expect to provide information that would allow a U.S. Holder to make a QEF Election in the event that we
are classified as a PFIC and, therefore, U.S. Holders should assume such election would not be available. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, if we were a PFIC
or, with respect to a particular U.S. Holder, were treated as a PFIC for the taxable year in which we paid a dividend or for the prior taxable year, the preferential dividend rates discussed above with respect to dividends paid to certain <FONT
STYLE="white-space:nowrap">non-corporate</FONT> U.S. Holders would not apply. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If a U.S. Holder owns common shares during any year in
which we are a PFIC, the U.S. Holder generally must file annual reports, containing such information as the U.S. Treasury Department may require on IRS Form 8621 (or any successor form) with respect to us, generally with the U.S. Holder&#146;s
federal income tax return for that year, unless otherwise specified in the instructions with respect to such form. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">U.S. Holders should
consult their tax advisors concerning our potential PFIC status and the potential application of the PFIC rules. The U.S. federal income tax rules relating to PFICs are very complex. U.S. Holders are strongly urged to consult their tax advisors with
respect to the impact of PFIC status on the purchase, ownership and disposition of our common shares, as applicable, the consequences to them of an investment in a PFIC, any elections available with respect to the common shares and the IRS
information reporting obligations with respect to the purchase, ownership and disposition of common shares of a PFIC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Information Reporting and
Backup Withholding </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Information reporting to the IRS and backup withholding generally will apply to dividends in respect of our
common shares and the proceeds from the sale or exchange of our common shares that are paid to U.S. Holders within the United States (and in certain cases, outside the United States). However, backup withholding generally will not apply if the U.S.
Holder furnishes a correct taxpayer identification number and make any other required certification, generally on IRS Form <FONT STYLE="white-space:nowrap">W-9,</FONT> or otherwise establishes an exemption from backup withholding. Backup withholding
is not an additional tax. Amounts withheld as backup withholding generally are allowed as a credit against U.S. federal income tax liability and U.S. Holders may be entitled to obtain a refund of any excess amounts withheld under the backup
withholding rules if you file an appropriate claim for refund is filed and the required information is furnished to the IRS in a timely manner. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Each U.S. Holder should consult its tax advisor regarding the application of the information reporting and backup withholding rules. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Information with Respect to Foreign Financial Assets </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Each U.S. Holder who is an individual generally will be required to report our name, address and such information relating to an interest in
the common shares as is necessary to identify the class or issue of which its common shares are a part. These requirements are subject to exceptions, including an exception for common shares held in accounts maintained by certain financial
institutions and an exception applicable if the aggregate value of all &#147;specified foreign financial assets&#148; (as defined in the Code) does not exceed certain thresholds. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Each U.S. Holder should consult its tax advisor regarding the application of these information reporting rules. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">218 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom744414_20"></A>UNDERWRITING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">BofA Securities, Inc., Goldman Sachs&nbsp;&amp; Co. LLC and Piper Sandler&nbsp;&amp; Co. are acting as representatives of the underwriters
named below. Subject to the terms and conditions set forth in an underwriting agreement among us and the underwriters, we have agreed to sell to the underwriters, and each of the underwriters has agreed, severally and not jointly, to purchase from
us, the number of shares of common shares set forth opposite its name below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&#8196;&#8202;<U>Underwriter</U></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Number&nbsp;of<BR>Shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BofA Securities, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goldman Sachs&nbsp;&amp; Co. LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Piper Sandler&nbsp;&amp; Co.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wells Fargo Securities, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stifel, Nicolaus &amp; Company, Incorporated </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nomura Securities International, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">WR Securities, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.15em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;Wolfe | Nomura Alliance&#148; is the marketing name used by Wolfe Research Securities and Nomura
Securities International, Inc. in connection with certain equity capital markets activities conducted jointly by the firms. Both Nomura Securities International, Inc. and WR Securities, LLC are serving as underwriters in the offering described
herein. In addition, WR Securities, LLC and certain of its affiliates may provide sales support services, investor feedback, investor education, and/or other independent equity research services in connection with this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Subject to the terms and conditions set forth in the underwriting agreement, the underwriters have agreed, severally and not jointly, to
purchase all of the shares sold under the underwriting agreement if any of these shares are purchased. If an underwriter defaults, the underwriting agreement provides that the purchase commitments of the nondefaulting underwriters may be increased
or the underwriting agreement may be terminated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have agreed to indemnify the underwriters against certain liabilities, including
liabilities under the Securities Act, or to contribute to payments the underwriters may be required to make in respect of those liabilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The underwriters are offering the shares, subject to prior sale, when, as and if issued to and accepted by them, subject to approval of legal
matters by their counsel, including the validity of the shares, and other conditions contained in the underwriting agreement, such as the receipt by the underwriters of officer&#146;s certificates and legal opinions. The underwriters reserve the
right to withdraw, cancel or modify offers to the public and to reject orders in whole or in part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Commissions and Discounts </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The representatives have advised us that the underwriters propose initially to offer the shares to the public at the public offering price set
forth on the cover page of this prospectus and to dealers at that price less a concession not in excess of $&#8195;&#8195;&#8195;&#8195;per share. After the initial offering, the public offering price, concession or any other term of the offering
may be changed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table shows the public offering price, underwriting discount and proceeds before expenses to us. The
information assumes either no exercise or full exercise by the underwriters of their over-allotment option to purchase additional shares. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Per&nbsp;Share</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Without&nbsp;Option</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>With&nbsp;Option</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting discount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds, before expenses, to us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">219 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The expenses of the offering, not including the underwriting discount, are estimated at
approximately $6,228,290 and are payable by us.<SUP STYLE="font-size:75%; vertical-align:top"> </SUP>We have agreed to reimburse the underwriters for expenses relating to clearance of this offering with the Financial Industry Regulatory Authority
and other regulatory fees up to $40,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have also agreed to reimburse the underwriters for certain fees and expenses in connection
with the reserved share program described below, including the fees and disbursements of counsel to the underwriters in an amount up to $25,000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Option to Purchase Additional Shares </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have granted an over-allotment option to the underwriters, exercisable for 30 days after the date of this prospectus, to purchase up to
1,500,000 additional shares at the public offering price, less the underwriting discount. If the underwriters exercise this option, each will be obligated, subject to conditions contained in the underwriting agreement, to purchase a number of
additional shares proportionate to that underwriter&#146;s initial amount reflected in the above table. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Sales of Similar Securities </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We, our executive officers and directors and our other existing security holders that collectively own substantially all of our common shares
before this offering have agreed not to sell or transfer any common shares or securities convertible into, exchangeable for, exercisable for, or repayable with common shares (collectively, the &#147;Lock-Up Securities&#148;), for 180 days after the
date of this prospectus without first obtaining the written consent of BofA Securities, Inc., Goldman Sachs &amp; Co. LLC and Piper Sandler &amp; Co. Specifically, we and these other persons have agreed, with certain limited exceptions, not to
directly or indirectly </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">offer, pledge, sell or contract to sell any Lock-Up Securities; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sell any option or contract to purchase any Lock-Up Securities; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">purchase any option or contract to sell any Lock-Up Securities; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">grant any option, right or warrant for the sale of any Lock-Up Securities; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">lend or otherwise dispose of or transfer any common Lock-Up Securities; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">request or demand that we file or make a confidential submission of a registration statement related to the
Lock-Up Securities; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">enter into any hedging, swap, loan or any other agreement or any transaction that transfers, in whole or in part,
the economic consequence of ownership of any Lock-Up Securities whether any such swap or transaction is to be settled by delivery of shares or other securities, in cash or otherwise; or </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">publicly disclose the intention to do any of the foregoing. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This <FONT STYLE="white-space:nowrap">lock-up</FONT> provision applies to Lock-Up Securities owned now or acquired later by the person
executing the agreement or for which the person executing the agreement has or later acquires the power of disposition, or the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities. BofA Securities, Inc., Goldman Sachs &amp; Co. LLC and Piper
Sandler &amp; Co., in their sole discretion, may release the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities subject to the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described above in whole or in part at any time with or
without notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exchange Listing </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have applied to list our common shares on The Nasdaq Global Select Market under the symbol &#147;KMTS.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">220 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Before this offering, there has been no public market for our common shares. The initial
public offering price will be determined through negotiations between us and the representatives. In addition to prevailing market conditions, the factors to be considered in determining the initial public offering price are: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the valuation multiples of publicly traded companies that the representatives believe to be comparable to us,
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our financial information, </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the history of, and the prospects for, our company and the industry in which we compete, </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an assessment of our management, its past and present operations, and the prospects for, and timing of, our
future revenue, </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the present state of our development, and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the above factors in relation to market values and various valuation measures of other companies engaged in
activities similar to ours. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">An active trading market for the shares may not develop. It is also possible that after the
offering the shares will not trade in the public market at or above the initial public offering price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The underwriters do not expect to
sell more than 5% of the shares in the aggregate to accounts over which they exercise discretionary authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Price Stabilization, Short Positions
and Penalty Bids </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Until the distribution of the shares is completed, SEC rules may limit underwriters and selling group members from
bidding for and purchasing our common shares. However, the representatives may engage in transactions that stabilize the price of the common shares, such as bids or purchases to peg, fix or maintain that price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In connection with the offering, the underwriters may purchase and sell our common shares in the open market. These transactions may include
short sales, purchases on the open market to cover positions created by short sales and stabilizing transactions. Short sales involve the sale by the underwriters of a greater number of shares than they are required to purchase in the offering.
&#147;Covered&#148; short sales are sales made in an amount not greater than the underwriters&#146; over-allotment option to purchase additional shares described above. The underwriters may close out any covered short position by either exercising
their over-allotment option to purchase additional shares or purchasing shares in the open market. In determining the source of shares to close out the covered short position, the underwriters will consider, among other things, the price of shares
available for purchase in the open market as compared to the price at which they may purchase shares through the option granted to them. &#147;Naked&#148; short sales are sales in excess of such option. The underwriters must close out any naked
short position by purchasing shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of our common shares in the open market after pricing that
could adversely affect investors who purchase in the offering. Stabilizing transactions consist of various bids for or purchases of shares of common shares made by the underwriters in the open market prior to the completion of the offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The underwriters may also impose a penalty bid. This occurs when a particular underwriter repays to the underwriters a portion of the
underwriting discount received by it because the representatives have repurchased shares sold by or for the account of such underwriter in stabilizing or short covering transactions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">221 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Similar to other purchase transactions, the underwriters&#146; purchases to cover the
syndicate short sales may have the effect of raising or maintaining the market price of our common shares or preventing or retarding a decline in the market price of our common shares. As a result, the price of our common shares may be higher than
the price that might otherwise exist in the open market. The underwriters may conduct these transactions on the Nasdaq Global Select Market, in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT>
market or otherwise. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Neither we nor any of the underwriters make any representation or prediction as to the direction or magnitude
of any effect that the transactions described above may have on the price of our common shares. In addition, neither we nor any of the underwriters make any representation that the representatives will engage in these transactions or that these
transactions, once commenced, will not be discontinued without notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Electronic Distribution </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In connection with the offering, certain of the underwriters or securities dealers may distribute prospectuses by electronic means, such as <FONT
STYLE="white-space:nowrap">e-mail.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Relationships </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The underwriters and their respective affiliates are full service financial institutions engaged in various activities, which may include
sales and trading, commercial and investment banking, advisory, investment management, investment research, principal investment, hedging, market making, brokerage, and other financial and <FONT STYLE="white-space:nowrap">non-financial</FONT>
activities and services. Some of the underwriters and their affiliates have engaged in, and may in the future engage in, investment banking and other commercial dealings in the ordinary course of business with us or our affiliates. They have
received, or may in the future receive, customary fees and commissions for these transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, in the ordinary course of
their business activities, the underwriters and their affiliates may make or hold a broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for
their own account and for the accounts of their customers. Such investments and securities activities may involve securities and/or instruments of ours or our affiliates. The underwriters and their affiliates may also make investment recommendations
and/or publish or express independent research views in respect of such securities or financial instruments and may hold, or recommend to clients that they acquire, long and/or short positions in such securities and instruments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Reserved Shares </B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">At our request, the
underwriters have reserved up to 5% of the common shares offered hereby, for sale at the initial public offering price to our officers, directors, team members and certain of their friends or family. The sales will be made to certain entities and
individuals identified by management through a reserved shares program. Management will provide the list of potential participants to Merrill Lynch, Pierce, Fenner &amp; Smith Incorporated, an underwriter of this offering, which will administer the
reserved shares program. At this time, no indications of interest will be taken. Once the preliminary prospectus has been filed, an invitation package will be made available or sent to each person identified by management, which will include the
preliminary prospectus and other reserved shares program documentation. An invitation to participate in the reserved shares program does not guarantee that the participant will receive an allocation of common shares. Accordingly, we cannot provide
any assurance that any director, officer, team member, or participant will receive an invitation or an allocation in the reserved shares program. If a potential participant is interested in participating, that participant will be required to
complete the required documentation and will be required to return such documentation to the program administrator. The program administrator will not accept funds from any participant until after the registration statement for this offering is
declared effective, this offering is priced, and the participants are notified of their final allocation and given an opportunity to confirm that they wish to purchase the common shares allocated to them. After the registration statement has been
declared effective and this offering is priced, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">222 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
we and the program administrator will prepare a final approved list of allocations. The program administrator will notify each participant who has been allocated common shares of the number of
common shares that have been allocated and the total purchase price due upon confirmation of their participation. Thereafter, participants will be required to wire or transfer their funds to the program administrator. The common shares under the
reserved shares program will be allocated following pricing and settle in the same manner as the common shares sold to the general public. If purchased by directors, officers or team members, these common shares will be subject to a 180-day lock-up
restriction described in this prospectus. If any potential participants purchase reserved common shares, it will reduce the number of common shares available for sale to the general public. Any reserved common shares that are not so purchased will
be offered by the underwriters to the general public on the same terms as the other common shares offered hereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in
the European Economic Area </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In relation to each member state of the European Economic Area (each a &#147;Relevant State&#148;), no
shares have been offered, or will be offered pursuant to this offering to the public in that Relevant State prior to the publication of a prospectus in relation to the shares which has been approved by the competent authority in that Relevant State
or, where appropriate, approved in another Relevant State and notified to the competent authority in that Relevant State, all in accordance with the Prospectus Regulation), except that offers of shares may be made to the public in that Relevant
State at any time under the following exemptions under the Prospectus Regulation: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to any legal entity which is a qualified investor as defined under the Prospectus Regulation;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to fewer than 150 natural or legal persons (other than qualified investors as defined under the Prospectus
Regulation), subject to obtaining the prior consent of the representatives for any such offer; or </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in any other circumstances falling within Article 1(4) of the Prospectus Regulation, </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:12%; font-size:10pt; font-family:Times New Roman">provided that no such offer of shares shall require the Company or any underwriter to publish a prospectus pursuant to Article 3 of the
Prospectus Regulation or supplement a prospectus pursuant to Article 23 of the Prospectus Regulation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Each person in a Relevant State who
initially acquires any shares or to whom any offer is made will be deemed to have represented, acknowledged and agreed to and with the Company and the underwriters that it is a qualified investor within the meaning of the Prospectus Regulation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the case of any shares being offered to a financial intermediary as that term is used in Article 5(1) of the Prospectus Regulation, each
such financial intermediary will be deemed to have represented, acknowledged and agreed that the shares acquired by it in the offer have not been acquired on a <FONT STYLE="white-space:nowrap">non-discretionary</FONT> basis on behalf of, nor have
they been acquired with a view to their offer or resale to, persons in circumstances which may give rise to an offer to the public other than their offer or resale in a Relevant State to qualified investors, in circumstances in which the prior
consent of the underwriters has been obtained to each such proposed offer or resale. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company, the underwriters and their respective
affiliates will rely upon the truth and accuracy of the foregoing representations, acknowledgements and agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For the purposes of
this provision, the expression an &#147;offer to the public&#148; in relation to any shares in any Relevant State means the communication in any form and by any means of sufficient information on the terms of the offer and any shares to be offered
so as to enable an investor to decide to purchase or subscribe for any shares, and the expression &#147;Prospectus Regulation&#148; means Regulation (EU) 2017/1129. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">223 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The above selling restriction is in addition to any other selling restrictions set out
below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In connection with the offering, the underwriters are not acting for anyone other than the Company and will not be responsible to
anyone other than the Company for providing the protections afforded to their clients nor for providing advice in relation to the offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to
Prospective Investors in the United Kingdom </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In relation to the United Kingdom (&#147;UK&#148;), no shares have been offered or will
be offered pursuant to this offering to the public in the UK prior to the publication of a prospectus in relation to the shares which has been approved by the Financial Conduct Authority in the UK in accordance with the UK Prospectus Regulation and
the FSMA, except that offers of shares may be made to the public in the UK at any time under the following exemptions under the UK Prospectus Regulation and the FSMA: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to any legal entity which is a qualified investor as defined under the UK Prospectus Regulation;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to fewer than 150 natural or legal persons (other than qualified investors as defined under the UK Prospectus
Regulation), subject to obtaining the prior consent of the representatives for any such offer; or </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at any time in other circumstances falling within section 86 of the FSMA, </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:12%; font-size:10pt; font-family:Times New Roman">provided that no such offer of shares shall require the Company or any underwriter to publish a prospectus pursuant to Section&nbsp;85 of the
FSMA or Article 3 of the UK Prospectus Regulation or supplement a prospectus pursuant to Article 23 of the UK Prospectus Regulation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Each
person in the UK who initially acquires any shares or to whom any offer is made will be deemed to have represented, acknowledged and agreed to and with the Company and the underwriters that it is a qualified investor within the meaning of the UK
Prospectus Regulation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the case of any shares being offered to a financial intermediary as that term is used in Article 5(1) of the UK
Prospectus Regulation, each such financial intermediary will be deemed to have represented, acknowledged and agreed that the shares acquired by it in the offer have not been acquired on a <FONT STYLE="white-space:nowrap">non-discretionary</FONT>
basis on behalf of, nor have they been acquired with a view to their offer or resale to, persons in circumstances which may give rise to an offer to the public other than their offer or resale in the UK to qualified investors, in circumstances in
which the prior consent of the underwriters has been obtained to each such proposed offer or resale. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company, the underwriters and
their respective affiliates will rely upon the truth and accuracy of the foregoing representations, acknowledgements and agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For
the purposes of this provision, the expression an &#147;offer to the public&#148; in relation to any shares in the UK means the communication in any form and by any means of sufficient information on the terms of the offer and any shares to be
offered so as to enable an investor to decide to purchase or subscribe for any shares, the expression &#147;UK Prospectus Regulation&#148; means Regulation (EU) 2017/1129 as it forms part of domestic law by virtue of the European Union (Withdrawal)
Act 2018, and the expression &#147;FSMA&#148; means the Financial Services and Markets Act 2000, as amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In connection with the
offering, the underwriters are not acting for anyone other than the Company and will not be responsible to anyone other than the Company for providing the protections afforded to their clients nor for providing advice in relation to the offering.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">224 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This document is for distribution only to persons who (i)&nbsp;have professional experience
in matters relating to investments and who qualify as investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the &#147;Financial Promotion
Order&#148;), (ii) are persons falling within Article 49(2)(a) to (d) (&#147;high net worth companies, unincorporated associations etc.&#148;) of the Financial Promotion Order, (iii)&nbsp;are outside the UK, or (iv)&nbsp;are persons to whom an
invitation or inducement to engage in investment activity (within the meaning of Section&nbsp;21 of the FSMA in connection with the issue or sale of any securities may otherwise lawfully be communicated or caused to be communicated (all such persons
together being referred to as &#147;relevant persons&#148;). This document is directed only at relevant persons and must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this
document relates is available only to relevant persons and will be engaged in only with relevant persons. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in
Switzerland </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The shares may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange ( &#147;SIX&#148;)
or on any other stock exchange or regulated trading facility in Switzerland. This document has been prepared without regard to the disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the
disclosure standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland. Neither this document nor any other offering or marketing
material relating to the shares or the offering may be publicly distributed or otherwise made publicly available in Switzerland. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Neither
this document nor any other offering or marketing material relating to the offering, the Company or the shares have been or will be filed with or approved by any Swiss regulatory authority. In particular, this document will not be filed with, and
the offer of shares will not be supervised by, the Swiss Financial Market Supervisory Authority, and the offer of shares has not been and will not be authorized under the Swiss Federal Act on Collective Investment Schemes (&#147;CISA&#148;). The
investor protection afforded to acquirers of interests in collective investment schemes under the CISA does not extend to acquirers of shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice
to Prospective Investors in the Dubai International Financial Centre </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This prospectus relates to an Exempt Offer in accordance with
the Offered Securities Rules of the Dubai Financial Services Authority (&#147;DFSA&#148;). This prospectus is intended for distribution only to persons of a type specified in the Offered Securities Rules of the DFSA. It must not be delivered to, or
relied on by, any other person. The DFSA has no responsibility for reviewing or verifying any documents in connection with Exempt Offers. The DFSA has not approved this prospectus nor taken steps to verify the information set forth herein and has no
responsibility for the prospectus. The shares to which this prospectus relates may be illiquid and/or subject to restrictions on their resale. Prospective purchasers of the shares offered should conduct their own due diligence on the shares. If you
do not understand the contents of this prospectus you should consult an authorized financial advisor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Australia
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">No placement document, prospectus, product disclosure statement or other disclosure document has been lodged with the Australian
Securities and Investments Commission in relation to the offering. This prospectus does not constitute a prospectus, product disclosure statement or other disclosure document under the Corporations Act 2001 (the &#147;Corporations Act&#148;), and
does not purport to include the information required for a prospectus, product disclosure statement or other disclosure document under the Corporations Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Any offer in Australia of the shares may only be made to persons (the &#147;Exempt Investors&#148;) who are &#147;sophisticated
investors&#148; (within the meaning of section 708(8) of the Corporations Act), &#147;professional investors&#148; (within the meaning of section 708(11) of the Corporations Act) or otherwise pursuant to one or more
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">225 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
exemptions contained in section 708 of the Corporations Act so that it is lawful to offer the shares without disclosure to investors under Chapter 6D of the Corporations Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The shares applied for by Exempt Investors in Australia must not be offered for sale in Australia in the period of 12 months after the date of
allotment under the offering, except in circumstances where disclosure to investors under Chapter 6D of the Corporations Act would not be required pursuant to an exemption under section 708 of the Corporations Act or otherwise or where the offer is
pursuant to a disclosure document which complies with Chapter 6D of the Corporations Act. Any person acquiring shares must observe such Australian <FONT STYLE="white-space:nowrap">on-sale</FONT> restrictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This prospectus contains general information only and does not take account of the investment objectives, financial situation or particular
needs of any particular person. It does not contain any securities recommendations or financial product advice. Before making an investment decision, investors need to consider whether the information in this prospectus is appropriate to their
needs, objectives and circumstances, and, if necessary, seek expert advice on those matters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Hong Kong </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The shares have not been offered or sold and will not be offered or sold in Hong Kong, by means of any document, other than (a)&nbsp;to
&#147;professional investors&#148; as defined in the Securities and Futures Ordinance (Cap.&nbsp;571) of Hong Kong and any rules made under that Ordinance; or (b)&nbsp;in other circumstances which do not result in the document being a
&#147;prospectus&#148; as defined in the Companies Ordinance (Cap. 32) of Hong Kong or which do not constitute an offer to the public within the meaning of that Ordinance. No advertisement, invitation or document relating to the shares has been or
may be issued or has been or may be in the possession of any person for the purposes of issue, whether in Hong Kong or elsewhere, which is directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if
permitted to do so under the securities laws of Hong Kong) other than with respect to shares which are or are intended to be disposed of only to persons outside Hong Kong or only to &#147;professional investors&#148; as defined in the Securities and
Futures Ordinance and any rules made under that Ordinance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Japan </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The shares have not been and will not be registered under the Financial Instruments and Exchange Law of Japan (Law No.&nbsp;25 of 1948, as
amended) and, accordingly, will not be offered or sold, directly or indirectly, in Japan, or for the benefit of any Japanese Person or to others for <FONT STYLE="white-space:nowrap">re-offering</FONT> or resale, directly or indirectly, in Japan or
to any Japanese Person, except in compliance with all applicable laws, regulations and ministerial guidelines promulgated by relevant Japanese governmental or regulatory authorities in effect at the relevant time. For the purposes of this paragraph,
&#147;Japanese Person&#148; shall mean any person resident in Japan, including any corporation or other entity organized under the laws of Japan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Singapore </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, the shares were not offered or
sold or caused to be made the subject of an invitation for subscription or purchase and will not be offered or sold or caused to be made the subject of an invitation for subscription or purchase, and this prospectus or any other document or material
in connection with the offer or sale, or invitation for subscription or purchase, of the shares, has not been circulated or distributed, nor will it be circulated or distributed, whether directly or indirectly, to any person in Singapore other than
(i)&nbsp;to an institutional investor (as defined in Section&nbsp;4A of the Securities and Futures Act (Chapter 289) of Singapore, as modified or amended from time to time (the &#147;SFA&#148;)) pursuant to Section&nbsp;274 of the SFA, (ii)&nbsp;to
a relevant person (as defined in Section&nbsp;275(2) of the SFA) pursuant to Section&nbsp;275(1) of the SFA, or any person pursuant to Section&nbsp;275(1A) of the SFA, and in accordance with the conditions specified in Section&nbsp;275 of the SFA,
or (iii)&nbsp;otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">226 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Where the shares are subscribed or purchased under Section&nbsp;275 of the SFA by a relevant
person which is: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a corporation (which is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole business
of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each
beneficiary of the trust is an individual who is an accredited investor, </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">securities or securities-based derivatives contracts (each
term as defined in Section&nbsp;2(1) of the SFA) of that corporation or the beneficiaries&#146; rights and interest (howsoever described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the
shares pursuant to an offer made under Section&nbsp;275 of the SFA except: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to an institutional investor or to a relevant person, or to any person arising from an offer referred to in
Section&nbsp;275(1A) or Section&nbsp;276(4)(i)(B) of the SFA; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">where no consideration is or will be given for the transfer; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">where the transfer is by operation of law; or </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">as specified in Section&nbsp;276(7) of the SFA. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Canada </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The shares may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in
National Instrument <FONT STYLE="white-space:nowrap">45-106</FONT> <I>Prospectus Exemptions</I> or subsection 73.3(1) of the <I>Securities Act</I> (Ontario), and are permitted clients, as defined in National Instrument
<FONT STYLE="white-space:nowrap">31-103</FONT> <I>Registration Requirements, Exemptions and Ongoing Registrant Obligations</I>. Any resale of the shares must be made in accordance with an exemption from, or in a transaction not subject to, the
prospectus requirements of applicable securities laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Securities legislation in certain provinces or territories of Canada may provide a
purchaser with remedies for rescission or damages if this prospectus (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed
by the securities legislation of the purchaser&#146;s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#146;s province or territory for particulars of these rights or
consult with a legal advisor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pursuant to section 3A.3 (or, in the case of securities issued or guaranteed by the government of a <FONT
STYLE="white-space:nowrap">non-Canadian</FONT> jurisdiction, section 3A.4) of National Instrument <FONT STYLE="white-space:nowrap">33-105</FONT> <I>Underwriting Conflicts</I> (NI <FONT STYLE="white-space:nowrap">33-105),</FONT> the underwriters are
not required to comply with the disclosure requirements of NI <FONT STYLE="white-space:nowrap">33-105</FONT> regarding underwriter conflicts of interest in connection with this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">227 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom744414_21"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The validity of the common shares and certain other matters of Bermuda law will be passed upon for us by Walkers (Bermuda) Limited, our
special Bermuda counsel. Certain other legal matters will be passed upon for us by Kirkland&nbsp;&amp; Ellis LLP, New York, New York, and for the underwriters by Allen Overy Shearman Sterling US LLP, New York, New York. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom744414_22"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of West Affum Intermediate Holdings Corp. as of April&nbsp;30, 2024 and 2023 and for the years then
ended included in this prospectus have been so included in reliance on the report (which contains an explanatory paragraph relating to the Company&#146;s ability to continue as a going concern as described in Note 1 to the financial statements) of
PricewaterhouseCoopers LLP, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The financial statements of Kestra Medical Technologies, Ltd. as of April&nbsp;30, 2024 and 2023 included in this prospectus have been so
included in reliance on the report of PricewaterhouseCoopers LLP, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom744414_23"></A>WHERE YOU CAN FIND ADDITIONAL INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have filed with the SEC a registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> under the Securities Act, with respect
to the common shares being offered by this prospectus. This prospectus, which constitutes part of the registration statement, does not contain all of the information in the registration statement and its exhibits. For further information with
respect to our company and the common shares offered by this prospectus, we refer you to the registration statement and its exhibits. Statements or summaries contained in this prospectus as to the material contents of any contract or any other
document referred to herein are not necessarily complete, and in each instance, we refer you to the copy of the contract or other document filed as an exhibit to the registration statement. Each of these statements or summaries is qualified in all
respects by this reference. You can read our SEC filings, including the registration statement, over the internet at the SEC&#146;s website at www.sec.gov. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Upon the closing of this offering, we will be subject to the information reporting requirements of the Exchange Act, and we will file reports,
proxy statements and other information with the SEC. These reports, proxy statements and other information will be available for review at the SEC&#146;s website at www.sec.gov. We also maintain a website at https://www.kestramedical.com, at which
you may access these materials free of charge as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC. The information contained in, or that can be accessed through, our website is not part of, and is not
incorporated into, this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom744414_24"></A>EXCHANGE CONTROLS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The permission of the Bermuda Monetary Authority is required, pursuant to the provisions of the Exchange Control Act 1972 and related
regulations, for all issuances and transfers of shares (which includes our common shares) of Bermuda companies to or from a <FONT STYLE="white-space:nowrap">non-resident</FONT> of Bermuda for exchange control purposes, other than in cases where the
Bermuda Monetary Authority has granted a general permission. The Bermuda Monetary Authority, in its notice to the public dated June&nbsp;1, 2005, has granted a general permission for the issue and subsequent transfer of any securities of a Bermuda
company from or to a <FONT STYLE="white-space:nowrap">non-resident</FONT> of Bermuda for exchange control purposes for so long as any &#147;Equity Securities&#148; of the company (which would include our common shares) are listed on an
&#147;Appointed Stock Exchange&#148; (which would include the Nasdaq Global Select Market). Certain issues and transfers of common shares involving persons deemed resident in Bermuda for exchange control purposes require the specific consent of the
Bermuda Monetary Authority. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">228 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom744414_25"></A>ENFORCEMENT OF CIVIL LIABILITIES UNDER U.S. FEDERAL SECURITIES
LAWS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are a Bermuda exempted company limited by shares. As a result, the rights of holders of our common shares will be governed by
Bermuda law, our memorandum of association and the amended and restated <FONT STYLE="white-space:nowrap">bye-laws</FONT> to be in effect upon the closing of this offering. The rights of shareholders under Bermuda law may differ from the rights of
shareholders of companies incorporated in other jurisdictions. It may be difficult for investors to enforce in the United States judgments obtained in U.S. courts against us based on the civil liability provisions of the U.S. securities laws. Our
principal office is located at 3933 Lake Washington Blvd NE, Suite 200, Kirkland, Washington 98033, and our registered office is located in Bermuda at Cumberland House, 7th Floor, 1 Victoria Street, Hamilton HM 11, Bermuda. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have been advised by our special Bermuda counsel that there is no treaty in force between the United States and Bermuda providing for the
reciprocal recognition and enforcement of judgments in civil and commercial matters. As a result, whether a U.S. judgment would be enforceable in Bermuda against us or our directors and officers depends on whether the U.S. court that entered the
judgment is recognized by a Bermuda court as having jurisdiction over us or our directors and officers, as determined by reference to Bermuda conflict of law rules. The courts of Bermuda would recognize as a valid judgment, a final and conclusive
judgment in personam obtained in a U.S. court pursuant to which a sum of money is payable (other than a sum of money payable in respect of multiple damages, taxes or other charges of a like nature or in respect of a fine or other penalty). The
courts of Bermuda would give a judgment based on such a U.S. judgment as long as (1)&nbsp;the U.S. court had proper jurisdiction over the parties subject to the judgment; (2)&nbsp;the U.S. court did not contravene the rules of natural justice of
Bermuda; (3)&nbsp;the U.S. judgment was not obtained by fraud; (4)&nbsp;the enforcement of the U.S. judgment would not be contrary to the public policy of Bermuda; (5)&nbsp;no new admissible evidence relevant to the action is submitted prior to the
rendering of the judgment by the courts of Bermuda; (6)&nbsp;there is due compliance with the correct procedures under the laws of Bermuda; and (7)&nbsp;the U.S. judgment is not inconsistent with any judgment of the courts of Bermuda in respect of
the same matter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, and irrespective of jurisdictional issues, the Bermuda courts will not enforce a U.S. federal securities
law that is either penal or contrary to Bermuda public policy. We have been advised that an action brought pursuant to a public or penal law, the purpose of which is the enforcement of a sanction, power or right at the instance of the state in its
sovereign capacity, is unlikely to be entertained by a Bermuda court. Certain remedies available under the laws of U.S. jurisdictions, including certain remedies under U.S. federal securities laws, would not be available under Bermuda law or
enforceable in a Bermuda court, as they are likely to be contrary to Bermuda public policy. Further, it may not be possible to pursue direct claims in Bermuda against us or our directors and officers for alleged violations of U.S. federal securities
laws because these laws are unlikely to have extraterritorial effect and do not have force of law in Bermuda. A Bermuda court may, however, impose civil liability on us or our directors and officers if the facts alleged and proved in the Bermuda
proceedings constitute or give rise to a cause of action under the applicable governing law, not being a foreign public, penal or revenue law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">229 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom744414_26"></A>INDEX TO FINANCIAL STATEMENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#fin744414_1">Kestra Medical Technologies, Ltd.</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#fin744414_2">Unaudited Condensed Balance Sheets of Kestra Medical Technologies,
Ltd.</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin744414_3">Condensed Balance Sheets as of October 31, 2024 and April 30,
2024</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>F-2</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin744414_4">Notes to Unaudited Condensed Balance Sheets</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B><FONT STYLE="white-space:nowrap">F-3</FONT></B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#fin744414_5">Audited Balance Sheet of Kestra Medical Technologies,
Ltd.</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin744414_6">Report of Independent Registered Public Accounting Firm</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B><FONT STYLE="white-space:nowrap">F-4</FONT></B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin744414_7">Balance Sheets as of April&nbsp;30, 2024 and 2023</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B><FONT STYLE="white-space:nowrap">F-5</FONT></B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin744414_8">Notes to Balance Sheets</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B><FONT STYLE="white-space:nowrap">F-6</FONT></B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#fin744414_9">West Affum Intermediate Holdings Corp.</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#fin744414_10">Unaudited Condensed Consolidated Financial Statements of West Affum Intermediate
 Holdings Corp.</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin744414_11">Condensed Consolidated Balance Sheets as of October 31, 2024 and April&nbsp;30,
 2024</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B><FONT STYLE="white-space:nowrap">F-7</FONT></B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin744414_12">Condensed Consolidated Statements of Operations and Comprehensive Loss for
 the Six Months Ended October 31, 2024 and 2023</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B><FONT STYLE="white-space:nowrap">F-8</FONT></B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin744414_13">Condensed Consolidated Statements of Changes in Redeemable Preferred Stock
 and Stockholder&#146;s Deficit for the Six Months Ended October 31, 2024 and 2023</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B><FONT STYLE="white-space:nowrap">F-9</FONT></B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin744414_14">Condensed Consolidated Statements of Cash Flows for the Six Months Ended October
 31, 2024 and 2023</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B><FONT STYLE="white-space:nowrap">F-10</FONT></B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin744414_15">Notes to Condensed Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B><FONT STYLE="white-space:nowrap">F-11</FONT></B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin744414_16"><B>Audited Consolidated Financial Statements of West Affum Intermediate Holdings
Corp.</B></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin744414_17">Report of Independent Registered Public Accounting Firm</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B><FONT STYLE="white-space:nowrap">F-25</FONT></B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin744414_18">Consolidated Balance Sheets as of April&nbsp;30, 2024 and
2023</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B><FONT STYLE="white-space:nowrap">F-26</FONT></B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin744414_19">Consolidated Statements of Operations and Comprehensive Loss for the Years
 Ended April&nbsp;30, 2024 and 2023</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B><FONT STYLE="white-space:nowrap">F-27</FONT></B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin744414_20">Consolidated Statements of Changes in Redeemable Preferred Stock and Stockholder&#146;s
 Deficit for the Years Ended April&nbsp;30, 2024 and 2023</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B><FONT STYLE="white-space:nowrap">F-28</FONT></B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin744414_21">Consolidated Statements of Cash Flows for the Years Ended April&nbsp;
30, 2024 and 2023</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B><FONT STYLE="white-space:nowrap">F-29</FONT></B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin744414_22">Notes to Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B><FONT STYLE="white-space:nowrap">F-30</FONT></B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>KESTRA MEDICAL TECHNOLOGIES, LTD. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin744414_3"></A>CONDENSED BALANCE SHEETS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>October&nbsp;31, 2024 and April 30, 2024 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>(in dollars) </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>October&nbsp;31,<BR>2024</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>April&nbsp;30,<BR>2024</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Commitments and contingencies (Note 3)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Shareholder&#146;s equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares subscription receivable from West Affum Holdings, L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(100</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(100</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ordinary Shares, $1.00 par value; 100 shares authorized, issued and outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total shareholder&#146;s equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>See accompanying notes to the Condensed Balance Sheets. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>KESTRA MEDICAL TECHNOLOGIES, LTD. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin744414_4"></A>NOTES TO UNAUDITED CONDENSED BALANCE SHEETS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. Description of Business </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Kestra
Medical Technologies, Ltd. (the &#147;Company&#148;) was formed as a limited company in Bermuda on May 20, 2021 and is a wholly owned subsidiary of West Affum Holdings, L.P. (&#147;West Affum LP&#148;), a company in the Cayman Islands. The Company
was formed for the purpose of completing a public offering and related transactions to carry on the business of West Affum Intermediate Holdings Corp. and subsidiaries. Upon completion of a public offering, the Company&#146;s principal asset will be
a controlling interest in the business and affairs of West Affum Intermediate Holdings Corp. and subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Significant Accounting Policies
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Basis of Presentation </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The unaudited interim condensed Balance Sheets are presented in accordance with generally accepted accounting principles in the United States
of America. Separate statements of income, comprehensive income, changes in shareholder&#146;s equity, and cash flows have not been presented because the Company has not engaged in any activities except in connection with its formation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company&#146;s fiscal year end is April 30. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The unaudited interim condensed Balance Sheets have been prepared assuming the Company will continue as a going concern, which contemplates,
among other things, the realization of assets and satisfaction of liabilities in the normal course of business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. Commitments and Contingencies
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of October&nbsp;31, 2024 and April 30, 2024, the Company has no commitments and contingencies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. Shareholder&#146;s Equity </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of
October&nbsp;31, 2024 and April 30, 2024, the Company has authorized for issuance 100 Ordinary Shares with $1.00 par value, all of which are outstanding with $100 shares subscription receivable from West Affum LP accounted for as contra-equity on
the unaudited interim condensed Balance Sheets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. Subsequent Events </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company has evaluated subsequent events through the date the unaudited interim condensed Balance Sheets were available to be issued on
January&nbsp;17, 2025, and through February&nbsp;26, 2025, the date the unaudited interim condensed Balance Sheets were available to be reissued. The Company concluded that there were no subsequent events that require adjustment to the unaudited
interim condensed Balance Sheets or disclosure in the notes to the unaudited interim condensed Balance Sheets. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin744414_6"></A>Report of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the Board of Directors and Shareholder of Kestra Medical Technologies, Ltd. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Opinion on the Financial Statements </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We
have audited the accompanying balance sheets of Kestra Medical Technologies, Ltd. (the &#147;Company&#148;) as of April 30, 2024 and 2023, including the related notes (collectively referred to as the &#147;financial statements&#148;). In our
opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of April 30, 2024 and 2023 in conformity with accounting principles generally accepted in the United States of America. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Basis for Opinion </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">These financial
statements are the responsibility of the Company&#146;s management. Our responsibility is to express an opinion on the Company&#146;s financial statements based on our audits. We are a public accounting firm registered with the Public Company
Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission
and the PCAOB. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We conducted our audits of these financial statements in accordance with the standards of the PCAOB. Those standards
require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or
fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting
principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ PricewaterhouseCoopers LLP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Irvine, California </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">August 28, 2024 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have served as the Company&#146;s auditor
since 2021. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>KESTRA MEDICAL TECHNOLOGIES, LTD. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin744414_7"></A>BALANCE SHEETS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>April&nbsp;30, 2024 and 2023 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>(in dollars) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2024</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Commitments and contingencies (Note 3)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Shareholder&#146;s equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares subscription receivable from West Affum Holdings, L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(100</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(100</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ordinary Shares, $1.00 par value; 100 shares authorized, issued and outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total shareholder&#146;s equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>See accompanying notes to the Balance Sheets. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>KESTRA MEDICAL TECHNOLOGIES, LTD. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin744414_8"></A>NOTES TO BALANCE SHEETS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. Description of Business </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Kestra
Medical Technologies, Ltd. (the &#147;Company&#148;) was formed as a limited company in Bermuda on May&nbsp;20, 2021 and is a wholly owned subsidiary of West Affum Holdings, L.P. (&#147;West Affum LP&#148;), a company in the Cayman Islands. The
Company was formed for the purpose of completing a public offering and related transactions to carry on the business of West Affum Intermediate Holdings Corp. and subsidiaries. Upon completion of a public offering, the Company&#146;s principal asset
will be a controlling interest in the business and affairs of West Affum Intermediate Holdings Corp. and subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Significant Accounting
Policies </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Basis of Presentation </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Balance Sheets are presented in accordance with generally accepted accounting principles in the United States of America. Separate
statements of income, comprehensive income, changes in shareholder&#146;s equity, and cash flows have not been presented because the Company has not engaged in any activities except in connection with its formation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company&#146;s fiscal year end is April 30. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Balance Sheets have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the
realization of assets and satisfaction of liabilities in the normal course of business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. Commitments and Contingencies </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of April&nbsp;30, 2024, the Company has no commitments and contingencies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. Shareholder&#146;s Equity </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of
April&nbsp;30, 2024 and 2023, the Company has authorized for issuance 100 Ordinary Shares with $1.00 par value, all of which are outstanding with $100 shares subscription receivable from West Affum LP accounted for as contra-equity on the Balance
Sheets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. Subsequent Events </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The
Company has evaluated subsequent events through the date the Balance Sheets were available to be issued on August&nbsp;28, 2024. The Company concluded that there were no subsequent events that require adjustment to the Balance Sheets or disclosure
in the notes to the Balance Sheets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. Subsequent Events (unaudited) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company has evaluated subsequent events from the date the Balance Sheets were originally available to be issued on August&nbsp;28, 2024
through February&nbsp;26, 2025, the date the Balance Sheets were available to be reissued. The Company concluded that there were no subsequent events that require adjustment to the Balance Sheets or disclosure in the notes to the Balance Sheets.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WEST AFFUM INTERMEDIATE HOLDINGS CORP. AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin744414_11"></A>CONDENSED CONSOLIDATED BALANCE SHEETS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>October&nbsp;31, 2024 and April&nbsp;30, 2024 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>(in thousands, except share and per share amounts) </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>October&nbsp;31,&nbsp;2024</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>April&nbsp;30,&nbsp;2024</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">76,918</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,249</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,394</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Disposable medical equipment supplies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,323</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,295</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87,930</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,907</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT>
assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,043</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,286</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deposits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,947</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other long-term assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">607</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">121,454</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">45,949</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities, Redeemable Preferred Stock and Stockholder&#146;s Deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">23,892</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,079</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,312</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,971</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,758</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other long-term liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term debt, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,536</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77,489</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78,216</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commitments and contingencies (Note 14)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable preferred stock, $0.01 par value; 5,000,000 shares authorized; 280,510 and 177,110
shares issued and outstanding as of October&nbsp;31, 2024 and April&nbsp;30, 2024, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">280,510</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">177,110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholder&#146;s deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.01 par value; 5,000,000 shares authorized; 105,808&nbsp;shares issued and
outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">193,733</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">197,057</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(446,687</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(406,435</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total West Affum Intermediate Holdings Corp. stockholder&#146;s deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(252,953</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(209,377</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-controlling</FONT> interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholder&#146;s deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(236,545</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(209,377</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities and stockholder&#146;s deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">121,454</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">45,949</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The accompanying notes are an integral part of these condensed consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WEST AFFUM INTERMEDIATE HOLDINGS CORP. AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin744414_12"></A>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>(in thousands, except share and per share amounts) </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Six&nbsp;Months&nbsp;Ended<BR>October&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2024</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27,492</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,483</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Costs of revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,462</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,398</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross margin</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,915</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,913</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,934</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,682</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,919</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,595</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,853</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(37,565</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(44,768</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,276</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,644</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,768</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss before provision for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(40,929</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(50,180</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(40,944</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(50,217</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to <FONT STYLE="white-space:nowrap">non-controlling</FONT> interest</P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(692</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss attributable to West Affum Intermediate Holdings Corp.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(40,252</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(50,217</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Undeclared preferred stock dividends</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,706</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,915</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common stockholder, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(45,958</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(53,132</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to common stockholder, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(434</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(502</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares of common stock outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105,808</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105,808</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The accompanying notes are an integral part of these condensed consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WEST AFFUM INTERMEDIATE HOLDINGS CORP. AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin744414_13"></A>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN REDEEMABLE PREFERRED STOCK AND STOCKHOLDER&#146;S DEFICIT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>(in thousands, except share and per share amounts) </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Redeemable<BR>Preferred
Stock</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Common Stock</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Additional<BR><FONT STYLE="white-space:nowrap">Paid-In</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Capital</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Accumulated</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Deficit</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Non-</FONT><BR>controlling</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Interests</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Total<BR>Stockholder&#146;s</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Deficit</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Amount</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Amount</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balances at April&nbsp;30, 2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102,110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">102,110</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105,808</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">194,736</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(312,315</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(117,578</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">727</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">727</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of redeemable preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deemed dividend for payments to third party on behalf of stockholder</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(426</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(426</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Capital contribution from Parent related to warrant obligation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,632</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,632</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(50,217</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(50,217</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balances at October&nbsp;31, 2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">152,110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">152,110</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105,808</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">196,669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(362,532</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(165,862</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balances at April&nbsp;30, 2024</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">177,110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">177,110</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105,808</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">197,057</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(406,435</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(209,377</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,499</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,499</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of redeemable preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">103,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">103,400</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of stock to <FONT STYLE="white-space:nowrap">non-controlling</FONT> interest</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deemed dividend for payments to third party on behalf of stockholder</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,823</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,823</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(40,252</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(692</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(40,944</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balances at October&nbsp;31, 2024</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">280,510</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">280,510</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105,808</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">193,733</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(446,687</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(236,545</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The accompanying notes are an integral part of these condensed consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WEST AFFUM INTERMEDIATE HOLDINGS CORP. AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin744414_14"></A>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>(in thousands) </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Six Months
Ended<BR>October&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2024</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Cash flows from operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(40,944</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(50,217</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,244</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,695</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Loss on disposal of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">972</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">769</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Interest
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">paid-in-kind</FONT></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">640</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Amortization of debt discounts and issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">861</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">213</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,499</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">727</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-cash</FONT> lease expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">242</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">545</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-cash</FONT> loss on debt extinguishment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">930</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Disposable medical equipment supplies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,032</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,292</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">297</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,396</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(542</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,786</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,272</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(686</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Other long-term assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(35,525</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(41,491</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Cash flows from investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,484</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,217</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Deposits for medical rental equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(128</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Refund of deposits for medical rental equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,484</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,105</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Cash flows from financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Proceeds from issuance of redeemable preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">103,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Deemed dividend for payments to third party on behalf of stockholder</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,598</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(426</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Proceeds from issuance of stock to <FONT STYLE="white-space:nowrap">non-controlling</FONT>
interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Proceeds from issuance of long-term debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Payment of debt issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,859</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Payment of equity issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,224</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Repayment of long-term debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(39,123</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">115,678</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,592</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Net increase in cash, cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68,669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Cash, cash equivalents and restricted cash</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,322</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">End of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">77,252</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24,318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Reconciliation of cash, cash equivalents and restricted cash reported in the condensed
consolidated balance sheets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">76,918</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">23,806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">512</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Cash, cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">77,252</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24,318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-cash</FONT> investing and financing
activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Purchases of property and equipment in accrued liabilities and accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,914</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,566</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Capital contribution from Parent to settle warrant obligation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,632</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Supplemental disclosure of cash flow information</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Income taxes paid</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Interest paid</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,451</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,207</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The accompanying notes are an integral part of these condensed consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WEST AFFUM INTERMEDIATE HOLDINGS CORP. AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin744414_15"></A>NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(unaudited) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>(in
thousands, except share, per share data and percentages) </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. Nature of Operations and Liquidity </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">West Affum Intermediate Holdings Corp., a Cayman Islands exempted company (the &#147;Company&#148;), was incorporated on August&nbsp;6, 2020,
in order to carry on the business of West Affum Holdings Corp. (&#147;WAH Corp.&#148;) and its consolidated subsidiaries. West Affum Intermediate Holdings Corp, is wholly owned by West Affum Holdings L.P., a Cayman Islands limited partnership (the
&#147;Parent&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company and its consolidated subsidiaries own certain intellectual property related to the development of
personal Wearable Cardioverter Defibrillators (&#147;WCD&#148;) approved by the U.S. Food and Drug Administration (&#147;FDA&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The
Company generates revenue through leasing the ASSURE<SUP STYLE="font-size:75%; vertical-align:top">&copy;</SUP> System, which consists of a Wearable Cardioverter Defibrillator, to patients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidity and Going Concern </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The
Company has incurred negative operating cash flows and significant losses from operations since its inception. For the six months ended October&nbsp;31, 2024 and 2023, the Company incurred net losses of $40,944 and $50,217, respectively. Cash used
in operating activities was $35,525 and $41,491 for the six months ended October&nbsp;31, 2024 and 2023, respectively. As of October&nbsp;31, 2024, the Company had an accumulated deficit of $446,687. Management has prepared the unaudited interim
condensed consolidated financial statements on a going concern basis which contemplates continuity of normal business activities and the realization of assets and liabilities in the ordinary course of business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company has historically financed its operations primarily through capital contributions, issuance of preferred stock and redeemable stock
and term loans. The Company expects to continue to incur substantial losses for the foreseeable future, and its ability to achieve and sustain profitability will depend on the successful commercialization of its device and on the achievement of
sufficient revenue to support its cost structure. As of October&nbsp;31, 2024 and April&nbsp;30, 2024 the Company had cash, cash equivalents and restricted cash of $77,252 and $8,583, respectively. In May and July 2024, through additional capital
contributions and the closing of a private placement, the Company received $116,500 in total net cash proceeds. However, management believes that its cash and cash equivalents balance may not be sufficient to fund its planned current operations for
the next twelve&nbsp;months from the date these unaudited interim condensed consolidated financial statements are issued. Management plans on raising additional capital to continue operations but cannot predict with certainty the ability to obtain
such funding. If the Company is unable to obtain additional funding, it would be required to suspend operations or reduce its spending profile to a level which would not allow for planned product commercialization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Additionally, as discussed in Note 7, the Company&#146;s debt agreement requires certain financial and
<FONT STYLE="white-space:nowrap">non-financial</FONT> covenants, including minimum revenue and cash thresholds, which if not achieved may be considered an event of default under the terms of the debt agreement. Based upon the factors discussed
above, there is substantial doubt as to whether the Company will continue as a going concern for the next twelve months from the date these unaudited interim condensed consolidated financial statements were available to be issued. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Significant Accounting Policies </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Basis of Presentation </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The
accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (&#147;SEC&#148;) and generally accepted accounting principles in
the United States of America (&#147;US GAAP&#148;) and include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. The Company&#146;s reporting currency is
the U.S. dollar. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The unaudited interim condensed consolidated balance sheet as of April&nbsp;30, 2024 included herein was derived from
the audited financial statements as of that date. Certain information and disclosures normally included in the financial statements prepared in accordance with US&nbsp;GAAP have been condensed or omitted pursuant to such regulations. Accordingly,
these unaudited interim condensed consolidated financial statements and accompanying footnotes should be read in conjunction with the Company&#146;s financial statements as of and for the years ended April&nbsp;30, 2024 and 2023. The results for the
interim periods are not necessarily indicative of results for the full year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the opinion of management, all adjustments, of a normal
recurring nature, considered necessary for a fair statement have been included in the unaudited interim condensed consolidated financial statements. The Company believes that the disclosures provided herein are adequate to prevent the information
presented from being misleading. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Use of Estimates </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The preparation of the unaudited interim condensed consolidated financial statements in conformity with accounting principles generally
accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the unaudited interim
condensed consolidated financial statements, and the reported amounts of expenses during the reporting period. Estimates are required as part of determining the collectability of lease payments for revenue recognition, estimated lives of property
and equipment, losses for unreturned property and equipment, stock-based compensation expense, fair value of warrant obligations and valuation allowance for deferred tax assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company bases its estimates on historical experience and other market-specific or relevant assumptions that it believes to be reasonable
under the circumstances. Actual results could differ from those estimates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Accounts Receivable </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Accounts receivable and net revenues are based on contractually agreed-upon rates for services provided, reduced by estimated adjustments,
including contractual adjustments. Inherent in these estimates is the risk that they will have to be revised or updated as additional information becomes available. The complexity of third-party billing arrangements and laws and regulations
governing Medicare may result in adjustments to amounts originally recorded. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company performs a periodic analysis to review the
valuation of accounts receivable and collectability of outstanding balances. These estimates are determined utilizing historical realization data under a portfolio approach which is then assessed by management to evaluate whether adjustments should
be made based on accounts receivable aging trends, other operating trends, and relevant business conditions such as governmental and managed care payor claims processing procedures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company records a reserve for estimated probable losses as part of net revenue adjustments in order to report revenue at an expected
collectable amount based on the total portfolio of receivables for which </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
collectability has been deemed probable. The accounts receivable are presented on the unaudited interim condensed consolidated balance sheets net of the adjustments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Receivables are considered past due when not collected by established due dates. Specific patient balances are written off after collection
efforts have been followed and the account has been determined to be uncollectible. Changes to reserve estimate impacts are recorded as an adjustment to net revenue in the period during which changes in circumstances support a change to the
estimate. The estimates of the allowance for uncollectible accounts were $1,573 and $500 as of October&nbsp;31, 2024 and April&nbsp;30, 2024, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Property and Equipment </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Property
and equipment consist of medical rental equipment, test equipment, computer software and equipment, and leasehold improvements. Medical rental equipment used in the delivery of our ASSURE<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> WCD
system consists of therapy cables, batteries, battery chargers, assistants and WCD monitors, all of which have different useful lives. Upon completion of use by a patient, medical rental equipment is returned to our third-party manufacturing and
supply partner and inspected, tested and recertified for use by another patient. When not in use by patients, medical rental equipment resides with our third-party manufacturing and supply partner, at third-party warehouses or with the
Company&#146;s territory managers. Physical counts of components are conducted at least annually at our third-party manufacturing and supply partner locations and at least quarterly at other locations.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Property and equipment are stated at cost less accumulated depreciation. Depreciation of medical rental equipment commences at the date when
it becomes available for service, which represents the date that the asset is ready for intended use by the patients and continues through the estimated useful life of the asset. Expenditures for major renewals and betterments that extend the useful
lives of property and equipment are capitalized. Expenditures for maintenance and repairs, including planned major maintenance activities, are expensed as incurred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Property and equipment are depreciated using the straight-line method based on the following estimated useful lives: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="36%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>October&nbsp;31, 2024</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>April&nbsp;30, 2024</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Asset Classification</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Estimated&nbsp;Useful&nbsp;Lives</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Estimated&nbsp;Useful&nbsp;Lives</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Computer software and equipment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">3 years</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">3 years</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Test equipment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">5 years</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">5 years</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Leasehold improvements</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="white-space:nowrap">Lesser&nbsp;of&nbsp;useful&nbsp;life&nbsp;or&nbsp;lease-term</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="white-space:nowrap">Lesser&nbsp;of&nbsp;useful&nbsp;life&nbsp;or&nbsp;lease-term</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Medical rental equipment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">2&#150;8 years</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">1.5&#150;7 years</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">During the six months ended October&nbsp;31, 2024, the estimated useful life of the Medical rental equipment
asset class was changed prospectively from 1.5&#150;7 years to 2&#150;8 years. This change was the result of an FDA approval allowing therapy cables to be repaired up to three times which increased the estimated useful life of this component from
two years to eight years. The impact was a reduction of depreciation expense, which is included within costs of revenue, by $1,208 in the six months ended October&nbsp;31, 2024, compared to if the useful life of therapy cables had remained at two
years. This change in estimated useful life reduced net loss and comprehensive loss by the same amount. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">When assets are retired or
otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts, and any resulting gain or loss is recognized in the unaudited interim condensed consolidated statements of operations and comprehensive loss for the
period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Deposits </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Deposits represent advance payments to contracted suppliers for medical rental equipment. These payments are classified as long-term assets in
the unaudited interim condensed consolidated balance sheets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company generates revenue from the leases of ASSURE<SUP STYLE="font-size:75%; vertical-align:top">&copy;</SUP> System, which consists of a
Wearable Cardioverter Defibrillator combined with a proprietary digital healthcare platform, to <FONT STYLE="white-space:nowrap">at-risk</FONT> patients for a fixed amount on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">month-to-month</FONT></FONT> basis. The lease payments generally consist of the contracted amounts based on reimbursement arrangements with third-party payors including Medicare,
Medicaid and private commercial payors, and/or certain patient <FONT STYLE="white-space:nowrap">co-payments.</FONT> The patient has the right to cancel the lease at any time during the rental period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The equipment leases are classified as operating leases at lease commencement, and the Company recognizes the revenue associated with ASSURE<SUP
STYLE="font-size:75%; vertical-align:top">&copy;</SUP> rentals in accordance with Accounting Standards Codification Topic 842, <I>Leases</I> (&#147;ASC Topic 842&#148;). The Company elected the practical expedient provided under ASC Topic 842 to
combine the lease of ASSURE<SUP STYLE="font-size:75%; vertical-align:top">&copy;</SUP> System with the <FONT STYLE="white-space:nowrap">non-lease</FONT> components, which includes the digital healthcare platform. The ASSURE<SUP
STYLE="font-size:75%; vertical-align:top">&copy;</SUP> System is expected to be the predominant component and, as a result, the Company accounts for the combined revenue components under ASC Topic 842. Revenue is recognized on a straight-line basis
over the contractual <FONT STYLE="white-space:nowrap">non-cancellable</FONT> lease term, which is one month, when collectability of the lease payments is deemed to be probable. If collectability of the lease payments is not deemed to be probable,
the lease income is limited to the lesser of the income that would have been recognized if collectability was probable or the lease payments collected. Collectability of all lease payments, which includes amounts reimbursed by third-party payors
and/or amounts covered by the patient, is assessed for each contract upon lease commencement and is subject to subsequent reassessment throughout the lease term, as necessary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Due to the nature of the industry and the reimbursement environment in which we operate, we periodically evaluate the need to record a general
reserve under ASC 450, <I>Contingencies, </I>for a portfolio of operating lease receivables that are probable of collection. Inherent in the reserve estimates is the risk that they will have to be revised or updated as additional information becomes
available. Specifically, the complexity of many third-party billing arrangements and the uncertainty of reimbursement amounts for certain services from certain payors may result in adjustments to amounts originally recorded. Such adjustments are
expected to be identified and recorded at the point of cash application or claim denial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Payments on Behalf of Stockholder </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">During the six months ended October&nbsp;31, 2024 and 2023, the Company paid administrative costs to a third party on behalf of stockholder,
Parent, of $4,823 and $426, respectively. The payments to a third party on behalf of stockholder were recorded as a deemed dividend in the unaudited interim condensed consolidated statements of changes in redeemable preferred stock and
stockholder&#146;s deficit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Non-controlling</FONT> interests </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company reports a <FONT STYLE="white-space:nowrap">non-controlling</FONT> interest of a consolidated subsidiary within equity in the
unaudited interim condensed consolidated balance sheet and the amount of consolidated net loss attributable to the Parent and to the <FONT STYLE="white-space:nowrap">non-controlling</FONT> interest is presented in the unaudited interim condensed
consolidated statements of operations and comprehensive loss. The amount attributed is calculated based on ownership in the consolidated subsidiary. Changes in ownership interests in the subsidiary in which the Company maintains a controlling
interest are recorded in equity. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Accounting Pronouncements Not Yet Adopted </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In November 2023, the Financial Accounting Standards Board (&#147;FASB&#148;) issued Accounting Standards Update (&#147;ASU&#148;) <FONT
STYLE="white-space:nowrap">2023-07,</FONT> <I>Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</I>, which enables investors to better understand an entity&#146;s overall performance and assists in assessing potential
future cash flows. The guidance is effective for fiscal years beginning after December&nbsp;15, 2023. The Company is still evaluating the impact that this ASU will have on their financial statement disclosures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In December 2023, the FASB issued ASU <FONT STYLE="white-space:nowrap">2023-09,</FONT> <I>Income Taxes (Topic 740): Improvements to Income Tax
Disclosures</I>, which enhances transparency and decision usefulness of income tax disclosures, primarily related to the income tax rate reconciliation and income taxes paid information. The guidance is effective for private business entities for
annual reporting periods beginning after December&nbsp;15, 2025. The Company does not anticipate a material impact to the required financial statement disclosure as a result of this ASU. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In November 2024, the FASB issued ASU <FONT STYLE="white-space:nowrap">2024-03,</FONT> <I>Income Statement&#151;Reporting Comprehensive
Income&#151;Expense Disaggregation Disclosures (Subtopic <FONT STYLE="white-space:nowrap">220-40)</FONT> (&#147;ASU <FONT STYLE="white-space:nowrap">2024-03&#148;)</FONT></I>, requiring disclosure in the notes to the financial statements for
specified information about certain costs and expenses. ASU <FONT STYLE="white-space:nowrap">2024-03</FONT> is effective for annual periods beginning after December&nbsp;15, 2026, and interim periods beginning after December&nbsp;15, 2027; however
early adoption is permitted and can be applied either prospectively or retrospectively. The Company is still evaluating the impact that this ASU will have on their financial statement disclosures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company has reviewed other recent accounting pronouncements and concluded that they are either not applicable to the business, or that no
material effect is expected on the unaudited interim condensed consolidated financial statements as a result of future adoption. No new accounting pronouncements were adopted during the six months ended October&nbsp;31, 2024.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. Prepaid Expenses and Other Current Assets </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets consisted of the following at: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>October&nbsp;31,<BR>2024</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>April&nbsp;30,<BR>2024</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid software fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">870</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">951</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">425</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">419</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,295</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. Property and Equipment </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Property and equipment consisted of the following at: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>October&nbsp;31,<BR>2024</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>April&nbsp;30,<BR>2024</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Medical rental equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">44,214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">38,097</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computer software and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,439</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Test equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,224</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">891</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">891</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,877</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,651</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: accumulated depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20,930</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,546</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">28,947</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">26,105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company recorded $4,244 and $4,695 of depreciation expense for the six months ended October&nbsp;31, 2024
and 2023, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. Leases </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In June 2021, the Company amended its office lease that began on May&nbsp;1, 2020 to expand the leased space, commencing on September&nbsp;1,
2021. The amendment is subject to all terms and conditions of the original office lease agreement and expires in April 2024. In October 2023, the Company amended the existing arrangements into an extended office lease set to expire in April 2029.
The Company has the option to renew for 3 or 5 years upon expiration of the extended term. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The October 2023 amendment provided rent
abatement from November&nbsp;1, 2023 through April&nbsp;30, 2024. The same amendment further provided a tenant improvement allowance of $943 to be used as rent abatement or tenant improvement reimbursement by June 2026, and $786 specific for tenant
improvements. In August of 2024, the Company amended its office lease to allow for two additional months of rent abatement and also allowed the specific tenant improvement reimbursement to be used for rent abatement or tenant improvements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Operating lease expense was as follows for the periods below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="55.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Six&nbsp;Months<BR>Ended<BR>October&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2024</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">367</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">589</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Variable lease expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">306</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating lease expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">673</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">907</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Operating lease expense includes amortization and interest expense associated with operating lease <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets and liabilities. Variable lease expense includes payments related to taxes, insurance and maintenance costs as required by the lease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Cash paid for operating leases was $333 and $977 for the six months ended October&nbsp;31, 2024 and 2023, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The weighted average remaining lease term for the Company&#146;s operating leases was 54 months as of October&nbsp;31, 2024 and 60 months as
of April&nbsp;30, 2024. The weighted average discount rate used to calculate the net present value of the Company&#146;s operating lease liabilities was 15.2% as of October&nbsp;31, 2024 and April&nbsp;30, 2024, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. Accrued Liabilities </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Accrued
liabilities consisted of the following at: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="55.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>October&nbsp;31,<BR>2024</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>April&nbsp;30,<BR>2024</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bonuses and commissions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,424</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,043</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,651</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vacation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,982</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,903</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payroll and payroll taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">336</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">234</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">330</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,079</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. Long-Term Debt </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On September&nbsp;24, 2020, WAH Corp. and Kestra entered into the Loan and Security Agreement (the &#147;Loan Agreement&#148;) with a lender,
which provided for a Senior Secured Delayed-Draw Term Loan in an </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
aggregate principal amount of up to $50.0&nbsp;million (the &#147;Term Loan&#148;). Borrowings under the original Term Loan are made available in up to three tranches, which are subject to the
Company achieving certain funding, regulatory or revenue milestones as defined in the Loan Agreement. The term loan includes certain six month trailing revenue targets beginning in July of 2022, if breached, will increase the interest rate on the
Term Loan by 1.0% and require the then outstanding balance to accelerate to be repaid over a <FONT STYLE="white-space:nowrap">24-month</FONT> period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On December&nbsp;28, 2020, the Company drew the first tranche of the Term Loan pursuant to the terms of the Loan Agreement in the amount of
$20.0&nbsp;million. The Company incurred a 1.0% facility fee of the total available loan amount of $50.0&nbsp;million upon the draw of the first tranche and legal fees of $832 for both the Company and the lender. The Company recognized a portion of
the facility fee and legal fees as a discount to the long-term debt liability and a portion in other long-term assets, relative to the tranche draws, both of which are amortized as interest expense over the term of the loan on a straight-line basis.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In conjunction with the draw on the first tranche, the Parent issued a warrant to the lender to purchase up to 49,044 shares of the
Parent&#146;s common units at an exercise price of $22.63 per share. The fair value of the warrant is $320 and is recognized as a debt discount and as a capital contribution, and the debt discount is amortized over the term of the loan to interest
expense. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On January&nbsp;21, 2022, the Company drew the second tranche of the Delayed Senior Secured Term Loan pursuant to the terms of
the Loan Agreement in the amount of $15.0&nbsp;million. Relative to the second tranche draw, the Company reclassified a portion of the facility fee and legal fees from other long-term assets to the long-term debt liability as a debt discount, with
both facility and legal fees being amortized as interest expense over the term of the loan on a straight-line basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In conjunction with
the draw of the second tranche, the Parent issued a warrant to the lender to purchase up to 36,783 shares of the Parent&#146;s common units at an exercise price of $26.24 per share. The fair value of the warrant is $375 and is recognized as a debt
discount and as a capital contribution, and the debt discount is amortized over the term of the loan to interest expense. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Term Loan
originally bore interest on outstanding balances of 14.5% per annum, all of which could be <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">paid-in-kind,</FONT></FONT> accrued and added to the principal balance and compounded
quarterly until the earlier of the repayment or maturity date of the Term Loan. Following achievement of Premarket Approval from the FDA of the Company&#146;s ASSURE<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> WCD system, the Term Loan
would bear interest of 12.5% per annum, up to 6.5% of which can be <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">paid-in-kind,</FONT></FONT> accrued and added to the principal and compounded quarterly until the earlier of either
the repayment or maturity date of the Term Loan. On July&nbsp;27, 2021, the Company received FDA Premarket Approval for the ASSURE<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>WCD system and submitted evidence of the FDA Premarket
Approval to the lender of the Term Loan. As such, the Term Loan began to bear interest on outstanding balances of 12.5% per annum, up to 6.5% of which could be
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">paid-in-kind,</FONT></FONT> accrued and added to the principal and compounded quarterly until the earlier of either the repayment or maturity date of the Term Loan. On April&nbsp;11,
2022, the Company and the lender entered into a First Amendment to Loan and Security Agreement (the &#147;Amendment&#148;), pursuant to which the parties agreed to amend the existing Loan Agreement to (i)&nbsp;provide for additional funding under
additional tranche Loan (&#147;Tranche D Draw&#148;) in the amount of $10.0&nbsp;million, (ii)&nbsp;increase the aggregated principal amount by $10.0&nbsp;million, to a total of $60.0&nbsp;million, (iii)&nbsp;increase the portion of <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">paid-in-kind</FONT></FONT> interest to 100% of a stated interest rate at 12.5% for the period starting February&nbsp;1, 2022 through April&nbsp;30, 2023 and thereafter at a rate of 6.5% in
accordance with the terms of the loan, and (iv)&nbsp;modify the certain revenue targets and defer the first measurement date to October of 2022. The Amendment included the ability to draw on the third tranche of the debt until March&nbsp;24, 2023,
provided the Company could achieve $9.0&nbsp;million in three-month trailing revenue. Further, the fourth tranche (&#147;Tranche D Draw&#148;) for $10.0&nbsp;million is available until July&nbsp;24, 2023 upon achievement of a <FONT
STYLE="white-space:nowrap">six-month</FONT> trailing revenue of $25.0&nbsp;million. The original loan maturity date of September&nbsp;24, 2025 under the loan modification remained unchanged. The Company evaluated the Amendment to the Term Loan under
accounting guidance ASC 470, Debt and determined that the amendment should be treated as a debt modification, as such no gain or loss was recognized in the year ended April&nbsp;30, 2022. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of October&nbsp;31, 2022, the Company did not meet the required revenue target for the
preceding <FONT STYLE="white-space:nowrap">six-months</FONT> trailing revenue. As a result, the Company began to make principal payments over a <FONT STYLE="white-space:nowrap">24-month</FONT> period, payable at the beginning of the following
quarter and the interest rate increased by 1% to 13.5%. The Company made its first principal payment of $5,333 on February&nbsp;1, 2023. The Company did not meet its revenue target for the preceding six months as of January&nbsp;31, 2023 and
principal payments continued. The Company made a second principal payment on May&nbsp;1, 2023 for $5,511. The Company did not meet its revenue target for the preceding six months as of April&nbsp;30, 2023 and the next principal payment was due on
August&nbsp;1, 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On July&nbsp;28, 2023, the Company entered into an agreement with the holder of the Term Loan, to defer a principal
payment that was due on August&nbsp;1, 2023 to extend the payment date to September&nbsp;1, 2023. On August&nbsp;31, 2023, the Company entered into an agreement to defer the principal payment that was due on August&nbsp;1, 2023 to October&nbsp;31,
2023. The agreement also changed the loan prepayment fee of 6% through from September&nbsp;24, 2022 to September&nbsp;24, 2023 to a loan prepayment fee of 5% from September&nbsp;24, 2022 through December&nbsp;31, 2023 and for the prepayment fee to
be changed to 3% beyond December&nbsp;31, 2023. On September&nbsp;29, 2023, the Company terminated the Term Loan by paying off the loan balance of $34,209, accrued interest of $757, a prepayment fee of $1,710 and a loss on extinguishment of debt of
$1,006, including the <FONT STYLE="white-space:nowrap">non-cash</FONT> portion of $930. Loss on extinguishment of debt is part of Other expense on the unaudited condensed consolidated statements of operations and comprehensive loss. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On September&nbsp;29, 2023 the Company entered into a Credit Agreement with a separate lender which provided a Senior Secured Delayed Draw
Term Loan Facility (&#147;Term Loan 2024&#148;) in an aggregate principal amount of up to $60.0&nbsp;million which matures on September&nbsp;29, 2028. Borrowings are made available in up to three tranches, the first of which is available upon
closing of the agreement, which included committed equity funding of at least $75&nbsp;million, and two follow on tranches of $7.5&nbsp;million which become available before November&nbsp;1, 2024 and February&nbsp;1, 2025 and are dependent on upon
achievement of revenue milestones of trailing twelve month revenues of $50.0&nbsp;million and $70.0&nbsp;million, respectively. The Term Loan 2024 bears interest equal to the sum of Term Secured Overnight Financing Rate plus 7.25% for each interest
period which is measured monthly and is payable on the last day of each fiscal quarter. Through March&nbsp;31, 2025, the Company has the ability to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">pay-in-kind</FONT></FONT> up to 2%
of the payable interest. The Term Loan 2024 requires a minimum level of cash of $3.0&nbsp;million and certain revenue thresholds based upon trailing twelve month revenue results. The revenue covenant began to be measured on April&nbsp;30, 2024. As
of October&nbsp;31, 2024, the Company was in compliance with both financial covenants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On September&nbsp;29, 2023, the Company drew the
initial $45.0&nbsp;million. In connection with the first draw, the Company incurred a 1% facility fee of the total available loan amount of $60.0&nbsp;million upon the draw of the first tranche of $600 and legal fees of $1,753 for both the Company
and the lender. The Company recognized the facility fee and legal fees as a discount of $1,765 to the Term Loan 2024 for the initial draw on the loan, and $588 as an Other long-term asset, for the remainder available to draw. Each of these will be
amortized as interest expense over the term of the loan on a straight-line basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of October&nbsp;31, 2024, the Company determined
that the revenue milestones related to the second tranche was not met and the third tranche were not probable of being achieved. As a result, the Company expensed the asset related to debt issuance costs and facility fees in the amount of $462. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In conjunction with the draw of the first tranche, the Parent issued a warrant to the lender to purchase up to 256,410 shares of the
Parent&#146;s common units at an exercise price of $17.55 per share. The fair value of the warrant was $1,632 and was recognized as a debt discount and as a capital contribution, and the debt discount is amortized over the term of the loan to
interest expense. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company&#146;s long-term debt consisted of the following at: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>October&nbsp;31,<BR>2024</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>April&nbsp;30,<BR>2024</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Term loans</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">45,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">45,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">paid-in-kind</FONT></FONT> interest applied to term loan balance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,008</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">540</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: unamortized debt issuance costs and debt discount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,665</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,004</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total long-term debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">43,343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">42,536</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Current portion of long term debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total long-term debt, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">43,343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">42,536</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">During the six months ended October&nbsp;31, 2024, the Company recognized expense of $3,779 related to the
Term Loan 2024. Of this amount, $697 was related to amortization of the facility fee and legal fees, $164 was related to amortization of the debt discount recognized in connection with the warrant, $2,451 was cash interest expense and $467 was
interest expense <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">paid-in-kind</FONT></FONT> and applied to the Term Loan 2024 balance as of October&nbsp;31, 2024. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">During the six months ended October&nbsp;31, 2023, the Company recognized expense of $2,644 related to the Term Loan. Of this amount, $130 was
related to amortization of the facility fee and legal fees, $83 was related to amortization of the debt discount recognized in connection with the warrant, $1,207 was cash interest expense and $1,224 was interest expense <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">paid-in-kind</FONT></FONT> prior to the extinguishment of the Term Loan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. Fair Value
Measurement </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table presents the Company&#146;s fair value hierarchy for its classified assets and liabilities measured
at fair value on a recurring basis as of October&nbsp;31, 2024 and April&nbsp;30, 2024. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="63%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Level&nbsp;1</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Level&nbsp;2</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Level&nbsp;3</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><U>October&nbsp;31, 2024</U></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">76,918</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">77,252</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><U>April&nbsp;30, 2024</U></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,249</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company classifies its money market funds, which are valued based on quoted market prices in active
markets with no valuation adjustment, as cash and cash equivalents within the fair value hierarchy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of October&nbsp;31, 2024 and
April&nbsp;30, 2024, the fair value of the long-term debt, net of discounts, approximated $45,710 and $43,870, respectively. The fair value of long-term debt was determined using quoted market prices, when available, or discounted cash flows based
on various factors, including maturity schedules and current market rates. Long-term debt has been classified as Level&nbsp;2 of the fair value hierarchy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">There were no transfers into or out of the Level&nbsp;1, 2 or 3 fair value hierarchies during the six months ended October&nbsp;31, 2024. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. Stockholder&#146;s Deficit </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company had 5,000,000 shares of common stock authorized and 105,808 shares issued and outstanding with a par value of $0.01 as of
October&nbsp;31, 2024 and April&nbsp;30, 2024. Each share of common stock is entitled to one vote. Contributions are recorded to additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. Redeemable Preferred Stock </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In May
2022, the Company amended and restated the Memorandum and Articles of Association of the Company, according to which the Company&#146;s existing share capital of 5,000,000 shares can upon the discretion of the Company be issued in the form of either
common and/or preferred stock with a par value of $0.01 each. Preferred stock issued is considered <FONT STYLE="white-space:nowrap">non-voting</FONT> and are subject to preferred dividend accrued daily with a set payment &#147;yield&#148; capped at
4.7%. The preferred dividend is declared upon the discretion of the directors of the Company on the interim basis and paid out on the annual basis upon discretion of the Company, provided there are funds lawfully available for distribution. No
dividends were declared as of the six months ended October&nbsp;31, 2024 and October&nbsp;31, 2023 and the cumulative unpaid dividends were $5,706 and $2,915, respectively. In the event of liquidation, dissolution or winding up, assets will be
applied first, to pay preferred stock dividends and second to pay issue price of preferred stock.&nbsp;Preferred stock may be converted to common stock at the option of the directors upon a successful public offering based on the criteria outlined
by the directors of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For the six months ended October&nbsp;31, 2024 and October&nbsp;31, 2023, the Company issued a total of
103,400 and 50,000 preferred shares, respectively, to the Parent for proceeds of $103,400 and $50,000, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The preferred stock
is presented within mezzanine equity as it is redeemable for cash or other assets and is redeemable upon the occurrence of an event that is not solely within the control of the Company (specifically, an Initial Public Offering that is at the
directors&#146; request). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. <FONT STYLE="white-space:nowrap">Non-Controlling</FONT> Interest </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In July 2024, West Affum Holdings Designated Activity Company (the &#147;DAC&#148;), a subsidiary of the Company, received a $17,100
investment from a third party (the &#147;Investor&#148;) in exchange for shares. The DAC sold the Investor 171 Class&nbsp;A Redeemable Ordinary Shares of the DAC at a price per share equal to $100,000 for an aggregate cash purchase price of $17,100.
The Company allocates net income (loss) of the consolidated subsidiary to the Investor based on their proportional ownership. Concurrently with the execution and delivery of this agreement, the Company entered into an agreement with the Investor and
the Parent wherein, at the discretion of the Investor, the DAC Class&nbsp;A redeemable ordinary shares &#147;(Class A Redeemable Ordinary Shares&#148;) held by the Investor can be exchanged into common shares of the Company, and subsequently
exchanged into class A common units of the Parent (&#147;Class A Common Units&#148;). The exchange ratio is calculated based on the DAC price per share of $100,000 and the Class&nbsp;A Common Unit price of $14.67 as of July 2024 which
allows&nbsp;the Investor to exchange 171 DAC Class&nbsp;A Redeemable Ordinary Shares into 1,165,644.17 Class&nbsp;A Common Units of the Parent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">There are no freestanding features requiring recognition or embedded features requiring bifurcation and there is no redemption feature that is
not solely within the Company&#146;s control. The agreement does not allow for a redemption for cash or other assets at a fixed or determinable price on a fixed or determinable date outside the Company&#146;s control at the option of the Investor.
Any redemption is at the discretion of the DAC. Therefore, the <FONT STYLE="white-space:nowrap">non-controlling</FONT> interest is classified within permanent equity as it does not meet the liability or mezzanine classification criteria. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12. Equity Incentive Plan </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Certain
employees and contractors of the Company have been granted equity incentive units (&#147;Incentive Units&#148;) of the Parent. The Parent has the ability to issue any number of additional Incentive Units at its
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
discretion. The Incentive Units allow the holder to participate in the equity of the Parent subject to participation thresholds as defined by the Parent. Upon termination, the Company has the
right but not the obligation to repurchase vested Incentive Units at fair market value within seven months following termination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The
Parent has issued Incentive Units to certain employees of the Company, which vest based on continued service on a straight-line basis over the applicable service periods. Any unvested Incentive Units are automatically forfeited upon a separation.
Incentive Units do not expire and have no exercise price. Compensation cost of Incentive Units is estimated on the date of grant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of
October&nbsp;31, 2024 and April&nbsp;30, 2024, total Incentive Units vested were 1,814,809 and 1,262,179, respectively. The total number of Incentive Units authorized is determined at the Parent&#146;s discretion and is not limited. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table summarizes Incentive Unit activity: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="55.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Incentive<BR>Units</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at April&nbsp;30, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,087,651</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited / repurchased</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(51,800</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at October&nbsp;31, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,145,851</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at April&nbsp;30, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,130,143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,121,599</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited / repurchased</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(141,319</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at October&nbsp;31, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,110,423</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company recorded stock-based compensation in the following expense categories of its unaudited interim
condensed consolidated statements of operations and comprehensive loss: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Six&nbsp;Months&nbsp;Ended<BR>October&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2024</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">640</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,499</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">727</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of October&nbsp;31, 2024 and April&nbsp;30, 2024, total unvested Incentive Units were 1,295,614 and
867,963, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of October&nbsp;31, 2024, unrecognized compensation cost for outstanding Incentive Units was $2,833, with the
weighted-average period over which this cost is expected to be recognized at 2.89 years. As of April&nbsp;30, 2024, unrecognized compensation cost for outstanding Incentive Units was $3,389, with the weighted-average period over which this cost is
expected to be recognized at 3.18 years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In determining the compensation cost of the Incentive Units, the fair value for each Incentive
Unit has been estimated at the date of grant using the Black-Scholes or PWERM models. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company&#146;s PWERM approach estimated its
enterprise value. This method considered various exit scenarios including an initial public offering (the &#147;IPO Scenario&#148;), or staying private, and assigned a probability weight to each scenario. Using the PWERM, the enterprise value under
each potential exit scenario and the timing of each scenario were weighted based on our estimated probability of occurrence for such scenario. The Company&#146;s equity values under the IPO Scenarios were each estimated using the market approach
based on the valuation of comparable public companies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">There is no intrinsic value or exercise price associated with these Incentive Units as they
are participation units rather than options. The weighted average significant assumptions used in these calculations were summarized as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="59%"></TD>

<TD VALIGN="bottom" WIDTH="18%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="17%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>October&nbsp;31,&nbsp;2024</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>April&nbsp;30,&nbsp;2024</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected time to liquidity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.1&nbsp;years</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.5&nbsp;years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk free rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.58</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.04</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Estimated fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The weighted average grant date fair value of Incentive Units outstanding for the six months ended
October&nbsp;31, 2024 and for the year ended April&nbsp;30, 2024 were $4.42 and $5.65, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Certain directors and advisors of
the Company have also been granted 17,149 shares of restricted common shares and 25,562 shares of restricted class A common units of the Parent (&#147;RSA&#148;) between September&nbsp;1, 2022 and October&nbsp;9, 2024, with a vesting period of 3
years. As of October&nbsp;31, 2024, 8,575 and 8,575 restricted common units and 0 and 25,562 of restricted class A common units were vested and unvested, respectively. As of April&nbsp;30, 2024, 2,858 and 14,291 restricted common units were vested
and unvested, respectively. All restricted class A common units were granted after April&nbsp;30, 2024. Share-based compensation expense associated with restricted common units and restricted class A common units has historically been immaterial and
recorded within selling, general and administrative expense. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13. Income Taxes </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table presents details of the provision for income taxes and effective tax rates: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="55.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Six&nbsp;Months&nbsp;Ended<BR>October&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2024</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effective tax rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.03</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.06</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company is subject to U.S. federal income tax as well as income tax in various states. Additionally, the
Company consists of a Cayman Islands parent company with subsidiaries in U.S. and Ireland. Under the current laws of the Cayman Islands, the Company is not subject to tax on its income. The Company accounts for the provision for income taxes in
accordance with ASC 740, Income Taxes, which requires an estimate of the annual effective tax rate for the full year to be applied to the interim period, taking into account
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">year-to-date</FONT></FONT> amounts and projected results for the full year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our effective tax rate varies from the statutory Irish tax rate due to the effect of state income taxes and research and development credits.
Our effective tax rate could fluctuate from quarter to quarter based on variations in the estimated and actual level of <FONT STYLE="white-space:nowrap">pre-tax</FONT> income or loss by jurisdiction, changes in enacted tax laws and regulations, and
changes in estimates regarding the realizability of deferred tax assets. As of October&nbsp;31, 2024 and April&nbsp;30, 2024, we provided a valuation allowance against our net deferred tax assets that we believe, based on the weight of available
evidence, are not more likely than not to be realized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14. Commitments and Contingencies </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">From time to time, the Company may become involved in litigation relating to claims arising from the ordinary course of business. The Company
considers the likelihood of loss or impairment of an asset, or the incurrence of a liability, as well as the ability to reasonably estimate the amount of loss, in determining loss contingencies. An estimated loss contingency is accrued when
information available prior to issuance of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
unaudited interim condensed consolidated financial statements indicates that it is probable that an asset has been impaired or a liability has been incurred at the date of the unaudited interim
condensed consolidated financial statements, and the amount or range of loss can be reasonably estimated. Legal costs are expensed as incurred. Gain contingencies are not recognized until they&#146;re realized or realizable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company enters into indemnification agreements with its officers and directors, and the Company&#146;s certificate of incorporation and
bylaws include similar indemnification obligations to its officers and directors. To date, there have been no claims under any indemnification provisions, therefore there is no accrual of such amounts as of October&nbsp;31, 2024 and April&nbsp;30,
2024. The Company is unable to determine the maximum potential impact of these indemnifications on the future results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Management believes that there are currently no other claims or actions pending against the Company where the ultimate disposition could have
a material effect on the Company&#146;s results of operations, financial condition or cash flows. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15. Defined Contribution Plan </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company sponsors a defined contribution retirement savings plan under Section&nbsp;401(k) of the Internal Revenue Code of 1986, as amended
(the &#147;401(k) Plan&#148;), for its full-time employees, which covers all eligible employees in the United States. The 401(k) Plan provides for matching and discretionary contributions by the Company. For the six months ended October&nbsp;31,
2024 and 2023, matching and discretionary contributions by the Company totaled $766 and $681, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16. Net Loss Per Share Attributable to
Common Stockholder </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Basic net loss per share attributable to the common stockholder is calculated by dividing net loss by the weighted
average number of shares of common stock outstanding during the period and excludes any dilutive effects of employee stock-based awards. Diluted net loss per share attributable to the common stockholder is computed giving effect to all potentially
dilutive shares of common stock, including common stock issuable upon vesting of stock-based payment awards. For the six months ended October&nbsp;31, 2024 and 2023, the Company did not have any dilutive shares. For both periods presented, there is
no difference in the number of shares used to compute basic and diluted shares outstanding due to the Company&#146;s net loss position. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Potentially anti-dilutive shares excluded from the calculation of diluted net loss per share for the periods ended October&nbsp;31, 2024 and
April&nbsp;30, 2024 include 280,510 and 177,110 shares of redeemable preferred stock, respectively. Based on the conversion terms of the redeemable preferred stock and circumstances existing as of October&nbsp;31, 2024 and April&nbsp;30, 2024, the
Company is unable to quantify the quantity of shares of common stock the redeemable preferred stock is convertible into. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table sets forth the computation of basic and diluted net loss per share
attributable to the common stockholder: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Six Months</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Ended</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>October&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2024</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Numerator:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to West Affum Intermediate Holdings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(40,252</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(50,217</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Undeclared preferred dividends</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,706</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,915</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common stockholder</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(45,958</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(53,132</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Denominator:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average shares of common stock outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105,808</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105,808</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss per share attributable to common stockholder</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(434</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(502</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company has Incentive Units issued and outstanding under an equity incentive plan that may be settled in
common units of the Parent. The Parent also issued warrants in connection with the draws of the first and second tranches under the Term Loan and the first tranche under the Term Loan 2024 that may be settled in common units of the Parent. The
Incentive Units and warrants are not considered participating securities as they do not participate in undistributed earnings of the Company and therefore, would not be included in the calculation of both the basic and diluted loss per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">non-controlling</FONT> interest is in the form of Class&nbsp;A redeemable ordinary shares and can be
exchanged into common shares of the Company and subsequently exchanged into Class&nbsp;A common units of the Parent. There is no redemption feature that is not solely within the Company&#146;s control, thus, the
<FONT STYLE="white-space:nowrap">non-controlling</FONT> interest is not entitled to receive dividends from the Company. The <FONT STYLE="white-space:nowrap">non-controlling</FONT> interest is not considered to be participating securities and is not
included in the calculation of basic or diluted loss per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The restricted common units and restricted Class&nbsp;A common units
granted to certain directors represent equity interests in the Parent. Each of these classes of units are not considered to be participating securities and are not included in the calculation of basic or diluted loss per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>17. Subsequent Events </B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company
has evaluated subsequent events through the date the unaudited interim condensed consolidated financial statements were available to be issued on January&nbsp;17, 2025, and through February&nbsp;26, 2025, the date the unaudited interim condensed
consolidated financial statements were available to be reissued. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In February of 2025, the Company amended the Term Loan 2024 facility to
adjust the revenue milestones applicable to the debt covenants and amend the ability to draw an additional $15.0&nbsp;million under the third tranche through July&nbsp;31, 2026 upon the achievement of revenue of at least $60.0&nbsp;million for any
twelve consecutive month period prior to the third tranche borrowing date. In addition, upon the funding of additional amounts under the third tranche, the Company will issue warrants equal to 10% of the amount funded. If the Company does not
complete an initial public offering by July&nbsp;31, 2025, the revenue milestones applicable to the debt covenants will revert to the original revenue milestones. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin744414_17"></A>Report of Independent Registered Public Accounting Firm
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the Board of Directors and Stockholder of West Affum Intermediate Holdings Corp. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Opinion on the Financial Statements </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We
have audited the accompanying consolidated balance sheets of West Affum Intermediate Holdings Corp. and its subsidiaries (the &#147;Company&#148;) as of April 30, 2024 and 2023, and the related consolidated statements of operations and comprehensive
loss, of changes in redeemable preferred stock and stockholder&#146;s deficit and of cash flows for the years then ended, including the related notes (collectively referred to as the &#147;consolidated financial statements&#148;). In our opinion,
the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of April 30, 2024 and 2023, and the results of its operations and its cash flows for the years then ended in conformity with
accounting principles generally accepted in the United States of America. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Substantial Doubt about the Company&#146;s Ability to Continue as a Going
Concern </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going
concern. As discussed in Note 1 to the consolidated financial statements, the Company has incurred negative operating cash flows and losses from operations since inception that raise substantial doubt about its ability to continue as a going
concern. Management&#146;s plans in regard to these matters are also described in Note&nbsp;1. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Basis for Opinion </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">These consolidated
financial statements are the responsibility of the Company&#146;s management. Our responsibility is to express an opinion on the Company&#146;s consolidated financial statements based on our audits. We are a public accounting firm registered with
the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and
Exchange Commission and the PCAOB. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We conducted our audits of these consolidated financial statements in accordance with the standards of
the PCAOB and in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements
are free of material misstatement, whether due to error or fraud. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our audits included performing procedures to assess the risks of
material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures
in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We
believe that our audits provide a reasonable basis for our opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ PricewaterhouseCoopers LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Irvine, California </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">August&nbsp;28, 2024, except with respect to
the matters that raise substantial doubt about the Company&#146;s ability to continue as a going concern discussed in Note 1, as to which the date is December&nbsp;11, 2024 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have served as the Company&#146;s auditor since 2016. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WEST AFFUM INTERMEDIATE HOLDINGS CORP. AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin744414_18"></A>CONSOLIDATED BALANCE SHEETS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>April&nbsp;30, 2024 and 2023 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>(in thousands, except share and per share amounts) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2024</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,249</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,810</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Disposable medical equipment supplies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,907</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,423</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT>
assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,286</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,278</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deposits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,642</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">512</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,445</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other long-term assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">607</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">356</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">45,949</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">38,656</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities, Redeemable Preferred Stock and Stockholder&#146;s Deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">23,892</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,079</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,765</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities, current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,366</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term debt, current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,446</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,971</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,739</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other long-term liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term debt, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,536</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,322</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78,216</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commitments and contingencies (Note 13)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable preferred stock, $0.01 par value; 5,000,000 shares authorized, 177,110 shares issued
and outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">177,110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102,110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholder&#146;s deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.01 par value; 5,000,000 shares authorized; 105,808 shares issued and
outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">197,057</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">194,736</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(406,435</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(312,315</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholder&#146;s deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(209,377</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(117,578</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities and stockholder&#146;s deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">45,949</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">38,656</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The accompanying notes are an integral part of these consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WEST AFFUM INTERMEDIATE HOLDINGS CORP. AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin744414_19"></A>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Years Ended April&nbsp;30, 2024 and 2023 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>(in thousands, except share and per share amounts) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2024</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27,814</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Costs of revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,452</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,281</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross margin</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">362</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,651</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,490</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,756</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69,935</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85,425</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69,770</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(85,063</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(80,421</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,629</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense (income)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,803</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,827</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss before provision for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(94,096</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(84,223</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(94,120</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(84,238</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Undeclared preferred stock dividends</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,721</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,499</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common stockholder, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(100,841</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(86,737</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to common stockholder, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(953</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(820</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares of common stock outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105,808</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105,808</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The accompanying notes are an integral part of these consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WEST AFFUM INTERMEDIATE HOLDINGS CORP. AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin744414_20"></A>CONSOLIDATED STATEMENTS OF CHANGES IN REDEEMABLE PREFERRED STOCK AND </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STOCKHOLDER&#146;S DEFICIT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Years Ended April 30, 2024 and 2023 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>(in thousands, except share and per share amounts) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Redeemable<BR>Preferred&nbsp;Stock</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Common Stock</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Additional</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B><FONT STYLE="white-space:nowrap">Paid-In</FONT><BR>Capital</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center">
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Accumulated<BR>Deficit</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Total</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Stockholder&#146;s<BR>Deficit</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Amount</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Amount</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balances at April&nbsp;30, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105,808</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">194,198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(228,077</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(33,878</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Capital contributions</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,209</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,209</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of redeemable preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102,110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102,110</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deemed dividend for payments to third party on behalf of stockholder</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(671</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(671</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(84,238</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(84,238</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balances at April&nbsp;30, 2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102,110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102,110</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105,808</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">194,736</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(312,315</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(117,578</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,488</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,488</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of redeemable preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,000</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deemed dividend for payments to third party on behalf of stockholder</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(799</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(799</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Capital contribution from Parent to settle warrant obligation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,632</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,632</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(94,120</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(94,120</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balances at April&nbsp;30, 2024</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">177,110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">177,110</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105,808</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">197,057</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(406,435</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(209,377</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The accompanying notes are an integral part of these consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WEST AFFUM INTERMEDIATE HOLDINGS CORP. AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin744414_21"></A>CONSOLIDATED STATEMENTS OF CASH FLOWS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Years Ended April&nbsp;30, 2024 and 2023 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>(in thousands) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2024</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Cash flows from operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(94,120</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(84,238</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,560</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,855</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Loss on disposal of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,070</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">560</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Interest
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">paid-in-kind</FONT></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,098</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,183</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Amortization of debt discounts and issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">610</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">446</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,488</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,209</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-cash</FONT> lease expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">729</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,090</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Deferred income tax expense (benefit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(45</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-cash</FONT> loss on extinguishment of debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">930</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Disposable medical equipment supplies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,177</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(733</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">331</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(271</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,998</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,340</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">371</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,284</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(469</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,141</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Other long-term assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(72,235</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(69,642</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Cash flows from investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,226</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,927</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Deposits paid for medical rental equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(288</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,534</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Refund of deposits for medical rental equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">285</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,229</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,461</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Cash flows from financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Proceeds from issuance of redeemable preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102,110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Deemed dividend for payments to third party on behalf of stockholder</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(799</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(671</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Proceeds from issuance of long-term debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Payment of debt issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,353</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Repayment of long-term debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(39,123</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,333</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77,725</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96,106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Net increase (decrease) in cash, cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,739</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,003</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Cash, cash equivalents and restricted cash</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,322</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">End of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,322</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Reconciliation of cash, cash equivalents and restricted cash reported in the consolidated
balance sheets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,249</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,810</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">512</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Cash, cash equivalents and restricted cash shown in the Consolidated Statements of Cash
Flows</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,322</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-cash</FONT> investing and financing
activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Purchases of property and equipment in accrued liabilities and accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,066</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">273</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Capital contribution from Parent to settle warrant obligation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,632</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Supplemental disclosure of cash flow information</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Income taxes paid (refunds received)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(30</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Interest paid</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The accompanying notes are an integral part of these consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WEST AFFUM INTERMEDIATE HOLDINGS CORP. AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin744414_22"></A>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>April&nbsp;30, 2024 and 2023 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>(in thousands, except share and per share amounts) </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. Nature of Operations and Liquidity </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">West Affum Intermediate Holdings Corp., a Cayman Islands exempted company (the &#147;Company&#148;), was incorporated on August&nbsp;6, 2020,
in order to carry on the business of West Affum Holdings Corp. (&#147;WAH Corp.&#148;) and its consolidated subsidiaries. West Affum Intermediate Holdings Corp., is wholly owned by West Affum Holdings L.P., a Cayman Islands limited partnership (the
&#147;Parent&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company and its consolidated subsidiaries own certain intellectual property related to the development of
personal Wearable Cardioverter Defibrillators (&#147;WCD&#148;) approved by the U.S. Food and Drug Administration (&#147;FDA&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The
Company generates revenue through leasing the WCD system to patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidity and Going Concern </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company has incurred negative operating cash flows and significant losses from operations since its inception. For the years ended
April&nbsp;30, 2024 and 2023, the Company incurred net losses of $94,120 and $84,238, respectively. Cash used in operating activities was $72,235 and $69,642 for the years ended April&nbsp;30, 2024 and 2023, respectively. As of April&nbsp;30, 2024,
the Company had an accumulated deficit of $406,435. Management has prepared the consolidated financial statements on a going concern basis which contemplates continuity of normal business activities and the realization of assets and liabilities in
the ordinary course of business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company has historically financed its operations primarily through capital contributions, issuance
of preferred stock and redeemable stock and term loans. The Company expects to continue to incur substantial losses for the foreseeable future, and its ability to achieve and sustain profitability will depend on the successful commercialization of
its device and on the achievement of sufficient revenue to support its cost structure. As of April&nbsp;30, 2024 and 2023, the Company had cash, cash equivalents and restricted cash of $8,583 and $15,322, respectively. In May and July 2024, through
additional capital contributions and the closing of a private placement, the Company received $116,500 in total net cash proceeds. However, management believes that its cash and cash equivalents balance may not be sufficient to fund its planned
current operations for the next twelve months from the date these consolidated financial statements were issued. Management plans on raising additional capital to continue operations but cannot predict with certainty the ability to obtain such
funding. If the Company is unable to obtain additional funding, it would be required to suspend operations or reduce its spending profile to a level which would not allow for planned product commercialization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Additionally, as discussed in Note&nbsp;7, the Company&#146;s debt agreement requires certain financial and non-financial covenants, including
minimum revenue and cash thresholds, which if not achieved may be considered an event of default under the terms of the debt agreement. Based upon the factors discussed above, there is substantial doubt as to whether the Company will continue as a
going concern for the next twelve months from the date these consolidated financial statements were available to be issued. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Significant Accounting
Policies </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Basis of Presentation </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of
America (&#147;U.S. GAAP&#148;) and include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. The Company&#146;s reporting currency is the U.S. dollar.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Use of Estimates </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of
America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements, and the reported
amounts of expenses during the reporting period. Estimates are required as part of determining the estimated lives of property and equipment, stock-based compensation expense, fair value of warrant obligations and valuation allowance for deferred
tax assets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company bases its estimates on historical experience and other market-specific or relevant assumptions that it believes
to be reasonable under the circumstances. Actual results could differ from those estimates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash, Cash Equivalents and Restricted Cash </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. Cash and cash
equivalents are recorded at cost, which approximates fair value. Restricted cash consists entirely of amounts related to the Company&#146;s office lease agreement. In lieu of a cash security deposit, the landlord required an irrevocable standby
letter of credit upon execution of the lease be maintained throughout the term of the lease agreement in the amount of $109 and $512 as of April&nbsp;30, 2024 and 2023, respectively. The Company also has restricted cash of $225 and $0 for credit
card collateralization as of April&nbsp;30, 2024 and 2023, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Disposable Medical Equipment Supplies </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Disposable medical equipment supplies consist of equipment parts, consumables, and associated product supplies that are expensed to the costs
of revenue at the time of order delivery to the patient or first use. Disposable medical equipment supplies are valued at standard cost. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Accounts
Receivable </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Accounts receivable and net revenues are based on contractually agreed-upon rates for services provided, reduced by
estimated adjustments, including contractual adjustments. Inherent in these estimates is the risk that they will have to be revised or updated as additional information becomes available. The complexity of third-party billing arrangements and laws
and regulations governing Medicare may result in adjustments to amounts originally recorded. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company performs a periodic analysis to
review the valuation of accounts receivable and collectability of outstanding balances. These estimates are determined utilizing historical realization data under a portfolio approach which is then assessed by management to evaluate whether
adjustments should be made based on accounts receivable aging trends, other operating trends, and relevant business conditions such as governmental and managed care payor claims processing procedures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company records a reserve for estimated probable losses as part of net revenue adjustments in order to report revenue at an expected
collectable amount based on the total portfolio of receivables for which collectability has been deemed probable. The accounts receivable are presented on the Consolidated Balance Sheets net of the adjustments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Receivables are considered past due when not collected by established due dates. Specific patient balances are written off after collection
efforts have been followed and the account has been determined to be uncollectible. Revisions in reserve estimates are recorded as an adjustment to net revenue in the period of revision. The estimates of the allowance for uncollectible accounts were
$500 and $0 as of April&nbsp;30, 2024 and 2023, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Property and Equipment </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Property and equipment are stated at cost less accumulated depreciation. Depreciation of medical rental equipment commences at the date when
it becomes available for service, which represents the date that the asset is ready for intended use by the patients and continues through the estimated useful life of the asset. Expenditures for major renewals and betterments that extend the useful
lives of property and equipment are capitalized. Expenditures for maintenance and repairs, including planned major maintenance activities, are expensed as incurred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Property and equipment are depreciated using the straight-line method based on the following estimated useful lives: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Asset Classification</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Estimated&nbsp;Useful&nbsp;Lives</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Computer software and equipment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">3.0 years</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Test equipment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">5.0 years</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Leasehold improvements</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="white-space:nowrap">Lesser&nbsp;of&nbsp;useful&nbsp;life&nbsp;or&nbsp;lease-term</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Medical rental equipment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">1.5&#150;7.0 years</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">When assets are retired or otherwise disposed of, the cost and related accumulated depreciation are removed
from the accounts, and any resulting gain or loss is recognized in the Consolidated Statements of Operations and Comprehensive Loss for the year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Deposits </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Deposits represent
advance payments to contracted suppliers for medical rental equipment and disposable medical equipment supplies. These payments are classified as long-term assets in the Consolidated Balance Sheets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Leases </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company determines if
an arrangement is a lease at inception and on the lease commencement date, the Company recognizes an asset for the right to use a leased asset and a liability based on the present value of remaining lease payments over the lease term. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company determines whether a contract contains a lease at the inception of a contract. If the contract conveys the right to control the
use of an identified asset for a period of time in exchange for consideration, the Company considers the contract to contain a lease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The
Company determines whether a contract conveys the right to control the use of an identified asset for a period of time if the contract contains both the right to obtain substantially all of the economic benefits from use of the identified asset and
the right to direct the use of the identified asset. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company&#146;s leases do not provide an implicit rate. As such, the Company uses
its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Lease and <FONT STYLE="white-space:nowrap">non-lease</FONT> components are combined for all leases. The measurement of lease <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets and liabilities includes amounts related to lease payments made prior to the lease commencement date, incentives from landlords received by the Company for
signing a lease, including tenant improvement allowances or deferred lease credits paid to the Company by landlords, fixed payments related to lease components, such as rent escalation payments schedules at the lease commencement date, and fixed
payments related to <FONT STYLE="white-space:nowrap">non-lease</FONT> components, such as taxes, insurance and maintenance costs. The measurement of lease <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT>
assets and liabilities excludes amounts related to variable payments related to lease components, such as contingent rent payments. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Variable payments related to <FONT STYLE="white-space:nowrap">non-lease</FONT> components,
such as taxes, insurance and maintenance costs, are expensed as incurred in the Consolidated Statements of Operations and Comprehensive Loss. The Company has elected not to recognize <FONT STYLE="white-space:nowrap">right-of</FONT> <FONT
STYLE="white-space:nowrap">use-assets</FONT> and lease liabilities for leases with a term of twelve months or less. Lease costs for short-term leases are recognized on a straight-line basis over the lease term. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Certain of the Company&#146;s leases may include options to extend the lease or to terminate the lease.&nbsp;The Company assesses these leases
and, depending on the facts and circumstances, has not included these options in the measurement of the Company&#146;s lease <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets and liabilities since
extending the lease under an option is not reasonably certain of such option being exercised. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-cash</FONT> amortization related to the lease <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets and liabilities is calculated on a straight-line basis over the lease term and is reflected in research and development costs and selling, general and administrative expense in the
Consolidated Statements of Operations and Comprehensive Loss. Operating lease payments are classified as cash flows from operating activities in the Consolidated Statements of Cash Flows. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Impairment of Long-Lived Assets </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company periodically reviews its long-lived assets, including property and equipment and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company compares the carrying value of the long-lived assets (asset group) with the estimated future net undiscounted future cash flows
expected to result from the use of the assets (asset group), including cash flows from disposition. An impairment loss is measured as the amount by which the carrying value exceeds the fair value of the long-lived assets (asset group).&nbsp;No
impairment of long-lived assets was recorded during the years ended April&nbsp;30, 2024 and 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company generates revenue from the leases of ASSURE<SUP STYLE="font-size:75%; vertical-align:top">&copy;</SUP> System, which consists of a
Wearable Cardioverter Defibrillator (&#147;WCD&#148;) combined with a proprietary digital healthcare platform, to <FONT STYLE="white-space:nowrap">at-risk</FONT> patients for a fixed amount on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">month-to-month</FONT></FONT> basis. The lease payments generally consist of the contracted amounts based on reimbursement arrangements with third-party payors including Medicare, Medicaid and private commercial payors,
and/or certain patient <FONT STYLE="white-space:nowrap">co-payments.</FONT> The patient has the right to cancel the lease at any time during the rental period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The equipment leases are classified as operating leases at lease commencement, and the Company recognizes the revenue associated with ASSURE<SUP
STYLE="font-size:75%; vertical-align:top">&copy;</SUP> rentals in accordance with Accounting Standards Codification Topic 842, <I>Leases</I> (&#147;ASC Topic 842&#148;). The Company elected the practical expedient provided under ASC Topic 842 to
combine the lease of ASSURE<SUP STYLE="font-size:75%; vertical-align:top">&copy;</SUP> System with the <FONT STYLE="white-space:nowrap">non-lease</FONT> components, which includes the digital healthcare platform. The ASSURE<SUP
STYLE="font-size:75%; vertical-align:top">&copy;</SUP> System is expected to be the predominant component and, as a result, the Company accounts for the combined revenue components under ASC Topic 842. Revenue is recognized on a straight-line basis
over the contractual <FONT STYLE="white-space:nowrap">non-cancellable</FONT> lease term, which is one month, when collectability of the lease payments is deemed to be probable. If collectability of the lease payments is not deemed to be probable,
the lease income is limited to the lesser of the income that would have been recognized if collectability was probable or the lease payments collected. Collectability of all lease payments, which includes amounts reimbursed by third-party payors
and/or amounts covered by the patient, is assessed for each contract upon lease commencement and is subject to subsequent reassessment throughout the lease term, as necessary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Due to the nature of the industry and the reimbursement environment in which we operate, we periodically evaluate the need to record a general
reserve under ASC 450, <I>Contingencies, </I>for a portfolio of operating lease receivables that are probable of collection. Inherent in the reserve estimates is the risk that they </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
will have to be revised or updated as additional information becomes available. Specifically, the complexity of many third-party billing arrangements and the uncertainty of reimbursement amounts
for certain services from certain payors may result in adjustments to amounts originally recorded. Such adjustments are expected to be identified and recorded at the point of cash application or claim denial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Costs of Revenue </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Costs of
revenue consist of direct material, labor and indirect costs related to lease performance of ASSURE<SUP STYLE="font-size:75%; vertical-align:top">&copy;</SUP> System. It includes the cost of disposable WCD device components, depreciation cost of
medical rental equipment reusable components, shipping, and order fulfillment costs, as well as other indirect costs incurred to support the manufacture and medical rental equipment delivery to and ongoing support for the patient&#146;s costs
incurred in connection with providing the ASSURE<SUP STYLE="font-size:75%; vertical-align:top">&copy;</SUP> System to the patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income Taxes
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company accounts for income taxes using the asset and liability method. Deferred tax assets and liabilities are recognized
for the future tax consequences attributable to differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax
assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change
in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances are established if it is more likely than not that some, or all of the net deferred tax assets will not be realized. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company recognizes the effect of income tax positions only if it is more likely than not that the tax position will be sustained upon
examination by the tax authorities. Recognized income tax positions are measured at the largest amount that has a greater than 50.0% likelihood of being recognized. Changes in recognition or measurement are reflected in the period in which the
change in judgement occurs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Research and development expenses consist of salaries and related benefits of product development personnel, prototype materials and other
expenses related to the development of new products. Research and development expenses are expensed as incurred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Patent Costs </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Costs related to filing and pursuing patent applications are expensed as incurred, as recoverability of such expenditures is uncertain.
Patent-related legal costs are included as a component of selling, general and administrative expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock-Based Compensation </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense for equity incentive units is measured at the grant date based on the fair value of the award and is
recognized as compensation expense as vesting milestones are met. The Company uses the Black-Scholes option pricing model to determine the fair value of incentive units. The model requires various assumptions involving the judgement of management,
including the fair value of common units, volatility in the unit price, time to liquidity and risk-free interest rate. Since the units are not publicly traded, expected volatility is estimated based on the average historical volatility of similar
entities with publicly traded shares. Forfeitures are recognized as they occur. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Payments on Behalf of Stockholder </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">During the years ended April&nbsp;30, 2024 and 2023, the Company paid administrative costs related to its stockholder, Parent, of $799 and
$671, respectively. The payments on behalf of the stockholder were recorded as a deemed dividend in the Consolidated Statements of Changes in Redeemable Preferred Stock and Stockholder&#146;s Equity (Deficit). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Concentrations of Risk </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Credit Risk </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Financial instruments which potentially subject the Company to significant concentrations of credit risk consist primarily of cash. The
Company&#146;s cash is mainly held in financial institutions. Amounts on deposit may at times exceed federally insured limits. The Company has not experienced any losses on its deposits of cash and does not believe that it is subject to unusual
credit risk beyond the normal credit risk associated with commercial banking relationships. Further, the Company holds some cash balances in its accounts located in the Cayman Islands which are not insured. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Business Risk </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company relies and
expects to continue to rely on a small number of vendors to manufacture supplies and materials for its use in our commercial product and the clinical trial programs. These programs could be adversely affected by a significant interruption in these
manufacturing services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Customer Risk </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company earns revenues by seeking reimbursement for our product from governmental healthcare programs and private health insurance
companies, primarily from the federal Medicare program. If the Medicare program were to slow payments of our receivables for any reason, we would be adversely impacted. In addition, both governmental healthcare programs and private health insurance
companies may seek ways to avoid or delay reimbursement, which could adversely affect our cash flow and revenues. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Segment Information </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company has determined that its Chief Executive Officer is its chief operating decision maker. The Company&#146;s Chief Executive Officer
reviews financial information presented on a consolidated basis for purposes of assessing performance and making decisions on how to allocate resources. Accordingly, the Company has determined that it operates in a single reportable segment and all
of the Company&#146;s consolidated net income is attributable to the single reportable segment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value of Financial Instruments </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the
principal or most advantageous market for the asset or liability in an orderly transaction between market participants as of the measurement date. There are three levels of inputs that may be used to measure fair value: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Level&nbsp;1: Unadjusted quoted prices in active markets that are accessible at the measurement date for
identical, unrestricted assets or liabilities </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Level&nbsp;2: Significant other observable inputs other than Level&nbsp;1 prices such as quoted prices in markets
that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Level&nbsp;3: Prices or valuation techniques that require inputs that are both significant to the fair value
measurement and unobservable (i.e., supported by little or no market activity). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comprehensive Loss </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Comprehensive loss consists of net loss and other gains or losses affecting stockholder&#146;s equity that, under accounting principles
generally accepted in the United States of America, are excluded from net loss. For the years ended April&nbsp;30, 2024 and 2023, there were no items which qualify as components of other comprehensive loss and therefore, the Company&#146;s
comprehensive loss was the same as its reported net loss. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Accounting Pronouncements Not Yet Adopted </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In November 2023, the Financial Accounting Standards Board (&#147;FASB&#148;) issued Accounting Standards Update (&#147;ASU&#148;) 2023-07,
<I>Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</I>, which enables investors to better understand an entity&#146;s overall performance and assists in assessing potential future cash flows. The guidance is effective
for fiscal years beginning after December 15, 2023. The Company is still evaluating the impact that this ASU will have on their financial statement disclosures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In December 2023, the FASB issued ASU <FONT STYLE="white-space:nowrap">2023-09,</FONT> <I>Income Taxes (Topic 740): Improvements to Income Tax
Disclosures</I>, which enhances transparency and decision usefulness of income tax disclosures, primarily related to the income tax rate reconciliation and income taxes paid information. The guidance is effective for private business entities for
annual reporting periods beginning after December&nbsp;15, 2025. The Company does not anticipate a material impact to the required financial statement disclosure as a result of this ASU. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company has reviewed other recent accounting pronouncements and concluded that they are either not applicable to the business, or that no
material effect is expected on the consolidated financial statements as a result of future adoption. No new accounting pronouncements were adopted during the year ended April&nbsp;30, 2024.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. Prepaid Expenses and Other Current Assets </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets consisted of the following at: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2024</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid software fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">951</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">419</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. Property and Equipment </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Property and equipment consisted of the following at: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2024</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Medical rental equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">38,097</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,827</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computer software and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,439</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,471</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Test equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,224</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,435</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">891</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">872</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,651</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,605</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: accumulated depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,546</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,160</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">26,105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,445</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company recorded $11,560 and $4,855 of depreciation expense for the years ended
April&nbsp;30, 2024 and 2023, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. Leases </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company had two operating leases for office space that commenced on May&nbsp;1, 2020 and January&nbsp;1, 2021 with a <FONT
STYLE="white-space:nowrap">48-month</FONT> term and <FONT STYLE="white-space:nowrap">40-month</FONT> term, respectively. The Company determined at the commencement of both leases that it is reasonably certain that the Company will not exercise the
option to extend the terms of either lease. The office leases have variable lease payments to reimburse the lessor for costs, such as insurance and taxes but do not depend on an index rate and are excluded from the measurement of the lease liability
and are recognized in operating expense. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In June 2021, the Company amended its office lease that began on May&nbsp;1, 2020 to expand the
leased space, commencing on September&nbsp;1, 2021. The amendment is subject to all terms and conditions of the original office lease agreement and expires in April 2024. In October 2023, the Company amended the existing arrangements into an
extended office lease set to expire in April 2029. The Company has the option to renew for <FONT STYLE="white-space:nowrap">3.0-</FONT> or <FONT STYLE="white-space:nowrap">5.0-years</FONT> upon expiration of the extended term. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The amendment provided rent abatement from November&nbsp;1, 2023 through April&nbsp;30, 2024. The amendment further provided a tenant
improvement allowance of $943 to be used as rent abatement or tenant improvement reimbursement by June 2026, and $786 specific for tenant improvements. The Company expects the $943 to be used for rent abatement. These items are included in the lease
liability calculation and maturity analysis shown below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Operating lease expense was as follows for the years ended: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="55.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>April&nbsp;30,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2024</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">991</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Variable lease expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">602</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">527</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating lease expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,593</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,902</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Operating lease expense includes amortization and interest expense associated with operating lease <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets and liabilities. Variable lease expense includes payments related to taxes, insurance and maintenance costs as required by the lease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Cash paid for operating leases was $1,269 and $1,894 for the years ended April&nbsp;30, 2024 and 2023, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The weighted average remaining lease term for the Company&#146;s operating leases was 60 months as of April&nbsp;30, 2024 and 12 months as of
April&nbsp;30, 2023. The weighted average discount rate used to calculate the net present value of the Company&#146;s operating lease liabilities was 15.2% and 14.8% as of April&nbsp;30, 2024 and April&nbsp;30, 2023, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Maturities of operating lease liabilities (net reimbursements) were as follows as of
April&nbsp;30, 2024: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="55.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2024</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fiscal Year:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(581</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2026</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2027</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,219</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2028</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,256</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2029</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,293</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thereafter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total future lease payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,371</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: imputed interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,738</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total lease liability balance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: current portion of lease liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total lease liability, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. Accrued Liabilities </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Accrued liabilities consisted of the following at: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="55.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>April&nbsp;30,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2024</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,651</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,884</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bonuses and commissions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vacation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,903</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,491</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payroll and payroll taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">234</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,079</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,765</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. Long-Term Debt </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On September&nbsp;24, 2020, WAH Corp. and Kestra entered into the Loan and Security Agreement (the &#147;Loan Agreement&#148;) with a lender,
which provided for a Senior Secured Delayed-Draw Term Loan in an aggregate principal amount of up to $50.0&nbsp;million (the &#147;Term Loan&#148;). Borrowings under the original Term Loan are made available in up to three tranches, which are
subject to the Company achieving certain funding, regulatory or revenue milestones as defined in the Loan Agreement. The term loan includes certain six month trailing revenue thresholds beginning in July of 2022, which if not met, will increase the
interest rate on the Term Loan by 1.0% and require the then outstanding balance to accelerate to be repaid over a <FONT STYLE="white-space:nowrap">24-month</FONT> period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On December&nbsp;28, 2020, the Company drew the first tranche of the Term Loan pursuant to the terms of the Loan Agreement in the amount of
$20.0&nbsp;million. The Company incurred a 1.0% facility fee of the total available loan amount of $50.0&nbsp;million upon the draw of the first tranche and legal fees of $832 for both the Company and the lender. The Company recognized a portion of
the facility fee and legal fees as a discount to the long-term debt liability and a portion in other long-term assets, relative to the tranche draws, both of which are amortized as interest expense over the term of the loan on a straight-line basis.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In conjunction with the draw on the first tranche, the Parent issued a warrant to the lender to purchase up to 49,044 shares of the
Parent&#146;s common units at an exercise price of $22.63 per share. The fair value of the warrant is $320 and is recognized as a debt discount and as a capital contribution, and the debt discount is amortized over the term of the loan to interest
expense. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On January&nbsp;21, 2022, the Company drew the second tranche of the Delayed Senior Secured
Term Loan pursuant to the terms of the Loan Agreement in the amount of $15.0&nbsp;million. Relative to the second tranche draw, the Company reclassified a portion of the facility fee and legal fees from other long-term assets to the long-term debt
liability as a debt discount, with both facility and legal fees being amortized as interest expense over the term of the loan on a straight-line basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In conjunction with the draw of the second tranche, the Parent issued a warrant to the lender to purchase up to 36,783 shares of the
Parent&#146;s common units at an exercise price of $26.24 per share. The fair value of the warrant is $375 and is recognized as a debt discount and as a capital contribution, and the debt discount is amortized over the term of the loan to interest
expense. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Term Loan originally bore interest on outstanding balances of 14.5% per annum, all of which could be <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">paid-in-kind,</FONT></FONT> accrued and added to the principal balance and compounded quarterly until the earlier of the repayment or maturity date of the Term Loan. Following achievement
of Premarket Approval from the FDA of the Company&#146;s ASSURE<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> WCD system, the Term Loan would bear interest of 12.5% per annum, up to 6.5% of which can be <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">paid-in-kind,</FONT></FONT> accrued and added to the principal and compounded quarterly until the earlier of either the repayment or maturity date of the Term Loan. On July&nbsp;27, 2021, the Company received FDA Premarket
Approval for the ASSURE<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>WCD system and submitted evidence of the FDA Premarket Approval to the lender of the Term Loan. As such, the Term Loan began to bear interest on outstanding balances of
12.5% per annum, up to 6.5% of which could be <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">paid-in-kind,</FONT></FONT> accrued and added to the principal and compounded quarterly until the earlier of either the repayment or
maturity date of the Term Loan. On April&nbsp;11, 2022, the Company and the lender entered into a First Amendment to Loan and Security Agreement (the &#147;Amendment&#148;), pursuant to which the parties agreed to amend the existing Loan Agreement
to (i)&nbsp;provide for additional funding under additional tranche Loan (&#147;Tranche D Draw&#148;) in the amount of $10.0&nbsp;million, (ii)&nbsp;increase the aggregated principal amount by $10.0&nbsp;million, to a total of $60.0&nbsp;million,
(iii)&nbsp;increase the portion of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">paid-in-kind</FONT></FONT> interest to 100% of a stated interest rate at 12.5% for the period starting February&nbsp;1, 2022 through April&nbsp;30,
2023 and thereafter at a rate of 6.5% in accordance with the terms of the loan, and (iv)&nbsp;modify the certain minimum revenue thresholds and defer the first measurement date to October of 2022. The Amendment included the ability to draw on the
third tranche of the debt until March&nbsp;24, 2023, provided the Company could achieve $9.0&nbsp;million in three-month trailing revenue. Further, the fourth tranche (&#147;Tranche D Draw&#148;) for $10.0&nbsp;million is available until
July&nbsp;24, 2023 upon achievement of a <FONT STYLE="white-space:nowrap">six-month</FONT> trailing revenue of $25.0&nbsp;million. The original loan maturity date of September&nbsp;24, 2025 under the loan modification remained unchanged. The Company
evaluated the Amendment to the Term Loan under accounting guidance ASC 470, Debt and determined that the amendment should be treated as a debt modification, as such no gain or loss was recognized in the year ended April&nbsp;30, 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of October&nbsp;31, 2022, the Company did not meet the required revenue target for the preceding
<FONT STYLE="white-space:nowrap">six-months</FONT> trailing revenue. As a result, the Company began to make principal payments over a <FONT STYLE="white-space:nowrap">24-month</FONT> period, payable at the beginning of the following quarter and the
interest rate increased by 1.0% to 13.5%. The Company made its first principal payment of $5,333 on February&nbsp;1, 2023. The Company did not meet its revenue target for the preceding six months as of January&nbsp;31, 2023 and principal payments
continued. The Company made a second principal payment on May&nbsp;1, 2023 for $5,511. The Company did not meet its revenue target for the preceding six months as of April&nbsp;30, 2023 and the next principal payment was due on August&nbsp;1, 2023.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On July&nbsp;28, 2023, the Company entered into an agreement with the holder of the Term Loan, to defer a principal payment that was due
on August&nbsp;1, 2023 to extend the payment date to September&nbsp;1, 2023. On August&nbsp;31, 2023, the Company entered into an agreement to defer the principal payment that was due on August&nbsp;1, 2023 to October&nbsp;31, 2023. The agreement
also changed the loan prepayment fee of 6.0% through from September&nbsp;24, 2022 to September&nbsp;24, 2023 to a loan prepayment fee of 5.0% from September&nbsp;24, 2022 through December&nbsp;31, 2023 and for the prepayment fee to be changed to
3.0% beyond December&nbsp;31, 2023. On September&nbsp;29, 2023, the Company terminated the Term Loan by paying off the loan balance of $34,209, accrued interest of $757, a prepayment fee of $1,710 and a loss on extinguishment of debt of $1,006,
including the <FONT STYLE="white-space:nowrap">non-cash</FONT> portion of $930. Loss on extinguishment of debt is part of Other expense (income) on the Consolidated Statements of Operations and Comprehensive Loss. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On September&nbsp;29, 2023 the Company entered into a Credit Agreement with a separate
lender which provided a Senior Secured Delayed Draw Term Loan Facility (&#147;Term Loan 2024&#148;) in an aggregate principal amount of up to $60.0&nbsp;million which matures on September&nbsp;29, 2028. Borrowings are made available in up to three
tranches, the first of which is available upon closing of the agreement, which included committed equity funding of at least $75.0&nbsp;million, and two follow on tranches of $7.5&nbsp;million which become available before November&nbsp;1, 2024 and
February&nbsp;1, 2025 and are dependent on upon achievement of revenue milestones of trailing twelve month revenues of $50.0&nbsp;million and $70.0&nbsp;million, respectively. The Term Loan 2024 bears interest equal to the sum of Term Secured
Overnight Financing Rate plus 7.25% for each interest period which is measured monthly and is payable on the last day of each fiscal quarter. Through March&nbsp;31, 2025, the Company has the ability to <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">pay-in-kind</FONT></FONT> up to 2.0% of the payable interest. The Term Loan 2024 requires a minimum level of cash of $3.0&nbsp;million and revenues starting at $16.0&nbsp;million for the trailing twelve-month period ending
April&nbsp;30, 2024 and increasing on a quarterly basis through maturity up to $125.0&nbsp;million. The revenue covenant began to be measured on April&nbsp;30, 2024. As of April&nbsp;30, 2024, the Company was in compliance with its debt covenants.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On September&nbsp;29, 2023, the Company drew the initial $45.0&nbsp;million. In connection with the first draw, the Company incurred a 1%
facility fee of the total available loan amount of $60.0&nbsp;million upon the draw of the first tranche of $600 and legal fees of $1,753 for both the Company and the lender. The Company recognized the facility fee and legal fees as a discount of
$1,765 to the Term Loan 2024 for the initial draw on the loan, and $588 as an Other asset, for the remainder available to draw. Each of these will be amortized as interest expense over the term of the loan on a straight-line basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In conjunction with the draw of the first tranche, the Parent issued a warrant to the lender to purchase up to 256,410 shares of the
Parent&#146;s common units at an exercise price of $17.55 per share. The fair value of the warrant is $1,632 and is recognized as a debt discount and as a capital contribution, and the debt discount is amortized over the term of the loan to interest
expense. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company&#146;s long-term debt consisted of the following at: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2024</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Term loans</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">45,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">29,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">paid-in-kind</FONT></FONT> interest applied to term loan balance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">540</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,899</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: unamortized debt issuance costs and debt discount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,004</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(798</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total long-term debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,536</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,768</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Current portion of long term debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20,446</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total long-term debt, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">42,536</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,322</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">During the year ended April&nbsp;30, 2024, the Company recognized expense of $4,109 related to the Term Loan
2024. Of this amount, $271 was related to amortization of the facility fee and legal fees, $438 was related to amortization of the debt discount recognized in connection with the warrant, $2,860 was cash interest expense and $540 was interest
expense <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">paid-in-kind</FONT></FONT> and applied to the Term Loan 2024 balance as of April&nbsp;30, 2024. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">During the year ended April&nbsp;30, 2024, the Company recognized expense of $2,061 related to the Term Loan. Of this amount, $93 was related
to amortization of the facility fee and legal fees, $56 was related to amortization of the debt discount recognized in connection with the warrant, $771 was cash interest expense and $1,141 was interest expense <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">paid-in-kind</FONT></FONT> prior to the extinguishment of the Term Loan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">During the year ended April&nbsp;30,
2023, the Company recognized expense of $5,629 related to the Term Loan. Of this amount, $279 was related to amortization of the facility fee and legal fees, $167 was related to amortization of the debt discount recognized in connection with the
warrant and $5,183 was interest expense <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">paid-in-kind</FONT></FONT> and applied to Term Loan balance as of April&nbsp;30, 2023. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. Fair Value Measurement </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table presents the Company&#146;s fair value hierarchy for its classified assets and liabilities measured at fair value on a
recurring basis as of April&nbsp;30, 2024 and 2023. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Level&nbsp;1</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Level&nbsp;2</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Level&nbsp;3</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><U>April&nbsp;30, 2024</U></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,249</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">43,870</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">43,870</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><U>April&nbsp;30, 2023</U></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,810</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">512</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,322</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">40,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">40,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company classifies its money market funds, which are valued based on quoted market prices in active
markets with no valuation adjustment, as cash and cash equivalents within the fair value hierarchy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of April&nbsp;30, 2024 and 2023,
the fair value of the long-term debt, net of discounts, approximated $43,870 and $40,300, respectively. The fair value of long-term debt was determined using quoted market prices, when available, or discounted cash flows based on various factors,
including maturity schedules and current market rates. Long-term debt has been classified as Level&nbsp;2 of the fair value hierarchy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The only transfer associated with the fair value hierarchies relates to Term Loan 2024 into the Level&nbsp;2 fair value hierarchy for the year
ended April&nbsp;30, 2024. Other than this item, there were no transfers into or out of the Level&nbsp;1, 2 or 3 fair value hierarchies during the years ended April&nbsp;30, 2024 and 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. Stockholder&#146;s Equity </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The
Company had 5,000,000 shares of common stock authorized and 105,808 shares issued and outstanding with a par value of $0.01 as of April&nbsp;30, 2024 and 2023. Each share of common stock is entitled to one vote. Contributions are recorded to
additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. Redeemable Preferred Stock </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In May 2022, the Company amended and restated the Memorandum and Articles of Association of the Company, according to which the Company&#146;s
existing share capital of 5,000,000 shares can upon the discretion of the Company be issued in the form of either common and/or preferred stock with a par value of $0.01 each. Preferred stock issued is considered
<FONT STYLE="white-space:nowrap">non-voting</FONT> and are subject to preferred dividend accrued daily with a set payment &#147;yield&#148; capped at 4.7%. The preferred dividend is declared upon the discretion of the directors of the Company on the
interim basis and paid out on the annual basis upon discretion of the Company, provided there </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
are funds lawfully available for distribution. No dividends were declared as of April&nbsp;30, 2024 or 2023 and the cumulative unpaid dividends were $6,721 and $2,499, respectively. In the event
of liquidation, dissolution or winding up, assets will be applied first, to pay preferred stock dividends and second to pay issue price of preferred stock.&nbsp;Preferred stock may be converted to common stock at the option of the directors upon a
successful public offering based on the criteria outlined by the directors of the Company. For the years ended April&nbsp;30, 2024 and 2023, the Company issued a total of 75,000 and 102,110 preferred shares, respectively, to the Parent for proceeds
of $75,000 and $102,110, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The preferred stock is presented within mezzanine as it is redeemable for cash or other assets and
is redeemable upon the occurrence of an event that is not solely within the control of the Company (specifically, an Initial Public Offering that is at the directors&#146; request).</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. Equity Incentive Plan </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Certain
employees and contractors of the Company have been granted equity incentive units (&#147;Incentive Units&#148;) of the Parent. The Parent has the ability to issue any number of additional Incentive Units at its discretion. The Incentive Units allow
the holder to participate in the equity of the Parent subject to participation thresholds as defined by the Parent. Upon termination, the Company has the right but not the obligation to repurchase vested Incentive Units at fair market value within
seven months following termination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Parent has issued Incentive Units to certain employees of the Company which are vested based on
continued service. Any unvested Incentive Units are automatically forfeited upon a separation. Compensation cost of Incentive Units is estimated on the date of grant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company recognized $1,488 and $1,209 of stock-based compensation expense related to time-based vested Incentive Units during the years
ended April&nbsp;30, 2024 and 2023, respectively. As of April&nbsp;30, 2024 and 2023, total Incentive Units vested were 1,262,179 and 1,043,285, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table summarizes all Incentive Unit activity: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="55.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Incentive<BR>Units</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at April&nbsp;30, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,426,945</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">719,796</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited / repurchased</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(59,090</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at April&nbsp;30, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,087,651</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">141,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited / repurchased</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(99,308</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at April&nbsp;30, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,130,143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company recorded stock-based compensation in the following expense categories of its Consolidated
Statements of Operations and Comprehensive Loss for the years ended: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>April&nbsp;30,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2024</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Costs of revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,062</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,488</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,209</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of April&nbsp;30, 2024 and 2023, total unvested Incentive Units were 867,963 and 1,044,366, respectively.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of April&nbsp;30, 2024, unrecognized compensation cost for outstanding Incentive Units
was $3,389, with the weighted-average period over which this cost is expected to be recognized at 3.18 years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In determining the
compensation cost of the Incentive Units, the fair value for each Incentive Unit has been estimated at the date of grant using the Black-Scholes model. The significant assumptions used in these calculations were summarized as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="55.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="19%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="18%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2024</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected time to liquidity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.5&nbsp;years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.5&nbsp;years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk free rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.04</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.04</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Estimated fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The weighted average grant date fair value of Incentive Units granted for the years ended April&nbsp;30, 2024
and 2023 were $5.65 and $5.27, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12. Income Taxes </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The components of income (loss) before income taxes are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>April&nbsp;30,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2024</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(75,374</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(62,739</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,722</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21,484</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss before provision for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(94,096</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(84,223</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company is subject to U.S. federal income tax as well as income tax in various states. Additionally, the
Company consists of a Cayman Islands parent company with subsidiaries in U.S. and Ireland. Under the current laws of the Cayman Islands, the Company is not subject to tax on its income. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For purposes of the reconciliation between the provision (benefit) for income taxes at the statutory rate and the effective tax rate, a
notional U.S. 21.0% rate is applied to pretax income as a result of the following for the years ended: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>April&nbsp;30,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2024</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax benefit at U.S. statutory rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(19,760</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,687</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-taxable</FONT> foreign income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(373</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">204</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State tax(net of federal tax benefit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,325</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(381</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-deductible</FONT> expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">719</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">701</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">R&amp;D credit (net of reserve)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(704</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(874</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,444</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Significant components of the deferred tax assets and liabilities at April&nbsp;30, 2024 and
2023 are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>April&nbsp;30,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2024</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Deferred tax assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss carryforwards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">34,572</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,643</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest carryforward</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,786</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">354</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Disposable medical equipment supplies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">271</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. research and development credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible asset</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,696</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: valuation allowance for deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(79,028</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(56,584</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,597</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Deferred tax liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,161</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,627</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(228</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(267</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT>
assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(284</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(281</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred tax liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,673</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,175</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net deferred tax liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(76</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(63</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In assessing the realizability of deferred tax assets, management considers whether it is more likely than not
that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during periods in which those temporary differences become
deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income, carry back opportunities and tax planning strategies in making the assessment. The Company believes it is more likely than not it
will not realize the benefits of these deductible differences and has applied a full valuation allowance against them. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">During the year
ended April&nbsp;30, 2022, the Company transferred certain intellectual property (&#147;IP&#148;) rights between our wholly-owned subsidiaries (&#147;IP transfer&#148;) to align with its evolving business operations, resulting in the recognition of
a deferred tax asset of $35,375 (offset by the Company&#146;s valuation allowance), which represents the book and tax basis difference in the IP and was based on the fair value of the IP upon the transfer, updated during the year ended
April&nbsp;30, 2023 for subsequent changes in facts and circumstances in accordance with the purchase agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company has $5,116
in U.S. research and development credits which will begin to expire in 2039. Net operating losses and tax credit carryforwards as of April&nbsp;30, 2024 are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="63%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2024</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Expiration&nbsp;Years</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net operating losses, federal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">138,213</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Indefinite</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net operating losses, state</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,327</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Various</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax credits, federal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,890</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">2039&nbsp;-&nbsp;2043</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net operating losses, foreign</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,046</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Indefinite</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company determines whether a tax position is more likely than not to be sustained upon examination based
on the technical merits of the position in accordance with ASC 740. For tax positions meeting the more likely than not threshold, the tax amount recognized in the consolidated financial statements is reduced
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
by the largest benefit that has a greater than 50.0% likelihood of being realized upon ultimate settlement with the relevant taxing authority. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table summarizes the activity related to unrecognized tax benefits for the years ended: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>April&nbsp;30,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2024</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrecognized tax benefits at beginning of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(696</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(599</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additions based on tax positions taken in the current year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(78</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(97</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additions based on tax positions taken in the prior year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Decreases based on tax positions taken in prior years</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrecognized tax benefits at end of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(774</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(696</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">All of the unrecognized tax benefits as of April&nbsp;30, 2024 are accounted for as a reduction in our
deferred tax assets. Due to the valuation allowance, none of the $774 of unrecognized tax benefits would affect our effective tax rate, if recognized. We do not believe it is reasonably possible that our unrecognized tax benefits will significantly
change in the next twelve months. We recognize interest and penalties related to unrecognized tax benefits as income tax expense. There were no accrued interest or penalties related to unrecognized tax benefits for the year ended April&nbsp;30, 2024
or April&nbsp;30, 2023. We do not expect any significant change in our unrecognized tax benefits during the next twelve months. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13. Commitments and
Contingencies </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">From time to time, the Company may become involved in litigation relating to claims arising from the ordinary course of
business. The Company considers the likelihood of loss or impairment of an asset, or the incurrence of a liability, as well as the ability to reasonably estimate the amount of loss, in determining loss contingencies. An estimated loss contingency is
accrued when information available prior to issuance of the consolidated financial statements indicates that it is probable that an asset has been impaired or a liability has been incurred at the date of the consolidated financial statements, and
the amount or range of loss can be reasonably estimated. Legal costs are expensed as incurred. Gain contingencies are not recognized until they&#146;re realized or realizable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In December 2019, the Company applied for a refund from the State of Washington for Business and Occupation (&#147;B&amp;O&#148;) taxes paid
in 2014. Management concluded the B&amp;O tax is not applicable as its only source of current income generated through a transfer pricing arrangement between Kestra Medical Technologies and West Affum Holdings Corp was not attributable to the State
of Washington. In February 2020, the Company received the full tax refund for the year of 2014 in the amount of $25, and further applied for refunds of B&amp;O taxes for the subsequent years, totaling $1,600. Additionally, the Company ceased
payments of B&amp;O taxes in Washington State beginning in 2020. In October 2021, the Washington State Department of Revenue (&#147;DOR&#148;) denied the Company&#146;s request for a refund. The Company is appealed the decision to DOR and received a
favorable ruling in January of 2023. As a result, the Company received $1,800 from the DOR to include the amounts paid plus interest. The refund was recorded as Other Income within the Consolidated Statement of Operations and Comprehensive Loss.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company enters into indemnification agreements with its officers and directors, and the Company&#146;s certificate of incorporation
and bylaws include similar indemnification obligations to its officers and directors. To date, there have been no claims under any indemnification provisions, therefore there is no accrual of such amounts as of April&nbsp;30, 2024. The Company is
unable to determine the maximum potential impact of these indemnifications on the future results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Management believes that
there are currently no other claims or actions pending against the Company where the ultimate disposition could have a material effect on the Company&#146;s results of operations, financial condition or cash flows. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14. Defined Contribution Plan </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company sponsors a defined contribution retirement savings plan under Section&nbsp;401(k) of the Internal Revenue Code of 1986, as amended
(the &#147;401(k) Plan&#148;), for its full-time employees, which covers all eligible employees in the United States. The 401(k) Plan provides for matching and discretionary contributions by the Company. For the years ended April&nbsp;30, 2024 and
2023, matching and discretionary contributions by the Company totaled $1,345 and $1,017, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15. Net Loss Per Share Attributable to Common
Stockholder </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Basic net loss per share attributable to the common stockholder is calculated by dividing net loss by the weighted
average number of shares of common stock outstanding during the year and excludes any dilutive effects of employee stock-based awards. Diluted net loss per share attributable to the common stockholder is computed giving effect to all potentially
dilutive shares of common stock, including common stock issuable upon vesting of stock-based payment awards. For the years ended April&nbsp;30, 2024 and 2023, the Company did not have any dilutive shares. For all years presented, there is no
difference in the number of shares used to compute basic and diluted shares outstanding due to the Company&#146;s net loss position. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Potentially anti-dilutive shares excluded from the calculation of diluted net loss per share for the years ended April&nbsp;30, 2024 and 2023
include 177,110 and 102,110 shares of redeemable preferred stock. Based on the conversion terms of the redeemable preferred stock and circumstances existing as of August&nbsp;28, 2024, the Company is unable to quantify the quantity of shares of
common stock the redeemable preferred stock is convertible into. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table sets forth the computation of basic and diluted net
loss per share attributable to the common stockholder for the years ended <I>(in thousands, except share and per share amounts)</I>: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>April&nbsp;30,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2024</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Numerator:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common stockholder</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(94,120</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(84,238</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Undeclared preferred dividends</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,721</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,499</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common stockholder</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(100,841</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(86,737</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Denominator:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average shares of common stock outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105,808</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105,808</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss per share attributable to common stockholder</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(953</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(820</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company has Incentive Units issued and outstanding under an equity incentive plan that may be settled in
common units of the Parent. The Parent also issued warrants in connection with the draws of the first and second tranches under the Term Loan and the first tranche under the Term Loan 2024 that may be settled in common units of the Parent. The
Incentive Units and warrants are not considered participating securities as they do not participate in undistributed earnings of the Company and therefore, would not be included in the calculation of both the basic and diluted loss per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16. Subsequent Events </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company has
evaluated subsequent events through the date the consolidated financial statements were available to be issued on August&nbsp;28, 2024. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In May 2024, the Company received $12,500 from its stockholder in return for the issuance of preferred stock. In July 2024, the Company
received $90,900 from its stockholder in return for the issuance of preferred </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
stock. The preferred stock issued by the Company in May and July has the same characteristics as described in Note 10. Also, in July of 2024, a subsidiary of the Company received $17,100 from a
third-party investor in return for redeemable shares of the subsidiary. The Company incurred $3,780 in expenses that are considered payments on behalf of stockholder related to the funding transactions in July 2024. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In July 2024, the Company amended their lease agreement to allow for the use of $786, originally for tenant improvement allowances, to also be
used for rent abatement at the Company&#146;s discretion. This is consistent with the $943 from the October 2023 amendment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>17. Subsequent Events
(unaudited) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company has evaluated subsequent events from the date the consolidated financial statements were originally available
to be issued on August&nbsp;28, 2024 through December&nbsp;11, 2024, the date the consolidated financial statements were available to be reissued. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company determined that it will not meet the revenue milestone required to draw on the second tranche of the Term Loan, which was
potentially available on November&nbsp;1, 2024. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>Through and including
&#8195;&#8195;&#8195;&#8195;, 2025 (25 days after the commencement of this offering), all dealers effecting transactions in these securities, whether or not participating in this offering, may be required to deliver a prospectus. This delivery
requirement is in addition to the obligation of dealers to deliver a prospectus when acting as underwriters and with respect to their unsold allotments or subscription. </B></P>
<P STYLE="margin-top:72pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>10,000,000&nbsp;Shares </B></P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g744414g62z73.jpg" ALT="LOGO" STYLE="width:4.55963in;height:1.2554in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Shares </B></P> <P STYLE="font-size:72pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:20%">&nbsp;</P></center> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS
</B></P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:20%">&nbsp;</P></center>
<P STYLE="margin-top:72pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>BofA Securities </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Goldman Sachs&nbsp;&amp; Co. LLC </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Piper Sandler </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>Wells
Fargo Securities </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>Stifel </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>Wolfe | Nomura Alliance </B></P>
<P STYLE="margin-top:72pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>&#8195;&#8195;&#8195;, 2025 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P><center> <P STYLE="line-height:3.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P></center>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PART II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ITEM&#8201;13. OTHER EXPENSES OF ISSUANCE AND DISTRIBUTION. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table sets forth all costs and expenses, other than underwriting discounts and commissions, payable by us in connection with the
sale of the common shares being registered. All amounts shown are estimates except for the SEC registration fee, the Financial Industry Regulatory Authority, Inc. (&#147;FINRA&#148;) filing fee and the initial listing fee. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>AMOUNT</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SEC registration fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">28,170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial Industry Regulatory Authority, Inc. filing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27,450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Listing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">295,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,400,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounting fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,400,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Printing and engraving expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">300,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transfer agent and registrar fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Miscellaneous expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,704,120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>    <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ITEM&#8201;14. INDEMNIFICATION OF DIRECTORS AND OFFICERS. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Section&nbsp;98 of the Companies Act provides generally that a Bermuda company may indemnify its directors, officers and auditors against any
liability which by virtue of any rule of law would otherwise be imposed on them in respect of any negligence, default, breach of duty or breach of trust, except in cases where such liability arises from fraud or dishonesty of which such director,
officer or auditor may be guilty in relation to the company. Section&nbsp;98 further provides that a Bermuda company may indemnify its directors, officers and auditors against any liability incurred by them in defending any proceedings, whether
civil or criminal, in which judgment is awarded in their favor or in which they are acquitted or granted relief by the Supreme Court of Bermuda pursuant to Section&nbsp;281 of the Companies Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We will adopt provisions in our amended and restated <FONT STYLE="white-space:nowrap">bye-laws</FONT> to be in effect upon the closing of this
offering that will provide that we shall indemnify our directors and any officers appointed by our Board of Directors to the fullest extent permitted by applicable law; provided, however, that if a director or officer is a party to an
indemnification agreement with us, then the terms of the indemnification agreement shall apply instead of the provisions in our amended and restated bye-laws. Our amended and restated <FONT STYLE="white-space:nowrap">bye-laws</FONT> to be in effect
upon the closing of this offering will provide that the shareholders waive all claims or rights of action that they might have, individually or in right of the company, against any of the company&#146;s directors or officers for any act or failure
to act in the performance of such director&#146;s or officer&#146;s duties, except in respect of any fraud or dishonesty of such director or officer or any claims of violations of the Securities Act or the Exchange Act. Section&nbsp;98A of the
Companies Act permits us to purchase and maintain insurance for the benefit of any officer or director in respect of any loss or liability attaching to him in respect of any negligence, default, breach of duty or breach of trust, whether or not we
may otherwise indemnify such officer or director. We have purchased and maintain a directors&#146; and officers&#146; liability policy for such a purpose. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In connection with this offering, we expect to enter into indemnification agreements with each of our directors and certain officers. These
indemnification agreements will provide the directors and such officers with contractual rights to indemnification and expense advancement to the fullest extent permitted by applicable law, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
subject to certain exceptions and procedures. In addition, we would be obligated under these agreements to make commercially reasonable efforts to obtain one or more policies of insurance with
reputable insurance companies to provide such persons with commercially reasonable coverage for losses from wrongful acts and omissions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, the underwriting agreement filed as Exhibit 1.1 to this Registration Statement provides for indemnification by the underwriters
of us and our officers and directors for certain liabilities arising under the Securities Act, or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ITEM&#8201;15. RECENT SALES OF
UNREGISTERED SECURITIES. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the three years preceding the filing of this registration statement, we have issued the following
securities that were not registered under the Securities Act. No underwriters were involved in any of the following transactions and no commissions were paid in connection with the sale of any such securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Incentive Units </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the fiscal
year ended April&nbsp;30, 2022, we granted 398,300 incentive units of West Affum Holdings, L.P. to certain employees and service providers pursuant to our 2014 Employee Equity Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the fiscal year ended April&nbsp;30, 2023, we granted 719,796 incentive units of West Affum Holdings, L.P. to certain employees and service
providers pursuant to our 2014 Employee Equity Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the fiscal year ended April&nbsp;30, 2024, we granted 141,800 incentive units of
West Affum Holdings, L.P. to certain employees and service providers pursuant to our 2014 Employee Equity Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">From May 2024 through
January&nbsp;31, 2025, we granted 1,184,677 incentive units of West Affum Holdings, L.P. to certain employees and service providers pursuant to our 2014 Employee Equity Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pursuant to the Organizational Transactions, West Affum Holdings, L.P. will deliver to holders of all outstanding incentive units our common
shares as consideration for the exchange of such holders&#146; incentive units. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Warrants </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On December&nbsp;28, 2020, we issued warrants to purchase 49,044 common units of West Affum Holdings, L.P. to Kennedy Lewis Capital Partners
Master Fund II LP at an exercise price of $22.63 per unit and on March 7, 2022, we issued warrants to purchase 36,783 common units of West Affum Holdings, L.P. to Kennedy Lewis Capital Partners Master Fund II LP at an exercise price of $26.24 per
unit. On September&nbsp;29, 2023, we issued warrants to purchase 256,410.26 common units of West Affum Holdings, L.P. to Perceptive Credit Holdings IV, LP at an exercise price of $17.55 per unit, which exercise price was amended to $14.67 on July
12, 2024. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In connection with this offering, (i)&nbsp;the warrants issued to Kennedy Lewis Capital Partners Master Fund&nbsp;II LP by West
Affum Holdings, L.P. will be canceled and Kestra Medical Technologies, Ltd. will issue new warrants to purchase an aggregate of 110,077 common shares of Kestra Medical Technologies, Ltd. and (ii)&nbsp;the warrants issued to Perceptive Credit
Holdings IV, LP by West Affum Holdings, L.P. will be canceled and Kestra Medical Technologies, Ltd. will issue new warrants to purchase an aggregate of 328,859 common shares of Kestra Medical Technologies, Ltd., assuming in each case an initial
public offering price of $15.00&nbsp;per share, the midpoint of the price range set forth on the cover page of this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">See
&#147;Organizational Transactions&#151;Warrant Transactions&#148; for more information on the Warrants. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Organizational Transactions
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pursuant to the Organizational Transactions described in the prospectus that forms a part of this Registration Statement, we will
issue common shares to West Affum Holdings, L.P. in exchange for the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
contribution by West Affum Holdings, L.P. to us of all of its equity interests in West Affum Intermediate Holdings. In addition, West Affum Holdings, L.P. will deliver to holders of all of its
Class A common units (including a third-party investor who will receive Class A common units in West Affum Holdings, L.P. immediately prior to the distribution in exchange for its equity interests in West Affum Holdings Designated Activity Company)
our common shares in consideration for the exchange of such holders&#146; interests in West Affum Holdings, L.P. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The offers and
sales of the above securities were deemed to be exempt from registration under the Securities Act of 1933 in reliance upon Section&nbsp;4(a)(2) of the Securities Act or Regulation D promulgated thereunder, or Rule&nbsp;701 promulgated under
Section&nbsp;3(b) of the Securities Act, as transactions by an issuer not involving any public offering or pursuant to benefit plans and contracts relating to compensation as provided under Rule 701. The recipients of the above securities
represented their intentions to acquire the securities for investment only and not with a view to or for sale in connection with any distribution thereof. Appropriate legends were placed upon any stock certificates issued in these transactions. All
recipients had adequate access, through their relationships with us, to information about us. The sales of these securities were made without any general solicitation or advertising. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>ITEM&#8201;16.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>EXHIBITS AND FINANCIAL STATEMENT SCHEDULES. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>(a) Exhibits. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The list of
exhibits set forth under the Exhibit Index appearing immediately prior to the signature pages to this registration statement is incorporated herein by reference. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>(b) Financial Statement Schedules. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">See Index to consolidated financial statements on Page <FONT STYLE="white-space:nowrap">F-1.</FONT> All schedules have been omitted because
they are not required or are not applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ITEM&#8201;17. UNDERTAKINGS. </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to
directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public
policy as expressed in the Securities Act of 1933 and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer
or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the
opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question of whether such indemnification by it is against public policy as expressed in the Securities Act of 1933 and
will be governed by the final adjudication of such issue. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The undersigned registrant hereby undertakes that: </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For purposes of determining any liability under the Securities Act of 1933, the information omitted from the
form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4)&nbsp;or 497(h) under the Securities Act shall be deemed to be
part of this registration statement as of the time it was declared effective. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the purpose of determining any liability under the Securities Act of 1933, each post-effective amendment
that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="88%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Exhibit&nbsp;No.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;1.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d744414dex11.htm">Form of Underwriting Agreement</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;3.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1877184/000119312525023649/d744414dex31.htm">Certificate of Incorporation</A>*</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;3.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1877184/000119312525023649/d744414dex32.htm">Memorandum of Association</A>*</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;3.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d744414dex33.htm">Form of Amended and Restated <FONT STYLE="white-space:nowrap">Bye-laws</FONT> of the Registrant </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;4.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d744414dex41.htm">Form of Warrants to Purchase Common Shares to be issued to Kennedy Lewis Capital Partners Master Fund II LP</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;4.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d744414dex42.htm">Form of Warrant to Purchase Common Shares to be issued to Perceptive Credit Holdings IV, LP </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;5.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d744414dex51.htm">Opinion of Walkers (Bermuda) Limited, Bermuda Counsel to the Registrant</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d744414dex101.htm">Assignment and Assumption of Registration Rights Agreement, dated as of February&nbsp;26, 2025, by and between West Affum Holdings, L.P., and Kestra Medical Technologies, Ltd.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d744414dex102.htm">Kestra Medical Technologies, Ltd. 2025 Omnibus Incentive Plan+ </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d744414dex103.htm">Forms of Equity Award Agreements under Kestra Medical Technologies, Ltd. 2025 Omnibus Incentive Plan+</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d744414dex104.htm">Form of Indemnification Agreement+ </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1877184/000119312525023649/d744414dex106.htm">Employment Agreement, dated as of October&nbsp;17, 2016, between Kestra Medical Technologies, Inc. and Brian Webster+</A>*</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1877184/000119312525023649/d744414dex107.htm">Employment Agreement, dated as of September&nbsp;10, 2021, between Kestra Medical Technologies, Inc. and Vaseem Mahboob+</A>*</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1877184/000119312525023649/d744414dex108.htm">Employment Agreement, dated as of October&nbsp;26, 2016, between Kestra Medical Technologies, Inc. and Traci S. Umberger+</A>*</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1877184/000119312525023649/d744414dex109.htm">Director Compensation and Securities Agreement, dated as of November 3, 2024, between West&nbsp;
Affum Holdings, L.P., Orly Mishan and West Affum GP Ltd.+</A>*</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.9</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d744414dex109.htm">Form of Severance and Change in Control Policy+ </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.10</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d744414dex1010.htm">Form of Director Compensation Policy+ </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.11</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d744414dex1011.htm">Credit Agreement and Guaranty, dated as of September 29, 2023, among Kestra Medical Technologies, Inc. and West Affum Holdings Corp., as borrowers, the guarantors from time to time party thereto, the lenders
 from time to time party thereto and Perceptive Credit Holdings IV, LP, as administrative agent and as a lender#</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.12</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d744414dex1012.htm">Amended and Restated Credit Agreement and Guaranty, dated as of February&nbsp;
25, 2025, among Kestra Medical Technologies, Inc. and West Affum Holdings Corp., as borrowers, the guarantors from time to time party thereto, the lenders from time to time party thereto and Perceptive Credit Holdings IV, LP, as administrative agent and
 as a lender#</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>21.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1877184/000119312525023649/d744414dex211.htm">Subsidiaries of the Registrant* </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d744414dex231.htm">Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting Firm, as to West Affum Intermediate Holdings Corp.</A></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD WIDTH="88%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Exhibit&nbsp;No.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d744414dex232.htm">Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting Firm, as to Kestra Medical Technologies, Ltd.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d744414dex51.htm">Consent of Walkers (Bermuda) Limited (included as part of Exhibit 5.1)</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>24.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d744414ds1a.htm#sig">Power of Attorney (included in signature page)</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>107</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d744414dexfilingfees.htm">Filing Fee Table</A></TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Previously filed. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#134;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To be filed by amendment. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">+</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Indicates management contract or compensatory plan. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">#</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Certain schedules and exhibits to this agreement have been omitted in accordance with Item 601(b)(10) of
Regulation <FONT STYLE="white-space:nowrap">S-K.</FONT> A copy of any omitted schedule and/or exhibit will be furnished to the Securities and Exchange Commission on request. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="sig"></A>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act, the Registrant has duly caused this Registration Statement to be signed on its behalf by
the undersigned, thereunto duly authorized, in Kirkland, Washington, on the 26<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> day of February, 2025. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>KESTRA MEDICAL TECHNOLOGIES, LTD.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Brian Webster</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Brian Webster</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: &#8194;President and Chief Executive Officer</TD></TR>
</TABLE></DIV>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>POWER OF ATTORNEY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">KNOW ALL BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Brian Webster and Traci S.
Umberger, and each of them, his or her true and lawful agent, proxy and attorney-in-fact, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to (i) act on, sign and
file with the Securities and Exchange Commission any and all amendments (including post-effective amendments) to this Registration Statement together with all schedules and exhibits thereto and any subsequent registration statement filed pursuant to
Rule 462(b) under the Securities Act of 1933, as amended, together with all schedules and exhibits thereto, (ii) act on, sign and file such certificates, instruments, agreements and other documents as may be necessary or appropriate in connection
therewith, (iii) act on and file any supplement to any prospectus included in this registration statement or any such amendment or any subsequent registration statement filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended, and
(iv) take any and all actions which may be necessary or appropriate to be done, as fully for all intents and purposes as he or she might or could do in person, hereby approving, ratifying and confirming all that such agent, proxy and
attorney-in-fact or any of his or her substitutes may lawfully do or cause to be done by virtue thereof. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pursuant to the
requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="38%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="18%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>SIGNATURE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>TITLE</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>DATE</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Brian Webster</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Brian Webster</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">President, Chief Executive Officer and Director (Principal Executive Officer)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">February&nbsp;26, 2025</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Vaseem Mahboob</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Vaseem Mahboob</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Chief Financial Officer (Principal Financial and Accounting Officer)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">February&nbsp;26, 2025</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Traci S. Umberger</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">General Counsel, Chief Administrative Officer and Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">February&nbsp;26, 2025</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Jeffrey Schwartz</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director, Chairman of the Board of Directors</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">February&nbsp;26, 2025</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Christopher Gordon</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">February&nbsp;26, 2025</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Kevin Reilly</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Kevin Reilly</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">February&nbsp;26, 2025</TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="38%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="18%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>SIGNATURE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>TITLE</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>DATE</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Maxwell Bikoff</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Maxwell Bikoff</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">February&nbsp;26, 2025</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Mary Kay Ladone</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">February&nbsp;26, 2025</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Raymond W. Cohen</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">February&nbsp;26, 2025</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Toby AuWerter</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Toby AuWerter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">February 26, 2025</TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">*By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Brian Webster</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Brian Webster</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">As Attorney-in-Fact</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AUTHORIZED REPRESENTATIVE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of Section&nbsp;6(a) of the Securities Act of 1933, the undersigned has signed this Registration Statement,
solely in its capacity as the duly authorized representative of Kestra Medical Technologies, Ltd., in Kirkland, Washington, on February&nbsp;26, 2025. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>KESTRA MEDICAL TECHNOLOGIES, INC.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">/s/&nbsp;Brian Webster</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Brian Webster</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">President and Chief Executive Officer</P></TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>d744414dex11.htm
<DESCRIPTION>EX-1.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-1.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 1.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Kestra Medical Technologies, Ltd. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(a Bermuda exempted company) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[&#149;] of Common Shares </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>UNDERWRITING AGREEMENT </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: [&#149;],
2025 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Kestra Medical Technologies, Ltd. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(a Bermuda exempted company) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[&#149;] of Common Shares </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNDERWRITING AGREEMENT </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">[&#149;], 2025 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BofA Securities, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Goldman Sachs&nbsp;&amp; Co. LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Piper Sandler&nbsp;&amp; Co.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">as Representatives of the several Underwriters </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>c/o BofA
Securities, Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">One Bryant Park </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York
10036 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>c/o Goldman Sachs&nbsp;&amp; Co. LLC </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">200 West
Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10282 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>c/o Piper
Sandler&nbsp;&amp; Co. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1251 Avenue of the Americas </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New
York, New York 10020 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Kestra Medical Technologies, Ltd., a Bermuda exempted company (the &#147;Company&#148;), confirms its agreement with BofA Securities, Inc.
(&#147;BofA&#148;), Goldman Sachs&nbsp;&amp; Co. LLC (&#147;GS&#148;) and Piper Sandler&nbsp;&amp; Co. (&#147;PSC&#148;) and each of the other Underwriters named in Schedule A hereto (collectively, the &#147;Underwriters,&#148; which term shall also
include any underwriter substituted as hereinafter provided in Section&nbsp;10 hereof), for whom BofA, GS and PSC are acting as representatives (in such capacity, the &#147;Representatives&#148;), with respect to (i)&nbsp;the sale by the Company and
the purchase by the Underwriters, acting severally and not jointly, of the respective numbers of common shares, par value $1.00 per share, of the Company (&#147;Common Shares&#148;) set forth in Schedule&nbsp;A hereto and (ii)&nbsp;the grant by the
Company to the Underwriters, acting severally and not jointly, of the option described in Section&nbsp;2(b) hereof to purchase all or any part of [&#149;] additional Common Shares. The aforesaid [&#149;] Common Share (the &#147;Initial
Securities&#148;) to be purchased by the Underwriters and all or any part of the [&#149;] Common Shares subject to the option described in Section&nbsp;2(b) hereof (the &#147;Option Securities&#148;) are herein called, collectively, the
&#147;Securities.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company understands that the Underwriters propose to make a public offering of the Securities as soon as the
Representatives deem advisable after this underwriting agreement (this &#147;Agreement&#148;) has been executed and delivered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Company and Merrill Lynch, Pierce, Fenner&nbsp;&amp; Smith Incorporated, (an affiliate of BofA Securities, Inc., a participating Underwriter, hereafter referred to as &#147;Merrill Lynch&#148;) agree that up to 5% of the Firm Shares to be purchased
by the Underwriters (the &#147;Reserved Securities&#148;) shall be reserved for sale by Merrill Lynch to certain persons designated by the Company (the &#147;Invitees&#148;), as part of the distribution of the Securities by the Underwriters, subject
to the terms of this Agreement, the applicable rules, regulations and interpretations of the Financial Industry Regulatory Authority, Inc. (&#147;FINRA&#148;) and </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
all other applicable laws, rules and regulations. The Company has solely determined, without any direct or indirect participation by the Underwriters or Merrill Lynch, the Invitees who will
purchase Reserved Securities (including the amount to be purchased by such persons) sold by Merrill Lynch. To the extent that such Reserved Securities are not orally confirmed for purchase by Invitees by 11:59 P.M. (New York City time) on the date
of this Agreement, such Reserved Securities may be offered to the public as part of the public offering contemplated hereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company
has filed with the Securities and Exchange Commission (the &#147;Commission&#148;) a registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-1</FONT> (No. <FONT STYLE="white-space:nowrap">333-284807),</FONT> including the related
preliminary prospectus or prospectuses, covering the registration of the sale of the Securities under the Securities Act of 1933, as amended (the &#147;1933 Act&#148;). Promptly after execution and delivery of this Agreement, the Company will
prepare and file a prospectus in accordance with the provisions of Rule 430A (&#147;Rule 430A&#148;) of the rules and regulations of the Commission under the 1933 Act (the &#147;1933 Act Regulations&#148;) and Rule 424(b) (&#147;Rule 424(b)&#148;)
of the 1933 Act Regulations. The information included in such prospectus that was omitted from such registration statement at the time it became effective but that is deemed to be part of such registration statement at the time it became effective
pursuant to Rule 430A(b) is herein called the &#147;Rule 430A Information.&#148; Such registration statement, including the amendments thereto, the exhibits thereto and any schedules thereto, at the time it became effective, and including the Rule
430A Information, is herein called the &#147;Registration Statement.&#148; Any registration statement to register additional Common Shares filed pursuant to Rule 462(b) of the 1933 Act Regulations is herein called the &#147;Rule 462(b) Registration
Statement&#148; and, after such filing, the term &#147;Registration Statement&#148; as used herein shall include the Rule 462(b) Registration Statement. Each prospectus used prior to the effectiveness of the Registration Statement, and each
prospectus that omitted the Rule 430A Information that was used after such effectiveness and prior to the execution and delivery of this Agreement, is herein called a &#147;preliminary prospectus.&#148; The final prospectus, in the form first
furnished to the Underwriters for use in connection with the offering of the Securities, is herein called the &#147;Prospectus.&#148; For purposes of this Agreement, all references to the Registration Statement, any preliminary prospectus, the
Prospectus or any amendment or supplement to any of the foregoing shall be deemed to include the copy filed with the Commission pursuant to its Electronic Data Gathering, Analysis and Retrieval system or any successor system (&#147;EDGAR&#148;).
<B></B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As used in this Agreement: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Applicable Time&#148; means [&#149;] P.M., New York City time, on [&#149;], 2025 or such other time as agreed by the
Company and the Representatives. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;General Disclosure Package&#148; means any Issuer General Use Free Writing
Prospectuses issued at or prior to the Applicable Time, the most recent preliminary prospectus that is distributed to investors prior to the Applicable Time and the information included on Schedule <FONT STYLE="white-space:nowrap">B-1</FONT> hereto,
all considered together. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Issuer Free Writing Prospectus&#148; means any &#147;issuer free writing prospectus,&#148;
as defined in Rule 433 of the 1933 Act Regulations (&#147;Rule 433&#148;), including without limitation any &#147;free writing prospectus&#148; (as defined in Rule 405 of the 1933 Act Regulations (&#147;Rule 405&#148;)) relating to the Securities
that is (i)&nbsp;required to be filed with the Commission by the Company, (ii)&nbsp;a &#147;road show for an offering that is a written communication&#148; within the meaning of Rule 433(d)(8)(i), whether or not required to be filed with the
Commission, or (iii)&nbsp;exempt from filing with the Commission pursuant to Rule 433(d)(5)(i) because it contains a description of the Securities or of the offering that does not reflect the final terms, in each case in the form filed or required
to be filed with the Commission or, if not required to be filed, in the form retained in the Company&#146;s records pursuant to Rule 433(g). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Issuer General Use Free Writing Prospectus&#148; means any Issuer Free
Writing Prospectus that is intended for general distribution to prospective investors (other than a &#147;<I>bona fide</I> electronic road show,&#148; as defined in Rule 433 (the &#147;Bona Fide Electronic Road Show&#148;)), as evidenced by its
being specified in Schedule <FONT STYLE="white-space:nowrap">B-2</FONT> hereto. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Issuer Limited Use Free Writing
Prospectus&#148; means any Issuer Free Writing Prospectus that is not an Issuer General Use Free Writing Prospectus. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;Testing-the-Waters</FONT></FONT> Communication&#148; means any oral or written communication with potential investors undertaken in reliance on Section&nbsp;5(d) or Rule 163B of the
1933 Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT>
Communication&#148; means any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication that is a written communication within the meaning of Rule 405 under the 1933 Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise stated or required by the context, references to each subsidiary or the subsidiaries of the Company in this
Agreement refer to entities that will become subsidiaries of the Company after giving effect to the transactions described under the heading &#147;Organizational Transactions&#148; in the Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 1. <U>Representations and Warranties</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Representations and Warranties by the Company</I>. The Company represents and warrants to each Underwriter as of the date hereof, the
Applicable Time, the Closing Time (as defined below) and any Date of Delivery (as defined below), and agrees with each Underwriter, as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <U>Registration Statement</U><U> and Prospectuses</U>. Each of the Registration Statement and any amendment thereto has
become effective under the 1933 Act. No stop order suspending the effectiveness of the Registration Statement or any post-effective amendment thereto has been issued under the 1933 Act, no order preventing or suspending the use of any preliminary
prospectus or the Prospectus has been issued and no proceedings for any of those purposes or pursuant to Section&nbsp;8A of the 1933 Act have been instituted or are pending or, to the Company&#146;s knowledge, contemplated by the Commission. The
Company has complied with each request (if any) from the Commission for additional information. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of the Registration
Statement and any post-effective amendment thereto, at the time it became effective, the Applicable Time, the Closing Time and any Date of Delivery, complied and will comply in all material respects with the requirements of the 1933 Act and the 1933
Act Regulations. Each preliminary prospectus, the Prospectus and any amendment or supplement thereto, at the time each was filed with the Commission, and, in each case, at the Applicable Time, the Closing Time and any Date of Delivery complied and
will comply in all material respects with the requirements of the 1933 Act and the 1933 Act Regulations. Each preliminary prospectus delivered to the Underwriters for use in connection with the offering of the Securities and the Prospectus was or
will be identical to the electronically transmitted copies thereof filed with the Commission pursuant to EDGAR, except to the extent permitted by Regulation <FONT STYLE="white-space:nowrap">S-T.</FONT> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) <U>Accurate Disclosure</U>. Neither the Registration Statement nor any amendment thereto, when considered together with
the Registration Statement, at its effective time, on the date hereof, at the Closing Time or at any Date of Delivery, contained, contains or will contain an untrue statement of a material fact or omitted, omits or will omit to state a material fact
required to be stated therein or necessary to make the statements therein not misleading. At the Applicable Time </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
and any Date of Delivery, none of (A)&nbsp;the General Disclosure Package, (B)&nbsp;any individual Issuer Limited Use Free Writing Prospectus, when considered together with the General Disclosure
Package and (C)&nbsp;any individual Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication, when considered together with the General Disclosure Package, included, includes or will
include an untrue statement of a material fact or omitted, omits or will omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. Neither the
Prospectus nor any amendment or supplement thereto, when considered together with the Prospectus, as of its issue date, at the time of any filing with the Commission pursuant to Rule 424(b), at the Closing Time or at any Date of Delivery, included,
includes or will include an untrue statement of a material fact or omitted, omits or will omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">The representations and warranties in this subsection shall not apply to statements in or omissions from the Registration
Statement (or any amendment thereto), the General Disclosure Package or the Prospectus (or any amendment or supplement thereto) made in reliance upon and in conformity with written information furnished to the Company by or on behalf of any
Underwriter through the Representatives expressly for use therein. For purposes of this Agreement, the only information so furnished shall be the information in the first paragraph under the heading &#147;Underwriting&#150;Commissions and
Discounts,&#148; the information in the second, third and fourth paragraphs under the heading &#147;Underwriting&#150;Price Stabilization, Short Positions and Penalty Bids&#148; and the information under the heading
&#147;Underwriting&#150;Electronic Distribution&#148; in each case contained in the Prospectus (collectively, the &#147;Underwriter Information&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) <U>Issuer Free Writing Prospectuses</U>. No Issuer Free Writing Prospectus conflicts or will conflict with the
information contained in the Registration Statement or the Prospectus, and any preliminary or other prospectus deemed to be a part thereof that has not been superseded or modified; provided that the representations and warranties in this subsection
shall not apply to statements in or omission from any Issuer Free Writing Prospectus made in reliance upon and in conformity with the Underwriter Information. The Company has made available a Bona Fide Electronic Road Show in compliance with Rule
433(d)(8)(ii) such that no filing of any &#147;road show&#148; (as defined in Rule 433(h)) is required in connection with the offering of the Securities. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) <U><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Materials.</U> The
Company (A)&nbsp;has not engaged in any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication other than
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications with the consent of the Representatives with entities that are reasonably believed to be qualified institutional buyers within the
meaning of Rule 144A under the 1933 Act or institutions that are accredited investors within the meaning of Rule 501 under the 1933 Act and (B)&nbsp;has not authorized anyone other than the Representatives to engage in
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications. The Company reconfirms that the Representatives have been authorized to act on its behalf in undertaking <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications. The Company has not distributed any Written
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications other than those listed on Schedule <FONT STYLE="white-space:nowrap">B-2</FONT> hereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) <U>Company Not Ineligible Issuer</U>. At the time of filing the Registration Statement and any post-effective amendment
thereto, at the earliest time thereafter that the Company or another offering participant made a <I>bona fide</I> offer (within the meaning of Rule 164(h)(2) of the 1933 Act Regulations) of the Securities and at the date hereof, the Company was not
and is not an &#147;ineligible issuer,&#148; as defined in Rule 405, without taking account of any determination by the Commission pursuant to Rule 405 that it is not necessary that the Company be considered an ineligible issuer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) <U>Emerging Growth Company Status.</U> From the time of the initial
confidential submission of the Registration Statement to the Commission (or, if earlier, the first date on which the Company engaged directly or through any individual or entity (&#147;Person&#148;) authorized to act on its behalf in any <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication) through the date hereof, the Company has been and is an &#147;emerging growth company,&#148; as defined in Section&nbsp;2(a) of the 1933 Act
(an &#147;Emerging Growth Company&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii) <U>Independent Accountants</U>. The accountants who certified the
financial statements and supporting schedules included in the Registration Statement, the General Disclosure Package and the Prospectus are independent public accountants as required by the 1933 Act, the 1933 Act Regulations and the Public Company
Accounting Oversight Board. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(viii) <U>Financial Statements</U>. The financial statements included in the Registration
Statement, the General Disclosure Package and the Prospectus, together with the related schedules and notes thereto, present fairly, in all material respects, the financial position of the Company and its consolidated subsidiaries at the dates
indicated and the statement of operations, stockholders&#146; equity and cash flows of the Company and its consolidated subsidiaries for the periods specified; said financial statements have been prepared in conformity with U.S. generally accepted
accounting principles (&#147;GAAP&#148;) applied on a consistent basis throughout the periods involved, except in the case of unaudited interim consolidated financial statements, subject to normal <FONT STYLE="white-space:nowrap">year-end</FONT>
audit adjustments and the exclusion of certain footnotes as permitted by the applicable rules of the Commission. The summary financial information included in the Registration Statement, the General Disclosure Package and the Prospectus present
fairly, in all material respects, the information shown therein and have been compiled on a basis consistent with that of the audited financial statements included therein. Except as included therein, no historical or pro forma financial statements
or supporting schedules are required to be included in the Registration Statement, the General Disclosure Package or the Prospectus under the 1933 Act or the 1933 Act Regulations. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ix) <U>No Material Adverse Change in Business</U>. Except as otherwise stated therein, since the respective dates as of which
information is given in the Registration Statement, the General Disclosure Package or the Prospectus, (A)&nbsp;there has been no material adverse change in the condition, financial or otherwise, or in the earnings, business affairs or business
prospects of the Company and its subsidiaries considered as one enterprise, whether or not arising in the ordinary course of business (a &#147;Material Adverse Effect&#148;), (B)&nbsp;there have been no transactions entered into by the Company or
any of its subsidiaries, other than those in connection with the transactions described under the heading &#147;Organizational Transactions&#148; in the Prospectus and those in the ordinary course of business, which are material with respect to the
Company and its subsidiaries considered as one enterprise, and (C)&nbsp;there has been no dividend or distribution of any kind declared, paid or made by the Company on any class of its capital stock. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x) <U>Good Standing of the Company</U>. The Company has been duly organized and is validly existing as an exempt company in
good standing under the laws of Bermuda and has corporate power and authority to own, lease and operate its properties and to conduct its business as described in the Registration Statement, the General Disclosure Package and the Prospectus and to
enter into and perform its obligations under this Agreement; and the Company is duly qualified as a foreign corporation to transact business and is in good standing (or such equivalent concept to the extent it exists under the laws of such
jurisdiction) in each other jurisdiction in which such qualification is required, whether by reason of the ownership or leasing of property or the conduct of business, except where the failure to so qualify or to be in good standing would not
reasonably be expected to result in a Material Adverse Effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xi) <U>Good Standing of Subsidiaries</U>. Each &#147;significant
subsidiary&#148; of the Company (as such term is defined in Rule <FONT STYLE="white-space:nowrap">1-02</FONT> of Regulation <FONT STYLE="white-space:nowrap">S-X)</FONT> (each, a &#147;Subsidiary&#148; and, collectively, the &#147;Subsidiaries&#148;)
has been duly organized and is validly existing in good standing (or such equivalent concept to the extent it exists under the laws of such jurisdiction) under the laws of the jurisdiction of its incorporation or organization, has the corporate or
other similar power and authority, as applicable, to own, lease and operate its properties and to conduct its business as described in the Registration Statement, the General Disclosure Package and the Prospectus and is duly qualified to transact
business and is in good standing (or such equivalent concept to the extent it exists under the laws of such jurisdiction) in each jurisdiction in which such qualification is required, whether by reason of the ownership or leasing of property or the
conduct of business, except where the failure to so qualify or to be in good standing would not reasonably be expected to result in a Material Adverse Effect. Except as otherwise disclosed in the Registration Statement, the General Disclosure
Package and the Prospectus, all of the issued and outstanding capital stock of each Subsidiary has been duly authorized and validly issued, is fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> and is owned by the Company,
directly or indirectly through subsidiaries, free and clear of any security interest, mortgage, pledge, lien, encumbrance, claim or equity. None of the outstanding shares of capital stock of any Subsidiary were issued in violation of the preemptive
or similar rights of any securityholder of such Subsidiary. The only subsidiaries of the Company are the subsidiaries listed on Exhibit 21 to the Registration Statement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xii) <U>Capitalization</U>. The authorized, issued and outstanding shares of the Company set forth in the column titled
&#147;Pro Forma&#148; in the Registration Statement, the General Disclosure Package and the Prospectus under the heading &#147;Capitalization&#148; accurately reflect the shares of the Company that are outstanding on a pro forma basis after giving
effect to the transactions described under the heading &#147;Organizational Transactions&#148; in the Prospectus (except for subsequent issuances, if any, pursuant to this Agreement, pursuant to reservations, agreements or employee benefit plans
referred to in the Registration Statement, the General Disclosure Package and the Prospectus or pursuant to the exercise of convertible securities or options referred to in the Registration Statement, the General Disclosure Package and the
Prospectus). The issued and outstanding shares of the Company have been duly authorized and validly issued and are fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> None of the issued shares of the Company were issued in
violation of the preemptive or other similar rights of any securityholder of the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xiii) <U>Authorization of
Agreement</U>. This Agreement has been duly authorized, executed and delivered by the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xiv) <U>Authorization and
Description of Securities</U>. The Securities to be purchased by the Underwriters from the Company have been duly authorized by the Company for issuance and sale to the Underwriters pursuant to this Agreement and, when issued and delivered by the
Company pursuant to this Agreement against payment of the consideration set forth herein, will be validly issued and fully paid and <FONT STYLE="white-space:nowrap">non-assessable;</FONT> and the issuance of the Securities is not subject to the
preemptive or other similar rights of any securityholder of the Company. The Common Shares conform in all material respects to all statements relating thereto contained in the Registration Statement, the General Disclosure Package and the Prospectus
and such description conforms in all material respects to the rights set forth in the instruments defining the same. No holder of Securities will be subject to personal liability solely by reason of being such a holder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xv) <U>Registration Rights</U>. There are no persons with registration rights or other similar rights to have any securities
registered for sale pursuant to the Registration Statement or otherwise registered for sale or sold by the Company under the 1933 Act pursuant to this Agreement, other than those rights that have been disclosed in the Registration Statement, the
General Disclosure Package and the Prospectus which have been waived. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xvi) <U>Absence of Violations, Defaults and Conflicts</U>. Neither the
Company nor any of its subsidiaries is (A)&nbsp;in violation of its charter, <FONT STYLE="white-space:nowrap">by-laws</FONT> or similar organizational document, (B)&nbsp;in default in the performance or observance of any obligation, agreement,
covenant or condition contained in any contract, indenture, mortgage, deed of trust, loan or credit agreement, note, lease or other agreement or instrument to which the Company or any of its subsidiaries is a party or by which it or any of them is
bound or to which any of the properties or assets of the Company or any subsidiary is subject (collectively, &#147;Agreements and Instruments&#148;), except for such defaults that would not, singly or in the aggregate, reasonably be expected to
result in a Material Adverse Effect, or (C)&nbsp;in violation of any law, statute, rule, regulation, judgment, order, writ or decree of any arbitrator, court, governmental body, regulatory body, administrative agency or other authority, body or
agency having jurisdiction over the Company or any of its subsidiaries or any of their respective properties, assets or operations (each, a &#147;Governmental Entity&#148;), except for such violations that would not, singly or in the aggregate,
reasonably be expected to result in a Material Adverse Effect. The execution, delivery and performance of this Agreement and the consummation of the transactions contemplated herein and in the Registration Statement, the General Disclosure Package
and the Prospectus (including the issuance and sale of the Securities and the use of the proceeds from the sale of the Securities as described therein under the heading &#147;Use of Proceeds&#148;) and compliance by the Company with its obligations
hereunder have been duly authorized by all necessary corporate or other similar action, as applicable, and do not and will not, whether with or without the giving of notice or passage of time or both, conflict with or constitute a breach of, or
default or Repayment Event (as defined below) under, or result in the creation or imposition of any lien, charge or encumbrance upon any properties or assets of the Company or any subsidiary pursuant to, the Agreements and Instruments (except for
such conflicts, breaches, defaults or Repayment Events or liens, charges or encumbrances that would not, singly or in the aggregate, reasonably be expected to result in a Material Adverse Effect), nor will such action result in any violation of
(i)&nbsp;the provisions of the charter, <FONT STYLE="white-space:nowrap">by-laws</FONT> or similar organizational document of the Company or any of its subsidiaries or (ii)&nbsp;any law, statute, rule, regulation, judgment, order, writ or decree of
any Governmental Entity, except in the case of the foregoing clause (ii), for any such violation that would not, singly or in the aggregate, reasonably be expected to result in a Material Adverse Effect. As used herein, a &#147;Repayment Event&#148;
means any event or condition which gives the holder of any note, debenture or other evidence of indebtedness (or any person acting on such holder&#146;s behalf) the right to require the repurchase, redemption or repayment of all or a portion of such
indebtedness by the Company or any of its subsidiaries. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xvii) <U>Absence of Labor Dispute</U>. No labor dispute with the
employees of the Company or any of its subsidiaries exists or, to the knowledge of the Company, is imminent, and the Company is not aware of any existing or imminent labor disturbance by the employees of any of its or any subsidiary&#146;s principal
suppliers, manufacturers, customers or contractors, which, in either case, would reasonably be expected to result in a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xviii) <U>Absence of Proceedings</U>. Except as disclosed in the Registration Statement, the General Disclosure Package and
the Prospectus, there is no action, suit, proceeding, inquiry or investigation before or brought by any Governmental Entity now pending or, to the knowledge of the Company, threatened, against or affecting the Company or any of its subsidiaries,
which would reasonably be expected to result in a Material Adverse Effect, or which would reasonably be expected to materially and adversely affect their respective properties or assets or the consummation of the transactions contemplated in this
Agreement or the performance by the Company of its obligations hereunder; and the aggregate of all pending legal or governmental proceedings to which the Company or any such subsidiary is a party or of which any of their respective properties or
assets is the subject which are not described in the Registration Statement, the General Disclosure Package and the Prospectus, including ordinary routine litigation incidental to the business, would not, singly or in the aggregate, reasonably be
expected to result in a Material Adverse Effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xix) <U>Accuracy of Exhibits</U>. There are no contracts or documents which
are required under the 1933 Act or the 1933 Act Regulations to be described in the Registration Statement, the General Disclosure Package or the Prospectus or to be filed as exhibits to the Registration Statement which have not been so described and
filed as required. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xx) <U>Absence of Further Requirements</U>. No filing with, or authorization, approval, consent,
license, order, registration, qualification or decree of, any Governmental Entity is necessary or required for the performance by the Company of its obligations hereunder, in connection with the offering, issuance or sale of the Securities hereunder
or the consummation of the transactions contemplated by this Agreement, except (A)&nbsp;such as have been already obtained or as may be required under the 1933 Act, the 1933 Act Regulations, the rules of the Nasdaq Global Market, state securities
laws or the rules of Financial Industry Regulatory Authority, Inc. (&#147;FINRA&#148;) and (B)&nbsp;such as have been obtained under the laws and regulations of jurisdictions outside the United States in which the Reserved Securities were offered.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxi) <U>Possession of Licenses and Permits</U>. Each of the Company and its subsidiaries possesses, and is in compliance
with the terms of, all applications, certificates, approvals, clearances, registrations, exemptions, franchises, licenses, permits, consents and other authorizations materially necessary to conduct their respective businesses, issued by the relevant
Governmental Entities (collectively, &#147;Governmental Licenses&#148;), including, without limitation, all Governmental Licenses required by the FDA and/or by any other U.S., state, local or foreign government or regulatory agency, except where the
failure to hold such Governmental Licenses and be in compliance therewith would not, singly or in the aggregate, reasonably be expected to reasonably result in a Material Adverse Effect on the Company and its subsidiaries, taken as a whole. All
Governmental Licenses are in full force and effect and neither the Company nor any of its subsidiaries is in violation of any term or conditions of any Governmental License other than for such violations which would not, singly or in the aggregate,
reasonably be expected to result in a Material Adverse Effect. Each of the Company and its subsidiaries has fulfilled and performed all of its respective obligations with respect to the Governmental Licenses, except where the failure to have
performed such obligations would not, singly or in the aggregate, reasonably be expected to result in a Material Adverse Effect. All of the Governmental Licenses are valid and in full force and effect, except when the invalidity of such Governmental
Licenses or the failure of such Governmental Licenses to be in full force and effect would not, singly or in the aggregate, reasonably be expected to result in a Material Adverse Effect. No event has occurred which allows, or after notice or lapse
of time would allow, revocation or termination thereof or results in any other impairment of the rights of the holder of any Governmental License, other than such revocations, terminations, or impairments which would not, singly or in the aggregate,
reasonably be expected to result in a Material Adverse Effect. Neither the Company nor any of its subsidiaries has received any notice of proceedings relating to the revocation or modification of any Governmental Licenses and no Governmental Entity
has taken any action to limit, suspend or revoke any Governmental License possessed by the Company, the revocation, modification, limitation or suspension of which would, singly or in the aggregate, if the subject of an unfavorable decision, ruling
or finding, reasonably be expected to result in a Material Adverse Effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxii) <U>Title to Property</U>. The Company and its subsidiaries do not own
any real property and have good title to all other real properties owned by them (other than Company Intellectual Property (as defined below), which is addressed exclusively in Section&nbsp;1(xxiii) below), in each case, free and clear of all
mortgages, pledges, liens, security interests, claims, restrictions or encumbrances of any kind except such as (A)&nbsp;are described in the Registration Statement, the General Disclosure Package and the Prospectus or (B)&nbsp;do not, singly or in
the aggregate, materially and adversely affect the value of such property and do not materially interfere with the use made and proposed to be made of such property by the Company or any of its subsidiaries; and all of the leases and subleases
material to the business of the Company and its subsidiaries, considered as one enterprise, and under which the Company or any of its subsidiaries holds properties described in the Registration Statement, the General Disclosure Package or the
Prospectus, are in full force and effect, and neither the Company nor any such subsidiary has received any written notice of any material claim of any sort that has been asserted by anyone adverse to the rights of the Company or any subsidiary under
any of the leases or subleases mentioned above, or affecting or questioning the rights of the Company or such subsidiary to the continued possession of the leased or subleased premises under any such lease or sublease. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxiii) <U>Possession of Intellectual Property</U>. The Company and its subsidiaries own or possess, have valid license to, or
can acquire on reasonable terms, adequate rights to all (A)&nbsp;patents, patent applications, inventions, statutory invention rights, invention disclosures, rights in utility models and industrial designs, (B)&nbsp;registered and unregistered
copyrights, (C)&nbsp;rights in technology and software, <FONT STYLE="white-space:nowrap">(D)&nbsp;know-how</FONT> (including trade secrets and other unpatented and/or unpatentable proprietary or confidential information, systems or procedures), (E)
Internet domain names, trademarks, service marks, business or trade names, logos, slogans, trade dress and any other designations of source or origin, and any applications (including provisional applications), registrations, or renewals for any of
the foregoing, together with the goodwill associated with any of the foregoing, (F)&nbsp;rights to publicity and privacy, and (G)&nbsp;other intellectual property (collectively, (A)-(G), &#147;Intellectual Property&#148;) which are used in, held for
use in or necessary to carry on their respective businesses now operated by them or as proposed to be conducted by them in the Registration Statement, the General Disclosure Package and the Prospectus, except where such failure to own, possess,
license, or acquire would not, singly or in the aggregate, result in a Material Adverse Effect, provided that this representation and warranty is not a representation or warranty as to no infringement, misappropriation or other violation of any
third-party Intellectual Property. Neither the Company nor any of its subsidiaries in the past six (6)&nbsp;years has received any written notice or is otherwise aware of any facts or circumstances which would render any Intellectual Property owned
by the Company or any of its subsidiaries invalid, narrower in scope, unenforceable or subject to a claim of ownership by a third party, and which the foregoing conditions, singly or in the aggregate, would reasonably be expected to have a Material
Adverse Effect. Neither the Company nor any of its subsidiaries in the past six (6)&nbsp;years has received any written notice of any infringement, misappropriation or other violation of any Intellectual Property of any other Person. The Company, to
its knowledge, has not engaged in any infringement, misappropriation or other violation of any valid and enforceable Intellectual Property of any other Person that, singly or in the aggregate, would result in a Material Adverse Effect. Except as
would not reasonably be expected to have a Material Adverse Effect, in each case, there is no pending or, to the knowledge of the Company threatened in writing, action, suit, proceeding or claim regarding any such infringement, misappropriation or
violation. The Company is unaware of any facts or circumstances which would form a reasonable basis for a claim that the Company has engaged in any infringement, misappropriation or other violation of any valid and enforceable Intellectual Property
of any other Person that, singly or in the aggregate, would result in a Material Adverse Effect. Except as would not, singly or in the aggregate, result in a Material Adverse Effect, (1)&nbsp;all Intellectual Property, except for applications
therein, owned by the Company or any of its </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
subsidiaries (such Intellectual Property, the &#147;Company Intellectual Property&#148;) is subsisting, in full force and effect, and, to the Company&#146;s knowledge, valid and enforceable,
(2)&nbsp;with respect to all Company Intellectual Property that is registered, filed or issued under the authority of any Governmental Authority, all such Company Intellectual Property has been duly maintained and there are no defects in, including
in connection with the filing and prosecution of, any of the Company Intellectual Property. There is no pending, and the Company and its subsidiaries have received no written notice of any threatened, action, suit, proceeding or claim by any third
party challenging the Company&#146;s or any of its subsidiaries rights in or the validity, ownership, registrability, enforceability or scope of any Company Intellectual Property that would reasonably be expected to have a Material Adverse Effect
and the Company and its subsidiaries are unaware of any facts or circumstances which would form a reasonable basis for any such claim. No third party is, to the Company&#146;s knowledge, infringing, misappropriating or otherwise violating any of the
Company Intellectual Property, and there is no pending or threatened action, suit, proceeding or claim by the Company or any of its subsidiaries against a third party regarding the foregoing, except, in each case, as would not reasonably be expected
to have a Material Adverse Effect. Except as would not, singly or in the aggregate, result in a Material Adverse Effect, and to the knowledge of the Company, (A)&nbsp;the Company and its subsidiaries have complied with the terms of each agreement
pursuant to which Intellectual Property has been licensed to the Company or any of its subsidiaries, (B)&nbsp;the Company and its subsidiaries have not received any written notice alleging any such noncompliance and are unaware of any facts which
would form a reasonable basis for any such claim and (C)&nbsp;all such agreements are in full force and effect. Except as would not, singly or in the aggregate, result in a Material Adverse Effect, (1)&nbsp;each person who is or was an employee or
contractor of the Company or any of its subsidiaries and who is, was or is expected to be involved in the creation or development of any Intellectual Property for or on behalf of the Company or any of its subsidiaries has executed a valid written
agreement containing an enforceable assignment to the Company or any of its subsidiaries such person&#146;s rights in and to such Intellectual Property and, (2)&nbsp;and to the Company&#146;s knowledge, no employee of the Company or any of its
subsidiaries is in or has ever been in violation of any term of any agreement or covenant to or with a former employer where the basis of such violation relates to such employee&#146;s employment with the Company or any of its subsidiaries or
actions undertaken by the employee while employed with the Company or any of its subsidiaries. The Company and its subsidiaries take and have taken commercially reasonable steps necessary to maintain and protect the confidentiality of material trade
secrets and other material confidential Company Intellectual Property used or held for use in connection with the business of the Company and its subsidiaries as now operated by them and the confidentiality of such material trade secrets and
material confidential Company Intellectual Property has not been disclosed to or accessed by any third party that is not bound by appropriate nondisclosure and confidentiality obligations. Except as would not, singly or in the aggregate, result in a
Material Adverse Effect, no university, military, educational institution, research center, Governmental Entity or other similar organization has funded, sponsored or contributed to research and development conducted in connection with the business
of the Company or any of its subsidiaries now operated by them in a manner that (1)&nbsp;creates a claim of right to, ownership of or other lien (other than a Permitted Lien) on any Company Intellectual Property or (2)&nbsp;would restrict the
ability of the Company or any of its subsidiaries to enforce, license or exclude others from using any Company Intellectual Property. Except as would not, singly or in the aggregate, reasonably be expected to have a Material Adverse Effect, with
respect to generative artificial intelligence models or advanced machine learning models (&#147;AI Tools&#148;), the Company and its subsidiaries, (i)&nbsp;use AI Tools in compliance with applicable licenses terms, consents, agreements and laws;
(ii)&nbsp;to the knowledge of the Company, have not used AI Tools to create or develop any products, or Intellectual Property in a manner that resulted in a third party having rights in such products or Intellectual Property; and (iii)&nbsp;have not
included and do not include personally identifiable information, protected health information, consumer information, trade secrets or other confidential information in any prompts or inputs into any AI Tools, for the avoidance of doubt, prong
(ii)&nbsp;and (iii) do not include machine learning functionalities of the Company&#146;s products or product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxiv) <U>Environmental Laws</U>. Except as described in the Registration
Statement, the General Disclosure Package and the Prospectus or would not, singly or in the aggregate, reasonably be expected to result in a Material Adverse Effect, (A)&nbsp;neither the Company nor any of its subsidiaries is in violation of any
applicable federal, state, local or foreign statute, law, rule, regulation, ordinance, code or rule of common law or any legally binding judicial or administrative interpretation thereof, including any judicial or administrative order, consent,
decree or judgment, relating to pollution or protection of human health (to the extent relating to the handling of or exposure to Hazardous Materials (as defined below)), the environment (including, without limitation, ambient air, surface water,
groundwater, land surface or subsurface strata) or wildlife, including, without limitation, laws and regulations relating to the release or threatened release of chemicals, pollutants, contaminants, wastes, toxic substances, hazardous substances,
petroleum or petroleum products, asbestos-containing materials or toxic mold (collectively, &#147;Hazardous Materials&#148;) or to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous
Materials (collectively, &#147;Environmental Laws&#148;), (B) the Company and its subsidiaries have all permits, authorizations and approvals required under any applicable Environmental Laws and are each in compliance with their requirements,
(C)&nbsp;there are no pending or, to the Company&#146;s knowledge, threatened administrative, regulatory or judicial actions, suits, demands, demand letters, claims, liens, notices of noncompliance or violation, investigations or proceedings
relating to any Environmental Law against the Company or any of its subsidiaries and (D)&nbsp;to the Company&#146;s knowledge, there are no events or circumstances that would reasonably be expected to form the basis of an order for <FONT
STYLE="white-space:nowrap">clean-up</FONT> or remediation, or an action, suit or proceeding by any private party or Governmental Entity, against or affecting the Company or any of its subsidiaries relating to Hazardous Materials or any Environmental
Laws. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxv) <U>Accounting Controls</U>. Except as described in the Registration Statement, the General Disclosure Package
and the Prospectus, the Company and each of its subsidiaries maintain a system of internal control over financial reporting (as defined under Rules <FONT STYLE="white-space:nowrap">13a-15</FONT> and <FONT STYLE="white-space:nowrap">15d-15</FONT>
under the rules and regulations of the Commission under the 1934 Act (the &#147;1934 Act Regulations&#148;)) and a system of internal accounting controls sufficient to provide reasonable assurances that (A)&nbsp;transactions are executed in
accordance with management&#146;s general or specific authorization; (B)&nbsp;transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain accountability for assets; (C)&nbsp;access to
assets is permitted only in accordance with management&#146;s general or specific authorization; and (D)&nbsp;the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with
respect to any differences. Except as described in the Registration Statement, the General Disclosure Package and the Prospectus, since the end of the Company&#146;s most recent audited fiscal year, there has been (1)&nbsp;no material weakness in
the Company&#146;s internal control over financial reporting (whether or not remediated) and (2)&nbsp;no change in the Company&#146;s internal control over financial reporting that has materially and adversely affected, or is reasonably likely to
materially and adversely affect, the Company&#146;s internal control over financial reporting. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxvi) <U>Compliance with
the Sarbanes-Oxley Act.</U> The Company has taken all necessary actions to ensure that, upon the effectiveness of the Registration Statement, it will be in compliance with all provisions of the Sarbanes-Oxley Act of 2002 and all rules and
regulations promulgated thereunder or implementing the provisions thereof (the &#147;<U>Sarbanes-Oxley Act</U>&#148;) that are then in effect and with which the Company is required to comply as of the effectiveness of the Registration Statement, and
is actively taking steps to ensure that it will be in compliance with other provisions of the Sarbanes-Oxley Act not currently in effect, upon the effectiveness of such provisions, or which will become applicable to the Company at all times after
the effectiveness of the Registration Statement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxvii) <U>Payment of Taxes</U>. All United States federal income tax
returns of the Company and its subsidiaries required by law to be filed have been filed or a timely extension in accordance with the applicable law has been requested thereof and all taxes shown by such returns or otherwise assessed, which are due
and payable, have been paid, except assessments against which appeals have been or will be promptly taken and as to which adequate reserves have been provided. The Company and its subsidiaries have filed all other tax returns that are required to
have been filed by them pursuant to applicable <FONT STYLE="white-space:nowrap">non-United</FONT> States, state, local or other law except insofar as the failure to file such returns would not reasonably be expected to result, singly or in the
aggregate, in a Material Adverse Effect, and have paid all taxes due and payable pursuant to such returns or pursuant to any assessment received by the Company and its subsidiaries, except for such taxes, if any, as are being contested in good faith
and as to which adequate reserves have been established by the Company and except insofar as the failure to pay such taxes would not reasonably be expected to result in a Material Adverse Effect. The charges, accruals and reserves on the books of
the Company in respect of any income and corporation tax liability for any years not finally determined are adequate to meet any assessments or <FONT STYLE="white-space:nowrap">re-assessments</FONT> for additional income tax for any years not
finally determined, except to the extent of any inadequacy that would not reasonably be expected to result, singly or in the aggregate, in a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxviii) <U>Insurance</U>. Except as described in the Registration Statement, the General Disclosure Package and the
Prospectus, the Company and its subsidiaries carry or are entitled to the benefits of insurance, with financially sound and reputable insurers, in such amounts and covering such risks as, in the Company&#146;s reasonable judgment, is generally
maintained by companies of established repute and comparable size engaged in the same or similar business, and all such insurance is in full force and effect. The Company has no reason to believe that it or any of its subsidiaries will not be able
(A)&nbsp;to renew its existing insurance coverage as and when such policies expire or (B)&nbsp;to obtain comparable coverage from similar institutions as may be necessary or appropriate to conduct its business as presently conducted and at a cost
that would not reasonably be expected to result in a Material Adverse Effect. Neither the Company nor any of its subsidiaries has been denied any insurance coverage which it has sought or for which it has applied. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxix) <U>Investment Company Act</U>. The Company is not required, and upon the issuance and sale of the Securities as herein
contemplated and the application of the net proceeds therefrom as described in the Registration Statement, the General Disclosure Package and the Prospectus will not be required, to register as an &#147;investment company&#148; under the Investment
Company Act of 1940, as amended (the &#147;1940 Act&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxx) <U>Absence of Manipulation</U>. Neither the Company nor
any affiliate of the Company has taken, nor will the Company or any affiliate take, directly or indirectly, any action which is designed, or would reasonably be expected, to cause or result in, or which constitutes, the stabilization or manipulation
of the price of any security of the Company to facilitate the sale or resale of the Securities or to result in a violation of Regulation M under the 1934 Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxxi) <U>Anti-Corruption Laws</U>. None of the Company, any of its subsidiaries or, to the knowledge of the Company, any
director, officer, agent, employee, affiliate or other person acting on behalf of the Company or any of its subsidiaries is aware of or has taken any action, directly or indirectly, that would result in a violation by such persons of the Foreign
Corrupt Practices Act of 1977, as amended, and the rules and regulations thereunder (the &#147;FCPA&#148;), any applicable law or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
regulation implementing the OECD Convention on Combating Bribery of Foreign Public Officials in International Business Transactions, the Bribery Act 2010 of the United Kingdom or any other
applicable anti-bribery or anti-corruption law (collectively, including the FCPA, the &#147;Anti-Corruption Laws&#148;), including, without limitation, making use of the mails or any means or instrumentality of interstate commerce corruptly in
furtherance of an offer, payment, promise to pay or authorization of the payment of any money, or other property, gift, promise to give, or authorization of the giving of anything of value to any &#147;foreign official&#148; (as such term is defined
in the FCPA) or any foreign political party or official thereof or any candidate for foreign political office, in contravention of any Anti-Corruption Laws, and the Company and, to the knowledge of the Company, its affiliates have conducted their
businesses in compliance with the Anti-Corruption Laws and have instituted and maintain policies and procedures designed to ensure, and which are reasonably expected to continue to ensure, continued compliance therewith. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxxii) <U>Money Laundering Laws</U>. The operations of the Company and its subsidiaries are and have been conducted at all
times in compliance with applicable financial recordkeeping and reporting requirements, including those of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the applicable money laundering statutes of all jurisdictions in
which the Company conducts business, the rules and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by any Governmental Entity (collectively, the &#147;Money Laundering Laws&#148;);
and no action, suit or proceeding by or before any Governmental Entity involving the Company or any of its subsidiaries with respect to the Money Laundering Laws is pending or, to the best knowledge of the Company, threatened. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxxiii) <U>OFAC</U>. None of the Company, any of its subsidiaries or, to the knowledge of the Company, any director, officer,
agent, employee, affiliate or representative of the Company or any of its subsidiaries is a Person currently the subject or target of any sanctions administered or enforced by the United States Government, including, without limitation, the U.S.
Department of the Treasury&#146;s Office of Foreign Assets Control (&#147;OFAC&#148;) or the U.S. Department of State, the United Nations Security Council (&#147;UNSC&#148;), the European Union, His Majesty&#146;s Treasury (&#147;HMT&#148;), or
other relevant sanctions authority (collectively, &#147;Sanctions&#148;), nor is the Company located, organized or resident in a country or territory that is the subject of Sanctions; and the Company will not directly or indirectly use the proceeds
of the sale of the Securities, or lend, contribute or otherwise make available such proceeds to any subsidiaries, joint venture partners or other Person, to fund any activities of or business with any Person, or in any country or territory, that, at
the time of such funding, is the subject of Sanctions or in any other manner that will result in a violation by any Person (including any Person participating in the transaction, whether as underwriter, advisor, investor or otherwise) of Sanctions.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxxiv) <U>Sales of Reserved Securities</U>. In connection with any offer and sale of Reserved Securities outside the
United States, each preliminary prospectus, the Prospectus and any amendment or supplement thereto, at the time it was filed, complied and will comply in all material respects with any applicable laws or regulations of foreign jurisdictions in which
the same is distributed. The Company has not offered, or caused the Representatives or Merrill Lynch to offer, Reserved Securities to any person with the specific intent to unlawfully influence (i)&nbsp;a customer or supplier of the Company or any
of its affiliates to alter the customer&#146;s or supplier&#146;s level or type of business with any such entity or (ii)&nbsp;a trade journalist or publication to write or publish favorable information about the Company or any of its affiliates, or
their respective businesses or products. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxxv) <U>Lending Relationship</U><I>. </I>Except as disclosed in the
Registration Statement, the General Disclosure Package and the Prospectus, the Company (i)&nbsp;does not have any&nbsp;material lending or other relationship with any bank or lending affiliate of any Underwriter and (ii)&nbsp;does not intend to use
any of the proceeds from the sale of the Securities to repay any outstanding debt owed to any affiliate of any Underwriter. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxxvi) <U>Statistical and Market-Related Data</U>. Any statistical and
market-related data included in the Registration Statement, the General Disclosure Package or the Prospectus are based on or derived from sources that the Company believes, after reasonable inquiry, to be reliable and accurate in all material
respects and, to the extent required, the Company has obtained the written consent to the use of such data from such sources. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxxvii) <U>Information Technology, Cybersecurity and Data Protection</U>. In the past five (5)&nbsp;years, except as would
not, singly or in the aggregate, result in a Material Adverse Effect, (A)&nbsp;to the Company&#146;s knowledge, there has been no security breach or incident, unauthorized access, use or disclosure, or other compromise of or relating to the
Company&#146;s or its subsidiaries&#146; information technology and computer systems, networks, hardware, software, data and databases (including personally identifiable information, the confidential data and information of their respective
customers, employees, suppliers, vendors and any personally identifiable or confidential third party data maintained, processed or stored by the Company and its subsidiaries, and, to the Company&#146;s Knowledge, any such data processed or stored by
third parties on behalf of the Company and its subsidiaries), equipment or technology (collectively, &#147;IT Systems and Data&#148;), (B) neither the Company nor any of its subsidiaries have been notified of any security breach or incident,
unauthorized access, use or disclosure or other compromise to their IT Systems and Data, and (C)&nbsp;the Company and its subsidiaries have taken commercially reasonable steps to implement, and have implemented, appropriate controls, policies,
procedures, and technological safeguards to maintain and protect the integrity, continuous operation, redundancy and security of their IT Systems and Data as required by applicable laws, contractual obligations and regulatory standards. The IT
Systems and Data are, in all material respects, adequate and operational for, in accordance with their documentation and functional specifications, the business of the Company and its subsidiaries as now operated and as currently proposed to be
conducted in the Registration Statement, the General Disclosure Package and the Prospectus Supplement. None of the software that is material to the operation of the Company and its subsidiaries and developed or owned by the Company or its
subsidiaries is subject to any escrow obligation or any condition, obligation or other requirement that it be licensed pursuant to a free, open source or similar software license or that the source code for such software be delivered, disclosed,
licensed or otherwise made available. Except as would not, singly or in the aggregate, result in a Material Adverse Effect, the Company and its subsidiaries are presently in material compliance with all applicable laws or statutes and all judgments,
orders, rules and regulations of any court or arbitrator or Governmental Entity or regulatory authority, relating to the privacy and security of IT Systems and Data, including the collection, use, transfer, processing, disposal, disclosure,
handling, storage and analysis of personally identifiable information, protected health information, consumer information and other confidential information of the Company and any third parties in their possession (&#147;Sensitive Company
Data&#148;), and to the protection of such IT Systems and Data from unauthorized use, access, misappropriation or modification. The Company and its subsidiaries have taken commercially reasonable steps necessary to maintain the confidentiality of
the Sensitive Company Data. Except as would not, singly or in the aggregate, result in a Material Adverse Effect, (1)&nbsp;the Company and its subsidiaries have not received any notice, claim, complaint, demand or letter from any person or
Governmental Entity under applicable data security and data protection laws and regulations and industry standards alleging the misuse, loss, unauthorized destruction or unauthorized disclosure of any Sensitive Company Data, (2)&nbsp;there has been
no unauthorized or illegal use of or access to any Sensitive Company Data by any third party, and (3)&nbsp;the Company has not been required to notify any individual or data protection authority of any information security breach, compromise or
incident involving Sensitive Company Data and, to the Company&#146;s knowledge, is not the subject of any inquiry or investigation by any Governmental Entity or data protection authority regarding any of the foregoing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxxviii) <U>Uyghur Forced Labor Prevention Act.</U> The operations of
neither the Company nor any of its subsidiaries involve the sale or import into the United States of any goods, wares, articles, or merchandise mined, produced, or manufactured wholly or in part in the Xinjiang Uyghur Autonomous Region of the
People&#146;s Republic of China, or produced by an entity on the Department of Homeland Security&#146;s UFLPA Entity List. <U></U>In the past five (5)&nbsp;years, None of the goods the Company or any of its subsidiaries have sold or imported into
the United States have been seized by Customs and Border Patrol as being contrary to Section&nbsp;307 of the Tariff Act of 1930 due to the use of forced labor in China in the production of such goods, and neither the Company nor its subsidiaries
have been the subject of any fines, penalties, enforcement actions, litigation, or other liability in relation to the use of forced labor or alleged forced labor in the supply chain of the products it sells or imports into the United States. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxxix) <U>Compliance with Health Care Laws</U>. The Company and its subsidiaries are and at all times have been, in compliance
in all respects, except where <FONT STYLE="white-space:nowrap">non-compliance</FONT> would not, singly or in the aggregate, reasonably be expected to have a Material Adverse Effect on the Company and its subsidiaries, taken as a whole, with all
applicable Health Care Laws. For purposes of this Agreement, &#147;Health Care Laws&#148; shall mean all federal, state, local and foreign health care laws applicable to the Company and its subsidiaries, each as amended from time to time, including,
but not limited to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(1) the Federal Food, Drug, and Cosmetic Act (21 U.S.C. &#167;&#167; 301 et seq.), and the regulations promulgated
thereunder; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(2) all applicable federal, state, local and foreign health care fraud and abuse laws, including, without limitation, the
Anti-Kickback Statute (42 U.S.C. <FONT STYLE="white-space:nowrap">&#167;1320a-7b(b)),</FONT> the Physician Payments Sunshine Act (42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7h),</FONT> the civil False Claims Act (31 U.S.C. &#167;&#167;
3729 et seq.), the criminal False Claims Act (42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7b(a)),</FONT> all criminal laws relating to health care fraud and abuse, including, but not limited to, 18 U.S.C. Sections 286, 287, 1347 and
1349, and the health care fraud criminal provisions under the Health Insurance Portability and Accountability Act of 1996 (42 U.S.C. &#167;&#167; 1320d et seq.) as amended by the Health Information Technology for Economic and Clinical Health Act (42
U.S.C. &#167;17921 et seq.) (&#147;HIPAA&#148;), the exclusion laws (42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7),</FONT> the Stark Law (42 U.S.C. &#167; 1395nn), the civil monetary penalties law (42 U.S.C. &#167; <FONT
STYLE="white-space:nowrap">1320a-7a),</FONT> and applicable laws governing government funded or sponsored healthcare programs; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(3)
licensure, quality, safety and accreditation requirements under applicable federal, state, local or foreign laws or regulatory bodies; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(4)
all other laws and regulations applicable to ownership, testing, development, manufacture, packaging, processing, use, distribution, storage, import, export or disposal of the products distributed by the Company; including, but not limited to, the
FDA&#146;s current good manufacturing practice regulations at 21 CFR Part 820; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(5) the rules, directives and regulations promulgated
pursuant to such laws, or any other similar federal, state, local or foreign laws, if applicable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In the past five (5)&nbsp;years, either the Company nor any of its subsidiaries has received
any written notification or correspondence of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any court, arbitrator, governmental or regulatory authority or third party of potential or
actual <FONT STYLE="white-space:nowrap">non-compliance</FONT> by, or liability of, the Company or its subsidiaries under any applicable Health Care Laws nor is any such claim, action, suit, proceeding, hearing, enforcement, investigation,
arbitration or other action threatened, which singly or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would reasonably be expected to have a Material Adverse Effect on the Company and its subsidiaries, taken as a
whole. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Except as would not, singly or in the aggregate, reasonably be expected to have a Material Adverse Effect on the Company and its
subsidiaries, taken as a whole, (i)&nbsp;the Company and its subsidiaries have filed, maintained or submitted all reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required by any Health
Care Laws, and (ii)&nbsp;all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were complete and accurate on the date filed in all material respects (or were corrected or supplemented
by a subsequent submission). Neither the Company nor any of its subsidiaries is a party to or has any ongoing reporting obligations pursuant to any corporate integrity agreements, deferred prosecution agreements, monitoring agreements, consent
decrees, settlement orders, plans of correction, or similar agreements with or imposed by any governmental or regulatory authority. Additionally, none of the Company or any of its subsidiaries or controlled affiliates, or to the Company&#146;s
knowledge, any other affiliate, or any director, officer, or employee thereof, or, to the Company&#146;s knowledge, any agent or representative of the Company or of any of its subsidiaries or affiliates, has been excluded, suspended, disqualified or
debarred from participation in any U.S. federal health care program or is subject to a governmental inquiry, investigation, proceeding, or other similar action that could result in debarment, suspension, disqualification or exclusion, or has been
convicted of any crime or engaged in any conduct that would reasonably be expected to result in debarment under 21 U.S.C. &#167; 335a or comparable foreign law. In the past five (5)&nbsp;years, the Company has not received any warning letter,
untitled letter or other correspondence or written notice from any court or arbitrator or governmental or regulatory authority alleging or assert noncompliance with (x)&nbsp;any Health Care Laws or (y)&nbsp;any Governmental Licenses required by any
such Health Care Laws, which singly or in the aggregate, would reasonably be expected to have a Material Adverse Effect on the Company and its subsidiaries, taken as a whole. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xl) <U>Compliance by Suppliers</U>. To the knowledge of Company, the manufacturing facilities and operations of its
manufacturers and suppliers, with respect to the manufacturing or supply of the Company&#146;s products, are operated in compliance with all Health Care Laws, except as would not reasonably be expected to result in a Material Adverse Effect on the
Company and its subsidiaries, taken as a whole. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xli) <U>Safety Notices</U>. (i)&nbsp;There have been no warnings,
investigator notices, safety alerts or other written notices of action relating to an alleged lack of safety, efficacy, or regulatory compliance of the Company&#146;s or any of its subsidiaries&#146; products (&#147;Safety Notices&#148;), and
(ii)&nbsp;there are no facts that would be reasonably likely to result in (x)&nbsp;a Safety Notice with respect to the Company&#146;s or any of its subsidiaries&#146; products, (y)&nbsp;a change in labeling of any of the Company&#146;s or any of its
subsidiaries&#146; products, or (z)&nbsp;a termination or suspension of testing of any of the Company&#146;s or any of its subsidiaries&#146; products, except, in each of cases (x), (y) or (z)&nbsp;such as would not, singly or in the aggregate,
reasonably be expected to have a Material Adverse Effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xlii) <U>ERISA Compliance</U>.&nbsp;Except as would not, singly or in the
aggregate, reasonably be expected to have a Material Adverse Effect, the Company and any &#147;Employee Benefit Plan&#148; (within the meaning of Section&nbsp;3(3) of the Employee Retirement Income Security Act of 1974, as amended, and the
regulations and published interpretations thereunder (collectively, &#147;ERISA&#148;))&nbsp;for which the Company or its &#147;ERISA Affiliates&#148; (as defined below) would have any liability (each, a &#147;Plan&#148;) are in compliance with
ERISA and each Plan has been established and maintained in compliance with its terms and the requirements of any applicable statutes, orders, rules and regulations, including but not limited to, ERISA and the Internal Revenue Code of 1986, as
amended, and the regulations and published interpretations thereunder (the &#147;Code&#148;). No &#147;reportable event&#148; (as defined under ERISA) has occurred or is reasonably expected to occur with respect to any Plan. No Plan, if such Plan
were terminated, would have any &#147;amount of unfunded benefit liabilities&#148; (as defined under ERISA). The fair market value of the assets under each Plan exceeds the present value of all benefits accrued under such Plan (determined based on
those assumptions used to fund such Plan). Neither the Company nor any of its ERISA Affiliates has incurred or reasonably expects to incur any obligation or liability under (i)&nbsp;Title&nbsp;IV of ERISA with respect to termination of, or
withdrawal from, any Plan, (ii)&nbsp;Sections&nbsp;412 and 430, 4971, 4975 or 4980B of the Code or (iii)&nbsp;Sections 302 and 303, 406, 4063 and 4064 of ERISA. Each Plan that is intended to be qualified under Section&nbsp;401(a) of the Code has
received a favorable determination letter from the Internal Revenue Service that it is so qualified and nothing has occurred, whether by action or failure to act, which would cause the loss of such qualification. There is no pending audit or
investigation by the Internal Revenue Service, the U.S. Department of Labor, the Pension Benefit Guaranty Corporation or any other governmental agency or any foreign regulatory agency with respect to any Plan that could reasonably be expected to
result in liability to the Company. The Company does not have any &#147;accumulated postretirement benefit obligations&#148; (within the meaning of Statement of Financial Accounting Standards 106).&nbsp;&#147;ERISA Affiliate&#148; means, with
respect to the Company, any member of any group of organizations described in Sections&nbsp;414(b), (c), (m) or (o)&nbsp;of the Code of which the Company is a member. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xliii) <I>Stamp Taxes</I>. Except as disclosed in the Registration Statement, the Pricing Disclosure Package and the
Prospectus, no stamp, registration, documentary, issuance, transfer or other similar taxes or duties (&#147;Stamp Taxes&#148;) are payable by or on behalf of the Underwriters in Bermuda or the United States (each, a &#147;Relevant Taxing
Jurisdiction&#148;) in connection with (A)&nbsp;the execution, delivery and performance of this Agreement, (B)&nbsp;the creation, issuance and delivery of the Common Shares in the manner contemplated by this Agreement and the Prospectus, or
(C)&nbsp;the sale and delivery by the Underwriters of the Common Shares to the initial purchasers thereof as contemplated herein and in the Prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xliv) <I>Enforcement of Foreign Judgments</I>. Any final judgment for a fixed or determined sum of money rendered by any U.S.
federal or New York state court located in the State of New York having jurisdiction under its own laws in respect of any suit, action or proceeding against the Company based upon this Agreement would be declared enforceable against the Company by
the courts of Bermuda, without reconsideration or reexamination of the merits. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xlv) <I>Valid Choice of Law</I>. The
choice of laws of the State of New York as the governing law of this Agreement is a valid choice of law under the laws of Bermuda and will be recognized and given effect to in any action brought before a court of competent jurisdiction in Bermuda,
subject to the restrictions described under the heading &#147;Enforcement of Civil Liabilities Under United States Federal Securities Laws&#148; in the Registration Statement, the Pricing Disclosure Package and the Prospectus and except for those
laws (i)&nbsp;which such court considers to be procedural in nature; (ii)&nbsp;which are revenue or penal laws or (iii)&nbsp;the application of which would be inconsistent with public policy, as such term is interpreted under the laws of Bermuda.
The Company has the power to submit, and pursuant to Section&nbsp;17 of this Agreement, has legally, validly, effectively and irrevocably submitted, to the personal jurisdiction of each New York state and United States federal court sitting in the
City of New York and has validly and irrevocably waived any objection to the laying of venue of any suit, action or proceeding brought in such court. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xlvi) <I>Indemnification and Contribution</I>. The indemnification and
contribution provisions set forth in Section&nbsp;6 hereof do not contravene Bermuda law or public policy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(xlvii)</I><I></I><I>&nbsp;Outbound Investment Security Program.</I> Neither the Company nor any of its subsidiaries is a &#147;covered
foreign person&#148;, as that term is defined in 31 C.F.R. &#167; 850.209. Neither the Company nor any of its subsidiaries currently engages, or has plans to engage, directly or indirectly, in a &#147;covered activity&#148;, as that term is defined
in 31 C.F.R. &#167; 850.208 (&#147;Covered Activity&#148;). The Company does not have any joint ventures that engage in or plan to engage in any Covered Activity. The Company also does not, directly or indirectly, hold a board seat on, have a voting
or equity interest in, or have any contractual power to direct or cause the direction of the management or policies of any person or persons that engages or plans to engage in any Covered Activity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Officer&#146;s Certificates</I>. Any certificate signed by any officer of the Company or any of its subsidiaries delivered to the
Representatives or to counsel for the Underwriters shall be deemed a representation and warranty by the Company to each Underwriter as to the matters covered thereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 2. <U>Sale and Delivery to Underwriters; Closing</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Initial Securities</I>. On the basis of the representations and warranties herein contained and subject to the terms and conditions
herein set forth, the Company agrees to sell to each Underwriter, severally and not jointly, and each Underwriter, severally and not jointly, agrees to purchase from the Company, at the price per share set forth in Schedule A, that number of Initial
Securities set forth in Schedule A opposite the name of such Underwriter, plus any additional number of Initial Securities which such Underwriter may become obligated to purchase pursuant to the provisions of Section&nbsp;10 hereof, subject, in each
case, to such adjustments among the Underwriters as the Representatives in their sole discretion shall make to eliminate any sales or purchases of fractional shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Option Securities</I>. In addition, on the basis of the representations and warranties herein contained and subject to the terms and
conditions herein set forth, the Company hereby grants an option to the Underwriters, severally and not jointly, to purchase up to an additional [&#149;] Common Shares, at the price per share set forth in Schedule A, less an amount per share equal
to any dividends or distributions declared by the Company and payable on the Initial Securities but not payable on the Option Securities. The option hereby granted may be exercised for 30&nbsp;days after the date hereof and may be exercised in whole
or in part at any time from time to time within the 30 day period upon written notice by the Representatives to the Company setting forth the number of Option Securities as to which the several Underwriters are then exercising the option and the
time and date of payment and delivery for such Option Securities. Any such time and date of delivery (a &#147;Date of Delivery&#148;) shall be determined by the Representatives, but shall not be later than seven full business days after the exercise
of said option, nor in any event prior to the Closing Time. If the option is exercised as to all or any portion of the Option Securities, each of the Underwriters, acting severally and not jointly, will purchase that proportion of the total number
of Option Securities then being purchased as is equivalent to the proportion which the number of Initial Securities set forth in Schedule A opposite the name of such Underwriter bears to the total number of Initial Securities, subject, in each case,
to such adjustments as the Representatives in their sole discretion shall make to eliminate any sales or purchases of fractional shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Payment</I>. Payment of the purchase price for, and delivery of security entitlements for, the Initial Securities shall be made at the
offices of Allen Overy Shearman Sterling US LLP, 599 Lexington Avenue, New York, New York 10022, or at such other place as shall be agreed upon by the Representatives and the Company, at 9:00&nbsp;A.M. (New York City time) on the first (second, if
the Applicable Time is after 4:30 P.M. (New York City time) on any given day) business day after the date hereof (unless postponed in accordance with the provisions of Section&nbsp;10), or such other time not later than ten business days after such
date as shall be agreed upon by the Representatives and the Company (such time and date of payment and delivery being herein called &#147;Closing Time&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in the event that any or all of the Option Securities are purchased by the
Underwriters, payment of the purchase price for, and delivery of security entitlements for, such Option Securities shall be made at the <FONT STYLE="white-space:nowrap">above-mentioned</FONT> offices, or at such other place as shall be agreed upon
by the Representatives and the Company, on each Date of Delivery as specified in the notice from the Representatives to the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payment shall be made to the Company by wire transfer of immediately available funds to a bank account designated by the Company against
delivery to the Representatives for the respective accounts of the Underwriters of security entitlements for the Securities to be purchased by them. It is understood that each Underwriter has authorized the Representatives, for its account, to
accept delivery of, receipt for, and make payment of the purchase price for, the Initial Securities and the Option Securities, if any, which it has agreed to purchase. Each of the Representatives, individually and not as representative of the
Underwriters, may (but shall not be obligated to) make payment of the purchase price for the Initial Securities or the Option Securities, if any, to be purchased by any Underwriter whose funds have not been received by the Closing Time or the
relevant Date of Delivery, as the case may be, but such payment shall not relieve such Underwriter from its obligations hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 3. <U>Covenants of the Company</U>. The Company covenants with each Underwriter as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Compliance with Securities Regulations and Commission Requests</I>. The Company, subject to Section&nbsp;3(b), will comply with the
requirements of Rule 430A, and will notify the Representatives as soon as practicable, and confirm the notice in writing (which may be by electronic mail), (i) when any post-effective amendment to the Registration Statement shall become effective or
any amendment or supplement to the Prospectus shall have been filed, (ii)&nbsp;of the receipt of any comments from the Commission, (iii)&nbsp;of any request by the Commission for any amendment to the Registration Statement or any amendment or
supplement to the Prospectus or for additional information, (iv)&nbsp;of the issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement or any post-effective amendment or of any order preventing or
suspending the use of any preliminary prospectus or the Prospectus, or of the suspension of the qualification of the Securities for offering or sale in any jurisdiction, or of the initiation or threatening of any proceedings for any of such purposes
or of any examination pursuant to Section&nbsp;8(d) or 8(e) of the 1933 Act concerning the Registration Statement and (v)&nbsp;if the Company becomes the subject of a proceeding under Section&nbsp;8A of the 1933 Act in connection with the offering
of the Securities. The Company will effect all filings required under Rule 424(b), in the manner and within the time period required by Rule 424(b) (without reliance on Rule 424(b)(8)), and will take such steps as it deems necessary to ascertain
promptly whether the form of prospectus transmitted for filing under Rule 424(b) was received for filing by the Commission and, in the event that it was not, it will promptly file such prospectus. The Company will use commercially reasonable efforts
to prevent the issuance of any stop order or suspension of the Registration Statement and, if any such order is issued, use commercially reasonable efforts to obtain the lifting thereof as soon as practicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Continued Compliance with Securities Laws</I>. The Company will comply with the 1933 Act and the 1933 Act Regulations so as to permit
the completion of the distribution of the Securities as contemplated in this Agreement and in the Registration Statement, the General Disclosure Package and the Prospectus. If at any time when a prospectus relating to the Securities is (or, but for
the exception afforded by Rule 172 of the 1933 Act Regulations (&#147;Rule 172&#148;), would be) required by the 1933 Act to be delivered in connection with sales of the Securities, any event shall occur or condition shall exist as a result of which
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
it is necessary, in the opinion of counsel for the Underwriters or for the Company, to (i)&nbsp;amend the Registration Statement in order that the Registration Statement will not include an
untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading, (ii)&nbsp;amend or supplement the General Disclosure Package or the Prospectus in order
that the General Disclosure Package or the Prospectus, as the case may be, will not include any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein not misleading in the light of the
circumstances existing at the time it is delivered to a purchaser or (iii)&nbsp;amend the Registration Statement or amend or supplement the General Disclosure Package or the Prospectus, as the case may be, in order to comply with the requirements of
the 1933 Act or the 1933 Act Regulations, the Company will promptly (A)&nbsp;give the Representatives notice of such event, (B)&nbsp;prepare any amendment or supplement as may be necessary to correct such statement or omission or to make the
Registration Statement, the General Disclosure Package or the Prospectus comply with such requirements and, a reasonable amount of time prior to any proposed filing or use, furnish the Representatives with copies of any such amendment or supplement
and (C)&nbsp;file with the Commission any such amendment or supplement; provided that the Company shall not file or use any such amendment or supplement to which the Representatives or counsel for the Underwriters shall reasonably object in a timely
manner. The Company will furnish to the Underwriters such number of copies of such amendment or supplement as the Underwriters may reasonably request. The Company has given the Representatives notice of any filings made pursuant to the 1934 Act or
1934 Act Regulations within 48 hours prior to the Applicable Time and will furnish the Representatives with copies of any such documents a reasonable amount of time prior to such proposed filing and will not file or use any such document to which
the Representatives or counsel for the Underwriters shall reasonably object. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Delivery of Registration Statements</I>. The Company
has furnished or will deliver to the Representatives and counsel for the Underwriters, if requested in writing, without charge, conformed copies of the Registration Statement as originally filed and each amendment thereto (including exhibits filed
therewith) and conformed copies of all consents and certificates of experts. The copies of the Registration Statement and each amendment thereto furnished to the Underwriters will be identical to the electronically transmitted copies thereof filed
with the Commission pursuant to EDGAR, except to the extent permitted by Regulation <FONT STYLE="white-space:nowrap">S-T.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)
<I>Delivery of Prospectuses</I>. The Company has delivered to each Underwriter, without charge, as many copies of each preliminary prospectus as such Underwriter reasonably requested in writing, and the Company hereby consents to the use of such
copies for purposes permitted by the 1933 Act. The Company will furnish to each Underwriter, without charge, during the period when a prospectus relating to the Securities is (or, but for the exception afforded by Rule 172, would be) required to be
delivered under the 1933 Act, such number of copies of the Prospectus (as amended or supplemented) as such Underwriter may reasonably request in writing. The Prospectus and any amendments or supplements thereto furnished to the Underwriters will be
identical to the electronically transmitted copies thereof filed with the Commission pursuant to EDGAR, except to the extent permitted by Regulation <FONT STYLE="white-space:nowrap">S-T.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <I>Blue Sky Qualifications</I>. If required by applicable law, the Company will use its commercially reasonable efforts, in cooperation
with the Underwriters, to qualify the Securities for offering and sale under the applicable securities laws of such states and other jurisdictions (domestic or foreign) as the Representatives may reasonably designate and to maintain such
qualifications in effect so long as required to complete the distribution of the Securities; provided, however, that the Company shall not be obligated to file any general consent to service of process or to qualify as a foreign corporation or as a
dealer in securities in any jurisdiction in which it is not so qualified or to subject itself to taxation in respect of doing business in any jurisdiction in which it is not otherwise so subject. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <I>Rule 158</I>. The Company will timely file such reports pursuant to the 1934 Act as
are necessary in order to make generally available (which may be satisfied by filing with the Commission pursuant to EDGAR) to its securityholders as soon as practicable an earnings statement for the purposes of, and to provide to the Underwriters
the benefits contemplated by, the last paragraph of Section&nbsp;11(a) of the 1933 Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <I>Use of Proceeds</I>. The Company will use
the net proceeds received by it from the sale of the Securities in the manner specified in the Registration Statement, the General Disclosure Package and the Prospectus under the heading &#147;Use of Proceeds.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <I>Listing</I>. The Company will use its commercially reasonable efforts to effect and maintain the listing of the Common Shares
(including the Securities) on the Nasdaq Global Select Market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <I>Restriction on Sale of Securities</I>. During a period of 180 days
from the date of the Prospectus, the Company will not, without the prior written consent of BofA, GS and PSC, (i)&nbsp;directly or indirectly, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or
contract to sell, grant any option, right or warrant to purchase or otherwise transfer or dispose of any Common Shares or any securities convertible into or exercisable or exchangeable for Common Shares or file or confidentially submit any
registration statement under the 1933 Act with respect to any of the foregoing; provided that the Company may undertake preparations related thereto, (ii)&nbsp;enter into any swap or any other agreement or any transaction that transfers, in whole or
in part, directly or indirectly, the economic consequence of ownership of the Common Shares, whether any such swap or transaction described in clause (i)&nbsp;or (ii) above is to be settled by delivery of Common Shares or other securities, in cash
or otherwise, or (iii)&nbsp;publicly disclose the intention to do any of the foregoing. The foregoing sentence shall not apply to (A)&nbsp;the Securities to be sold hereunder, (B)&nbsp;any Common Shares issued by the Company upon the exercise of an
option, other equity award or warrant or the conversion of a security issued on the date hereof and referred to in the Registration Statement, the General Disclosure Package and the Prospectus, (C)&nbsp;any Common Shares issued or options to
purchase Common Shares or other equity awards granted pursuant to employee benefit plans and employee share purchase plans of the Company referred to in the Registration Statement, the General Disclosure Package and the Prospectus or created as
successor employee benefit plans and employee share purchase plans to any such plans of the Company referred to in the Registration Statement, the General Disclosure Package and the Prospectus, (D)&nbsp;any Common Shares issued pursuant to any <FONT
STYLE="white-space:nowrap">non-employee</FONT> director share plan or dividend reinvestment plan referred to in the Registration Statement, the General Disclosure Package and the Prospectus, (E)&nbsp;any Common Shares issued in connection with the
transactions described under the heading &#147;Organizational Transactions&#148; in the Prospectus, including, for the avoidance of doubt, any Common Shares issued in connection with the conversion of vested and unvested incentive units of West
Affum Holdings, L.P. into Common Shares of the Company; provided that each recipient of Common Shares pursuant to this clause (E)&nbsp;shall execute a <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement substantially in the form of Exhibit A
hereto, (F)&nbsp;the filing of a registration statement on Form <FONT STYLE="white-space:nowrap">S-8</FONT> or any successor form thereto with respect to the registration of securities to be offered under any employee benefit or equity incentive
plans of the Company referred to in the Registration Statement, the General Disclosure Package and the Prospectus or (G)&nbsp;the sale or issuance of or entry into an agreement to sell or issue Common Shares, restricted share awards or securities
convertible into or exercisable or exchangeable for Common Shares in connection with (i)&nbsp;the acquisition of the securities, business, property or other assets of another Person or pursuant to any employee benefit plan assumed in connection with
any such acquisition, (ii)&nbsp;joint ventures, (iii)&nbsp;commercial relationships or (iv)&nbsp;other strategic transactions; provided that the aggregate number of Common Shares, restricted share awards and Common Shares issuable upon the
conversion, exercise or exchange of securities (on an as converted or as exercised basis, as the case may be) issued pursuant to this clause (G)&nbsp;shall not exceed 5% of the total number of Common Shares issued immediately following the issuance
and sale of the Initial Securities at the Closing Time pursuant hereto; and provided, further, that each recipient of Common Shares, restricted share awards or securities convertible into or exercisable or exchangeable for Common Shares pursuant to
this clause shall execute a <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement substantially in the form of Exhibit A hereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) <I>Waiver of <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement</I>. If BofA, GS
and PSC, in their sole discretion, agree to release or waive the restrictions set forth in a <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement described in Section&nbsp;5(i) hereof for an officer or director of the Company and provide the
Company with notice of the impending release or waiver at least three business days before the effective date of the release or waiver, the Company agrees to announce the impending release or waiver by a press release substantially in the form of
Exhibit B hereto through a major news service at least two business days before the effective date of the release or waiver or such other manner in satisfaction of FINRA Rule 5131(d)(2). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) <I>Reporting Requirements</I>. The Company, during the period when a Prospectus relating to the Securities is (or, but for the exception
afforded by Rule 172, would be) required to be delivered under the 1933 Act, will file all documents required to be filed with the Commission pursuant to the 1934 Act within the time periods required by the 1934 Act and 1934 Act Regulations.
Additionally, the Company shall report the use of proceeds from the issuance of the Securities as may be required under Rule 463 under the 1933 Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) <I>Issuer Free Writing Prospectuses</I>. The Company agrees that, unless it obtains the prior written consent of the Representatives, it
will not make any offer relating to the Securities that would constitute an Issuer Free Writing Prospectus or that would otherwise constitute a &#147;free writing prospectus,&#148; or a portion thereof, required to be filed by the Company with the
Commission or retained by the Company under Rule 433; provided that the Representatives will be deemed to have consented to the Issuer Free Writing Prospectuses listed on Schedule <FONT STYLE="white-space:nowrap">B-2</FONT> hereto and any &#147;road
show for an offering that is a written communication&#148; within the meaning of Rule 433(d)(8)(i) that has been reviewed by the Representatives. The Company represents that it has treated or agrees that it will treat each such free writing
prospectus consented to, or deemed consented to, by the Representatives as an &#147;issuer free writing prospectus,&#148; as defined in Rule 433, and that it has complied and will comply with the applicable requirements of Rule 433 with respect
thereto, including timely filing with the Commission where required, legending and record keeping. If at any time following issuance of an Issuer Free Writing Prospectus there occurred or occurs an event or development as a result of which such
Issuer Free Writing Prospectus conflicted or would conflict with the information contained in the Registration Statement, any preliminary prospectus or the Prospectus or included or would include an untrue statement of a material fact or omitted or
would omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances existing at that subsequent time, not misleading, the Company will promptly notify the Representatives and will promptly amend
or supplement, at its own expense, such Issuer Free Writing Prospectus to eliminate or correct such conflict, untrue statement or omission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) <I>Certification Regarding Beneficial Owners</I>. The Company will deliver to the Representatives, on or prior to the date of execution of
this Agreement, a properly completed and executed Certification Regarding Beneficial Owners of Legal Entity Customers, together with copies of identifying documentation, and the Company undertakes to provide such additional supporting documentation
as the Representatives may reasonably request in connection with the verification of the foregoing certification. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) <I>Compliance with
FINRA Rules</I>. The Company hereby agrees that it will ensure that the Reserved Securities will be restricted as required by FINRA or the FINRA rules from sale, transfer, assignment, pledge or hypothecation for a period of three months following
the date of this Agreement. Merrill Lynch will notify the Company as to which persons will need to be so restricted. At the request of the Underwriters, the Company will direct the transfer agent to place a stop transfer restriction upon such
securities for such period of time. Should the Company release, or seek to release, from such restrictions any of the Reserved Securities, the Company agrees to reimburse Merrill Lynch for any reasonable expenses (including, without limitation,
legal expenses) they incur in connection with such release. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o)
<I><U><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Materials</U></I><I>. </I>If at any time following the distribution of any Written <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication there occurred or occurs an event or development as a result of which such Written
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication included or would include an untrue statement of a material fact or omitted or would omit to state a material fact necessary in order to
make the statements therein, in the light of the circumstances existing at that subsequent time, not misleading, the Company will promptly notify the Representatives and will promptly amend or supplement, at its own expense, such Written <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication to eliminate or correct such untrue statement or omission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) <I><U>Emerging Growth Company Status.</U></I> The Company will promptly notify the Representatives if the Company ceases to be an Emerging
Growth Company at any time prior to the later of (i)&nbsp;completion of the distribution of the Securities within the meaning of the 1933 Act and (ii)&nbsp;completion of the <FONT STYLE="white-space:nowrap">180-day</FONT> restricted period referred
to in Section&nbsp;3(i) hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q) <I><U>Tax Indemnity</U></I>. The Company will indemnify and hold harmless the Underwriters against
any Stamp Taxes, including any interest and penalties, imposed under the laws of a Relevant Taxing Jurisdiction on the sale of the Common Shares by the Company to the Underwriters and on the execution and delivery of this Agreement. All indemnity
payments to be made by the Company hereunder in respect of this Section&nbsp;3(q) shall be made without withholding or deduction for or on account of any present or future Bermuda taxes, duties or governmental shares whatsoever unless the Company is
compelled by law to deduct or withhold such taxes, duties or charges. In that event, except for (i)&nbsp;any net income, capital gains or franchise taxes imposed on the Underwriters by Bermuda or the United States or any political subdivision or
taxing authority thereof or therein as a result of any present or former connection (other than any connection resulting from the transactions contemplated by this Agreement) between the Underwriters and the jurisdiction imposing such withholding or
deductions or (ii)&nbsp;taxes that would not have been imposed but for the failure of the recipient of such payment to comply, upon request by the Company, with any reasonable certification or other reporting requirements concerning the nationality,
residence, identity or connection with the taxing authority of the recipient, the Company shall pay such additional amounts as may be necessary in order to ensure that the net amounts received after such withholding or deductions shall equal the
amounts that would have been received if no withholding or deduction has been made. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 4. <U>Payment of Expenses</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Expenses</I>. The Company will pay or cause to be paid all expenses incident to the performance of its obligations under this
Agreement, including (i)&nbsp;the preparation, printing and filing of the Registration Statement (including financial statements and exhibits) as originally filed and each amendment thereto, (ii)&nbsp;the preparation, printing and delivery to the
Underwriters of copies of each preliminary prospectus, each Issuer Free Writing Prospectus and the Prospectus and any amendments or supplements thereto and reasonable costs associated with electronic delivery of any of the foregoing by the
Underwriters to investors, (iii)&nbsp;the preparation, issuance and delivery of the certificates or security entitlements for the Securities to the Underwriters, including any stock or other transfer taxes and any stamp or other duties payable upon
the sale, issuance or delivery of the Securities, (iv)&nbsp;the fees and disbursements of the Company&#146;s counsel, accountants and other advisors, (v)&nbsp;the qualification of the Securities under securities laws in accordance with the
provisions of Section&nbsp;3(e) hereof, including filing fees and the reasonable and documented fees and disbursements of counsel for the Underwriters in connection therewith and in connection with the preparation of the Blue Sky Survey and any
supplement thereto, (vi)&nbsp;the fees and expenses of any transfer agent or registrar for the Securities, (vii)&nbsp;the costs and expenses of the Company relating to investor presentations on any &#147;road show&#148; undertaken in connection with
the marketing of the Securities, including without limitation, expenses associated with the production of road show slides and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
graphics, fees and expenses of any consultants engaged by the Company or with the Company&#146;s prior written consent in connection with the road show presentations, travel and lodging expenses
of the representatives and officers of the Company and any such consultants (provided that, for the avoidance of doubt, the travel and lodging expenses of the Underwriters shall be paid for by the Underwriters), and 50% of the cost of aircraft and
other transportation chartered in connection with the road show (with the Underwriters paying for the remaining 50% of the cost of such aircraft and other chartered transportation to be paid by the Underwriters), (viii) the filing fees incident to,
and the reasonable and documented fees and disbursements of counsel to the Underwriters in connection with, the review by FINRA of the terms of the sale of the Securities; provided that the amount of fees and disbursements of counsel to the
Underwriters payable by the Company pursuant to this clause (viii)&nbsp;and clause (v)&nbsp;above shall not exceed $40,000, (ix) the fees and expenses incurred in connection with the listing of the Securities on the Nasdaq Global Market,
(x)&nbsp;the reasonable and documented costs and expenses (including, without limitation, any damages or other amounts payable in connection with legal or contractual liability) associated with the reforming of any contracts for sale of the
Securities made by the Underwriters caused by a breach of the representation contained in the third sentence of Section&nbsp;1(a)(ii) and (xi)&nbsp;all reasonable and documented costs and expenses of Merrill Lynch, including the fees and
disbursements of counsel for Merrill Lynch, in connection with matters related to the Reserved Securities which are designated by the Company for sale to Invitees; provided that the amount of fees and disbursements of counsel to Merrill Lynch
payable by the Company pursuant to this clause (xi)&nbsp;shall not exceed $25,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Termination of Agreement</I>. If this Agreement
is terminated by the Representatives in accordance with the provisions of Section&nbsp;5, Section&nbsp;9(a)(i) or (iii)&nbsp;or Section&nbsp;10 hereof, the Company shall reimburse the Underwriters for all of their reasonably incurred and documented <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses, including the reasonable and documented fees and disbursements of counsel for the Underwriters. For the avoidance of doubt, in the case of termination
by the Underwriters in accordance with the provisions of Section&nbsp;10 hereof, the Company shall have no obligation to reimburse any defaulting Underwriter pursuant to Section&nbsp;4(b). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 5. <U>Conditions of Underwriters&#146; Obligations</U>. The obligations of the several Underwriters hereunder are subject to the
accuracy of the representations and warranties of the Company contained herein or in certificates of any officer of the Company or any of its subsidiaries delivered pursuant to the provisions hereof, to the performance by the Company of its
covenants and other obligations hereunder, and to the following further conditions: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Effectiveness of Registration Statement; Rule
430A Information</I>. The Registration Statement, including any Rule 462(b) Registration Statement, has become effective and, at the Closing Time, no stop order suspending the effectiveness of the Registration Statement or any post-effective
amendment thereto has been issued under the 1933 Act, no order preventing or suspending the use of any preliminary prospectus or the Prospectus has been issued and no proceedings for any of those purposes or pursuant to Section&nbsp;8A of the 1933
Act have been instituted or are pending or, to the Company&#146;s knowledge, contemplated; and the Company has complied with each request (if any) from the Commission for additional information. A prospectus containing the Rule 430A Information
shall have been filed with the Commission in the manner and within the time frame required by Rule 424(b) without reliance on Rule 424(b)(8) or a post-effective amendment providing such information shall have been filed with, and declared effective
by, the Commission in accordance with the requirements of Rule 430A. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Opinions of Counsel for Company</I>. At the Closing Time, the
Representatives shall have received, each dated the Closing Time, (i)&nbsp;the favorable opinion and negative assurance letter of Kirkland&nbsp;&amp; Ellis LLP (&#147;K&amp;E&#148;), counsel for the Company, in form and substance satisfactory to
counsel for the Underwriters as previously agreed upon by the Representatives and such counsel, together with signed or reproduced copies of such letters for each of the other Underwriters; (ii)&nbsp;the opinion of Walkers (Bermuda)
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Limited, special Bermuda counsel to the Company, in form and substance satisfactory to counsel for the Underwriters as previously agreed upon by the Representatives and such counsel, together
with signed or reproduced copies of such letters for each of the other Underwriters; and (iii)&nbsp;the opinion, dated the Closing Time, of Spectrum IP Law Group LLC, Polsinelli and Christensen O&#146;Connor Johnson Kindness, counsel to the Company
with respect to intellectual property matters, and of the Senior Patent Counsel of the Company, in form and substance satisfactory to counsel for the Underwriters previously agreed upon by the Representatives and such counsel, together with signed
or reproduced copies of such letter for each of the other Underwriters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Opinion of Counsel for Underwriters</I>. At the Closing
Time, the Representatives shall have received the favorable opinion and negative assurance letter, each dated the Closing Time, of Allen Overy Shearman Sterling US LLP (&#147;A&amp;O Shearman&#148;), counsel for the Underwriters, together with
signed or reproduced copies of such letters for each of the other Underwriters in form and substance reasonably satisfactory to the Underwriters. In giving such opinion such counsel may rely, as to all matters governed by the laws of jurisdictions
other than the law of the State of New York, the General Corporation Law of the State of Delaware and the federal securities laws of the United States, upon the opinions of counsel satisfactory to the Representatives. Such counsel may also state
that, insofar as such opinion involves factual matters, they have relied, to the extent they deem proper, upon certificates of officers and other representatives of the Company and its subsidiaries and certificates of public officials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>Officers&#146; Certificate</I>. At the Closing Time, there shall not have been, since the date hereof or since the respective dates as
of which information is given in the Registration Statement, the General Disclosure Package or the Prospectus, any material adverse change in the condition, financial or otherwise, or in the earnings, business affairs or business prospects of the
Company and its subsidiaries considered as one enterprise, whether or not arising in the ordinary course of business, and the Representatives shall have received a certificate of the chief executive officer or the president of the Company and of the
chief financial or chief accounting officer of the Company, dated the Closing Time, to the effect that (i)&nbsp;there has been no such material adverse change, (ii)&nbsp;the representations and warranties of the Company in this Agreement are true
and correct with the same force and effect as though expressly made at and as of the Closing Time, (iii)&nbsp;the Company has complied with all agreements and satisfied all conditions on its part to be performed or satisfied at or prior to the
Closing Time, and (iv)&nbsp;no stop order suspending the effectiveness of the Registration Statement under the 1933 Act has been issued, no order preventing or suspending the use of any preliminary prospectus or the Prospectus has been issued and no
proceedings for any of those purposes have been instituted or are pending or, to their knowledge, contemplated by the Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)
<I>Accountant&#146;s Comfort Letter</I>. At the time of the execution of this Agreement, the Representatives shall have received from PricewaterhouseCoopers LLP (&#147;PwC&#148;) a letter, dated such date, in form and substance reasonably
satisfactory to the Representatives, together with signed or reproduced copies of such letter for each of the other Underwriters containing statements and information of the type ordinarily included in accountants&#146; &#147;comfort letters&#148;
to underwriters with respect to the financial statements and certain financial information contained in the Registration Statement, the General Disclosure Package and the Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <I>Bring-down Comfort Letter</I>. At the Closing Time, the Representatives shall have received from PwC a letter, dated as of the Closing
Time, to the effect that they reaffirm the statements made in the letter furnished pursuant to subsection (e)&nbsp;of this Section, except that the specified date referred to shall be a date not more than two business days prior to the Closing Time.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <I>Approval of Listing</I>. At the Closing Time, the Securities shall have been approved for listing on the Nasdaq Global Market,
subject only to official notice of issuance. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <I>No Objection</I>. FINRA has confirmed that it has not raised any objection with
respect to the fairness and reasonableness of the underwriting terms and arrangements relating to the offering of the Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <I><FONT
STYLE="white-space:nowrap">Lock-up</FONT> Agreements</I>. At the date of this Agreement, the Representatives shall have received an agreement substantially in the form of Exhibit A hereto signed by each of the Company&#146;s directors and officers
and all of the holders of Common Shares of the Company, except for such holders as have been notified in writing to the Representatives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) <I>No Rating. </I>Neither the Company nor its subsidiaries have any debt securities or preferred stock that are rated by any
&#147;nationally recognized statistical rating organization&#148; (as defined in Section&nbsp;3(a)(62) of the 1934 Act). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) <I>Chief
Financial Officer&#146;s Certificate</I>. At the time of the execution of this Agreement and at the Closing Time, the Representatives shall have received from the chief financial officer of the Company a certificate with respect to certain financial
information contained in the Registration Statement, the General Disclosure Package and the Prospectus in form and substance satisfactory to counsel for the Underwriters as previously agreed upon by the Representatives and such counsel. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) <I>Conditions to Purchase of Option Securities</I>. In the event that the Underwriters exercise their option provided in Section&nbsp;2(b)
hereof to purchase all or any portion of the Option Securities, the representations and warranties of the Company contained herein and the statements in any certificates furnished by the Company and any of its subsidiaries hereunder shall be true
and correct as of each Date of Delivery and, at the relevant Date of Delivery, the Representatives shall have received: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <U>Officers&#146; Certificate</U>. A certificate, dated such Date of Delivery, of the chief executive officer or the
president of the Company and of the chief financial or chief accounting officer of the Company confirming that the certificate delivered at the Closing Time pursuant to Section&nbsp;5(d) hereof remains true and correct as of such Date of Delivery.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) <U>Opinions of Counsel for Company</U>. If requested by the Representatives, (i)&nbsp;the opinion and negative
assurance letter of K&amp;E, counsel for the Company (ii)&nbsp;the opinion of Walkers (Bermuda) Limited, special Bermuda counsel to the Company and (iii)&nbsp;the opinion of Spectrum IP Law Group LLC, Polsinelli and Christensen O&#146;Connor Johnson
Kindness, counsel to the Company with respect to intellectual property matters, and of the Senior Patent Counsel of the Company; each in form and substance satisfactory to counsel for the Underwriters, dated such Date of Delivery, relating to the
Option Securities to be purchased on such Date of Delivery and otherwise to the same effect as the opinions and/or negative assurance letter of such firm required by Section&nbsp;5(b) hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) <U>Opinion of Counsel for Underwriters</U>. If requested by the Representatives, the favorable opinion and negative
assurance letter of A&amp;O Shearman, counsel for the Underwriters, dated such Date of Delivery, relating to the Option Securities to be purchased on such Date of Delivery and otherwise to the same effect as the opinion and negative assurance letter
required by Section&nbsp;5(c) hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) <U>Bring-down Comfort Letter</U>. If requested by the Representatives, a letter
from PwC, in form and substance reasonably satisfactory to the Representatives and dated such Date of Delivery, substantially in the same form and substance as the letter furnished to the Representatives pursuant to Section&nbsp;5(e) hereof, except
that the &#147;specified date&#148; in the letter furnished pursuant to this paragraph shall be a date not more than two business days prior to such Date of Delivery. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) <I>Chief Financial Officer&#146;s Certificate</I>. If requested by the
Representatives, the Representatives shall have received from the chief financial officer of the Company a certificate with respect to certain financial information contained in the Registration Statement, the General Disclosure Package and the
Prospectus in form and substance satisfactory to counsel for the Underwriters as previously agreed upon by the Representatives and such counsel. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) <I>Additional Documents</I>. At the Closing Time and at each Date of Delivery (if any) counsel for the Underwriters shall have been
furnished with such documents and opinions as they may reasonably require for the purpose of enabling them to pass upon the issuance and sale of the Securities as herein contemplated, or in order to evidence the accuracy of any of the
representations or warranties, or the fulfillment of any of the conditions, herein contained. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) <I>Termination of Agreement</I>. If any
condition specified in this Section shall not have been fulfilled when and as required to be fulfilled, this Agreement, or, in the case of any condition to the purchase of Option Securities on a Date of Delivery which is after the Closing Time, the
obligations of the several Underwriters to purchase the relevant Option Securities, may be terminated by the Representatives by notice to the Company at any time at or prior to Closing Time or such Date of Delivery, as the case may be, and such
termination shall be without liability of any party to any other party except as provided in Section&nbsp;4 and except that Sections 1, 6, 7, 8, 14, 15, 16 and 17 shall survive any such termination and remain in full force and effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 6. <U>Indemnification</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Indemnification of Underwriters</I>. The Company agrees to indemnify and hold harmless each Underwriter, its affiliates (as such term
is defined in Rule 501(b) under the 1933 Act (each, an &#147;Affiliate&#148;)), its selling agents and each person, if any, who controls any Underwriter within the meaning of Section&nbsp;15 of the 1933 Act or Section&nbsp;20 of the 1934 Act as
follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) against any and all loss, liability, claim, damage and reasonable and documented expense whatsoever, as
incurred, arising out of any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement (or any amendment thereto), including the Rule 430A Information, or the omission or alleged omission therefrom of a
material fact required to be stated therein or necessary to make the statements therein not misleading or arising out of any untrue statement or alleged untrue statement of a material fact included (A)&nbsp;in any preliminary prospectus, any Issuer
Free Writing Prospectus, any Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication, the General Disclosure Package or the Prospectus (or any amendment or supplement thereto), or
(B)&nbsp;in any materials or information provided to investors by, or with the approval of, the Company in connection with the marketing of the offering of the Securities (&#147;Marketing Materials&#148;), including any roadshow or investor
presentations made to investors by the Company (whether in person or electronically), or the omission or alleged omission in any preliminary prospectus, Issuer Free Writing Prospectus, any Written <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication, Prospectus or in any Marketing Materials of a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made,
not misleading; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) against any and all loss, liability, claim, damage and reasonable and documented expense whatsoever,
as incurred, to the extent of the aggregate amount paid in settlement of any litigation, or any investigation or proceeding by any governmental agency or body, commenced or threatened, or of any claim whatsoever based upon any such untrue statement
or omission, or any such alleged untrue statement or omission; provided that (subject to Section&nbsp;6(d) below) any such settlement is effected with the written consent of the Company; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) against any and all reasonable and documented expense whatsoever, as
incurred (including the reasonable and documented fees and disbursements of counsel chosen by the Representatives provided, however, that the Company shall not be liable for more than one separate counsel for all Underwriters (in addition to a
single local counsel per each relevant jurisdiction)), reasonably incurred in investigating, preparing or defending against any litigation, or any investigation or proceeding by any governmental agency or body, commenced or threatened, or any claim
whatsoever based upon any such untrue statement or omission, or any such alleged untrue statement or omission, to the extent that any such expense is not paid under (i)&nbsp;or (ii) above; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">provided, however, that this indemnity agreement shall not apply to any loss, liability, claim, damage or expense to the extent arising out of or based on any
untrue statement or omission or alleged untrue statement or omission made in the Registration Statement (or any amendment thereto), including the Rule 430A Information, the General Disclosure Package or the Prospectus (or any amendment or supplement
thereto) in reliance upon and in conformity with the Underwriter Information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Indemnification of Company, Directors and
Officers</I>. Each Underwriter severally agrees to indemnify and hold harmless the Company, its directors, each of its officers who signed the Registration Statement, and each person, if any, who controls the Company within the meaning of
Section&nbsp;15 of the 1933 Act or Section&nbsp;20 of the 1934 Act, against any and all loss, liability, claim, damage and expense described in the indemnity contained in subsection (a)&nbsp;of this Section, as incurred, but only with respect to
untrue statements or omissions, or alleged untrue statements or omissions, made in the Registration Statement (or any amendment thereto), including the Rule 430A Information, the General Disclosure Package or the Prospectus (or any amendment or
supplement thereto) in reliance upon and in conformity with the Underwriter Information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Actions against Parties;
Notification</I>. Each indemnified party shall give notice as promptly as reasonably practicable to each indemnifying party of any action commenced against it in respect of which indemnity may be sought hereunder, but failure to so notify an
indemnifying party shall not relieve such indemnifying party from any liability hereunder to the extent it is not materially prejudiced as a result thereof and in any event shall not relieve it from any liability which it may have otherwise than on
account of this indemnity agreement. In the case of parties indemnified pursuant to Section&nbsp;6(a) above, counsel to the indemnified parties shall be selected by the Representatives, and, in the case of parties indemnified pursuant to
Section&nbsp;6(b) above, counsel to the indemnified parties shall be selected by the Company. An indemnifying party may participate at its own expense in the defense of any such action; provided, however, that counsel to the indemnifying party shall
not (except with the consent of the indemnified party) also be counsel to the indemnified party. In no event shall the indemnifying parties be liable for fees and expenses of more than one counsel (in addition to any local counsel) separate from
their own counsel for all indemnified parties in connection with any one action or separate but similar or related actions in the same jurisdiction arising out of the same general allegations or circumstances. No indemnifying party shall, without
the prior written consent of the indemnified parties, settle or compromise or consent to the entry of any judgment with respect to any litigation, or any investigation or proceeding by any governmental agency or body, commenced or threatened, or any
claim whatsoever in respect of which indemnification or contribution could be sought under this Section&nbsp;6 or Section&nbsp;7 hereof (whether or not the indemnified parties are actual or potential parties thereto), unless such settlement,
compromise or consent (i)&nbsp;includes an unconditional release of each indemnified party from all liability arising out of such litigation, investigation, proceeding or claim and (ii)&nbsp;does not include a statement as to or an admission of
fault, culpability or a failure to act by or on behalf of any indemnified party. </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>Settlement without Consent if Failure to Reimburse</I>. If at any time an indemnified
party shall have requested an indemnifying party to reimburse the indemnified party for fees and expenses of counsel, such indemnifying party agrees that it shall be liable for any settlement of the nature contemplated by Section&nbsp;6(a)(ii) or
settlement of any claim in connection with any violation referred to in Section&nbsp;6(f) effected without its written consent if (i)&nbsp;such settlement is entered into more than 45 days after receipt by such indemnifying party of the aforesaid
request, (ii)&nbsp;such indemnifying party shall have received notice of the terms of such settlement at least 30 days prior to such settlement being entered into and (iii)&nbsp;such indemnifying party shall not have reimbursed such indemnified
party in accordance with such request prior to the date of such settlement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <I>Indemnification for Reserved Securities</I>. In
connection with the offer and sale of the Reserved Securities, the Company agrees to indemnify and hold harmless the Underwriters, their Affiliates (including Merrill Lynch),and selling agents and each person, if any, who controls any Underwriter or
Merrill Lynch within the meaning of either Section&nbsp;15 of the 1933 Act or Section&nbsp;20 of the 1934 Act, from and against any and all loss, liability, claim, damage and expense (including, without limitation, any legal or other expenses
reasonably incurred in connection with defending, investigating or settling any such action or claim), as incurred, (i)&nbsp;arising out of the violation of any applicable laws or regulations of foreign jurisdictions where Reserved Securities have
been offered, (ii)&nbsp;arising out of any untrue statement or alleged untrue statement of a material fact contained in any material prepared by or with the consent of the Company for distribution to Invitees in connection with the offering of the
Reserved Securities or caused by any omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, (iii)&nbsp;caused by the failure of any Invitee to pay for
and accept delivery of Reserved Securities which have been orally confirmed for purchase by any Invitee by 11:59 P.M. (New York City time) on the date of the Agreement or (iv)&nbsp;related to, or arising out of or in connection with, the offering of
the Reserved Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 7. <U>Contribution</U>. If the indemnification provided for in Section&nbsp;6 hereof is for any reason
unavailable to or insufficient to hold harmless an indemnified party in respect of any losses, liabilities, claims, damages or expenses referred to therein, then each indemnifying party shall contribute to the aggregate amount of such losses,
liabilities, claims, damages and expenses incurred by such indemnified party, as incurred, (i)&nbsp;in such proportion as is appropriate to reflect the relative benefits received by the Company, on the one hand, and the Underwriters, on the other
hand, from the offering of the Securities pursuant to this Agreement or (ii)&nbsp;if the allocation provided by clause (i)&nbsp;is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits
referred to in clause (i)&nbsp;above but also the relative fault of the Company, on the one hand, and of the Underwriters, on the other hand, in connection with the statements or omissions, or in connection with any violation of the nature referred
to in Section&nbsp;6(f) hereof, which resulted in such losses, liabilities, claims, damages or expenses, as well as any other relevant equitable considerations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The relative benefits received by the Company, on the one hand, and the Underwriters, on the other hand, in connection with the offering of
the Securities pursuant to this Agreement shall be deemed to be in the same respective proportions as the total net proceeds from the offering of the Securities pursuant to this Agreement (after deducting underwriting discounts and commissions but
before deducting expenses) received by the Company, on the one hand, and the total underwriting discount received by the Underwriters, on the other hand, in each case as set forth on the cover of the Prospectus, bear to the aggregate initial public
offering price of the Securities as set forth on the cover of the Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The relative fault of the Company, on the one hand, and the
Underwriters, on the other hand, shall be determined by reference to, among other things, whether any such untrue or alleged untrue statement of a material fact or omission or alleged omission to state a material fact relates to information supplied
by the Company or by the Underwriters and the parties&#146; relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission or any violation of the nature referred to in Section&nbsp;6(f) hereof.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company and the Underwriters agree that it would not be just and equitable if
contribution pursuant to this Section&nbsp;7 were determined by pro rata allocation (even if the Underwriters were treated as one entity for such purpose) or by any other method of allocation which does not take account of the equitable
considerations referred to above in this Section&nbsp;7. The aggregate amount of losses, liabilities, claims, damages and expenses incurred by an indemnified party and referred to above in this Section&nbsp;7 shall be deemed to include any legal or
other expenses reasonably incurred by such indemnified party in investigating, preparing or defending against any litigation, or any investigation or proceeding by any governmental agency or body, commenced or threatened, or any claim whatsoever
based upon any such untrue or alleged untrue statement or omission or alleged omission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the provisions of this
Section&nbsp;7, no Underwriter shall be required to contribute any amount in excess of the underwriting commissions received by such Underwriter in connection with the Securities underwritten by it and distributed to the public. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No person guilty of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f) of the 1933 Act) shall be entitled to contribution
from any person who was not guilty of such fraudulent misrepresentation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this Section&nbsp;7, each person, if any, who
controls an Underwriter within the meaning of Section&nbsp;15 of the 1933 Act or Section&nbsp;20 of the 1934 Act and each Underwriter&#146;s Affiliates and selling agents shall have the same rights to contribution as such Underwriter, and each
director of the Company, each officer of the Company who signed the Registration Statement, and each person, if any, who controls the Company within the meaning of Section&nbsp;15 of the 1933 Act or Section&nbsp;20 of the 1934 Act shall have the
same rights to contribution as the Company. The Underwriters&#146; respective obligations to contribute pursuant to this Section&nbsp;7 are several in proportion to the number of Initial Securities set forth opposite their respective names in
Schedule A hereto and not joint. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 8. <U>Representations, Warranties and Agreements to Survive</U>. All representations, warranties
and agreements contained in this Agreement or in certificates of officers of the Company or any of its subsidiaries submitted pursuant hereto, shall remain operative and in full force and effect regardless of (i)&nbsp;any investigation made by or on
behalf of any Underwriter or its Affiliates or selling agents, any person controlling any Underwriter, its officers or directors or any person controlling the Company and (ii)&nbsp;delivery of and payment for the Securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 9. <U>Termination of Agreement</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Termination</I>. The Representatives may terminate this Agreement, by notice to the Company, at any time at or prior to the Closing
Time (i)&nbsp;if there has been, in the judgment of the Representatives, since the time of execution of this Agreement or since the respective dates as of which information is given in the Registration Statement, the General Disclosure Package or
the Prospectus, any material adverse change in the condition, financial or otherwise, or in the earnings, business affairs or business prospects of the Company and its subsidiaries considered as one enterprise, whether or not arising in the ordinary
course of business, or (ii)&nbsp;if there has occurred any material adverse change in the financial markets in the United States or the international financial markets, any outbreak of hostilities or escalation thereof or other calamity or crisis or
any change or development involving a prospective change in national or international political, financial or economic conditions, in each case the effect of which is such as to make it, in the judgment of the Representatives, impracticable or
inadvisable to proceed with the completion of the offering or to enforce contracts for the sale of the Securities, or (iii)&nbsp;if trading in any securities of the Company has been suspended or materially limited by the Commission or the Nasdaq
Global Market, or (iv)&nbsp;if trading generally on the NYSE MKT, New York Stock Exchange or the Nasdaq Global Market has been suspended or materially limited, or minimum or maximum prices for trading have been fixed, or
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
maximum ranges for prices have been required, by any of said exchanges or by order of the Commission, FINRA or any other governmental authority, or (v)&nbsp;a material disruption has occurred in
commercial banking or securities settlement or clearance services in the United States or with respect to Clearstream or Euroclear systems in Europe, or (vi)&nbsp;if a banking moratorium has been declared by either Federal or New York authorities.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Liabilities</I>. If this Agreement is terminated pursuant to this Section, such termination shall be without liability of any
party to any other party except as provided in Section&nbsp;4 hereof, and provided further that Sections 1, 6, 7, 8, 14, 15, 16 and 17 shall survive such termination and remain in full force and effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 10. <U>Default by One or More of the Underwriters</U>. If one or more of the Underwriters shall fail at the Closing Time or a Date of
Delivery to purchase the Securities which it or they are obligated to purchase under this Agreement (the &#147;Defaulted Securities&#148;), the Representatives shall have the right, within 24&nbsp;hours thereafter, to make arrangements for one or
more of the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters, or any other underwriters, to purchase all, but not less than all, of the Defaulted Securities in such amounts as may be agreed upon and upon the terms herein set
forth; if, however, the Representatives shall not have completed such arrangements within such <FONT STYLE="white-space:nowrap">24-hour</FONT> period, then: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) if the number of Defaulted Securities does not exceed 10% of the number of Securities to be purchased on such date, each of
the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters shall be obligated, severally and not jointly, to purchase the full amount thereof in the proportions that their respective underwriting obligations hereunder bear to the
underwriting obligations of all <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters, or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) if the number
of Defaulted Securities exceeds 10% of the number of Securities to be purchased on such date, this Agreement or, with respect to any Date of Delivery which occurs after the Closing Time, the obligation of the Underwriters to purchase, and the
Company to sell, the Option Securities to be purchased and sold on such Date of Delivery shall terminate without liability on the part of any <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No action taken pursuant to this Section&nbsp;10 shall relieve any defaulting Underwriter from liability in respect of its default. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of any such default which does not result in a termination of this Agreement or, in the case of a Date of Delivery which is after
the Closing Time, which does not result in a termination of the obligation of the Underwriters to purchase and the Company to sell the relevant Option Securities, as the case may be, either the (i)&nbsp;Representatives or (ii)&nbsp;the Company shall
have the right to postpone Closing Time or the relevant Date of Delivery, as the case may be, for a period not exceeding seven days in order to effect any required changes in the Registration Statement, the General Disclosure Package or the
Prospectus or in any other documents or arrangements. As used herein, the term &#147;Underwriter&#148; includes any person substituted for an Underwriter under this Section&nbsp;10. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 11. <U>Notices</U>. All notices and other communications hereunder shall be in writing and shall be deemed to have been duly given if
mailed (including by electronic mail) or transmitted by any standard form of telecommunication. Notices to the Underwriters shall be directed to (i)&nbsp;BofA Securities, Inc. at One Bryant Park, New York, New York 10036, attention of Syndicate
Department (email: dg.ecm_execution_services@bofa.com), with a copy to ECM Legal (email: dg.ecm_legal@bofa.com), (ii) Goldman Sachs&nbsp;&amp; Co. LLC at 200 West Street, New York, New York 10282, Attention: Registration Department, Email:
registration-syndops@ny.email.gs.com, and (iii)&nbsp;Piper Sandler&nbsp;&amp; Co. at 800 Nicollet Mall, Minneapolis, MN 55402, Attention: General Counsel, email: LegalCapMarkets@psc.com; with a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
copy to A&amp;O Shearman at 599 Lexington Avenue, New York, New York 10022, attention: Ilir Mujalovic. Notices to the Company shall be directed to it at 3933 Lake Washington Blvd NE #200,
Kirkland, WA 98033, attention of Traci S. Umberger, General Counsel and Chief Administrative Officer, with a copy to K&amp;E at 601 Lexington Avenue, New York, New York 10022, attention: Sophia Hudson, P.C. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 12. <U>No Advisory or Fiduciary Relationship</U>. The Company acknowledges and agrees that (a)&nbsp;the purchase and sale of the
Securities pursuant to this Agreement, including the determination of the initial public offering price of the Securities and any related discounts and commissions, is an <FONT STYLE="white-space:nowrap">arm&#146;s-length</FONT> commercial
transaction between the Company, on the one hand, and the several Underwriters, on the other hand, (b)&nbsp;in connection with the offering of the Securities and the process leading thereto, each Underwriter is and has been acting solely as a
principal and is not the agent or fiduciary of the Company, any of its subsidiaries or their respective shareholders, creditors, employees or any other party, (c)&nbsp;no Underwriter has assumed or will assume an advisory or fiduciary responsibility
in favor of the Company with respect to the offering of the Securities or the process leading thereto (irrespective of whether such Underwriter has advised or is currently advising the Company or any of its subsidiaries on other matters) and no
Underwriter has any obligation to the Company with respect to the offering of the Securities except the obligations expressly set forth in this Agreement, (d)&nbsp;the Underwriters and their respective affiliates may be engaged in a broad range of
transactions that involve interests that differ from those of the Company and (e)&nbsp;the Underwriters have not provided any legal, accounting, regulatory or tax advice with respect to the offering of the Securities and the Company has consulted
its own respective legal, accounting, regulatory and tax advisors to the extent it deemed appropriate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 13. <U>Recognition of the
U.S. Special Resolution Regimes</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) In the event that any Underwriter that is a Covered Entity becomes subject to a proceeding under
a U.S. Special Resolution Regime, the transfer from such Underwriter of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent as the transfer would be effective under the U.S. Special
Resolution Regime if this Agreement, and any such interest and obligation, were governed by the laws of the United States or a state of the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) In the event that any Underwriter that is a Covered Entity or a BHC Act Affiliate of such Underwriter becomes subject to a proceeding
under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Underwriter are permitted to be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special
Resolution Regime if this Agreement were governed by the laws of the United States or a state of the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of this Section&nbsp;13,
a &#147;BHC Act Affiliate&#148; has the meaning assigned to the term &#147;affiliate&#148; in, and shall be interpreted in accordance with, 12 U.S.C. &#167; 1841(k). &#147;Covered Entity&#148; means any of the following: (i)&nbsp;a &#147;covered
entity&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 252.82(b); (ii) a &#147;covered bank&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 47.3(b); or (iii)&nbsp;a
&#147;covered FSI&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 382.2(b). <B>&#147;</B>Default Right&#148; has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R.
&#167;&#167; 252.81, 47.2 or 382.1, as applicable. &#147;U.S. Special Resolution Regime&#148; means each of (i)&nbsp;the Federal Deposit Insurance Act and the regulations promulgated thereunder and (ii)&nbsp;Title II of the Dodd-Frank Wall Street
Reform and Consumer Protection Act and the regulations promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 14. <U>Parties</U>. This Agreement shall each
inure to the benefit of and be binding upon each of the Underwriters and the Company and their respective successors. Nothing expressed or mentioned in this Agreement is intended or shall be construed to give any person, firm or corporation, other
than the Underwriters and the Company and their respective successors and the controlling persons and officers and directors referred to in Sections&nbsp;6 and 7 hereof, as applicable, and their heirs and legal
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
representatives, any legal or equitable right, remedy or claim under or in respect of this Agreement or any provision herein contained. This Agreement and all conditions and provisions hereof are
intended to be for the sole and exclusive benefit of the Underwriters and the Company and their respective successors, and said controlling persons and officers and directors and their heirs and legal representatives, as applicable, and for the
benefit of no other person, firm or corporation. No purchaser of Securities from any Underwriter shall be deemed to be a successor by reason merely of such purchase. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 15. <U>Trial by Jury</U>. The Company (on its behalf and, to the extent permitted by applicable law, on behalf of its shareholders and
affiliates) and each of the Underwriters hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right to trial by jury in any legal proceeding arising out of or relating to this Agreement or the transactions
contemplated hereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 16. <U>GOVERNING LAW</U>. THIS AGREEMENT AND ANY CLAIM, CONTROVERSY OR DISPUTE ARISING UNDER OR RELATED TO
THIS AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF, THE STATE OF NEW YORK WITHOUT REGARD TO ITS CHOICE OF LAW PROVISIONS. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 17. <U>Consent to Jurisdiction; Waiver of Immunity</U>. Any legal suit, action or proceeding arising out of or based upon this
Agreement or the transactions contemplated hereby (&#147;Related Proceedings&#148;) shall&nbsp;be instituted in (i)&nbsp;the federal courts of the United States of America located in the City and County of New York, Borough of Manhattan or&nbsp;(ii)
the courts of the State of New York located in the City and County of New York, Borough of Manhattan (collectively, the &#147;Specified Courts&#148;), and each party irrevocably submits to the exclusive jurisdiction (except for proceedings
instituted in regard to the enforcement of a judgment of any such court (a &#147;Related Judgment&#148;), as to which such jurisdiction is <FONT STYLE="white-space:nowrap">non-exclusive)</FONT> of such courts in any such suit, action or proceeding.
Service of any process, summons, notice or document by mail to such party&#146;s address set forth above shall be effective service of process for any suit, action or other proceeding brought in any such court. The parties irrevocably and
unconditionally waive any objection to the laying of venue of any suit, action or other proceeding in the Specified Courts and irrevocably and unconditionally waive and agree not to plead or claim in any such court that any such suit, action or
other proceeding brought in any such court has been brought in an inconvenient forum. The Company irrevocably appoints Kestra Medical Technologies, Inc. as its agent to receive service of process or other legal summons for purposes of any such suit,
action or proceeding that may be instituted in any state or federal court in the City and County of New York. With respect to any Related Proceeding, each party irrevocably waives, to the fullest extent permitted by applicable law, all immunity
(whether on the basis of sovereignty or otherwise) from jurisdiction, service of process, attachment (both before and after judgment) and execution to which it might otherwise be entitled in the Specified Courts, and with respect to any Related
Judgment, each party waives any such immunity in the Specified Courts or any other court of competent jurisdiction, and will not raise or claim or cause to be pleaded any such immunity at or in respect of any such Related Proceeding or Related
Judgment, including, without limitation, any immunity pursuant to the United States Foreign Sovereign Immunities Act of 1976, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 18. <U>TIME</U>. TIME SHALL BE OF THE ESSENCE OF THIS AGREEMENT. EXCEPT AS OTHERWISE SET FORTH HEREIN, SPECIFIED TIMES OF DAY REFER TO
NEW YORK CITY TIME. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 19. <U>Counterparts and Electronic Signatures</U>. This Agreement may be executed in any number of
counterparts, each of which shall be deemed to be an original, but all such counterparts shall together constitute one and the same Agreement. Electronic signatures complying with the New York Electronic Signatures and Records Act (N.Y. State Tech.
&#167;&#167; <FONT STYLE="white-space:nowrap">301-309),</FONT> as amended from time to time, or other applicable law will be deemed original signatures for purposes of this Agreement. Transmission by telecopy, electronic mail or other transmission
method of an executed counterpart of this Agreement will constitute due and sufficient delivery of such counterpart. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 20. <U>Effect of Headings</U>. The Section headings herein are for convenience only
and shall not affect the construction hereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the foregoing is in accordance with your understanding of our agreement, please sign and
return to the Company a counterpart hereof, whereupon this instrument, along with all counterparts, will become a binding agreement among the Underwriters and the Company in accordance with its terms. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Kestra Medical Technologies, Ltd.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&#8195;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="93%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONFIRMED AND ACCEPTED,</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">as of the date first above written:</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">BOFA SECURITIES, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&#8195;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Authorized Signatory</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">GOLDMAN SACHS&nbsp;&amp; CO. LLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&#8195;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Authorized Signatory</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">PIPER SANDLER&nbsp;&amp; CO.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&#8195;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Authorized Signatory</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For themselves and as Representatives of the other Underwriters named in Schedule A hereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SCHEDULE A </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The initial public offering price per share for the Securities shall be $[&#149;]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The purchase price per share for the Securities to be paid by the several Underwriters shall be $[&#149;], being an amount equal to the initial public
offering price set forth above less $[&#149;] per share, subject to adjustment in accordance with Section&nbsp;2(b) for dividends or distributions declared by the Company and payable on the Initial Securities but not payable on the Option
Securities. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">Name of Underwriter</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Number&nbsp;of<BR>Initial&nbsp;Securities</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BofA Securities, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[&#149;]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goldman Sachs&nbsp;&amp; Co. LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[&#149;]</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Piper Sandler&nbsp;&amp; Co.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[&#149;]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wells Fargo Securities, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[&#149;]</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stifel, Nicolaus&nbsp;&amp; Company, Incorporated</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[&#149;]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nomura Securities International, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[&#149;]</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">WR Securities, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[&#149;]</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[&#149;]</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Sch A-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SCHEDULE <FONT STYLE="white-space:nowrap">B-1</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Pricing Terms </U></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company is selling [&#149;] Common Shares. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company has granted an option to the Underwriters, severally and not jointly, to purchase up to an
additional [&#149;] Common Shares. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The initial public offering price per share for the Securities shall be $[&#149;]. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Sch B-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SCHEDULE <FONT STYLE="white-space:nowrap">B-2</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Free Writing Prospectuses </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[None] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Written <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[&#149;] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Sch B-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EXHIBIT A </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">FORM OF <FONT STYLE="white-space:nowrap">LOCK-UP</FONT> FROM DIRECTORS, OFFICERS AND OTHER STOCKHOLDERS </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">TO BE DELIVERED PURSUANT TO SECTION 5(i) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8195;&#8195;&#8195;&#8195;, 2025 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BofA Securities, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Goldman Sachs&nbsp;&amp; Co. LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Piper Sandler&nbsp;&amp; Co.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">as Representatives of the several </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Underwriters to be named
in the </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">within-mentioned</FONT> Underwriting Agreement </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c/o</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">BofA Securities, Inc. </P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">One Bryant Park </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">New York, New
York 10036 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c/o</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Goldman Sachs&nbsp;&amp; Co. LLC </P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">200 West Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">New York, New
York 10282 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c/o</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Piper Sandler&nbsp;&amp; Co. </P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">1251 Avenue of the Americas </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">New
York, New York 10020 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Re: <U>Proposed Initial Public Offering of Common Shares by Kestra Medical Technologies, Ltd.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Ladies and Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned, a
securityholder and/or an officer and/or a director, as applicable, of Kestra Medical Technologies, Ltd., a Bermuda exempted company (the &#147;Company&#148;), understands that BofA Securities, Inc. (&#147;BofA&#148;), Goldman Sachs&nbsp;&amp; Co.
LLC (&#147;GS&#148;) and Piper Sandler&nbsp;&amp; Co. (together with BofA and GS, the &#147;Representatives&#148;) propose to enter into an Underwriting Agreement (the &#147;Underwriting Agreement&#148;) with the Company providing for the initial
public offering (the &#147;Public Offering&#148;) of the Company&#146;s common shares, par value $1.00 per share (the &#147;Common Shares&#148;). In recognition of the benefit that the Public Offering will confer upon the undersigned as a
securityholder and/or an officer and/or a director, as applicable, of the Company, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the undersigned agrees with each underwriter to be named
in the Underwriting Agreement that, during the period beginning on the date hereof and ending on the date that is 180 days from the date of the Underwriting Agreement (the <FONT STYLE="white-space:nowrap">&#147;Lock-Up</FONT> Period&#148;), the
undersigned will not, without the prior written consent of the Representatives (i)&nbsp;directly or indirectly, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any
option, right or warrant to purchase, lend or otherwise transfer or dispose of any of the Company&#146;s Common Shares or any securities convertible into or exercisable or exchangeable for Common Shares, whether now owned or hereafter acquired by
the undersigned or with respect to which the undersigned has or hereafter acquires the power of disposition (including, without limitation, Common Shares or such other securities which may be deemed to be beneficially owned by the undersigned in
accordance with the rules and regulations of the U.S. Securities and Exchange Commission (the &#147;Commission&#148;) and securities which may be issued upon exercise of a stock option or warrant) (collectively, the
<FONT STYLE="white-space:nowrap">&#147;Lock-Up</FONT> Securities&#148;), or exercise any right with respect to the registration of any of the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities, or file, cause to be filed or cause to be
confidentially submitted any registration statement in connection therewith, under the Securities Act </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of 1933, as amended (the &#147;Securities Act&#148;); <I>provided</I> that, to the extent the undersigned has demand and/or piggyback registration rights under any registration rights agreement,
investor rights agreement or similar agreement described in the final prospectus relating to the Public Offering (the &#147;Final Prospectus&#148;), the undersigned may notify the Company privately that the undersigned is or will be exercising its
demand and/or piggyback registration rights under any such agreement following the expiration of the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period and undertake preparations related thereto; (ii)&nbsp;enter into any hedging, swap, loan or
any other agreement or any transaction (including, without limitation, any short sale or the purchase or sale of, or entry into, any put or call option, or combination thereof, forward or any other derivative transaction or instrument, however
described or defined) that transfers, in whole or in part, directly or indirectly, the economic consequence of ownership of the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities, whether any such hedging, swap, loan or transaction is to be
settled by delivery of Common Shares or other securities, in cash or otherwise; or (iii)&nbsp;publicly disclose the intention to do any of the foregoing described in clauses (i)&nbsp;and (ii) above. If the undersigned is an officer or director of
the Company (whether as of the date hereof or at the time of receiving any of the Common Shares), the undersigned further agrees that the foregoing provisions shall be equally applicable to any Company-directed Common Shares the undersigned may
purchase in the Public Offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the undersigned is an officer or director of the Company (whether as of the date hereof or at the
time of receiving any Common Shares), (1) the Representatives agree that, at least three business days before the effective date of any release or waiver of the foregoing restrictions in connection with a transfer of the Common Shares, the
Representatives will notify the Company of the impending release or waiver, and (2)&nbsp;the Company has agreed, or will agree, in the Underwriting Agreement to announce the impending release or waiver by press release through a major news service
at least two business days before the effective date of the release or waiver. Any release or waiver granted by the Representatives hereunder to any such officer or director shall only be effective two business days after the publication date of
such press release. The provisions of this paragraph will not apply if (i)&nbsp;the release or waiver is effected solely to permit a transfer not for consideration and (ii)&nbsp;the transferee has agreed in writing to be bound by the same terms
described in this <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement to the extent and for the duration that such terms remain in effect at the time of the transfer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, and subject to the conditions below, the undersigned may transfer the
<FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities without the prior written consent of the Representatives as described below, provided that (1)&nbsp;in the case of transfers pursuant to clauses (i), (ii), (iii), (iv), (v), (vi), (vii),
(viii) and (x), the Representatives receive a signed <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement in the form of this <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement for the balance of the
<FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period from each donee, devisee, trustee, distributee, or transferee, as the case may be, (2)&nbsp;in the case of any transfers pursuant to clauses (i), (ii), (iii), (iv), (v), (vi), (vii), (viii) and
(xiii), any such transfer shall not involve a disposition for value, (3)&nbsp;such transfers are not required to be reported during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period with the Commission on Form 4 or Form 5 in accordance with
Section&nbsp;16(a) of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), or in the case of transfers pursuant to clauses (i), (ii), (iii), (iv), (vii), (viii), (ix), (x), (xi), (xii) and (xiii)&nbsp;below, any filing
required to be made under Section&nbsp;16 of the Exchange Act shall clearly indicate in the footnotes thereto that the filing relates to circumstances described in such a clause, and (4)&nbsp;the undersigned does not otherwise voluntarily effect any
public filing or report regarding such transfers during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">as a <I>bona fide</I> gift or gifts, including, without limitation, to a charitable organization or educational
institution, or for <I>bona fide </I>estate planning purposes; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by will, testamentary document or intestate succession to the legal representative, heir, beneficiary or a
member of the immediate family of the undersigned (for purposes of this <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement, &#147;immediate family&#148; of the undersigned shall mean any relationship by blood, marriage, domestic partnership
or adoption, not more remote than first cousin of the undersigned); </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by operation of law, such as pursuant to a qualified domestic order, divorce settlement, divorce decree or
separation agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">pursuant to an order of a court or regulatory agency having jurisdiction over the undersigned;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to any trust, corporation, partnership, limited liability company or other entity that directly, or indirectly
through one or more intermediaries, controls or is controlled by, or is under common control with, the undersigned and/or the immediate family of the undersigned, or is wholly-owned by the undersigned and/or by members of the immediate family of the
undersigned; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to any immediate family member or any trust, partnership, limited liability company or other entity for the
direct or indirect benefit of the undersigned or one or more immediate family members of the undersigned, or if the undersigned is a trust, to a trustor or beneficiary of the trust or to the estate of a beneficiary or similar person of such trust;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(vii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to a nominee or custodian of a person or entity to whom a disposition or transfer would be permissible under
clauses (i)&nbsp;through (vi) above; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(viii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the undersigned is a corporation, partnership, limited liability company, trust or other business entity,
(A)&nbsp;to another corporation, partnership, limited liability company, trust or other business entity that is an affiliate (as defined in Rule 405 promulgated under the Securities Act) of the undersigned, or to any investment fund or other entity
controlling, controlled by, managing or managed by or under common control or common management with or who shares a common investment advisor with the undersigned or affiliates of the undersigned (including, for the avoidance of doubt, where the
undersigned is a partnership, to its general partner or a successor partnership or fund, or any other funds managed by such partnership), or (B)&nbsp;as part of a distribution to current or former partners, members, stockholders or other
equityholders of the undersigned or holders of similar equity interests in the undersigned and any direct or indirect partner, member, stockholder or other equityholder of such transferee until the Common Shares come to be held by a natural person;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ix)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to the Company upon the undersigned&#146;s death, disability or termination of employment or other service
relationship with the Company; <I>provided that</I> such Common Shares were issued to the undersigned pursuant to an agreement or equity award granted pursuant to an employee benefit plan, option, warrant or other right disclosed in the Final
Prospectus; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(x)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in any transactions described under the heading &#147;Organizational Transactions&#148; in the Final
Prospectus; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(xi)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in connection with (i)&nbsp;transfers to the Company pursuant to the exercise, on a &#147;cashless&#148; or
&#147;net exercise&#148; basis, of any option to purchase Common Shares granted by the Company pursuant to equity incentive plans described in the Final Prospectus, or for the purpose of satisfying any withholding taxes (including estimated taxes)
due as a result of the exercise of any option to purchase Common Shares or the vesting or settlement of any awards granted by the Company pursuant to equity incentive plans described in the Final
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Prospectus, or (ii)&nbsp;the exercise of options or other rights to purchase Common Shares whether by means of &#147;net settlement&#148; or otherwise in connection with equity incentive plans
described in the Final Prospectus; provided that any such Common Shares will be subject to the terms of this agreement; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(xii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in connection with any pledge, charge, hypothecation or other granting of a security interest in <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Securities held by entities affiliated with Bain Capital, L.P. (collectively, the &#147;Bain Funds&#148;) (the &#147;Pledged Securities&#148;) to one or more banks, financial or other lending institutions
(&#147;Lenders&#148;) as collateral or security for or in connection with any margin loan or other loans, advances or extensions of credit entered into by the undersigned or any of its direct or indirect subsidiaries and any transfers of such
Pledged Securities by Bain Funds to the applicable Lender(s) or other third parties upon or following foreclosure upon or enforcement of such Pledged Securities in accordance with the terms of the documentation governing any margin loan or other
loan, advance, or extension of credit (including, without limitation, pursuant to any agreement or arrangement existing as of the date hereof); <I>provided </I>that with respect to any pledge, charge, hypothecation or other granting of a security
interest set forth above after the execution of this agreement, the applicable Lender(s) shall be informed of the existence and contents of this agreement before entering into any margin loan or other loans, advances or extensions of credit; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(xiii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">as a bona fide gift or gifts, including, without limitation, to a charitable organization or educational
institution, by Bain Funds, either directly or indirectly (including through any related distributions or dividends to the direct or indirect equity holders of the Bain Funds or to managing directors of Bain Capital Investors, LLC, in each case as
necessary to facilitate any such bona fide gifts). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding anything herein to the contrary, nothing herein
shall prevent or restrict: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) transfers by the undersigned of the <FONT STYLE="white-space:nowrap">Lock-Up</FONT>
Securities pursuant to a bona fide third-party tender offer, merger, consolidation or other similar transaction, in one transaction or a series of related transactions, made to all holders of Common Shares of the Company that has been approved by
the board of directors of the Company, the result of which is that any &#147;person&#148; (as defined in Section&nbsp;13(d)(3) of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;)), or group of persons, shall become,
after the closing of the transaction, the beneficial owner (as defined in Rules <FONT STYLE="white-space:nowrap">13d-3</FONT> and <FONT STYLE="white-space:nowrap">13d-5</FONT> of the Exchange Act) of more than 50% of the total voting power of the
voting securities of the Company (or the surviving entity); provided that in the event that such tender offer, merger, consolidation or other such transaction is not completed, the undersigned&#146;s Common Shares shall remain subject to the
provisions of this agreement during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) establishing or
facilitating the establishment of a trading plan on behalf of a shareholder, officer or director of the Company pursuant to Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act for the transfer of Common Shares; <I>provided</I>
that (i)&nbsp;such plan does not provide for the transfer of Common Shares during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period and (ii)&nbsp;to the extent a public announcement or filing under the Exchange Act, if any, is required and
made by or on behalf of the undersigned or the Company regarding the establishment of such plan, such announcement or filing shall include a statement to the effect that no transfer of Common Shares may be made under such plan during the <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Period and the undersigned does not otherwise voluntarily effect any other public filings or report regarding such sales or transfers during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, the undersigned may sell Common Shares of the Company purchased by the
undersigned in the Public Offering or on the open market following the Public Offering if and only if (i)&nbsp;such sales are not required to be reported during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period in any public report or
filing with the Securities and Exchange Commission or otherwise (other than a filing on a Form 4 or Form 5 or a Schedule 13D (or 13D/A) or Schedule 13G (or 13G/A) or Form 13F (or 13F/A) that is required to be filed during the <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Period), (ii) any required filing on a Form 4 or Form 5 or Schedule 13D (or 13D/A) or Schedule 13G (or 13G/A) or Form 13F (or 13F/A) shall clearly indicate in the footnotes thereto that the filing relates to
the circumstances described in this clause and (iii)&nbsp;the undersigned does not otherwise voluntarily effect any public filing or report regarding such sales. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">[If any record or beneficial owner of any <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities of the Company is granted an early
release from the restrictions described herein during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period with respect to an aggregate amount of any <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities of the Company having a fair
market value in excess of $2,000,000 in the aggregate (whether in one or multiple releases), then each Major Holder (as defined below) shall also be granted an early release from its obligations hereunder on a pro rata basis with all other record or
beneficial holders of similarly restricted <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities of the Company based on the maximum percentage of shares held by any such record or beneficial holder being released from such holder&#146;s <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreement (a <FONT STYLE="white-space:nowrap">&#147;Pro-Rata</FONT> Release&#148;); provided, however, that in the case of an early release from the restrictions described herein during the <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Period in connection with an underwritten public offering, whether or not such offering or sale is wholly or partially a secondary offering of the Company&#146;s Common Shares (an &#147;Underwritten
Sale&#148;), the Major Holder is offered the opportunity to participate in such Underwritten Sale and such early release shall only apply to the extent of such Major Holder&#146;s participation in such Underwritten Sale. For the avoidance of doubt,
there shall be no <FONT STYLE="white-space:nowrap">Pro-Rata</FONT> Release if the Major Holder was offered and declined the opportunity to participate in the Underwritten Sale. Notwithstanding any other provisions of this <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreement, if the Representatives in their sole judgment determine that a record or beneficial owner of any securities should be granted an early release from a
<FONT STYLE="white-space:nowrap">lock-up</FONT> agreement due to circumstances of an emergency or hardship, then no Major Holder shall have any right to be granted an early release pursuant to the terms of this paragraph. For purposes of this <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreement, each of the following persons is a &#147;Major Holder&#148;: each record or beneficial owner, as of the date hereof, of more than 1% of the outstanding shares of Common Shares of the Company (for
purposes of determining record or beneficial ownership of a stockholder, all shares of Common Shares held by investment funds affiliated with such stockholder shall be aggregated. In the event that, as a result of this paragraph, the undersigned is
released from any of its obligations under this letter agreement or, by virtue of this agreement, becomes entitled to offer, pledge, sell, contract to sell, or otherwise transfer or dispose of any Common Shares of the Company or any security
convertible into or exercisable or exchangeable for Common Shares of the Company during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period, the Representatives shall use commercially reasonable efforts to notify the Company within one
(1)&nbsp;business day of the effective date of such release, provided that in the absence of bad faith the failure to give such notice shall not give rise to any claim or liability against the underwriters, and the Company, in turn, in consultation
with the Representatives, shall notify the undersigned, to the extent that such release gives rise to a corresponding release of the undersigned from its obligations hereunder pursuant to the terms of this paragraph, within two (2)&nbsp;business
days thereafter.]<SUP STYLE="font-size:75%; vertical-align:top">1</SUP> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned acknowledges and agrees that the underwriters
have neither provided any recommendation or investment advice nor solicited any action from the undersigned with respect to the Public Offering of the Common Shares and the undersigned has consulted their own legal, accounting, financial, regulatory
and tax advisors to the extent deemed appropriate. The undersigned further acknowledges and agrees that, although the underwriters may be required or choose to provide certain Regulation Best Interest and Form CRS disclosures to you in connection
with the Public Offering, the underwriters are not making a recommendation to you to enter into this <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement and nothing set forth in such disclosures is intended to suggest that any underwriter is
making such a recommendation. </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">NTD: MFN clause to be included only in <FONT STYLE="white-space:nowrap">lock-ups</FONT> of Major Holders.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned hereby represents and warrants that the undersigned has full power, capacity
and authority to enter into this <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement. The undersigned understands that the Company and the underwriters are relying upon the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement in
proceeding toward the consummation of the Public Offering. The undersigned further understands that this <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement is irrevocable and shall be binding upon the undersigned&#146;s heirs, legal
representatives, successors and assigns. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned also agrees and consents to the entry of stop transfer instructions with the
Company&#146;s transfer agent and registrar against the transfer of the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities except in compliance with the foregoing restrictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that a Representative withdraws or is terminated from, or declines to participate in, the Public Offering, all references in this
<FONT STYLE="white-space:nowrap">lock-up</FONT> agreement to the Representatives shall refer to the remaining Representatives. If all Representatives withdraw, are terminated from or decline to participate in the Public Offering, all references in
this <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement to the Representatives shall refer to the lead left book runner in the Public Offering (&#147;Replacement Entity&#148;), and in such event, any written consent, waiver or notice given or
delivered in connection with this <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement by or to such Replacement Entity shall be deemed to be sufficient and effective for all purposes under this <FONT STYLE="white-space:nowrap">lock-up</FONT>
agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding anything to the contrary contained herein, this <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement will
automatically terminate and be of no further effect, and the undersigned will be released from all of their or its obligations hereunder upon the earliest to occur, if any, of the following: (i)&nbsp;prior to the execution of the Underwriting
Agreement, the Company advises the Representatives in writing that it has determined not to proceed with the Public Offering, (ii)&nbsp;the Company files an application with the Commission to withdraw the registration statement relating to the
Public Offering, (iii)&nbsp;the Underwriting Agreement is executed but is terminated (other than with respect to the provisions thereof which survive termination) prior to payment for and delivery of the Common Shares to be sold thereunder or
(iv)&nbsp;May&nbsp;31, 2025 in the event that the Public Offering shall not have occurred on or before such date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreement shall be governed by and construed in accordance with the laws of the State of New York. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement may be executed in any number of counterparts, each of which shall be deemed to
be an original, but all such counterparts shall together constitute one and the same <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement. Electronic signatures complying with the New York Electronic Signatures and Records Act (N.Y. State Tech.
&#167;&#167; <FONT STYLE="white-space:nowrap">301-309),</FONT> as amended from time to time, or other applicable law will be deemed original signatures for purposes of this <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement. Transmission by
telecopy, electronic mail or other transmission method of an executed counterpart of this <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement will constitute due and sufficient delivery of such counterpart. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature page follows</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">[NAME OF STOCKHOLDER / OFFICER/ DIRECTOR]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&#8195;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">If not signing in an individual capacity:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name of Authorized Signatory (Print)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title of Authorized Signatory (Print)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><I>(Indicate capacity of person signing if signing as custodian, trustee, or on behalf of an entity.)</I></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to <FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreement] </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EXHIBIT B </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">FORM OF PRESS RELEASE </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">TO BE
ISSUED PURSUANT TO SECTION 3(j) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kestra Medical Technologies, Ltd. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[Date] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kestra Medical Technologies, Ltd. (the
&#147;Company&#148;) announced today that BofA Securities, Inc. and Goldman Sachs&nbsp;&amp; Co. LLC, the lead book-running managers in the Company&#146;s recent public sale of [&#149;] common shares, are [waiving] [releasing] a <FONT
STYLE="white-space:nowrap">lock-up</FONT> restriction with respect to [&#149;] of the Company&#146;s common shares held by [certain officers or directors] [an officer or director] of the Company. The [waiver] [release] will take effect on [&#149;],
20[&#149;], and the common shares may be sold on or after such date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>This press release is not an offer for sale of the securities in the United
States or in any other jurisdiction where such offer is prohibited, and such securities may not be offered or sold in the United States absent registration or an exemption from registration under the United States Securities Act of 1933, as amended.
</B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-1 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.3
<SEQUENCE>3
<FILENAME>d744414dex33.htm
<DESCRIPTION>EX-3.3
<TEXT>
<HTML><HEAD>
<TITLE>EX-3.3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 3.3 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED AND RESTATED <FONT STYLE="white-space:nowrap">BYE-LAWS</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>of </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Kestra Medical
Technologies, Ltd. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B>We HEREBY CERTIFY that the attached Amended and Restated <FONT STYLE="white-space:nowrap">Bye-Laws</FONT> are a true copy
of the Amended and Restated <FONT STYLE="white-space:nowrap">Bye-laws</FONT> of Kestra Medical Technologies, Ltd. (the &#147;Company&#148;) as adopted by a resolution of the shareholder passed on [<B>&#149;</B><B>]</B> 2025. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For and on behalf of</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Maples Corporate Services (Bermuda) Limited</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Secretary</P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B><FONT STYLE="white-space:nowrap">BYE-</FONT> LAW</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>PAGE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">POWER TO ISSUE SHARES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">POWER OF THE COMPANY TO PURCHASE ITS SHARES</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RIGHTS ATTACHING TO SHARES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">LIEN</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CALL ON SHARES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FORFEITURE OF SHARES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">UNCERTIFICATED SHARES</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">FRACTIONAL SHARES</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">REGISTER OF SHAREHOLDERS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">REGISTERED HOLDER ABSOLUTE OWNER</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">TRANSFER OF REGISTERED SHARES</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">TRANSMISSION OF REGISTERED SHARES</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">POWER TO ALTER CAPITAL</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">VARIATION OF RIGHTS ATTACHING TO SHARES</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">DIVIDENDS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">POWER TO SET ASIDE PROFITS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">METHOD OF PAYMENT</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">CAPITALISATION</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">ANNUAL GENERAL MEETINGS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">SPECIAL GENERAL MEETINGS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">REQUISITIONED GENERAL MEETINGS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">NOTICE</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">GIVING NOTICE AND ACCESS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">POSTPONEMENT OF GENERAL MEETING</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="97%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">ELECTRONIC PARTICIPATION IN MEETINGS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">QUORUM AT GENERAL MEETINGS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">CHAIR TO PRESIDE AT GENERAL MEETINGS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">VOTING ON RESOLUTIONS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">VOTING BY JOINT HOLDERS OF SHARES</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">INSTRUMENT OF PROXY</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">REPRESENTATION OF CORPORATE SHAREHOLDER</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">ADJOURNMENT OF GENERAL MEETING</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">WRITTEN RESOLUTIONS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">DIRECTORS&#146; ATTENDANCE AT GENERAL MEETINGS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">ELECTION OF DIRECTORS AND NOTICE OF SHAREHOLDER BUSINESS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">NUMBER OF DIRECTORS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">TERM OF OFFICE OF DIRECTORS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">REMOVAL OF DIRECTORS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">VACANCY IN THE OFFICE OF DIRECTOR</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">DIRECTORS TO MANAGE BUSINESS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">POWERS OF THE BOARD OF DIRECTORS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">REGISTER OF DIRECTORS AND OFFICERS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">APPOINTMENT OF OFFICERS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">APPOINTMENT OF SECRETARY AND RESIDENT REPRESENTATIVE</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">DUTIES OF OFFICERS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">DUTIES OF THE SECRETARY</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">REMUNERATION OF OFFICERS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">REMUNERATION OF DIRECTORS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">CONFLICTS OF INTEREST</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">CORPORATE OPPORTUNITY</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="97%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">INDEMNIFICATION AND EXCULPATION OF DIRECTORS AND OFFICERS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">BOARD MEETINGS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">NOTICE OF BOARD MEETINGS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">ELECTRONIC PARTICIPATION IN MEETINGS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">QUORUM AT BOARD MEETINGS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">BOARD TO CONTINUE IN THE EVENT OF VACANCY</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">CHAIR TO PRESIDE</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">WRITTEN RESOLUTIONS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">VALIDITY OF PRIOR ACTS OF THE BOARD</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">MINUTES</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">PLACE WHERE CORPORATE RECORDS KEPT</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">FORM AND USE OF SEAL</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">BOOKS OF ACCOUNT</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">FINANCIAL YEAR END</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">ANNUAL AUDIT</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">APPOINTMENT OF AUDITOR</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">REMUNERATION OF AUDITOR</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">DUTIES OF AUDITOR</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">CHANGE TO THE COMPANY&#146;S AUDITORS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">ACCESS TO RECORDS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">FINANCIAL STATEMENTS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">DISTRIBUTION OF AUDITOR&#146;S REPORT</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">VACANCY IN THE OFFICE OF AUDITOR</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">WINDING-UP</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">CHANGES TO <FONT STYLE="white-space:nowrap">BYE-LAWS</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">CHANGES TO THE MEMORANDUM OF ASSOCIATION</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="97%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">EXCLUSIVE JURISDICTION</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">MERGER AND AMALGAMATION</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">DISCONTINUANCE</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">BUSINESS COMBINATIONS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DEFINITIONS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In these Amended and Restated <FONT STYLE="white-space:nowrap">Bye-laws,</FONT> the following words and
expressions shall, where not inconsistent with the context, have the following meanings, respectively: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Affiliate(s)</B>&#148; and &#147;<B>Associate(s)</B>&#148; shall have the meanings attributed to such terms in Rule <FONT
STYLE="white-space:nowrap">12b-2</FONT> under the Exchange Act and the rules and regulations promulgated thereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Appointed
Stock Exchange</B>&#148; means an appointed stock exchange as defined under the Companies Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Auditor</B>&#148; means the
auditor of the Company appointed by the Company to examine and report upon its accounts in accordance with the Companies Act, U.S. securities laws and accounting standards. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Bermuda</B>&#148; means the Islands of Bermuda. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Board</B>&#148; means the board of directors appointed or elected pursuant to these <FONT STYLE="white-space:nowrap">Bye-laws.</FONT>
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Business Day</B>&#148; means each Monday, Tuesday, Wednesday, Thursday and Friday that is not a day on which banking institutions
in New York, NY or Bermuda are authorized or obligated by law or executive order to close. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><FONT STYLE="white-space:nowrap">Bye-laws</FONT></B>&#148; means these amended and restated
<FONT STYLE="white-space:nowrap">bye-laws</FONT> adopted by the Company with effect on the completion of the Listing, as from time to time amended. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>chair</B>&#148; means the Chair of the Board appointed in accordance with <FONT STYLE="white-space:nowrap">Bye-law</FONT> 128<B>.</B>
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>close of business</B>&#148; means 5:00 p.m. Eastern Standard Time, and if an applicable deadline falls on the close of business
on a day that is not a Business Day, then the applicable deadline shall be deemed to be the close of business on the immediately preceding Business Day. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Companies Act</B>&#148; means the Companies Act 1981 as amended from time to time. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company</B>&#148; means the company incorporated in Bermuda under the name of Kestra Medical Technologies, Ltd. on 20&nbsp;May 2021
for which these <FONT STYLE="white-space:nowrap">Bye-laws</FONT> are approved and confirmed. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Corporate Status</B>&#148; means the
status of a person who is or was a Director or Officer, of the Company or, while a Director or Officer of the Company, is or was serving at the request of the Company as a director, officer, partner, trustee, member, manager, employee, agent or
fiduciary of any other Enterprise. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Derivative Instrument</B>&#148; means any short position, profits interest, option, warrant,
convertible security, share appreciation right, or similar right with an exercise or conversion privilege or a settlement payment or mechanism at a price related to any class or series of shares of the Company or with a value derived in whole or in
part from the value of any class or series of shares of the Company, or any derivative or synthetic arrangement having the characteristics of a long position in any class or series of shares of the Company, or any contract, derivative, swap or other
transaction or series of transactions designed to produce economic benefits and risks that correspond substantially to the ownership of any class or series of shares of the Company, including due to the fact that the value of such contract,
derivative, swap or other transaction or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
series of transactions is determined by reference to the price, value or volatility of any class or series of shares of the Company, whether or not such instrument, contract or right shall be
subject to settlement in the underlying class or series of shares of the Company, through the delivery of cash or other property, or otherwise, and without regard to whether the Holder and any Shareholder Associated Person of such Holder may have
entered into transactions that hedge or mitigate the economic effect of such instrument, contract or right, or any other direct or indirect opportunity to profit or share in any profit derived from any increase or decrease in the value of shares of
the Company; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Director</B>&#148; means a director of the Company for the time being. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Enterprise</B>&#148; means the Company and any corporation, partnership, joint venture, trust, limited liability company, employee
benefit plan or other enterprise that the Indemnitee is or was serving at the request of the Company as a director, officer, trustee, partner, member, manager, employee, agent or fiduciary. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>ERISA</B>&#148; means the Employee Retirement Income Security Act of 1974, as amended from time to time. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Expenses</B>&#148; means all reasonable direct and indirect costs, fees and expenses of any type or nature whatsoever and shall
specifically include, without limitation, all reasonable attorneys&#146; fees, retainers, court costs, transcript costs, fees and costs of experts and other professionals, witness fees, travel expenses, duplicating costs, printing and binding costs,
telephone charges, postage, delivery service fees, and all other disbursements or expenses of the types customarily incurred in connection with prosecuting, defending, preparing to prosecute or defend, investigating, participating, or being or
preparing to be a witness in, or otherwise participating in, a Proceeding, or responding to, or objecting to, a request to provide discovery in any Proceeding. Expenses also shall include Expenses incurred in connection with any appeal resulting
from any Proceeding, including without limitation the premium, security for, and other costs relating to any cost bond, supersedeas bond, or other appeal bond or its equivalent, and any federal, state, local or foreign taxes imposed on a person as a
result of the actual or deemed receipt of any payments under <FONT STYLE="white-space:nowrap">Bye-law</FONT> 147, as well as all reasonable attorneys&#146; fees and all other expenses incurred by or on behalf of the Indemnitee in connection with
preparing and submitting any requests or statements for indemnification, advancement, contribution or any other right provided by <FONT STYLE="white-space:nowrap">Bye-law</FONT> 147. Expenses, however, shall not include amounts paid in settlement by
the Indemnitee or the amount of judgments or fines against the Indemnitee. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Exchange Act</B>&#148; means the U.S. Securities
Exchange Act of 1934, as amended. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Fullest Extent Permitted By Applicable Law</B>&#148; includes, but is not limited to:
(i)&nbsp;to the fullest extent permitted by the applicable provision of the Companies Act, or the corresponding provision of any amendment to or replacement of the Companies Act, and (ii)&nbsp;in the case of
<FONT STYLE="white-space:nowrap">Bye-laws</FONT> 146 to 151, to the fullest extent authorized or permitted by any amendments to or replacements of the Companies Act adopted hereafter that increase the extent to which a company may indemnify its
directors and officers. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Holder(s)</B>&#148; has the meaning given to such term in <FONT STYLE="white-space:nowrap">Bye-law</FONT>
111(1)(c). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Indemnitee</B>&#148; means a person entitled to be indemnified by the Company pursuant to <FONT
STYLE="white-space:nowrap">Bye-law</FONT> 147. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Indemnification Agreement</B>&#148; means any agreement between the Company and an
Indemnitee providing Indemnitee with rights to indemnification and advancement of expenses incurred in defending any Proceeding brought against the Indemnitee by virtue of Indemnitee&#146;s Corporate Status, whether now existing or hereafter entered
into. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Identified Person</B>&#148; has the meaning given to such term in <FONT STYLE="white-space:nowrap">Bye-law</FONT> 140. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Interested Director</B>&#148; has the meaning given to such term in <FONT STYLE="white-space:nowrap">Bye-law</FONT> 136. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Listing</B>&#148; means the listing of the Company&#146;s common shares on an Appointed Stock Exchange. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Losses</B>&#148; means all liabilities, judgments, fines, penalties, costs, losses, excise taxes or penalties under ERISA, amounts
paid in settlement (including all interest assessments and other charges paid or payable in connection with or in respect of such liabilities, losses, judgements, fines, excise taxes, penalties and costs) and other amounts that the Indemnitee
reasonably incurs and that result from, arise in connection with or are by reason of the Indemnitee&#146;s Corporate Status. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Noticing Shareholder</B>&#148; has the meaning given to such term in <FONT STYLE="white-space:nowrap">Bye-law</FONT> 111(1). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Officer</B>&#148; means any person appointed by the Board to hold an office in the Company pursuant to section 91(4) of the Companies
Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Person</B>&#148; shall be construed broadly and shall include, without limitation, an individual, a partnership, a
corporation, a limited liability partnership, an investment fund, a limited liability company, a company, an association, a joint stock company, a trust, a joint venture, an unincorporated organization and a governmental entity or any department,
agency or political subdivision thereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Principal Shareholder</B>&#148; means, collectively, Bain Charger Holdings, L.P. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Proceeding</B>&#148; includes any threatened, pending or completed action, suit, claim, counterclaim, cross claim, arbitration,
mediation, alternate dispute resolution mechanism, investigation, inquiry, administrative hearing or any other actual, threatened or completed proceeding, whether brought by or in the right of the Company or otherwise and whether civil, criminal,
administrative or investigative, in which the Indemnitee was, is or will be involved as a party, potential party, <FONT STYLE="white-space:nowrap">non-party</FONT> witness or otherwise, by reason of the Indemnitee&#146;s Corporate Status or by
reason of any action taken by the Indemnitee or of any inaction on the Indemnitee&#146;s part while acting in the Indemnitee&#146;s Corporate Status, in each case whether or not the Indemnitee is acting or serving in any such capacity at the time
any liability or expense is incurred for which indemnification can be provided under these <FONT STYLE="white-space:nowrap">Bye-laws,</FONT> but excluding one initiated by an Indemnitee to enforce the Indemnitee&#146;s rights under <FONT
STYLE="white-space:nowrap">Bye-law</FONT> 147. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>public announcement</B>&#148; means disclosure (a)&nbsp;in a press release
released by the Company, provided such press release is released by the Company following its customary procedures, is reported by the Dow Jones News Service, Associated Press or comparable national news service, or is generally available on
internet news sites, or (b)&nbsp;in a document publicly filed by the Company with the Securities and Exchange Commission pursuant to Section&nbsp;13, 14 or 15(d) of the Exchange Act and the rules and regulations promulgated thereunder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Register of Directors and Officers</B>&#148; means the register of directors and officers of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Register of Shareholders</B>&#148; means the register of Shareholders of the
Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Registered Office</B>&#148; shall be at such place in Bermuda as the Board shall from time to time appoint. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Resident Representative</B>&#148; means any person appointed to act as resident representative and includes any deputy or assistant
resident representative. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Resolution</B>&#148; means a resolution passed by a simple majority of votes cast by Shareholders who
are entitled to vote at such general meeting or by written resolution, each in accordance with the provisions of these <FONT STYLE="white-space:nowrap">Bye-laws.</FONT> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Secretary</B>&#148; means the person appointed to perform any or all of the duties of secretary of the Company and includes any deputy
or assistant secretary and any person appointed by the Board to perform any of the duties of the Secretary. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Securities
Act</B>&#148; means the U.S. Securities Act of 1933, as amended. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Shareholder</B>&#148; means the person registered in the
Register of Shareholders as the holder of shares in the Company and, when two or more persons are so registered as joint holders of shares, means the person whose name stands first in the Register of Shareholders as one of such joint holders or all
of such persons, as the context so requires. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Shareholder Associated Person</B>&#148; shall mean as to any Holder (as defined in <FONT
STYLE="white-space:nowrap">Bye-law</FONT> 111): (1) any participant (as defined in paragraphs (a)(ii)-(vi) of Instruction 3 to Item 4 of Schedule 14A under the Exchange Act, or any successor instructions) with any such Holder in a solicitation of
proxies in respect of any business or director nomination proposed by such Holder, (2)&nbsp;any person acting in concert with such Holder, (3)&nbsp;any person controlling, controlled by or under common control with such Holder or any of their
respective Affiliates and Associates, or person acting in concert therewith, (4)&nbsp;any member of the immediate family of such Holder or an Affiliate or Associate of such Holder, and (5)&nbsp;any person who is a member of a &#147;group&#148; (as
such term is used in Rule <FONT STYLE="white-space:nowrap">13d-5</FONT> under the Exchange Act (or any successor provision)) with such Holder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>shares</B>&#148; means a share in the capital of the Company of any class. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Short Interest</B>&#148; means any agreement, arrangement, understanding relationship or otherwise, including any repurchase or
similar <FONT STYLE="white-space:nowrap">so-called</FONT> &#147;share borrowing&#148; agreement or arrangement, involving any Holder or any Shareholder Associated Person, the purpose or effect of which is to mitigate loss to, reduce the economic
risk (of ownership or otherwise) or any shares of the Company by, manage the risk of share price changes for, or increase or decrease the voting power of, such Holder or any Shareholder Associated Person with respect to any shares or other
securities of the Company, or which provides, directly or indirectly, the opportunity to profit or share in any profit derived from any decrease in the price or value of any shares or other securities of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Specified Information</B>&#148; has the meaning given to such term in <FONT STYLE="white-space:nowrap">Bye-law</FONT> 111(c)(ii). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Special Resolution</B>&#148; means a resolution passed by Shareholders holding at least 66 2/3% of the issued shares who are entitled
to vote at such general meeting or by written resolution, each in accordance with the provisions of these <FONT STYLE="white-space:nowrap">Bye-laws.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Treasury Share</B>&#148; means a share of the Company that was or is treated as
having been acquired and held by the Company and has been held continuously by the Company since it was so acquired and has not been cancelled. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">[&#147;<B>Trigger Event</B>&#148; means the date on which the Principal Shareholder and its Affiliates collectively cease to beneficially own
(as defined in Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> under the Exchange Act (or any successor provision) of at least 50% of the issued common shares of the Company.]<SUP STYLE="font-size:75%; vertical-align:top">1</SUP> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Voting Commitment</B>&#148; has the meaning given to such term in <FONT STYLE="white-space:nowrap">Bye-law</FONT> 111(7). </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In these <FONT STYLE="white-space:nowrap">Bye-laws,</FONT> where not inconsistent with the context:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">words denoting the plural number include the singular number and vice versa; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">words denoting the masculine gender include the feminine and neuter genders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a reference to statutory provision shall be deemed to include any amendment or
<FONT STYLE="white-space:nowrap">re-enactment</FONT> thereof; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the word &#147;may&#148; shall be construed as permissive and the word &#147;shall&#148; shall be construed as
imperative; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">unless otherwise provided herein, words or expressions defined in the Companies Act shall bear the same meaning
in these <FONT STYLE="white-space:nowrap">Bye-laws.</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In these <FONT STYLE="white-space:nowrap">Bye-laws</FONT> expressions referring to writing or its cognates
shall, unless the contrary intention appears, include facsimile, printing, lithography, photography, electronic mail and other modes of representing words in visible form. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Headings used in these <FONT STYLE="white-space:nowrap">Bye-laws</FONT> are for convenience only and are not to
be used or relied upon in the construction hereof. </P></TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>POWER TO ISSUE SHARES </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to these <FONT STYLE="white-space:nowrap">Bye-laws,</FONT> the Board shall have the power to issue any
unissued shares on such terms and conditions as it may determine and any shares or class of shares may be issued with such preferred, deferred or other special rights or such restrictions, whether in regard to dividend, voting, return of capital, or
otherwise as the Board may determine. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Board is expressly authorised (and the Board is hereby authorised to exercise such power from time to time
without a Resolution) to issue, pursuant to a resolution of the Board, all or any preference shares in one or more series, to fix the number of shares constituting such series and to increase or decrease the number of shares of any such series (but
not below the number of shares thereof then issued) and to fix for each such series such voting powers and such distinctive designations, powers, preferences and relative, participating, optional or other special rights and such qualifications,
limitations or restrictions thereof, as shall be stated and expressed in the resolution or resolutions adopted by the Board providing for the issuance of such series (and, for the avoidance of doubt, such matters and the issuance of such preference
shares shall not be deemed to vary the rights attached to the common shares or, subject to the terms of any other series of preference shares, to vary the rights attached to any other series of preference shares) including, without limitation, the
authority to provide that any such series may be (a)&nbsp;subject to redemption at such time or times (including at a determinable date or at the option of the Company or the holder) and at such price or prices; (b)&nbsp;entitled to receive
dividends (which may be cumulative or <FONT STYLE="white-space:nowrap">non-cumulative)</FONT> at such rates, on such conditions, and at such times, and payable in preference to, or in such relation to, the dividends payable on any other class or
classes or any other series; (c)&nbsp;entitled to such rights upon the dissolution of, or upon any distribution of the assets of, the </P></TD></TR></TABLE>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[NTD: Bracketed language to be deleted in final bye-laws if the Principal Stockholder and its Affiliates
collectively beneficially own less than 50% of the issued common shares of the Company at the IPO closing.] </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Company; or (d)&nbsp;convertible into, or exchangeable for, shares of any other class or classes of shares, or of any other series of the same or any other class or classes of shares, of the
Company at such price or prices or at such rates of exchange and with such adjustments, all as may be stated in such resolution or resolutions of the Board. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to the Companies Act and the terms of any preference shares established by the Board, any preference
shares may be convertible into, or exchangeable for shares that (at a determinable date or at the option of the Company or the holder) are liable to be redeemed on such terms and in such manner as may be determined by the Board without a Resolution.
</P></TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>POWER OF THE COMPANY TO PURCHASE ITS SHARES </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company may purchase its own shares for cancellation or acquire them as Treasury Shares in accordance with
the Companies Act on such terms as the Board shall think fit. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Board may exercise all the powers of the Company to purchase or acquire all or any part of its own shares
in accordance with the Companies Act. </P></TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RIGHTS ATTACHING TO SHARES </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">10.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to any Resolution to the contrary (and without prejudice to any special rights conferred thereby on the
holders of any other shares or class of shares) and to the authority of the Board to issue preference shares pursuant to <FONT STYLE="white-space:nowrap">Bye-law</FONT> 6, the share capital shall be divided into shares of a single class the holders
of which shall, subject to these <FONT STYLE="white-space:nowrap">Bye-laws:</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">be entitled to one vote per share; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">be entitled to such dividends as the Board may from time to time declare; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the event of a <FONT STYLE="white-space:nowrap">winding-up</FONT> or dissolution of the Company, whether
voluntary or involuntary or for the purpose of a reorganisation or otherwise or upon any distribution of capital, be entitled to the surplus assets of the Company; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">generally be entitled to enjoy all of the rights attaching to shares. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All the rights attaching to a Treasury Share shall be suspended and shall not be exercised by the Company while
it holds such Treasury Share and, except where required by the Companies Act, all Treasury Shares shall be excluded from the calculation of any percentage or fraction of the share capital, or shares, of the Company. </P></TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LIEN </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">12.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company shall have a first and paramount lien on every share (not being a fully paid share) for all moneys
called or payable to the Company (whether presently or not) in respect of that share. The Company&#146;s lien on a share shall extend to any amount (including without limitation dividends) payable in respect of it. The Board may at any time
(generally or in a particular case) waive any lien or declare any share to be wholly or in part exempt from the provisions of this <FONT STYLE="white-space:nowrap">Bye-law</FONT> 12. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">13.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company may sell, in such manner as the Board may think fit, any share on which the Company has a lien if a
sum in respect of which the lien exists is presently payable and is not paid within 14 days after notice in writing has been sent to the holder of the share, or to the person entitled to it by transmission, demanding payment and stating that if the
notice is not complied with the share may be sold. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">14.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To give effect to that sale the Board may, if the share is a certificated share, authorise any person to
execute an instrument of transfer in respect of the share sold to, or in accordance with the directions of, the buyer. If the share is an uncertificated share, the Board may exercise any of the Company&#146;s powers under <FONT
STYLE="white-space:nowrap">Bye-law</FONT> 34 to effect the sale of the share to, or in accordance with the directions of, the buyer. The buyer shall not be bound to see to the application of the purchase money and his or her title to the share shall
not be affected by any irregularity in or invalidity of the proceedings in relation to the sale. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">15.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The net proceeds of the sale by the Company of any shares on which it has a lien, after payment of the costs,
shall be applied in or towards payment or satisfaction of so much of the sum in respect of which the lien exists as is presently payable. Any residue shall (if the share sold is a certificated share, on surrender to the Company for cancellation of
the certificate in respect of the share sold and, whether the share sold is a certificated or uncertificated share, subject to a like lien for any moneys not presently payable as existed on the share before the sale) be paid to the person entitled
to the share at the date of the sale. </P></TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CALL ON SHARES </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">16.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Board may make such calls as it thinks fit upon the Shareholders in respect of any moneys (whether in
respect of nominal value or premium) unpaid on the shares allotted to or held by such Shareholders and, if a call is not paid on or before the day appointed for payment thereof, the Shareholder may at the discretion of the Board be liable to pay the
Company interest on the amount of such call at such rate as the Board may determine, from the date when such call was payable up to the Company&#146;s actual date of payment. The Board may differentiate between the holders as to the amount of calls
to be paid and the times of payment of such calls. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">17.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The joint holders of a share shall be jointly and severally liable to pay all calls and any interest, costs and
expenses in respect thereof. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">18.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company may accept from any Shareholder the whole or a part of the amount remaining unpaid on any shares
held by such Shareholder, although no part of that amount has been called up. </P></TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORFEITURE OF SHARES </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">19.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If a Shareholder fails to pay any call or instalment of a call on the day appointed for payment thereof, the
Board may at any time thereafter during such time as any part of such call or instalment remains unpaid serve a notice on such Shareholder, requiring payment of so much of the call or instalment as is unpaid, together with any interest which may
have accrued. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">20.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The notice shall name a further day (not being less than 14 days from the date of the notice) on or before
which, and the place where, the payment required by the notice is to be made and shall state that, in the event of <FONT STYLE="white-space:nowrap">non-payment</FONT> on or before the day and at the place appointed, the shares in respect of which
such call is made or instalment is payable will be liable to be forfeited. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">21.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the requirements of any such notice as aforesaid are not complied with, any share in respect of which such
notice has been given may at any time thereafter, before payment of all calls or instalments and interest due in respect thereof has been made, be forfeited by a resolution of the Board to that effect. Such forfeiture shall include all dividends or
other moneys payable declared in respect of the forfeited shares and not actually paid before the forfeiture. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">22.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">When any share has been forfeited, notice of the forfeiture shall be served upon the person who was the holder
of the share before the forfeiture. Where the forfeited share is held in certificated form, an entry shall be made promptly in the register opposite the entry of the share showing that notice has been sent, that the share has been forfeited and the
date of forfeiture. No forfeiture shall be in any manner invalidated by any omission or neglect to give such notice. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">23.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A forfeited share shall be deemed to be the property of the Company and may be sold, <FONT
STYLE="white-space:nowrap">re-offered</FONT> or otherwise disposed of either to the person who was the holder of the share before the forfeiture or to any other person upon such terms and in such manner as the Board shall think fit. At any time
before a sale, <FONT STYLE="white-space:nowrap">re-allotment</FONT> or disposal, the forfeiture may be cancelled on such terms as the Board may think fit. Where for the purposes of its disposal a forfeited share held in certificated form is to be
transferred to any person, the Board may authorise any person to execute an instrument of transfer of the share to that person. Where for the purposes of its disposal a forfeited share held in uncertificated form is to be transferred to any person,
the Board may exercise any of the Company&#146;s powers under <FONT STYLE="white-space:nowrap">Bye-law</FONT> 34. The Company may receive the consideration given for the share on its sale, <FONT STYLE="white-space:nowrap">re-offer</FONT> or disposal
and may register the transferee as holder of the share. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">24.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A person shall cease to be a Shareholder in respect of any share which has been forfeited and shall, if the
share is a certificated share, surrender the certificate for any forfeited share to the Company for cancellation. Notwithstanding the forfeiture, the person shall remain liable to the Company for all moneys which at the date of forfeiture were
presently payable by such person to the Company in respect of that share with interest on that amount at the rate at which interest was payable on those moneys before the forfeiture or, if no interest was so payable, at the rate determined by the
Board from the date of forfeiture until payment. The Board may waive payment wholly or in part or enforce payment without any allowance for the value of the share at the time of forfeiture or for any consideration received on its disposal.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">25.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Board may accept the surrender of any share liable to be forfeited hereunder on such terms and conditions
as may be agreed and, in such case, subject to those terms and conditions, references in these <FONT STYLE="white-space:nowrap">Bye-laws</FONT> to forfeiture shall include surrender. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">26.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The forfeiture of a share shall involve the extinction at the time of forfeiture of all interest in and all
claims and demands against the Company in respect of the share and all other rights and liabilities incidental to the share as between the person whose share is forfeited and the Company, except only those rights and liabilities expressly saved by
these <FONT STYLE="white-space:nowrap">Bye-laws,</FONT> or as are given or imposed in the case of past Shareholders by the Companies Act. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">27.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">An affidavit in writing that the deponent is a Director or the Secretary and that a share has been duly
forfeited on the date stated in the affidavit shall be conclusive evidence of the facts therein stated as against all persons claiming to be entitled to the share. The declaration shall (subject if necessary to the execution of an instrument of
transfer or transfer by means of the relevant system, as the case may be) constitute a good title to the share. The person to whom the share is disposed of shall not be bound to see to the application of the purchase money, if any, and such
person&#146;s title to the share shall not be affected by any irregularity in, or invalidity of, the proceedings in reference to the forfeiture, surrender, sale, <FONT STYLE="white-space:nowrap">re-allotment</FONT> or disposal of the share.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SHARE CERTIFICATES </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">28.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Every Shareholder of certificated shares shall be entitled to a certificate under the common seal of the
Company or bearing the signature (or a facsimile thereof) of a Director or the Secretary or a person expressly authorised to sign specifying the number and, where appropriate, the class of shares held by such Shareholder and whether the same are
fully paid up and, if not, specifying the amount paid on such shares. The Board may by resolution determine, either generally or in a particular case, that any or all signatures on certificates may be printed thereon or affixed by mechanical means.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">29.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company shall be under no obligation to complete and deliver a share certificate unless specifically called
upon to do so by the person to whom the certificated shares have been allotted. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">30.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The holder of any certificated shares of the Company shall immediately notify the Company of any loss,
destruction or mutilation of the certificate therefor, and the Board may, in its discretion, cause to be issued to such holder a new certificate or certificates for such shares, upon the surrender of the mutilated certificates or, in the case of
loss or destruction of the certificate, upon satisfactory proof of such loss or destruction, and the Board may, in its discretion, require the owner of the lost or destroyed certificate or their legal representative to give the Company a bond in
such sum and with such surety or sureties as it may direct to indemnify the Company against any claim that may be made against it on account of the alleged loss or destruction of any such certificate. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">31.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For such time as any shares of the Company are traded on an Appointed Stock Exchange, nothing in these <FONT
STYLE="white-space:nowrap">Bye-laws</FONT> shall prevent title to any shares of the Company from being evidenced and/or transferred without a written instrument in accordance with the rules or regulations applicable to shares listed on any such
Appointed Stock Exchange, and the Board shall have power to implement any arrangements which it may think fit for such evidencing and/or transfer. </P></TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNCERTIFICATED SHARES </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">32.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to the provisions of the Companies Act, the Board may permit the holding of shares in any class of
shares in uncertificated form and the transfer of title of shares in that class by means of the relevant system used by an Appointed Stock Exchange or any other relevant system and may determine that any class of shares shall cease to be a
participating security of any relevant system. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">33.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Shares in the capital of the Company that fall within a certain class shall not form a separate class of shares
from other shares in that class because any share in that class is held in uncertificated form. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">34.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Where any class of shares is uncertificated and the Company is entitled under any provision of the Companies
Act or these <FONT STYLE="white-space:nowrap">Bye-laws</FONT> to sell, transfer or otherwise dispose of, forfeit, <FONT STYLE="white-space:nowrap">re-allot,</FONT> accept the surrender of, or otherwise enforce a lien over, a share held in
uncertificated form, the Company shall be entitled, subject to the provisions of the Companies Act or these <FONT STYLE="white-space:nowrap">Bye-laws</FONT> and the facilities and requirements of the relevant system: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to require the holder of that uncertificated share by notice to change that share into certificated form within
the period specified in the notice and to hold that share in certificated form so long as required by the Company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to require the holder of that uncertificated share by notice to give any instructions necessary to transfer
title to that share by means of the relevant system within the period specified in the notice; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to require the holder of that uncertificated share by notice to appoint any person to take any step, including,
without limitation, the giving of any instructions by means of the relevant system, necessary to transfer the share within the period specified in the notice; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to take any action that the Board considers appropriate to achieve the sale, transfer, disposal, forfeiture, <FONT
STYLE="white-space:nowrap">re-allotment</FONT> or surrender of that share, or otherwise to enforce a lien in respect of that share. </P></TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FRACTIONAL SHARES </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">35.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company may issue its shares in fractional denominations and deal with such fractions to the same extent as
its whole shares and shares in fractional denominations shall have in proportion to the respective fractions represented thereby all of the rights of whole shares including (but without limiting the generality of the foregoing) the right to vote, to
receive dividends and distributions and to participate in a <FONT STYLE="white-space:nowrap">winding-up.</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REGISTER OF SHAREHOLDERS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">36.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Board shall cause to be kept in one or more books a Register of Shareholders and shall enter therein the
particulars required by the Companies Act. Subject to the provisions of the Companies Act, the Company may keep one or more overseas or branch registers in any place, and the Board may make, amend and revoke any such regulations as it may think fit
regarding the keeping of such registers. The Board may authorise any share on the Register of Shareholders to be included in a branch register or any share registered on a branch register to be registered on another branch register; provided that at
all times the Register of Shareholders is maintained in accordance with the Companies Act. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">37.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Register of Shareholders shall be open to inspection, by Shareholders and other persons entitled to inspect
it under applicable law, without charge at the Registered Office of the Company on every Business Day, subject to such reasonable restrictions as the Board may impose, so that not less than two hours in each Business Day be allowed for inspection.
The Register of Shareholders may, after notice has been given in accordance with the Companies Act, be closed for any time or times not exceeding in the whole 30 days in each year. </P></TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REGISTERED HOLDER ABSOLUTE OWNER </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">38.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company shall be entitled to treat the registered holder of any share as the absolute owner thereof and
accordingly shall not be bound to recognise any equitable claim or other claim to, or interest in, such share on the part of any other person. </P></TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TRANSFER OF REGISTERED SHARES </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">39.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">An instrument of transfer of a certificated share shall be in writing in such form as the Board may accept.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">40.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Such instrument of transfer shall be signed by or on behalf of the transferor and transferee; provided that, in
the case of a fully paid share, the Board may accept the instrument signed by or on behalf of the transferor alone. The transferor shall be deemed to remain the holder of such share until the same has been registered as having been transferred to
the transferee in the Register of Shareholders. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">41.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Board may refuse to recognise any instrument of transfer on the basis that such share is not fully paid.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">42.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Board may refuse to recognise any instrument of transfer of a certificated share unless it is accompanied
by the certificate in respect of the shares to which it relates and by such other evidence as the Board may reasonably require to show the right of the transferor to make the transfer. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">43.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the case of a transfer of a certificated share, the certificate in respect of the shares to which it relates
will only be necessary if and to the extent that a certificate has been issued in respect of the share in question. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">44.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The joint holders of any share may transfer such share to one or more of such joint holders, and the surviving
holder or holders of any share previously held by them jointly with a deceased Shareholder may transfer any such share to the executors or administrators of such deceased Shareholder. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">45.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Board shall refuse to register a transfer unless all applicable consents, authorisations and permissions of
any governmental body or agency in Bermuda have been obtained. If the Board refuses to register a transfer of any share the Secretary shall, within three months after the date on which the transfer was lodged with the Company, send to the transferor
and transferee notice of the refusal. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">46.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Shares may be transferred without a written instrument if transferred by an appointed agent or otherwise in
accordance with the Companies Act. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">47.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding anything to the contrary in these <FONT STYLE="white-space:nowrap">Bye-laws,</FONT> shares that
are listed or admitted to trading on an Appointed Stock Exchange may be transferred in accordance with the rules and regulations of such exchange. </P></TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TRANSMISSION OF REGISTERED SHARES </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">48.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the case of the death of a Shareholder, the survivor or survivors where the deceased Shareholder was a joint
holder, and the legal personal representatives of the deceased Shareholder where the deceased Shareholder was a sole holder, shall be the only persons recognised by the Company as having any title to the deceased Shareholder&#146;s interest in the
shares. Nothing herein contained shall release the estate of a deceased joint holder from any liability in respect of any share which had been jointly held by such deceased Shareholder with other persons. Subject to the Companies Act, for the
purpose of this <FONT STYLE="white-space:nowrap">Bye-law,</FONT> legal personal representative means the executor or administrator of a deceased Shareholder or such other person as the Board may, in its absolute discretion, decide as being properly
authorised to deal with the shares of a deceased Shareholder. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">49.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any person becoming entitled to a share in consequence of the death or bankruptcy of any Shareholder may be
registered as a Shareholder upon such evidence as the Board may deem sufficient or may elect to nominate some person to be registered as a transferee of such share, and in such case the person becoming entitled shall (a)&nbsp;if the share is a
certificated share, execute in favour of such nominee an instrument of transfer in writing in such form as the Board may accept, or (b)&nbsp;if the share is an uncertificated share, take any action the Board may require (including without limitation
the execution of any document and the giving of any instruction by means of a relevant system of an Appointed Stock Exchange). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">50.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">On the presentation of the foregoing materials to the Board, accompanied by such evidence as the Board may
require to prove the title of the transferor, the transferee shall be registered as a Shareholder. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">51.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Where two or more persons are registered as joint holders of a share or shares, then in the event of the death
of any joint holder or holders the remaining joint holder or holders shall be absolutely entitled to such share or shares and the Company shall recognise no claim in respect of the estate of any joint holder except in the case of the last survivor
of such joint holders. </P></TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>POWER TO ALTER CAPITAL </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">52.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company may, if authorised by resolution of the Board, divide, consolidate and subdivide its share capital
in any manner permitted by the Companies Act. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">53.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company may, if authorised by Resolution, increase, reduce, change the currency denomination of, cancel,
diminish or otherwise alter its share capital in any manner permitted by the Companies Act. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">54.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Where, on any alteration or reduction of share capital, fractions of shares or some other difficulty would
arise, the Board may deal with or resolve the same in such manner as it thinks fit. </P></TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VARIATION OF RIGHTS ATTACHING TO
SHARES </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">55.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If, at any time, the share capital is divided into different classes of shares, the rights attached to any
class (unless otherwise provided by the terms of issue of the shares of that class) may, whether or not the Company is being <FONT STYLE="white-space:nowrap">wound-up,</FONT> be varied with the consent in writing of the holders of three-fourths of
the issued shares of that class or with the sanction of a resolution passed by a majority of the votes cast at a separate general meeting of the holders of the shares of the class at which meeting the necessary quorum (where the Company has more
than one shareholder) shall be two persons at least holding or representing by proxy <FONT STYLE="white-space:nowrap">one-third</FONT> of the issued shares of the class. The rights conferred upon the holders of the shares of any class issued with
preferred or other rights shall not, unless otherwise expressly provided by the terms of issue of the shares of that class, be deemed to be varied by the creation or issue of further shares ranking <I>pari passu</I> therewith. </P></TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DIVIDENDS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">56.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Board may, subject to these <FONT STYLE="white-space:nowrap">Bye-laws</FONT> and the preferred dividend
rights of the holders of any preference shares and in accordance with the Companies Act, declare a dividend to be paid to the Shareholders, in proportion to the number of shares held by them, and such dividend may be paid in cash or wholly or partly
in specie in which case the Board may fix the value for distribution in specie of any assets. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">57.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Board may fix any date as the record date for determining the Shareholders entitled to receive any
dividend. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">58.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company may pay dividends in proportion to the amount paid up on each share where a larger amount is paid
up on some shares than on others. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">59.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Board may declare and make such other distributions (in cash or in specie) to the Shareholders as may be
lawfully made out of the assets of the Company. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>POWER TO SET ASIDE PROFITS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">60.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Board may, before declaring a dividend, set aside out of the surplus or profits of the Company, such amount
as it thinks proper as a reserve to be used to meet contingencies or for equalising dividends or for any other purpose. </P></TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>METHOD OF PAYMENT </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">61.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any dividend, interest or other moneys payable in cash in respect of the shares may be paid by cheque or draft
sent through the post directed to the Shareholder at such Shareholder&#146;s address in the Register of Shareholders, or to such person and to such address as the Shareholder may in writing direct. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">62.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the case of joint holders of shares, any dividend, interest or other moneys payable in cash in respect of
shares may be paid by cheque or draft sent through the post directed to the address of the holder first named in the Register of Shareholders, or to such person and to such address as the joint holders may in writing direct. If two or more persons
are registered as joint holders of any shares any one can give an effectual receipt for any dividend paid in respect of such shares. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">63.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Board may deduct from the dividends or distributions payable to any Shareholder all moneys due from such
Shareholder to the Company on account of calls or otherwise. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">64.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any dividend and or other monies payable in respect of a share which has remained unclaimed for 6 years from
the date when it became due for payment shall, if the Board so resolves, be forfeited and cease to remain owing by the Company. The payment of any unclaimed dividend or other moneys payable in respect of a share may (but need not) be paid by the
Company into an account separate from the Company&#146;s own account. Such payment shall not constitute the Company a trustee in respect thereof. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">65.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company shall be entitled to cease sending dividend cheques and warrants by post or otherwise to a
Shareholder if those instruments have been returned undelivered to, or left uncashed by, that Shareholder on at least two consecutive occasions, or, following one such occasion, reasonable enquiries have failed to establish the Shareholder&#146;s
new address. The entitlement conferred on the Company by this <FONT STYLE="white-space:nowrap">Bye-law</FONT> in respect of any Shareholder shall cease if the Shareholder claims a dividend or cashes a dividend cheque or warrant.
</P></TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CAPITALISATION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">66.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Board may capitalise any amount for the time being standing to the credit of any of the Company&#146;s
share premium or other reserve accounts or to the credit of the profit and loss account or otherwise available for distribution by applying such amount in paying up unissued shares to be allotted as fully paid bonus shares pro rata to the
Shareholders. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">67.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Board may capitalise any amount for the time being standing to the credit of a reserve account or amounts
otherwise available for dividend or distribution by applying such amounts in paying up in full, partly or nil paid shares of those Shareholders who would have been entitled to such amounts if they were distributed by way of dividend or distribution.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANNUAL GENERAL MEETINGS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">68.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to any rights to waive the annual general meeting pursuant to the Companies Act, the annual general
meeting of Shareholders for the election of directors and for the transaction of such other business as may properly come before the meeting in accordance with these <FONT STYLE="white-space:nowrap">Bye-laws</FONT> shall be held in each calendar
year (other than the year of incorporation) at such place, date and hour as shall be fixed by the Board. The Board may postpone, reschedule or cancel any previously scheduled annual general meeting. </P></TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPECIAL GENERAL MEETINGS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">69.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Board may convene a special general meeting of Shareholders for any purpose or purposes whenever in their
judgment such a meeting is necessary to be held at such place, date and hour as fixed by the Board. The Board may postpone, reschedule or cancel any previously scheduled special general meeting. </P></TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REQUISITIONED GENERAL MEETINGS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">70.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Board shall, on the requisition of Shareholders holding at the date of the deposit of the requisition not
less than <FONT STYLE="white-space:nowrap">one-tenth</FONT> of such of the <FONT STYLE="white-space:nowrap">paid-up</FONT> share capital of the Company as at the date of the deposit carries the right to vote at general meetings, proceed duly to
convene a special general meeting and the provisions of the Companies Act shall apply. </P></TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTICE </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">71.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notice of an annual general meeting shall be given to each Shareholder entitled to attend and vote thereat at
least 10 days but no more than 60 days prior to the date of such meeting. The notice shall state the date, time and place at which the meeting is to be held, that the election of Directors will take place thereat, and the general nature of the other
business to be conducted at the meeting. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">72.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notice of a special general meeting shall be given to each Shareholder entitled to attend and vote thereat at
least 10 days but no more than 60 days prior to the date of such meeting. The notice shall state the date, time, place at which the meeting is to be held and the general nature of the business to be considered at the meeting. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">73.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Board may fix any date as the record date for determining the Shareholders entitled to receive notice of
and to vote at any general meeting. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">74.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A general meeting shall, notwithstanding that it is called on shorter notice than that specified in these <FONT
STYLE="white-space:nowrap">Bye-laws,</FONT> be deemed to have been properly called if it is so agreed by (i)&nbsp;all the Shareholders entitled to attend and vote thereat in the case of an annual general meeting; and (ii)&nbsp;by a majority in
number of the Shareholders having the right to attend and vote at the meeting, being a majority together holding not less than 95% in nominal value of the shares giving a right to attend and vote thereat in the case of a special general meeting.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">75.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The accidental omission to give notice of a general meeting to, or the
<FONT STYLE="white-space:nowrap">non-receipt</FONT> of a notice of a general meeting by, any person entitled to receive notice shall not invalidate the proceedings at that meeting. </P></TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GIVING NOTICE AND ACCESS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">76.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A notice may be given by the Company to a Shareholder: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by delivering it to such Shareholder in person; or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by sending it by letter mail or courier to such Shareholder&#146;s address in the Register of Shareholders; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by transmitting it by electronic means (including facsimile and electronic mail, but not telephone) in
accordance with such directions as may be given by such Shareholder to the Company for such purpose; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in accordance with <FONT STYLE="white-space:nowrap">Bye-law</FONT> 79. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">77.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any notice required to be given to a Shareholder shall, with respect to any shares held jointly by two or more
persons, be given to whichever of such persons is named first in the Register of Shareholders and notice so given shall be sufficient notice to all the holders of such shares. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">78.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any notice (save for one delivered in accordance with <FONT STYLE="white-space:nowrap">Bye-law</FONT> 79) shall
be deemed to have been served at the time when the same would be delivered in the ordinary course of transmission and, in proving such service, it shall be sufficient to prove that the notice was properly addressed and prepaid, if posted, and the
time when it was posted, delivered to the courier or transmitted by electronic means. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">79.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Where a Shareholder indicates their consent (in a form and manner satisfactory to the Board), to receive
information or documents by accessing them on a website rather than by other means, or receipt in this manner is otherwise permitted by the Companies Act, the Board may deliver such information or documents by providing the Shareholder the address
of the website where such information or documents are available and instructions as to how such information or documents may be accessed on the website. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">80.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the case of information or documents delivered in accordance with
<FONT STYLE="white-space:nowrap">Bye-law</FONT> 79, service shall be deemed to have occurred on the later of the date when (i)&nbsp;the Shareholder is notified in accordance with that <FONT STYLE="white-space:nowrap">Bye-law;</FONT> and
(ii)&nbsp;the information or document is published on the website. </P></TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>POSTPONEMENT OF GENERAL MEETING </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">81.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The chair may postpone any general meeting called in accordance with these
<FONT STYLE="white-space:nowrap">Bye-laws</FONT> (other than a meeting requisitioned under these <FONT STYLE="white-space:nowrap">Bye-laws)</FONT> provided that notice of postponement is given to the Shareholders before the time for such meeting.
Fresh notice of the date, time and place for the postponed meeting shall be given to each Shareholder in accordance with these <FONT STYLE="white-space:nowrap">Bye-laws.</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ELECTRONIC PARTICIPATION IN MEETINGS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">82.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In relation to any general meeting, the Board may at its discretion, and subject to any restrictions it may
impose, permit the participation by Shareholders in such general meeting by telephonic, electronic or other communication facilities or means that permit all persons participating in the meeting to communicate with each other simultaneously and
instantaneously and participation in such a meeting shall constitute presence in person at such meeting. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">83.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Board, and at any general meeting, the chair of such meeting, may make any arrangement and impose any
requirement or restriction it considers appropriate to ensure the safety and security of a general meeting including, without limitation, requirements for evidence of identity to be produced by those attending the meeting, the searching of their
personal property and the restriction of items that may be taken into the meeting place. The Board and, at any general meeting, the chair of such meeting, are entitled to refuse entry to a person who refuses to comply with any such arrangements,
requirements or restrictions. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>QUORUM AT GENERAL MEETINGS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">84.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">At any general meeting two or more persons present in person and representing in person or by proxy in excess
of 50% of the total issued shares in the Company that are entitled to vote throughout the meeting shall form a quorum for the transaction of business; provided that if the Company shall at any time have only one Shareholder, one Shareholder present
in person or by proxy shall form a quorum for the transaction of business at any general meeting held during such time. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">85.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If at the time appointed for the meeting a quorum is not present, then, in the case of a meeting convened on a
requisition, the meeting shall be deemed cancelled and, in any other case, the meeting shall stand adjourned to the same day one week later, at the same time and place or to such other day, time or place as any Officer may determine. Unless the
meeting is adjourned to a specific date, time and place announced at the meeting being adjourned, fresh notice of the resumption of the meeting shall be given to each Shareholder entitled to attend and vote thereat in accordance with these <FONT
STYLE="white-space:nowrap">Bye-laws.</FONT> </P></TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CHAIR TO PRESIDE AT GENERAL MEETINGS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">86.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Unless otherwise agreed by Shareholders holding at least a majority of the shares entitled to vote and present
in person or by proxy at the applicable general meeting, the chair, if there be one, and if not the president, if there be one, shall act as chair at all general meetings at which such person is present. In their absence, a chair shall be appointed
or elected by the Board or, if not appointed or elected by the Board, the chair shall be appointed by any Officer of the Company. </P></TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VOTING ON RESOLUTIONS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">87.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to the Companies Act and these <FONT STYLE="white-space:nowrap">Bye-laws,</FONT> any question proposed
for the consideration of the Shareholders at any general meeting shall be decided by the affirmative votes of a majority of the votes cast at such general meeting in accordance with these <FONT STYLE="white-space:nowrap">Bye-laws</FONT> and in the
case of an equality of votes the resolution shall fail. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">88.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No Shareholder shall be entitled to vote at a general meeting unless such Shareholder has paid all the calls on
all shares held by such Shareholder. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">89.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">At any general meeting a resolution put to the vote of the meeting shall be voted on by way of a poll. Subject
to any rights or restrictions for the time being lawfully attached to any class of shares, and subject to these <FONT STYLE="white-space:nowrap">Bye-laws,</FONT> every person present at such meeting shall have one vote for each share of which such
person is the holder or for which such person holds a valid proxy. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">90.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">At any general meeting if an amendment is proposed to any resolution under consideration and the chair of the
meeting rules on whether or not the proposed amendment is out of order, the proceedings on the substantive resolution shall not be invalidated by any error in such ruling. </P></TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VOTING BY JOINT HOLDERS OF SHARES </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">91.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the case of joint holders, the vote of the senior who tenders a vote (whether in person or by proxy) shall
be accepted to the exclusion of the votes of the other joint holders, and for this purpose seniority shall be determined by the order in which the names stand in the Register of Shareholders. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INSTRUMENT OF PROXY </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">92.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">An instrument appointing a proxy shall be in writing in such form as the chair of the meeting shall accept.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">93.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The instrument appointing a proxy must be received by the Company at the Registered Office or at such other
place or in such manner as is specified in the notice convening the meeting or in any instrument of proxy sent out by the Company in relation to the meeting at which the person named in the instrument appointing a proxy proposes to vote, and an
instrument appointing a proxy which is not received in the manner so prescribed shall be invalid. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">94.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A Shareholder who is the holder of two or more shares may appoint more than one proxy to represent such
Shareholder and vote on such Shareholder&#146;s behalf in respect of different shares. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">95.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The decision of the chair of any general meeting as to the validity of any appointment of a proxy shall be
final. </P></TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REPRESENTATION OF CORPORATE SHAREHOLDER </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">96.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A corporation which is a Shareholder may, by written instrument, authorise such person or persons as it thinks
fit to act as its representative at any meeting and any person so authorised shall be entitled to exercise the same powers on behalf of the corporation which such person represents as that corporation could exercise if it were an individual
Shareholder, and that Shareholder shall be deemed to be present in person at any such meeting attended by its authorised representative or representatives. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">97.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding the foregoing, the chair of the meeting may accept such assurances as he or she thinks fit as
to the right of any person to attend and vote at general meetings on behalf of a corporation which is a Shareholder. </P></TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ADJOURNMENT OF GENERAL MEETING </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">98.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The chair of a general meeting may, with the consent of Shareholders holding at least a majority of the shares
entitled to vote and present in person or by proxy at a general meeting at which quorum is present, and shall if so directed by the meeting, adjourn the meeting. Unless the meeting is adjourned to a specific date, place and time announced at the
meeting being adjourned, fresh notice of the date, place and time for the resumption of the adjourned meeting shall be given to each Shareholder entitled to attend and vote thereat in accordance with these
<FONT STYLE="white-space:nowrap">Bye-laws.</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">99.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In addition, the chair of a general meeting may adjourn the meeting to another time and place without such
consent or direction if it appears to such person that: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">it is likely to be impracticable to hold or continue to that meeting because of the number of Shareholders
wishing to attend who are not present; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the unruly conduct of persons attending the meeting prevents, or is likely to prevent, the orderly continuation
of the business of the meeting; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">an adjournment is otherwise necessary, in the sole discretion of the chair, so that the business of the meeting
may be properly conducted. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WRITTEN RESOLUTIONS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">100.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to these <FONT STYLE="white-space:nowrap">Bye-laws,</FONT> anything which may be done by Resolution or
Special Resolution in a general meeting or by Resolution or Special Resolution of a meeting of any class of the Shareholders may, without a meeting, be done by written resolution in accordance with <FONT STYLE="white-space:nowrap">Bye-laws</FONT> <FONT
STYLE="white-space:nowrap">101-107.</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">101.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notice of a written Resolution or Special Resolution shall be given, and a copy of the Resolution or Special
Resolution, as applicable, shall be circulated to all Shareholders who would be entitled to attend a meeting and vote thereon. The accidental omission to give notice to, or the <FONT STYLE="white-space:nowrap">non-receipt</FONT> of a notice by, any
Shareholder does not invalidate the passing of a resolution. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">102.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[Prior to the Trigger Event, a written Resolution or Special Resolution is passed when it is signed by, or on
behalf of, the Shareholders who at the date that the notice is given represent such number of votes as would be required if the resolution was voted on at a meeting of Shareholders at which all Shareholders entitled to attend and vote thereat were
present and voting. From and after the Trigger Event,]<SUP STYLE="font-size:75%; vertical-align:top">2</SUP> [a] written Resolution or Special Resolution is passed when it is unanimously signed by, or on behalf of, the Shareholders who at the date
that the notice is given represent all Shareholders who would be entitled to attend the meeting and vote on the Resolution or Special Resolution, as applicable. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">103.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A resolution in writing may be signed in any number of counterparts. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">104.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A written Resolution or Special Resolution made in accordance with these
<FONT STYLE="white-space:nowrap">Bye-laws</FONT> is as valid as if it had been passed by the Company in general meeting or by a meeting of the relevant class of Shareholders, as the case may be, and any reference in any <FONT
STYLE="white-space:nowrap">Bye-law</FONT> to a meeting at which a Resolution or Special Resolution is passed or to Shareholders voting in favour of a Resolution or Special Resolution shall be construed accordingly. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">105.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A written Resolution or Special Resolution made in accordance with these
<FONT STYLE="white-space:nowrap">Bye-laws</FONT> shall constitute minutes for the purposes of the Companies Act. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">106.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Bye-law</FONT> 100 shall not apply to: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a Resolution passed to remove an Auditor from office before the expiration of their term of office; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a Resolution or Special Resolution passed for the purpose of removing a Director before the expiration of their
term of office. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">107.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the purposes of these <FONT STYLE="white-space:nowrap">Bye-laws,</FONT> the effective date of a written
Resolution or Special Resolution is the date when it is signed by, or in the case of a Shareholder that is a corporation whether or not a company within the meaning of the Companies Act, on behalf of, the last Shareholder whose signature results in
the necessary voting threshold being achieved and any reference in any <FONT STYLE="white-space:nowrap">Bye-law</FONT> to the date of passing of a Resolution or Special Resolution is, in relation to a Resolution or Special Resolution made in
accordance with these <FONT STYLE="white-space:nowrap">Bye-laws,</FONT> a reference to such date. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">2</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[NTD: Bracketed language to be deleted in final bye-laws if the Principal Stockholder and its Affiliates
collectively beneficially own less than 50% of the issued common shares of the Company at the IPO closing.] </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DIRECTORS&#146; ATTENDANCE AT GENERAL MEETINGS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">108.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Directors shall be entitled to receive notice of, attend and be heard at any general meeting.
</P></TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ELECTION OF DIRECTORS AND NOTICE OF SHAREHOLDER BUSINESS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">109.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Board shall be elected or appointed in the first place at the statutory meeting of the Company and
thereafter, except in the case of a casual vacancy, by Resolution at the annual general meeting or at any special general meeting called for that purpose in accordance with these <FONT STYLE="white-space:nowrap">Bye-laws.</FONT>
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">110.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">(1) Nominations of persons for election to the Board and the proposal of other business may be made at any
annual general meeting only: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">pursuant to the Company&#146;s notice of meeting (or any supplement thereto) delivered pursuant to <FONT
STYLE="white-space:nowrap">Bye-law</FONT> 71; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by or at the direction of the Board (or any duly authorised committee thereof) or at the direction of the Court
pursuant to the Companies Act; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by any Shareholder who: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(i) is a Shareholder on the record date for the determination of Shareholders entitled to vote at such meeting, on the date of the giving of
the notice referred to in <FONT STYLE="white-space:nowrap">Bye-law</FONT> 111 and at the time of the meeting; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(ii) complies with the
notice procedures set out in <FONT STYLE="white-space:nowrap">Bye-law</FONT> 111; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(2) Only such business (including the election of
specific individuals to fill vacancies or newly created directorships on the Board) shall be conducted at a special general meeting as shall have been brought before the meeting pursuant to the Company&#146;s notice of meeting (or any supplement
thereto) delivered pursuant to <FONT STYLE="white-space:nowrap">Bye-law</FONT> 72. At any time that Shareholders are not prohibited from filling vacancies or newly created directorships on the Board, nominations of persons for election to the Board
may be made at a special general meeting at which directors are to be elected pursuant to the Company&#146;s notice of meeting only: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by or at the direction of the Board (or any duly authorised committee thereof) or at the direction of the Court
pursuant to the Companies Act; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by any Shareholder who submitted a valid requisition request for the applicable special general meeting in
accordance with <FONT STYLE="white-space:nowrap">Bye-Law</FONT> 70 and section 74 of the Companies Act and complies with the notice procedures set out in <FONT STYLE="white-space:nowrap">Bye-Law</FONT> 111; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">provided that the Board has determined that directors shall be elected at such special general meeting, by any
Shareholder who: </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(i) is a Shareholder on the record date for the determination of Shareholders entitled to vote at such
meeting, on the date of the giving of the notice referred to in <FONT STYLE="white-space:nowrap">Bye-law</FONT> 111 and at the time of the meeting; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(ii) complies with the notice procedures set out in <FONT STYLE="white-space:nowrap">Bye-law</FONT> 111; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(3) Paragraphs (1)(c), 2(b) and (2)(c) of this <FONT STYLE="white-space:nowrap">Bye-law</FONT> 110 shall be the exclusive means for a
Shareholder to make nominations or submit other business before an annual general meeting or special general meeting (other than pursuant to Rule <FONT STYLE="white-space:nowrap">14a-8</FONT> under the Exchange Act). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">111.</TD>
<TD WIDTH="5%">(1) </TD>
<TD>For nominations or other business to be properly brought before an annual general meeting or special general meeting by a Shareholder pursuant to <FONT STYLE="white-space:nowrap">Bye-law</FONT> 110, the Shareholder bringing the notice (the
&#147;<B>Noticing Shareholder</B>&#148;) must have given timely notice thereof in proper written form in accordance with <FONT STYLE="white-space:nowrap">Bye-law</FONT> 112, and, in the case of business other than nominations of persons for election
to the Board, such other business must constitute a proper matter for Shareholder action. To be in proper written form, such Noticing Shareholder&#146;s notice delivered pursuant to Bye-law 110 shall set forth: </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">as to each person whom the Noticing Shareholder proposes to nominate for election or <FONT
STYLE="white-space:nowrap">re-election</FONT> as a director (i)&nbsp;the name, age, citizenship, business address and residence address of such person, (ii)&nbsp;a complete biography and statement of such person&#146;s qualifications, including the
principal occupation or employment of such person (at present and for the past five years), (iii) the Specified Information (as defined below) for such person and any member of the immediate family of such person, or any Affiliate or Associate of
such person, or any person acting in concert therewith, as if such person were a Holder (as defined below), (iv) all information relating to such person that would be required to be disclosed in a proxy statement or other filings required to be made
in connection with solicitations of proxies for election of directors in a contested election pursuant to the Exchange Act or that is otherwise required pursuant to and in accordance with Section&nbsp;14 of the Exchange Act,, and the rules and
regulations promulgated thereunder (including such person&#146;s written consent to being named in the Company&#146;s proxy statement as a nominee of the Noticing Shareholder and to serving as a director if elected), (v) a complete and accurate
description of agreements, arrangements and understandings (whether written or oral), including, without limitation, all direct and indirect compensation and other material monetary agreements, arrangements and understandings at present and for the
past three years, and any other material relationships, between or among each Holder and any Shareholder Associated Person of each such Holder, on the one hand, and each proposed nominee and any member of the immediate family of such proposed
nominee, and his or her respective Affiliates and Associates, or others acting in concert therewith, on the other hand, including, without limitation, all biographical and related party transaction and other information that would be required to be
disclosed pursuant to the US federal and state securities laws, including Rule 404 promulgated under Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> under the Securities Act (or any successor provision), if any Holder and any Shareholder
Associated Person were the &#147;registrant&#148; for purposes of such rule and the nominee were a director or executive officer of such registrant, and (vi)&nbsp;a completed and signed questionnaire, representation and agreement and any and all
other information required by paragraph (7)&nbsp;of this <FONT STYLE="white-space:nowrap">Bye-law</FONT> 111; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">as to any other business that the Noticing Shareholder proposes to bring before the meeting, (i)&nbsp;a brief
description of the business desired to be brought before the meeting, (ii)&nbsp;the reasons for conducting such business at the meeting, (iii)&nbsp;a description of all agreements, arrangements and understandings between each Holder and any
Shareholder Associated Person of each such Holder and any other person or persons (including their names) in connection with the proposal of such business by the Noticing Shareholder, (iv)&nbsp;the text of the proposal or business (including the
text of any resolutions proposed for consideration and, in the event that such business includes a proposal to amend these <FONT STYLE="white-space:nowrap">Bye-laws,</FONT> the specific language of the proposed amendment), (v) the reasons for
conducting such business at the meeting and (vi)&nbsp;any material interest in such business of each Holder r and any Shareholder Associated Person of each such Holder, if any; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">as to the Noticing Shareholder and the beneficial owner, if any, on whose behalf the nomination is made or the
other business is being proposed (collectively with the Noticing Shareholder, the &#147;<B>Holders</B>&#148; and each, a &#147;<B>Holder</B>&#148;): </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the full name and address of each Holder and the name and address of any Shareholder Associated Person of each
such Holder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">as of the date of the notice (which information, for the avoidance of doubt, shall be updated and supplemented
pursuant to paragraph (2)&nbsp;of <FONT STYLE="white-space:nowrap">Bye-law</FONT> 111): (A) the class or series and number of shares of the Company which are, directly or indirectly, held of record or owned beneficially by each Holder and any
Shareholder Associated Person of each such Holder (provided, however, that for purposes of this paragraph (1)(c) of <FONT STYLE="white-space:nowrap">Bye-law</FONT> 111, any such person shall in all events be deemed to beneficially own any shares of
the Company as to which such person has a right to acquire beneficial ownership of at any time in the future, whether such right is exercisable immediately or only after the passage of time or the fulfilment of a condition or both), (B) any
Derivative Instrument directly or indirectly owned or held, including beneficially, by each such Holder and any Shareholder Associated Person of each such Holder presently or within the last 12 months in any shares or other securities of the
Company, (C)&nbsp;a description of any proxy, contract, arrangement, understanding or relationship pursuant to which each Holder and any Shareholder Associated Person of each such Holder has a right to vote or has granted a right to vote any shares
of any security of the Company, (D)&nbsp;any Short Interest held by each Holder and any Shareholder Associated Person of each such Holder presently or within the last 12 months in any shares or other securities of the Company, (E)&nbsp;any
agreement, arrangement or understanding (including any contract to purchase or sell, acquisition or grant of any option, right or warrant to purchase or sell, swap or other instrument) between and among each Holder, any Shareholder Associated Person
of each such Holder, on the one hand, and any person acting in concert with any such person, on the other hand, with the intent or effect of which may be to transfer to or from any such person, in whole or in part, any of the economic consequences
of ownership of any security of the Company or to increase or decrease the voting power of any such person with respect to any security of the Company, (F)&nbsp;any direct or indirect legal, economic or financial interest (including Short Interest)
of each Holder and any Shareholder Associated Person of each such Holder in the outcome of any vote to be taken (x)&nbsp;at any annual general meeting or special general meeting of Shareholders or (y) any other entity with respect to any matter that
is related, directly or indirectly, to any nomination or business proposed by any Holder under these <FONT STYLE="white-space:nowrap">Bye-laws,</FONT> (G)&nbsp;a description of any agreement, arrangement or understanding with respect to any rights
to dividends on the shares of the Company owned beneficially by each Holder or any Shareholder Associated Person of each such Holder that are separated or separable pursuant to such agreement, arrangement or understanding from the underlying shares
of the Company, (H)&nbsp;any proportionate interest in shares of the Company or Derivative Instruments held, directly or indirectly, by a general or limited partnership or limited liability company or similar entity in which any Holder and any
Shareholder Associated Person of each such Holder is a general partner or, directly or indirectly, beneficially </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
owns any interest in a general partner or is the manager or managing member or, directly or indirectly, beneficially owns any interest in the manager or managing member of a limited liability
company or similar entity, (I)&nbsp;any direct or indirect legal, economic or financial interest (including Short Interest) in any principal competitor of the Company held by each Holder and any Shareholder Associated Person of each such Holder,
(J)&nbsp;any performance-related fees (other than an asset-based fee) that each Holder and any Shareholder Associated Person of each such Holder is entitled to based on any increase or decrease in the value of shares of the Company or Derivative
Instruments, if any, as of the date of such notice and (K)&nbsp;any material pending or threatened action, suit or proceeding (whether civil, criminal, investigative, administrative or otherwise) in which any Holder or any Shareholder Associated
Person of each such Holder is, or is reasonably expected to be made, a party or material participant involving the Company or any of its officers, directors or employees, or any Affiliate of the Company, or any officer, director or employee of such
Affiliate <FONT STYLE="white-space:nowrap">(sub-paragraphs</FONT> (A)&nbsp;through (K) above of this <FONT STYLE="white-space:nowrap">Bye-law</FONT> 111(1)(c) shall be referred, collectively, as the &#147;<B>Specified Information</B>&#148;);
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a representation by the Noticing Shareholder that such shareholder is a holder of record of shares of the
Company entitled to vote at such meeting on the matter proposed, will continue to be a shareholder of record of the Company entitled to vote at such meeting on the matter proposed through the date of such meeting and intends to appear in person or
by proxy at the meeting to propose such nomination or other business; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a representation whether any Holder and/or any Shareholder Associated Person of each such Holder intends or is
part of a group which intends (A)&nbsp;to deliver a proxy statement and/or form of proxy to holders of at least the percentage of the Company&#146;s issued share capital required to elect the proposed nominee or approve or adopt the other business
being proposed and/or (B)&nbsp;otherwise to solicit proxies from Shareholders in support of such nomination or other business; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a certification by the Noticing Shareholder that each Holder and any Shareholder Associated Person of each such
Holder has complied with all applicable US federal, state and other legal requirements in connection with its acquisition of shares or other securities of the Company and/or such person&#146;s acts or omissions as a shareholder of the Company;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the names and addresses of other shareholders (including beneficial owners) known by any Holder or Shareholder
Associated Person of each such Holder to provide financial or otherwise material support for such proposal or nomination or nominations, and to the extent known the class and number of all shares of the Company&#146;s capital stock owned
beneficially or of record by such other shareholder(s) or other beneficial owner(s) (it being understood that delivery of a revocable proxy with respect to such proposal or nomination shall not in itself require disclosure under this <U>subclause
(vi)</U>), </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(vii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the information and statement required by Rule <FONT STYLE="white-space:nowrap">14a-19(b)</FONT> of the
Exchange Act (or any successor provision); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(viii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all information that would be required to be set forth in a Schedule 13D filed pursuant to Rule <FONT
STYLE="white-space:nowrap">13d-1(a)</FONT> or an amendment pursuant to Rule <FONT STYLE="white-space:nowrap">13d-2(a)</FONT> if such a statement were required to be filed under the Exchange Act and the rules and regulations promulgated thereunder by
each Holder and each Shareholder Associated Person, if any, of each such Holder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ix)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any other information relating to each Holder and each Shareholder Associated Person, if any, of such Holder
that would be required to be disclosed in a proxy statement and form of proxy or other filings required to be made in connection with solicitations of proxies for, as applicable, the proposal and/or for the election of directors in a contested
election pursuant to Section&nbsp;14 of the Exchange Act and the rules and regulations promulgated thereunder; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(x)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a representation by the Noticing Shareholder as to the accuracy of the information set forth in the notice;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a description of any agreement, arrangement or understanding with respect to the nomination or proposal and/or
the voting of shares of any class or series of shares of the Company between or among the Holders and any Shareholder Associated Person of each such Holder, on whose behalf the nomination or proposal is made, any of their respective affiliates or
associates and/or any others acting in concert with any of the foregoing; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any Noticing Shareholder who submits a notice pursuant to <FONT STYLE="white-space:nowrap">Bye-law</FONT>
110(c) is required to update and supplement the information disclosed in such notice in accordance with the provisions of this paragraph. To be considered timely, a Noticing Shareholder&#146;s notice shall further be updated and supplemented from
time to time to the extent necessary so that the information provided or required to be provided in such notice shall be true and correct (x)&nbsp;as of the record date for determining the Shareholders entitled to notice of the meeting and
(y)&nbsp;as of the date that is ten days prior to the meeting or any adjournment, recess, rescheduling or postponement thereof ; provided that if the record date for determining the Shareholders entitled to vote at the meeting is less than ten days
prior to the meeting or any adjournment, recess, rescheduling or postponement thereof, the information shall be supplemented and updated as of such later date. Any such update and supplement shall be delivered in writing to the Secretary at the
principal executive offices of the Company and electronically at corporatesecretary@kestramedical.com (or such other address as may be specified by the Board from time to time) not later than five days after the record date for determining the
Shareholders entitled to notice of the meeting (in the case of any update and supplement required to be made as of the record date for determining the Shareholders entitled to notice of the meeting), not later than eight days prior to the date for
the meeting or any adjournment, recess, rescheduling or postponement thereof (in the case of any update or supplement required to be made as of ten days prior to the meeting or adjournment or postponement thereof) and not later than five days after
the record date for determining the Shareholders entitled to vote at the meeting, but no later than the day prior to the meeting or any adjournment, recess, rescheduling or postponement thereof (in the case of any update and supplement required to
be made as of a date less than five days prior the date of the meeting or any adjournment or postponement thereof). In addition, if the Noticing Shareholder has delivered to the Company a notice relating to the
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
nomination of directors, the Noticing Shareholder shall deliver to the Company not later than eight days prior to the date of the meeting or any adjournment, recess, rescheduling or postponement
thereof (or, if not practicable, on the first practicable date prior to the date to which the annual meeting has been adjourned or postponed) reasonable evidence that it has complied with the requirements of Rule
<FONT STYLE="white-space:nowrap">14a-19</FONT> of the Exchange Act (or any successor provision). For the avoidance of doubt, the obligation to update and supplement set forth in this paragraph or any other Section of these <FONT
STYLE="white-space:nowrap">Bye-laws</FONT> shall not limit the Company&#146;s rights with respect to any deficiencies in any notice provided by a Shareholder, extend any applicable deadlines hereunder or enable or be deemed to permit a Shareholder
who has previously submitted notice hereunder to amend or update any proposal or to submit any new proposal, including by changing or adding nominees, matters, business and/or resolutions proposed to be brought before a meeting of the Shareholders.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company may also, as a condition to any such nomination or business being deemed properly brought before an
annual general meeting or special general meeting, require any Holder or any proposed nominee to deliver to the Secretary, within five Business Days of any such request, such other information as may reasonably be requested by the Company, including
such other information as may be reasonably required by the Board, in its sole discretion, to determine (1)&nbsp;the eligibility of such proposed nominee to serve as a director of the Company, (2)&nbsp;whether such nominee qualifies as an
&#147;independent director&#148; or &#147;audit committee financial expert&#148; under applicable law, securities exchange rule or regulation, or any publicly disclosed corporate governance guidelines or committee charter of the Company and
(3)&nbsp;such other information that the Board determines, in its sole discretion, could be material to a reasonable Shareholder&#146;s understanding of the independence, or lack thereof, of such proposed nominee. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Except for directors who are appointed by the Board pursuant to these
<FONT STYLE="white-space:nowrap">Bye-laws,</FONT> only such persons who are nominated in accordance and compliance with the procedures set forth in <FONT STYLE="white-space:nowrap">Bye-laws</FONT> <FONT STYLE="white-space:nowrap">110-117</FONT>
(inclusive) shall be eligible for election to serve as directors at a meeting of Shareholders and only such other business shall be conducted at a meeting of Shareholders as shall have been brought before the meeting in accordance with the
procedures set forth in <FONT STYLE="white-space:nowrap">Bye-laws</FONT> <FONT STYLE="white-space:nowrap">111-117</FONT> (inclusive). Except as otherwise provided by law or these <FONT STYLE="white-space:nowrap">Bye-laws,</FONT> the Board or a duly
authorized committee thereof (in advance of the meeting) or chair of the meeting (during the meeting) shall, in addition to making any other determination that may be appropriate for the conduct of the meeting of the Board, have the power and duty
to determine whether a nomination or any other business proposed to be brought before the meeting was made or proposed, as the case may be, in accordance with the procedures set forth in these <FONT STYLE="white-space:nowrap">Bye-laws</FONT>
(including whether the Noticing Shareholder or other Holder, if any, on whose behalf the nomination is made or other business is being proposed solicited (or is part of a group which solicited) or did not so solicit, as the case may be, proxies in
support of such Noticing Shareholder&#146;s nominee or other business in compliance with such Shareholder&#146;s&#146; representation as required by paragraph (iv) of <FONT STYLE="white-space:nowrap">Bye-law</FONT> 111(1)(c)). If any proposed
nomination or other business was not made or proposed in compliance with these <FONT STYLE="white-space:nowrap">Bye-laws,</FONT> the chair of the meeting shall have the power and duty to declare to the meeting that any such nomination or other
business was not properly brought before the meeting and in accordance with the provisions of these <FONT STYLE="white-space:nowrap">Bye-laws,</FONT> and that such nomination or other business not properly brought before the meeting shall be
disregarded and/or shall not be transacted. Notwithstanding anything contained herein, unless otherwise required by the Companies Act, if the Shareholder (or a qualified representative of the Shareholder) does not appear at the annual general
meeting or special general meeting to present a nomination or business, such nomination shall be disregarded and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
such proposed business shall not be transacted, notwithstanding that proxies in respect of such vote may have been received by the Company. For purposes of this
<FONT STYLE="white-space:nowrap">Bye-law</FONT> 111, to be considered a qualified representative of the Shareholder, a person must be a duly authorized officer, manager or partner of such Shareholder or must be authorized by a writing executed by
such Shareholder or an electronic transmission delivered by such Shareholder to act for such Shareholder as proxy at the meeting of Shareholders and such person must produce such writing or electronic transmission, or a reliable reproduction of the
writing or electronic transmission, at the meeting of Shareholders. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding anything contained herein, a Shareholder shall also comply with all applicable requirements of
the Exchange Act and the rules and regulations promulgated thereunder with respect to the matters set forth in this <FONT STYLE="white-space:nowrap">Bye-law</FONT> 111; provided, however, that, any references in these
<FONT STYLE="white-space:nowrap">Bye-laws</FONT> to the Exchange Act or the rules and regulations promulgated thereunder are not intended to and shall not limit any requirements applicable to nominations or proposals as to any other business to be
considered pursuant to these <FONT STYLE="white-space:nowrap">bye-laws</FONT> (including clauses (1)(c), (2)(b) and 2(c) of <FONT STYLE="white-space:nowrap">Bye-law</FONT> 110), and compliance with clauses (1)(c), (2)(b) or 2(c) of <FONT
STYLE="white-space:nowrap">Bye-law</FONT> 110 shall be the exclusive means for a Shareholder to make nominations or submit other business. Nothing in these <FONT STYLE="white-space:nowrap">Bye-laws</FONT> shall be deemed to affect any rights of
(i)&nbsp;the holders of any class or series of shares having a preference over the common shares as to dividends or upon liquidation to elect directors under specified circumstances; or (ii)&nbsp;Shareholders to request inclusion of proposals in the
Company&#146;s proxy statement pursuant to Rule <FONT STYLE="white-space:nowrap">14a-8</FONT> under the Exchange Act or any other applicable federal or state securities law with respect to that Shareholder&#146;s request to include proposals in the
Company&#146;s proxy statement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In addition to the other requirements of this <FONT STYLE="white-space:nowrap">Bye-law</FONT> 111, each person
who a Noticing Shareholder proposes to nominate for election or <FONT STYLE="white-space:nowrap">re-election</FONT> as a director of the Company must deliver in writing (in accordance with the time periods prescribed for delivery of notice under <FONT
STYLE="white-space:nowrap">Bye-law</FONT> 112) to the Secretary (i)&nbsp;a written questionnaire with respect to the background and qualification of such person and the background of any other person or entity on whose behalf the nomination is being
made (which questionnaire shall be provided by the Secretary upon written request of any Shareholder identified by name within five Business Days of such written request) and (ii)&nbsp;a written representation and agreement (in the form provided by
the Secretary upon written request of any Shareholder identified by name within five Business Days of such request) that such person (A)&nbsp;is not and will not become a party to (1)&nbsp;any agreement, arrangement or understanding (whether written
or oral) with, and has not given any commitment or assurance to, any person or entity as to how such person, if elected as a director of the Company, will act or vote on any issue or question (a &#147;<B>Voting </B><B>Commitment</B>&#148;) that has
not been disclosed to the Company or (2)&nbsp;any Voting Commitment that could limit or interfere with such person&#146;s ability to comply, if elected as a director of the Company, with such person&#146;s fiduciary duties under applicable law,
(B)&nbsp;is not and will not become a party to any agreement, arrangement or understanding with any person or entity other than the Company with respect to any direct or indirect compensation, reimbursement or indemnification in connection with
service or action as a director that has not been disclosed to the Company, (C)&nbsp;in such person&#146;s individual capacity and on behalf of any person or entity on whose behalf the nomination is being made, would be in compliance, if elected as
a director of the Company, and will comply with all applicable rules of the exchanges upon which the securities of the Company are listed and all applicable publicly disclosed corporate governance, conflict of interest, confidentiality and stock
ownership and trading policies and guidelines of the Company and (D)&nbsp;in such person&#146;s individual capacity and on behalf of any Holder on whose behalf the nomination is being made, intends to serve a full term if elected as a director of
the Company. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">112.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any notice or other documents required to be given to the Secretary pursuant to
<FONT STYLE="white-space:nowrap">Bye-law</FONT> 111 must be in writing and delivered to or mailed and received by the Secretary at the principal executive offices of the Company and electronically at corporatesecretary@kestramedical.com (or such
other address as may be specified by the Board from time to time), who must receive the notice not later than the following dates: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the case of an annual general meeting, not later than the close of business on the 90th day nor earlier than
the close of business on the 120th day before the first anniversary of the preceding year&#146;s annual general meeting (which anniversary date shall, for purposes of the Company&#146;s first annual general meeting of Shareholders after its common
shares are first publicly traded, be deemed to have occurred on September&nbsp;15, 2025), or, if no annual general meeting was held in the previous year (excluding the Company&#146;s first annual general meeting of Shareholders after its common
shares are first publicly traded) or the date of the annual general meeting is advanced by more than 30 days, or delayed by more than 70 days from such anniversary date, such notice shall be delivered to the Secretary not earlier than the opening of
business on the 120th day prior to such annual general meeting and not later than the close of business on the later of the 90th day prior to such annual general meeting or the tenth day following the day on which the public announcement (as defined
below) of the date of such meeting is first made by the Company; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the case of a special general meeting, not later than the close of business on the tenth day following the
day on which public announcement is first made by the Company of the date of the special general meeting at which directors are to be elected. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In no event shall an adjournment, recess, rescheduling or postponement (or the public announcement of adjournment, recess, rescheduling or
postponement) of an annual general meeting or special general meeting commence a new time period (or extend any time period) for the giving of a notice as described above. Notwithstanding anything in these
<FONT STYLE="white-space:nowrap">Bye-laws</FONT> to the contrary, if the number of directors to be elected to the Board at an annual general meeting is increased, and there is no public announcement by the Company naming all of the nominees for
director or specifying the size of the increased Board at least 10 days prior to last day a Noticing Shareholder may deliver a notice of nominations in accordance with <FONT STYLE="white-space:nowrap">Bye-law</FONT> 111(a), then a notice required by
<FONT STYLE="white-space:nowrap">Bye-law</FONT> 111 shall be considered timely, but only with respect to nominees for any new positions created by such increase, if it is received by the Secretary not later than the close of business on the 10th day
following the day on which a public announcement of such increase in the number of directors to be elected is first made by the Company. For the avoidance of doubt, a Shareholder shall not be entitled to make additional or substitute nominations
following the expiration of the time periods set forth in these <FONT STYLE="white-space:nowrap">Bye-laws.</FONT> </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">113.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The date and time of the opening and the closing of the polls for each matter upon which the Shareholders will
vote at a meeting shall be announced at the meeting by the chair of the meeting. The Board may adopt by resolution such rules and regulations for the conduct of the meeting of Shareholders as it shall deem appropriate. Except to the extent
inconsistent with such rules and regulations as adopted by the Board, the chair of the meeting shall have the right and authority to convene and (for any or no reason) to recess and/or adjourn the meeting in accordance with <FONT
STYLE="white-space:nowrap">Bye-law</FONT> 98, and shall have the power to prescribe such rules, regulations and procedures and to do all such acts as, in the judgement of such chair, are appropriate for the proper conduct of the meeting. Such rules,
regulations or procedures, whether adopted by the Board or prescribed by the chair of </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
the meeting, may include, without limitation, the following: (i)&nbsp;the establishment of an agenda or order of business for the meeting; (ii)&nbsp;the determination of when the polls shall open
and close for any given matter to be voted on at the meeting; (iii)&nbsp;rules and procedures for maintaining order at the meeting and the safety of those present; (iv)&nbsp;limitations on attendance at or participation in the meeting to
Shareholders of the Company, their duly authorized and constituted proxies, or such other persons as the chair of the meeting shall determine; (v)&nbsp;restrictions on entry to the meeting after the time fixed for the commencement thereof;
(vi)&nbsp;limitations on the time allotted to questions or comments by participants and on shareholder approvals; and (vii)&nbsp;restricting the use of cell phones, audio or video recording devices and similar devices at the meeting. The chair of
the meeting&#146;s rulings on procedural matters shall be final. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">114.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding the provisions of <FONT STYLE="white-space:nowrap">Bye-law</FONT> 109, where the number of
persons validly proposed for <FONT STYLE="white-space:nowrap">re-election</FONT> or election as a Director is greater than the number of Directors to be elected, the persons receiving the most votes (up to the number of Directors to be elected)
shall be elected as Directors, and an absolute majority of the votes cast shall not be a prerequisite to the election of such Directors. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">115.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">At any general meeting the Shareholders may authorise the Board to fill any vacancy in their number left
unfilled at a general meeting. </P></TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NUMBER OF DIRECTORS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">116.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Except as otherwise provided for or fixed pursuant to the provisions of
<FONT STYLE="white-space:nowrap">Bye-law</FONT> 5 in relation to the right of the holders of any series of preference shares to elect additional directors, the number of Directors shall be a minimum number of six and a maximum number of
<B>eleven</B>, or such number in excess thereof as the Company may from time to time determine by resolution of the Board. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">117.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Directors shall have the power by resolution of the Board, without the need of any Resolution approved by
the Shareholders, to increase or decrease the size of the Board at any time and from time to time, subject to the minimum number set in accordance with <FONT STYLE="white-space:nowrap">Bye-law</FONT> 116. </P></TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TERM OF OFFICE OF DIRECTORS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">118.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Board (other than those directors elected by the holders of any series of preferred shares, voting
separately as a series or together with one or more other such series, as the case may be) shall be divided into three classes, designated as Class&nbsp;I, Class&nbsp;II and Class&nbsp;III. Each class of Directors shall consist, as nearly as
reasonably possible, of <FONT STYLE="white-space:nowrap">one-third</FONT> of the total number of Directors. Notwithstanding the foregoing, immediately prior to the opening of the polls at the seventh annual general meeting of Shareholders after its
common shares are first publicly traded (such meeting, the &#147;<U>Triggering Annual Meeting</U>&#148;), the Board shall cease to be divided into three classes and, subject to the rights granted to the holders of any series of preferred shares then
issued, shall consist of a single class. At the Triggering Annual Meeting, and at each annual general meeting of Shareholders thereafter, all Directors elected by a vote of the Shareholders generally shall be elected to hold office for a <FONT
STYLE="white-space:nowrap">one-year</FONT> term expiring at the next annual general meeting of Shareholders, notwithstanding that any such Director may have been previously elected to a term extending beyond the Triggering Annual Meeting or any
subsequent annual general meeting. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">119.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each Class&nbsp;I Director shall (unless his or her office is vacated in accordance with these <FONT
STYLE="white-space:nowrap">Bye-laws)</FONT> initially serve until the conclusion of the first annual general meeting of the Shareholders held following the Listing (unless his or her office is vacated in accordance with these <FONT
STYLE="white-space:nowrap">Bye-laws)</FONT> and, prior to the Triggering Annual Meeting, shall subsequently (unless his or her office is vacated in accordance with these <FONT STYLE="white-space:nowrap">Bye-laws)</FONT> serve for a term of three
years concluding at the third annual </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
general meeting after the Class&nbsp;I Directors were last appointed or reappointed. Each Class&nbsp;II Director shall (unless his or her office is vacated in accordance with these <FONT
STYLE="white-space:nowrap">Bye-laws)</FONT> serve initially until the conclusion of the second annual general meeting of the Shareholders held following the Listing and, prior to the Triggering Annual Meeting, shall subsequently (unless his or her
office is vacated in accordance with these <FONT STYLE="white-space:nowrap">Bye-laws)</FONT> serve for a term of three-years concluding at the third annual general meeting after the Class&nbsp;II Directors were last appointed or reappointed. Each
Class&nbsp;III Director shall (unless his or her office is vacated in accordance with these <FONT STYLE="white-space:nowrap">Bye-laws)</FONT> serve initially until the conclusion of the third annual general meeting of the Shareholders held following
the Listing and, prior to the Triggering Annual Meeting, shall subsequently (unless his or her office is vacated in accordance with these <FONT STYLE="white-space:nowrap">Bye-laws)</FONT> serve for a terms of three years concluding at the third
annual general meeting after the Class&nbsp;III Directors were last appointed or reappointed. At each annual general meeting of the Shareholders thereafter and prior to the Triggering Annual Meeting, the successors to the class of Directors whose
term shall then expire shall be elected to hold office for a three-year term so that the term of office of one class of Directors shall expire each year. Prior to the Triggering Annual Meeting, if the number of Directors is changed, any increase or
decrease shall be apportioned among the classes so as to maintain the number of Directors in each class as nearly equal as possible, and any additional Directors of any class elected to fill a vacancy resulting from an increase in such class shall
hold office for a term that shall coincide with the remaining term of that class, but in no case will a decrease in the number of Directors shorten the term of any incumbent Director. For the avoidance of doubt, a decrease in the number of Directors
effective upon the election of Directors at an annual general meeting shall not be deemed to shorten the term of any incumbent Director who is not <FONT STYLE="white-space:nowrap">re-elected</FONT> at such annual general meeting. A Director shall
hold office until the annual general meeting for the year in which his or her term expires or until his or her successor shall be duly elected and qualified, subject however, to prior death, resignation, retirement, disqualification or removal from
office in accordance with these Bye-laws. Any director may resign at any time by notice given in writing or by electronic transmission to the Company. Such resignation shall take effect at the date of receipt of such notice by the Company or at such
later effective date or upon the happening of an event or events as is therein specified. </TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REMOVAL OF DIRECTORS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">120.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Section&nbsp;93 of the Companies Act shall not apply to the removal of Directors. Subject to the rights of the
holders of any series of preferred shares, [a Director may be removed by the Shareholders with or without cause with the affirmative vote of Shareholders holding at least a majority of the issued shares entitled to vote thereon; provided that, from
and after the Trigger Event,]<SUP STYLE="font-size:75%; vertical-align:top">3</SUP> a Director can be removed by the Shareholders only with cause by Special Resolution. Notice of any special general meeting shall be served on the Director concerned
not less than 14 days before the meeting and she or he shall be provided the opportunity to be heard at such meeting; provided that nothing in these <FONT STYLE="white-space:nowrap">Bye-laws</FONT> shall have effect to deprive any director of any
compensation or damages which may be payable to her or him in respect of the termination of his appointment as a director or any other appointment with the Company. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">121.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If a Director is removed from the Board under <FONT STYLE="white-space:nowrap">Bye-law</FONT> 120, the
Shareholders may fill the vacancy at the meeting at which such Director is removed. In the absence of such election or appointment the Board may fill the vacancy. </P></TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VACANCY IN THE OFFICE OF DIRECTOR </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">122.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The office of Director shall be vacated if the Director: </P></TD></TR></TABLE>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">3</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[NTD: Bracketed language to be deleted in final bye-laws if the Principal Stockholder and its Affiliates
collectively beneficially own less than 50% of the issued common shares of the Company at the IPO closing.] </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">is removed from office pursuant to these <FONT STYLE="white-space:nowrap">Bye-laws</FONT> or is prohibited from
being a Director by law; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">is or becomes bankrupt or insolvent; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">is or becomes of unsound mind or a patient for any purpose of any statute or applicable law relating to mental
health and the Board resolves that their office is vacated, or dies; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">resigns their office by notice to the Company. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">123.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any one or more vacancies on the Board not filled at any general meeting, and any new vacancy created by the
Board as a result of increasing the size of the Board, in accordance with <FONT STYLE="white-space:nowrap">Bye-law</FONT> 117, shall be deemed a vacancy for the purposes of these <FONT STYLE="white-space:nowrap">Bye-laws.</FONT> Without prejudice to
the power of the Company by Resolution in pursuance to any of the provisions of these <FONT STYLE="white-space:nowrap">Bye-laws</FONT> to appoint any person to be a Director, the Board shall have power at any time and from time to time, subject to <FONT
STYLE="white-space:nowrap">Bye-laws</FONT> 118 and 124 to appoint any individual to be a Director so as to fill a vacancy. Prior to the Triggering Annual Meeting, a Director so appointed shall hold office for a term that shall coincide with the
remaining term of its class of Directors in accordance with <FONT STYLE="white-space:nowrap">Bye-law</FONT> 118. From and after the Triggering Annual Meeting, a Director so appointed shall hold office until the next election of Directors and until
his or her successor shall be duly elected and qualified, subject however, to prior death, resignation, retirement, disqualification or removal from office in accordance with these <FONT STYLE="white-space:nowrap">Bye-laws.</FONT>
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">124.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Upon the office of Director being vacated in accordance with <FONT STYLE="white-space:nowrap">Bye-law</FONT>
122, if a new Director is appointed to the Board he or she will be designated to fill the vacancy arising and shall for the purposes of these <FONT STYLE="white-space:nowrap">Bye-laws,</FONT> prior to the Triggering Annual Meeting (subject to the
rights granted to the holders of any series of preferred shares then issued), constitute a member of the class of Directors represented by the person that he replaces. </P></TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DIRECTORS TO MANAGE BUSINESS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">125.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The business of the Company shall be managed and conducted by the Board. In managing the business of the
Company, the Board may exercise all such powers of the Company as are not, by the Companies Act or by these <FONT STYLE="white-space:nowrap">Bye-laws,</FONT> required to be exercised by the Company in general meeting. </P></TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>POWERS OF THE BOARD OF DIRECTORS </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">126.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Without prejudice to the generality of <FONT STYLE="white-space:nowrap">Bye-law</FONT> 125, the Board may:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">appoint, suspend or remove any manager, secretary, clerk, agent or employee of the Company and may fix their
remuneration and determine their duties; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">exercise all the powers of the Company to borrow money and to mortgage or charge its undertaking, property and
uncalled capital, or any part thereof, and may issue debentures, debenture stock and other securities whether outright or as security for any debt, liability or obligation of the Company or any third party; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">appoint one or more Directors to the office of chief executive officer of the Company, who shall, subject to
the control of the Board, supervise and administer all of the general business and affairs of the Company and the Board may entrust and confer upon the chief executive officer such additional powers and duties as the Board deems appropriate for the
transaction or conduct of such business and affairs of the Company; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by power of attorney, appoint any company, firm, person or body of persons, whether nominated directly or
indirectly by the Board, to be an attorney of the Company for such purposes and with such powers, authorities and discretions (not exceeding those vested in or exercisable by the Board) and for such period and subject to such conditions as it may
think fit and any such power of attorney may contain such provisions for the protection and convenience of persons dealing with any such attorney as the Board may think fit and may also authorise any such attorney to
<FONT STYLE="white-space:nowrap">sub-delegate</FONT> all or any of the powers, authorities and discretions so vested in the attorney; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">procure that the Company pays all expenses incurred in promoting and incorporating the Company;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">designate any lead independent director and designate one or more committees, such committee or committees to
have such name or names as may be determined from time to time by resolution adopted by the Board, and each such committee to consist of one or more directors of the Company as may be determined from time to time by resolution adopted by the Board,
which to the extent provided in said resolution or resolutions shall have and may exercise the powers of the Board as may be delegated to such committee in the management of the business and affairs of the Company; provided that the meetings and
proceedings of any such committee shall be governed by the provisions of these <FONT STYLE="white-space:nowrap">Bye-laws</FONT> regulating then meetings and proceedings of the Board, so far as the same are applicable and are not superseded by
directions imposed by the Board or any committee charters as approved by the Board. A majority of all the members of any such committee may determine its action and fix the time and place of its meetings, unless the Board shall otherwise provide.
The Board shall have power to change the members of any such committee at any time, to fill vacancies and to discharge any such committee, either with or without cause, at any time; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">delegate any of its powers (including the power to <FONT STYLE="white-space:nowrap">sub-delegate)</FONT> to any
person on such terms and in such manner as the Board may see fit; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">present any petition and make any application in connection with the liquidation or reorganisation of the
Company; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in connection with the issue of any share, pay such commission and brokerage as may be permitted by law; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(j)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">authorise any company, firm, person or body of persons to act on behalf of the Company for any specific purpose
and in connection therewith to execute any deed, agreement, document or instrument on behalf of the Company. </P></TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REGISTER
OF DIRECTORS AND OFFICERS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">127.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Secretary shall establish and maintain a Register of the Directors and Officers of the Company as required
by the Companies Act. The Register of the Directors and Officers shall be open to inspection without charge at the Registered Office of the Company on every Business Day, subject to such reasonable restrictions as the Board may impose, so that not
less than two hours in each Business Day be allowed for inspection. The Register of the Directors and Officers may, after notice has been given in accordance with the Companies Act, be closed for any time or times not exceeding in the whole thirty
days in each year. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>APPOINTMENT OF OFFICERS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">128.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Board may appoint such Officers (who may or may not be Directors) as the Board may determine. The chair of
the Board shall be appointed by the Board from amongst the Directors. </P></TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>APPOINTMENT OF SECRETARY AND RESIDENT
REPRESENTATIVE </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">129.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Secretary and Resident Representative, if necessary, shall be appointed by the Board at such remuneration
(if any) and upon such terms as it may think fit and any Secretary and Resident Representative so appointed may be removed by the Board. </P></TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DUTIES OF OFFICERS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">130.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Officers shall have such powers and perform such duties in the management, business and affairs of the
Company as may be delegated to them by the Board from time to time. </P></TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DUTIES OF THE SECRETARY </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">131.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The duties of the Secretary shall be those prescribed by the Companies Act together with such other duties as
shall from time to time be prescribed by the Board. </P></TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REMUNERATION OF OFFICERS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">132.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Officers shall receive such remuneration as the Board or any authorised committee thereof may determine.
</P></TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REMUNERATION OF DIRECTORS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">133.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The remuneration (if any) of the Directors shall be determined by the Board and shall be deemed to accrue from
day to day. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">134.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Directors may be paid all travel, hotel and other expenses properly incurred by them in attending and
returning from the meetings of the Board, any committee appointed by the Board, general meetings of the Company or separate meetings of the holders of any class of shares or of debentures of the Company, or otherwise in connection with the business
the Company or their duties as Directors generally. </P></TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFLICTS OF INTEREST </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">135.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to any rules and regulations of an Appointed Stock Exchange on which the shares are then listed or
admitted to trading, any Director, or any Director&#146;s firm, partner or any company with whom any Director is associated, may act in any capacity for, be employed by or render services to the Company and such Director or such Director&#146;s
firm, partner or company shall be entitled to remuneration as if such Director were not a Director. Nothing herein contained shall authorise a Director or Director&#146;s firm, partner or company to act as Auditor to the Company.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">136.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A Director who is directly or indirectly interested (an &#147;<B>Interested Director</B>&#148;) in a contract
or proposed contract or arrangement with the Company shall declare the nature of such interest as required by the Companies Act; provided that no such declaration shall be required to be made by a <FONT STYLE="white-space:nowrap">Non-Employee</FONT>
Directors (as defined below) in respect of such <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director being involved in any business opportunity which may be a corporate opportunity for the
<FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director and the Company or any of its Affiliates, as described in <FONT STYLE="white-space:nowrap">Bye-law</FONT> 139, subject to <FONT STYLE="white-space:nowrap">Bye-law</FONT> 142.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">137.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Following a declaration being made pursuant to <FONT STYLE="white-space:nowrap">Bye-laws</FONT> 136 or 138 or
the Companies Act, the Interested Director shall not be disqualified from participating in the discussion or voting on the matter unless the chair of the meeting determines that such Interested Director shall be disqualified as such. In the event
the chair of the meeting is the Interested Director making a declaration under <FONT STYLE="white-space:nowrap">Bye-laws</FONT> 136 or 138, the determination as to whether or not he should be disqualified may be made by a majority of the votes cast
by the Directors not having such interest. In addition, an Interested Director may, but shall not be required to, recuse himself from the discussion or voting on any particular matter because of possible conflict or for any other reason disclosed to
the other Directors. Any Interested Director that is so disqualified or that elects to be recused shall nevertheless be counted toward a quorum for the meeting. In the event that one or more Interested Directors are disqualified or elect to be
recused from voting on a matter, or one or more Directors are later found to have an interest or conflict that should have been declared, the matter shall be approved or stand approved if it is or was approved by a majority of the votes cast by the
Directors that do not have any interest or conflict in the matter, even if less than a quorum. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">138.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to the Companies Act and any further disclosure required thereby, a general notice to the Directors by
a Director or officer declaring that he or she is a director or officer or has an interest in any business entity and is to be regarded as interested in any transaction or arrangement made with that business entity shall be sufficient declaration of
interest in relation to any transaction or arrangement so made. </P></TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CORPORATE OPPORTUNITY </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">139.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In recognition and anticipation that (i)&nbsp;certain directors, principals, members, officers, associated
funds, employees and/or other representatives of the Principal Shareholder and its Affiliates may serve as directors, officers or agents of the Company, (ii)&nbsp;one or more of the Principal Shareholder and its Affiliates may now engage and may
continue to engage in the same or similar activities or related lines of business as those in which the Company, directly or indirectly, may engage and/or other business activities that overlap with or compete with those in which the Company,
directly or indirectly, may engage, and (iii)&nbsp;members of the Board who are not employees of the Company (the &#147;<B><FONT STYLE="white-space:nowrap">Non-Employee</FONT></B><B></B><B>&nbsp;Directors</B>&#148;) and their respective Affiliates
may now engage and may continue to engage in the same or similar activities or related lines of business as those in which the Company, directly or indirectly, may engage and/or other business activities that overlap with or compete with those in
which the Company, directly or indirectly, may engage, <FONT STYLE="white-space:nowrap">Bye-laws</FONT> <FONT STYLE="white-space:nowrap">139-145</FONT> (inclusive) are set forth to regulate and define the conduct of certain affairs of the Company
with respect to certain classes or categories of business opportunities as they may involve the Principal <FONT STYLE="white-space:nowrap">Shareholder,&nbsp;the&nbsp;Non-Employee&nbsp;Directors&nbsp;or</FONT> any of their respective Affiliates and
the powers, rights, duties and liabilities of the Company and its directors, officers and shareholders in connection therewith. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">140.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">None of (i)&nbsp;Principal Shareholder and its Affiliates or (ii)&nbsp;any
<FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director or his or her Affiliates (the Persons (as defined below) identified in (i)&nbsp;and (ii)&nbsp;above being referred to, collectively, as &#147;<B>Identified Persons</B>&#148; and,
individually, as an &#147;<B>Identified Person</B>&#148;) shall, to the Fullest Extent Permitted By Applicable Law, have any duty to refrain from directly or indirectly (1)&nbsp;engaging in the same or similar business activities or lines of
business in which the Company or any of its Affiliates now engages or proposes to engage or (2)&nbsp;otherwise competing with the </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Company or any of its Affiliates, and, to the Fullest Extent Permitted By Applicable Law, no Identified Person shall be liable to the Company or its shareholders or to any Affiliate of the
Company for breach of any fiduciary duty solely by reason of the fact that such Identified Person engages in any such activities. To the Fullest Extent Permitted By Applicable Law, the Company hereby renounces any interest or expectancy in, or right
to be offered an opportunity to participate in, any business opportunity which may be a corporate opportunity for an Identified Person and the Company or any of its Affiliates, except as provided in <FONT STYLE="white-space:nowrap">Bye-law</FONT>
142. Subject to <FONT STYLE="white-space:nowrap">Bye-law</FONT> 142, in the event that any Identified Person acquires knowledge of a potential transaction or other matter or business opportunity which may be a corporate opportunity for itself,
herself or himself and the Company or any of its Affiliates, such Identified Person shall, to the fullest extent permitted by law, have no fiduciary duty or other duty (contractual or otherwise) to communicate, present or offer such transaction or
other business opportunity to the Company or any of its Affiliates and, to the Fullest Extent Permitted By Applicable Law, shall not be liable to the Company or its shareholders or to any Affiliate of the Company for breach of any fiduciary duty or
other duty (contractual or otherwise) as a shareholder, director or officer of the Company solely by reason of the fact that such Identified Person pursues or acquires such corporate opportunity for itself, herself or himself, offers or directs such
corporate opportunity to another Person, or does not present such corporate opportunity to the Company or any of its Affiliates. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">141.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company and its Affiliates do not have any rights in and to the business ventures of any Identified Person,
or the income or profits derived therefrom, and the Company agrees that each of the Identified Persons may do business with any potential or actual customer or supplier of the Company or may employ or otherwise engage any officer or employee of the
Company. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">142.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding anything contained herein, the Company does not renounce its interest in any corporate
opportunity offered to any <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director&nbsp;if such opportunity is expressly offered to such person in writing solely in his or her capacity as a director of the Company, and the provisions of <FONT
STYLE="white-space:nowrap">Bye-law</FONT> 140 shall not apply to any such corporate opportunity. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">143.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding anything contained herein, a corporate opportunity shall not be deemed to be a potential
corporate opportunity for the Company if it is a business opportunity that (i)&nbsp;the Company is neither financially or legally able, nor contractually permitted to undertake, (ii)&nbsp;from its nature, is not in the line of the Company&#146;s
business or is of no practical advantage to the Company or (iii)&nbsp;is one in which the Company has no interest or reasonable expectancy. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">144.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For purposes of <FONT STYLE="white-space:nowrap">Bye-laws</FONT>
<FONT STYLE="white-space:nowrap">139-145,</FONT> (i) &#147;<B>Affiliate</B>&#148; shall mean with respect to the Principal Shareholder (a)&nbsp;any Person that, directly or indirectly, is controlled by the Principal Shareholder, controls the
Principal Shareholder or is under common control with the Principal Shareholder and shall include any principal, member, director, partner, shareholder, officer, employee or other representative of any of the foregoing (other than the Company and
any entity that is controlled by the Company), (b)&nbsp;in respect <FONT STYLE="white-space:nowrap">of&nbsp;a&nbsp;Non-Employee&nbsp;Director,&nbsp;any</FONT> Person that, directly or indirectly, is controlled
<FONT STYLE="white-space:nowrap">by&nbsp;such&nbsp;Non-Employee&nbsp;Director&nbsp;(other</FONT> than the Company and any entity that is controlled by the Company) and (c)&nbsp;in respect of the Company, any Person that, directly or indirectly, is
controlled by the Company; (ii) &#147;<B>control</B>&#148; (including the terms &#147;controlled by&#148; and &#147;under common control with&#148;), with respect to the relationship between or among two or more Persons, shall mean the possession,
directly or indirectly, of the power to direct or cause the direction of the affairs or management of a Person, whether through the ownership of voting securities, by contract or otherwise. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">145.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To the Fullest Extent Permitted By Applicable Law, any Person purchasing or otherwise acquiring or holding any
interest in shares of the Company shall be deemed to have notice of and to have consented to the provisions contained in <FONT STYLE="white-space:nowrap">Bye-laws</FONT> <FONT STYLE="white-space:nowrap">139-145</FONT> (inclusive). The alteration,
amendment, addition to or repeal of these <FONT STYLE="white-space:nowrap">Bye-laws</FONT> shall not eliminate or reduce the effect of <FONT STYLE="white-space:nowrap">Bye-laws</FONT> <FONT STYLE="white-space:nowrap">139-145</FONT> (inclusive) in
respect of any business opportunity first identified or any other matter occurring, or any cause of action, suit or claim that, but for <FONT STYLE="white-space:nowrap">Bye-laws</FONT> <FONT STYLE="white-space:nowrap">141-147</FONT> (inclusive).
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">would accrue or arise, prior to such alteration, amendment, addition, repeal or adoption.
</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INDEMNIFICATION AND EXCULPATION OF DIRECTORS AND OFFICERS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">146.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To the Fullest Extent Permitted by Applicable Law, a Director or Officer of the Company shall not be liable to
the Company or its Shareholders for breach of fiduciary duty as a Director or Officer. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">147.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">(1) Each person who was or is made a party or is threatened to be made a party to or participant in, or
otherwise becomes involved in, any Proceeding shall be indemnified by the Company to the Fullest Extent Permitted By Applicable Law against all Losses and Expenses actually and reasonably incurred by such person, or on such person&#146;s behalf, in
connection with such Proceeding or any claim, issue or matter therein. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(2) To the extent that the Indemnitee is
successful, on the merits or otherwise, in defence of any Proceeding, the Indemnitee shall be indemnified to the Fullest Extent Permitted By Applicable Law, against all Expenses actually and reasonably incurred by the Indemnitee or on the
Indemnitee&#146;s behalf in connection therewith. If the Indemnitee is not wholly successful in such Proceeding but is successful, on the merits or otherwise, as to one or more but less than all claims, issues or matters in such Proceeding, the
Company shall indemnify the Indemnitee against all Expenses actually and reasonably incurred by the Indemnitee or on the Indemnitee&#146;s behalf in connection with each successfully resolved claim, issue or matter. For purposes of this <FONT
STYLE="white-space:nowrap">Bye-law</FONT> 147(2) and without limitation, the termination of any claim, issue or matter in such a Proceeding by dismissal, with or without prejudice, on substantive or procedural grounds, shall be deemed to be a
successful result as to such claim, issue or matter. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(3) The Company shall advance, to the Fullest Extent Permitted By Applicable Law, all
Expenses incurred by or on behalf of the Indemnitee in connection with any Proceeding within thirty (30)&nbsp;days after the receipt by the Company of a statement or statements from the Indemnitee requesting such advance or advances from time to
time, whether prior to or after final disposition of such Proceeding. Such statement or statements shall reasonably evidence the Expenses incurred by the Indemnitee. The Indemnitee shall qualify for advances upon the execution and delivery to the
Company of an Indemnification Agreement, which shall constitute an undertaking providing that the Indemnitee undertakes to repay the amounts advanced by the Company, if and only to the extent that it is ultimately determined that the Indemnitee is
not entitled to be indemnified by the Company. Unless otherwise determined by the Board, no other form of undertaking shall be required other than the execution of an Indemnification Agreement. Any advances and undertakings to repay pursuant to the
Indemnification Agreement shall be unsecured and interest free. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">148.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">(1) Persons who after the date of the adoption of these <FONT STYLE="white-space:nowrap">Bye-Laws</FONT> become
or remain Directors or Officers of the Company or who, while a Director or Officer of the Company, become or remain, at the request of the Company, a director, officer, partner, trustee, member, manager, employee, agent or fiduciary of any
Enterprise, shall be conclusively presumed to have relied on the rights to indemnity, advancement of Expenses and other rights contained in <FONT STYLE="white-space:nowrap">Bye-law</FONT> 147 in entering into or continuing such service. To the
Fullest Extent Permitted By Applicable Law, the rights to indemnification and to the advancement of Expenses conferred in <FONT STYLE="white-space:nowrap">Bye-law</FONT> 147 shall apply to claims made against an Indemnitee arising out of acts or
omissions which occurred or occur both prior and subsequent to the adoption hereof. Any amendment or repeal of these <FONT STYLE="white-space:nowrap">Bye-laws</FONT> that adversely affects any right of an Indemnitee or its successors shall be
prospective only and shall not eliminate, reduce or otherwise adversely affect any such right or protection with respect to any Proceeding involving any action or omission that occurred or allegedly occurred prior to such amendment or repeal.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(2) Any person serving as a director, officer, partner, trustee, member, manager, employee,
agent or fiduciary of any Enterprise, at least 50% of whose equity interests are owned, directly or indirectly, by the Company shall be conclusively presumed to be serving in such capacity at the request of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(3) Any references to the &#147;Company&#148; in <FONT STYLE="white-space:nowrap">Bye-law</FONT> 147 shall include, in addition to the
resulting corporation, any constituent corporation (including any constituent of a constituent) absorbed in a consolidation, amalgamation or merger which, if its separate existence had continued, would have had power and authority to indemnify its
directors, officers and employees or agents, so that any Indemnitee shall stand in the same position under <FONT STYLE="white-space:nowrap">Bye-law</FONT> 149 with respect to the resulting or surviving corporation as they would have with respect to
such constituent corporation if its separate existence had continued. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(4) Any reference to an officer of any other Enterprise in <FONT
STYLE="white-space:nowrap">Bye-law</FONT> 147 shall be deemed to refer exclusively to an officer appointed by the board of directors or equivalent governing body of such other entity pursuant to the certificate of incorporation and <FONT
STYLE="white-space:nowrap">bye-laws</FONT> or equivalent organizational documents of such other corporation, partnership, joint venture, trust, employee benefit plan or other enterprise. The fact that any person who is or was an employee of the
Company or an employee of any other Enterprise, but not an officer thereof as described in the preceding sentence, has been given or has used the title of &#147;Vice President&#148; or any other title that could be construed to suggest or imply that
such person is or may be such an officer of the Company or of such other Enterprise shall not result in such person being constituted as, or being deemed to be, such an officer of the Company or of such other Enterprise for purposes of <FONT
STYLE="white-space:nowrap">Bye-law</FONT> 147. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">149.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each Shareholder agrees to waive any claim or right of action such Shareholder might have, whether individually
or by or in the right of the Company, against any Director or Officer on account of any action taken by such Director or Officer, or the failure of such Director or Officer to take any action in the performance of their duties with or for the
Company or any subsidiary thereof; provided that such waiver shall not extend to any matter in respect of any fraud or dishonesty which may attach to such Director or Officer, nor shall such waiver extend to any claims of violations of the
Securities Act or the Exchange Act, which waiver would be prohibited by&nbsp;Section 14 of the Securities Act and Section&nbsp;29(a) of the Exchange Act. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">150.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">(1) All rights to indemnification and advancement of Expenses under
<FONT STYLE="white-space:nowrap">Bye-law</FONT> 147 shall be deemed to be a contract between the Company and each Director or Officer of the Company who serves or served in such capacity at any time while this
<FONT STYLE="white-space:nowrap">Bye-law</FONT> is in effect. The rights to indemnification and to the advancement of Expenses conferred in <FONT STYLE="white-space:nowrap">Bye-law</FONT> 147 shall not be exclusive of any other right which any
person may have or hereafter acquire under these <FONT STYLE="white-space:nowrap">Bye-Laws</FONT> or under any statute, agreement, vote of stockholders or disinterested directors or otherwise; provided that, if the Indemnitee and the Company are
parties to an Indemnification Agreement, for so long as such Indemnification Agreement is in effect, the rights and obligations of the Company and the Indemnitee with respect to indemnification and the advancement of Expenses under such
Indemnification Agreement shall supersede and replace the rights to indemnification and advancement provided to such Indemnitee under these Bylaws, and such Indemnitee shall have no rights of indemnification and to the advancement of expenses except
as provided in such Indemnification Agreement, which are incorporated into these Bylaws by reference and made a part hereof. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(2) To the Fullest Extent Permitted By Applicable Law, if
<FONT STYLE="white-space:nowrap">Bye-law</FONT> 147 or any portion thereof shall be invalidated on any ground by any court of competent jurisdiction, then the Company shall nevertheless indemnify and advance Expenses to each person entitled to
indemnification under <FONT STYLE="white-space:nowrap">Bye-law</FONT> 147 as to all Expenses and Losses actually and reasonably incurred or suffered by such person and for which indemnification and advancement of Expenses is available to such person
pursuant to <FONT STYLE="white-space:nowrap">Bye-law</FONT> 147 to the fullest extent permitted by any applicable portion of <FONT STYLE="white-space:nowrap">Bye-law</FONT> 147 that shall not have been invalidated. Any repeal or amendment of <FONT
STYLE="white-space:nowrap">Bye-law</FONT> 147 or, to the Fullest Extent Permitted By Applicable Law, repeal or modification of relevant provisions of the Companies Act or any other applicable laws shall not in any way eliminate, reduce or otherwise
adversely affect any rights to indemnification and advancement of Expenses of such Director or Officer or the obligations of the Company arising hereunder with respect to any Proceeding arising out of, or relating to, any actions or omissions that
occurred or alleged to have occurred prior to the final adoption of such repeal, amendment or modification. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">151.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company may purchase and maintain insurance, at its expense, to protect itself and any person who is or was
or has agreed to become a Director, Officer, employee or agent of the Company or is or was serving at the request of the Company as a director, officer, partner, trustee, member, manager, employee, agent or fiduciary of any other Enterprise against
any Expenses or Losses asserted against them, whether or not the Company would have the power to indemnify such person against such Expenses or Losses under the Companies Act. </P></TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BOARD MEETINGS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">152.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Board may meet for the transaction of business, adjourn and otherwise regulate its meetings as it sees fit.
A resolution put to the vote at a meeting of the Board shall be carried by the affirmative votes of a majority of the votes cast and in the case of an equality of votes the resolution shall fail. </P></TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTICE OF BOARD MEETINGS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">153.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A Director may, and the Secretary on the requisition of a Director shall, at any time summon a meeting of the
Board. Notice of a meeting of the Board shall be deemed to be duly given to a Director if it is given to such Director orally (including in person or by telephone) or otherwise communicated or sent to such Director by post, electronic means or other
mode of representing words in a visible form at such Director&#146;s last known address or in accordance with any other instructions given by such Director to the Company for this purpose. </P></TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ELECTRONIC PARTICIPATION IN MEETINGS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">154.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Directors may participate in any meeting by such telephonic, electronic or other communication facilities or
means that permit all persons participating in the meeting to communicate with each other simultaneously and instantaneously, and participation in such a meeting shall constitute presence in person at such meeting. </P></TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>QUORUM AT BOARD MEETINGS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">155.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The quorum necessary for the transaction of business at a meeting of the Board shall be a majority of the
number of Directors then in office. </P></TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BOARD TO CONTINUE IN THE EVENT OF VACANCY </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">156.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Board may act notwithstanding any vacancy in its number but, if and so long as its number is reduced below
the number fixed by these <FONT STYLE="white-space:nowrap">Bye-laws</FONT> as the quorum necessary for the transaction of business at meetings of the Board, the continuing Directors or Director may act for the purpose of (i)&nbsp;summoning a general
meeting; or (ii)&nbsp;preserving the assets of the Company. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CHAIR TO PRESIDE </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">157.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Unless otherwise agreed by a majority of the Directors attending, the chair, if there be one, shall act as
chair at all meetings of the Board at which such person is present. In their absence a chair shall be appointed or elected by the Directors present at the meeting. </P></TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WRITTEN RESOLUTIONS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">158.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A resolution signed by all the Directors, which may be in counterparts, shall be as valid as if it had been
passed at a meeting of the Board duly called and constituted, such resolution to be effective on the date on which the last Director signs the resolution. A copy of the resolution shall be filed with the minutes in accordance with <FONT
STYLE="white-space:nowrap">Bye-law</FONT> 160. </P></TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VALIDITY OF PRIOR ACTS OF THE BOARD </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">159.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No regulation or alteration to these <FONT STYLE="white-space:nowrap">Bye-laws</FONT> made by the Company in a
general meeting shall invalidate any prior act of the Board which would have been valid if that regulation or alteration had not been made. </P></TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MINUTES </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">160.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Board shall cause minutes to be duly entered in books provided for the purpose: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">of all elections and appointments of Officers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">of the names of the Directors present at each meeting of the Board and of any committee appointed by the Board;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">of all resolutions and proceedings of general meetings of the Shareholders, meetings of the Board and meetings
of committees appointed by the Board. </P></TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PLACE WHERE CORPORATE RECORDS KEPT </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">161.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Minutes prepared in accordance with the Companies Act and these
<FONT STYLE="white-space:nowrap">Bye-laws</FONT> shall be kept by the Secretary at the Registered Office of the Company. </P></TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM AND USE OF SEAL </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">162.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company may adopt a seal in such form as the Board may determine. The Board may adopt one or more duplicate
seals for use in or outside Bermuda. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">163.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A seal may, but need not, be affixed to any deed, instrument, share certificate or document, and if the seal is
to be affixed thereto, it shall be attested by the signature of (i)&nbsp;any Director, (ii)&nbsp;any Officer, (iii)&nbsp;the Secretary or (iv)&nbsp;any person authorised by the Board for that purpose. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">164.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A Resident Representative may, but need not, affix the seal of the Company to certify the authenticity of any
copies of documents. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BOOKS OF ACCOUNT </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">165.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Board shall cause to be kept proper records of account with respect to all transactions of the Company and
in particular with respect to: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all amounts of money received and expended by the Company and the matters in respect of which the receipt and
expenditure relates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all sales and purchases of goods by the Company; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all assets and liabilities of the Company. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">166.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Such records of account shall be kept at the Registered Office of the Company, or subject to the Companies Act,
at such other place as the Board thinks fit and shall be available for inspection by the Directors during normal business hours. </P></TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FINANCIAL YEAR END </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">167.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The financial year end of the Company may be determined by resolution of the Board and failing such resolution
shall be 30&nbsp;April in each year. </P></TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANNUAL AUDIT </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">168.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to any rights to waive laying of accounts or appointment of an Auditor pursuant to the Companies Act,
the accounts of the Company shall be audited at least once in every year. </P></TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>APPOINTMENT OF AUDITOR </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">169.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to the Companies Act, at the annual general meeting or at a subsequent special general meeting in each
year, an Auditor shall be appointed by the Shareholders to audit the accounts of the Company. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">170.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Auditor may be a Shareholder but no Director, Officer or employee of the Company shall, during their
continuance in office, be eligible to act as an Auditor of the Company. </P></TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REMUNERATION OF AUDITOR </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">171.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Save in the case of an Auditor appointed pursuant to <FONT STYLE="white-space:nowrap">Bye-law</FONT> 178, the
remuneration of the Auditor shall be fixed by the Company in a general meeting or in such manner as the Shareholders may determine. In the case of an Auditor appointed pursuant to <FONT STYLE="white-space:nowrap">Bye-law</FONT> 178, the remuneration
of the Auditor shall be fixed by the Board. </P></TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DUTIES OF AUDITOR </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">172.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The financial statements provided for by these <FONT STYLE="white-space:nowrap">Bye-laws</FONT> shall be
audited by the Auditor in accordance with generally accepted auditing standards. The Auditor shall make a written report thereon in accordance with generally accepted auditing standards. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">173.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The generally accepted auditing standards referred to in this <FONT STYLE="white-space:nowrap">Bye-law</FONT>
may be U.S. generally accepted accounting principles or those of a country or jurisdiction other than Bermuda or such other generally accepted auditing standards as may be provided for in the Companies Act. If so, the financial statements and the
report of the Auditor shall identify the generally accepted auditing standards used. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CHANGE TO THE COMPANY&#146;S AUDITORS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">174.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No change to the Company&#146;s Auditors may be made save in accordance with the Companies Act.
</P></TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ACCESS TO RECORDS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">175.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Auditor shall at all reasonable times have access to all books kept by the Company and to all accounts and
vouchers relating thereto, and the Auditor may call on the Directors or Officers of the Company for any information in their possession relating to the books or affairs of the Company. </P></TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">176.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to any rights to waive laying of accounts pursuant to the Companies Act, financial statements as
required by the Companies Act shall be laid before the Shareholders in an annual general meeting. A resolution in writing made in accordance with <FONT STYLE="white-space:nowrap">Bye-law</FONT> 100 receiving, accepting, adopting, approving or
otherwise acknowledging financial statements shall be deemed to be the laying of such statements before the Shareholders in a general meeting. </P></TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DISTRIBUTION OF AUDITOR&#146;S REPORT </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">177.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The report of the Auditor shall be submitted to the Shareholders in an annual general meeting.
</P></TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VACANCY IN THE OFFICE OF AUDITOR </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">178.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Board may fill any casual vacancy in the office of the Auditor. </P></TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">WINDING-UP</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">179.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the Company shall be wound up the liquidator may, with the sanction of a Resolution, divide amongst the
Shareholders in specie or in kind the whole or any part of the assets of the Company (whether they shall consist of property of the same kind or not) and may, for such purpose, set such value as he or she deems fair upon any property to be divided
as aforesaid and may determine how such division shall be carried out as between the Shareholders or different classes of Shareholders. The liquidator may, with the like sanction, vest the whole or any part of such assets in the trustees upon such
trusts for the benefit of the Shareholders as the liquidator shall think fit, but so that no Shareholder shall be compelled to accept any shares or other securities or assets whereon there is any liability. </P></TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CHANGES TO <FONT STYLE="white-space:nowrap">BYE-LAWS</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">180.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No <FONT STYLE="white-space:nowrap">Bye-law</FONT> may be rescinded, altered or amended and no new <FONT
STYLE="white-space:nowrap">Bye-law</FONT> may be made save in accordance with the Companies Act and until the same has been approved by a resolution of the Board [and by a Resolution; provided that, from and after the Trigger Event, no <FONT
STYLE="white-space:nowrap">Bye-law</FONT> may be rescinded, altered or amended and no new <FONT STYLE="white-space:nowrap">Bye-law</FONT> may be made save in accordance with the Companies Act and until the same has been approved by a resolution of
the Board]<SUP STYLE="font-size:75%; vertical-align:top">4</SUP> and by a Special Resolution. </P></TD></TR></TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">4</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Bracketed language to be deleted in final bye-laws if the Principal Stockholder and its Affiliates collectively
beneficially own less than 50% of the issued common shares of the Company after giving effect to the IPO closing.] </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CHANGES TO THE MEMORANDUM OF ASSOCIATION </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">181.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No alteration or amendment to the Memorandum of Association may be made save in accordance with the Companies
Act and until same has been approved by a resolution of the Board [and by a Resolution; provided that, from and after the Trigger Event, no alteration or amendment to the Memorandum of Association may be made save in accordance with the Companies
Act and until same has been approved by a resolution of the Board]<SUP STYLE="font-size:75%; vertical-align:top">5</SUP> and by a Special Resolution. </P></TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXCLUSIVE JURISDICTION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">182.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the event that any dispute arises out of or in connection with the Companies Act or out of or in connection
with these <FONT STYLE="white-space:nowrap">Bye-laws,</FONT> including any question regarding the existence, validity, application, enforceability or scope of any <FONT STYLE="white-space:nowrap">Bye-law</FONT> and/or whether there has been any
breach of the Companies Act or these <FONT STYLE="white-space:nowrap">Bye-laws,</FONT> or any breach of a duty (including any fiduciary duty) by, or other wrongdoing by, a current or former Officer, Director, employee, agent or shareholder of the
Company to the Company or its shareholders (whether or not such a claim is brought in the name of a Shareholder or in the name of the Company), any such dispute shall be subject to the exclusive jurisdiction of the Supreme Court of Bermuda, unless
the Company (to the Fullest Extent Permitted By Applicable Law) selects or consents in writing to the selection of an alternative forum. Unless the Company consents in writing to the selection of an alternative forum, to the Fullest Extent Permitted
By Applicable Law,&nbsp;the federal district courts of the United States of America shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act against the Company or any director,
officer, employee or agent of the Company. To the Fullest Extent Permitted By Applicable Law, any Person purchasing or otherwise acquiring or holding any interest in shares of the Company shall be deemed to have notice of and consented to the
provisions of this <FONT STYLE="white-space:nowrap">Bye-law</FONT> 182. </P></TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MERGER AND AMALGAMATION </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">183.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company may merge or amalgamate in accordance with the Companies Act upon the approval by a<B>
</B>resolution of the Board and by the approval of Shareholders holding at least a majority of the issued shares entitled to vote and present in person or by proxy at such meeting; provided that the quorum for such meeting must be two or more
persons holding or representing at least a majority of the issued shares of the Company entitled to vote and present in person or by proxy at such meeting; provided, further, that if the Company shall at any time have only one Shareholder, one
Shareholder present in person or by proxy shall form a quorum for such meeting. </P></TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DISCONTINUANCE </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">184.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Board may exercise all the powers of the Company to discontinue the Company to a jurisdiction outside
Bermuda pursuant to the Companies Act. </P></TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BUSINESS COMBINATIONS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">185.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding anything contained in <FONT STYLE="white-space:nowrap">Bye-law</FONT> 183, any Business
Combination with any Interested Shareholder within a period of three years following the time of the transaction in which the person become an Interested Shareholder must be approved by the Board and authorised at an annual general meeting or
special general meeting by the affirmative vote of Shareholders holding at least 66 2/3% of the issued shares entitled to vote thereon that are not owned by the Interested Shareholder unless: </P></TD></TR></TABLE>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">5</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Bracketed language to be deleted in final bye-laws if the Principal Stockholder and its Affiliates collectively
beneficially own less than 50% of the issued common shares of the Company after giving effect to the IPO closing.] </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(i) prior to the time that the person became an Interested Shareholder, the Board approved
either the Business Combination or the transaction which resulted in the person becoming an Interested Shareholder; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(ii) upon
consummation of the transaction which resulted in the person becoming an Interested Shareholder, the Interested Shareholder owned at least 85% of the number of issued voting shares of the Company at the time the transaction commenced. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">186.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The restrictions contained in <FONT STYLE="white-space:nowrap">Bye-law</FONT> 185 shall not apply if:
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(i) a Shareholder becomes an Interested Shareholder inadvertently and (1)&nbsp;as soon as practicable divests itself of
ownership of sufficient shares so that the Shareholder ceases to be an Interested Shareholder; and (2)&nbsp;would not, at any time within the three-year period immediately prior to a Business Combination between the Company and such Shareholder,
have been an Interested Shareholder but for the inadvertent acquisition of ownership; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(ii) the Business Combination is proposed prior
to the consummation or abandonment of, and subsequent to the earlier of the public announcement or the notice required hereunder of, a proposed transaction which (1)&nbsp;constitutes one of the transactions described in the following sentence;
(2)&nbsp;is with or by a person who either was not an Interested Shareholder during the previous three years or who became an Interested Shareholder with the approval of the Board; and (3)&nbsp;is approved or not opposed by a majority of the members
of the Board then in office who were Directors prior to any person becoming an Interested Shareholder during the previous three years or were recommended for election or elected to succeed such Directors by resolution of the Board approved by a
majority of such Directors. The proposed transactions referred to in the preceding sentence are limited to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(a) a merger, amalgamation or
consolidation of the Company (except an amalgamation in respect of which, pursuant to the Companies Act, no vote of the shareholders of the Company is required); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(b) a sale, lease, exchange, mortgage, pledge, transfer or other disposition (in one transaction or a series of transactions), whether as part
of a dissolution or otherwise, of assets of the Company or of any entity directly or indirectly wholly-owned or majority-owned by the Company (other than to the Company or any entity directly or indirectly wholly-owned by the Company) having an
aggregate market value equal to 50% or more of either the aggregate market value of all of the assets of the Company determined on a consolidated basis or the aggregate market value of all the issued shares of the Company; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(c) a proposed tender or exchange offer for 50% or more of the issued voting shares of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company shall give not less than 20 days&#146; notice to all Interested Shareholders prior to the consummation of any of the transactions
described in subparagraphs (a)&nbsp;or (b) of the second sentence of this paragraph (ii). </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">187.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the purpose of <FONT STYLE="white-space:nowrap">Bye-laws</FONT> 185 - 187 only, the term:
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(i) &#147;<B>affiliate</B>&#148; means a person that directly, or indirectly through one or more intermediaries,
controls, or is controlled by, or is under common control with, another person; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(ii) &#147;<B>associate</B>&#148;, when used to indicate a relationship with any person,
means: (1)&nbsp;any company, partnership, unincorporated association or other entity of which such person is a director, officer or partner or is, directly or indirectly, the owner of 20% or more of any class of voting shares; (2)&nbsp;any trust or
other estate in which such person has at least a 20% beneficial interest or as to which such person serves as trustee or in a similar fiduciary capacity; and (3)&nbsp;any relative or spouse of such person, or any relative of such spouse, who has the
same residence as such person; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(iii) &#147;<B>Business Combination</B>&#148;, when used in reference to the Company and any Interested
Shareholder of the Company, means: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(a) any merger, amalgamation or consolidation of the Company or any entity directly or indirectly
wholly-owned or majority-owned by the Company, wherever incorporated, with (A)&nbsp;the Interested Shareholder or any of its affiliates, or (B)&nbsp;with any other company, partnership, unincorporated association or other entity if the merger,
amalgamation or consolidation is caused by the Interested Shareholder; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(b) any sale, lease, exchange, mortgage, pledge, transfer or other
disposition (in one transaction or a series of transactions), except proportionately as a shareholder of the Company, to or with the Interested Shareholder, whether as part of a dissolution or otherwise, of assets of the Company or of any entity
directly or indirectly wholly-owned or majority-owned by the Company which assets have an aggregate market value equal to 10% or more of either the aggregate market value of all the assets of the Company determined on a consolidated basis or the
aggregate market value of all the issued shares of the Company; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(c) any transaction which results in the issuance or transfer by the
Company or by any entity directly or indirectly wholly-owned or majority-owned by the Company of any shares of the Company, or any share of such entity, to the Interested Shareholder, except: (A)&nbsp;pursuant to the exercise, exchange or conversion
of securities exercisable for, exchangeable for or convertible into shares of the Company, or shares of any such entity, which securities were issued prior to the time that the Interested Shareholder became such; (B)&nbsp;pursuant to a dividend or
distribution paid or made, or the exercise, exchange or conversion of securities exercisable for, exchangeable for or convertible into shares of the Company, or shares of any such entity, which security is distributed, pro rata to all holders of a
class or series of shares subsequent to the time the Interested Shareholder became such; (C)&nbsp;pursuant to an exchange offer by the Company to purchase shares made on the same terms to all holders of such shares; or (D)&nbsp;any issuance or
transfer of shares by the Company; provided however, that in no case under items (B)-(D) of this subparagraph shall there be an increase in the Interested Shareholder&#146;s proportionate share of any class or series of shares; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(d) any transaction involving the Company or any entity directly or indirectly wholly-owned or majority-owned by the Company which has the
effect, directly or indirectly, of increasing the proportionate share of any class or series of shares, or securities convertible into any class or series of shares of the Company, or shares of any such entity, or securities convertible into such
shares, which is owned by the Interested Shareholder, except as a result of immaterial changes due to fractional share adjustments or as a result of any repurchase or redemption of any shares not caused, directly or indirectly, by the Interested
Shareholder; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(e) any receipt by the Interested Shareholder of the benefit, directly or indirectly (except proportionately as a
shareholder of the Company), of any loans, advances, guarantees or pledges (other than those expressly permitted in subparagraphs (A)-(D) of this paragraph) provided by or through the Company or any entity directly or indirectly wholly-owned or
majority-owned by the Company; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(iv) &#147;<B>control</B>&#148;, including the terms &#147;<B>controlling</B>&#148;,
&#147;<B>controlled by</B>&#148; and &#147;<B>under common control with</B>&#148;, means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a person, whether through the ownership
of voting shares, by contract or otherwise. A person who is the owner of 20% or more of the issued and outstanding voting shares of any company, partnership, unincorporated association or other entity shall be presumed to have control of such
entity, in the absence of proof by a preponderance of the evidence to the contrary; provided that notwithstanding the foregoing, such presumption of control shall not apply where such person holds voting shares, in good faith and not for the purpose
of circumventing this provision, as an agent, bank, broker, nominee, custodian or trustee for one or more owners who do not individually or as a group have control of such entity; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(v) &#147;I<B>nterested Shareholder</B>&#148; means any person (other than the Company and any entity directly or indirectly wholly-owned or
majority owned by the Company) that (1)&nbsp;is the owner of 15% or more of the issued voting shares of the Company (other than the Principal Shareholder and its Affiliates), or (2)&nbsp;is an affiliate or associate of any person listed in
(1)&nbsp;above; provided, however, that the term &#147;Interested Shareholder&#148; shall not include any person whose ownership of shares in excess of the 15% limitation set forth herein is the result of action taken solely by the Company unless
such person referred to in this proviso acquires additional voting shares of the Company otherwise than as a result of further corporate action not caused, directly or indirectly, by such person. For the purpose of determining whether a person is an
Interested Shareholder, the voting shares of the Company deemed to be issued shall include voting shares deemed to be owned by the person through application of paragraph (viii)&nbsp;below, but shall not include any other unissued shares which may
be issuable pursuant to any agreement, arrangement or understanding, or upon exercise of conversion rights, warrants or options, or otherwise; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(vi) &#147;<B>person</B>&#148; means any individual, company, partnership, unincorporated association or other entity; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(vii) &#147;<B>voting shares</B>&#148; means, with respect to any company, shares of any class or series entitled to vote generally in the
election of directors and, with respect to any entity that is not a company, any equity interest entitled to vote generally in the election of the governing body of such entity; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(viii) &#147;<B>owner</B>&#148;, including the terms &#147;<B>own</B>&#148; and &#147;<B>owned</B>&#148;, when used with respect to any shares,
means a person that individually or with or through any of its affiliates or associates: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(a) beneficially owns such shares, directly or
indirectly; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(b) has (A)&nbsp;the right to acquire such shares (whether such right is exercisable immediately or only after the passage of
time) pursuant to any agreement, arrangement or understanding, or upon the exercise of conversion rights, exchange rights, warrants or options, or otherwise; provided, however, that a person shall not be deemed the owner of shares tendered pursuant
to a tender or exchange offer made by such person or any of such person&#146;s affiliates or associates until such tendered shares are accepted for purchase or exchange; or (B)&nbsp;the right to vote such shares pursuant to any agreement,
arrangement or understanding; provided, however, that a person shall not be deemed the owner of any shares because of such person&#146;s right to vote such shares if the agreement, arrangement or understanding to vote such shares arises solely from
a revocable proxy or consent given in response to a proxy or consent solicitation made to 10 or more persons; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(c) has any agreement,
arrangement or understanding for the purpose of acquiring, holding, voting (except voting pursuant to a revocable proxy or consent as described in item (B)&nbsp;of subparagraph (b)&nbsp;of this paragraph), or disposing of such shares with any other
person that beneficially owns, or whose affiliates or associates beneficially own, directly or indirectly, such shares.<B> </B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>4
<FILENAME>d744414dex41.htm
<DESCRIPTION>EX-4.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 4.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#147;<U>ACT</U>&#148;), OR THE
SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR IN FORM AND SUBSTANCE SATISFACTORY TO THE COMPANY,
SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION. THE SECURITIES ISSUABLE HEREUNDER ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE FOR A PERIOD OF 180 DAYS FOLLOWING [&#149;], 2025 PURSUANT TO A <FONT
STYLE="white-space:nowrap">LOCK-UP</FONT> AGREEMENT EXECUTED BY THE HOLDER OF THIS WARRANT ON THE DATE OF ISSUANCE OF THIS WARRANT. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WARRANT TO PURCHASE SHARES </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="80%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I>Company</I>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Kestra Medical Technologies, Ltd., a limited company organized under the laws of Bermuda (the &#147;Company&#148;)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I>Number of Shares</I>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[&#149;]<SUP STYLE="font-size:75%; vertical-align:top">1</SUP> Common Shares (the &#147;Shares&#148;)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I>Type/Series of Shares</I>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Common Shares, par value $1.00 per share, of the Company (the &#147;Common Shares&#148;)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I>Warrant Price</I>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$[&#149;]<SUP STYLE="font-size:75%; vertical-align:top">2</SUP> per Common Share</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I>Issue Date</I>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[&#149;], 2025</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I>Expiration Date</I>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[December 28, 2030 // March&nbsp;7, 2032] <SUP STYLE="font-size:75%; vertical-align:top">3</SUP> (See also Section&nbsp;5.1(b))</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS WARRANT TO PURCHASE SHARES (THIS &#147;<U>WARRANT</U>&#148;) CERTIFIES THAT, for good and valuable
consideration, Kennedy Lewis Capital Partners Master Fund II LP, a Cayman Islands limited partnership, an affiliate of Kennedy Lewis Management LP, a Delaware limited partnership, with an office located at 80 Broad Street, 22nd Floor, New York, New
York, 10004, United States, Attention: [***], email: [***] (together with any successor or permitted assignee or transferee of this Warrant or of any Shares issued upon exercise hereof, &#147;<U>Holder</U>&#148;) is entitled to purchase the Shares
at the above-stated Warrant Price, all as set forth above and as adjusted pursuant to Section&nbsp;2 of this Warrant, subject to the provisions and upon the terms and conditions set forth in this Warrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Reference is made to that certain Warrant to Purchase Units, issued on [December 20, 2020 // March&nbsp;7, 2022]<SUP
STYLE="font-size:75%; vertical-align:top">4</SUP>, by West Affum Holdings, L.P., an exempted limited partnership registered in the Cayman Islands (&#147;<U>Holdings</U>&#148;) to Holder (as amended, restated or otherwise modified from time to time,
the &#147;<U>Prior Warrant</U>&#148;). The parties hereto, on behalf of themselves and each of their affiliates, hereby acknowledge and agree that this Warrant hereby replaces and supersedes the Prior Warrant in its entirety, the Prior Warrant is
hereby terminated in full, and no Person shall have any further rights or obligations pursuant to or in connection with the Prior Warrant without any further action by any Person (this sentence, the &#147;<U>Prior Warrant Termination</U>&#148;).
</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Note to Draft</U>: To be [&#149;] Common Shares in the warrant replacing the existing Tranche A warrant and
[&#149;] Common Shares in the warrant replacing the existing Tranche B warrant. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">2</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Note to Draft</U>: To be $[&#149;] per Common Shares in the warrant replacing the existing Tranche A warrant
and $[&#149;] per Common Shares in the warrant replacing the existing Tranche B warrant. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">3</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Note to Draft</U>: To be December&nbsp;28, 2030 in the warrant replacing the existing Tranche A warrant and
March&nbsp;7, 2032 in the warrant replacing the existing Tranche B warrant. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">4</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Note to Draft</U>: To be December&nbsp;20, 2022 in the warrant replacing the existing Tranche A warrant and
March&nbsp;7, 2022 in the warrant replacing the existing Tranche B warrant </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">SECTION 1 <U>EXERCISE</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.1 <U>Method of Exercise</U>. Holder may at any time and from time to time exercise this Warrant, in whole or in part, by delivering to the
Company the original of this Warrant together with (i)&nbsp;a duly executed Notice of Exercise in substantially the form attached hereto as Appendix 1 and, unless Holder is exercising this Warrant pursuant to a cashless exercise as set forth in
Section&nbsp;1.2, wire transfer of <FONT STYLE="white-space:nowrap">same-day</FONT> funds (to an account designated by the Company), or other form of payment acceptable to the Company, for the aggregate Warrant Price for the Shares being purchased
and (ii)&nbsp;any documentation required by Computershare Trust Company, National Association or any successor transfer agent of the Company (the &#147;<U>Transfer Agent</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.2 <U>Cashless Exercise</U>. In lieu of payment of the Warrant Price in the manner as specified in Section&nbsp;1.1 above, but otherwise in
accordance with the requirements of Section&nbsp;1.1, Holder may elect to surrender in payment of the aggregate Warrant Price for the Shares being purchased Shares equal in value to the aggregate Warrant Price for the Shares being purchased, in
which event the Company shall instruct the Transfer Agent to issue to the Holder such number of Shares in book entry form and Holder shall irrevocably surrender for no value the number of Shares subject to the Warrant as are computed using the
following formula: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">X = <FONT STYLE="white-space:nowrap">Y(A-B)/A</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">where: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">X = the number of
Shares to be issued to the Holder; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Y = the number of Shares with respect to which this Warrant is being exercised (inclusive of the
Shares subject to the Warrant surrendered to the Company in payment of the aggregate Warrant Price); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">A = the Fair Market Value; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">B = the Warrant Price; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">Y-X</FONT> = the number of Shares subject to the Warrant to be irrevocably surrendered for no value by the Holder in exchange for X number of Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.3 <U>Fair Market Value</U>. For the purpose of this Warrant, &#147;<U>Fair Market Value</U>&#148; shall mean, for any date: (a)&nbsp;if
Common Shares are then listed or quoted on the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock Exchange, OTCQB or OTCQX (or any successors to any of the foregoing) (each, a
&#147;<U>Trading Market</U>&#148;), the daily volume weighted average price of a Common Share for the trading day preceding such date on the Trading Market on which the Common Shares are then listed or quoted as reported by Bloomberg L.P., or
(b)&nbsp;if the Common Shares are not then listed or quoted for trading on a Trading Market, the fair market value of a Common Share as determined by the board of directors (or equivalent governing body) of the Company (the &#147;<U>Board</U>&#148;)
in its reasonable good faith judgment using all factors, information and data deemed by it to be pertinent. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.4 <U>Delivery of Shares and New Warrant</U>. Promptly after Holder exercises this Warrant
in the manner set forth in Section&nbsp;1.1 or 1.2 above, the Company shall: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) instruct the Transfer Agent to issue the applicable
Shares to Holder in book entry form; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) if this Warrant has not been fully exercised and has not expired, a new warrant of like
tenor representing the Shares not so acquired. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.5 <U>Replacement of </U>Warrant. On receipt of evidence reasonably satisfactory to the
Company of the loss, theft, destruction or mutilation of this Warrant and, in the case of loss, theft or destruction, on delivery of an indemnity agreement reasonably satisfactory in form, substance and amount to the Company or, in the case of
mutilation, on surrender of this Warrant to the Company for cancellation, the Company shall, within a reasonable time, execute and deliver to Holder, in lieu of this Warrant, a new warrant of like tenor and amount. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.6 <U>Treatment of Warrant Upon Acquisition of Company</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Acquisition. For the purpose of this Warrant, &#147;<U>Acquisition</U>&#148; means (i)&nbsp;the Company, directly or indirectly, in one
or more related transactions effects any merger or consolidation of the Company with or into another person (other than a transaction where the surviving entity has substantially the same shareholders (with substantially the same proportionate
shareholdings) as the Company immediately before such transaction), (ii) the Company, directly or indirectly, effects any sale, lease, exclusive license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets
in one or a series of related transactions, (iii)&nbsp;any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another person) is completed pursuant to which holders of Common Shares are permitted to sell,
tender or exchange their Common Shares for other securities, cash or property and such offer has been accepted by the holders of 50% or more of the outstanding Common Shares, or (iv)&nbsp;the Company, directly or indirectly, in one or more related
transactions consummates a share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, <FONT STYLE="white-space:nowrap">spin-off,</FONT> merger, amalgamation or scheme of arrangement)
with another person or group of persons whereby such other person or group acquires more than 50% of the outstanding Common Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b)
<U>Treatment of Warrant at Acquisition</U>. In the event of an Acquisition in which the consideration to be received by the Company&#146;s equityholders consists solely of cash, solely of Marketable Securities or a combination of cash and Marketable
Securities (a &#147;Cash/Public Acquisition&#148;), either (i)&nbsp;Holder shall exercise this Warrant pursuant to Section&nbsp;1.1 and/or 1.2 and such exercise will be deemed effective immediately prior to and contingent upon the consummation of
such Acquisition (or upon the Holder&#146;s written election to the Company, the Company shall cause this Warrant to be exchanged for the consideration that the Holder would have received in such Acquisition if the Holder had chosen to exercise its
right to have the Shares issued pursuant to Section&nbsp;1.2 without actually exercising such right, acquiring such Shares and exchanging such Shares for such consideration in such Acquisition) or (ii)&nbsp;if Holder elects not to exercise the
Warrant (or exchange the Warrant for the consideration that the Holder would have received in such Acquisition), this Warrant will expire immediately prior to the consummation of such Acquisition. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) The Company shall provide Holder with written notice of the Cash/Public Acquisition
(together with such reasonable information as Holder may reasonably require regarding the treatment of this Warrant in connection with such contemplated Cash/Public Acquisition giving rise to such notice), which is to be delivered to Holder not less
than seven (7)&nbsp;Business Days prior to the closing of the proposed Cash/Public Acquisition. Notwithstanding the foregoing, if, immediately prior to the consummation of the Cash/Public Acquisition, the Fair Market Value would be greater than the
Warrant Price in effect on such date, then this Warrant shall automatically be deemed on and as of such date to be exercised pursuant to Section&nbsp;1.2 above as to all Shares (or such other securities) for which it shall not previously have been
exercised, and the Company shall promptly notify the Holder of the number of Shares (or such other securities) issued upon such exercise to the Holder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) Upon the closing of any Acquisition other than a Cash/Public Acquisition defined above, the acquiring, surviving or successor entity
shall assume the obligations of this Warrant, and this Warrant shall thereafter be exercisable for the same securities and/or other property as would have been paid for the Shares issuable upon exercise of the unexercised portion of this Warrant as
if such Shares were outstanding on and as of the closing of such Acquisition, subject to further adjustment from time to time in accordance with the provisions of this Warrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.7 As used in this Warrant, &#147;Marketable Securities&#148; means securities meeting all of the following requirements: (i)&nbsp;the issuer
thereof is then subject to the reporting requirements of Section&nbsp;13 or Section&nbsp;15(d) of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), and is then current in its filing of all required reports and other
information under the Securities Act of 1933, as amended (the &#147;Act&#148;) and the Exchange Act; (ii)&nbsp;the class and series of units or other security of the issuer that would be received by Holder in connection with the Acquisition were
Holder to exercise this Warrant on or prior to the closing thereof is then traded in Trading Market; and (iii)&nbsp;Holder would be able to publicly <FONT STYLE="white-space:nowrap">re-sell,</FONT> within six (6)&nbsp;months following the closing of
such Acquisition, all of the issuer&#146;s units and/or other securities that would be received by Holder in such Acquisition were Holder to exercise this Warrant in full on or prior to the closing of such Acquisition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">SECTION 2 <U>ADJUSTMENTS TO THE </U><U>SHARES</U> AND WARRANT PRICE. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.1 <U>Share Dividends, Splits, Etc</U>. If the Company declares or pays a dividend or distribution on the outstanding Common Shares (or other
shares of the Company&#146;s capital stock into which this Warrant is then exercisable) payable in securities or property (other than cash), then upon exercise of this Warrant, for each Share acquired, Holder shall receive, without additional cost
to Holder, the total number and kind of securities and property which Holder would have received had Holder owned the Shares of record as of the date the dividend or distribution occurred. If the Company subdivides the outstanding Common Shares (or
other shares of the Company&#146;s capital stock into which this Warrant is then exercisable) by reclassification or otherwise into a greater number of shares, the number of Shares purchasable hereunder shall be proportionately increased and the
Warrant Price shall be proportionately decreased. If the outstanding shares of the Class&nbsp;are combined or consolidated, by reclassification or otherwise, into a lesser number of shares, the Warrant Price shall be proportionately increased and
the number of Shares shall be proportionately decreased. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.2 <U>Reclassification, Exchange, Combinations or Substitution</U>. Upon any
event other than an Acquisition whereby all of the outstanding Common Shares (or other shares of the Company&#146;s capital stock into which this Warrant is then exercisable) are reclassified, exchanged, combined, substituted, or replaced for, into,
with or by Company securities of a different class and/or series, then from and after the consummation of such event, this Warrant will be exercisable for the number, class and series of Company securities that Holder would have received had the
Shares been outstanding on and as of the consummation of such event, and subject to further adjustment thereafter from time to time in accordance with the provisions of this Warrant. The provisions of this Section&nbsp;2.2 shall similarly apply to
successive reclassifications, exchanges, combinations substitutions, replacements or other similar events. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.3 No <U>Fractional </U>Share. No fractional Share shall be issuable upon exercise of this
Warrant and the number of Shares to be issued shall be rounded down to the nearest whole Share. If a fractional Share interest arises upon any exercise of the Warrant, the Company shall eliminate such fractional Share interest by paying Holder in
cash the amount computed by multiplying the fractional interest by (a)&nbsp;the Fair Market Value, less (b)&nbsp;the then-effective Warrant Price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.4 <U>Notice/Certificate as to Adjustments</U>. Upon each adjustment of the Warrant Price, the Company, at the Company&#146;s expense, shall
notify Holder in writing within a reasonable time setting forth the adjustments to the Warrant Price and facts upon which such adjustment is based. The Company shall, upon written request from Holder, furnish Holder with a certificate of its Chief
Financial Officer, including computations of such adjustment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">SECTION 3 <U>REPRESENTATIONS AND COVENANTS OF THE COMPANY</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.1 <U>Representations and Warranties</U>. The Company represents and warrants to, and agrees with, the Holder that all Shares which may be
issued upon the exercise of this Warrant, and all securities, if any, issuable upon conversion of the Shares, shall, upon issuance, be duly authorized, validly issued, and free of any liens and encumbrances except for restrictions on transfer
provided for herein or under applicable federal and state securities laws. The Company covenants that it shall at all times cause to be reserved and kept available out of its authorized and unissued share capital such number of Shares as will be
sufficient to permit the exercise in full of this Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.2 <U>Notice of Certain Events</U>. If the Company proposes at any time to:
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) declare any distribution upon the outstanding Common Shares (or other shares of the Company&#146;s capital stock into which this
Warrant is then exercisable), whether in cash, property, units, or other securities and whether or not a regular cash distribution; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b)
offer for subscription or sale pro rata to the holders of the outstanding units of the Class&nbsp;any additional shares of any class or series of the Company&#146;s shares (other than pursuant to contractual
<FONT STYLE="white-space:nowrap">pre-emptive</FONT> rights); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) effect any reclassification, exchange, combination, substitution,
reorganization or recapitalization of the outstanding Common Shares (or other shares of the Company&#146;s capital stock into which this Warrant is then exercisable); or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) effect an Acquisition or to liquidate, dissolve or wind up; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">then, in connection with each such event, the Company shall give Holder: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(1) at least five (5)&nbsp;Business Days prior written notice of the date on which a record will be taken for such
distribution, or subscription rights (and specifying the date on which the holders of outstanding Common Shares (or other shares of the Company&#146;s capital stock into which this Warrant is then exercisable) will be entitled thereto) or for
determining rights to vote, if any, in respect of the matters referred to in (a)&nbsp;and (b) above; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(2) in the case of the matters referred to in (c)&nbsp;and (d) above at
least five (5)&nbsp;Business Days prior written notice of the date when the same will take place (and specifying the date on which the holders of outstanding Common Shares (or other shares of the Company&#146;s capital stock into which this Warrant
is then exercisable) will be entitled to exchange their units for the securities or other property deliverable upon the occurrence of such event). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Reference is made to Section&nbsp;1.6(c) whereby this Warrant will be deemed to be exercised pursuant to Section&nbsp;1.2 hereof if the
Company does not give written notice to Holder of a Cash/Public Acquisition as required by the terms hereof. Company will also provide information requested by Holder that is reasonably necessary to enable Holder to comply with Holder&#146;s
accounting or reporting requirements consistent with other investments of this type. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">SECTION 4 <U>REPRESENTATIONS AND WARRANTIES OF THE
HOLDER.</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Holder represents and warrants to the Company as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.1 <U>Purchase for Own Account</U>. This Warrant and the securities to be acquired upon exercise of this Warrant by Holder are being acquired
for investment for Holder&#146;s account, not as a nominee or agent, and not with a view to the public resale or distribution within the meaning of the Act. Holder also represents that it has not been formed for the specific purpose of acquiring
this Warrant or the Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.2 <U>Disclosure of Information</U>. Holder is aware of the Company&#146;s business affairs and financial
condition and has received or has had full access to all the information it considers necessary or appropriate to make an informed investment decision with respect to the acquisition of this Warrant and its underlying securities. Holder further has
had an opportunity to ask questions and receive answers from the Company regarding the terms and conditions of the offering of this Warrant and its underlying securities and to obtain additional information (to the extent the Company possessed such
information or could acquire it without unreasonable effort or expense) necessary to verify any information furnished to Holder or to which Holder has access. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.3 <U>Investment Experience</U>. Holder understands that the purchase of this Warrant and its underlying securities involves substantial
risk. Holder has experience as an investor in securities of companies in the development stage and acknowledges that Holder can bear the economic risk of such Holder&#146;s investment in this Warrant and its underlying securities and has such
knowledge and experience in financial or business matters that Holder is capable of evaluating the merits and risks of its investment in this Warrant and its underlying securities and/or has a preexisting personal or business relationship with the
Company and certain of its officers, directors or controlling persons of a nature and duration that enables Holder to be aware of the character, business acumen and financial circumstances of such persons. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.4 <U>Accredited Investor Status</U>. Holder is an &#147;accredited investor&#148; within the meaning of Regulation D promulgated under the
Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.5 <U>The Act</U>. Holder understands that this Warrant and the Units issuable upon
exercise hereof have not been registered under the Act in reliance upon a specific exemption therefrom, which exemption depends upon, among other things, the bona fide nature of the Holder&#146;s investment intent as expressed herein. Holder
understands that this Warrant and the Shares issued upon any exercise hereof must be held indefinitely unless subsequently registered under the Act and qualified under applicable state securities laws, or unless exemption from such registration and
qualification are otherwise available. Holder is aware of the provisions of Rule 144 promulgated under the Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.6 <U>No </U>Voting<U>
Rights</U>. Holder, as a Holder of this Warrant, will not have any voting or other rights as a shareholder of the Company until the exercise of this Warrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">SECTION 5 MISCELLANEOUS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.1
<U>Term and Automatic Conversion Upon Expiration</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) <U>Term</U>. Subject to the provisions of Section&nbsp;1.6 above, this Warrant
is exercisable in whole or in part at any time and from time to time on or before 6:00 P.M. Pacific time, on the Expiration Date and shall be void thereafter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Automatic Cashless Exercise upon Expiration. In the event that, on the Expiration Date, the Fair Market Value of one Share (or other
security issuable upon the exercise hereof) is greater than the Warrant Price in effect on such date, then this Warrant shall automatically be deemed on and as of such date to be exercised pursuant to Section&nbsp;1.2 above as to all Shares (or such
other securities) for which it shall not previously have been exercised, and the Company shall, within a reasonable time and if certificated, deliver a certificate representing the Shares (or such other securities) issued upon such exercise to
Holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.2 <U>Legends</U>. The Shares (and the securities issuable, directly or indirectly, upon conversion of the Shares, if any) shall
be imprinted with a legend in substantially the following form unless the Company has received an opinion of counsel acceptable to the Company stating that such Shares need not bear any such legend: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">THE SHARES EVIDENCED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#147;ACT&#148;), OR THE
SECURITIES LAWS OF ANY STATE AND MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER, SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT
FROM SUCH REGISTRATION. THE SHARES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE FOR A PERIOD OF 180 DAYS FOLLOWING [&#149;], 2025 PURSUANT TO A <FONT STYLE="white-space:nowrap">LOCK-UP</FONT> AGREEMENT A COPY OF WHICH MAY BE OBTAINED AT
THE PRINCIPAL OFFICE OF THE ISSUER. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.3 <U>Compliance with Securities Laws on Transfer</U>. This Warrant and the Shares issuable
upon exercise of this Warrant (or other shares of the Company&#146;s capital stock into which this Warrant is then exercisable) may not be transferred or assigned in whole or in part except in compliance with applicable federal and state securities
laws by the transferor and the transferee (including, without limitation, the delivery of investment representation letters and legal opinions reasonably satisfactory to the Company, as reasonably requested by the Company). The Company shall not
require Holder to provide an opinion of counsel if the transfer is to any affiliate of Holder. Additionally, the Company shall also not require an opinion of counsel if there is no material question as to the availability of Rule 144 promulgated
under the Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.4 <U>Transfer Procedure</U>. Without in any way limiting the provisions of Section&nbsp;5.3, the Holder shall not
Transfer, or agree or offer to Transfer, all or any part of any interest in this Warrant without the prior written consent of the Company, which consent may be withheld in the Company&#146;s discretion, <U>provided</U>, <U>however</U>, in connection
with any such transfer, Holder will give the Company notice of the portion of this Warrant being transferred with the name, address and taxpayer identification number of the transferee and Holder will surrender this Warrant to the Company for
reissuance to the transferee(s) (and Holder if applicable); and provided further, that any subsequent transferee shall agree in writing with the Company to be bound by all of the terms and conditions of this Warrant. For purposes of this Warrant,
&#147;Transfer&#148; means any sale, transfer, assignment, pledge, mortgage, exchange, hypothecation, grant of a security interest or other direct or indirect disposition or encumbrance of an interest (including by operation of law and whether with
or without consideration) or the act thereof, but explicitly excluding the exercise of this Warrant issued hereunder in accordance with its terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.5 <U>Notices</U>. All notices and other communications hereunder from the Company to the Holder, or vice versa, shall be deemed delivered
and effective (i)&nbsp;when given personally, (ii)&nbsp;on the third (3<SUP STYLE="font-size:75%; vertical-align:top">rd</SUP>) Business Day after being mailed by first-class registered or certified mail, postage prepaid, (iii)&nbsp;upon actual
receipt if given by electronic mail and such receipt is confirmed in writing by the recipient, or (iv)&nbsp;on the first Business Day following delivery to a reliable overnight courier service, courier fee prepaid, in any case at such address as may
have been furnished to the Company or Holder, as the case may be, in writing by the Company or such Holder from time to time in accordance with the provisions of this Section&nbsp;5.5. All notices to Holder shall be addressed as follows until the
Company receives notice of a change of address in connection with a transfer or otherwise:<U> </U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Kennedy Lewis Capital Partners Master
Fund II LP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">c/o Kennedy Lewis Investment Management </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">80 Broad Street, 22nd Floor </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">New York, NY 10004, United States </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: [***] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Email: [***]
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">With a copy (which shall not constitute notice) to: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Latham&nbsp;&amp; Watkins LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">505 Montgomery Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Suite
2000 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">San Francisco, CA 94111-6538 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attn: [***] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Email: [***] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notice to the Company shall be addressed as follows until Holder receives notice of a change
in address: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">c/o West Affum Holdings, L.P. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">3933 Lake Washington Blvd NE, Suite 200 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Kirkland, Washington 98033 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: [***] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Email: [***]
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">With a copy (which shall not constitute notice) to: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Kirkland&nbsp;&amp; Ellis LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">333 West Wolf Point Plaza </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Chicago, Illinois 606054 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: [***] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Email: [***]
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.6 <U>Waiver</U>. This Warrant and any term hereof may be changed, waived, discharged or terminated (either generally or in a particular
instance and either retroactively or prospectively) only by an instrument in writing signed by the party against which enforcement of such change, waiver, discharge or termination is sought. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.7 <U>Attorneys</U><U>&#146;</U><U> </U><U>Fees</U>. In the event of any dispute between the parties concerning the terms and provisions of
this Warrant, the party prevailing in such dispute shall be entitled to collect from the other party all costs incurred in such dispute, including reasonable attorneys&#146; fees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.8 <U>Counterparts</U>; Facsimile/Electronic Signatures. This Warrant may be executed in counterparts, all of which together shall constitute
one and the same agreement. Any signature page delivered electronically or by facsimile shall be binding to the same extent as an original signature page with regards to any agreement subject to the terms hereof or any amendment thereto. The words
&#147;execution,&#148; &#147;execute&#148;, &#147;signed,&#148; &#147;signature,&#148; and words of like import in or related to any document to be signed in connection with this Warrant and the transactions contemplated hereby (including without
limitation assignments, assumptions, amendments, waivers and consents) shall be deemed to include electronic signatures, the electronic matching of assignment terms and contract formations on electronic platforms approved by the Holder, or the
keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature or the use of a paper-based recordkeeping system, as the case may be, to the extent and as provided
for in any applicable law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records Act, or any other similar state laws based on the Uniform Electronic Transactions Act.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.9 <U>Governing Law</U>. This Warrant shall be governed by and construed in accordance with the laws of the State of New York without
giving effect to any choice or conflict of law provision or rule (whether of the State of New York or any other jurisdiction) that would cause the application of the substantive laws of any jurisdiction other than the State of New York. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.10 Headings. The headings in this Warrant are for purposes of reference only and shall not limit or otherwise affect the meaning of any
provision of this Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.11 Business Days. &#147;<U>Business Day</U>&#148; is any day that is not a Saturday, Sunday or a day on
which banks in New York, New York are closed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.12 <U>United States Dollars</U>. All dollar ($) amounts specified in this Warrant are
United States dollar amounts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature page follows</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have caused this Warrant to Purchase Units to be executed by
their duly authorized representatives effective as of the Issue Date written above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;COMPANY&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">KESTRA MEDICAL TECHNOLOGIES, LTD. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;HOLDER&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">KENNEDY
LEWIS CAPITAL PARTNERS MASTER FUND II LP, a Cayman Islands limited partnership </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Anthony Pasqua</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Authorized Signatory</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to Warrant to Purchase Shares] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Accepted and agreed, solely for purposes of the </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Prior Warrant Termination, in its capacity as </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">the Partnership (as defined in the Prior </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Warrant): </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">&#147;HOLDINGS&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">WEST
AFFUM HOLDINGS, L.P., a Cayman </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Islands exempted limited partnership by its </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">general partner WEST AFFUM GP LTD. a </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cayman Islands exempted
limited company. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"><FONT STYLE="font-size:10pt">Name:</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Print)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to Warrant to Purchase Shares] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>APPENDIX 1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>NOTICE OF EXERCISE </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.
The undersigned Holder hereby exercises its right purchase ___________ Common Shares, par value $1.00 per share, of Kestra Medical Technologies, Ltd., a limited company organized under the laws of Bermuda (the &#147;<U>Company</U>&#148;), in
accordance with the attached Warrant To Purchase Shares, and tenders payment of the aggregate Warrant Price for such Common Shares as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">[&#8195;]</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Wire transfer of immediately available funds to the Company&#146;s account </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">[&#8195;]</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Cashless Exercise pursuant to Section&nbsp;1.2 of the Warrant </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">[&#8195;]</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Other [describe] <U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U>
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. Please instruct the Transfer Agent to issue such Common Shares in the name(s) specified below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name(s): <U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. By its execution below and for the benefit of the Company, Holder hereby restates each of the representations and warranties in SECTION 4
of the Warrant to Purchase Shares as of the date hereof. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">HOLDER:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(Date):</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Appendix 3 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>5
<FILENAME>d744414dex42.htm
<DESCRIPTION>EX-4.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 4.2 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WARRANT CERTIFICATE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS
WARRANT CERTIFICATE AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#147;<B><I>SECURITIES ACT</I></B>&#148;), OR QUALIFIED UNDER ANY STATE OR FOREIGN
SECURITIES LAWS AND MAY NOT BE OFFERED FOR SALE, SOLD, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED OR ASSIGNED UNLESS (I)&nbsp;A REGISTRATION STATEMENT COVERING SUCH SECURITIES IS EFFECTIVE UNDER THE SECURITIES ACT AND IS QUALIFIED UNDER
APPLICABLE STATE AND FOREIGN LAW OR (II)&nbsp;THE TRANSACTION IS EXEMPT FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS UNDER THE SECURITIES ACT AND THE QUALIFICATION REQUIREMENTS UNDER APPLICABLE STATE AND FOREIGN LAW. THIS WARRANT
CERTIFICATE AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT CERTIFICATE ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE FOR A PERIOD OF 180 DAYS FOLLOWING [&#149;], 2025 PURSUANT TO A
<FONT STYLE="white-space:nowrap">LOCK-UP</FONT> AGREEMENT EXECUTED BY THE HOLDER OF THIS WARRANT PRIOR TO THE DATE OF ISSUANCE OF THIS WARRANT. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="22%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="75%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Warrant Securities Issuable:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Initially, up to [&#149;] Common Shares, par value $1.00 per share, of the Issuer (the &#147;<B><I>Common Shares</I></B>&#148;), as such number of Warrant Securities may be increased pursuant to <B>Section</B><B></B><B>&nbsp;2(a)
</B>or adjusted pursuant to <B>Section</B><B></B><B>&nbsp;4.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Warrant Certificate No.:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">2025-01</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Issue Date:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[&#149;], 2025 (the &#147;<B><I>Initial Issue Date</I></B>&#148;)</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FOR VALUE RECEIVED, <B>KESTRA MEDICAL TECHNOLOGIES, LTD., </B>an exempted company limited by shares
incorporated under the laws of Bermuda (the &#147;<B><I>Issuer</I></B>&#148;), hereby certifies that Perceptive Credit Holdings IV, LP, a Delaware limited partnership (the &#147;<B><I>Holder</I></B>&#148;) is entitled to purchase from the Issuer
that number of Warrant Securities calculated in accordance with <B>Section</B><B></B><B>&nbsp;2(a), </B>at the per share Exercise Price (defined below), subject to the terms, conditions and adjustments set forth below in this Warrant Certificate.
Certain capitalized terms used herein are defined in <B>Section</B><B></B><B>&nbsp;1</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Reference is made to that certain Warrant
Certificate, Number <FONT STYLE="white-space:nowrap">2023-01,</FONT> issued on September&nbsp;29, 2023, by West Affum Holdings, L.P., an exempted limited partnership registered in the Cayman Islands (&#147;<B><I>Holdings</I></B>&#148;) to the
Holder, as amended by that certain First Amendment to Warrant Certificate, dated July&nbsp;12, 2024 (the &#147;<B><I>Prior Warrant</I></B>&#148;). The parties hereto, on behalf of themselves and each of their Affiliates, hereby acknowledge and agree
that this Warrant Certificate hereby replaces and supersedes the Prior Warrant in its entirety, the Prior Warrant is hereby terminated in full, and no Person shall have any further rights or obligations pursuant to or in connection with the Prior
Warrant, in each case, without any further action by any Person (this sentence, the &#147;<B><I>Prior Warrant Termination</I></B>&#148;). </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;1.</B> <B>Definitions</B>. The following terms when used herein have the
following meanings: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Acquisition</I></B>&#148; has the meaning set forth in <B>Section</B><B></B><B>&nbsp;3(m)</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Additional Warrant Securities</I></B>&#148; has the meaning set forth in Section&nbsp;2(a)(ii). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Affiliate</I></B>&#148; means, with respect to a specified Person, another Person that directly, or indirectly through one or more
intermediaries, Controls or is Controlled by or is under common Control with the Person specified, where <I>&#147;</I><B><I>Control</I></B><I>&#148;</I> means, in respect of a particular Person, the possession, directly or indirectly, of the power
to direct or cause the direction of the management or policies of such Person, whether through the ability to exercise voting power, by contract or otherwise. <I>&#147;</I><B><I>Controlled</I></B><I>&#148;</I> have meanings correlative
thereto.<B><I> </I></B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Aggregate Exercise Price</I></B>&#148; means, with respect to any exercise of this Warrant
Certificate for Warrant Securities, an amount equal to the product of (i)&nbsp;the number of Warrant Securities in respect of which this Warrant Certificate is then being exercised pursuant to <B>Section</B><B></B><B>&nbsp;3 </B>multiplied by
(ii)&nbsp;the Exercise Price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Anticipated Sale</I></B>&#148; has the meaning set forth in
<B>Section</B><B></B><B>&nbsp;3(j)</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Bloomberg</I></B>&#148; has the meaning set forth within the definition of VWAP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Business Day</I></B>&#148; means any day, except a Saturday, Sunday or legal holiday on which banking institutions in the city of
New York, New York are authorized or obligated by law or executive order to close. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I><FONT STYLE="white-space:nowrap">Bye-Laws</FONT></I></B>&#148; means the Issuer&#146;s
<FONT STYLE="white-space:nowrap">bye-laws</FONT> from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Cash Acquisition</I></B>&#148; has the meaning set forth
in <B>Section</B><B></B><B>&nbsp;3(m)</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Cashless Exercise</I></B>&#148; has the meaning set forth in
<B>Section</B><B></B><B>&nbsp;3(b)</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Common Shares</I></B>&#148; has the meaning set forth in the preamble. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Convertible Securities</I></B>&#148; means any debt, equity or other securities that are, directly or indirectly, convertible into
or exchangeable for Warrant Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Credit Agreement</I></B>&#148; means that certain Credit Agreement and Guaranty dated
as of September&nbsp;29, 2023, among Kestra Medical Technologies, Inc. and West Affum Holdings Corp. as borrowers, the guarantors party thereto, the lenders from time to time party thereto, and Perceptive Credit Opportunities Fund IV, LP, as the
administrative agent, as amended by that certain Consent and First Amendment to Credit Agreement, dated as of July&nbsp;12, 2024, that certain Second Amendment to Credit Agreement, dated as of February 25, 2025, and as may be further amended&nbsp;or
otherwise modified from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>&#147;Delivery Deadline&#148; </I></B>means, (x)&nbsp;at any time that the Issuer&#146;s
equity securities are not being traded on a Trading Market, five (5)&nbsp;Business Days after the Exercise Date in respect of such exercise, and (y)&nbsp;at any time that the Issuer&#146;s equity securities are traded on a Trading Market, two
(2)&nbsp;Business Days after the Exercise Date in respect of such exercise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Delivery Failure</I></B>&#148; means the failure by the Issuer, for any reason,
to deliver Warrant Securities to the Holder or its designee on or prior to the Delivery Deadline. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>DTC</I></B>&#148; means the
Depository Trust Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Exercise Certificate</I></B>&#148; has the meaning set forth in
<B>Section</B><B></B><B>&nbsp;3(a)(i)</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Exercise Date</I></B>&#148; means, for any given exercise of this Warrant
Certificate, whether in whole or in part, the date on which the conditions to such exercise as set forth in <B>Section</B><B></B><B>&nbsp;3</B> shall have been satisfied at or prior to 5:00&nbsp;p.m., Eastern time, on a Trading Day, including,
without limitation, the receipt by the Issuer of the Exercise Certificate and the Aggregate Exercise Price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Exercise
Period</I></B>&#148; has the meaning set forth in <B>Section</B><B></B><B>&nbsp;2(b)</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Exercise Price</I></B>&#148; means
$[&#149;] per Warrant Security, as the same may be adjusted as set forth herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Fair Market Value</I></B>&#148; means, as of
any particular Trading Day,&nbsp;the VWAP of such equity securities for such day. If the Issuer&#146;s equity securities are not listed, quoted or otherwise available for trading, the &#147;Fair Market Value&#148; of the applicable class of equity
securities shall be the fair market value, per share, of such equity securities as determined jointly by the Issuer and the Holder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Fundamental Change</I></B>&#148; means any event or circumstance that constitutes or results in (i)&nbsp;an Acquisition or
(ii)&nbsp;the Liquidation of the Issuer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Holder</I></B>&#148; has the meaning set forth in the preamble. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Holdings</I></B>&#148; has the meaning set forth in the preamble. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Initial Issue Date</I></B>&#148; has the meaning set forth in the preamble. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Issue Date</I></B><I>&#148; </I>means the Initial Issue Date or the applicable date that Additional Warrant Securities are issued
pursuant to <B>Section</B><B></B><B>&nbsp;2(a)</B>, as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Issuer</I></B>&#148; has the meaning set forth in the
preamble and, for the avoidance of doubt, includes any corporation or other entity into which the Issuer may convert, amalgamate or merge following the date hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Liquidation</I></B>&#148;<B><I> </I></B>means the liquidation, dissolution or winding up of the Issuer, whether voluntary or
involuntary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Nasdaq</I></B>&#148; means The Nasdaq Stock Market, Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Options</I></B>&#148; means any warrants or other rights or options to subscribe for or purchase Warrant Securities or Convertible
Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>OTC Bulletin Board</I></B>&#148; means the National Association of Securities Dealers, Inc. OTC Bulletin Board.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Perceptive Fund</I></B>&#148; means Perceptive Credit Holdings IV, LP and any
Affiliate of Perceptive Credit Holdings IV, LP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Person</I></B>&#148; means any individual, sole proprietorship, partnership,
limited liability company, corporation, exempted company, exempted limited partnership, joint venture, trust, incorporated organization or government or department or agency thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Prior Warrant</I></B>&#148; has the meaning set forth in the preamble. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Purchase Rights</I></B>&#148; has the meaning set forth in <B>Section</B><B></B><B>&nbsp;5</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Registration Agreement</I></B>&#148; means the Second Amended and Restated Registration Rights Agreement, dated July&nbsp;15,
2024, which was assigned to and assumed by the Issuer in connection with its initial public offering and to which the Holder has become a party by signing a joinder thereto in connection with this Warrant Certificate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>SEC</I></B>&#148; means the Securities and Exchange Commission or any successor thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Securities Act</I></B>&#148; means the Securities Act of 1933, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Trading Day</I></B>&#148; means, (x)&nbsp;at any time that the Issuer&#146;s equity securities are not being traded on a Trading
Market, a Business Day, and (y)&nbsp;at any time that the Issuer&#146;s equity securities are traded on a Trading Market, a day on which the applicable Trading Market is open for trading. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Trading Market</I></B>&#148; means Nasdaq or, if the Issuer&#146;s equity securities are not listed on Nasdaq, such other
principal US or foreign exchange or market (including the OTC Bulletin Board) on which the Issuer&#146;s equity securities are quoted or available for trading. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Transfer Agent</I></B>&#148; means Computershare Trust Company, National Association or any successor transfer agent of the
Issuer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Unlegended Securities</I></B>&#148; has the meaning set forth in <B>Section</B><B></B><B>&nbsp;12(a)(iii)</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Unrestricted Conditions</I></B>&#148; has the meaning set forth in <B>Section</B><B></B><B>&nbsp;12(a)(ii)</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>VWAP</I></B>&#148; means, for any security as of any day or period of days (as the case may be), the volume weighted average sale
price on the Trading Market as reported by, or based upon data reported by Bloomberg Financial Markets or an equivalent, reliable reporting service reasonably acceptable to the Holder and the Issuer (collectively,
&#147;<B><I>Bloomberg</I></B>&#148;) or, if no volume weighted average sale price is reported for such security by Bloomberg, then the last closing trade price of such security as reported by Bloomberg, or, if no last closing trade price is reported
for such security by Bloomberg, the average of the bid prices of any market makers for such security that are listed in the over the counter market by the Financial Industry Regulatory Authority, Inc. or on the OTC Bulletin Board (or any successor)
or in the &#147;pink sheets&#148; (or any successor) by the OTC Markets Group, Inc. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Warrant</I></B>&#148; or<B><I> &#147;Warrant Certificate</I></B>&#148; means
this Warrant Certificate and all subsequent warrant certificates issued upon division, combination or transfer of, or in substitution for, this Warrant Certificate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Warrant Register</I></B>&#148; has the meaning set forth in <B>Section</B><B></B><B>&nbsp;7</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Warrant Securities</I></B>&#148; means the Common Shares or other equity securities or equivalent interests of the Issuer then
purchasable upon exercise of this Warrant Certificate in accordance with the terms of this Warrant Certificate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;2.</B>
<B>Number of Warrant Securities; Term of Warrant Certificate</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <B>Number of Warrant Securities</B>. The number of Warrant
Securities that are subject to this Warrant Certificate shall be determined in accordance with the following terms: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) On the date
hereof, this Warrant Certificate shall be exercisable for [&#149;] Warrant Securities (such Warrant Securities, the &#147;<B><I>Initial Warrant Securities</I></B>&#148;). The Issuer represents and warrants that, as of the Issue Date, the Initial
Warrant Securities have an Aggregate Exercise Price equal to $[&#149;]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) On each date that additional funds are advanced under the
Credit Agreement, the number of Warrant Securities purchasable pursuant to this Warrant Certificate shall automatically increase such that the Aggregate Exercise Price for all Warrant Securities purchasable hereunder is equal to 10% of the aggregate
amount funded under the Credit Agreement (such Warrant Securities, the &#147;<B><I>Additional Warrant Securities</I></B>&#148;). For the avoidance of doubt, the initial Exercise Price for the Additional Warrant Securities shall be the same as the
initial Exercise Price for the Initial Warrant Securities, subject to any adjustment pursuant to <B>Section</B><B></B><B>&nbsp;4</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Holder shall be entitled to exercise this Warrant Certificate to purchase all or any portion of the Warrant Securities that are issuable hereunder pursuant to the terms of this <B>Section</B><B></B><B>&nbsp;2(a)</B>, and all references herein to the
&#147;<B><I>Warrant Securities</I></B>&#148; shall refer to the Initial Warrant Securities and the Additional Warrant Securities (if any), calculated as of the relevant date of determination. As promptly as reasonably practicable following the
receipt by the Issuer of a written request by the Holder, but in any event not later than five Business Days thereafter, the Issuer shall furnish to the Holder a certificate executed by any duly authorized officer of the Issuer certifying the number
of Warrant Securities for which this Warrant Certificate is exercisable, or the amount, if any, of other securities or assets then issuable upon exercise of this Warrant Certificate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <B>Exercise Period. </B>Subject to the terms and conditions hereof, at any time or from time to time on or after the applicable Issue Date
and prior to 5:00&nbsp;p.m., Eastern time, on the tenth anniversary of such date or, if such day is not a Trading Day, on the next preceding Trading Day (the &#147;<B><I>Exercise Period</I></B>&#148;), the Holder of this Warrant Certificate may
exercise this Warrant Certificate for all or any part of the Warrant Securities purchasable hereunder (subject to adjustment as provided herein); <U>provided</U> that, the Exercise Period with respect to the Initial Warrant Securities shall expire
on September&nbsp;29, 2033. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3.</B> <B>Exercise of Warrant Certificate</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <B>Exercise Procedure</B>. This Warrant Certificate may be exercised from time to time on any Trading Day during the Exercise Period, for
all or any part of the unexercised Warrant Securities, upon: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) delivery to the Issuer at its registered office of an Exercise
Certificate in the form attached hereto as <B>Exhibit</B><B></B><B>&nbsp;A</B> (each, an &#147;<B><I>Exercise Certificate</I></B>&#148;), duly completed (including specifying the number of Warrant Securities to be purchased) and executed; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) payment to the Issuer of the Aggregate Exercise Price in accordance with <B>Section</B><B></B><B>&nbsp;3(b)</B>; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) delivery to the Issuer of any other documentation required by the Transfer Agent in connection with exercise of this Warrant Certificate
or the issuance of the applicable Warrant Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <B>Payment of the Aggregate Exercise Price</B>. Payment of the Aggregate
Exercise Price shall be made, at the option of the Holder as expressed in the Exercise Certificate, by any of the following methods: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i)
by delivery to the Issuer of a certified or official bank check payable to the order of the Issuer or by wire transfer of immediately available funds to an account designated in writing by the Issuer, in the amount of such Aggregate Exercise Price;
or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) in lieu of payment of the Aggregate Exercise Price in the manner as specified in <B>Section</B><B></B><B>&nbsp;3(b)(i)</B>, but
otherwise in accordance with the requirements of <B>Section</B><B></B><B>&nbsp;3</B>, by electing to surrender in payment of the Aggregate Exercise Price for the Warrant Securities then issuable upon exercise of this Warrant Certificate a number of
Warrant Securities equal in value to the Aggregate Exercise Price of the Warrant Securities being purchased, in which case, the Issuer shall instruct the Transfer Agent to issue to the Holder such number of Warrant Securities in book entry form and
Holder shall irrevocably surrender for no value the number of Warrant Securities subject to this Warrant Certificate as are computed using the following formula: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="22%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="69%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">X =</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">Y[(A-B)/A]</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">where:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">X =</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">the number of Warrant Securities to be issued to the Holder;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Y = the number of Warrant Securities with respect to which this Warrant Certificate is being exercised
(inclusive of the Warrant Securities subject to this Warrant Certificate surrendered to the Issuer in payment of the Aggregate Exercise Price);</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">A = Fair Market Value per Warrant Security as of the Exercise Date;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">B =</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">the Exercise Price; and</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Y-X</FONT> = the number of Warrant Securities subject to this Warrant
Certificate to be irrevocably surrendered for no value by the Holder in exchange for X number of Warrant Securities.</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of any withholding or surrender of Warrant Securities pursuant to
<B>Section</B><B></B><B>&nbsp;3(b)(ii)</B> (solely to the extent of such withholding or surrender, a &#147;<B><I>Cashless Exercise</I></B>&#148;) where the number of equity securities whose value is equal to the Aggregate Exercise Price is not a
whole number, the number of equity securities or equivalent interests withheld by or surrendered to the Issuer shall be rounded up to the nearest whole equity security or equivalent interest and the Issuer shall make a cash payment to the Holder (by
delivery of a certified or official bank check or by wire transfer of immediately available funds) based on the incremental fraction of an equity security or equivalent interest being so withheld by or surrendered to the Issuer in an amount equal to
the product of (x)&nbsp;such incremental fraction of an equity security or equivalent interest being so withheld or surrendered multiplied by (y)&nbsp;in the case of Common Shares, the Fair Market Value per Warrant Security as of the Exercise Date.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of Rule&nbsp;144, to the extent permitted by applicable law, it is acknowledged and agreed that (i)&nbsp;the Warrant
Securities issuable upon any exercise of this Warrant Certificate in any Cashless Exercise transaction shall be deemed to have been acquired on the applicable Issue Date, and (ii)&nbsp;the holding period for any Warrant Securities issuable upon the
exercise of this Warrant Certificate in any Cashless Exercise transaction shall be deemed to have commenced on the applicable Issue Date; <U>provided </U>that the Issuer makes no representation or warranty regarding the commencement of the holding
period of any Warrant Securities or the availability of Rule 144 (or any equivalent rule). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <B>Delivery of Warrant Securities</B>.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) Following any Exercise Date, the Issuer shall, on or before the applicable Delivery Deadline, issue and deliver (or cause its
Transfer Agent to issue and deliver) in accordance with the terms hereof to or upon the order of the Holder that number Warrant Securities for the portion of this Warrant Certificate so exercised on such Exercise Date in book entry form, and shall
register (or cause its Transfer Agent to register) such securities in the register of members of the Issuer in the name of the Holder or, subject to compliance with <B>Section</B><B></B><B>&nbsp;8</B>, in such other Person&#146;s name as shall be
designated in the Exercise Certificate. If requested in writing by the Holder, the Issuer shall deliver to the Holder evidence of the issuance of the Warrant Securities purchased in connection with such exercise in a form and substance reasonably
acceptable to the Holder. This Warrant Certificate shall be deemed to have been exercised and the Warrant Securities shall be deemed to have been issued, and the Holder or any other Person so designated to be named therein shall be deemed to have
become a holder of record of such Warrant Securities for all purposes, as of the applicable Issue Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) If, at the time of exercise,
the Issuer has a Transfer Agent, then upon the exercise this Warrant Certificate in whole or in part, the Issuer shall, at its own cost and expense, take all necessary action, including obtaining and delivering an opinion of counsel, to assure that
the Transfer Agent shall issue Warrant Securities in the name of the Holder (or its nominee) or such other Persons as designated by the Holder (in compliance with <B>Section</B><B></B><B>&nbsp;8</B>) and in such denominations to be specified in the
applicable Exercise Certificate. The Issuer represents and warrants that no instructions other than the foregoing instructions will be given to the Transfer Agent and that, if the Unrestricted Conditions are met, the Warrant Securities will be
free-trading, and freely transferable, and will not contain a legend restricting the resale or transferability of the Warrant Securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) In addition to any other remedies which may be available to the Holder, in the event
of any Delivery Failure relating to the issuance of Warrant Securities upon exercise of this Warrant Certificate, the Holder will be entitled to revoke all or part of the relevant Exercise Certificate by delivery of a notice to such effect to the
Issuer whereupon the Issuer and the Holder shall each be restored to their respective positions immediately prior to the delivery of such Exercise Certificate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <B>Fractional Warrant Securities</B>. The Issuer may issue fractional Warrant Securities in accordance with the <FONT
STYLE="white-space:nowrap">Bye-Laws.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <B>Surrender of this Warrant Certificate; Delivery of New Warrant Certificate</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) Subject to <B>Section</B><B></B><B>&nbsp;3(e)(ii)</B>, the Holder shall not be required to physically surrender this Warrant Certificate
to the Issuer until the Holder has purchased (or acquired or surrendered pursuant to a Cashless Exercise) all of the Warrant Securities available hereunder and this Warrant Certificate has been exercised in full, in which case, the Holder shall, at
the written request of the Issuer, surrender this Warrant Certificate to the Issuer for cancellation within three&nbsp;(3) Business Days after the date the final Exercise Certificate is delivered to the Issuer. Partial exercises of this Warrant
Certificate resulting in purchases (or acquisition pursuant to a Cashless Exercise) of a portion of the total number of Warrant Securities available hereunder shall have the effect of lowering the outstanding number of Warrant Securities purchasable
hereunder in an amount equal to the applicable number of Warrant Securities purchased (or acquired or surrendered pursuant to a Cashless Exercise). The Holder and the Issuer shall maintain (or cause to be maintained, including through a Transfer
Agent) records showing the number of Warrant Securities purchased, otherwise acquired or surrendered and the date of such purchases, other acquisitions or surrenders. The Holder and any assignee, by acceptance of this Warrant Certificate,
acknowledge and agree that, by reason of the provisions of this <B>Section</B><B></B><B>&nbsp;3(e)</B>, following the purchase (or acquisition or surrender pursuant to a Cashless Exercise) of a portion of the Warrant Securities hereunder, the number
of Warrant Securities available for purchase hereunder at any given time may be less than the amount stated on the face hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii)
Notwithstanding the foregoing, the Holder may request that the Issuer (and the Issuer shall), following Holder&#146;s surrender of this Warrant Certificate to the Issuer, deliver to the Holder a new Warrant Certificate evidencing the rights of the
Holder to purchase the unexpired and unexercised Warrant Securities called for by this Warrant Certificate. Unless otherwise agreed upon by the Holder in its sole discretion, such new Warrant Certificate shall in all other respects be identical to
this Warrant Certificate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <B>Valid Issuance of Warrant Certificate and Warrant Securities; Payment of Taxes;
Covenants</B>. The Issuer hereby represents, covenants and agrees as of the date hereof, as of each subsequent Issue Date, and as of the Tranche C Borrowing Date (each as defined in the Credit Agreement): </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) The transactions contemplated by this Warrant Certificate are within the Issuer&#146;s organizational powers and have been duly authorized
by all necessary corporate action of the Issuer and, if required, by all necessary shareholder action. This Warrant Certificate has been duly executed and delivered by the Issuer and constitutes a legal, valid and binding obligation of the Issuer,
enforceable against the Issuer in accordance with its terms, except as such enforceability may be limited by (A)&nbsp;bankruptcy, insolvency, reorganization, moratorium or similar laws of general applicability affecting the enforcement of
creditors&#146; rights and (B)&nbsp;the application of general principles of equity (regardless of whether such enforceability is considered in a proceeding in equity or at law). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) This Warrant Certificate is, and any Warrant Certificate issued in substitution for or replacement of this Warrant Certificate delivered
in accordance with <B>Section</B><B></B><B>&nbsp;3(e)(ii)</B> shall be, upon issuance, duly authorized and validly issued. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) All
Warrant Securities issuable upon the exercise of this Warrant Certificate (or any substitute or replacement Warrant Certificate delivered in accordance with <B>Section</B><B></B><B>&nbsp;3(e)(ii)</B>) pursuant to the terms hereof shall be, upon
issuance, and the Issuer shall take all such actions as may be necessary or appropriate in order that such Warrant Securities are, validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable,</FONT> issued without violation of any
preemptive or similar rights of any shareholder of the Issuer and free and clear of all liens, except for restrictions on transfer provided for herein or in any <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement to which the Holder is a
party, or under applicable federal and state securities laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv) The Issuer shall take all such actions as may be necessary to ensure
that all such Warrant Securities are issued without violation by the Issuer of any applicable law or governmental regulation, or any requirements of any Trading Market upon which Common Shares, or other securities constituting Warrant Securities may
be listed at the time of such exercise (except for official notice of issuance which shall be promptly delivered by the Issuer upon each such issuance). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(v) Without duplication of any expense reimbursement provisions of the Credit Agreement, the Issuer shall bear and reimburse all of the
Holder&#146;s reasonable and documented <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs and expenses in connection with the evaluation and negotiation of this Warrant Certificate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(vi) Each of the Issuer on the one hand, and the Holder, on the other bear all of their and their respective Affiliates taxes that may be
imposed with respect to the issuance or delivery of Warrant Securities upon exercise of this Warrant Certificate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <B>Conditional
Exercise</B>. Notwithstanding any other provision hereof, if an exercise of any portion of this Warrant Certificate is to be made in connection with a Fundamental Change, such exercise may, at the election of the Holder, be conditioned upon the
consummation of such transaction, in which case such exercise shall not be deemed to be effective until immediately prior to the consummation of such transaction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <B>Reservation of Warrant Securities</B>. During the Exercise Period the Issuer shall at
all times reserve and keep available out of its authorized but unissued Common Shares or other securities or equivalent interests constituting Warrant Securities, solely for the purpose of issuance upon the exercise of this Warrant Certificate, the
maximum number of Warrant Securities issuable upon the exercise of this Warrant Certificate. The Issuer shall take all such actions as may be necessary or appropriate in order that the Issuer may validly and legally issue fully paid and
nonassessable Common Shares upon the exercise of this Warrant Certificate without the need for the passing of any further resolutions of its shareholders or obtaining any further consents from any party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <B>Delivery of Electronic Securities</B>. To the extent the Unrestricted Conditions are satisfied with respect to the Warrant Securities
to be issued to the Holder upon the exercise of this Warrant Certificate, the Issuer shall use its commercially reasonable best efforts to cause the Transfer Agent to electronically transmit such Warrant Securities to the Holder by crediting the
account of the Holder&#146;s prime broker with the DTC through its Deposit Withdrawal Agent Commission system. The time periods for delivery and penalties described herein shall apply to the electronic transmittals described herein. Any delivery not
effected by electronic transmission shall be effected by delivery of physical certificates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) <B>Make Whole</B>. In addition to any
other rights available to the Holder, if, as a result of a Delivery Failure in respect of Warrant Securities, the Holder is required by its broker to purchase (in an open market transaction or otherwise), or the Holder&#146;s brokerage firm
otherwise purchases, Warrant Securities to deliver in satisfaction of a sale anticipated to be made by the Holder of all or portion of such Warrant Securities which are the subject of such Delivery Failure (an &#147;<B><I>Anticipated
Sale</I></B>&#148;), then the Issuer shall (i)&nbsp;pay to the Holder, in cash, an amount equal to the reasonable and documented <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs and expenses
incurred by Holder in covering the trade (including reasonable and documented brokerage fees, if any), and (ii)&nbsp;at the option of the Holder, either reinstate the portion of this Warrant Certificate and equivalent number of Warrant Securities in
respect of which such Delivery Failure occurred, or deliver to the Holder the number of Warrant Securities that would have been issued had the Issuer timely complied with its obligations hereunder to issue such Warrant Securities upon such exercise.
For the avoidance of doubt, this <B>Section</B><B></B><B>&nbsp;3(j)</B> is intended as a &#147;make whole&#148; and shall not be interpreted in any manner that would result in the Holder being in a better economic position following application of
the provisions of this <B>Section</B><B></B><B>&nbsp;3(j)</B> than if there had not been a Delivery Failure. Holder shall provide the Issuer written notice indicating the amounts payable to the Holder, together with applicable confirmations and
other evidence reasonably requested by the Issuer. Nothing herein shall limit the Holder&#146;s right to pursue any other remedies available to it hereunder at law or in equity including, without limitation, a decree of specific performance and/or
injunctive relief with respect to any Delivery Failure. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) <B>Dispute Resolution</B>. In the case of any dispute as to the determination
of Fair Market Value =, the arithmetic calculation of the Exercise Price or any other computation required to be made hereunder, in the event the Holder and the Issuer, negotiating in good faith, are unable to settle such dispute within
five&nbsp;(5) Business Days (or such longer period as the parties may agree), then either party may elect to submit the disputed matter(s) for resolution by an independent accountant, appraiser or investment bank (with relevant experience)
acceptable to the other party. Such independent party&#146;s determination of such disputed matter(s) shall be binding upon all parties absent demonstrable error, and the Issuer and the Holder shall each pay one half of the fees and costs of such
independent party. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) <B>Automatic Exercise at Expiration or Liquidation</B>. If a Liquidation occurs with
respect to the Issuer at any time prior to the expiration of the Exercise Period and there remain any Warrant Securities subject to this Warrant Certificate, or if immediately prior to the expiration of the Exercise Period there remain any Warrant
Securities subject to this Warrant Certificate, this Warrant Certificate shall be deemed to be automatically exercised in full for the full number of remaining Warrant Securities, without the requirement for the delivery of an Exercise Certificate,
and if the automatic exercise is in connection with a Liquidation, the Holder shall receive its pro rata share of the proceeds from such Liquidation as if the Warrant Securities were outstanding immediately prior to the Liquidation (subject to <FONT
STYLE="white-space:nowrap">set-off</FONT> against the Aggregate Exercise Price); <U>provided</U> that,<I> </I>unless the giving of notice is not practicable due to the circumstances of the Liquidation, the Issuer shall give the Holder notice of any
pending Liquidation as soon as practicable but in any event not less than 10 Business Days prior to the anticipated consummation of the Liquidation and if the Holder does not wish to automatically have this Warrant Certificate exercised, the Holder
may opt out of such automatic exercise by written notice to the Issuer in advance of the consummation of the Liquidation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m)
<B>Treatment of Warrant Certificate Upon Acquisition of Issuer</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) For the purpose of this Warrant Certificate,
&#147;<B><I>Acquisition</I></B>&#148; means any transaction or series of related transactions involving: (w)&nbsp;the sale, lease, exclusive license or other disposition of all or substantially all of the assets of the Issuer to one or more third
parties not Controlled by the Issuer; (x)&nbsp;any amalgamation, merger or consolidation of the Issuer into or with another Person or entity (other than an amalgamation, merger or consolidation effected exclusively to change the Issuer&#146;s
domicile), or any other reorganization, in which the shareholders of the Issuer immediately prior to such amalgamation, merger, consolidation or reorganization, own less than a majority of the Issuer&#146;s (or the amalgamated company, surviving or
successor entity&#146;s) outstanding voting power immediately after such amalgamation, merger, consolidation or reorganization; and (y)&nbsp;any sale or other transfer by the shareholders of the Issuer to one or more Persons or group of Persons not
Controlled by the Issuer of equity securities or equivalent interests representing a majority of the Issuer&#146;s then-total outstanding combined voting power. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) In the event of an Acquisition in which the consideration to be received by the Issuer&#146;s shareholders consists solely of cash (a
&#147;<B><I>Cash Acquisition</I></B>&#148;), either (x)&nbsp;Holder shall exercise this Warrant Certificate pursuant to <B>Section</B><B></B><B>&nbsp;3</B> and such exercise will be deemed effective immediately prior to and contingent upon the
consummation of such Cash Acquisition or (y)&nbsp;if Holder elects not to exercise the Warrant, this Warrant will expire immediately prior to the consummation of such Cash Acquisition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) The Issuer shall provide Holder with written notice of its request relating to the Cash Acquisition (together with such information as
Holder may reasonably require regarding the treatment of this Warrant in connection with such contemplated Cash Acquisition giving rise to such notice), which is to be delivered to Holder not less than 10 days prior to the closing of the proposed
Cash Acquisition unless the giving of such notice is not legally permissible in connection with such Cash Acquisition. Notwithstanding the foregoing, if, immediately prior to the Cash </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Acquisition, the Fair Market Value of one Warrant Security would be greater than the Exercise Price in effect on such date, then this Warrant shall automatically be deemed on and as of such date
to be exercised pursuant a Cashless Exercise with respect to all Warrant Securities for which it shall not previously have been exercised, and the Issuer shall promptly notify the Holder of the number of Common Shares (or such other securities)
issued upon such exercise to the Holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv) Upon the closing of any Acquisition other than a Cash Acquisition, the acquiring, surviving
or successor entity shall assume the obligations of this Warrant, and this Warrant shall thereafter be exercisable for the same securities and/or other property as would have been paid for the Warrant Securities issuable upon exercise of the
unexercised portion of this Warrant as if such Warrant Securities were outstanding on and as of the closing of such Acquisition, subject to further adjustment from time to time in accordance with the provisions of this Warrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) <B>Holder</B><B>&#146;</B><B>s Exercise Limitations</B>. The Issuer shall not effect any exercise of this Warrant, and a Holder shall not
have the right to exercise any portion of this Warrant, pursuant to this <B>Section</B><B></B><B>&nbsp;3</B> or otherwise, to the extent that after giving effect to such issuance after exercise as set forth on the applicable Exercise Certificate,
the Holder (together with the Holder&#146;s Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder&#146;s Affiliates), would beneficially own in excess of the Beneficial Ownership Limitation (as defined
below).&nbsp;For purposes of the foregoing sentence, the number of Common Share equivalents beneficially owned by the Holder and its Affiliates shall include the number of Common Share equivalents issuable upon exercise of this Warrant with respect
to which such determination is being made, but shall exclude the number of Common Share equivalents which would be issuable upon (i)&nbsp;exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its
Affiliates, and (ii)&nbsp;exercise or conversion of the unexercised or nonconverted portion of any other securities of the Issuer (including, without limitation, any other Common Share equivalents) subject to a limitation on conversion or exercise
analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates.&nbsp;Except as set forth in the preceding sentence, for purposes of this <B>Section</B><B></B><B>&nbsp;3(n),</B> beneficial ownership shall be
calculated in accordance with Section&nbsp;13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Issuer is not representing to the Holder that such calculation is in compliance
with Section&nbsp;13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in this <B>Section</B><B></B><B>&nbsp;3(n)</B> applies, the
determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the
submission of an Exercise Certificate shall be deemed to be the Holder&#146;s determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates) and of which portion of this
Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Issuer shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated
above shall be determined in accordance with Section&nbsp;13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this <B>Section</B><B></B><B>&nbsp;3(n),</B> in determining the number of outstanding Common
Shares, Holder may rely on the number of outstanding Common Shares as reflected in the most recent public announcement by the Issuer. Upon the written request of a Holder, the Issuer shall within five (5)&nbsp;Business Days confirm orally
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and in writing to the Holder the number of Common Shares then outstanding. In any case, the number of outstanding Common Shares shall be determined after giving effect to the conversion or
exercise of securities of the Issuer, including this Warrant, by the Holder or its Affiliates since the date as of which such number of outstanding Common Shares was reported. The &#147;<B><I>Beneficial Ownership Limitation</I></B>&#148; shall be
9.99% of the number of Common Shares and Common Share equivalents outstanding immediately after giving effect to the applicable issuance of Warrant Securities issuable upon exercise of this Warrant if at the time of exercise the Issuer is a
&#147;reporting issuer&#148; under the Securities Exchange Act of 1934. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this <B>Section</B><B></B><B>&nbsp;3(n)</B>
to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such
limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) <B>Holder Cancellation
Right</B>. Notwithstanding the other rights granted to Holder herein, so long as the Holder of this Warrant Certificate is a Perceptive Fund, then following a Fund Administration Event (as defined below), the Holder shall have the right (the
&#147;<B><I>Cancellation Right</I></B>&#148;), without the consent of the Issuer or any other Person, to irrevocably cancel and render void this Warrant Certificate and all of the Holder&#146;s rights and the Issuer&#146;s obligations hereunder
shall survive the cancellation. The Holder may exercise its Cancellation Right by written notice to the Issuer (the &#147;<B><I>Cancellation Notice</I></B>&#148;), which notice shall specify the circumstances of the Fund Administration Event. The
cancellation contemplated by this <B>Section</B><B></B><B>&nbsp;3(o) </B>shall be effective as of the date specified in the Cancellation Notice and the Holder shall remain liable for all obligations and liabilities as Holder of this Warrant
Certificate through such effective date specified in the Cancellation Notice. As used in this <B>Section</B><B></B><B>&nbsp;3(o)</B>,<B> </B>&#147;<B><I>Fund Administration Event</I></B>&#148; means that the Holder has entered its wind down phase
and the Holder has reasonably determined in good faith that the value of this Warrant Certificate is <I>de minimis</I>. For the avoidance of doubt, if a Perceptive Fund is no longer the Holder of this Warrant Certificate, the rights under this
<B>Section</B><B></B><B>&nbsp;3(o) </B>shall automatically terminate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.</B> <B>Adjustments</B>. In order to prevent
dilution of the Purchase Rights granted under this Warrant Certificate, the number of Warrant Securities issuable upon exercise of this Warrant Certificate shall be subject to adjustment from time to time as provided in this
<B>Section</B><B></B><B>&nbsp;4</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <B>Other Dividends and Distributions</B>. If the Issuer shall, at any time or from time to time
after the Issue Date, make or declare, or fix a record date for the determination of holders of equity securities or equivalent interests entitled to receive, a dividend or any other distribution payable in cash, securities or interests of the
Issuer (other than a dividend or distribution of Common Shares, Options or Convertible Securities in respect of outstanding equity securities or equivalent interests of the Issuer) or other property, then, and in each such event, the Issuer shall
ensure that provisions are made so that the Holder shall receive upon exercise of this Warrant Certificate, in addition to the number of Warrant Securities receivable thereupon, the kind and amount of cash, securities or interests of the Issuer or
other property which the Holder would have been entitled to receive had this Warrant Certificate been exercised in full into Warrant Securities on the date of such event and had the Holder thereafter, during the period from the date of such event to
and including the Exercise Date, retained such cash, securities, interests or other property receivable by them as aforesaid during such period, giving application to all adjustments called for during such period under this
<B>Section</B><B></B><B>&nbsp;4 </B>with respect to the rights of the Holder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <B>Adjustment to Number of Warrant Securities Upon Dividend, Subdivision or Combination
of Common Shares</B>. If the Issuer shall, at any time or from time to time after the Issue Date, (i)&nbsp;pay a bonus issue, dividend or make any other distribution upon the Common Shares (or other shares of the Issuer&#146;s share capital into
which this Warrant is then exercisable) payable in Common Shares (or other shares of the Issuer&#146;s share capital into which this Warrant is then exercisable) or in Options or Convertible Securities, or (ii)&nbsp;subdivide (by any equity split or
equivalent interest split, recapitalization or otherwise) its outstanding Common Shares (or other shares of the Issuer&#146;s share capital into which this Warrant is then exercisable) into a greater number of shares, the number of Warrant
Securities issuable upon exercise of this Warrant Certificate immediately prior to any such bonus issue, dividend, distribution or subdivision shall be proportionately increased and the Exercise Price applicable to each such Warrant Security shall
be proportionately decreased. If the Issuer at any time combines (by combination, consolidation, reverse equity split or otherwise) its outstanding Common Shares (or other shares of the Issuer&#146;s share capital into which this Warrant is then
exercisable) into a smaller number of shares, the number of Warrant Securities issuable upon exercise of this Warrant Certificate immediately prior to such combination shall be proportionately decreased and the Exercise Price applicable to each such
Warrant Security shall be proportionately increased. Any adjustment under this <B>Section</B><B></B><B>&nbsp;4(b)</B> shall become automatically effective upon the effectiveness of such bonus issue, dividend, subdivision, consolidation or
combination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <B>Adjustment to Number of Warrant Securities Upon Reorganization, Reclassification, Consolidation, Amalgamations or
Merger</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) Unless the Holder otherwise consents (in its sole discretion), the event of any (A)&nbsp;capital reorganization of the
Issuer, (B)&nbsp;reclassification of the equity securities or equivalent interests of the Issuer (other than as a result of a bonus issue, dividend or subdivision, <FONT STYLE="white-space:nowrap">split-up,</FONT> consolidation or combination of
equity securities or equivalent interests already covered by this <B>Section</B><B></B><B>&nbsp;4</B>), (C)&nbsp;Fundamental Change or (D)&nbsp;other similar transaction (other than a Cash Acquisition covered by
<B>Section</B><B></B><B>&nbsp;3(m)</B> (Treatment of Warrant Upon an Acquisition), or an event covered by <B>Section</B><B></B><B>&nbsp;4(b) </B>(Adjustment Upon Dividend, Subdivision, or Combination of Common Shares)), including a Liquidation or an
acquisition, amalgamation, merger, or other transaction in which the Warrant Certificate is not exercised, in each case which entitles the holders of Common Shares (or other shares of the Issuer&#146;s share capital into which this Warrant is then
exercisable) to receive (either directly or upon subsequent liquidation) securities, interests or assets with respect to or in exchange for Common Shares (or other shares of the Issuer&#146;s share capital into which this Warrant is then
exercisable): </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(1) this Warrant Certificate shall, immediately after such reorganization, reclassification, consolidation, amalgamation,
merger, sale or similar transaction, remain outstanding and shall thereafter, in lieu of or in addition to (as the case may be) the number of Warrant Securities then exercisable under this Warrant Certificate, be exercisable for the kind and number
of equity securities or equivalent interest or other assets of the Issuer or of the successor Person resulting from such transaction to which the Holder would have been entitled upon such reorganization, reclassification, consolidation,
amalgamation, merger, sale or similar transaction if the Holder had exercised this Warrant Certificate in full immediately prior to the time of such reorganization, reclassification, consolidation, amalgamation, merger, sale or similar transaction
and acquired the applicable number of Warrant Securities then issuable hereunder as a result of such exercise (without taking into account any limitations or restrictions on the exercisability of this Warrant Certificate); and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(2) appropriate adjustment (in form and substance reasonably satisfactory to the Holder and
Issuer) shall be made with respect to the Holder&#146;s rights under this Warrant Certificate to insure that the provisions of this <B>Section</B><B></B><B>&nbsp;4</B> shall thereafter be applicable, as nearly as possible, to this Warrant
Certificate in relation to any securities or assets thereafter acquirable upon exercise of this Warrant Certificate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The provisions of
this <B>Section</B><B></B><B>&nbsp;4(c)</B> shall similarly apply to successive reorganizations, reclassifications, consolidations, amalgamations, mergers, sales or similar transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) Notwithstanding anything to the contrary contained herein, with respect to any event or other transaction contemplated by this
<B>Section</B><B></B><B>&nbsp;4(c)</B>, the Holder shall have the right to elect, upon written notice delivered to the Issuer prior to the consummation of such event or transaction, to exercise its rights under <B>Section</B><B></B><B>&nbsp;2</B>
instead of giving effect to <B>Section</B><B></B><B>&nbsp;4(c)(i)</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <B>Certain Events</B>. Upon the occurrence of any event of the
type contemplated by the provisions of this <B>Section</B><B></B><B>&nbsp;4 </B>but not expressly provided for herein, the Issuer shall make an appropriate adjustment in the number of Warrant Securities issuable upon exercise of this Warrant
Certificate and the Exercise Price applicable thereto so as to protect the rights of the Holder in a manner consistent with the provisions of this <B>Section</B><B></B><B>&nbsp;4</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <B>Certificate as to Adjustment</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) As promptly as reasonably practicable following any adjustment of the number of Warrant Securities issuable upon exercise of this Warrant
Certificate, but in any event not later than five Business Days thereafter, the Issuer shall furnish to the Holder a certificate of an executive officer of the Issuer setting forth in reasonable detail such adjustment and the facts upon which it is
based and certifying the calculation thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) As promptly as reasonably practicable following the receipt by the Issuer of a written
request by the Holder, but in any event not later than five Business Days thereafter, the Issuer shall furnish to the Holder a certificate of an executive officer of the Issuer certifying the number of Warrant Securities for which this Warrant
Certificate is exercisable, or the amount, if any, of other securities, interests or assets then issuable upon exercise of this Warrant Certificate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <B>Notices</B>. In the event that the Issuer shall take a record of the holders of its Common Shares (or other securities or interests at
the time issuable upon exercise of this Warrant Certificate): </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) for the purpose of entitling or enabling them to receive any dividend
or other distribution, to vote at a meeting (or by written consent), to receive any right to subscribe for or purchase any securities or interests, or to receive any other security; or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) approving or enabling any reorganization or restructuring of the Issuer, any
reclassification of the Common Shares or any Fundamental Change; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">then, and in each such case, the Issuer shall, to the extent legally permissible and
reasonably practicable, send or cause to be sent to the Holder at least ten&nbsp;(10) days prior to the applicable record date or the applicable expected effective date, as the case may be, for the event, a written notice specifying, as the case may
be, (A)&nbsp;the record date for such dividend, distribution, meeting or consent or other right or action, and a description of such dividend, distribution or other right or action to be taken at such meeting or by written consent, or (B)&nbsp;the
effective date on which such Fundamental Change is proposed to take place, and the date, if any is to be fixed, as of which the books of the Issuer shall close or a record shall be taken with respect to which the holders of record of Common Shares
(or such other securities or interests at the time issuable upon exercise of this Warrant Certificate) shall be entitled to exchange their Common Shares (or such other securities or interests) for securities, interests or other property deliverable
upon such Fundamental Change, and the amount per equity security or equivalent interest and character of such exchange applicable to this Warrant Certificate and the Warrant Securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.</B> <B>Purchase Rights</B>. In addition to any adjustments pursuant to <B>Section</B><B></B><B>&nbsp;4</B>, if at any time
the Issuer grants the right to purchase, or otherwise issues or sells any Common Shares, Options, Convertible Securities or rights to purchase securities, interests or other property <I>pro rata</I> to the record holders of Common Shares (the
&#147;<B><I>Purchase Rights</I></B>&#148;), then the Holder shall be entitled (but not required) to acquire, upon the same terms applicable to the record holders of Common Shares, the aggregate Purchase Rights which the Holder would have acquired if
the Holder had held the number of Warrant Securities acquirable upon complete exercise of this Warrant Certificate immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record
is taken, the date as of which the record holders of Common Shares are to be determined for the grant, issue or sale of such Purchase Rights. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;6. [Reserved] </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;7.</B> <B>Warrant Register</B>. The Issuer shall keep and properly maintain (or cause to be kept and maintained, including
through a Transfer Agent) a register (the &#147;<B><I>Warrant Register</I></B>&#148;) for the registration of this Warrant Certificate and any transfers thereof. The Issuer may deem and treat the Person in whose name this Warrant Certificate is
registered on such register as the holder thereof for all purposes, and the Issuer shall not be affected by any notice to the contrary, except any assignment, division, combination or other transfer of this Warrant Certificate effected in accordance
with the provisions of this Warrant Certificate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;8.</B> <B>Transfer of Warrant Certificate and Warrant Securities</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Subject to the final sentence of this<B> Section</B><B></B><B>&nbsp;8(a) </B>and<B> </B>to the extent the Unrestricted Conditions are
satisfied, this Warrant Certificate and all rights hereunder are transferable, in whole or in part, by the Holder without the prior consent of any other Person. Any transfer of this Warrant Certificate and the rights hereunder shall be made without
charge to the Holder, upon surrender of this Warrant Certificate to the Issuer at its then registered office with a properly completed and duly executed Assignment in the form attached hereto as <B>Exhibit</B><B></B><B>&nbsp;B</B>. Upon such
compliance, surrender and delivery, the Issuer shall execute and deliver a new Warrant Certificate or Warrant </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Certificates in the name of the assignee or assignees and in the denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant Certificate evidencing the
portion of this Warrant Certificate, if any, not so assigned and this Warrant Certificate shall promptly be cancelled. For the avoidance of doubt, nothing in this <B>Section</B><B></B><B>&nbsp;8(a)</B> shall limit the restrictions on transfer set
forth in the Registration Agreement, including the lock up agreements applicable to the Warrant Securities contemplated in Section&nbsp;4 of the Registration Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) [Reserved]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) In
connection with any transfer of this Warrant Certificate, and in addition to any other applicable requirements of this <B>Section</B><B></B><B>&nbsp;8</B>, Holder will give the Issuer notice of the portion of this Warrant Certificate being
transferred with the name, address and taxpayer identification number of the transferee and Holder will surrender this Warrant Certificate to the Issuer for reissuance to the transferee(s) (and Holder if applicable); and <U>provided further</U>,
that any subsequent transferee shall agree in writing with the Issuer to be bound by all of the terms and conditions of this Warrant Certificate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;9.</B> <B>The Holder Not Deemed an Equity Holder; Limitations on Liability; Information Rights</B>. Except as otherwise
specifically provided herein, prior to the issuance to the Holder of the Warrant Securities to which the Holder is then entitled to receive upon the due exercise of this Warrant Certificate, the Holder shall not be entitled to vote or receive
dividends or be deemed the holder of Common Shares of the Issuer or otherwise have any rights as a holder of Common Shares for any purpose, nor shall anything contained in this Warrant Certificate be construed to confer upon the Holder, as such, any
of the rights of an equity holder of the Issuer or any right to vote, give or withhold consent to any action (whether any reorganization, issuance of securities, reclassification of securities, consolidation, amalgamation, merger, conveyance or
otherwise), receive notice of meetings, receive dividends or subscription rights, or otherwise. In addition, nothing contained in this Warrant Certificate shall be construed as imposing any liabilities on the Holder to purchase any securities or
interests (upon exercise of this Warrant Certificate or otherwise) or as an equity holder of the Issuer, whether such liabilities are asserted by the Issuer or by creditors of the Issuer. Notwithstanding this Section&nbsp;9, the Issuer shall
promptly provide the Holder with copies of any notices or other information provided to the Issuer&#146;s shareholders that are not otherwise made publicly available. To the extent that the Holder is or becomes aware of any breach by the Issuer of
the provisions of this <B>Section</B><B></B><B>&nbsp;9</B>, the Holder shall provide the Issuer with prompt written notice thereof and the Issuer shall be afforded a commercially reasonable period of time to cure such breach. This
<B>Section</B><B></B><B>&nbsp;9 </B>shall survive the exercise of this Warrant Certificate for so long as the Holder holds any Warrant Securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;10.</B> <B>Replacement on Loss; Division and Combination</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <B>Replacement of Warrant Certificate</B> <B>on Loss</B>. Upon receipt of evidence reasonably satisfactory to the Issuer of the loss,
theft, destruction or mutilation of this Warrant Certificate and upon delivery of an indemnity reasonably satisfactory to the Issuer (it being understood that a written indemnification agreement or affidavit of loss of the Holder shall be a
sufficient indemnity) and, in case of mutilation, upon surrender of such Warrant Certificate for cancellation to the Issuer, the Issuer (at the Holder&#146;s expense) shall execute and deliver to the Holder, in lieu hereof, a new Warrant Certificate
of like tenor and exercisable for an equivalent number of Warrant Securities as this Warrant Certificate so lost, stolen, mutilated or destroyed; <U>provided</U> that, in the case of mutilation, no indemnity shall be required if this Warrant
Certificate in identifiable form is surrendered to the Issuer for cancellation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <B>Division and Combination of Warrant Certificate</B>. Subject to compliance with the
applicable provisions of this Warrant Certificate as to any transfer or other assignment which may be involved in such division or combination, this Warrant Certificate may be divided or, following any such division of this Warrant Certificate,
subsequently combined with other Warrant Certificates, upon the surrender of this Warrant Certificate or Warrant Certificates to the Issuer at its then registered office, together with a written notice specifying the names and denominations in which
new Warrant Certificates are to be issued, signed by the respective Holders or their agents or attorneys. Subject to compliance with the applicable provisions of this Warrant Certificate as to any transfer or assignment which may be involved in such
division or combination, the Issuer shall at its expense execute and deliver a new Warrant Certificate or Warrant Certificates in exchange for this Warrant Certificate or Warrant Certificates so surrendered in accordance with such notice. Such new
Warrant Certificate or Warrant Certificates shall be of like tenor to the surrendered Warrant Certificate or Warrant Certificates and shall be exercisable in the aggregate for an equivalent number of Warrant Securities as this Warrant Certificate or
Warrant Certificates so surrendered in accordance with such notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;11.</B> <B>No Impairment</B>. The Issuer shall not, by
amendment of any of its organizational documents, through any securityholder, voting or similar agreement, or through any reorganization, restructuring, transfer of assets, consolidation, amalgamation, merger, dissolution, issue or sale of
securities or interests, or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms to be observed or performed by it hereunder, but shall at all times in good faith assist in the carrying out of all the
provisions of this Warrant Certificate and in the taking of all such action as may reasonably be requested by the Holder in order to protect the exercise rights of the Holder against dilution or other impairment, consistent with the tenor and
purpose of this Warrant Certificate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;12.</B> <B>Compliance with the Securities Act</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <B>Agreement to Comply with the Securities Act, etc.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) <B>Legend</B>. The Holder, by acceptance of this Warrant Certificate, agrees to comply in all respects with the provisions of this
<B>Section</B><B></B><B>&nbsp;12</B> and the restrictive legend requirements set forth on the face of this Warrant Certificate and further agrees that such Holder shall not offer, sell or otherwise dispose of this Warrant Certificate or any Warrant
Securities to be issued upon exercise hereof except under circumstances that will not result in a violation of the Securities Act. Subject to <B>clause</B><B></B><B>&nbsp;(ii)</B> below, this Warrant Certificate and all Warrant Securities issued
upon exercise of this Warrant Certificate (unless registered under the Securities Act) may be stamped or imprinted with a legend in substantially the following form: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;THIS WARRANT CERTIFICATE AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT
CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#148;<B><I>ACT</I></B>&#147;), OR QUALIFIED UNDER ANY STATE OR FOREIGN SECURITIES LAWS AND MAY NOT BE OFFERED FOR SALE, SOLD, PLEDGED, HYPOTHECATED OR OTHERWISE
TRANSFERRED OR ASSIGNED UNLESS (I)&nbsp;A REGISTRATION STATEMENT COVERING SUCH SECURITIES IS EFFECTIVE UNDER THE ACT AND IS QUALIFIED UNDER APPLICABLE STATE AND FOREIGN LAW OR (II)&nbsp;THE TRANSACTION IS EXEMPT FROM THE REGISTRATION AND PROSPECTUS
DELIVERY REQUIREMENTS UNDER THE ACT AND THE QUALIFICATION REQUIREMENTS UNDER APPLICABLE STATE AND FOREIGN LAW AND, IF THE ISSUER REQUESTS, AN OPINION SATISFACTORY TO THE ISSUER TO SUCH EFFECT HAS BEEN RENDERED BY COUNSEL. THIS WARRANT CERTIFICATE
AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT CERTIFICATE ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE FOR A PERIOD OF 180 DAYS FOLLOWING [&#149;], 2025 PURSUANT TO A <FONT STYLE="white-space:nowrap">LOCK-UP</FONT>
AGREEMENT, A COPY OF WHICH MAY BE OBTAINED AT THE PRINCIPAL OFFICE OF THE ISSUER.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) <B>Removal of Restrictive Legends</B>. To
the extent this Warrant Certificate and the Warrant Securities or any other equity securities issuable or deliverable under or in connection with this Warrant Certificate are not then subject to any restrictions on transferability and resale
pursuant to any <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement, neither this Warrant Certificate nor any book-entry position or certificate, as applicable, evidencing Warrant Securities or any other equity securities issuable or
deliverable under or in connection with this Warrant Certificate shall contain any legend restricting the transfer thereof (including the legend set forth above in <B>clause</B><B></B><B>&nbsp;(i)</B>) in any of the following circumstances:
(A)&nbsp;while a registration statement covering the sale or resale of Warrant Securities is effective under the Securities Act, (B)&nbsp;following any sale of this Warrant Certificate, any Warrant Securities issued or delivered to the Holder under
or in connection here with pursuant to Rule 144, (C)&nbsp;if this Warrant Certificate or Warrant Securities are eligible for sale under Rule 144(b)(1), or (D)&nbsp;if such legend is not required under applicable requirements of the Securities Act
(including judicial interpretations and pronouncements issued by the staff of the SEC) (collectively, the &#147;<B><I>Unrestricted Conditions</I></B>&#148;). The Issuer shall cause its counsel to issue a legal opinion to the Transfer Agent if
required by such Transfer Agent to effect the issuance of Warrant Securities or any other equity securities issuable or deliverable under or in connection with this Warrant Certificate, as applicable, without a restrictive legend or removal of the
legend hereunder. If the Unrestricted Conditions are met at the time of issuance of this Warrant Certificate, the Warrant Securities or such other equity securities, then this Warrant Certificate, Warrant Securities or other equity securities, as
the case may be, shall be issued free of all legends. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) <B>Replacement Warrant Certificate</B>. The Issuer agrees that at such time
as the Unrestricted Conditions have been satisfied it shall promptly (but in any event within five (5)&nbsp;Business Days) following written request from the Holder issue a replacement Warrant Certificate or replacement Warrant Securities, as the
case may be, free of all restrictive legends. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv) <B>Sale of Unlegended Securities</B>. The Holder agrees that the removal of the
restrictive legend from this Warrant Certificate and any book-entry position or certificates, as applicable, representing securities as set forth in <B>Section</B><B></B><B>&nbsp;12(a)(ii)</B> above is predicated upon the Issuer&#146;s reliance that
the Holder will sell this Warrant Certificate or any such securities pursuant to either an effective registration statement or otherwise pursuant to the requirements of the Securities Act, including any applicable prospectus delivery requirements,
or an exemption therefrom, and that if such securities are sold pursuant to a registration statement, they will be sold in compliance with the plan of distribution set forth therein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <B>Representations of the Holder</B>. In connection with the issuance of this Warrant Certificate, the Holder specifically represents, as
of the date hereof, to the Issuer by acceptance of this Warrant Certificate as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) The Holder is an &#147;accredited
investor&#148; as defined in Rule 501 of Regulation D promulgated under the Securities Act. The Holder is acquiring this Warrant Certificate and the Warrant Securities to be issued upon exercise hereof for investment for its own account and not with
a view towards, or for resale in connection with, the public sale or distribution of this Warrant Certificate or the Warrant Securities, except pursuant to sales registered or exempted under the Securities Act and otherwise permitted pursuant to
this Warrant Certificate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) The Holder understands and acknowledges that this Warrant Certificate and the Warrant Securities to be
issued upon exercise hereof are &#147;restricted securities&#148; under the federal securities laws inasmuch as they are being acquired from the Issuer in a transaction not involving a public offering and that, under such laws and applicable
regulations, such securities may be resold without registration under the Securities Act only in certain limited circumstances. In addition, the Holder represents that it is familiar with Rule 144 under the Securities Act, as presently in effect,
and understands the resale limitations imposed thereby and by the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) The Holder acknowledges that it can bear the
economic and financial risk of its investment for an indefinite period, and has such knowledge and experience in financial or business matters that it is capable of evaluating the merits and risks of the investment in this Warrant Certificate and
the Warrant Securities. The Holder has had an opportunity to ask questions and receive answers from the Issuer regarding the terms and conditions of the offering of this Warrant Certificate and the business, properties, prospects and financial
condition of the Issuer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;13. [Reserved]. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;14.</B> <B>Notices</B>. All notices, requests, consents, claims, demands, waivers and other communications hereunder shall be in
writing and shall be deemed to have been given: (a)&nbsp;when delivered by hand (with written confirmation of receipt); (b) when received by the addressee if sent by a nationally recognized overnight courier (receipt requested); (c) on the date sent
by <FONT STYLE="white-space:nowrap">e-mail</FONT> of a PDF document (with confirmation of transmission) if sent on a Business Day during or before normal business hours of the recipient, and on the next Business Day if sent after normal business
hours of the recipient or on a day that is not a Business Day; or (d)&nbsp;on the third day after the date mailed, by certified or registered mail, return receipt requested, postage prepaid. Such communications must be sent to the respective parties
at the addresses indicated below (or at such other address for a party as shall be specified in a notice given in accordance with this <B>Section</B><B></B><B>&nbsp;14</B>). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="22%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="77%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">If to the Issuer:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Kestra Medical Technologies, Ltd.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">3933 Lake Washington Blvd NE, Suite 200</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Kirkland, Washington 98033</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Attention: [***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Email: [***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">With a copy to:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Kirkland&nbsp;&amp; Ellis LLP</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">333 West Wolf Point Plaza</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chicago, Illinois 60654</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Attention: [***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Email: [***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">If to the Holder:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Perceptive Credit Holdings IV, LP</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">c/o Perceptive Advisors LLC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">51 Astor Place, 10th Floor</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">New York, NY 10003</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Attention: [***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">E-mail:</FONT> [***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">with a copy to:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chapman and Cutler LLP</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">1270 Avenue of the Americas</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">New York, NY 10020</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Attention: [***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Email: [***]</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;15.</B> <B>Cumulative Remedies</B>. The rights and remedies provided in this Warrant Certificate
are cumulative and are not exclusive of, and are in addition to and not in substitution for, any other rights or remedies available at law, in equity or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;16.</B> <B>Equitable Relief</B>. Each of the Issuer and the Holder acknowledges that a breach or threatened breach by such party
of any of its obligations under this Warrant Certificate may give rise to irreparable harm to the other party hereto for which monetary damages would not be an adequate remedy and hereby agrees that in the event of a breach or a threatened breach by
such party of any such obligations, the other party hereto shall, in addition to any and all other rights and remedies that may be available to it in respect of such breach, be entitled to seek equitable relief, including a restraining order, an
injunction, specific performance and any other relief that may be available from a court of competent jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;17.</B>
<B>Entire Agreement</B>. This Warrant Certificate constitutes the sole and entire agreement of the parties to this Warrant Certificate with respect to the subject matter contained herein, and supersedes all prior and contemporaneous understandings
and agreements, both written and oral, with respect to such subject matter. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;18.</B> <B>Successor and Assigns</B>. This Warrant Certificate and the rights
evidenced hereby shall be binding upon and shall inure to the benefit of the parties hereto and the successors of the Issuer and the successors and permitted assigns of the Holder. Such successors and/or permitted assigns of the Holder shall be
deemed to be a &#147;Holder&#148; for all purposes hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;19.</B> <B>No Third-Party Beneficiaries</B>. This Warrant
Certificate is for the sole benefit of the Issuer and the Holder and their respective successors and, in the case of the Holder, permitted assigns and nothing herein, express or implied, is intended to or shall confer upon any other Person any legal
or equitable right, benefit or remedy of any nature whatsoever, under or by reason of this Warrant Certificate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;20.</B>
<B>Headings</B>. The headings in this Warrant Certificate are for reference only and shall not affect the interpretation of this Warrant Certificate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;21.</B> <B>Amendment and Modification; Waiver</B>. Except as otherwise provided herein, this Warrant Certificate may only be
amended, modified or supplemented by an agreement in writing signed by each party hereto. No waiver by the Issuer or the Holder of any of the provisions hereof shall be effective unless explicitly set forth in writing and signed by the party so
waiving. No waiver by any party shall operate or be construed as a waiver in respect of any failure, breach or default not expressly identified by such written waiver, whether of a similar or different character, and whether occurring before or
after that waiver. No failure to exercise, or delay in exercising, any rights, remedy, power or privilege arising from this Warrant Certificate shall operate or be construed as a waiver thereof; nor shall any single or partial exercise of any right,
remedy, power or privilege hereunder preclude any other or further exercise thereof or the exercise of any other right, remedy, power or privilege. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;22.</B> <B>Severability</B>. If any term or provision of this Warrant Certificate is invalid, illegal or unenforceable in any
jurisdiction, such invalidity, illegality or unenforceability shall not affect any other term or provision of this Warrant Certificate or invalidate or render unenforceable such term or provision in any other jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;23.</B> <B>Governing Law</B>. This Warrant Certificate shall be governed by and construed in accordance with the internal laws
of the State of New York without giving effect to any choice or conflict of law provision or rule (whether of the State of New York or any other jurisdiction) that would cause the application of laws of any jurisdiction other than those of the State
of New&nbsp;York. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;24.</B> <B>Submission to Jurisdiction</B>. Any legal suit, action or proceeding arising out of or based
upon this Warrant Certificate or the transactions contemplated hereby may be instituted in the federal courts of the United States of America or the courts of the State of New York in each case located in the city of New York and County of New York,
and each party irrevocably submits to the exclusive jurisdiction of such courts in any such suit, action or proceeding. Service of process, summons, notice or other document by certified or registered mail to such party&#146;s address set forth
herein shall be effective service of process for any suit, action or other proceeding brought in any such court. The parties irrevocably and unconditionally waive any objection to the laying of venue of any suit, action or any proceeding in such
courts and irrevocably waive and agree not to plead or claim in any such court that any such suit, action or proceeding brought in any such court has been brought in an inconvenient forum. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;25. Waiver of Jury Trial. E<SMALL>ACH</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL>
I<SMALL>SSUER</SMALL> <SMALL>AND</SMALL> <SMALL>THE</SMALL> H<SMALL>OLDER</SMALL> <SMALL>ACKNOWLEDGES</SMALL> <SMALL>AND</SMALL> <SMALL>AGREES</SMALL> <SMALL>THAT</SMALL> <SMALL>ANY</SMALL> <SMALL>CONTROVERSY</SMALL> <SMALL>WHICH</SMALL>
<SMALL>MAY</SMALL> <SMALL>ARISE</SMALL> <SMALL>UNDER</SMALL> <SMALL>THIS</SMALL> W<SMALL>ARRANT</SMALL> C<SMALL>ERTIFICATE</SMALL> <SMALL>IS</SMALL> <SMALL>LIKELY</SMALL> <SMALL>TO</SMALL> <SMALL>INVOLVE</SMALL> <SMALL>COMPLICATED</SMALL>
<SMALL>AND</SMALL> <SMALL>DIFFICULT</SMALL> <SMALL>ISSUES</SMALL> <SMALL>AND</SMALL>, <SMALL>THEREFORE</SMALL>, <SMALL>EACH</SMALL> <SMALL>SUCH</SMALL> <SMALL>PARTY</SMALL> <SMALL>IRREVOCABLY</SMALL> <SMALL>AND</SMALL> <SMALL>UNCONDITIONALLY</SMALL>
<SMALL>WAIVES</SMALL> <SMALL>ANY</SMALL> <SMALL>RIGHT</SMALL> <SMALL>IT</SMALL> <SMALL>MAY</SMALL> <SMALL>HAVE</SMALL> <SMALL>TO</SMALL> <SMALL>A</SMALL> <SMALL>TRIAL</SMALL> <SMALL>BY</SMALL> <SMALL>JURY</SMALL> <SMALL>IN</SMALL>
<SMALL>RESPECT</SMALL> <SMALL>OF</SMALL> <SMALL>ANY</SMALL> <SMALL>LEGAL</SMALL> <SMALL>ACTION</SMALL> <SMALL>ARISING</SMALL> <SMALL>OUT</SMALL> <SMALL>OF</SMALL> <SMALL>OR</SMALL> <SMALL>RELATING</SMALL> <SMALL>TO</SMALL> <SMALL>THIS</SMALL>
W<SMALL>ARRANT</SMALL> C<SMALL>ERTIFICATE</SMALL> <SMALL>OR</SMALL> <SMALL>THE</SMALL> <SMALL>TRANSACTIONS</SMALL> <SMALL>CONTEMPLATED</SMALL> <SMALL>HEREBY</SMALL>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;26.</B> <B>Counterparts</B>. This Warrant Certificate may be executed in counterparts, each of which shall be deemed an
original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Warrant Certificate delivered by facsimile, <FONT STYLE="white-space:nowrap">e-mail</FONT> or other means of electronic transmission shall be
deemed to have the same legal effect as delivery of an original signed copy of this Warrant Certificate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;27.</B> <B>No
Strict Construction</B>. This Warrant Certificate shall be construed without regard to any presumption or rule requiring construction or interpretation against the party drafting an instrument or causing any instrument to be drafted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[SIGNATURE PAGE FOLLOWS] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Issuer has duly executed this Warrant Certificate on the Initial Issue Date. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>KESTRA MEDICAL TECHNOLOGIES, LTD., </B>an exempted company limited by shares incorporated in Bermuda</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><SMALL>SIGNATURE</SMALL> <SMALL>PAGE</SMALL> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><SMALL>WARRANT</SMALL> </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Accepted and agreed,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">PERCEPTIVE CREDIT HOLDINGS IV, LP</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Perceptive Credit Opportunities GP, LLC, its general partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Sandeep Dixit</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Chief Credit Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Sam Chawla</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Portfolio Manager</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><SMALL>SIGNATURE</SMALL> <SMALL>PAGE</SMALL> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><SMALL>WARRANT</SMALL> </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accepted and agreed, solely for purposes of the Prior Warrant Termination: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>WEST AFFUM HOLDINGS, L.P., </B>an exempted limited partnership registered in the Cayman Islands </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By <B>West Affum GP Ltd.</B>, its general partner </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><SMALL>SIGNATURE</SMALL> <SMALL>PAGE</SMALL> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><SMALL>WARRANT</SMALL> </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit A </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>to Warrant Certificate </B></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">FORM
OF EXERCISE CERTIFICATE </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(To be signed only upon exercise of Warrant Certificate) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To: ________________ </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned, as
holder of a right to purchase [Common Shares, par value $1.00 per share], of <B>KESTRA MEDICAL TECHNOLOGIES, LTD., </B>an exempted company limited by shares incorporated in Bermuda (the &#147;<B><I>Issuer</I></B>&#148;), pursuant to that certain
Warrant Certificate of the Issuer, dated as of [&#149;], 2025 and bearing Warrant Certificate <FONT STYLE="white-space:nowrap">No.&nbsp;2025-01</FONT> (the &#147;<B><I>Warrant Certificate</I></B>&#148;), hereby irrevocably elects to exercise the
purchase right represented by such Warrant Certificate for, and to purchase thereunder, [________ (_____)] [Common Shares] of the Issuer comprising and herewith makes payment of [___________ Dollars ($________)] therefor by the following method:
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(Check all that apply): </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">______ (check if applicable) The undersigned hereby elects to make payment of the Aggregate Exercise Price of [__________ Dollars ($_______)]
for [(______)] [Common Shares] using the method described in <B>Section</B><B></B><B>&nbsp;3(b)(i)</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">______ (check if applicable) The
undersigned hereby elects to make payment of the Aggregate Exercise Price of [__________ Dollars ($_______)] for [(______)] [Common Shares] using the method described in <B>Section</B><B></B><B>&nbsp;3(b)(ii)</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise defined herein, capitalized terms have the meanings provided in the Warrant Certificate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">DATED: ______________ </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PERCEPTIVE CREDIT HOLDINGS IV, LP</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit B </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>to Warrant Certificate </B></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">FORM
OF ASSIGNMENT </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THE UNDERSIGNED, Perceptive Credit Holdings IV, LP, is the holder (in such capacity, the &#147;<B><I>Holder</I></B>&#148;)
of a warrant certificate issued <B>KESTRA MEDICAL TECHNOLOGIES, LTD., </B>an exempted company limited by shares incorporated under the laws of Bermuda (the &#147;<B><I>Issuer</I></B>&#148;), bearing Warrant Certificate
<FONT STYLE="white-space:nowrap">No.&nbsp;2025-01</FONT> (the &#147;<B><I>Warrant Certificate</I></B>&#148;), entitling the Holder to purchase [Common Shares]. Unless otherwise defined, capitalized terms used herein have the meanings ascribed
thereto in the Warrant Certificate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FOR VALUE RECEIVED, the Holder hereby sells, assigns and transfers to [NAME OF ASSIGNEE] (the
&#147;<B><I>Assignee</I></B>&#148;) the right to acquire [all Warrant Securities entitled to be purchased upon exercise of the Warrant Certificate] [[______] Warrant Securities entitled to be purchased upon exercise of the Warrant Certificate]. In
furtherance of the foregoing assignment, the Holder hereby irrevocably instructs the Issuer to (i)&nbsp;memorialize such assignment on the Warrant Register as required pursuant to <B>Section</B><B></B><B>&nbsp;7</B> of the Warrant Certificate, and
(ii)&nbsp;pursuant to <B>Section</B><B></B><B>&nbsp;8</B> of the Warrant Certificate, execute and deliver to the Assignee [and the Holder] [a new Warrant Certificate / new Warrant Certificates] reflecting the foregoing assignment
([each]&nbsp;a&nbsp;&#147;<B><I>Substitute Warrant Certificate</I></B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Assignee acknowledges and agrees that its Substitute
Warrant Certificate and the Warrant Securities to be issued upon exercise thereof are being acquired for investment and that the Assignee will not offer, sell or otherwise dispose of its Substitute Warrant Certificate or any Warrant Securities to be
issued upon exercise or conversion thereof except under circumstances which will not result in a violation of the Securities Act or any applicable state securities laws or foreign securities laws. The Assignee represents and warrants for the benefit
of the Issuer that the Assignee is an &#147;accredited investor&#148; within the meaning of Rule 501 of Regulation D promulgated under the Securities Act of 1933, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent required pursuant to <B>Section</B><B></B><B>&nbsp;12</B> of the Warrant Certificate, the Assignee acknowledges and agrees that
a restrictive legend shall be applied to the Assignee&#146;s Substitute Warrant Certificate and the Warrant Securities issuable upon exercise of such certificate substantially consistent with the legend set forth in
<B>Section</B><B></B><B>&nbsp;12(a)(i)</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[SIGNATURE PAGE FOLLOWS] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">PERCEPTIVE CREDIT HOLDINGS IV, LP</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Accepted and agreed,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">[NAME OF ASSIGNEE]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>6
<FILENAME>d744414dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXHIBIT 5.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g744414g34r82.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">26&nbsp;February 2025</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Our Ref: RN/MS/js/W3229-A04572</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kestra Medical Technologies, Ltd. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cumberland House, 7<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> Floor </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1 Victoria Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Hamilton, HM11 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bermuda </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Addressee </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>KESTRA MEDICAL TECHNOLOGIES, LTD (THE &#147;COMPANY&#148;) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have been asked to provide this legal opinion to you with regard to the laws of Bermuda in connection with the preparation and filing on behalf of&nbsp;the
Company of a Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (as may be amended or supplemented, the &#147;<B>Registration Statement</B>&#148;), initially filed by the Company on or about 10&nbsp;February 2025 with the
Securities and Exchange Commission under the Securities Act of 1933, as amended.&nbsp;The Registration Statement relates to the proposed offering of up to 10,000,000 common shares of par value of US$1.00 each in the capital of the Company (the
&#147;<B>Shares</B>&#148;), and up to 1,500,000 additional Shares to cover the underwriters&#146; option to purchase additional shares, all to be offered for sale or issue at the price and on the terms as determined in the Registration Statement
(the &#147;<B>Offering</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the purposes of giving this opinion, we have examined and relied upon the originals, copies or translations of the
documents listed in Schedule 1 (the &#147;<B>Documents</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In giving this opinion we have relied upon the assumptions set out in Schedule 2,
which we have not independently verified. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are Bermuda Barristers and Attorneys and express no opinion as to any laws other than the laws of Bermuda in
force and as interpreted at the date of this opinion.&nbsp;We have not, for the purposes of this opinion, made any investigation of the laws, rules or regulations of any other jurisdiction.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based upon the foregoing examinations and assumptions and having regard to legal considerations which we consider relevant, and subject to the qualifications
set out in Schedule 3, and under the laws of Bermuda, we are of the opinion that the Shares have been duly authorised and will be validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> upon payment for and delivery of
the Shares as contemplated by the Registration Statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This opinion is limited to the matters referred to herein and shall not be construed as
extending to any other matter or document not referred to herein.&nbsp;This opinion is given solely for your benefit and the benefit of your legal advisers acting in that capacity in relation to this Offering and may not be relied upon by any other
person without our prior written consent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We understand that the Company wishes to file this opinion as an exhibit to the Registration Statement as
Exhibit 5.1 and to reference this firm under the caption &#147;Legal Matters&#148; in the Registration Statement, and we hereby consent thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Walkers (Bermuda) Limited </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Park Place, 55 Par La Ville Road, Hamilton HM11, Bermuda </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>T</B> +1 441 242 1500 www.walkersglobal.com </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Bermuda | British Virgin Islands | Cayman Islands | Dubai | Guernsey | Hong Kong | Ireland | Jersey | London | Singapore </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">The title of &#147;partner&#146; is used to refer to a consultant or employee of Walkers (Bermuda) Limited with equivalent standing and
qualifications. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>WALKERS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"> Page
 2
</TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This opinion shall be construed in accordance with the laws of Bermuda. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Yours faithfully </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>/s/ Walkers (Bermuda) Limited </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>WALKERS (BERMUDA) LIMITED </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>WALKERS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"> Page
 3
</TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LIST OF DOCUMENTS EXAMINED </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Certificate of Incorporation dated 20&nbsp;May 2021, the Memorandum of Association as registered on
20&nbsp;May 2021 (the &#147;<B>Memorandum of Association</B>&#148;), the <FONT STYLE="white-space:nowrap">Bye-laws</FONT> (the &#147;<B><FONT STYLE="white-space:nowrap">Bye-laws</FONT></B>&#148;) of the Company as adopted on 21&nbsp;May 2021,
Register of Members, Register of Directors and Officers, in each case of the Company, copies of which have been provided to us (together the &#147;<B>Company Records</B>&#148;). </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A copy of the executed unanimous written resolutions of the board of directors of the Company dated
24&nbsp;August 2021 and 25&nbsp;February 2025 (the &#147;<B>Resolutions</B>&#148;). </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A copy of the final form of the Registration Statement. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>WALKERS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"> Page
 4
</TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ASSUMPTIONS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">There are no provisions of the laws of any jurisdiction outside Bermuda which would be contravened by the
execution or delivery of the Documents or in any contracts or instruments, including but not limited to indentures and instruments, prepared in relation to the offer and creation of any of the Shares, as contemplated by the Registration Statement
and, insofar as any obligation expressed to be incurred under the Registration Statement is to be performed in or is otherwise subject to the laws of any jurisdiction outside Bermuda, its performance will not be illegal by virtue of the laws of that
jurisdiction. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The originals of all documents examined in connection with this opinion are authentic.&nbsp;The signatures,
initials and seals on the Documents are genuine and are those of a person or persons given power to execute the Documents under the Resolutions or any power of attorney given by the Company to execute the Documents.&nbsp;All documents purporting to
be sealed have been so sealed.&nbsp;All copies are complete and conform to their originals. Any translations are a true translation of the original document they purport to translate.&nbsp;The Documents conform in every material respect to the
latest drafts of the same produced to us. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Memorandum of Association and <FONT STYLE="white-space:nowrap">Bye-laws</FONT> reviewed by us are the
memorandum of association and amended and restated <FONT STYLE="white-space:nowrap">bye-laws</FONT> of the Company and are in force at the date hereof. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company Records are complete and accurate and all matters required by law and the Memorandum of Association
and <FONT STYLE="white-space:nowrap">Bye-laws</FONT> to be recorded therein are so recorded. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Resolutions have been duly executed by or on behalf of each director of the Company and the signatures and
initials thereon are those of a person or persons in whose name the Resolutions have been expressed to be signed. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>WALKERS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"> Page
 5
</TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 3 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>QUALIFICATIONS </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">We express no opinion upon any provisions in the Documents which contain a reference to any law or statute that
is not a Bermudian law or statute. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Except as explicitly stated in this opinion, we express no opinion in relation to any representation or
warranty contained in the Documents nor upon matters of fact or the commercial terms of the transactions contemplated by the Documents. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;Non-assessability&#148; is not a legal concept under Bermuda law. Reference in this opinion to shares
being <FONT STYLE="white-space:nowrap">&#147;non-assessable&#148;</FONT> shall mean, in relation to fully-paid shares of the Company and subject to any contrary provision in any agreement in writing between the Company and the holder of shares, that
no member shall be: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">obliged to contribute further amounts to the capital of the Company, either in order to complete payment for
their shares, to satisfy claims of creditors of the Company, or otherwise; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">bound by an alteration of the Memorandum of Association or <FONT STYLE="white-space:nowrap">Bye-laws</FONT> of
the Company after the date on which they became a member, if and so far as the alteration requires them to take, or subscribe for additional shares, or in any way increases their liability to contribute to the share capital of, or otherwise to pay
money to, the Company. </P></TD></TR></TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>7
<FILENAME>d744414dex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.1 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>ASSIGNMENT AND ASSUMPTION OF REGISTRATION RIGHTS AGREEMENT </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THIS ASSIGNMENT AND ASSUMPTION OF REGISTRATION RIGHTS AGREEMENT</B> (this&nbsp;&#147;<B><I>Agreement</I></B>&#148;) is entered into as of
February&nbsp;26, 2025, by and between West Affum Holdings, L.P., a Cayman Islands exempted limited partnership (&#147;<B><I>Assignor</I></B>&#148;) and Kestra Medical Technologies, Ltd., a limited company organized under the laws of Bermuda
(&#147;<B><I>Assignee</I></B>&#148;). Each such entity is referred to herein as a &#147;<B><I>Party</I></B>&#148; and, collectively, are referred to as the &#147;<B><I>Parties</I></B>.&#148; Capitalized terms used but not defined herein have the
respective meaning given to them in the Registration Rights Agreement (as defined below). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, Assignor is a party under that
certain Second Amended and Restated Registration Rights Agreement, dated as of July&nbsp;15, 2024, attached hereto as <U>Exhibit A</U> (the &#147;<B><I>Registration Rights Agreement</I></B>&#148;); and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, in connection with the initial Public Offering of the Assignee, Assignor desires to assign, and Assignee is willing to assume,
all of Assignor&#146;s rights, duties, liabilities and obligations under the Registration Rights Agreement, in each case, on the terms and subject to the conditions set forth herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW, THEREFORE</B>, in consideration of the mutual covenants, agreements and understandings contained in this Agreement and for other good
and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereto agree as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.
<U>Assignment and Assumption.</U> Subject to the terms hereof, the Assignor hereby assigns, transfers and conveys to Assignee all of its rights, duties, liabilities and obligations under the Registration Rights Agreement, and Assignee hereby accepts
such assignment from the Assignor, assumes all of such rights, duties, liabilities and obligations and agrees to be bound by all of the terms, conditions and provisions of the Registration Rights Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Effectiveness</U>. This Agreement shall be effective upon the initial closing of the sale of shares of the Assignee in the initial
Public Offering of the Assignee (the &#147;<B><I>Effective Time</I></B>&#148;). For the avoidance of doubt, from and after the Effective Time, all references to (i)&nbsp;the &#147;Partnership&#148; and the &#147;Corporation&#148; in the Registration
Rights Agreement shall mean the Assignee and (ii) &#147;Common Stock&#148; shall mean Common Shares, par value $1.00 per share, of the Assignee, unless, in each case, the context otherwise requires. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Miscellaneous.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Governing Law; Jurisdiction; Severability</U>. The terms and conditions set forth in Sections 12(f)
(<I>Severability</I>), (j) (<I>Governing Law</I>), (k) (<I>Jurisdiction; Venue; Service of Process</I>) and (l) (<I>Mutual Waiver of Jury Trial)</I> of the Registration Rights Agreement shall be applied, <I>mutatis mutandis</I>, to this Agreement.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Further Assurances</U>. From time to time following the execution and delivery of this Agreement, the Parties
shall execute and deliver such other instruments of assignment, transfer and delivery and shall take such other actions as any other Party hereto reasonably may request in order to consummate, complete and carry out the transactions contemplated by
this Agreement. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Successors and Assigns</U>. This Agreement is intended to bind and
inure to the benefit of and be enforceable by the Parties and their respective successors, heirs and permitted assigns. No Party shall assign any of its rights or obligations under this Agreement without the prior written consent of the other Party.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Counterparts</U>. This Agreement may be executed in two or more counterparts (delivery of which may be by
facsimile or via email as a portable document format (.pdf)), each of which will be deemed an original and all of which taken together shall constitute one and the same agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Pages Follow</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF, </B>the Parties hereto have executed this Agreement to be effective
as of the date first written above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>ASSIGNOR</U>: </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">WEST AFFUM HOLDINGS, L.P., a Cayman Islands </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">exempted limited
partnership by its general partner </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">WEST AFFUM GP LTD. a Cayman Islands exempted limited company. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Brian Webster</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Brian Webster</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(Print)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:1.00em; font-size:10pt; font-family:Times New Roman"><B>ASSIGNEE:</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:1.00em; font-size:10pt; font-family:Times New Roman">KESTRA MEDICAL TECHNOLOGIES, LTD.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Brian Webster</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Brian Webster</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(Print)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">President and Chief Executive Officer</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Signature Page to Assignment and Assumption of Registration Rights Agreement </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Second Amended and Restated Registration Rights Agreement, dated as of July&nbsp;15, 2024 </U></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXECUTION VERSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>SECOND AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">THIS SECOND AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT (this &#147;<U>Agreement</U>&#148;) is made as of July&nbsp;15, 2024, by and
among (a)&nbsp;West Affum Holdings, L.P., a Cayman Islands exempted limited partnership (the &#147;<U>Partnership</U>&#148;), (b)&nbsp;Bain Charger Holdings, L.P., a Cayman Islands exempted limited partnership (the &#147;<U>Bain Investor</U>&#148;),
Endeavour Medtech Growth II LP, Endeavour Medtech Growth II Parallel LP and the other Securityholders party to the Existing Registration Rights Agreement (as defined below) (collectively, the &#147;<U>Existing Securityholders</U>&#148;), any other
Sponsor Fund that at any time executes a counterpart of this Agreement or otherwise agrees to be bound by this Agreement and any other Person designated by the Partnership from time to time as an &#147;Investor&#148; under this Agreement by joinder
or otherwise (each, an &#147;<U>Investor</U>&#148; and collectively, the &#147;<U>Investors</U>&#148;), (c) each of the Persons designated by the Partnership from time to time as a &#147;Service Provider&#148; under this Agreement and any other
employee or service provider of the Partnership or its Subsidiaries who, at any time, acquires securities of the Partnership in accordance with <U>Section</U><U></U><U>&nbsp;9</U> hereof and executes a counterpart of this Agreement or otherwise
agrees to be bound by this Agreement (each, a &#147;<U>Service Provider</U>&#148; and collectively, the &#147;<U>Service Providers</U>&#148;), and (d)&nbsp;each of the other Persons designated by the Partnership from time to time as an &#147;Other
Securityholder&#148; under this Agreement who, at any time, acquires securities of the Partnership in accordance with <U>Section</U><U></U><U>&nbsp;9</U> hereof and executes a counterpart of this Agreement or otherwise agrees to be bound by this
Agreement (the &#147;<U>Other Securityholders</U>&#148;). The Investors, the Service Providers and the Other Securityholders are collectively referred to herein as the &#147;<U>Securityholders</U>.&#148; Unless otherwise provided in this Agreement,
capitalized terms used herein shall have the meanings set forth in <U>Section</U><U></U><U>&nbsp;10</U> hereof; <U>provided</U> that if any term is not defined herein, then such term shall have the meaning assigned to it in the Partnership
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Partnership and the Existing Securityholders previously entered into that certain Amended and Restated
Registration Rights Agreement, dated as of June&nbsp;30, 2022 (the &#147;<U>Existing Registration Rights Agreement</U>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">WHEREAS,
the Partnership and the undersigned Securityholders desire to amend and restate the Existing Registration Rights Agreement in its entirety in connection with the Partnership&#146;s issuance of equity interests in the Partnership to certain new
Investors; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">WHEREAS, the amendment and restatement of the Existing Registration Rights Agreement has been approved by (i)&nbsp;the
General Partner and (ii)&nbsp;the undersigned Securityholders, which represent the holders of a majority of the Investor Registrable Securities (as defined below) required to amend the Existing Registration Rights Agreement pursuant to
<U>Section</U><U></U><U>&nbsp;11(c)(i)</U> thereof. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the mutual covenants contained herein and other good and
valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties to this Agreement hereby agree as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1. <U>Effectiveness</U>. This Agreement shall become effective upon the execution thereof (the &#147;<U>Effective Date</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2. <U>Demand Registrations</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Requests for Registration</U>. The Securityholders contemplate the organization of a corporation and reorganization or recapitalization
of the Partnership pursuant to <U>Section</U><U></U><U>&nbsp;12.1</U> of the Partnership Agreement. The corporate successor to the Partnership shall be referred to herein as the &#147;<U>Corporation</U>.&#148; At any time following the Effective
Date and from time to time thereafter and subject to the written consent of the Bain Investor, holders of Investor Registrable Securities may request from the Corporation registration under the Securities Act of all or any portion of their
Registrable Securities on <FONT STYLE="white-space:nowrap">Form&nbsp;S-1</FONT> or any similar <FONT STYLE="white-space:nowrap">long-form</FONT> registration statement (&#147;<U>Long</U><U><FONT STYLE="white-space:nowrap">-Form</FONT>
Registrations</U>&#148;), or, if available, on <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> or any similar <FONT STYLE="white-space:nowrap">short-form</FONT> registration statement
(&#147;<U>Short</U><U><FONT STYLE="white-space:nowrap">-Form</FONT> Registrations</U>&#148;), if available (any such requested registration, a &#147;<U>Demand Registration</U>&#148;). Such holders may request that any Demand Registration be made
pursuant to Rule 415 under the Securities Act (a &#147;<U>Shelf Registration</U>&#148;) and (if the Corporation is a &#147;well-known seasoned issuer&#148; (as defined in Rule 405 under the Securities Act) at the time any such request is submitted
to the Corporation or will become one by the time of the filing of such Shelf Registration) that such Shelf Registration be an automatic shelf registration statement (as defined in Rule 405 under the Securities Act) (an &#147;<U>Automatic Shelf
Registration Statement</U>&#148;). Each request for a Demand Registration shall specify the approximate number or dollar value of Registrable Securities requested to be registered and (if known) the intended method or methods of disposition thereof.
Within 10 days after receipt of any such request, the Corporation shall give written notice of such requested registration to all other holders of Registrable Securities and, subject to <U>Section</U><U></U><U>&nbsp;2(d)</U>, shall include in such
registration all Registrable Securities with respect to which the Corporation has received written requests for inclusion therein within 10 days after the receipt of the Corporation&#146;s notice; <U>provided</U> that, with the consent of or at the
written request of the Bain Investor, the Corporation may instead provide notice of the Demand Registration to all other holders of Registrable Securities within three Business Days following the
<FONT STYLE="white-space:nowrap">non-confidential</FONT> filing of the registration statement with respect to the Demand Registration so long as such registration statement is not an Automatic Shelf Registration Statement and all other holders of
Registrable Securities shall provide to the Corporation written requests for inclusion therein within 10 days after the receipt of the Corporation&#146;s notice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Investor Long</U><U><FONT STYLE="white-space:nowrap">-Form</FONT> Registrations</U>. The holders of Investor Registrable Securities
shall be entitled to request pursuant to <U>Section</U><U></U><U>&nbsp;2(a),</U> subject to the written consent of the Bain Investor, unlimited <FONT STYLE="white-space:nowrap">Long-Form</FONT> Registrations in which the Corporation shall pay all
Registration Expenses, whether or not any such registration is consummated. All <FONT STYLE="white-space:nowrap">Long-Form</FONT> Registrations shall be underwritten registrations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Investor Short</U><U><FONT STYLE="white-space:nowrap">-Form</FONT> Registrations</U>. In addition to the
<FONT STYLE="white-space:nowrap">Long-Form</FONT> Registrations provided pursuant to <U>Section</U><U></U><U>&nbsp;2(b)</U>, the holders of Investor Registrable Securities shall be entitled to request pursuant to
<U>Section</U><U></U><U>&nbsp;2(a),</U> subject to the written consent of the Bain Investor, unlimited <FONT STYLE="white-space:nowrap">Short-Form</FONT> Registrations in which the Corporation shall pay all Registration Expenses, whether or not any
such registration is consummated. Demand Registrations shall be <FONT STYLE="white-space:nowrap">Short-Form</FONT> Registrations whenever the Corporation is permitted to use any applicable short form. After the Corporation has become subject to the
reporting requirements of the Securities Act, the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Corporation shall use reasonable best efforts to make <FONT STYLE="white-space:nowrap">Short-Form</FONT> Registrations on <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> available for the
sale of Registrable Securities. If the Corporation, pursuant to the request of the holders of the Investor Registrable Securities and with the consent of the Bain Investor, is qualified to and has filed with the Securities and Exchange Commission a
registration statement under the Securities Act on <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> pursuant to Rule 415 under the Securities Act (the &#147;<U>Required Registration</U>&#148;), then the Corporation shall use reasonable best
efforts to cause the Required Registration to be declared effective under the Securities Act as soon as practicable after filing, and, once effective, the Corporation shall cause such Required Registration to remain effective for a period ending on
the earlier of (i)&nbsp;the date on which all Investor Registrable Securities included in such registration have been sold pursuant to the Required Registration and (ii)&nbsp;the date as of which the holder(s) of the Investor Registrable Securities
included in such registration (assuming such holder(s) are affiliates of the Corporation) are able to sell all of the Investor Registrable Securities included in such registration within a single 90 day period in compliance with Rule 144 (or any
similar rule then in force) under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Priority on Demand Registrations</U>. The Corporation shall not include in
any Demand Registration any securities that are not Registrable Securities without the prior written consent of the Bain Investor. If a Demand Registration or a Shelf Offering (as defined below) is an underwritten offering and the managing
underwriters advise the Corporation in writing that, in their opinion, the number of Registrable Securities and, if permitted hereunder, other securities requested to be included in such offering exceeds the number of Registrable Securities and
other securities, if any, that can be sold in an orderly manner in such offering within a price range acceptable to the Bain Investor, then the Corporation shall include in such registration or offering, prior to the inclusion of any securities that
are not Registrable Securities, the number of Registrable Securities requested to be included that, in the opinion of such underwriters, can be sold in an orderly manner within the price range of such offering, pro rata among the respective holders
thereof on the basis of the amount of Registrable Securities owned by each such holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Restrictions on Long</U><U><FONT
STYLE="white-space:nowrap">-Form</FONT> Registrations</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) The Corporation shall not be obligated to effect any <FONT
STYLE="white-space:nowrap">Long-Form</FONT> Registration within 90 days after the effective date of a previous <FONT STYLE="white-space:nowrap">Long-Form</FONT> Registration or a previous registration in which the holders of Registrable Securities
were given piggyback rights pursuant to <U>Section</U><U></U><U>&nbsp;3</U> and in which there was no reduction in the number of Registrable Securities requested to be included. The Corporation may postpone for up to 90 days (or with the written
consent of the Bain Investor, a longer period) the filing or the effectiveness of a registration statement for a Demand Registration or suspend the use of a prospectus that is part of a Shelf Registration Statement (and therefore suspend sales of
the Shelf Registration Securities) if (A)&nbsp;the Corporation and the Bain Investor agree in good faith that such Demand Registration or Shelf Offering would reasonably be expected to have a material adverse effect on any proposal or plan by the
Corporation or any of its Subsidiaries to engage in any material acquisition of assets or stock (other than in the ordinary course of business) or any material merger, consolidation, tender offer, reorganization, recapitalization, financing or
similar transaction and (B)&nbsp;upon advice of counsel, the sale of Registrable Securities pursuant to the registration statement would require disclosure of material <FONT STYLE="white-space:nowrap">non-public</FONT> information not otherwise
required to be disclosed under applicable law, and either (x)&nbsp;the Corporation has a bona fide business </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
purpose for preserving the confidentiality of such transaction, (y)&nbsp;disclosure would have a material adverse effect on the Corporation or the Corporation&#146;s ability to consummate such
transaction or (z)&nbsp;such transaction renders the Corporation unable to comply with the requirements of the Securities and Exchange Commission, in each case under circumstances that would make it impractical or inadvisable to cause the
registration statement (or such filings) to become effective or to promptly amend or supplement the registration statement on a post effective basis, as applicable; <U>provided</U> that, in such event, the holders of Investor Registrable Securities
initially requesting such Demand Registration shall be entitled to withdraw such request and the Corporation shall pay all Registration Expenses in connection with such registration. The Corporation may delay a Demand Registration hereunder only
once in any <FONT STYLE="white-space:nowrap">12-month</FONT> period, unless additional delays or suspensions are approved by the Bain Investor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) In the case of an event that causes the Corporation to suspend the use of a Shelf Registration Statement as set forth
in<U> Section</U><U></U><U>&nbsp;2(e)(i)</U> above or pursuant to <U>Section</U><U></U><U>&nbsp;5(e)</U><B> </B>(a &#147;<U>Suspension Event</U>&#148;), the Corporation will give a notice to the holders whose Registrable Securities are registered
pursuant to such Shelf Registration Statement (a &#147;<U>Suspension Notice</U>&#148;) to suspend sales of the Registrable Securities and such notice must state generally the basis for the notice and that such suspension will continue only for so
long as the Suspension Event or its effect is continuing. Each holder agrees not to effect any sales of its Registrable Securities pursuant to such Shelf Registration Statement (or such filings) at any time after it has received a Suspension Notice
from the Corporation and prior to receipt of an End of Suspension Notice. A holder may recommence effecting sales of the Registrable Securities pursuant to the Shelf Registration Statement (or such filings) following further written notice to such
effect (an &#147;<U>End of Suspension Notice</U>&#148;) from the Corporation, which End of Suspension Notice will be given by the Corporation to the holders promptly following the conclusion of any Suspension Event (and in any event during the
permitted Suspension Period). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <U>Selection of Underwriters</U>. The Bain Investor shall have the right to select the investment
banker(s) and manager(s) to administer any underwritten offering in connection with any Demand Registration or Shelf Offering, if participating in such Demand Registration or Shelf Offering; <U>provided</U> that the selection of the investment
banker(s) and manager(s) by the applicable Investors in any Demand Registration or Shelf Offering in which the Bain Investor is not participating shall be subject to the consent of the Corporation and the Bain Investor (with such consent not to be
unreasonably withheld or delayed). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) <U>Other Registration Rights</U>. Except as provided in this Agreement, the Corporation shall not
grant to any Persons the right to request the Corporation or any Subsidiary to register any equity securities of the Corporation or any Subsidiary, or any securities, options, or rights convertible or exchangeable into or exercisable for such equity
securities, without the prior written consent of the Bain Investor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) <U>Obligations of Holders of Registrable Securities</U>. Subject
to the Corporation&#146;s obligations under <U>Section</U><U></U><U>&nbsp;5(e)</U>, each holder of Registrable Securities shall cease using any prospectus after receipt of written notice from the Corporation of the happening of any event as a result
of which such prospectus contains an untrue statement of a material fact or omits any fact necessary to make the statements therein not misleading in light of the circumstances under which they were made or is otherwise not legally available to
support sales of Registrable Securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) <U>Shelf Registrations.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) For so long as a registration statement for a Shelf Registration (a &#147;<U>Shelf Registration Statement</U>&#148;) is
and remains effective, the holders of Investor Registrable Securities will have the right, subject to the written consent of the Bain Investor, at any time or from time to time to elect to sell pursuant to an offering (including an underwritten
offering) Registrable Securities pursuant to such registration statement (&#147;<U>Shelf Registrable Securities</U>&#148;). Subject to the immediately preceding sentence, if the applicable holders of Investor Registrable Securities desire to sell
Registrable Securities pursuant to an underwritten offering, then such holders may deliver to the Corporation a written notice (a &#147;<U>Shelf Offering Notice</U>&#148;) specifying the number of Shelf Registrable Securities that such holders
desire to sell pursuant to such underwritten offering (the &#147;<U>Shelf Offering</U>&#148;). As promptly as practicable, but in no event later than two Business Days after receipt of a Shelf Offering Notice, the Corporation will give written
notice of such Shelf Offering Notice to all other holders of Shelf Registrable Securities that have been identified as selling shareholders in such Shelf Registration Statement and are otherwise permitted to sell in such Shelf Offering, which such
notice shall request that each such holder specify, within two Business Days after the Corporation&#146;s receipt of the Shelf Offering Notice, the maximum number of Shelf Registrable Securities such holder desires to be disposed of in such Shelf
Offering. The Corporation, subject to <U>Section</U><U></U><U>&nbsp;2(d)</U> and <U>Section</U><U></U><U>&nbsp;8(a)</U>, will include in such Shelf Offering all Shelf Registrable Securities with respect to which the Corporation has received timely
written requests for inclusion. The Corporation will, as expeditiously as possible (and in any event within 14 days after the receipt of a Shelf Offering Notice), but subject to <U>Section</U><U></U><U>&nbsp;2(d)</U>, use its best efforts to
consummate such Shelf Offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) Subject to the written consent of the Bain Investor, if one or more holders of Investor Registrable
Securities desire to engage in an underwritten block trade or bought deal pursuant to a Shelf Registration Statement (either through filing an Automatic Shelf Registration Statement or through a take-down from an already existing Shelf Registration
Statement) (each, an &#147;<U>Underwritten Block Trade</U>&#148;), then notwithstanding the time periods set forth in <U>Section</U><U></U><U>&nbsp;2(i)(i)</U>, such holders may notify the Corporation of the Underwritten Block Trade not less than
two Business Days prior to the day such offering is first anticipated to commence. If requested by such holders, the Corporation will promptly notify other holders of such Underwritten Block Trade and such notified holders (each, a
&#147;<U>Potential Participant</U>&#148;) may elect whether or not to participate no later than the next Business Day (<I>i.e.</I> one Business Day prior to the day such offering is to commence) (unless a longer period is agreed to by such holders),
and the Corporation will as expeditiously as possible use its best efforts to facilitate such Underwritten Block Trade (which may close as early as two Business Days after the date it commences); <U>provided</U> <U>further</U> that, notwithstanding
the provisions of <U>Section</U><U></U><U>&nbsp;2(i)(i)</U>, no holder (other than the Bain Investor) will be permitted to participate in an Underwritten Block Trade without the written consent of the Bain Investor. Any Potential Participant&#146;s
request to participate in an Underwritten Block Trade shall be binding on the Potential Participant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) All determinations as to whether to complete any Shelf Offering and as to the timing,
manner, price and other terms of any Shelf Offering contemplated by this <U>Section</U><U></U><U>&nbsp;2(i) </U>shall be subject to the approval of the Bain Investor, if participating in such Shelf Offering, and the Corporation shall use its best
efforts to cause such Shelf Offering to occur in accordance with such determinations as promptly as practicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv) The Corporation
will, at the request of any holders of Investor Registrable Securities included in any Shelf Offering, subject to the written consent of the Bain Investor, file any prospectus supplement or any post-effective amendments and otherwise take any action
necessary to include therein all disclosure and language deemed necessary or advisable by such holders to effect such Shelf Offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) If the Corporation files any Automatic Shelf Registration Statement for the benefit of the holders of any of its
securities other than the holders of Registrable Securities, and none of the holders of Investor Registrable Securities request that their Registrable Securities be included in such Shelf Registration Statement, the Corporation agrees that, at the
request of such holders, it will include in such Automatic Shelf Registration Statement such disclosures as may be required by Rule 430B in order to ensure that such holders may be added to such Shelf Registration Statement at a later time through
the filing of a prospectus supplement rather than a post-effective amendment. If the Corporation has filed any Automatic Shelf Registration Statement for the benefit of the holders of any of its securities other than the holders of Registrable
Securities, the Corporation shall, at the request of any holders of Investor Registrable Securities, subject to the written consent of the Bain Investor, file any post-effective amendments necessary to include therein all disclosure and language
necessary to ensure that the holders of Registrable Securities may be added to such Shelf Registration Statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) <U>Revocation of
Demand Notice or Shelf Offering Notice</U>.&nbsp;At any time prior to the effective date of the registration statement relating to a Demand Registration or the &#147;pricing&#148; of any offering relating to a Shelf Offering Notice, the holders of
Investor Registrable Securities who initiated such Demand Registration or Shelf Offering may revoke or withdraw such notice of a Demand Registration or Shelf Offering Notice on behalf of all holders participating in such Demand Registration or Shelf
Offering without liability to such holders (including, for the avoidance of doubt, the other holders of Investor Registrable Securities participating in such Demand Registration or Shelf Offering), in each case by providing written notice to the
Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) <U>Confidentiality</U>. Each holder agrees to treat as confidential the receipt of any notice hereunder (including
notice of a Demand Registration, a Shelf Offering Notice and a Suspension Notice) and the information contained therein, and not to disclose or use the information contained in any such notice (or the existence thereof) without the prior written
consent of the Corporation until such time as the information contained therein is or becomes available to the public generally (other than as a result of disclosure by such holder in breach of the terms of this Agreement). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3. <U>Piggyback Registrations</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Right to Piggyback</U>. Whenever the Corporation proposes to register any of its equity securities (including any proposed registration
of the Corporation&#146;s equity securities by any third party) under the Securities Act (other than (i)&nbsp;pursuant to a Demand Registration, which is addressed by <U>Section</U><U></U><U>&nbsp;2</U>, (ii) in connection with an initial Public
Offering of the Corporation&#146;s equity securities or (iii)&nbsp;in connection with registrations on <FONT STYLE="white-space:nowrap">Form&nbsp;S-4,</FONT> <FONT STYLE="white-space:nowrap">S-8</FONT> or any successor or similar forms) and the
registration form to be used may be used for the registration of Registrable Securities (each, a &#147;<U>Piggyback Registration</U>&#148;), the Corporation shall give prompt written notice (and in any event within three Business Days after its
receipt of notice of any exercise of demand registration rights other than under this Agreement) to all holders of Registrable Securities of its intention to effect such a registration and shall include in such registration all Registrable
Securities with respect to which the Corporation has received written requests for inclusion therein within 20 days after the receipt of the Corporation&#146;s notice. Any Investor may withdraw its request for inclusion at any time prior to
executing the underwriting agreement, or if none, prior to the applicable registration statement becoming effective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Piggyback
Expenses</U>. The Registration Expenses of the holders of Registrable Securities shall be paid by the Corporation in all Piggyback Registrations as provided in <U>Section</U><U></U><U>&nbsp;6</U>, whether or not any such registration is consummated.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Priority on Primary Registrations</U>. If a Piggyback Registration is an underwritten primary registration on behalf of the
Corporation, and the managing underwriters advise the Corporation in writing that, in their opinion, the number of securities requested to be included in such registration exceeds the number which can be sold in an orderly manner in such offering
within a price range acceptable to the Corporation, then the Corporation shall include in such registration, (i)&nbsp;first, the securities the Corporation proposes to sell that, in the opinion of such underwriters, can be sold in an orderly manner
within the price range of such offering, (ii)&nbsp;second, the Registrable Securities requested to be included in such registration that, in the opinion of such underwriters, can be sold in an orderly manner within the price range of such offering
(if any), pro rata among the respective holders thereof on the basis of the amount of Registrable Securities owned by each such holder, and (iii)&nbsp;third, the other securities requested to be included in such registration that, in the opinion of
such underwriters, can be sold in an orderly manner within the price range of such offering (if any). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Priority on Secondary
Registrations</U>. If a Piggyback Registration is an underwritten secondary registration on behalf of holders of the Corporation&#146;s securities other than holders of Registrable Securities (it being understood that secondary registrations on
behalf of holders of Registrable Securities are addressed in <U>Section</U><U></U><U>&nbsp;2</U> rather than this <U>Section</U><U></U><U>&nbsp;3(d)</U>), and the managing underwriters advise the Corporation in writing that, in their opinion, the
number of securities requested to be included in such registration exceeds the number which can be sold in an orderly manner in such offering within a price range acceptable to the holders of a majority of the Registrable Securities to be included
in such registration, then the Corporation shall include in such registration, (i)&nbsp;first, the securities requested to be included therein by the holders requesting such registration and the Registrable Securities requested to be included in
such registration, in each case that, in the opinion of such underwriters, can be sold in an orderly manner within the price range of such offering (if any), pro rata among the holders of such securities and the holders
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of such Registrable Securities on the basis of the number of shares of Common Stock owned by each such holder, and (ii)&nbsp;second, the other securities requested to be included in such
registration that, in the opinion of such underwriters, can be sold in an orderly manner within the price range of such offering (if any). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Selection of Underwriters</U>. If any Piggyback Registration is an underwritten offering, then the selection of investment banker(s)
and manager(s) for the offering must be approved by the Bain Investor, if participating in the Piggyback Registration, and if not, by the holders of a majority of the Registrable Securities included in such Piggyback Registration, which approval
shall not be unreasonably withheld. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <U>Other Registrations</U>. If the Corporation has previously filed a registration statement with
respect to Registrable Securities pursuant to <U>Section</U><U></U><U>&nbsp;2</U> or pursuant to this <U>Section</U><U></U><U>&nbsp;3</U>, and if such previous registration has not been withdrawn or abandoned, then, unless such previous registration
is a Required Registration, the Corporation shall not file or cause to be effected any other registration of any of its equity securities or securities convertible or exchangeable into or exercisable for its equity securities under the Securities
Act (except on Form <FONT STYLE="white-space:nowrap">S-8</FONT> or any successor form), whether on its own behalf or at the request of any holder or holders of such securities, until a period of at least 90 days has elapsed from the effective date
of such previous registration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4. <U>Lockup Agreements; Transfers</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Prohibited Actions during Holdback Period</U>. Each holder of Registrable Securities agrees that in connection with any Public Sale or
any Demand Registration, Shelf Offering or Piggyback Registration, in each case that is an underwritten public offering of the Corporation&#146;s equity securities, he, she or it shall not (i)&nbsp;offer, sell, contract to sell, pledge or otherwise
dispose of (including sales pursuant to Rule&nbsp;144), directly or indirectly, any equity securities of the Corporation (including equity securities of the Corporation that may be deemed to be owned beneficially by such holder in accordance with
the rules and regulations of the Securities and Exchange Commission) (collectively, &#147;<U>Securities</U>&#148;), or any securities, options, or rights convertible into or exchangeable or exercisable for Securities (collectively, &#147;<U>Other
Securities</U>&#148;), (ii)&nbsp;enter into a transaction which would have the same effect as any action described in clause (i)&nbsp;of this <U>Section</U><U></U><U>&nbsp;4(a)</U>, (iii)&nbsp;enter into any swap, hedge or other arrangement that
transfers, in whole or in part, any of the economic consequences or ownership of any Securities or Other Securities, whether such transaction is to be settled by delivery of such Securities, Other Securities, in cash or otherwise, or
(iv)&nbsp;publicly disclose the intention to enter into any transaction described in clauses (i), (ii) or (iii)&nbsp;of this <U>Section</U><U></U><U>&nbsp;4(a)</U>, from the date on which the Corporation gives notice to the holders of Registrable
Securities that a preliminary prospectus has been circulated for such underwritten public offering through such period as is mutually agreed between the Company, the Bain Investor and the underwriters of such underwritten public offering (each such
period referred to herein as a &#147;<U>Holdback Period</U>&#148;); <U>provided</U>, <U>however</U>, that such Holdback Period shall not exceed 180 days following the completion of the Corporation&#146;s initial Public Offering or 90 days in the
case of any other Public Sale or any Demand Registration, Shelf Offering or Piggyback Registration. The Corporation may impose <FONT STYLE="white-space:nowrap">stop-transfer</FONT> instructions with respect to its Securities and Other Securities
that are subject to the foregoing restriction until the end of such Holdback Period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Lockup Agreements</U>. In connection with any underwritten public offering of the
Corporation&#146;s equity securities, each holder of Registrable Securities agrees to enter into any holdback, lockup or similar agreement requested by the underwriters managing such underwritten public offering that the Bain Investor agrees to
enter into. Any such holdback, lockup or similar agreement entered into with the underwriters managing such underwritten public offering shall supersede the provisions of <U>Section</U><U></U><U>&nbsp;4(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Limitation on Public Sales and Distributions</U>. The Corporation (i)&nbsp;shall not effect any Public Sale or distribution of its
equity securities, or any securities, options or rights convertible into or exchangeable or exercisable for such equity securities, during the seven days prior to and during the <FONT STYLE="white-space:nowrap">180-day</FONT> period beginning on the
effective date of any underwritten Demand Registration or any underwritten Piggyback Registration (except as part of such underwritten registration or pursuant to registrations on Form <FONT STYLE="white-space:nowrap">S-4</FONT> or Form <FONT
STYLE="white-space:nowrap">S-8</FONT> or any successor form), unless the underwriters managing the registered public offering otherwise agree and, (ii)&nbsp;to the extent not inconsistent with applicable law, except as otherwise permitted by the
Bain Investor, shall cause each holder of its equity securities, or any securities convertible into or exchangeable or exercisable for equity securities, purchased from the Corporation at any time after the date of this Agreement (other than in a
registered public offering) to agree not to effect any public sale or distribution (including sales pursuant to Rule 144) of any such securities during such period (except as part of such underwritten registration, if otherwise permitted), unless
the underwriters managing the registered public offering otherwise agree. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Permitted Transfer</U>.<SUP
STYLE="font-size:75%; vertical-align:top"> </SUP>Notwithstanding anything to the contrary herein, except in the case of (i)&nbsp;a Transfer to the Corporation, (ii)&nbsp;a Transfer by the Bain Investor to its partners in connection with a pro rata <FONT
STYLE="white-space:nowrap">in-kind</FONT> distribution thereto, (iii)&nbsp;a Public Sale or sales pursuant to Rule 144 permitted hereunder or (iv)&nbsp;a Transfer in connection with an Approved Sale (as defined in the Securityholders Agreement)
(each of <U>clauses</U> <U>(i)</U>&nbsp;through <U>(iv)</U>, a &#147;<U>Permitted Transfer</U>&#148;), prior to Transferring any Registrable Securities to any Person (including by operation of law), the Securityholder making such Transfer shall
cause the prospective Transferee to execute and deliver to the Corporation a counterpart of this Agreement thereby agreeing to be bound by the terms hereof. Any Transfer or attempted Transfer of any Registrable Securities in violation of any
provision of this Agreement shall be void, and the Corporation shall not record such Transfer on its books or treat any purported Transferee of such securities as the owner of such securities for any purpose. Other than in the case of a Permitted
Transfer, whether or not any such Transferee has executed a counterpart hereto, such Transferee shall be subject to the obligations of the Transferor hereunder. The provisions of this <U>Section</U><U></U><U>&nbsp;4(d)</U> shall terminate upon a
Sale of the Partnership. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U><FONT STYLE="white-space:nowrap">In-Kind</FONT> Distributions</U><U>.</U> If any Investor (and/or any of
its Affiliates) seeks to effectuate an <FONT STYLE="white-space:nowrap">in-kind</FONT> distribution of all or part of its Registrable Securities to its respective direct or indirect equityholders, the Corporation will, subject to any applicable <FONT
STYLE="white-space:nowrap">lock-ups,</FONT> reasonably cooperate with and assist such Investor, such equityholders and the Corporation&#146;s transfer agent to facilitate such <FONT STYLE="white-space:nowrap">in-kind</FONT> distribution in the
manner reasonably requested by such Investor (including the delivery of instruction letters by the Corporation or its counsel to the Corporation&#146;s transfer agent, the delivery of customary legal opinions by counsel to the Corporation and the
delivery of shares of Common Stock without restrictive legends, to the extent no longer applicable). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <U>Registerable Securities Transactions</U>. If requested by any holder in connection
with any transaction involving any Registrable Securities (including any sale or other transfer of such securities without registration under the Securities Act, any margin loan with respect to such securities and any pledge of such securities), the
Corporation agrees to provide such holder with customary and reasonable assistance to facilitate such transaction, including, without limitation, (i)&nbsp;such action as such holder may reasonably request from time to time to enable such holder to
sell Registrable Securities without registration under the Securities Act and (ii)&nbsp;entering into an &#147;issuer&#146;s agreement&#148; in connection with any margin loan with respect to such securities in customary form. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5. <U>Registration Procedures</U>. Whenever the holders of Registrable Securities have requested that any Registrable Securities be registered
pursuant to this Agreement or have initiated a Shelf Offering, the Corporation shall use reasonable best efforts to effect the registration and the sale of such Registrable Securities in accordance with the intended method of disposition thereof,
and pursuant thereto the Corporation shall as expeditiously as possible: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) prepare and, within 60 days after the end of the period
within which requests for registration may be given to the Corporation, file with (or submit confidentially to) the Securities and Exchange Commission a registration statement with respect to such Registrable Securities, make all required filings
with the Financial Industry Regulatory Authority, Inc. (&#147;<U>FINRA</U>&#148;), and use reasonable best efforts to cause such registration statement to become effective as soon as practicable thereafter, in each case in accordance with the
Securities Act and all applicable rules and regulations promulgated thereunder; <U>provided</U> that, before filing (or confidentially submitting) a registration statement or prospectus or any amendments or supplements thereto, the Corporation shall
furnish to the counsel selected by the holders of a majority of the Investor Registrable Securities covered by such registration statement copies of all such documents proposed to be filed or submitted, which documents shall be subject to the review
and comment of such counsel; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) notify in writing each holder of Registrable Securities of the effectiveness of each registration
statement filed hereunder and prepare and file with the Securities and Exchange Commission such amendments and supplements to such registration statement and the prospectus used in connection therewith as may be necessary to keep such registration
statement effective for a period of not less than 180 days (or, if such registration statement relates to an underwritten offering, such longer period as in the opinion of counsel for the underwriters a prospectus is required by law to be delivered
in connection with sales of Registrable Securities by an underwriter or dealer) and comply with the provisions of the Securities Act with respect to the disposition of all securities covered by such registration statement during such period in
accordance with the intended methods of disposition by the sellers thereof set forth in such registration statement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) furnish, without
charge, to each seller of Registrable Securities and each underwriter, if any, such number of copies of such registration statement, each amendment and supplement thereto, the prospectus included in such registration statement (including each
preliminary prospectus), each Free Writing Prospectus and such other documents as such seller or underwriter, if any, may reasonably request in order to facilitate the disposition of the Registrable Securities owned by such seller (the Corporation
hereby consenting to the use in accordance with all applicable laws of each such registration statement, each such amendment and supplement thereto, and each such prospectus (or preliminary prospectus or supplement thereto) or Free Writing
Prospectus by each such seller of Registrable Securities and the underwriters, if any, in connection with the offering and sale of the Registrable Securities covered by such registration statement or prospectus); </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) use reasonable best efforts to register or qualify such Registrable Securities under
such other securities or &#147;blue sky&#148; laws of such jurisdictions as any seller reasonably requests and do any and all other acts and things which may be reasonably necessary or advisable to enable such seller of Registrable Securities to
consummate the disposition in such jurisdictions of the Registrable Securities owned by such seller of Registrable Securities (<U>provided</U> that the Corporation shall not be required to (i)&nbsp;qualify generally to do business in any
jurisdiction where it would not otherwise be required to qualify but for this <U>Section</U><U></U><U>&nbsp;5(d)</U>, (ii)&nbsp;subject itself to taxation in any such jurisdiction or (iii)&nbsp;consent to general service of process in any such
jurisdiction); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) promptly notify in writing each seller of such Registrable Securities, (i)&nbsp;promptly after it receives notice
thereof, of the date and time when such registration statement and each post-effective amendment thereto has become effective or a prospectus or supplement to any prospectus relating to a registration statement has been filed and when any
registration or qualification has become effective under a state securities or blue sky law or any exemption thereunder has been obtained, (ii)&nbsp;promptly after receipt thereof, of any request by the Securities and Exchange Commission for the
amendment or supplementing of such registration statement or prospectus or for additional information, (iii)&nbsp;at any time when a prospectus relating thereto is required to be delivered under the Securities Act, of the happening of any event as a
result of which the prospectus included in such registration statement (A)&nbsp;contains an untrue statement of a material fact or omits any fact necessary to make the statements therein not misleading in light of the circumstances under which they
were made or (B)&nbsp;is otherwise not legally available to support sales of Registrable Securities, and, at the request of the holders of a majority of the Investor Registrable Securities covered by such registration statement, the Corporation
shall promptly prepare and furnish to each such seller a reasonable number of copies of a supplement or amendment to such prospectus so that, as thereafter delivered to the purchasers of such Registrable Securities, such prospectus shall not contain
an untrue statement of a material fact or omit to state any fact necessary to make the statements therein not misleading in light of the circumstances under which they were made and (iv)&nbsp;if at any time the representations and warranties of the
Corporation in any underwriting agreement, securities sale agreement, or other similar agreement, relating to the offering shall cease to be true and correct; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) (i) cause all such Registrable Securities to be listed on each securities exchange on which similar securities issued by the Corporation
are then listed and, without limiting the generality of the foregoing, to arrange for at least two market markers to register as such with respect to such Registrable Securities with FINRA, and (ii)&nbsp;comply (and continue to comply) with the
requirements of any self-regulatory organization applicable to the Corporation, including without limitation all corporate governance requirements; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) provide a transfer agent and registrar for all such Registrable Securities not later than the effective date of such registration
statement; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) enter into and perform such customary agreements (including underwriting agreements in
customary form) and take all such other actions as the holders of a majority of the Investor Registrable Securities being sold or the underwriters, if any, reasonably request in order to expedite or facilitate the disposition of Registrable
Securities (including participation in &#147;road shows,&#148; investor presentations, and marketing events and effecting a share or unit split or a combination of shares or units); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) make available for inspection by any seller of Registrable Securities, any underwriter participating in any disposition or sale pursuant
to such registration statement, and any attorney, accountant, or other agent retained by any such seller or underwriter, all financial and other records, pertinent corporate documents and properties of the Corporation, and cause the
Corporation&#146;s officers, directors, employees, and independent accountants to supply all information reasonably requested by any such seller, underwriter, attorney, accountant, or agent in connection with such registration statement and assist
and, at the request of any participating seller or underwriter, use reasonable best efforts to cause such officers or directors to participate in presentations to prospective purchasers; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) otherwise use reasonable best efforts to comply with all applicable rules and regulations of the Securities and Exchange Commission, and
make available to its security holders, as soon as reasonably practicable, an earnings statement covering the period of at least twelve months beginning with the first day of the Corporation&#146;s first full calendar quarter after the effective
date of the registration statement, which earnings statement shall satisfy the provisions of Section&nbsp;11(a) of the Securities Act and Rule&nbsp;158 thereunder; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) in the event of the issuance of any stop order suspending the effectiveness of a registration statement, or of any order suspending or
preventing the use of any related prospectus or suspending the qualification of any equity securities included in such registration statement for sale in any jurisdiction, the Corporation shall notify in writing each holder of Registrable Securities
of such order and use reasonable best efforts promptly to obtain the withdrawal of such order; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l) use reasonable best efforts to cause
such Registrable Securities covered by such registration statement to be registered with or approved by such other governmental agencies or authorities as may be necessary to enable the sellers thereof to consummate the disposition of such
Registrable Securities; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(m) take all reasonable actions to ensure that any Free Writing Prospectus utilized in connection with any Demand
Registration or Piggyback Registration hereunder complies in all material respects with the Securities Act, is filed in accordance with the Securities Act to the extent required thereby, is retained in accordance with the Securities Act to the
extent required thereby and, when taken together with the related prospectus, will not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in light of the circumstances under
which they were made, not misleading; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(n) obtain one or more &#147;cold comfort&#148; letters, including any updates thereof, dated the
effective date of such registration statement (and, if such registration includes an underwritten public offering, dated the date of the closing under the underwriting agreement and addressed to the underwriters), from the Corporation&#146;s
independent public accountants in customary form and covering such matters of the type customarily covered by such letters as the holders of a majority of the Investor Registrable Securities being sold in such registered offering reasonably request;
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(o) provide a legal opinion of the Corporation&#146;s outside counsel, dated the effective
date of such registration statement (or, if such registration includes an underwritten public offering, dated the date of the closing under the underwriting agreement and addressed to the underwriters), with respect to the registration statement,
each amendment and supplement thereto, the prospectus included therein (including the preliminary prospectus) and such other documents relating thereto in customary form and covering such matters of the type customarily covered by legal opinions of
such nature; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(p) reasonably cooperate with each seller of Registrable Securities and each underwriter participating in the disposition of
such Registrable Securities and their respective counsel in connection with any filings required to be made with FINRA and, to the extent required by the rules and regulations of FINRA, retain a &#147;qualified independent underwriter&#148; within
the meaning of the rules of FINRA acceptable to the managing underwriter participating in the disposition of such Registrable Securities; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(q) permit any holder which, in its sole and exclusive judgment, might be deemed to be an underwriter or a controlling person of the
Corporation, to participate in the preparation of such registration or comparable statement and to allow such holder to provide language for insertion therein, in form and substance satisfactory to the Corporation, which in the reasonable judgment
of such holder and its counsel should be included; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(r) cooperate with the holders covered by the registration statement and the managing
underwriter or agent, if any, to facilitate the timely preparation and delivery of certificates representing Registrable Securities to be sold and not bearing any restrictive legends (or arrange for book entry transfer of securities in the case of
uncertificated securities), and enable such Registrable Securities to be in such denominations and registered in such names as the managing underwriter, or agent, if any, or such holders may request at least two Business Days prior to any proposed
sale of Registrable Securities to the underwriters; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(s) if requested by any managing underwriter, include in any prospectus or prospectus
supplement updated financial or business information for the Corporation&#146;s most recent period or current quarterly period (including estimated results or ranges of results) if required for purposes of marketing the offering in the view of the
managing underwriter; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(t) take no direct or indirect action prohibited by Regulation M under the Exchange Act; <U>provided</U>,
<U>however</U>, that to the extent that any prohibition is applicable to the Corporation, the Corporation will take such action as is necessary to make any such prohibition inapplicable; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(u) if the Corporation files an Automatic Shelf Registration Statement covering any Registrable Securities, use its best efforts to remain a
well-known seasoned issuer (and not become an ineligible issuer (as defined in Rule 405 under the Securities Act)) during the period during which such Automatic Shelf Registration Statement is required to remain effective; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(v) if the Corporation does not pay the filing fee covering the Registrable Securities at
the time an Automatic Shelf Registration Statement is filed, pay such fee at such time or times as the Registrable Securities are to be sold; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(w) if the Automatic Shelf Registration Statement has been outstanding for at least three years, at the end of the third year, refile a new
Automatic Shelf Registration Statement covering the Registrable Securities, and, if at any time when the Corporation is required to <FONT STYLE="white-space:nowrap">re-evaluate</FONT> its well-known seasoned issuer status the Corporation determines
that it is not a well-known seasoned issuer, use its best efforts to refile the Shelf Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> and, if such form is not available, Form <FONT STYLE="white-space:nowrap">S-1</FONT> and
keep such registration statement effective during the period during which such registration statement is required to be kept effective; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(x) if requested by any Investor, cooperate with such Investor and with the managing underwriter or agent, if any, on reasonable notice to
facilitate any Charitable Gifting Event and to prepare and file with the Securities and Exchange Commission such amendments and supplements to such Registration Statement and the Prospectus used in connection therewith as may be necessary to permit
any such recipient Charitable Organization to sell in the underwritten offering if it so elects; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(y) take all such other commercially
reasonable actions as are necessary or advisable in order to expedite or facilitate the disposition of such Registrable Securities in accordance with the terms of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6. <U>Registration Expenses</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Registration Expenses Generally</U>. Subject to <U>Section</U><U></U><U>&nbsp;6(b)</U>, all expenses incident to the Corporation&#146;s
performance of or compliance with this Agreement, including all registration and filing fees, fees and expenses of compliance with securities or &#147;blue sky&#148; laws, printing expenses, travel expenses, filing expenses, messenger and delivery
expenses, fees and disbursements of custodians, and fees and disbursements of counsel for the Corporation, and fees and disbursements of all independent certified public accountants, underwriters including, if necessary, a &#147;qualified
independent underwriter&#148; within the meaning of the FINRA rules (in each case, excluding discounts and commissions), and other Persons retained by the Corporation or by holders of Investor Registrable Securities or their affiliates on behalf of
the Corporation (all such expenses being herein called &#147;<U>Registration Expenses</U>&#148;), shall be borne as provided in this Agreement, except that the Corporation shall, in any event, pay its internal expenses (including all salaries and
expenses of its officers and employees performing legal or accounting duties), the expense of any annual audit or quarterly review, the expense of any liability insurance and the expenses and fees for listing the securities to be registered on each
securities exchange on which similar securities issued by the Corporation are then listed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Reimbursement of Fees of Counsel</U>.
In connection with each Demand Registration, each Shelf Offering and each Piggyback Registration, the Corporation shall reimburse the holders of Registrable Securities included in such registration for the reasonable fees and disbursements of one
counsel chosen by the holders of a majority of the Investor Registrable Securities included in such registration. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Other Registration Expenses</U>. To the extent Registration Expenses are not required
to be paid by the Corporation, each holder of securities included in any registration hereunder shall pay those Registration Expenses allocable to the registration of such holder&#146;s securities so included, and any Registration Expenses not so
allocable shall be borne by all sellers of securities included in such registration in proportion to the aggregate selling price of the securities to be so registered. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7. <U>Indemnification</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)
<U>Indemnification of Holders of Registrable Securities and Underwriters</U>. The Corporation agrees to indemnify and hold harmless, to the fullest extent permitted by law, each holder of Registrable Securities, its officers, directors, advisors,
agents, and employees, and each Person who controls such holder (within the meaning of the Securities Act) against all losses, claims, damages, liabilities, and expenses (or actions or proceedings, whether commenced or threatened, in respect
thereof), whether joint and several or several, together with reasonable costs and expenses (including reasonable attorney&#146;s fees) to which any such indemnified party may become subject under the Securities Act or otherwise
(collectively,&nbsp;&#147;<U>Losses</U>&#148;) caused by, resulting from, arising out of, based upon, or relating to (i)&nbsp;any untrue or alleged untrue statement of material fact contained in (A)&nbsp;any registration statement, prospectus,
preliminary prospectus or Free-Writing Prospectus, or any amendment thereof or supplement thereto or (B)&nbsp;any application or other document or communication (in this <U>Section</U><U></U><U>&nbsp;7</U>, each,
an&nbsp;&#147;<U>application</U>&#148;) executed by or on behalf of the Corporation or based upon written information furnished by or on behalf of the Corporation filed in any jurisdiction in order to qualify any securities covered by such
registration under the &#147;blue sky&#148; or securities laws thereof, (ii)&nbsp;any omission or alleged omission of a material fact required to be stated therein or necessary to make the statements therein not misleading or (iii)&nbsp;any
violation by the Corporation of any rule or regulation promulgated pursuant to any federal, state or common law rule or regulation including the Securities Act, applicable to the Corporation and relating to action or inaction required of the
Corporation in connection with any such registration hereunder, and the Corporation will reimburse such holder and each such director, officer and controlling Person for any legal or any other expenses incurred by them in connection with
investigating or defending any such Losses; <U>provided</U> that the Corporation shall not be liable in any such case to the extent that any such Losses result from, arise out of, are based upon, or relate to an untrue statement or alleged untrue
statement, or omission or alleged omission, made in such registration statement, any such prospectus, or preliminary prospectus or any amendment thereof or supplement thereto, or in any application, in each case, made in reliance upon, and in
conformity with, written information prepared and furnished in writing to the Corporation by such holder expressly for use therein or by such holder&#146;s failure to deliver a copy of the registration statement or prospectus or any amendments or
supplements thereto after the Corporation has furnished such holder with a sufficient number of copies of the same. In connection with an underwritten offering, the Corporation shall indemnify such underwriters, their officers and directors, and
each Person who controls such underwriters (within the meaning of the Securities Act) to the same extent as provided above with respect to the indemnification of the holders of Registrable Securities or as otherwise agreed to in the underwriting
agreement executed in connection with such underwritten offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Provision of Information; Indemnity of holders of Registrable Securities</U>. In
connection with any registration statement in which a holder of Registrable Securities is participating, each such holder will furnish to the Corporation in writing such information and affidavits as the Corporation reasonably requests for use in
connection with any such registration statement or prospectus and, to the fullest extent permitted by law, shall indemnify and hold harmless the other holders of Registrable Securities and the Corporation, and their respective officers, directors,
agents, and employees, and each other Person who controls the Corporation (within the meaning of the Securities Act) against any Losses caused by, resulting from, arising out of, based upon, or relating to (i)&nbsp;any untrue or alleged untrue
statement of material fact contained in the registration statement, prospectus or preliminary prospectus, or any amendment thereof or supplement thereto or in any application, or (ii)&nbsp;any omission or alleged omission of a material fact required
to be stated therein or necessary to make the statements therein not misleading, but in each case only to the extent that such untrue statement or omission is made in such registration statement, any such prospectus or preliminary prospectus or any
amendment or supplement thereto, or in any application, in each case, in reliance upon and in conformity with written information prepared and furnished to the Corporation by such holder expressly for use therein, and such holder will reimburse the
Corporation and each such other indemnified party for any legal or any other expenses incurred by them in connection with investigating or defending any such Losses; <U>provided</U> that the obligation to indemnify will be individual, not joint and
several, for each holder and shall be limited to the net amount of proceeds received by such holder from the sale of Registrable Securities pursuant to such registration statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Claims</U>. Any Person entitled to indemnification hereunder will (i)&nbsp;give prompt written notice to the indemnifying party of any
claim with respect to which it seeks indemnification (<U>provided</U> that the failure to give prompt notice shall not impair any Person&#146;s right to indemnification hereunder to the extent such failure has not prejudiced the indemnifying party)
and (ii)&nbsp;unless in such indemnified party&#146;s reasonable judgment a conflict of interest between such indemnified and indemnifying parties may exist with respect to such claim, permit such indemnifying party to assume the defense of such
claim with counsel reasonably satisfactory to the indemnified party. If such defense is assumed, then the indemnifying party will not be subject to any liability for any settlement made by the indemnified party without its consent (but such consent
will not be unreasonably withheld). An indemnifying party who is not entitled to, or elects not to, assume the defense of a claim will not be obligated to pay the fees and expenses of more than one counsel for all parties indemnified by such
indemnifying party with respect to such claim, unless in the reasonable judgment of any indemnified party a conflict of interest may exist between such indemnified party and any other of such indemnified parties with respect to such claim. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Additional Indemnification Rights</U>. The indemnification provided for under this Agreement shall be in addition to any other rights
to indemnification or contribution which any indemnified party may have pursuant to law or contract, and will remain in full force and effect regardless of any investigation made or omitted by or on behalf of the indemnified party or any officer,
director, or controlling Person of such indemnified party and shall survive the transfer of securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Contribution</U>. If the
indemnification provided for in this <U>Section</U><U></U><U>&nbsp;7</U> is unavailable to or is insufficient to hold harmless an indemnified party under the provisions above in respect to any Losses referred to therein, then each indemnifying party
shall contribute to the amount paid or payable by such indemnified party as a result of such Losses (i)&nbsp;in such proportion as is appropriate to reflect the relative fault of the Corporation on the one hand and the sellers of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Registrable Securities and any other sellers participating in the registration statement on the other hand or (ii)&nbsp;if the allocation provided by <U>clause (i)</U>&nbsp;of this
<U>Section</U><U></U><U>&nbsp;7(e)</U> is not permitted by applicable law, then in such proportion as is appropriate to reflect not only the relative fault referred to in <U>clause</U><U></U><U>&nbsp;(i)</U> of this
<U>Section</U><U></U><U>&nbsp;7(e)</U> but also the relative benefit of the Corporation on the one hand and of the sellers of Registrable Securities and any other sellers participating in the registration statement on the other in connection with
the statement or omissions which resulted in such Losses, as well as any other relevant equitable considerations. The relative benefits received by the Corporation on the one hand and the sellers of Registrable Securities and any other sellers
participating in the registration statement on the other shall be deemed to be in the same proportion as the total net proceeds from the offering (before deducting expenses) to the Corporation bear to the total net proceeds from the offering (before
deducting expenses) to the sellers of Registrable Securities and any other sellers participating in the registration statement. The relative fault of the Corporation on the one hand and of the sellers of Registrable Securities and any other sellers
participating in the registration statement on the other shall be determined by reference to, among other things, whether the untrue statement or alleged omission to state a material fact relates to information supplied by the Corporation or by the
sellers of Registrable Securities or other sellers participating in the registration statement and the parties&#146; relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <U>Contribution Limits</U>. The Corporation and the sellers of Registrable Securities agree that it would not be just and equitable if
contribution pursuant to this <U>Section</U><U></U><U>&nbsp;7</U> were determined by pro rata allocation (even if the sellers of Registrable Securities were treated as one entity for such purpose) or by any other method of allocation which does not
take account of the equitable considerations referred to in <U>Section</U><U></U><U>&nbsp;7(e)</U>. The amount paid or payable by an indemnified party as a result of the Losses referred to in <U>Section</U><U></U><U>&nbsp;7(e)</U> shall be deemed to
include, subject to the limitations set forth above, any legal or other expenses reasonably incurred by such indemnified party in connection with investigating or defending any such action or claim. Notwithstanding the provisions of this
<U>Section</U><U></U><U>&nbsp;7</U>, no seller of Registrable Securities shall be required to contribute pursuant to this <U>Section</U><U></U><U>&nbsp;7</U> any amount in excess of the sum of (i)&nbsp;any amounts paid pursuant to
<U>Section</U><U></U><U>&nbsp;7(b)</U> and (ii)&nbsp;the net proceeds received by such seller from the sale of Registrable Securities covered by the registration statement filed pursuant hereto. No Person guilty of fraudulent misrepresentation
(within the meaning of Section&nbsp;11(f) of the Securities Act) shall be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) To the extent that any of holder of Registrable Securities is, or would be expected to be, deemed to be an underwriter of Registrable
Securities pursuant to any Securities and Exchange Commission comments or policies or any court of law or otherwise, the Corporation agrees that the indemnification and contribution provisions contained in this <U>Section</U><U></U><U>&nbsp;7</U>
shall be applicable to the benefit of such holder of Registrable Securities in its role as deemed underwriter in addition to its capacity as a holder of Registrable Securities (so long as the amount for which any other holder of Registrable
Securities is or becomes responsible does not exceed the amount for which such holder of Registrable Securities would be responsible if the holder of Registrable Securities were not deemed to be an underwriter of Registrable Securities). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8. <U>Participation in Underwritten Registrations</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Cooperation with Underwriting Arrangements</U>. No Person may participate in any underwritten registration hereunder unless such Person
(i)&nbsp;agrees to sell such Person&#146;s securities on the basis provided in any underwriting arrangements approved by the Person or Persons entitled hereunder to approve such arrangements (including pursuant to the terms of any <FONT
STYLE="white-space:nowrap">over-allotment</FONT> or &#147;green shoe&#148; option requested by the managing underwriter(s); <U>provided</U> that no holder of Registrable Securities will be required to sell more than the number of Registrable
Securities that such holder has requested the Corporation to include in any registration) and (ii)&nbsp;completes and executes all questionnaires, powers of attorney, indemnities, underwriting agreements and other documents reasonably required under
the terms of such underwriting arrangements; <U>provided</U> that no holder of Registrable Securities included in any underwritten registration shall be required to make any representations or warranties to the Corporation or the underwriters (other
than representations and warranties regarding such holder and such holder&#146;s intended method of distribution) or to undertake any indemnification obligations to the Corporation or the underwriters with respect thereto, except as otherwise
provided in <U>Section</U><U></U><U>&nbsp;7</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Supplements or Amendments to Prospectus</U>. Each Person that is participating in
any registration hereunder agrees that, upon receipt of any notice from the Corporation of the happening of any event of the kind described in <U>Section</U><U></U><U>&nbsp;5(e)</U>, such Person will immediately discontinue the disposition of its
Registrable Securities pursuant to the registration statement until such Person&#146;s receipt of the copies of a supplemented or amended prospectus as contemplated by <U>Section</U><U></U><U>&nbsp;5(e)</U>. In the event the Corporation shall give
any such notice, the applicable time period mentioned in <U>Section</U><U></U><U>&nbsp;5(b)</U> during which a registration statement is to remain effective shall be extended by the number of days during the period from and including the date of the
giving of such notice pursuant to this <U>Section</U><U></U><U>&nbsp;8(b)</U> to and including the date when each seller of a Registrable Security covered by such registration statement shall have received the copies of the supplemented or amended
prospectus contemplated by <U>Section</U><U></U><U>&nbsp;5(e)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9. <U>Additional Securityholders</U>. In connection with the issuance
of any additional equity securities of the Corporation, the Corporation, with the written consent of the Bain Investor, may permit such Person to become a party to this Agreement and succeed to all of the rights and obligations of a holder of any
particular category of Registrable Securities under this Agreement by obtaining an executed counterpart signature page to this Agreement, and, upon such execution, such Person shall for all purposes be a holder of such category of Registrable
Securities and party to this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">10. <U>Definitions</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) &#147;<U>Business Day</U>&#148; shall mean any day that is not a Saturday, a Sunday or other day on which banks are required or authorized
by law to be closed in the City of New York. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) &#147;<U>Charitable Gifting Event</U>&#148; means any transfer by an Investor, or any
subsequent transfer by such holder&#146;s members, partners or other employees, in connection with a bona fide gift to any Charitable Organization on the date of, but prior to, the execution of the underwriting agreement entered into in connection
with any underwritten offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) &#147;<U>Charitable Organization</U>&#148; means a charitable organization as described
by Section&nbsp;501(c)(3) of the Internal Revenue Code of 1986, as in effect from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) &#147;<U>Common Stock</U>&#148;
means, collectively, (a)&nbsp;following the organization of a corporation and reorganization or recapitalization of the Partnership into such corporation as provided in <U>Section</U><U></U><U>&nbsp;12.1</U> of the Partnership Agreement, the common
equity securities of such corporation and any other class or series of authorized capital stock of such corporation that is not limited to a fixed sum or percentage of par or stated value in respect of the rights of the holders thereof to
participate in dividends or in the distribution of assets upon any liquidation, dissolution or winding up of such corporation, and (b)&nbsp;any common stock of a Subsidiary of either the Partnership or such corporation distributed by the Partnership
or such corporation to its partners, unitholders or shareholders, as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) &#147;<U>Company Equity Securities</U>&#148; means
(a)&nbsp;Common Stock or other interests in the Corporation or a successor (including other classes or groups thereof having such relative rights, powers preferences and duties as may from time to time be established by the board of directors of the
Corporation, including rights, powers, preferences or duties senior to existing classes and groups of Common Stock and other interests in the Corporation), (b) obligations, evidences of indebtedness, or other securities or interests convertible or
exchangeable into Common Stock or other interests in the Corporation or a successor and (c)&nbsp;warrants, options, or other rights to purchase or otherwise acquire Common Stock or other interests in the Corporation or a successor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) &#147;<U>Free Writing Prospectus</U>&#148; means a <FONT STYLE="white-space:nowrap">free-writing</FONT> prospectus, as defined in
Rule&nbsp;405 of the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) &#147;<U>Group of Holders of Registrable Securities</U>&#148; means, separately, each of
(i)&nbsp;the Investors, (ii)&nbsp;the Service Providers and (iii)&nbsp;the Other Securityholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) &#147;<U>Investor Registrable
Securities</U>&#148; means (i)&nbsp;any Common Stock issued or distributed in respect of Units of the Partnership issued to or held by the Investors and (ii)&nbsp;common equity securities of the Corporation or a Subsidiary of either the Partnership
or the Corporation issued or issuable with respect to the securities referred to in <U>clause (i)</U>&nbsp;of this definition by way of dividend, distribution, split or combination of securities, or any recapitalization, merger, consolidation or
other reorganization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) &#147;<U>Other Registrable Securities</U>&#148; means (i)&nbsp;any Common Stock issued or distributed in
respect of Units of the Partnership issued to or held by the Other Securityholders and (ii)&nbsp;common equity securities of the Corporation or a Subsidiary of either the Partnership or the Corporation issued or issuable with respect to the
securities referred to in <U>clause (i)</U>&nbsp;of this definition by way of dividend, distribution, split or combination of securities, or any recapitalization, merger, consolidation or other reorganization; <U>provided</U> that none of the
following shall constitute Other Registrable Securities or Registrable Securities for any purpose hereunder: (w)&nbsp;shares of Common Stock or other common equity securities issuable upon the exercise of options (or similar equity-like incentive
shares or units) which have not vested or are otherwise not exercisable, (x)&nbsp;shares of Common Stock or other common equity securities issuable upon the exercise of vested options (or similar <FONT STYLE="white-space:nowrap">equity-like</FONT>
incentive shares or units) whose per share or per unit exercise price is more than the price to be paid for such share or unit in such offering, (y)&nbsp;shares of Common Stock or other common equity securities whose per share or per unit
participation threshold is more than the price to be paid for such share or unit in such offering, and (z)&nbsp;shares of Common Stock or other common equity securities that are subject to vesting (including if subject to possible repurchase by the
Partnership or the Corporation at less than fair market value). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) &#147;<U>Partnership Agreement</U>&#148; means that certain Fourth Amended and Restated
Limited Liability Partnership Agreement of the Partnership, dated as of July&nbsp;15, 2024, as amended or modified from time to time in accordance with its terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) &#147;<U>Public Offering</U>&#148; means the sale in an underwritten public offering registered under the Securities Act of the equity
securities of the Corporation (or any successor thereto) approved by the Corporation&#146;s board of managers or board of directors, as the case may be. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l) &#147;<U>Public Sale</U>&#148; means any sale of Registrable Securities to the public pursuant to an offering registered under the
Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(m) &#147;<U>Registrable Securities</U>&#148; means the Investor Registrable Securities, the Service Provider Registrable
Securities and the Other Registrable Securities. As to any particular Registrable Securities, such securities shall cease to be Registrable Securities when they (i)&nbsp;have been distributed to the public pursuant to an offering registered under
the Securities Act or sold to the public through a broker, dealer or market maker in compliance with Rule 144 under the Securities Act (or any similar rule then in force), (ii) have been distributed to the direct or indirect partners or members of
any Investor, (iii)&nbsp;have been effectively registered under a registration statement including a registration statement on Form <FONT STYLE="white-space:nowrap">S-8</FONT> (or any successor form) or (iv)&nbsp;have been repurchased by the
Corporation. In addition, all Registrable Securities held by any Person (other than the Bain Investor) shall cease to be Registrable Securities when all such Registrable Securities become eligible to be sold to the public through a broker, dealer or
market maker pursuant to Rule 144 under the Securities Act (or any similar rule then in force) during a single <FONT STYLE="white-space:nowrap">90-day</FONT> period. For purposes of this Agreement, a Person shall be deemed to be a holder of
Registrable Securities whenever such Person has the right to acquire such Registrable Securities (upon conversion or exercise in connection with a transfer of securities or otherwise, but disregarding any restrictions or limitations upon the
exercise of such right), whether or not such acquisition has actually been effected; <U>provided</U> that this sentence shall not apply to shares of the common equity securities of the Corporation issuable upon the exercise of unvested options
originally issued to employees or former employees of the Partnership, the Corporation or their Subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(n) &#147;<U>Securities
Act</U>&#148; means the Securities Act of 1933, as amended, or any successor federal law then in force, together with all rules and regulations promulgated thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(o) &#147;<U>Securities Exchange Act</U>&#148; means the Securities Exchange Act of 1934, as amended, or any successor federal law then in
force, together with all rules and regulations promulgated thereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(p) &#147;<U>Service Provider Registrable Securities</U>&#148; means, (i)&nbsp;any shares of
Common Stock issued or distributed in respect of Units of the Partnership issued to or held by the Service Providers and (ii)&nbsp;common equity securities of the Corporation or a Subsidiary of either the Partnership or the Corporation issued or
issuable with respect to the securities referred to in <U>clause </U><U>(i)</U> of this definition by way of dividend, distribution, split or combination of securities, or any recapitalization, merger, consolidation or other reorganization;
<U>provided</U> that none of the following shall constitute Service Provider Registrable Securities or Registrable Securities for any purpose hereunder: (w)&nbsp;shares of Common Stock or other common equity securities issuable upon the exercise of
employee options (or similar equity-like incentive shares or units) which have not vested or are otherwise not exercisable, (x)&nbsp;shares of Common Stock or other common equity securities issuable upon the exercise of vested employee options (or
similar <FONT STYLE="white-space:nowrap">equity-like</FONT> incentive shares or units) whose per share or per unit exercise price is more than the price to be paid for such share or unit in such offering, (y)&nbsp;shares of Common Stock or other
common equity securities whose per share or per unit participation threshold is more than the price to be paid for such share or unit in such offering, and (z)&nbsp;shares of Common Stock or other common equity securities that are subject to vesting
(including if subject to possible repurchase by the Partnership or the Corporation at less than fair market value). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(q) &#147;<U>Sponsor
Fund</U>&#148; means any existing or subsequently formed investment fund formed, operated or managed, directly or indirectly, by the Bain Investor or any of its Affiliates and any parallel fund, executive fund or alternative investment vehicle of
any such investment fund. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(r) &#147;<U>Transfer</U>&#148; means any sale, transfer, assignment, pledge, mortgage, exchange,
hypothecation, grant of a security interest or other direct or indirect disposition or encumbrance of an interest (including by operation of law and whether with or without consideration) or the acts thereof, but explicitly excluding conversions or,
to the extent the Corporation is party thereto, exchanges of one class of Company Equity Security to or for another class of Company Equity Security. The terms &#147;Transferee,&#148; &#147;Transferred,&#148; and other forms of the word
&#147;Transfer&#148; shall have correlative meanings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11. <U>Termination and Effect of Termination</U>. This Agreement shall terminate
upon the date on which no Securityholder holds any Registrable Securities; except for the provisions of <U>Section</U>&nbsp;7, which shall survive any such termination. No termination under this Agreement shall relieve any Person of liability for
breach or Registration Expenses incurred prior to termination. In the event this Agreement is terminated, each Person entitled to indemnification rights pursuant to <U>Section</U><U></U><U>&nbsp;7</U> hereof shall retain such indemnification rights
with respect to any matter that (a)&nbsp;may be an indemnified liability thereunder and (b)&nbsp;occurred prior to such termination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">12.
<U>Miscellaneous</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>No Inconsistent Agreements; Entire Agreement</U>. Neither the Partnership nor the Corporation will hereafter
enter into any agreement with respect to its equity securities that is inconsistent with or violates the rights granted to the holders of Registrable Securities in this Agreement. This Agreement, those documents expressly referred to herein and
other documents of even date herewith embody the complete agreement and understanding among the parties hereto with respect to the subject matter hereof and supersede and preempt any prior understandings, agreements or representations by or among
the parties hereto, written or oral, that may have related to the subject matter hereof in any way. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Remedies</U>. Each of the parties to this Agreement shall have all rights and
remedies set forth in this Agreement and all rights and remedies which such Person has been granted at any time under any other agreement or contract and all of the rights which such Person has under any law. Each of the parties to this Agreement
will be entitled to enforce its rights under this Agreement specifically, to recover damages and costs caused by any breach of any provision of this Agreement and to exercise all other rights existing in its favor. The parties hereto agree and
acknowledge that money damages may not be an adequate remedy for any breach of the provisions of this Agreement and that any party may in its sole discretion apply to any court of law or equity of competent jurisdiction (without posting any bond or
deposit) for specific performance and/or other injunctive relief in order to enforce or prevent any violations of the provisions of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Amendments</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i)
Subject to <U>Sections</U><U></U><U>&nbsp;12(c)(ii)</U> and <U>12(c)(iii)</U>, any provision of this Agreement may be amended or modified if, but only if, such amendment or modification is in writing and is approved in writing by (A)&nbsp;the board
of directors of the Corporation and the holders of a majority of the Investor Registrable Securities or (B)&nbsp;prior to the organization of a corporation or a reorganization or recapitalization of the Partnership pursuant to Article XII of the
Partnership Agreement, the General Partner and the holders of a majority of the Investor Registrable Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) Notwithstanding
<U>Section</U><U></U><U>&nbsp;12(c)(i)</U> but subject to <U>Section</U><U></U><U>&nbsp;12(c)(iii)</U>, if an amendment or modification of this Agreement: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A) would alter or change the special rights hereunder of a holder of Registrable Securities or Group of Holders of
Registrable Securities specifically granted such special rights by the legal name (for example, &#147;XYZ, Inc.&#148; as opposed to a holder of a certain class of Securityholder Securities) of such holder(s) of Registrable Securities, such amendment
or modification shall not be effective against such holder of Registrable Securities or Group of Holders of Registrable Securities (as the case may be) without the prior written consent of such holder of Registrable Securities or, in the case of a
Group of Holders of Registrable Securities, the holders of at least a majority of Registrable Securities held by such Group of Holders of Registrable Securities; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B) would alter or change the powers, preferences or special rights hereunder of the holders of a class of Registrable
Securities (holders of any such class, the &#147;<U>Subject Securityholders</U>&#148;) so as to treat them in a way that is materially and adversely different than the holders of any other class of Registrable Securities, such amendment or
modification shall not be effective against the Subject Securityholders without the prior written consent of the holders of at least a majority of such class of Registrable Securities held by the Subject Securityholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) The provisions of <U>Sections</U> <U>12(c)(i)</U> and <U>12(c)(ii)</U> shall not apply to any amendments or modifications otherwise
expressly permitted by this Agreement including any required to add a party hereto pursuant to <U>Sectio</U><U>n</U><U></U><U>&nbsp;9</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Notwithstanding anything herein to the contrary, the only right that any Securityholder
shall have with respect to any amendment made in connection with the creation, authorization or issuance of a new Registrable Security shall be the right, if any, of such Securityholder to purchase such new Registrable Security in accordance with
<U>Section</U><U></U><U>&nbsp;9</U> hereof. Accordingly, any amendment in connection with the issuance of a class of new Registrable Securities (including the creation, authorization or issuance of a class of new new Registrable Securities that is
senior, <I>pari passu</I> or junior to any Registrable Security existing prior to such amendment or modification) shall be permitted hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Successors and Assigns</U>. All covenants and agreements in this Agreement by or on behalf of any of the parties hereto shall bind and
inure to the benefit and detriment of the respective successors and assigns of the parties hereto whether so expressed or not. In addition, whether or not any express assignment has been made, the provisions of this Agreement which are for the
benefit or detriment of purchasers or holders of Registrable Securities are also for the benefit of, and enforceable by, and for the detriment of, and enforceable against, any subsequent holder of Registrable Securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <U>Severability</U>. Whenever possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid
under applicable law, but if any provision of this Agreement is held to be invalid, illegal, or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality, or unenforceability will not affect any
other provision or the effectiveness or validity of any provision in any other jurisdiction, and this Agreement will be reformed, construed, and enforced in such jurisdiction as if such invalid, illegal, or unenforceable provision had never been
contained herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) <U>Counterparts</U>. This Agreement may be executed in separate counterparts each of which shall be an original and
all of which taken together shall constitute one and the same agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) <U>Waiver of Breach</U>. No failure by any party to insist
upon the strict performance of any covenant, duty, agreement, or condition of this Agreement or to exercise any right or remedy consequent upon a breach thereof shall constitute a waiver of any such breach or any other covenant, duty, agreement, or
condition. The waiver by any party of a breach of any covenant, duty, agreement, or condition of this Agreement of any other party shall not operate or be construed as a waiver of any subsequent breach of that provision or any other provision
hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) <U>Descriptive Headings; Interpretation; No Strict Construction</U>. The descriptive headings of this Agreement are inserted
for convenience only and do not constitute a substantive part of this Agreement. Whenever required by the context, any pronoun used in this Agreement shall include the corresponding masculine, feminine, or neuter forms, and the singular form of
nouns, pronouns, and verbs shall include the plural and vice versa. The use of the word &#147;including&#148; in this Agreement shall be by way of example rather than by limitation. Reference to any agreement, document, or instrument means such
agreement, document, or instrument as amended or otherwise modified from time to time in accordance with the terms thereof, and, if applicable, hereof. The use of the words &#147;or,&#148; &#147;either,&#148; and &#147;any&#148; shall not be
exclusive. The parties hereto have participated jointly in the negotiation and drafting of this Agreement. In the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the
parties hereto, and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship of any of the provisions of this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) <U>Governing Law</U>. This Agreement shall be governed by and construed in accordance
with the laws of the State of New York without giving effect to any choice or conflict of law provision or rule (whether of the State of New York or any other jurisdiction) that would cause the application of the substantive laws of any jurisdiction
other than the State of New York. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) <U>Jurisdiction; Venue; Service of Process</U>. Each party to this Agreement, by its execution
hereof, (i)&nbsp;hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the State of New York for the purpose of any action, claim, cause of action or suit (in contract, tort or otherwise), inquiry,
proceeding or investigation arising out of or based upon this Agreement or relating to the subject matter hereof, (ii)&nbsp;hereby waives to the extent not prohibited by applicable law, and agrees not to assert, and agrees not to allow any of its
subsidiaries to assert, by way of motion, as a defense or otherwise, in any such action, any claim that it is not subject personally to the jurisdiction of the above-named courts, that its property is exempt or immune from attachment or execution,
that any such proceeding brought in one of the above-named courts is improper, or that this Agreement or the subject matter hereof or thereof may not be enforced in or by such court and (iii)&nbsp;hereby agrees not to commence or maintain any
action, claim, cause of action or suit (in contract, tort or otherwise), inquiry, proceeding or investigation arising out of or based upon this Agreement or relating to the subject matter hereof or thereof other than before one of the above-named
courts nor to make any motion or take any other action seeking or intending to cause the transfer or removal of any such action, claim, cause of action or suit (in contract, tort or otherwise), inquiry, proceeding or investigation to any court other
than one of the above-named courts whether on the grounds of inconvenient forum or otherwise. Notwithstanding the foregoing, to the extent that any party hereto is or becomes a party in any litigation in connection with which it may assert
indemnification rights set forth in this Agreement, the court in which such litigation is being heard shall be deemed to be included in clause (i)&nbsp;above. Notwithstanding the foregoing, any party to this Agreement may commence and maintain an
action to enforce a judgment of any of the above-named courts in any court of competent jurisdiction. Each party hereto hereby consents to service of process in any such proceeding in any manner permitted by New York law, and agrees that service of
process upon such party in any such action shall be effective if notice is given in accordance with <U>Section</U><U></U><U>&nbsp;12(m)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l) <U>M<SMALL>UTUAL</SMALL> W<SMALL>AIVER</SMALL> <SMALL>OF</SMALL> J<SMALL>URY</SMALL> T<SMALL>RIAL</SMALL></U><SMALL></SMALL>.
B<SMALL>ECAUSE</SMALL> <SMALL>DISPUTES</SMALL> <SMALL>ARISING</SMALL> <SMALL>IN</SMALL> <SMALL>CONNECTION</SMALL> <SMALL>WITH</SMALL> <SMALL>COMPLEX</SMALL> <SMALL>TRANSACTIONS</SMALL> <SMALL>ARE</SMALL> <SMALL>MOST</SMALL> <SMALL>QUICKLY</SMALL>
<SMALL>AND</SMALL> <SMALL>ECONOMICALLY</SMALL> <SMALL>RESOLVED</SMALL> <SMALL>BY</SMALL> <SMALL>AN</SMALL> <SMALL>EXPERIENCED</SMALL> <SMALL>AND</SMALL> <SMALL>EXPERT</SMALL> <SMALL>PERSON</SMALL> <SMALL>AND</SMALL> <SMALL>THE</SMALL>
<SMALL>PARTIES</SMALL> <SMALL>HERETO</SMALL> <SMALL>WISH</SMALL> <SMALL>APPLICABLE</SMALL> <SMALL>STATE</SMALL> <SMALL>AND</SMALL> <SMALL>FEDERAL</SMALL> <SMALL>LAWS</SMALL> <SMALL>TO</SMALL> <SMALL>APPLY</SMALL> (<SMALL>RATHER</SMALL>
<SMALL>THAN</SMALL> <SMALL>ARBITRATION</SMALL> <SMALL>RULES</SMALL>), <SMALL>THE</SMALL> <SMALL>PARTIES</SMALL> <SMALL>HERETO</SMALL> <SMALL>DESIRE</SMALL> <SMALL>THAT</SMALL> <SMALL>THEIR</SMALL> <SMALL>DISPUTES</SMALL> <SMALL>BE</SMALL>
<SMALL>RESOLVED</SMALL> <SMALL>BY</SMALL> <SMALL>A</SMALL> <SMALL>JUDGE</SMALL> <SMALL>APPLYING</SMALL> <SMALL>SUCH</SMALL> <SMALL>APPLICABLE</SMALL> <SMALL>LAWS</SMALL>. T<SMALL>HEREFORE</SMALL>, <SMALL>TO</SMALL> <SMALL>ACHIEVE</SMALL>
<SMALL>THE</SMALL> <SMALL>BEST</SMALL> <SMALL>COMBINATION</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL> <SMALL>BENEFITS</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL> <SMALL>JUDICIAL</SMALL> <SMALL>SYSTEM</SMALL> <SMALL>AND</SMALL> <SMALL>OF</SMALL>
<SMALL>ARBITRATION</SMALL>, <SMALL>EACH</SMALL> <SMALL>PARTY</SMALL> <SMALL>TO</SMALL> <SMALL>THIS</SMALL> <SMALL>AGREEMENT</SMALL> <SMALL>HEREBY</SMALL> <SMALL>WAIVES</SMALL> <SMALL>ALL</SMALL> <SMALL>RIGHTS</SMALL> <SMALL>TO</SMALL>
<SMALL>TRIAL</SMALL> <SMALL>BY</SMALL> <SMALL>JURY</SMALL> <SMALL>IN</SMALL> <SMALL>ANY</SMALL> <SMALL>ACTION</SMALL>, <SMALL>SUIT</SMALL>, <SMALL>OR</SMALL> <SMALL>PROCEEDING</SMALL> <SMALL>BROUGHT</SMALL> <SMALL>TO</SMALL> <SMALL>RESOLVE</SMALL>
<SMALL>ANY</SMALL> <SMALL>DISPUTE</SMALL> <SMALL>BETWEEN</SMALL> <SMALL>OR</SMALL> <SMALL>AMONG</SMALL> <SMALL>ANY</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL> <SMALL>PARTIES</SMALL> <SMALL>HERETO</SMALL>, <SMALL>WHETHER</SMALL>
<SMALL>ARISING</SMALL> <SMALL>IN</SMALL> <SMALL>CONTRACT</SMALL>, <SMALL>TORT</SMALL>, <SMALL>OR</SMALL> <SMALL>OTHERWISE</SMALL>, <SMALL>ARISING</SMALL> <SMALL>OUT</SMALL> <SMALL>OF</SMALL>, <SMALL>CONNECTED</SMALL> <SMALL>WITH</SMALL>,
<SMALL>RELATED</SMALL> <SMALL>OR</SMALL> <SMALL>INCIDENTAL</SMALL> <SMALL>TO</SMALL> <SMALL>THIS</SMALL> <SMALL>AGREEMENT</SMALL> <SMALL>AND</SMALL>/<SMALL>OR</SMALL> <SMALL>THE</SMALL> <SMALL>TRANSACTIONS</SMALL> <SMALL>CONTEMPLATED</SMALL>
<SMALL>HEREBY</SMALL>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(m) <U>Notices</U>. All notices, demands, or other communications to be given or delivered
under or by reason of the provisions of this Agreement shall be in writing and shall be deemed to have been given or made when (a)&nbsp;delivered personally to the recipient, (b)&nbsp;sent to the recipient by electronic mail (in which case, it will
be effective upon receipt of confirmation of good transmission, including, but not limited to, any response to such electronic mail), (c) sent by facsimile to the recipient (with hard copy sent to the recipient by reputable overnight courier service
(charges prepaid) that same day) if sent by facsimile before 5:00 p.m. Chicago, Illinois time on a Business Day, and otherwise on the next Business Day, or (d)&nbsp;one Business Day after being sent to the recipient by reputable overnight courier
service (charges prepaid). Such notices, demands and other communications shall be sent to each Investor, each Service Provider and each Other Securityholder at the respective addresses on file with the Partnership and to the Partnership at the
address of its corporate headquarters or to such other address or to the attention of such other Person as the recipient party has specified by prior written notice to the sending party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(n) <U>No Third</U><U><FONT STYLE="white-space:nowrap">-Party</FONT> Beneficiaries</U>. No term or provision of this Agreement is intended to
be, or shall be, for the benefit of any Person not a party hereto, and no such other Person shall have any right or cause of action hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(o) <U>Electronic Delivery</U>. This Agreement, the agreements referred to herein, and each other agreement or instrument entered into in
connection herewith or therewith or contemplated hereby or thereby, and any amendments hereto or thereto, to the extent signed and delivered by means of a photographic, photostatic, facsimile, portable document format (.pdf), or similar reproduction
of such signed writing using a facsimile machine or electronic mail shall be treated in all manner and respects as an original agreement or instrument and shall be considered to have the same binding legal effect as if it were the original signed
version thereof delivered in person. At the request of any party hereto or to any such agreement or instrument, each other party hereto or thereto shall <FONT STYLE="white-space:nowrap">re-execute</FONT> original forms thereof and deliver them to
all other parties hereto. No party hereto or to any such agreement or instrument shall raise the use of a facsimile machine or electronic mail to deliver a signature or the fact that any signature or agreement or instrument was transmitted or
communicated through the use of a facsimile machine or electronic mail as a defense to the formation or enforceability of a contract and each such party forever waives any such defense. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(p) <U>No Recourse</U>. Notwithstanding anything that may be expressed or implied in this Agreement, the Partnership and each party hereto
covenant, agree and acknowledge that no recourse under this Agreement or any documents or instruments delivered in connection with this Agreement shall be had against any current or future director, officer, employee, general or limited partner or
member of any Securityholder or of any Affiliate or assignee thereof, as such, whether by the enforcement of any assessment or by any legal or equitable proceeding, or by virtue of any statute, regulation or other applicable law, it being expressly
agreed and acknowledged that no personal liability whatsoever shall attach to, be imposed on or otherwise be incurred by any current or future officer, agent or employee of any Securityholder or any current or future member of any Securityholder or
any current or future director, officer, employee, partner or member of any Securityholder or of any Affiliate or assignee thereof, as such, for any obligation of any Securityholder under this Agreement or any documents or instruments delivered in
connection with this Agreement for any claim based on, in respect of or by reason of such obligations or their creation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(q) <U>Subsidiary Public Offering</U>. If, after an initial Public Offering of the equity
securities of a Subsidiary of the Partnership, the Partnership distributes securities of such Subsidiary to members of the Partnership, then the rights and obligations of the Corporation pursuant to this Agreement shall apply, <U>mutatis
mutandis</U>, to such Subsidiary, and the Partnership or the Corporation, as applicable, shall cause such Subsidiary to comply with such Subsidiary&#146;s obligations under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">* * * * * </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have executed this Second Amended and Restated
Registration Rights Agreement as of the date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">WEST AFFUM HOLDINGS, L.P.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By: .</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">West Affum GP Ltd.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Its:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">General Partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Yun Zheng</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Yun Zheng</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Its:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">EXISTING SECURITYHOLDERS:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">BAIN CHARGER HOLDINGS, L.P.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Bain Capital Investors, LLC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Its:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">General Partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Christopher Gordon</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Christopher Gordon</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Its:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Authorized Signatory</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">ENDEAVOUR MEDTECH GROWTH II LP</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Endeavour Medtech II GP Limited,</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">its General Partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Nick Barton</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Nick Barton</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Its:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">ENDEAVOUR MEDTECH GROWTH II PARALLEL LP</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: Endeavour Medtech II GP Limited,</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">its General Partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Nick Barton</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Nick Barton</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Its:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to Second Amended and Restated Registration Rights Agreement] </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Brian D. Webster</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Brian D. Webster</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Traci Umberger</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Traci Umberger</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to Second Amended and Restated Registration Rights Agreement] </I></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>8
<FILENAME>d744414dex102.htm
<DESCRIPTION>EX-10.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXHIBIT 10.2 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>KESTRA MEDICAL TECHNOLOGIES, LTD. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2025 OMNIBUS
INCENTIVE PLAN </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE I </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PURPOSE
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purpose of this Kestra Medical Technologies, Ltd. 2025 Omnibus Incentive Plan (this &#147;<B><U>Plan</U></B>&#148;) is to promote
the success of the Company&#146;s business for the benefit of its stockholders by enabling the Company to offer Eligible Individuals cash and <FONT STYLE="white-space:nowrap">stock-based</FONT> incentives in order to attract, retain, and reward such
individuals and strengthen the mutuality of interests between such individuals and the Company&#146;s stockholders. This Plan is effective as of the date set forth in <U>Article</U><U></U><U>&nbsp;XIV</U>. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE II </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DEFINITIONS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this Plan, the following terms shall have the following meanings: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.1</B> <B>&#147;</B><B><U>Affiliate</U></B><B>&#148;</B> means a corporation or other entity controlled by, controlling, or under common
control with the Company. The term &#147;control&#148; (including, with correlative meaning, the terms &#147;controlled by&#148; and &#147;under common control with&#148;), as applied to any Person, means the possession, directly or indirectly, of
the power to direct or cause the direction of management and policies of such Person, whether through the ownership of voting or other securities, by contract or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.2</B> <B>&#147;</B><B><U>Applicable Law</U></B><B>&#148; </B>means the requirements relating to the administration of equity-based awards
and the related shares under U.S. state corporate law, U.S. federal and state securities laws, the rules or requirements of any stock exchange or quotation system on which the shares are listed or quoted, and any other applicable laws, including tax
laws, of any U.S. or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> jurisdictions where Awards are, or will be, granted under this Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.3</B> <B>&#147;</B><B><U>Award</U></B><B>&#148;</B> means any award under this Plan of any Stock Option, Stock Appreciation Right,
Restricted Stock, Restricted Stock Units, Performance Award, Other Stock-Based Award, or Cash Award. All Awards shall be evidenced by and subject to the terms of an Award Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.4</B> <B>&#147;</B><B><U>Award Agreement</U></B><B>&#148;</B> means the written or electronic agreement, contract, certificate, or other
instrument or document evidencing the terms and conditions of an individual Award. Each Award Agreement shall be subject to the terms and conditions of this Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.5</B> <B>&#147;</B><B><U>Board</U></B><B>&#148;</B> means the Board of Directors of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.6</B> <B>&#147;</B><B><U>Cash Award</U></B><B>&#148;</B> means an Award granted to an Eligible Individual pursuant to
<U>Section</U><U></U><U>&nbsp;9.3</U> of this Plan and payable in cash at such time or times and subject to such terms and conditions as determined by the Committee in its sole discretion. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.7</B> <B>&#147;</B><B><U>Cause</U></B><B>&#148;</B> means, unless otherwise determined
by the Committee in the applicable Award Agreement, with respect to a Participant&#146;s Termination of Service, the following: (a)&nbsp;in the case where there is no employment agreement, offer letter, consulting agreement, change in control
agreement, or similar agreement in effect between the Company or an Affiliate and the Participant at the time of the grant of the Award (or where there is such agreement in effect but it does not define &#147;cause&#148; (or words of like import)),
the Participant&#146;s (i)&nbsp;continued failure to perform any portion of his or her duties or the Participant&#146;s continued failure to follow the lawful directives of the Board or any executive to whom the Participant reports that are
consistent with the Participant&#146;s position in the Company, (ii)&nbsp;misconduct or negligence, (iii)&nbsp;indictment for, or conviction of, a felony (including a plea of <I>nolo contendere</I>), (iv) negligent performance of his or her duties,
(v)&nbsp;breach of the terms of the Participant&#146;s employment agreement, offer letter, or any other agreement with the Company or any of its Affiliates to which the Participant is a party, (vi)&nbsp;violation of the Company&#146;s written
policies regarding ethical business practices or any other violation of any written policy of the Company or any of its Affiliates, (vii)&nbsp;act of theft, embezzlement, fraud, or misappropriation of or in respect of the Company&#146;s property, or
(viii)&nbsp;continued failure to cooperate in any audit or investigation of financial or business practices of the Company, or (ix)&nbsp;breach of any of the restrictive covenants in any written agreement between the Participant and the Company
and/or its Affiliates; or (b)&nbsp;in the case where there is an employment agreement, offer letter, consulting agreement, change in control agreement, or similar agreement in effect between the Company or an Affiliate and the Participant at the
time of the grant of the Award that defines &#147;cause&#148; (or words of like import), &#147;cause&#148; as defined under such agreement; provided, however, that with regard to any agreement under which the definition of &#147;cause&#148; only
applies on occurrence of a change in control, such definition of &#147;cause&#148; shall not apply until a change in control (as defined in such agreement) actually takes place and then only with regard to a termination thereafter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.8</B> <B>&#147;</B><B><U>Change in Control</U></B><B>&#148;</B> means and includes each of the following, unless otherwise determined by
the Committee in the applicable Award Agreement or other written agreement with a Participant approved by the Committee: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) any Person
(other than the Company, any trustee or other fiduciary holding securities under any employee benefit plan of the Company, or any company owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as
their ownership of the Company), becoming the beneficial owner (as defined in Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> under the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more
of the combined voting power of the Company&#146;s then outstanding securities, excluding for purposes herein, acquisitions pursuant to a Business Combination (as defined below) that does not constitute a Change in Control as defined in
<U>Section</U><U></U><U>&nbsp;2.8(b)</U>; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) a merger, reorganization, or consolidation of the Company or in which equity securities of
the Company are issued (each, a &#147;<U>Business Combination</U>&#148;), other than a merger, reorganization or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent
(either by remaining outstanding or by being converted into voting securities of the surviving entity or its direct or indirect parent) more than fifty percent (50%) of the combined voting power of the voting securities of the Company or such
surviving entity (or, as applicable, a direct or indirect parent of the Company or such surviving entity) outstanding immediately after such merger, reorganization or consolidation; <I>provided, however</I>, that a merger, reorganization or
consolidation effected to implement a recapitalization of the Company (or similar transaction) in which no Person (other than those covered by the exceptions in <U>Section</U><U></U><U>&nbsp;2.8(a)</U>) acquires more than 50% of the combined voting
power of the Company&#146;s then outstanding securities shall not constitute a Change in Control; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) during the period of two (2)&nbsp;consecutive years, individuals who, at the beginning
of such period, constitute the Board together with any new director(s) (other than a director designated by a Person who has entered into an agreement with the Company to effect a transaction described in <U>Sections 2.8(a)</U> or <U>(b)</U>) whose
election by the Board or nomination for election by the Company&#146;s stockholders was approved by a vote of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the directors then still in office who either were directors at the
beginning of the two (2)&nbsp;year period or whose election or nomination for election was previously so approved, cease for any reason to constitute a majority thereof; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) a complete liquidation or dissolution of the Company or the consummation of a sale or disposition by the Company of all or substantially
all of the Company&#146;s assets other than the sale or disposition of all or substantially all of the assets of the Company to a Person or Persons who beneficially own, directly or indirectly, fifty percent (50%) or more of the combined voting
power of the outstanding voting securities of the Company at the time of the sale. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of this <U>Section</U><U></U><U>&nbsp;2.8</U>,
acquisitions of securities of the Company by Bain Capital, LP, any of its respective affiliates, or any investment vehicle or fund controlled by or managed by, or otherwise affiliated with Bain Capital, LP shall not constitute a Change in Control.
Notwithstanding the foregoing, with respect to any Award that is characterized as &#147;nonqualified deferred compensation&#148; within the meaning of Section&nbsp;409A of the Code, an event shall not be considered to be a Change in Control under
this Plan for purposes of payment of such Award unless such event is also a &#147;change in ownership,&#148; a &#147;change in effective control,&#148; or a &#147;change in the ownership of a substantial portion of the assets&#148; of the Company
within the meaning of Section&nbsp;409A of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.9</B> <B>&#147;</B><B><U>Change in Control Price</U></B><B>&#148;</B> means the
highest price per Share paid in any transaction related to a Change in Control as determined by the Committee in its discretion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.10</B> <B>&#147;</B><B><U>Code</U></B><B>&#148; </B>means the U.S. Internal Revenue Code of 1986, as amended from time to time. Any
reference to any section of the Code shall also be a reference to any successor provision and any guidance and treasury regulation promulgated thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.11</B> <B>&#147;</B><B><U>Committee</U></B><B>&#148;</B> means any committee of the Board duly authorized by the Board to administer this
Plan; <I>provided</I>, <I>however</I>, that unless otherwise determined by the Board, the Committee shall consist solely of two or more members of the Board who are each (a)&nbsp;a <FONT STYLE="white-space:nowrap">&#147;non-employee</FONT>
director&#148; within the meaning of Rule <FONT STYLE="white-space:nowrap">16b-3(b),</FONT> and (b) &#147;independent&#148; under the listing standards or rules of the securities exchange upon which the Common Stock is traded, but only to the extent
such independence is required in order to take the action at issue pursuant to such standards or rules. If no committee is duly authorized by the Board to administer this Plan, the term &#147;Committee&#148; shall be deemed to refer to the Board for
all purposes under this Plan. The Board may abolish any Committee or <FONT STYLE="white-space:nowrap">re-vest</FONT> in itself any previously delegated authority from time to time and will retain the right to exercise the authority of the Committee
to the extent consistent with Applicable Law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.12</B> <B>&#147;</B><B><U>Common Stock</U></B><B>&#148;</B> means the common shares,
$[&#149;] par value per share, of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.13</B> <B>&#147;</B><B><U>Company</U></B><B>&#148;</B> means Kestra Medical
Technologies, Ltd., a Bermuda corporation, and its successors by operation of law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.14</B>
<B>&#147;</B><B><U>Consultant</U></B><B>&#148;</B> means any natural person who is an advisor or consultant or other service provider to the Company or any of its Affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.15</B> <B>&#147;</B><B><U>Disability</U></B><B>&#148;</B> means, unless otherwise determined by the Committee in the applicable Award
Agreement, with respect to a Participant&#146;s Termination of Service, that the Participant is unable to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment, after accounting for
reasonable accommodations (if applicable and required by Applicable Law); <I>provided, however</I>, for purposes of an Incentive Stock Option, the term Disability shall have the meaning ascribed to it under Section&nbsp;22(e)(3) of the Code. The
determination of whether an individual has a Disability shall be determined by the Committee, and the Committee may rely on any determination that a Participant is disabled for purposes of benefits under any long-term disability plan in which a
Participant participates that is maintained by the Company or any Affiliate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.16</B> <B>&#147;</B><B><U>Dividend Equivalent
Rights</U></B><B>&#148;</B> means a right granted to a Participant under this Plan to receive the equivalent value (in cash or Shares) of dividends paid on Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.17</B> <B>&#147;</B><B><U>Effective Date</U></B><B>&#148;</B> means the effective date of this Plan as defined in <U>Article XIV</U>.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.18</B> <B>&#147;</B><B><U>Eligible Employee</U></B><B>&#148;</B> means each employee of the Company or any of its Affiliates. An
employee on a leave of absence may be an Eligible Employee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.19</B> <B>&#147;</B><B><U>Eligible Individual</U></B><B>&#148;</B> means
an Eligible Employee, <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director, or Consultant who is designated by the Committee in its discretion as eligible to receive Awards subject to the terms and conditions set forth herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.20</B> <B>&#147;</B><B><U>Exchange Act</U></B><B>&#148;</B> means the Securities Exchange Act of 1934, as amended from time to time.
Reference to a specific section of the Exchange Act or regulation thereunder shall include such section or regulation, any valid regulation or interpretation promulgated under such section, and any comparable provision of any future legislation or
regulation amending, supplementing, or superseding such section or regulation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.21</B> <B>&#147;</B><B><U>Fair Market
Value</U></B><B>&#148;</B> means, for purposes of this Plan, unless otherwise required by any applicable provision of the Code or any regulations issued thereunder, as of any date and except as provided below, the last sales price reported for the
Common Stock on the applicable date: (a)&nbsp;as reported on the principal national securities exchange in the United States on which it is then traded, listed or otherwise reported or quoted or (b)&nbsp;if the Common Stock is not traded, listed, or
otherwise reported or quoted, the Committee shall determine in good faith the Fair Market Value in whatever manner it considers appropriate, taking into account the requirements of Section&nbsp;409A of the Code. For purposes of the grant of any
Award, the applicable date shall be the trading day immediately prior to the date on which the Award is granted. For purposes of the exercise of any Award, the applicable date shall be the date a notice of exercise is received by the Committee or,
if </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
not a date on which the applicable market is open, the next day that it is open. Notwithstanding the foregoing, with respect to any Award granted on the pricing date of the Company&#146;s initial
public offering, the Fair Market Value shall mean the initial public offering price of a Share as set forth in the Company&#146;s final prospectus relating to its initial public offering filed with the Securities and Exchange Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.22</B> <B>&#147;</B><B><U>Family Member</U></B><B>&#148;</B> means &#147;family member&#148; as defined in Section A.1.(a)(5) of the
general instructions of Form <FONT STYLE="white-space:nowrap">S-8.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.23</B> <B>&#147;</B><B><U>Incentive Stock
Option</U></B><B>&#148;</B> means any Stock Option granted to an Eligible Employee who is an employee of the Company, its Parents or its Subsidiaries under this Plan and that is intended to be, and is designated as, an &#147;Incentive Stock
Option&#148; within the meaning of Section&nbsp;422 of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.24</B>
<B>&#147;</B><B><U><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director</U></B><B>&#148;</B> means a director on the Board who is not an employee of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.25</B> <B>&#147;</B><B><U><FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Stock Option</U></B><B>&#148;</B> means any Stock Option
granted under this Plan that is not an Incentive Stock Option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.26</B> <B>&#147;</B><B><U>Other Stock-Based
Award</U></B><B>&#148;</B> means an Award granted under <U>Article IX</U> of this Plan that is valued in whole or in part by reference to, or is payable in or otherwise based on, Shares, but may be settled in the form of Shares or cash. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.27</B> <B>&#147;</B><B><U>Parent</U></B><B>&#148;</B> means any parent corporation of the Company within the meaning of
Section&nbsp;424(e) of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.28</B> <B>&#147;</B><B><U>Participant</U></B><B>&#148; </B>means an Eligible Individual to whom an
Award has been granted pursuant to this Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.29</B> <B>&#147;</B><B><U>Performance Award</U></B><B>&#148;</B> means an Award
granted under <U>Article VIII</U> of this Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.30</B> <B>&#147;</B><B><U>Performance Goals</U></B><B>&#148;</B> means goals
established by the Committee as contingencies for Awards to vest and/or become exercisable or distributable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.31</B>
<B>&#147;</B><B><U>Performance Period</U></B><B>&#148;</B> means the designated period during which the Performance Goals must be satisfied with respect to the Award to which the Performance Goals relate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.32</B> <B>&#147;</B><B><U>Person</U></B><B>&#148;</B> means any &#147;person&#148; as such term is used in Sections 13(d) and 14(d) of
the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.33</B> <B>&#147;</B><B><U>Restricted Stock</U></B><B>&#148;</B> means an Award of Shares granted under <U>Article
VII</U> of this Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.34</B> <B>&#147;</B><B><U>Restricted Stock Unit</U></B>&#148; means an unfunded, unsecured right to receive,
on the applicable settlement date, one Share or an amount in cash or other consideration determined by the Committee to be of equal value as of such settlement date, subject to certain vesting conditions and other restrictions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.35</B> <B>&#147;</B><B><U>Rule
<FONT STYLE="white-space:nowrap">16b-3</FONT></U></B><B>&#148;</B> means Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> under Section&nbsp;16(b) of the Exchange Act as then in effect or any successor provision. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.36</B> <B>&#147;</B><B><U>Section</U></B><B><U></U></B><B><U>&nbsp;409A of the Code</U></B><B>&#148;</B> means the nonqualified deferred
compensation rules under Section&nbsp;409A of the Code and any applicable treasury regulations and other official guidance thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.37</B> <B>&#147;</B><B><U>Securities Act</U></B><B>&#148;</B> means the Securities Act of 1933, as amended, and all rules and regulations
promulgated thereunder. Reference to a specific section of the Securities Act or regulation thereunder shall include such section or regulation, any valid regulation or interpretation promulgated under such section, and any comparable provision of
any future legislation or regulation amending, supplementing, or superseding such section or regulation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.38</B>
<B>&#147;</B><B><U>Shares</U></B><B>&#148;</B> means shares of Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.39</B> <B>&#147;</B><B><U>Stock Appreciation
Right</U></B><B>&#148;</B> means a stock appreciation right granted under <U>Article</U><U></U><U>&nbsp;VI</U> of this Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.40</B>
<B>&#147;</B><B><U>Stock Option</U></B><B>&#148;</B> or <B>&#147;</B><B><U>Option</U></B><B>&#148;</B> means any option to purchase Shares granted pursuant to <U>Article VI</U> of this Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.41</B> <B>&#147;</B><B><U>Subsidiary</U></B><B>&#148;</B> means any subsidiary corporation of the Company within the meaning of
Section&nbsp;424(f) of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.42</B> <B>&#147;</B><B><U>Ten Percent Stockholder</U></B><B>&#148; </B>means a Person owning stock
representing more than ten percent (10%) of the total combined voting power of all classes of stock of the Company, its Parent, or its Subsidiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.43</B> <B>&#147;</B><B><U>Termination of Service</U></B><B>&#148; </B>means the termination of the applicable Participant&#146;s
employment with, or performance of services for, the Company and its Affiliates. Unless otherwise determined by the Committee, (a)&nbsp;if a Participant&#146;s employment or services with the Company and its Affiliates terminates but such
Participant continues to provide services to the Company and its Affiliates in a <FONT STYLE="white-space:nowrap">non-employee</FONT> capacity, such change in status shall not be deemed a Termination of Service with the Company and its Affiliates
and (b)&nbsp;a Participant employed by, or performing services for an Affiliate that ceases to be an Affiliate shall also be deemed to have incurred a Termination of Service provided the Participant does not immediately thereafter become an employee
of the Company or another Affiliate. Notwithstanding the foregoing provisions of this definition, with respect to any Award that constitutes a &#147;nonqualified deferred compensation plan&#148; within the meaning of Section&nbsp;409A of the Code, a
Participant shall not be considered to have experienced a &#147;Termination of Service&#148; unless the Participant has&nbsp;experienced a &#147;separation from service&#148; within the meaning of Section&nbsp;409A of the Code. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE III </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ADMINISTRATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.1</B>
<B><U>Authority of the Committee</U></B>.<B> </B>This Plan shall be administered by the Committee. Subject to the terms of this Plan and Applicable Law, the Committee shall have full authority to grant Awards to Eligible Individuals under this Plan.
In particular, the Committee shall have the authority to: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) determine whether and to what extent Awards, or any combination thereof,
are to be granted hereunder to one or more Eligible Individuals; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) determine the number of Shares to be covered by each Award granted
hereunder; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) determine the terms and conditions, not inconsistent with the terms of this Plan, of any Award granted hereunder
(including, but not limited to, the exercise or purchase price (if any), any restriction or limitation, any vesting schedule or acceleration thereof, or any forfeiture restrictions or waiver thereof, regarding any Award and the Shares, if any,
relating thereto, based on such factors, if any, as the Committee shall determine, in its sole discretion); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) determine the amount of
cash to be covered by each Award granted hereunder; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) determine whether, to what extent, and under what circumstances grants of Options
and other Awards under this Plan are to operate on a tandem basis and/or in conjunction with or apart from other awards made by the Company outside of this Plan; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) determine whether and under what circumstances an Award may be settled in cash, Shares, other property, or a combination of the foregoing;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) determine whether, to what extent and under what circumstances cash, Shares, or other property and other amounts payable with respect
to an Award under this Plan shall be deferred either automatically or at the election of the Participant; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) modify, waive, amend, or
adjust the terms and conditions of any Award, at any time or from time to time, including but not limited to Performance Goals; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i)
determine whether a Stock Option is an Incentive Stock Option or <FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Stock Option; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j)
determine whether to require a Participant, as a condition of the granting of any Award, to not sell or otherwise dispose of Shares acquired pursuant to the exercise or vesting of an Award for a period of time as determined by the Committee, in its
sole discretion, following the date of the acquisition of such Award or Shares; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) modify, extend, or renew an Award, subject to
<U>Article XI</U> and <U>Section</U><U></U><U>&nbsp;6.8(g)</U> of this Plan; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l) determine how the Disability, death, retirement,
authorized leave of absence or any other change or purported change in a Participant&#146;s status affects an Award and the extent to which, and the period during which, the Participant, the Participant&#146;s legal representative, conservator,
guardian or beneficiary may exercise rights under the Award, if applicable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.2</B> <B><U>Guidelines</U></B>. Subject to <U>Article XI</U> of this Plan, the
Committee shall have the authority to adopt, alter, and repeal such administrative rules, guidelines, and practices governing this Plan and perform all acts, including the delegation of its responsibilities (to the extent permitted by Applicable Law
and applicable stock exchange rules), as it shall, from time to time, deem advisable; to construe and interpret the terms and provisions of this Plan and any Award issued under this Plan (and any agreements or
<FONT STYLE="white-space:nowrap">sub-plans</FONT> relating thereto); and to otherwise supervise the administration of this Plan. The Committee may correct any defect, supply any omission, or reconcile any inconsistency in this Plan or in any
agreement relating thereto in the manner and to the extent it shall deem necessary to effectuate the purpose and intent of this Plan. The Committee may adopt special rules, <FONT STYLE="white-space:nowrap">sub-plans,</FONT> guidelines, and
provisions for persons who are residing in or employed in, or subject to, the taxes of any domestic or foreign jurisdictions to satisfy or accommodate applicable foreign laws or to qualify for preferred tax treatment of such domestic or foreign
jurisdictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.3</B> <B><U>Decisions Final</U></B>. Any decision, interpretation, or other action made or taken in good faith by or
at the direction of the Company, the Board, or the Committee (or any of its members) arising out of or in connection with this Plan shall be within the absolute discretion of all and each of them, as the case may be, and shall be final, binding, and
conclusive on the Company and all employees and Participants and their respective heirs, executors, administrators, successors, and assigns. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.4</B> <B><U>Designation of Consultants/Liability; Delegation of Authority</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Committee may employ such legal counsel, consultants, and agents as it may deem desirable for the administration of this Plan and may
rely upon any opinion received from any such counsel or consultant and any computation received from any such consultant or agent. Expenses incurred by the Committee or the Board in the engagement of any such counsel, consultant, or agent shall be
paid by the Company. The Committee, its members, and any person designated pursuant to this <U>Section</U><U></U><U>&nbsp;3.4</U> shall not be liable for any action or determination made in good faith with respect to this Plan. To the maximum extent
permitted by Applicable Law, no officer of the Company or member or former member of the Committee or of the Board shall be liable for any action or determination made in good faith with respect to this Plan or any Award granted under it. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Committee may delegate any or all of its powers and duties under this Plan to a subcommittee of directors or to any officer of the
Company, including the power to perform administrative functions (including executing agreements or other documents on behalf of the Committee) and grant Awards; <U>provided</U>, that such delegation does not (i)&nbsp;violate Applicable Law, or
(ii)&nbsp;result in the loss of an exemption under Rule <FONT STYLE="white-space:nowrap">16b-3(d)(1)</FONT> for Awards granted to Participants subject to Section&nbsp;16 of the Exchange Act in respect of the Company. Upon any such delegation, all
references in this Plan to the &#147;Committee,&#148; shall be deemed to include any subcommittee or officer of the Company to whom such powers have been delegated by the Committee. Any such delegation shall not limit the right of such subcommittee
members or such an officer to receive Awards; <U>provided</U>, <U>however</U>, that such subcommittee members and any such officer may not grant Awards to himself or herself, a member of the Board, or any executive officer of the Company or an
Affiliate, or take any action with respect to any Award previously granted to himself or herself, a member of the Board, or any executive officer of the Company or an Affiliate. The Committee may also designate employees or professional advisors who
are not executive officers of the Company or members of the Board to assist in administering this Plan, <U>provided</U>, <U>however</U>, that such individuals may not be delegated the authority to grant or modify any Awards that will, or may, be
settled in Shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.5</B> <B><U>Indemnification</U></B>. To the maximum extent permitted by Applicable Law
and to the extent not covered by insurance directly insuring such person, each current and former officer or employee of the Company or any of its Affiliates and member or former member of the Committee or the Board shall be indemnified and held
harmless by the Company against any cost or expense (including reasonable fees of counsel acceptable to the Committee) or liability (including any sum paid in settlement of a claim with the approval of the Committee), and advanced amounts necessary
to pay the foregoing at the earliest time and to the fullest extent permitted, arising out of any act or omission to act in connection with the administration of this Plan, except to the extent arising out of such officer&#146;s, employee&#146;s,
member&#146;s, or former member&#146;s own fraud or bad faith. Such indemnification shall be in addition to any right of indemnification that the current or former employee, officer or member may have under Applicable Law or under the <FONT
STYLE="white-space:nowrap">by-laws</FONT> of the Company or any of its Affiliates. Notwithstanding anything else herein, this indemnification will not apply to the actions or determinations made by an individual with regard to Awards granted to such
individual under this Plan. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE IV </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SHARE LIMITATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.1</B> <B><U>Shares</U></B>. The aggregate number of Shares that may be issued pursuant to this Plan shall not exceed [&#149;]<SUP
STYLE="font-size:75%; vertical-align:top">1</SUP> Shares (subject to any increase or decrease pursuant to this <U>Article IV</U>), which may be either authorized and unissued Shares or Shares held in or acquired for the treasury of the Company or
both. The number of Shares that may be issued pursuant to this Plan shall be subject to an annual increase on January&nbsp;1 of each calendar year beginning in January&nbsp;1, 2026, and ending and including December&nbsp;31, 2036, equal to the
lesser of (a) 5% of the aggregate number of Shares outstanding on December&nbsp;31 of the immediately preceding calendar year and (b)&nbsp;such smaller number of Shares as is determined by the Board. The aggregate number of Shares that may be issued
or used with respect to any Incentive Stock Option shall not exceed [&#149;]<SUP STYLE="font-size:75%; vertical-align:top">2</SUP> Shares (subject to any increase or decrease pursuant to <U>Section</U><U></U><U>&nbsp;4.3</U>). Any Award under this
Plan settled in cash shall not be counted against the foregoing maximum share limitations. Notwithstanding anything to the contrary contained herein, Shares subject to an Award under this Plan shall again be made available for issuance or delivery
under this Plan if such Shares are (i)&nbsp;Shares delivered, withheld or surrendered in payment of the exercise or purchase price of an Award, (ii)&nbsp;Shares delivered, withheld, or surrendered to satisfy any tax withholding obligation or
(iii)&nbsp;Shares subject to a stock-settled Award that expires or is canceled, forfeited, or terminated without issuance of the full number of Shares to which the Award related. </P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Note to Draft</U></B>: To be the number equal to 15% of the total Common Shares outstanding at the time
of the IPO, plus the number of Common Shares underlying the Option grants made upon the IPO and the number of restricted Shares granted to Reinoud E. Knops, MD, PhD, Raymond Cohen, and Mary Kay Ladone. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">2</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Note to Draft</U></B>: To be the same as the initial reserve. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.2</B> <B><U>Substitute Awards</U></B>. In connection with an entity&#146;s merger or
consolidation with the Company or the Company&#146;s acquisition of an entity&#146;s property or stock, the Committee may grant Awards in substitution for any options or other stock or stock-based awards granted before such merger or consolidation
by such entity or its affiliate (&#147;<U>Substitute Awards</U>&#148;). Substitute Awards may be granted on such terms as the Committee deems appropriate, notwithstanding limitations on Awards in this Plan. Substitute Awards will not count against
the Shares authorized for grant under this Plan (nor shall Shares subject to a Substitute Award be added to the Shares available for Awards under this Plan as provided under <U>Section</U><U></U><U>&nbsp;4.1</U> above), except that Shares acquired
by exercise of substitute Incentive Stock Options will count against the maximum number of Shares that may be issued pursuant to the exercise of Incentive Stock Options under this Plan, as set forth in <U>Section</U><U></U><U>&nbsp;4.1</U> above.
Additionally, in the event that a Person acquired by the Company or any Subsidiary or with which the Company or any Subsidiary combines has shares available under a <FONT STYLE="white-space:nowrap">pre-existing</FONT> plan approved by stockholders
and not adopted in contemplation of such acquisition or combination, the shares available for grants pursuant to the terms of such <FONT STYLE="white-space:nowrap">pre-existing</FONT> plan (as adjusted, to the extent appropriate, using the exchange
ratio or other adjustment or valuation ratio or formula used in such acquisition or combination to determine the consideration payable to the holders of common stock of the entities party to such acquisition or combination) may be used for Awards
under this Plan and shall not reduce the Shares authorized for grant under this Plan (and Shares subject to such Awards shall not be added to the Shares available for Awards under this Plan as provided under <U>Section</U><U></U><U>&nbsp;4.1</U>
above); provided that Awards using such available shares shall not be made after the date awards or grants could have been made under the terms of the <FONT STYLE="white-space:nowrap">pre-existing</FONT> plan, absent the acquisition or combination,
and shall only be made to individuals who were not Eligible Employees or <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors prior to such acquisition or combination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.3</B> <B><U>Adjustments</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The existence of this Plan and the Awards granted hereunder shall not affect in any way the right or power of the Board or the
stockholders of the Company to make or authorize (i)&nbsp;any adjustment, recapitalization, reorganization, or other change in the Company&#146;s capital structure or its business, (ii)&nbsp;any merger or consolidation of the Company or any
Affiliate, (iii)&nbsp;any issuance of bonds, debentures, or preferred or prior preference stock ahead of or affecting the Shares, (iv)&nbsp;the dissolution or liquidation of the Company or any Affiliate, (v)&nbsp;any sale or transfer of all or part
of the assets or business of the Company or any Affiliate, or (vi)&nbsp;any other corporate act or proceeding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Subject to the
provisions of <U>Section</U><U></U><U>&nbsp;10.1</U>: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) If the Company at any time subdivides (by any split, recapitalization or
otherwise) the outstanding Shares into a greater number of Shares, or combines (by reverse split, combination, or otherwise) its outstanding Shares into a lesser number of Shares, then the respective exercise prices for outstanding Awards that
provide for a Participant-elected exercise and the number of Shares covered by outstanding Awards shall be appropriately adjusted by the Committee to prevent dilution or enlargement of the rights granted to, or available for, Participants under this
Plan; provided, that the Committee in its sole discretion shall determine whether an adjustment is appropriate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) Excepting transactions covered by <U>Section</U><U></U><U>&nbsp;4.3(b)(i)</U>, if the
Company effects any merger, consolidation, statutory exchange, <FONT STYLE="white-space:nowrap">spin-off,</FONT> reorganization, sale or transfer of all or substantially all the Company&#146;s assets or business, or other corporate transaction or
event in such a manner that the Company&#146;s outstanding Shares are converted into the right to receive (or the holders of Common Stock are entitled to receive in exchange therefor), either immediately or upon liquidation of the Company,
securities or other property of the Company or other entity, then, subject to the provisions of <U>Section</U><U></U><U>&nbsp;10.1</U>, (A) the aggregate number or kind of securities that thereafter may be issued under this Plan, (B)&nbsp;the number
or kind of securities or other property (including cash) to be issued pursuant to Awards granted under this Plan (including as a result of the assumption of this Plan and the obligations hereunder by a successor entity, as applicable), or
(C)&nbsp;the exercise or purchase price thereof, shall be appropriately adjusted by the Committee to prevent dilution or enlargement of the rights granted to, or available for, Participants under this Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) If there shall occur any change in the capital structure of the Company other than those covered by <U>Sections 4.3(b)(i)</U> or
<U>4.3(b)(ii)</U>, any conversion, any adjustment, or any issuance of any class of securities convertible or exercisable into, or exercisable for, any class of equity securities of the Company, then the Committee shall adjust any Award and make such
other adjustments to this Plan to prevent dilution or enlargement of the rights granted to, or available for, Participants under this Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) In the event of any pending stock dividend, stock split, combination or exchange of shares, merger, consolidation or other distribution
(other than normal cash dividends) of Company assets to stockholders, or any other extraordinary transaction or change affecting the Shares or the Share price, including any securities offering or other similar transaction, for administrative
convenience, the Committee may refuse to permit the exercise of any Award for up to sixty (60)&nbsp;days before or after such transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) The Committee may adjust the Performance Goals applicable to any Awards to reflect any unusual or
<FONT STYLE="white-space:nowrap">non-recurring</FONT> events and other extraordinary items, impact of charges for restructurings, discontinued operations, and the cumulative effects of accounting or tax changes, each as defined by generally accepted
accounting principles or as identified in the Company&#146;s financial statements, notes to the financial statements, management&#146;s discussion and analysis, or other Company public filing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vi) Any such adjustment determined by the Committee pursuant to this <U>Section</U><U></U><U>&nbsp;4.3(b)</U> shall be final, binding, and
conclusive on the Company and all Participants and their respective heirs, executors, administrators, successors, and permitted assigns. Any adjustment to, or assumption or substitution of, an Award under this Section<U>&nbsp;4.3(b)</U> shall be
intended to comply with the requirements of Section&nbsp;409A of the Code and Treasury Regulation <FONT STYLE="white-space:nowrap">&#167;1.424-1</FONT> (and any amendments thereto), to the extent applicable. Except as expressly provided in this
<U>Section</U><U></U><U>&nbsp;4.3</U> or in the applicable Award Agreement, a Participant shall have no additional rights under this Plan by reason of any transaction or event described in this <U>Section</U><U></U><U>&nbsp;4.3</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.4</B> <B><U>Annual Limit on <FONT STYLE="white-space:nowrap">Non-Employee</FONT>
Director Compensation</U></B>. In each calendar year during any part of which this Plan is in effect, a <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director may not receive for such individual&#146;s service on the Board compensation (in
any combination of Awards and cash) that have a value in excess of $750,000 (calculating the value of any such Awards based on the grant date fair value of such Awards for financial reporting purposes); <I>provided</I>, that (a)&nbsp;the Committee
may make exceptions to this limit, except that the <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director receiving such additional compensation may not participate in the decision to award such compensation or in other contemporaneous
decisions involving compensation for <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors and (b)&nbsp;for any calendar year in which a <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director first commences service on the Board,
such limit shall be increased to $1,000,000; <I>provided, further</I>, that the limit set forth in this <U>Section</U><U></U><U>&nbsp;4.4</U> shall be applied without regard to Awards or other compensation, if any, provided to a <FONT
STYLE="white-space:nowrap">Non-Employee</FONT> Director during any period in which such individual was an employee of the Company or any Affiliate or was otherwise providing services to the Company or to any Affiliate other than in the capacity as a
<FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE V </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ELIGIBILITY </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.1</B>
<B><U>General Eligibility</U></B>. All current and prospective Eligible Individuals are eligible to be granted Awards. Eligibility for the grant of Awards and actual participation in this Plan shall be determined by the Committee in its sole
discretion. No Eligible Individual will automatically be granted any Award under this Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.2</B> <B>Incentive Stock Options</B>.
Notwithstanding the foregoing, only Eligible Employees who are employees of the Company, its Parents, or its Subsidiaries are eligible to be granted Incentive Stock Options under this Plan. Eligibility for the grant of an Incentive Stock Option and
actual participation in this Plan shall be determined by the Committee in its sole discretion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.3</B> <B><U>General
Requirement</U></B>. The vesting and exercise of Awards granted to a prospective Eligible Individual are conditioned upon such individual actually becoming an Eligible Employee, Consultant, or <FONT STYLE="white-space:nowrap">Non-Employee</FONT>
Director, as applicable. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VI </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STOCK OPTIONS; STOCK APPRECIATION RIGHTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.1</B> <B><U>General</U></B>. Stock Options or Stock Appreciation Rights may be granted alone or in addition to other Awards granted under
this Plan Each Stock Option granted under this Plan shall be of one of two types: (a)&nbsp;an Incentive Stock Option or (b)&nbsp;a <FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Stock Option. Stock Options and Stock Appreciation Rights
granted under this Plan shall be evidenced by an Award Agreement and subject to the terms, conditions and limitations in this Plan, including any limitations applicable to Incentive Stock Options. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.2</B> <B><U>Grants</U></B>. The Committee shall have the authority to grant to any Eligible Individual one or more Incentive Stock
Options, <FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Stock Options, and/or Stock Appreciation Rights; <I>provided</I>, <I>however</I>, that Incentive Stock Options may only be granted to an Eligible Employee who is an employee of the
Company, its Parents, or its Subsidiaries. To the extent that any Stock Option does not qualify as an Incentive Stock Option (whether because of its provisions or the time or manner of its exercise or otherwise), such Stock Option or the portion
thereof which does not so qualify shall constitute a separate <FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Stock Option. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.3</B> <B><U>Exercise Price</U></B>. The exercise price per Share subject to a Stock
Option or Stock Appreciation Right shall be determined by the Committee at the time of grant, <I>provided</I> that the per share exercise price of a Stock Option or Stock Appreciation Right shall not be less than 100% (or, in the case of an
Incentive Stock Option granted to a Ten Percent Stockholder, 110%) of the Fair Market Value at the time of grant. Notwithstanding the foregoing, in the case of a Stock Option or Stock Appreciation Right that is a Substitute Award, the exercise price
per Share for such Stock Option or Stock Appreciation Right may be less than the Fair Market Value on the date of grant; provided, that, such exercise price is determined in a manner consistent with the provisions of Section&nbsp;409A of the Code
and, if applicable, Section&nbsp;424(a) of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.4</B> <B><U>Term</U></B>. The term of each Stock Option or Stock Appreciation
Right shall be fixed by the Committee, <I>provided</I> that no Stock Option or Stock Appreciation Right shall be exercisable more than ten (10)&nbsp;years (or, in the case of an Incentive Stock Option granted to a Ten Percent Stockholder, five
(5)&nbsp;years) after the date on which the Stock Option or Stock Appreciation Right, as applicable, is granted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.5</B>
<B><U>Exercisability</U></B>. Unless otherwise provided by the Committee in accordance with the provisions of this <U>Section</U><U></U><U>&nbsp;6.5</U>, Stock Options and Stock Appreciation Rights granted under this Plan shall be exercisable at
such time or times and subject to such terms and conditions as shall be determined by the Committee at the time of grant. The Committee may, but shall not be required to, provide for an acceleration of vesting and exercisability upon the occurrence
of a specified event. Unless otherwise determined by the Committee, if the exercise of a <FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Stock Option or Stock Appreciation Right within the permitted time periods is prohibited because such
exercise would violate the registration requirements under the Securities Act or any other Applicable Law or the rules of any securities exchange or interdealer quotation system, the Company&#146;s insider trading policy (including any blackout
periods) or a <FONT STYLE="white-space:nowrap">&#147;lock-up&#148;</FONT> agreement entered into in connection with the issuance of securities by the Company, then the expiration of such <FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Stock
Option or Stock Appreciation Right shall be extended until the date that is thirty (30)&nbsp;days after the end of the period during which the exercise of the <FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Stock Option or Stock Appreciation
Right would be in violation of such registration requirement or other Applicable Law or rules, blackout period or <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement, as determined by the Committee; <I>provided, however</I>, that in no event
shall any such extension result in any <FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Stock Option or Stock Appreciation Right remaining exercisable after the ten (10)-year term of the applicable
<FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Stock Option or Stock Appreciation Right. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.6</B> <B><U>Method of
Exercise</U></B>. Subject to any applicable waiting period or exercisability provisions under <U>Section</U><U></U><U>&nbsp;6.5</U>, to the extent vested, Stock Options and Stock Appreciation Rights may be exercised in whole or in part at any time
during the term of the applicable Stock Option or Stock Appreciation Right, by giving written notice of exercise (which may be electronic) to the Company specifying the number of Stock Options or Stock Appreciation Rights, as applicable, being
exercised. Such notice shall be accompanied by payment in full of the exercise price (which shall equal the product of such number of Shares to be purchased multiplied by the applicable exercise price). The exercise price for the Stock Options may
be paid upon such terms and conditions as shall be established by the Committee and set forth in the applicable Award Agreement. Without limiting the foregoing, the Committee may establish payment terms for the exercise of Stock Options pursuant to
which the Company may withhold a number of Shares that otherwise would be issued to the Participant in connection with the exercise of the Stock Option </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
having a Fair Market Value on the date of exercise equal to the exercise price, or that permit the Participant to deliver cash or Shares with a Fair Market Value equal to the exercise price on
the date of payment, or through a simultaneous sale through a broker of Shares acquired on exercise, all as permitted by Applicable Law. No Shares shall be issued until payment therefor, as provided herein, has been made or provided for. Upon the
exercise of a Stock Appreciation Right a Participant shall be entitled to receive, for each right exercised, up to, but no more than, an amount in cash and/or Shares (as chosen by the Committee in its sole discretion) equal in value to the excess of
the Fair Market Value of one (1)&nbsp;Share on the date that the right is exercised over the Fair Market Value of one (1)&nbsp;Share on the date that the right was awarded to the Participant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.7</B> <B><U><FONT STYLE="white-space:nowrap">Non-Transferability</FONT></U></B>. No Stock Option or Stock Appreciation Right shall be
transferable by the Participant other than by will or by the laws of descent and distribution, and all Stock Options and Stock Appreciation Rights shall be exercisable, during the Participant&#146;s lifetime, only by the Participant. Notwithstanding
the foregoing, the Committee may determine, in its sole discretion, at the time of grant or thereafter that a <FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Stock Option that is otherwise not transferable pursuant to this
<U>Section</U><U></U><U>&nbsp;6.7</U> is transferable to a Family Member of the Participant in whole or in part and in such circumstances, and under such conditions, as specified by the Committee. A
<FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Stock Option that is transferred to a Family Member pursuant to the preceding sentence (a)&nbsp;may not be subsequently transferred other than by will or by the laws of descent and distribution
and (b)&nbsp;remains subject to the terms of this Plan and the applicable Award Agreement. Any Shares acquired upon the exercise of a <FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Stock Option by a permissible transferee of a <FONT
STYLE="white-space:nowrap">Non-Qualified</FONT> Stock Option or a permissible transferee pursuant to a transfer after the exercise of the <FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Stock Option shall be subject to the terms of this Plan
and the applicable Award Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.8</B> <B><U>Termination</U></B>. Unless otherwise determined by the Committee at grant or, if no
rights of the Participant are reduced, thereafter, subject to the provisions of the applicable Award Agreement and this Plan, upon a Participant&#146;s Termination of Service for any reason, Stock Options and Stock Appreciation Rights may remain
exercisable following a Participant&#146;s Termination of Service as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Termination by Death or Disability</U>. Unless
otherwise provided in the applicable Award Agreement, or otherwise determined by the Committee at the time of grant or, if no rights of the Participant are reduced, thereafter, if a Participant&#146;s Termination of Service is by reason of death or
Disability, all Stock Options and Stock Appreciation Rights that are held by such Participant that are vested and exercisable at the time of the Participant&#146;s Termination of Service may be exercised by the Participant (or in the case of the
Participant&#146;s death, by the legal representative of the Participant&#146;s estate) at any time within a period of one (1)&nbsp;year from the date of such Termination of Service, but in no event beyond the expiration of the stated term of such
Stock Options and Stock Appreciation Rights; <I>provided, however</I>, that, in the event of a Participant&#146;s Termination of Service by reason of Disability, if the Participant dies within such exercise period, all unexercised Stock Options and
Stock Appreciation Rights held by such Participant shall thereafter be exercisable, to the extent to which they were exercisable at the time of death, for a period of one (1)&nbsp;year from the date of such death, but in no event beyond the
expiration of the stated term of such Stock Options and/or Stock Appreciation Rights. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Involuntary Termination Without Cause</U>. Unless otherwise provided in the
applicable Award Agreement or otherwise determined by the Committee at the time of grant or, if no rights of the Participant are reduced, thereafter, if a Participant&#146;s Termination of Service is by involuntary termination by the Company without
Cause, all Stock Options and Stock Appreciation Rights that are held by such Participant that are vested and exercisable at the time of the Participant&#146;s Termination of Service may be exercised by the Participant at any time within a period of
ninety (90)&nbsp;days from the date of such Termination of Service, but in no event beyond the expiration of the stated term of such Stock Options or Stock Appreciation Rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Voluntary Resignation</U>. Unless otherwise provided in the applicable Award Agreement or otherwise determined by the Committee at the
time of grant or, if no rights of the Participant are reduced, thereafter, if a Participant&#146;s Termination of Service is voluntary (other than a voluntary termination described in <U>Section</U><U></U><U>&nbsp;6.8(d)</U> hereof), all Stock
Options and Stock Appreciation Rights that are held by such Participant that are vested and exercisable at the time of the Participant&#146;s Termination of Service may be exercised by the Participant at any time within a period of thirty
(30)&nbsp;days from the date of such Termination of Service, but in no event beyond the expiration of the stated term of such Stock Options or Stock Appreciation Rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Termination for Cause</U>. Unless otherwise provided in the applicable Award Agreement or determined by the Committee at the time of
grant, or if no rights of the Participant are reduced, thereafter, if a Participant&#146;s Termination of Service (i)&nbsp;is for Cause or (ii)&nbsp;is a voluntary Termination of Service (as provided in <U>Section</U><U></U><U>&nbsp;6.8(c)</U>)
after the occurrence of an event that would be grounds for a Termination of Service for Cause, all Stock Options and Stock Appreciation Rights, whether vested or not vested, that are held by such Participant shall thereupon immediately terminate and
expire as of the date of such Termination of Service. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Unvested Stock Options </U><U>and Stock Appreciation Rights</U><U>.</U>
Unless otherwise provided in the applicable Award Agreement or determined by the Committee at the time of grant or, if no rights of the Participant are reduced, thereafter, Stock Options and Stock Appreciation Rights that are not vested as of the
date of a Participant&#146;s Termination of Service for any reason shall terminate and expire as of the date of such Termination of Service. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <U>Incentive Stock Option Limitations</U>. To the extent that the aggregate Fair Market Value (determined as of the time of grant) of the
Shares with respect to which Incentive Stock Options are exercisable for the first time by an Eligible Employee during any calendar year under this Plan and/or any other stock option plan of the Company, any Parent, or any Subsidiary exceeds
$100,000, such Options shall be treated as <FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Stock Options. In addition, if an Eligible Employee does not remain employed by the Company, any Parent, or any Subsidiary at all times from the time an
Incentive Stock Option is granted until three (3)&nbsp;months prior to the date of exercise thereof (or such other period as required by Applicable Law), such Stock Option shall be treated as a <FONT STYLE="white-space:nowrap">Non-Qualified</FONT>
Stock Option. Should any provision of this Plan not be necessary in order for the Stock Options to qualify as Incentive Stock Options, or should any additional provisions be required, the Committee may amend this Plan accordingly, without the
necessity of obtaining the approval of the stockholders of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) <U>Modification, Extension and Renewal of Stock Options</U>. The Committee may
(i)&nbsp;modify, extend, or renew outstanding Stock Options granted under this Plan (provided that the rights of a Participant are not reduced without such Participant&#146;s consent and <I>provided</I>, <I>further</I> that such action does not
subject the Stock Options to Section&nbsp;409A of the Code without the consent of the Participant), and (ii)&nbsp;accept the surrender of outstanding Stock Options (to the extent not theretofore exercised) and authorize the granting of new Stock
Options in substitution therefor (to the extent not theretofore exercised). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.9</B> <B><U>Automatic Exercise</U></B>. The Committee
may include a provision in an Award Agreement providing for the automatic exercise of a <FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Stock Option or Stock Appreciation Right on a cashless basis on the last day of the term of such Option or
Stock Appreciation Right if the Participant has failed to exercise the <FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Stock Option or Stock Appreciation Right as of such date, with respect to which the Fair Market Value of the Shares
underlying the <FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Stock Option or Stock Appreciation Right exceeds the exercise price of such <FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Stock Option or Stock Appreciation Right on the
date of expiration of such Option or Stock Appreciation Right, subject to Section&nbsp;13.4. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.10</B> <B>Dividends</B>. No dividends
or Dividend Equivalent Rights shall be granted with respect to Stock Options or Stock Appreciation Rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.11</B> <B>Other Terms and
Conditions</B>. As the Committee shall deem appropriate, Stock Options and Stock Appreciation Rights may be subject to additional terms and conditions or other provisions, which shall not be inconsistent with any of the terms of this Plan. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VII </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RESTRICTED
STOCK; RESTRICTED STOCK UNITS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.1</B> <B><U>Awards of Restricted Stock and Restricted Stock Units</U></B>. Shares of Restricted
Stock and Restricted Stock Units may be granted alone or in addition to other Awards granted under this Plan. The Committee shall determine the Eligible Individuals to whom, and the time or times at which, grants of Restricted Stock and/or
Restricted Stock Units shall be made, the number of shares of Restricted Stock or Restricted Stock Units to be awarded, the price (if any) to be paid by the Participant (subject to <U>Section</U><U></U><U>&nbsp;7.2</U>), the time or times within
which such Awards may be subject to forfeiture, the vesting schedule and rights to acceleration thereof, and all other terms and conditions of the Awards. The Committee shall determine and set forth in the Award Agreement the terms and conditions
for each Award of Restricted Stock and Restricted Stock Units, subject to the conditions and limitations contained in this Plan, including any vesting or forfeiture conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Committee may condition the grant or vesting of Restricted Stock and Restricted Stock Units upon the attainment of specified Performance
Goals or such other factor as the Committee may determine in its sole discretion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.2</B> <B><U>Awards and Certificates</U></B>.
Restricted Stock and Restricted Stock Units granted under this Plan shall be evidenced by an Award Agreement and subject to the following terms and conditions and shall be in such form and contain such additional terms and conditions not
inconsistent with the terms of this Plan, as the Committee shall deem desirable: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Restricted Stock</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) <U>Purchase Price</U>. The purchase price of Restricted Stock shall be fixed by the
Committee. The purchase price for shares of Restricted Stock may be zero to the extent permitted by Applicable Law, and, to the extent not so permitted, such purchase price may not be less than par value. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) <U>Legend</U>. Each Participant receiving Restricted Stock shall be issued a stock certificate in respect of such shares of Restricted
Stock, unless the Committee elects to use another system, such as book entries by the Company&#146;s transfer agent, as evidencing ownership of shares of Restricted Stock. Such certificate shall be registered in the name of such Participant, and
shall, in addition to such legends required by Applicable Law, bear an appropriate legend referring to the terms, conditions, and restrictions applicable to such Restricted Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) <U>Custody</U>. If stock certificates are issued in respect of shares of Restricted Stock, the Committee may require that any stock
certificates evidencing such shares be held in custody by the Company until the restrictions thereon shall have lapsed, and that, as a condition of any grant of Restricted Stock, the Participant shall have delivered a duly signed stock power or
other instruments of assignment (including a power of attorney), each endorsed in blank with a guarantee of signature if deemed necessary or appropriate by the Company, which would permit transfer to the Company of all or a portion of the shares
subject to the Award of Restricted Stock in the event that such Award is forfeited in whole or part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) <U>Rights as a
Stockholder</U>. Except as provided in <U>Section</U><U></U><U>&nbsp;7.3(a) </U>and this <U>Section</U><U></U><U>&nbsp;7.2(a) </U>or as otherwise determined by the Committee in an Award Agreement, the Participant shall have, with respect to the
shares of Restricted Stock, all of the rights of a holder of Shares, including, without limitation, the right to receive dividends, the right to vote such shares, and, subject to and conditioned upon the full vesting of shares of Restricted Stock,
the right to tender such shares; <I>provided</I> that the Award Agreement shall specify on what terms and conditions the applicable Participant shall be entitled to dividends payable on the Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) <U>Lapse of Restrictions</U>. If and when the Restriction Period expires without a prior forfeiture of the Restricted Stock, the
certificates for such Shares shall be delivered to the Participant. All legends shall be removed from said certificates at the time of delivery to the Participant, except as otherwise required by Applicable Law or other limitations imposed by the
Committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Restricted Stock Units</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) <U>Settlement</U>. The Committee may provide that settlement of Restricted Stock Units will occur upon or as soon as reasonably practical
after the Restricted Stock Units vest or will instead be deferred, on a mandatory basis or at the Participant&#146;s election, in a manner intended to comply with Section&nbsp;409A of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) <U>Rights as a Stockholder</U>. A Participant will have no rights of a stockholder with respect to Shares subject to any Restricted
Stock Unit unless and until Shares are delivered in settlement of the Restricted Stock Units. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) <U>Dividend Equivalent Rights</U>. If the Committee so provides, a grant of
Restricted Stock Units may provide a Participant with the right to receive Dividend Equivalent Rights. Dividend Equivalent Rights may be paid currently or credited to an account for the Participant, settled in cash or Shares, and subject to the same
restrictions on transferability and forfeitability as the Restricted Stock Units with respect to which the Dividend Equivalent Rights are granted and subject to other terms and conditions as set forth in the Award Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.3</B> <B><U>Restrictions and Conditions</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Restriction Period</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) The Participant shall not be permitted to transfer shares of Restricted Stock awarded under this Plan or vest in Restricted Stock Units
during the period or periods set by the Committee (the &#147;<U>Restriction Period</U>&#148;) commencing on the date of such Award, as set forth in the applicable Award Agreement and such agreement shall set forth a vesting schedule and any event
that would accelerate vesting of the Restricted Stock and/or Restricted Stock Units. Within these limits, based on service, attainment of Performance Goals pursuant to <U>Section</U><U></U><U>&nbsp;7.3(a)(i)</U>, and/or such other factors or
criteria as the Committee may determine in its sole discretion, the Committee may condition the grant or provide for the lapse of such restrictions in installments in whole or in part, or may accelerate the vesting of all or any part of any Award of
Restricted Stock or Restricted Stock Units and/or waive the deferral limitations for all or any part of any Award of Restricted Stock or Restricted Stock Units. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) If the grant of shares of Restricted Stock or Restricted Stock Units or the lapse of restrictions or vesting schedule is based on the
attainment of Performance Goals, the Committee shall establish the objective Performance Goals and the applicable vesting percentage applicable to each Participant or class of Participants in the applicable Award Agreement prior to the beginning of
the applicable fiscal year or at such later date as otherwise determined by the Committee and while the outcome of the Performance Goals are substantially uncertain. Such Performance Goals may incorporate provisions for disregarding (or adjusting
for) changes in accounting methods, corporate transactions (including, without limitation, dispositions and acquisitions), and other similar types of events or circumstances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Termination</U>. Unless otherwise provided in the applicable Award Agreement or determined by the Committee at grant or, if no rights
of the Participant are reduced, thereafter, upon a Participant&#146;s Termination of Service for any reason during the relevant Restriction Period, all Restricted Stock or Restricted Stock Units still subject to restriction will be forfeited in
accordance with the terms and conditions established by the Committee at grant or thereafter. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VIII </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PERFORMANCE AWARDS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Committee may grant a Performance Award to a Participant payable upon the attainment of specific Performance Goals either alone or in addition to other Awards granted under this Plan. The Performance Goals to be achieved during the Performance
Period and the length of the Performance Period shall be determined by the Committee upon the grant of each Performance </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Award. The conditions for grant or vesting and the other provisions of Performance Awards (including, without limitation, any applicable Performance Goals) need not be the same with respect to
each Participant. Performance Awards may be paid in cash, Shares, other property, or any combination thereof, in the sole discretion of the Committee as set forth in the applicable Award Agreement. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE IX </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OTHER
STOCK-BASED AND CASH AWARDS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.1</B> <B><U>Other Stock-Based Awards</U></B>. The Committee is authorized to grant to Eligible
Individuals Other <FONT STYLE="white-space:nowrap">Stock-Based</FONT> Awards that are payable in, valued in whole or in part by reference to, or otherwise based on or related to Shares, including but not limited to, Shares awarded purely as a bonus
and not subject to restrictions or conditions, Shares in payment of the amounts due under an incentive or performance plan sponsored or maintained by the Company, stock equivalent units, and Awards valued by reference to the book value of Shares.
Other Stock-Based Awards may be granted either alone or in addition to or in tandem with other Awards granted under this Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to
the provisions of this Plan, the Committee shall have authority to determine the Eligible Individuals, to whom, and the time or times at which, such Other Stock-Based Awards shall be made, the number of Shares to be awarded pursuant to such Awards,
and all other conditions of the Awards. The Committee may also provide for the grant of Shares under such Awards upon the completion of a specified Performance Period. The Committee may condition the grant or vesting of Other Stock-Based Awards upon
the attainment of specified Performance Goals as the Committee may determine, in its sole discretion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.2</B> <B><U>Terms and
Conditions</U></B>. Other Stock-Based Awards made pursuant to this <U>Article</U><U></U><U>&nbsp;IX</U> shall be evidenced by an Award Agreement and subject to the following terms and conditions and shall be in such form and contain such additional
terms and conditions not inconsistent with the terms of this Plan, as the Committee shall deem desirable: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U><FONT
STYLE="white-space:nowrap">Non-Transferability</FONT></U>. Subject to the applicable provisions of the Award Agreement and this Plan, Shares subject to Other Stock-Based Awards may not be transferred prior to the date on which the Shares are issued
or, if later, the date on which any applicable restriction, performance, or deferral period lapses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Dividends</U>. Unless
otherwise determined by the Committee at the time of the grant of an Other Stock-Based Award, subject to the provisions of the Award Agreement and this Plan, the recipient of an Other Stock-Based Award shall not be entitled to receive, currently or
on a deferred basis, dividends or Dividend Equivalent Rights in respect of the number of Shares covered by the Other Stock-Based Award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Vesting</U>. Any Other Stock-Based Award and any Shares covered by any such Other Stock-Based Award shall vest or be forfeited to the
extent so provided in the Award Agreement, as determined by the Committee, in its sole discretion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Price</U>. Shares under this
<U>Article IX</U> may be issued for no cash consideration. Shares purchased pursuant to a purchase right awarded pursuant to an Other Stock-Based Award shall be priced, as determined by the Committee in its sole discretion. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.3</B> <B><U>Cash Awards</U></B>. The Committee may from time to time grant Cash Awards
to Eligible Individuals in such amounts, on such terms and conditions, and for such consideration, including no consideration or such minimum consideration as may be required by Applicable Law, as it shall determine in its sole discretion. Cash
Awards may be granted subject to the satisfaction of vesting conditions or may be awarded purely as a bonus and not subject to restrictions or conditions, and if subject to vesting conditions, the Committee may accelerate the vesting of such Awards
at any time in its sole discretion. The grant of a Cash Award shall not require a segregation of any of the Company&#146;s assets for satisfaction of the Company&#146;s payment obligation thereunder. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE X </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CHANGE IN
CONTROL PROVISIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.1</B> <B><U>Benefits</U></B>. In the event of a Change in Control of the Company, and except as otherwise
provided by the Committee in an Award Agreement or any applicable employment agreement, offer letter, consulting agreement, change in control agreement, or similar agreement in effect between the Company or an Affiliate and the Participant, a
Participant&#146;s unvested Awards shall not vest automatically and a Participant&#146;s Awards shall be treated in accordance with one or more of the following methods as determined by the Committee: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Awards, whether or not then vested, shall be continued, be assumed, or have new rights substituted therefor, as determined by the
Committee in a manner consistent with the requirements of Section&nbsp;409A of the Code, and restrictions to which shares of Restricted Stock or any other Award granted prior to the Change in Control are subject shall not lapse upon a Change in
Control and the Restricted Stock or other Award shall, where appropriate in the sole discretion of the Committee, receive the same distribution as other Shares on such terms as determined by the Committee; <I>provided</I> that the Committee may
decide to award additional Restricted Stock or other Awards in lieu of any cash distribution. Notwithstanding anything to the contrary herein, for purposes of Incentive Stock Options, any assumed or substituted Stock Option shall comply with the
requirements of Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.424-1</FONT> (and any amendment thereto). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The
Committee, in its sole discretion, may provide for the purchase of any Awards by the Company for an amount of cash equal to the excess (if any) of the Change in Control Price of the Shares covered by such Awards, over the aggregate exercise price of
such Awards; <I>provided, however</I>, that if the exercise price of an Option or Stock Appreciation Right exceeds the Change in Control Price, such Award may be cancelled for no consideration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The Committee may, in its sole discretion, terminate all outstanding and unexercised Stock Options, Stock Appreciation Rights, or any
Other Stock-Based Award that provides for a Participant-elected exercise, effective as of the date of the Change in Control, by delivering notice of termination to each Participant at least twenty (20)&nbsp;days prior to the date of consummation of
the Change in Control, in which case during the period from the date on which such notice of termination is delivered to the consummation of the Change in Control, each such Participant shall have the right to exercise in full all of such
Participant&#146;s Awards that are then outstanding (without regard to any limitations on exercisability otherwise contained in the Award Agreements), but any such exercise shall be contingent on the occurrence of the Change in Control, and,
<I>provided</I> that, if the Change in Control does not take place within a specified period after giving such notice for any reason whatsoever, the notice and exercise pursuant thereto shall be null and void. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Notwithstanding any other provision herein to the contrary, the Committee may, in its
sole discretion, provide for accelerated vesting or lapse of restrictions, of an Award at any time. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE XI </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TERMINATION OR AMENDMENT OF PLAN </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding any other provision of this Plan, the Board or the Committee may at any time, and from time to time, amend, in whole or in
part, any or all of the provisions of this Plan (including any amendment deemed necessary to ensure that the Company may comply with any Applicable Law), or suspend or terminate it entirely, retroactively or otherwise; <I>provided, however</I>,
that, unless otherwise required by Applicable Law or specifically provided herein, the rights of a Participant with respect to Awards granted prior to such amendment, suspension, or termination may not be materially impaired without the consent of
such Participant and, <I>provided</I>, <I>further</I>, that without the approval of the holders of the Shares entitled to vote in accordance with Applicable Law, no amendment may be made that would (a)&nbsp;increase the aggregate number of Shares
that may be issued under this Plan (except by operation of <U>Section</U><U></U><U>&nbsp;4.1</U>); or (b)&nbsp;change the classification of individuals eligible to receive Awards under this Plan. In addition, the Board or the Committee shall,
without the approval of the holders of the Shares entitled to vote in accordance with Applicable Law, have the authority to (i)&nbsp;amend any outstanding Option or Stock Appreciation Right to reduce its exercise price per Share or (ii)&nbsp;cancel
any Option or Stock Appreciation Right in exchange for cash or another Award. Notwithstanding anything herein to the contrary, the Board or the Committee may amend this Plan or any Award Agreement at any time without a Participant&#146;s consent to
comply with Applicable Law, including Section&nbsp;409A of the Code. The Committee may amend the terms of any Award theretofore granted, prospectively or retroactively, but, subject to <U>Article IV</U> or as otherwise specifically provided herein,
no such amendment or other action by the Committee shall materially impair the rights of any Participant without the Participant&#146;s consent. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE XII </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNFUNDED
STATUS OF PLAN </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Plan is intended to constitute an &#147;unfunded&#148; plan for incentive and deferred compensation. With respect
to any payment as to which a Participant has a fixed and vested interest but which is not yet made to a Participant by the Company, nothing contained herein shall give any such Participant any right that is greater than those of a general unsecured
creditor of the Company. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE XIII </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GENERAL PROVISIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.1</B> <B><U><FONT STYLE="white-space:nowrap">Lock-Up;</FONT> Legend</U></B>. The Committee may require each person receiving Shares
pursuant to a Stock Option or other Award under this Plan to represent to and agree with the Company in writing that the Participant is acquiring the Shares without a view to distribution thereof. The Company may, in connection with registering the
offering of any Company securities under the Securities Act, prohibit Participants from, directly or indirectly, selling or otherwise </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
transferring any Shares or other Company securities during any period determined by the underwriter or the Company. In addition to any legend required by this Plan, the certificates for such
Shares may include any legend that the Committee deems appropriate to reflect any restrictions on transfer. All certificates for Shares delivered under this Plan shall be subject to such stop transfer orders and other restrictions as the Committee
may deem advisable under the rules, regulations, and other requirements of the Securities and Exchange Commission, any stock exchange upon which the Common Stock is then listed or any national securities exchange system upon whose system the Common
Stock is then quoted, and any Applicable Law, and the Committee may cause a legend or legends to be put on any such certificates to make appropriate reference to such restrictions. If the Shares are held in book-entry form, then the book-entry will
indicate any restrictions on such Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.2</B> <B><U>Other Plans</U></B>. Nothing contained in this Plan shall prevent the Board
from adopting other or additional compensation arrangements, subject to stockholder approval if such approval is required, and such arrangements may be either generally applicable or applicable only in specific cases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.3</B> <B><U>No Right to Employment/Directorship/Consultancy</U></B>. Neither this Plan nor the grant of any Award hereunder shall give
any Participant or other employee, Consultant or <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director any right with respect to continuance of employment, consultancy or directorship by the Company or any Affiliate, nor shall there be a
limitation in any way on the right of the Company or any Affiliate by which an employee is employed or a Consultant or <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director is retained to terminate such employment, consultancy, or
directorship at any time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.4</B> <B><U>Withholding of Taxes</U></B>. A Participant shall be required to pay to the Company or one of
its Affiliates, as applicable, or make arrangements satisfactory to the Company regarding the payment of, any income tax, social insurance contribution or other applicable taxes that are required to be withheld in respect of an Award. The Committee
may (but is not obligated to), in its sole discretion, permit or require a Participant to satisfy all or any portion of the applicable taxes that are required to be withheld with respect to an Award by (a)&nbsp;the delivery of Shares (which are not
subject to any pledge or other security interest) that have been both held by the Participant and vested for at least six (6)&nbsp;months (or such other period as established from time to time by the Committee in order to avoid adverse accounting
treatment under applicable accounting standards) having an aggregate Fair Market Value equal to such withholding liability (or portion thereof); (b)&nbsp;having the Company withhold from the Shares otherwise issuable or deliverable to, or that would
otherwise be retained by, the Participant upon the grant, exercise, vesting, or settlement of the Award, as applicable, a number of Shares with an aggregate Fair Market Value equal to the amount of such withholding liability; or (c)&nbsp;by any
other means specified in the applicable Award Agreement or otherwise determined by the Committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.5</B> <B><U>Fractional
Shares</U></B>. No fractional Shares shall be issued or delivered pursuant to this Plan. The Committee shall determine whether cash, additional Awards, or other securities or property shall be used or paid in lieu of fractional Shares or whether any
fractional shares should be rounded, forfeited, or otherwise eliminated. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.6</B> <B><U>No Assignment of Benefits</U></B>. No Award or other benefit payable under
this Plan shall, except as otherwise specifically provided in this Plan or under Applicable Law or permitted by the Committee, be transferable in any manner, and any attempt to transfer any such benefit shall be void, and any such benefit shall not
in any manner be liable for or subject to the debts, contracts, liabilities, engagements, or torts of any person who shall be entitled to such benefit, nor shall it be subject to attachment or legal process for or against such person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.7</B> <B><U>Clawback Policy</U></B>. All awards, amounts, or benefits received or outstanding under this Plan will be subject to
clawback, cancellation, recoupment, rescission, payback, reduction, or other similar action in accordance with any Company clawback or similar policy or any Applicable Law related to such actions. A Participant&#146;s acceptance of an Award will
constitute the Participant&#146;s acknowledgement of and consent to the Company&#146;s application, implementation, and enforcement of any applicable Company clawback or similar policy that may apply to the Participant, whether adopted before or
after the Effective Date, and any Applicable Law relating to clawback, cancellation, recoupment, rescission, payback, or reduction of compensation, and the Participant&#146;s agreement that the Company may take any actions that may be necessary to
effectuate any such policy or Applicable Law, without further consideration or action. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.8</B> <B><U>Listing and Other
Conditions</U></B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Unless otherwise determined by the Committee, as long as the Common Stock is listed on a national securities
exchange or system sponsored by a national securities association, the issuance of Shares pursuant to an Award shall be conditioned upon such Shares being listed on such exchange or system. The Company shall have no obligation to issue such Shares
unless and until such Shares are so listed, and the right to exercise any Option or other Award with respect to such Shares shall be suspended until such listing has been effected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) If at any time counsel to the Company advises the Company that any sale or delivery of Shares pursuant to an Award is or may in the
circumstances be unlawful or result in the imposition of excise taxes on the Company under Applicable Law, the Company shall have no obligation to make such sale or delivery, or to make any application or to effect or to maintain any qualification
or registration under the Securities Act or otherwise, with respect to Shares or Awards, and the right to exercise any Option or other Award shall be suspended until, based on the advice of said counsel, such sale or delivery shall be lawful or will
not result in the imposition of excise taxes on the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Upon termination of any period of suspension under this
<U>Section</U><U></U><U>&nbsp;13.8</U>, any Award affected by such suspension which shall not then have expired or terminated shall be reinstated as to all Shares available before such suspension and as to Shares which would otherwise have become
available during the period of such suspension, but no such suspension shall extend the term of any Award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) A Participant shall be
required to supply the Company with certificates, representations, and information that the Company requests and otherwise cooperate with the Company in obtaining any listing, registration, qualification, exemption, consent, or approval that the
Company deems necessary or appropriate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.9</B> <B><U>Governing Law</U></B>. This Plan and actions taken in connection herewith
shall be governed and construed in accordance with the laws of the State of New York, without reference to principles of conflict of laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.10</B> <B><U>Construction</U></B>. Wherever any words are used in this Plan in the masculine gender they shall be construed as though
they were also used in the feminine gender in all cases where they would so apply, and wherever words are used herein in the singular form they shall be construed as though they were also used in the plural form in all cases where they would so
apply. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.11</B> <B><U>Other Benefits</U></B>. No Award granted or paid out under this Plan shall be deemed compensation for purposes
of computing benefits under any retirement plan of the Company or its Affiliates or affect any benefit or compensation under any other plan now or subsequently in effect under which the availability or amount of benefits is related to the level of
compensation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.12</B> <B><U>Costs</U></B>. The Company shall bear all expenses associated with administering this Plan, including
expenses of issuing Shares pursuant to Awards hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.13</B> <B><U>No Right to Same Benefits</U></B>. The provisions of Awards
need not be the same with respect to each Participant, and such Awards to individual Participants need not be the same in subsequent years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.14</B> <B><U>Death/Disability</U></B>. The Committee may in its discretion require the transferee of a Participant to supply it with
written notice of the Participant&#146;s death or Disability and to supply it with a copy of the will (in the case of the Participant&#146;s death) or such other evidence as the Committee deems necessary to establish the validity of the transfer of
an Award. The Committee may also require the agreement of the transferee to be bound by all of the terms and conditions of this Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.15</B> <B><U>Section 16(b) of the Exchange Act</U></B>. It is the intent of the Company that this Plan satisfy, and be interpreted in a
manner that satisfies, the applicable requirements of Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> as promulgated under Section&nbsp;16 of the Exchange Act so that Participants will be entitled to the benefit of Rule <FONT
STYLE="white-space:nowrap">16b-3,</FONT> or any other rule promulgated under Section&nbsp;16 of the Exchange Act, and will not be subject to short-swing liability under Section&nbsp;16 of the Exchange Act. Accordingly, if the operation of any
provision of this Plan would conflict with the intent expressed in this <U>Section</U><U></U><U>&nbsp;13.15</U>, such provision to the extent possible shall be interpreted and/or deemed amended so as to avoid such conflict. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.16</B> <B><U>Deferral of Awards</U></B>. The Committee may establish one or more programs under this Plan to permit selected
Participants the opportunity to elect to defer receipt of consideration upon exercise of an Award, satisfaction of performance criteria, or other event that absent the election would entitle the Participant to payment or receipt of Shares or other
consideration under an Award. The Committee may establish the election procedures, the timing of such elections, the mechanisms for payments of, and accrual of interest or other earnings, if any, on amounts, Shares or other consideration so
deferred, and such other terms, conditions, rules, and procedures that the Committee deems advisable for the administration of any such deferral program. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.17</B> <B><U>Section 409A of the Code</U></B>. This Plan and Awards are intended to
comply with or be exempt from the applicable requirements of Section&nbsp;409A of the Code and shall be limited, construed, and interpreted in accordance with such intent. To the extent that any Award is subject to Section&nbsp;409A of the Code, it
shall be paid in a manner that will comply with Section&nbsp;409A of the Code. Notwithstanding anything herein to the contrary, any provision in this Plan that is inconsistent with Section&nbsp;409A of the Code shall be deemed to be amended to
comply with or be exempt from Section&nbsp;409A of the Code and, to the extent such provision cannot be amended to comply therewith or be exempt therefrom, such provision shall be null and void. The Company shall have no liability to a Participant,
or any other party, if an Award that is intended to be exempt from, or compliant with, Section&nbsp;409A of the Code is not so exempt or compliant or for any action taken by the Committee or the Company and, in the event that any amount or benefit
under this Plan becomes subject to penalties under Section&nbsp;409A of the Code, responsibility for payment of such penalties shall rest solely with the affected Participants and not with the Company. Notwithstanding any contrary provision in this
Plan or Award Agreement, any payment(s) of &#147;nonqualified deferred compensation&#148; (within the meaning of Section&nbsp;409A of the Code) that are otherwise required to be made under this Plan to a &#147;specified employee&#148; (as defined
under Section&nbsp;409A of the Code) as a result of such employee&#146;s separation from service (other than a payment that is not subject to Section&nbsp;409A of the Code) shall be delayed for the first six (6)&nbsp;months following such separation
from service (or, if earlier, until the date of death of the specified employee) and shall instead be paid (in a manner set forth in the Award Agreement) upon expiration of such delay period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.18</B> <B><U>Data Privacy</U></B>. As a condition of receipt of any Award, each Participant explicitly and unambiguously consents to the
collection, use, and transfer, in electronic or other form, of personal data as described in this <U>Section</U><U></U><U>&nbsp;13.18</U> by and among, as applicable, the Company and its Affiliates, for the exclusive purpose of implementing,
administering, and managing this Plan and Awards and the Participant&#146;s participation in this Plan. In furtherance of such implementation, administration, and management, the Company and its Affiliates may hold certain personal information about
a Participant, including, but not limited to, the Participant&#146;s name, home address, telephone number, date of birth, social security or insurance number or other identification number, salary, nationality, job title(s), information regarding
any securities of the Company or any of its Affiliates, and details of all Awards (the&nbsp;&#147;<B><U>Data</U></B>&#148;). In addition to transferring the Data amongst themselves as necessary for the purpose of implementation, administration, and
management of this Plan and Awards and the Participant&#146;s participation in this Plan, the Company and its Affiliates may each transfer the Data to any third parties assisting the Company in the implementation, administration, and management of
this Plan and Awards and the Participant&#146;s participation in this Plan. Recipients of the Data may be located in the Participant&#146;s country or elsewhere, and the Participant&#146;s country and any given recipient&#146;s country may have
different data privacy laws and protections. By accepting an Award, each Participant authorizes such recipients to receive, possess, use, retain, and transfer the Data, in electronic or other form, for the purposes of assisting the Company in the
implementation, administration, and management of this Plan and Awards and the Participant&#146;s participation in this Plan, including any requisite transfer of such Data as may be required to a broker or other third party with whom the Company or
the Participant may elect to deposit any shares of Common Stock. The Data related to a Participant will be held only as long as is necessary to implement, administer, and manage this Plan and Awards and the Participant&#146;s participation in this
Plan. A Participant may, at any time, view the Data held by the Company with respect to such Participant, request additional information about the storage and processing of the Data with respect to such Participant, recommend any necessary
corrections to the Data with respect to the Participant, or refuse or withdraw the consents herein in writing, in any case without cost, by contacting his or her local human resources representative. The Company may cancel the Participant&#146;s
eligibility to participate in this Plan, and in the Committee&#146;s discretion, the Participant may forfeit any outstanding Awards if the Participant refuses or withdraws the consents described herein. For more information on the consequences of
refusal to consent or withdrawal of consent, Participants may contact their local human resources representative. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.19</B> <B><U>Successor and Assigns</U></B>. This Plan shall be binding on all
successors and permitted assigns of a Participant, including, without limitation, the estate of such Participant and the executor, administrator, or trustee of such estate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.20</B> <B><U>Severability of Provisions</U></B>. If any provision of this Plan shall be held invalid or unenforceable, such invalidity
or unenforceability shall not affect any other provisions hereof, and this Plan shall be construed and enforced as if such provisions had not been included. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.21</B> <B><U>Headings and Captions</U></B>. The headings and captions herein are provided for reference and convenience only, shall not
be considered part of this Plan, and shall not be employed in the construction of this Plan. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE XIV </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EFFECTIVE DATE OF PLAN </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Plan shall become effective on [&#149;]<SUP STYLE="font-size:75%; vertical-align:top">3</SUP>, which is the date of its adoption by the
Board, subject to the approval of this Plan by the stockholders of the Company in accordance with the requirements of the laws of the State of New York. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE XV </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TERM OF PLAN
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No Award shall be granted pursuant to this Plan on or after the tenth (10th) anniversary of the earlier of the date that this Plan is
adopted by the Board or the date of stockholder approval, but Awards granted prior to such tenth (10th) anniversary may extend beyond that date. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>***** </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">3</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Note to Draft</U></B>: To be the date shareholder approval of the plan is obtained.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>9
<FILENAME>d744414dex103.htm
<DESCRIPTION>EX-10.3
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXHIBIT 10.3 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>KESTRA MEDICAL TECHNOLOGIES, LTD. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2025 OMNIBUS INCENTIVE PLAN </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STOCK OPTION GRANT NOTICE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms and conditions of the Kestra Medical Technologies, Ltd. 2025 Omnibus Incentive Plan, as amended from time to time (the
&#147;<B><U>Plan</U></B>&#148;), Kestra Medical Technologies, Ltd., a Bermuda corporation (the&nbsp;&#147;<B><U>Company</U></B>&#148;), hereby grants to the individual listed below (&#147;<B><U>you</U></B>&#148; or the
&#147;<B><U>Participant</U></B>&#148;) the right and option to purchase all or any part of the number of Shares set forth below (the &#147;<B><U>Option</U></B>&#148;). This Option award (this &#147;<B><U>Award</U></B>&#148;) is subject to the terms
and conditions set forth herein and in the Stock Option Agreement attached hereto as <U>Exhibit A</U> (the&nbsp;&#147;<B><U>Agreement</U></B>&#148;), the restrictive covenants attached hereto as <U>Exhibit B</U> (the &#147;<B><U>Restrictive
Covenants</U></B>&#148;) and the Plan, each of which is incorporated herein by reference. Capitalized terms used but not defined herein shall have the meanings set forth in the Plan. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="20%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="78%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Type of Option:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">[Non-Qualified</FONT> Stock Option] [Incentive Stock Option]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Participant:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[&#149;]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Date of Grant:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[&#149;]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Total Number of Shares Subject to this Option:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[&#149;] Shares</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Exercise Price:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$[&#149;] per Share</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Expiration Date:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[&#149;]<SUP STYLE="font-size:75%; vertical-align:top">1</SUP></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Vesting Schedule:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[Subject to Sections 3 and 5 of the Agreement, the Plan and the other terms and conditions set forth herein, the Option shall vest and become exercisable on the following schedule provided you remain continuously employed by the
Company or an Affiliate from the Date of Grant through such vesting date[s]:&nbsp;[&#149;]]</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By your signature below, you agree to be bound by the terms and conditions of the Plan, the Agreement and this
Stock Option Grant Notice (this &#147;<B><U>Grant Notice</U></B>&#148;). You acknowledge that you have reviewed the Agreement, the Plan and this Grant Notice in their entirety and fully understand all provisions of the Agreement, the Plan and this
Grant Notice and have had an opportunity to obtain the advice of counsel prior to executing this Grant Notice. You hereby agree to accept as binding, conclusive and final all decisions or interpretations of the Committee regarding any questions or
determinations arising under the Agreement, the Plan or this Grant Notice. This Grant Notice may be executed in one or more counterparts (including portable document format (.pdf) and facsimile counterparts), each of which shall be deemed to be an
original, but all of which together shall constitute one and the same agreement. </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Note to Draft</U></B>: Expiration date to be the <FONT STYLE="white-space:nowrap">10-year</FONT>
anniversary of the Date of Grant. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding any provision of this Grant Notice or the Agreement, if you have not
executed and delivered to the Company this Grant Notice within 90 days following the Date of Grant, then this Award will terminate automatically without any further action by the Company and will be forfeited without further notice and at no cost to
the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the Company has caused this Grant Notice to be executed by an
officer thereunto duly authorized, and the Participant has executed this Grant Notice, effective for all purposes as provided above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>KESTRA MEDICAL TECHNOLOGIES, LTD.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>PARTICIPANT</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: [&#149;]</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S<SMALL>TOCK</SMALL> O<SMALL>PTION</SMALL> G<SMALL>RANT</SMALL> N<SMALL>OTICE</SMALL> </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT A </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STOCK OPTION AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Stock Option Agreement (together with the Grant Notice to which this Agreement is attached and <U>Exhibit B</U>,
this&nbsp;&#147;<B><U>Agreement</U></B>&#148;) is made as of the Date of Grant set forth in the Grant Notice to which this Agreement is attached by and between Kestra Medical Technologies, Ltd., a Bermuda corporation
(the&nbsp;&#147;<B><U>Company</U></B>&#148;), and [&#149;] (the &#147;<B><U>Participant</U></B>&#148;). Capitalized terms used but not specifically defined herein shall have the meanings specified in the Plan or the Grant Notice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.</B> <B><U>Award</U></B>. In consideration of the Participant&#146;s past and/or continued employment with, or service to, the Company or
an Affiliate and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, effective as of the Date of Grant set forth in the Grant Notice (the &#147;<B><U>Date of Grant</U></B>&#148;), the Company
hereby grants to the Participant the right and option to purchase all or any part of an aggregate of the number of Shares set forth in the Grant Notice on the terms and conditions set forth in the Grant Notice, this Agreement and the Plan, which is
incorporated herein by reference as a part of this Agreement. In the event of any inconsistency between the Plan and this Agreement, the terms of the Plan shall control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.</B> <B><U>Exercise Price</U></B>. The exercise price of each Share subject to this Option shall be the exercise price set forth in the
Grant Notice (the &#147;<B><U>Exercise Price</U></B>&#148;), which has been determined to be not less than the Fair Market Value of a Share at the Date of Grant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.</B> <B><U>Vesting</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Except as otherwise set forth in this Section, the Option shall vest in accordance with the vesting schedule set forth in the Grant
Notice. Upon the Participant&#146;s Termination of Service prior to the Option vesting in full (but after giving effect to any accelerated vesting pursuant to this <U>Section</U><U></U><U>&nbsp;3</U>), the unvested portion of the Option (and all
rights arising from such portion and from being a holder thereof) will terminate automatically without any further action by the Company and will be forfeited without further notice and at no cost to the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Notwithstanding anything in the Grant Notice, this Agreement or the Plan to the contrary, subject to <U>Section</U><U></U><U>&nbsp;10</U>:
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) upon the Participant&#146;s Termination of Service due to the Participant&#146;s death or Disability, any portion of
this Option that remains unvested shall become vested with respect to 100% of the Shares subject to this Option as of the date of such Termination of Service; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) upon a Change in Control, any portion of this Option that remains unvested shall become vested with respect to 100% of
the Shares subject to this Option as of the date of such Change in Control. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.</B> <B><U>Exercise of Option</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Subject to the earlier expiration of this Option as provided herein, this Option may be exercised by (i)&nbsp;providing written notice to
the Company in the form prescribed by the Committee from time to time at any time and from time to time after the Date of Grant, which notice shall be delivered to the Company in the form, and in the manner, designated by the Committee from time to
time, and (ii)&nbsp;paying the Exercise Price in full in a manner permitted by <U>Section</U><U></U><U>&nbsp;4(a)</U>; <I>provided</I>, <I>however</I>, that this Option shall not be exercisable for more than the percentage of the aggregate number of
Shares subject to this Option with respect to which this Option has become vested and exercisable pursuant to the vesting schedule set forth in the Grant Notice or as provided in this <U>Section</U><U></U><U>&nbsp;4</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) This Option may be exercised only while the Participant remains an employee or other service provider of the Company or an Affiliate and
will terminate and cease to be exercisable upon the Participant&#146;s Termination of Service, except as otherwise provided pursuant to Section&nbsp;6.8 of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) This Option shall not be exercisable in any event after the Expiration Date set forth in the Grant Notice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) If this Option is exercisable but unexercised as of the day immediately before the Expiration Date (or any earlier expiration date
provided in <U>Section</U><U></U><U>&nbsp;4(b)</U>), this Option will be automatically exercised, in accordance with procedures established for this purpose by the Committee, but only if (i)&nbsp;the Exercise Price is less than the Fair Market Value
of a Share on such date and (ii)&nbsp;the automatic exercise will result in the issuance of at least one (1)&nbsp;Share to the Participant after payment of the Exercise Price and any applicable tax withholding requirements. Payment of the Exercise
Price and any applicable tax withholding requirements with respect to the Option will be made by a &#147;net issuance exercise&#148; pursuant to which the Company reduces the number of Shares otherwise deliverable upon exercise of this Option by a
number of Shares with an aggregate Fair Market Value equal to the aggregate Exercise Price at the time of exercise and any applicable tax withholding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Exercise Price for the Shares as to which this Option is exercised shall be paid in full at the time of exercise&nbsp;in cash
(including check, bank draft or money order payable to the order of the Company or wire transfer of immediately available funds). If permitted by the Committee in its sole discretion, the Exercise Price for the Shares as to which this Option is
exercised may be paid (i)&nbsp;by delivering or constructively tendering to the Company Shares having a Fair Market Value equal to the Exercise Price (provided such Shares used for this purpose must have been held by the Participant for such minimum
period of time as may be established from time to time by the Committee to avoid adverse accounting consequences), (ii) through a broker-assisted &#147;cashless exercise&#148; in accordance with a Company-established policy or program for the same,
(iii)&nbsp;by &#147;net issuance exercise&#148; pursuant to which the Company reduces the number of Shares otherwise deliverable upon exercise of this Option by a number of Shares with an aggregate Fair Market Value equal to the aggregate Exercise
Price at the time of exercise or (iv)&nbsp;any combination of the foregoing. No fraction of a Share shall be issued by the Company upon exercise of an Option or accepted by the Company in payment of the exercise price thereof; rather, the
Participant shall provide a cash payment for such amount as is necessary to effect the issuance and acceptance of only whole Shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The holder of this Option shall not be, and shall not have any of the rights or
privileges of, a stockholder of the Company in respect of any Shares purchasable upon the exercise of any part of this Option unless and until such Shares shall have been issued by the Company to such holder (as evidenced by the appropriate entry on
the books of the Company or of a duly authorized transfer agent of the Company). No adjustment will be made for a dividend or other right for which the record date is prior to the date the Shares are issued, except as provided in
Section&nbsp;4.3(b)(iii) of the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.</B> <B><U>Restrictive Covenants</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Participant acknowledges and agrees that the grant of this Option further aligns the Participant&#146;s interests with the
Company&#146;s long-term business interests, and as a condition to the Company&#146;s willingness to enter into this Agreement, the Participant agrees to abide by the terms set forth in <U>Exhibit B</U>, which <U>Exhibit B</U> is deemed to be part
of this Agreement as if fully set forth herein. The Participant acknowledges and agrees that the Restrictive Covenants are reasonable and enforceable in all respects. By accepting this Award, the Participant agrees to be bound, and promises to
abide, by the terms set forth in <U>Exhibit B</U> and expressly acknowledges and affirms that this Award would not be granted to the Participant if the Participant had not agreed to be bound by such provisions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Notwithstanding any provision in this Agreement or the Plan to the contrary, in the event the Committee determines that the Participant
has failed to abide by any of the terms set forth in <U>Exhibit B</U> or the provisions of any other confidentiality, <FONT STYLE="white-space:nowrap">non-disclosure,</FONT> <FONT STYLE="white-space:nowrap">non-competition,</FONT> <FONT
STYLE="white-space:nowrap">non-solicitation,</FONT> <FONT STYLE="white-space:nowrap">non-disparagement,</FONT> property ownership, third-party information, or other restrictive covenant(s) in any other agreement by and between the Company or any
Affiliate and the Participant, then, in addition to and without limiting the remedies set forth in <U>Exhibit B</U>: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)
Any portion of this Option that remains unexercised as of the date of such determination will terminate automatically without any further action by the Company and will be forfeited without further notice and at no cost to the Company; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) The Participant shall, within 30 days following the Participant&#146;s receipt of a written notice from the Company, pay
to the Company a cash amount equal to the Fair Market Value of any Shares previously received by the Participant pursuant to this Option as of the date of receipt of such Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Permitted Disclosures</U>.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Notwithstanding anything to the contrary contained herein, no provision of this Agreement or any other agreement with or
policy of the Company, its subsidiaries or Affiliates (including for the avoidance of doubt, any employment agreement the Participant may have with the Company, its subsidiaries or Affiliates) will be interpreted so as to impede the Participant (or
any other individual) from (A)&nbsp;making any disclosure of relevant and necessary information </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">
or documents in any action, investigation or proceeding relating to this Agreement, or as required by law or legal process, including with respect to possible violations of law,
(B)&nbsp;participating, cooperating or testifying in any action, investigation or proceeding with, or providing information to, any governmental agency, legislative body or any self-regulatory organization, including, but not limited to, the
Department of Justice, the Securities and Exchange Commission, Congress, any agency Inspector General, the Department of Justice, the Equal Employment Opportunity Commission, or the National Labor Relations Board, (C)&nbsp;accepting any Securities
and Exchange Commission awards or similar recoveries for the provision of information to other governmental agencies, (D)&nbsp;making other disclosures under the whistleblower provisions of federal law or regulation, (E)&nbsp;discussing or
disclosing information about unlawful acts in the workplace, such as harassment or discrimination or any other conduct that the Participant has reason to believe is unlawful, or (F)&nbsp;exercising any rights the Participant may have under
Section&nbsp;7 of the National Labor Relations Act. In addition, nothing in this Agreement or any other agreement or policy of the Company, its subsidiaries or Affiliates prohibits or restricts the Participant from initiating communications with, or
responding to any inquiry from, any administrative, governmental, regulatory or supervisory authority regarding any good faith concerns about possible violations of law or regulation. The Participant does not need the prior authorization of the
Company, its subsidiaries or Affiliates to make any such reports or disclosures to any administrative, governmental, legislative, regulatory or supervisory authority or self-regulatory organization, and the Participant will not be required to notify
the Company, its subsidiaries or Affiliates that such reports or disclosures have been made. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) Pursuant to 18 U.S.C.
&#167; 1833(b), the Participant shall not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret of the Company, its subsidiaries or Affiliates that (A)&nbsp;is made (1)&nbsp;in
confidence to a federal, state, or local government official, either directly or indirectly, or to the Participant&#146;s attorney and (2)&nbsp;solely for the purpose of reporting or investigating a suspected violation of law; or (B)&nbsp;is made in
a complaint or other document that is filed under seal in a lawsuit or other proceeding.&nbsp;If the Participant files a lawsuit for retaliation by the Company, its subsidiaries or Affiliates for reporting a suspected violation of law, the
Participant may disclose the trade secret to the Participant&#146;s attorney and use the trade secret information in the court proceeding, if the Participant files any document containing the trade secret under seal and does not disclose the trade
secret except under court order. Nothing in this Agreement is intended to conflict with 18 U.S.C. &#167; 1833(b) or create liability for disclosures of trade secrets that are expressly allowed by such section. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.</B> <B><U>Tax Withholding</U></B>. To the extent that the receipt, vesting or exercise of this Award results in compensation income or
wages to the Participant for federal, state, local and/or foreign tax purposes, the Participant shall make arrangements satisfactory to the Company regarding the payment of any income tax, social insurance contribution or other applicable taxes that
are required to be withheld in respect of this Award, which arrangements include the delivery of cash or cash </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
equivalents, Shares (including previously owned Shares (which are not subject to any pledge or other security interest), net exercise, a broker-assisted sale, or other cashless withholding or
reduction of the amount of shares otherwise issuable or delivered pursuant to this Award), other property, or any other legal consideration the Committee deems appropriate. If such tax obligations are satisfied through net exercise or the surrender
of previously owned Shares, the maximum number of Shares that may be so withheld (or surrendered) shall be the number of Shares that have an aggregate Fair Market Value on the date of withholding or surrender equal to the aggregate amount of such
tax liabilities determined based on the greatest withholding rates for federal, state, local and/or foreign tax purposes, including payroll taxes, that may be utilized without creating adverse accounting treatment for the Company with respect to
this Award, as determined by the Committee. Any fraction of a Share required to satisfy such tax obligations shall be disregarded and the amount due shall be paid instead in cash to the Participant. The Participant acknowledges that there may be
adverse tax consequences upon the receipt, vesting or exercise of this Award or disposition of the underlying shares and that the Participant has been advised, and hereby is advised, to consult a tax advisor. The Participant represents that the
Participant is in no manner relying on the Board, the Committee, the Company or an Affiliate or any of their respective managers, directors, officers, employees or authorized representatives (including attorneys, accountants, consultants, bankers,
lenders, prospective lenders and financial representatives) for tax advice or an assessment of such tax consequences. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.</B> <B><U><FONT
STYLE="white-space:nowrap">Non-Transferability</FONT></U></B>.&nbsp;During the lifetime of the Participant, this Option may not be sold, pledged, assigned or transferred in any manner other than by will or the laws of descent and distribution,
unless and until the Shares underlying the Option have been issued, and all restrictions applicable to such Shares have lapsed, and this Option shall be exercisable, during the Participant&#146;s lifetime, only by the Participant. Neither the Option
nor any interest or right therein shall be liable for the debts, contracts or engagements of the Participant or his or her successors in interest or shall be subject to disposition by transfer, alienation, anticipation, pledge, encumbrance,
assignment or any other means, whether such disposition be voluntary or involuntary or by operation of law by judgment, levy, attachment, garnishment or any other legal or equitable proceedings (including bankruptcy), and any attempted disposition
thereof shall be null and void and of no effect, except to the extent that such disposition is permitted by the preceding sentence. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.</B> <B><U>Compliance with Applicable Law</U></B>. Notwithstanding any provision of this Agreement to the contrary, the issuance of
Shares hereunder will be subject to compliance with all applicable requirements of applicable law with respect to such securities and with the requirements of any stock exchange or market system upon which the Shares may then be listed. No Shares
will be issued hereunder if such issuance would constitute a violation of any applicable law or regulation or the requirements of any stock exchange or market system upon which the Shares may then be listed. In addition, Shares will not be issued
hereunder unless (a)&nbsp;a registration statement under the Securities Act is in effect at the time of such issuance with respect to the shares to be issued or (b)&nbsp;in the opinion of legal counsel to the Company, the shares to be issued are
permitted to be issued in accordance with the terms of an applicable exemption from the registration requirements of the Securities Act. The inability of the Company to obtain from any regulatory body having jurisdiction the authority, if any,
deemed by the Company&#146;s legal counsel to be necessary for the lawful issuance and sale of any Shares hereunder will relieve the Company of any liability in respect of the failure to issue such shares as to which such requisite authority has not
been obtained. As a condition to any issuance of Shares hereunder, the Company may require the Participant to satisfy any requirements that may be necessary or appropriate to evidence compliance with any applicable law or regulation and to make any
representation or warranty with respect to such compliance as may be requested by the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.</B> <B><U>Rights as a Stockholder</U></B>. The Participant shall have no rights or
privileges of a stockholder of the Company with respect to any Shares purchasable upon the exercise of any part of the Option unless and until the Participant has become the holder of record of such Shares and such Shares have been delivered to the
Participant (including through electronic delivery to a brokerage account). No adjustments shall be made for dividends in cash or other property, distributions or other rights for which the record date is prior to the date of such issuance,
recordation and delivery, except as otherwise specifically provided for in the Plan or this Agreement. Except as otherwise provided herein, after such issuance, recordation and delivery, Participant will have all the rights of a stockholder of the
Company with respect to such Shares, including, without limitation, the right to receipt of dividends and distributions on such Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.</B> <B><U>Execution of Receipts and Releases</U></B>. Any issuance or transfer of Shares or other property to the Participant or the
Participant&#146;s legal representative, heir, legatee or distributee, in accordance with this Agreement shall be in full satisfaction of all claims of such Person hereunder. As a condition precedent to such payment or issuance, the Company may
require the Participant or the Participant&#146;s legal representative, heir, legatee or distributee to execute (and not revoke within any time provided to do so) a release and receipt therefor in such form as it shall determine appropriate;<I>
provided</I>, <I>however</I>, that any review period under such release will not modify the exercise period with respect to vested Option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.</B> <B><U>No Right to Continued Employment, Service or Awards</U></B>. Nothing in the adoption of the Plan, nor the award of this
Option thereunder pursuant to the Grant Notice and this Agreement, shall confer upon the Participant the right to continued employment by, or a continued service relationship with, the Company or any Affiliate, or any other entity, or affect in any
way the right of the Company or any such Affiliate, or any other entity to terminate such employment or other service relationship at any time. Unless otherwise provided in a written employment agreement or by applicable law, the Participant&#146;s
employment by the Company, or any such Affiliate, or any other entity shall be on an <FONT STYLE="white-space:nowrap">at-will</FONT> basis, and the employment relationship may be terminated at any time by either the Participant or the Company, or
any such Affiliate, or other entity for any reason whatsoever, with or without cause or notice. Any question as to whether and when there has been a termination of such employment, and the cause of such termination, shall be determined by the
Committee or its delegate, and such determination shall be final, conclusive and binding for all purposes. The grant of this Option is a <FONT STYLE="white-space:nowrap">one-time</FONT> benefit that was made at the sole discretion of the Company and
does not create any contractual or other right to receive a grant of Awards or benefits in the future in lieu of Awards in the future, including any adjustment to wages, overtime, benefits or other compensation. Any future Awards will be granted at
the sole discretion of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.</B> <B><U>Legal and Equitable Remedies</U></B>. The Participant acknowledges that a violation
or attempted breach of any of the Participant&#146;s covenants and agreements in this Agreement will cause such damage as will be irreparable, the exact amount of which would be difficult to ascertain and for which there will be no adequate remedy
at law, and accordingly, the parties hereto agree that the Company and its Affiliates shall be entitled as a matter of right to an injunction issued by any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
court of competent jurisdiction, restraining the Participant or the affiliates, partners or agents of the Participant from such breach or attempted violation of such covenants and agreements, as
well as to recover from the Participant any and all costs and expenses sustained or incurred by the Company or any Affiliate in obtaining such an injunction, including reasonable attorneys&#146; fees. The parties to this Agreement agree that no bond
or other security shall be required in connection with such injunction. Any exercise by either of the parties to this Agreement of its rights pursuant to this <U>Section</U><U></U><U>&nbsp;12</U> shall be cumulative and in addition to any other
remedies to which such party may be entitled. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.</B> <B><U>Notices</U></B>. All notices and other communications under this Agreement
shall be in writing and shall be delivered to the parties at the following addresses (or at such other address for a party as shall be specified by like notice): </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) If to the Company, unless otherwise designated by the Company in a written notice to the Participant (or other holder): </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Kestra Medical Technologies, Ltd. </P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">Attn:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Vaseem Mahboob </P></TD></TR></TABLE> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#8195;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Chief Financial Officer </P></TD></TR></TABLE>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#8195;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">3933 Lake Washington Blvd NE, Suite 200 </P></TD></TR></TABLE>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#8195;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Kirkland, Washington 98033 </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If to the Participant, at the Participant&#146;s last known address on file with the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any notice that is delivered personally or by overnight courier or telecopier in the manner provided herein shall be deemed to have been duly given to the
Participant when it is mailed by the Company or, if such notice is not mailed to the Participant, upon receipt by the Participant. Any notice that is addressed and mailed in the manner herein provided shall be conclusively presumed to have been
given to the party to whom it is addressed at the close of business, local time of the recipient, on the fourth day after the day it is so placed in the mail. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14.</B> <B><U>Consent to Electronic Delivery; Electronic Signature</U></B>. In lieu of receiving documents in paper format, the Participant
agrees, to the fullest extent permitted by law, to accept electronic delivery of any documents that the Company may be required to deliver (including, but not<B> </B>limited to, prospectuses, prospectus supplements, grant or award notifications and
agreements, account statements, annual and quarterly reports and all other forms of communications) in connection with this and any other Award made or offered by the Company. Electronic delivery may be via a Company electronic mail system or by
reference to a location on a Company intranet to which the Participant has access. The Participant hereby consents to any and all procedures the Company has established or may establish for an electronic signature system for delivery and acceptance
of any such documents that the Company may be required to deliver, and agrees that his or her electronic signature is the same as, and shall have the same force and effect as, his or her manual signature. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>15.</B> <B><U>Agreement to Furnish Information</U></B>. The Participant agrees to furnish to the Company all information requested by the
Company to enable it to comply with any reporting or other requirement imposed upon the Company by or under any applicable statute or regulation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>16.</B> <B><U>Entire Agreement; Amendment</U></B>. This Agreement constitutes the entire
agreement of the parties with regard to the subject matter hereof, and contains all the covenants, promises, representations, warranties and agreements between the parties with respect to this Option; <I>provided</I>&cedil; <I>however</I>, that
(a)&nbsp;the terms of this Agreement shall not modify and shall be subject to the terms and conditions of any employment, consulting and/or severance agreement between the Company (or an Affiliate or other entity) and the Participant in effect as of
the date a determination is to be made under this Agreement; and (b)&nbsp;the terms of Exhibit B are in addition to and complement (and do not replace or supersede) all other agreements and obligations between the Company or any Affiliate and the
Participant with respect to confidentiality, <FONT STYLE="white-space:nowrap">non-disclosure,</FONT> <FONT STYLE="white-space:nowrap">non-competition,</FONT> <FONT STYLE="white-space:nowrap">non-solicitation,</FONT>
<FONT STYLE="white-space:nowrap">non-disparagement</FONT> and other restrictive covenants. Without limiting the scope of the preceding sentence, except as provided therein, all prior understandings and agreements, if any, among the parties hereto
relating to the subject matter hereof are hereby null and void and of no further force and effect. The Committee may, in its sole discretion, amend this Agreement from time to time in any manner that is not inconsistent with the Plan;
<I>provided</I>, <I>however</I>, that except as otherwise provided in the Plan or this Agreement, any such amendment that materially reduces the rights of Participant shall be effective only if it is in writing and signed by both Participant and an
authorized officer of the Company.&nbsp;Notwithstanding the foregoing, prior to an initial public offering, the Company may take any of the following actions (including with respect to the Shares issued under this Agreement) without the consent or
authorization of the Participant or any other Person: (a)&nbsp;subdivide (by any split, recapitalization or otherwise) its outstanding Shares into a greater number of Shares, (b)&nbsp;combine (by reverse split, combination, or otherwise) its
outstanding Shares into a lesser number of Shares, (c)&nbsp;make adjustments as determined by the Committee to prevent dilution or enlargement of the rights granted to, or available for, Participant under the Plan or this Agreement, and
(d)&nbsp;provide for separate classes or series of common stock such as Class&nbsp;A Common Stock and Class&nbsp;B Common Stock (including, without limitation, to provide for specific voting powers, full or limited, or no voting powers, and such
designations, preferences and other applicable rights and qualifications, limitations or restrictions as provided therein). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>17.</B>
<B><U>Severability and Waiver</U></B>. If a court of competent jurisdiction determines that any provision of this Agreement is invalid or unenforceable, then the invalidity or unenforceability of such provision shall not affect the validity or
enforceability of any other provision of this Agreement, and all other provisions shall remain in full force and effect. Waiver by any party of any breach of this Agreement or failure to exercise any right hereunder shall not be deemed to be a
waiver of any other breach or right. The failure of any party to take action by reason of such breach or to exercise any such right shall not deprive the party of the right to take action at any time while or after such breach or condition giving
rise to such rights continues. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>18.</B> <B><U>Company Recoupment of Awards</U></B>. The Participant&#146;s rights with respect to this
Award shall in all events be subject to (a)&nbsp;any right that the Company may have under the Kestra Medical Technologies, Ltd. Clawback Policy, as well as any other Company recoupment policy or other agreement or arrangement with the Participant,
and (b)&nbsp;any right or obligation that the Company may have regarding the clawback of &#147;incentive-based compensation&#148; under Section&nbsp;10D of the Exchange Act and any applicable rules and regulations promulgated thereunder from time to
time by the U.S. Securities and Exchange Commission or any other Applicable Law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>19.</B> <B><U>Governing Law</U></B>. THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN
ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK APPLICABLE TO CONTRACTS MADE AND TO BE PERFORMED THEREIN, EXCLUSIVE OF THE CONFLICT OF LAWS PROVISIONS OF NEW YORK LAW. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>20.</B> <B><U>Conformity to Securities Laws</U></B><B><U>.</U></B><B> </B>Participant acknowledges that this Agreement is intended to
conform to the extent necessary with all Applicable Laws, including, without limitation, the provisions of the Securities Act and the Exchange Act, and any and all regulations and rules promulgated thereunder by the Securities and Exchange
Commission and state securities laws and regulations. Notwithstanding anything herein to the contrary, this Option shall be administered, granted and exercised only in such a manner as to conform to Applicable Law. To the extent permitted by
Applicable Law and the Plan, this Agreement shall be deemed amended to the extent necessary to conform to Applicable Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>21.</B>
<B><U>Successors and Assigns</U></B>. The Company may assign any of its rights under this Agreement without the Participant&#146;s consent. This Agreement will be binding upon and inure to the benefit of the successors and assigns of the Company.
Subject to the restrictions on transfer set forth herein and in the Plan, this Agreement will be binding upon the Participant and the Participant&#146;s beneficiaries, executors, administrators and the Person(s) to whom this Option may be
transferred by will or the laws of descent or distribution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>22.</B> <B><U>Headings</U></B><B><U>;</U></B><B><U> References;
Interpretation</U></B>. Headings are for convenience only and are not deemed to be part of this Agreement. The words &#147;hereof,&#148; &#147;herein&#148; and &#147;hereunder&#148; and words of similar import, when used in this Agreement, shall
refer to this Agreement as a whole, including <U>Exhibit B</U> attached hereto, and not to any particular provision of this Agreement. All references herein to Sections and <U>Exhibit B</U> shall, unless the context requires a different
construction, be deemed to be references to the Sections and <U>Exhibit B</U> of this Agreement. The word &#147;or&#148; as used herein is not exclusive and is deemed to have the meaning &#147;and/or.&#148; All references to &#147;including&#148;
shall be construed as meaning &#147;including without limitation.&#148; Unless the context requires otherwise, all references herein to a law, agreement, instrument or other document shall be deemed to refer to such law, agreement, instrument or
other document as amended, supplemented, modified and restated from time to time to the extent permitted by the provisions thereof. All references to &#147;dollars&#148; or &#147;$&#148; in this Agreement refer to United States dollars. Whenever the
context may require, any pronouns used herein shall include the corresponding masculine, feminine or neuter forms, and the singular form of nouns and pronouns shall include the plural and vice versa. Neither this Agreement nor any uncertainty or
ambiguity herein shall be construed or resolved against any party hereto, whether under any rule of construction or otherwise. On the contrary, this Agreement has been reviewed by each of the parties hereto and shall be construed and interpreted
according to the ordinary meaning of the words used so as to fairly accomplish the purposes and intentions of the parties hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>23.</B> <B><U>Counterparts</U></B>. The Grant Notice may be executed in one or more counterparts, each of which shall be deemed an original
and all of which together shall constitute one instrument. Delivery of an executed counterpart of the Grant Notice by facsimile or portable document format (.pdf) attachment to electronic mail shall be effective as delivery of a manually executed
counterpart of the Grant Notice. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>24.</B> <B><U>Section 409A</U></B>. This Option is not intended to constitute
&#147;nonqualified deferred compensation&#148; within the meaning of Section&nbsp;409A. However, notwithstanding any other provision of the Plan, the Grant Notice or this Agreement, if at any time the Committee determines that this Option (or any
portion thereof) may be subject to Section&nbsp;409A, the Committee shall have the right in its sole discretion (without any obligation to do so or to indemnify Participant or any other Person for failure to do so) to adopt such amendments to the
Plan, the Grant Notice or this Agreement, or adopt other policies and procedures (including amendments, policies and procedures with retroactive effect), or take any other actions, as the Committee determines are necessary or appropriate for this
Option either to be exempt from the application of Section&nbsp;409A or to comply with the requirements of Section&nbsp;409A. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>25.</B>
<B><U>Incentive Stock Options</U></B>. The Participant acknowledges that to the extent the aggregate Fair Market Value of Shares (determined as of the time the option with respect to the Shares is granted) with respect to which Incentive Stock
Options, including this Option (if applicable), are exercisable for the first time by the Participant during any calendar year exceeds $100,000 or if for any other reason such Incentive Stock Options do not qualify or cease to qualify for treatment
as &#147;incentive stock options&#148; under Section&nbsp;422 of the Code, such Incentive Stock Options shall be treated as <FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Stock Options. The Participant further acknowledges that the rule set
forth in the preceding sentence shall be applied by taking the Option and other stock options into account in the order in which they were granted, as determined under Section&nbsp;422(d) of the Code and the Treasury Regulations thereunder. The
Participant also acknowledges that an Incentive Stock Option exercised more than three (3)&nbsp;months after the Participant&#146;s Termination of Service, other than by reason of death or Disability, will be taxed as a <FONT
STYLE="white-space:nowrap">Non-Qualified</FONT> Stock Option. If this Option is designated as an Incentive Stock Option, the Participant shall give prompt written notice to the Company of any disposition or other transfer of any Shares acquired
under this Agreement if such disposition or transfer is made (a)&nbsp;within two (2)&nbsp;years from the Date of Grant or (b)&nbsp;within one (1)&nbsp;year after the transfer of such Shares to the Participant. Such notice shall specify the date of
such disposition or other transfer and the amount realized, in cash, other property, assumption of indebtedness or other consideration, by the Participant in such disposition or other transfer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT B </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RESTRICTIVE COVENANTS </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Exhibit B </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RESTRICTIVE COVENANT AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Kestra Medical Technologies, Ltd. (the &#147;<U>Company</U>&#148;) and the undersigned participant (the &#147;<U>Participant</U>&#148;)
recognize it is important that the Company protect its rights with respect to its confidential business and product information, inventions, and customer relationships without unduly impairing the Participant&#146;s ability to pursue their
profession. The Company and the Participant also recognize that the Company provides valuable training to the Participant, entrusts the Participant with confidential information, business and customer relationships and goodwill, and compensates the
Participant to support, develop, administer, maintain, promote, market and sell Company products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accordingly, the Participant enters
into this agreement (the &#147;<U>Agreement</U>&#148;) in consideration for the receipt of incentive equity in the Company (in the form of stock options), which the Participant acknowledges was received and was sufficient consideration for the
promises in this Agreement. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Definitions</U></B><B><U>.</U></B>. The terms defined in this <U>Section</U><U></U><U>&nbsp;1</U> shall
have the following meanings as set forth in this Agreement: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>Competitive Product</U>&#148; means goods, products, product lines or services, and each and every
component thereof, developed, designed, produced, manufactured, marketed, promoted, sold, supported, serviced, or that are in development or the subject of research by anyone other than the Company that are the same or similar, perform any of the
same or similar functions, may be substituted for, or are intended or used for any of the same purposes as a Kestra Medical Technologies, Ltd. Product. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>Competitive Research and Support</U>&#148; means any research, development, analysis, planning or
support services of any kind or nature, including without limitation theoretical and applied research, or business, technical, regulatory or systems research, analysis, planning or support, for a Conflicting Organization that is intended for, or may
be useful in, assisting, improving or enhancing any aspect of the development, design, production, manufacture, marketing, promotion, sale, support or service of a Competitive Product. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>Confidential Information</U>&#148; means any information relating to Kestra Medical Technologies,
Ltd.&#146;s or any affiliate&#146;s business, including a formula, pattern, compilation, program, device, method, technique, system, plan, or process, that the Participant learns or develops during the course of the Participant&#146;s employment by
or provision of services to Kestra Medical Technologies, Ltd. that derives independent economic value from not being generally known, or readily ascertainable by proper means, by other persons who can obtain economic value from its disclosure or
use. Confidential Information includes but is not limited to trade secrets and Inventions and, without limitation, may relate to research; development; experiments; clinical investigations; clinical trials; clinical and product development results
and data; engineering; product specifications; computer programs; computer software; hardware configurations; manufacturing </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
processes; compositions; algorithms; <FONT STYLE="white-space:nowrap">know-how;</FONT> methods; machines; management systems and techniques; strategic plans; long-range plans; operating plans;
organizational plans; financial plans; financial models; financial projections; nonpublic financial information; business, financial, planning, and strategic systems and methods; operating systems; information systems; acquisition and divestiture
goals, plans, strategies or targets; regulatory strategies, plans and approaches; quality control systems and techniques; patent and intellectual property strategies, plans and approaches; vendor and customer data; sales volumes; pricing strategies;
sales and marketing plans and strategies; contracts and bids; and any business management techniques that are being planned or developed, utilized or executed by Kestra Medical Technologies, Ltd. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>Conflicting Organization</U>&#148; means any person (including the Participant) or entity, and any
parent, subsidiary, partner or affiliate (regardless of their legal form) of any person or entity, that engages in, or is preparing to become engaged in, the development, design, production, manufacture, promotion, marketing, sale, support or
service of a Competitive Product or in Competitive Research and Support. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>Invention</U>&#148; means any and all inventions, discoveries, ideas, processes, writings, works of
authorship, designs, developments and improvements, whether or not protectable under the applicable patent, trademark or copyright statutes, generated, conceived or reduced to practice by the Participant, during or not during work hours, alone or in
conjunction with others, while employed by or providing services to the Company related to the business of Kestra Medical Technologies, Ltd. or to any reasonable expansion of such business, or resulting from the Participant&#146;s work or services
for Kestra Medical Technologies, Ltd. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>Kestra Medical Technologies, Ltd.</U>&#148; means Kestra Medical Technologies, Ltd., a Bermuda
corporation, and all of its subsidiaries, and their successors and assigns, that exist or may exist during all or any portion of the time this Agreement is in effect. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>Kestra Medical Technologies, Ltd. Customer</U>&#148; means any customer, client or other business
relation who or which the Participant was introduced to, had business contact with or learned Confidential Information regarding during Participant&#146;s employment with Kestra Medical Technologies, Ltd. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>Kestra Medical Technologies, Ltd. Product</U>&#148; means any goods, products, or product lines
(a)&nbsp;that the services the Participant (or persons under the Participant&#146;s management, direction or supervision) performed for Kestra Medical Technologies, Ltd. related to, directly or indirectly, during the last one (1)&nbsp;year in which
the Participant was employed by Kestra Medical Technologies, Ltd., including without limitation services in the areas of research, design, development, production, manufacture, marketing, promotion, sales, or business, technical, regulatory or
systems research, analysis, planning or support relating to such goods, products, or product lines, or (b)&nbsp;with respect to which the Participant at any time received or otherwise obtained or learned Confidential Information.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>Restricted Territory</U>&#148; means each country, province, state, city, or other political
subdivision in the United States in which Kestra Medical Technologies, Ltd. (i)&nbsp;is engaged in business, or (ii)&nbsp;otherwise distributes, licenses or sells Kestra Medical Technologies, Ltd. Products, in each case while the Participant is
employed or engaged by Kestra Medical Technologies, Ltd. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>No Right to Employment</U></B><B><U> or Engagement</U></B>. This Agreement will not be construed to
create any association, partnership, joint venture, employee, or agency relationship between the Participant and the Company for any purpose. The parties agree that either party may terminate the Participant&#146;s employment or engagement at any
time for any or no reason, with or without notice. This Agreement is ancillary to <FONT STYLE="white-space:nowrap">at-will</FONT> employment and does not purport to include all of the terms of, or supersede, that relationship. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Training, Confidential Information and Goodwill</U></B>. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Goodwill</U>. The Participant acknowledges that Kestra Medical Technologies, Ltd. owns the goodwill in the
Participant&#146;s relationships with Kestra Medical Technologies, Ltd. Customers that the Participant maintains or develops in the course and scope of the Participant&#146;s employment by or engagement with Kestra Medical Technologies, Ltd. If the
Participant owned goodwill in customer relationships when the Participant commenced employment or engagement with Kestra Medical Technologies, Ltd., the Participant assigns any and all such goodwill to Kestra Medical Technologies, Ltd., and Kestra
Medical Technologies, Ltd. shall become the owner of such goodwill. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>The Participant</U><U>&#146;</U><U>s Use of Training, Business and Customer Relationships, Goodwill and
Confidential Information</U>. Kestra Medical Technologies, Ltd. agrees to provide the Participant with valuable training and to entrust the Participant with such of Kestra Medical Technologies, Ltd.&#146;s valuable business and customer
relationships, goodwill and Confidential Information as is necessary for the Participant to discharge the Participant&#146;s duties. The Participant agrees to use such valuable training and to continue to develop such relationships, goodwill and
Confidential Information solely and exclusively for Kestra Medical Technologies, Ltd.&#146;s benefit. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Fiduciary Duties</U>. The Participant agrees that the Participant shall treat all Confidential Information,
training, business and customer relationships, and goodwill entrusted to the Participant by Kestra Medical Technologies, Ltd. as a fiduciary, and the Participant accepts and undertakes all of the obligations of a fiduciary, including good faith,
trust, confidence and candor, and the Participant agrees to use such training and to maintain, protect and develop Confidential Information, business and customer relationships, and goodwill solely and exclusively for the benefit of Kestra Medical
Technologies, Ltd. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Kestra Medical Technologies, Ltd. Property</U>. All documents, information and property provided to the
Participant by Kestra Medical Technologies, Ltd. for use in connection with the Participant&#146;s employment, or created by the Participant in the course and scope of the Participant&#146;s employment by Kestra Medical Technologies, Ltd., are the
property of Kestra Medical Technologies, Ltd. and shall be held by the Participant as a fiduciary on behalf of Kestra Medical Technologies, Ltd. Upon termination of the Participant&#146;s employment to or engagement with the Company, the Participant
shall return promptly to Kestra Medical Technologies, Ltd., without the requirement of a prior demand by Kestra Medical Technologies, Ltd., all such documents, information and property, together with all copies, recordings, abstracts, notes,
reproductions or electronic versions of any kind made from or about the documents and things or the information they contain. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Nondisclosure</U>. Subject to <U>Sections 7.9</U> and <U>7.10</U>, the Participant agrees not to use or
disclose any Confidential Information to or for the benefit of anyone other than Kestra Medical Technologies, Ltd., either during or after employment, for as long as the information retains the characteristics described in
<U>Section</U><U></U><U>&nbsp;1.3</U>. This provision is intended to govern any disclosure outside of Kestra Medical Technologies, Ltd. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Restrictions</U></B><B>.</B> </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Restrictions on Competition</U>. The Participant agrees that while employed by Kestra Medical Technologies,
Ltd., and for [eighteen (18)&nbsp;months][twelve (12)&nbsp;months] after the last day the Participant is employed or engaged by Kestra Medical Technologies, Ltd. (the &#147;<U>Noncompete Period</U>&#148;), the Participant will not, within the
Restricted Territory, be employed or engaged by or otherwise perform services for, lend the Participant&#146;s name or assistance to, invest in, manage, or control, a Conflicting Organization in connection with or relating to a Competitive Product
or Competitive Research and Support. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Prohibition on Solicitation of Kestra Medical Technologies, Ltd. Participants</U>. The Participant agrees
that at all times while employed by Kestra Medical Technologies, Ltd., and for one (1)&nbsp;year thereafter (the &#147;<U>Nonsolicitation Period</U>&#148;), the Participant will not solicit, cause to be solicited, or participate in or promote the
solicitation of any person to terminate that person&#146;s employment or engagement with Kestra Medical Technologies, Ltd. or to breach any agreement that person has with Kestra Medical Technologies, Ltd. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Post-Employment Disclosure</U>. In the event the Participant&#146;s employment or engagement with Kestra
Medical Technologies, Ltd. terminates, the Participant agrees that during the term of the restrictions described in <U>Section</U><U></U><U>&nbsp;4.1</U>, the Participant will promptly inform Kestra Medical Technologies, Ltd. of the identity of any
new employer, the job title of the Participant&#146;s new position, and a description of any services to be rendered to that employer. In addition, the Participant agrees to respond within ten (10)&nbsp;days to any written request from Kestra
Medical Technologies, Ltd. for further information concerning the Participant&#146;s work activities sufficient to provide Kestra Medical Technologies, Ltd. with assurances that the Participant is not violating any of the obligations the Participant
has undertaken in this Agreement. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Prohibition on Solicitation of Kestra Medical Technologies, Ltd. Customers</U>. The Participant agrees that
during the Nonsolicitation Period, the Participant will not solicit, induce, or endeavor to entice away from Kestra Medical Technologies, Ltd., or otherwise enter into business dealings with any Kestra Medical Technologies, Ltd. Customer.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U><FONT STYLE="white-space:nowrap">Non-Disparagement</FONT></U>. Subject to
<U>Section</U><U></U><U>&nbsp;7.10</U>, Participant shall not, directly or indirectly, make, publish or communicate (or cause to be made, published or communicated) to any person or entity any statement, comment or remark, whether written or oral,
which in any way disparages or defames or could reasonably be expected to impugn the personal or professional character, reputation or integrity of Kestra Medical Technologies, Ltd., its representatives (including, but not limited to, employees,
directors, officers and agents), and its customers, clients, suppliers, investors and other associated third parties, or their businesses, business practices, prospects, products or services. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Inventions</U></B><B>. </B> </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Disclosure</U>. The Participant agrees to promptly disclose to Kestra Medical Technologies, Ltd. in writing
all Inventions. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Ownership, Assignment and Recordkeeping</U>. All Inventions shall be the exclusive property of the Company.
The Participant hereby assigns all Inventions to the Company. The Participant agrees to keep accurate, complete and timely records of the Participant&#146;s Inventions, which records shall be the property of the Company. and shall be retained on its
premises. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Cooperation</U>. During and after the termination of the Participant&#146;s employment or engagement, the
Participant agrees to give Kestra Medical Technologies, Ltd. all cooperation and assistance necessary to perfect, protect, and use its rights to Inventions. Without limiting the generality of the foregoing, the Participant agrees to sign all
documents, take all actions, and supply all information that Kestra Medical Technologies, Ltd. may deem necessary to (a)&nbsp;transfer or record the transfer of the Participant&#146;s entire right, title and interest in Inventions, and
(b)&nbsp;enable Kestra Medical Technologies, Ltd. to obtain patent, copyright or trademark protection for Inventions anywhere in the world. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Attorney-in-Fact</FONT></FONT></U>. The
Participant irrevocably designates and appoints Kestra Medical Technologies, Ltd. and its duly authorized officers and agents as <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> to act for and on the
Participant&#146;s behalf and stead to execute and file any lawful and necessary documents, and to do all other lawfully permitted acts, required for the assignment of, application for, or prosecution of any United States or foreign application for
letters patent, copyright or trademark with the same legal force and effect as if executed by the Participant. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Waiver</U>. The Participant hereby waives and quitclaims to Kestra Medical Technologies, Ltd. any and all
claims, of any nature whatsoever, which the Participant may now have or may hereafter have for infringement of any patent, copyright, or trademark resulting from any Invention. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Future Patents</U>. Any Invention relating to the business of Kestra Medical Technologies, Ltd. with respect
to which the Participant files a patent application within one (1)&nbsp;year following termination of the Participant&#146;s employment shall be presumed to cover Inventions conceived by the Participant during the term of the Participant&#146;s
employment or engagement, subject to proof to the contrary by the Participant by good faith, contemporaneous, written and duly corroborated records establishing that such Invention was conceived and made following termination of employment or
engagement and without using Confidential Information. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Release or License</U>. If an Invention does not relate to the existing or reasonably foreseeable business
interests of Kestra Medical Technologies, Ltd., Kestra Medical Technologies, Ltd. may, in its sole and unreviewable discretion, release or license the Invention to the Participant upon written request by the Participant. No release or license shall
be valid unless in writing signed by Kestra Medical Technologies, Ltd.&#146;s General Counsel. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Notice</U>. This Agreement does not apply to any Invention for which no equipment, supplies, facility or
trade secret information of Kestra Medical Technologies, Ltd. was used and which was developed entirely on the Participant&#146;s own time, and (1)&nbsp;which does not relate (a)&nbsp;directly to the business of Kestra Medical Technologies, Ltd. or
(b)&nbsp;to Kestra Medical Technologies, Ltd.&#146;s actual or demonstrably anticipated research or development, or (2)&nbsp;which does not result from any work performed by the Participant for Kestra Medical Technologies, Ltd.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>List of Excluded Inventions</U>. Attached hereto as <U>Schedule 1</U> is a complete list and description of
all inventions, patent applications, and patents for inventions conceived prior to becoming a Participant and which Kestra Medical Technologies, Ltd. and the Participant agree are removed from the operation of this Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Governing Law, Venue and Jurisdiction</U></B><B><U>.</U></B> </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Place of Agreement</U>. Because Kestra Medical Technologies, Ltd. is a Bermuda corporation, and because it
is mutually agreed that it is in the best interests of Kestra Medical Technologies, Ltd. and all of its Participants that a uniform body of law consistently interpreted be applied to the agreements between Kestra Medical Technologies, Ltd. and all
of its Participants, this Agreement is deemed entered into in the State of New York between Kestra Medical Technologies, Ltd. and the Participant, and the substantive laws of New York and the exclusive jurisdiction of the courts of New York shall be
applicable hereto on the terms and conditions specified below. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Governing Law</U>. The validity, enforceability, construction and interpretation of this Agreement shall be
governed by the laws of the State of New York. The Participant irrevocably waives the Participant&#146;s right, if any, to have the laws of any state other than the State of New York apply to this Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Venue and Personal Jurisdiction</U>. Any dispute arising out of or related to this Agreement, or any breach
or alleged breach hereof, shall be exclusively decided by a state court in the State of New York. The Participant irrevocably waives the Participant&#146;s right, if any, to have any disputes between the Participant and Kestra Medical Technologies,
Ltd. arising out of or related to this Agreement decided in any jurisdiction or venue other than a state court in the State of New York. The Participant hereby irrevocably consents to the personal jurisdiction of the state courts in the State of New
York for the purposes of any action arising out of or related to this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Covenant Not to Sue</U>. The Participant irrevocably covenants not to sue Kestra Medical Technologies, Ltd.
in any jurisdiction other than a state court in the State of New York for the purposes of any action arising out of or related to this Agreement. The Participant further agrees not to assist, aid, abet, encourage, be a party to, or participate in
the commencement or prosecution of any lawsuit or action by any <FONT STYLE="white-space:nowrap">non-governmental</FONT> third party arising out of or related to this Agreement in any jurisdiction or venue other than a state court in the State of
New York; <I>provided</I>, <I>however</I>, that nothing herein shall prohibit or restrict the Participant from being a witness or otherwise providing evidence in any action pursuant to court order or subpoena. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Other Provisions</U></B><B><U>.</U></B> </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Obligations Unconditional</U>. The obligation of the parties to perform the terms of this Agreement is
unconditional and does not depend on the performance or nonperformance of any terms, duties, or obligations not specifically recited in this Agreement. The Participant irrevocably waives the Participant&#146;s right to challenge the enforceability
or validity of any portion of this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Waiver</U>. No waiver by Kestra Medical Technologies, Ltd. of any breach of this Agreement by the
Participant shall be valid unless contained in a writing signed by the General Counsel of Kestra Medical Technologies, Ltd. or the General Counsel&#146;s designee. Waiver of any breach of this Agreement shall not constitute, or be deemed, a waiver
of any other breach of this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Provisions Survive Termination</U>. To the extent that any provisions of this Agreement apply to the time
period after, or require performance or enforcement after, termination of the Participant&#146;s employment, all such provisions survive the termination of the Participant&#146;s employment and termination of this Agreement and may be enforced
subsequent thereto. Without limiting the generality of the foregoing, Sections <U>1, 3, 4, 5, 6,</U> and <U>7.3</U> each survive termination of the Participant&#146;s employment or engagement and termination of this Agreement. </P></TD></TR></TABLE>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Prior Agreements</U>. Except to the extent provided in <U>Section</U><U></U><U>&nbsp;7.5</U><U>,</U> all
prior agreements, if any, between Kestra Medical Technologies, Ltd. and the Participant relating to any part of the subject matter of this Agreement are superseded and rendered null and void upon execution of this Agreement by the Participant;
<I>provided</I>, <I>however</I>, that nothing in this Agreement invalidates, renders null or void, or otherwise affects any term or provision of any Kestra Medical Technologies, Ltd. compensation or benefit plan or any agreements related thereto, or
any written term employment agreement, or any other restrictive covenant. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Application to the Participants Who Are Attorneys</U>. This agreement will not be interpreted or enforced so
as to conflict with any applicable attorney Rules of Professional Conduct relating to the right of a lawyer to practice law (as applicable). </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Validity Not Impaired</U>. In the event that any provision of this Agreement is unenforceable under
applicable law, the validity or enforceability of the remaining provisions shall not be affected. To the extent any provision of this Agreement is judicially determined to be unenforceable, any provisions of any prior agreement between the
Participant and Kestra Medical Technologies, Ltd. addressing the subject matter of the unenforceable provision shall be deemed to govern the relationship between the Participant and Kestra Medical Technologies, Ltd. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Transfer or Assignment</U>. Kestra Medical Technologies, Ltd. may freely transfer or assign its rights and
obligations pursuant to this Agreement to its affiliates, successors or assigns. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Tolling</U>. In the event the Participant breaches or violates <U>Sections 4.1</U>, <U>4.2</U> or <U>4.3</U>
hereinabove, the duration of the restrictions contained therein shall be extended by the number of days the Participant remains in breach or violation thereof to the fullest extent permitted by law. This provision may be specifically enforced.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>DTSA Confidentiality Disclaimer</U>. Notwithstanding any provisions in this agreement or company policy
applicable to the unauthorized use or disclosure of trade secrets, you are hereby notified that, pursuant to Section&nbsp;7 of the DTSA (Defend Trade Secrets Act of 2016), you cannot be held criminally or civilly liable under any Federal or State
trade secret law for the disclosure of a trade secret that is made (i)&nbsp;in confidence to a Federal, State, or local government official, either directly or indirectly, or to an attorney; and (ii)&nbsp;solely for the purpose of reporting or
investigating a suspected violation of law. You also may not be held so liable for such disclosures made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. In addition, individuals who file a
lawsuit for retaliation by an employer for reporting a suspected violation of law may disclose the trade secret to the attorney of the individual and use the trade secret information in the court proceeding, if the individual files any document
containing the trade secret under seal and does not disclose the trade secret, except pursuant to court order. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Whistleblower Protection</U>. Nothing in this Agreement or any other agreement with or policy of Kestra
Medical Technologies, Ltd. shall prohibit the Participant, or the Participant&#146;s attorneys from: (a)&nbsp;making any disclosure of relevant and necessary information or documents in any action, investigation, or proceeding relating to this
Agreement, or as required by law or legal process, including with respect to possible violations of law; (b)&nbsp;participating, cooperating, or testifying in any action, investigation, or proceeding with, or providing information to, any
governmental agency or legislative body, any self-regulatory organization, and/or pursuant to the Sarbanes-Oxley Act or the Dodd-Frank Act, to the extent that such rights cannot be waived by agreement; or (c)&nbsp;accepting any U.S. Securities and
Exchange Commission awards or other relief in connection with protected whistleblower activity. In addition, nothing in this Agreement prohibits or restricts the Participant from initiating communications with, or responding to any inquiry from, any
regulatory or supervisory authority regarding any good faith concerns about possible violations of law or regulation or making other disclosures that are protected under the whistleblower provisions of any applicable law, rule, or regulation.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>State Law Considerations</U></B>. Notwithstanding the foregoing provisions of this Agreement, the
provisions set forth in <U>Schedule II</U> hereto shall apply to employees primarily working in the states set forth in <U>Schedule II</U> hereto. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Agreement becomes binding and effective on Kestra Medical Technologies, Ltd. and the
Participant upon signature by the Participant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Participant Name (please print) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U> </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Participant Signature </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>SCHEDULE I </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>List of Inventions </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following is a list of
inventions, patent applications, or patents for inventions I conceived prior to becoming a Participant or that do not relate to the business of Kestra Medical Technologies, Ltd. or to any reasonable expansion of such business, or result from my work
for Kestra Medical Technologies, Ltd. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="88%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Add and sign additional sheets, if necessary</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Participant Name (please print)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Participant Signature</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>SCHEDULE II </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain foregoing provisions in this Agreement are hereby modified in certain states as described in following sections. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Alabama </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Section&nbsp;4.2
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of <U>Section</U><U></U><U>&nbsp;4.2</U>, the restriction shall be limited to the solicitation, inducement or hire of any person in
a position uniquely essential to the management, organization or service of the business of Kestra Medical Technologies, Ltd. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Arizona </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Section&nbsp;3.5
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The nondisclosure restriction set forth in <U>Section</U><U></U><U>&nbsp;3.5</U> shall be limited to the period of the Participant&#146;s
employment and/or service with Kestra Medical Technologies, Ltd., and for five (5)&nbsp;years thereafter, or if longer, for such duration that the information qualifies as a trade secret under applicable law. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Arkansas </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Section&nbsp;3.5
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The nondisclosure restriction set forth in <U>Section</U><U></U><U>&nbsp;3.5</U> shall be limited to the period of the Participant&#146;s
employment and/or service with Kestra Medical Technologies, Ltd., and for five (5)&nbsp;years thereafter, or if longer, for such duration that the information qualifies as a trade secret under applicable law. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>California </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Section&nbsp;4.1
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The &#147;<U>Noncompete Period</U>&#148; shall be limited to the Participant&#146;s employment or engagement with Kestra Medical Technologies,
Ltd. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Section&nbsp;4.2 </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
&#147;<U>Nonsolicitation Period</U>&#148; shall be limited to the Participant&#146;s employment or engagement with Kestra Medical Technologies, Ltd. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Section&nbsp;4.4 </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The &#147;<U>Nonsolicitation
Period</U>&#148; shall be limited to the Participant&#146;s employment or engagement with Kestra Medical Technologies, Ltd. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Section&nbsp;7.8
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Section</U><U></U><U>&nbsp;7.8</U> shall be deemed deleted. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Section&nbsp;7.10 </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following language shall be included at the end of <U>Section</U><U></U><U>&nbsp;7.10</U>: &#147;Nothing in this <U>Section</U><U></U><U>&nbsp;7.10</U> or
otherwise in this Agreement prohibits or restricts the Participant from discussing or disclosing information about unlawful acts in the workplace, such as harassment or discrimination or any other conduct that the Participant has reason to believe
is unlawful.&#148; </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Colorado </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Section&nbsp;4.1 </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following language shall be
included at the end of <U>Section</U><U></U><U>&nbsp;4.1</U>: &#147;Notwithstanding the foregoing, nothing in <U>Section</U><U></U><U>&nbsp;4.1</U> shall prohibit the Participant from being employed or engaged by any person in a <FONT
STYLE="white-space:nowrap">non-executive</FONT> role that does not have responsibility for, or require performance of, any of the same or similar functions, duties or activities that the Participant performed or had oversight for on behalf of Kestra
Medical Technologies, Ltd.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The post-employment <FONT STYLE="white-space:nowrap">non-competition</FONT> restrictions set forth in
<U>Section</U><U></U><U>&nbsp;4.1</U> shall not apply if Participant does not earn more than the annually-determined compensation threshold ($127,091 in 2025). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Section&nbsp;4.4 </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The post-employment <FONT
STYLE="white-space:nowrap">non-solicitation</FONT> restrictions set forth in <U>Section</U><U></U><U>&nbsp;4.4 </U>shall not apply if Participant does not earn more than the annually-determined compensation threshold ($76,254 in 2025). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Section&nbsp;4.5 </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following language shall be
included as a new <U>Section</U><U></U><U>&nbsp;4.5</U> titled &#147;<U>Acknowledgements</U>&#148;: &#147;In receiving an Award, the Participant gives Kestra Medical Technologies, Ltd. assurance that the Participant has carefully read and considered
all of the terms and conditions of this Agreement and the Plan, including the restraints imposed under this Agreement. The Participant acknowledges that Kestra Medical Technologies, Ltd.&#146;s business success and competitive position in the
industry are dependent on Kestra Medical Technologies, Ltd.&#146;s exclusive possession of trade secrets. The Participant agrees that the restraints contained in this Agreement are no broader than reasonably necessary for the protection of trade
secrets of Kestra Medical Technologies, Ltd., and that each and every one of the restraints is reasonable in respect of subject matter, length of time, and geographic area, and that these restraints, individually or in the aggregate, will not
prevent the Participant from obtaining other suitable employment or other service relationships during the period in which the Participant is bound by such restraints. The Participant acknowledges that each of these covenants has a unique, very
substantial, and immeasurable value to Kestra Medical Technologies, Ltd., and that the Participant has sufficient assets and skills to provide a livelihood while such covenants remain in force. The Participant acknowledges receipt of a separate
notice from Kestra Medical Technologies, Ltd., at least fourteen (14)&nbsp;days before the earlier of the effective date of this Agreement, or the effective date of the grant of any Awards that provide consideration for this Agreement, that
identifies this Agreement by name and directs the Participant to the specific sections of this Agreement containing a covenant not to compete, including in <U>Section</U><U></U><U>&nbsp;4.1</U>.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Section&nbsp;6.2. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following language shall be included at the end of <U>Section</U><U></U><U>&nbsp;6.2</U>: &#147;Notwithstanding anything to the contrary in Section&nbsp;6
of this Agreement, if at the time Participant&#146;s cessation or termination of employment with Kestra Medical Technologies, Ltd., Participant primarily resides in and works in Colorado, any dispute regarding the enforceability of <U>Sections
4.1</U>, <U>4.2,</U> <U>4.3</U> or <U>4.4</U> shall be resolved in the jurisdiction, and governed, construed and interpreted under the laws, of the State of Colorado, without regard to the application of any <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">choice-of-law</FONT></FONT> rules that would result in the application of another state&#146;s laws.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Section&nbsp;7.10 </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following language shall
be included at the end of <U>Section</U><U></U><U>&nbsp;7.10</U>: &#147;Notwithstanding anything to the contrary set forth in this Agreement, Confidential Information shall not include any information that arises from the Participant&#146;s general
training, knowledge skill, or experience (whether gained on the job or otherwise), information that is readily ascertainable to the public (other than as a result of the Participant&#146;s breach of this Plan or any other agreement between the
Participant and Kestra Medical Technologies, Ltd.), or information that a worker otherwise has a right to disclose as legally protected conduct. Furthermore, for the avoidance of doubt, any provision in the Plan interpreted by an arbitrator or, if
applicable, court of competent jurisdiction to be a &#147;nondisclosure provision&#148; as defined in and under the Colorado Protecting Opportunities and Workers&#146; Rights Act, Colo. Rev. Stat. &#167; <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">24-34-407(1)(a)</FONT></FONT> (referred to herein as a <FONT STYLE="white-space:nowrap">&#147;Non-Disclosure</FONT> Provision&#148;), shall apply equally to the Participant and Kestra Medical Technologies, Ltd.. Nothing in
<U>Section</U><U></U><U>&nbsp;3.5</U>, or otherwise in this Agreement prohibits or restricts the Participant from disclosing the underlying facts about alleged discriminatory or unfair employment practices of Kestra Medical Technologies, Ltd.,
including the existence and terms of any settlement agreement, to (A)&nbsp;the Participant&#146;s immediate family, religious advisor, medical or mental health provider, legal counsel, financial advisor, or tax preparer, or as required by law, or
(B)&nbsp;to any government agency or in response to a subpoena without first having to notify the Company, and in each case, the disclosure of any such underlying facts shall not constitute disparagement. No party hereto that makes a material
misrepresentation about the other party may enforce any <FONT STYLE="white-space:nowrap">Non-Disclosure</FONT> Provision (including under <U>Section</U><U></U><U>&nbsp;3.5</U>) against such other party, but all remaining terms of this Agreement
shall remain enforceable.&#148; </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Florida </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Section&nbsp;3.5 </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The nondisclosure restriction
set forth in <U>Section</U><U></U><U>&nbsp;3.5</U> shall be limited to the period of the Participant&#146;s employment and/or service with Kestra Medical Technologies, Ltd., and for five (5)&nbsp;years thereafter, or if longer, for such duration
that the information qualifies as a trade secret under applicable law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Georgia </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Section&nbsp;3.5. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The nondisclosure restriction
set forth in <U>Section</U><U></U><U>&nbsp;3.5</U> shall be limited to the period of the Participant&#146;s employment and/or service with Kestra Medical Technologies, Ltd., and for five (5)&nbsp;years thereafter, or if longer, for such duration
that the information qualifies as a trade secret under applicable law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Section&nbsp;4.1 </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Section</U><U></U><U>&nbsp;4.1</U> shall only apply if the Participant: (i)&nbsp;customarily and regularly solicits for Kestra Medical Technologies, Ltd.
customers or prospective customers, (ii)&nbsp;customarily and regularly engages in making sales or obtaining orders or contracts for products or services to be performed by others, (iii)&nbsp;performs duties where the Participant primarily manages a
customarily recognized department or subdivision or the enterprise in which the Participant is employed, customarily and regularly directs the work of two or more employees, and has authority to make or influence employment decisions, including
hiring, firing, advancement, promotion or other change of status of other employees, or (iv)&nbsp;performs the duties of a key employee or professional. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following language shall be included at the end of <U>Section</U><U></U><U>&nbsp;4.1</U>: &#147;Notwithstanding the foregoing, nothing in
<U>Section</U><U></U><U>&nbsp;4.1</U> shall prohibit the Participant from being employed or engaged by any person in a <FONT STYLE="white-space:nowrap">non-executive</FONT> role that does not have responsibility for, or require performance of, any
of the same or similar functions, duties or activities that the Participant performed or had oversight for on behalf of Kestra Medical Technologies, Ltd.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Section&nbsp;4.4 </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The restrictions set forth in
<U>Section</U><U></U><U>&nbsp;4.4</U> shall be limited to solicitations of and other prohibited actions solely with respect to Competitive Products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Section&nbsp;7.8 </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Section</U><U></U><U>&nbsp;7.8</U> shall be replaced with the following: &#147;In the event of any violation of the provisions of <U>Sections 4.1</U>,
<U>4.2,</U> <U>4.3</U> or <U>4.4</U> in any material respect (as determined by the Company in good faith within a reasonable period of time upon becoming aware of such violation), the Participant acknowledges and agrees that to the fullest extent
permitted by applicable law, the post-termination restrictions contained in <U>Sections 4.1</U>, <U>4.2,</U> <U>4.3</U> or <U>4.4</U> shall cease to run during the pendency of any litigation over such violation, provided that such litigation was
initiated during the applicable restricted period and provided that the Company is successful on the merits in any such litigation.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Idaho </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Section&nbsp;1.9 </I></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The definition of
&#147;<U>Restricted Territory</U>&#148; shall be limited to those jurisdictions in which the Participant had a material business presence or influence, or customer relationships, during their employment or service with Kestra Medical Technologies,
Ltd. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Section&nbsp;4.1 </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following
language shall be included at the end of <U>Section</U><U></U><U>&nbsp;4.1</U>: &#147;Notwithstanding the foregoing, nothing in <U>Section</U><U></U><U>&nbsp;4.1</U> shall prohibit the Participant from being employed or engaged by any person in a <FONT
STYLE="white-space:nowrap">non-executive</FONT> role that does not have responsibility for, or require performance of, any of the same or similar functions, duties or activities that the Participant performed or had oversight for on behalf of Kestra
Medical Technologies, Ltd.&#148; The post-employment portion of the Restrictive Covenant Period shall apply only if Participant is a &#147;key employee,&#148; which means any employee or independent contractor who (i)&nbsp;has, by reason of the
Partnership Group&#146;s investment of time, money, trust, exposure to the public or exposure to technologies, intellectual property, business plans, business processes and methods of operation, customers, vendors or other business relationships
during the course of employment or service, gained a high level of inside knowledge, influence, credibility, notoriety, fame, reputation or public persona as a representative or spokesperson of the Partnership Group and, as a result, has the ability
to harm or threaten the Partnership Group&#146;s legitimate business interests, and/or (ii)&nbsp;is among the highest paid five percent (5%) of the Partnership Group&#146;s employees and independent contractors.&#148; </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Illinois </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Section&nbsp;1.9
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The definition of &#147;<U>Restricted Territory</U>&#148; shall be limited to those jurisdictions in which the Participant had a material
business presence or influence, or customer relationships, during their employment or service with Kestra Medical Technologies, Ltd. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Section&nbsp;3.5. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The nondisclosure restriction
set forth in <U>Section</U><U></U><U>&nbsp;3.5</U> shall be limited to the period of the Participant&#146;s employment and/or service with Kestra Medical Technologies, Ltd., and for five (5)&nbsp;years thereafter, or if longer, for such duration
that the information qualifies as a trade secret under applicable law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Section&nbsp;4.1 </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following language shall be included at the end of <U>Section</U><U></U><U>&nbsp;4.1</U>: &#147;Notwithstanding the foregoing, nothing in
<U>Section</U><U></U><U>&nbsp;4.1</U> shall prohibit the Participant from being employed or engaged by any person in a <FONT STYLE="white-space:nowrap">non-executive</FONT> role that does not have responsibility for, or require performance of, any
of the same or similar functions, duties or activities that the Participant performed or had oversight for on behalf of Kestra Medical Technologies, Ltd.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The post-employment <FONT STYLE="white-space:nowrap">non-competition</FONT> restrictions set forth in <U>Section</U><U></U><U>&nbsp;4.1</U> shall not apply if
Participant does not earn more than the statutory threshold ($75,000 in 2025). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Section&nbsp;4.4 </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The post-employment <FONT STYLE="white-space:nowrap">non-solicitation</FONT> restrictions set forth in <U>Section</U><U></U><U>&nbsp;4.4</U> shall not apply
if Participant does not earn more than the statutory threshold ($45,000 in 2025). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Section&nbsp;4.5 </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following language shall be included as a new <U>Section</U><U></U><U>&nbsp;4.</U><U>5</U> titled &#147;<U>Acknowledgements</U>&#148;: &#147;The
Participant acknowledges that (i)&nbsp;the noncompetition provisions in <U>Section</U><U></U><U>&nbsp;4.1</U> are supported by mutually agreed upon, fair, reasonable, valid, and sufficient consideration, which is independent of the
Participant&#146;s employment and/or service with Kestra Medical Technologies, Inc, including the grant of any award of stock options to the Participant pursuant to this Agreement, and (ii)&nbsp;the Participant has been advised of the
Participant&#146;s right to consult with counsel prior to agreeing to be bound by the restrictive covenants set forth in this Agreement. The Participant acknowledges and agrees that the Participant has had at least 14&nbsp;calendar days to review
the restrictive covenants set forth in this Agreement, including in <U>Section</U><U></U><U>&nbsp;4.1</U>.&#148; </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Indiana
</U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Section&nbsp;3.5 </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The nondisclosure
restriction set forth in <U>Section</U><U></U><U>&nbsp;3.5</U> shall be limited to the period of the Participant&#146;s employment and/or service with Kestra Medical Technologies, Ltd., and for five (5)&nbsp;years thereafter, or if longer, for such
duration that the information qualifies as a trade secret under applicable law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Section&nbsp;4.1 </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following language shall be included at the end of <U>Section</U><U></U><U>&nbsp;4.1</U>: &#147;Notwithstanding the foregoing, nothing in
<U>Section</U><U></U><U>&nbsp;4.1</U> shall prohibit the Participant from being employed or engaged by any person in a <FONT STYLE="white-space:nowrap">non-executive</FONT> role that does not have responsibility for, or require performance of, any
of the same or similar functions, duties or activities that the Participant performed or had oversight for on behalf of Kestra Medical Technologies, Ltd.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Section&nbsp;4.2 </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The restrictions contained in
<U>Section</U><U></U><U>&nbsp;4.2</U> apply only to individual service providers of Kestra Medical Technologies, Ltd. who have access to or possesses any knowledge or Confidential Information that would give an unfair advantage to a competitor that
engages in competition with Kestra Medical Technologies, Ltd.&#146;s business. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Louisiana </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Section&nbsp;1.9 </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The definition of
&#147;<U>Restricted Territory</U>&#148; shall be replaced with the following: &#147;the following parishes and municipalities and only for so long as Kestra Medical Technologies, Ltd. carries on the business in such parishes and municipalities:
Acadia, Allen, Ascension, Assumption, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Avoyelles, Beauregard, Bienville, Bossier, Caddo, Calcasieu, Caldwell, Cameron, Catahoula, Claiborne, Concordia, De Soto, East Baton Rouge, East Carroll, East Feliciana, Evangeline, Franklin,
Grant, Iberia, Iberville, Jackson, Jefferson, Jefferson Davis, La Salle, Lafayette, Lafourche, Lincoln, Livingston, Madison, Morehouse, Natchitoches, Orleans, Ouachita, Plaquemines, Pointe Coupee, Rapides, Red River, Richland, Sabine, St. Bernard,
St. Charles, St. Helena, St. James, St. John The Baptist, St. Landry, St. Martin, St. Mary, St. Tammany, Tangipahoa, Tensas, Terrebonne, Union, Vermilion, Vernon, Washington, Webster, West Baton Rouge, West Carroll, West Feliciana, and Winn.&#148;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Section&nbsp;4.4 </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The restrictions contained
in <U>Section</U><U></U><U>&nbsp;4.4</U> shall only apply within the Restricted Territory. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Section&nbsp;7.8 </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Section</U><U></U><U>&nbsp;7.8</U> shall be deemed deleted. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Maryland </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Section&nbsp;4.1
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following language shall be included at the end of <U>Section</U><U></U><U>&nbsp;4.1</U>: &#147;Notwithstanding the foregoing, nothing in
<U>Section</U><U></U><U>&nbsp;4.1</U> shall prohibit the Participant from being employed or engaged by any person in a <FONT STYLE="white-space:nowrap">non-executive</FONT> role that does not have responsibility for, or require performance of, any
of the same or similar functions, duties or activities that the Participant performed or had oversight for on behalf of Kestra Medical Technologies, Ltd.&#148; </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Massachusetts </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Section&nbsp;1.9. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following shall replace
the definition of &#147;<U>Restricted Territory</U>&#148;: &#147;each country, province, state, city, or other political subdivision in the United States in which Kestra Medical Technologies, Ltd. (i)&nbsp;is engaged in business, or
(ii)&nbsp;otherwise distributes, licenses or sells Kestra Medical Technologies, Ltd. Products, in each case while the Participant is employed or engaged by Kestra Medical Technologies, Ltd., and in each case, in which the Participant provided
services or had a material presence or influence during the last two (2)&nbsp;years of his or her employment with Kestra Medical Technologies, Ltd.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Section&nbsp;4.1 </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Section</U><U></U><U>&nbsp;4.1</U> shall be replaced with the following: &#147;The Participant agrees that while employed by Kestra Medical Technologies,
Ltd., and for twelve (12)&nbsp;months after the last day the Participant is employed or engaged by Kestra Medical Technologies, Ltd., or, to the extent the Participant breaches a fiduciary duty owed to Kestra Medical Technologies, Ltd. or commits an
unlawful taking of Kestra Medical Technologies, Ltd. Property, the twenty-four (24)&nbsp;months period thereafter (the &#147;<U>Noncompete Period</U>&#148;) the Participant will not, within the Restricted Territory, be employed or engaged by or
otherwise perform services for, lend the Participant&#146;s name or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
assistance to, invest in, manage, or control, a Conflicting Organization in connection with or relating to a Competitive Product or Competitive Research and Support, in each case, in any capacity
in which the Participant would provide the same or similar services that the Participant provided to Kestra Medical Technologies, Ltd. during the last two (2)&nbsp;years of the Participant&#146;s employment with Kestra Medical Technologies, Ltd.
Notwithstanding anything to the contrary in this <U>Section</U><U></U><U>&nbsp;4.1</U>, the post-termination portion of the Noncompetition Period shall not apply if Kestra Medical Technologies, Ltd. terminates the employment of the Participant
without Cause or because of a layoff. For this purpose, &#147;<U>Cause</U>&#148; means, in addition to &#147;Cause&#148; as defined in the Plan or any other agreement between Participant and Kestra Medical Technologies, Ltd., a reasonable and good
faith basis for Kestra Medical Technologies, Ltd. to be dissatisfied with the Participant&#146;s job performance, conduct, or behavior.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Section&nbsp;4.5 </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following language shall be
included as a new <U>Section</U><U></U><U>&nbsp;4.5</U> titled &#147;<U>Acknowledgements</U>&#148;: &#147;The Participant acknowledges that the restrictions contained in this <U>Section</U><U></U><U>&nbsp;4</U> are supported by mutually agreed upon,
fair, reasonable, valid, and sufficient consideration, which is independent of the Participant&#146;s continued employment with or service to Kestra Medical Technologies, Ltd., including, without limitation the grant of any Award(s) to the
Participant pursuant to the Plan and the Stock Option Agreement. The Participant has been advised of the Participant&#146;s right to consult with counsel prior to agreeing to be bound by this Agreement, and the Participant acknowledges that the
Participant has had the opportunity to review <U>Section</U><U></U><U>&nbsp;4.1</U> and the other restrictive covenants set forth in this Agreement for at least ten (10)&nbsp;business days prior to agreeing to be bound by the provisions
herein.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Section&nbsp;6.2 </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
following language shall be included at the end of <U>Section</U><U></U><U>&nbsp;6.2</U>: &#147;Notwithstanding any provision in <U>Section</U><U></U><U>&nbsp;6</U> to the contrary, the provisions of <U>Section</U><U></U><U>&nbsp;4</U> shall be
governed by and construed in accordance with the internal laws of the Commonwealth of Massachusetts without giving effect to any choice- or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">conflict-of-laws</FONT></FONT> provision or
rule that would cause the application of the laws of any other jurisdiction to apply to <U>Section</U><U></U><U>&nbsp;4</U>, and any suit, action, or proceeding brought by or against the Participant in connection with the enforcement of
<U>Section</U><U></U><U>&nbsp;4</U> shall be brought in Suffolk County, Massachusetts, and the superior court or the business litigation session of the superior court shall have jurisdiction to adjudicate such dispute. Any judgment with respect to a
proceeding entered by the courts contemplated by this <U>Section</U><U></U><U>&nbsp;6.2</U> will be enforceable in any other court of competent jurisdiction. For the avoidance of doubt, all other provisions of the Plan aside from
<U>Section</U><U></U><U>&nbsp;4</U> remain subject to the Governing Law, Venue, and Jurisdiction provisions set forth in this <U>Section</U><U></U><U>&nbsp;6</U>.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Michigan </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Section&nbsp;4.1 </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following language shall be
included at the end of <U>Section</U><U></U><U>&nbsp;4.1</U>: &#147;Notwithstanding the foregoing, nothing in <U>Section</U><U></U><U>&nbsp;4.1</U> shall prohibit the Participant from being employed or engaged by any person in a <FONT
STYLE="white-space:nowrap">non-executive</FONT> role that does not have responsibility for, or require performance of, any of the same or similar functions, duties or activities that the Participant performed or had oversight for on behalf of Kestra
Medical Technologies, Ltd.&#148; </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Minnesota </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Section&nbsp;4.1 </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The &#147;<U>Noncompete
Period</U>&#148; shall be limited to the Participant&#146;s employment or engagement with Kestra Medical Technologies, Ltd. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Missouri
</U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Section&nbsp;4.1 </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
&#147;<U>Noncompete Period</U>&#148; shall be the period of the Participant&#146;s employment or engagement with Kestra Medical Technologies, Ltd. and twelve (12)&nbsp;months following the Participant&#146;s termination of employment or service for
any reason. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Section&nbsp;4.2 </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Section</U><U></U><U>&nbsp;4.2</U> shall be deemed deleted if the Participant&#146;s services to Kestra Medical Technologies, Ltd. are limited to
secretarial or clerical services. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Montana </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Section&nbsp;4.1 </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The &#147;<U>Noncompete
Period</U>&#148; shall be limited to the Participant&#146;s employment or engagement with Kestra Medical Technologies, Ltd. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>New
Jersey </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Section&nbsp;3.5 </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
nondisclosure restriction set forth in <U>Section</U><U></U><U>&nbsp;3.5</U> shall be limited to the period of the Participant&#146;s employment and/or service with Kestra Medical Technologies, Ltd., and for five (5)&nbsp;years thereafter, or if
longer, for such duration that the information qualifies as a trade secret under applicable law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Section&nbsp;7.10 </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following language shall be included at the end of <U>Section</U><U></U><U>&nbsp;7.10</U>: &#147;Nothing in this Agreement shall prevent the Participant
from (i)&nbsp;disclosing or discussing discrimination (including harassment occurring between employees or between an employer and an employee) in the workplace, at work-related events coordinated by or through Kestra Medical Technologies, Ltd., or
off the employment premises, (ii)&nbsp;opposing, disclosing, reporting, or participating in an investigation of sexual harassment, or (iii)&nbsp;speaking with law enforcement, the Equal Employment Opportunity Commission, the state division of human
rights, a local commission on human rights or an attorney retained by the Participant.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>New York </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><U>Section&nbsp;5.8 </U></I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following shall
replace <U>Section</U><U></U><U>&nbsp;5.8</U>: &#147;The Participant understands that in accordance with N.Y. Lab. Law &#167; <FONT STYLE="white-space:nowrap">203-f,</FONT> any provision in this Agreement which provides that the Participant shall
assign, or offer to assign, any of the Participant&#146;s rights in an invention to Kestra Medical Technologies, Ltd. shall not apply to an invention that the Participant developed entirely on his or her own time without using Kestra Medical
Technologies, Ltd.&#146;s equipment, supplies, facilities, or trade secret information, except for those inventions that either: (a)&nbsp;relate at the time of conception or reduction to practice of the invention to Kestra Medical Technologies,
Ltd.&#146;s business, or actual or demonstrably anticipated research or development of the Company Group; or (b)&nbsp;result from any work performed by the Participant for the Kestra Medical Technologies, Ltd.. All Inventions that fall within the
scope of N.Y. Lab. Law &#167; <FONT STYLE="white-space:nowrap">203-f</FONT> shall be excluded from the assignment in <U>Section5</U>.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Section&nbsp;7.10. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following language shall
be included at the end of <U>Section</U><U></U><U>&nbsp;7.10</U>: &#147;Nothing in this Agreement shall prevent the Participant from (i)&nbsp;disclosing or discussing discrimination (including harassment occurring between employees or between an
employer and an employee) in the workplace, at work-related events coordinated by or through Kestra Medical Technologies, Ltd., or off the employment premises, (ii)&nbsp;opposing, disclosing, reporting, or participating in an investigation of sexual
harassment, or (iii)&nbsp;speaking with law enforcement, the Equal Employment Opportunity Commission, the state division of human rights, the attorney general, a local commission on human rights or an attorney retained by the Participant.&#148; </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Nevada </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Section&nbsp;4.1
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following sentence shall be included at the end of <U>Section</U><U></U><U>&nbsp;4.1</U>: &#147;Notwithstanding the foregoing, this
<U>Section</U><U></U><U>&nbsp;4.1</U> and <U>Section</U><U></U><U>&nbsp;4.4</U> shall not restrict the Participant from providing a service to a former customer if: (i)&nbsp;the Participant did not solicit such customer; (ii)&nbsp;the former
customer voluntarily chose to leave and seek services from the Participant; and (iii)&nbsp;the Participant is otherwise complying with the limitations set forth in <U>Section</U><U></U><U>&nbsp;4.1</U> regarding time, geographic area, and scope of
the restrained activity, other than any limitation on providing services to a former customer who seeks the services of the Participant without any contact instigated by the Participant. Notwithstanding anything in this Agreement to the contrary, if
the Participant&#146;s employment is terminated as a result of a reduction of force, reorganization or similar restructuring of the Kestra Medical Technologies, Ltd., the post-employment restrictions contemplated by this
<U>Section</U><U></U><U>&nbsp;4.1</U> shall only apply during the period in which Kestra Medical Technologies, Ltd. is paying the Participant&#146;s salary, benefits or equivalent compensation, including, without limitation, severance pay to the
extent required by applicable law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>North Carolina </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Section&nbsp;3.5 </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The nondisclosure restriction
set forth in <U>Section</U><U></U><U>&nbsp;3.5</U> shall be limited to the period of the Participant&#146;s employment and/or service with Kestra Medical Technologies, Ltd., and for five (5)&nbsp;years thereafter, or if longer, for such duration
that the information qualifies as a trade secret under applicable law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Section&nbsp;4.1 </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following language shall be included at the end of <U>Section</U><U></U><U>&nbsp;4.1</U>: &#147;Notwithstanding the foregoing, nothing in
<U>Section</U><U></U><U>&nbsp;4.1</U> shall prohibit the Participant from being employed or engaged by any person in a <FONT STYLE="white-space:nowrap">non-executive</FONT> role that does not have responsibility for, or require performance of, any
of the same or similar functions, duties or activities that the Participant performed or had oversight for on behalf of Kestra Medical Technologies, Ltd.&#148; </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Oklahoma </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Section&nbsp;4.1
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Section</U><U></U><U>&nbsp;4.1</U> shall be deemed deleted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Section&nbsp;4.4 </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Section</U><U></U><U>&nbsp;4.4</U> shall be replaced with the following: &#147;Except as otherwise provided in this Agreement, the Participant agrees that,
during the Nonsolicitation Period, the Participant shall not, on the Participant&#146;s own behalf or on behalf of any other person or entity (other than Kestra Medical Technologies, Ltd.), directly solicit the sale of goods, services, or a
combination of goods and services from the established customers of Kestra Medical Technologies, Ltd.&#148; </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Oregon </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Section&nbsp;4.1 </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The &#147;<U>Noncompete
Period</U>&#148; shall be limited to the Participant&#146;s employment or engagement with Kestra Medical Technologies, Ltd. and for a period of twelve (12)&nbsp;months following Participant&#146;s termination of employment or service for any reason.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The post-employment <FONT STYLE="white-space:nowrap">non-competition</FONT> restrictions set forth in <U>Section</U><U></U><U>&nbsp;4.1</U> shall not
apply if Participant does not earn more than the annually-determined compensation threshold ($116,427 in 2025). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Section&nbsp;7.10 </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following language shall be included at the end of <U>Section</U><U></U><U>&nbsp;7.10</U>: &#147;Nothing in this Agreement shall prevent the Participant
from disclosing or discussing discrimination (including harassment occurring between employees or between an employer and an employee) in the workplace, at work-related events coordinated by or through Kestra Medical Technologies, Ltd., or off the
employment premises.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Pennsylvania </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Section&nbsp;1.9 </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The definition of
&#147;<U>Restricted Territory</U>&#148; shall be limited to those jurisdictions in which the Participant had a material business presence or influence, or customer relationships, during their employment or service with Kestra Medical Technologies,
Ltd. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Section&nbsp;4.1 </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following
language shall be included at the end of <U>Section</U><U></U><U>&nbsp;4.1</U>: &#147;Notwithstanding the foregoing, nothing in <U>Section</U><U></U><U>&nbsp;4.1</U> shall prohibit the Participant from being employed or engaged by any person in a <FONT
STYLE="white-space:nowrap">non-executive</FONT> role that does not have responsibility for, or require performance of, any of the same or similar functions, duties or activities that the Participant performed or had oversight for on behalf of Kestra
Medical Technologies, Ltd.&#148; </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>South Carolina </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Section&nbsp;3.5 </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The nondisclosure restriction
set forth in <U>Section</U><U></U><U>&nbsp;3.5</U> shall be limited to the period of the Participant&#146;s employment and/or service with Kestra Medical Technologies, Ltd., and for five (5)&nbsp;years thereafter, or if longer, for such duration
that the information qualifies as a trade secret under applicable law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Section&nbsp;4.1 </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following language shall be included at the end of <U>Section</U><U></U><U>&nbsp;4.1</U>: &#147;Notwithstanding the foregoing, nothing in
<U>Section</U><U></U><U>&nbsp;4.1</U> shall prohibit the Participant from being employed or engaged by any person in a <FONT STYLE="white-space:nowrap">non-executive</FONT> role that does not have responsibility for, or require performance of, any
of the same or similar functions, duties or activities that the Participant performed or had oversight for on behalf of Kestra Medical Technologies, Ltd.&#148; </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Texas </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Section&nbsp;1.9
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The definition of &#147;<U>Restricted Territory</U>&#148; shall be limited to those jurisdictions in which the Participant had a material
business presence or influence, or customer relationships, during their employment or service with Kestra Medical Technologies, Ltd. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Section&nbsp;4.1 </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following language shall be
included at the end of <U>Section</U><U></U><U>&nbsp;4.1</U>: &#147;Notwithstanding the foregoing, nothing in <U>Section</U><U></U><U>&nbsp;4.1</U> shall prohibit the Participant from being employed or engaged by any person in a <FONT
STYLE="white-space:nowrap">non-executive</FONT> role that does not have responsibility for, or require performance of, any of the same or similar functions, duties or activities that the Participant performed or had oversight for on behalf of Kestra
Medical Technologies, Ltd.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Section&nbsp;4.2 </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The restrictions set forth in <U>Section</U><U></U><U>&nbsp;4.2</U> shall only apply to those employees of Kestra Medical Technologies, Ltd. with whom the
Participant had contact during the Participant&#146;s employment with or service to Kestra Medical Technologies, Ltd. or who otherwise worked in the same department as the Participant. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Utah </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Section&nbsp;4.1
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The &#147;Noncompete Period&#148; shall be limited to during Participant&#146;s period of employment or service with Kestra Medical Technologies,
Ltd. and for a period of twelve (12)&nbsp;months following the Participant&#146;s termination of employment or service for any reason. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Virginia </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Section&nbsp;3.5.
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The nondisclosure restriction set forth in <U>Section</U><U></U><U>&nbsp;3.5</U> shall be limited to the period of the Participant&#146;s
employment and/or service with Kestra Medical Technologies, Ltd., and for five (5)&nbsp;years thereafter, or if longer, for such duration that the information qualifies as a trade secret under applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Section&nbsp;4.1 </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following language shall be
included at the end of <U>Section</U><U></U><U>&nbsp;4.1</U>: &#147;Notwithstanding the foregoing, nothing in <U>Section</U><U></U><U>&nbsp;4.1</U> shall prohibit the Participant from being employed or engaged by any person in a <FONT
STYLE="white-space:nowrap">non-executive</FONT> role that does not have responsibility for, or require performance of, any of the same or similar functions, duties or activities that the Participant performed or had oversight for on behalf of Kestra
Medical Technologies, Ltd.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Section&nbsp;4.4 </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following sentence shall be included at the end of <U>Section</U><U></U><U>&nbsp;4.4</U>: &#147;Notwithstanding the foregoing, this
<U>Section</U><U></U><U>&nbsp;4.4</U> shall not restrict the Participant from providing a service to a former customer if: (i)&nbsp;the Participant did not solicit such customer; (ii)&nbsp;the former customer voluntarily chose to leave and seek
services from the Participant; and (iii)&nbsp;the Participant is otherwise complying with the limitations set forth in <U>Section</U><U></U><U>&nbsp;4.1</U> regarding time, geographic area, and scope of the restrained activity, other than any
limitation on providing services to a former customer who seeks the services of the Participant without any contact instigated by the Participant.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Section&nbsp;7.10. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following language shall be included at the end of <U>Section</U><U></U><U>&nbsp;7.10</U>: &#147;Nothing in this Agreement shall prevent the Participant
from (i)&nbsp;disclosing or discussing discrimination (including harassment occurring between employees or between an employer and an employee) in the workplace, at work-related events coordinated by or through Kestra Medical Technologies, Ltd., or
off the employment premises, (ii)&nbsp;opposing, disclosing, reporting, or participating in an investigation of sexual harassment, or (iii)&nbsp;speaking with law enforcement, the Equal Employment Opportunity Commission, the state division of human
rights, the attorney general, a local commission on human rights or an attorney retained by the Participant.&#148; </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Washington
</U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Section&nbsp;4.1 </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the
Participant&#146;s employment and/or service with Kestra Medical Technologies, Ltd. is terminated as the result of a layoff, in exchange for the Participant&#146;s obligations in <U>Section</U><U></U><U>&nbsp;4.1</U>, to the extent required by
applicable law to enforce such section, Kestra Medical Technologies, Ltd. may elect to provide the Participant with a payment equivalent to the Participant&#146;s base salary at the time of termination for the duration of the Noncompete Period,
minus any compensation earned by the Participant through later employment during the Noncompete Period. The Participant acknowledges and agrees that the Participant is executing this Agreement knowingly and voluntarily. Further, the Participant
acknowledges and agrees that the terms of this Agreement, including each of the restrictive covenants contained in <U>Section</U><U></U><U>&nbsp;4.1</U> hereof, were disclosed in writing to the Participant prior to the date the Participant executed
this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Section&nbsp;7.10 </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
following language shall be included at the end of <U>Section</U><U></U><U>&nbsp;7.10</U>: &#147;Nothing in this Agreement shall prevent the Participant from (i)&nbsp;disclosing or discussing discrimination (including harassment occurring between
employees or between an employer and an employee) in the workplace, at work-related events coordinated by or through Kestra Medical Technologies, Ltd., or off the employment premises, (ii)&nbsp;opposing, disclosing, reporting, or participating in an
investigation of sexual harassment, or (iii)&nbsp;speaking with law enforcement, the Equal Employment Opportunity Commission, the state division of human rights, a local commission on human rights or an attorney retained by the Participant.&#148;
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COLORADO ADDENDUM TO KESTRA MEDICAL TECHNOLOGIES, LTD. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2025 OMNIBUS INCENTIVE PLAN </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By signing
below, the parties acknowledge and agree that this Kestra Medical Technologies, Ltd. 2025 Omnibus Incentive Plan, including the terms set forth in <U>Section</U><U></U><U>&nbsp;3</U> therein, is compliant with the Colorado Protecting Opportunities
and Workers&#146; Rights Act, specifically, Colo. Rev. Stat. &#167; <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">24-34-407(1).</FONT></FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF, </B>the parties have executed this Addendum on the below-indicated dates. </P>
<P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[<I>Participant</I>]</P>
<P STYLE="margin-top:0pt;margin-bottom:1pt;border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date</P>
<P STYLE="margin-top:0pt;margin-bottom:1pt;border-bottom:1px solid #000000">&nbsp;</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE III </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COLORADO NOTICE OF RESTRICTIVE COVENANTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This notice is to advise Participant that, contemporaneously with this notice, Participant is being provided with the Kestra Medical
Technologies, Ltd. 2025 Omnibus Incentive Plan, as amended from time to time (the &#147;<U>Plan</U>&#148;), which includes restrictive covenants that could restrict Participant&#146;s options for subsequent employment or engagement following
Participant&#146;s employment or engagement with Kestra Medical Technologies, Ltd. (the &#147;<U>Company</U>&#148;), in that Participant will be prohibited from the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Competing with the business of the Company in the specified territory, as specified in the section of the Plan
titled &#147;<U>Restrictions on Competition</U>&#148;; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting, calling upon or otherwise interfering with customers, as specified in the section of the Plan
titled &#147;<U>Prohibition on Solicitation of Kestra Medical Technologies, Ltd. Customers</U>&#148;; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting, recruiting or hiring employees, as specified in the section of the Plan titled &#147;<U>Prohibition
on Solicitation of Kestra Medical Technologies, Ltd. Participants</U>&#148;. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Participant acknowledges and agrees that
Participant is entering into the Plan, including the section of the Plan titled &#147;<U>Post-Employment Restrictions</U>&#148;, knowingly, freely and voluntarily after an opportunity to consult with counsel of Participant&#146;s choosing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Participant acknowledges and agrees that Participant has had at least 14&nbsp;calendar days to review the restrictive covenants set forth in
the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF, </B>the Participant has executed this notice on the below-indicated date. </P>
<P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[<I>Participant</I>]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&#8195;&#8195;&#8195;&#8195;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Date</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>10
<FILENAME>d744414dex104.htm
<DESCRIPTION>EX-10.4
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.4</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit&nbsp;10.4</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INDEMNIFICATION AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS INDEMNIFICATION AGREEMENT (this &#147;<U>Agreement</U>&#148;) is made and entered into as of [&#9679;], 202[&#9679;] between Kestra
Medical Technologies, Ltd., a Bermuda exempted company (the &#147;<U>Company</U>&#148;), and [&#9679;] (the &#147;<U>Indemnitee</U>&#148;). Capitalized terms used but not otherwise defined herein shall have the meaning set forth in
<U>Section</U><U></U><U>&nbsp;[12 / 13]</U> hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, highly competent persons have become more reluctant to serve companies as
directors or officers or in other capacities unless they are provided with adequate protection through insurance or adequate indemnification against inordinate risks of claims and actions against them arising out of their service to and activities
on behalf of the company; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the <FONT STYLE="white-space:nowrap">Bye-laws</FONT> of the Company (as amended, restated, modified
and/or supplemented from to time, the &#147;<U><FONT STYLE="white-space:nowrap">Bye-laws</FONT></U>&#148;) provide for indemnification of the directors and officers of the Company and section 98(1) the Companies Act 1981 of Bermuda (as amended) (the
&#147;<U>Companies Act</U>&#148;) expressly provides that the indemnification provisions contemplated therein may be in its <FONT STYLE="white-space:nowrap">bye-laws</FONT> or in any contractor arrangement between the Company and its directors and
officers; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the uncertainties relating to insurance and indemnification have increased the difficulty of attracting and retaining
directors and officers; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Board has determined that the increased difficulty in attracting and retaining directors and
officers is detrimental to the best interests of the Company and its shareholders and that the Company should act to assure such persons that there will be increased certainty of such protection in the future; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, it is reasonable, prudent and necessary for the Company to indemnify, and to advance Expenses on behalf of, the Company&#146;s
directors and officers to the Fullest Extent Permitted By Applicable Law; [and] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">[WHEREAS, the Indemnitee may have certain rights to
indemnification, advancement of Expenses and/or insurance provided by Bain, which the Indemnitee, the Company and Bain intend to be secondary to the primary obligation of the Company to indemnify the Indemnitee as provided herein, with the
Company&#146;s acknowledgment of and agreement to the foregoing being a material condition to the Indemnitee&#146;s willingness to serve as a director or officer of the Company; and ]<SUP STYLE="font-size:75%; vertical-align:top">1</SUP> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Indemnitee may not be willing to serve or continue to serve as a director or officer without adequate protection, and the Company
desires the Indemnitee to serve or continue to serve in such capacity. </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>NTD</B>: Bracketed language to be included for sponsor-affiliated directors. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, each party hereto, intending to be legally bound hereby, agrees as follows:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Indemnity of the Indemnitee</U>. The Company shall indemnify the Indemnitee to the Fullest Extent Permitted
By Applicable Law if the Indemnitee is, or is threatened to be made, a party to or a participant in any Proceeding (including a Proceeding by or in the right of the Company to procure a judgment in its favor) for all Losses and Expenses actually and
reasonably incurred by the Indemnitee in connection with such Proceeding. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Contribution</U>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Whether or not the indemnification provided in <U>Section</U><U></U><U>&nbsp;1</U> hereof is available, in
respect of any threatened, pending or completed Proceeding in which the Company is jointly liable with the Indemnitee (or would be if joined in such Proceeding), to the Fullest Extent Permitted By Applicable Law, the Company shall pay, in the first
instance, the entire amount of any judgment or settlement of such Proceeding without requiring the Indemnitee to contribute to such payment and the Company hereby waives and relinquishes any right of contribution it may have against the Indemnitee.
The Company shall not enter into any settlement of any Proceeding in which the Company is jointly liable with the Indemnitee (or would be if joined in such Proceeding) unless such settlement (i)&nbsp;provides for a full and final release of all
claims asserted against the Indemnitee and (ii)&nbsp;does not impose any Loss, Expense or limitation on the Indemnitee. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Without diminishing or impairing the obligations of the Company set forth in the preceding subsection, if, for
any reason, the Indemnitee shall elect or be required to pay all or any portion of any judgment or settlement in any threatened, pending or completed Proceeding in which the Company is jointly liable with the Indemnitee (or would be if joined in
such Proceeding), to the Fullest Extent Permitted By Applicable Law, the Company shall contribute to the amount of Losses and Expenses actually and reasonably incurred and paid or payable by the Indemnitee in proportion to the relative benefits
received by the Company and all officers, directors or employees of the Company, other than the Indemnitee, who are jointly liable with the Indemnitee (or would be if joined in such Proceeding), on the one hand, and the Indemnitee, on the other
hand, from the transaction or events from which such Proceeding arose; <U>provided</U>, <U>however</U>, that the proportion determined on the basis of relative benefit may, to the extent necessary to conform to law, be further adjusted by reference
to the relative fault of the Company and all officers, directors or employees of the Company, other than the Indemnitee, who are jointly liable with the Indemnitee (or would be if joined in such Proceeding), on the one hand, and the Indemnitee, on
the other hand, in connection with the transaction or events that resulted in such Losses or Expenses, as well as any other equitable considerations which applicable law may require to be considered. The relative fault of the Company and all
officers, directors or employees of the Company, other than the Indemnitee, who are jointly liable with the Indemnitee (or would be if joined in such Proceeding), on the one hand, and the Indemnitee, on the other hand, shall be determined by
reference to, among other things, the degree to which their actions were motivated by intent to gain personal profit or advantage, the degree to which their liability is primary or secondary and the degree to which their conduct is active or
passive. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To the Fullest Extent Permitted By Applicable Law, the Company hereby agrees to fully indemnify and hold the
Indemnitee harmless from any claims of contribution that may be brought by officers, directors or employees of the Company, other than the Indemnitee, who may be jointly liable with the Indemnitee. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To the Fullest Extent Permitted By Applicable Law, if the indemnification provided for in this Agreement is
unavailable to the Indemnitee for any reason whatsoever, the Company, in lieu of indemnifying the Indemnitee, shall contribute to the amount incurred by the Indemnitee, whether for Losses and/or for Expenses, in connection with any claim relating to
an indemnifiable event under this Agreement, in such proportion as is deemed fair and reasonable in light of all of the circumstances of such Proceeding in order to reflect (i)&nbsp;the relative benefits received by the Company and the Indemnitee as
a result of the event(s) and/or transaction(s) giving cause to such Proceeding, and/or (ii)&nbsp;the relative fault of the Company (and its directors, officers, employees and agents) and the Indemnitee in connection with such event(s) and/or
transaction(s). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Indemnification for Expenses of a Witness</U>. Notwithstanding any other provision of this Agreement (other
than <U>Section</U><U></U><U>&nbsp;8</U>), to the Fullest Extent Permitted By Applicable Law and to the extent that the Indemnitee is a witness, or is made (or asked) to respond to discovery requests, in any Proceeding to which the Indemnitee is not
a party, the Indemnitee shall be indemnified against all Expenses actually and reasonably incurred by the Indemnitee or on the Indemnitee&#146;s behalf in connection therewith. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Advancement of Expenses</U>. Notwithstanding any other provision of this Agreement, the Company shall
advance, to the Fullest Extent Permitted By Applicable Law, all Expenses incurred by or on behalf of the Indemnitee in connection with any Proceeding within thirty (30)&nbsp;days after the receipt by the Company of a statement or statements from the
Indemnitee requesting such advance or advances from time to time, whether prior to or after final disposition of such Proceeding. Such statement or statements shall reasonably evidence the Expenses incurred by the Indemnitee. The Indemnitee&#146;s
execution and delivery to the Company of this Agreement shall constitute an undertaking providing that the Indemnitee undertakes to repay the amounts advanced by the Company pursuant to this Agreement, if and only to the extent that it is ultimately
determined that the Indemnitee is not entitled to be indemnified by the Company. No other form of undertaking shall be required other than the execution of this Agreement. Any advances and undertakings to repay pursuant to this Agreement shall be
unsecured and interest free. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Procedures and Presumptions for Determination of Entitlement to Indemnification</U>. It is the intent of
this Agreement to secure for the Indemnitee rights of indemnity that are as favorable as may be permitted under the Companies Act and the public policy of Bermuda. Accordingly, the parties agree that the following procedures and presumptions shall
apply in the event of any question as to whether the Indemnitee is entitled to indemnification under this Agreement: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To obtain indemnification under this Agreement, the Indemnitee shall submit to the Company a written request,
including therein or therewith such documentation and information as is reasonably available to the Indemnitee and is reasonably necessary to determine whether and to what extent the Indemnitee is entitled to indemnification. The Secretary of the
Company shall, promptly upon receipt of such a request for indemnification, advise the Board in writing that the Indemnitee has requested indemnification. Notwithstanding the foregoing, any failure of the Indemnitee to provide such a request to the
Company, or to provide such a request in a timely fashion, shall not relieve the Company of any liability that it may have to the Indemnitee unless, and to the extent that, such failure actually and materially prejudices the interests of the
Company. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Upon written request by the Indemnitee for indemnification pursuant to the first sentence of
<U>Section</U><U></U><U>&nbsp;5(a)</U> hereof, a determination with respect to the Indemnitee&#146;s entitlement thereto shall be made in the specific case by one of the following four methods, which shall be at the election of the Board:
(i)&nbsp;by a majority vote of the Disinterested Directors, even though less than a quorum, (ii)&nbsp;by a committee of Disinterested Directors designated by a majority vote of the Disinterested Directors, even though less than a quorum,
(iii)&nbsp;if there are no Disinterested Directors or if the Disinterested Directors so direct, by Independent Counsel in a written opinion to the Board, a copy of which shall be delivered to the Indemnitee, or (iv)&nbsp;if so directed by the Board,
by the shareholders of the Company; <U>provided</U>, <U>however</U>, that if a Change in Control has occurred, the determination with respect to the Indemnitee&#146;s entitlement to indemnification shall be made by Independent Counsel.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the determination of entitlement to indemnification is to be made by Independent Counsel pursuant to
<U>Section</U><U></U><U>&nbsp;5(b)</U> hereof, the Independent Counsel shall be selected as provided in this <U>Section</U><U></U><U>&nbsp;5(c)</U>. If a Change in Control has not occurred, the Independent Counsel shall be selected by the Board, and
the Company shall give written notice to the Indemnitee advising the Indemnitee of the identity of the Independent Counsel so selected. The Indemnitee may, within ten (10)&nbsp;days after such written notice of selection shall have been given,
deliver to the Company a written objection to such selection; <U>provided</U>,<U> however</U>, that such objection may be asserted only on the ground that the Independent Counsel so selected does not meet the requirements of &#147;Independent
Counsel&#148; as defined in <U>Section</U><U></U><U>&nbsp;13</U> of this Agreement, and the objection shall set forth with particularity the factual basis of such assertion. Absent a proper and timely objection, the person so selected shall act as
Independent Counsel. If a written objection is made and substantiated, the Independent Counsel selected may not serve as Independent Counsel unless and until such objection is withdrawn or a court has determined that such objection is without merit.
If a Change in Control has occurred, the Independent Counsel shall be selected by the Indemnitee (unless the Indemnitee requests that such selection be made by the Board, in which event the preceding sentence shall apply) and approved by the Board
(which approval shall not be unreasonably withheld). If (i)&nbsp;an Independent Counsel is to make the determination of entitlement pursuant to this <U>Section</U><U></U><U>&nbsp;5</U>, and (ii)&nbsp;within twenty (20)
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
days after submission by the Indemnitee of a written request for indemnification pursuant to <U>Section</U><U></U><U>&nbsp;5(a)</U> hereof, no Independent Counsel shall have been selected (and
not objected to), either the Company or the Indemnitee may petition the Supreme Court of Bermuda for resolution of any objection which shall have been made by the Indemnitee to the Company&#146;s selection of Independent Counsel and/or for the
appointment as Independent Counsel of a person selected by the court or by such other person as the court shall designate, and the person with respect to whom all objections are so resolved or the person so appointed shall act as Independent Counsel
under <U>Section</U><U></U><U>&nbsp;5(b)</U> hereof. The Company shall pay any and all reasonable fees and expenses of Independent Counsel incurred by such Independent Counsel in connection with acting pursuant to
<U>Section</U><U></U><U>&nbsp;5(b)</U> hereof, and the Company shall pay all reasonable fees and expenses incident to the procedures of this <U>Section</U><U></U><U>&nbsp;5(c)</U>, regardless of the manner in which such Independent Counsel was
selected or appointed. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In making a determination with respect to entitlement to indemnification hereunder, the person or persons or
entity making such determination shall, to the Fullest Extent Permitted By Applicable Law, presume that the Indemnitee is entitled to indemnification under this Agreement, and the burden of proof and the burden of persuasion by clear and convincing
evidence to overcome this presumption shall be on the Company. Neither the failure of the Company (including by its directors or Independent Counsel) to have made a determination prior to the commencement of any action pursuant to this Agreement
that indemnification is proper in the circumstances because the Indemnitee has met the applicable standard of conduct, nor an actual determination by the Company (including by its directors or Independent Counsel) that the Indemnitee has not met
such applicable standard of conduct, shall be a defense to the action or create a presumption that the Indemnitee has not met the applicable standard of conduct. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Indemnitee shall be deemed to have acted in good faith if the Indemnitee&#146;s action is based on the
records or books of account of the Enterprise, including financial statements, on information supplied to the Indemnitee by the officers of the Enterprise in the course of their duties, on the advice of legal counsel for the Enterprise, or on
information or records given or reports made to the Enterprise by an independent certified public accountant or by an appraiser or other expert selected with reasonable care by the Enterprise. In addition, the knowledge and/or actions, or failure to
act, of any other director, officer, agent or employee of the Enterprise shall not be imputed to the Indemnitee for purposes of determining the right to indemnification under this Agreement. Whether or not the foregoing provisions of this
<U>Section</U><U></U><U>&nbsp;5(e)</U> are satisfied, it shall in any event be presumed that the Indemnitee has at all times acted in good faith and the burden of proof and the burden of persuasion by clear and convincing evidence to overcome this
presumption shall be on the Company. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the person, persons or entity empowered or selected under <U>Section</U><U></U><U>&nbsp;5</U> to determine
whether the Indemnitee is entitled to indemnification shall not have made a determination within sixty (60)&nbsp;days after receipt by the Company of the </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
request therefor, the requisite determination of entitlement to indemnification shall, to the Fullest Extent Permitted By Applicable Law, be deemed to have been made and the Indemnitee shall be
entitled to such indemnification absent (i)&nbsp;a misstatement by the Indemnitee of a material fact, or an omission of a material fact necessary to make the Indemnitee&#146;s statement not materially misleading, in connection with the request for
indemnification, (ii)&nbsp;a prohibition of such indemnification under applicable law or (iii)&nbsp;if the determination of entitlement to indemnification is to be made by Independent Counsel pursuant to <U>Section</U><U></U><U>&nbsp;5(b)</U> of
this Agreement; <U>provided</U>, <U>however</U>, that such <FONT STYLE="white-space:nowrap">60-day</FONT> period may be extended for a reasonable time, not to exceed an additional thirty (30)&nbsp;days, if the person, persons or entity making such
determination with respect to entitlement to indemnification in good faith requires such additional time to obtain or evaluate documentation and/or information relating thereto; and <U>provided</U>, <U>further</U>, that the foregoing provisions of
this <U>Section</U><U></U><U>&nbsp;5(f)</U> shall not apply if the determination of entitlement to indemnification is to be made by the shareholders pursuant to <U>Section</U><U></U><U>&nbsp;5(b)</U> of this Agreement and if (A)&nbsp;within fifteen
(15)&nbsp;days after receipt by the Company of the request for such determination, the Board or the Disinterested Directors, if appropriate, resolve to submit such determination to the shareholders for their consideration at an annual general
meeting thereof to be held within seventy-five (75)&nbsp;days after such receipt and such determination is made thereat, or (B)&nbsp;a special general meeting of shareholders is called within fifteen (15)&nbsp;days after such receipt for the purpose
of making such determination, such meeting is held for such purpose within sixty (60)&nbsp;days after having been so called and such determination is made thereat. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Indemnitee shall cooperate with the person, persons or entity making such determination with respect to the
Indemnitee&#146;s entitlement to indemnification, including providing to such person, persons or entity upon reasonable advance request any documentation or information that is not privileged or otherwise protected from disclosure and that is
reasonably available to the Indemnitee and reasonably necessary to such determination. Any Independent Counsel, member of the Board or stockholder of the Company shall act reasonably and in good faith in making a determination regarding the
Indemnitee&#146;s entitlement to indemnification under this Agreement. Any costs or expenses (including attorneys&#146; fees and disbursements) incurred by the Indemnitee in so cooperating with the person, persons or entity making such determination
shall be borne by the Company (irrespective of the determination as to the Indemnitee&#146;s entitlement to indemnification) and the Company hereby indemnifies and agrees to hold the Indemnitee harmless therefrom. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company acknowledges that a settlement or other disposition of any Proceeding to which the Indemnitee is a
party or potential party short of final judgment may be successful on the merits or otherwise if it permits the Indemnitee to avoid the expense, delay, distraction, disruption and uncertainty of litigation. In the event that any Proceeding to which
the Indemnitee is a party is resolved in any manner other than by adverse judgment against the Indemnitee (including, without limitation, settlement of such action, claim or proceeding with
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
or without payment of money or other consideration), it shall to the Fullest Extent Permitted By Applicable Law be presumed that the Indemnitee has been successful on the merits or otherwise in
such Proceeding, and the burden of proof and the burden of persuasion by clear and convincing evidence to overcome this presumption shall be on the Company. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The termination of any Proceeding or of any claim, issue or matter therein, by judgment, order, settlement or
conviction, or upon a plea of nolo contendere or its equivalent, shall not (except as otherwise expressly provided in this Agreement) of itself adversely affect the right of the Indemnitee to indemnification or create a presumption that the
Indemnitee did not act in good faith. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Remedies of the Indemnitee</U>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the event that (i)&nbsp;a determination is made pursuant to <U>Section</U><U></U><U>&nbsp;5</U> of this
Agreement that the Indemnitee is not entitled to indemnification under this Agreement, (ii)&nbsp;advancement of Expenses is not timely made pursuant to <U>Section</U><U></U><U>&nbsp;4</U> of this Agreement, (iii)&nbsp;no determination of entitlement
to indemnification is made pursuant to <U>Section</U><U></U><U>&nbsp;5(b)</U> of this Agreement within ninety (90)&nbsp;days after receipt by the Company of the request for indemnification, or (iv)&nbsp;payment of indemnification is not made within
thirty (30)&nbsp;days after a determination has been made that the Indemnitee is entitled to indemnification or such determination is deemed to have been made pursuant to <U>Section</U><U></U><U>&nbsp;5</U> of this Agreement, the Indemnitee shall be
entitled to an adjudication in an appropriate court, pursuant to <U>Section</U><U></U><U>&nbsp;21</U> of this Agreement, of the Indemnitee&#146;s entitlement to such indemnification, contribution or advancement of Expenses. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the event that a determination shall have been made pursuant to <U>Section</U><U></U><U>&nbsp;5(b)</U> of
this Agreement that the Indemnitee is not entitled to indemnification, any judicial proceeding commenced pursuant to this <U>Section</U><U></U><U>&nbsp;6</U> shall be conducted in all respects as a de novo trial, or arbitration, on the merits, and
the Indemnitee shall not be prejudiced by reason of the adverse determination under <U>Section</U><U></U><U>&nbsp;5(b)</U>. In any judicial proceeding or arbitration commenced pursuant to this <U>Section</U><U></U><U>&nbsp;6</U>, the Indemnitee
shall be presumed to be entitled to indemnification under this Agreement and the Company shall have the burden of proving the Indemnitee is not entitled to indemnification or advancement of Expenses, as the case may be. If the Indemnitee commences a
judicial proceeding or arbitration pursuant to this <U>Section</U><U></U><U>&nbsp;6</U>, the Indemnitee shall not be required to reimburse the Company for any advances pursuant to <U>Section</U><U></U><U>&nbsp;4</U> until a final determination is
made with respect to the Indemnitee&#146;s entitlement to indemnification (as to which all rights of appeal have been exhausted or lapsed). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If a determination shall have been made pursuant to <U>Section</U><U></U><U>&nbsp;5(b)</U> of this Agreement
that the Indemnitee is entitled to indemnification, the Company shall be bound by such determination in any judicial proceeding commenced pursuant to this <U>Section</U><U></U><U>&nbsp;6</U>, absent (i)&nbsp;a misstatement by the Indemnitee of a
material fact, or an omission of a material fact, necessary to make the Indemnitee&#146;s misstatement not materially misleading in connection with the application for indemnification, or (ii)&nbsp;a prohibition of such indemnification under
applicable law. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the event that the Indemnitee, pursuant to this <U>Section</U><U></U><U>&nbsp;6</U>, incurs costs in a
judicial proceeding or otherwise seeking to enforce the Indemnitee&#146;s rights under, or to recover damages for breach of, this Agreement, or to recover under any directors&#146; and officers&#146; liability insurance policies maintained by the
Company, the Company shall, to the Fullest Extent Permitted By Applicable Law, indemnify the Indemnitee against any and all Expenses and, if requested by the Indemnitee, shall (within ten (10)&nbsp;days after receipt by the Company of a written
request therefor) advance, to the Fullest Extent Permitted By Applicable Law, such Expenses to the Indemnitee that are incurred by or on behalf of the Indemnitee in connection with any action brought by the Indemnitee for indemnification or
advancement of Expenses from the Company under this Agreement or under any directors&#146; and officers&#146; liability insurance policies maintained by the Company. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">In the case of any action brought by the Indemnitee for indemnification, if the Indemnitee (i)&nbsp;is wholly successful, on the merits or
otherwise, on the underlying claims, the Company shall indemnify the Indemnitee to the Fullest Extent Permitted By Applicable Law, against all Expenses actually and reasonably incurred by the Indemnitee or on the Indemnitee&#146;s behalf in
connection therewith, or (ii)&nbsp;is not wholly successful on the underlying claims but is successful, on the merits or otherwise, as to one or more but less than all claims, the Company shall indemnify the Indemnitee against all Expenses actually
and reasonably incurred by the Indemnitee or on the Indemnitee&#146;s behalf in connection with each successfully resolved claim. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company agrees that it shall not assert in any judicial proceeding commenced pursuant to this
<U>Section</U><U></U><U>&nbsp;6</U> that the procedures and presumptions of this Agreement are not valid, binding and enforceable and shall stipulate in any such court or before any such arbitrator that the Company is bound by all the provisions of
this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding anything in this Agreement to the contrary, no determination as to entitlement to
indemnification under this Agreement shall be required to be made prior to the final disposition of the Proceeding. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U><FONT STYLE="white-space:nowrap">Non-Exclusivity;</FONT> Survival of Rights; Insurance; Subrogation</U>.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The rights of indemnification and to receive advancement of Expenses as provided by this Agreement shall not be
deemed exclusive of any other rights to which the Indemnitee may at any time be entitled under applicable law, the <FONT STYLE="white-space:nowrap">Bye-Laws,</FONT> any agreement, a vote of shareholders, a resolution of directors of the Company, or
otherwise; <U>provided</U>, <U>however</U>, that this Agreement shall supersede and replace any rights and obligations of the Company and the Indemnitee with respect to indemnification and the advancement of Expenses that are granted pursuant to the
<FONT STYLE="white-space:nowrap">Bye-laws,</FONT> and, for so long as this Agreement is in effect, the </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Indemnitee waives any right to indemnification or advancement of Expenses from the Company under the <FONT STYLE="white-space:nowrap">Bye-laws</FONT> that is not permitted or provided by this
Agreement. No amendment, alteration or repeal of this Agreement or of any provision hereof shall eliminate, reduce or otherwise adversely affect any right or protection of the Indemnitee under this Agreement with respect to any Proceeding involving
any action or omission that occurred or allegedly occurred prior to such amendment, alteration or repeal. To the extent that a change in the Companies Act, whether by statute or judicial decision, permits greater indemnification than would be
afforded currently under the <FONT STYLE="white-space:nowrap">Bye-laws</FONT> and this Agreement, it is the intent of the parties hereto that the Indemnitee shall enjoy by this Agreement the greater benefits so afforded by such change, and the scope
of indemnification provided by this Agreement shall be automatically extended to include such greater indemnification rights. No right or remedy herein conferred is intended to be exclusive of any other right or remedy, and every other right and
remedy shall be cumulative and in addition to every other right and remedy given hereunder or now or hereafter existing at law or in equity or otherwise. The assertion or employment of any right or remedy hereunder, or otherwise, shall not prevent
the concurrent assertion or employment of any other right or remedy. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company shall make commercially reasonable efforts to obtain and maintain in effect during the entire
period for which the Company is obligated to indemnify the Indemnitee under this Agreement, one or more policies of insurance with reputable insurance companies to provide the directors and officers of the Company with commercially reasonable
coverage for losses from wrongful acts and omissions and to ensure the Company&#146;s performance of its indemnification obligations under this Agreement. The Indemnitee shall be covered by such policy or policies in accordance with its or their
terms to the maximum extent of the coverage available for any director or officer under such policy or policies. In all such insurance policies, the Indemnitee shall be named as an insured in such a manner as to provide the Indemnitee with the same
rights and benefits as are accorded to the most favorably insured of the Company&#146;s directors and officers. At the time of the receipt of a notice of a claim pursuant to the terms hereof, the Company shall give prompt notice of the commencement
of such proceeding to the insurers in accordance with the procedures set forth in the respective policies. The Company shall thereafter take all necessary or desirable action to cause such insurers to pay, on behalf of the Indemnitee, all amounts
payable as a result of such proceeding in accordance with the terms of such policies. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[The Company hereby acknowledges that the Indemnitee has certain rights to indemnification, advancement of
Expenses and/or insurance provided by Bain. With respect to any amounts that are subject to indemnity under this Agreement and also subject to an indemnity obligation owed by Bain, the Company hereby agrees (i)&nbsp;that, as compared to Bain, the
Company is the indemnitor of first resort with respect to any rights to indemnification provided to the Indemnitee herein (i.e., its obligations to the Indemnitee are primary and any obligation of Bain to advance Expenses or to provide
indemnification for the same Expenses or liabilities incurred by the Indemnitee is secondary), (ii) that the Company shall be </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
required to advance the full amount of Expenses incurred by the Indemnitee and shall be liable for the full amount of all Losses and Expenses to the extent legally permitted and as required by
the terms of this Agreement and the <FONT STYLE="white-space:nowrap">Bye-laws</FONT> of the Company (or any other agreement between the Company and the Indemnitee), without regard to any rights the Indemnitee may have against Bain, and
(iii)&nbsp;that the Company irrevocably waives, relinquishes and releases Bain from any and all claims against Bain for contribution, subrogation or any other recovery of any kind in respect thereof. The Company further agrees that no advancement or
payment by Bain on behalf of the Indemnitee with respect to any claim for which the Indemnitee has sought indemnification from the Company shall affect the foregoing and Bain shall have a right of contribution and/or be subrogated to the extent of
such advancement or payment to all of the rights of recovery of the Indemnitee against the Company. The Company and the Indemnitee agree that Bain is an express third-party beneficiary of the terms of this Section&nbsp;7(c).]<SUP
STYLE="font-size:75%; vertical-align:top">2</SUP> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[Except as provided in Section&nbsp;7(c) above, in] In the event of any payment under this Agreement, the
Company shall be subrogated to the extent of such payment to all of the rights of recovery of the Indemnitee [other than against Bain)], who shall execute all papers required and take all action necessary to secure such rights, including execution
of such documents as are necessary to enable the Company to bring suit to enforce such rights. <SUP STYLE="font-size:75%; vertical-align:top">3</SUP> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[Except as provided in Section&nbsp;7(c) above, the] The Company shall not be liable under this Agreement to
make any payment of amounts otherwise indemnifiable (or for which advancement of Expenses is provided) hereunder if and to the extent that the Indemnitee has otherwise actually received such payment under any insurance policy, contract, agreement or
otherwise. <SUP STYLE="font-size:75%; vertical-align:top">4</SUP> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Exception to Right of Indemnification</U>. Notwithstanding any provision in this Agreement or the <FONT
STYLE="white-space:nowrap">Bye-laws,</FONT> the Company shall not be obligated under this Agreement or the <FONT STYLE="white-space:nowrap">Bye-laws</FONT> to make any indemnity or advancement of Expenses in connection with any claim made against
the Indemnitee: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">for which payment has actually been made to or on behalf of the Indemnitee under any insurance policy or other
indemnity provision, except with respect to any excess beyond the amount paid under any insurance policy or other indemnity provision; [provided, that the foregoing shall not affect the rights of the Indemnitee [or Bain set forth in
Section&nbsp;7(c) above;] <SUP STYLE="font-size:75%; vertical-align:top">5</SUP> or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">2</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>NTD</B>: Bracketed language to be included for sponsor-affiliated directors. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">3</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>NTD</B>: Bracketed language to be included for sponsor-affiliated directors. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">4</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>NTD</B>: Bracketed language to be included for sponsor-affiliated directors. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">5</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>NTD</B>: Bracketed language to be included for sponsor-affiliated directors. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">for an accounting of profits made from the purchase and sale (or sale and purchase) by the Indemnitee of
securities of the Company within the meaning of Section&nbsp;16(b) of the Exchange Act, or similar provisions of state statutory law or common law; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">for reimbursement to the Company of any bonus or other incentive-based or equity-based compensation or of any
profits realized by the Indemnitee from the sale of securities of the Company, in each case as required under the Exchange Act (including any such reimbursements that arise from an accounting restatement of the Company pursuant to Section&nbsp;304
of the Sarbanes-Oxley Act of 2002, as amended (the &#147;<U>Sarbanes-Oxley Act</U>&#148;), or Section&nbsp;954 of the Dodd-Frank Wall Street Reform and Consumer Protection Act in connection with an accounting restatement of the Company or the
payment to the Company of profits arising from the purchase and sale by the Indemnitee of securities in violation of Section&nbsp;306 of the Sarbanes-Oxley Act); or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in connection with any Proceeding (or any part of any Proceeding) initiated by the Indemnitee, including any
Proceeding (or any part of any Proceeding) initiated by the Indemnitee against the Company or its directors, officers, employees or other indemnitees, unless (i)&nbsp;the Board authorized the Proceeding (or any such part of any Proceeding) prior to
its initiation, (ii)&nbsp;the Company provides the indemnification, in its sole discretion, pursuant to the powers vested in the Company under applicable law, or (iii)&nbsp;the Proceeding is one to enforce the Indemnitee&#146;s rights under this
Agreement; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">reimbursement of the Company (such Proceeding, a &#147;<U>Clawback</U><U> Proceeding</U>&#148;) by the
Indemnitee of any compensation pursuant to any compensation recoupment or clawback policy adopted by the Board or the compensation committee of the Board, including but not limited to any such policy adopted to comply with stock exchange listing
requirements implementing Section&nbsp;10D of the Exchange Act (a &#147;<U>Clawback</U><U> Policy</U>&#148;). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In furtherance of paragraph (e)&nbsp;of this <U>Section</U><U></U><U>&nbsp;8</U>, the Indemnitee hereby agrees
to abide by the terms of any Clawback Policy, including, without limitation, by returning any compensation to the Company to the extent required by, and in a manner permitted by, the Clawback Policy, and hereby understands and agrees that Indemnitee
shall not be entitled to any (x)&nbsp;indemnification for any liability (including any amounts owed by the Indemnitee in a judgment or settlement of any Clawback Proceeding) or Losses incurred by the Indemnitee in connection with any Clawback
Proceeding or (y)&nbsp;indemnification or advancement of Expenses from the Company or any subsidiary of the Company incurred by the Indemnitee in connection with any Clawback Proceeding; <U>provided</U>, <U>however</U>, that if the Indemnitee is
successful on the merits in the defense of any claim asserted against the Indemnitee in a Clawback Proceeding, the Indemnitee shall be indemnified for the Expenses that the Indemnitee reasonably incurred to defend such claim. The Indemnitee hereby
knowingly, voluntarily and intentionally waives, and agrees not to assert any claim regarding, all indemnification, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
advancement of Expenses and other rights to which the Indemnitee is now or becomes entitled to under this Agreement, the <FONT STYLE="white-space:nowrap">Bye-laws,</FONT> the governing documents
of each subsidiary of the Company and the Companies Act, in each case to the extent such waiver and agreement is necessary to give effect to the preceding sentence of this paragraph. The Indemnitee agrees and acknowledges that the compensation the
Indemnitee has or will receive from the Company or any of its subsidiaries constitutes fair and adequate consideration in exchange for the waiver and agreement provided by the Indemnitee in this paragraph. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Duration of Agreement</U>. All agreements and obligations of the Company contained herein shall continue
after the Indemnitee has ceased to be a director, officer, partner, trustee, member, manager, employee, agent or fiduciary of the Company or of any other Enterprise. This Agreement shall be binding upon and inure to the benefit of and be enforceable
by the parties hereto and their respective successors (including any direct or indirect successor by purchase, merger, consolidation or otherwise to all, substantially all or a substantial part of the business and/or assets of the Company), assigns,
spouses, heirs, executors, administrators and personal and legal representatives. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">10.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Security</U>. To the extent requested by the Indemnitee and approved by the Board, the Company may at any
time and from time to time provide security to the Indemnitee for the Company&#146;s obligations hereunder through an irrevocable bank line of credit, funded trust or other collateral. Any such security, once provided to the Indemnitee, may not be
revoked or released without the prior written consent of the Indemnitee. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[<U>Indemnification of Bain</U>. If (i)&nbsp;the Indemnitee is or was affiliated with Bain, (ii)&nbsp;Bain is,
or is threatened to be made, a party to or a participant in any Proceeding, and (iii)&nbsp;Bain&#146;s involvement in the Proceeding results from any claim based on the Indemnitee&#146;s service to the Company as a director or other fiduciary of the
Company, Bain will be entitled to indemnification and advancement of Expenses hereunder to the same extent, and upon the same terms and conditions, as the Indemnitee. The Company and the Indemnitee agree that Bain is an express third-party
beneficiary of the terms of this Section&nbsp;11.] <SUP STYLE="font-size:75%; vertical-align:top">6</SUP> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">12.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Enforcement</U>. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company expressly confirms and agrees that it has entered into this Agreement and assumes the obligations
imposed on it hereby in order to induce the Indemnitee to serve and to continue to serve as a director or officer of the Company, and the Company acknowledges that the Indemnitee is relying upon this Agreement in serving and continuing to serve as a
director or officer of the Company. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This Agreement constitutes the entire agreement between the parties hereto with respect to the subject matter
hereof and supersedes all prior agreements and understandings, oral, written and implied, between the parties hereto with respect to the subject matter hereof. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">6</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>NTD</B>: Bracketed language to be included for sponsor-affiliated directors. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company shall not seek from a court, or agree to, a &#147;bar order&#148; that would have the effect of
prohibiting or limiting the Indemnitee&#146;s rights to receive advancement of Expenses under this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company shall require and cause any successor (including any direct or indirect successor by purchase,
merger, consolidation or otherwise to all, substantially all or a substantial part of the business and/or assets of the Company) to expressly assume and agree to perform this Agreement in the same manner and to the same extent that the Company would
be required to perform if no such succession had taken place. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company and the Indemnitee agree herein that a monetary remedy for breach of this Agreement, at some later
date, may be inadequate, impracticable and difficult of proof, and further agree that such breach may cause the Indemnitee irreparable harm. Accordingly, the parties hereto agree that the Indemnitee may enforce this Agreement by seeking injunctive
relief and/or specific performance hereof, without any necessity of showing actual damage or irreparable harm and that by seeking injunctive relief and/or specific performance, the Indemnitee shall not be precluded from seeking or obtaining any
other relief to which the Indemnitee may be entitled. The Company and the Indemnitee further agree that the Indemnitee shall be entitled to such specific performance and injunctive relief, including temporary restraining orders, preliminary
injunctions and permanent injunctions, without the necessity of posting bonds or other undertaking in connection therewith. The Company acknowledges that in the absence of a waiver, a bond or undertaking may be required of the Indemnitee by the
court, and the Company hereby waives any such requirement of such a bond or undertaking. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">13.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Definitions</U>. For purposes of this Agreement: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>Beneficial Owner</U>&#148; shall have the meaning given to such term in Rule <FONT
STYLE="white-space:nowrap">13d-3</FONT> under the Exchange Act. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>Change in Control</U>&#148; shall be deemed to occur upon the earliest to occur after the date of this
Agreement of any of the following events: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a change in ownership or control of the Company effected through a transaction or series of transactions (other
than an offering of shares to the general public through a registration statement filed with the U.S. Securities and Exchange Commission or similar <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory agency) whereby any &#147;person,&#148;
as such term is used in Sections&nbsp;13(d) and&nbsp;14(d) of the Exchange Act (other than the Company, any trustee or other fiduciary holding securities under any employee benefit plan of the Company, or any company owned, directly or indirectly,
by the </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
shareholders of the Company in substantially the same proportions as their ownership of the Company), becomes the Beneficial Owner, directly or indirectly, of securities of the Company
representing 50% or more of the combined voting power of the Company&#146;s then-outstanding securities, excluding for purposes herein, acquisitions pursuant to a Business Combination that does not constitute a Change in Control as defined
in<U>&nbsp;Section</U><U></U><U>&nbsp;13(b)(ii)</U>; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the consummation of a merger, amalgamation, reorganization or consolidation of the Company with or into the
Company or in which equity securities of the Company are issued (each, a &#147;<U>Business Combination</U>&#148;), other than a merger, amalgamation, reorganization or consolidation that would result in the voting securities of the Company
outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its direct or indirect parent) more than 50% of the combined voting power of the
voting securities of the Company or such surviving entity (or, as applicable, a direct or indirect parent of the Company or such surviving entity), outstanding immediately after such merger, reorganization or consolidation; <U>provided</U>,
<U>however</U>, that a merger, reorganization or consolidation effected to implement a recapitalization of the Company (or similar transaction) in which no person (other than those covered by the exceptions in
<U>Section</U><U></U><U>&nbsp;13(b)(</U><U>i</U><U>)</U>) acquires more than 50% of the combined voting power of the Company&#146;s then-outstanding securities shall not constitute a Change in Control; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the date, within any consecutive <FONT STYLE="white-space:nowrap">two-year</FONT> period commencing on or after
the date of this Agreement, upon which individuals who, at the beginning of such period, constitute the Board together with any new director(s) (other than a director designated by a person who has entered into an agreement with the Company to
effect a transaction described in <U>Section</U><U></U><U>&nbsp;13(b)(</U><U>i</U><U>)</U>, <U>13(b)(ii)</U> or <U>13(b)(iv)</U> of this Agreement) whose election by the Board or nomination for election by the Company&#146;s shareholders was
approved by a vote of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the directors then in office who either were directors at the beginning of the <FONT STYLE="white-space:nowrap">two-year</FONT> period or whose election or
nomination for election was previously so approved, cease for any reason to constitute a majority thereof; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a complete liquidation or dissolution of the Company or the consummation of a sale or disposition by the
Company of all or substantially all of the Company&#146;s assets other than the sale or disposition of all or substantially all of the assets of the Company to a person or persons who beneficially own, directly or indirectly, 50% or more of the
combined voting power of the outstanding voting securities of the Company at the time of the sale; or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the occurrence of any other event of a nature that would be required to be reported in response to Item 6(e) of
Schedule 14A of Regulation 14A (or a response to any similar item on any similar schedule or form) promulgated under the Exchange Act, whether or not the Company is then subject to such reporting requirement, except the completion of the
Company&#146;s initial public offering shall not be considered a Change in Control. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Notwithstanding anything contained
herein, a transaction shall not constitute a &#147;Change in Control&#148; for the purposes of this definition if (1)&nbsp;the Company becomes a direct or indirect wholly owned subsidiary of a holding company and (2)&nbsp;the direct or indirect
holders of the voting stock of such holding company immediately following that transaction are substantially the same as the holders of the Company&#146;s voting stock immediately prior to that transaction. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>Corporate Status</U>&#148; describes the status of a person who is or was a director, officer,
partner, trustee, member, manager, employee, agent or fiduciary of the Company or of any other Enterprise. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>Disinterested Director</U>&#148; means a director of the Company who is not and was not a party to the
Proceeding in respect of which indemnification is sought by the Indemnitee. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>Enterprise</U>&#148; shall mean the Company and any corporation, partnership, joint venture, trust,
limited liability company, employee benefit plan or other enterprise that the Indemnitee is or was serving at the request of the Company as a director, officer, trustee, partner, member, manager, employee, agent or fiduciary. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>Exchange Act</U>&#148; means the Securities Exchange Act of 1934, as amended. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>Expenses</U>&#148; shall mean all reasonable direct and indirect costs, fees and expenses of any type
or nature whatsoever and shall specifically include, without limitation, all reasonable attorneys&#146; fees, retainers, court costs, transcript costs, fees and costs of experts and other professionals, witness fees, travel expenses, duplicating
costs, printing and binding costs, telephone charges, postage, delivery service fees and all other disbursements or expenses of the types customarily incurred in connection with prosecuting, defending, preparing to prosecute or defend,
investigating, participating, or being or preparing to be a witness in, or otherwise participating in, a Proceeding, or responding to, or objecting to, a request to provide discovery in any Proceeding. Expenses also shall include Expenses incurred
in connection with any appeal resulting from any Proceeding, including without limitation the premium, security for, and other costs relating to any cost bond, supersedeas bond, or other appeal bond or its equivalent, and any federal, state, local
or foreign taxes imposed on the Indemnitee as a result of the actual or deemed receipt of any payments under this Agreement, as well as all reasonable attorneys&#146; fees and all other expenses incurred by or on behalf of the Indemnitee in
connection with preparing and submitting any requests or statements for </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
indemnification, advancement, contribution or any other right provided by this Agreement. Expenses, however, shall not include amounts paid in settlement by the Indemnitee or the amount of
judgments or fines against the Indemnitee. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>Fullest Extent Permitted </U><U>By</U><U> Applicable Law</U>&#148; includes, but is not limited to:
(a)&nbsp;to the fullest extent permitted by the applicable provision of the Companies Act, or the corresponding provision of any amendment to or replacement of the Companies Act, and (b)&nbsp;to the fullest extent authorized or permitted by any
amendments to or replacements of the Companies Act adopted after the date of this Agreement that increase the extent to which a corporation may indemnify its directors and officers. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>Independent Counsel</U>&#148; means a law firm, or a member of a law firm, that is experienced in
matters of Bermuda company law and neither presently is, nor in the past five (5)&nbsp;years has been, retained to represent: (i)&nbsp;the Company or the Indemnitee in any matter material to either such party (other than with respect to matters
concerning the Indemnitee under this Agreement, or of other indemnitees under similar indemnification agreements), or (ii)&nbsp;any other party to the Proceeding giving rise to a claim for indemnification hereunder. Notwithstanding the foregoing,
the term &#147;Independent Counsel&#148; shall not include any person who, under the applicable standards of professional conduct then prevailing, would have a conflict of interest in representing either the Company or the Indemnitee in an action to
determine the Indemnitee&#146;s rights under this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(j)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>Losses</U>&#148; means all liabilities, judgments, fines, penalties, costs, losses, excise taxes or
penalties under the Employee Retirement Income Security Act of 1974, as amended from time to time, amounts paid in settlement (including all interest assessments and other charges paid or payable in connection with or in respect of such liabilities,
losses, judgements, fines, excise taxes, penalties and costs) and other amounts that the Indemnitee reasonably incurs and that result from, arise in connection with or are by reason of the Indemnitee&#146;s Corporate Status. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(k)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>Proceeding</U>&#148; includes any threatened, pending or completed action, suit, claim, counterclaim,
cross claim, arbitration, mediation, alternate dispute resolution mechanism, investigation, inquiry, administrative hearing or any other actual, threatened or completed proceeding, whether brought by or in the right of the Company or otherwise and
whether civil, criminal, administrative or investigative, in which the Indemnitee was, is or will be involved as a party, potential party, <FONT STYLE="white-space:nowrap">non-party</FONT> witness or otherwise, by reason of the Indemnitee&#146;s
Corporate Status or by reason of any action taken by the Indemnitee or of any inaction on the Indemnitee&#146;s part while acting in the Indemnitee&#146;s Corporate Status, in each case whether or not the Indemnitee is acting or serving in any such
capacity at the time any liability or expense is incurred for which indemnification can be provided under this Agreement, and including one pending on or before the date of this Agreement, but excluding one initiated by an Indemnitee pursuant to
<U>Section</U><U></U><U>&nbsp;6</U> of this Agreement to enforce the Indemnitee&#146;s rights under this Agreement. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(l)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[&#147;Bain&#148; means, collectively, Bain Capital L.P. and any entity that controls, is controlled by or
under common control with Bain Capital L.P. (other than the Company and any entity that is controlled by the Company) and any investment vehicles or funds managed or controlled, directly or indirectly, by or otherwise affiliated with Bain Capital
L.P.] <SUP STYLE="font-size:75%; vertical-align:top">7</SUP> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">14.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Severability</U>. If any provision or provisions of this Agreement shall be held to be invalid, illegal or
unenforceable for any reason whatsoever: (i)&nbsp;the validity, legality and enforceability of the remaining provisions of this Agreement (including, without limitation, each portion of any section, paragraph or sentence of this Agreement containing
any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) shall not in any way be affected or impaired thereby and shall remain enforceable to the Fullest Extent Permitted By Applicable
Law, (ii)&nbsp;such provision or provisions shall be deemed reformed to the fullest extent necessary to conform to applicable law and to give the maximum effect to the intent of the parties hereto, and (iii)&nbsp;to the Fullest Extent Permitted By
Applicable Law, the provisions of this Agreement (including, without limitation, each portion of any section, paragraph or sentence of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not itself
invalid, illegal or unenforceable) shall be construed so as to give effect to the intent manifested thereby. Without limiting the generality of the foregoing, this Agreement is intended to confer upon the Indemnitee [and Bain] <SUP
STYLE="font-size:75%; vertical-align:top">8</SUP> indemnification rights to the Fullest Extent Permitted By Applicable Law. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">15.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Modification and Waiver</U>. No supplement, modification, termination or amendment of this Agreement shall
be binding unless executed in writing by both of the parties hereto. No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other provisions hereof (whether or not similar) nor shall such waiver
constitute a continuing waiver. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">16.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Notice </U><U>By</U><U> the Indemnitee</U>. The Indemnitee agrees to promptly notify the Company in writing
upon being served with or otherwise receiving any summons, citation, subpoena, complaint, indictment, information or other document relating to any Proceeding or matter which may be subject to indemnification or advancement of Expenses covered
hereunder. The failure to so notify the Company shall not relieve the Company of any obligation which it may have to the Indemnitee under this Agreement or otherwise unless and only to the extent that such failure or delay materially prejudices the
interests of the Company. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">17.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Notices</U>. All notices and other communications given or made pursuant to this Agreement shall be in
writing and shall be deemed effectively given: (i)&nbsp;upon personal delivery to the party to be notified, (ii)&nbsp;when sent by confirmed electronic mail or facsimile if sent during normal business hours of the recipient, and if not so confirmed,
then on the next business day, (iii)&nbsp;five (5) days after having been sent by registered or certified mail, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">7</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>NTD</B>: Bracketed language to be included for sponsor-affiliated directors. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">8</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>NTD</B>: Bracketed language to be included for sponsor-affiliated directors.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
return receipt requested, postage prepaid, or (iv)&nbsp;one (1) day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification of
receipt. All communications shall be sent: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To the Indemnitee at the address set forth below the Indemnitee&#146;s signature hereto. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To the Company at: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">c/o West Affum Holdings, L.P. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">3933 Lake Washington Blvd NE, Suite 200 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Kirkland, Washington 98033 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention: [&#9679;] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Email:
[&#9679;] </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">or to such other address as may have been furnished to the Indemnitee by the Company or to the Company by the Indemnitee, as the
case may be. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">18.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Construction</U>. Whenever required by the context, as used in this Agreement the singular number shall
include the plural, the plural shall include the singular, and all words herein in any gender shall be deemed to include (as appropriate) the masculine, feminine and neuter genders. References to &#147;day&#148; shall mean a calendar day unless
expressly stated to the contrary. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">19.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Counterparts</U>. This Agreement may be executed in two or more counterparts, each of which shall be deemed
an original, but all of which together shall constitute one and the same Agreement. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000,
<I>e.g.</I>, www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">20.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Headings</U>. The headings of the paragraphs of this Agreement are inserted for convenience only and shall
not be deemed to constitute part of this Agreement or to affect the construction thereof. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">21.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Governing Law and Consent to Jurisdiction</U>. This Agreement and the legal relations among the parties
shall be governed by, and construed and enforced in accordance with, the laws of Bermuda, without regard to its conflict of laws rules. The Company and the Indemnitee hereby irrevocably and unconditionally (i)&nbsp;agree that any action or
proceeding arising out of or in connection with this Agreement shall, unless the Company consents in writing to the selection of an alternate forum, be brought only in the Supreme Court of Bermuda, (ii)&nbsp;generally and unconditionally consent to
submit to the exclusive jurisdiction of the Supreme Court of Bermuda for purposes of any action or proceeding arising out of or in connection with this Agreement, (iii)&nbsp;irrevocably appoint, to the extent such party is not otherwise subject to
service of process in Bermuda, Maples Corporate Services (Bermuda) Limited, Cumberland House, 7th Floor, 1 Victoria Street, Hamilton, HM11, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Bermuda as its agent in Bermuda, as its agent in Bermuda, as such party&#146;s agent for acceptance of legal process in connection with any such action or proceeding against such party with the
same legal force and validity as if such party had been personally served within Bermuda, (iv)&nbsp;waive any objection to the laying of venue of any such action or proceeding in the Supreme Court of Bermuda, and (v)&nbsp;waive, and agree not to
plead or to make, any claim that any such action or proceeding brought in the Supreme Court of Bermuda has been brought in an improper or inconvenient forum. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">22.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[<U><FONT STYLE="white-space:nowrap">Non-Exclusive</FONT> Capacities of Indemnitee</U>. The Company
acknowledges and agrees that Indemnitee provides services to entities other than the Company. The Company further acknowledges and agrees that Bain invests in entities other than the Company, and may also provide financial, operational and other
advisory services to such entities in connection with such investments.] <SUP STYLE="font-size:75%; vertical-align:top">9</SUP> </P></TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[SIGNATURE PAGE FOLLOWS] </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">9</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>NTD</B>: Bracketed language to be included for sponsor-affiliated directors. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties hereto have executed this Agreement on and as of the
day and year first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="96%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>KESTRA MEDICAL TECHNOLOGIES, LTD.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INDEMNITEE</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR></TABLE></DIV>
<DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I></I>[<I>Signature Page to Indemnification Agreement</I>]<I> </I></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.9
<SEQUENCE>11
<FILENAME>d744414dex109.htm
<DESCRIPTION>EX-10.9
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.9</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXHIBIT 10.9 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g744414dsp384.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>KESTRA MEDICAL TECHNOLOGIES, LTD. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXECUTIVE SEVERANCE AND CHANGE IN CONTROL POLICY </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>EFFECTIVE DATE:</B> [&#9679;] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Purpose </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The purpose of the Kestra Medical Technologies, Ltd. Severance and Change in Control Policy (this &#147;<B>Policy</B>&#148;) is to outline the severance and
certain other payment benefit policies of Kestra Medical Technologies, Ltd. (together with its subsidiaries, the &#147;<B>Company</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Definitions </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Cause</B>&#148; has the meaning
set forth in the Equity Incentive Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Change in Control</B>&#148; has the meaning set forth in the Equity Incentive Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Change in Control Protection Period</B>&#148; means the three (3)-month period before a Change in Control of the Company and the twelve (12)-month
period following a Change in Control of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>COBRA</B>&#148; means the Consolidated Omnibus Budget Reconciliation Act, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Code</B>&#148; means the Internal Revenue Code of 1986, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Committee</B>&#148; means the Compensation Committee of the Board of Directors of the Company (the &#147;<B>Board</B>&#148;) or such other committee
duly authorized by the Board to administer this Policy. If no committee is duly authorized by the Board to administer this Policy, the term &#147;Committee&#148; shall be deemed to refer to the Board for all purposes under this Policy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Employment Agreement</B>&#148; means, with respect to an Executive, the employment agreement entered into between such Executive and the Company or
one of its affiliates, in effect as of the relevant date of termination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Equity Incentive Plan</B>&#148; means the Kestra Medical Technologies,
Ltd. 2025 Omnibus Incentive Plan, as may be amended, restated or otherwise modified from time to time, or any successor equity incentive plan established by the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Executive</B>&#148; means an employee of the Company whose titles include Chief Level Officers, Vice Presidents, Directors, and above. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>&#147;</B><B>Target Bonus</B><B>&#148;</B> means Executive&#146;s target annual bonus for the fiscal year
that includes such Executive&#146;s date of termination of employment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Administration </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Committee shall be responsible for the management and control of the operation and the administration of this Policy, including interpretation of this
Policy, decisions pertaining to eligibility to participate in the Policy, computation of severance benefits, granting or denial of severance benefit claims, and review of claims denials. The Committee has absolute discretion in the exercise of its
powers and responsibilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Eligibility </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Policy applies to all Executives, except where severance benefits are otherwise specifically provided for in an Employment Agreement. In order to receive
any severance benefits hereunder, any Executive is required to (i)&nbsp;execute and not revoke a release of claims in favor of the Company, its affiliates and its subsidiaries and (ii)&nbsp;continue to remain in compliance with any restrictive
covenant obligations such Executive has in place with the Company, its affiliates, and its subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Triggering Events </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event of an involuntary termination of employment other than for Cause, the Company will provide a severance benefit for the affected Executive.
Executives are entitled to enhanced severance in connection with a termination of employment during a Change in Control Protection Period. This Policy does not apply to terminations for Cause, refusals to be reassigned, refusals to be relocated, or
voluntary resignations. An involuntary termination of employment other than for Cause during the Change in Control Protection Period that occurs in the three (3)&nbsp;months prior to a Change in Control will be deemed to occur upon the occurrence of
the Change in Control for purposes of this Policy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Payment Amount </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For Executives (other than those where severance benefits are otherwise specifically provided for in an Employment Agreement), their rate of severance is
based on position, as follows: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Executive Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Termination without</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Cause</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Termination without Cause during a</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Change in Control Protected Period</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Senior Vice Presidents and above</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">12 months base salary</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">12 months base salary + 100% of Target Bonus</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Other Executives</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">6 months base salary</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">9 months base salary + 75% of Target Bonus</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Executives will receive severance in the form of (i)&nbsp;a salary continuation benefit (continued payments made through
payroll) over the applicable severance period and (ii)&nbsp;subject to the timely election of continued health care coverage under COBRA, will also be entitled to reimbursement of the COBRA premiums until the last day of such severance period (or if
earlier, until (x)&nbsp;the date such Executive is no longer eligible to receive COBRA continuation coverage or (y)&nbsp;the date on which such Executive becomes eligible to receive coverage under a group health plan sponsored by another employer
(and any such eligibility shall be promptly reported to the Company by such Executive)). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Vacation/Paid Time Off (PTO) </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accrued but unused vacation/PTO will be paid out to Executives in connection with a termination of employment under this Policy. Vacation/PTO will stop
accruing as of the Executive&#146;s date of termination. For Executives who take vacation on an as needed basis, the Company&#146;s policy is to accrue the following as unused vacation/PTO: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Chief Level Executives:</B> 8 weeks per year, not to exceed 16 weeks </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Vice Presidents:</B> 5 weeks per year, not to exceed 10 weeks </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Commissions </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any commissions earned by an
Executive as of the date of the termination will be paid out at the time of termination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Insurance Benefits </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Health and dental insurance coverage, if applicable, end on the last day of the month in which an Executive receives the severance benefit. Upon termination
of coverage, COBRA notification will be forwarded. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>No Duplication </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Policy shall be construed and administered in a manner which avoids duplication of compensation and benefits which may be provided under any other plan,
program, policy or other arrangement or individual contract or under any statute, rule or regulation, including, without limitation, any applicable Employment Agreement and the Kestra Medical Technologies, Inc. Severance and Other Pay Benefit
Policy, dated as of March&nbsp;1, 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Certain Excise Taxes </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding anything to the contrary in this Policy, if an Executive is a &#147;disqualified individual&#148; (as defined in Section&nbsp;280G(c) of the
Code), and the payments and benefits provided for in this Policy, together with any other payments and benefits which such Executive has the right to receive from the Company or any of its affiliates, and taking into account reductions in respect of
reasonable compensation for personal services to be rendered by the Executive on or following the date of the relevant &#147;change in ownership or control&#148; (within the meaning of Section&nbsp;280G of the Code), including pursuant to applicable
<FONT STYLE="white-space:nowrap">non-competition</FONT> and other restrictive covenant obligations, would constitute a &#147;parachute payment&#148; (as defined in Section&nbsp;280G(b)(2) of the Code), then the payments and benefits provided for in
this Policy shall be either (a)&nbsp;reduced (but not below zero (0)) so that the present value of such total amounts and benefits received by such Executive from the Company and its affiliates will be one (1)&nbsp;dollar less than three
(3)&nbsp;times such Executive&#146;s &#147;base amount&#148; (as defined in Section&nbsp;280G(b)(3) of the Code) and so that no portion of such amounts and benefits received by such Executive shall be subject to the excise tax imposed by
Section&nbsp;4999 of the Code or (b)&nbsp;paid in full, whichever produces the better net <FONT STYLE="white-space:nowrap">after-tax</FONT> position to such Executive (taking into account any applicable excise tax under Section&nbsp;4999 of the Code
and any other applicable taxes). The reduction of payments and benefits hereunder, if applicable, shall be made by reducing, first, payments or benefits to be paid in cash hereunder in the order in which such payment or benefit would be paid or
provided (beginning with such payment or benefit that would be made last in time and continuing, to the extent necessary, through to such payment or benefit that would be made first in time) and, then, reducing any benefit to be provided <FONT
STYLE="white-space:nowrap">in-kind</FONT> hereunder in a similar order. The determination as to whether any such reduction in the amount of the payments and benefits provided hereunder is necessary shall be made by the Company in good faith. If a
reduced payment or benefit is made or provided and through error or otherwise that payment or benefit, when aggregated with other payments and benefits from the Company (or its affiliates) used in determining if a &#147;parachute payment&#148;
exists, exceeds one (1)&nbsp;dollar less than three (3)&nbsp;times such Executive&#146;s base amount, then such Executive shall immediately repay such excess to the Company upon notification that an overpayment has been made. Nothing in this<I>
</I>paragraph shall require the Company to be responsible for, or have any liability or obligation with respect to, such Executives&#146; excise tax liabilities under Section&nbsp;4999 of the Code. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Section&nbsp;409A </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Policy is intended to comply with Section&nbsp;409A or an exemption thereunder and shall be construed and administered in accordance with
Section&nbsp;409A. Notwithstanding any other provision of this Policy, payments provided under this Policy may only be made upon an event and in a manner that complies with Section&nbsp;409A or an applicable exemption. Any payments under this Policy
that may be excluded from Section&nbsp;409A either as separation pay due to an involuntary separation from service or as a short-term deferral shall be excluded from Section&nbsp;409A to the maximum extent possible. Any payments to be made under
this Policy upon the termination of an Executive&#146;s employment shall only be made if such termination of employment constitutes a &#147;separation from service&#148; under Section&nbsp;409A. In no event may an Executive, directly or indirectly,
designate the calendar year of any payment under this Policy. Each installment payment under this Policy is intended to be a separate payment for purposes of Section&nbsp;409A. Notwithstanding any provision in this Policy to the contrary, if any
payment or benefit provided for herein would be subject to additional taxes and interest under Section&nbsp;409A if an Executive&#146;s receipt of such payment or benefit is not delayed until the earlier of (i)&nbsp;the date of such Executive&#146;s
death or (ii)&nbsp;the date that is six months after such Executive&#146;s termination date (such date, the &#147;<B>Section</B><B></B><B>&nbsp;409A</B><B> </B><B>Payment Date</B>&#148;), then such payment or benefit shall not be provided to such
Executive (or such Executive&#146;s estate, if applicable) until the Section&nbsp;409A Payment Date. Notwithstanding the foregoing, the Company makes no representations that the payments and benefits provided under this Policy are exempt from, or
compliant with, Section&nbsp;409A and in no event shall the Company or any of its Affiliates be liable for all or any portion of any taxes, penalties, interest or other expenses that may be incurred by any Executive on account of <FONT
STYLE="white-space:nowrap">non-compliance</FONT> with Section&nbsp;409A. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>ERISA </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company intends that this Policy constitute an unfunded &#147;welfare plan&#148; as such term is defined under the Employee Retirement Income Security Act
of 1974 (&#147;<B>ERISA</B>&#148;), as it may be amended from time to time, for the benefit of a select group of management and highly compensated employees. No participant, employee of the Company or any other person shall have any rights to or
interest in any specific assets or accounts of the Company or any of its affiliates by reason of this Policy. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Claims Procedure and Review </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Filing a Claim</U>. Any Executive that the Committee determines is entitled to severance benefits under this Policy is not required to file a claim for
benefits. Any Executive (i)&nbsp;who is not paid severance benefits hereunder and who believes that such Executive is entitled to severance benefits hereunder or (ii)&nbsp;who has been paid severance benefits hereunder and believes that such
Executive is entitled to greater benefits hereunder may file a claim for severance benefits under the Policy in writing with the Committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Initial
Determination of a Claim</U>. If a claim for severance benefits hereunder is wholly or partially denied, the Committee shall, within a reasonable period of time but no later than ninety (90)&nbsp;days after receipt of the claim (or <FONT
STYLE="white-space:nowrap">one-hundred</FONT> and eighty (180)&nbsp;days after receipt of the claim if special circumstances require an extension of time for processing the claim), notify the claimant of the denial. Such notice shall (i)&nbsp;be in
writing, (ii)&nbsp;be written in a manner calculated to be understood by the claimant, (iii)&nbsp;contain the specific reason or reasons for denial of the claim, (iv)&nbsp;refer specifically to the pertinent Policy provisions upon which the denial
is based, (v)&nbsp;describe any additional material or information necessary for the claimant to perfect the claim (and explain why such material or information is necessary), and (vi)&nbsp;describe the Policy&#146;s claim review procedures and time
limits applicable to such procedures, including a statement of the claimant&#146;s right to bring a civil action under Section&nbsp;502(a) of ERISA following an adverse benefit determination on review. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Appeal of a Denied Claim</U>. Within sixty (60)&nbsp;days of the receipt by the claimant of this notice, the claimant may file a written appeal with the
Committee. In connection with the appeal, the claimant may review Policy documents and may submit written issues and comments. The Committee shall deliver to the claimant a written decision on the appeal promptly, but not later than sixty
(60)&nbsp;days after the receipt of the claimant&#146;s appeal (or <FONT STYLE="white-space:nowrap">one-hundred</FONT> and twenty (120)&nbsp;days after receipt of the claimant&#146;s appeal if there are special circumstances which require an
extension of time for processing). Such decision shall (i)&nbsp;be in writing, (ii)&nbsp;be written in a manner calculated to be understood by the claimant, (iii)&nbsp;include specific reasons for the decision, (iv)&nbsp;refer specifically to the
Policy provisions upon which the decision is based, (v)&nbsp;state that the claimant is entitled to receive, on request and free of charge, reasonable access to and copies of all documents, records, and other information relevant to the
claimant&#146;s claim for benefits, and (vi)&nbsp;a statement of the claimant&#146;s right to bring an action under Section&nbsp;502(a) of ERISA. If special circumstances require an extension of up to
<FONT STYLE="white-space:nowrap">one-hundred</FONT> and eighty (180)&nbsp;days for an initial claim or <FONT STYLE="white-space:nowrap">one-hundred</FONT> and twenty (120)&nbsp;days for an appeal, whichever applies, the Committee shall send written
notice of the extension. This notice shall indicate the special circumstances requiring the extension and state when the Committee expects to render the decision. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This severance benefits claim procedure is intended to comply with the provisions of 29 C.F.R. <FONT
STYLE="white-space:nowrap">&#167;2560.503-1.</FONT> All provisions of this Policy shall be interpreted, construed, and limited in accordance with such intent. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.10
<SEQUENCE>12
<FILENAME>d744414dex1010.htm
<DESCRIPTION>EX-10.10
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.10</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXHIBIT 10.10 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>KESTRA MEDICAL TECHNOLOGIES, LTD. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DIRECTOR COMPENSATION POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Director Compensation Policy (this &#147;<U>Policy</U>&#148;) of Kestra Medical Technologies, Ltd. (the &#147;<U>Company</U>&#148;), as
adopted by the Board of Directors of the Company (the &#147;<U>Board</U>&#148;), effective as of [&#149;] (the &#147;<U>Effective Date</U>&#148;), sets forth the compensation payable to each member of the Board who is not an employee of the Company
or any of its subsidiaries (each, a &#147;<U><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director</U>&#148;) and each member of the Board who is an employee of the Company or any of its subsidiaries (each, an &#147;<U>Executive
Director</U>&#148; and together with the <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors, the &#147;<U>Directors</U>&#148;) as consideration solely for service on the Board. For the avoidance of doubt, nothing in this Policy will
prohibit the Company from compensating any Director for services provided to the Company outside of such Director&#146;s service on the Board. This Policy shall become effective on the Effective Date and shall remain in effect until it is revised or
rescinded by the Board in its sole discretion at any time and from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <B><U>General</U></B>. This Policy shall be followed
in connection with all compensation paid by the Company to Directors. The terms and conditions of this Policy shall supersede any prior cash and/or equity compensation arrangements for service as a member of the Board between the Company and any of
its Directors and between any subsidiary of the Company and any of its directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <B><U>Cash Compensation</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <I>Executive Director Annual Stipend</I><I>. </I>Each Executive Director serving as a member of the Board shall receive an annual cash
stipend of $50,000 (the &#147;<U>Annual Stipend</U>&#148;) for service on the Board. Executive Directors shall not be entitled to any other cash, equity or other compensation under this Policy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Annual Retainer. </I>Each
<FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director serving as a member of the Board shall receive an annual cash retainer of $60,000 for service on the Board, and (ii)&nbsp;the <FONT STYLE="white-space:nowrap">non-executive</FONT> chair,
if any, shall receive an additional annual cash retainer of $60,000 ((i) and (ii), as applicable, the &#147;<U>Annual Retainer</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <I>Committee Chair Compensation. </I>A <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director shall receive the following
additional annual retainers for serving as a committee chair (the &#147;<U>Committee Chair Compensation</U>&#148;): </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) The chair of the
Audit Committee shall receive an additional annual retainer of $25,000 for such service. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) The chair of the Compensation Committee
shall receive an additional annual retainer of $18,000 for such service. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) The chair of the Governance Committee shall receive an
additional annual retainer of $12,000 for such service. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <I>Committee Member Compensation</I>. A
<FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director, excluding the chair of the applicable committee, shall receive the following additional annual retainers for serving as a committee member (the &#147;<U>Committee Member
Compensation</U>&#148;): </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) Each member of the Audit Committee shall receive an additional annual retainer of $12,000 for such service.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) Each member of the Compensation Committee shall receive an additional annual retainer of $9,000 for such service. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) Each member of the Governance Committee shall receive an additional annual retainer of $6,000 for such service. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <I>Payment Schedule and Prorated Compensation for the Annual Stipend, Annual Retainers, Committee Chair Compensation and Committee Member
Compensation</I>. The Annual Stipend, Annual Retainer, Committee Chair Compensation and Committee Member Compensation (collectively, &#147;<U>Cash Compensation</U>&#148;) for each Director shall be paid by the Company in quarterly installments in
arrears within 60 days following the completion of each quarter. Such amounts shall be paid in the calendar quarter immediately following the quarter to which such amount relates. If a Director does not serve as a Director (or in the applicable
positions described in <U>Sections 2(b)</U> or<U> 2(c)</U>) for an entire calendar quarter, such Director shall receive a prorated portion of the Cash Compensation otherwise payable to such Director for such calendar quarter pursuant to <U>Sections
2(a)</U>, <U>2(b)</U> and <U>2(c)</U>, with such prorated portion determined by multiplying such otherwise payable Cash Compensation by a fraction, the numerator of which is the number of days during which the Director serves as a Director (or in
the applicable positions described in <U>Sections 2(b)</U> or <U>2(c)</U>) during the applicable calendar quarter and the denominator of which is the number of days in the applicable calendar quarter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <B><U>Equity Compensation</U></B>. <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors shall be granted the equity awards
described below, subject to the Board&#146;s approval. The awards described below shall be granted under and shall be subject to the terms and provisions of the Kestra Medical Technologies, Ltd. 2025 Omnibus Incentive Plan or any other applicable
Company equity incentive plan then-maintained by the Company (such plan, as may be amended from time to time, the &#147;<U>Equity Plan</U>&#148;) and shall be granted subject to award agreements in substantially the forms approved by the Board. All
applicable terms of the Equity Plan apply to this Policy as if fully set forth herein, and all equity grants hereunder are subject in all respects to the terms of the Equity Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <I>Annual Award</I>. Each <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director who (i)&nbsp;serves on the Board as of the date of
any annual meeting of the Company&#146;s stockholders (an &#147;<U>Annual Meeting</U>&#148;) and (ii)&nbsp;will continue to serve as a <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director immediately following such Annual Meeting shall be
granted, subject to the Board&#146;s approval, on the date of such Annual Meeting, an award of Restricted Stock Units (as defined in the Equity Plan, &#147;<U>RSUs</U>&#148;) pursuant to the Equity Plan with a grant date value equal to approximately
$185,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <I>Additional Terms of Awards</I>. Each award will be granted under and subject to the terms and conditions of the Equity
Plan and the applicable form of award agreement (if any) previously approved by the Board. The Board may change or otherwise revise the terms of awards to be granted in the future pursuant to this Policy in its discretion. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <B><U>Expense Reimbursement</U></B>. All Directors will be eligible to be reimbursed for
reasonable <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred to attend meetings of the Board or committees thereof or otherwise performing duties consistent with service on the Board in
accordance with the Company&#146;s expense reimbursement policy, subject to the provision by the applicable Director of documentation evidencing such expenses in a form reasonably satisfactory to the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <B><U>Section 409A</U></B>. In no event will cash compensation or expense reimbursement payments under this Policy be paid after the later
of (a)&nbsp;the 15th day of the third month following the end of the Company&#146;s taxable year in which the compensation is earned or expenses are incurred, as applicable, or (b)&nbsp;the 15th day of the third month following the end of the
calendar year in which the compensation is earned or expenses are incurred, as applicable, in compliance with the &#147;short-term deferral&#148; exception under Section&nbsp;409A. It is the intent of this Policy that this Policy and all payments
hereunder be exempt from or otherwise comply with the requirements of Section&nbsp;409A so that none of the compensation to be provided hereunder will be subject to the additional tax imposed under Section&nbsp;409A, and any ambiguities or ambiguous
terms herein will be interpreted to be so exempt or comply. In no event will the Company have any responsibility, liability, or obligation to reimburse, indemnify, or hold harmless a Director (or any other person) for any taxes imposed, or other
costs incurred, as a result of Section&nbsp;409A. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <B><U>Insider Trading</U></B>. All Directors are subject to the Company&#146;s
Insider Trading Policy. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.11
<SEQUENCE>13
<FILENAME>d744414dex1011.htm
<DESCRIPTION>EX-10.11
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.11</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>E<SMALL>XHIBIT</SMALL> 10.11 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">E<SMALL>XECUTION</SMALL> V<SMALL>ERSION</SMALL> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS EXHIBIT MARKED BY [***] HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION
THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C<SMALL>REDIT</SMALL>
A<SMALL>GREEMENT</SMALL> <SMALL>AND</SMALL> G<SMALL>UARANTY</SMALL> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">dated as of </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">September&nbsp;29, 2023 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">among
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">K<SMALL>ESTRA</SMALL> M<SMALL>EDICAL</SMALL> T<SMALL>ECHNOLOGIES</SMALL>, I<SMALL>NC</SMALL>. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">W<SMALL>EST</SMALL> A<SMALL>FFUM</SMALL> H<SMALL>OLDINGS</SMALL> C<SMALL>ORP</SMALL>. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">as Borrowers, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">T<SMALL>HE</SMALL>
G<SMALL>UARANTORS</SMALL> <SMALL>FROM</SMALL> T<SMALL>IME</SMALL> <SMALL>TO</SMALL> T<SMALL>IME</SMALL> P<SMALL>ARTY</SMALL> <SMALL>HERETO</SMALL>, </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">as Guarantors, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">T<SMALL>HE</SMALL>
L<SMALL>ENDERS</SMALL> <SMALL>FROM</SMALL> T<SMALL>IME</SMALL> <SMALL>TO</SMALL> T<SMALL>IME</SMALL> P<SMALL>ARTY</SMALL> <SMALL>HERETO</SMALL>, </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">as Lenders, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">P<SMALL>ERCEPTIVE</SMALL> C<SMALL>REDIT</SMALL> H<SMALL>OLDINGS</SMALL>&nbsp;IV, LP, </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">as Administrative Agent and as a Lender </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>T<SMALL>ABLE</SMALL> <SMALL>OF</SMALL> C<SMALL>ONTENTS</SMALL> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">S<SMALL>ECTION</SMALL></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">H<SMALL>EADING</SMALL></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">P<SMALL>AGE</SMALL></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">A<SMALL>RTICLE</SMALL>&nbsp;1.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">D<SMALL>EFINITIONS</SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.01.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Certain Defined Terms</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.02.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Accounting Terms and Principles</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.03.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Interpretation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.04.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Divisions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.05.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Interest Rates</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">A<SMALL>RTICLE</SMALL>&nbsp;2.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">T<SMALL>HE</SMALL> C<SMALL>OMMITMENTS</SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.01.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Term Loans</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.02.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Proportionate Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.03.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.04.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.05.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Use of Proceeds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">A<SMALL>RTICLE</SMALL>&nbsp;3.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">P<SMALL>AYMENTS</SMALL> <SMALL>OF</SMALL> P<SMALL>RINCIPAL</SMALL> <SMALL>AND</SMALL>
I<SMALL>NTEREST</SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.01.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Repayment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.02.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.03.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Prepayments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">A<SMALL>RTICLE</SMALL>&nbsp;4.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">P<SMALL>AYMENTS</SMALL>, E<SMALL>TC</SMALL>.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.01.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.02.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Computations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.03.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Notices</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.04.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Set-Off</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">A<SMALL>RTICLE</SMALL>&nbsp;5.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Y<SMALL>IELD</SMALL> P<SMALL>ROTECTION</SMALL>, E<SMALL>TC</SMALL>.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.01.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Additional Costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.02.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Illegality</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.03.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.04.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Delay in Requests</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">A<SMALL>RTICLE</SMALL>&nbsp;6.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">C<SMALL>ONDITIONS</SMALL> P<SMALL>RECEDENT</SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.01.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Conditions to Tranche&nbsp;A Term Loan; Closing Date</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.02.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Conditions to Tranche&nbsp;B Term Loan; Tranche&nbsp;B Term Loan Borrowing Date</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.03.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Conditions to Tranche&nbsp;C Term Loan; Tranche&nbsp;C Term Loan Borrowing Date</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-i- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">A<SMALL>RTICLE</SMALL>&nbsp;7.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">R<SMALL>EPRESENTATIONS</SMALL> <SMALL>AND</SMALL> W<SMALL>ARRANTIES</SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.01.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Power and Authority</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.02.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Authorization; Enforceability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.03.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Governmental and Other Approvals; No Conflicts</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.04.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Financial Statements; Projections; Material Adverse Change</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.05.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Properties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.06.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">No Actions or Proceedings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.07.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Compliance with Laws and Agreements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.08.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.09.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Full Disclosure</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.10.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Regulation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.11.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Solvency</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.12.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">[Reserved]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.13.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Indebtedness and Liens</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.14.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Material Agreements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.15.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Restrictive Agreements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.16.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Real Property</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.17.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Pension and Other Plans</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.18.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Collateral; Security Interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.19.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Regulatory Approvals</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.20.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Capitalization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.21.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Insurance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.22.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Certain Fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.23.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Sanctions Laws</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.24.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Anti-Corruption</FONT> Laws</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.25.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Anti-Terrorism</FONT> Laws</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.26.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Royalty and Other Payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.27.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Irish Representations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">A<SMALL>RTICLE</SMALL>&nbsp;8.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">A<SMALL>FFIRMATIVE</SMALL> C<SMALL>OVENANTS</SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.01.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Financial Statements and Other Information</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.02.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Notices of Material Events</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.03.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Existence; Maintenance of Properties, Etc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.04.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Payment of Obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.05.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Insurance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.06.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Books and Records; Inspection Rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.07.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Compliance with Laws</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.08.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Licenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.09.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Action under Environmental Laws</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.10.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Use of Proceeds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.11.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Certain Obligations Respecting Subsidiaries; Further Assurances; Intellectual Property</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.12.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Termination of <FONT STYLE="white-space:nowrap">Non-Permitted</FONT> Liens</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.13.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-Consolidation</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-ii- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.14.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Anti-Terrorism</FONT> and <FONT STYLE="white-space:nowrap">Anti-Corruption</FONT>
Laws</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.15.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Financial Covenants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.16.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Maintenance of Regulatory Approvals, Contracts, Intellectual Property, Etc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.17.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Cash Management</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.18.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Observer Rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.19.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">COMI</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.20.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Post-Closing</FONT> Obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">A<SMALL>RTICLE</SMALL>&nbsp;9.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">N<SMALL>EGATIVE</SMALL> C<SMALL>OVENANTS</SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.01.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Indebtedness</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.02.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Liens</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.03.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Fundamental Changes and Acquisitions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.04.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Lines of Business</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.05.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.06.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Restricted Payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.07.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Payments of Indebtedness</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.08.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Change in Fiscal Year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.09.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Sales of Assets, Etc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.10.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Transactions with Affiliates</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.11.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Restrictive Agreements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.12.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Organizational Documents, Material Agreements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.13.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Holding Company</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.14.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Sales and Leasebacks</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.15.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Hazardous Material</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.16.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Accounting Changes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.17.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Compliance with ERISA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.18.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Outbound Licenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.19.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Inbound Licenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">A<SMALL>RTICLE</SMALL>&nbsp;10.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">E<SMALL>VENTS</SMALL> <SMALL>OF</SMALL> D<SMALL>EFAULT</SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;10.01.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Events of Default</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;10.02.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Remedies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;10.03.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Prepayment Premium and Redemption Price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">A<SMALL>RTICLE</SMALL>&nbsp;11.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">G<SMALL>UARANTEE</SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;11.01.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">The Guarantee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;11.02.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Obligations Unconditional</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;11.03.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Reinstatement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;11.04.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Subrogation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;11.05.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Remedies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;11.06.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Instrument for the Payment of Money</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;11.07.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Continuing Guarantee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;11.08.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Rights of Contribution</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;11.09.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">General Limitation on Guarantee Obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;11.10.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Irish Limitation on Guarantee Obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-iii- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">A<SMALL>RTICLE</SMALL>&nbsp;12.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">A<SMALL>DMINISTRATIVE</SMALL> A<SMALL>GENT</SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;12.01.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Appointment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;12.02.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Rights as a Lender</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;12.03.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Exculpatory Provisions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;12.04.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Reliance by Administrative Agent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;12.05.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Delegation of Duties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;12.06.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Resignation of Agent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;12.07.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-Reliance</FONT> on Administrative Agent and Other Lenders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;12.08.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Administrative Agent May File Proofs of Claim</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;12.09.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Collateral and Guaranty Matters; Appointment of Administrative Agent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;12.10.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Irish Security Matters</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">A<SMALL>RTICLE</SMALL>&nbsp;13.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">M<SMALL>ISCELLANEOUS</SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;13.01.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">No Waiver</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;13.02.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Notices</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;13.03.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Expenses, Indemnification, Etc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;13.04.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Amendments, Etc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;13.05.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Successors and Assigns</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;13.06.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Survival</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;13.07.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Captions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;13.08.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Counterparts</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;13.09.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Governing Law</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;13.10.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Jurisdiction, Service of Process and Venue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">117</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;13.11.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Waiver of Jury Trial</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">117</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;13.12.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Waiver of Immunity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">117</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;13.13.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Entire Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">117</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;13.14.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Severability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;13.15.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">No Fiduciary Relationship</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;13.16.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">USA&nbsp;Patriot Act</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;13.17.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Treatment of Certain Information; Confidentiality</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;13.18.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Releases of Guarantees and Liens</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;13.19.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Acknowledgement and Consent to <FONT STYLE="white-space:nowrap">Bail-In</FONT> of Affected Financial
Institutions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;13.20.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Administrative Borrower</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;13.21.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Joint and Several Liability of Borrowers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">121</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;13.22.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Judgment Currency</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">123</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-iv- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="78%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">S<SMALL>CHEDULES</SMALL>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">S<SMALL>CHEDULE</SMALL>&nbsp;1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commitments</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">S<SMALL>CHEDULE</SMALL> 2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Notice Addresses</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">S<SMALL>CHEDULE</SMALL> 3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Products</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">S<SMALL>CHEDULE</SMALL> 4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Letters of Credit</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">S<SMALL>CHEDULE</SMALL>&nbsp;7.05(b) </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Obligor Intellectual Property</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">S<SMALL>CHEDULE</SMALL>&nbsp;7.13A </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Existing Indebtedness</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">S<SMALL>CHEDULE</SMALL>&nbsp;7.13B </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Existing Liens</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">S<SMALL>CHEDULE</SMALL>&nbsp;7.14 </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Material Agreements</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">S<SMALL>CHEDULE</SMALL>&nbsp;7.15 </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restrictive Agreements</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">S<SMALL>CHEDULE</SMALL>&nbsp;7.16 </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Real Property</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">S<SMALL>CHEDULE</SMALL>&nbsp;7.19(b)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Regulatory Approvals</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">S<SMALL>CHEDULE</SMALL>&nbsp;7.19(e)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Regulatory Authority Notifications</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">S<SMALL>CHEDULE</SMALL>&nbsp;7.20</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Capitalization</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">S<SMALL>CHEDULE</SMALL> 7.22</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Broker&#146;s Fee</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">S<SMALL>CHEDULE</SMALL> 7.26</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Royalty and Other Payments</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">S<SMALL>CHEDULE</SMALL> 8.20</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Post-Closing Obligations</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">S<SMALL>CHEDULE</SMALL>&nbsp;9.05 </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Existing Investments</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">S<SMALL>CHEDULE</SMALL>&nbsp;9.10 </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transactions with Affiliates</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">E<SMALL>XHIBITS</SMALL>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">E<SMALL>XHIBIT</SMALL>&nbsp;A</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Form of Guarantee Assumption Agreement</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">E<SMALL>XHIBIT</SMALL>&nbsp;B</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Form of Borrowing Notice</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">E<SMALL>XHIBIT</SMALL>&nbsp;C</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Form of Note</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">E<SMALL>XHIBIT</SMALL>&nbsp;D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Form of U.S.&nbsp;Tax Compliance Certificate</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">E<SMALL>XHIBIT</SMALL>&nbsp;E</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Form of Compliance Certificate</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">E<SMALL>XHIBIT</SMALL>&nbsp;F</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Form of Assignment Agreement</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">E<SMALL>XHIBIT</SMALL>&nbsp;G</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Form of Security Agreement</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">E<SMALL>XHIBIT</SMALL><FONT STYLE="white-space:nowrap">&nbsp;H-1</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Form of Patent&nbsp;&amp; Trademark Security Agreement</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">E<SMALL>XHIBIT</SMALL><FONT STYLE="white-space:nowrap">&nbsp;H-2</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Form of Copyright Security Agreement</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">E<SMALL>XHIBIT</SMALL>&nbsp;I</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Form of Collateral Questionnaire</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">E<SMALL>XHIBIT</SMALL> J</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Form of Warrant Certificate</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">E<SMALL>XHIBIT</SMALL> K</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Form of Intercompany Subordinated Demand Promissory Note</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-v- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>C<SMALL>REDIT</SMALL> A<SMALL>GREEMENT</SMALL> <SMALL>AND</SMALL> G<SMALL>UARANTY</SMALL>
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">C<SMALL>REDIT</SMALL> A<SMALL>GREEMENT</SMALL> A<SMALL>ND</SMALL> G<SMALL>UARANTY</SMALL>, dated as of September&nbsp;29, 2023 (this
<I>&#147;Agreement&#148;</I>), among K<SMALL>ESTRA</SMALL> M<SMALL>EDICAL</SMALL> T<SMALL>ECHNOLOGIES</SMALL>, I<SMALL>NC</SMALL>., a Delaware corporation (<I>&#147;OpCo&#148;</I>), W<SMALL>EST</SMALL> A<SMALL>FFUM</SMALL> H<SMALL>OLDINGS</SMALL>
C<SMALL>ORP</SMALL>., an exempted company incorporated with limited liability in the Cayman Islands (<I>&#147;West Affum Corp.&#148;</I> and together with OpCo, each a <I>&#147;Borrower&#148;</I> and collectively, the <I>&#147;Borrowers&#148;</I>),
certain Guarantors from time to time parties hereto, the lenders from time to time party hereto (each, as a <I>&#147;Lender&#148;</I> and collectively, the <I>&#147;Lenders&#148;</I>), and P<SMALL>ERCEPTIVE</SMALL> C<SMALL>REDIT</SMALL>
H<SMALL>OLDINGS</SMALL> IV, LP, a Delaware limited partnership (<I>&#147;Perceptive&#148;</I>), as administrative agent for the Lenders (in such capacity, together with its successors and assigns, the<I> &#147;Administrative Agent&#148;</I>). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>W <SMALL>I</SMALL> <SMALL>T</SMALL> <SMALL>N</SMALL> <SMALL>E</SMALL> <SMALL>S</SMALL> <SMALL>S</SMALL> <SMALL>E</SMALL> <SMALL>T</SMALL>
<SMALL>H</SMALL>: </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Borrowers have requested the Lenders to make term loans to Borrowers, and the Lenders are prepared to make such
loans on and subject to the terms and conditions hereof. Accordingly, the parties agree as follows: </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>RTICLE</SMALL>&nbsp;1.
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>D<SMALL>EFINITIONS</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;1.01.</I> <I>Certain Defined Terms</I>. As used herein, the following terms have the following respective
meanings: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;510(k)&#148; </I>means (a)&nbsp;any premarket notification and corresponding FDA clearance for a Device
pursuant to FDA regulations and (b)&nbsp;all amendments, supplements and other additions and modifications thereto, and all documents, data and other information concerning any applicable Device which are necessary for, filed with, incorporated by
reference in, or otherwise supportive of any of the foregoing. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Accounting Change&#148;</I> has the meaning set
forth in Section&nbsp;1.02. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Accounting Change Notice&#148;</I> has the meaning set forth in Section&nbsp;1.02.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Acquisition&#148;</I> means any transaction, or any series of related transactions, by which any Person directly
or indirectly, by means of a <FONT STYLE="white-space:nowrap">take-over</FONT> bid, tender offer, amalgamation, merger, purchase of assets, or similar transaction having the same effect as any of the foregoing, (a)&nbsp;acquires all or substantially
all of the assets of any Person engaged in any business, (b)&nbsp;acquires all or substantially all of a business line or unit or division of any other Person, (c)&nbsp;acquires Control of securities of a Person engaged in a business representing
more than 50% of the ordinary voting power for the election of directors or other governing body if the business affairs of such Person are managed by a Board or other governing body, or (d)&nbsp;acquires control of more than 50% of the ownership
interest in any Person engaged in any business that is not managed by a Board or other governing body. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Act&#148;</I> has the meaning set forth in Section&nbsp;13.16. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;</I><I>Administrative Agent</I><I>&#148;</I><I> </I>has the meaning set forth in the introduction hereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Administrative Borrower&#148; </I>has the meaning set forth in Section&nbsp;13.20. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Affected Financial Institution</I>&#148; means (a)&nbsp;any EEA&nbsp;Financial Institution or (b)&nbsp;any
UK&nbsp;Financial Institution. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Affiliate&#148;</I> means, with respect to a specified Person, another Person that
directly, or indirectly through one or more intermediaries, Controls or is Controlled by or is under common Control with the Person specified. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Agreement&#148;</I> has the meaning set forth in the introduction hereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Anti</I><I><FONT STYLE="white-space:nowrap">-Corruption</FONT> Laws&#148;</I> means all laws, rules and regulations of
any jurisdiction applicable to the Obligors and their Affiliates concerning or relating to bribery or corruption, including, without limitation, the Foreign Corrupt Practices Act of 1977, as amended and the Cayman Islands Anti-Corruption Act (as
amended). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Anti</I><I><FONT STYLE="white-space:nowrap">-Terrorism</FONT> Laws&#148;</I> means any laws or
regulations relating to terrorism or money laundering, including, without limitation the <I>Bank Secrecy Act</I> (31&nbsp;U.S.C. &#167;&#167;&nbsp;5311 <I>et</I><I></I><I>&nbsp;seq.</I>), the <I>Money Laundering Control Act of 1986</I>
(18&nbsp;U.S.C. &#167;&#167;&nbsp;1956 <I>et</I><I></I><I>&nbsp;seq.</I>), the USA&nbsp;Patriot Act, the Cayman Islands Proceeds of Crime Act (as amended), Cayman Islands Anti-Money Laundering Regulations (as amended), the Cayman Islands
Proliferation Financing (Prohibition) Act (as amended), the Cayman Islands Terrorism Act (as amended) and any similar law enacted in the United States or the Cayman Islands after the date of this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Applicable Margin&#148;</I> means 7.25% per annum. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Appointee&#148; </I>means any receiver, administrator or other insolvency officer appointed in respect of any Obligor
or its assets. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Approved Fund&#148;</I> means any Person (other than a natural person) that is engaged in making,
purchasing, holding or investing in bank loans and similar extensions of credit in the ordinary course of its business and that is administered or managed by (a)&nbsp;a Lender, (b)&nbsp;an Affiliate of a Lender or (c)&nbsp;an entity or an Affiliate
of an entity that administers or manages a Lender. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Asset Sale&#148;</I> has the meaning set forth in
Section&nbsp;9.09. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Assignment Agreement&#148;</I> means an assignment and assumption entered into by a Lender and
an assignee of such Lender in substantially the form of Exhibit&nbsp;F. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;ASU&#148;</I> has the meaning set forth
in Section&nbsp;1.02. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-2- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Available Tenor&#148;</I> means, as of the Closing Date, the only
Available Tenor for Term SOFR is an interest period of one (1)&nbsp;month; <I>provided</I> that the Administrative Agent may select to use additional interest periods in accordance with the terms of Section&nbsp;3.02(c)(iv) and such interest periods
shall become Available Tenors upon such selection. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Bail</I><I><FONT STYLE="white-space:nowrap">-In</FONT>
Action&#148;</I> means the exercise of any <FONT STYLE="white-space:nowrap">Write-Down</FONT> and Conversion Powers by the applicable Resolution Authority in respect of any liability of an Affected Financial Institution. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Bail</I><I><FONT STYLE="white-space:nowrap">-In</FONT> Legislation&#148;</I> means (a)&nbsp;with respect to any
EEA&nbsp;Member Country implementing Article&nbsp;55 of Directive&nbsp;2014/59/EU of the European Parliament and of the Council of the European Union, the implementing law, regulation rule or requirement for such EEA&nbsp;Member Country from time to
time which is described in the <FONT STYLE="white-space:nowrap">EU&nbsp;Bail-In</FONT> Legislation Schedule and (b)&nbsp;with respect to the United Kingdom, Part&nbsp;I of the United Kingdom Banking Act 2009 (as amended from time to time) and any
other law, regulation or rule applicable in the United Kingdom relating to the resolution of unsound or failing banks, investment firms or other financial institutions or their affiliates (other than through liquidation, administration or other
Insolvency Proceedings). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Bankruptcy Code&#148;</I> means Title&nbsp;11 of the United States Code entitled
&#147;Bankruptcy.&#148; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Benchmark&#148;</I> means, initially, the Term SOFR&nbsp;Reference Rate; <I>provided</I>
that if a Benchmark Transition Event has occurred with respect to the Term SOFR&nbsp;Reference Rate or the <FONT STYLE="white-space:nowrap">then-current</FONT> Benchmark, then &#147;Benchmark&#148; means the applicable Benchmark Replacement to the
extent that such Benchmark Replacement has replaced such prior benchmark rate pursuant to Section&nbsp;3.02(c). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Benchmark Replacement&#148;</I> means the first alternative set forth in the order below that can be determined by the
Administrative Agent for the applicable Benchmark Replacement Date: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Daily Simple SOFR; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) the sum of: (i)&nbsp;the alternate benchmark rate that has been selected by the Administrative Agent and Administrative
Borrower giving due consideration to (A)&nbsp;any selection or recommendation of a replacement benchmark rate or the mechanism for determining such a rate by the Relevant Governmental Body or (B)&nbsp;any evolving or
<FONT STYLE="white-space:nowrap">then-prevailing</FONT> market convention for determining a benchmark rate as a replacement to the <FONT STYLE="white-space:nowrap">then-current</FONT> Benchmark for
<FONT STYLE="white-space:nowrap">Dollar-denominated</FONT> syndicated credit facilities and (ii)&nbsp;the related Benchmark Replacement Adjustment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-3- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Benchmark Replacement as determined pursuant to
clause&nbsp;(a)&nbsp;or (b)&nbsp;above would be less than the Floor, the Benchmark Replacement will be deemed to be the Floor for the purposes of this Agreement and the other Loan Documents. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Benchmark Replacement Adjustment&#148; </I>means, with respect to any replacement of the <FONT
STYLE="white-space:nowrap">then-current</FONT> Benchmark with an Unadjusted Benchmark Replacement, the spread adjustment, or method for calculating or determining such spread adjustment, (which may be a positive or negative value or zero) that has
been selected by the Administrative Agent and Administrative Borrower&nbsp;giving due consideration to (a)&nbsp;any selection or recommendation of a spread adjustment, or method for calculating or determining such spread adjustment, for the
replacement of such Benchmark with the applicable Unadjusted Benchmark Replacement by the Relevant Governmental Body or (b)&nbsp;any evolving or <FONT STYLE="white-space:nowrap">then-prevailing</FONT> market convention for determining a spread
adjustment, or method for calculating or determining such spread adjustment, for the replacement of such Benchmark with the applicable Unadjusted Benchmark Replacement for <FONT STYLE="white-space:nowrap">Dollar-denominated</FONT> syndicated credit
facilities at such time. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Benchmark Replacement Date&#148; </I>means a date and time determined by the
Administrative Agent, which date shall be no later than the earliest to occur of the following events with respect to the <FONT STYLE="white-space:nowrap">then-current</FONT> Benchmark: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) in the case of clause&nbsp;(a) or (b)&nbsp;of the definition of &#147;Benchmark Transition Event,&#148; the later of
(i)&nbsp;the date of the public statement or publication of information referenced therein and (ii)&nbsp;the date on which the administrator of such Benchmark (or the published component used in the calculation thereof) permanently or indefinitely
ceases to provide all Available Tenors of such Benchmark (or such component thereof); or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) in the case of
clause&nbsp;(c) of the definition of &#147;Benchmark Transition Event&#148;, the first date on which such Benchmark (or the published component used in the calculation thereof) has been determined and announced by the regulatory supervisor for the
administrator of such Benchmark (or such component thereof) to be <FONT STYLE="white-space:nowrap">non-representative;</FONT> <I>provided</I> that such <FONT STYLE="white-space:nowrap">non-representativeness</FONT> will be determined by reference to
the most recent statement or publication referenced in such clause&nbsp;(c) and even if any Available Tenor of such Benchmark (or such component thereof) continues to be provided on such date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">For the avoidance of doubt, the &#147;Benchmark Replacement Date&#148; will be deemed to have occurred in the case of clause&nbsp;(a) or
(b)&nbsp;with respect to any Benchmark upon the occurrence of the applicable event or events set forth therein with respect to all <FONT STYLE="white-space:nowrap">then-current</FONT> Available Tenors of such Benchmark (or the published component
used in the calculation thereof). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-4- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Benchmark Transition Event&#148;</I> means the occurrence of one or
more of the following events with respect to the <FONT STYLE="white-space:nowrap">then-current</FONT> Benchmark: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) a
public statement or publication of information by or on behalf of the administrator of such Benchmark (or the published component used in the calculation thereof) announcing that such administrator has ceased or will cease to provide all Available
Tenors of such Benchmark (or such component thereof), permanently or indefinitely; <I>provided</I> that, at the time of such statement or publication, there is no successor administrator that will continue to provide any Available Tenor of such
Benchmark (or such component thereof); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) a public statement or publication of information by the regulatory supervisor
for the administrator of such Benchmark (or the published component used in the calculation thereof), the Federal Reserve Board, the Federal Reserve Bank of New&nbsp;York, an insolvency official with jurisdiction over the administrator for such
Benchmark (or such component), a resolution authority with jurisdiction over the administrator for such Benchmark (or such component) or a court or an entity with similar insolvency or resolution authority over the administrator for such Benchmark
(or such component), which states that the administrator of such Benchmark (or such component) has ceased or will cease to provide all Available Tenors of such Benchmark (or such component thereof) permanently or indefinitely; <I>provided</I> that,
at the time of such statement or publication, there is no successor administrator that will continue to provide any Available Tenor of such Benchmark (or such component thereof); or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) a public statement or publication of information by the regulatory supervisor for the administrator of such Benchmark (or
the published component used in the calculation thereof) announcing that all Available Tenors of such Benchmark (or such component thereof) are not, or as of a specified future date will not be, representative. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">For the avoidance of doubt, a &#147;Benchmark Transition Event&#148; will be deemed to have occurred with respect to any Benchmark if a public
statement or publication of information set forth above has occurred with respect to each <FONT STYLE="white-space:nowrap">then-current</FONT> Available Tenor of such Benchmark (or the published component used in the calculation thereof). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Beneficial Ownership Regulation&#148;</I> has the meaning set forth in Section&nbsp;13.16. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Benefit Plan&#148;</I> means any &#147;employee benefit plan&#148; as defined in Section&nbsp;3(3) of ERISA to which
any Obligor has any obligation or liability, contingent or otherwise. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Board&#148;</I> means, with respect to any
Person, the board of managers or directors (as applicable) (or equivalent governing body) of such Person or any committee thereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Borrower&#148;</I> and &#147;<I>Borrowers</I>&#148; have the meaning set forth in the introduction hereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-5- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Borrowing&#148;</I> means a borrowing consisting of the
Tranche&nbsp;A Term Loan made by the Lenders on the Closing Date, the Tranche&nbsp;B Term Loan made by the Lenders on the Tranche&nbsp;B Term Loan Borrowing Date and the Tranche&nbsp;C Term Loan made by the Lenders on the Tranche&nbsp;C Term Loan
Borrowing Date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Borrowing Notice&#148;</I> means a notice substantially in the form attached hereto as
Exhibit&nbsp;B. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Business Day&#148;</I> means a day (other than a Saturday or Sunday) on which commercial banks
are not authorized or not required to close in New&nbsp;York City. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Capital Lease Obligations&#148;</I> means, as
to any Person, the obligations of such Person to pay rent or other amounts under a lease of (or other agreement conveying the right to use) real and/or personal Property which obligations are required to be classified and accounted for as a capital
lease on a balance sheet of such Person under GAAP and, for purposes of this Agreement, the amount of such obligations shall be the capitalized amount thereof, determined substantially in accordance with GAAP; <I>provided</I> that any obligations
that were not required to be included on the balance sheet of such Person as capital lease obligations when incurred (whether now outstanding or at any time incurred or entered into) but are subsequently
<FONT STYLE="white-space:nowrap">re-characterized</FONT> as capital lease obligations due to a change in accounting rules under GAAP after the Closing Date shall for all purposes hereunder not be treated as a Capital Lease Obligation. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Casualty Event&#148;</I> means any actual or constructive loss, condemnation, destruction, confiscation, requisition,
seizure or forfeiture of all or any material portion of the assets of Borrowers or any other Obligor, excluding only those assets, individually or in the aggregate, subject to any such event during any calendar year with a fair market value as of
the date thereof equal to or less than $1,500,000. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Cayman Security Documents&#148;</I> means, collectively,
(a)&nbsp;the West Affum Corp. Fixed and Floating Charge, (b)&nbsp;the Intermediate Holdings Fixed and Floating Charge, (c)&nbsp;the Intermediate Holdings Equitable Share Charge and (d)&nbsp;the West Affum Corp. Account Charge. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Change of Control&#148; </I>means (a)&nbsp;prior to a Qualified Public Offering, any transaction or series of related
transactions in which, as applicable, (i)&nbsp;the General Partner of the Parent ceases to be an Affiliate of the Sponsor or (ii)&nbsp;the Sponsor (or its Affiliate) ceases to (A)&nbsp;be the &#147;Controlling Investor&#148; (as such term is defined
in the Amended and Restated Agreement of Limited Partnership of the Parent dated October&nbsp;21, 2014) of the Parent and (B)&nbsp;beneficially own at least 50.1% of the voting and economic interests of the Parent with the ability to control the
management of the Parent, (b)&nbsp;after a Qualified Public Offering, any &#147;person&#148; or &#147;group&#148; (within the meaning of <FONT STYLE="white-space:nowrap">Rule&nbsp;13d-5</FONT> of the Exchange Act as in effect on the date hereof),
other than the Sponsor, shall own, directly or indirectly, beneficially or of record, shares representing 40% or more of the aggregate ordinary voting power represented by the issued and outstanding Equity Interests of Intermediate Holdings,
(c)&nbsp;prior to a Qualified Public Offering, Parent ceases to own, directly or indirectly, 100% </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-6- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
of the Equity Interests in Intermediate Holdings, (d)&nbsp;Intermediate Holdings ceases to own 100% of the Equity Interests in West Affum Corp., (e) West Affum Corp. ceases to own 100% of the
Equity Interests in the Irish Obligor, (f)&nbsp;the Irish Obligor ceases to own 100% of the Equity Interests in OpCo or (g)&nbsp;except as permitted pursuant to Section&nbsp;9.05 or 9.09, OpCo ceases to own directly or indirectly, 100% of Equity
Interests of its Subsidiaries. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Charged Property&#148; </I>means the assets of an Obligor subject to a security
interest under an Irish Security Document. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Claims&#148;</I> includes claims, litigation, demands, complaints,
grievances, actions, applications, suits, causes of action, orders, charges, indictments, prosecutions, information (brought by a public prosecutor without grand jury indictment) or other similar processes, assessments or reassessments. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Closing Date&#148;</I> means the Business Day on which all of the conditions set forth in Section&nbsp;6.01 have been
satisfied or waived by the Lenders and the Tranche&nbsp;A Term Loan is made. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Closing Fee&#148;</I> has the
meaning set forth in Section&nbsp;2.03. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Code&#148;</I> means the Internal Revenue Code of 1986, as amended from
time to time. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Collateral&#148;</I> means any Property in which a Lien is purported to be granted under any of the
Security Documents (or all such Property, as the context may require). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Collateral Questionnaire&#148;</I> means
that certain Collateral Questionnaire and certification by a Responsible Officer of Administrative Borrower substantially in the form of attached hereto as Exhibit&nbsp;I and otherwise in form and substance satisfactory to the Administrative Agent.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>COMI&#148;</I> means center of main interests within the meaning, and for the purposes, of the EU Insolvency
Regulation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Commitment&#148;</I> means, with respect to each Lender, such Lender&#146;s Tranche&nbsp;A Term Loan
Commitment, Tranche&nbsp;B Term Loan Commitment, and Tranche&nbsp;C Term Loan Commitment, and <I>&#147;Commitments&#148;</I> means all such commitments of all Lenders. The aggregate amount of the Commitments as of the Closing Date is $60,000,000.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Commodity Account&#148;</I> has the meaning set forth in the Security Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Competitor&#148;</I> means any Person that is a bona fide direct competitor of any Obligor in the same industry or a
substantially similar industry which offers a substantially similar product or service as any Obligor; <I>provided</I> that no Lender or Affiliate of a Lender (other than a Disqualified Lender) shall be deemed to be a direct competitor of any
Obligor as a result of such Lender or Affiliate of such Lender being an investor in a business that may be a competitor of any Obligor. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-7- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Compliance Certificate&#148;</I> has the meaning set forth in
Section&nbsp;8.01(d). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Conforming Changes&#148;</I> means, with respect to either the use or administration of
Term SOFR or the use, administration, adoption or implementation of any Benchmark Replacement, any technical, administrative or operational changes (including changes to the definition of &#147;Business Day,&#148; the definition of
&#147;U.S.&nbsp;Government Securities Business Day,&#148; the definition of &#147;Interest Period&#148; or any similar or analogous definition (or the addition of a concept of &#147;interest period&#148;), timing and frequency of determining rates
and making payments of interest, timing of borrowing requests or prepayment, conversion or continuation notices, the applicability and length of lookback periods and other technical, administrative or operational matters) that the Administrative
Agent reasonably decides (in consultation with Borrowers) may be appropriate to reflect the adoption and implementation of any such rate or to permit the use and administration thereof by the Administrative Agent in a manner substantially consistent
with market practice (or, if the Administrative Agent reasonably decides that adoption of any portion of such market practice is not administratively feasible or if the Administrative Agent reasonably determines that no market practice for the
administration of any such rate exists, in such other manner of administration as the Administrative Agent decides is reasonably necessary in connection with the administration of this Agreement and the other Loan Documents (in consultation with
Borrowers)). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Connection Income Taxes&#148; </I>means Other Connection Taxes that are imposed on or measured by
net income (however denominated) or that are franchise Taxes or branch profits Taxes. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Contracts&#148;</I> means
any contract, license, lease, agreement, obligation, promise, undertaking, understanding, arrangement, document, commitment, entitlement or engagement under which a Person has, or will have, any liability or contingent liability (in each case,
whether written or oral, express or implied, and whether in respect of monetary or payment obligations, performance obligations or otherwise), excluding the Loan Documents. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Control&#148;</I> means, in respect of a particular Person, the possession, directly or indirectly, of the power to
direct or cause the direction of the management or policies of such Person, whether through the ability to exercise voting power, by contract or otherwise. <I>&#147;Controlling&#148;</I> and <I>&#147;Controlled&#148;</I> have meanings correlative
thereto. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Controlled Account&#148;</I> has the meaning set forth in Section&nbsp;8.17(a)(i). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Copyrights&#148;</I> has the meaning set forth in the Security Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Cure Amount&#148;</I> has the meaning set forth in Section&nbsp;8.15(b). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Cure Right&#148;</I> has the meaning set forth in Section&nbsp;8.15(b). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-8- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Daily Simple SOFR&#148;</I> means, for any day (a
<I>&#147;SOFR</I><I></I><I>&nbsp;Rate Day&#148;</I>), a rate per annum equal to the greater of (a)&nbsp;SOFR for the day (such day, a <I>&#147;SOFR</I><I></I><I>&nbsp;Determination Day&#148;</I>) that is two (2)&nbsp;U.S.&nbsp;Government Securities
Business Days prior to (i)&nbsp;if such SOFR&nbsp;Rate Day is a U.S.&nbsp;Government Securities Business Day, such SOFR&nbsp;Rate Day or (ii)&nbsp;if such SOFR&nbsp;Rate Day is not a U.S.&nbsp;Government Securities Business Day, the
U.S.&nbsp;Government Securities Business Day immediately preceding such SOFR&nbsp;Rate Day, in each case, as such SOFR is published by the SOFR&nbsp;Administrator on the SOFR&nbsp;Administrator&#146;s Website, and (b)&nbsp;the Floor. If by
5:00&nbsp;p.m. (New&nbsp;York City time) on the second (2nd) U.S.&nbsp;Government Securities Business Day immediately following any SOFR&nbsp;Determination Day, SOFR in respect of such SOFR&nbsp;Determination Day has not been published on the
SOFR&nbsp;Administrator&#146;s Website and a Benchmark Replacement Date with respect to the Daily Simple SOFR has not occurred, then SOFR for such SOFR&nbsp;Determination Day will be SOFR as published in respect of the first preceding
U.S.&nbsp;Government Securities Business Day for which such SOFR was published on the SOFR&nbsp;Administrator&#146;s Website; <I>provided</I> that, any SOFR determined pursuant to this sentence shall be utilized for purposes of calculation of Daily
Simple SOFR for no more than three (3)&nbsp;consecutive SOFR&nbsp;Rate Days; <I>provided, further,</I> Daily Simple SOFR shall be rounded upwards to the next 1/100% (if necessary). Any change in Daily Simple SOFR due to a change in SOFR shall be
effective from and including the effective date of such change in SOFR without notice to Borrowers. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Default&#148;</I> means any Event of Default and any event that, upon the giving of notice, the lapse of time or both,
would constitute an Event of Default. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Default Rate&#148;</I> has the meaning set forth in Section&nbsp;3.02(d).
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Delegate&#148; </I>means any delegate, agent, attorney or <FONT STYLE="white-space:nowrap">co-trustee</FONT>
appointed by the Administrative Agent (in its capacity as security trustee). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Deposit Account&#148;</I> has the
meaning set forth in the Security Agreement and relates to such accounts located and/or maintained in the United States of America. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Designated Person&#148;</I> means a person or entity: (a)&nbsp;listed in the annex to, or otherwise targeted by the
provisions of, the Executive Order (as disclosed by <FONT STYLE="white-space:nowrap">World-Check</FONT> or another reputable commercially available database); (b)&nbsp;named as a &#147;Specially Designated National and Blocked Person&#148; on the
most current list published by OFAC at its official website or any replacement website or other replacement official publication of such list (as disclosed by <FONT STYLE="white-space:nowrap">World-Check</FONT> or another reputable commercially
available database) or listed in the consolidated list of financial sanctions targets maintained by OFSI or any other Sanctions-related list of designated persons maintained by any other Governmental Authority; or (c)&nbsp;with which the Lenders
and/or Obligors are prohibited or restricted from dealing or otherwise engaging in any transaction by any Economic Sanctions Laws, Sanctions Laws or Irish Economic Sanctions Laws; or (d)&nbsp;that is owned or controlled directly or indirectly by any
person or entity described in this definition. For the purposes of this definition, the meaning of &#147;owned or controlled directly or indirectly&#148; shall be determined in accordance with applicable Sanctions Laws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-9- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Device&#148;</I> means (a)&nbsp;any medical instrument, apparatus,
implement, machine, contrivance, implant, in vitro reagent or other similar or related item, including any component, part or accessory, that (i)&nbsp;is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation,
treatment or prevention of disease, in man, or is intended to affect the structure or any function of the body of man, (ii)&nbsp;does not achieve its primary intended purpose or purposes through chemical action within or on the body of man and
(iii)&nbsp;is not dependent upon being metabolized for the achievement of its primary intended purpose or purposes, or (b)&nbsp;any other product that meets the definition of &#147;device&#148; as set forth in Section&nbsp;201 of the
FD&amp;C&nbsp;Act (21&nbsp;U.S.C. &#167;&nbsp;321); unless, in either case, such Device is exempt pursuant to Section&nbsp;520(o) of the FD&amp;C Act (21&nbsp;U.S.C. &#167;&nbsp;360j(o)). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Device Clearance Application&#148;</I> means (a)&nbsp;any premarket approval application submitted under
Section&nbsp;515 of the FD&amp;C&nbsp;Act (21&nbsp;U.S.C. &#167;&nbsp;360e) (a <I>&#147;PMA&#148;</I>), (b)&nbsp;any <I>de</I><I></I><I>&nbsp;novo</I> request submitted under Section&nbsp;513(f) of the FD&amp;C&nbsp;Act (21&nbsp;U.S.C.
&#167;&nbsp;360c(f)), (c) any 510(k) submitted under Section&nbsp;510(k) of the FD&amp;C&nbsp;Act (21&nbsp;U.S.C. &#167;&nbsp;360(k)) seeking clearance from the FDA for a Device that is substantially equivalent to a legally marketed predicate
Device, as defined in the FD&amp;C&nbsp;Act, or (d)&nbsp;any corresponding or substantially equivalent notification, application or clearance of a <FONT STYLE="white-space:nowrap">non-U.S.&nbsp;Regulatory</FONT> Authority, including, with respect to
the European Union, any equivalent submission to a Standard Body pursuant to an applicable directive of the European Council with respect to CE marking (or, if applicable, a <FONT STYLE="white-space:nowrap">self-certification</FONT> of conformity
with respect to any such directive through a &#147;declaration of conformity&#148;) and (e)&nbsp;all amendments, variations, extensions and renewals of any of the foregoing. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Disqualified Equity Interests&#148;</I> means, with respect to any Person, any Equity Interest of such Person that, by
its terms (or by the terms of any security or other Equity Interest into which it is convertible or for which it is exchangeable upon exercise or otherwise), or upon the happening of any event or condition (a)&nbsp;matures or is mandatorily
redeemable (other than solely for Qualified Equity Interests), including pursuant to a sinking fund obligation or otherwise, (b)&nbsp;is redeemable at the option of the holder thereof (other than solely for Qualified Equity Interests), in whole or
in part, (c)&nbsp;provides for the scheduled payments of dividends or other distributions in cash or other securities that would constitute Disqualified Equity Interests, or (d)&nbsp;is or becomes convertible into or exchangeable for Indebtedness or
any other Equity Interests that would constitute Disqualified Equity Interests, in each case, prior to the date that is one hundred and eighty (180)&nbsp;days after the Stated Maturity Date; <I>provided</I> that, if such Equity Interests are issued
pursuant to any plan for the benefit of directors, officers, employees or consultants of such Person or by any such plan to such directors, officers, employees or consultants, such Equity Interests shall not constitute Disqualified Equity Interests
solely because they may be required to be repurchased by such Person upon the death, disability, retirement or termination of employment or service of such director, officer, employee or consultant. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Disqualified Lender</I>&#148; means (a)&nbsp;any Competitor or (b)&nbsp;any Person identified by or on behalf of the
Administrative Borrower (or one of its Affiliates) to the Administrative Agent in writing from time to time (and such Person&#146;s Affiliates identified in writing from time to time or reasonably identifiable as such solely on the basis of their
names);<I> provided</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-10- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
that no updates to the list of Disqualified Lenders in this clause (b)&nbsp;shall be deemed to retroactively disqualify any parties that have previously validly acquired an assignment or
participation in respect of the Term Loans from continuing to hold or vote such previously acquired assignments and participations on the terms set forth herein for Lenders that are not Disqualified Lenders. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Dollars&#148;</I> and <I>&#147;$&#148;</I> means lawful money of the United States of America. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Domestic Subsidiary&#148; </I>means any Subsidiary that is organized under the laws of the United States, any state
thereof or the District of Columbia. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Economic Sanctions Laws&#148;</I> means: (a)&nbsp;the Executive Order, the
<I>International Emergency Economic Powers Act</I> (50&nbsp;U.S.C. &#167;&#167;&nbsp;1701 <I>et</I><I></I><I>&nbsp;seq.</I>), the <I>Trading with the Enemy Act</I> (50&nbsp;U.S.C. App. &#167;&#167;&nbsp;1 <I>et</I><I></I><I>&nbsp;seq.</I>), any
other law or regulation promulgated thereunder from time to time and administered by OFAC and any similar law enacted in the United States; and (b)&nbsp;any other similar applicable law, rule or regulation now or hereafter enacted in any other
applicable jurisdiction related to economic sanctions or trade embargos, including the United Kingdom or the Cayman Islands. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;EEA</I><I></I><I>&nbsp;Financial Institution&#148;</I> means (a)&nbsp;any credit institution or investment firm
established in any EEA&nbsp;Member Country which is subject to the supervision of an EEA&nbsp;Resolution Authority, (b)&nbsp;any entity established in an EEA&nbsp;Member Country which is a parent of an institution described in clause&nbsp;(a) of
this definition, or (c)&nbsp;any financial institution established in an EEA&nbsp;Member Country which is a subsidiary of an institution described in clauses&nbsp;(a) or (b)&nbsp;of this definition and is subject to consolidated supervision with its
parent. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;EEA</I><I></I><I>&nbsp;Member Country&#148;</I> means any of the member states of the European Union,
Iceland, Liechtenstein, and Norway. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;EEA</I><I></I><I>&nbsp;Resolution Authority&#148;</I> means any public
administrative authority or any person entrusted with public administrative authority of any EEA&nbsp;Member Country (including any delegee) having responsibility for the resolution of any EEA&nbsp;Financial Institution. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Environmental Law&#148;</I> means any national, federal, state, provincial or local governmental law, rule,
regulation, order, writ, judgment, injunction or decree relating to pollution or protection of the environment or the treatment, storage, disposal, release, threatened release or handling of Hazardous Materials, and all local laws and regulations
related to environmental matters and any specific agreements entered into with any competent authorities which include commitments related to environmental matters. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Equity Interest&#148;</I> means, with respect to any Person, any and all shares, interests, participations or other
equivalents, including membership interests (however designated, whether voting or nonvoting), of equity of such Person, including, if such Person is a partnership, partnership interests (whether general or limited) and any other interest or
participation that confers on a Person the right to receive a share of the profits and losses of, or distributions of property of, such partnership, but excluding debt securities convertible or exchangeable into such equity. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-11- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;ERISA&#148;</I> means the United States Employee Retirement Income
Security Act of 1974, as amended. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;ERISA Affiliate&#148;</I> means any Person treated as a single employer with
any Obligor, within the meaning of Section&nbsp;414(b), (c), (m) or (o)&nbsp;of the Code. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;ERISA Event&#148;</I>
means (a)&nbsp;a reportable event as defined in Section&nbsp;4043 of ERISA with respect to a Title&nbsp;IV Plan, excluding, however, such events as to which the PBGC by regulation has waived the requirement of Section&nbsp;4043(a) of ERISA that it
be notified within thirty (30)&nbsp;days of the occurrence of such event; (b)&nbsp;the applicability of the requirements of Section&nbsp;4043(b) of ERISA with respect to a contributing sponsor, as defined in Section&nbsp;4001(a)(13) of ERISA, to any
Title&nbsp;IV Plan where an event described in paragraph&nbsp;(9), (10), (11), (12) or (13)&nbsp;of Section&nbsp;4043(c) of ERISA is reasonably expected to occur with respect to such plan within the following thirty (30)&nbsp;days; (c)&nbsp;a
withdrawal by any Obligor or any ERISA Affiliate thereof from a Title&nbsp;IV Plan or the termination of any Title&nbsp;IV Plan resulting in liability under Sections&nbsp;4063 or 4064 of ERISA; (d)&nbsp;the withdrawal of any Obligor or any ERISA
Affiliate thereof in a complete or partial withdrawal (within the meaning of Section&nbsp;4203 and 4205 of ERISA) from any Multiemployer Plan if there is any potential liability therefore, or the receipt by any Obligor or any ERISA Affiliate thereof
of notice from any Multiemployer Plan that it is in insolvency pursuant to Section&nbsp;4245 of ERISA; (e)&nbsp;the filing of a notice of intent to terminate, the treatment of a plan amendment as a termination under Section&nbsp;4041 or 4041A of
ERISA, or the commencement of proceedings by the PBGC to terminate a Title&nbsp;IV Plan or Multiemployer Plan; (f)&nbsp;the imposition of liability on any Obligor or any ERISA Affiliate thereof pursuant to Sections&nbsp;4062(e) or 4069 of ERISA or
by reason of the application of Section&nbsp;4212(c) of ERISA; (g)&nbsp;the failure by any Obligor or any ERISA Affiliate thereof to make any required contribution to a Title IV Plan, or the failure to meet the minimum funding standard of
Section&nbsp;412 of the Code with respect to any Title&nbsp;IV Plan (whether or not waived in accordance with Section&nbsp;412(c) of the Code) or the failure to make by its due date a required installment under Section&nbsp;430 of the Code with
respect to any Title&nbsp;IV Plan or the failure to make any required contribution to a Multiemployer Plan; (h)&nbsp;the determination that any Title&nbsp;IV Plan is considered an <FONT STYLE="white-space:nowrap">at-risk</FONT> plan or a plan in
endangered to critical status within the meaning of Sections&nbsp;430, 431 and 432 of the Code or Sections&nbsp;303, 304 and 305 of ERISA; (i)&nbsp;an event or condition constitutes grounds under Section&nbsp;4042 of ERISA for the termination of, or
the appointment of a trustee to administer, any Title&nbsp;IV Plan or Multiemployer Plan; (j)&nbsp;the imposition of any liability under Title&nbsp;I or Title&nbsp;IV of ERISA, other than PBGC premiums due but not delinquent under Section&nbsp;4007
of ERISA, upon any Obligor or any ERISA Affiliate thereof; (k)&nbsp;an application for a funding waiver under Section&nbsp;303 of ERISA or an extension of any amortization period pursuant to Section&nbsp;412 of the Code with respect to any
Title&nbsp;IV Plan; (l)&nbsp;the occurrence of a <FONT STYLE="white-space:nowrap">non-exempt</FONT> prohibited transaction under Sections&nbsp;406 or 407 of ERISA for which any Obligor is directly or indirectly liable; or (m)&nbsp;the imposition of
any Lien (or the fulfillment of the conditions for the imposition of any Lien) on any of the rights, properties or assets of any Obligor or any ERISA Affiliate thereof, in either case pursuant to Section&nbsp;302(f), 303(k), or 4068 of ERISA or to
Section&nbsp;401(a)(29) or 430(k) of the Code. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-12- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;ERISA Funding Rules&#148;</I> means the rules regarding minimum
required contributions (including any installment payment thereof) to Title&nbsp;IV Plans, as set forth in Sections&nbsp;412, 430, 431, 432 and 436 of the Code and Sections&nbsp;302, 303, 304 and 305 of ERISA. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;EU</I><I></I><I>&nbsp;Bail</I><I><FONT STYLE="white-space:nowrap">-In</FONT> Legislation Schedule&#148;</I> means the <FONT
STYLE="white-space:nowrap">EU&nbsp;Bail-In</FONT> Legislation Schedule published by the Loan Market Association (or any successor Person), as in effect from time to time. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;EU Insolvency Regulation&#148; </I>means Regulation (EU) 2015/848 of the European Parliament and of the Council of
20&nbsp;May 2015 on insolvency proceedings (recast). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Event of Default&#148;</I> has the meaning set forth in
Section&nbsp;10.01. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Excess Funding Guarantor&#148;</I> has the meaning set forth in Section&nbsp;11.08. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Excess Payment&#148;</I> has the meaning set forth in Section&nbsp;11.08. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Exchange Act&#148;</I> means the Securities Exchange Act of 1934, as amended, and the rules and regulations
promulgated thereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Excluded Accounts&#148;</I> means Deposit Accounts, Securities Accounts or Commodity
Accounts (a)&nbsp;maintained outside of the United States of America in an aggregate balance thereof not to exceed One Hundred Thousand ($100,000.00) at any time, (b)&nbsp;used exclusively to maintain deposits subject to a Lien described in
Section&nbsp;9.02(m), (o) or (p), (c) that are <FONT STYLE="white-space:nowrap">zero-balance</FONT> accounts and (d)&nbsp;exclusively used for withholding payroll, payroll taxes and other employee wage and benefit payments to or for the benefit of
the employees of Borrowers and their Subsidiaries. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Excluded Subsidiary</I>&#148; means any Subsidiary
(a)&nbsp;that constitutes an Immaterial Subsidiary or (b)&nbsp;for which the provision of a Guarantee of the Obligations would result in material adverse tax consequences (as reasonably agreed by the Borrowers and the Administrative Agent);
<I>provided</I> that, in respect of clause (b)&nbsp;above, such material adverse tax consequences shall not have resulted from such Subsidiary being formed or organized in a foreign jurisdiction in contemplation of avoiding compliance with the
requirement to provide a Guarantee of the Obligations; <I>provided</I>, <I>further</I>, no Excluded Subsidiary shall own or exclusively control any Material Intellectual Property. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Excluded Taxes&#148;</I> means any of the following Taxes imposed on or with respect to a Recipient or required to be
withheld or deducted from a payment to a Recipient: (a)&nbsp;Taxes imposed on or measured by net income (however denominated), franchise Taxes and branch profits Taxes in each case (i)&nbsp;imposed as a result of such Recipient being organized
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-13- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
under the laws of, or having its principal office or, in the case of a Lender, its applicable lending office located in, the jurisdiction imposing such Tax or (ii)&nbsp;that are Other Connection
Taxes, (b)&nbsp;any U.S.&nbsp;federal withholding Taxes that are imposed on amounts payable to Lender to the extent that the obligation to withhold amounts existed on the date that (i)&nbsp;Lender became a &#147;Lender&#148; under this Agreement or
(ii)&nbsp;Lender changes its lending office, except in each case to the extent Lender is a direct or indirect assignee of any other Lender that was entitled, at the time the assignment of such other Lender became effective, to receive additional
amounts under Section&nbsp;5.03 or Lender was entitled to receive additional amounts under Section&nbsp;5.03 immediately before it changed its lending office, (c)&nbsp;any Taxes imposed in connection with FATCA and (d)&nbsp;Taxes attributable to
such Recipient&#146;s failure to comply with Section&nbsp;5.03(e). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Executive Order&#148;</I> means the
US&nbsp;Executive Order No.&nbsp;13224 on Blocking Property and Prohibiting Transactions with Persons who commit, Threaten to Commit, or Support Terrorism. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Existing Indebtedness&#148; </I>means Indebtedness and other obligations outstanding under that certain Loan and
Security Agreement dated as of September&nbsp;24, 2020 by and among the Obligors and Kennedy Lewis Management LP, as amended prior to the Closing Date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Existing Letters of Credit</I>&#148; means any letter of credit previously issued that will remain outstanding on and
after the Closing Date and is listed on Schedule 4. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Expense Deposit&#148;</I> means a cash deposit in the amount
of $50,000 made by Administrative Borrower to an Affiliate of Perceptive Advisors LLC pursuant to the Proposal Letter for the prepayment of the Lenders&#146; costs and expenses (payable pursuant to Section&nbsp;13.03(a) and/or the Proposal Letter)
incurred prior to the Closing Date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;FATCA&#148;</I> means Sections&nbsp;1471 through 1474 of the Code, as of the
date of this Agreement (or any amended or successor version that is substantively comparable and not materially more onerous to comply with), any current or future regulations or official interpretations thereof, any agreements entered into pursuant
to Section&nbsp;1471(b)(1) of the Code and any fiscal or regulatory legislation, rules or practices adopted pursuant to any intergovernmental agreement, treaty or convention among Governmental Authorities entered into in connection with the
implementation of the foregoing. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;FD&amp;C</I><I></I><I>&nbsp;Act&#148;</I> means the U.S.&nbsp;Food, Drug and
Cosmetic Act of 1938 (or any successor thereto), as amended from time to time. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;FDA&#148;</I> means the
U.S.&nbsp;Food and Drug Administration and any successor entity. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;FDA</I><I></I><I>&nbsp;Laws&#148;</I> means all
applicable statutes, rules, regulations and orders administered or issued by the (a)&nbsp;FDA, including without limitation, the FD&amp;C&nbsp;Act and its implementing regulations or (b)&nbsp;any <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
Regulatory Authority equivalent of the FDA, including the European Medicines Agency. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-14- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Federal Health Care Program&#148;</I> has the meaning specified in
Section&nbsp;1128B(f) of the Social Security Act and includes the programs commonly known as Medicare, Medicaid, TRICARE and CHAMPVA. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Floor&#148; </I>means a rate of interest equal to 4.75%. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Foreign Lender&#148;</I> means a Lender that is not a U.S.&nbsp;Person. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Foreign Subsidiary&#148; </I>means any Subsidiary that is not a Domestic Subsidiary. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>FRB</I>&#148; shall mean the Board of Governors of the Federal Reserve System of the United States. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;GAAP&#148;</I> means generally accepted accounting principles in the United States of America, as in effect from time
to time, set forth in the opinions and pronouncements of the Accounting Principles Board and the American Institute of Certified Public Accountants, in the statements and pronouncements of the Financial Accounting Standards Board and in such other
statements by such other entity as may be in general use by significant segments of the accounting profession that are applicable to the circumstances as of the date of determination. Subject to Section&nbsp;1.02, all references to &#147;GAAP&#148;
shall be to GAAP applied consistently with the principles used in the preparation of the financial statements described in Section&nbsp;7.04(a). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;General Partner&#148;</I> means West Affum GP Ltd., an exempted company incorporated with limited liability in the
Cayman Islands. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Governmental Approval&#148;</I> means any consent, authorization, approval, order, license,
franchise, permit, certification, accreditation, registration, clearance, exemption, filing or notice that is issued or granted by or from (or pursuant to any act of) any Governmental Authority, including any application or submission related to any
of the foregoing. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Governmental Authority&#148;</I> means any nation, government, branch of power (whether
executive, legislative or judicial), state, municipality or other political subdivision thereof and any entity exercising executive, legislative, judicial, monetary, regulatory or administrative functions of or pertaining to government, including
without limitation Regulatory Authorities, governmental departments, agencies, commissions, bureaus, officials, ministers, courts, bodies, boards, tribunals and dispute settlement panels, and other <FONT STYLE="white-space:nowrap">law-,</FONT> <FONT
STYLE="white-space:nowrap">rule-</FONT> or <FONT STYLE="white-space:nowrap">regulation-making</FONT> organizations or entities of any State, territory, county, city or other political subdivision of the United States, the United Kingdom, Ireland or
the Cayman Islands. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-15- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Guarantee&#148;</I> of or by any Person (the
<I>&#147;guarantor&#148;</I>) means any obligation, contingent or otherwise, of the guarantor guaranteeing or having the economic effect of guaranteeing any Indebtedness or other obligation of any other Person (the <I>&#147;primary
obligor&#148;</I>) in any manner, whether directly or indirectly, and including any obligation of the guarantor, direct or indirect, (a)&nbsp;to purchase or pay (or advance or supply funds for the purchase or payment of) such Indebtedness or other
obligation or to purchase (or to advance or supply funds for the purchase of) any security for the payment thereof, (b)&nbsp;to purchase or lease property, securities or services for the purpose of assuring the owner of such Indebtedness or other
obligation of the payment thereof, (c)&nbsp;to maintain working capital, equity capital or any other financial statement condition or liquidity of the primary obligor so as to enable the primary obligor to pay such Indebtedness or other obligation
or (d)&nbsp;as an account party in respect of any letter of credit or letter of guaranty issued to support such Indebtedness or obligation; <I>provided,</I> that the term Guarantee shall not include endorsements for collection or deposit in the
Ordinary Course of Business. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Guarantee Assumption Agreement&#148;</I> means a Guarantee Assumption Agreement
substantially in the form of Exhibit&nbsp;A by an entity that, pursuant to Section&nbsp;8.11(a), is required to become a &#147;Guarantor&#148;. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Guaranteed Obligations&#148;</I> has the meaning set forth in Section&nbsp;11.01. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Guarantor&#148;</I> means, collectively, Intermediate Holdings and each Subsidiary of a Borrower (other than OpCo) on
the Closing Date or joined as a Guarantor from time to time pursuant to Section&nbsp;8.11(a). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Hazardous
Material&#148;</I> means any substance, element, chemical, compound, product, solid, gas, liquid, waste, <FONT STYLE="white-space:nowrap">by-product,</FONT> pollutant, contaminant or material which is hazardous or toxic, and includes, without
limitation, (a)&nbsp;asbestos, polychlorinated biphenyls and petroleum (including crude oil or any fraction thereof) and (b)&nbsp;any material classified or regulated as &#147;hazardous&#148; or &#147;toxic&#148; or words of like import pursuant to
an Environmental Law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Health Care Compliance Program&#148;</I> has the meaning set forth in Section&nbsp;7.07(g).
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Health Care Laws&#148;</I> means, collectively, all Laws applicable to the business of Borrower or any other
Obligor regulating the manufacturing, sale, distribution, labeling, marketing, or promotion, or the provision of and payment for, health care products, items and services, including but not limited to (a)&nbsp;all applicable Laws relating to the
privacy, security, storage, or collection of consumer information, including but not limited to the HIPAA and state health information privacy and security laws; (b)&nbsp;all applicable Laws relating to fraud and abuse, false claims, self-referral,
kickbacks, <FONT STYLE="white-space:nowrap">fee-splitting,</FONT> or patient brokering, including but not limited to (i)&nbsp;the federal Anti-Kickback Statute (42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7b(b))</FONT> and any similar
state laws, (ii)&nbsp;the Ethics in Patient Referrals Act (Stark Law) (42 U.S.C. &#167; 1395nn) and any similar state laws, (iii)&nbsp;the civil False Claims Act (31 U.S.C. &#167; 3729 et seq.) and any similar state laws, (iv)&nbsp;the federal
health care program exclusion provisions (42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7),</FONT> (v) the Civil Monetary Penalties Act (42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7a),</FONT> (vi) the Medicare Prescription
Drug, Improvement, and Modernization Act of 2003 (Pub. L. <FONT STYLE="white-space:nowrap">No.&nbsp;108-173)),</FONT> and (vii)&nbsp;other applicable requirements relating to prohibited remuneration, or the defrauding of, or making of any false
claim, false statement, or misrepresentation of material facts to the Federal Health Care Programs or any Third-Party </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-16- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Payor Program); (c)&nbsp;all applicable FDA&nbsp;Laws; (d)&nbsp;all applicable Laws regarding the provision of health care supplies, items or services to Federal Health Care Program beneficiaries
or the billing of the Federal Health Care Programs; (e)&nbsp;all applicable Law regarding clinical research and patient consent; (f)&nbsp;required Permits, including relating to the licensure or registration of health care providers, suppliers,
facilities, and manufacturers; and (g)&nbsp;all rules and regulations promulgated under or pursuant to any of the foregoing. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Hedging Agreement&#148;</I> means any interest rate exchange agreement, foreign currency exchange agreement, commodity
price protection agreement or other interest or currency exchange rate or commodity price hedging arrangement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;HIPAA&#148;</I> means the Health Insurance Portability and Accountability Act of 1996, 42 U.S.C. &#167;&#167; <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1320d-1329d-8,</FONT></FONT> as amended by the Health Information Technology for Economic and Clinical Health Act, enacted as Title XIII of the American Recovery and Reinvestment Act of
2009, Public Law <FONT STYLE="white-space:nowrap">111-5,</FONT> as the same may be further amended, modified or supplemented from time to time, and its implementing regulations. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;IDE&#148;</I> means an application, including an application filed with any Regulatory Authority, for authorization to
commence human clinical studies with respect to any Device, including (a)&nbsp;an Investigational Device Exemption as defined in the FD&amp;C&nbsp;Act or any successor application or procedure filed with the FDA, (b)&nbsp;an abbreviated
Investigational Device Exemption as specified in FDA regulations in 21&nbsp;C.F.R. &#167;&nbsp;812.2(b), (c)&nbsp;any equivalent of any of the foregoing pursuant to or under any <FONT STYLE="white-space:nowrap">non-U.S.</FONT> country or regulatory
jurisdiction, (d)&nbsp;all amendments, variations, extensions and renewals of any of the foregoing that may be filed with respect thereto, and (e)&nbsp;all documents and correspondence with Institutional Review Boards, whether U.S. or <FONT
STYLE="white-space:nowrap">non-U.S.,</FONT> or equivalent. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Immaterial Subsidiary&#148;</I> is a Subsidiary other
than an Obligor, that (a)&nbsp;generates revenue in the aggregate less than $500,000 in any trailing twelve (12)&nbsp;month period and (b)&nbsp;holds in the aggregate assets that constitute less than $500,000 in any trailing twelve (12)&nbsp;month
period; <I>provided</I> that if the consolidated revenue or consolidated assets of all Subsidiaries that would otherwise be an &#147;Immaterial Subsidiary&#148; pursuant to clauses (a)&nbsp;and (b) above exceeds (i)&nbsp;in the case of consolidated
revenues in clause (a), $2,500,000 in any trailing twelve (12)&nbsp;month period and (ii)&nbsp;in the case of consolidated total assets in clause (b), $2,500,000&nbsp;in any trailing twelve (12)&nbsp;month period, then Borrowers shall designate in
writing to the Administrative Agent one or more of such Subsidiaries to become Obligors to the extent necessary to eliminate such excess. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Indebtedness&#148;</I> of any Person means, without duplication, (a)&nbsp;all obligations of such Person for borrowed
money, (b)&nbsp;all obligations of such Person evidenced by bonds, debentures, notes, loan agreements or similar instruments, (c)&nbsp;[reserved], (d)&nbsp;all obligations of such Person under conditional sale or other title retention agreements
relating to Property acquired by such Person, (e)&nbsp;all obligations of such Person in respect of the deferred purchase price of Property or services (excluding current accounts payable incurred in the Ordinary Course of Business not overdue by
more than one hundred twenty (120)&nbsp;days), </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-17- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
(f)&nbsp;all Indebtedness of others secured by (or for which the holder of such Indebtedness has an existing right, contingent or otherwise, to be secured by) any Lien on Property owned or
acquired by such Person, whether or not the Indebtedness secured thereby has been assumed, (g)&nbsp;all Guarantees by such Person of Indebtedness of others, (h)&nbsp;all Capital Lease Obligations of such Person, (i)&nbsp;all obligations, contingent
or otherwise, of such Person as an account party in respect of letters of credit and letters of guaranty, (j)&nbsp;obligations under any Hedging Agreement, currency swaps, forwards, futures or derivatives transactions, (k)&nbsp;all obligations,
contingent or otherwise, of such Person in respect of bankers&#146; acceptances, (l)&nbsp;all obligations of such Person under license or other agreements containing a guaranteed minimum payment or purchase by such Person, (m)&nbsp;any Disqualified
Equity Interests of such Person, (n)&nbsp;any earnout obligation at the time such obligation is both required to be reflected as a liability on the balance sheet of such Person in accordance with GAAP and not paid after becoming due and payable and
(o)&nbsp;all other obligations required to be classified as indebtedness of such Person under GAAP. The Indebtedness of any Person shall include the Indebtedness of any other entity (including any partnership in which such Person is a general
partner) to the extent such Person is liable therefor as a result of such Person&#146;s ownership interest in or other relationship with such entity, except to the extent the terms of such Indebtedness provide that such Person is not liable
therefor. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Indemnified Party&#148;</I> has the meaning set forth in Section&nbsp;13.03(b). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Indemnified Taxes&#148;</I> means (a)&nbsp;Taxes, other than Excluded Taxes, imposed on or with respect to any payment
made by or on account of any Obligation and (b)&nbsp;to the extent not otherwise described in clause&nbsp;(a), Other Taxes. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Ineligible Assignee&#148;</I> means (a)&nbsp;a natural person, (b)&nbsp;the Obligors or any of their respective
Affiliates and (c)&nbsp;so long as no Event of Default shall have occurred and is continuing, any Disqualified Lender. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Information&#148;</I> has the meaning set forth in Section&nbsp;13.17. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Insolvency Proceeding&#148;</I> means (a)&nbsp;any case, action or proceeding before any court or other Governmental
Authority relating to bankruptcy, restructuring, reorganization, examinership (in the case of the Irish Obligor, or an Obligor with a COMI in Ireland), rescue process, insolvency, liquidation, receivership, dissolution, <FONT
STYLE="white-space:nowrap">winding-up</FONT> or relief of debtors, or (b)&nbsp;any general assignment for the benefit of creditors, composition, marshaling of assets for creditors, or other, similar arrangement in respect of any Person&#146;s
creditors generally or any substantial portion of such Person&#146;s creditors, in each case undertaken under U.S.&nbsp;Federal, state or foreign law, including the Bankruptcy Code. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Institutional Review Board</I>&#148; means any board, committee, or other group formally designated by an institution
to review, to approve the initiation of, and to conduct periodic review of, biomedical research involving human subjects, or any Institutional Review Board as defined by 21 C.F.R. Part 56 or 45 C.F.R. Part 46. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-18- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Intellectual Property&#148;</I> means all Patents, Trademarks,
Copyrights, industrial designs, Technical Information, whether registered or not, whether domestic or foreign, including all of the following: (a)&nbsp;applications, registrations, amendments and extensions relating to any of the foregoing;
(b)&nbsp;rights and privileges arising under any applicable Laws with respect to any of the foregoing; (c)&nbsp;rights to sue for or collect any damages from any past, present or future infringements of any of the foregoing; and (d)&nbsp;rights of
the same or similar effect or nature as described above in any jurisdiction corresponding to any of the foregoing throughout the world. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Intercompany Subordinated Demand Promissory Note&#148; </I>means an Intercompany Subordinated Demand Promissory Note
in substantially the form of Exhibit&nbsp;K. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Interest Period&#148;</I> means a period of one month or such other
period as may be agreed to by the Administrative Agent (and in each case, subject to the availability thereof); <I>provided</I> that (a)&nbsp;the Interest Period shall commence on the date of an advance and, in the case of immediately successive
Interest Periods, each successive Interest Period shall commence on the date on which the next preceding Interest Period expires, (b)&nbsp;if any Interest Period would otherwise expire on a day that is not a Business Day, such Interest Period shall
expire on the next succeeding Business Day, <I>provided,</I> that if any Interest Period would otherwise expire on a day that is not a Business Day but is a day of the month after which no further Business Day occurs in such month, such Interest
Period shall expire on the next preceding Business Day, (c)&nbsp;any Interest Period that begins on the last Business Day of a calendar month (or on a day for which there is not a numerically corresponding day in the calendar month at the end of
such Interest Period) shall end on the last Business Day of the relevant calendar month at the end of such Interest Period, (d)&nbsp;no Interest Period shall extend beyond the Maturity Date and (e)&nbsp;no tenor that has been removed from this
definition pursuant to 3.02(c)(iv) shall be available. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Intermediate Holdings&#148;</I> means West Affum
Intermediate Holdings Corp., an exempted company incorporated with limited liability in the Cayman Islands. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Intermediate Holdings Equitable Share Charge&#148;</I> means a Cayman Islands law governed equitable share mortgage,
dated as of the Closing Date and issued by Intermediate Holdings in favor of the Administrative Agent over the shares of West Affum Corp. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Intermediate Holdings Fixed and Floating Charge&#148;</I> means a Cayman Islands law governed Debenture, dated as of
the Closing Date and issued by Intermediate Holdings in favor of the Administrative Agent. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Invention&#148;</I>
means any novel, inventive or useful art, apparatus, method, process, machine (including any article or Device), manufacture or composition of matter, or any novel, inventive and useful improvement in any art, method, process, machine (including any
article or Device), manufacture or composition of matter. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-19- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Investment&#148;</I> means, for any Person: (a)&nbsp;the
acquisition (whether for cash, Property, services or securities or otherwise) of Equity Interests, bonds, notes, debentures, partnership or other ownership interests or other securities of any other Person or any agreement to make any such
acquisition (including any &#147;short sale&#148; or any sale of any securities at a time when such securities are not owned by the Person entering into such sale); (b)&nbsp;the making of any deposit with, or advance, loan, assumption of debt or
other extension of credit to, any other Person (including the purchase of Property from another Person subject to an understanding or agreement, contingent or otherwise, to resell such Property to such Person), but excluding any such advance, loan
or extension of credit in the nature of an ordinary course trade receivable having a term not exceeding ninety (90)&nbsp;days arising in connection with the sale of services, inventory or supplies by such Person in the Ordinary Course of Business;
(c)&nbsp;the entering into of any Guarantee of, or other contingent obligation with respect to, Indebtedness or other liability of any other Person and (without duplication) any amount committed to be advanced, lent or extended to such Person;
(d)&nbsp;the entering into any joint venture; or (e)&nbsp;the entering into of any Hedging Agreement. The amount of an Investment will be determined at the time the Investment is made without giving effect to any subsequent changes in value. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Ireland</I>&#148; means Ireland, excluding Northern Ireland (and &#147;Irish&#148; shall be construed accordingly).
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Irish Anti-Corruption Laws</I>&#148; means the Criminal Justice (Corruption Offences) Act 2018 of Ireland. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Irish Anti-Terrorism Laws</I>&#148; means the Criminal Justice (Money Laundering and Terrorist Financing) Act 2010.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Irish Debenture&#148;</I> means the Irish law debenture, dated as of the Closing Date, among the Irish Obligor
and the Administrative Agent, granting a security interest in the assets, rights, title, interests and property constituting &#147;Security Assets&#148; thereunder in favor of the Administrative Agent for the benefit of the Lenders. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Irish Economic Sanctions Laws&#148; </I>means the Financial Transfers Act 1992 and all Irish laws and regulations
which implement EU and UN trade and/or financial sanctions. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Irish Obligor&#148;</I> means West Affum Holdings
Designated Activity Company, a designated company limited by shares incorporated in Ireland with company number 696250. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Irish Security Documents&#148; </I>means, collectively, the Irish Debenture and the Irish Share Charge. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Irish Share Charge&#148;</I> means an Irish law governed share charge, dated as of the Closing Date, between West
Affum Corp., as mortgagor and Administrative Agent in respect of shares held in the Irish Obligor. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-20- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;IRS&#148;</I> means the U.S.&nbsp;Internal Revenue Service or any
successor agency, and to the extent relevant, the U.S.&nbsp;Department of the Treasury. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Judgment
Currency</I>&#148; has the meaning set forth in Section&nbsp;13.22(a). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Judgment Currency Conversion
Date</I>&#148; has the meaning set forth in Section&nbsp;13.22(a). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Key Person&#148; </I>means Brian Webster or
such other person as may be appointed by Administrative Borrower as its replacement from time to time. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Laws&#148;</I> means, collectively, all international, foreign, federal, state, provincial, territorial, municipal and
local statutes, treaties, rules, regulations, ordinances, codes and administrative or judicial precedents or authorities, including the interpretation or administration thereof by any Governmental Authority charged with the enforcement,
interpretation or administration thereof, and all applicable administrative orders, directed duties, requests, licenses, authorizations and permits of, and agreements with, any Governmental Authority, in each case whether or not having the force of
law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Lenders&#148;</I> has the meaning set forth in the introduction hereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Lien&#148;</I> means any mortgage, lien, pledge, assignment by way of security, charge or other security interest, or
any lease, title retention agreement, mortgage, restriction, easement, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-way,</FONT></FONT> option or adverse Claim (of ownership or possession) or other encumbrance of any
kind or character whatsoever or any preferential arrangement that has the practical effect of creating a security interest. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Loan Documents&#148;</I> means, collectively, this Agreement, any Note, the Security Documents, any Guarantee
Assumption Agreement, any landlord collateral access agreement, any subordination agreement, intercreditor agreement or other present or future document, instrument, agreement or certificate delivered to any Lender in connection with this Agreement
or any of the other Loan Documents, in each case, as amended, restated, supplemented or otherwise modified. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Loan
Exposure&#148;</I> means, with respect to any Lender, as of any date of determination, the outstanding principal amount of such Lender&#146;s portion of the Term Loans; <I>provided,</I> at any time prior to the making of any Term Loans, the Loan
Exposure of any Lender shall be equal to such Lender&#146;s Commitment with respect to such Term Loan. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Loss&#148;</I> means judgments, debts, liabilities, expenses, costs, damages or losses, contingent or otherwise,
whether liquidated or unliquidated, matured or unmatured, disputed or undisputed, contractual, legal or equitable, including loss of value, professional fees, including fees and disbursements of legal counsel on a full indemnity basis, and all costs
incurred in investigating or pursuing any Claim or any proceeding relating to any Claim. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-21- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Majority Lenders&#148;</I> means, at any time, one or more Lenders
having or holding Loan Exposure and representing more than 50% of the aggregate Loan Exposure of all Lenders. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Margin Stock&#148;</I> means &#147;margin stock&#148; within the meaning of Regulations&nbsp;U and X. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Material Adverse Change&#148;</I> and <I>&#147;Material Adverse Effect&#148;</I> mean a material adverse change in or
effect on (a)&nbsp;the business, financial condition, operations, performance or Property of the Obligors taken as a whole, (b)&nbsp;the ability of any Obligor to perform its obligations under any Loan Document, or (c)&nbsp;the legality, validity,
binding effect or enforceability of the Loan Documents or the rights and remedies of any Lender under any of the Loan Documents. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Material Agreement&#148;</I> means (a)&nbsp;any Contract which is listed in Schedule&nbsp;7.14, (b)&nbsp;any other
Contract to which any Obligor is a party or a beneficiary from time to time, or to which any assets or properties of any Obligor is bound, the loss or termination of which would reasonably be expected to result in a Material Adverse Effect, and
(c)&nbsp;any other Contract to which any Obligor is a party or a guarantor (or equivalent) whether existing as of the date hereof or in the future that during any period of twelve (12)&nbsp;consecutive months is reasonably expected to
(A)&nbsp;result in payments or receipts (including royalty, licensing or similar payments) made to any Obligor in an aggregate amount in excess of $1,000,000 or (B)&nbsp;require payments or expenditures (including royalty, licensing or similar
payments) made by any Obligor in an aggregate amount in excess of $1,000,000. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Material Indebtedness&#148;</I>
means, at any time, any Indebtedness of any Obligor, the outstanding principal amount of which, individually or in the aggregate, exceeds $1,000,000. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Material Intellectual Property&#148;</I> means all Obligor Intellectual Property, whether currently owned, acquired,
developed or obtained after the date hereof (a)&nbsp;the loss of which would reasonably be expected to have or result in a Material Adverse Effect or (b)&nbsp;that has a fair market value in excess of $1,000,000. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Maturity Date&#148;</I> means the earlier to occur of (a)&nbsp;the Stated Maturity Date, and (b)&nbsp;the date on
which the Term Loans are accelerated pursuant to Section&nbsp;10.02. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Minimum Liquidity&#148;</I> has the meaning
set forth in Section&nbsp;8.15(a). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Multiemployer Plan&#148;</I> means any &#147;multiemployer plan,&#148; as
defined in Section&nbsp;400l(a)(3) of ERISA, to which any Obligor or ERISA Affiliate has any obligation or liability, contingent or otherwise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-22- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Net Cash Proceeds&#148;</I> means, </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) with respect to the incurrence or issuance of any Indebtedness incurred by an Obligor not permitted under
Section&nbsp;9.01, the excess, if any, of (i)&nbsp;the sum of the cash received in connection with such incurrence or issuance over (ii)&nbsp;the investment banking fees, underwriting discounts, commissions, costs and other reasonable expenses and
other customary expenses (including reasonable attorney&#146;s, accountant&#146;s and other similar professional advisor&#146;s fees), incurred by such Obligor in connection with such incurrence or issuance to third parties (other than any other
Obligor or any of their respective Affiliates); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) with respect to any Casualty Event, the amount of cash proceeds
actually received from time to time by or on behalf of an Obligor after deducting therefrom only (i)&nbsp;actual costs and expenses related thereto incurred by such Obligor in connection therewith and (ii)&nbsp;Taxes paid or payable in connection
therewith; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) with respect to any Asset Sale, the excess, if any, of (i)&nbsp;cash proceeds received in respect of
such Asset Sale (including cash proceeds subsequently received (as and when received)) over (ii)&nbsp;the sum of (A)&nbsp;the direct costs of such Asset Sale then payable by the recipient of such proceeds excluding amounts payable to any Obligor,
(B)&nbsp;taxes paid or payable, including sales, uses taxes and income taxes by such recipient as a result thereof, (C)&nbsp;amounts required to be applied to repay principal, interest and prepayment premiums and penalties on Indebtedness secured by
a Permitted Lien on the properties subject to such Asset Sale and (D)&nbsp;amounts reserved or deposited in escrow with respect to indemnity payments or price adjustments until such amounts are released to the Obligors. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Net Revenue&#148;</I> means, with respect to Intermediate Holdings and its Subsidiaries, all amounts paid to and
received by such Person in the ordinary course of business that, in accordance with GAAP, would be classified as net revenue. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Note&#148;</I> means a promissory note executed and delivered by Borrowers to any Lender in the form attached hereto
as Exhibit&nbsp;C. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Notice of Intent to Cure&#148;</I> has the meaning set forth in Section&nbsp;8.15(b). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Obligations&#148;</I> means, with respect to any Obligor, all amounts, obligations, liabilities, covenants and duties
of every type and description owing by such Obligor to any Lender or any other Indemnified Party hereunder, arising out of, under, or in connection with, any Loan Document, whether direct or indirect (regardless of whether acquired by assignment),
absolute or contingent, due or to become due, whether liquidated or not, now existing or hereafter arising and however acquired, and whether or not evidenced by any instrument for the payment of money, including, without duplication, (a)&nbsp;the
principal amount of the Term Loans, (b)&nbsp;all interest on the Term Loans (including accrued but uncapitalized PIK&nbsp;Interest and interest accruing at the Default Rate), whether </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-23- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
or not accruing after the filing of any petition in bankruptcy or after the commencement of any insolvency, reorganization or similar proceeding, and whether or not a Claim for <FONT
STYLE="white-space:nowrap">post-filing</FONT> or <FONT STYLE="white-space:nowrap">post-petition</FONT> interest is allowed in any such proceeding, (c)&nbsp;any Prepayment Premium, and (d)&nbsp;all other fees, expenses, interest, commissions,
charges, costs, disbursements, indemnities and reimbursement of amounts paid and other sums chargeable to such Obligor under any Loan Document. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Obligor Intellectual Property&#148;</I> means Intellectual Property owned by any of the Obligors. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Obligors&#148;</I> means, collectively, Borrowers, each Guarantor and each of their respective successors and
permitted assigns. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Observer&#148;</I> has the meaning set forth in Section&nbsp;8.18. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;OFAC&#148;</I> means the Office of Foreign Assets Control of the U.S.&nbsp;Department of the Treasury (or any
successor thereto). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;OFSI&#148; </I>means the Office of Financial Sanctions Implementation of His Majesty&#146;s
Treasury of the United Kingdom. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;OpCo&#148;</I> has the meaning set forth in the introduction hereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Ordinary Course of Business&#148;</I> means, with respect to the Obligors, the ordinary course of business generally
consistent with past custom and practice (including with respect to nature, scope, magnitude, quantity and frequency). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Organizational Documents&#148;</I> means (a)&nbsp;with respect to any corporation, its certificate or articles of
incorporation or organization, as amended, and its <FONT STYLE="white-space:nowrap">by-laws,</FONT> as amended, (b)&nbsp;with respect to any limited partnership or exempted limited partnership, its certificate of limited partnership or certificate
of registration (as applicable), as amended, section 9 and 10 (if any) statements (if applicable) and its partnership agreement or exempted limited partnership agreement, as amended, (c)&nbsp;with respect to any general partnership, its partnership
agreement, as amended, (d)&nbsp;with respect to any limited liability company or any exempted company, its articles of organization or certificate of incorporation, including on change of name (as applicable), as amended, statutory registers (if
applicable) and its operating agreement or memorandum and articles of association (as applicable), as amended, and (e)&nbsp;with respect to any designated activity company incorporated in Ireland, its constitution together with its certificate of
incorporation (together with any applicable certificate of incorporation on change of name, <FONT STYLE="white-space:nowrap">re-registration</FONT> or conversion). In the event any term or condition of this Agreement or any other Loan Document
requires any Organizational Document to be certified by a secretary of state or similar government official, the reference to any such &#147;Organizational Document&#148; shall only be to a document of a type customarily certified by such government
official. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-24- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Other Connection Taxes&#148;</I> means, with respect to any
Recipient, Taxes imposed as a result of a present or former connection between such Recipient and the jurisdiction imposing such Tax (other than connections arising solely from such Recipient having executed, delivered, become a party to, performed
its obligations under, received payments under, received or perfected a security interest under, engaged in any other transaction pursuant to or enforced any Loan Document, or sold or assigned an interest in the Term Loans or any Loan Document).
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Other Taxes&#148;</I> means all present or future stamp, court or documentary, intangible, recording, filing or
similar Taxes that arise from any payment made under, from the execution, delivery, performance, enforcement or registration of, from the receipt or perfection of a security interest under, or otherwise with respect to, any Loan Document, except any
such Taxes that are Other Connection Taxes imposed with respect to an assignment (other than an assignment made pursuant to Section&nbsp;5.03(h)). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;</I><I>Parent</I><I>&#148;</I> means West Affum Holdings, L.P., a Cayman Islands exempted limited partnership, acting
at all times by and through its general partner, West Affum GP Ltd., a Cayman Islands exempted company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Participant&#148;</I> has the meaning set forth in Section&nbsp;13.05(e). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Participant Register&#148;</I> has the meaning set forth in Section&nbsp;13.05(f). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Patents&#148;</I> has the meaning set forth in the Security Documents. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Payment Date&#148;</I> means the last day of each fiscal quarter of the Borrowers, commencing on September&nbsp;30,
2023; <I>provided</I> that if such last day of such Interest Period is not a Business Day, then the Payment Date for such Interest Period will be the next succeeding Business Day. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;PBGC&#148;</I> means the United States Pension Benefit Guaranty Corporation referred to and defined in ERISA and any
successor entity performing similar functions. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Perceptive&#148;</I> has the meaning set forth in the introduction
hereto. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Periodic Term SOFR</I><I></I><I>&nbsp;Determination Day&#148;</I> has the meaning specified in the
definition of &#147;Term SOFR.&#148; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Permits&#148;</I> means all permits, licenses, registrations, certificates,
orders, approvals, authorizations, consents, waivers, franchises, variances and similar rights issued by or obtained from any Governmental Authority or any other Person, including, without limitation, those relating to Environmental Laws and Health
Care Laws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-25- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Permitted Acquisition&#148;</I> means any Acquisition by any
Obligor or any of its <FONT STYLE="white-space:nowrap">wholly-owned</FONT> Subsidiaries, by (a)&nbsp;purchase, merger, amalgamation, license or otherwise, of all or substantially all of the assets of, all of the Equity Interests of, or a business
line or unit or a division of, any Person or (b)&nbsp;license arrangement for the rights to use, develop, market or otherwise commercialize any Patents, Trademarks, Copyrights or other Intellectual Property (other than Permitted Licenses);
<I>provided</I> that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) immediately prior to, and immediately after giving effect thereto, no Default shall have
occurred and be continuing or would result therefrom; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) all transactions in connection therewith shall be consummated,
in all material respects, in accordance with all applicable Laws and in conformity in all material respects with all applicable Governmental Approvals; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) in the case of the Acquisition of all of the Equity Interests of such Person, all of the Equity Interests (except for any
such securities in the nature of directors&#146; qualifying shares required pursuant to applicable Law) acquired, or otherwise issued by such Person or any newly formed Subsidiary of such Obligor in connection with such Acquisition, shall be owned
100% by an Obligor and Borrowers shall have taken, or caused to be taken, as of the date such Person becomes a Subsidiary of an Obligor, each of the actions set forth in Section&nbsp;8.11, if applicable; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) such Person (in the case of an Acquisition of Equity Interests) or assets (in the case of an Acquisition of assets or a
division) (A)&nbsp;shall be engaged or used, as the case may be, in the same business or lines of business in which a Borrower and/or its Subsidiaries are engaged or a business reasonably and substantially related thereto or (B)&nbsp;shall have a
similar customer base as Borrowers and/or their Subsidiaries; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) Administrative Borrower shall have provided the
Administrative Agent with at least ten&nbsp;(10) Business Days&#146; prior written notice of the consummation of any such Acquisition, together with summaries, prepared in reasonable detail, of all due diligence conducted by or on behalf of
Borrowers or the applicable Subsidiary prior to such Acquisition; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) the Acquisition shall have been approved by the
Board or other governing body or controlling Person of the Person acquired or the Person from whom such assets or division is acquired; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii) on a <I>pro forma</I> basis after giving effect to such Acquisition, Intermediate Holdings and its Subsidiaries shall be
in compliance with the covenants set forth in Section&nbsp;8.15. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Permitted Cash Equivalent Investments&#148;</I>
means (a)&nbsp;marketable direct obligations issued or unconditionally guaranteed by the United States or any agency or any State thereof having maturities of not more than two (2)&nbsp;years from the date of acquisition, (b)&nbsp;commercial paper
with an average maturity of no more than one (1)&nbsp;year and having the highest rating from either Standard&nbsp;&amp; Poor&#146;s Ratings Group or Moody&#146;s Investors Service, Inc., (c) any money market funds or other investment vehicles whose
principal investments are in investments described in clauses&nbsp;(a) or (b)&nbsp;above, and (d)&nbsp;certificates of deposit maturing no more than one (1)&nbsp;year after issue. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-26- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Permitted Indebtedness&#148;</I> means any Indebtedness permitted
under Section&nbsp;9.01. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Permitted IPO Reorganization&#148;</I> means any transactions or actions taken in
connection with and reasonably related to consummating an initial public offering of a Borrower or any direct or indirect parent thereof, so long as (a)&nbsp;such transaction does not result in a Change of Control, (b)&nbsp;after giving effect
thereto, the security interest of the Administrative Agent, on behalf of the Lenders in the Collateral, taken as a whole, is not materially impaired (as reasonably determined by Borrowers and the Administrative Agent in good faith) and (c)&nbsp;such
offering is not a result of a &#147;reverse merger&#148;, special purpose acquisition company transaction or similar transactions. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Permitted Licenses&#148;</I> means (a)&nbsp;licenses of off the shelf software that is commercially available to the
public, <FONT STYLE="white-space:nowrap">(b)&nbsp;non-exclusive</FONT> licenses or sublicenses of Intellectual Property entered into in the Ordinary Course of Business, (c)&nbsp;licenses permitted pursuant to Section&nbsp;9.09(k) and
(d)&nbsp;licenses for the use of Obligor Intellectual Property, in each case, entered into in the Ordinary Course of Business or as otherwise may be approved by the applicable Obligor&#146;s Board and so long as (i)&nbsp;no Event of Default has
occurred and is continuing at the time such license is entered into and (ii)&nbsp;such license does not materially impair the Lenders from exercising their rights under any of the Loan Documents. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Permitted Liens&#148;</I> means any Liens permitted under Section&nbsp;9.02. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;</I><I>Permitted Refinancing</I><I>&#148;</I> means, with respect to any Indebtedness permitted to be refinanced,
extended, renewed or replaced hereunder, any refinancings, extensions, renewals and replacements of such Indebtedness; <I>provided</I> that such refinancing, extension, renewal or replacement shall not (a)&nbsp;increase the outstanding principal
amount of the Indebtedness being refinanced, extended, renewed or replaced other than by an amount equal to the amount of fees, expenses, premium incurred in connection with such refinancings, extensions, renewals and replacements, (b)&nbsp;contain
terms relating to outstanding principal amount, amortization, interest rate or equivalent yield, maturity, collateral security (if any) or subordination (if any), or other material terms that, taken as a whole, are less favorable in any material
respect to any Obligor or the Lenders than the terms of any agreement or instrument governing the Indebtedness being refinanced, (c)&nbsp;contain any new requirement to grant any Lien or to give any Guarantee that was not an existing requirement of
the Indebtedness being refinanced and (d)&nbsp;after giving effect to such refinancing, extension, renewal or replacement, no Default shall have occurred (or could reasonably be expected to occur) as a result thereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Person&#148;</I> means any individual, corporation, exempted company, exempted limited partnership, company, voluntary
association, partnership, limited liability company, joint venture, trust, unincorporated organization or Governmental Authority or other entity of whatever nature. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-27- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;PFIC&#148;</I> has the meaning set forth in Section&nbsp;8.01(j).
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;PIK</I><I></I><I>&nbsp;Interest&#148; </I>shall mean <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">payment-in-kind</FONT></FONT> of interest in respect of the Term Loans by increasing the outstanding principal amount of each Term Loan to which such interest relates by an amount equal to such portion of interest, rather
than paying such portion of interest in cash. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Prepayment Premium&#148;</I> has the meaning set forth in
Section&nbsp;3.03(a). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Pro Rata Share&#148;</I> has the meaning set forth in Section&nbsp;11.08. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Product&#148;</I> means (a)&nbsp;those Devices set forth (and described in reasonable detail) on Schedule&nbsp;3
attached hereto, and (b)&nbsp;any current or future Device subject to any Product Development and Commercialization Activities by any Obligor, including any such Device currently in development. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Product Agreement&#148;</I> means, with respect to any Product, any Contract, license, document, instrument, interest
(equity or otherwise) or the like under which one or more Persons grants or receives (a)&nbsp;any right, title or interest with respect to any Product Development and Commercialization Activities of such Product, or (b)&nbsp;any right to exclude any
other Person from engaging in, or otherwise restricting any right, title or interest as to, any Product Development and Commercialization Activities with respect to such Product, including any Contract with suppliers, manufacturers, distributors,
clinical research organizations, hospitals, group purchasing organizations, wholesalers, pharmacies or any other Person related to such entity. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Product Assets&#148;</I> means, with respect to any Product, (a)&nbsp;any and all rights, title and interest of a
Borrower or any of its Subsidiaries in any assets relating to such Product or any Product Development and Commercialization Activities with respect to such Product, (b)&nbsp;all Product Related Information with respect to such Product or any related
Product Development and Commercialization Activities, (c)&nbsp;any Product Agreement related to such Product or any such Product Development and Commercialization Activities, (d)&nbsp;any Intellectual Property, Regulatory Approvals and similar
assets with respect to such Product or any such Product Development and Commercialization Activities, and (e)&nbsp;all rights, title and interests in any other property, tangible or intangible, manifesting or otherwise in respect of such Product or
any such Product Development and Commercialization Activities, including, without limitation, inventory, accounts receivable or similar rights to receive money or payment pertaining thereto and all proceeds of the foregoing. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Product Authorizations&#148;</I> means any and all Governmental Approvals (including all applicable IDEs, Device
Clearance Applications, supplements, amendments, governmental price and reimbursement approvals and approvals of applications for regulatory exclusivity), safety or quality specifications and standards, or any other authorizations of any applicable
Regulatory Authority in each case necessary for the manufacturing, development, distribution, ownership, use, storage, import, export, transport, promotion, marketing, sale or other commercialization of any Product or for any Product Development and
Commercialization Activities with respect thereto in any country or jurisdiction, whether U.S. or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-28- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Product Development and Commercialization Activities&#148;</I>
means, with respect to any Product, any combination of research, development, manufacture, import, use, sale, licensing, importation, storage, design, labeling, marketing, promotion, supply, distribution, testing, packaging, purchasing or other
commercialization activities, receipt of payment in respect of any of the foregoing (including, without limitation, in respect of licensing, royalty or similar payments), or any similar or other activities the purpose of which is to commercially
exploit such Product. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Product Related Information&#148; </I>means, with respect to any Product, all books,
records, lists, ledgers, files, manuals, Contracts, correspondence, reports, plans, drawings and data (in any form or medium), and all techniques and other <FONT STYLE="white-space:nowrap">know-how,</FONT> owned or possessed by a Borrower or any of
its Subsidiaries that is necessary or required for any Product Development and Commercialization Activities relating to such Product, including (a)&nbsp;brand materials, packaging and other trade dress, customer targeting and other marketing,
promotion and sales materials and information, referral, customer, supplier and other contact lists and information, product, business, marketing and sales plans, research, studies and reports, sales, maintenance and production records, training
materials and other marketing, sales and promotional information, (b)&nbsp;clinical data, information included or supporting any Product Authorization or other Regulatory Approval, any regulatory filings, updates, notices and correspondence
(including adverse event and other pharmacovigilance and other <FONT STYLE="white-space:nowrap">post-marketing</FONT> reports and information, etc.), technical information, product development and operational data and records, and all other
documents, records, files, data and other information relating to product development, manufacture and use, (c)&nbsp;litigation and dispute records, and accounting records, (d)&nbsp;all documents, records and files relating to Intellectual Property,
including all correspondence from and to third parties (including Intellectual Property counsel and patent, trademark and other Intellectual Property registries, including the United States Patent and Trademark Office), and (e)&nbsp;all other
information, techniques and <FONT STYLE="white-space:nowrap">know-how</FONT> necessary or required in connection with the Product Development and Commercialization Activities for any Product. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Prohibited Payment&#148;</I> means any bribe, rebate, payoff, influence payment, kickback or other payment or gift of
money or anything of value (including meals or entertainment) to any officer, employee or ceremonial office holder of any government or instrumentality thereof, political party or <FONT STYLE="white-space:nowrap">supra-national</FONT> organization
(such as the United Nations), any political candidate, any royal family member or any other person who is connected or associated personally with any of the foregoing that is prohibited under any Requirement of Law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Projections&#148;</I> has the meaning set forth in Section&nbsp;7.04(b). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Property&#148;</I> of any Person means any property or assets, or interest therein, of such Person. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-29- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Proportionate Share&#148;</I> means, with respect to any Lender,
the percentage obtained by dividing (a)&nbsp;the Loan Exposure of such Lender then in effect by (b)&nbsp;the aggregate Loan Exposure of all Lenders then in effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Proposal Letter&#148;</I> means the letter agreement, dated May&nbsp;22, 2023, among Administrative Borrower and
Perceptive Advisors LLC, regarding the transactions contemplated hereby and the outline of proposed terms and conditions attached thereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Publicly Reporting Company&#148;</I> means an issuer generally subject to the public reporting requirements of the
Exchange Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Qualified Equity Interest&#148;</I> means, with respect to any Person, any Equity Interest of such
Person that is not a Disqualified Equity Interest. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Qualified Public Offering&#148;</I> shall mean the initial
underwritten public offering of common Equity Interests of a Borrower (or any direct or indirect parent thereof) pursuant to an effective registration statement filed with the United States Securities and Exchange Commission in accordance with the
Securities Act of 1933 or similar laws of other jurisdictions, raising net cash proceeds of at least $50,000,000. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Recipient&#148;</I> means any Lender or the Administrative Agent. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Redemption Date&#148;</I> has the meaning set forth in Section&nbsp;3.03(a). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Redemption Price&#148;</I> has the meaning set forth in Section&nbsp;3.03(a). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Referral Source&#148; </I>has the meaning set forth in Section&nbsp;7.07(b). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Register&#148;</I> has the meaning set forth in Section&nbsp;13.05(d). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Regulation</I><I></I><I>&nbsp;T&#148;</I> means Regulation&nbsp;T of the Board of Governors of the Federal Reserve
System, as amended. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Regulation</I><I></I><I>&nbsp;U&#148;</I> means Regulation&nbsp;U of the Board of Governors
of the Federal Reserve System, as amended. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Regulation</I><I></I><I>&nbsp;X&#148;</I> means Regulation&nbsp;X of
the Board of Governors of the Federal Reserve System, as amended. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Regulatory Approvals&#148;</I> means any
Governmental Approval relating to any Product or any Product Development and Commercialization Activities related to such Product, including any Product Authorizations with respect thereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Regulatory Authority&#148;</I> means any Governmental Authority that is concerned with or has regulatory or
supervisory oversight with respect to any Product or any Product Development and Commercialization Activities relating to any Product, including the FDA and all equivalent Governmental Authorities, whether U.S. or
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-30- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Relevant Governmental Body</I>&#148; shall mean the FRB or the
Federal Reserve Bank of New York, or a committee officially endorsed or convened by the FRB or the Federal Reserve Bank of New York, or any successor thereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Representatives&#148;</I> has the meaning set forth in Section&nbsp;13.17. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Requirement of Law&#148;</I> means, as to any Person, any Law applicable to or binding upon such Person or any of its
Properties or revenues. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Resignation Effective Date&#148;</I> has the meaning set forth in Section&nbsp;12.06(a).
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Resolution Authority&#148;</I> means an EEA&nbsp;Resolution Authority or, with respect to any UK&nbsp;Financial
Institution, a UK&nbsp;Resolution Authority. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Responsible Officer&#148;</I> of any Person means each of the
president, chief executive officer and chief financial officer of such Person or, in the case of an Obligor incorporated in Ireland, a director or the secretary of such Obligor. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Restricted Payment&#148;</I> means any dividend or other distribution (whether in cash, securities or other Property)
with respect to any Equity Interest of the Obligors, or any payment (whether in cash, securities or other Property), including any sinking fund or similar deposit, on account of the purchase, redemption, retirement, acquisition, cancellation or
termination of any such shares of capital stock of the Obligors or any option, warrant or other right to acquire any such shares of capital stock of an Obligor. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Restrictive Agreement&#148;</I> means any indenture, agreement, instrument or other binding arrangement that
prohibits, restricts or imposes any condition upon (a)&nbsp;the ability of any Obligor to create, incur or permit to exist any Lien upon any of its Property (other than (i)&nbsp;customary provisions in Contracts (including without limitation leases
and <FONT STYLE="white-space:nowrap">in-bound</FONT> licenses of Intellectual Property) restricting the assignment thereof, (ii)&nbsp;restrictions or conditions imposed by any agreement governing secured Permitted Indebtedness permitted under
Section&nbsp;9.01(g), to the extent that such restrictions or conditions apply only to the Property securing such Indebtedness and (iii)&nbsp;software and other Intellectual Property licenses pursuant to which an Obligor is the licensee of the
relevant software or Intellectual Property, as the case may be (in which case, any prohibition or limitation shall relate only to the assets or rights subject to the applicable license and/or the license itself)), or (b)&nbsp;the ability of any
Obligor to pay dividends or other distributions with respect to any shares of its Equity Interests or to make or repay loans or advances to any Obligor or to Guarantee Indebtedness of any Obligor, in each case of clauses (a)&nbsp;and (b), other than
(i)&nbsp;agreements that are binding on an Obligor at the time such Obligor first becomes a wholly-owned Subsidiary of any Borrower, so long as such agreement were not entered into solely in contemplation of such Person becoming a wholly-owned
Subsidiary of any Borrower, (ii)&nbsp;agreements which are customary in joint </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-31- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
venture or similar arrangements applicable to joint ventures permitted under Section&nbsp;9.05(l) and applicable solely to such joint venture entered into in the Ordinary Course of Business,
(iii)&nbsp;leases, subleases, licenses or asset sale agreement otherwise permitted hereby so long as such restrictions relate to the assets subject thereto, (iv)&nbsp;restrictions which are customary provisions restricting subletting or assignment
of any lease governing a leasehold interest of the Borrowers or any Obligors or the assignment of any license or sublicense agreement, (v)&nbsp;customary provisions restricting assignment of any agreement entered into in the Ordinary Course of
Business or consistent with past practice, (vi)&nbsp;restrictions on cash or deposits imposed by customers under contracts entered into in the Ordinary Course of Business or consistent with past practice and (vii)&nbsp;customary restrictions
contained in any Permitted Refinancing thereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Rights&#148; </I>has the meaning set forth in
Section&nbsp;12.10(i). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Sanctions&#148;</I> means economic or financial sanctions, requirements or trade embargoes
imposed, administered or enforced from time to time by any Governmental Authority (including, but not limited to, OFAC, the U.S.&nbsp;Department of State, the U.S.&nbsp;Department of Commerce or OFSI). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Sanctions Laws&#148;</I> means all laws, rules, regulations and requirements of any jurisdiction applicable to the
Lender, any Obligor (as applicable) or any other Loan Documents concerning or relating to Sanctions, terrorism or money laundering. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;SEC&#148;</I> means United States Securities and Exchange Commission. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Securities Account&#148;</I> has the meaning set forth in the Security Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Security Agreement&#148;</I> means the Security Agreement, dated as of the date hereof, in substantially the form of
Exhibit&nbsp;G, among the Obligors, the Lenders and the Administrative Agent, granting a security interest in the personal Property constituting Collateral thereunder in favor of the Administrative Agent for the benefit of the Lenders. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Security Documents&#148;</I> means, collectively, the Security Agreement, each
<FONT STYLE="white-space:nowrap">Short-Form</FONT> IP Security Agreement, the Cayman Security Documents, the Irish Security Documents, and each other security document, control agreement or financing statement executed to perfect Liens in favor of
the Administrative Agent for the benefit of the Lenders. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Segregated Health Care Account&#148;</I> means a deposit
account of an Obligor in the name of such Obligor and under the sole dominion and control of such Obligor maintained in accordance with the requirements of Section&nbsp;8.17(b) hereof, the only funds on deposit in which constitute the direct
proceeds of payments made by Federal Health Care Programs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-32- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Short</I><I><FONT STYLE="white-space:nowrap">-Form</FONT> IP
Security Agreements&#148;</I> means <FONT STYLE="white-space:nowrap">short-form</FONT> copyright, patent or trademark (as the case may be) security agreements, dated as of the date hereof, in substantially the form of
<FONT STYLE="white-space:nowrap">Exhibits&nbsp;H-1</FONT> and <FONT STYLE="white-space:nowrap">H-2,</FONT> entered into by one or more Obligors in favor of the Administrative Agent for the benefit of the Lenders, each in form and substance
satisfactory to the Administrative Agent. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;SOFR&#148;</I> means a rate equal to the secured overnight financing
rate as administered by the SOFR&nbsp;Administrator. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;SOFR</I><I></I><I>&nbsp;Administrator&#148;</I> means the
Federal Reserve Bank of New&nbsp;York (or a successor administrator of the secured overnight financing rate). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Solvent&#148;</I> means, with respect to any Person, that (a)&nbsp;the present fair saleable value of the Property of
such Person is greater than the total amount of liabilities (including contingent liabilities) of such Person, (b)&nbsp;the present fair saleable value of the Property of such Person is not less than the amount that will be required to pay the
probable liability of such Person on its debts as they become absolute and matured, and (c)&nbsp;such Person: (i) (where such is not the Irish Obligor) has not incurred and does not intend to, and does not believe that it will, incur debts or
liabilities beyond such Person&#146;s ability to pay as such debts and liabilities mature; and (ii) (where such Person is the Irish Obligor) is not &#147;unable to pay its debts&#148; (within the meaning of Section&nbsp;509 or 570 of the Companies
Act 2014 of Ireland (as amended)). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Sponsor&#148; </I>means Bain Capital Private Equity, LP and its Affiliates
(other than any portfolio operating companies). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Sponsor Equity Commitment Letter&#148;</I> means a commitment
letter provided by Bain Charger Holdings, LP to contribute equity to West Affum Holdings, L.P. (which may be in the form of either preferred equity or Sponsor Convertible Notes) for gross proceeds of no less than $25,000,000. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Sponsor Convertible Notes&#148;</I> means unsecured subordinated convertible notes issued to Sponsor by Borrowers in
an aggregate principal amount not to exceed $25,000,000. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Standard Bodies&#148;</I> means any of the organizations
that create, sponsor or maintain safety, quality or other standards, including ISO, ANSI, CEN and SCC and the like. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Stated Maturity Date&#148;</I> means the fifth (5th) anniversary of the Closing Date; <I>provided</I> that if any such
date shall occur on a day that is not a Business Day, then the Stated Maturity Date shall be the immediately succeeding Business Day. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Subsidiary&#148;</I> means, with respect to any Person (the <I>&#147;parent&#148;</I>) at any time of determination,
any other Person of which more than 50% of the outstanding capital stock or similar equity interests of such other Person having ordinary voting powers, determined on a fully diluted basis, is at the time directly or indirectly owned or controlled
by the parent and in relation to the Irish Obligor includes a &#147;subsidiary&#148; as defined in section 7 of the Companies Act 2014 of Ireland (as amended). Unless the context otherwise specifically requires, the term &#147;Subsidiary&#148; shall
be a reference to a Subsidiary of Intermediate Holdings. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-33- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Sweep Agreement&#148;</I> means an agreement, in form and substance
reasonably satisfactory to the Administrative Agent, between an Obligor maintaining a Segregated Health Care Account, the Administrative Agent and applicable bank or other financial institution at which such Segregated Health Care Account is
maintained, pursuant to which such bank or financial institution (a)&nbsp;agrees to automatically sweep amounts deposited in such Segregated Health Care Account to another account of such Obligor subject to a
<FONT STYLE="white-space:nowrap">tri-party</FONT> springing account control agreement in favor of the Administrative Agent satisfying the requirements set forth in Section&nbsp;8.17(b) hereof, as and when funds clear and become available in
accordance with such bank&#146;s or financial institution&#146;s standard practices and procedures, and (b)&nbsp;agrees not to change such standing sweep instructions until the date at least five (5)&nbsp;days (or such lesser period as the
Administrative Agent may agree in its sole discretion or as may be required by applicable Federal Health Care Program laws, rules, regulations, orders, guidelines, requirements, manual provisions or policies) after receipt of notice from the
applicable Obligor maintaining such Segregated Health Care Account by Administrative Agent and such bank or financial institution of the termination of such standing sweep instruction. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Taxes&#148;</I> means all present or future taxes, levies, imposts, duties, deductions, withholdings (including backup
withholding), assessments, fees or other charges imposed by any Governmental Authority, including any interest, additions to tax or penalties applicable thereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Technical Information&#148;</I> means all trade secrets and other proprietary or confidential information, which may
include any information of a scientific, technical, or business nature in any form or medium, standards and specifications, conceptions, ideas, innovations, discoveries, Invention disclosures, all documented research, developmental, demonstration or
engineering work, data, plans, specifications, reports, summaries, experimental data, manuals, models, samples, <FONT STYLE="white-space:nowrap">know-how,</FONT> technical information, systems, methodologies, computer programs or information
technology. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Term Loans&#148;</I> means the Tranche&nbsp;A Term Loan, the Tranche&nbsp;B Term Loan and the
Tranche&nbsp;C Term Loan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Term SOFR&#148;</I> means the Term SOFR&nbsp;Reference Rate for a tenor comparable to
the applicable Interest Period on the day (such day, the <I>&#147;Periodic Term SOFR</I><I></I><I>&nbsp;Determination Day&#148;</I>) that is two (2)&nbsp;U.S.&nbsp;Government Securities Business Days prior to the first day of such Interest Period,
as such rate is published by the Term SOFR&nbsp;Administrator; <I>provided, however,</I> that if as of 5:00&nbsp;p.m. (New&nbsp;York City time) on any Periodic Term SOFR&nbsp;Determination Day the Term SOFR&nbsp;Reference Rate for the applicable
tenor has not been published by the Term SOFR&nbsp;Administrator and a Benchmark Replacement Date with respect to the Term SOFR&nbsp;Reference Rate has not occurred, then Term SOFR will be the Term SOFR&nbsp;Reference Rate for such tenor as
published by the Term SOFR&nbsp;Administrator on the first preceding U.S.&nbsp;Government </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-34- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Securities Business Day for which such Term SOFR&nbsp;Reference Rate for such tenor was published by the Term SOFR&nbsp;Administrator so long as such first preceding U.S.&nbsp;Government
Securities Business Day is not more than three (3)&nbsp;U.S.&nbsp;Government Securities Business Days prior to such Periodic Term SOFR&nbsp;Determination Day; <I>provided, further,</I> Term SOFR shall be rounded upwards to the next 1/100% (if
necessary); <I>provided</I>, <I>further, however,</I> if Term SOFR as so determined shall ever be less than the Floor, then Term SOFR shall be deemed to be the Floor. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Term SOFR</I><I></I><I>&nbsp;Administrator&#148;</I> means CME Group Benchmark Administration Limited (CBA) (or a
successor administrator of the Term SOFR&nbsp;Reference Rate selected by the Administrative Agent in its reasonable discretion). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Term SOFR</I><I></I><I>&nbsp;Reference Rate&#148;</I> means the
<FONT STYLE="white-space:nowrap">forward-looking</FONT> term rate based on SOFR. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Third-Party Payor
Authorizations&#148;</I><B> </B>means all participation agreements, provider or supplier agreements, enrollments, accreditations, and billing numbers required to participate in and receive reimbursement from a Third-Party Payor Program. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Third</I><I><FONT STYLE="white-space:nowrap">-Party</FONT> Payor Program&#148;</I> means any Federal Health Care
Program, or any other health care payment or reimbursement program in which an Obligor or Subsidiary participates, including programs sponsored by private insurers or managed care plans. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Title</I><I></I><I>&nbsp;IV Plan&#148;</I> means an &#147;employee pension benefit plan&#148; (as defined in
Section&nbsp;3(2) of ERISA) other than a Multiemployer Plan (a)&nbsp;that is maintained or sponsored by any Obligor or any ERISA Affiliate thereof or to which any Obligor or any ERISA Affiliate thereof makes contributions&nbsp;or (b)&nbsp;with
respect to which any Obligor has any liability, contingent of otherwise, including on account of an ERISA Affiliate, and (iii)&nbsp;that is subject to Section&nbsp;412 of the Code, Section&nbsp;302 of ERISA or Title&nbsp;IV of ERISA. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Trademarks&#148;</I> has the meaning set forth in the Security Documents. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Tranche</I><I></I><I>&nbsp;A Term Loan&#148; </I>means each loan advanced by a Lender pursuant to
Section&nbsp;2.01(a). For purposes of clarification, any calculation of the aggregate outstanding principal amount of the Tranche&nbsp;A Term Loan on any date of determination shall mean the aggregate principal amount of the Tranche&nbsp;A Term Loan
made pursuant to Section&nbsp;2.01(a) that has not yet been repaid as of such date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Tranche</I><I></I><I>&nbsp;A
Term Loan Commitment&#148;</I> means the commitment of a Lender to make or otherwise fund a Tranche&nbsp;A Term Loan and <I>&#147;Tranche</I><I></I><I>&nbsp;A Term Loan Commitments&#148;</I> means such commitments of all Lenders in the aggregate.
The amount of each Lender&#146;s Tranche&nbsp;A Term Loan Commitment, if any, is set forth on Schedule&nbsp;1. The aggregate amount of the Tranche&nbsp;A Term Loan Commitments as of the Closing Date is $45,000,000. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-35- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Tranche</I><I></I><I>&nbsp;B Term Loan&#148;</I> means each loan
advanced by a Lender pursuant to Section&nbsp;2.01(b). For purposes of clarification, any calculation of the aggregate outstanding principal amount of the Tranche&nbsp;B Term Loan on any date of determination shall mean the aggregate principal
amount of the Tranche&nbsp;B Term Loan made pursuant to Section&nbsp;2.01(b) that has not yet been repaid as of such date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Tranche</I><I></I><I>&nbsp;B Term Loan Borrowing Date&#148;</I> means with respect to the Tranche&nbsp;B Term Loan,
the Business Day on which all conditions set forth in Section&nbsp;6.02 have been satisfied or waived by the Lenders and the Tranche&nbsp;B Term Loan is made hereunder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Tranche</I><I></I><I>&nbsp;B Term Loan Commitment&#148;</I> means the commitment of a Lender to make or otherwise fund
a Tranche&nbsp;B Term Loan and <I>&#147;Tranche</I><I></I><I>&nbsp;B Term Loan Commitments&#148;</I> means such commitments of all Lenders in the aggregate. The amount of each Lender&#146;s Tranche&nbsp;B Term Loan Commitment, if any, is set forth
on Schedule&nbsp;1. The aggregate amount of the Tranche&nbsp;B Term Loan Commitments as of the Closing Date is $7,500,000. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Tranche</I><I></I><I>&nbsp;B Term Loan Commitment Termination Date&#148;</I> means November&nbsp;1, 2024. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Tranche</I><I></I><I>&nbsp;C Term Loan&#148;</I> means each loan advanced by a Lender pursuant to
Section&nbsp;2.01(c). For purposes of clarification, any calculation of the aggregate outstanding principal amount of the Tranche&nbsp;C Term Loan on any date of determination shall mean the aggregate principal amount of the Tranche&nbsp;C Term Loan
made pursuant to Section&nbsp;2.01(c) that has not yet been repaid as of such date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Tranche</I><I></I><I>&nbsp;C
Term Loan Borrowing Date&#148;</I> means with respect to the Tranche&nbsp;C Term Loan, the Business Day on which all conditions set forth in Section&nbsp;6.03 have been satisfied or waived by the Lenders and the Tranche&nbsp;C Term Loan is made
hereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Tranche</I><I></I><I>&nbsp;C Term Loan Commitment&#148;</I> means the commitment of a Lender to make
or otherwise fund a Tranche&nbsp;C Term Loan and <I>&#147;Tranche</I><I></I><I>&nbsp;C Term Loan Commitments&#148;</I> means such commitments of all Lenders in the aggregate. The amount of each Lender&#146;s Tranche&nbsp;C Term Loan Commitment, if
any, is set forth on Schedule&nbsp;1. The aggregate amount of the Tranche&nbsp;C Term Loan Commitments as of the Closing Date is $7,500,000. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Tranche</I><I></I><I>&nbsp;C Term Loan Commitment Termination Date&#148;</I> means February&nbsp;1, 2025. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Transactions&#148;</I> means the execution, delivery and performance by each Obligor of this Agreement and the other
Loan Documents to which such Obligor is a party and the other transactions contemplated hereby and thereby, including disbursement and application of the proceeds of the Term Loans. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;UK</I><I></I><I>&nbsp;Financial Institution&#148;</I> means any BRRD&nbsp;Undertaking (as such term is defined under
the PRA&nbsp;Rulebook (as amended from time to time) promulgated by the United Kingdom Prudential Regulation Authority) or any person falling within IFPRU&nbsp;11.6 of the FCA&nbsp;Handbook (as amended from time to time) promulgated by the United
Kingdom Financial Conduct Authority, which includes certain credit institutions and investment firms, and certain affiliates of such credit institutions or investment firms. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-36- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;UK</I><I></I><I>&nbsp;Resolution Authority&#148;</I> means the Bank
of England or any other public administrative authority having responsibility for the resolution of any UK&nbsp;Financial Institution. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Unadjusted Benchmark Replacement&#148;</I> means the applicable Benchmark Replacement excluding the related Benchmark
Replacement Adjustment. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Unrestricted Cash&#148;</I> means the balance of unencumbered cash (other than cash
encumbered by the Liens permitted pursuant to Sections 9.02(a) and (h)) and Permitted Cash Equivalent Investments (which for greater certainty shall not include any undrawn credit lines), in each case, to the extent held in a Deposit Account subject
to a springing account control agreement reasonably satisfactory to the Administrative Agent. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;U.S.</I><I></I><I>&nbsp;Government Securities Business Day&#148;</I> means any day except for (a)&nbsp;a Saturday,
(b)&nbsp;a Sunday or (c)&nbsp;a day on which the Securities Industry and Financial Markets Association recommends that the fixed income departments of its members be closed for the entire day for purposes of trading in United States government
securities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;U.S.</I><I></I><I>&nbsp;Person&#148;</I> means a &#147;United States person&#148; within the meaning
of Section&nbsp;7701(a)(30) of the Code. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;U.S.</I><I></I><I>&nbsp;Tax Compliance Certificate&#148;</I> has the
meaning set forth in Section&nbsp;5.03(f)(ii)(B)(3). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Warrant Certificate&#148;</I> means the warrant, in
substantially the form of Exhibit&nbsp;I, to be delivered to the Administrative Agent pursuant to Section&nbsp;6.01(e)(x) with an aggregate value equivalent of 10% of the aggregate amount of Term Loans funded under Section&nbsp;2.01, as the Warrant
Certificate may be amended, replaced or otherwise modified pursuant to the terms thereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;West Affum
Corp.&#148;</I> has the meaning set forth in the introduction hereto. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;West Affum Corp. Account Charge&#148;
</I>means a Cayman Islands law governed account charge issued by West Affum Corp., dated as of the Closing Date, in favor of the Administrative Agent over certain accounts described therein and located in the Cayman Islands. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;West Affum Corp. Fixed and Floating Charge&#148;</I> means a Cayman Islands law governed Debenture, dated as of the
Closing Date, issued by West Affum Corp. in favor of the Administrative Agent. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Write</I><I><FONT
STYLE="white-space:nowrap">-Down</FONT> and Conversion Powers&#148;</I> means, (a)&nbsp;with respect to any EEA&nbsp;Resolution Authority, the <FONT STYLE="white-space:nowrap">write-down</FONT> and conversion powers of such EEA&nbsp;Resolution
Authority from time to time under the <FONT STYLE="white-space:nowrap">Bail-In</FONT> Legislation for the applicable EEA&nbsp;Member Country, which <FONT STYLE="white-space:nowrap">write-down</FONT> and conversion powers are described in the <FONT
STYLE="white-space:nowrap">EU&nbsp;Bail-In</FONT> Legislation Schedule, and (b)&nbsp;with respect to the United Kingdom, any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-37- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
powers of the applicable Resolution Authority under the <FONT STYLE="white-space:nowrap">Bail-In</FONT> Legislation to cancel, reduce, modify or change the form of a liability of any
UK&nbsp;Financial Institution or any contract or instrument under which that liability arises, to convert all or part of that liability into shares, securities or obligations of that person or any other person, to provide that any such Contract or
instrument is to have effect as if a right had been exercised under it or to suspend any obligation in respect of that liability or any of the powers under that <FONT STYLE="white-space:nowrap">Bail-In</FONT> Legislation that are related to or
ancillary to any of those powers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;1.02.</I> <I>Accounting Terms and Principles</I>. All accounting
determinations required to be made pursuant hereto shall, unless expressly otherwise provided herein, be made substantially in accordance with GAAP. If, after the date hereof, any change occurs in GAAP or in the application thereof (an
<I>&#147;Accounting Change&#148;</I>) and such change would cause any amount required to be determined for the purposes of the covenants to be maintained or calculated pursuant to Article&nbsp;8 or 9 to be materially different than the amount that
would be determined prior to such change, then Administrative Borrower will provide a detailed notice of such change (an <I>&#147;Accounting Change Notice&#148;</I>) to the Administrative Agent in conjunction with the next required delivery of
financial statements pursuant to Section&nbsp;8.01. If Administrative Borrower requests an amendment to any provision hereof to eliminate the effect of any Accounting Change occurring after the Closing Date or in the application thereof on the
operation of such provision, regardless of whether any Accounting Change Notice is given before or after such Accounting Change or in the application thereof, then the Administrative Agent and Administrative Borrower agree that they will negotiate
in good faith amendments to the provisions of this Agreement that are directly affected by such Accounting Change with the intent of having the respective positions of the Administrative Agent and Borrowers after such Accounting Change conform as
nearly as possible to their respective positions as of the date of this Agreement and, until any such amendments have been agreed upon, (a)&nbsp;the provisions in this Agreement shall be calculated as if no such Accounting Change had occurred and
(b)&nbsp;Administrative Borrower shall provide to the Administrative Agent a written reconciliation in form and substance reasonably satisfactory to the Administrative Agent, between calculations of any baskets and other requirements hereunder
before and after giving effect to such Accounting Change. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All components of financial calculations made to determine compliance with this
Agreement shall be adjusted to include or exclude, as the case may be, without duplication, such components of such calculations attributable to any Acquisition or disposition of assets consummated after the first day of the applicable period of
determination and prior to the end of such period, as determined in good faith by Borrowers based on assumptions expressed therein and that were reasonable based on the information available to Borrowers at the time of preparation of the Compliance
Certificate setting forth such calculations. Anything in this Agreement to the contrary notwithstanding, for purposes of calculations made pursuant to the terms of this Agreement, any lease (or similar arrangement conveying the right to use) that is
treated as an operating lease for purposes of GAAP prior to the issuance by the Financial Accounting Standards Board on February&nbsp;25, 2016 of an Accounting Standards Update (<I>&#147;</I><I>ASU</I><I>&#148;</I>) shall not be treated as
Indebtedness or as a finance lease, and shall continue to be treated as an operating lease (and any future lease or similar arrangement conveying the right to use that would be treated as an operating lease for purposes of GAAP without giving effect
to the implementation of ASC&nbsp;842 shall be treated as an operating lease), in each case for purposes of Indebtedness under this Agreement, notwithstanding such change in GAAP after the issuance of such ASU. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-38- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;1.03.</I> <I>Interpretation</I>. For all purposes of this
Agreement, except as otherwise expressly provided herein or unless the context otherwise requires, (a)&nbsp;the terms defined in this Agreement include the plural as well as the singular and vice versa; (b)&nbsp;words importing gender include all
genders; (c)&nbsp;any reference to a Section, Article, Annex, Schedule or Exhibit refers to a Section or Article of, or Annex, Schedule or Exhibit to, this Agreement; (d)&nbsp;any reference to &#147;this Agreement&#148; refers to this Agreement,
including all Annexes, Schedules and Exhibits hereto, and the words herein, hereof, hereto and hereunder and words of similar import refer to this Agreement and its Annexes, Schedules and Exhibits as a whole and not to any particular Section,
Article, Annex, Schedule, Exhibit or any other subdivision; (e)&nbsp;references to days, months and years refer to calendar days, months and years, respectively; (f)&nbsp;all references herein to &#147;include&#148; or &#147;including&#148; shall be
deemed to be followed by the words &#147;without limitation&#148;; (g)&nbsp;the word &#147;from&#148; when used in connection with a period of time means &#147;from and including&#148; and the word &#147;until&#148; means &#147;to but not
including&#148;; and (h)&nbsp;accounting terms not specifically defined herein shall be construed substantially in accordance with GAAP (except for the term &#147;property,&#148; which shall be interpreted as broadly as possible, including, in any
case, cash, securities, other assets, rights under contractual obligations and permits and any right or interest in any property, except where otherwise noted). Unless otherwise expressly provided herein, references to Organizational Documents,
agreements (including the Loan Documents) and other contractual instruments shall be deemed to include all subsequent amendments, restatements, extensions, supplements and other modifications thereto permitted by the Loan Documents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;1.04.</I> <I>Divisions</I>. For all purposes under the Loan Documents, in connection with any division or plan
of division under Delaware law (or any comparable event under a different jurisdiction&#146;s laws): (a)&nbsp;if any asset, right, obligation or liability of any Person becomes the asset, right, obligation or liability of a different Person, then it
shall be deemed to have been transferred from the original Person to the subsequent Person; and (b)&nbsp;if any new Person comes into existence, such new Person shall be deemed to have been organized on the first date of its existence by the holders
of its Equity Interests at such time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;1.05.</I> <I>Interest Rates</I>. The Administrative Agent does not
warrant or accept responsibility for, and shall not have any liability with respect to (a)&nbsp;the continuation of, administration of, submission of, calculation of or any other matter related to the Term SOFR&nbsp;Reference Rate, Term SOFR, or any
component definition thereof or rates referred to in the definition thereof, or any alternative, successor or replacement rate thereto (including any Benchmark Replacement), including whether the composition or characteristics of any such
alternative, successor or replacement rate (including any Benchmark Replacement) will be similar to, or produce the same value or economic equivalence of, or have the same volume or liquidity as, the Term SOFR&nbsp;Reference Rate, Term SOFR or any
other Benchmark prior to its discontinuance or unavailability, or (b)&nbsp;the effect, implementation or composition of any Conforming Changes. The Administrative Agent and its affiliates or other related entities may engage in transactions that
affect the calculation of the Term SOFR&nbsp;Reference Rate, Term SOFR, any alternative, successor or replacement rate (including any Benchmark Replacement) or any relevant adjustments thereto, in each case, in a manner adverse to the Obligors. The
Administrative </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-39- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Agent may select information sources or services in its reasonable discretion to ascertain the Term SOFR&nbsp;Reference Rate, Term SOFR or any other Benchmark, in each case pursuant to the terms
of this Agreement, and shall have no liability to the Obligors, any Lender or any other person or entity for damages of any kind, including direct or indirect, special, punitive, incidental or consequential damages, costs, losses or expenses
(whether in tort, contract or otherwise and whether at law or in equity), for any error or calculation of any such rate (or component thereof) provided by any such information source or service. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>RTICLE</SMALL>&nbsp;2. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>T<SMALL>HE</SMALL> C<SMALL>OMMITMENTS</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;2.01.</I> <I>Term Loans</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Tranche</I><I></I><I>&nbsp;A Term Loan</I>. (i)&nbsp;Subject to the terms and conditions of this Agreement and relying on the
representations and warranties set forth herein, each Lender, severally and not jointly, agrees to provide its share of the Tranche&nbsp;A Term Loan to Borrowers on the Closing Date in Dollars in a principal amount equal to such Lender&#146;s
Tranche&nbsp;A Term Loan Commitment. No Lender shall have an obligation to make a Tranche&nbsp;A Term Loan in excess of such Lender&#146;s Tranche&nbsp;A Term Loan Commitment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) Subject to the terms and conditions of this Agreement (including Section&nbsp;6.01), Administrative Borrower shall deliver to the
Administrative Agent a fully executed Borrowing Notice no later than 5&nbsp;p.m. (Eastern time) at least one (1)&nbsp;Business Day in advance of the Closing Date (or such shorter period to which the Administrative Agent may agree). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) Borrowers may make one borrowing under the Tranche&nbsp;A Term Loan Commitment which shall be on the Closing Date. Subject to
Sections&nbsp;3.01 and 3.03, all amounts owed hereunder with respect to the Tranche&nbsp;A Term Loan shall be paid in full no later than the Maturity Date. Each Lender&#146;s Tranche&nbsp;A Term Loan Commitment shall terminate immediately and
without further action on the Closing Date after giving effect to the funding of such Lender&#146;s Tranche&nbsp;A Term Loan Commitment on such date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Tranche</I><I></I><I>&nbsp;B Term Loan</I>. (i)&nbsp;Subject to the terms and conditions of this Agreement and relying on the
representations and warranties set forth herein, each Lender, severally and not jointly, agrees to provide its share of the Tranche&nbsp;B Term Loan to Borrowers, at the request of Administrative Borrower on the Tranche&nbsp;B Term Loan Borrowing
Date in Dollars in a principal amount equal to such Lender&#146;s Tranche&nbsp;B Term Loan Commitment. No Lender shall have an obligation to make a Tranche&nbsp;B Term Loan in excess of such Lender&#146;s Tranche&nbsp;B Term Loan Commitment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) Subject to the terms and conditions of this Agreement (including Section&nbsp;6.02), Administrative Borrower shall deliver to the
Administrative Agent a fully executed Borrowing Notice no later than 5&nbsp;p.m. (Eastern time) at least three (3)&nbsp;Business Days in advance of the proposed Tranche&nbsp;B Term Loan Borrowing Date (or such shorter period to which the
Administrative Agent may agree). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-40- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) Borrowers may make one borrowing under the Tranche&nbsp;B Term Loan Commitment which
shall be on the Tranche&nbsp;B Term Loan Borrowing Date. Subject to Sections&nbsp;3.01 and 3.03, all amounts owed hereunder with respect to the Tranche&nbsp;B Term Loan shall be paid in full no later than the Maturity Date. Each Lender&#146;s
Tranche&nbsp;B Term Loan Commitment shall terminate immediately and without further action (A)&nbsp;on the Tranche&nbsp;B Term Loan Borrowing Date after giving effect to the funding of such Lender&#146;s Tranche&nbsp;B Term Loan Commitment on such
date and (B)&nbsp;automatically on the Tranche&nbsp;B Term Loan Commitment Termination Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Tranche</I><I></I><I>&nbsp;C Term
Loan</I>. (i)&nbsp;Subject to the terms and conditions of this Agreement and relying on the representations and warranties set forth herein, each Lender, severally and not jointly, agrees, at the request of Administrative Borrower, to provide its
share of the Tranche&nbsp;C Term Loan to Borrowers on the Tranche&nbsp;C Term Loan Borrowing Date in Dollars in a principal amount equal to such Lender&#146;s Tranche&nbsp;C Term Loan Commitment. No Lender shall have an obligation to make a
Tranche&nbsp;C Term Loan in excess of such Lender&#146;s Tranche&nbsp;C Term Loan Commitment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) Subject to the terms and conditions of
this Agreement (including Section&nbsp;6.03), Administrative Borrower shall deliver to the Administrative Agent a fully executed Borrowing Notice no later than 5&nbsp;p.m. (Eastern time) at least three (3)&nbsp;Business Days (or such shorter period
to which the Administrative Agent may agree) in advance of the proposed Tranche&nbsp;C Term Loan Borrowing Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) Borrowers may make
one borrowing under the Tranche&nbsp;C Term Loan Commitment which shall be on the Tranche&nbsp;C Term Loan Borrowing Date. Subject to Sections&nbsp;3.01 and 3.03, all amounts owed hereunder with respect to the Tranche&nbsp;C Term Loan shall be paid
in full no later than the Maturity Date. Each Lender&#146;s Tranche&nbsp;C Term Loan Commitment shall terminate immediately and without further action (A)&nbsp;on the Tranche&nbsp;C Term Loan Borrowing Date after giving effect to the funding of such
Lender&#146;s Tranche&nbsp;C Term Loan Commitment on such date and (B)&nbsp;automatically on the Tranche&nbsp;C Term Loan Commitment Termination Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any principal amount of the Term Loans borrowed under Sections&nbsp;2.01(a), 2.01(b) and 2.01(c) hereof and subsequently repaid or prepaid may
not be reborrowed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;2.02.</I> <I>Proportionate Shares</I>. Each Term Loan shall be made, and all
participations purchased, by the Lenders simultaneously and proportionately to their respective Proportionate Shares, it being understood that no Lender shall be responsible for any default by any other Lender in such other Lender&#146;s obligation
to make a Term Loan hereunder or purchase a participation required hereby nor shall the Commitment of any Lender be increased or decreased as a result of a default by any other Lender in such other Lender&#146;s obligation to make a Term Loan
requested hereunder or purchase a participation required hereby. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-41- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;2.03.</I> <I>Fees</I>. On the Closing Date, Borrowers shall
pay to the Administrative Agent (out of the proceeds of the Tranche&nbsp;A Term Loan advanced by such Lenders on the Closing Date) for distribution to each Lender in accordance with its Pro Rata Share of the Tranche&nbsp;A Term Loan, a <FONT
STYLE="white-space:nowrap">non-refundable</FONT> fee (the <I>&#147;</I><I>Closing Fee</I><I>&#148;</I>) in the amount of $600,000. Such payments shall be in addition to such fees, costs and expenses due and payable pursuant to Section&nbsp;12.03.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;2.04.</I> <I>Notes</I>. Upon the request of any Lender, Borrowers shall prepare, execute and deliver to
such Lender one or more Notes evidencing the Term Loan payable to such Lender (or if requested by it, to it and its registered assigns). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;2.05.</I> <I>Use of Proceeds</I>. Borrowers shall use the proceeds of the Term Loans (a)&nbsp;for general
working capital purposes and corporate purposes permitted hereunder, (b)&nbsp;to refinance certain existing Indebtedness on the Closing Date and (c)&nbsp;to pay, in accordance with the funds flow attached to the Borrowing Notice, fees, costs and
expenses incurred in connection with the Transactions. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>RTICLE</SMALL>&nbsp;3. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>P<SMALL>AYMENTS</SMALL> <SMALL>OF</SMALL> P<SMALL>RINCIPAL</SMALL> <SMALL>AND</SMALL> I<SMALL>NTEREST</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;3.01.</I> <I>Repayment</I>. There will be no scheduled repayments of principal on the Term Loans prior to the
Maturity Date. The entire outstanding principal amount of the Term Loans, together with all accrued and unpaid interest thereon (including accrued and uncapitalized PIK&nbsp;Interest on the Term Loans), will be due and payable on the Maturity Date.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;3.02.</I> <I>Interest</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Interest Generally.</I> Each Borrower agrees to pay to the Lenders interest in cash on the outstanding principal amount of the Term
Loans for each Interest Period at a rate per annum equal to the sum of (i)&nbsp;Term SOFR plus (ii)&nbsp;the Applicable Margin; <I>provided, however,</I> that during period commencing on the Closing Date and ending on March&nbsp;31, 2025,
Administrative Borrower may elect by providing written notice to the Administrative Agent to have up to 2.00% of the Applicable Margin on the Term Loans paid as PIK&nbsp;Interest. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Term SOFR Conforming Changes</I>. In connection with the use or administration of Term SOFR, the Administrative Agent will have the
right in consultation with the Administrative Borrower to make Conforming Changes from time to time and, notwithstanding anything to the contrary herein or in any other Loan Document, any amendments implementing such Conforming Changes will become
effective without any further action or consent of any other party to this Agreement or any other Loan Document. The Administrative Agent will promptly notify Administrative Borrower and the Lenders of the effectiveness of any Conforming Changes in
connection with the use or administration of Term SOFR. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-42- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Effect of Benchmark Transition Event</I>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <I>Benchmark Replacement</I>. Notwithstanding anything to the contrary herein or in any other Loan Document, if a Benchmark
Transition Event and its related Benchmark Replacement Date have occurred prior to any setting of the <FONT STYLE="white-space:nowrap">then-current</FONT> Benchmark, then (A)&nbsp;if a Benchmark Replacement is determined in accordance with
clause&nbsp;(a) of the definition of &#147;Benchmark Replacement&#148; for such Benchmark Replacement Date, such Benchmark Replacement will replace such Benchmark for all purposes hereunder and under any Loan Document in respect of such Benchmark
setting and subsequent Benchmark settings without any amendment to, or further action or consent of any other party to, this Agreement or any other Loan Document and (B)&nbsp;if a Benchmark Replacement is determined in accordance with
clause&nbsp;(b) of the definition of &#147;Benchmark Replacement&#148; for such Benchmark Replacement Date, such Benchmark Replacement will replace such Benchmark for all purposes hereunder and under any Loan Document in respect of any Benchmark
setting at or after 5:00&nbsp;p.m. (New&nbsp;York City time) on the fifth (5<SUP STYLE="font-size:75%; vertical-align:top">th</SUP>) Business Day after the date notice of such Benchmark Replacement is provided to the Lenders without any amendment
to, or further action or consent of any other party to, this Agreement or any other Loan Document so long as the Administrative Agent has not received, by such time, written notice of objection to such Benchmark Replacement from Lenders comprising
the Majority Lenders. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) <I>Conforming Changes</I>. In connection with the implementation of a Benchmark Replacement,
the Administrative Agent will have the right to make Conforming Changes from time to time and, notwithstanding anything to the contrary herein or in any other Loan Document, any amendments implementing such Conforming Changes will become effective
without any further action or consent of any other party to the Loan Documents. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) <I>Notices; Standards for Decisions
and Determinations</I>. The Administrative Agent will promptly notify Administrative Borrower and the Lenders of (A)&nbsp;the implementation of any Benchmark Replacement and (B)&nbsp;the effectiveness of any Conforming Changes in connection with the
use, administration, adoption or implementation of a Benchmark Replacement. Any determination, decision or election that may be made by the Administrative Agent or the Lenders pursuant to this Section&nbsp;3.02(c) including any determination with
respect to a tenor, rate or adjustment or of the occurrence or <FONT STYLE="white-space:nowrap">non-occurrence</FONT> of an event, circumstance or date and any decision to take or refrain from taking any action, will be conclusive and binding absent
manifest error and may be made in its or their sole discretion and without consent from any other party hereto, except, in each case, as expressly required pursuant to this Section&nbsp;3.02(c). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) <I>Unavailability of Tenor of Benchmark</I>. Notwithstanding anything to the contrary herein or in any other Loan
Document, at any time (including in connection with the implementation of a Benchmark Replacement), (A)&nbsp;if the <FONT STYLE="white-space:nowrap">then-current</FONT> Benchmark is a term rate (including the Term SOFR&nbsp;Reference Rate) and
either (x)&nbsp;any tenor for such Benchmark is not displayed on a screen or other information service that publishes such rate from time to time as selected by the Administrative Agent in its reasonable discretion or (y)&nbsp;the regulatory
supervisor for the administrator of such Benchmark has provided a public statement or publication of information announcing that any tenor for such Benchmark is not or will not be representative, then the Administrative Agent may modify the
definition of &#147;Interest Period&#148; (or any similar or analogous definition) for any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-43- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Benchmark settings at or after such time to remove such unavailable or <FONT STYLE="white-space:nowrap">non-representative</FONT> tenor and (B)&nbsp;if a tenor that was removed pursuant to
clause&nbsp;(A) above either (x)&nbsp;is subsequently displayed on a screen or information service for a Benchmark (including a Benchmark Replacement) or (y)&nbsp;is not, or is no longer, subject to an announcement that it is not or will not be
representative for a Benchmark (including a Benchmark Replacement), then the Administrative Agent may modify the definition of &#147;Interest Period&#148; (or any similar or analogous definition) for all Benchmark settings at or after such time to
reinstate such previously removed tenor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>Default Interest.</I> Notwithstanding the foregoing, upon the occurrence and during the
continuance of any Event of Default, all overdue Obligations shall bear interest (including post-petition interest in any proceeding under any Insolvency Proceeding) payable on demand in cash at a rate that is equal to 4.00% per annum (the interest
rate, as increased pursuant to this Section&nbsp;3.02(d), being the <I>&#147;Default Rate&#148;</I>). If any Obligation is not paid when due under any applicable Loan Document, the amount thereof shall accrue interest at the Default Rate. Payment or
acceptance of the increased rates of interest provided for in this Section&nbsp;3.02(d) is not a permitted alternative to timely payment and shall not constitute a waiver of any Default or otherwise prejudice or limit any rights or remedies of the
Administrative Agent or any Lender. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <I>Payment Dates.</I> Accrued interest on the Term Loans shall be payable in arrears on each
Payment Date with respect to the most recently completed Interest Period in cash (other than PIK&nbsp;Interest), and upon the payment or prepayment of the Term Loans (on the principal amount being so paid or prepaid); <I>provided</I> that interest
payable at the Default Rate shall be payable from time to time on demand by the Majority Lenders. PIK&nbsp;Interest on the Term&nbsp;Loans shall be capitalized and added to the outstanding principal amount of the Term&nbsp;Loans on each Payment Date
with respect to the most recently completed Interest Period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <I>Maximum Rate.</I> Notwithstanding any other provision of this
Agreement, in no event will any interest or rates referred to herein exceed the maximum interest rate permitted by applicable Law. If such maximum interest rate would be exceeded by the terms hereof, the rates of interest payable hereunder will be
reduced to the extent necessary so that such rates (together with any fees or other amounts which are construed by a court of competent jurisdiction to be interest or in the nature of interest) equal the maximum interest rate permitted by applicable
Law, and any overpayment of interest received by the Lenders before such rates are so construed will be applied, forthwith after determination of such overpayment, to pay all then outstanding interest, and thereafter to pay outstanding principal.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;3.03.</I> <I>Prepayments</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Optional Prepayments</I>. (i)&nbsp;Borrowers shall have the right to optionally prepay in whole or in part (in a minimum amount of
$500,000 and integral multiples of $100,000 in excess of that amount for each partial prepayment, or, if less, the entire outstanding principal amount of the Term Loans) the outstanding principal amount of the Term Loans on any Business Day (a
<I>&#147;Redemption Date&#148;</I>) for an amount equal to the sum of (i)&nbsp;the aggregate principal amount of the Term Loans being prepaid, (ii)&nbsp;the applicable Prepayment Premium in respect of the aggregate principal amount of the Term Loans
being prepaid and (iii)&nbsp;any accrued but unpaid interest in respect of the aggregate principal amount of the Term Loans being prepaid (such aggregate amount, the <I>&#147;Redemption Price&#148;</I>). The applicable &#147;Prepayment Premium&#148;
shall be an amount calculated pursuant to Section&nbsp;3.03(a)(ii). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-44- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) If the Redemption Date occurs: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A) on or prior to the first anniversary of the Closing Date, the Prepayment Premium shall be an amount equal to ten percent
(10%) of the aggregate outstanding principal amount of the Term Loans being prepaid on such Redemption Date; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B) after the
first anniversary of the Closing Date and on or prior to the second anniversary of the Closing Date, the Prepayment Premium shall be an amount equal to nine percent (9%) of the aggregate outstanding principal amount of the Term Loans being prepaid
on such Redemption Date; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(C) after the second anniversary of the Closing Date and on or prior to the third anniversary of
the Closing Date, the Prepayment Premium shall be an amount equal to eight percent (8%) of the aggregate outstanding principal amount of the Term Loans being prepaid on such Redemption Date; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(D) after the third anniversary of the Closing Date and on or prior to the fourth anniversary of the Closing Date, the
Prepayment Premium shall be an amount equal to six percent (6%) of the aggregate outstanding principal amount of the Term Loan being prepaid on such Redemption Date; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(E) after the fourth anniversary of the Closing Date and prior to the Stated Maturity Date, the Prepayment Premium shall be an
amount equal to four percent (4%) of the aggregate outstanding principal amount of the Term Loan being prepaid on such Redemption Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No Prepayment
Premium shall be due with respect to repayment of the Term Loans on the Stated Maturity Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Mandatory Prepayments</I>. Borrowers
shall promptly prepay the Term Loans in amounts as provided below, plus a Prepayment Premium on the principal amount of the Term Loans being prepaid pursuant to clauses&nbsp;(ii) and (iii)&nbsp;below (calculated in accordance with
Section&nbsp;3.03(a)(ii), it being agreed that the relevant payment date shall be deemed to be the &#147;Redemption Date&#148; for purposes of such calculation), plus any accrued but unpaid interest and fees then due and owing, as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) In the event of any Casualty Event, an amount equal to 100% of the Net Cash Proceeds received by any Obligor with respect
thereto; <I>provided, however,</I> so long as no Default has occurred and is continuing, within one hundred eighty (180)&nbsp;days after receipt of such Net Cash Proceeds (or if such Obligor enters into a bona fide commitment to reinvest such Net
Cash Proceeds within one hundred eighty (180)&nbsp;days following receipt thereof, within the later of (x)&nbsp;one hundred eighty (180)&nbsp;days following receipt thereof and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-45- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
(y)&nbsp;ninety (90) days of the date of such commitment), the Obligors may use such Net Cash Proceeds not exceeding $2,500,000 in the aggregate for all losses under all casualty policies during
the term of this Agreement, toward the replacement or repair of destroyed or damaged property; <I>provided, further,</I> that any such replaced or repaired property shall be Collateral in which the Administrative Agent for the benefit of the Lenders
has been granted a security interest under the Security Documents. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) In the event any Obligor incurs Indebtedness other
than Indebtedness that is permitted by Section&nbsp;9.01 hereof, 100% of the Net Cash Proceeds thereof received by such Obligor. For the avoidance of doubt, any prepayment made pursuant to this Section&nbsp;3.03(b)(ii) shall not be deemed to be a
consent to any such incurrence of Indebtedness or a cure or waiver of any Event of Default which occurs in connection therewith, it being understood that any such Event of Default may only be waived with the express consent of the Majority Lenders.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) In the event any Obligor consummates an Asset Sale other than an Asset Sale that is permitted by Section&nbsp;9.09
hereof (other than Section&nbsp;9.09(j)), 100% of the Net Cash Proceeds received by such Obligor in connection with such Asset Sale; <I>provided, however,</I> so long as no Default has occurred and is continuing, within one hundred eighty
(180)&nbsp;days after receipt of such Net Cash Proceeds (or if such Obligor enters into a bona fide commitment to reinvest such Net Cash Proceeds within one hundred eighty (180)&nbsp;days following receipt thereof, within the later of (x)&nbsp;one
hundred eighty (180)&nbsp;days following receipt thereof and (y)&nbsp;ninety (90) days of the date of such commitment), the Obligors may use such Net Cash Proceeds not exceeding $2,500,000 in the aggregate for all Asset Sales during the term of this
Agreement, to purchase, replace, repair or restore properties or assets used in the Obligors&#146; businesses; <I>provided, further,</I> that any such purchased, replaced, repaired or restored property shall be Collateral in which the Administrative
Agent for the benefit of the Lenders has been granted a security interest under the Security Documents. For the avoidance of doubt, any prepayment made pursuant to this Section&nbsp;3.03(b)(iii) shall not be deemed to be a consent to any Asset Sale
or a cure or waiver of any Event of Default which occurs in connection therewith, it being understood that any such Event of Default may only be waived with the express consent of the Majority Lenders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Prepayment Premium</I>. Payment of any Prepayment Premium under this Section&nbsp;3.03 constitutes liquidated damages, not unmatured
interest or a penalty, as the actual amount of damages to the Lenders as a result of the relevant triggering event, prepayment or repayment would be impracticable and extremely difficult to ascertain. Accordingly, any Prepayment Premium hereunder is
provided by mutual agreement of the Obligors and the Lenders as a reasonable estimation and calculation of such actual lost profits and other actual damages of the Lenders. Without limiting the generality of the foregoing, it is understood and
agreed that upon the occurrence of any prepayment event, any Prepayment Premium shall be automatically and immediately due and payable as though any prepaid or repaid portion of the Term Loans were voluntarily prepaid as of such date and shall
constitute part of the Obligations secured by the Collateral. Any Prepayment Premium shall also be automatically and immediately due and payable if the Term Loans are satisfied or released by foreclosure (whether by power of judicial
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-46- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
proceeding or otherwise), deed in lieu of foreclosure or by any other means. E<SMALL>ACH</SMALL> O<SMALL>BLIGOR</SMALL> <SMALL>HEREBY</SMALL> <SMALL>EXPRESSLY</SMALL> <SMALL>WAIVES</SMALL>
(<SMALL>TO</SMALL> <SMALL>THE</SMALL> <SMALL>FULLEST</SMALL> <SMALL>EXTENT</SMALL> <SMALL>IT</SMALL> <SMALL>MAY</SMALL> <SMALL>LAWFULLY</SMALL> <SMALL>DO</SMALL> <SMALL>SO</SMALL>) <SMALL>THE</SMALL> <SMALL>PROVISIONS</SMALL> <SMALL>OF</SMALL>
<SMALL>ANY</SMALL> <SMALL>PRESENT</SMALL> <SMALL>OR</SMALL> <SMALL>FUTURE</SMALL> <SMALL>STATUTE</SMALL> <SMALL>OR</SMALL> <SMALL>OTHER</SMALL> <SMALL>LAW</SMALL> <SMALL>THAT</SMALL> <SMALL>PROHIBITS</SMALL> <SMALL>OR</SMALL> <SMALL>MAY</SMALL>
<SMALL>PROHIBIT</SMALL> <SMALL>THE</SMALL> <SMALL>COLLECTION</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL> <SMALL>FOREGOING</SMALL> <SMALL>PREPAYMENT</SMALL> <SMALL>PREMIUM</SMALL> <SMALL>IN</SMALL> <SMALL>CONNECTION</SMALL> <SMALL>WITH</SMALL>
<SMALL>ANY</SMALL> <SMALL>SUCH</SMALL> <SMALL>EVENTS</SMALL>. Borrowers and the other Obligors expressly agree (to the fullest extent it and they may lawfully do so) that with respect to any Prepayment Premium payable under the terms of this
Agreement: (i)&nbsp;such Prepayment Premium is reasonable and is the product of an arm&#146;s length transaction between sophisticated business parties, ably represented by counsel; (ii)&nbsp;such Prepayment Premium shall be payable notwithstanding
the <FONT STYLE="white-space:nowrap">then-prevailing</FONT> market rates at the time payment is made; (iii)&nbsp;there has been a course of conduct between the Lenders and the Obligors giving specific consideration in this transaction for such
agreement to pay such Prepayment Premium; and (iv)&nbsp;the Obligors shall be estopped hereafter from claiming differently than as agreed to in this paragraph. The Obligors expressly acknowledge that their agreement to pay such Prepayment Premium as
herein described is a material inducement to the Lenders to provide the Commitments and to make the Term Loans. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>RTICLE</SMALL>&nbsp;4. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>P<SMALL>AYMENTS</SMALL>, E<SMALL>TC</SMALL>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;4.01.</I> <I>Payments</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Payments Generally</I>. Each payment of principal, interest and other amounts to be made by the Obligors under this Agreement or any
other Loan Document shall be made in Dollars, in immediately available funds, without deduction, set off or counterclaim, to the deposit account of the Administrative Agent specified to Borrowers from time to time, not later than 2:00&nbsp;p.m.
(Eastern time) on the date on which such payment shall become due (each such payment made after such time on such due date to be deemed to have been made on the next succeeding Business Day). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Application of Payments Prior to a Default</I>. Prior to the occurrence of a Default, each payment under this Agreement or any other
Loan Document shall be applied in the following order of priority, with proceeds being applied to a succeeding level of priority only if amounts owing pursuant to the immediately preceding level of priority have been paid in full in cash: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <I>first</I>, in reduction of Borrowers&#146; obligation to pay any unpaid interest and any fees then due and owing
including, without limitation, any Prepayment Premium, if applicable; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) <I>second</I>, to the payment of unpaid
principal of the Term Loans on a pro rata basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Application of Payments Following a Default</I>. Following the occurrence of a
Default, each payment under this Agreement or any other Loan Document shall be applied in the following order of priority, with proceeds being applied to a succeeding level of priority only if amounts owing pursuant to the immediately preceding
level of priority have been paid in full in cash: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-47- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <I>first</I>, to the payment of any unpaid costs and expenses referred
to in Section&nbsp;13.03(a) then due and owing; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) <I>second</I>, in reduction of Borrowers&#146; obligation to pay any
unpaid interest and any fees then due and owing including, without limitation, (A)&nbsp;interest payable pursuant to Section&nbsp;3.02(d) and (B)&nbsp;any Prepayment Premium, if applicable; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) <I>third</I>, to the payment of unpaid principal of the Term Loans on a pro rata basis; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) <I>fourth, </I>in reduction of Borrowers&#146; obligation to pay any Claims or Losses referred to in Section&nbsp;13.03(b)
then due and owing; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) <I>fifth</I>, in reduction of any other Obligation then due and owing; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) <I>sixth</I>, to Borrowers or such other Persons as may lawfully be entitled to or directed by Borrowers to receive the
remainder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise directed by the Majority Lenders, all payments of principal, interest and fees under this Agreement and the
other Loan Documents shall be made by the Obligors to the Lenders pro rata in accordance with the Lenders&#146; respective Proportionate Shares of such payments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>Non</I><I><FONT STYLE="white-space:nowrap">-Business</FONT> Days</I>. If the due date of any payment under this Agreement (whether in
respect of principal, interest, fees, costs or otherwise) would otherwise fall on a day that is not a Business Day, such date shall be extended to the next succeeding Business Day, and, in the case of any payment accruing interest, interest thereon
shall be payable for the period of such extension. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;4.02.</I> <I>Computations</I><I>.</I> All computations
of interest and fees hereunder shall be computed on the basis of a year of 360&nbsp;days and actual days elapsed during the period for which payable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;4.03.</I> <I>Notices</I><I>.</I> Each notice of optional prepayment shall be effective only if received by the
Lenders not later than 2:00&nbsp;p.m. (Eastern time) on the date three (3)&nbsp;Business Days prior to the date of prepayment. Each notice of optional prepayment shall specify the amount to be prepaid and the date of prepayment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;4.04.</I> <I>Set</I><I><FONT STYLE="white-space:nowrap">-Off</FONT></I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Set</I><I><FONT STYLE="white-space:nowrap">-Off</FONT> Generally</I>. Upon the occurrence and during the continuance of any Event of
Default, the Administrative Agent, the Lenders and each of their respective Affiliates are hereby authorized at any time and from time to time, to the fullest extent permitted by Law, to set off and apply any and all deposits (general or special,
time or demand, provisional or final, other than </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-48- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
deposits held in any account set forth in clause (d)&nbsp;of the definition of &#147;Excluded Accounts&#148;) at any time held and other Indebtedness at any time owing by the Lenders or such
Affiliates to or for the credit or the account of any Obligor against any and all of the Obligations, whether or not the Lenders shall have made any demand and although such Obligations may be unmatured. Any Person exercising rights of <FONT
STYLE="white-space:nowrap">set-off</FONT> hereunder agrees to promptly notify Administrative Borrower after any such <FONT STYLE="white-space:nowrap">set-off</FONT> and application, <I>provided</I> that the failure to give such notice shall not
affect the validity of such <FONT STYLE="white-space:nowrap">set-off</FONT> and application. The rights of the Lenders and their respective Affiliates under this Section&nbsp;4.04 are in addition to other rights and remedies (including other rights
of <FONT STYLE="white-space:nowrap">set-off)</FONT> that the Lenders and their respective Affiliates may have. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Exercise of Rights
Not Required</I>. Nothing contained herein shall require the Administrative Agent, the Lenders or any of their respective Affiliates to exercise any such right or shall affect the right of such Persons to exercise, and retain the benefits of
exercising, any such right with respect to any other Indebtedness or obligation of any Obligor. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>RTICLE</SMALL>&nbsp;5. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Y<SMALL>IELD</SMALL> P<SMALL>ROTECTION</SMALL>, E<SMALL>TC</SMALL>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;5.01.</I> <I>Additional Costs</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Change in Requirements of Law Generally</I>. If, on or after the date hereof, the adoption of any Requirement of Law, or any change in
any Requirement of Law, or any change in the interpretation or administration thereof by any court or other Governmental Authority charged with the interpretation or administration thereof, or compliance by any Lender (or its lending office) with
any request or directive (whether or not having the force of law) of any such Governmental Authority, shall impose, modify or deem applicable any reserve (including any such requirement imposed by the Board of Governors of the Federal Reserve
System), special deposit, contribution, insurance assessment or similar requirement, in each case that becomes effective after the date hereof, against assets of, deposits with or for the account of, or credit extended by, a Lender (or its lending
office) or shall impose on a Lender (or its lending office) any other condition affecting the Term Loans or the Commitments, not as a result of any action or inaction on the part of such Lender, and the result of any of the foregoing is to increase
the cost to any Lender of making or maintaining its portion of the Term Loans, or to reduce the amount of any sum received or receivable by any Lender under this Agreement or any other Loan Document, by an amount reasonably deemed by such Lender in
good faith to be material (other than (i)&nbsp;Indemnified Taxes, (ii)&nbsp;Taxes described in clauses&nbsp;(b) through (d)&nbsp;of the definition of <I>&#147;Excluded Taxes&#148;</I> and (iii)&nbsp;Connection Income Taxes), then Borrowers shall pay
to such Lender on demand therefor such additional amount or amounts as will compensate such Lender for such increased cost or reduction. Notwithstanding anything herein to the contrary, (i)&nbsp;the <FONT STYLE="white-space:nowrap">Dodd-Frank</FONT>
Wall Street Reform and Consumer Protection Act and all requests, rules, guidelines or directives thereunder or issued in connection therewith and (ii)&nbsp;all requests, rules, guidelines or directives promulgated by the Bank for International
Settlements, the Basel Committee on Banking Supervision (or any successor or similar authority) or the United States or foreign regulatory authorities, in each case pursuant to Basel&nbsp;III, shall in each case be deemed to constitute a change in
Requirements of Law for all purposes of this Section&nbsp;5.01, regardless of the date enacted, adopted or issued. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-49- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Change in Capital Requirements</I>. If a Lender shall have determined that, on or
after the date hereof, the adoption of any Requirement of Law regarding capital adequacy, or any change therein, or any change in the interpretation or administration thereof by any Governmental Authority charged with the interpretation or
administration thereof, or any request or directive regarding capital adequacy (whether or not having the force of law) of any such Governmental Authority, in each case that becomes effective after the date hereof, has or would have the effect of
reducing the rate of return on capital of a Lender (or its parent) as a consequence of a Lender&#146;s obligations hereunder or the Term Loans to a level below that which a Lender (or its parent) could have achieved but for such adoption, change,
request or directive by an amount reasonably deemed by it to be material, then Borrowers shall pay to such Lender on demand therefor such additional amount or amounts as will compensate such Lender (or its parent) for such reduction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Notification by Lender</I>. The Lenders will promptly notify Administrative Borrower of any event of which it has knowledge, occurring
after the date hereof, which will entitle a Lender to compensation pursuant to this Section&nbsp;5.01. Before giving any such notice pursuant to this Section&nbsp;5.01(c) such Lender shall designate a different lending office if such designation
(i)&nbsp;will, in the reasonable judgment of such Lender, avoid the need for, or reduce the amount of, such compensation and (ii)&nbsp;will not, in the reasonable judgment of such Lender, be materially disadvantageous to such Lender. A certificate
of the Lender claiming compensation under this Section&nbsp;5.01, setting forth the amount or amounts to be paid to it hereunder, shall be conclusive and binding on Borrowers in the absence of manifest error. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;5.02.</I> <I>Illegality</I><I>.</I> Notwithstanding any other provision of this Agreement, in the event that on
or after the date hereof the adoption of or any change in any Requirement of Law or in the interpretation or application thereof by any competent Governmental Authority shall make it unlawful for a Lender or its lending office to make or maintain
the Term Loans (and, in the opinion of such Lender, the designation of a different lending office would either not avoid such unlawfulness or would be disadvantageous to such Lender), then such Lender shall promptly notify Administrative Borrower
thereof following which (a)&nbsp;the Lender&#146;s Commitment shall be suspended until such time as such Lender may again make and maintain the Term Loans hereunder and (b)&nbsp;if such Requirement of Law shall so mandate, the Term Loans shall be
prepaid by Borrowers on or before such date as shall be mandated by such Requirement of Law in an amount equal to the Redemption Price applicable on the date of such prepayment in accordance with Section&nbsp;3.03(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;5.03.</I> <I>Taxes</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Payments Free of Taxes</I>. Any and all payments by or on account of any Obligation shall be made without deduction or withholding for
any Taxes, except as required by applicable Law. If any applicable Law (as determined in the good faith discretion of the Administrative Agent) requires the deduction or withholding of any Tax from any such payment by an Obligor, then such Obligor
shall be entitled to make such deduction or withholding and shall timely pay the full amount deducted or withheld to the relevant Governmental Authority in accordance with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-50- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
applicable Law and, if such Tax is an Indemnified Tax, then the sum payable by such Obligor shall be increased as necessary so that after such deduction or withholding for Indemnified Taxes has
been made (including such deductions and withholdings for Indemnified Taxes applicable to additional sums payable under this Section&nbsp;5.03) the applicable Recipient receives an amount equal to the sum it would have received had no such deduction
or withholding for Indemnified Taxes been made. For purposes of this Section, the term &#147;applicable Law&#148; includes FATCA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)
<I>Payment of Other Taxes by Borrowers</I>. Borrowers shall timely pay to the relevant Governmental Authority in accordance with applicable Law, or at the option of the Administrative Agent, timely reimburse it for, Other Taxes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Evidence of Payments</I>. As soon as practicable after any payment of Taxes by Borrowers to a Governmental Authority, as a withholding
Tax pursuant to this Section&nbsp;5.03, Borrowers shall deliver to the Administrative Agent the original or a certified copy of a receipt issued by such Governmental Authority evidencing such payment, or a copy of the return reporting such payment
or other evidence of such payment reasonably satisfactory to the Administrative Agent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>Indemnification</I>. Borrowers shall
reimburse and indemnify each Recipient, within ten (10)&nbsp;days after demand therefor, for the full amount of any Indemnified Taxes (including Indemnified Taxes imposed or asserted on or attributable to amounts payable under this
Section&nbsp;5.03) payable or paid by such Recipient or required to be withheld or deducted from a payment to such Recipient and any reasonable expenses arising therefrom or with respect thereto, whether or not such Indemnified Taxes were correctly
or legally imposed or asserted by the relevant Governmental Authority. A certificate as to the amount of such payment or liability delivered to Administrative Borrower by a Lender (with a copy to the Administrative Agent), or by the Administrative
Agent on its own behalf or on behalf of a Lender shall be conclusive absent manifest error. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <I>Indemnification by the Lender</I>.
Each Lender shall severally indemnify the Administrative Agent, within ten (10)&nbsp;days after demand therefor, for (i)&nbsp;any Indemnified Taxes attributable to such Lender (but only to the extent that Borrowers have not already indemnified the
Administrative Agent for such Indemnified Taxes and without limiting the obligation of Borrowers to do so), and (ii)&nbsp;any Taxes attributable to such Lender, in each case, that are payable or paid by the Administrative Agent in connection with
any Loan Document, and any reasonable expenses arising therefrom or with respect thereto, whether or not such Taxes were correctly or legally imposed or asserted by the relevant Governmental Authority. A certificate as to the amount of such payment
or liability delivered to any Lender by the Administrative Agent shall be conclusive absent manifest error. Each Lender hereby authorizes the Administrative Agent to set off and apply any and all amounts at any time owing to such Lender under any
Loan Document or otherwise payable by the Administrative Agent to such Lender from any other source against any amount due to the Administrative Agent under this paragraph&nbsp;(e). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-51- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <I>Status of Lenders</I>. (i)&nbsp;Any Lender that is entitled to an exemption from, or
reduction of withholding Tax with respect to payments made under any Loan Document shall deliver to Administrative Borrower and the Administrative Agent at the time or times reasonably requested by Administrative Borrower or the Administrative Agent
such properly completed and executed documentation reasonably requested by Administrative Borrower or the Administrative Agent as will permit such payments to be made without withholding or at a reduced rate of withholding. In addition, any Lender,
if reasonably requested by Administrative Borrower or the Administrative Agent, shall deliver such other documentation prescribed by applicable Law or as reasonably requested by Administrative Borrower or the Administrative Agent as will enable
Administrative Borrower or the Administrative Agent to determine whether or not such Lender is subject to backup withholding or information reporting requirements. Notwithstanding anything to the contrary in the preceding two sentences, the
completion, execution and submission of such documentation (other than such documentation set forth in Section&nbsp;5.03(f)(ii)(A), (B) and (D)) shall not be required if in the Lender&#146;s reasonable judgment such completion, execution or
submission would subject such Lender to any material unreimbursed cost or expense or would materially prejudice the legal or commercial position of such Lender. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) Without limiting the generality of the foregoing: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A) any Lender that is a U.S.&nbsp;Person shall deliver to Administrative Borrower and the Administrative Agent on or prior to
the date on which such Lender becomes a Lender under this Agreement (and from time to time thereafter upon the reasonable request of Administrative Borrower or the Administrative Agent), duly completed, valid, executed copies of IRS <FONT
STYLE="white-space:nowrap">Form&nbsp;W-9</FONT> (or successor form) certifying that such Lender is exempt from U.S.&nbsp;Federal backup withholding Tax; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B) any Foreign Lender shall, to the extent it is legally entitled to do so, deliver to Administrative Borrower and the
Administrative Agent (in such number of copies as shall be requested by the Recipient) on or prior to the date on which such Foreign Lender becomes a Lender under this Agreement (and from time to time thereafter upon the reasonable request of
Administrative Borrower or the Administrative Agent), whichever of the following is applicable: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(1) in the case of a
Foreign Lender claiming the benefits of an income Tax treaty to which the United States is a party (x)&nbsp;with respect to payments of interest under any Loan Document, duly completed, valid executed copies of IRS
<FONT STYLE="white-space:nowrap">Form&nbsp;W-8BEN</FONT> (or successor form) or IRS <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Form&nbsp;W-8BEN-E</FONT></FONT> (or successor form) establishing an exemption from, or reduction
of, U.S. Federal withholding Tax pursuant to the &#147;interest&#148; article of such Tax treaty and (y)&nbsp;with respect to any other applicable payments under any Loan Document, duly completed, valid, executed originals of IRS <FONT
STYLE="white-space:nowrap">Form&nbsp;W-8BEN</FONT> (or successor form) or IRS <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Form&nbsp;W-8BEN-E</FONT></FONT> (or successor form) establishing an exemption from, or reduction of,
U.S.&nbsp;Federal withholding Tax pursuant to the &#147;business profits&#148; or &#147;other income&#148; article of such Tax treaty; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(2) duly completed, valid, executed copies of IRS Form <FONT STYLE="white-space:nowrap">W-8ECI</FONT> (or successor form); </P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-52- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(3) in the case of a Foreign Lender claiming the benefits of the exemption
for portfolio interest under Section&nbsp;881(c) of the Code, (x)&nbsp;a certificate substantially in the form of Exhibit&nbsp;D to the effect that such Foreign Lender is not a &#147;bank&#148; within the meaning of Section&nbsp;881(c)(3)(A) of the
Code, a &#147;10&nbsp;percent shareholder&#148; of a Borrower within the meaning of Section&nbsp;881(c)(3)(B) of the Code, or a &#147;controlled foreign corporation&#148; related to the Administrative Borrower as described in
Section&nbsp;881(c)(3)(C) of the Code (a <I>&#147;U.S.</I><I></I><I>&nbsp;Tax Compliance Certificate&#148;</I>) and (y)&nbsp;executed copies of IRS <FONT STYLE="white-space:nowrap">Form&nbsp;W-8BEN</FONT> (or successor form) or IRS <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Form&nbsp;W-8BEN-E</FONT></FONT> (or successor form); or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(4)
to the extent a Foreign Lender is not the beneficial owner, duly completed, valid, executed copies of IRS <FONT STYLE="white-space:nowrap">Form&nbsp;W-8IMY</FONT> (or successor form), accompanied by IRS
<FONT STYLE="white-space:nowrap">Form&nbsp;W-8ECI</FONT> (or successor form), IRS <FONT STYLE="white-space:nowrap">Form&nbsp;W-8BEN</FONT> (or successor form), IRS
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Form&nbsp;W-8BEN-E</FONT></FONT> (or successor form), a U.S.&nbsp;Tax Compliance Certificate, IRS <FONT STYLE="white-space:nowrap">Form&nbsp;W-9</FONT> (or successor form), and/or
other certification documents from each beneficial owner, as applicable; <I>provided</I> that if the Foreign Lender is a partnership and one or more direct or indirect partners of such Foreign Lender are claiming the portfolio interest exemption,
such Foreign Lender may provide a U.S.&nbsp;Tax Compliance Certificate on behalf of each such direct and indirect partner; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(C) any Foreign Lender shall, to the extent it is legally entitled to do so, deliver to Administrative Borrower and the
Administrative Agent (in such number of copies as shall be requested by the Recipient) on or prior to the date on which such Foreign Lender becomes a Lender under this Agreement (and from time to time thereafter upon the reasonable request of
Administrative Borrower or the Administrative Agent), executed copies of any other form prescribed by applicable Law as a basis for claiming exemption from or a reduction in U.S.&nbsp;Federal withholding Tax, duly completed, together with such
supplementary documentation as may be prescribed by applicable Law to permit Administrative Borrower or the Administrative Agent to determine the withholding or deduction required to be made; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(D) if a payment made to a Lender under any Loan Document would be subject to U.S.&nbsp;federal withholding Tax imposed by
FATCA if such Lender were to fail to comply with the applicable reporting requirements of FATCA (including those contained in Section&nbsp;1471(b) or 1472(b) of the Code, as applicable), such Lender shall deliver to Administrative Borrower and the
Administrative Agent at the time or times prescribed by Law and at such time or times reasonably requested by Administrative Borrower or the Administrative Agent such documentation prescribed by applicable Law (including as prescribed by
Section&nbsp;1471(b)(3)(C)(i) of the Code) and such additional documentation reasonably requested by Administrative Borrower or the Administrative Agent as may be necessary for Administrative Borrower or the Administrative Agent to comply with its
obligations under FATCA and to determine that such Lender has complied with such Lender&#146;s obligations under FATCA or to determine the amount, if any, to deduct and withhold from such payment. Solely for purposes of this clause&nbsp;(D),
&#147;FATCA&#148; shall include any amendments made to FATCA after the date of this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-53- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each Recipient agrees that if any form or certification it previously delivered expires or
becomes obsolete or inaccurate in any respect, it shall promptly update such form or certification or promptly notify Administrative Borrower and the Administrative Agent in writing of its legal inability to do so. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <I>Treatment of Certain Refunds</I>. If any party to this Agreement determines, in its sole discretion exercised in good faith, that it
has received a refund of any Taxes as to which it has been indemnified pursuant to this Section&nbsp;5.03 (including by the payment of additional amounts pursuant to this Section&nbsp;5.03), it shall pay to the indemnifying party an amount equal to
such refund (but only to the extent of indemnity payments made under this Section with respect to the Taxes giving rise to such refund), net of all <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT>
expenses (including Taxes) of such indemnified party and without interest (other than any interest paid by the relevant Governmental Authority with respect to such refund). Such indemnifying party, upon the written request of such indemnified party,
shall repay to such indemnified party the amount paid over pursuant to this paragraph (plus any penalties, interest or other charges imposed by the relevant Governmental Authority) in the event that such indemnified party is required to repay such
refund to such Governmental Authority. Notwithstanding anything to the contrary in this Section&nbsp;5.03(g), in no event will the indemnified party be required to pay any amount to an indemnifying party pursuant to this Section&nbsp;5.03(g) the
payment of which would place the indemnified party in a less favorable net <FONT STYLE="white-space:nowrap">after-Tax</FONT> position than the indemnified party would have been in if the Tax subject to indemnification and giving rise to such refund
had not been deducted, withheld or otherwise imposed and the indemnification payments or additional amounts giving rise to such refund had never been paid. This Section&nbsp;5.03(g) shall not be construed to require any indemnified party to make
available its Tax returns (or any other information relating to its Taxes that it deems confidential) to the indemnifying party or any other Person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <I>Mitigation Obligations.</I> If Borrowers are required to pay any Indemnified Taxes or additional amounts to any Lender or to any
Governmental Authority for the account of any Lender pursuant to Section&nbsp;5.01 or this Section&nbsp;5.03, then such Lender shall (at the request of Administrative Borrower) use commercially reasonable efforts to designate a different lending
office for funding or booking the Term Loans hereunder or to assign and delegate its rights and obligations hereunder to another of its offices, branches or Affiliates if, in the sole reasonable judgment of such Lender, such designation or
assignment and delegation would (i)&nbsp;eliminate or reduce amounts payable pursuant to Section&nbsp;5.01 or this Section&nbsp;5.03, as the case may be, in the future, (ii)&nbsp;not subject such Lender to any unreimbursed cost or expense and
(iii)&nbsp;not otherwise be disadvantageous to such Lender. Each Borrower hereby agrees to pay all reasonable costs and expenses incurred by any Lender in connection with any such designation or assignment and delegation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <I>Survival</I>. Each party&#146;s obligations under this Article&nbsp;5 shall survive the resignation or replacement of the
Administrative Agent or any assignment of rights by, or the replacement of, a Lender, the termination of the Commitments and the repayment, satisfaction or discharge of all Obligations under any Loan Document. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-54- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;5.04.</I> <I>Delay in Requests</I>. Failure or delay on the
part of any Lender to demand compensation pursuant to this Article&nbsp;5 shall not constitute a waiver of such Lender&#146;s right to demand such compensation; <I>provided</I> that Borrowers shall not be required to compensate a Lender pursuant to
this Article for any increased costs incurred or reductions suffered more than nine (9)&nbsp;months prior to the date that such Lender notifies Administrative Borrower of the change in Law giving rise to such increased costs or reductions, and of
such Lender&#146;s intention to Claim compensation therefor (except that, if the change in Law giving rise to such increased costs or reductions is retroactive, then the nine (9)&nbsp;month period referred to above shall be extended to include the
period of retroactive effect thereof). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>RTICLE</SMALL>&nbsp;6. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>C<SMALL>ONDITIONS</SMALL> P<SMALL>RECEDENT</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;6.01.</I> <I>Conditions to Tranche</I><I></I><I>&nbsp;A Term Loan; Closing Date</I><I>.</I> The obligation of
each Lender to make the Tranche&nbsp;A Term Loan on the Closing Date shall not become effective until the following conditions precedent shall have been reasonably satisfied or waived in writing by the Administrative Agent (which satisfaction or
waiver may be made simultaneously with the making of the Tranche&nbsp;A Term Loan hereunder): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Organization and
Capitalization</I>. The organizational structure and <FONT STYLE="white-space:nowrap">pro-forma</FONT> capitalization of the Obligors, after giving effect to the Transactions, as set forth on Schedule&nbsp;7.20 shall be satisfactory to the
Administrative Agent. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Terms of Material Agreements</I>. The Administrative Agent shall be satisfied in its sole
discretion with the terms and conditions of all of the Obligors&#146; Material Agreements, including without limitation, the Material Agreements that are directly or indirectly associated with Product manufacturing, distribution and payment of
royalties by any Obligor. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>No Law Restraining Transactions</I>. No applicable Law or regulation shall restrain,
prevent or, in the reasonable judgment of the Administrative Agent, impose materially adverse conditions upon the Transactions. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>Searches</I>. The Administrative Agent shall be satisfied with: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Lien searches regarding the Obligors made prior to the Closing Date; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) In respect of the Irish Obligor, (A)&nbsp;a search of the judgments office of the central office of the High Court of
Ireland, (B)&nbsp;a search of the index of petitions and winding up notices at the central office of the High Court of Ireland and (C)&nbsp;a search of the Companies Registration Office in Ireland to determine if an examiner or liquidator has been
appointed to the Irish Obligor and if the Irish Obligor has been dissolved. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-55- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <I>Documentary Deliveries</I>. The Administrative Agent shall have
received the following documents, each of which shall be in form and substance satisfactory to the Administrative Agent: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <I>Agreement</I>. This Agreement duly executed and delivered by the Obligors and each of the other parties hereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) <I>Security Documents</I>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A) Except as set forth in Section&nbsp;8.20, the Security Documents, including, without limitation, financing statements,
each in form and substance satisfactory to the Administrative Agent and duly executed and delivered by each of the Obligors and the other parties thereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B) The Collateral Questionnaire, duly executed and delivered by a Responsible Officer of Administrative Borrower,
substantially in the form of Exhibit&nbsp;I hereto and otherwise in form and substance satisfactory to the Administrative Agent. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(C) Without limitation, all other documents and instruments reasonably required to perfect the Administrative Agent&#146;s
Lien on, and security interest in, the Collateral required to be delivered on or prior to the Closing Date shall have been duly executed and delivered and be in proper form for filing, and shall create in favor of the Administrative Agent, a
perfected Lien on, and security interest in, the Collateral, subject to no Liens other than Permitted Liens. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(D) All
documents required to be delivered to the Administrative Agent pursuant to the Irish Share Charge shall have been duly delivered and a copy of all notices required to be sent pursuant to the Irish Debenture executed by the relevant Obligor to be
duly delivered to the Administrative Agent on or prior to the Closing Date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(E) The Administrative Agent shall have
received written authorization from the Irish Obligor authorizing each solicitor in Matheson LLP or any other legal advisor appointed by the Administrative Agent as to Irish law to sign on behalf of such Irish Obligor all required security related
registration forms and notifications required to be delivered to the Companies Registration Office in Ireland or to the Revenue Commissioners of Ireland or the Property Registration Authority in Ireland in connection with any of the Irish Security
Documents. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) <I>Note</I>. Any Notes requested in accordance with Section&nbsp;2.04. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-56- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) <I>Approvals</I>. Administrative Borrower shall certify to the
Administrative Agent that all Regulatory Approvals have been made or obtained, and all material licenses, consents, authorizations and approvals of, and notices to and filings and registrations with, any Governmental Authority (including all foreign
exchange approvals) in connection with the Transactions have been made or obtained, and all material <FONT STYLE="white-space:nowrap">third-party</FONT> consents and approvals, necessary in connection with the execution, delivery and performance by
the Obligors of the Loan Documents and the Transactions have been obtained. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) <I>Organizational Documents</I>.
(A)(x)&nbsp;Certified copies of the Organizational Documents (as amended or restated to the satisfaction of the Administrative Agent, if required by the Administrative Agent in connection with the Liens created pursuant to the Security Documents) of
each Obligor and of resolutions of the Board of each Obligor approving and authorizing the execution, delivery and performance of this Agreement and each of the other Loan Documents to which it is a party, certified as of the Closing Date by the
secretary or a Responsible Officer of such Obligor as being in full force and effect without modification or amendment; (y)&nbsp;a good standing certificate and/or compliance certificate from the applicable Governmental Authority of each
Obligor&#146;s jurisdiction of incorporation or registration (other than in the case of the Irish Obligor) and in each jurisdiction in which it is qualified as a foreign corporation or other entity to do business, each dated a recent date prior to
the Closing Date; and (z)&nbsp;such other documents as the Administrative Agent may reasonably request. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B) Certified
copies of the Organizational Documents of the general partner of Parent and Parent and of resolutions of the general partner of Parent approving and authorizing the execution, delivery and performance of the Warrant Certificate, certified as of the
Closing Date by the secretary or a Responsible Officer of the general partner of Parent as being in full force and effect without modification or amendment; (y)&nbsp;a good standing certificate and/or compliance certificate from the applicable
Governmental Authority of the general partner of Parent&#146;s jurisdiction of incorporation and Parent&#146;s jurisdiction of registration and in each jurisdiction in which it is qualified as a foreign corporation or other entity to do business,
each dated a recent date prior to the Closing Date; and (z)&nbsp;such other documents as the Administrative Agent may reasonably request. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) <I>Incumbency Certificate</I>. A certificate of each Obligor as to the authority, incumbency and specimen signatures of
the persons who have executed the Loan Documents and any other documents in connection herewith on behalf of the Obligors. A certificate of the general partner of Parent as to the authority, incumbency and specimen signatures of the persons who have
executed the Warrant Certificate. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii) <I>Officer&#146;s Certificate</I>. (A)&nbsp;a certificate, in form and substance
satisfactory to the Administrative Agent, dated as of the Closing Date and signed by a Responsible Officer of Administrative Borrower, confirming compliance with the conditions set forth in this Section&nbsp;6.01 and (B)&nbsp;a certificate, in form
and substance satisfactory to the Administrative Agent, dated as of the Closing Date and signed by a Responsible Officer of the Irish Obligor. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-57- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(viii) <I>Opinion of Counsel</I>. A favorable opinion or opinions, dated as
of the Closing Date, of (A)&nbsp;Kirkland and Ellis, LLP, U.S. counsel to the Obligors, (B)&nbsp;Maples and Calder (Cayman) LLP, special Cayman Islands counsel to the Obligors and (C)&nbsp;Matheson LLP, as special Irish counsel to the Administrative
Agent, each in form reasonably acceptable to the Administrative Agent. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ix) <I>Evidence of Insurance</I>. Certificates
from each Obligor&#146;s insurance broker or other evidence satisfactory to the Administrative Agent that all insurance required to be maintained pursuant to Section&nbsp;8.05 is in full force and effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x) <I>Warrant Certificate</I>. Perceptive shall have received the executed Warrant Certificate dated as of the Closing Date.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xi) <I>Borrowing Notice</I>. The Administrative Agent shall have received a Borrowing Notice in accordance with
Section&nbsp;2.01(a)(ii) duly executed and delivered by a Responsible Officer of Administrative Borrower, in form and substance satisfactory to the Administrative Agent. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <I>Due Diligence.</I> The Administrative Agent shall have received and be satisfied with all due diligence regarding Parent
and the Obligors (including without limitation historical financial statements, Projections, technical, operational, legal, Intellectual Property, commercial market forecasts, clinical and regulatory assessments, supply chain, securities, labor,
Tax, litigation, environmental, reimbursement and regulatory authority matters) in its sole discretion. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g)
<I>Indebtedness</I>. As of the Closing Date, after giving effect to the Transactions, the Obligors shall have (A)&nbsp;repaid in full all Existing Indebtedness, (B)&nbsp;terminated any commitments to lend or make other extensions of credit
thereunder, (C)&nbsp;delivered to the Administrative Agent all documents or instruments necessary to release (including updated statutory registers, if applicable) all Liens securing Existing Indebtedness or other obligations of the Obligors
thereunder being repaid on the Closing Date, and (D)&nbsp;made arrangements satisfactory to Administrative Agent with respect to the cancellation of any letters of credit outstanding thereunder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <I>Equity Raise. </I>Parent shall have completed a $50,000,000 equity raise on terms and provisions reasonably satisfactory
to the Administrative Agent and shall have contributed the net proceeds from such equity raise to OpCo. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <I>Sponsor
Equity Commitment Letter</I>. The Administrative Agent shall have received the Sponsor Equity Commitment Letter which shall be pledged to the Administrative Agent as Collateral for the benefit of itself and on behalf of the Lenders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-58- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) <I>Closing Fees, Expenses, Etc.</I> The Lenders and their Affiliates
shall have received for their own account, the Closing Fee and all fees, costs and expenses due (including applicable attorney costs and the reasonable and documented
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> fees and expenses of any other advisors to the Lenders) and payable pursuant to Section&nbsp;13.03, after deducting therefrom the Expense Deposit. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) <I>Representations and Warranties</I>. The representations and warranties of the Obligors contained in Article&nbsp;7 or
any other Loan Document shall be true and correct in all material respects on and as of the Closing Date; <I>provided</I> that to the extent that such representations and warranties specifically refer to an earlier date, they shall be true and
correct in all material respects as of such earlier date; <I>provided, further,</I> that any representation and warranty that is qualified as to &#147;materiality&#148;, &#147;Material Adverse Effect&#148; or similar language shall be true and
correct (after giving effect to any qualification therein) in all respects. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) <I>No Default</I>. No Default shall exist,
or would result from such proposed Borrowing or from the application of the proceeds therefrom. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) <I>Miscellaneous</I>.
Such other opinions, instruments, certificates and documents as the Administrative Agent or any Lender shall have reasonably requested with prior notice to Administrative Borrower. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;6.02.</I> <I>Conditions to Tranche</I><I></I><I>&nbsp;B Term Loan; Tranche</I><I></I><I>&nbsp;B Term Loan
Borrowing Date.</I> The obligation of each Lender to make the Tranche&nbsp;B Term Loan on the Tranche&nbsp;B Term Loan Borrowing Date shall not become effective until the following conditions precedent shall have been reasonably satisfied or waived
in writing by the Administrative Agent (which satisfaction or waiver may be made simultaneously with the making of the Tranche&nbsp;B Term Loan hereunder): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Tranche</I><I></I><I>&nbsp;B Loan Commitment Termination Date</I>. The Tranche&nbsp;B Term Loan Commitment Termination
Date shall not have occurred. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Borrowing Notice</I>. The Administrative Agent shall have received a Borrowing Notice
in accordance with Section&nbsp;2.01(b)(ii) duly executed and delivered by a Responsible Officer of Administrative Borrower. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Representations and Warranties</I>. The representations and warranties of the Obligors contained in Article&nbsp;7 or
any other Loan Document shall be true and correct in all material respects on and as of the Tranche&nbsp;B Term Loan Borrowing Date; <I>provided</I> that to the extent that such representations and warranties specifically refer to an earlier date,
they shall be true and correct in all material respects as of such earlier date; <I>provided, further,</I> that any representation and warranty that is qualified as to &#147;materiality&#148;, &#147;Material Adverse Effect&#148; or similar language
shall be true and correct (after giving effect to any qualification therein) in all respects. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>No Default</I>. No
Default or Event of Default shall exist, or would result from such proposed Borrowing or from the application of the proceeds therefrom. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-59- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <I>Milestone</I>. The Administrative Agent shall have received evidence
satisfactory to the Administrative Agent that Intermediate Holdings and its Subsidiaries have achieved Net Revenue of at least $50,000,000 for any twelve (12)&nbsp;consecutive month period prior to the Tranche&nbsp;B Term Loan Borrowing Date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <I>Expenses, Etc.</I> The Lenders and their Affiliates shall have received for their own account, all fees, costs and
expenses due (including applicable attorney costs and the reasonable and documented <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> fees and expenses of any other advisors to the Lenders) and payable
pursuant to Section&nbsp;13.03. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;6.03.</I> <I>Conditions to Tranche</I><I></I><I>&nbsp;C Term Loan;
Tranche</I><I></I><I>&nbsp;C Term Loan Borrowing Date.</I> The obligation of each Lender to make the Tranche&nbsp;C Term Loan on the Tranche&nbsp;C Term Loan Borrowing Date shall not become effective until the following conditions precedent shall
have been reasonably satisfied or waived in writing by the Administrative Agent (which satisfaction or waiver may be made simultaneously with the making of the Tranche&nbsp;C Term Loan hereunder): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Tranche</I><I></I><I>&nbsp;C Term Loan Commitment Termination Date</I>. The Tranche&nbsp;C Term Loan Commitment
Termination Date shall not have occurred. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Borrowing Notice</I>. The Administrative Agent shall have received a
Borrowing Notice in accordance with Section&nbsp;2.01(c)(ii) duly executed and delivered by a Responsible Officer of Administrative Borrower. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Representations and Warranties</I>. The representations and warranties of the Obligors contained in Article&nbsp;7 or
any other Loan Document shall be true and correct in all material respects on and as of the Tranche&nbsp;C Term Loan Borrowing Date; <I>provided</I> that to the extent that such representations and warranties specifically refer to an earlier date,
they shall be true and correct in all material respects as of such earlier date; <I>provided, further,</I> that any representation and warranty that is qualified as to &#147;materiality&#148;, &#147;Material Adverse Effect&#148; or similar language
shall be true and correct (after giving effect to any qualification therein) in all respects. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>No Default</I>. No
Default or Event of Default shall exist, or would result from such proposed Borrowing or from the application of the proceeds therefrom. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <I>Milestones</I>. The Administrative Agent shall have received evidence satisfactory to the Administrative Agent that
Intermediate Holdings and its Subsidiaries have achieved Net Revenue of at least $[***] for any twelve (12)&nbsp;consecutive month period prior to the Tranche&nbsp;C Term Loan Borrowing Date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <I>Expenses, Etc.</I> The Lenders and their Affiliates shall have received for their own account, all fees, costs and
expenses due (including applicable attorney costs and the reasonable and documented <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> fees and expenses of any other advisors to the Lenders) and payable
pursuant to Section&nbsp;13.03. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-60- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The borrowing of the Term Loans shall constitute a certification by Borrowers to the effect that the
conditions set forth in Sections&nbsp;6.01, 6.02 and 6.03 as applicable, have been fulfilled as of the Closing Date, the Tranche&nbsp;B Term Loan Borrowing Date, or the Tranche&nbsp;C Term Loan Borrowing Date, as applicable. For the avoidance of
doubt, the Tranche&nbsp;C Term Loans shall be available and may be borrowed (subject to the conditions in Section&nbsp;6.03) regardless of whether or not the Tranche&nbsp;B Term Loan Borrowing Date shall have occurred. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>RTICLE</SMALL>&nbsp;7. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>R<SMALL>EPRESENTATIONS</SMALL> <SMALL>AND</SMALL> W<SMALL>ARRANTIES</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to induce the Lenders to enter into this Agreement and to extend the Term Loans hereunder, each Obligor represents and warrants to
the Administrative Agent and the Lenders, on the Closing Date and on each of the Tranche B Term Loan Borrowing Date and the Tranche C Term Loan Borrowing Date, that the following statements are true and correct: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;7.01.</I> <I>Power and Authority</I><I>.</I> Each Obligor and its Subsidiaries (a)&nbsp;is duly organized,
incorporated, validly existing and in good standing (to the extent such concept is applicable in its jurisdiction of organization or incorporation) under the Laws of its jurisdiction of organization or incorporation, as applicable, (b)&nbsp;has all
requisite corporate (or equivalent) power, and has all material governmental licenses, authorizations, consents and approvals necessary to own its assets and carry on its business as now being or as proposed to be conducted except to the extent that
failure to have the same would not reasonably be expected to have a Material Adverse Effect, (c)&nbsp;is qualified to do business and is in good standing in all jurisdictions in which the nature of the business conducted by it makes such
qualification necessary except where failure to so qualify would not (either individually or in the aggregate) reasonably be expected to have a Material Adverse Effect, and (d)&nbsp;has full power, authority and legal right to make and perform each
of the Loan Documents to which it is a party and, in the case of Borrowers, to borrow the Term Loans hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;7.02.</I> <I>Authorization; Enforceability</I><I>.</I> The Transactions are within each Obligor&#146;s corporate
(or equivalent) powers and have been duly authorized by all necessary corporate (or equivalent) action and, if required, by all necessary shareholder or other equity holder action. The Loan Documents have been duly executed and delivered by each
Obligor party thereto and constitutes, and each of the other Loan Documents to which it is a party when executed and delivered by such Obligor will constitute, a legal, valid and binding obligation of such Obligor, enforceable against such Obligor
in accordance with its terms, except as such enforceability may be limited by (a)&nbsp;bankruptcy, insolvency, reorganization, moratorium or similar Laws of general applicability affecting the enforcement of creditors&#146; rights and (b)&nbsp;the
application of general principles of equity (regardless of whether such enforceability is considered in a proceeding in equity or at law). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-61- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;7.03.</I> <I>Governmental and Other Approvals; No
Conflicts</I><I>.</I> The Transactions (a)&nbsp;do not require any consent or approval of, registration or filing with, or any other action by, any Governmental Authority or any other Person, except for (i)&nbsp;such as have been obtained or made
and are in full force and effect and (ii)&nbsp;filings and recordings in respect of perfecting or recording the Liens created pursuant to the Security Documents, (b)&nbsp;will not violate any Requirement of Law or the Organizational Documents of any
Obligor or any order of any Governmental Authority, other than any such violations that, individually or in the aggregate, would not reasonably be expected to have a Material Adverse Effect, (c)&nbsp;will not violate or result in a default under any
Material Agreement, or give rise to a right thereunder to require any payment to be made by any such Person, and (d)&nbsp;will not result in the creation or imposition of any Lien (other than Permitted Liens) on any asset of any Obligor or any of
its Subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;7.04.</I> <I>Financial Statements; Projections; Material Adverse Change</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Financial Statements</I>. Borrowers have heretofore furnished to the Administrative Agent certain financial statements as provided for
in Section&nbsp;8.01. Such financial statements present fairly, in all material respects, the financial position and results of operations and cash flows of the Obligors as of such dates and for such periods substantially in accordance with GAAP,
subject to quarterly or <FONT STYLE="white-space:nowrap">year-end</FONT> adjustments and the absence of footnotes. No Obligor has any material contingent liabilities or liabilities for taxes, <FONT STYLE="white-space:nowrap">long-term</FONT> lease
or unusual forward or <FONT STYLE="white-space:nowrap">long-term</FONT> commitments not disclosed in the aforementioned financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Projections</I>. On and as of the Closing Date, the projections of the Obligors (collectively, the <I>&#147;Projections&#148;</I>) are
based on good faith estimates and assumptions made by the management of the Obligors; <I>provided,</I> the Projections are not to be viewed as facts and that actual results during the period or periods covered by the Projections may differ from such
Projections and that the differences may be material; <I>provided, further,</I> as of the Closing Date, the management of the Obligors believe that the Projections are reasonable and attainable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>No Material Adverse Change</I>. Since December&nbsp;31, 2022, no event, circumstance or change has occurred that has caused or
evidences, either in individually or in the aggregate, a Material Adverse Change. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;7.05.</I>
<I>Properties</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Property Generally</I>. Each Obligor has good and marketable fee simple title to, or valid leasehold interests
in, all its real and personal Property material to its business, including all Product Assets, subject only to Permitted Liens and except as would not reasonably be expected to interfere with its ability to conduct its business as currently
conducted or to utilize such properties for their intended purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Intellectual Property</I>.
(i)&nbsp;Schedule&nbsp;7.05(b)&nbsp;(A) lists, with respect to each Obligor, all United States and foreign registrations of and applications for Patents, Trademarks, Copyrights, and industrial designs that are Obligor Intellectual Property,
including the applicable jurisdiction, registration or application number and date, as applicable thereto and (B)&nbsp;identifies which Obligor Intellectual Property is Material Intellectual Property on the Closing Date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-62- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) Each Obligor owns or possesses all legal and beneficial rights, title and interest in
and to its Material Intellectual Property with good and marketable title, free and clear of any Liens or Claims of any kind, other than Permitted Liens. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) To each Obligor&#146;s knowledge, the Material Intellectual Property does not violate any license or infringe any valid and enforceable
Intellectual Property right of another. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) Other than with respect to the Material Agreements, or as permitted by this Agreement, the
Obligors have not assigned or otherwise transferred ownership of, or agreed to assign or otherwise transfer ownership of, any Material Intellectual Property, in whole or in part, to any Person who is not an Obligor, in each case, other than
Permitted Liens. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) Other than as set forth on Schedule&nbsp;7.05(b), the Obligors have not received any written communications, nor is
there any pending or, to each Obligor&#146;s knowledge, threatened action in writing, suit, proceeding or Claim in writing by another, alleging that any of the Obligors has violated, infringed, diluted or misappropriated any Intellectual Property of
another in a manner that would be material to the operation of the business of such Obligor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) There is no pending or, to any
Obligor&#146;s knowledge, threatened action in writing, suit, proceeding or Claim in writing by another: (A)&nbsp;challenging an Obligor&#146;s rights in or to any Material Intellectual Property owned by such Obligor; or (B)&nbsp;challenging the
validity, enforceability or scope of any Material Intellectual Property. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii) To each Obligor&#146;s knowledge, the Patents within
Material Intellectual Property have not ever been finally adjudicated to be invalid, unpatentable or unenforceable for any reason in any administrative, arbitration, judicial or other proceeding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(viii) To each Obligor&#146;s knowledge, no Obligor has received any written notice asserting that the issued Patents within the Material
Intellectual Property are invalid, unpatentable or unenforceable and, to each Obligor&#146;s knowledge, no Obligor has engaged in any conduct, or omitted to perform any necessary act, the result of which would invalidate or render unpatentable or
unenforceable any such Patent within the Material Intellectual Property. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ix) To the knowledge of each Obligor, no third party is
infringing upon or misappropriating, or violating any Material Intellectual Property in a manner that would be material to an Obligor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x) Each Obligor has taken commercially reasonable precautions to protect the Material Intellectual Property (including without limitation, by
requiring that all current and former employees, contractors and consultants of the Obligors that have developed Material Intellectual Property execute written confidentiality and Invention assignment Contracts). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xi) Each Obligor has complied with the terms of each Material Agreement pursuant to which Intellectual Property has been licensed to the
Obligors, except as would not reasonably be expected to result in a Material Adverse Effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-63- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xii) All maintenance fees, annuities, and the like due or payable on the Patents within the
Material Intellectual Property have been timely paid or the failure to so pay was the result of an intentional decision by the applicable Obligor, which would not reasonably be expected to result in a Material Adverse Change. All documents and
instruments necessary to register or apply for or renew registration of all Patents, Trademarks and Copyrights within the Material Intellectual Property have been validly executed, delivered and filed in a timely manner with the United States Patent
and Trademark Office or the United States Copyright Office, as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;7.06.</I> <I>No Actions or
Proceedings</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Litigation</I>. There is no litigation, investigation or enforcement proceeding pending or, threatened in writing
with respect to any Obligor by or before any Governmental Authority or arbitrator&nbsp;that either individually or in the aggregate would reasonably be expected to have a Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Environmental Matters</I>. The operations and the real Property of the Obligors comply with all applicable Environmental Laws, except
to the extent the failure to so comply, either individually or in the aggregate, would not reasonably be expected to have a Material Adverse Effect. To each Obligor&#146;s knowledge, there have been no conditions, occurrences or release of Hazardous
Materials which would reasonably be expected to have a Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Labor Matters</I>. No Obligor has engaged in
unfair labor practices and there are no pending or, to any Obligor&#146;s knowledge, threatened in writing labor actions, disputes, grievance or arbitration proceedings involving the employees of any Obligor, in each case that would reasonably be
expected to have a Material Adverse Effect. There is no material strike or work stoppage in existence or threatened in writing against any Obligor and to the knowledge of such Obligor, no union organization activity is taking place. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;7.07.</I> <I>Compliance with Laws and Agreements</I>. (a)&nbsp;Each Obligor is in compliance with all
Requirements of Law (including Health Care Laws and Environmental Laws) and all Contracts binding upon it or its Property, except where the failure to do so, individually or in the aggregate, would not reasonably be expected to result in a Material
Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Without limiting the generality of the foregoing: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) To the best of each Obligor&#146;s knowledge, any financial relationships between or among any Obligor, on the one hand,
and any Person who is in a position to refer patients or other business to an Obligor (collectively a <I>&#147;Referral Source&#148;</I>), on the other hand, (A)&nbsp;comply in all material respects with all applicable Health Care Laws;
(B)&nbsp;reflect fair market value, have commercially reasonable terms and were negotiated at arm&#146;s length; and (C)&nbsp;do not obligate the Referral Source to purchase, use, recommend or arrange for the use of any products or services of an
Obligor. No Obligor, directly or indirectly, has guaranteed a loan, made a payment toward a loan or otherwise subsidized a loan for any Referral Source including, without limitation, any loans related to financing the Referral Source&#146;s
ownership, investment or financial interest in any Obligor. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-64- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) All Products have been developed, tested, manufactured, distributed,
marketed and sold in compliance in all material respects with all applicable FDA&nbsp;Laws, including, without limitation, good manufacturing practices/quality system regulations (21&nbsp;CFR Part&nbsp;820), labeling, advertising, <FONT
STYLE="white-space:nowrap">record-keeping,</FONT> and adverse event reporting. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) Each Obligor is in compliance in all
material respects with the Physician Payments Sunshine Act (Section&nbsp;6002 of the Affordable Care Act of 2010) and its implementing regulations and any applicable state disclosure and transparency laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Each Obligor holds all Third-Party Payor Authorizations in full force and effect that are necessary to participate in and be reimbursed by
all Third-Party Payor Programs in which it participates, if any. To the knowledge of any Obligor, there is no investigation, audit, claim review, or other action pending or threatened in writing, which could result in a suspension, revocation,
termination, restriction, limitation, modification or nonrenewal of any Third-Party Payor Authorization or in the exclusion of an Obligor from participation in any Third-Party Payor Program, except to the extent that such investigation, audit, claim
review or other action, or such suspension, revocation, termination, restriction, limitation, modification or nonrenewal, individually or in the aggregate, could not reasonably be expected to result in a Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) No Obligor, nor any owner, officer, director, partner, agent or managing employee or Person with a &#147;direct or indirect ownership
interest&#148; (as that phrase is defined in 42 C.F.R. &#167; 420.201) in any Obligor has been (i)&nbsp;excluded from any Federal Health Care Program, (ii) &#147;suspended&#148; or &#147;debarred&#148; from selling products to the U.S. government or
its agencies pursuant to the Federal Acquisition Regulation, relating to debarment and suspension applicable to federal government agencies generally (42 C.F.R. Subpart 9.4), (iii) debarred, disqualified, suspended or excluded from participation in
any Third-Party Payor Program or is listed on the General Services Administration list of excluded parties, nor, to the knowledge of the Obligors, is any such debarment, disqualification, suspension or exclusion threatened or pending, or
(iv)&nbsp;made a party to any other action by any Governmental Authority that may prohibit it from selling products or providing services to any governmental or other purchaser pursuant to any federal, state or local laws or regulations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) No Obligor is subject to any pending audit, claim review, investigation, proceeding, or other action (in each case, whether civil,
criminal, administrative or investigative) relating to any actual or alleged noncompliance with any applicable Health Care Law, which could result in, the repayment of any material monies received, or the imposition of any material penalties, from
any Third-Party Payor Program or Governmental Authority. No Obligor, nor any owner, officer, director, partner, agent or managing employee of any Obligor is a party to or bound by any individual integrity agreement, corporate integrity agreement,
corporate compliance agreement, deferred prosecution agreement, or other formal or informal agreement with any Governmental Authority concerning compliance with any Requirements of Law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-65- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) Each Obligor is in compliance in all material respects with HIPAA and state health
information privacy and security laws except to the extent that any noncompliance, individually or in the aggregate, could not reasonably be expected to have a Material Adverse Effect. In each contractual arrangement that is subject to HIPAA, each
Obligor has: (i)&nbsp;entered into a written business associate agreement (as such term is defined under the HIPAA regulations) that substantially meets the requirements of HIPAA; (ii)&nbsp;at all times complied with such business associate
agreements in respect of the HIPAA privacy or security standards; and (iii)&nbsp;at no time experienced or had an unauthorized use or disclosure of Protected Health Information (as defined in the HIPAA regulations) or privacy or security breach or
other privacy or security incident within the meaning of HIPAA that has affected more than five hundred (500)&nbsp;individuals, except to the extent failure to comply with clauses (i)&nbsp;or (ii) could not be reasonably excepted to have a Material
Adverse Effect. Each Obligor has created and maintains written policies and procedures to protect the privacy of all patient protected health information in accordance with HIPAA and applicable state health information privacy and security laws, and
has implemented appropriate security procedures including, without limitation, administrative, physical and technical safeguards, to protect the confidentiality, integrity and availability of all electronic protected health information that it
creates, receives, maintains or transmits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) Each Obligor will maintain and adhere to, in all material respects, a reasonable
compliance program designed to promote compliance with and to detect, prevent and address violations of all material Health Care Laws (a <I>&#147;Health Care Compliance Program&#148;</I>). No Obligor is aware of any complaints from any employees,
independent contractors, vendors, physicians, customers, patients or other persons that could reasonably be considered to indicate a violation of Health Care Laws which would be reasonably expected to result individually or in the aggregate in a
Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;7.08.</I> <I>Taxes</I><I>.</I> Each Obligor has timely filed or caused to be filed
all federal income and other material Tax returns and reports required to have been filed and has paid or caused to be paid all federal income and other material Taxes required to have been paid by it, except Taxes that are being contested in good
faith by appropriate proceedings and for which such Obligor has set aside on its books adequate reserves with respect thereto substantially in accordance with GAAP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;7.09.</I> <I>Full Disclosure</I><I>.</I> The Obligors have disclosed to the Lenders all Material Agreements to
which any Obligor is party, and all other matters to its knowledge, that, individually or in the aggregate, would reasonably be expected to result in a Material Adverse Effect. None of the reports, financial statements, certificates or other
information furnished by or on behalf of the Obligors to the Lenders in connection with the negotiation of this Agreement and the other Loan Documents or delivered hereunder or thereunder (as modified or supplemented by other information so
furnished) (other than information of a general economic or industry specific nature) contains any material misstatement of material fact or omits to state any material fact necessary to make the statements therein, in the light of the circumstances
under which they were made, not misleading; <I>provided</I> that, with respect to projected financial information, the Obligors represent only that such information was prepared in good faith based upon assumptions believed to be reasonable at the
time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-66- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;7.10.</I> <I>Regulation</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Investment Company Act</I>. No Obligor is an &#147;investment company&#148; as defined in, or subject to regulation under, the
Investment Company Act of 1940 or the Companies Act 2014 of Ireland (as amended) respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Margin Stock</I>. No Obligor is
engaged principally, or as one of its important activities, in the business of extending credit for the purpose, whether immediate, incidental or ultimate, of buying or carrying Margin Stock, and no part of the proceeds of the Term Loans will be
used to buy or carry any Margin Stock in violation of Regulation&nbsp;T, U or X. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;7.11.</I>
<I>Solvency</I><I>.</I> The Obligors, on a consolidated basis, are and, immediately after giving effect to the Borrowings, the use of proceeds thereof, and the consummation of the Transactions, will be, Solvent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;7.12.</I> <I>[Reserved]</I><I>.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;7.13.</I> <I>Indebtedness and Liens</I><I>.</I> Set forth on Schedule&nbsp;7.13A is a complete and correct list
of all Permitted Indebtedness of each Obligor described in Section&nbsp;9.01(b) as of the date hereof. Set forth on Schedule&nbsp;7.13B is a complete and correct list of all Permitted Liens described in Section&nbsp;9.02(b) granted by an Obligor
with respect to its respective Property and outstanding as of the date hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;7.14.</I> <I>Material
Agreements</I><I>.</I> Set forth on Schedule&nbsp;7.14 (as such Schedule may be updated by Borrowers from time to time) is a complete and correct list of (a)&nbsp;each Material Agreement and (b)&nbsp;each Contract creating or evidencing any Material
Indebtedness, together with a summary reference to the product or purpose of each such Material Agreement and such Contract, to which an Obligor is a party. Accurate and complete copies of each such Contract listed on such schedule has been made
available to the Lenders. Except as disclosed to the Administrative Agent in writing, no Obligor is in default in any material respect under any such Material Agreement or such Contract creating or evidencing any Material Indebtedness listed on such
schedule, and no Obligor has knowledge of any default in any material respect by any counterparty to such Material Agreement or such Contract. Except as otherwise disclosed on Schedule&nbsp;7.14 (as such Schedule may be updated by Borrowers from
time to time), all material vendor purchase agreements and provider Contracts of the Obligors, and all Material Agreements including a grant of rights under any Intellectual Property to an Obligor, are in full force and effect without material
modification from the form in which the same were disclosed to the Lenders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;7.15.</I> <I>Restrictive
Agreements</I><I>.</I> None of the Obligors is party to any Restrictive Agreement, except (a)&nbsp;those listed on Schedule&nbsp;7.15 or otherwise permitted under Section&nbsp;9.11, (b)&nbsp;restrictions and conditions imposed by Law or by the Loan
Documents and (c)&nbsp;limitations associated with Permitted Liens. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;7.16.</I> <I>Real Property</I><I>.</I>
No Obligor or any of its Subsidiaries owns or leases (as tenant thereof) any real Property on the Closing Date, except as described on Schedule&nbsp;7.16. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-67- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;7.17.</I> <I>Pension and Other Plans</I>. Except as would not
have a Material Adverse Effect, each Benefit Plan, and each trust thereunder, intended to qualify for Tax exempt status under Section&nbsp;401 or 501 of the Code or other Requirements of Law so qualifies. Except for those that would not, in the
aggregate, have a Material Adverse Effect, (a)&nbsp;each Benefit Plan is in compliance with applicable provisions of ERISA, the Code and other Requirements of Law, (b)&nbsp;there are no existing or pending (or to the knowledge of any Obligor
threatened) Claims (other than routine Claims for benefits in the normal course), sanctions, actions, lawsuits or other proceedings or investigation involving any Benefit Plan to which any Obligor has an obligation or any liability or Claim and
(c)&nbsp;no ERISA Event is reasonably expected to occur. Except as would not have a Material Adverse Effect: (i)&nbsp;each Borrower and each of their ERISA Affiliates has met all applicable requirements under the ERISA Funding Rules with respect to
each Title&nbsp;IV Plan, and no waiver of the minimum funding standards under the ERISA Funding Rules has been applied for or obtained;(ii) as of the most recent valuation date for any Title&nbsp;IV Plan, the funding target attainment percentage (as
defined in Section&nbsp;430(d)(2) of the Code) is at least 60%, and neither a Borrower nor any of their ERISA Affiliates knows of any facts or circumstances that would reasonably be expected to cause the funding target attainment percentage to fall
below 60% as of the most recent valuation date; and (iii)&nbsp;as of the date hereof, no ERISA Event has occurred in connection with which obligations and liabilities (contingent or otherwise) remain outstanding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;7.18.</I> <I>Collateral; Security Interest</I><I>.</I> Each Security Document is effective to create in favor of
the Administrative Agent for the benefit of the Lenders a legal, valid and enforceable security interest in the Collateral subject thereto and each such security interest is perfected to the extent required by (and has the priority required by) the
applicable Security Document, subject to Permitted Liens. The Security Documents collectively are effective to create in favor of the Administrative Agent for the benefit of the Lenders a legal, valid and enforceable security interest in the
Collateral, which (if applicable) upon the filing of financing statements and other similar statements filed in the appropriate offices, such security interests are perfected security interests (subject only to Permitted Liens) to the extent that
such perfection may be obtained by such filing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;7.19.</I> <I>Regulatory Approvals</I>. (a)&nbsp;With
respect to the Products, each Obligor and each of its Subsidiaries holds either directly or through licensees and agents, all Regulatory Approvals and Permits necessary or required for each Obligor and its Subsidiaries to conduct all Product
Development and Commercialization Activities with respect to the Products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Set forth on Schedule&nbsp;7.19(b) is a complete and
accurate list as of the date hereof of all Regulatory Approvals referred to in clause&nbsp;(a) above, setting forth (on a per Product basis) the Obligor that holds such Regulatory Approval and identifying the Product related to such Regulatory
Approval. All such Regulatory Approvals are (i)&nbsp;legally and beneficially owned exclusively by the Obligor identified on the Schedule, free and clear of all Liens other than Permitted Liens, (ii)&nbsp;validly registered and on file with the
applicable Regulatory Authority, in material compliance with all registration, filing and maintenance requirements (including any fee requirements) thereof, and (iii)&nbsp;in good standing, valid and enforceable with the applicable Regulatory
Authority. All required and material notices, registrations and listings, supplemental applications or notifications, reports (including annual reports, field alerts, Device reports or other reports of adverse experiences) and all other required and
material filings with respect to the Products or any related Product Development and Commercialization Activities have been filed with the FDA and all other applicable Governmental Authorities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-68- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) (i)&nbsp;All material regulatory filings required by any Regulatory Authority or in
respect of any Product Authorization or other Regulatory Approval with respect to any Product or any Product Development and Commercialization Activities have been made, and all such filings are complete and correct in all material respects and have
complied in all material respects with all applicable Requirements of Law, (ii)&nbsp;all clinical and <FONT STYLE="white-space:nowrap">pre-clinical</FONT> trials, if any, of investigational Products have been and are being conducted by each Obligor
according to all applicable Requirements of Law in all material respects along with appropriate monitoring of clinical investigator trial sites for their compliance, and (iii)&nbsp;each Obligor has disclosed to the Lenders all such material
regulatory filings and all material communications between representatives of each Obligor and any Regulatory Authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Each Obligor
and, to each Obligor&#146;s knowledge, each of its agents are in compliance in all material respects with all applicable statutes, rules and regulations (including all Product Authorizations and other Regulatory Approvals) of all applicable
Governmental Authorities, including the FDA and all other Regulatory Authorities, with respect to each Product and all Product Development and Commercialization Activities related thereto. Each Obligor has and maintains in full force and effect all
the necessary and requisite Product Authorizations and other Regulatory Approvals. Each Obligor is in compliance in all material respects with all applicable registration and listing requirements set forth in all applicable FDA&nbsp;Laws or
equivalent regulation of each other Governmental Authority having jurisdiction over such Person. Each Obligor adheres in all material respects to all applicable regulations of all Regulatory Authorities with respect to the Products and all Product
Development and Commercialization Activities related thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) Except as set forth on Schedule&nbsp;7.19(e), (i)&nbsp;no Obligor has
received from any Regulatory Authority any notice of adverse findings with respect to any Product or any Product Development and Commercialization Activities related thereto, including any FDA Form&nbsp;483 inspectional observations, notices of
violations, warning letters, criminal proceeding notices under Section&nbsp;305 of the FD&amp;C&nbsp;Act, or any other similar communication from any Regulatory Authority, (ii)&nbsp;there have been no seizures conducted or, to each Obligor&#146;s
knowledge, threatened by any Regulatory Authority with respect to any Product, and no recalls, market withdrawals, field notifications, notifications of misbranding or adulteration or safety alerts conducted, requested or, to each Obligor&#146;s
knowledge, threatened by any Regulatory Authority with respect to any Product, and no recalls, market withdrawals, field notifications, notifications of misbranding or adulteration or safety alerts have been conducted, requested or, to each
Obligor&#146;s knowledge, threatened by any Regulatory Authority relating to any Products and (iii)&nbsp;no Obligor has received any written notification that remains unresolved from the FDA or any other Regulatory Authority indicating any breach or
violation of any applicable Product Authorization or other Regulatory Approval, including that any of the Products are misbranded or adulterated as defined in the FD&amp;C&nbsp;Act or the rules and regulations promulgated thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) Neither any Obligor nor, to any Obligor&#146;s knowledge, any officer, employee or agent thereof, has made an untrue statement of a
material fact or fraudulent statements to the FDA or any other Regulatory Authority, failed to disclose a material fact required to be disclosed to the FDA or any other Regulatory Authority, or committed an act, made a statement, or failed to make a
statement that, at the time such disclosure was made (or was not made), would reasonably be expected to provide a basis for the FDA or any other Regulatory Authority to invoke its policy respecting Fraud, Untrue Statements of Material Facts, Bribery
and Illegal Gratuities, set forth in 56&nbsp;Fed. Reg.&nbsp;46191 (September&nbsp;10, 1991) or any similar policy. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-69- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) No Obligor has received any written notice that the FDA or any other applicable
Regulatory Authority has commenced or initiated, or, to the knowledge of any such Obligor, threatened to commence or initiate, any action to withdraw any Product Authorization and other Regulatory Approval or requested the recall of any Products or
commenced or initiated or, to the knowledge of such Obligor, threatened to commence or initiate, any action to enjoin any Product Development and Commercialization Activities of such Obligor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) The clinical, preclinical, safety and other studies and tests conducted by or on behalf of or sponsored by each Obligor, or in respect of
which any Products or Product candidates under development have participated, were (and if still pending, are) being conducted materially in accordance with reasonable medical and scientific research procedures and all applicable Product
Authorizations. Each Obligor has operated within, and currently is in compliance in all material respects with, all applicable Laws, Product Authorizations and other Regulatory Approvals, as well as the rules and regulations of the FDA and each
other Regulatory Authority. No Obligor has received any notices or other correspondence from the FDA or any other Regulatory Authority requiring the termination or suspension of any clinical, preclinical, safety or other studies or tests used to
support regulatory clearance of, or any Product Authorization or other Regulatory Approval for, any Product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) No material debarment or
exclusionary Claims, actions, proceedings or investigations in respect of any Obligor&#146;s business is pending, or to such Obligor&#146;s knowledge, threatened in writing against such Obligor or its officers, employees or agents. No Obligor or, to
such Obligor&#146;s knowledge, any officer, employee or agent of such Obligor, has been convicted of any crime or engaged in any conduct that would reasonably be expected to result in a debarment or exclusion under (i)&nbsp;Section&nbsp;335a of the
FD&amp;C&nbsp;Act or (ii)&nbsp;any similar applicable Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;7.20.</I> <I>Capitalization</I><I>.</I> All of
the issued and outstanding securities of each Obligor have been duly authorized, are validly issued, fully paid, and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> There are no: (a)&nbsp;outstanding or authorized options, warrants, purchase
rights, subscription rights, conversion rights, exchange rights, or other contracts or commitments that could require the Obligors to issue, sell, or otherwise cause to become outstanding any of their ownership interests; (b)&nbsp;outstanding or
authorized stock appreciation, phantom stock, profit participation, or similar rights with respect to the Obligors; and (c)&nbsp;voting trusts, proxies, or other agreements or understandings with respect to the voting of the ownership interests of
the Obligors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;7.21.</I> <I>Insurance</I><I>.</I> Each Obligor has obtained (and is maintaining), insurance
for its assets (including the Collateral) and business as required under the Loan Documents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;7.22.</I>
<I>Certain Fees</I><I>.</I> Except as described on Schedule&nbsp;7.22, no broker&#146;s or finder&#146;s fee will be payable in connection with the execution and delivery of this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-70- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;7.23.</I> <I>Sanctions Laws</I><I>.</I> Obligors and, to the
knowledge of the Obligors, any director, officer or employee of an Obligor acting on behalf of the Obligors, are in compliance with the Sanctions Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;7.24.</I> <I>Anti</I><I><FONT STYLE="white-space:nowrap">-Corruption</FONT> Laws</I><I>.</I> No Obligor nor any
of its Subsidiaries, nor, to the knowledge of any Responsible Officer of any Obligor, any director, officer, agent or employee of any Obligor acting on behalf of such Obligor has in the past five (5)&nbsp;years (a)&nbsp;taken any action, directly or
indirectly, that would result in a violation by such Persons of the <FONT STYLE="white-space:nowrap">Anti-Corruption</FONT> Laws or Irish Anti-Corruption Laws, (b)&nbsp;made, offered to make, promised to make or authorized the payment or giving of,
directly or indirectly, any Prohibited Payment or (c)&nbsp;been subject to any investigation by any Governmental Authority with regard to any actual or alleged Prohibited Payment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;7.25.</I> <I>Anti</I><I><FONT STYLE="white-space:nowrap">-Terrorism</FONT> Laws</I><I>.</I> The Obligors
(a)&nbsp;have taken reasonable measures to ensure compliance with applicable Sanctions Laws, Economic Sanctions Laws and <FONT STYLE="white-space:nowrap">Anti-Terrorism</FONT> Laws and Irish Anti-Terrorism Laws, (b)&nbsp;are not Designated Persons
and (c)&nbsp;have not in the past five (5)&nbsp;years used any part of the proceeds from any advance on behalf of any Designated Person or used, directly by it or indirectly through any Subsidiary, such proceeds in connection with any investment in,
or any transactions or dealings with, any Designated Person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;7.26.</I> <I>Royalty and Other Payments</I>.
Except as set forth on Schedule&nbsp;7.26, no Obligor, nor any of its Subsidiaries, is obligated to pay any royalty, milestone payment, deferred payment or any other contingent payment in respect of any Product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;7.27.</I> <I>Irish Representations</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) No Obligor (other than the Irish Obligor) is a relevant external company as that term is defined in section 1301 of the Companies Act 2014
of Ireland (as amended). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The Irish Obligor, to the extent applicable, has done all that is necessary to comply with section 82 of the
Companies Act 2014 of Ireland (as amended) in order to enable it to enter into the Loan Documents to which it is a party and perform its obligations under such Loan Documents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) The Irish Obligor, together with each other Obligor whose obligations are guaranteed by it or the subject of security granted by it under
the Loan Documents, together comprise a &#147;group&#148; for the purposes of section 243 of the Companies Act 2014 of Ireland (as amended). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-71- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>RTICLE</SMALL>&nbsp;8. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>FFIRMATIVE</SMALL> C<SMALL>OVENANTS</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each Obligor covenants and agrees with the Lenders that, until the Commitments have expired or been terminated and all Obligations (other than
inchoate indemnity obligations) have been paid in full in cash: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;8.01.</I> <I>Financial Statements and Other
Information</I><I>.</I> It will furnish to the Administrative Agent for distribution to the Lenders: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) as soon as
available and in any event within thirty (30)&nbsp;days after the end of each month (other than the last month of each fiscal quarter) prior to a Qualified Public Offering, the consolidated balance sheets of Intermediate Holdings and its
Subsidiaries as of the end of each such month, and the related consolidated statements of income and cash flows of Intermediate Holdings and its Subsidiaries for such month and the portion of the fiscal year through the end of such month, all in
reasonable detail and setting forth in comparative form the figures for the corresponding period in the preceding fiscal year, together with a certificate of a Responsible Officer of Administrative Borrower stating that such financial statements
fairly present in all material respects the financial condition of Intermediate Holdings and its Subsidiaries as at such date and the results of operations of Intermediate Holdings and its Subsidiaries for the period ended on such date and have been
prepared substantially in accordance with GAAP consistently applied, subject to changes resulting from normal, quarterly or <FONT STYLE="white-space:nowrap">year-end</FONT> adjustments and except for the absence of notes; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) as soon as available and in any event within forty (40)&nbsp;days after the end of each fiscal quarter prior to a Qualified
Public Offering, the consolidated balance sheets of Intermediate Holdings and its Subsidiaries as of the end of such quarter, and the related consolidated statements of income and cash flows of Intermediate Holdings and its Subsidiaries for such
quarter and the portion of the fiscal year through the end of such quarter, all in reasonable detail and setting forth in comparative form the figures for the corresponding period in the preceding fiscal year, together with a certificate of a
Responsible Officer of Administrative Borrower stating that such financial statements fairly present in all material respects the financial condition of Intermediate Holdings and its Subsidiaries as at such date and the results of operations of
Intermediate Holdings and its Subsidiaries for the period ended on such date and have been prepared substantially in accordance with GAAP consistently applied, subject to changes resulting from normal quarterly or
<FONT STYLE="white-space:nowrap">year-end</FONT> adjustments and except for the absence of footnotes; <I>provided</I> that, if Intermediate Holdings or a parent thereof becomes a Publicly Reporting Company, such Person&#146;s (or such parent&#146;s)
filing of a Quarterly Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-Q</FONT> with the SEC shall be deemed to satisfy the requirements of this Section&nbsp;8.01(b) on the date on which such report is first available via the SEC&#146;s EDGAR
system or a successor system related thereto; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-72- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) as soon as available and in any event within one hundred twenty
(120)&nbsp;days after the end of each fiscal year prior to a Qualified Public Offering, the consolidated balance sheets of Intermediate Holdings and its Subsidiaries as of the end of such fiscal year, and the related consolidated statements of
income, shareholders&#146; equity and cash flows of Intermediate Holdings and its Subsidiaries for such fiscal year, prepared substantially in accordance with GAAP consistently applied, all in reasonable detail and setting forth in comparative form
the figures for the previous fiscal year, accompanied by a report and opinion thereon of PricewaterhouseCoopers&nbsp;or another independent certified public accountant of national or international reputation, which report and opinion shall be
prepared in accordance with generally accepted auditing standards and shall not be subject to any &#147;going concern&#148; or like qualification or exception or any qualification or exception as to the scope of such audit (other than impending
maturity of Obligations); <I>provided</I> that, if Intermediate Holdings or a parent becomes a Publicly Reporting Company, Intermediate Holdings&#146; (or such parent&#146;s) filing of a Quarterly Report on
<FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> with the SEC shall be deemed to satisfy the requirements of this Section&nbsp;8.01(b) on the date on which such report is first available via the SEC&#146;s EDGAR system or a successor system
related thereto; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) within thirty (30)&nbsp;days after the end of each month (forty (40)&nbsp;days with respect to a
month that corresponds with the last day of a fiscal quarter), a compliance certificate of a Responsible Officer of Administrative Borrower as of the end of the applicable accounting period (which delivery may, unless a Lender requests executed
originals, be by electronic communication including email and shall be deemed to be an original authentic counterpart thereof for all purposes) in the form of Exhibit&nbsp;E (a <I>&#147;Compliance Certificate&#148;</I>) which, for purposes of
clarification, shall (i)&nbsp;demonstrate the Obligors&#146; compliance with Section&nbsp;8.15(a) in respect of the last day of such month, (ii)&nbsp;for each month end that coincides with the end of a fiscal quarter, demonstrate compliance with
Section&nbsp;8.15(b) in respect of such fiscal quarter and (iii)&nbsp;for each month end that coincides with the end of a fiscal year, (A)&nbsp;provide Obligors&#146; updated Schedules to Loan Documents (if any), (B) include details of any issues
that are material that are raised by auditors and (C)&nbsp;confirm that all of the requirements set forth in Section&nbsp;8.05 are satisfied; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) promptly, and in any event within five (5)&nbsp;Business Days after receipt thereof by an Obligor, copies of each notice or
other correspondence received from any securities regulator or exchange to the authority of which an Obligor is subject concerning any investigation or possible investigation or other inquiry by such agency regarding financial or other operational
results of such Obligor; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) [reserved]; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) promptly following the Lenders&#146; written request at any time, proof of the Obligors compliance with
Section&nbsp;8.15(a); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) within ten (10)&nbsp;days of delivery, copies of all periodic reports distributed by
Intermediate Holdings to its shareholders generally (or by Parent or any other parent entity); <I>provided</I> that (i)&nbsp;any such material may be redacted to exclude information relating to the Loan Documents or the Lenders and (ii)&nbsp;the
Lenders shall not be entitled to receive statements, reports and notices relating to topics that (A)&nbsp;are subject to <FONT STYLE="white-space:nowrap">attorney-client</FONT> privilege, (B)&nbsp;present a conflict of interest for the Lenders or
(C)&nbsp;constitute a trade secret, <FONT STYLE="white-space:nowrap">know-how</FONT> or commercially sensitive information; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-73- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) a financial forecast for Intermediate Holdings and its Subsidiaries for
each fiscal year, including forecasted balance sheets, statements of income and cash flows of Intermediate Holdings and its Subsidiaries, all of which shall be prepared on a consolidated basis and delivered not later than June&nbsp;29 of such year;
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) promptly following any Lender&#146;s written request, certification that such Obligor is not a passive foreign
investment company (<I>&#147;PFIC&#148;</I>) within the meaning of Sections&nbsp;1291 through 1297 of the Code, or, if such Obligor determines that it is a PFIC, such information as would allow the Lender to make a qualified electing fund election
with respect to the stock of the Obligor; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) after Parent or any other parent of Intermediate Holdings becomes a Publicly
Reporting Company, within five (5)&nbsp;Business Days of filing, provide access (via posting and/or links on OpCo&#146;s web site) to all reports on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> and
<FONT STYLE="white-space:nowrap">Form&nbsp;10-Q</FONT> filed with the SEC, any Governmental Authority succeeding to any or all of the functions of the SEC or with any national securities exchange; and within five (5)&nbsp;Business Days of filing,
provide notice and access (via posting and/or links on OpCo&#146;s web site) to all reports on <FONT STYLE="white-space:nowrap">Form&nbsp;8-K</FONT> filed with the SEC, and copies of (or access to, via posting and/or links on OpCo&#146;s web site)
all other reports, proxy statements and other materials filed by such Public Reporting Company with the SEC, any Governmental Authority succeeding to any of the functions of the SEC or with any national securities exchange; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) promptly after the receipt thereof, a copy of any &#147;management letter&#148; received from its certified public accounts
and the management&#146;s response thereto (other than draft versions thereof); and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) such other information respecting
the operations, properties, business or condition (financial or otherwise) of the Obligors (including with respect to the Collateral) as the Lenders may from time to time reasonably request. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;8.02.</I> <I>Notices of Material Events</I><I>.</I> It will furnish to the Administrative Agent for distribution
to the Lenders written notice of the following promptly after a Responsible Officer of an Obligor first learns of the existence of: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) the occurrence of any Default or Event of Default; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) the occurrence of any event with respect to any Obligor&#146;s Property resulting in a Loss (other than the Loss of
Inventory or Equipment in the Ordinary Course of Business), to the extent not covered by insurance, aggregating $1,500,000 or more; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-74- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) (i)&nbsp;any proposed Acquisition by any Obligor that would reasonably
be expected to result in environmental liability under Environmental Laws in excess of $1,500,000, and (ii)&nbsp;in each case, to the extent that any of the following would reasonably be expected to result in liability in excess of $1,500,000:
(A)&nbsp;spillage, leakage, discharge, disposal, leaching, migration or release of any Hazardous Material required to be reported to any Governmental Authority under applicable Environmental Laws, and (B)&nbsp;all actions, suits, Claims, notices of
violation, hearings, investigations or proceedings pending, or threatened in writing against or affecting any Obligor or any of its Subsidiaries or with respect to the ownership, use, maintenance and operation of their respective businesses,
operations or properties, relating to Environmental Laws or Hazardous Material; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) the assertion of any environmental
matter by any Person in writing against, or with respect to the activities of, any Obligor or any of its Subsidiaries and any alleged violation of or <FONT STYLE="white-space:nowrap">non-compliance</FONT> with any Environmental Laws or any permits,
licenses or authorizations, in each case, which would reasonably be expected to involve damages in excess of $1,500,000 other than any environmental matter or alleged violation that, if adversely determined, would not (either individually or in the
aggregate) have a Material Adverse Effect; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) the filing or commencement of any action, suit or proceeding by or before
any arbitrator or Governmental Authority against or directly affecting any Obligor or any of its Subsidiaries, in each case, that would reasonably be expected to result in a Material Adverse Effect; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) if a Material Adverse Effect would result: (i)&nbsp;on or prior to any filing by any Obligor&nbsp;or an ERISA Affiliate
thereof&nbsp;of any notice of intent to terminate any Title&nbsp;IV Plan, a copy of such notice and (ii)&nbsp;promptly, and in any event within ten (10)&nbsp;days, after any Responsible Officer of the Obligor knows&nbsp;or has reason to
know&nbsp;that a request for a minimum funding waiver under Section&nbsp;412 of the Code has been filed with respect to any Title&nbsp;IV Plan or Multiemployer Plan, a notice (which may be made by telephone if promptly confirmed in writing)
describing such waiver request and any action that the Obligor&nbsp;or an ERISA Affiliate thereof&nbsp;proposes to take with respect thereto, together with a copy of any notice filed with the PBGC or the IRS pertaining thereto; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) within five (5)&nbsp;Business Days of obtaining written notice or knowledge thereof, (i)&nbsp;the termination of any
Material Agreement; (ii)&nbsp;the receipt by any Obligor or any of its Subsidiaries of a written notice under any Material Agreement (and a copy thereof) asserting a default by such Obligor or any of its Subsidiaries where such alleged default would
permit such counterparty to terminate such Material Agreement; (iii)&nbsp;the entering into any new Material Agreement by an Obligor (and a copy thereof); or (iv)&nbsp;any amendment to a Material Agreement that would be materially adverse to the
Lenders (and a copy thereof) (which includes, but is not limited to, any amendments to provisions relating to pricing and term), <I>provided</I> that notices required under this subsection&nbsp;(g) may be delivered with the monthly Compliance
Certificate unless any of the foregoing events would reasonably be expected to have a Material Adverse Effect; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) any
product recalls, safety alerts, corrections, withdrawals, marketing suspensions, removals or the like conducted, to be undertaken or issued by any Obligor or any of its Subsidiaries, whether or not at the request, demand or order of any Governmental
Authority; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-75- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) within five (5)&nbsp;Business Days of obtaining written notice or
knowledge thereof, any infringement or other violation by any Person of any Obligor Intellectual Property that would reasonably be expected to result in a Material Adverse Effect; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) within five (5)&nbsp;Business Days of obtaining written notice or knowledge thereof, a material licensing agreement or
arrangement entered into by any Obligor or any of its Subsidiaries in connection with any material infringement or alleged material infringement of the Intellectual Property of another Person; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) within five (5)&nbsp;Business Days of obtaining written notice or knowledge thereof, any written Claim by any Person that
the conduct of any Obligor&#146;s (or any Subsidiary thereof) business, including the development, manufacture, use, sale or other commercialization of any Product, infringes any Intellectual Property of such Person, except to the extent any such
Claim would not reasonably be expected to result in a Material Adverse Effect; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) the reports and notices as and when
required by the Security Documents; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) concurrently with the delivery of any Compliance Certificate, notice of any
material change in accounting policies or financial reporting practices by the Obligors; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) promptly after the occurrence
thereof, notice of any labor controversy resulting in or threatening to result in any strike, work stoppage, boycott, shutdown or other material labor disruption against or involving an Obligor (or any Subsidiary thereof); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) any other development that results in, or would reasonably be expected to result in, a Material Adverse Effect; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) concurrently with the delivery of any Compliance Certificate, the creation or other acquisition of any Intellectual
Property by any Obligor or any Subsidiary after the date hereof and during such prior fiscal year which is registered or becomes registered or the subject of an application for registration with the United States Copyright Office or the United
States Patent and Trademark Office, as applicable, or with any other equivalent registration offices in the Cayman Islands, the European Union or Ireland, as applicable; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q) within five (5)&nbsp;Business Days of any change to any Obligor&#146;s ownership of Deposit Accounts, Securities Accounts
and Commodity Accounts, by delivering to the Lenders an updated Schedule&nbsp;7 to the Security Agreement setting forth a complete and correct list of all such accounts; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-76- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(r) (i) receipt of any subpoena, civil investigative demand letter, or other
notice from any Governmental Authority of any investigation or audit, or pending or threatened (in writing) proceedings relating to any material violation of any Health Care Law, (ii)&nbsp;receipt of notice from any Governmental Authority or
Third-Party Payor Program of any payment suspension, material overpayment demand, or prepayment review, validation review, program integrity review, relating to a Federal Health Care Program or any material Third-Party Payor Program,
(iii)&nbsp;loss, suspension or relinquishment of any material accreditation, approval or qualification for participation in a Federal Health Care Program or any material Third-Party Payor Program and (iv)&nbsp;voluntary disclosure to a Governmental
Authority of an overpayment amount greater than $250,000 related to an actual or potential violation of Health Care Laws; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(s) within ten (10)&nbsp;Business Days following the departure of a Key Person, provide written notice to the Administrative
Agent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each notice delivered under this Section&nbsp;8.02 shall be accompanied by a statement of a Responsible Officer of Administrative
Borrower setting forth in reasonable detail the event or development requiring such notice and any action taken or proposed to be taken with respect thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding any contrary provision of this Agreement or any other Loan Document (including, without limitation, Sections&nbsp;8.01 and
8.02), until such time as the Administrative Agent provides written notice to Administrative Borrower that it no longer desires to receive information that constitutes material <FONT STYLE="white-space:nowrap">non-public</FONT> information,
Borrowers shall provide any information required pursuant to the terms hereof, including any information that may be material <FONT STYLE="white-space:nowrap">non-public</FONT> information, to the Administrative Agent; <I>provided, </I>that
notwithstanding the foregoing, Borrowers shall at all times comply with Section&nbsp;8.01(d), 8.01(k) and 8.02(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;8.03.</I> <I>Existence; Maintenance of Properties, Etc.</I> (a)&nbsp;It will, and will cause each of its
Subsidiaries to, do or cause to be done all things necessary to preserve, renew and keep in full force and effect its legal existence; <I>provided</I> that the foregoing shall not prohibit any merger, amalgamation, consolidation, liquidation or
dissolution permitted under Section&nbsp;9.03. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) It shall, and shall cause each of its Subsidiaries to, maintain and preserve all
rights, licenses, permits, privileges and franchises necessary to the conduct of its business, and maintain and preserve all of its assets and properties, including all Product Assets, necessary to the conduct of its business in good working order
and condition, ordinary wear and tear and damage from casualty or condemnation excepted, except where failure to do so would not reasonably be expected to result in a Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;8.04.</I> <I>Payment of Obligations</I><I>.</I> It will, and will cause each of its Subsidiaries to, pay and
discharge (a)&nbsp;all federal income and other material Taxes, fees, assessments and governmental charges or levies imposed upon it or upon its properties or assets prior to the date on which penalties attach thereto, and all lawful Claims for
labor, materials and supplies which, if unpaid, might become a Lien (other than a Permitted Lien) upon any properties or assets of any Obligor, except to the extent such Taxes, fees, assessments or governmental charges or levies, or such Claims, are
being contested in good faith by appropriate proceedings and are adequately reserved against substantially in accordance with GAAP, (b)&nbsp;all lawful Claims which, if unpaid, would by Law become a Lien upon its Property not constituting a
Permitted Lien and (c)&nbsp;all other obligations if the failure to discharge such obligation would reasonably be expected to result in a Material Adverse Effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-77- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;8.05.</I> <I>Insurance</I><I>.</I> At its own cost and
expense, it will, and will cause each of its Subsidiaries, to obtain and maintain, with financially sound and reputable insurers, insurance of the kinds, and in the amounts, as are consistent with customary practices and standards of its industry in
the same or similar locations, it being understood and agreed that the insurance held by the Obligors on the Closing Date is deemed to fulfill this requirement on the date hereof. All of the insurance policies required pursuant to this
Section&nbsp;8.05 will name the Administrative Agent as a &#147;lender&#146;s loss payee,&#148; &#147;additional insured&#148; or &#147;mortgagee,&#148; as applicable and as its interests may appear. Borrowers will use their commercially reasonable
efforts to ensure, or to cause others to ensure, that all insurance policies required pursuant to this Section&nbsp;8.05 shall provide that they shall not be terminated or cancelled nor shall any policy be materially changed in a manner adverse to
the insured Person without at least thirty (30)&nbsp;days&#146; written notice to insured Person and the Administrative Agent. Receipt of notice of termination or cancellation of any such insurance policies shall entitle the Administrative Agent to
renew any such policies, all in accordance with the first sentence of this Section&nbsp;8.05 or otherwise to obtain similar insurance in place of such policies, in each case at the expense of Borrowers (payable within three (3)&nbsp;Business Days of
Administrative Borrower&#146;s receipt of written demand therefor) and, unless an Event of Default has occurred and is continuing, with the prior written consent of Administrative Borrower (such consent not to be unreasonably withheld). The amount
of any such expenses shall accrue interest at the Default Rate if not paid when due and shall constitute &#147;Obligations&#148;. All of the insurance policies required hereby will be evidenced by one or more certificates of insurance, together with
appropriate lender&#146;s loss payee or additional insured clauses or endorsements in favor of the Administrative Agent as required by this Section, delivered to the Administrative Agent on or before the Closing Date and at such other times as the
Administrative Agent may request from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;8.06.</I> <I>Books and Records; Inspection
Rights</I><I>.</I> It will, and will cause each of its Subsidiaries to, keep proper books of record and account in which full, true and correct entries are made of all dealings and transactions in relation to its business and activities in all
material respect. It will, and will cause each of its Subsidiaries to, permit any representatives designated by the Administrative Agent, upon reasonable prior notice and at reasonable times, to visit and inspect its properties, to examine and make
extracts from its books and records, and to discuss its affairs, finances and condition with its officers and independent accountants, all at such reasonable times during normal business hours and with reasonable advance notice as the Administrative
Agent may request. It will, and will cause each of its Subsidiaries to, pay all reasonable and documented <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred by the Administrative Agent
(a)&nbsp;so long as no Default has occurred and is continuing, two (2)&nbsp;such inspections each calendar year and (b)&nbsp;upon the occurrence and&nbsp;during the continuance of a Default, all such inspections. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;8.07.</I> <I>Compliance with Laws</I>. (a)&nbsp;It will, and will cause each of its Subsidiaries to,
(i)&nbsp;comply in all material respects with all Requirements of Law (including Health Care Laws and Environmental Laws) and (ii)&nbsp;comply in all material respects with all terms of outstanding Indebtedness and all Material Agreements, except
where the failure to do so, individually or in the aggregate, would not reasonably be expected to result in a Material Adverse Effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-78- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Each Obligor will maintain, and will cause each of its Subsidiaries to maintain, all
records required to be maintained by a Governmental Authority or otherwise under any applicable Health Care Law, except where failure to do so, individually or in the aggregate, would not reasonably be expected to have a Material Adverse Effect.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Each Obligor will maintain, and will cause each of its Subsidiaries to maintain, a Health Care Compliance Program, which will be
reviewed and updated annually, as necessary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;8.08.</I> <I>Licenses</I><I>.</I> It will, and will cause each
of its Subsidiaries to, obtain and maintain all licenses, authorizations, consents, filings, exemptions, registrations and other Governmental Approvals necessary in connection with the execution, delivery and performance of the Loan Documents, the
consummation of the Transactions or the operation and conduct of its business and ownership of its properties, except where failure to do so would not reasonably be expected to have a Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;8.09.</I> <I>Action under Environmental Laws</I><I>.</I> It will, and will cause each of its Subsidiaries to,
upon a Responsible Officer becoming aware of the release of any Hazardous Materials or the existence of any environmental liability under applicable Environmental Laws with respect to their respective businesses, operations or properties, take all
actions, at their cost and expense, as shall be required by applicable Law to investigate and clean up the condition of their respective businesses, operations or properties, including all required removal, containment and remedial actions, and
restore their respective businesses, operations or properties to a condition, in each case in material compliance with applicable Environmental Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;8.10.</I> <I>Use of Proceeds</I><I>.</I> The proceeds of the Term Loans will be used only as provided in
Section&nbsp;2.05. No part of the proceeds of the Term Loans will be used, whether directly or indirectly, for any purpose that violates any of the regulations of the Board of Governors of the Federal Reserve System, including Regulations&nbsp;T, U
and X. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;8.11.</I> <I>Certain Obligations Respecting Subsidiaries; Further Assurances; Intellectual
Property</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Subsidiaries</I>. It will take such action, and will cause each of its Subsidiaries to take such action, from time
to time as shall be necessary to ensure that all Subsidiaries are &#147;Guarantors&#148; hereunder (other than an Excluded Subsidiary). Without limiting the generality of the foregoing, in the event that any Obligor shall form or acquire any new
Subsidiary, it and its Subsidiaries will promptly and in any event within forty-five (45)&nbsp;days (or such longer time as consented to by the Administrative Agent in writing) of the formation or Acquisition of such Subsidiary: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) cause such new Subsidiary to become a &#147;Guarantor&#148; hereunder, and a &#147;Grantor&#148; under the Security
Documents, pursuant to a Guarantee Assumption Agreement (or, to the extent the new Subsidiary is a Foreign Subsidiary, the equivalent form of document in such Foreign Subsidiary&#146;s jurisdiction); </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-79- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) take such action or cause such Subsidiary to take such action
(including delivering such Equity Interests together with undated transfer powers executed in blank and any intercompany notes with undated endorsements executed in blank) as shall be necessary to create and perfect valid and enforceable first
priority (subject to Permitted Liens) Liens on substantially all of the personal Property of such new Subsidiary as collateral security for the obligations of such new Subsidiary hereunder (or, to the extent such new Subsidiary is a Foreign
Subsidiary, as is customary in such Foreign Subsidiary&#146;s jurisdiction); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) to the extent that the parent of such
Subsidiary is not a party to the Security Documents or has not otherwise pledged Equity Interests in its Subsidiaries in accordance with the terms of the Security Documents and this Agreement, cause the parent of such Subsidiary to execute and
deliver a pledge agreement in favor of the Lenders, in respect of all outstanding issued shares of such Subsidiary; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) deliver such proof of corporate action, incumbency of officers, opinions of counsel and other documents as is consistent
with those delivered by each Obligor pursuant to Section&nbsp;6.01 or as the Majority Lenders shall have requested; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>provided</I> that, solely with
respect to any Subsidiary that is an Excluded Subsidiary, no such actions shall be required other than a pledge by the owner of such Excluded Subsidiary (to the extent such owner is an Obligor) of 100% of the Equity Interests of such Excluded
Subsidiary, which pledge shall not be required to be perfected under the Law of such Excluded Subsidiary&#146;s jurisdiction of formation. In the event one or more Subsidiaries that were previously Excluded Subsidiaries no longer qualify as an
Excluded Subsidiary, such Subsidiary shall be treated as a Guarantor hereunder and shall be required to take such actions set forth in this Section&nbsp;8.11(a) and Section&nbsp;8.11(b). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Further Assurances</I>. It will, and will cause each of its Subsidiaries (other than an Excluded Subsidiary) to, take such action from
time to time as shall reasonably be requested in writing by the Majority Lenders to effectuate the purposes and objectives of this Agreement. Without limiting the generality of the foregoing, it will, and will cause each Person that is required to
be a Guarantor to, take such action from time to time (including executing and delivering such assignments, security agreements, control agreements and other instruments) as shall be reasonably requested in writing by the Majority Lenders to create,
in favor of the Lenders, perfected security interests and Liens (subject to Permitted Liens) in substantially all of the personal Property of such Obligor as collateral security for the Obligations; <I>provided</I> that any such security interest or
Lien shall be subject to the relevant requirements of the Security Documents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Intellectual Property</I>. In the event that any
Obligor creates, develops or acquires Obligor Intellectual Property during the term of this Agreement, then the provisions of this Agreement shall automatically apply thereto and any such Obligor Intellectual Property shall automatically constitute
part of the Collateral under the Security Documents, without further action by any party, in each case from and after the date of such creation, development or acquisition (except that any representations or warranties of any Obligor shall apply to
any such Obligor Intellectual Property only from and after the date, if any, subsequent to such acquisition that such representations and warranties are brought down or made anew as provided herein). In the event that any Obligor holds or acquires
Obligor Intellectual Property during the term of this Agreement, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-80- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
then, upon the request of the Administrative Agent, such Obligor shall take any action as shall be reasonably necessary and reasonably requested by the Administrative Agent to ensure that the
provisions of this Agreement and the Security Agreement shall apply thereto and any such Obligor Intellectual Property shall constitute part of the Collateral under the Security Documents; <I>provided</I> that no Obligor shall be required
(i)&nbsp;to register Intellectual Property, (ii)&nbsp;to file Security Documents other than short-form security interest filings in the United States Patent and Trademark Office and the United States Copyright Office, or (iii)&nbsp;to take any
action that the cost, burden, difficulty or consequence of outweighs the benefit to the Lenders of the security afforded thereby as reasonably determined by the Administrative Agent in consultation with the Administrative Borrower. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;8.12.</I> <I>Termination of Non</I><I><FONT STYLE="white-space:nowrap">-Permitted</FONT> Liens</I><I>.</I> In
the event that any Responsible Officer of an Obligor shall become aware or be notified by the Lenders of the existence of any outstanding Lien against any Property of any Obligor, which Lien is not a Permitted Lien, such Obligor shall use its best
efforts to promptly terminate or cause the termination of such Lien. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;8.13.</I> <I>Non</I><I><FONT
STYLE="white-space:nowrap">-Consolidation</FONT></I><I>.</I> It will, and will cause each of its Subsidiaries to, (a)&nbsp;maintain entity records and books of account separate from those of any other entity which is an Affiliate of such entity; and
(b)&nbsp;not commingle its funds or assets with those of any other entity which is an Affiliate of such entity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;8.14.</I> <I>Anti</I><I><FONT STYLE="white-space:nowrap">-Terrorism</FONT> and Anti</I><I><FONT
STYLE="white-space:nowrap">-Corruption</FONT> Laws</I>. No Obligor shall engage in any transaction that violates any of the applicable prohibitions set forth in any Sanctions Laws, Economic Sanctions Law, Irish Economic Sanctions Laws, <FONT
STYLE="white-space:nowrap">Anti-Terrorism</FONT> Law, Irish Anti-Terrorism Laws, or the <I>US</I><I></I><I>&nbsp;Foreign Corrupt Practices Act of 1977</I> (15&nbsp;USC. <FONT STYLE="white-space:nowrap">&#167;&#167;&nbsp;78dd-1</FONT>
<I>et</I><I></I><I>&nbsp;seq.</I>). None of the funds or assets of such Obligor or any Subsidiary that are used to repay the Term Loans shall constitute property of, or shall be owned by, any Designated Person or, to such Obligor&#146;s knowledge,
be the direct proceeds derived from any transactions that violate the prohibitions set forth in any applicable Sanctions Laws, Economic Sanctions Law or Irish Economic Sanctions Laws, and no Designated Person shall have any direct or indirect
interest in such Obligor insofar as such interest would violate any Sanctions Laws, Economic Sanctions Laws or Irish Economic Sanctions Law applicable to such Obligor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;8.15.</I> <I>Financial Covenants</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Minimum Liquidity</I>. Borrowers shall ensure that the Obligors shall have aggregate Unrestricted Cash of not less than $3,000,000 at
all times. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-81- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Minimum Net Revenue</I>. As of the end of the fiscal quarter ended April&nbsp;30,
2024 and each fiscal quarter thereafter, Intermediate Holdings and its Subsidiaries shall maintain, on a consolidated basis, Net Revenue for the twelve (12)&nbsp;month period most recently ended on such date of not less than the amount set forth in
the table below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP>
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">T<SMALL>WELVE</SMALL><FONT STYLE="white-space:nowrap">-M</FONT><SMALL>ONTH</SMALL>
P<SMALL>ERIOD</SMALL> E<SMALL>NDING</SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">M<SMALL>INIMUM</SMALL>&nbsp;N<SMALL>ET</SMALL>&nbsp;R<SMALL>EVENUE</SMALL></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">April&nbsp;30, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">July&nbsp;31, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">October&nbsp;31, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">January&nbsp;31, 2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">April&nbsp;30, 2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">July&nbsp;31, 2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">October&nbsp;31, 2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">January&nbsp;31, 2026</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">April&nbsp;30, 2026</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">July&nbsp;31, 2026</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">October&nbsp;31, 2026</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">January&nbsp;31, 2027</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">April&nbsp;30, 2027</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">July&nbsp;31, 2027</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">October&nbsp;31, 2027</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">January&nbsp;31, 2028</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">April&nbsp;30, 2028</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to any fiscal quarter for which either financial covenant above could be breached, Intermediate
Holdings shall have the right (the <I>&#147;Cure Right&#148;</I>) to issue equity (which shall be common equity or other equity (such other equity to be on terms reasonably acceptable to the Administrative Agent)) during such fiscal quarter or
thereafter until the date that is ten (10)&nbsp;Business Days after the date that financial statements delivered pursuant to Section&nbsp;8.01(b) are required to be delivered for cash or otherwise receive cash contributions in respect of such equity
(the <I>&#147;Cure Amount&#148;</I>) deposited in a Controlled Account, and thereupon Borrowers&#146; compliance with the applicable financial covenant shall be recalculated giving effect to the following pro forma adjustment: (a)&nbsp;with respect
to the Minimum Liquidity covenant, Borrowers&#146; Unrestricted Cash balance shall be increased or (b)&nbsp;with respect to the Net Revenue covenant, Borrowers&#146; Net Revenue shall be increased, in each case solely for the purposes of determining
compliance with the applicable financial covenant, including, with respect to the Net Revenue covenant, determining compliance with the such financial covenant as of the end of such fiscal quarter and applicable subsequent periods that include such
fiscal quarter, by an amount equal to the Cure Amount; <I>provided</I> that with respect to the Net Revenue covenant, Borrowers&#146; Net Revenue shall be increased with respect to such applicable fiscal quarter only. If, after giving effect to the
foregoing recalculations, the requirements of the applicable financial covenant shall be satisfied, then the requirements of the applicable financial covenant shall be deemed satisfied with the same effect as though there had been no failure to
comply therewith at such date, and the applicable </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-82- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Event of Default with respect to the applicable financial covenant that had occurred shall be deemed cured for the purposes of this Agreement. Notwithstanding anything herein to the contrary,
(a)&nbsp;in each four consecutive fiscal quarter period there shall be at least two fiscal quarters in which the Cure Right is not exercised, (b)&nbsp;the Cure Right may not be exercised in two consecutive fiscal quarters, (c)&nbsp;during the term
of this Agreement, the Cure Right shall not be exercised more than two times with respect to each financial covenant, (d)&nbsp;the Cure Amount shall be in an amount equal to two times the amount required for purposes of complying with the applicable
financial covenant (it being understood that only the amount required to comply with the applicable financial covenant shall be included in the calculation of the Cure Amount), (e)&nbsp;upon the Lender&#146;s receipt of a written notice from
Administrative Borrower that it intends to exercise the Cure Right (a <I>&#147;Notice of Intent to Cure&#148;</I>), until the tenth (10<SUP STYLE="font-size:75%; vertical-align:top">th</SUP>) Business Day following the date that financial statements
for the fiscal quarter to which such Notice of Intent to Cure relates are required to be delivered, neither the Administrative Agent nor the Lenders shall exercise the right to accelerate the Obligations or terminate any unused Commitments, and the
Lender shall not exercise any right to foreclose on or take possession of the Collateral or any other right or remedy under this Agreement solely on the basis of such Event of Default having occurred and being continuing under the applicable
financial covenant and (f)&nbsp;the Cure Amount shall be disregarded for any other purpose. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;8.16.</I>
<I>Maintenance of Regulatory Approvals, Contracts, Intellectual Property, Etc.</I> With respect to each Product, such Obligor will, and will cause each of its Subsidiaries (to the extent applicable) to: (a)&nbsp;maintain in full force and effect all
material Regulatory Approvals (including the Product Authorizations), Material Agreements, or other material rights necessary for the current operations of such Obligor&#146;s or such Subsidiary&#146;s business, as the case may be, including in
respect of all related Product Development and Commercialization Activities, (b)&nbsp;maintain in full force and effect all Material Intellectual Property that is necessary for related Product Development and Commercialization Activities and
(c)&nbsp;use commercially reasonable efforts to pursue and maintain in full force and effect legal protection for all new, Material Intellectual Property developed or controlled by such Obligor or any of its Subsidiaries, as the case may be, that is
necessary for Product Development and Commercialization Activities relating to any Product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;8.17.</I>
<I>Cash Management</I>. (a)&nbsp;It will: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) maintain all Deposit Accounts, Securities Accounts, Commodity Accounts and
lockboxes (other than Excluded Accounts) with a bank or financial institution that has executed and delivered to the Administrative Agent a springing account control agreement, in form and substance reasonably acceptable to the Administrative Agent
(each such Deposit Account, Securities Account, Commodity Account and lockbox, a <I>&#147;Controlled Account&#148;</I>); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) deposit promptly, and in any event no later than five (5)&nbsp;Business Days after the date of receipt thereof, all cash,
checks, drafts or other similar items of payment relating to or constituting payments made in respect of any and all accounts and other rights and interests into Controlled Accounts; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-83- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) deposit promptly, and in any event no later than five
(5)&nbsp;Business Days after the date of receipt thereof, all proceeds received by an Obligor pursuant to the Sponsor Equity Commitment Letter into a Controlled Account in the name of OpCo. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) In order to segregate and to facilitate perfection of the security interest in any funds an Obligor receives from Third-Party Payor
Programs, to the extent any Obligor receives payments from a Federal Health Care Program as of the Closing Date, such Obligor shall, within sixty (60)&nbsp;days after the Closing Date (or such later date as may be agreed to by the Administrative
Agent) (or, with respect to future participation in any Federal Health Care Program, prior to such Obligor&#146;s receipt of payments from such Federal Health Care Program) notify all Governmental Authorities making any payments under any Federal
Health Care Program to make any such payments only to one or more Segregated Health Care Accounts. No Obligor shall deposit any funds to a Segregated Health Care Account or direct or permit any other Person to deposit any funds to a Segregated
Health Care Account, other than payments received from Federal Health Care Program. The Obligors shall have until the date that is one hundred fifty (150)&nbsp;days following (i)&nbsp;the Closing Date, or (ii)&nbsp;the date the applicable Obligor
begins receiving payments from any Federal Health Care Program, to cause all amounts deposited into the Segregated Health Care Accounts to be automatically swept on a daily basis to a Controlled Account pursuant to a Sweep Agreement; <I>provided</I>
that, in each case, the Obligors shall have the option to extend the foregoing requirement by an additional thirty (30)&nbsp;days by written notice to the Administrative Agent if the Obligors are working in good faith to enter into such Sweep
Agreement (as determined by the Administrative Agent in its reasonable discretion). Any such Sweep Agreement will require such depository bank to waive all of its existing and future rights of recoupment and
<FONT STYLE="white-space:nowrap">set-off</FONT> and banker&#146;s lien against any Segregated Health Care Accounts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;8.18.</I> <I>Observer Rights</I>. Until the Obligations have been paid in full in cash, the Obligors shall
permit the Administrative Agent on behalf of all of the Lenders (the<I> </I><I>&#147;</I><I>Observer</I><I>&#148;</I>) to attend and observe (but not vote) at all meetings of OpCo&#146;s Board, whether in person, by telephone or otherwise as
requested by such Obligor; <I>provided</I> that the Observer shall not be permitted to attend any committee meetings or executive sessions. OpCo shall notify the Observer in writing at the same time as furnished to members or the applicable
committee of (a)&nbsp;the date and time for each general or special meeting of OpCo&#146;s Board and (b)&nbsp;the adoption of any resolutions or actions by the Board by written consent (describing, in reasonable detail, the nature and substance of
such action). OpCo shall concurrently deliver to the Observer all notices and any materials delivered by OpCo to its Board in connection with a meeting or action to be taken by written consent, including a draft of any material resolutions or
actions proposed to be adopted by written consent. The Observer shall be free prior to such meeting or adoption by written consent to contact members of the Board and discuss the pending actions to be taken. Notwithstanding the foregoing, the
Observer shall not be entitled to receive materials relating to, or be in attendance for, any discussions relating to topics which (a)&nbsp;are subject to attorney client privilege, (b)&nbsp;present a conflict of interest for the Observer or
(c)&nbsp;are trade secrets, <FONT STYLE="white-space:nowrap">know-how</FONT> or other commercially sensitive information. All such discussions and materials shall be subject to the confidentiality provisions set forth in Section&nbsp;13.17. If at
any time the functions of the Board of Opco is performed by any direct or indirect parent of Opco and Opco ceases to have a Board attended by representative of the Sponsor, Opco shall cause any such parent entity to provide the rights set forth
above to the Observer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-84- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;8.19.</I> <I>COMI</I>. The Irish Obligor will maintain its
COMI in Ireland and not have an establishment (within the meaning of the EU Insolvency Regulation) outside Ireland. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;8.20.</I> <I>Post</I><I><FONT STYLE="white-space:nowrap">-Closing</FONT> Obligations</I>. Within the time
periods specified on Schedule&nbsp;8.20 (as each may be extended by the Administrative Agent in its sole discretion), complete such undertakings as are set forth on Schedule&nbsp;8.20. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>RTICLE</SMALL>&nbsp;9. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N<SMALL>EGATIVE</SMALL> C<SMALL>OVENANTS</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each Obligor covenants and agrees with the Administrative Agent and the Lenders that, until the Commitments have expired or been terminated
and all Obligations (other than inchoate indemnity obligations) have been paid in full in cash: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;9.01.</I>
<I>Indebtedness</I><I>.</I> It will not, and will not permit any of its Subsidiaries to, create, incur, assume or permit to exist any Indebtedness, whether directly or indirectly, except: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) the Obligations; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Indebtedness existing on the date hereof and set forth in Schedule&nbsp;7.13A and Permitted Refinancings thereof; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) intercompany Indebtedness: (i)&nbsp;among&nbsp;Obligors;<I> provided</I> such Indebtedness is pledged to the Administrative
Agent for the benefit of the Lenders under the Security Agreement and otherwise subordinate in right of payment to the Obligations pursuant to an Intercompany Subordinated Demand Promissory Note; (ii)&nbsp;among Subsidiaries that are not Obligors;
and (iii)&nbsp;so long as no Default or Event of Default shall occurred and is continuing, (i)&nbsp;Indebtedness owed by a Foreign Subsidiary to an Obligor in an aggregate amount not to exceed, together with Investments made in Foreign Subsidiaries
pursuant to Section&nbsp;9.05(m) and transfers of property to Foreign Subsidiaries made pursuant to Section&nbsp;9.09(f)(iii), $250,000 in any fiscal year and (ii)&nbsp;Indebtedness owed by a Subsidiary which is not an Obligor to an Obligor in an
aggregate amount not to exceed, together with Investments made in Subsidiaries which are not Obligors pursuant to Section&nbsp;9.05(m) and transfers of property to Subsidiaries which are not Obligors made pursuant to Section&nbsp;9.09(f)(iii),
$100,000 in any fiscal year; <I>provided</I> that the amount of any intercompany Indebtedness owed by the payor to the payee and the corresponding amount of intercompany Investment made by the payee in such payor arising out of such intercompany
Indebtedness shall only be counted once for purpose of determining the cap set forth above; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) accounts payable to trade
creditors for goods and services and current operating liabilities (not the result of the borrowing of money) incurred in the Ordinary Course of Business; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-85- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) Indebtedness consisting of Guarantees resulting from endorsement of
negotiable instruments for collection by it or any of its Subsidiaries in the Ordinary Course of Business; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) (i)
Guarantees by any Obligor of Indebtedness of any other Obligor or (ii)&nbsp;Guarantees by any Obligor of Indebtedness of a Subsidiary not constituting an Obligor, to the extent permitted pursuant to Section&nbsp;9.05(n); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) Purchase money Indebtedness and Capital Lease Obligations; <I>provided</I> that (i)&nbsp;if secured, the collateral
therefor consists solely of the assets being financed, the products and proceeds thereof and books and records related thereto; (ii)&nbsp;in the case of purchase money Indebtedness, such Indebtedness shall not constitute less than 75% of the
aggregate consideration paid with respect to such asset; and (iii)&nbsp;the aggregate outstanding principal amount of such Indebtedness does not exceed $1,000,000 at any time; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) workers&#146; compensation Claims, payment obligations in connection with health, disability or other types of social
security benefits, unemployment or other insurance obligations, reclamation and statutory obligations, in each case incurred in the Ordinary Course of Business; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Indebtedness under Hedging Agreements permitted pursuant to Section&nbsp;9.05(f); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) Indebtedness of Intermediate Holdings and its Subsidiaries with respect to corporate credit cards not to exceed $650,000 at
any time outstanding; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) the Existing Letters of Credit; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) reimbursement obligations in connection with letters of credit that are secured by cash or cash equivalents and issued on
behalf of an Obligor, not to exceed $500,000 at any time outstanding; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) Indebtedness consisting of financing of
insurance premiums incurred in the ordinary course of business not to exceed at any time the amount of such insurance premiums; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) Indebtedness with respect to performance bonds, appeal bonds and other similar obligations not to exceed $500,000 in the
aggregate; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) so long as no Default shall have occurred and is continuing at the time of such Indebtedness is incurred,
or after giving effect thereto, other unsecured Indebtedness in an aggregate principal amount not to exceed $500,000 at any time outstanding; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) Sponsor Convertible Notes on terms and provisions (including a subordination agreement) satisfactory to the Administrative
Agent. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-86- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;9.02.</I> <I>Liens</I><I>.</I> It will not, and will not
permit any of its Subsidiaries to, create, incur, assume or permit to exist any Lien on any Property now owned by it, except: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Liens securing the Obligations; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) any Lien on any Property of any Obligor existing on the date hereof and set forth in Schedule&nbsp;7.13B; <I>provided</I>
that (i)&nbsp;no such Lien shall extend to any other Property of such Obligor and (ii)&nbsp;any such Lien shall secure only those obligations which it secures on the date hereof and extensions, renewals and replacements thereof that do not increase
the outstanding principal amount thereof; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Liens securing Indebtedness permitted under Section&nbsp;9.01(g);
<I>provided</I> that such Liens are restricted solely to the collateral described in Section&nbsp;9.01(g); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Liens
imposed by Law which were incurred in the Ordinary Course of Business, including (but not limited to) carriers&#146;, warehousemen&#146;s, landlords&#146; and mechanics&#146; Liens, Liens relating to leasehold improvements and other similar liens
arising in the Ordinary Course of Business and which (i)&nbsp;do not in the aggregate materially detract from the value of the Property subject thereto or materially impair the use thereof in the operations of the business of such Person or
(ii)&nbsp;are being contested in good faith by appropriate proceedings, which proceedings have the effect of preventing the forfeiture or sale of the Property subject to such Liens and for which adequate reserves have been made if required
substantially in accordance with GAAP; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) Liens, pledges or deposits made in the Ordinary Course of Business in
connection with bids, Contracts, leases, appeal bonds, workers&#146; compensation, unemployment insurance or other similar social security legislation; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) Liens securing Taxes, assessments and other governmental charges, the payment of which is not yet due or is being contested
in good faith by appropriate proceedings promptly initiated and diligently conducted and for which such reserve or other appropriate provisions, if any, as shall be required by GAAP shall have been made; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) servitudes, easements, rights of way, restrictions and other similar encumbrances on real Property imposed by applicable
Laws and encumbrances consisting of zoning or building restrictions, easements, licenses, restrictions on the use of Property or minor imperfections in title thereto which, in the aggregate, are not material, and which do not in any case materially
detract from the value of the Property subject thereto or interfere with the ordinary conduct of the business of any of the Obligors; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) bankers&#146; Liens, rights of setoff and similar Liens incurred in the Ordinary Course of Business and arising in
connection with the Obligors&#146; deposit accounts or securities accounts held at financial institutions solely to secure payment of fees and similar costs and expenses of such financial institutions with respect to such accounts; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Liens in connection with transfers permitted under Section&nbsp;9.09; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-87- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) any judgment Lien or Lien arising from decrees or attachments not
constituting an Event of Default; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) leases or subleases of real property granted in the Ordinary Course of Business, and
leases, subleases, nonexclusive licenses or sublicenses of personal property (other than Intellectual Property) granted in the Ordinary Course of Business; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) Liens in favor of customs and revenue authorities arising as a matter of law to secure the payment of custom duties in
connection with the importation of goods, not securing an amount in the aggregate in excess of $100,000 at any given time; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) Liens on a deposit account of the Obligors and the cash and cash equivalents therein, in each case, securing Indebtedness
described in Section&nbsp;9.01(j); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) Permitted Licenses solely to the extent that such Permitted License would
constitute a Lien; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) Liens on cash collateral securing reimbursement obligations of the applicable Person under letters
of credit to the extent permitted pursuant to Section&nbsp;9.01(k) or (l); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) deposits as security for contested taxes or
contested import or customs duties in an aggregate amount not to exceed $1,000,000; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q) other Liens securing
obligations (other than Indebtedness for borrowed money) in an aggregate amount not to exceed $500,000; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>provided</I> that no Lien
otherwise permitted under any of the foregoing Sections 9.02 (excluding Sections 9.02(a) and 9.02(n)) shall apply to any Material Intellectual Property to secure any Indebtedness. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;9.03.</I> <I>Fundamental Changes and Acquisitions</I><I>.</I> It will not, and will not permit any of its
Subsidiaries to, (a)&nbsp;enter into or consummate any transaction of merger, amalgamation or consolidation, including without limitation, a <FONT STYLE="white-space:nowrap">reverse-triangular</FONT> merger, or other similar transaction or series of
related transactions, (b)&nbsp;liquidate, wind up or dissolve itself (or suffer any liquidation or dissolution) (including in connection with any division or plan of division under Delaware law or any comparable event under a different
jurisdiction&#146;s laws), (c)&nbsp;make or consummate any Acquisition, (d)&nbsp;make any public offering or (e)&nbsp;sell or issue any Disqualified Equity Interests, except: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Investments permitted under Section&nbsp;9.05; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) Permitted Acquisitions for aggregate consideration for all such acquisitions not to exceed $10,000,000 in the aggregate
during for the course of this Agreement (which may include net proceeds of a substantially concurrent issuance of Qualified Equity Interests issued specifically for the purpose of funding such Permitted Acquisitions in an aggregate amount not to
exceed $5,000,000 during the course of this Agreement); </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-88- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) the merger, amalgamation or consolidation of any Obligor with or into
any other Obligor, <I>provided</I> that if a Borrower is a party to such merger, amalgamation or consolidation, such Borrower shall be the surviving entity; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) a Qualified Public Offering and a Permitted IPO Reorganization in connection therewith. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;9.04.</I> <I>Lines of Business</I><I>.</I> It will not, and will not permit any of its Subsidiaries to, engage
to any material extent in any business other than the business engaged in on the date hereof by such Obligor, or a business reasonably related, incidental or complementary thereto or reasonable extensions thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;9.05.</I> <I>Investments</I><I>.</I> It will not, and will not permit any of its Subsidiaries to, make, directly
or indirectly, or permit to remain outstanding any Investments except: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Investments outstanding on the date hereof and
identified in Schedule&nbsp;9.05 and any modification, replacement, renewal or extension thereof to the extent not involving new or additional Investments; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) operating deposit accounts with banks; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) extensions of credit in the nature of accounts receivable or notes receivable arising from the sales of goods or services
in the Ordinary Course of Business; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Permitted Cash Equivalent Investments (or were Permitted Cash Equivalents at the
time acquired); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) (i)&nbsp;Investments consisting of 100% of the ownership of the Equity Interests of its Subsidiaries
and (ii)&nbsp;intercompany Investments by a Borrower or a Subsidiary in any Subsidiary Guarantor; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) Hedging Agreements
entered into in the ordinary course of any Obligor&#146;s financial planning solely to hedge interest rate risks (and not for speculative purposes) in respect of Permitted Indebtedness and in aggregate amount for all such Hedging Agreements not in
excess of $500,000; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) Investments consisting of prepaid expenses, negotiable instruments held for collection or deposit,
security deposits with utilities, landlords and other like Persons, and deposits in connection with workers&#146; compensation and similar deposits, in each case made in the Ordinary Course of Business; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-89- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) Investments received in connection with any Insolvency Proceedings in
respect of any customers, suppliers or clients and in settlement of delinquent obligations of, and other disputes with, customers, suppliers or clients; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Investments permitted under Section&nbsp;9.01(c) and Section&nbsp;9.03; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) Investments consisting of notes receivable of, or prepaid royalties and other credit extensions, to customers and suppliers
who are not Affiliates, in the Ordinary Course of Business; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) Investments consisting of (i)&nbsp;travel advances and
employee relocation loans and other employee loans and advances in the Ordinary Course of Business, and (ii)&nbsp;loans to employees, officers or managers relating to the purchase of equity securities of Intermediate Holdings or its Subsidiaries
pursuant to employee stock purchase plans or agreements in an aggregate amount not to exceed $250,000 for subclauses&nbsp;(i) and (ii)&nbsp;in any fiscal year; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) <FONT STYLE="white-space:nowrap">non-cash</FONT> Investments in joint ventures or strategic alliances in the Ordinary
Course of Business consisting of the <FONT STYLE="white-space:nowrap">non-exclusive</FONT> licensing of technology, the development of technology or the providing of technical support; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) Investments consisting of loans not involving the net transfer on a substantially contemporaneous basis of cash proceeds to
employees, officers or directors relating to the purchase of capital stock of the Administrative Borrower pursuant to employee stock purchase plans or other similar agreements, as approved by Administrative Borrower&#146;s board of directors and not
to exceed $500,000 in the aggregate; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) so long as no Default or Event of Default shall occurred and is continuing,
Investments (i)&nbsp;in Foreign Subsidiaries in an aggregate amount not to exceed, together with Indebtedness of Foreign Subsidiaries pursuant to Section&nbsp;9.01(c) and transfers of property to Foreign Subsidiaries made pursuant to
Section&nbsp;9.09(f)(iii), $250,000 in any fiscal year and (ii)&nbsp;in Subsidiaries which are not Obligors, in an aggregate amount not to exceed, together with Indebtedness of Subsidiaries which are not Obligors pursuant to Section&nbsp;9.01(c) and
transfers of property to Subsidiaries which are not Obligors made pursuant to Section&nbsp;9.09(f)(iii), $100,000 in any fiscal year; <I>provided</I> that the amount of any intercompany Indebtedness owed by the payor to the payee and the
corresponding amount of intercompany Investment made by the payee in such payor arising out of such intercompany Indebtedness shall only be counted once for purpose of determining the cap set forth above; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) so long as no Default shall have occurred and is continuing at the time of such Investment, or after giving effect thereto,
other Investments in an amount not to exceed $500,000 in any fiscal year. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-90- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;9.06.</I> <I>Restricted Payments</I><I>.</I> It will not, and
will not permit any of its Subsidiaries to, declare or make, or agree to pay or make, directly or indirectly, any Restricted Payment, other than: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) dividends or distributions with respect to any Equity Interests of a Borrower or any of its Subsidiaries payable solely in
additional units of its Qualified Equity Interests; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) any Restricted Payment by a Subsidiary to a Borrower; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) any purchase, redemption, retirement, or other Acquisition by Intermediate Holdings or any of its Subsidiaries of units of
its Equity Interests with the proceeds received from a substantially concurrent issue of a new units of its Equity Interests; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) dividends or distributions paid by any Guarantor to any other Obligor; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) cashless exercises of options and warrants; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) repurchases pursuant to the terms of employee incentive plans, manager or consultant incentive plans, or similar plans in
an aggregate amount not to exceed $500,000 in any fiscal year; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) any dividends, distributions or payment in respect of
or the redemption, retirement or purchase of any capital stock constituting any part of a Permitted IPO Reorganization, so long as, in each case, the assets or other property (including for the avoidance of doubt, cash and Intellectual Property)
transferred in connection with such Permitted IPO Reorganization remains the assets or property of the Obligors (e.g., no dividend, distribution or payment of any assets or property is permitted to any entity that is not an Obligor); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) any purchase of shares of capital stock from minority shareholders in an amount not to exceed $100,000 in the aggregate;
and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) (x) cash payments made directly or indirectly to Parent or any other parent company of Intermediate Holdings, the
proceeds which shall be used to pay operating costs and documented expenses of such parent entities incurred in the ordinary course of business and other corporate overhead costs and documented expenses (including administrative, legal, accounting
and similar documented expenses provided by third parties), which are attributable to the ownership and operations of Intermediate Holdings and its Subsidiaries, in an aggregate amount not to exceed $500,000 in any fiscal year and (y)&nbsp;cash
payments in respect of transaction expenses in connection with equity issuances by Intermediate Holdings or any direct or indirect parent thereof, to the extent the cash proceeds of such equity issuances have been contributed to the Administrative
Borrower (and in an amount not to exceed such cash proceeds so contributed). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-91- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;9.07.</I> <I>Payments of Indebtedness</I><I>.</I> It will not,
and will not permit any of its Subsidiaries to, make any payments in respect of any Material Indebtedness incurred under Section&nbsp;9.01(o) other than, so long as no Event of Default shall have occurred and is continuing, payment of regularly
scheduled interest payments or principal payments at maturity, any Permitted Refinancing thereof or the conversion of such Material Indebtedness into Qualified Equity Interests. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;9.08.</I> <I>Change in Fiscal Year</I><I>.</I> It will not, and will not permit any of its Subsidiaries to,
change the last day of its fiscal year from that in effect on the date hereof, without prior written notice to the Administrative Agent, except to change the fiscal year of a Subsidiary acquired in connection with a Permitted Acquisition to conform
its fiscal year to that of Borrowers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;9.09.</I> <I>Sales of Assets, Etc</I><I>.</I> It will not, and will
not permit any of its Subsidiaries to, sell, lease, exclusively license (in terms of geography or field of use), as a licensor, transfer (including in connection with any division or plan of division under Delaware law or any comparable event under
a different jurisdiction&#146;s laws) or otherwise dispose of any of its Property (including accounts receivable and Equity Interests of Subsidiaries), or forgive, release or compromise any amount owed to any Obligor or any of its Subsidiaries, in
each case, in one transaction or series of transactions (any thereof, an <I>&#147;</I><I>Asset Sale</I><I>&#148;</I>), except: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) transfers of cash in the Ordinary Course of Business for equivalent value; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) sales or leases of inventory in the Ordinary Course of Business on ordinary business terms; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) the forgiveness, release or compromise of any amount owed to any Obligor in the Ordinary Course of Business; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) entering into, or becoming bound, by a Permitted License to the extent not otherwise prohibited by this Agreement; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) development and other collaborative arrangements where such arrangements provide for the license or disclosure of Patents,
Trademarks, Copyrights or other Intellectual Property rights of any Obligor in the Ordinary Course of Business; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f)
transfers of Property (i)&nbsp;among Obligors, (ii)&nbsp;among Subsidiaries that are not Obligors and (iii)&nbsp;by an Obligor to a Subsidiary that is not an Obligor, in an aggregate amount not to exceed for this clause (iii), (x) with respect to
transfers to Foreign Subsidiaries, together with Indebtedness of Foreign Subsidiaries pursuant to Section&nbsp;9.01(c) and investments in Foreign Subsidiaries made pursuant to Section&nbsp;9.05(m), $250,000 in any fiscal year and (y)&nbsp;with
respect to transfers to Subsidiaries which are not Obligors, together with Indebtedness of Subsidiaries which are not Obligors pursuant to Section&nbsp;9.01(c) and investments in Subsidiaries which are not Obligors made pursuant to
Section&nbsp;9.05(m), $100,000 in any fiscal year;<U> </U><I>provided</I> that the amount of any intercompany Indebtedness owed by the payor to the payee and the corresponding amount of intercompany Investment made by the payee in such payor arising
out of such intercompany Indebtedness shall only be counted once for purpose of determining the cap set forth above; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-92- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) a sale, lease, exclusive license, transfer or other disposition
(including by way of abandonment, cancellation or <FONT STYLE="white-space:nowrap">trade-in)</FONT> of any Property that is obsolete, worn out, surplus or no longer used or useful in connection with the business of the Obligors or with respect to
which a newer and improved version is available; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) dispositions resulting from Casualty Events; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) any transaction permitted under Section&nbsp;9.02, 9.03, 9.05 and 9.20; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) so long as no Default shall have occurred and is continuing at the time of such Asset Sale or after giving effect thereto,
Asset Sales of other property not to exceed $500,000 in the aggregate per fiscal year; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) cross-licenses (including
by way of exclusive licenses) of Intellectual Property subject to cross-license with Medtronic, Inc. and Stryker in existence of the Closing Date (including pursuant to litigation settlements) so long as any license so granted to third parties is of
equivalent value to the license so received by the Administrative Borrower or any Subsidiary, as determined by the Administrative Borrower in good faith. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;9.10.</I> <I>Transactions with Affiliates</I><I>.</I> It will not, and will not permit any of its Subsidiaries
to, sell, lease, license or otherwise transfer any assets to, or purchase, lease, license or otherwise acquire any assets from, or otherwise engage in any other transactions with, any of its Affiliates, except: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) transactions between or among the Obligors; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) any transaction permitted under Section&nbsp;9.01, 9.05, 9.06 or 9.09; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) customary compensation and indemnification of, and other employment arrangements with, directors, officers and employees of
any Obligor in the Ordinary Course of Business; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) transactions upon fair and reasonable terms that are no less favorable
to any Obligor than would be obtained in a comparable <FONT STYLE="white-space:nowrap">arm&#146;s-length</FONT> transaction with a Person not an Affiliate; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) the transactions set forth on Schedule&nbsp;9.10; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) transactions constituting any part of a Permitted IPO Reorganization and otherwise permitted herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;9.11.</I> <I>Restrictive Agreements</I><I>.</I> It will not, and will not permit any of its Subsidiaries to,
directly or indirectly, enter into, incur or permit to exist any Restrictive Agreement other than (a)&nbsp;restrictions and conditions imposed by Law or by the Loan Documents, (b)&nbsp;Restrictive Agreements listed on Schedule&nbsp;7.15,
(c)&nbsp;Organizational Documents of an Obligor as in effect on the date hereof or (d)&nbsp;limitations associated with Permitted Liens or with any transaction permitted under Sections&nbsp;9.01, 9.03, 9.05, 9.06 or 9.09. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-93- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;9.12.</I> <I>Organizational Documents, Material
Agreements</I>. (a)&nbsp;Except in connection with a Permitted IPO Reorganization, it will not, and will not permit any of its Subsidiaries to, enter into any amendment to or modification of any Organizational Document without the prior written
consent of the Administrative Agent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) It will not, and will not permit any of its Subsidiaries to (i)&nbsp;enter into any material
waiver, amendment or modification of any Material Agreement (including, but not limited to, any amendments to provisions relating to pricing and term) that would be reasonably expected to adversely affect the Lenders in any material respect or
(ii)&nbsp;take or omit to take any action that results in the termination of, or permits any other Person to terminate, any Material Agreement or Material Intellectual Property that would be reasonably expected to adversely affect the Lenders in any
material respect, without, in each case, the prior written consent of the Administrative Agent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;9.13.</I>
<I>Holding Company</I>. Intermediate Holdings shall not: (a)&nbsp;incur, directly or indirectly, any Indebtedness or any other obligation or liability whatsoever other than the Obligations; (b)&nbsp;create or suffer to exist any Lien upon any
property or assets now owned or hereafter acquired by it other than the Liens created under the Security Documents to which it is a party or permitted pursuant to Section&nbsp;9.02; (c)&nbsp;engage in any business or activity or own any assets other
than: (i)&nbsp;holding 100% of the Equity Interests of West Affum Corp.; (ii)&nbsp;performing its obligations and activities incidental thereto under the Loan Documents; and (iii)&nbsp;making Restricted Junior Payments and Investments to the extent
permitted by this Agreement; (d)&nbsp;consolidate with or merge with or into, or convey, transfer or lease all or substantially all its assets to, any Person; (e)&nbsp;sell or otherwise dispose of any Equity Interests of any of its Subsidiaries;
(f)&nbsp;create or acquire any Subsidiary or make or own any Investment in any Person other than West Affum Corp.; or (g)&nbsp;fail to hold itself out to the public as a legal entity separate and distinct from all other Persons. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;9.14.</I> <I>Sales and Leasebacks</I><I>.</I> Except as permitted by Section&nbsp;9.01(g), it will not, and will
not permit any of its Subsidiaries to, become liable, directly or indirectly, with respect to any lease, whether an operating lease or a Capital Lease Obligation, of any Property (whether real, personal, or mixed), whether now owned or hereafter
acquired, which (a)&nbsp;any Obligor has sold or transferred or is to sell or transfer to any other Person and (b)&nbsp;any Obligor intends to use for substantially the same purposes as Property which has been or is to be sold or transferred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;9.15.</I> <I>Hazardous Material</I><I>.</I> It will not, and will not permit any of its Subsidiaries to, use,
generate, manufacture, install, treat, release, store or dispose of any Hazardous Material, except in compliance with all applicable Environmental Laws or where the failure to comply would not reasonably be expected to result in a Material Adverse
Change. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;9.16.</I> <I>Accounting Changes</I><I>.</I> It will not, and will not permit any of its
Subsidiaries to, make any significant change in accounting treatment, except as required or permitted by GAAP. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-94- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;9.17.</I> <I>Compliance with ERISA</I><I>.</I> No Obligor
shall cause or permit to exist&nbsp;any event that would result in the imposition of a Lien with respect to any Title&nbsp;IV Plan or Multiemployer Plan or&nbsp;any other ERISA Event that would, in the aggregate, have a Material Adverse Effect. No
Obligor shall cause or permit to exist any event that would result in the imposition of a Lien with respect to any Benefit Plan that would have a Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;9.18.</I> <I>Outbound Licenses.</I> It will not, and will not permit any of its Subsidiaries to, enter into or
become bound by any outbound license or agreement unless such outbound license or agreement is a Permitted License. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;9.19.</I> <I>Inbound Licenses</I><I>.</I> It will not, and will not permit any of its Subsidiaries to, enter
into or become bound by any inbound license or agreement (other than Permitted Licenses) unless (a)&nbsp;no Default has occurred and is continuing, (b)&nbsp;such Obligor has provided written notice to the Administrative Agent of the material terms
of such license or agreement with a description of its anticipated and projected impact on such Obligor&#146;s business or financial condition, and (c)&nbsp;such Obligor has taken such commercially reasonable actions as the Administrative Agent may
reasonably request to obtain the consent of, or waiver by, any Person whose consent or waiver is necessary for the Administrative Agent to be granted a valid and perfected security interest in such license or agreement allowing the Administrative
Agent to fully exercise its rights under any of the Loan Documents in the event of a disposition or liquidation of the rights, assets or property that is the subject of such license or agreement; <I>provided</I> that the aggregate consideration paid
for all such inbound licenses pursuant to this Section&nbsp;9.19 shall not exceed an amount equal to $2,500,000 per fiscal year. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>RTICLE</SMALL>&nbsp;10. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>E<SMALL>VENTS</SMALL> <SMALL>OF</SMALL> D<SMALL>EFAULT</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;10.01.</I> <I>Events of Default</I><I>.</I> Each of the following events shall constitute an
<I>&#147;</I><I>Event of Default</I><I>&#148;</I>: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Borrowers shall fail to pay any principal of the Term Loans when
and as the same shall become due and payable, whether at the due date thereof or at a date fixed for prepayment thereof or otherwise; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) any Obligor shall fail to pay any Obligation (other than an amount referred to in Section&nbsp;10.01(a)) when and as the
same shall become due and payable, and such failure shall continue unremedied for a period of three (3)&nbsp;Business Days; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) any representation or warranty made by or on behalf of an Obligor or any of its Subsidiaries in or in connection with this
Agreement or any other Loan Document or any amendment or modification hereof or thereof, or in any report, certificate, financial statement or other document furnished pursuant to or in connection with this Agreement or any other Loan Document or
any amendment or modification hereof or thereof, shall: (i)&nbsp;prove to have been incorrect when made or deemed made to the extent that such representation or warranty contains any materiality or Material Adverse Effect qualifier; or
(ii)&nbsp;prove to have been incorrect in any material respect when made or deemed made to the extent that such representation or warranty does not otherwise contain any materiality or Material Adverse Effect qualifier; or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-95- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) any Obligor shall fail to observe or perform any covenant, condition or
agreement contained in Sections&nbsp;8.01, 8.02, 8.03(a) (with respect to a Borrower&#146;s existence), 8.10, 8.11(a), 8.13, 8.15 (subject to the last paragraph of Section&nbsp;8.15), 8.17, 8.18 (solely with respect to any act of denying the right
of the Observer&#146;s attendance and observation of a meeting of OpCo&#146;s Board (or any direct or indirect parent entity of OpCo, if applicable) and the Observer&#146;s access to such Board or preventing such attendance or observation), 8.20 or
Article&nbsp;9; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) any Obligor shall fail to observe or perform any covenant, condition or agreement contained in this
Agreement (other than those specified in Section&nbsp;10.01(a), (b) or (d)) or any other Loan Document, and, in the case of any failure that is capable of cure, such failure shall continue unremedied for a period of thirty (30)&nbsp;or more days
after the occurrence thereof; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) any Obligor shall fail to make any payment in respect of any Material Indebtedness,
when and as the same shall become due and payable after giving effect to any applicable grace or cure period as originally provided by the terms of such Indebtedness; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) [reserved]; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) (i)&nbsp;any &#147;event of default&#148; or similar event under, the Contract governing any Material Indebtedness shall
occur and such &#147;event of default&#148; or similar event shall continue unremedied, uncured or unwaived after a period of five (5)&nbsp;Business Days after the expiration of any cure period thereunder, or (ii)&nbsp;any event or condition occurs
(A)&nbsp;that results in any Material Indebtedness becoming due prior to its scheduled maturity or (B)&nbsp;that enables or permits (with or without the giving of notice, the lapse of time or both) the holder or holders of such Material Indebtedness
or any trustee or agent on its or their behalf to cause such Material Indebtedness to become due, or to require the prepayment, repurchase, redemption or defeasance thereof, prior to its scheduled maturity; <I>provided</I> that this
Section&nbsp;10.01(h) shall not apply to secured Indebtedness that becomes due as a result of the voluntary sale or transfer of the Property securing such Material Indebtedness; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) any Obligor or any of its Subsidiaries: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) ceases to be Solvent, or generally does not or becomes unable to pay its debts or meet its liabilities as the same become
due, or admits in writing its inability to pay its debts generally, or declares any general moratorium on its Indebtedness, or proposes a compromise or arrangement or deed of company arrangement between it and any class of its creditors; or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-96- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) shall (A)&nbsp;voluntarily commence any proceeding or file any petition
seeking liquidation, <FONT STYLE="white-space:nowrap">winding-up,</FONT> dissolution, <FONT STYLE="white-space:nowrap">strike-off</FONT> reorganization or other relief under any Federal, state or foreign bankruptcy, insolvency, receivership or
similar law now or hereafter in effect, (B)&nbsp;consent to the institution of, or fail to contest in a timely and appropriate manner, any proceeding or petition described in Section&nbsp;10.01(j), (C)&nbsp;apply for or consent to the appointment of
a restructuring officer, receiver, liquidator, trustee, custodian, sequestrator, conservator or similar official for an Obligor or for a substantial part of its assets, (D)&nbsp;file an answer admitting the material allegations of a petition filed
against it in any such proceeding, (E)&nbsp;make a general assignment for the benefit of creditors or (F)&nbsp;take any action for the purpose of effecting any of the foregoing; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) an involuntary proceeding shall be commenced or an involuntary petition shall be filed seeking (i)&nbsp;liquidation, <FONT
STYLE="white-space:nowrap">winding-up,</FONT> reorganization or other relief in respect of an Obligor or any Subsidiary of an Obligor or its debts, or of a substantial part of its assets, under any Federal, state or foreign bankruptcy, insolvency,
receivership or similar law now or hereafter in effect or (ii)&nbsp;the appointment of a receiver, liquidator, restructuring officer, trustee, custodian, sequestrator, conservator, examiner, process adviser or similar official for an Obligor or any
Subsidiary of an Obligor or for a substantial part of its assets, and, in any such case, such proceeding or petition shall continue undismissed for sixty (60)&nbsp;days or an order or decree approving or ordering any of the foregoing shall be
entered; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) one or more judgments for the payment of money in an aggregate amount in excess of $500,000 (excluding any
amounts covered by insurance as to which the applicable carrier has accepted coverage) shall be rendered against any Obligor or any combination thereof and the same shall remain undischarged for a period of sixty (60)&nbsp;consecutive days during
which execution shall not be effectively stayed, or any action shall be legally taken by a judgment creditor to attach or levy upon any assets of any Obligor to enforce any such judgment; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) an ERISA Event shall have occurred that when taken together with all other ERISA Events that have occurred, would
reasonably be expected to result in a Material Adverse Effect; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) a Change of Control shall have occurred; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) a Material Adverse Change shall have occurred; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) (i)&nbsp;any Lien created by any of the Security Documents shall at any time not constitute a valid and perfected Lien in
favor of the Administrative Agent on Collateral with an aggregate value in excess of $250,000, free and clear of all other Liens (other than Permitted Liens) except due to the action or inaction of the Administrative Agent or any Lender(s),
(ii)&nbsp;the Security Documents or any Guarantee of any of the Obligations shall for whatever reason cease to be in full force and effect, or (iii)&nbsp;any of the Security Documents or any Guarantee of any of the Obligations, or the enforceability
thereof, shall be repudiated or contested by any Obligor; or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-97- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) any injunction, whether temporary or permanent, shall be rendered
against any Obligor that prevents the Obligors from selling or manufacturing the Product in the United States for more than one hundred twenty (120)&nbsp;consecutive calendar days; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q) (i)&nbsp;the FDA or any other Governmental Authority (A)&nbsp;issues a letter or other communication asserting that any
Product lacks a required Product Authorization, including in respect of CE marks, PMAs or 510(k)s, or (B)&nbsp;initiates enforcement action against, or issues a warning letter with respect to, any Obligor, or any of their Products or the
manufacturing facilities therefor, that causes any Obligor or Subsidiary thereof to discontinue marketing or withdraw any of its material Products, or causes a delay in the manufacture of any of its material Products, which discontinuance,
withdrawal or delay would reasonably be expected to last for more than ninety (90)&nbsp;days, (ii)&nbsp;there is a recall of any Product that has generated or is expected to generate an aggregate amount of revenue equal to at least $500,000 over any
consecutive twelve&nbsp;(12)&nbsp;month period, or (iii)&nbsp;any Obligor or Subsidiary thereof enters into a settlement agreement, consent decree or similar agreement with the FDA or any other Governmental Authority that results in aggregate
liability as to any single or related series of transactions, incidents or conditions, in excess of $500,000; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(r) any
material Permit relating to any Product (including all Product Authorizations and other Regulatory Approvals), or any of the Obligors&#146; or their Subsidiaries&#146; material rights or interests thereunder, is terminated, adversely amended or
otherwise determined to be ineffective in any manner adverse to any of the Products or Obligors or Subsidiaries, in each case, for more than ninety (90)&nbsp;days; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(s) (i) any Obligor is required to pay a fine, penalty, damages, judgment, settlement amount or other payment (whether imposed
by judicial order or settlement) which, individually or in the aggregate, is in excess of $250,000 for any violation or alleged violation of any Health Care Law or (ii)&nbsp;any Obligor receives notice that it will be debarred or excluded from
participation in a Federal Health Care Program; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(t) Borrowers shall fail to receive gross proceeds from the issuance of
equity or unsecured convertible promissory notes of at least $25,000,000 on or prior to April&nbsp;30, 2024. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;10.02.</I> <I>Remedies</I>. (a)&nbsp;Upon the occurrence of any Event of Default, then, and in every such event
(other than an Event of Default described in Section&nbsp;10.01(i) or (j)), and at any time thereafter during the continuance of such event, the Majority Lenders may, by notice to Administrative Borrower, take either or both of the following
actions, at the same or different times: (i)&nbsp;terminate the Commitments, and thereupon the Commitments shall terminate immediately, and (ii)&nbsp;declare the Term Loans then outstanding to be due and payable in whole (or in part, in which case
any principal not so declared to be due and payable may thereafter be declared to be due and payable), and thereupon the principal of the Term Loans so declared to be due and payable, together with accrued interest thereon and all fees and other
Obligations, shall become due and payable immediately (in the case of the Term Loans, at the Redemption Price therefor), without presentment, demand, protest or other notice of any kind, all of which are hereby waived by each Obligor. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-98- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Upon the occurrence of any Event of Default described in Section&nbsp;10.01(i) or (j),
the Commitments shall automatically terminate and the principal amount of the Term Loans then outstanding, together with accrued interest thereon and all fees and other Obligations, shall automatically become due and payable immediately (in the case
of the Term Loans, at the Redemption Price therefor), without presentment, demand, protest or other notice of any kind, all of which are hereby waived by each Obligor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) If any Lender collects any money or property pursuant to this Article&nbsp;10, they shall pay out the money or property in the order set
forth in Section&nbsp;4.01(c). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;10.03.</I> <I>Prepayment Premium and Redemption Price</I><I>.</I> For the
avoidance of doubt, any Prepayment Premium (as a component of the Redemption Price) shall be due and payable at any time the Term Loans become due and payable prior to the Stated Maturity Date for any reason other than pursuant to
Section&nbsp;3.03(b)(i), whether due to acceleration pursuant to the terms of this Agreement (in which case it shall be due immediately, upon the giving of notice to Administrative Borrower in accordance with Section&nbsp;10.02(a), or automatically,
in accordance with Section&nbsp;10.02(b)), by operation of law or otherwise (including, without limitation, on account of any bankruptcy filing). In view of the impracticability and extreme difficulty of ascertaining the actual amount of damages to
the Lenders or profits lost by the Lenders as a result of such acceleration, and by mutual agreement of the parties as to a reasonable estimation and calculation of the lost profits or damages of the Lenders, any Prepayment Premium shall be due and
payable upon such date. Each Obligor hereby waives any defense to payment, whether such defense may be based in public policy, ambiguity, or otherwise. The Obligors and the Lenders acknowledge and agree that the Prepayment Premium due and payable in
accordance with this Agreement shall not constitute unmatured interest, whether under Section&nbsp;502(b)(2) of the Bankruptcy Code or otherwise. Each Obligor further acknowledges and agrees, and waives any argument to the contrary, that payment of
such amount does not constitute a penalty or an otherwise unenforceable or invalid obligation. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>RTICLE</SMALL>&nbsp;11. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>G<SMALL>UARANTEE</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;11.01.</I> <I>The Guarantee</I><I>.</I> The Guarantors hereby jointly and severally guarantee to the
Administrative Agent and each Lender, and its successors and assigns, the prompt payment in full when due (whether at stated maturity, by acceleration or otherwise) of the principal of and interest on the Term Loans, all fees and other amounts and
Obligations from time to time owing to the Administrative Agent and any Lender by Borrowers under this Agreement or under any other Loan Document and by any other Obligor under any of the Loan Documents, in each case strictly in accordance with the
terms thereof (such obligations being herein collectively called the <I>&#147;</I><I>Guaranteed Obligations</I><I>&#148;</I>). The Guarantors hereby further jointly and severally agree that if Borrowers shall fail to pay in full when due (whether at
stated maturity, by acceleration or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-99- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
otherwise) any of the Guaranteed Obligations, the Guarantors will promptly pay the same, without any demand or notice whatsoever, and that in the case of any extension of time of payment or
renewal of any of the Guaranteed Obligations, the same will be promptly paid in full when due (whether at extended maturity, by acceleration or otherwise) in accordance with the terms of such extension or renewal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;11.02.</I> <I>Obligations Unconditional</I><I>.</I> The obligations of the Guarantors under Section&nbsp;11.01
are absolute and unconditional, joint and several, irrespective of the value, genuineness, validity, regularity or enforceability of the obligations of Borrowers under this Agreement or any other agreement or instrument referred to herein, or any
substitution, release or exchange of any other guarantee of or security for any of the Guaranteed Obligations, and, to the fullest extent permitted by applicable Law, irrespective of any other circumstance whatsoever that might otherwise constitute
a legal or equitable discharge or defense of a surety or Guarantor (other than the payment in full in cash of the Obligations (other than inchoate indemnity obligations)), it being the intent of this Section&nbsp;11.02 that the obligations of the
Guarantors hereunder shall be absolute and unconditional, joint and several, under any and all circumstances. Without limiting the generality of the foregoing, it is agreed that the occurrence of any one or more of the following shall not alter or
impair the liability of the Guarantors hereunder, which shall remain absolute and unconditional as described above: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) at
any time or from time to time, without notice to the Guarantors, the time for any performance of or compliance with any of the Guaranteed Obligations shall be extended, or such performance or compliance shall be waived; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) any of the acts mentioned in any of the provisions of this Agreement or any other agreement or instrument referred to
herein shall be done or omitted; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) the maturity of any of the Guaranteed Obligations shall be accelerated, or any of the
Guaranteed Obligations shall be modified, supplemented or amended in any respect, or any right under this Agreement or any other agreement or instrument referred to herein shall be waived or any other Guarantee of any of the Guaranteed Obligations
or any security therefor shall be released or exchanged in whole or in part or otherwise dealt with; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) any Lien or
security interest granted to, or in favor of, any Lender as security for any of the Guaranteed Obligations shall fail to be perfected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Guarantors hereby expressly waive diligence, presentment, demand of payment, protest and all notices whatsoever, and any requirement that
the Administrative Agent or any Lender exhaust any right, power or remedy or proceed against any Borrower under this Agreement or any other agreement or instrument referred to herein, or against any other Person under any other Guarantee of, or
security for, any of the Guaranteed Obligations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-100- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;11.03.</I> <I>Reinstatement</I><I>.</I> The obligations of the
Guarantors under this Article&nbsp;11 shall be automatically reinstated if and to the extent that for any reason any payment by or on behalf of Borrowers in respect of the Guaranteed Obligations is rescinded or must be otherwise restored by any
holder of any of the Guaranteed Obligations, whether as a result of any proceedings in bankruptcy or reorganization or otherwise, and the Guarantors jointly and severally agree that they will indemnify the Administrative Agent and each Lender on
demand for all reasonable costs and expenses (including reasonable fees of counsel) incurred by such Persons in connection with such rescission or restoration, including any such reasonable costs and expenses incurred in defending against any Claim
alleging that such payment constituted a preference, fraudulent transfer or similar payment under any bankruptcy, insolvency or similar Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;11.04.</I> <I>Subrogation</I><I>.</I> The Guarantors hereby jointly and severally agree that, until the payment
and satisfaction in full of all Guaranteed Obligations and the expiration and termination of the Commitments, they shall not exercise any right or remedy arising by reason of any performance by them of their Guarantee in Section&nbsp;11.01, whether
by subrogation or otherwise, against Borrowers or any other guarantor of any of the Guaranteed Obligations or any security for any of the Guaranteed Obligations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;11.05.</I> <I>Remedies</I><I>.</I> The Guarantors jointly and severally agree that, as between the Guarantors,
on one hand, and the Lenders, on the other hand, the obligations of Borrowers under this Agreement and under the other Loan Documents may be declared to be forthwith due and payable as provided in Article&nbsp;10 (and shall be deemed to have become
automatically due and payable in the circumstances provided in Article&nbsp;10) for purposes of Section&nbsp;11.01 notwithstanding any stay, injunction or other prohibition preventing such declaration (or such obligations from becoming automatically
due and payable) as against Borrowers and that, in the event of such declaration (or such obligations being deemed to have become automatically due and payable), such obligations (whether or not due and payable by Borrowers) shall forthwith become
due and payable by the Guarantors for purposes of Section&nbsp;11.01. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;11.06.</I> <I>Instrument for the
Payment of Money</I><I>.</I> Each Guarantor hereby acknowledges that the Guarantee in this Article&nbsp;11 constitutes an instrument for the payment of money, and consents and agrees that each Lender, at its sole option, in the event of a dispute by
such Guarantor in the payment of any moneys due hereunder, shall have the right to proceed by motion for summary judgment in lieu of complaint pursuant to N.Y.&nbsp;Civ. Prac. L&amp;R &#167;&nbsp;3213. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;11.07.</I> <I>Continuing Guarantee</I><I>.</I> The Guarantee in this Article&nbsp;11 is a continuing guarantee,
and shall apply to all Guaranteed Obligations whenever arising. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;11.08.</I> <I>Rights of
Contribution</I><I>.</I> The Guarantors hereby agree, as between themselves, that if any Guarantor shall become an Excess Funding Guarantor (as defined below) by reason of the payment by such Guarantor of any Guaranteed Obligations, each other
Guarantor shall, on demand of such Excess Funding Guarantor (but subject to the next sentence), pay to such Excess Funding Guarantor an amount equal to such Guarantor&#146;s Pro Rata Share (as defined below and determined, for this purpose, without
reference to the properties, debts and liabilities of such Excess Funding Guarantor) of the Excess Payment (as defined below) in respect of such Guaranteed Obligations. The payment obligation of a Guarantor to any Excess Funding Guarantor under this
Section&nbsp;11.08 shall be subordinate and subject in right of payment to the prior payment in full of the obligations of such Guarantor under the other provisions of this Article&nbsp;11 and such Excess Funding Guarantor shall not exercise any
right or remedy with respect to such excess until payment and satisfaction in full of all of such obligations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-101- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this Section&nbsp;11.08, (i)<I>&nbsp;&#147;Excess Funding
Guarantor&#148;</I> means, in respect of any Guaranteed Obligations, a Guarantor that has paid an amount in excess of its Pro Rata Share of such Guaranteed Obligations, (ii)<I>&nbsp;&#147;Excess Payment&#148;</I> means, in respect of any Guaranteed
Obligations, the amount paid by an Excess Funding Guarantor in excess of its Pro Rata Share of such Guaranteed Obligations and (iii)<I>&nbsp;&#147;Pro Rata Share&#148;</I> means, as of the date of determination, for any Guarantor, the ratio
(expressed as a percentage) of (x)&nbsp;the amount by which the aggregate present fair saleable value of all properties of such Guarantor (excluding any shares of stock of any other Guarantor) exceeds the amount of all the debts and liabilities of
such Guarantor (including contingent, subordinated, unmatured and unliquidated liabilities, but excluding the obligations of such Guarantor hereunder and any obligations of any other Guarantor that have been guaranteed by such Guarantor) to
(y)&nbsp;the amount by which the aggregate fair saleable value of all properties of all of the Guarantors exceeds the amount of all the debts and liabilities (including contingent, subordinated, unmatured and unliquidated liabilities, but excluding
the obligations of Borrowers and the Guarantors hereunder and under the other Loan Documents) of all of the Guarantors, determined (A)&nbsp;with respect to any Guarantor that is a party hereto on the Closing Date, as of such date, and (B)&nbsp;with
respect to any other Guarantor, as of the date such Guarantor becomes a Guarantor hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;11.09.</I>
<I>General Limitation on Guarantee Obligations</I><I>.</I> In any action or proceeding involving any provincial, territorial or state corporate law, or any national, state or federal bankruptcy, insolvency, reorganization or other Law affecting the
rights of creditors generally, if the obligations of any Guarantor under Section&nbsp;11.01 would otherwise, taking into account the provisions of Section&nbsp;11.08, be held or determined to be void, invalid or unenforceable, or subordinated to the
Claims of any other creditors, on account of the amount of its liability under Section&nbsp;11.01, then, notwithstanding any other provision hereof to the contrary, the amount of such liability shall, without any further action by such Guarantor,
the Administrative Agent, the Lenders or any other Person, be automatically limited and reduced to the highest amount that is valid and enforceable and not subordinated to the Claims of other creditors as determined in such action or proceeding.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;11.10.</I> <I>Irish Limitation on Guarantee Obligations</I>. The obligations of the Irish Obligor under
Section&nbsp;11.01 shall be deemed not to be undertaken or incurred to the extent the same would: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) constitute unlawful
financial assistance prohibited by section 82 of the Companies Act 2014 of Ireland (as amended); or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) constitute a
breach of section 239 of the Companies Act 2014 of Ireland (as amended); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>provided </I>that (in the case of both (a)&nbsp;and (b) above), for the
avoidance of doubt, to the extent that any such obligations under Section&nbsp;11.01 have been validated by a summary approval procedure in accordance with the Companies Act 2014 of Ireland (as amended), they shall not constitute unlawful financial
assistance under the said section 82 or a breach of the said section 239 (as applicable). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-102- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>RTICLE</SMALL>&nbsp;12. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>DMINISTRATIVE</SMALL> A<SMALL>GENT</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;12.01.</I> <I>Appointment</I>. Each of the Lenders hereby irrevocably appoints Perceptive to act on its behalf
as the Administrative Agent hereunder and under the other Loan Documents and authorizes the Administrative Agent to take such actions on its behalf and to exercise such powers as are delegated to the Administrative Agent by the terms hereof or
thereof, together with such actions and powers as are reasonably incidental thereto. Other than as set forth in Section&nbsp;12.06 and Section&nbsp;12.09, the provisions of this Article&nbsp;12 are solely for the benefit of the Administrative Agent
and the Lenders, and neither Borrowers nor any other Obligor will have rights as a <FONT STYLE="white-space:nowrap">third-party</FONT> beneficiary of any of such provisions. It is understood and agreed that the use of the term &#147;agent&#148;
herein or in any other Loan Documents (or any other similar term) with reference to the Administrative Agent is not intended to connote any fiduciary or other implied (or express) obligations arising under agency doctrine of any applicable Law.
Instead, such term is used as a matter of market custom, and is intended to create or reflect only an administrative relationship between contracting parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;12.02.</I> <I>Rights as a Lender</I>. The Person serving as the Administrative Agent hereunder will have the
same rights and powers in its capacity as a Lender as any other Lender and may exercise the same as though it were not the Administrative Agent, and the term &#147;Lender&#148; or &#147;Lenders&#148; will, unless otherwise expressly indicated or
unless the context otherwise requires, include the Person serving as the Administrative Agent hereunder in its individual capacity to the extent such Person is a Lender. The Lenders acknowledge and agree that such Person and its Affiliates may
accept deposits from, lend money to, own securities of, act as the financial advisor or in any other advisory capacity for, and generally engage in any kind of business with, Borrowers, the other Obligors or any other Subsidiaries or Affiliates of
the Obligors as if such Person were not the Administrative Agent hereunder and without any duty to account therefor to the Lenders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;12.03.</I> <I>Exculpatory Provisions</I>. (a)&nbsp;The Administrative Agent will not have any duties or
obligations except those expressly set forth herein and in the other Loan Documents, and its duties hereunder are administrative in nature. Without limiting the generality of the foregoing, the Administrative Agent: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) will not be subject to any fiduciary or other implied duties, regardless of whether a Default has occurred and is
continuing; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-103- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) will not have any duty to take any discretionary action or exercise any
discretionary powers, except discretionary rights and powers expressly contemplated hereby or by the other Loan Documents that the Administrative Agent is required to exercise as directed in writing by the Majority Lenders (or such other number or
percentage of the Lenders as will be expressly provided for herein or in the other Loan Documents); <I>provided</I> that the Administrative Agent will not be required to take any action that, in its opinion or the opinion of its counsel, may expose
the Administrative Agent to liability or that is contrary to any Loan Document or applicable Law, including any action that may be in violation of the automatic stay under any Insolvency Proceeding; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) will not, except as expressly set forth herein and in the other Loan Documents, have any duty to disclose, and will not
be liable for the failure to disclose, any information relating to the Obligors or any of its Subsidiaries or Affiliates that is communicated to or obtained by the Person serving as the Administrative Agent or any of its Affiliates in any capacity.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The Administrative Agent will not be liable for any action taken or not taken by it (i)&nbsp;with the consent or at the request of
the Majority Lenders (or such other number or percentage of the Lenders as will be necessary, or as the Administrative Agent believes in good faith will be necessary, under the circumstances), or (ii)&nbsp;in the absence of its own gross negligence
or willful misconduct as determined by a court of competent jurisdiction by final and <FONT STYLE="white-space:nowrap">non-appealable</FONT> judgment. The Administrative Agent will be deemed not to have knowledge of any Default unless and until
notice describing such Default is given to the Administrative Agent in writing by Borrowers or a Lender. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) The Administrative Agent
will not be responsible for or have any duty to ascertain or inquire into (i)&nbsp;any statement, warranty or representation made in or in connection with this Agreement or any other Loan Document, (ii)&nbsp;the contents of any certificate, report
or other document delivered hereunder or thereunder or in connection herewith or therewith, (iii)&nbsp;the performance or observance of any of the covenants, agreements or other terms or conditions set forth herein or therein or the occurrence of
any Default, (iv)&nbsp;the validity, enforceability, effectiveness or genuineness of this Agreement, any other Loan Document or any other agreement, instrument or document or (v)&nbsp;the satisfaction of any condition set forth in Article&nbsp;6 or
elsewhere herein, other than to confirm receipt of items expressly required to be delivered to the Administrative Agent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;12.04.</I> <I>Reliance by Administrative Agent</I>. The Administrative Agent will be entitled to rely upon, and
will not incur any liability for relying upon, any notice, request, certificate, consent, statement, instrument, document or other writing (including any electronic message, Internet or intranet website posting or other distribution) believed by it
to be genuine and to have been signed, sent or otherwise authenticated by the proper Person. The Administrative Agent also may rely upon any statement made to it orally or by telephone and believed by it to have been made by the proper Person, and
will not incur any liability for relying thereon. In determining compliance with any condition hereunder to the making of the Term Loans that by its terms must be fulfilled to the satisfaction of a Lender, the Administrative Agent may presume that
such condition is satisfactory to such Lender unless the Administrative Agent has received notice to the contrary from such Lender prior to the making of such Term Loan. The Administrative Agent may consult with legal counsel (who may be counsel for
Borrowers), independent accountants and other experts selected by it, and will not be liable for any action taken or not taken by it in accordance with the advice of any such counsel, accountants or experts. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-104- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;12.05.</I> <I>Delegation of Duties</I>. The Administrative
Agent may perform any and all of its duties and exercise its rights and powers hereunder or under any other Loan Document by or through any one or more <FONT STYLE="white-space:nowrap">sub-agents</FONT> appointed by the Administrative Agent. The
Administrative Agent and any such <FONT STYLE="white-space:nowrap">sub-agent</FONT> may perform any and all of its duties and exercise its rights and powers by or through their respective Affiliates. The exculpatory provisions of this
Section&nbsp;will apply to any such <FONT STYLE="white-space:nowrap">sub-agent</FONT> and to the Affiliates of the Administrative Agent and any such <FONT STYLE="white-space:nowrap">sub-agent,</FONT> and will apply to their respective activities in
connection with the syndication of the facility as well as activities as Administrative Agent. The Administrative Agent will not be responsible for the negligence or misconduct of any <FONT STYLE="white-space:nowrap">sub-agents</FONT> except to the
extent that a court of competent jurisdiction determines in a final and <FONT STYLE="white-space:nowrap">non-appealable</FONT> judgment that the Administrative Agent acted with gross negligence or willful misconduct in the selection of such <FONT
STYLE="white-space:nowrap">sub-agents.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;12.06.</I> <I>Resignation of Agent</I>. (a)&nbsp;The
Administrative Agent may at any time give notice of its resignation to the Lenders and Administrative Borrower, which notice shall set forth the effective date of such resignation (the <I>&#147;</I><I>Resignation Effective Date</I><I>&#148;</I>),
such date not to be earlier than the thirtieth (30th) day following the date of such notice. The Majority Lenders and Borrowers shall mutually agree upon a successor to the Administrative Agent. If the Majority Lenders and Borrowers are unable to so
mutually agree and no successor shall have been appointed within <FONT STYLE="white-space:nowrap">twenty-five&nbsp;(25)</FONT> days after the retiring Administrative Agent gives notice of its resignation, then the retiring Administrative Agent may
(but will not be obligated to), on behalf of the Lenders, appoint a successor Administrative Agent it shall designate (in its reasonable discretion after consultation with Borrowers and the Majority Lenders). Whether or not a successor has been
appointed, such resignation will become effective in accordance with such notice on the Resignation Effective Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">(b) With effect from
the Resignation Effective Date (i)&nbsp;the retiring Administrative Agent will be discharged from its duties and obligations hereunder and under the other Loan Documents (except that in the case of any Collateral held by the Administrative Agent on
behalf of the Lenders under any of the Loan Documents, the retiring Administrative Agent will continue to hold such Collateral until such time as a successor Administrative Agent is appointed) and (ii)&nbsp;except for any indemnity payments owed to
the retiring Administrative Agent, all payments, communications and determinations provided to be made by, to or through the Administrative Agent will instead be made by or to each Lender directly, until such time, if any, as the Majority Lenders
appoint a successor Administrative Agent as provided for above. Upon the acceptance of a successor&#146;s appointment as Administrative Agent hereunder, such successor will succeed to and become vested with all of the rights, powers, privileges and
duties of the retiring Administrative Agent (other than any rights to indemnity payments owed to the retiring Administrative Agent), and the retiring Administrative Agent will be discharged from all of its duties and obligations hereunder or under
the other Loan Documents. The fees payable by Borrowers to a successor Administrative Agent will be the same as those payable to its predecessor unless otherwise agreed between Borrowers and such successor. After the retiring Administrative
Agent&#146;s resignation hereunder and under the other Loan Documents, the provisions of this Article&nbsp;12 and Sections&nbsp;13.03 and 13.06 will continue in effect for the benefit of such retiring Administrative Agent, its <FONT
STYLE="white-space:nowrap">sub-agents</FONT> and their respective Affiliates in respect of any actions taken or omitted to be taken by any of them while the retiring Administrative Agent was acting as Administrative Agent. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-105- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;12.07.</I>
<I>Non</I><I><FONT STYLE="white-space:nowrap">-Reliance</FONT> on Administrative Agent and Other Lenders</I>. Each Lender acknowledges that it has, independently and without reliance upon the Administrative Agent or any other Lender or any of their
Affiliates and based on such documents and information as it has deemed appropriate, made its own credit analysis and decision to enter into this Agreement. Each Lender also acknowledges that it will, independently and without reliance upon the
Administrative Agent or any other Lender or any of their Affiliates and based on such documents and information as it will from time to time deem appropriate, continue to make its own decisions in taking or not taking action under or based upon this
Agreement, any other Loan Document or any related agreement or any document furnished hereunder or thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;12.08.</I> <I>Administrative Agent May File Proofs of Claim</I>. In case of the pendency of any Insolvency
Proceeding or any other judicial proceeding relative to an Obligor, the Administrative Agent (irrespective of whether the principal of the Term Loans will then be due and payable as herein expressed or by declaration or otherwise and irrespective of
whether the Administrative Agent has made any demand on an Obligor) will be entitled and empowered (but not obligated), by intervention in such proceeding or otherwise: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) to file and prove a Claim for the whole amount of the principal and interest owing and unpaid in respect of the Term Loans
and all other Obligations that are owing and unpaid hereunder or under any other Loan Document and to file such other documents as may be necessary or advisable in order to have the Claims of the Lenders and the Administrative Agent (including any
claim for the reasonable compensation, expenses, disbursements and advances of the Lenders and the Administrative Agent and their respective agents and counsel and all other amounts due the Lenders and the Administrative Agent under this Agreement
or any other Loan Document) allowed in such judicial proceeding; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) to collect and receive any monies or other
property payable or deliverable on any such Claims and to distribute the same. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any custodian, receiver, assignee, trustee, liquidator,
sequestrator or other similar official in any such judicial proceeding is hereby authorized by each Lender to make any payments of the type described above in this Section&nbsp;12.08 to the Administrative Agent and, in the event that the
Administrative Agent consents to the making of such payments directly to the Lenders, to pay to the Administrative Agent any amount due for the reasonable compensation, expenses, disbursements and advances of the Administrative Agent and its agents
and counsel, and any other amounts due the Administrative Agent under this Agreement or any other Loan Document. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;12.09.</I> <I>Collateral and Guaranty Matters; Appointment of Administrative Agent</I>. (a)&nbsp;Without
limiting the provisions of Section&nbsp;12.08, the Lenders irrevocably agree as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) the Administrative Agent is
authorized, at its option and in its discretion, to release any Lien on any property granted to or held by the Administrative Agent under any Loan Document (A)&nbsp;on the date when all Obligations have been satisfied in full in cash (other than
contingent obligations as to which no Claims have been asserted), (B)&nbsp;that is sold or otherwise disposed of or to be sold or otherwise disposed of as part of or in connection with any sale or other disposition permitted under the Loan
Documents, or (C)&nbsp;subject to Sections&nbsp;13.01 and 13.04, if approved, authorized or ratified in writing by the Majority Lenders; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-106- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) the Administrative Agent is authorized, at its option and discretion,
to release any Guarantor from its obligations hereunder if such Person ceases to be a Subsidiary as a result of a transaction permitted under the Loan Documents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon request by the Administrative Agent at any time, each Lender will confirm in writing the Administrative Agent&#146;s authority to release or subordinate
its interest in particular types or items of Collateral, or to release any Guarantor from its obligations under its guaranty pursuant to this Section&nbsp;12.09. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The Administrative Agent will not be responsible for or have a duty to ascertain or inquire into any representation or warranty regarding
the existence, value or collectability of the Collateral, the existence, priority or perfection of the Administrative Agent&#146;s Lien thereon, or any certificate prepared by any Obligor in connection therewith, nor will the Administrative Agent be
responsible or liable to the Lenders for any failure to monitor or maintain any portion of the Collateral. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Each Lender hereby
appoints the Administrative Agent as its collateral agent under each of the Security Documents and agrees that, in so acting, the Administrative Agent will have all of the rights, protections, exculpations, indemnities and other benefits provided to
the Administrative Agent under this Agreement, and hereby authorizes and directs the Administrative Agent, on behalf of such Lender and all Lenders, without the necessity of any notice to or further consent from any of the Lenders, from time to time
to (i)&nbsp;take any action with respect to any Collateral or any Security Document which may be necessary to perfect and maintain perfected the Liens on the Collateral granted pursuant to any such Security Document or protect and preserve the
Administrative Agent&#146;s ability to enforce the Liens or realize upon the Collateral, (ii)&nbsp;act as collateral agent for each Lender for purposes of acquiring, holding, enforcing and perfecting all Liens created by the Loan Documents and all
other purposes stated therein, (iii)&nbsp;enter into intercreditor or subordination agreements, as the case may be, in connection with Indebtedness permitted pursuant to Sections&nbsp;9.01(c) and 9.01(k), as applicable, (iv)&nbsp;enter into <FONT
STYLE="white-space:nowrap">non-disturbance</FONT> or similar agreements in connection with licensing agreements and arrangements permitted by this Agreement and the other Loan Documents and (v)&nbsp;otherwise to take or refrain from taking any and
all action that the Administrative Agent shall deem necessary or advisable in fulfilling its role as collateral agent under any of the Security Documents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;12.10.</I> <I>Irish Security Matters.</I> (a)&nbsp;the Lenders appoint the Administrative Agent to hold the
security interests constituted by the Irish Security Documents on trust for the Lenders on the terms of the Loan Documents and the Administrative Agent accepts that appointment. The Administrative Agent declares that it shall hold the Charged
Property on trust for the Lenders on the terms of the Loan Documents<I>.</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Administrative Agent, its subsidiaries and
associated companies may each retain for its own account and benefit any fee, remuneration and profits paid to it in connection with (i)&nbsp;its activities under the Loan Documents and (ii)&nbsp;its engagement in any kind of banking or other
business with any Obligor<I>.</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-107- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Nothing in this Agreement constitutes the Administrative Agent<B><I> </I></B>as a
trustee or fiduciary of, nor shall the Administrative Agent have any duty or responsibility to, any Obligor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The Administrative Agent
shall have no duties or obligations to any other Person except for those which are expressly specified in the Loan Documents or mandatorily required by applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) The Administrative Agent may appoint one or more Delegates on such terms (which may include the power to
<FONT STYLE="white-space:nowrap">sub-delegate)</FONT> and subject to such conditions as it thinks fit, to exercise and perform all or any of the duties, rights, powers and discretions vested in it by the Irish Security Documents and shall not be
obliged to supervise any Delegate or be responsible to any person for any loss incurred by reason of any act, omission, misconduct or default on the part of any Delegate<I>.</I><B><I> </I></B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) The Administrative Agent may (whether for the purpose of complying with any law or regulation of any overseas jurisdiction, or for any
other reason) appoint (and subsequently remove) any person to act jointly with the Administrative Agent either as a separate trustee or as a <FONT STYLE="white-space:nowrap">co-trustee</FONT> on such terms and subject to such conditions as the
Administrative Agent thinks fit and with such of the duties, rights, powers and discretions vested in the Administrative Agent by the Irish Security Documents<B><I> </I></B>as may be conferred by the instrument of appointment of that person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) The Administrative Agent shall notify the Lenders of the appointment of each Appointee (other than a Delegate). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) The Administrative Agent may pay reasonable remuneration to any Delegate or Appointee, together with any costs and expenses (including
legal fees) reasonably incurred by the Delegate or Appointee in connection with its appointment. All such remuneration, costs and expenses shall be treated, for the purposes of this Agreement, as paid or incurred by the Administrative Agent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) Each Delegate and each Appointee shall have every benefit, right, power and discretion and the benefit of every exculpation (together,
<I>&#147;Rights&#148;</I>) of the Administrative Agent (in its capacity as security trustee) under the Irish Security Documents, and each reference to the Administrative Agent<B><I> </I></B>(where the context requires that such reference is to the
Administrative Agent in its capacity as security trustee) in the provisions of the Irish Security Documents<B><I> </I></B>which confer Rights shall be deemed to include a reference to each Delegate and each Appointee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) Each Lender confirms its approval of the Irish Security Documents and authorizes and instructs the Administrative Agent (i)&nbsp;to
execute and deliver the Irish Security Documents, (ii)&nbsp;to exercise the rights, powers and discretions given to the Administrative Agent (in its capacity as security trustee) under or in connection with the Irish Security Documents together with
any other incidental rights, powers and discretions and (iii)&nbsp;to give any authorizations and confirmations to be given by the Administrative Agent<B><I> </I></B>(in its capacity as security trustee) on behalf of the Lenders under the Irish
Security Documents. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-108- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) The Administrative Agent<B><I> </I></B>may accept without inquiry the title (if any)
which any person may have to the Charged Property. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l) Each Lender confirms that it does not wish to be registered as a joint proprietor
of any security interest constituted by an Irish Security Document and accordingly authorizes (i)&nbsp;the Administrative Agent to hold such security interest in its sole name (or in the name of any Delegate) as trustee for the Lenders and
(ii)&nbsp;the Property Registration Authority of Ireland, the Companies Registration Office of Ireland (or other relevant registry) to register the Administrative Agent (or any Delegate or Appointee) as a sole proprietor of such security interest.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(m) Except to the extent that an Irish Security Document otherwise requires, any moneys which the Administrative Agent receives under or
pursuant to an Irish Security Document may be (i)&nbsp;invested in any investments which the Administrative Agent selects and which are authorized by applicable law or (ii)&nbsp;placed on deposit at any bank or institution (including the
Administrative Agent) on terms that the Administrative Agent thinks fit, in each case in the name or under the control of the Administrative Agent, and the Administrative Agent shall hold those moneys, together with any accrued income (net of any
applicable Taxes) to the order of the Lenders, and shall pay them to the Lenders on demand. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(n) On a disposal of any of the Charged
Property which is permitted under the Loan Documents, the Administrative Agent shall (at the cost of the Obligors) execute any release of the Irish Security Documents or other claim over that Charged Property and issue any certificates of <FONT
STYLE="white-space:nowrap">non-crystallization</FONT> of floating charges that may be required or take any other action that the Administrative Agent considers desirable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(o) The Administrative Agent shall not be liable for (i)&nbsp;any defect in or failure of the title (if any) which any person may have to any
assets over which security is intended to be created by an Irish Security Document, (ii)&nbsp;any loss resulting from the investment or deposit at any bank of moneys which it invests or deposits in a manner permitted by an Irish Security Document,
(iii)&nbsp;the exercise of, or the failure to exercise, any right, power or discretion given to it by or in connection with any Loan Document or any other agreement, arrangement or document entered into, or executed in anticipation of, under or in
connection with, any Loan Document or (iv)&nbsp;any shortfall which arises on enforcing an Irish Security Document. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(p) The
Administrative Agent shall not be obligated to (i)&nbsp;obtain any authorization or environmental permit in respect of any of the Charged Property or an Irish Security Document, (ii)&nbsp;hold in its own possession an Irish Security Document, title
deed or other document relating to the Charged Property or an Irish Security Document, (iii)&nbsp;perfect, protect, register, make any filing or give any notice in respect of an Irish Security Document (or the order of ranking of an Irish Security
Document), unless that failure arises directly from its own gross negligence or willful misconduct or (iv)&nbsp;require any further assurances in relation to an Irish Security Document. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-109- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(q) In respect of any Irish Security Document, the Administrative Agent shall not be
obligated to (i)&nbsp;insure, or require any other person to insure, the Charged Property or (ii)&nbsp;make any enquiry or conduct any investigation into the legality, validity, effectiveness, adequacy or enforceability of any insurance existing
over such Charged Property. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(r) In respect of any Irish Security Document, the Administrative Agent shall not have any obligation or duty
to any person for any loss suffered as a result of (i)&nbsp;the lack or inadequacy of any insurance or (ii)&nbsp;the failure of the Administrative Agent to notify the insurers of any material fact relating to the risk assumed by them, or of any
other information of any kind, unless Majority Lenders have requested it to do so in writing and the Administrative Agent has failed to do so within fourteen (14)&nbsp;days after receipt of that request. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(s) Every appointment of a successor Administrative Agent under an Irish Security Document<B><I> </I></B>shall be by deed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(t) The rights, powers and discretions conferred on the Administrative Agent by this Agreement shall be supplemental to the Trustee Acts of
Ireland 1888 to 1989 and in addition to any other rights, powers and discretions which may be vested in the Administrative Agent by the Loan Documents, law or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(u) The duties, rights, powers and discretions conferred on the Administrative Agent by this Section&nbsp;12.10 shall be supplemental to those
conferred on the Administrative Agent pursuant to other provisions of this Agreement. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>RTICLE</SMALL>&nbsp;13. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>M<SMALL>ISCELLANEOUS</SMALL> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;13.01.</I> <I>No Waiver</I><I>.</I> No failure on the part of the Administrative Agent or the Lenders to exercise
and no delay in exercising, and no course of dealing with respect to, any right, power or privilege under any Loan Document shall operate as a waiver thereof, nor shall any single or partial exercise of any right, power or privilege under any Loan
Document preclude any other or further exercise thereof or the exercise of any other right, power or privilege. The remedies provided herein are cumulative and not exclusive of any remedies provided by Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;13.02.</I> <I>Notices</I><I>.</I> All notices, requests, instructions, directions and other communications
provided for herein (including any modifications of, or waivers, requests or consents under, the Loan Documents) shall be given or made in writing (including by telecopy or electronic mail) delivered, if to Administrative Borrower, another Obligor,
the Administrative Agent or the Lenders, to its address specified on Schedule&nbsp;2 hereto or its Guarantee Assumption Agreement, as the case may be, or at such other address as shall be designated by such party in a notice to the other parties.
Except as otherwise provided in this Agreement, all such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-110- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
communications shall be deemed to have been duly given upon receipt of a legible copy thereof, in each case given or addressed as aforesaid. All such communications provided for herein by
telecopy or electronic mail shall be confirmed in writing promptly after the delivery of such communication (it being understood that <FONT STYLE="white-space:nowrap">non-receipt</FONT> of written confirmation of such communication shall not
invalidate such communication). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;13.03.</I> <I>Expenses, Indemnification, Etc.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Expenses</I>. Each Borrower agrees to pay or reimburse (i)&nbsp;the Lenders for all of their reasonable and documented out of pocket
costs and expenses (limited, in the case of legal fees and expenses, to the reasonable and documented out of pocket costs and expenses of one counsel to the Lenders, taken as a whole (and, if reasonably necessary, of one local counsel in any
relevant jurisdiction to all such persons, taken as a whole under the Loan Documents)), in connection with (A)&nbsp;the negotiation, preparation, execution and delivery of this Agreement and the other Loan Documents and the making of the Term Loans
(exclusive of <FONT STYLE="white-space:nowrap">post-closing</FONT> costs); <I>provided</I> that, so long as the Tranche&nbsp;A Term Loan is made, such fees shall be credited against the Expense Deposit paid by Administrative Borrower, <FONT
STYLE="white-space:nowrap">(B)&nbsp;post-closing</FONT> costs and (C)&nbsp;the negotiation or preparation of any amendment, modification, supplement or waiver of any of the terms of this Agreement or any of the other Loan Documents (whether or not
consummated) and (ii)&nbsp;the Administrative Agent and the Lenders for all of their reasonable and documented out of pocket costs and expenses (including the reasonable fees and expenses of legal counsel) in connection with any enforcement or
collection proceedings resulting from the occurrence of an Event of Default. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Indemnification</I>. Each Obligor hereby indemnifies
the Administrative Agent, the Lenders, their respective Affiliates, and their respective directors, officers, employees, attorneys, agents and advisors (each, an <I>&#147;Indemnified Party&#148;</I>) from and against, and agrees to hold them
harmless against, any and all Claims and Losses of any kind (limited, in the case of legal fees and expenses, to the reasonable and documented out of pocket costs and expenses of one counsel to the Lenders, taken as a whole (and, if reasonably
necessary, of one local counsel in any relevant jurisdiction to all such persons, taken as a whole under the Loan Documents) and solely to the extent any conflict exists, one conflict counsel for all similarly situated Indemnified Parties, taken as
a whole), joint or several, that is incurred by or asserted or awarded against any Indemnified Party, in each case arising out of or in connection with or relating to any investigation, litigation or proceeding or the preparation of any defense with
respect thereto arising out of or in connection with or relating to this Agreement or any of the other Loan Documents or the Transactions or any use made or proposed to be made with the proceeds of the Term Loans, whether or not such investigation,
litigation or proceeding is brought by an Obligor, any of its shareholders or creditors, an Indemnified Party or any other Person, or an Indemnified Party is otherwise a party thereto, and whether or not any of the conditions precedent set forth in
Article&nbsp;6 are satisfied or the other Transactions contemplated by this Agreement are consummated, except to the extent such Claim or Loss is found in a final, <FONT STYLE="white-space:nowrap">non-appealable</FONT> judgment by a court of
competent jurisdiction to have resulted from (i)&nbsp;any Indemnified Party&#146;s (or its Affiliate&#146;s) gross negligence or willful misconduct or material breach of the Loan Documents or (ii)&nbsp;disputes solely among the Indemnified Parties
(other than against the Administrative Agent in its capacity as such). No Obligor shall assert any Claim against any Indemnified Party, on any theory of liability, for consequential, indirect, special or punitive damages arising out of or otherwise
relating to this Agreement or any of the other Loan </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-111- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Documents or any of the Transactions or the actual or proposed use of the proceeds of the Term Loans. To the extent permitted by applicable law and except to the extent expressly provided for in
Section&nbsp;3.02(d), Section&nbsp;5.01 and Section&nbsp;5.02, neither Administrative Agent nor any Lender shall assert, and Administrative Agent and each Lender hereby waives, any claim against an Obligor, on any theory of liability, for special,
indirect, consequential or punitive damages (as opposed to direct or actual damages) arising out of, in connection with, or as a result of, this Agreement or any agreement or instrument contemplated hereby, the Transactions, any Term Loan or the use
of the proceeds thereof; <I>provided</I> that this shall in no manner limit any Indemnified Party&#146;s rights pursuant to this Section&nbsp;13.03(b) with respect to special, indirect, consequential or punitive damages payable by such Indemnified
Party to another Person. This Section shall not apply to Taxes other than Taxes relating to a <FONT STYLE="white-space:nowrap">non-Tax</FONT> Claim or Loss governed by this Section&nbsp;13.03(b). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;13.04.</I> <I>Amendments, Etc.</I> Except as otherwise expressly provided in this Agreement, any provision of
this Agreement or any other Loan Document may be amended, modified, waived or supplemented only by an instrument in writing signed by Borrowers, the Administrative Agent and the Majority Lenders; <I>provided</I> that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) no amendment, waiver or consent shall, unless in writing and signed by all of the Lenders, do any of the following at any
time: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) change the number of Lenders or the percentage of (A)&nbsp;the Commitments or (B)&nbsp;the aggregate unpaid
principal amount of the Term Loans that, in each case, shall be required for the Lenders or any of them to take any action hereunder (including pursuant to any change to the definition of <I>&#147;Majority Lenders&#148;</I>); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) release one or more Guarantors (or otherwise limit such Guarantors&#146; liability with respect to the Obligations owing
to the Lenders under the Guarantees) if such release or limitation is in respect of all or substantially all of the value represented by the Guarantees to the Lenders; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) release, or subordinate the Lenders&#146; Liens in, all or substantially all of the Collateral in any transaction or
series of related transactions (other than in connection with any sale of Collateral permitted herein); or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) amend any
provision of this Section&nbsp;13.04; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) no amendment, waiver or consent shall, unless in writing and signed by each
Lender specified below for such amendment, waiver or consent: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) increase the Commitments of a Lender without the consent
of such Lender; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) reduce the principal of, or stated rate of interest on, or any Prepayment Premium payable on, the
Term Loans owed to a Lender or any fees or other amounts stated to be payable hereunder or under the other Loan Documents to such Lender without the consent of such Lender; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-112- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) postpone any date scheduled for any payment of principal of, or
interest on, the Term Loans, any date scheduled for payment or for any date fixed for any payment of fees hereunder (excluding the due date of any mandatory prepayment of the Term Loans), in each case payable to a Lender without the consent of such
Lender; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) change the order of application of prepayment of the Term Loans from the application thereof set forth in the
applicable provisions of Sections&nbsp;4.01(b) and (c)&nbsp;in any manner that adversely affects the Lenders without the consent of holders of a majority of the Commitments or Term Loans outstanding or otherwise change any provision requiring the
pro rata distributions hereunder among the Lenders without all Lenders&#146; consent; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) modify Section&nbsp;2.02
without the consent of each Lender directly and adversely affected thereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;13.05.</I> <I>Successors and
Assigns</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>General</I>. The provisions of this Agreement shall be binding upon and inure to the benefit of the parties hereto
and their respective successors and assigns permitted hereby, except that (i)&nbsp;except to the extent permitted under Section&nbsp;9.03, no Obligor may assign or otherwise transfer any of its rights or obligations hereunder without the prior
written consent of the Administrative Agent and each Lender (and any attempted assignment or transfer by such Obligor without such consent shall be null and void) and (ii)&nbsp;no Lender may assign or otherwise transfer its rights or obligations
hereunder except in accordance with this Section (and any attempted assignment or transfer by such Lender without such consent shall be null and void). Nothing in this Agreement, expressed or implied, shall be construed to confer upon any Person
(other than the parties hereto, their respective successors and assigns permitted hereby, Participants (to the extent provided in paragraph&nbsp;(e) of this Section) and, to the extent expressly contemplated hereby, the Indemnified Parties of the
Lenders) any legal or equitable right, remedy or Claim under or by reason of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Amendments to Loan Documents;
Majority Lender Vote</I>. Each of the Lenders and the Obligors agrees to enter into such amendments to the Loan Documents, and such additional Security Documents and other instruments and agreements, in each case in form and substance reasonably
acceptable to the Lenders and the Obligors, as shall reasonably be necessary to implement and give effect to any assignment made by any Lender (or any direct or indirect assignee thereof) from time to time under this Section&nbsp;13.05. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Assignments by Lenders</I>. (i)&nbsp;Subject to the conditions set forth in paragraph&nbsp;(c)(ii) below, any Lender may assign to one
or more Persons (other than an Ineligible Assignee) all or a portion of its rights and obligations under the Loan Documents (including all or a portion of its Commitment and the Term Loan at the time owing to it) with the prior written consent (such
consent not to be unreasonably withheld) of the Administrative Agent, <I>provided</I> that no consent of the Administrative Agent shall be required for an assignment of any Commitment or of all or any portion of the Term Loan to a Lender, an
Affiliate of a Lender or an Approved Fund. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-113- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) Assignments shall be subject to the following additional conditions: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A) except in the case of an assignment to a Lender or an Affiliate of a Lender or an assignment of the entire remaining amount
of the assigning Lender&#146;s Commitment or Term Loan, the amount of the Commitment or Term Loan of the assigning Lender subject to each such assignment (determined as of the date the Assignment Agreement with respect to such assignment is
delivered to the Administrative Agent) shall not be less than $500,000, unless the Administrative Agent otherwise consents; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B) each partial assignment shall be made as an assignment of a proportionate part of all the assigning Lender&#146;s rights
and obligations under this Agreement and the other Loan Documents; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(C) the parties to each assignment shall execute
and deliver to the Administrative Agent an Assignment Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) Subject to acceptance and recording thereof pursuant to
paragraph&nbsp;(d) of this Section, from and after the effective date specified in each Assignment Agreement, the assignee thereunder shall be a party hereto and, to the extent of the interest assigned by such Assignment Agreement, have the rights
and obligations of a Lender under the Loan Documents, and the assigning Lender thereunder shall, to the extent of the interest assigned by such Assignment Agreement, be released from its obligations under the Loan Documents (and, in the case of an
Assignment Agreement covering all of the assigning Lender&#146;s rights and obligations under the Loan Documents, such Lender shall cease to be a party hereto). Any assignment or transfer by a Lender of rights or obligations under the Loan Documents
that does not comply with this Section&nbsp;13.05 shall be treated for purposes of the Loan Documents as a sale by such Lender of a participation in such rights and obligations in accordance with paragraph&nbsp;(e) of this Section. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>Register</I>. The Administrative Agent, acting for this purpose as a <FONT STYLE="white-space:nowrap">non-fiduciary</FONT> agent of
Borrowers, shall maintain at one of its offices a copy of each Assignment Agreement delivered to it and a register for the recordation of the names and addresses of the Lenders, and the Commitment of, and principal amount (and stated interest) of
the Term Loans owing to, each Lender pursuant to the terms hereof from time to time (the <I>&#147;Register&#148;</I>). The entries in the Register shall be conclusive absent manifest error, and Borrowers, the Administrative Agent, and the Lenders
shall treat each Person whose name is recorded in the Register pursuant to the terms hereof as a Lender hereunder for all purposes of this Agreement, notwithstanding notice to the contrary. The Register shall be available for inspection by Borrowers
and any Lender, at any reasonable time and from time to time upon reasonable prior notice. No assignment shall be effective for purposes of this Agreement unless (i)&nbsp;it has been recorded in the Register as provided in this paragraph and
(ii)&nbsp;any written consent to such assignment required by paragraph&nbsp;(b) of this Section has been obtained. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-114- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <I>Participations</I>. Any Lender may at any time, without the consent of, or notice to,
Borrowers, sell participations to any Person (a <I>&#147;Participant&#148;</I>), other than an Ineligible Assignee, in all or a portion of such Lender&#146;s rights and obligations under the Loan Documents (including all or a portion of its
Commitment and the Term Loans owing to it); <I>provided</I> that (i)&nbsp;such Lender&#146;s obligations under the Loan Documents shall remain unchanged, (ii)&nbsp;such Lender shall remain solely responsible to the other parties hereto for the
performance of such obligations and (iii)&nbsp;Borrowers shall continue to deal solely and directly with such Lender in connection therewith. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) Any agreement or instrument pursuant to which a Lender sells such a participation shall provide that such Lender shall retain the sole
right to enforce this Agreement and to approve any amendment, modification or waiver of any provision of this Agreement; <I>provided</I> that such agreement or instrument may provide that such Lender will not, without the consent of the Participant,
agree to any amendment, modification or waiver that would (i)&nbsp;increase or extend the term of such Lender&#146;s Commitment, (ii)&nbsp;extend the date fixed for the payment of principal of or interest on the Term Loan or any portion of any fee
hereunder payable to the Participant, (iii)&nbsp;reduce the amount of any such payment of principal, or (iv)&nbsp;reduce the rate at which interest is payable thereon to a level below the rate at which the Participant is entitled to receive such
interest. Each Borrower agrees that each Participant shall be entitled to the benefits of Section&nbsp;5.03 (subject to the requirements and limitations therein, including the requirements under Section&nbsp;5.03(f) (it being understood that the
documentation required under Section&nbsp;5.03(f) shall be delivered to Administrative Borrower and the participating Lender)) to the same extent as if it were a Lender and had acquired its interest by assignment pursuant to Section&nbsp;13.05(a),
<I>provided</I> that such Participant (A)&nbsp;agrees to be subject to the provisions of Section&nbsp;5.03(h) as if it were an assignee under Section&nbsp;13.05(a); and (B)&nbsp;shall not be entitled to receive any greater payment under
Section&nbsp;5.03, with respect to any participation, than its participating Lender would have been entitled to receive, unless the sale of the participation to such Participant is made with Borrowers&#146; prior written consent. To the extent
permitted by Law, each Participant also shall be entitled to the benefits of Section&nbsp;4.04(a) as though it were a Lender. Each Lender that sells a participation shall, acting solely for this purpose as a
<FONT STYLE="white-space:nowrap">non-fiduciary</FONT> agent of Borrowers, maintain a register on which it enters the name and address of each Participant and the principal amounts (and stated interest) of each Participant&#146;s interest in the Term
Loans or other obligations under the Loan Documents (the <I>&#147;Participant Register&#148;</I>); <I>provided</I> that no Lender shall have any obligation to disclose all or any portion of the Participant Register (including the identity of any
Participant or any information relating to a Participant&#146;s interest in any commitments, loans, letters of credit or its other obligations under any Loan Document) to any Person except to the extent that such disclosure is necessary to establish
that such commitment, loan, letter of credit or other obligation is in registered form under <FONT STYLE="white-space:nowrap">Section&nbsp;5f.103-1(c)</FONT> of the United States Treasury Regulations. The entries in the Participant Register shall be
conclusive absent manifest error, and such Lender shall treat each Person whose name is recorded in the Participant Register as the owner of such participation for all purposes of this Agreement notwithstanding any notice to the contrary. The
parties hereto intend that all commitments, loans, letters of credit or other obligations under any Loan Document are at all times maintained in &#147;registered form&#148; within the meaning of Section&nbsp;163(f), 871(h)(2) and 881(c)(2) of the
Code and any related United States Treasury Regulations (or any other relevant or successor provisions of the Code or of such United States Treasury Regulations), and the Register and Participant Register shall be maintained in accordance with such
intention. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-115- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <I>Certain Pledges</I>. Subject to Section&nbsp;13.05(d), the Lenders may at any time
pledge or assign a security interest in all or any portion of its rights under this Agreement and any other Loan Document to secure obligations of the Lenders, including any pledge or assignment to secure obligations to a Federal Reserve Bank or
another central bank; <I>provided</I> that no such pledge or assignment shall release the Lenders from any of their obligations hereunder or substitute any such pledgee or assignee for the Lenders as a party hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;13.06.</I> <I>Survival</I><I>.</I> The obligations of each Obligor under Sections&nbsp;5.01, 5.02, 5.03, 13.03,
13.05, 13.09, 13.10, 13.11, 13.12, 13.13, 13.14 and Article&nbsp;11 (solely to the extent guaranteeing any of the obligations under the foregoing Sections) shall survive the repayment of the Obligations and the termination of the Commitments and, in
the case of any Lender&#146;s assignment of any interest in the Commitments or the Term Loans hereunder, shall survive, in the case of any event or circumstance that occurred prior to the effective date of such assignment, the making of such
assignment, notwithstanding that such Lenders may cease to be a &#147;Lender&#148; hereunder. In addition, each representation and warranty made, or deemed to be made by a notice of the Term Loans, herein or pursuant hereto shall survive the making
of such representation and warranty. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;13.07.</I> <I>Captions</I><I>.</I> The table of contents and captions
and section headings appearing herein are included solely for convenience of reference and are not intended to affect the interpretation of any provision of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;13.08.</I> <I>Counterparts</I><I>.</I> This Agreement may be executed in any number of counterparts, all of
which taken together shall constitute one and the same instrument and any of the parties hereto may execute this Agreement by signing any such counterpart. Delivery of an executed signature page of this Agreement by facsimile transmission,
electronic transmission (in PDF format) or DocuSign shall be effective as delivery of a manually executed counterpart hereof. The words &#147;execution,&#148; &#147;signed,&#148; &#147;signature,&#148; and words of like import in any Assignment
Agreement shall be deemed to include electronic signatures or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature or the use of a <FONT
STYLE="white-space:nowrap">paper-based</FONT> recordkeeping system, as the case may be, to the extent and as provided for in any applicable Law, including the Federal Electronic Signatures in Global and National Commerce Act, the New&nbsp;York State
Electronic Signatures and Records Act, or any other similar state laws based on the Uniform&nbsp;Electronic Transactions Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;13.09.</I> <I>Governing Law</I><I>.</I> T<SMALL>HIS</SMALL> A<SMALL>GREEMENT</SMALL> <SMALL>AND</SMALL>
<SMALL>THE</SMALL> <SMALL>OTHER</SMALL> L<SMALL>OAN</SMALL> D<SMALL>OCUMENTS</SMALL> (<SMALL>OTHER</SMALL> <SMALL>THAN</SMALL> <SMALL>ANY</SMALL> L<SMALL>OAN</SMALL> D<SMALL>OCUMENT</SMALL> <SMALL>WHICH</SMALL> <SMALL>IS</SMALL>
<SMALL>SPECIFICALLY</SMALL> <SMALL>GOVERNED</SMALL> <SMALL>BY</SMALL> <SMALL>THE</SMALL> <SMALL>LAWS</SMALL> <SMALL>OF</SMALL> <SMALL>ANOTHER</SMALL> <SMALL>JURISDICTION</SMALL>), <SMALL>THE</SMALL> <SMALL>RIGHTS</SMALL> <SMALL>AND</SMALL>
<SMALL>OBLIGATIONS</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL> <SMALL>PARTIES</SMALL> <SMALL>HEREUNDER</SMALL> <SMALL>AND</SMALL> <SMALL>THEREUNDER</SMALL>, <SMALL>AND</SMALL> <SMALL>ALL</SMALL> <SMALL>CLAIMS</SMALL>, <SMALL>DISPUTES</SMALL>
<SMALL>AND</SMALL> <SMALL>MATTERS</SMALL> <SMALL>ARISING</SMALL> <SMALL>HEREUNDER</SMALL> <SMALL>OR</SMALL> <SMALL>THEREUNDER</SMALL> <SMALL>OR</SMALL> <SMALL>RELATED</SMALL> <SMALL>HERETO</SMALL> <SMALL>OR</SMALL> <SMALL>THERETO</SMALL>,
<SMALL>SHALL</SMALL> <SMALL>BE</SMALL> <SMALL>GOVERNED</SMALL> <SMALL>BY</SMALL>, <SMALL>AND</SMALL> <SMALL>CONSTRUED</SMALL> <SMALL>IN</SMALL> <SMALL>ACCORDANCE</SMALL> <SMALL>WITH</SMALL>, <SMALL>THE</SMALL> <SMALL>LAWS</SMALL> <SMALL>OF</SMALL>
<SMALL>THE</SMALL> S<SMALL>TATE</SMALL> <SMALL>OF</SMALL> N<SMALL>EW</SMALL>&nbsp;Y<SMALL>ORK</SMALL> <SMALL>APPLICABLE</SMALL> <SMALL>TO</SMALL> <SMALL>CONTRACTS</SMALL> <SMALL>EXECUTED</SMALL> <SMALL>IN</SMALL> <SMALL>AND</SMALL> <SMALL>TO</SMALL>
<SMALL>BE</SMALL> <SMALL>PERFORMED</SMALL> <SMALL>ENTIRELY</SMALL> <SMALL>WITHIN</SMALL> <SMALL>THAT</SMALL> S<SMALL>TATE</SMALL>, <SMALL>WITHOUT</SMALL> <SMALL>REFERENCE</SMALL> <SMALL>TO</SMALL> <SMALL>CONFLICTS</SMALL> <SMALL>OF</SMALL>
<SMALL>LAWS</SMALL> <SMALL>PROVISIONS</SMALL> (<SMALL>OTHER</SMALL> <SMALL>THAN</SMALL> S<SMALL>ECTION</SMALL><FONT STYLE="white-space:nowrap">&nbsp;5-1401</FONT> <SMALL>OF</SMALL> <SMALL>THE</SMALL> N<SMALL>EW</SMALL>&nbsp;Y<SMALL>ORK</SMALL>
G<SMALL>ENERAL</SMALL> O<SMALL>BLIGATIONS</SMALL> L<SMALL>AW</SMALL>). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-116- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;13.10.</I> <I>Jurisdiction, Service of Process and Venue</I>.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Submission to Jurisdiction</I>. E<SMALL>ACH</SMALL> <SMALL>PARTY</SMALL> <SMALL>HERETO</SMALL> <SMALL>AGREES</SMALL>
<SMALL>THAT</SMALL> <SMALL>ANY</SMALL> <SMALL>SUIT</SMALL>, <SMALL>ACTION</SMALL> <SMALL>OR</SMALL> <SMALL>PROCEEDING</SMALL> <SMALL>WITH</SMALL> <SMALL>RESPECT</SMALL> <SMALL>TO</SMALL> <SMALL>THIS</SMALL> A<SMALL>GREEMENT</SMALL> <SMALL>OR</SMALL>
<SMALL>ANY</SMALL> <SMALL>OTHER</SMALL> L<SMALL>OAN</SMALL> D<SMALL>OCUMENT</SMALL> (<SMALL>EXCEPT</SMALL>, <SMALL>WITH</SMALL> <SMALL>RESPECT</SMALL> <SMALL>TO</SMALL> <SMALL>ANY</SMALL> <SMALL>OTHER</SMALL> L<SMALL>OAN</SMALL>
D<SMALL>OCUMENT</SMALL> <SMALL>THAT</SMALL> <SMALL>EXPRESSLY</SMALL> <SMALL>PROVIDES</SMALL> <SMALL>FOR</SMALL> <SMALL>A</SMALL> <SMALL>DIFFERENT</SMALL> <SMALL>JURISDICTION</SMALL> <SMALL>AS</SMALL> <SMALL>SET</SMALL> <SMALL>FORTH</SMALL>
<SMALL>THEREIN</SMALL>) <SMALL>TO</SMALL> <SMALL>WHICH</SMALL> <SMALL>IT</SMALL> <SMALL>IS</SMALL> <SMALL>A</SMALL> <SMALL>PARTY</SMALL> <SMALL>OR</SMALL> <SMALL>ANY</SMALL> <SMALL>JUDGMENT</SMALL> <SMALL>ENTERED</SMALL> <SMALL>BY</SMALL>
<SMALL>ANY</SMALL> <SMALL>COURT</SMALL> <SMALL>IN</SMALL> <SMALL>RESPECT</SMALL> <SMALL>THEREOF</SMALL> <SMALL>SHALL</SMALL> <SMALL>BE</SMALL> <SMALL>BROUGHT</SMALL> <SMALL>IN</SMALL> <SMALL>THE</SMALL> S<SMALL>UPREME</SMALL> C<SMALL>OURT</SMALL>
<SMALL>OF</SMALL> <SMALL>THE</SMALL> S<SMALL>TATE</SMALL> <SMALL>OF</SMALL> N<SMALL>EW</SMALL>&nbsp;Y<SMALL>ORK</SMALL> <SMALL>SITTING</SMALL> <SMALL>IN</SMALL> N<SMALL>EW</SMALL>&nbsp;Y<SMALL>ORK</SMALL> C<SMALL>OUNTY</SMALL> <SMALL>OR</SMALL>
<SMALL>IN</SMALL> <SMALL>THE</SMALL> U<SMALL>NITED</SMALL> S<SMALL>TATES</SMALL> D<SMALL>ISTRICT</SMALL> C<SMALL>OURT</SMALL> <SMALL>FOR</SMALL> <SMALL>THE</SMALL> S<SMALL>OUTHERN</SMALL> D<SMALL>ISTRICT</SMALL> <SMALL>OF</SMALL>
N<SMALL>EW</SMALL>&nbsp;Y<SMALL>ORK</SMALL> <SMALL>AND</SMALL> <SMALL>IRREVOCABLY</SMALL> <SMALL>SUBMITS</SMALL> <SMALL>TO</SMALL> <SMALL>THE</SMALL> <SMALL>EXCLUSIVE</SMALL> <SMALL>JURISDICTION</SMALL> <SMALL>OF</SMALL> <SMALL>EACH</SMALL>
<SMALL>SUCH</SMALL> <SMALL>COURT</SMALL> <SMALL>FOR</SMALL> <SMALL>THE</SMALL> <SMALL>PURPOSE</SMALL> <SMALL>OF</SMALL> <SMALL>ANY</SMALL> <SMALL>SUCH</SMALL> <SMALL>SUIT</SMALL>, <SMALL>ACTION</SMALL>, <SMALL>PROCEEDING</SMALL> <SMALL>OR</SMALL>
<SMALL>JUDGMENT</SMALL>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Alternative Process</I>. Nothing herein shall in any way be deemed to limit the ability of any party to
serve any such process or summonses in any other manner permitted by applicable Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Waiver of Venue, Etc.</I> E<SMALL>ACH</SMALL>
<SMALL>PARTY</SMALL> <SMALL>HERETO</SMALL> <SMALL>IRREVOCABLY</SMALL> <SMALL>WAIVES</SMALL> <SMALL>TO</SMALL> <SMALL>THE</SMALL> <SMALL>FULLEST</SMALL> <SMALL>EXTENT</SMALL> <SMALL>PERMITTED</SMALL> <SMALL>BY</SMALL> <SMALL>LAW</SMALL>
<SMALL>ANY</SMALL> <SMALL>OBJECTION</SMALL> <SMALL>THAT</SMALL> <SMALL>IT</SMALL> <SMALL>MAY</SMALL> <SMALL>NOW</SMALL> <SMALL>OR</SMALL> <SMALL>HEREAFTER</SMALL> <SMALL>HAVE</SMALL> <SMALL>TO</SMALL> <SMALL>THE</SMALL> <SMALL>LAYING</SMALL>
<SMALL>OF</SMALL> <SMALL>THE</SMALL> <SMALL>VENUE</SMALL> <SMALL>OF</SMALL> <SMALL>ANY</SMALL> <SMALL>SUIT</SMALL>, <SMALL>ACTION</SMALL> <SMALL>OR</SMALL> <SMALL>PROCEEDING</SMALL> <SMALL>ARISING</SMALL> <SMALL>OUT</SMALL> <SMALL>OF</SMALL>
<SMALL>OR</SMALL> <SMALL>RELATING</SMALL> <SMALL>TO</SMALL> <SMALL>THIS</SMALL> A<SMALL>GREEMENT</SMALL> <SMALL>OR</SMALL> <SMALL>ANY</SMALL> <SMALL>OTHER</SMALL> L<SMALL>OAN</SMALL> D<SMALL>OCUMENT</SMALL> <SMALL>AND</SMALL> <SMALL>HEREBY</SMALL>
<SMALL>FURTHER</SMALL> <SMALL>IRREVOCABLY</SMALL> <SMALL>WAIVES</SMALL> <SMALL>TO</SMALL> <SMALL>THE</SMALL> <SMALL>FULLEST</SMALL> <SMALL>EXTENT</SMALL> <SMALL>PERMITTED</SMALL> <SMALL>BY</SMALL> <SMALL>LAW</SMALL> <SMALL>ANY</SMALL>
<SMALL>CLAIM</SMALL> <SMALL>THAT</SMALL> <SMALL>ANY</SMALL> <SMALL>SUCH</SMALL> <SMALL>SUIT</SMALL>, <SMALL>ACTION</SMALL> <SMALL>OR</SMALL> <SMALL>PROCEEDING</SMALL> <SMALL>BROUGHT</SMALL> <SMALL>IN</SMALL> <SMALL>ANY</SMALL> <SMALL>SUCH</SMALL>
<SMALL>COURT</SMALL> <SMALL>HAS</SMALL> <SMALL>BEEN</SMALL> <SMALL>BROUGHT</SMALL> <SMALL>IN</SMALL> <SMALL>AN</SMALL> <SMALL>INCONVENIENT</SMALL> <SMALL>FORUM</SMALL>. A <SMALL>FINAL</SMALL> <SMALL>JUDGMENT</SMALL> (<SMALL>IN</SMALL>
<SMALL>RESPECT</SMALL> <SMALL>OF</SMALL> <SMALL>WHICH</SMALL> <SMALL>TIME</SMALL> <SMALL>FOR</SMALL> <SMALL>ALL</SMALL> <SMALL>APPEALS</SMALL> <SMALL>HAS</SMALL> <SMALL>ELAPSED</SMALL>) <SMALL>IN</SMALL> <SMALL>ANY</SMALL> <SMALL>SUCH</SMALL>
<SMALL>SUIT</SMALL>, <SMALL>ACTION</SMALL> <SMALL>OR</SMALL> <SMALL>PROCEEDING</SMALL> <SMALL>SHALL</SMALL> <SMALL>BE</SMALL> <SMALL>CONCLUSIVE</SMALL> <SMALL>AND</SMALL> <SMALL>MAY</SMALL> <SMALL>BE</SMALL> <SMALL>ENFORCED</SMALL> <SMALL>IN</SMALL>
<SMALL>ANY</SMALL> <SMALL>COURT</SMALL> <SMALL>TO</SMALL> <SMALL>THE</SMALL> <SMALL>JURISDICTION</SMALL> <SMALL>OF</SMALL> <SMALL>WHICH</SMALL> <SMALL>SUCH</SMALL> O<SMALL>BLIGOR</SMALL> <SMALL>IS</SMALL> <SMALL>OR</SMALL> <SMALL>MAY</SMALL>
<SMALL>BE</SMALL> <SMALL>SUBJECT</SMALL>, <SMALL>BY</SMALL> <SMALL>SUIT</SMALL> <SMALL>UPON</SMALL> <SMALL>JUDGMENT</SMALL>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;13.11.</I> <I>Waiver of Jury Trial</I>. E<SMALL>ACH</SMALL> <SMALL>PARTY</SMALL> <SMALL>HERETO</SMALL>
<SMALL>HEREBY</SMALL> <SMALL>IRREVOCABLY</SMALL> <SMALL>WAIVES</SMALL>, <SMALL>TO</SMALL> <SMALL>THE</SMALL> <SMALL>FULLEST</SMALL> <SMALL>EXTENT</SMALL> <SMALL>PERMITTED</SMALL> <SMALL>BY</SMALL> <SMALL>APPLICABLE</SMALL> <SMALL>LAW</SMALL>,
<SMALL>ANY</SMALL> <SMALL>AND</SMALL> <SMALL>ALL</SMALL> <SMALL>RIGHT</SMALL> <SMALL>TO</SMALL> <SMALL>TRIAL</SMALL> <SMALL>BY</SMALL> <SMALL>JURY</SMALL> <SMALL>IN</SMALL> <SMALL>ANY</SMALL> <SMALL>SUIT</SMALL>, <SMALL>ACTION</SMALL>
<SMALL>OR</SMALL> <SMALL>PROCEEDING</SMALL> <SMALL>ARISING</SMALL> <SMALL>OUT</SMALL> <SMALL>OF</SMALL> <SMALL>OR</SMALL> <SMALL>RELATING</SMALL> <SMALL>TO</SMALL> <SMALL>THIS</SMALL> A<SMALL>GREEMENT</SMALL>, <SMALL>THE</SMALL> <SMALL>OTHER</SMALL>
<SMALL>LOAN</SMALL> <SMALL>DOCUMENTS</SMALL> <SMALL>OR</SMALL> <SMALL>THE</SMALL> <SMALL>TRANSACTIONS</SMALL> <SMALL>CONTEMPLATED</SMALL> <SMALL>HEREBY</SMALL> <SMALL>OR</SMALL> <SMALL>THEREBY</SMALL>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;13.12.</I> <I>Waiver of Immunity</I>. T<SMALL>O</SMALL> <SMALL>THE</SMALL> <SMALL>EXTENT</SMALL>
<SMALL>THAT</SMALL> <SMALL>ANY</SMALL> O<SMALL>BLIGOR</SMALL> <SMALL>MAY</SMALL> <SMALL>BE</SMALL> <SMALL>OR</SMALL> <SMALL>BECOME</SMALL> <SMALL>ENTITLED</SMALL> <SMALL>TO</SMALL> <SMALL>CLAIM</SMALL> <SMALL>FOR</SMALL> <SMALL>ITSELF</SMALL>
<SMALL>OR</SMALL> <SMALL>ITS</SMALL> <SMALL>PROPERTY</SMALL> <SMALL>OR</SMALL> <SMALL>REVENUES</SMALL> <SMALL>ANY</SMALL> <SMALL>IMMUNITY</SMALL> <SMALL>ON</SMALL> <SMALL>THE</SMALL> <SMALL>GROUND</SMALL> <SMALL>OF</SMALL> <SMALL>SOVEREIGNTY</SMALL>
<SMALL>OR</SMALL> <SMALL>THE</SMALL> <SMALL>LIKE</SMALL> <SMALL>FROM</SMALL> <SMALL>SUIT</SMALL>, <SMALL>COURT</SMALL> <SMALL>JURISDICTION</SMALL>, <SMALL>ATTACHMENT</SMALL> <SMALL>PRIOR</SMALL> <SMALL>TO</SMALL> <SMALL>JUDGMENT</SMALL>,
<SMALL>ATTACHMENT</SMALL> <SMALL>IN</SMALL> <SMALL>AID</SMALL> <SMALL>OF</SMALL> <SMALL>EXECUTION</SMALL> <SMALL>OF</SMALL> <SMALL>A</SMALL> <SMALL>JUDGMENT</SMALL> <SMALL>OR</SMALL> <SMALL>EXECUTION</SMALL> <SMALL>OF</SMALL> <SMALL>A</SMALL>
<SMALL>JUDGMENT</SMALL>, <SMALL>AND</SMALL> <SMALL>TO</SMALL> <SMALL>THE</SMALL> <SMALL>EXTENT</SMALL> <SMALL>THAT</SMALL> <SMALL>IN</SMALL> <SMALL>ANY</SMALL> <SMALL>SUCH</SMALL> <SMALL>JURISDICTION</SMALL> <SMALL>THERE</SMALL> <SMALL>MAY</SMALL>
<SMALL>BE</SMALL> <SMALL>ATTRIBUTED</SMALL> <SMALL>SUCH</SMALL> <SMALL>AN</SMALL> <SMALL>IMMUNITY</SMALL> (<SMALL>WHETHER</SMALL> <SMALL>OR</SMALL> <SMALL>NOT</SMALL> <SMALL>CLAIMED</SMALL>), <SMALL>SUCH</SMALL> O<SMALL>BLIGOR</SMALL>
<SMALL>HEREBY</SMALL> <SMALL>IRREVOCABLY</SMALL> <SMALL>AGREES</SMALL> <SMALL>NOT</SMALL> <SMALL>TO</SMALL> <SMALL>CLAIM</SMALL> <SMALL>AND</SMALL> <SMALL>HEREBY</SMALL> <SMALL>IRREVOCABLY</SMALL> <SMALL>WAIVES</SMALL> <SMALL>SUCH</SMALL>
<SMALL>IMMUNITY</SMALL> <SMALL>WITH</SMALL> <SMALL>RESPECT</SMALL> <SMALL>TO</SMALL> <SMALL>ITS</SMALL> <SMALL>OBLIGATIONS</SMALL> <SMALL>UNDER</SMALL> <SMALL>THIS</SMALL> A<SMALL>GREEMENT</SMALL> <SMALL>AND</SMALL> <SMALL>THE</SMALL>
<SMALL>OTHER</SMALL> <SMALL>LOAN</SMALL> <SMALL>DOCUMENTS</SMALL>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;13.13.</I> <I>Entire
Agreement</I><I>.</I> This Agreement and the other Loan Documents constitute the entire agreement among the parties with respect to the subject matter hereof and thereof and supersede any and all previous agreements and understandings, oral or
written, relating to the subject matter hereof. Each Obligor acknowledges, represents and warrants that in deciding to enter into this Agreement and the other Loan Documents or in taking or not taking any action hereunder or thereunder, it has not
relied, and will not rely, on any statement, representation, warranty, covenant, agreement or understanding, whether written or oral, of or with the Lenders other than those expressly set forth in this Agreement and the other Loan Documents. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-117- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;13.14.</I> <I>Severability</I><I>.</I> If any provision hereof
is found by a court to be invalid or unenforceable, to the fullest extent permitted by applicable Law the parties agree that such invalidity or unenforceability shall not impair the validity or enforceability of any other provision hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;13.15.</I> <I>No Fiduciary Relationship</I><I>.</I> The Administrative Agent, each Lender and their Affiliates
(collectively, solely for purposes of this paragraph, the <I>&#147;</I><I>Lenders</I><I>&#148;</I>), may have economic interests that conflict with those of the Obligors, their members or equity holders and/or their Affiliates (collectively, solely
for purposes of this paragraph, the <I>&#147;</I><I>Obligors</I><I>&#148;</I>). The Obligors acknowledge that the Lenders have no fiduciary relationship with, or fiduciary duty to, any Obligor arising out of or in connection with this Agreement or
the other Loan Documents, and the relationship between each Lender and each Obligor are solely that of creditors and debtors. This Agreement and the other Loan Documents do not create a joint venture among the parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;13.16.</I> <I>USA</I><I></I><I>&nbsp;Patriot Act</I><I>.</I> The Administrative Agent and the Lenders hereby
notify the Obligors that pursuant to the requirements of the USA&nbsp;PATRIOT Act (Title&nbsp;III of Pub. L. <FONT STYLE="white-space:nowrap">107-56</FONT> (signed into law October&nbsp;26, 2001)) (the <I>&#147;Act&#148;</I>) and 31&nbsp;C.F.R.
&#167;&nbsp;1010.230 (the <I>&#147;Beneficial Ownership Regulation&#148;</I>), they are required to obtain, verify and record information that identifies the Obligors, which information includes the name and address of each Obligor and other
information that will allow the Administrative Agent and such Lender to identify each Obligor in accordance with the Act and Beneficial Ownership Regulation, including a beneficial ownership certification in form and substance acceptable to the
Administrative Agent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;13.17.</I> <I>Treatment of Certain Information; Confidentiality</I><I>.</I> The
Lenders agree to maintain the confidentiality of the Information (as defined below), except that Information may be disclosed to (a)&nbsp;its Affiliates and to its and its Affiliates&#146; respective partners, directors, officers, employees, agents,
trustees, advisors and representatives (collectively, <I>&#147;</I><I>Representatives</I><I>&#148;</I>) (it being understood that the Persons to whom such disclosure is made will be informed of the confidential nature of such information and
instructed to keep such Information confidential), (b)&nbsp;to the extent requested by any regulatory authority purporting to have jurisdiction over it (including any <FONT STYLE="white-space:nowrap">self-regulatory</FONT> authority, such as FINRA
or the National Association of Insurance Commissioners) or any exchange, (c)&nbsp;to the extent required by the applicable Laws or by any subpoena or similar legal process, (d)&nbsp;to any other party hereto, (e)&nbsp;in connection with the exercise
of any remedies hereunder or under any other Loan Document or any action or proceeding relating to this Agreement or any other Loan Document or the enforcement of rights hereunder or thereunder, (f)&nbsp;subject to an agreement containing provisions
substantially the same as those in this Section, to (i)&nbsp;any assignee of or Participant in, or any prospective assignee of or Participant in, any of its rights or obligations under this Agreement or (ii)&nbsp;any actual or prospective
counterparty (or its advisors) to any swap or derivative transaction relating to Borrowers or any Obligor and its obligation, (g)&nbsp;with the consent of Borrowers or (h)&nbsp;to the extent such Information (x)&nbsp;becomes publicly available other
than as a result of a breach of this Section or (y)&nbsp;becomes available to the Lender, or any of its respective Representatives on a nonconfidential basis from a source other than Borrowers or any other Obligor. For purposes of this Section,
<I>&#147;</I><I>Information</I><I>&#148;</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-118- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
means all information received from an Obligor relating such Obligor or its Subsidiary or any of their respective businesses, except that the term &#147;Information&#148; shall not include, and
the Lenders shall not be subject to any confidentiality obligation with respect to any information that (i)&nbsp;is or becomes available to the Lender or any of its Representatives on a nonconfidential basis prior to disclosure by an Obligor or its
Subsidiary, (ii)&nbsp;becomes available to a Lender or any of its Representatives after disclosure by Parent, Borrowers or any other Obligor from a source that, to the knowledge of such Lender, is not subject to a confidentiality obligation to
Parent, Borrowers or such other Obligor, (iii)&nbsp;is or becomes publicly available other than as a result of a breach by such Lender, or (iv)&nbsp;is developed by a Lender or any of its Representatives. Any Person required to maintain the
confidentiality of Information as provided in this Section shall be considered to have complied with its obligation to do so if such Person has exercised the same degree of care to maintain the confidentiality of such Information as such Person
would accord to its own confidential information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the case of any Lender that has elected to receive material <FONT
STYLE="white-space:nowrap">non-public</FONT> information pursuant to the last paragraph of Section&nbsp;8.02, such Lender acknowledges that (a)&nbsp;the Information may include material <FONT STYLE="white-space:nowrap">non-public</FONT> information
concerning an Obligor or its Subsidiary, as the case may be, (b)&nbsp;it has developed compliance procedures regarding the use of material <FONT STYLE="white-space:nowrap">non-public</FONT> information and (c)&nbsp;it will handle such material <FONT
STYLE="white-space:nowrap">non-public</FONT> information in accordance with applicable Law, including United States federal and state securities Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;13.18.</I> <I>R</I><I>eleases of Guarantees and Liens</I>. Notwithstanding anything to the contrary contained
herein or in any other Loan Document, each Lender agrees, and the Administrative Agent is hereby irrevocably authorized by each Lender and given a limited power of attorney by each Lender to perform the actions described hereafter in this
Section&nbsp;13.18 (without requirement of notice to or consent of any Lender except as expressly required by Section&nbsp;13.04) to take any action reasonably requested by Borrowers having the effect of releasing any Collateral or Obligations
(i)&nbsp;to the extent necessary to permit consummation of any transaction not prohibited by any Loan Document or that has been consented to by the Lenders or (ii)&nbsp;under the circumstances described in Section&nbsp;12.09(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;13.19.</I> <I>Acknowledgement and Consent to Bail</I><I><FONT STYLE="white-space:nowrap">-In</FONT> of Affected
Financial Institutions</I><I>.</I> Notwithstanding anything to the contrary in any Loan Document or in any other agreement, arrangement or understanding among any such parties, each party hereto acknowledges that any liability of any Affected
Financial Institution arising under any Loan Document, to the extent such liability is unsecured, may be subject to the <FONT STYLE="white-space:nowrap">write-down</FONT> and conversion powers of the applicable Resolution Authority and agrees and
consents to, and acknowledges and agrees to be bound by: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) the application of any
<FONT STYLE="white-space:nowrap">Write-Down</FONT> and Conversion Powers by the applicable Resolution Authority to any such liabilities arising hereunder which may be payable to it by any party hereto that is an Affected Financial Institution; and
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) the effects of any <FONT STYLE="white-space:nowrap">Bail-In</FONT> Action on any such liability, including, if
applicable: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) a reduction in full or in part or cancellation of any such liability; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-119- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) a conversion of all, or a portion of, such liability into shares or
other instruments of ownership in such Affected Financial Institution, its parent undertaking, or a bridge institution that may be issued to it or otherwise conferred on it, and that such shares or other instruments of ownership will be accepted by
it in lieu of any rights with respect to any such liability under this Agreement or any other Loan Document; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) the
variation of the terms of such liability in connection with the exercise of the <FONT STYLE="white-space:nowrap">write-down</FONT> and conversion powers of the applicable Resolution Authority. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;13.20</I> <I>Administrative Borrower. </I>Each Borrower hereby designates OpCo as the administrative Borrower
(in such capacity, the <I>&#147;Administrative Borrower&#148;</I>) to act as its representative and agent on its behalf, for the purposes of giving instructions with respect to the disbursement of the proceeds of the Term Loans, giving and receiving
all notices and consents hereunder or under any of the other Loan Documents and taking all other actions on behalf of each Borrower under the Loan Documents. The Administrative Agent and each Lender may regard any notice or other communication
pursuant to any Loan Document from OpCo in its capacity as Administrative Borrower as a notice or communication from each Borrower. Each warranty, covenant, agreement and undertaking made on behalf of each Borrower by OpCo in its capacity as
Administrative Borrower for the Borrowers shall be deemed for all purposes to have been made by each Borrower and shall be binding upon and enforceable against each Borrower to the same extent as it if the same had been made directly by each
Borrower. Such appointment shall remain in full force and effect unless and until the Administrative Agent shall have received written notice signed by each Borrower terminating such appointment. Borrowers shall have the right, to appoint another
Borrower as Administrative Borrower with the prior written consent of the Administrative Agent (such consent not to be unreasonably withheld or delayed). It is understood that the handling of the loan account and Collateral of the Borrowers in a
combined fashion, as more fully set forth herein, is done solely as an accommodation to the Borrowers in order to utilize the collective borrowing powers of the Borrowers in the most efficient and economical manner and at their request, and that
neither the Administrative Agent nor the Lenders shall incur liability to the Borrowers as a result hereof. Each Borrower expects to derive benefit, directly or indirectly, from the handling of the loan account and the Collateral in a combined
fashion since the successful operation of each Borrower is dependent on the continued successful performance of the integrated group. To induce the Administrative Agent and the Lenders to do so, and in consideration thereof, each Borrower hereby
jointly and severally agrees to indemnify the Administrative Agent and hold each Indemnified Party harmless against any and all liability, expense, loss or claim of damage or injury, made against such Indemnified Party by any Borrower or by any
third party whosoever, arising from or incurred by reason of (a)&nbsp;the handling of the loan account and Collateral of the Borrowers as herein provided, (b)&nbsp;the Administrative Agent and the Lenders relying on any instructions of
Administrative Borrower, or (c)&nbsp;any other action taken by the Administrative Agent or any Lender hereunder or under the other Loan Documents. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-120- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section&nbsp;13.21. Joint and Several Liability of Borrowers.</I> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Each Borrower is accepting joint and several liability hereunder and under the other Loan Documents in consideration of the
financial accommodations to be provided by the Administrative Agent and the Lenders under the Loan Documents, for the mutual benefit, directly and indirectly, of each Borrower and in consideration of the undertakings of the Borrowers to accept joint
and several liability for the Obligations. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Each Borrower, jointly and severally, hereby irrevocably and conditionally
accepts, not merely as a surety but also as a <FONT STYLE="white-space:nowrap">co-debtor,</FONT> joint and several liability with the other Borrower, with respect to the payment and performance of all of the Obligations (including any Obligations
arising under this Section&nbsp;13.21), it being the intention of the parties hereto that all the Obligations shall be the joint and several obligations of each Borrower without preferences or distinction among them. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) If and to the extent that any Borrower shall fail to make any payment with respect to any of the Obligations as and when
due or to perform any of the Obligations in accordance with the terms thereof, then in each such event the other Borrower will make such payment with respect to, or perform, such Obligation until such time as all of the Obligations are paid in full.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) The Obligations of each Borrower under the provisions of this Section&nbsp;13.21 constitute the absolute and
unconditional, full recourse Obligations of each Borrower enforceable against each Borrower to the full extent of its properties and assets, irrespective of the validity, regularity or enforceability of the provisions of this Agreement (other than
this Section&nbsp;13.21(d)) or any other circumstances whatsoever. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) Except as otherwise expressly provided in this
Agreement, each Borrower hereby waives notice of acceptance of its joint and several liability, notice of any Term Loans, notice of the occurrence of any Default, Event of Default, or of any demand for any payment under this Agreement, notice of any
action at any time taken or omitted by the Administrative Agent or the Lenders under or in respect of any of the Obligations, any requirement of diligence or to mitigate damages and, generally, to the extent permitted by applicable law, all demands,
notices and other formalities of every kind in connection with this Agreement (except as otherwise provided in this Agreement). Each Borrower hereby assents to, and waives notice of, any extension or postponement of the time for the payment of any
of the Obligations, the acceptance of any payment of any of the Obligations, the acceptance of any partial payment thereon, any waiver, consent or other action or acquiescence by the Administrative Agent or the Lenders at any time or times in
respect of any default by any Borrower in the performance or satisfaction of any term, covenant, condition or provision of this Agreement, any and all other indulgences whatsoever by the Administrative Agent or the Lenders in respect of any of the
Obligations, and the taking, addition, substitution or release, in whole or in part, at any time or times, of any security for any of the Obligations or the addition, substitution or release, in whole or in part, of any Borrower. Without limiting
the generality of the foregoing, each Borrower assents to any other action or delay in acting or failure to act on the part of the Administrative Agent or a Lender with respect to the failure by any Borrower to comply with any of its respective
Obligations, including, without limitation, any failure strictly or diligently to assert any right </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-121- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
or to pursue any remedy or to comply fully with applicable laws or regulations thereunder, which would, but for the provisions of this Section&nbsp;13.21 afford grounds for terminating,
discharging or relieving any Borrower, in whole or in part, from any of its Obligations under this Section&nbsp;13.21, it being the intention of each Borrower that, so long as any of the Obligations hereunder remain unsatisfied, the Obligations of
each Borrower under this Section&nbsp;13.21 shall not be discharged except by performance and then only to the extent of such performance. The Obligations of each Borrower under this Section&nbsp;13.21 shall not be diminished or rendered
unenforceable by any winding up, reorganization, arrangement, liquidation, reconstruction or similar proceeding with respect to any other Borrower or the Administrative Agent or a Lender. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) Each Borrower represents and warrants to the Administrative Agent and the Lenders that such Borrower is currently informed
of the financial condition of the Borrowers and of all other circumstances which a diligent inquiry would reveal and which bear upon the risk of nonpayment of the Obligations. Each Borrower further represents and warrants to the Administrative Agent
and the Lenders that such Borrower has read and understands the terms and conditions of the Loan Documents. Each Borrower hereby covenants that such Borrower will continue to keep informed of the other Borrower&#146;s financial condition and of all
other circumstances which bear upon the risk of nonpayment or nonperformance of the Obligations. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) The provisions of
this Section&nbsp;13.21 are made for the benefit of the Administrative Agent and each Lender, and their successors and assigns, and may be enforced by it or them from time to time against any or all of the Borrowers as often as occasion therefor may
arise and without requirement on the part of the Administrative Agent or each Lender, or any of their successors or assigns first to marshal any of its or their claims or to exercise any of its or their rights against any Borrower or to exhaust any
remedies available to it or them against any Borrower or to resort to any other source or means of obtaining payment of any of the Obligations hereunder or to elect any other remedy. The provisions of this Section&nbsp;13.21 shall remain in effect
until all of the Obligations shall have been paid in full or otherwise fully satisfied. If at any time, any payment, or any part thereof, made in respect of any of the Obligations, is rescinded or must otherwise be restored or returned by the
Administrative Agent or any Lender upon the insolvency, bankruptcy or reorganization of any Borrower, or otherwise, the provisions of this Section&nbsp;13.21 will forthwith be reinstated in effect, as though such payment had not been made. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) Each Borrower hereby agrees that it will not enforce any of its rights of contribution or subrogation against the other
Borrower with respect to any liability incurred by it hereunder or under any of the other Loan Documents, any payments made by it to the Administrative Agent or the Lenders with respect to any of the Obligations or any collateral security therefor
until such time as all of the Obligations have been paid in full in cash. Any claim which the Administrative Agent or a Lender may have against any Borrower with respect to any payments to the Administrative Agent or any Lender hereunder are hereby
expressly made subordinate and junior in right of payment, without limitation as to any increases in the Obligations arising hereunder or thereunder, to the prior payment in full in cash of the Obligations and, in the event of any insolvency,
bankruptcy, receivership, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-122- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
liquidation, reorganization or other similar proceeding under the laws of any jurisdiction relating to any Borrower, its debts or its assets, whether voluntary or involuntary, all such
Obligations shall be paid in full in cash before any payment or distribution of any character, whether in cash, securities or other property, shall be made to any Borrower therefor. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Each Borrower hereby agrees that after the occurrence and during the continuance of any Default or Event of Default, such
Borrower will not demand, sue for or otherwise attempt to collect any Indebtedness of any other Borrower owing to such Borrower until the Obligations shall have been paid in full in cash. If, notwithstanding the foregoing sentence, such Borrower
shall collect, enforce or receive any amounts in respect of such Indebtedness, such amounts shall be collected, enforced and received by such Borrower as trustee for the Administrative Agent, and such Borrower shall deliver any such amounts to the
Administrative Agent for application to the Obligations in accordance with this Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Section&nbsp;13.22. Judgment Currency.
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The obligations of any Obligor under this Agreement and the other Loan Documents to make payments in Dollars shall
not be discharged or satisfied by any tender or recovery pursuant to any judgment expressed in or converted into any currency other than Dollars, except to the extent that such tender or recovery results in the effective receipt by the
Administrative Agent or a Lender of the full amount of Dollars expressed to be payable to the Administrative Agent or such Lender under this Agreement or the other Loan Documents. If, for the purpose of obtaining or enforcing a judgment against any
Obligor in any court or in any jurisdiction, it becomes necessary to convert into or from any currency other than Dollars (such other currency, the &#147;<I>Judgment Currency</I>&#148;) an amount due in Dollars, the conversion shall be made at the
rate of exchange quoted by the Administrative Agent, determined, in each case, as of the Business Day immediately preceding the day on which the judgment is given (such Business Day, the &#147;<I>Judgment Currency Conversion Date</I>&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) If there is a change in the rate of exchange prevailing between the Judgment Currency Conversion Date and the date of
actual payment of the amount due, each Obligor covenants and agrees to pay, or cause to be paid, such additional amounts, if any (but in any event not a lesser amount), as may be necessary to ensure that the amount paid in the Judgment Currency,
when converted at the rate of exchange prevailing on the actual date of payment, will produce the amount of Dollars that could have been purchased with the amount of the Judgment Currency stipulated in the judgment or judicial award at the rate of
exchange prevailing on the Judgment Currency Conversion Date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) For purposes of determining any rate of exchange for
this Section&nbsp;13.22, such amounts shall include any premium and costs payable in connection with the purchase of Dollars. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-123- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Remainder of the Page Intentionally Left Blank; Signature Pages Follow] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-124- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL>, the parties hereto have
caused this Agreement to be duly executed and delivered as of the day and year first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">B<SMALL>ORROWERS</SMALL>:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">K<SMALL>ESTRA</SMALL> M<SMALL>EDICAL</SMALL> T<SMALL>ECHNOLOGIES</SMALL>, I<SMALL>NC</SMALL>.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Brian Webster</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Brian Webster</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: President and Chief Executive Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">W<SMALL>EST</SMALL> A<SMALL>FFUM</SMALL> H<SMALL>OLDINGS</SMALL> C<SMALL>ORP</SMALL>.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Brian Webster</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Brian Webster</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">G<SMALL>UARANTORS</SMALL>:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">K<SMALL>ESTRA</SMALL> M<SMALL>EDICAL</SMALL> T<SMALL>ECHNOLOGY</SMALL> S<SMALL>ERVICES</SMALL>, I<SMALL>NC</SMALL>.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Brian Webster</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Brian Webster</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: President and Chief Executive Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">W<SMALL>EST</SMALL> A<SMALL>FFUM</SMALL> I<SMALL>NTERMEDIATE</SMALL> H<SMALL>OLDINGS</SMALL> C<SMALL>ORP</SMALL>.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Brian Webster</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Brian Webster</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">W<SMALL>EST</SMALL> A<SMALL>FFUM</SMALL> H<SMALL>OLDINGS</SMALL> D<SMALL>ESIGNATED</SMALL> A<SMALL>CTIVITY</SMALL> C<SMALL>OMPANY</SMALL></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Brian Webster</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Brian Webster</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Director</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">P<SMALL>ERCEPTIVE</SMALL> C<SMALL>REDIT</SMALL> H<SMALL>OLDINGS</SMALL>&nbsp;IV, LP, </TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">&#8195;as Administrative Agent and a Lender</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Perceptive Credit Opportunities GP, LLC,</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">its
general partner</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Sandeep Dixit</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Sandeep Dixit</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Chief Credit Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Sam Chawla</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Sam Chawla</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Portfolio Manager</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-126- </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.12
<SEQUENCE>14
<FILENAME>d744414dex1012.htm
<DESCRIPTION>EX-10.12
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.12</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>E<SMALL>XHIBIT</SMALL> 10.12 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>ECOND</SMALL> A<SMALL>MENDMENT</SMALL> <SMALL>TO</SMALL> C<SMALL>REDIT</SMALL> A<SMALL>GREEMENT</SMALL> <SMALL>AND</SMALL>
G<SMALL>UARANTY</SMALL> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Second Amendment to Credit Agreement and Guaranty (herein, this <I>&#147;Agreement&#148;</I>) is entered
into as of February&nbsp;25, 2025 (the &#147;<I>Second Amendment Effective Date</I>&#148;), by and among K<SMALL>ESTRA</SMALL> M<SMALL>EDICAL</SMALL> T<SMALL>ECHNOLOGIES</SMALL>, I<SMALL>NC</SMALL>., a Delaware corporation (&#147;<I>OpCo</I>&#148;),
W<SMALL>EST</SMALL> A<SMALL>FFUM</SMALL> H<SMALL>OLDINGS</SMALL> C<SMALL>ORP</SMALL>., an exempted company incorporated with limited liability in the Cayman Islands (&#147;<I>West Affum Corp.</I>&#148; and together with OpCo, each a
&#147;<I>Borrower</I>&#148; and collectively, the &#147;<I>Borrower</I>&#148;), the Guarantors party hereto (each a &#147;<I>Guarantor</I>&#148;, and collectively with the Borrowers, the &#147;<I>Obligors</I>&#148;), the Lenders party hereto (each a
<I>&#147;Lender&#148;</I> and collectively, the &#147;<I>Lenders&#148;</I>) and P<SMALL>ERCEPTIVE</SMALL> C<SMALL>REDIT</SMALL> H<SMALL>OLDINGS</SMALL> IV, LP, a Delaware limited partnership, as a Lender as administrative agent for the Lenders (in
such capacity, together with its successors and assigns, the <I>&#147;Administrative Agent&#148;</I>). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>R<SMALL>ECITALS</SMALL>:
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A. The Lenders have extended credit to the Borrowers on the terms and conditions set forth in that certain Credit Agreement and
Guaranty, dated as of September&nbsp;29, 2023 (the <I>&#147;Existing</I> <I>Credit Agreement&#148;</I>; the Existing Credit Agreement as amended by that certain Consent and First Amendment to Credit Agreement and Guaranty, dated as of July&nbsp;12,
2024, and as further amended by this Agreement, the &#147;<I>Credit Agreement</I>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">B. The Borrowers have requested that the
Administrative Agent and the Lenders agree to amend certain provisions of the Existing Credit Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">C. The parties hereto agree to
amend the Existing Credit Agreement pursuant to the terms and subject to the conditions of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">N<SMALL>OW</SMALL>,
T<SMALL>HEREFORE</SMALL>, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto agree as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <I>Incorporation of Recitals; Defined Terms.</I> The parties hereto acknowledge that the Recitals set forth above are true and correct in
all material respects. The defined terms in the Recitals set forth above are hereby incorporated into this Agreement by reference. All other capitalized terms used herein without definition shall have the same meanings herein as such terms have in
the Credit Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <I>Second Amendment to Existing Credit Agreement</I>. Upon satisfaction of the conditions set forth in
Section&nbsp;5 hereof, the Borrowers, the Lenders and the Administrative Agent hereby agree that the Existing Credit Agreement is hereby amended by the Credit Agreement attached hereto as <U>Annex A</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <I>Acknowledgement of Liens</I>. The Obligors hereby acknowledge and agree that the Obligations owing to the Administrative Agent and the
Lenders arising out of or in any manner relating to the Loan Documents shall continue to be secured by the Liens granted as security therefor in the Loan Documents, to the extent provided for in the Loan Documents heretofore executed and delivered
by the Borrowers;<B> </B>and nothing herein contained shall in any manner affect or impair the priority of the Liens created and provided for thereby as to the indebtedness, obligations, and liabilities which would be secured thereby prior to giving
effect to this Agreement. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <I>Representations And Warranties. </I>In order to induce the Administrative Agent and
the Lenders to enter into this Agreement, the Borrowers hereby represent and warrant to the Administrative Agent and the Lenders as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A) After giving effect to this Agreement, the representations and warranties of the Obligors contained in Article 7 of the
Credit Agreement and in each other Loan Document shall be true and correct in all material respects on and as of the date hereof; <I>provided</I> that to the extent that such representations and warranties specifically refer to an earlier date, they
shall be true and correct in all material respects as of such earlier date; <I>provided further</I> that any representation and warranty that is qualified as to &#147;materiality&#148;, &#147;Material Adverse Effect&#148; or similar language shall
be true and correct (after giving effect to any qualification therein) in all respects on such respective dates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B) The
execution, delivery and performance of this Agreement has been duly authorized by all necessary corporate action on the part of, and duly executed and delivered by, the Borrower. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(C) No Default or Event of Default has occurred and is continuing or shall occur and be continuing immediately after giving
effect to this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <I>Conditions Precedent.</I> The effectiveness of this Agreement is subject to the satisfaction of the
following conditions precedent: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A) The Administrative Agent and the Lenders shall have received: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">a. Certified copies of (x)&nbsp;the Organizational Documents of each Obligor and of resolutions of the Board of each Obligor
approving and authorizing the execution, delivery and performance of this Agreement, certified as of the Second Amendment Effective Date by the secretary or a Responsible Officer of such Obligor as being in full force and effect without modification
or amendment; and (y)&nbsp;a good standing certificate and/or compliance certificate from the applicable Governmental Authority of each Obligor&#146;s jurisdiction of incorporation or registration (other than in the case of the Irish Obligor), each
dated a recent date prior to the Second Amendment Effective Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">b. [Reserved]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">c. A certificate of each Obligor as to the authority, incumbency and specimen signatures of the persons who have executed the
Second Amendment and any other documents in connection herewith on behalf of the Obligors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">d. A favorable opinion or
opinions, dated as of the Closing Date, of Kirkland and Ellis, LLP, U.S. counsel to the Obligors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B) Perceptive shall
have received a copy of the Second Amendment Warrant Certificate substantially in the form attached hereto as <U>Annex B</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(C) The Administrative Agent and the Lenders shall have received a copy of a form of favorable opinion of Walkers (Bermuda)
Limited, special Bermuda counsel to the Obligors to be executed in accordance with Section&nbsp;8.21 of the Credit Agreement and substantially in the form attached hereto as <U>Annex C</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-2- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(D) The Administrative Agent and the Lenders shall have been reimbursed by
the Borrowers for all fees and expenses (including attorney&#146;s fees and expenses) incurred by the Administrative Agent and its counsel outstanding as of the date hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <I>Reference to and Effect on the Loan Documents; No Novation.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A) This Agreement constitutes a Loan Document. On and after the date hereof, words of like import referring to the Credit
Agreement, and each reference in the other Loan Documents to the &#147;Credit Agreement&#148;, &#147;thereunder&#148;, &#147;thereof&#148; or words of like import referring to the Credit Agreement shall mean and be a reference to the Credit
Agreement after giving effect to this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B) Except as specifically set forth in this Agreement, the Credit
Agreement and the other Loan Documents shall remain in full force and effect and are hereby ratified and confirmed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(C)
Except as expressly set forth in this Agreement, the Loan Documents and all of the obligations of the Loan Parties thereunder and the rights and benefits of the Administrative Agent and the Lenders thereunder remain in full force and effect. This
Agreement is not a novation nor is it to be construed as a release, waiver or modification of any of the terms, conditions, representations, warranties, covenants, rights or remedies set forth in the Loan Documents, except as specifically set forth
herein. Without limiting the foregoing, the Loan Parties agree to comply with all of the terms, conditions, and provisions of the Loan Documents except to the extent such compliance is irreconcilably inconsistent with the express provisions of this
Agreement. This Agreement may not be amended, supplemented, or otherwise modified except by a written agreement entered into in accordance with Section&nbsp;13.04 of the Credit Agreement. THIS AGREEMENT, THE CREDIT AGREEMENT AND THE OTHER LOAN
DOCUMENTS REPRESENTS THE ENTIRE AGREEMENT AMONG THE PARTIES WITH RESPECT TO THE SUBJECT MATTER HEREOF AND THEREOF AND SUPERSEDE ANY AND ALL PREVIOUS AGREEMENTS AND UNDERSTANDINGS, ORAL OR WRITTEN, RELATING TO THE SUBJECT MATTER HEREOF. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <I>R<SMALL>ELEASE</SMALL>. </I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(<SMALL>A</SMALL>) F<SMALL>OR</SMALL> <SMALL>VALUE</SMALL> <SMALL>RECEIVED</SMALL>, <SMALL>INCLUDING</SMALL> <SMALL>WITHOUT</SMALL>
<SMALL>LIMITATION</SMALL>, <SMALL>THE</SMALL> <SMALL>AGREEMENTS</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL> L<SMALL>ENDERS</SMALL> <SMALL>IN</SMALL> <SMALL>THIS</SMALL> A<SMALL>GREEMENT</SMALL>, E<SMALL>ACH</SMALL> O<SMALL>BLIGOR</SMALL>,
<SMALL>ON</SMALL> <SMALL>BEHALF</SMALL> <SMALL>OF</SMALL> <SMALL>ITSELF</SMALL> <SMALL>AND</SMALL> <SMALL>ITS</SMALL> <SMALL>SUCCESSORS</SMALL> <SMALL>AND</SMALL> <SMALL>ASSIGNS</SMALL>, <SMALL>AND</SMALL> <SMALL>ITS</SMALL> <SMALL>CURRENT</SMALL>
<SMALL>AND</SMALL> <SMALL>FORMER</SMALL> <SMALL>SHAREHOLDERS</SMALL>, <SMALL>MEMBERS</SMALL>, <SMALL>PARENTS</SMALL>, <SMALL>SUBSIDIARIES</SMALL>, <SMALL>DIVISIONS</SMALL>, <SMALL>AFFILIATES</SMALL>, <SMALL>DIRECTORS</SMALL>,
<SMALL>OFFICERS</SMALL>, <SMALL>EMPLOYEES</SMALL>, <SMALL>AGENTS</SMALL>, <SMALL>ATTORNEYS</SMALL>, <SMALL>ADVISORS</SMALL>, <SMALL>CONSULTANTS</SMALL>, <SMALL>AND</SMALL> <SMALL>OTHER</SMALL> <SMALL>REPRESENTATIVES</SMALL>
(<SMALL>COLLECTIVELY</SMALL>, <SMALL>THE<I></I></SMALL><I> &#147;R<SMALL>ELEASING</SMALL> P<SMALL>ARTIES</SMALL>&#148;</I>), <SMALL>HEREBY</SMALL> <SMALL>ABSOLUTELY</SMALL>, <SMALL>UNCONDITIONALLY</SMALL>, <SMALL>AND</SMALL>
<SMALL>IRREVOCABLY</SMALL> <SMALL>RELEASES</SMALL> <SMALL>AND</SMALL> <SMALL>FOREVER</SMALL> <SMALL>DISCHARGES</SMALL> <SMALL>THE</SMALL> A<SMALL>DMINISTRATIVE</SMALL> A<SMALL>GENT</SMALL> <SMALL>AND</SMALL> <SMALL>THE</SMALL>
L<SMALL>ENDERS</SMALL>, <SMALL>AND</SMALL> <SMALL>THEIR</SMALL> <SMALL>CURRENT</SMALL> <SMALL>AND</SMALL> <SMALL>FORMER</SMALL> <SMALL>SHAREHOLDERS</SMALL>, <SMALL>MEMBERS</SMALL>, <SMALL>PARENTS</SMALL>, <SMALL>SUBSIDIARIES</SMALL>,
<SMALL>DIVISIONS</SMALL>, <SMALL>AFFILIATES</SMALL>, <SMALL>DIRECTORS</SMALL>, <SMALL>OFFICERS</SMALL>, <SMALL>EMPLOYEES</SMALL>, <SMALL>AGENTS</SMALL>, <SMALL>ATTORNEYS</SMALL>, <SMALL>ADVISORS</SMALL>, <SMALL>CONSULTANTS</SMALL>,
<SMALL>AND</SMALL> <SMALL>OTHER</SMALL> <SMALL>REPRESENTATIVES</SMALL> (<SMALL>COLLECTIVELY</SMALL>, <SMALL>THE</SMALL> <I>&#147;R<SMALL>ELEASED</SMALL> P<SMALL>ARTIES</SMALL>&#148;</I>) <SMALL>OF</SMALL> <SMALL>AND</SMALL> <SMALL>FROM</SMALL>
<SMALL>ANY</SMALL> <SMALL>AND</SMALL> <SMALL>ALL</SMALL> <SMALL>CLAIMS</SMALL> (<SMALL>INCLUDING</SMALL>, <SMALL>WITHOUT</SMALL> <SMALL>LIMITATION</SMALL>, <SMALL>ALL</SMALL> <SMALL>COUNTERCLAIMS</SMALL>, <SMALL>CROSSCLAIMS</SMALL>,
<SMALL>DEFENSES</SMALL>, <SMALL>RIGHTS</SMALL> <SMALL>OF</SMALL> <SMALL>SET</SMALL><FONT STYLE="white-space:nowrap">-</FONT><SMALL>OFF</SMALL> <SMALL>AND</SMALL> <SMALL>RECOUPMENT</SMALL>), <SMALL>ACTIONS</SMALL>, <SMALL>CAUSES</SMALL>
<SMALL>OF</SMALL> <SMALL>ACTION</SMALL>, <SMALL>ACTS</SMALL> <SMALL>AND</SMALL> <SMALL>OMISSIONS</SMALL>, <SMALL>CONTROVERSIES</SMALL>, <SMALL>DEMANDS</SMALL>, <SMALL>SUITS</SMALL>, <SMALL>AND</SMALL> <SMALL>OTHER</SMALL> <SMALL>LIABILITIES</SMALL>
(<SMALL>COLLECTIVELY</SMALL>, <SMALL>THE<I></I></SMALL><I> &#147;C<SMALL>LAIMS</SMALL>&#148;</I>) <SMALL>OF</SMALL> <SMALL>EVERY</SMALL> <SMALL>KIND</SMALL> <SMALL>OR</SMALL> <SMALL>NATURE</SMALL> <SMALL>WHATSOEVER</SMALL>, <SMALL>BOTH</SMALL>
<SMALL>IN</SMALL> <SMALL>LAW</SMALL> <SMALL>AND</SMALL> <SMALL>IN</SMALL> <SMALL>EQUITY</SMALL>, <SMALL>KNOWN</SMALL> <SMALL>OR</SMALL> <SMALL>UNKNOWN</SMALL>, <SMALL>WHICH</SMALL> <SMALL>ANY</SMALL> R<SMALL>ELEASING</SMALL> P<SMALL>ARTY</SMALL>
<SMALL>HAS</SMALL> <SMALL>OR</SMALL> <SMALL>EVER</SMALL> <SMALL>HAD</SMALL> <SMALL>AGAINST</SMALL> <SMALL>THE</SMALL> R<SMALL>ELEASED</SMALL> P<SMALL>ARTIES</SMALL> <SMALL>PRIOR</SMALL> <SMALL>TO</SMALL>, <SMALL>THROUGH</SMALL>, <SMALL>AND</SMALL>
<SMALL>INCLUDING</SMALL> <SMALL>THIS</SMALL> <SMALL>DATE</SMALL>, <SMALL>INCLUDING</SMALL>, <SMALL>WITHOUT</SMALL> <SMALL>LIMITATION</SMALL>, C<SMALL>LAIMS</SMALL> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-3- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<SMALL>ARISING</SMALL> <SMALL>OUT</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL> <SMALL>EXISTING</SMALL> <SMALL>FINANCING</SMALL> <SMALL>ARRANGEMENTS</SMALL> <SMALL>BETWEEN</SMALL>
<SMALL>EACH</SMALL> O<SMALL>BLIGOR</SMALL> <SMALL>AND</SMALL> <SMALL>THE</SMALL> L<SMALL>ENDERS</SMALL> <SMALL>AND</SMALL> <SMALL>ANY</SMALL> C<SMALL>LAIM</SMALL> <SMALL>OF</SMALL> <SMALL>BREACH</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL>
<SMALL>DUTY</SMALL> <SMALL>OF</SMALL> <SMALL>GOOD</SMALL> <SMALL>FAITH</SMALL> <SMALL>AND</SMALL> <SMALL>FAIR</SMALL>&nbsp;<SMALL>DEALING</SMALL> <SMALL>BASED</SMALL> <SMALL>ON</SMALL>, <SMALL>AMONG</SMALL> <SMALL>OTHER</SMALL>
<SMALL>THINGS</SMALL>, <SMALL>THE</SMALL> R<SMALL>ELEASED</SMALL> P<SMALL>ARTIES</SMALL>&#146; <SMALL>EXERCISE</SMALL> <SMALL>OF</SMALL> <SMALL>DISCRETION</SMALL> <SMALL>UNDER</SMALL> <SMALL>THE</SMALL> L<SMALL>OAN</SMALL> D<SMALL>OCUMENTS</SMALL>.
E<SMALL>ACH</SMALL> O<SMALL>BLIGOR</SMALL> <SMALL>HEREBY</SMALL> <SMALL>REPRESENTS</SMALL> <SMALL>AND</SMALL> <SMALL>WARRANTS</SMALL> <SMALL>THAT</SMALL>, <SMALL>ON</SMALL> <SMALL>BEHALF</SMALL> <SMALL>OF</SMALL> <SMALL>ITSELF</SMALL>
<SMALL>AND</SMALL> <SMALL>ITS</SMALL> <SMALL>SUCCESSORS</SMALL>, <SMALL>ASSIGNS</SMALL> <SMALL>AND</SMALL> <SMALL>LEGAL</SMALL> <SMALL>REPRESENTATIVES</SMALL>, <SMALL>IT</SMALL> <SMALL>HAS</SMALL> <SMALL>NOT</SMALL> <SMALL>SOLD</SMALL>,
<SMALL>CONVEYED</SMALL>, <SMALL>ASSIGNED</SMALL>, <SMALL>PLEDGED</SMALL>, <SMALL>HYPOTHECATED</SMALL>, <SMALL>OR</SMALL> <SMALL>OTHERWISE</SMALL> <SMALL>ENCUMBERED</SMALL> <SMALL>ALL</SMALL> <SMALL>OR</SMALL> <SMALL>ANY</SMALL> <SMALL>PART</SMALL>
<SMALL>OF</SMALL> <SMALL>THE</SMALL> C<SMALL>LAIMS</SMALL> <SMALL>RELEASED</SMALL> <SMALL>IN</SMALL> <SMALL>THIS</SMALL> S<SMALL>ECTION</SMALL>. E<SMALL>ACH</SMALL> O<SMALL>BLIGOR</SMALL> <SMALL>HEREBY</SMALL> <SMALL>ACKNOWLEDGES</SMALL>
<SMALL>AND</SMALL> <SMALL>AGREES</SMALL> <SMALL>THAT</SMALL>, <SMALL>ON</SMALL> <SMALL>BEHALF</SMALL> <SMALL>OF</SMALL> <SMALL>ITSELF</SMALL> <SMALL>AND</SMALL> <SMALL>ITS</SMALL> <SMALL>SUCCESSORS</SMALL>, <SMALL>ASSIGNS</SMALL> <SMALL>AND</SMALL>
<SMALL>LEGAL</SMALL> <SMALL>REPRESENTATIVES</SMALL>, <SMALL>THE</SMALL> R<SMALL>ELEASED</SMALL> P<SMALL>ARTIES</SMALL> <SMALL>HAVE</SMALL> <SMALL>AT</SMALL> <SMALL>ALL</SMALL> <SMALL>TIMES</SMALL> <SMALL>ACTED</SMALL> <SMALL>IN</SMALL>
<SMALL>GOOD</SMALL> <SMALL>FAITH</SMALL>&nbsp;<SMALL>WITH</SMALL> <SMALL>REGARD</SMALL> <SMALL>TO</SMALL> <SMALL>THE</SMALL> <SMALL>CONSUMMATION</SMALL> <SMALL>AND</SMALL> <SMALL>ADMINISTRATION</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL>
L<SMALL>OAN</SMALL> D<SMALL>OCUMENTS</SMALL>. E<SMALL>ACH</SMALL> O<SMALL>BLIGOR</SMALL> <SMALL>ACKNOWLEDGES</SMALL> <SMALL>AND</SMALL> <SMALL>AGREES</SMALL> <SMALL>THAT</SMALL>, <SMALL>AS</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL>
<SMALL>DATE</SMALL> <SMALL>HEREOF</SMALL>, <SMALL>IT</SMALL> <SMALL>DOES</SMALL> <SMALL>NOT</SMALL> <SMALL>HAVE</SMALL> <SMALL>ANY</SMALL> C<SMALL>LAIM</SMALL> <SMALL>AGAINST</SMALL> <SMALL>THE</SMALL> R<SMALL>ELEASED</SMALL> P<SMALL>ARTIES</SMALL>,
<SMALL>EACH</SMALL> <SMALL>OF</SMALL> <SMALL>WHICH</SMALL> <SMALL>SUCH</SMALL> O<SMALL>BLIGOR</SMALL>, <SMALL>ON</SMALL> <SMALL>BEHALF</SMALL> <SMALL>OF</SMALL> <SMALL>ITSELF</SMALL> <SMALL>AND</SMALL> <SMALL>ITS</SMALL> <SMALL>SUCCESSORS</SMALL>,
<SMALL>ASSIGNS</SMALL> <SMALL>AND</SMALL> <SMALL>LEGAL</SMALL> <SMALL>REPRESENTATIVES</SMALL>, <SMALL>HEREBY</SMALL> <SMALL>EXPRESSLY</SMALL> <SMALL>WAIVES</SMALL>. E<SMALL>ACH</SMALL> O<SMALL>BLIGOR</SMALL> <SMALL>HEREBY</SMALL>
<SMALL>CONFIRMS</SMALL> <SMALL>THAT</SMALL> <SMALL>THE</SMALL> <SMALL>FOREGOING</SMALL> <SMALL>WAIVER</SMALL> <SMALL>AND</SMALL> <SMALL>RELEASE</SMALL> <SMALL>IS</SMALL> <SMALL>AN</SMALL> <SMALL>INFORMED</SMALL> <SMALL>WAIVER</SMALL>
<SMALL>AND</SMALL> <SMALL>RELEASE</SMALL> <SMALL>AND</SMALL> <SMALL>IS</SMALL> <SMALL>BEING</SMALL> <SMALL>FREELY</SMALL> <SMALL>GIVEN</SMALL>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(<SMALL>B</SMALL>) E<SMALL>ACH</SMALL> O<SMALL>BLIGOR</SMALL> <SMALL>FURTHER</SMALL> <SMALL>AGREES</SMALL>, <SMALL>ON</SMALL>
<SMALL>BEHALF</SMALL> <SMALL>OF</SMALL> <SMALL>ITSELF</SMALL> <SMALL>AND</SMALL> <SMALL>ITS</SMALL> <SMALL>SUCCESSORS</SMALL>, <SMALL>ASSIGNS</SMALL>, <SMALL>AND</SMALL> <SMALL>LEGAL</SMALL> <SMALL>REPRESENTATIVES</SMALL>, <SMALL>NOT</SMALL>
<SMALL>TO</SMALL> <SMALL>COMMENCE</SMALL>, <SMALL>INSTITUTE</SMALL>, <SMALL>OR</SMALL> <SMALL>PROSECUTE</SMALL> <SMALL>ANY</SMALL> <SMALL>LAWSUIT</SMALL>, <SMALL>ACTION</SMALL> <SMALL>OR</SMALL> <SMALL>OTHER</SMALL> <SMALL>PROCEEDING</SMALL>,
<SMALL>WHETHER</SMALL> <SMALL>JUDICIAL</SMALL>, <SMALL>ADMINISTRATIVE</SMALL> <SMALL>OR</SMALL> <SMALL>OTHERWISE</SMALL>, <SMALL>TO</SMALL> <SMALL>COLLECT</SMALL> <SMALL>OR</SMALL> <SMALL>ENFORCE</SMALL> <SMALL>ANY</SMALL> C<SMALL>LAIM</SMALL>
<SMALL>RELEASED</SMALL> <SMALL>HEREIN</SMALL>. I<SMALL>F</SMALL> <SMALL>ANY</SMALL> O<SMALL>BLIGOR</SMALL> <SMALL>OR</SMALL> <SMALL>ANY</SMALL> <SMALL>OF</SMALL> <SMALL>ITS</SMALL> <SMALL>SUCCESSORS</SMALL>, <SMALL>ASSIGNS</SMALL>, <SMALL>OR</SMALL>
<SMALL>LEGAL</SMALL> <SMALL>REPRESENTATIVES</SMALL> <SMALL>VIOLATES</SMALL> <SMALL>THE</SMALL> <SMALL>FOREGOING</SMALL> <SMALL>COVENANT</SMALL>, <SMALL>SUCH</SMALL> O<SMALL>BLIGOR</SMALL> <SMALL>HEREBY</SMALL> <SMALL>AGREES</SMALL>,
<SMALL>ON</SMALL> <SMALL>BEHALF</SMALL> <SMALL>OF</SMALL> <SMALL>ITSELF</SMALL> <SMALL>AND</SMALL> <SMALL>ITS</SMALL> <SMALL>SUCCESSORS</SMALL> <SMALL>AND</SMALL> <SMALL>ASSIGNS</SMALL>, <SMALL>TO</SMALL> <SMALL>PAY</SMALL>, <SMALL>IN</SMALL>
<SMALL>ADDITION</SMALL> <SMALL>TO</SMALL> <SMALL>ANY</SMALL> <SMALL>DAMAGES</SMALL> <SMALL>AS</SMALL> <SMALL>ANY</SMALL> R<SMALL>ELEASED</SMALL> P<SMALL>ARTY</SMALL> <SMALL>MAY</SMALL> <SMALL>SUSTAIN</SMALL> <SMALL>AS</SMALL> <SMALL>A</SMALL>
<SMALL>RESULT</SMALL> <SMALL>OF</SMALL> <SMALL>SUCH</SMALL> <SMALL>VIOLATION</SMALL>, <SMALL>ALL</SMALL> <SMALL>ATTORNEYS</SMALL>&#146; <SMALL>FEES</SMALL> <SMALL>AND</SMALL> <SMALL>COSTS</SMALL> <SMALL>INCURRED</SMALL> <SMALL>BY</SMALL>
<SMALL>ANY</SMALL> R<SMALL>ELEASED</SMALL> <SMALL>PARTY</SMALL> <SMALL>AS</SMALL> <SMALL>A</SMALL> <SMALL>RESULT</SMALL> <SMALL>OF</SMALL> <SMALL>SUCH</SMALL> <SMALL>VIOLATION</SMALL> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <I>Headings</I>. The headings in this Agreement are included solely for convenience of reference and are not intended to affect the
interpretation of any provision of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <I>Governing Law</I>. THIS AGREEMENT, THE RIGHTS AND OBLIGATIONS OF THE PARTIES
HEREUNDER, AND ALL CLAIMS, DISPUTES AND MATTERS ARISING HEREUNDER OR RELATED HERETO, SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK APPLICABLE TO CONTRACTS EXECUTED IN AND TO BE PERFORMED ENTIRELY WITHIN
THAT STATE, WITHOUT REFERENCE TO CONFLICTS OF LAWS PROVISIONS (OTHER THAN SECTION <FONT STYLE="white-space:nowrap">5-1401</FONT> OF THE NEW YORK GENERAL OBLIGATIONS LAW). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <I>Incorporation of Sections 13.10 and 13.11 of the Credit Agreement</I>. The provisions set forth in Sections 13.10 (Jurisdiction,
Service of Process and Venue) and 13.11 (Waiver of Jury Trial) of the Credit Agreement shall apply to this Agreement in all respects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.
<I>Counterparts</I>. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument and any of the parties hereto may execute this Agreement by signing any such counterpart.
Delivery of an executed signature page of this Agreement by facsimile transmission, electronic transmission (in PDF format) or DocuSign shall be effective as delivery of a manually executed counterpart hereof. The words &#147;execution,&#148;
&#147;signed,&#148; &#147;signature,&#148; and words of like import in this Agreement shall be deemed to include electronic signatures or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or
enforceability as a manually executed signature or the use of a paper-based recordkeeping system, as the case may be, to the extent and as provided for in any applicable Law, including the Federal Electronic Signatures in Global and National
Commerce Act, the New York State Electronic Signatures and Records Act, or any other similar state laws based on the Uniform&nbsp;Electronic Transactions Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-4- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. <I>Severability</I>. If any provision hereof is found by a court to be invalid or
unenforceable, to the fullest extent permitted by applicable Law the parties agree that such invalidity or unenforceability shall not impair the validity or enforceability of any other provision hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13. <I>Binding Effect</I>. This Agreement will be binding upon and inure to the benefit of and is enforceable by the respective successors and
permitted assigns of the parties hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[S<SMALL>IGNATURE</SMALL> P<SMALL>AGES</SMALL> <SMALL>TO</SMALL> F<SMALL>OLLOW</SMALL>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-5- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed and
delivered by their respective officers thereunto duly authorized as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B><U>B<SMALL>ORROWERS</SMALL></U><SMALL></SMALL>:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">K<SMALL>ESTRA</SMALL> M<SMALL>EDICAL</SMALL> T<SMALL>ECHNOLOGIES</SMALL>, I<SMALL>NC</SMALL>.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Brian Webster</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Brian Webster</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: President and Chief Executive Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">W<SMALL>EST</SMALL> A<SMALL>FFUM</SMALL> H<SMALL>OLDINGS</SMALL> C<SMALL>ORP</SMALL>.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Brian Webster</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Brian Webster</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Director</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to Second Amendment to Credit Agreement and Guaranty] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><U><B>G<SMALL>UARANTORS</SMALL>:</B></U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">K<SMALL>ESTRA</SMALL> M<SMALL>EDICAL</SMALL> T<SMALL>ECHNOLOGY</SMALL> S<SMALL>ERVICES</SMALL>, I<SMALL>NC</SMALL>.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Brian Webster</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Brian Webster</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: President and Chief Executive Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">W<SMALL>EST</SMALL> A<SMALL>FFUM</SMALL> I<SMALL>NTERMEDIATE</SMALL> H<SMALL>OLDINGS</SMALL> C<SMALL>ORP</SMALL>.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Brian Webster</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Brian Webster</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">W<SMALL>EST</SMALL> A<SMALL>FFUM</SMALL> H<SMALL>OLDINGS</SMALL> D<SMALL>ESIGNATED</SMALL> A<SMALL>CTIVITY</SMALL> C<SMALL>OMPANY</SMALL></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Brian Webster</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Brian Webster</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Director</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to Second Amendment to Credit Agreement and Guaranty] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">PERCEPTIVE CREDIT HOLDINGS&nbsp;IV, LP, <SMALL>AS</SMALL> A<SMALL>GENT</SMALL> <SMALL>AND</SMALL> L<SMALL>ENDER</SMALL></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Perceptive Credit Opportunities GP, LLC, its general partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Sandeep Dixit</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Sandeep Dixit</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Chief Credit Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Sam Chawla</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Sam Chawla</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Portfolio Manager</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to Second Amendment to Credit Agreement and Guaranty] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANNEX A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Amended Credit Agreement </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See attached. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">E<SMALL>XECUTION</SMALL> V<SMALL>ERSION</SMALL> </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C<SMALL>REDIT</SMALL>
A<SMALL>GREEMENT</SMALL> <SMALL>AND</SMALL> G<SMALL>UARANTY<SUP STYLE="font-size:75%; vertical-align:top">1</SUP></SMALL> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">dated as of </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">September&nbsp;29, 2023 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">among
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">K<SMALL>ESTRA</SMALL> M<SMALL>EDICAL</SMALL> T<SMALL>ECHNOLOGIES</SMALL>, I<SMALL>NC</SMALL>. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">W<SMALL>EST</SMALL> A<SMALL>FFUM</SMALL> H<SMALL>OLDINGS</SMALL> C<SMALL>ORP</SMALL>. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">as Borrowers, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">T<SMALL>HE</SMALL>
G<SMALL>UARANTORS</SMALL> <SMALL>FROM</SMALL> T<SMALL>IME</SMALL> <SMALL>TO</SMALL> T<SMALL>IME</SMALL> P<SMALL>ARTY</SMALL> <SMALL>HERETO</SMALL>, </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">as Guarantors, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">T<SMALL>HE</SMALL>
L<SMALL>ENDERS</SMALL> <SMALL>FROM</SMALL> T<SMALL>IME</SMALL> <SMALL>TO</SMALL> T<SMALL>IME</SMALL> P<SMALL>ARTY</SMALL> <SMALL>HERETO</SMALL>, </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">as Lenders, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">P<SMALL>ERCEPTIVE</SMALL> C<SMALL>REDIT</SMALL> H<SMALL>OLDINGS</SMALL>&nbsp;IV, LP, </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">as Administrative Agent and as a Lender </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Conformed to reflect changes from the Consent and First Amendment to Credit Agreement and Guaranty dated as of
July&nbsp;12, 2024 and the Second Amendment to Credit Agreement and Guaranty dated as of February&nbsp;25, 2025. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>T<SMALL>ABLE</SMALL> <SMALL>OF</SMALL> C<SMALL>ONTENTS</SMALL> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">S<SMALL>ECTION</SMALL></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">H<SMALL>EADING</SMALL></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">P<SMALL>AGE</SMALL></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">A<SMALL>RTICLE</SMALL>&nbsp;1.
&#8195;&#8195;&#8195;D<SMALL>EFINITIONS</SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.01.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Certain Defined Terms</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.02.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Accounting Terms and Principles</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.03.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Interpretation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.04.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Divisions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.05.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Interest Rates</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">A<SMALL>RTICLE</SMALL>&nbsp;2. &#8195;&#8195;&#8195;T<SMALL>HE</SMALL>
C<SMALL>OMMITMENTS</SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.01.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Term Loans</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.02.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Proportionate Shares</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.03.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Fees</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.04.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Notes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.05.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Use of Proceeds</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">A<SMALL>RTICLE</SMALL>&nbsp;3. &#8195;&#8195;&#8195;P<SMALL>AYMENTS</SMALL>
<SMALL>OF</SMALL> P<SMALL>RINCIPAL</SMALL> <SMALL>AND</SMALL> I<SMALL>NTEREST</SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.01.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Repayment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.02.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Interest</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.03.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Prepayments</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">A<SMALL>RTICLE</SMALL>&nbsp;4. &#8195;&#8195;&#8195;P<SMALL>AYMENTS</SMALL>,
E<SMALL>TC</SMALL>.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.01.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Payments</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.02.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Computations</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.03.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Notices</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.04.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="white-space:nowrap">Set-Off</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">A<SMALL>RTICLE</SMALL>&nbsp;5. &#8195;&#8195;&#8195;Y<SMALL>IELD</SMALL>
P<SMALL>ROTECTION</SMALL>, E<SMALL>TC</SMALL>.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.01.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Additional Costs</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.02.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Illegality</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.03.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Taxes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.04.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Delay in Requests</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">A<SMALL>RTICLE</SMALL>&nbsp;6. &#8195;&#8195;&#8195;C<SMALL>ONDITIONS</SMALL>
P<SMALL>RECEDENT</SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.01.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Conditions to Tranche&nbsp;A Term Loan; Closing Date</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.02.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Conditions to Tranche&nbsp;B Term Loan; Tranche&nbsp;B Term Loan Borrowing Date</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.03.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Conditions to Tranche&nbsp;C Term Loan; Tranche&nbsp;C Term Loan Borrowing Date</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">A<SMALL>RTICLE</SMALL>&nbsp;7. &#8195;&#8195;&#8195;R<SMALL>EPRESENTATIONS</SMALL>
<SMALL>AND</SMALL> W<SMALL>ARRANTIES</SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-i- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.01.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Power and Authority</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.02.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Authorization; Enforceability</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.03.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Governmental and Other Approvals; No Conflicts</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.04.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Financial Statements; Projections; Material Adverse Change</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.05.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Properties</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.06.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>No Actions or Proceedings</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.07.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Compliance with Laws and Agreements</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.08.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Taxes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.09.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Full Disclosure</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.10.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Regulation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.11.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Solvency</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.12.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>[Reserved]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.13.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Indebtedness and Liens</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.14.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Material Agreements</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.15.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Restrictive Agreements</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.16.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Real Property</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.17.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Pension and Other Plans</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.18.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Collateral; Security Interest</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.19.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Regulatory Approvals</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.20.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Capitalization</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.21.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Insurance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.22.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Certain Fees</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.23.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Sanctions Laws</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.24.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="white-space:nowrap">Anti-Corruption</FONT> Laws</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.25.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="white-space:nowrap">Anti-Terrorism</FONT> Laws</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.26.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Royalty and Other Payments</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.27.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Irish Representations</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">A<SMALL>RTICLE</SMALL>&nbsp;8. &#8195;&#8195;&#8195;A<SMALL>FFIRMATIVE</SMALL>
C<SMALL>OVENANTS</SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.01.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Financial Statements and Other Information</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.02.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Notices of Material Events</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.03.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Existence; Maintenance of Properties, Etc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.04.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Payment of Obligations</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.05.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Insurance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.06.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Books and Records; Inspection Rights</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.07.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Compliance with Laws</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.08.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Licenses</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.09.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Action under Environmental Laws</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.10.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Use of Proceeds</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.11.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Certain Obligations Respecting Subsidiaries; Further Assurances; Intellectual Property</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.12.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Termination of <FONT STYLE="white-space:nowrap">Non-Permitted</FONT> Liens</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.13.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="white-space:nowrap">Non-Consolidation</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.14.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="white-space:nowrap">Anti-Terrorism</FONT> and <FONT STYLE="white-space:nowrap">Anti-Corruption</FONT> Laws</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.15.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Financial Covenants</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-ii- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.16.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Maintenance of Regulatory Approvals, Contracts, Intellectual Property, Etc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.17.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Cash Management</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.18.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Observer Rights</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.19.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>COMI</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.20.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="white-space:nowrap">Post-Closing</FONT> Obligations</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.21.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Second Amendment Warrant Certificate</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">A<SMALL>RTICLE</SMALL>&nbsp;9. &#8195;&#8195;&#8195;N<SMALL>EGATIVE</SMALL>
C<SMALL>OVENANTS</SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.01.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Indebtedness</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.02.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Liens</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.03.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Fundamental Changes and Acquisitions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.04.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Lines of Business</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.05.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Investments</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.06.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Restricted Payments</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.07.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Payments of Indebtedness</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.08.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Change in Fiscal Year</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.09.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Sales of Assets, Etc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.10.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Transactions with Affiliates</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.11.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Restrictive Agreements</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.12.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Organizational Documents, Material Agreements</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.13.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Holding Company</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.14.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Sales and Leasebacks</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.15.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Hazardous Material</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.16.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Accounting Changes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.17.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Compliance with ERISA</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.18.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Outbound Licenses</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.19.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Inbound Licenses</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">A<SMALL>RTICLE</SMALL>&nbsp;10.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>E<SMALL>VENTS</SMALL> <SMALL>OF</SMALL> D<SMALL>EFAULT</SMALL></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;10.01.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Events of Default</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;10.02.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Remedies</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;10.03.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Prepayment Premium and Redemption Price</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">A<SMALL>RTICLE</SMALL>&nbsp;11. &#8195;&#8195;&#8195;G<SMALL>UARANTEE</SMALL></P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;11.01.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>The Guarantee</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;11.02.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Obligations Unconditional</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;11.03.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Reinstatement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;11.04.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Subrogation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;11.05.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Remedies</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;11.06.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Instrument for the Payment of Money</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;11.07.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Continuing Guarantee</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;11.08.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Rights of Contribution</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;11.09.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>General Limitation on Guarantee Obligations</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;11.10.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Irish Limitation on Guarantee Obligations</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-iii- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">A<SMALL>RTICLE</SMALL>&nbsp;12. &#8195;&#8195;&#8195;A<SMALL>DMINISTRATIVE</SMALL>
A<SMALL>GENT</SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;12.01.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Appointment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;12.02.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Rights as a Lender</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;12.03.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Exculpatory Provisions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;12.04.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Reliance by Administrative Agent</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;12.05.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Delegation of Duties</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;12.06.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Resignation of Agent</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;12.07.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="white-space:nowrap">Non-Reliance</FONT> on Administrative Agent and Other Lenders</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;12.08.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Administrative Agent May File Proofs of Claim</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;12.09.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Collateral and Guaranty Matters; Appointment of Administrative Agent</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;12.10.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Irish Security Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">109</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">A<SMALL>RTICLE</SMALL>&nbsp;13.
&#8195;&#8195;&#8195;M<SMALL>ISCELLANEOUS</SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;13.01.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>No Waiver</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;13.02.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Notices</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;13.03.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Expenses, Indemnification, Etc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;13.04.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Amendments, Etc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;13.05.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Successors and Assigns</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;13.06.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Survival</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;13.07.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Captions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;13.08.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Counterparts</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;13.09.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Governing Law</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;13.10.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Jurisdiction, Service of Process and Venue</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;13.11.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Waiver of Jury Trial</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;13.12.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Waiver of Immunity</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;13.13.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Entire Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;13.14.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Severability</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;13.15.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>No Fiduciary Relationship</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;13.16.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>USA&nbsp;Patriot Act</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;13.17.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Treatment of Certain Information; Confidentiality</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;13.18.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Releases of Guarantees and Liens</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">121</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;13.19.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Acknowledgement and Consent to <FONT STYLE="white-space:nowrap">Bail-In</FONT> of Affected Financial Institutions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">121</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;13.20.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Administrative Borrower</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;13.21.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Joint and Several Liability of Borrowers</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;13.22.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Judgment Currency</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-iv- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">S<SMALL>CHEDULES</SMALL>: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="82%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">S<SMALL>CHEDULE</SMALL>&nbsp;1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#151;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Tranche C Term Loan Commitment</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">S<SMALL>CHEDULE</SMALL> 2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#151;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Notice Addresses</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">S<SMALL>CHEDULE</SMALL> 3</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#151;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Products</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">S<SMALL>CHEDULE</SMALL> 4</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#151;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Letters of Credit</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">S<SMALL>CHEDULE</SMALL>&nbsp;7.05(b) </TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#151;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Obligor Intellectual Property</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">S<SMALL>CHEDULE</SMALL>&nbsp;7.13A </TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#151;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Existing Indebtedness</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">S<SMALL>CHEDULE</SMALL>&nbsp;7.13B </TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#151;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Existing Liens</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">S<SMALL>CHEDULE</SMALL>&nbsp;7.14 </TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#151;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Material Agreements</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">S<SMALL>CHEDULE</SMALL>&nbsp;7.15 </TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#151;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Restrictive Agreements</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">S<SMALL>CHEDULE</SMALL>&nbsp;7.16 </TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#151;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Real Property</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">S<SMALL>CHEDULE</SMALL>&nbsp;7.19(b)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#151;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Regulatory Approvals</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">S<SMALL>CHEDULE</SMALL>&nbsp;7.19(e)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#151;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Regulatory Authority Notifications</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">S<SMALL>CHEDULE</SMALL>&nbsp;7.20</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#151;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Capitalization</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">S<SMALL>CHEDULE</SMALL> 7.22</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#151;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Broker&#146;s Fee</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">S<SMALL>CHEDULE</SMALL> 7.26</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#151;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Royalty and Other Payments</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">S<SMALL>CHEDULE</SMALL> 8.20</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#151;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Post-Closing Obligations</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">S<SMALL>CHEDULE</SMALL>&nbsp;9.05 </TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#151;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Existing Investments</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">S<SMALL>CHEDULE</SMALL>&nbsp;9.10 </TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#151;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Transactions with Affiliates</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">E<SMALL>XHIBITS</SMALL>: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="85%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">E<SMALL>XHIBIT</SMALL>&nbsp;A</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#151;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Guarantee Assumption Agreement</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">E<SMALL>XHIBIT</SMALL>&nbsp;B</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#151;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Borrowing Notice</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">E<SMALL>XHIBIT</SMALL>&nbsp;C</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#151;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Note</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">E<SMALL>XHIBIT</SMALL>&nbsp;D</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#151;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of U.S.&nbsp;Tax Compliance Certificate</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">E<SMALL>XHIBIT</SMALL>&nbsp;E</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#151;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Compliance Certificate</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">E<SMALL>XHIBIT</SMALL>&nbsp;F</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#151;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Assignment Agreement</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">E<SMALL>XHIBIT</SMALL>&nbsp;G</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#151;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Security Agreement</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">E<SMALL>XHIBIT</SMALL><FONT STYLE="white-space:nowrap">&nbsp;H-1</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#151;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Patent&nbsp;&amp; Trademark Security Agreement</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">E<SMALL>XHIBIT</SMALL><FONT STYLE="white-space:nowrap">&nbsp;H-2</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#151;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Copyright Security Agreement</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">E<SMALL>XHIBIT</SMALL>&nbsp;I</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#151;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Collateral Questionnaire</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">E<SMALL>XHIBIT</SMALL> J</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#151;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Warrant Certificate</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">E<SMALL>XHIBIT</SMALL> K</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#151;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Intercompany Subordinated Demand Promissory Note</TD></TR>
</TABLE> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-v- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>C<SMALL>REDIT</SMALL> A<SMALL>GREEMENT</SMALL> <SMALL>AND</SMALL> G<SMALL>UARANTY</SMALL>
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">C<SMALL>REDIT</SMALL> A<SMALL>GREEMENT</SMALL> A<SMALL>ND</SMALL> G<SMALL>UARANTY</SMALL>, dated as of September&nbsp;29, 2023 (this
<I>&#147;Agreement&#148;</I>), among K<SMALL>ESTRA</SMALL> M<SMALL>EDICAL</SMALL> T<SMALL>ECHNOLOGIES</SMALL>, I<SMALL>NC</SMALL>., a Delaware corporation (<I>&#147;OpCo&#148;</I>), W<SMALL>EST</SMALL> A<SMALL>FFUM</SMALL> H<SMALL>OLDINGS</SMALL>
C<SMALL>ORP</SMALL>., an exempted company incorporated with limited liability in the Cayman Islands (<I>&#147;West Affum Corp.&#148;</I> and together with OpCo, each a <I>&#147;Borrower&#148;</I> and collectively, the <I>&#147;Borrowers&#148;</I>),
certain Guarantors from time to time parties hereto, the lenders from time to time party hereto (each, as a <I>&#147;Lender&#148;</I> and collectively, the <I>&#147;Lenders&#148;</I>), and P<SMALL>ERCEPTIVE</SMALL> C<SMALL>REDIT</SMALL>
H<SMALL>OLDINGS</SMALL> IV, LP, a Delaware limited partnership (<I>&#147;Perceptive&#148;</I>), as administrative agent for the Lenders (in such capacity, together with its successors and assigns, the<I> &#147;Administrative Agent&#148;</I>). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>W<SMALL>ITNESSETH</SMALL>: </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Borrowers have requested the Lenders to make term loans to Borrowers, and the Lenders are prepared to make such loans on and subject to the
terms and conditions hereof. Accordingly, the parties agree as follows: </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>RTICLE</SMALL>&nbsp;1. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>D<SMALL>EFINITIONS</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;1.01.</I> <I>Certain Defined Terms</I>. As used herein, the following terms have the following respective
meanings: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;510(k)&#148; </I>means (a)&nbsp;any premarket notification and corresponding FDA clearance for a
Device pursuant to FDA regulations and (b)&nbsp;all amendments, supplements and other additions and modifications thereto, and all documents, data and other information concerning any applicable Device which are necessary for, filed with,
incorporated by reference in, or otherwise supportive of any of the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Accounting Change&#148;</I> has
the meaning set forth in Section&nbsp;1.02. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Accounting Change Notice&#148;</I> has the meaning set forth in
Section&nbsp;1.02. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Acquisition&#148;</I> means any transaction, or any series of related transactions, by which
any Person directly or indirectly, by means of a <FONT STYLE="white-space:nowrap">take-over</FONT> bid, tender offer, amalgamation, merger, purchase of assets, or similar transaction having the same effect as any of the foregoing, (a)&nbsp;acquires
all or substantially all of the assets of any Person engaged in any business, (b)&nbsp;acquires all or substantially all of a business line or unit or division of any other Person, (c)&nbsp;acquires Control of securities of a Person engaged in a
business representing more than 50% of the ordinary voting power for the election of directors or other governing body if the business affairs of such Person are managed by a Board or other governing body, or (d)&nbsp;acquires control of more than
50% of the ownership interest in any Person engaged in any business that is not managed by a Board or other governing body. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Act&#148;</I> has the meaning set forth in Section&nbsp;13.16. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;</I><I>Administrative Agent</I><I>&#148;</I><I> </I>has the meaning set forth in the introduction hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Administrative Borrower&#148; </I>has the meaning set forth in Section&nbsp;13.20. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Affected Financial Institution</I>&#148; means (a)&nbsp;any EEA&nbsp;Financial Institution or (b)&nbsp;any
UK&nbsp;Financial Institution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Affiliate&#148;</I> means, with respect to a specified Person, another Person
that directly, or indirectly through one or more intermediaries, Controls or is Controlled by or is under common Control with the Person specified. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Agreement&#148;</I> has the meaning set forth in the introduction hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Anti</I><I><FONT STYLE="white-space:nowrap">-Corruption</FONT> Laws&#148;</I> means all laws, rules and regulations
of any jurisdiction applicable to the Obligors and their Affiliates concerning or relating to bribery or corruption, including, without limitation, the Foreign Corrupt Practices Act of 1977, as amended and the Cayman Islands Anti-Corruption Act (as
amended). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Anti</I><I><FONT STYLE="white-space:nowrap">-Terrorism</FONT> Laws&#148;</I> means any laws or
regulations relating to terrorism or money laundering, including, without limitation the <I>Bank Secrecy Act</I> (31&nbsp;U.S.C. &#167;&#167;&nbsp;5311 <I>et</I><I></I><I>&nbsp;seq.</I>), the <I>Money Laundering Control Act of 1986</I>
(18&nbsp;U.S.C. &#167;&#167;&nbsp;1956 <I>et</I><I></I><I>&nbsp;seq.</I>), the USA&nbsp;Patriot Act, the Cayman Islands Proceeds of Crime Act (as amended), Cayman Islands Anti-Money Laundering Regulations (as amended), the Cayman Islands
Proliferation Financing (Prohibition) Act (as amended), the Cayman Islands Terrorism Act (as amended) and any similar law enacted in the United States or the Cayman Islands after the date of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Applicable Margin&#148;</I> means 7.25% per annum. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Appointee&#148; </I>means any receiver, administrator or other insolvency officer appointed in respect of any Obligor
or its assets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Approved Fund&#148;</I> means any Person (other than a natural person) that is engaged in making,
purchasing, holding or investing in bank loans and similar extensions of credit in the ordinary course of its business and that is administered or managed by (a)&nbsp;a Lender, (b)&nbsp;an Affiliate of a Lender or (c)&nbsp;an entity or an Affiliate
of an entity that administers or manages a Lender. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Asset Sale&#148;</I> has the meaning set forth in
Section&nbsp;9.09. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-2- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Assignment Agreement&#148;</I> means an assignment and assumption
entered into by a Lender and an assignee of such Lender in substantially the form of Exhibit&nbsp;F. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;ASU&#148;</I> has the meaning set forth in Section&nbsp;1.02. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Available Tenor&#148;</I> means, as of the Closing Date, the only Available Tenor for Term SOFR is an interest period
of one (1)&nbsp;month; <I>provided</I> that the Administrative Agent may select to use additional interest periods in accordance with the terms of Section&nbsp;3.02(c)(iv) and such interest periods shall become Available Tenors upon such selection.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Bail</I><I><FONT STYLE="white-space:nowrap">-In</FONT> Action&#148;</I> means the exercise of any <FONT
STYLE="white-space:nowrap">Write-Down</FONT> and Conversion Powers by the applicable Resolution Authority in respect of any liability of an Affected Financial Institution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Bail</I><I><FONT STYLE="white-space:nowrap">-In</FONT> Legislation&#148;</I> means (a)&nbsp;with respect to any
EEA&nbsp;Member Country implementing Article&nbsp;55 of Directive&nbsp;2014/59/EU of the European Parliament and of the Council of the European Union, the implementing law, regulation rule or requirement for such EEA&nbsp;Member Country from time to
time which is described in the <FONT STYLE="white-space:nowrap">EU&nbsp;Bail-In</FONT> Legislation Schedule and (b)&nbsp;with respect to the United Kingdom, Part&nbsp;I of the United Kingdom Banking Act 2009 (as amended from time to time) and any
other law, regulation or rule applicable in the United Kingdom relating to the resolution of unsound or failing banks, investment firms or other financial institutions or their affiliates (other than through liquidation, administration or other
Insolvency Proceedings). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Bankruptcy Code&#148;</I> means Title&nbsp;11 of the United States Code entitled
&#147;Bankruptcy.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Benchmark&#148;</I> means, initially, the Term SOFR&nbsp;Reference Rate; <I>provided</I>
that if a Benchmark Transition Event has occurred with respect to the Term SOFR&nbsp;Reference Rate or the <FONT STYLE="white-space:nowrap">then-current</FONT> Benchmark, then &#147;Benchmark&#148; means the applicable Benchmark Replacement to the
extent that such Benchmark Replacement has replaced such prior benchmark rate pursuant to Section&nbsp;3.02(c). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Benchmark Replacement&#148;</I> means the first alternative set forth in the order below that can be determined by
the Administrative Agent for the applicable Benchmark Replacement Date: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Daily Simple SOFR; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) the sum of: (i)&nbsp;the alternate benchmark rate that has been selected by the Administrative Agent and Administrative
Borrower giving due consideration to (A)&nbsp;any selection or recommendation of a replacement benchmark rate or the mechanism for determining such a rate by the Relevant Governmental Body or (B)&nbsp;any evolving or
<FONT STYLE="white-space:nowrap">then-prevailing</FONT> market convention for determining a benchmark rate as a replacement to the <FONT STYLE="white-space:nowrap">then-current</FONT> Benchmark for
<FONT STYLE="white-space:nowrap">Dollar-denominated</FONT> syndicated credit facilities and (ii)&nbsp;the related Benchmark Replacement Adjustment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-3- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Benchmark Replacement as determined pursuant to
clause&nbsp;(a)&nbsp;or (b)&nbsp;above would be less than the Floor, the Benchmark Replacement will be deemed to be the Floor for the purposes of this Agreement and the other Loan Documents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Benchmark Replacement Adjustment&#148; </I>means, with respect to any replacement of the <FONT
STYLE="white-space:nowrap">then-current</FONT> Benchmark with an Unadjusted Benchmark Replacement, the spread adjustment, or method for calculating or determining such spread adjustment, (which may be a positive or negative value or zero) that has
been selected by the Administrative Agent and Administrative Borrower&nbsp;giving due consideration to (a)&nbsp;any selection or recommendation of a spread adjustment, or method for calculating or determining such spread adjustment, for the
replacement of such Benchmark with the applicable Unadjusted Benchmark Replacement by the Relevant Governmental Body or (b)&nbsp;any evolving or <FONT STYLE="white-space:nowrap">then-prevailing</FONT> market convention for determining a spread
adjustment, or method for calculating or determining such spread adjustment, for the replacement of such Benchmark with the applicable Unadjusted Benchmark Replacement for <FONT STYLE="white-space:nowrap">Dollar-denominated</FONT> syndicated credit
facilities at such time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Benchmark Replacement Date&#148; </I>means a date and time determined by the
Administrative Agent, which date shall be no later than the earliest to occur of the following events with respect to the <FONT STYLE="white-space:nowrap">then-current</FONT> Benchmark: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) in the case of clause&nbsp;(a) or (b)&nbsp;of the definition of &#147;Benchmark Transition Event,&#148; the later of
(i)&nbsp;the date of the public statement or publication of information referenced therein and (ii)&nbsp;the date on which the administrator of such Benchmark (or the published component used in the calculation thereof) permanently or indefinitely
ceases to provide all Available Tenors of such Benchmark (or such component thereof); or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) in the case of
clause&nbsp;(c) of the definition of &#147;Benchmark Transition Event&#148;, the first date on which such Benchmark (or the published component used in the calculation thereof) has been determined and announced by the regulatory supervisor for the
administrator of such Benchmark (or such component thereof) to be <FONT STYLE="white-space:nowrap">non-representative;</FONT> <I>provided</I> that such <FONT STYLE="white-space:nowrap">non-representativeness</FONT> will be determined by reference to
the most recent statement or publication referenced in such clause&nbsp;(c) and even if any Available Tenor of such Benchmark (or such component thereof) continues to be provided on such date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">For the avoidance of doubt, the &#147;Benchmark Replacement Date&#148; will be deemed to have occurred in the case of clause&nbsp;(a) or
(b)&nbsp;with respect to any Benchmark upon the occurrence of the applicable event or events set forth therein with respect to all <FONT STYLE="white-space:nowrap">then-current</FONT> Available Tenors of such Benchmark (or the published component
used in the calculation thereof). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-4- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Benchmark Transition Event&#148;</I> means the occurrence of one or
more of the following events with respect to the <FONT STYLE="white-space:nowrap">then-current</FONT> Benchmark: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) a
public statement or publication of information by or on behalf of the administrator of such Benchmark (or the published component used in the calculation thereof) announcing that such administrator has ceased or will cease to provide all Available
Tenors of such Benchmark (or such component thereof), permanently or indefinitely; <I>provided</I> that, at the time of such statement or publication, there is no successor administrator that will continue to provide any Available Tenor of such
Benchmark (or such component thereof); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) a public statement or publication of information by the regulatory supervisor
for the administrator of such Benchmark (or the published component used in the calculation thereof), the Federal Reserve Board, the Federal Reserve Bank of New&nbsp;York, an insolvency official with jurisdiction over the administrator for such
Benchmark (or such component), a resolution authority with jurisdiction over the administrator for such Benchmark (or such component) or a court or an entity with similar insolvency or resolution authority over the administrator for such Benchmark
(or such component), which states that the administrator of such Benchmark (or such component) has ceased or will cease to provide all Available Tenors of such Benchmark (or such component thereof) permanently or indefinitely; <I>provided</I> that,
at the time of such statement or publication, there is no successor administrator that will continue to provide any Available Tenor of such Benchmark (or such component thereof); or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) a public statement or publication of information by the regulatory supervisor for the administrator of such Benchmark (or
the published component used in the calculation thereof) announcing that all Available Tenors of such Benchmark (or such component thereof) are not, or as of a specified future date will not be, representative. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">For the avoidance of doubt, a &#147;Benchmark Transition Event&#148; will be deemed to have occurred with respect to any Benchmark if a public
statement or publication of information set forth above has occurred with respect to each <FONT STYLE="white-space:nowrap">then-current</FONT> Available Tenor of such Benchmark (or the published component used in the calculation thereof). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Beneficial Ownership Regulation&#148;</I> has the meaning set forth in Section&nbsp;13.16. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Benefit Plan&#148;</I> means any &#147;employee benefit plan&#148; as defined in Section&nbsp;3(3) of ERISA to which
any Obligor has any obligation or liability, contingent or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Bermuda Parent&#148;</I> means Kestra
Medical Technologies, Ltd., an exempted company limited by shares incorporated under the laws of Bermuda. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Board&#148;</I> means, with respect to any Person, the board of managers or directors (as applicable) (or equivalent
governing body) of such Person or any committee thereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-5- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Borrower&#148;</I> and &#147;<I>Borrowers</I>&#148; have the
meaning set forth in the introduction hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Borrowing&#148;</I> means a borrowing consisting of the
Tranche&nbsp;A Term Loan made by the Lenders on the Closing Date, the Tranche&nbsp;B Term Loan made by the Lenders on the Tranche&nbsp;B Term Loan Borrowing Date, and the Tranche C Term Loan made by the Lenders on the Tranche C Term Loan Borrowing
Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Borrowing Notice&#148;</I> means a notice substantially in the form attached hereto as Exhibit&nbsp;B.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Business Day&#148;</I> means a day (other than a Saturday or Sunday) on which commercial banks are not
authorized or not required to close in New&nbsp;York City. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Capital Lease Obligations&#148;</I> means, as to any
Person, the obligations of such Person to pay rent or other amounts under a lease of (or other agreement conveying the right to use) real and/or personal Property which obligations are required to be classified and accounted for as a capital lease
on a balance sheet of such Person under GAAP and, for purposes of this Agreement, the amount of such obligations shall be the capitalized amount thereof, determined substantially in accordance with GAAP; <I>provided</I> that any obligations that
were not required to be included on the balance sheet of such Person as capital lease obligations when incurred (whether now outstanding or at any time incurred or entered into) but are subsequently
<FONT STYLE="white-space:nowrap">re-characterized</FONT> as capital lease obligations due to a change in accounting rules under GAAP after the Closing Date shall for all purposes hereunder not be treated as a Capital Lease Obligation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Casualty Event&#148;</I> means any actual or constructive loss, condemnation, destruction, confiscation, requisition,
seizure or forfeiture of all or any material portion of the assets of Borrowers or any other Obligor, excluding only those assets, individually or in the aggregate, subject to any such event during any calendar year with a fair market value as of
the date thereof equal to or less than $1,500,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Cayman Parent&#148; </I>means West Affum Holdings, L.P., a
Cayman Islands exempted limited partnership, acting at all times by and through its general partner, West Affum GP Ltd., a Cayman Islands exempted company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Cayman Security Documents&#148;</I> means, collectively, (a)&nbsp;the West Affum Corp. Fixed and Floating Charge,
(b)&nbsp;the Intermediate Holdings Fixed and Floating Charge, (c)&nbsp;the Intermediate Holdings Equitable Share Charge and (d)&nbsp;the West Affum Corp. Account Charge. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Change of Control&#148; </I>means (a)&nbsp;prior to a Qualified Public Offering, any transaction or series of related
transactions in which, as applicable, (i)&nbsp;the General Partner of the Cayman Parent ceases to be an Affiliate of the Sponsor or (ii)&nbsp;the Sponsor (or its Affiliate) ceases to (A)&nbsp;be the &#147;Controlling Investor&#148; (as such term is
defined in the Amended and Restated Agreement of Limited Partnership of the Parent dated October&nbsp;21, 2014) of Cayman Parent and (B)&nbsp;beneficially own at least 50.1% of the voting and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-6- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">
economic interests of Cayman Parent with the ability to control the management of Cayman Parent, (b)&nbsp;after a Qualified Public Offering, any &#147;person&#148; or &#147;group&#148; (within
the meaning of <FONT STYLE="white-space:nowrap">Rule&nbsp;13d-5</FONT> of the Exchange Act as in effect on the date hereof), other than the Sponsor, shall own, directly or indirectly, beneficially or of record, shares representing 40% or more of the
aggregate ordinary voting power represented by the issued and outstanding Equity Interests of Bermuda Parent, (c)&nbsp;Parent ceases to own, directly or indirectly, 100% of the Equity Interests in Intermediate Holdings, (d)&nbsp;Intermediate
Holdings ceases to own 100% of the Equity Interests in West Affum Corp., (e) West Affum Corp. ceases to own 95% of the Equity Interests in the Irish Obligor, (f)&nbsp;the Irish Obligor ceases to own 100% of the Equity Interests in OpCo or
(g)&nbsp;except as permitted pursuant to Section&nbsp;9.05 or 9.09, OpCo ceases to own directly or indirectly, 100% of Equity Interests of its Subsidiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Charged Property&#148; </I>means the assets of an Obligor subject to a security interest under an Irish Security
Document. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Claims&#148;</I> includes claims, litigation, demands, complaints, grievances, actions, applications,
suits, causes of action, orders, charges, indictments, prosecutions, information (brought by a public prosecutor without grand jury indictment) or other similar processes, assessments or reassessments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Closing Date&#148;</I> means the Business Day on which all of the conditions set forth in Section&nbsp;6.01 have been
satisfied or waived by the Lenders and the Tranche&nbsp;A Term Loan is made. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Closing Date Warrant
Certificate&#148;</I> means the warrant, in substantially the form of Exhibit&nbsp;I, delivered to the Administrative Agent pursuant to Section&nbsp;6.01(e)(x) with an aggregate value equivalent of 10% of the aggregate amount of Term Loans funded
under Section&nbsp;2.01, as the Warrant Certificate may be amended or otherwise modified pursuant to the terms thereof. Upon the occurrence of a Qualified Public Offering the Closing Date Warrant Certificate shall be immediately cancelled and
replaced with the Second Amendment Warrant Certificate pursuant to the terms of the Second Amendment Date Warrant Certificate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Closing Fee&#148;</I> has the meaning set forth in Section&nbsp;2.03. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Code&#148;</I> means the Internal Revenue Code of 1986, as amended from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Collateral&#148;</I> means any Property in which a Lien is purported to be granted under any of the Security
Documents (or all such Property, as the context may require). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Collateral Questionnaire&#148;</I> means that
certain Collateral Questionnaire and certification by a Responsible Officer of Administrative Borrower substantially in the form of attached hereto as Exhibit&nbsp;I and otherwise in form and substance satisfactory to the Administrative Agent. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-7- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>COMI&#148;</I> means center of main interests within the meaning,
and for the purposes, of the EU Insolvency Regulation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Commitment&#148;</I> means, with respect to each Lender,
such Lender&#146;s Tranche&nbsp;A Term Loan Commitment, Tranche&nbsp;B Term Loan Commitment and Tranche C Term Loan Commitment, and <I>&#147;Commitments&#148;</I> means all such commitments of all Lenders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Commodity Account&#148;</I> has the meaning set forth in the Security Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Competitor&#148;</I> means any Person that is a bona fide direct competitor of any Obligor in the same industry or a
substantially similar industry which offers a substantially similar product or service as any Obligor; <I>provided</I> that no Lender or Affiliate of a Lender (other than a Disqualified Lender) shall be deemed to be a direct competitor of any
Obligor as a result of such Lender or Affiliate of such Lender being an investor in a business that may be a competitor of any Obligor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Compliance Certificate&#148;</I> has the meaning set forth in Section&nbsp;8.01(d). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Conforming Changes&#148;</I> means, with respect to either the use or administration of Term SOFR or the use,
administration, adoption or implementation of any Benchmark Replacement, any technical, administrative or operational changes (including changes to the definition of &#147;Business Day,&#148; the definition of &#147;U.S.&nbsp;Government Securities
Business Day,&#148; the definition of &#147;Interest Period&#148; or any similar or analogous definition (or the addition of a concept of &#147;interest period&#148;), timing and frequency of determining rates and making payments of interest, timing
of borrowing requests or prepayment, conversion or continuation notices, the applicability and length of lookback periods and other technical, administrative or operational matters) that the Administrative Agent reasonably decides (in consultation
with Borrowers) may be appropriate to reflect the adoption and implementation of any such rate or to permit the use and administration thereof by the Administrative Agent in a manner substantially consistent with market practice (or, if the
Administrative Agent reasonably decides that adoption of any portion of such market practice is not administratively feasible or if the Administrative Agent reasonably determines that no market practice for the administration of any such rate
exists, in such other manner of administration as the Administrative Agent decides is reasonably necessary in connection with the administration of this Agreement and the other Loan Documents (in consultation with Borrowers)). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Connection Income Taxes&#148; </I>means Other Connection Taxes that are imposed on or measured by net income (however
denominated) or that are franchise Taxes or branch profits Taxes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Contracts&#148;</I> means any contract,
license, lease, agreement, obligation, promise, undertaking, understanding, arrangement, document, commitment, entitlement or engagement under which a Person has, or will have, any liability or contingent liability (in each case, whether written or
oral, express or implied, and whether in respect of monetary or payment obligations, performance obligations or otherwise), excluding the Loan Documents. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-8- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Control&#148;</I> means, in respect of a particular Person, the
possession, directly or indirectly, of the power to direct or cause the direction of the management or policies of such Person, whether through the ability to exercise voting power, by contract or otherwise. <I>&#147;Controlling&#148;</I> and
<I>&#147;Controlled&#148;</I> have meanings correlative thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Controlled Account&#148;</I> has the meaning
set forth in Section&nbsp;8.17(a)(i). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Copyrights&#148;</I> has the meaning set forth in the Security Agreement.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Cure Amount&#148;</I> has the meaning set forth in Section&nbsp;8.15(b). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Cure Right&#148;</I> has the meaning set forth in Section&nbsp;8.15(b). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Daily Simple SOFR&#148;</I> means, for any day (a <I>&#147;SOFR</I><I></I><I>&nbsp;Rate Day&#148;</I>), a rate per
annum equal to the greater of (a)&nbsp;SOFR for the day (such day, a <I>&#147;SOFR</I><I></I><I>&nbsp;Determination Day&#148;</I>) that is two (2)&nbsp;U.S.&nbsp;Government Securities Business Days prior to (i)&nbsp;if such SOFR&nbsp;Rate Day is a
U.S.&nbsp;Government Securities Business Day, such SOFR&nbsp;Rate Day or (ii)&nbsp;if such SOFR&nbsp;Rate Day is not a U.S.&nbsp;Government Securities Business Day, the U.S.&nbsp;Government Securities Business Day immediately preceding such
SOFR&nbsp;Rate Day, in each case, as such SOFR is published by the SOFR&nbsp;Administrator on the SOFR&nbsp;Administrator&#146;s Website, and (b)&nbsp;the Floor. If by 5:00&nbsp;p.m. (New&nbsp;York City time) on the second (2nd) U.S.&nbsp;Government
Securities Business Day immediately following any SOFR&nbsp;Determination Day, SOFR in respect of such SOFR&nbsp;Determination Day has not been published on the SOFR&nbsp;Administrator&#146;s Website and a Benchmark Replacement Date with respect to
the Daily Simple SOFR has not occurred, then SOFR for such SOFR&nbsp;Determination Day will be SOFR as published in respect of the first preceding U.S.&nbsp;Government Securities Business Day for which such SOFR was published on the
SOFR&nbsp;Administrator&#146;s Website; <I>provided</I> that, any SOFR determined pursuant to this sentence shall be utilized for purposes of calculation of Daily Simple SOFR for no more than three (3)&nbsp;consecutive SOFR&nbsp;Rate Days;
<I>provided, further,</I> Daily Simple SOFR shall be rounded upwards to the next 1/100% (if necessary). Any change in Daily Simple SOFR due to a change in SOFR shall be effective from and including the effective date of such change in SOFR without
notice to Borrowers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Default&#148;</I> means any Event of Default and any event that, upon the giving of notice,
the lapse of time or both, would constitute an Event of Default. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Default Rate&#148;</I> has the meaning set
forth in Section&nbsp;3.02(d). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Delegate&#148; </I>means any delegate, agent, attorney or <FONT
STYLE="white-space:nowrap">co-trustee</FONT> appointed by the Administrative Agent (in its capacity as security trustee). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-9- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Deposit Account&#148;</I> has the meaning set forth in the Security
Agreement and relates to such accounts located and/or maintained in the United States of America. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Designated
Person&#148;</I> means a person or entity: (a)&nbsp;listed in the annex to, or otherwise targeted by the provisions of, the Executive Order (as disclosed by <FONT STYLE="white-space:nowrap">World-Check</FONT> or another reputable commercially
available database); (b)&nbsp;named as a &#147;Specially Designated National and Blocked Person&#148; on the most current list published by OFAC at its official website or any replacement website or other replacement official publication of such
list (as disclosed by <FONT STYLE="white-space:nowrap">World-Check</FONT> or another reputable commercially available database) or listed in the consolidated list of financial sanctions targets maintained by OFSI or any other Sanctions-related list
of designated persons maintained by any other Governmental Authority; or (c)&nbsp;with which the Lenders and/or Obligors are prohibited or restricted from dealing or otherwise engaging in any transaction by any Economic Sanctions Laws, Sanctions
Laws or Irish Economic Sanctions Laws; or (d)&nbsp;that is owned or controlled directly or indirectly by any person or entity described in this definition. For the purposes of this definition, the meaning of &#147;owned or controlled directly or
indirectly&#148; shall be determined in accordance with applicable Sanctions Laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Device&#148;</I> means
(a)&nbsp;any medical instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent or other similar or related item, including any component, part or accessory, that (i)&nbsp;is intended for use in the diagnosis of disease or
other conditions or in the cure, mitigation, treatment or prevention of disease, in man, or is intended to affect the structure or any function of the body of man, (ii)&nbsp;does not achieve its primary intended purpose or purposes through chemical
action within or on the body of man and (iii)&nbsp;is not dependent upon being metabolized for the achievement of its primary intended purpose or purposes, or (b)&nbsp;any other product that meets the definition of &#147;device&#148; as set forth in
Section&nbsp;201 of the FD&amp;C&nbsp;Act (21&nbsp;U.S.C. &#167;&nbsp;321); unless, in either case, such Device is exempt pursuant to Section&nbsp;520(o) of the FD&amp;C Act (21&nbsp;U.S.C. &#167;&nbsp;360j(o)). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Device Clearance Application&#148;</I> means (a)&nbsp;any premarket approval application submitted under
Section&nbsp;515 of the FD&amp;C&nbsp;Act (21&nbsp;U.S.C. &#167;&nbsp;360e) (a <I>&#147;PMA&#148;</I>), (b)&nbsp;any <I>de</I><I></I><I>&nbsp;novo</I> request submitted under Section&nbsp;513(f) of the FD&amp;C&nbsp;Act (21&nbsp;U.S.C.
&#167;&nbsp;360c(f)), (c) any 510(k) submitted under Section&nbsp;510(k) of the FD&amp;C&nbsp;Act (21&nbsp;U.S.C. &#167;&nbsp;360(k)) seeking clearance from the FDA for a Device that is substantially equivalent to a legally marketed predicate
Device, as defined in the FD&amp;C&nbsp;Act, or (d)&nbsp;any corresponding or substantially equivalent notification, application or clearance of a <FONT STYLE="white-space:nowrap">non-U.S.&nbsp;Regulatory</FONT> Authority, including, with respect to
the European Union, any equivalent submission to a Standard Body pursuant to an applicable directive of the European Council with respect to CE marking (or, if applicable, a <FONT STYLE="white-space:nowrap">self-certification</FONT> of conformity
with respect to any such directive through a &#147;declaration of conformity&#148;) and (e)&nbsp;all amendments, variations, extensions and renewals of any of the foregoing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-10- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Disqualified Equity Interests&#148;</I> means, with respect to any
Person, any Equity Interest of such Person that, by its terms (or by the terms of any security or other Equity Interest into which it is convertible or for which it is exchangeable upon exercise or otherwise), or upon the happening of any event or
condition (a)&nbsp;matures or is mandatorily redeemable (other than solely for Qualified Equity Interests), including pursuant to a sinking fund obligation or otherwise, (b)&nbsp;is redeemable at the option of the holder thereof (other than solely
for Qualified Equity Interests), in whole or in part, (c)&nbsp;provides for the scheduled payments of dividends or other distributions in cash or other securities that would constitute Disqualified Equity Interests, or (d)&nbsp;is or becomes
convertible into or exchangeable for Indebtedness or any other Equity Interests that would constitute Disqualified Equity Interests, in each case, prior to the date that is one hundred and eighty (180)&nbsp;days after the Stated Maturity Date;
<I>provided</I> that, if such Equity Interests are issued pursuant to any plan for the benefit of directors, officers, employees or consultants of such Person or by any such plan to such directors, officers, employees or consultants, such Equity
Interests shall not constitute Disqualified Equity Interests solely because they may be required to be repurchased by such Person upon the death, disability, retirement or termination of employment or service of such director, officer, employee or
consultant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Disqualified Lender</I>&#148; means (a)&nbsp;any Competitor or (b)&nbsp;any Person identified by or
on behalf of the Administrative Borrower (or one of its Affiliates) to the Administrative Agent in writing from time to time (and such Person&#146;s Affiliates identified in writing from time to time or reasonably identifiable as such solely on the
basis of their names);<I> provided</I> that no updates to the list of Disqualified Lenders in this clause (b)&nbsp;shall be deemed to retroactively disqualify any parties that have previously validly acquired an assignment or participation in
respect of the Term Loans from continuing to hold or vote such previously acquired assignments and participations on the terms set forth herein for Lenders that are not Disqualified Lenders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Dollars&#148;</I> and <I>&#147;$&#148;</I> means lawful money of the United States of America. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Domestic Subsidiary&#148; </I>means any Subsidiary that is organized under the laws of the United States, any state
thereof or the District of Columbia. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Economic Sanctions Laws&#148;</I> means: (a)&nbsp;the Executive Order, the
<I>International Emergency Economic Powers Act</I> (50&nbsp;U.S.C. &#167;&#167;&nbsp;1701 <I>et</I><I></I><I>&nbsp;seq.</I>), the <I>Trading with the Enemy Act</I> (50&nbsp;U.S.C. App. &#167;&#167;&nbsp;1 <I>et</I><I></I><I>&nbsp;seq.</I>), any
other law or regulation promulgated thereunder from time to time and administered by OFAC and any similar law enacted in the United States; and (b)&nbsp;any other similar applicable law, rule or regulation now or hereafter enacted in any other
applicable jurisdiction related to economic sanctions or trade embargos, including the United Kingdom or the Cayman Islands. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;EEA</I><I></I><I>&nbsp;Financial Institution&#148;</I> means (a)&nbsp;any credit institution or investment firm
established in any EEA&nbsp;Member Country which is subject to the supervision of an EEA&nbsp;Resolution Authority, (b)&nbsp;any entity established in an EEA&nbsp;Member Country which is a parent of an institution described in clause&nbsp;(a) of
this definition, or (c)&nbsp;any financial institution established in an EEA&nbsp;Member Country which is a subsidiary of an institution described in clauses&nbsp;(a) or (b)&nbsp;of this definition and is subject to consolidated supervision with its
parent. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-11- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;EEA</I><I></I><I>&nbsp;Member Country&#148;</I> means any of the
member states of the European Union, Iceland, Liechtenstein, and Norway. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;EEA</I><I></I><I>&nbsp;Resolution
Authority&#148;</I> means any public administrative authority or any person entrusted with public administrative authority of any EEA&nbsp;Member Country (including any delegee) having responsibility for the resolution of any EEA&nbsp;Financial
Institution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Environmental Law&#148;</I> means any national, federal, state, provincial or local governmental
law, rule, regulation, order, writ, judgment, injunction or decree relating to pollution or protection of the environment or the treatment, storage, disposal, release, threatened release or handling of Hazardous Materials, and all local laws and
regulations related to environmental matters and any specific agreements entered into with any competent authorities which include commitments related to environmental matters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Equity Interest&#148;</I> means, with respect to any Person, any and all shares, interests, participations or other
equivalents, including membership interests (however designated, whether voting or nonvoting), of equity of such Person, including, if such Person is a partnership, partnership interests (whether general or limited) and any other interest or
participation that confers on a Person the right to receive a share of the profits and losses of, or distributions of property of, such partnership, but excluding debt securities convertible or exchangeable into such equity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;ERISA&#148;</I> means the United States Employee Retirement Income Security Act of 1974, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;ERISA Affiliate&#148;</I> means any Person treated as a single employer with any Obligor, within the meaning of
Section&nbsp;414(b), (c), (m) or (o)&nbsp;of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;ERISA Event&#148;</I> means (a)&nbsp;a reportable event
as defined in Section&nbsp;4043 of ERISA with respect to a Title&nbsp;IV Plan, excluding, however, such events as to which the PBGC by regulation has waived the requirement of Section&nbsp;4043(a) of ERISA that it be notified within thirty
(30)&nbsp;days of the occurrence of such event; (b)&nbsp;the applicability of the requirements of Section&nbsp;4043(b) of ERISA with respect to a contributing sponsor, as defined in Section&nbsp;4001(a)(13) of ERISA, to any Title&nbsp;IV Plan where
an event described in paragraph&nbsp;(9), (10), (11), (12) or (13)&nbsp;of Section&nbsp;4043(c) of ERISA is reasonably expected to occur with respect to such plan within the following thirty (30)&nbsp;days; (c)&nbsp;a withdrawal by any Obligor or
any ERISA Affiliate thereof from a Title&nbsp;IV Plan or the termination of any Title&nbsp;IV Plan resulting in liability under Sections&nbsp;4063 or 4064 of ERISA; (d)&nbsp;the withdrawal of any Obligor or any ERISA Affiliate thereof in a complete
or partial withdrawal (within the meaning of Section&nbsp;4203 and 4205 of ERISA) from any Multiemployer Plan if there is any potential liability therefore, or the receipt by any Obligor or any ERISA Affiliate thereof of notice from any
Multiemployer Plan that it is in insolvency pursuant to Section&nbsp;4245 of ERISA; (e)&nbsp;the filing of a notice of intent to terminate, the treatment of a plan amendment as a termination under Section&nbsp;4041 or 4041A of ERISA, or the
commencement of proceedings by the PBGC to terminate a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-12- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">
Title&nbsp;IV Plan or Multiemployer Plan; (f)&nbsp;the imposition of liability on any Obligor or any ERISA Affiliate thereof pursuant to Sections&nbsp;4062(e) or 4069 of ERISA or by reason of the
application of Section&nbsp;4212(c) of ERISA; (g)&nbsp;the failure by any Obligor or any ERISA Affiliate thereof to make any required contribution to a Title IV Plan, or the failure to meet the minimum funding standard of Section&nbsp;412 of the
Code with respect to any Title&nbsp;IV Plan (whether or not waived in accordance with Section&nbsp;412(c) of the Code) or the failure to make by its due date a required installment under Section&nbsp;430 of the Code with respect to any Title&nbsp;IV
Plan or the failure to make any required contribution to a Multiemployer Plan; (h)&nbsp;the determination that any Title&nbsp;IV Plan is considered an <FONT STYLE="white-space:nowrap">at-risk</FONT> plan or a plan in endangered to critical status
within the meaning of Sections&nbsp;430, 431 and 432 of the Code or Sections&nbsp;303, 304 and 305 of ERISA; (i)&nbsp;an event or condition constitutes grounds under Section&nbsp;4042 of ERISA for the termination of, or the appointment of a trustee
to administer, any Title&nbsp;IV Plan or Multiemployer Plan; (j)&nbsp;the imposition of any liability under Title&nbsp;I or Title&nbsp;IV of ERISA, other than PBGC premiums due but not delinquent under Section&nbsp;4007 of ERISA, upon any Obligor or
any ERISA Affiliate thereof; (k)&nbsp;an application for a funding waiver under Section&nbsp;303 of ERISA or an extension of any amortization period pursuant to Section&nbsp;412 of the Code with respect to any Title&nbsp;IV Plan; (l)&nbsp;the
occurrence of a <FONT STYLE="white-space:nowrap">non-exempt</FONT> prohibited transaction under Sections&nbsp;406 or 407 of ERISA for which any Obligor is directly or indirectly liable; or (m)&nbsp;the imposition of any Lien (or the fulfillment of
the conditions for the imposition of any Lien) on any of the rights, properties or assets of any Obligor or any ERISA Affiliate thereof, in either case pursuant to Section&nbsp;302(f), 303(k), or 4068 of ERISA or to Section&nbsp;401(a)(29) or 430(k)
of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;ERISA Funding Rules&#148;</I> means the rules regarding minimum required contributions (including
any installment payment thereof) to Title&nbsp;IV Plans, as set forth in Sections&nbsp;412, 430, 431, 432 and 436 of the Code and Sections&nbsp;302, 303, 304 and 305 of ERISA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;EU</I><I></I><I>&nbsp;Bail</I><I><FONT STYLE="white-space:nowrap">-In</FONT> Legislation Schedule&#148;</I> means the
<FONT STYLE="white-space:nowrap">EU&nbsp;Bail-In</FONT> Legislation Schedule published by the Loan Market Association (or any successor Person), as in effect from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;EU Insolvency Regulation&#148; </I>means Regulation (EU) 2015/848 of the European Parliament and of the Council of
20&nbsp;May 2015 on insolvency proceedings (recast). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Event of Default&#148;</I> has the meaning set forth in
Section&nbsp;10.01. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Excess Funding Guarantor&#148;</I> has the meaning set forth in Section&nbsp;11.08. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Excess Payment&#148;</I> has the meaning set forth in Section&nbsp;11.08. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Exchange Act&#148;</I> means the Securities Exchange Act of 1934, as amended, and the rules and regulations
promulgated thereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-13- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Excluded Accounts&#148;</I> means Deposit Accounts, Securities
Accounts or Commodity Accounts (a)&nbsp;maintained outside of the United States of America in an aggregate balance thereof not to exceed One Hundred Thousand ($100,000.00) at any time, (b)&nbsp;used exclusively to maintain deposits subject to a Lien
described in Section&nbsp;9.02(m), (o) or (p), (c) that are <FONT STYLE="white-space:nowrap">zero-balance</FONT> accounts and (d)&nbsp;exclusively used for withholding payroll, payroll taxes and other employee wage and benefit payments to or for the
benefit of the employees of Borrowers and their Subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Excluded Subsidiary</I>&#148; means any Subsidiary
(a)&nbsp;that constitutes an Immaterial Subsidiary or (b)&nbsp;for which the provision of a Guarantee of the Obligations would result in material adverse tax consequences (as reasonably agreed by the Borrowers and the Administrative Agent);
<I>provided</I> that, in respect of clause (b)&nbsp;above, such material adverse tax consequences shall not have resulted from such Subsidiary being formed or organized in a foreign jurisdiction in contemplation of avoiding compliance with the
requirement to provide a Guarantee of the Obligations; <I>provided</I>, <I>further</I>, no Excluded Subsidiary shall own or exclusively control any Material Intellectual Property. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Excluded Taxes&#148;</I> means any of the following Taxes imposed on or with respect to a Recipient or required to be
withheld or deducted from a payment to a Recipient: (a)&nbsp;Taxes imposed on or measured by net income (however denominated), franchise Taxes and branch profits Taxes in each case (i)&nbsp;imposed as a result of such Recipient being organized under
the laws of, or having its principal office or, in the case of a Lender, its applicable lending office located in, the jurisdiction imposing such Tax or (ii)&nbsp;that are Other Connection Taxes, (b)&nbsp;any U.S.&nbsp;federal withholding Taxes that
are imposed on amounts payable to Lender to the extent that the obligation to withhold amounts existed on the date that (i)&nbsp;Lender became a &#147;Lender&#148; under this Agreement or (ii)&nbsp;Lender changes its lending office, except in each
case to the extent Lender is a direct or indirect assignee of any other Lender that was entitled, at the time the assignment of such other Lender became effective, to receive additional amounts under Section&nbsp;5.03 or Lender was entitled to
receive additional amounts under Section&nbsp;5.03 immediately before it changed its lending office, (c)&nbsp;any Taxes imposed in connection with FATCA and (d)&nbsp;Taxes attributable to such Recipient&#146;s failure to comply with
Section&nbsp;5.03(e). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Executive Order&#148;</I> means the US&nbsp;Executive Order No.&nbsp;13224 on Blocking
Property and Prohibiting Transactions with Persons who commit, Threaten to Commit, or Support Terrorism. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Existing Indebtedness&#148; </I>means Indebtedness and other obligations outstanding under that certain Loan and
Security Agreement dated as of September&nbsp;24, 2020 by and among the Obligors and Kennedy Lewis Management LP, as amended prior to the Closing Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Existing Letters of Credit</I>&#148; means any letter of credit previously issued that will remain outstanding on and
after the Closing Date and is listed on Schedule 4. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Expense Deposit&#148;</I> means a cash deposit in the amount
of $50,000 made by Administrative Borrower to an Affiliate of Perceptive Advisors LLC pursuant to the Proposal Letter for the prepayment of the Lenders&#146; costs and expenses (payable pursuant to Section&nbsp;13.03(a) and/or the Proposal Letter)
incurred prior to the Closing Date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-14- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;FATCA&#148;</I> means Sections&nbsp;1471 through 1474 of the Code,
as of the date of this Agreement (or any amended or successor version that is substantively comparable and not materially more onerous to comply with), any current or future regulations or official interpretations thereof, any agreements entered
into pursuant to Section&nbsp;1471(b)(1) of the Code and any fiscal or regulatory legislation, rules or practices adopted pursuant to any intergovernmental agreement, treaty or convention among Governmental Authorities entered into in connection
with the implementation of the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;FD&amp;C</I><I></I><I>&nbsp;Act&#148;</I> means the U.S.&nbsp;Food,
Drug and Cosmetic Act of 1938 (or any successor thereto), as amended from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;FDA&#148;</I> means the
U.S.&nbsp;Food and Drug Administration and any successor entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;FDA</I><I></I><I>&nbsp;Laws&#148;</I> means all
applicable statutes, rules, regulations and orders administered or issued by the (a)&nbsp;FDA, including without limitation, the FD&amp;C&nbsp;Act and its implementing regulations or (b)&nbsp;any <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
Regulatory Authority equivalent of the FDA, including the European Medicines Agency. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Federal Health Care
Program&#148;</I> has the meaning specified in Section&nbsp;1128B(f) of the Social Security Act and includes the programs commonly known as Medicare, Medicaid, TRICARE and CHAMPVA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Floor&#148; </I>means a rate of interest equal to 4.75%. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Foreign Lender&#148;</I> means a Lender that is not a U.S.&nbsp;Person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Foreign Subsidiary&#148; </I>means any Subsidiary that is not a Domestic Subsidiary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>FRB</I>&#148; shall mean the Board of Governors of the Federal Reserve System of the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;GAAP&#148;</I> means generally accepted accounting principles in the United States of America, as in effect from time
to time, set forth in the opinions and pronouncements of the Accounting Principles Board and the American Institute of Certified Public Accountants, in the statements and pronouncements of the Financial Accounting Standards Board and in such other
statements by such other entity as may be in general use by significant segments of the accounting profession that are applicable to the circumstances as of the date of determination. Subject to Section&nbsp;1.02, all references to &#147;GAAP&#148;
shall be to GAAP applied consistently with the principles used in the preparation of the financial statements described in Section&nbsp;7.04(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;General Partner&#148;</I> means West Affum GP Ltd., an exempted company incorporated with limited liability in the
Cayman Islands. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-15- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Governmental Approval&#148;</I> means any consent, authorization,
approval, order, license, franchise, permit, certification, accreditation, registration, clearance, exemption, filing or notice that is issued or granted by or from (or pursuant to any act of) any Governmental Authority, including any application or
submission related to any of the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Governmental Authority&#148;</I> means any nation, government,
branch of power (whether executive, legislative or judicial), state, municipality or other political subdivision thereof and any entity exercising executive, legislative, judicial, monetary, regulatory or administrative functions of or pertaining to
government, including without limitation Regulatory Authorities, governmental departments, agencies, commissions, bureaus, officials, ministers, courts, bodies, boards, tribunals and dispute settlement panels, and other <FONT
STYLE="white-space:nowrap">law-,</FONT> <FONT STYLE="white-space:nowrap">rule-</FONT> or <FONT STYLE="white-space:nowrap">regulation-making</FONT> organizations or entities of any State, territory, county, city or other political subdivision of the
United States, the United Kingdom, Ireland or the Cayman Islands. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Guarantee&#148;</I> of or by any Person (the
<I>&#147;guarantor&#148;</I>) means any obligation, contingent or otherwise, of the guarantor guaranteeing or having the economic effect of guaranteeing any Indebtedness or other obligation of any other Person (the <I>&#147;primary
obligor&#148;</I>) in any manner, whether directly or indirectly, and including any obligation of the guarantor, direct or indirect, (a)&nbsp;to purchase or pay (or advance or supply funds for the purchase or payment of) such Indebtedness or other
obligation or to purchase (or to advance or supply funds for the purchase of) any security for the payment thereof, (b)&nbsp;to purchase or lease property, securities or services for the purpose of assuring the owner of such Indebtedness or other
obligation of the payment thereof, (c)&nbsp;to maintain working capital, equity capital or any other financial statement condition or liquidity of the primary obligor so as to enable the primary obligor to pay such Indebtedness or other obligation
or (d)&nbsp;as an account party in respect of any letter of credit or letter of guaranty issued to support such Indebtedness or obligation; <I>provided,</I> that the term Guarantee shall not include endorsements for collection or deposit in the
Ordinary Course of Business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Guarantee Assumption Agreement&#148;</I> means a Guarantee Assumption Agreement
substantially in the form of Exhibit&nbsp;A by an entity that, pursuant to Section&nbsp;8.11(a), is required to become a &#147;Guarantor&#148;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Guaranteed Obligations&#148;</I> has the meaning set forth in Section&nbsp;11.01. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Guarantor&#148;</I> means, collectively, Intermediate Holdings and each Subsidiary of a Borrower (other than OpCo) on
the Closing Date or joined as a Guarantor from time to time pursuant to Section&nbsp;8.11(a). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Hazardous
Material&#148;</I> means any substance, element, chemical, compound, product, solid, gas, liquid, waste, <FONT STYLE="white-space:nowrap">by-product,</FONT> pollutant, contaminant or material which is hazardous or toxic, and includes, without
limitation, (a)&nbsp;asbestos, polychlorinated biphenyls and petroleum (including crude oil or any fraction thereof) and (b)&nbsp;any material classified or regulated as &#147;hazardous&#148; or &#147;toxic&#148; or words of like import pursuant to
an Environmental Law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-16- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Health Care Compliance Program&#148;</I> has the meaning set forth
in Section&nbsp;7.07(g). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Health Care Laws&#148;</I> means, collectively, all Laws applicable to the business of
Borrower or any other Obligor regulating the manufacturing, sale, distribution, labeling, marketing, or promotion, or the provision of and payment for, health care products, items and services, including but not limited to (a)&nbsp;all applicable
Laws relating to the privacy, security, storage, or collection of consumer information, including but not limited to the HIPAA and state health information privacy and security laws; (b)&nbsp;all applicable Laws relating to fraud and abuse, false
claims, self-referral, kickbacks, <FONT STYLE="white-space:nowrap">fee-splitting,</FONT> or patient brokering, including but not limited to (i)&nbsp;the federal Anti-Kickback Statute (42 U.S.C. &#167;
<FONT STYLE="white-space:nowrap">1320a-7b(b))</FONT> and any similar state laws, (ii)&nbsp;the Ethics in Patient Referrals Act (Stark Law) (42 U.S.C. &#167; 1395nn) and any similar state laws, (iii)&nbsp;the civil False Claims Act (31 U.S.C. &#167;
3729 et seq.) and any similar state laws, (iv)&nbsp;the federal health care program exclusion provisions (42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7),</FONT> (v) the Civil Monetary Penalties Act (42 U.S.C. &#167; <FONT
STYLE="white-space:nowrap">1320a-7a),</FONT> (vi) the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (Pub. L. <FONT STYLE="white-space:nowrap">No.&nbsp;108-173)),</FONT> and (vii)&nbsp;other applicable requirements relating
to prohibited remuneration, or the defrauding of, or making of any false claim, false statement, or misrepresentation of material facts to the Federal Health Care Programs or any Third-Party Payor Program); (c)&nbsp;all applicable FDA&nbsp;Laws;
(d)&nbsp;all applicable Laws regarding the provision of health care supplies, items or services to Federal Health Care Program beneficiaries or the billing of the Federal Health Care Programs; (e)&nbsp;all applicable Law regarding clinical research
and patient consent; (f)&nbsp;required Permits, including relating to the licensure or registration of health care providers, suppliers, facilities, and manufacturers; and (g)&nbsp;all rules and regulations promulgated under or pursuant to any of
the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Hedging Agreement&#148;</I> means any interest rate exchange agreement, foreign currency exchange
agreement, commodity price protection agreement or other interest or currency exchange rate or commodity price hedging arrangement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;HIPAA&#148;</I> means the Health Insurance Portability and Accountability Act of 1996, 42 U.S.C. &#167;&#167; <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1320d-1329d-8,</FONT></FONT> as amended by the Health Information Technology for Economic and Clinical Health Act, enacted as Title XIII of the American Recovery and Reinvestment Act of
2009, Public Law <FONT STYLE="white-space:nowrap">111-5,</FONT> as the same may be further amended, modified or supplemented from time to time, and its implementing regulations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;IDE&#148;</I> means an application, including an application filed with any Regulatory Authority, for authorization
to commence human clinical studies with respect to any Device, including (a)&nbsp;an Investigational Device Exemption as defined in the FD&amp;C&nbsp;Act or any successor application or procedure filed with the FDA, (b)&nbsp;an abbreviated
Investigational Device Exemption as specified in FDA regulations in 21&nbsp;C.F.R. &#167;&nbsp;812.2(b), (c)&nbsp;any equivalent of any of the foregoing pursuant to or under any <FONT STYLE="white-space:nowrap">non-U.S.</FONT> country or regulatory
jurisdiction, (d)&nbsp;all amendments, variations, extensions and renewals of any of the foregoing that may be filed with respect thereto, and (e)&nbsp;all documents and correspondence with Institutional Review Boards, whether U.S. or <FONT
STYLE="white-space:nowrap">non-U.S.,</FONT> or equivalent. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-17- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Immaterial Subsidiary&#148;</I> is a Subsidiary other than an
Obligor, that (a)&nbsp;generates revenue in the aggregate less than $500,000 in any trailing twelve (12)&nbsp;month period and (b)&nbsp;holds in the aggregate assets that constitute less than $500,000 in any trailing twelve (12)&nbsp;month period;
<I>provided</I> that if the consolidated revenue or consolidated assets of all Subsidiaries that would otherwise be an &#147;Immaterial Subsidiary&#148; pursuant to clauses (a)&nbsp;and (b) above exceeds (i)&nbsp;in the case of consolidated revenues
in clause (a), $2,500,000 in any trailing twelve (12)&nbsp;month period and (ii)&nbsp;in the case of consolidated total assets in clause (b), $2,500,000&nbsp;in any trailing twelve (12)&nbsp;month period, then Borrowers shall designate in writing to
the Administrative Agent one or more of such Subsidiaries to become Obligors to the extent necessary to eliminate such excess. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Indebtedness&#148;</I> of any Person means, without duplication, (a)&nbsp;all obligations of such Person for borrowed
money, (b)&nbsp;all obligations of such Person evidenced by bonds, debentures, notes, loan agreements or similar instruments, (c)&nbsp;[reserved], (d)&nbsp;all obligations of such Person under conditional sale or other title retention agreements
relating to Property acquired by such Person, (e)&nbsp;all obligations of such Person in respect of the deferred purchase price of Property or services (excluding current accounts payable incurred in the Ordinary Course of Business not overdue by
more than one hundred twenty (120)&nbsp;days), (f)&nbsp;all Indebtedness of others secured by (or for which the holder of such Indebtedness has an existing right, contingent or otherwise, to be secured by) any Lien on Property owned or acquired by
such Person, whether or not the Indebtedness secured thereby has been assumed, (g)&nbsp;all Guarantees by such Person of Indebtedness of others, (h)&nbsp;all Capital Lease Obligations of such Person, (i)&nbsp;all obligations, contingent or
otherwise, of such Person as an account party in respect of letters of credit and letters of guaranty, (j)&nbsp;obligations under any Hedging Agreement, currency swaps, forwards, futures or derivatives transactions, (k)&nbsp;all obligations,
contingent or otherwise, of such Person in respect of bankers&#146; acceptances, (l)&nbsp;all obligations of such Person under license or other agreements containing a guaranteed minimum payment or purchase by such Person, (m)&nbsp;any Disqualified
Equity Interests of such Person, (n)&nbsp;any earnout obligation at the time such obligation is both required to be reflected as a liability on the balance sheet of such Person in accordance with GAAP and not paid after becoming due and payable and
(o)&nbsp;all other obligations required to be classified as indebtedness of such Person under GAAP. The Indebtedness of any Person shall include the Indebtedness of any other entity (including any partnership in which such Person is a general
partner) to the extent such Person is liable therefor as a result of such Person&#146;s ownership interest in or other relationship with such entity, except to the extent the terms of such Indebtedness provide that such Person is not liable
therefor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Indemnified Party&#148;</I> has the meaning set forth in Section&nbsp;13.03(b). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Indemnified Taxes&#148;</I> means (a)&nbsp;Taxes, other than Excluded Taxes, imposed on or with respect to any
payment made by or on account of any Obligation and (b)&nbsp;to the extent not otherwise described in clause&nbsp;(a), Other Taxes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-18- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Ineligible Assignee&#148;</I> means (a)&nbsp;a natural person,
(b)&nbsp;the Obligors or any of their respective Affiliates and (c)&nbsp;so long as no Event of Default shall have occurred and is continuing, any Disqualified Lender. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Information&#148;</I> has the meaning set forth in Section&nbsp;13.17. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Insolvency Proceeding&#148;</I> means (a)&nbsp;any case, action or proceeding before any court or other Governmental
Authority relating to bankruptcy, restructuring, reorganization, examinership (in the case of the Irish Obligor, or an Obligor with a COMI in Ireland), rescue process, insolvency, liquidation, receivership, dissolution, <FONT
STYLE="white-space:nowrap">winding-up</FONT> or relief of debtors, or (b)&nbsp;any general assignment for the benefit of creditors, composition, marshaling of assets for creditors, or other, similar arrangement in respect of any Person&#146;s
creditors generally or any substantial portion of such Person&#146;s creditors, in each case undertaken under U.S.&nbsp;Federal, state or foreign law, including the Bankruptcy Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Institutional Review Board</I>&#148; means any board, committee, or other group formally designated by an institution
to review, to approve the initiation of, and to conduct periodic review of, biomedical research involving human subjects, or any Institutional Review Board as defined by 21 C.F.R. Part 56 or 45 C.F.R. Part 46. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Intellectual Property&#148;</I> means all Patents, Trademarks, Copyrights, industrial designs, Technical Information,
whether registered or not, whether domestic or foreign, including all of the following: (a)&nbsp;applications, registrations, amendments and extensions relating to any of the foregoing; (b)&nbsp;rights and privileges arising under any applicable
Laws with respect to any of the foregoing; (c)&nbsp;rights to sue for or collect any damages from any past, present or future infringements of any of the foregoing; and (d)&nbsp;rights of the same or similar effect or nature as described above in
any jurisdiction corresponding to any of the foregoing throughout the world. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Intercompany Subordinated Demand
Promissory Note&#148; </I>means an Intercompany Subordinated Demand Promissory Note in substantially the form of Exhibit&nbsp;K. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Interest Period&#148;</I> means a period of one month or such other period as may be agreed to by the Administrative
Agent (and in each case, subject to the availability thereof); <I>provided</I> that (a)&nbsp;the Interest Period shall commence on the date of an advance and, in the case of immediately successive Interest Periods, each successive Interest Period
shall commence on the date on which the next preceding Interest Period expires, (b)&nbsp;if any Interest Period would otherwise expire on a day that is not a Business Day, such Interest Period shall expire on the next succeeding Business Day,
<I>provided,</I> that if any Interest Period would otherwise expire on a day that is not a Business Day but is a day of the month after which no further Business Day occurs in such month, such Interest Period shall expire on the next preceding
Business Day, (c)&nbsp;any Interest Period that begins on the last Business Day of a calendar month (or on a day for which there is not a numerically corresponding day in the calendar month at the end of such Interest Period) shall end on the last
Business Day of the relevant calendar month at the end of such Interest Period, (d)&nbsp;no Interest Period shall extend beyond the Maturity Date and (e)&nbsp;no tenor that has been removed from this definition pursuant to 3.02(c)(iv) shall be
available. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-19- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Intermediate Holdings&#148;</I> means West Affum Intermediate
Holdings Corp., an exempted company incorporated with limited liability in the Cayman Islands. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Intermediate
Holdings Equitable Share Charge&#148;</I> means a Cayman Islands law governed equitable share mortgage, dated as of the Closing Date and issued by Intermediate Holdings in favor of the Administrative Agent over the shares of West Affum Corp. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Intermediate Holdings Fixed and Floating Charge&#148;</I> means a Cayman Islands law governed Debenture, dated as of
the Closing Date and issued by Intermediate Holdings in favor of the Administrative Agent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Invention&#148;</I>
means any novel, inventive or useful art, apparatus, method, process, machine (including any article or Device), manufacture or composition of matter, or any novel, inventive and useful improvement in any art, method, process, machine (including any
article or Device), manufacture or composition of matter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Investment&#148;</I> means, for any Person:
(a)&nbsp;the acquisition (whether for cash, Property, services or securities or otherwise) of Equity Interests, bonds, notes, debentures, partnership or other ownership interests or other securities of any other Person or any agreement to make any
such acquisition (including any &#147;short sale&#148; or any sale of any securities at a time when such securities are not owned by the Person entering into such sale); (b)&nbsp;the making of any deposit with, or advance, loan, assumption of debt
or other extension of credit to, any other Person (including the purchase of Property from another Person subject to an understanding or agreement, contingent or otherwise, to resell such Property to such Person), but excluding any such advance,
loan or extension of credit in the nature of an ordinary course trade receivable having a term not exceeding ninety (90)&nbsp;days arising in connection with the sale of services, inventory or supplies by such Person in the Ordinary Course of
Business; (c)&nbsp;the entering into of any Guarantee of, or other contingent obligation with respect to, Indebtedness or other liability of any other Person and (without duplication) any amount committed to be advanced, lent or extended to such
Person; (d)&nbsp;the entering into any joint venture; or (e)&nbsp;the entering into of any Hedging Agreement. The amount of an Investment will be determined at the time the Investment is made without giving effect to any subsequent changes in value.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Ireland</I>&#148; means Ireland, excluding Northern Ireland (and &#147;Irish&#148; shall be construed
accordingly). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Irish Anti-Corruption Laws</I>&#148; means the Criminal Justice (Corruption Offences) Act 2018 of
Ireland. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Irish Anti-Terrorism Laws</I>&#148; means the Criminal Justice (Money Laundering and Terrorist
Financing) Act 2010. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-20- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Irish Debenture&#148;</I> means the Irish law debenture, dated as
of the Closing Date, among the Irish Obligor and the Administrative Agent, granting a security interest in the assets, rights, title, interests and property constituting &#147;Security Assets&#148; thereunder in favor of the Administrative Agent for
the benefit of the Lenders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Irish Economic Sanctions Laws&#148; </I>means the Financial Transfers Act 1992 and
all Irish laws and regulations which implement EU and UN trade and/or financial sanctions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Irish
Obligor&#148;</I> means West Affum Holdings Designated Activity Company, a designated company limited by shares incorporated in Ireland with company number 696250. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Irish Security Documents&#148; </I>means, collectively, the Irish Debenture and the Irish Share Charge. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Irish Share Charge&#148;</I> means an Irish law governed share charge, dated as of the Closing Date, between West
Affum Corp., as mortgagor and Administrative Agent in respect of shares held in the Irish Obligor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;IRS&#148;</I>
means the U.S.&nbsp;Internal Revenue Service or any successor agency, and to the extent relevant, the U.S.&nbsp;Department of the Treasury. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Judgment Currency</I>&#148; has the meaning set forth in Section&nbsp;13.22(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Judgment Currency Conversion Date</I>&#148; has the meaning set forth in Section&nbsp;13.22(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Key Person&#148; </I>means Brian Webster or such other person as may be appointed by Administrative Borrower as its
replacement from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Laws&#148;</I> means, collectively, all international, foreign, federal, state,
provincial, territorial, municipal and local statutes, treaties, rules, regulations, ordinances, codes and administrative or judicial precedents or authorities, including the interpretation or administration thereof by any Governmental Authority
charged with the enforcement, interpretation or administration thereof, and all applicable administrative orders, directed duties, requests, licenses, authorizations and permits of, and agreements with, any Governmental Authority, in each case
whether or not having the force of law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Lenders&#148;</I> has the meaning set forth in the introduction hereto.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Lien&#148;</I> means any mortgage, lien, pledge, assignment by way of security, charge or other security
interest, or any lease, title retention agreement, mortgage, restriction, easement, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-way,</FONT></FONT> option or adverse Claim (of ownership or possession) or other
encumbrance of any kind or character whatsoever or any preferential arrangement that has the practical effect of creating a security interest. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-21- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Loan Documents&#148;</I> means, collectively, this Agreement, any
Note, the Security Documents, any Guarantee Assumption Agreement, any landlord collateral access agreement, any subordination agreement, intercreditor agreement or other present or future document, instrument, agreement or certificate delivered to
any Lender in connection with this Agreement or any of the other Loan Documents, in each case, as amended, restated, supplemented or otherwise modified. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Loan Exposure&#148;</I> means, with respect to any Lender, as of any date of determination, the outstanding principal
amount of such Lender&#146;s portion of the Term Loans; <I>provided,</I> at any time prior to the making of any Term Loans, the Loan Exposure of any Lender shall be equal to such Lender&#146;s Commitment with respect to such Term Loan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Loss&#148;</I> means judgments, debts, liabilities, expenses, costs, damages or losses, contingent or otherwise,
whether liquidated or unliquidated, matured or unmatured, disputed or undisputed, contractual, legal or equitable, including loss of value, professional fees, including fees and disbursements of legal counsel on a full indemnity basis, and all costs
incurred in investigating or pursuing any Claim or any proceeding relating to any Claim. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Majority
Lenders&#148;</I> means, at any time, one or more Lenders having or holding Loan Exposure and representing more than 50% of the aggregate Loan Exposure of all Lenders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Margin Stock&#148;</I> means &#147;margin stock&#148; within the meaning of Regulations&nbsp;U and X. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Material Adverse Change&#148;</I> and <I>&#147;Material Adverse Effect&#148;</I> mean a material adverse change in or
effect on (a)&nbsp;the business, financial condition, operations, performance or Property of the Obligors taken as a whole, (b)&nbsp;the ability of any Obligor to perform its obligations under any Loan Document, or (c)&nbsp;the legality, validity,
binding effect or enforceability of the Loan Documents or the rights and remedies of any Lender under any of the Loan Documents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Material Agreement&#148;</I> means (a)&nbsp;any Contract which is listed in Schedule&nbsp;7.14, (b)&nbsp;any other
Contract to which any Obligor is a party or a beneficiary from time to time, or to which any assets or properties of any Obligor is bound, the loss or termination of which would reasonably be expected to result in a Material Adverse Effect, and
(c)&nbsp;any other Contract to which any Obligor is a party or a guarantor (or equivalent) whether existing as of the date hereof or in the future that during any period of twelve (12)&nbsp;consecutive months is reasonably expected to
(A)&nbsp;result in payments or receipts (including royalty, licensing or similar payments) made to any Obligor in an aggregate amount in excess of $1,000,000 or (B)&nbsp;require payments or expenditures (including royalty, licensing or similar
payments) made by any Obligor in an aggregate amount in excess of $1,000,000. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-22- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Material Indebtedness&#148;</I> means, at any time, any
Indebtedness of any Obligor, the outstanding principal amount of which, individually or in the aggregate, exceeds $1,000,000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Material Intellectual Property&#148;</I> means all Obligor Intellectual Property, whether currently owned, acquired,
developed or obtained after the date hereof (a)&nbsp;the loss of which would reasonably be expected to have or result in a Material Adverse Effect or (b)&nbsp;that has a fair market value in excess of $1,000,000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Maturity Date&#148;</I> means the earlier to occur of (a)&nbsp;the Stated Maturity Date, and (b)&nbsp;the date on
which the Term Loans are accelerated pursuant to Section&nbsp;10.02. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Minimum Liquidity&#148;</I> has the meaning
set forth in Section&nbsp;8.15(a). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Multiemployer Plan&#148;</I> means any &#147;multiemployer plan,&#148; as
defined in Section&nbsp;400l(a)(3) of ERISA, to which any Obligor or ERISA Affiliate has any obligation or liability, contingent or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Net Cash Proceeds&#148;</I> means, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) with respect to the incurrence or issuance of any Indebtedness incurred by an Obligor not permitted under
Section&nbsp;9.01, the excess, if any, of (i)&nbsp;the sum of the cash received in connection with such incurrence or issuance over (ii)&nbsp;the investment banking fees, underwriting discounts, commissions, costs and other reasonable expenses and
other customary expenses (including reasonable attorney&#146;s, accountant&#146;s and other similar professional advisor&#146;s fees), incurred by such Obligor in connection with such incurrence or issuance to third parties (other than any other
Obligor or any of their respective Affiliates); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) with respect to any Casualty Event, the amount of cash proceeds
actually received from time to time by or on behalf of an Obligor after deducting therefrom only (i)&nbsp;actual costs and expenses related thereto incurred by such Obligor in connection therewith and (ii)&nbsp;Taxes paid or payable in connection
therewith; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) with respect to any Asset Sale, the excess, if any, of (i)&nbsp;cash proceeds received in respect of
such Asset Sale (including cash proceeds subsequently received (as and when received)) over (ii)&nbsp;the sum of (A)&nbsp;the direct costs of such Asset Sale then payable by the recipient of such proceeds excluding amounts payable to any Obligor,
(B)&nbsp;taxes paid or payable, including sales, uses taxes and income taxes by such recipient as a result thereof, (C)&nbsp;amounts required to be applied to repay principal, interest and prepayment premiums and penalties on Indebtedness secured by
a Permitted Lien on the properties subject to such Asset Sale and (D)&nbsp;amounts reserved or deposited in escrow with respect to indemnity payments or price adjustments until such amounts are released to the Obligors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-23- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Net Revenue&#148;</I> means, with respect to Intermediate Holdings
and its Subsidiaries, all amounts paid to and received by such Person in the ordinary course of business that, in accordance with GAAP, would be classified as net revenue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Note&#148;</I> means a promissory note executed and delivered by Borrowers to any Lender in the form attached hereto
as Exhibit&nbsp;C. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Notice of Intent to Cure&#148;</I> has the meaning set forth in Section&nbsp;8.15(b). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Obligations&#148;</I> means, with respect to any Obligor, all amounts, obligations, liabilities, covenants and duties
of every type and description owing by such Obligor to any Lender or any other Indemnified Party hereunder, arising out of, under, or in connection with, any Loan Document, whether direct or indirect (regardless of whether acquired by assignment),
absolute or contingent, due or to become due, whether liquidated or not, now existing or hereafter arising and however acquired, and whether or not evidenced by any instrument for the payment of money, including, without duplication, (a)&nbsp;the
principal amount of the Term Loans, (b)&nbsp;all interest on the Term Loans (including accrued but uncapitalized PIK&nbsp;Interest and interest accruing at the Default Rate), whether or not accruing after the filing of any petition in bankruptcy or
after the commencement of any insolvency, reorganization or similar proceeding, and whether or not a Claim for <FONT STYLE="white-space:nowrap">post-filing</FONT> or <FONT STYLE="white-space:nowrap">post-petition</FONT> interest is allowed in any
such proceeding, (c)&nbsp;any Prepayment Premium, and (d)&nbsp;all other fees, expenses, interest, commissions, charges, costs, disbursements, indemnities and reimbursement of amounts paid and other sums chargeable to such Obligor under any Loan
Document. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Obligor Intellectual Property&#148;</I> means Intellectual Property owned by any of the Obligors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Obligors&#148;</I> means, collectively, Borrowers, each Guarantor and each of their respective successors and
permitted assigns. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Observer&#148;</I> has the meaning set forth in Section&nbsp;8.18. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;OFAC&#148;</I> means the Office of Foreign Assets Control of the U.S.&nbsp;Department of the Treasury (or any
successor thereto). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;OFSI&#148; </I>means the Office of Financial Sanctions Implementation of His Majesty&#146;s
Treasury of the United Kingdom. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;OpCo&#148;</I> has the meaning set forth in the introduction hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Ordinary Course of Business&#148;</I> means, with respect to the Obligors, the ordinary course of business generally
consistent with past custom and practice (including with respect to nature, scope, magnitude, quantity and frequency). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-24- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Organizational Documents&#148;</I> means (a)&nbsp;with respect to
any corporation, its certificate or articles of incorporation or organization, as amended, and its <FONT STYLE="white-space:nowrap">by-laws,</FONT> as amended, (b)&nbsp;with respect to any limited partnership or exempted limited partnership, its
certificate of limited partnership or certificate of registration (as applicable), as amended, section 9 and 10 (if any) statements (if applicable) and its partnership agreement or exempted limited partnership agreement, as amended, (c)&nbsp;with
respect to any general partnership, its partnership agreement, as amended, (d)&nbsp;with respect to any limited liability company or any exempted company, its articles of organization or certificate of incorporation, including on change of name (as
applicable), as amended, statutory registers (if applicable) and its operating agreement or memorandum and articles of association (as applicable), as amended, and (e)&nbsp;with respect to any designated activity company incorporated in Ireland, its
constitution together with its certificate of incorporation (together with any applicable certificate of incorporation on change of name, <FONT STYLE="white-space:nowrap">re-registration</FONT> or conversion). In the event any term or condition of
this Agreement or any other Loan Document requires any Organizational Document to be certified by a secretary of state or similar government official, the reference to any such &#147;Organizational Document&#148; shall only be to a document of a
type customarily certified by such government official. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Other Connection Taxes&#148;</I> means, with respect to
any Recipient, Taxes imposed as a result of a present or former connection between such Recipient and the jurisdiction imposing such Tax (other than connections arising solely from such Recipient having executed, delivered, become a party to,
performed its obligations under, received payments under, received or perfected a security interest under, engaged in any other transaction pursuant to or enforced any Loan Document, or sold or assigned an interest in the Term Loans or any Loan
Document). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Other Taxes&#148;</I> means all present or future stamp, court or documentary, intangible, recording,
filing or similar Taxes that arise from any payment made under, from the execution, delivery, performance, enforcement or registration of, from the receipt or perfection of a security interest under, or otherwise with respect to, any Loan Document,
except any such Taxes that are Other Connection Taxes imposed with respect to an assignment (other than an assignment made pursuant to Section&nbsp;5.03(h)). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;</I><I>Parent</I><I>&#148;</I> means (a)&nbsp;prior to a Qualified Public Offering, Cayman Parent, and (b)&nbsp;upon
the occurrence of a Qualified Public Offering, Bermuda Parent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Participant&#148;</I> has the meaning set forth
in Section&nbsp;13.05(e). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Participant Register&#148;</I> has the meaning set forth in Section&nbsp;13.05(f).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Patents&#148;</I> has the meaning set forth in the Security Documents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Payment Date&#148;</I> means the last day of each fiscal quarter of the Borrowers, commencing on September&nbsp;30,
2023; <I>provided</I> that if such last day of such Interest Period is not a Business Day, then the Payment Date for such Interest Period will be the next succeeding Business Day. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-25- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;PBGC&#148;</I> means the United States Pension Benefit Guaranty
Corporation referred to and defined in ERISA and any successor entity performing similar functions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Perceptive&#148;</I> has the meaning set forth in the introduction hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Periodic Term SOFR</I><I></I><I>&nbsp;Determination Day&#148;</I> has the meaning specified in the definition of
&#147;Term SOFR.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Permits&#148;</I> means all permits, licenses, registrations, certificates, orders,
approvals, authorizations, consents, waivers, franchises, variances and similar rights issued by or obtained from any Governmental Authority or any other Person, including, without limitation, those relating to Environmental Laws and Health Care
Laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Permitted Acquisition&#148;</I> means any Acquisition by any Obligor or any of its <FONT
STYLE="white-space:nowrap">wholly-owned</FONT> Subsidiaries, by (a)&nbsp;purchase, merger, amalgamation, license or otherwise, of all or substantially all of the assets of, all of the Equity Interests of, or a business line or unit or a division of,
any Person or (b)&nbsp;license arrangement for the rights to use, develop, market or otherwise commercialize any Patents, Trademarks, Copyrights or other Intellectual Property (other than Permitted Licenses); <I>provided</I> that: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) immediately prior to, and immediately after giving effect thereto, no Default shall have occurred and be continuing or
would result therefrom; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) all transactions in connection therewith shall be consummated, in all material respects, in
accordance with all applicable Laws and in conformity in all material respects with all applicable Governmental Approvals; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) in the case of the Acquisition of all of the Equity Interests of such Person, all of the Equity Interests (except for
any such securities in the nature of directors&#146; qualifying shares required pursuant to applicable Law) acquired, or otherwise issued by such Person or any newly formed Subsidiary of such Obligor in connection with such Acquisition, shall be
owned 100% by an Obligor and Borrowers shall have taken, or caused to be taken, as of the date such Person becomes a Subsidiary of an Obligor, each of the actions set forth in Section&nbsp;8.11, if applicable; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) such Person (in the case of an Acquisition of Equity Interests) or assets (in the case of an Acquisition of assets or a
division) (A)&nbsp;shall be engaged or used, as the case may be, in the same business or lines of business in which a Borrower and/or its Subsidiaries are engaged or a business reasonably and substantially related thereto or (B)&nbsp;shall have a
similar customer base as Borrowers and/or their Subsidiaries; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) Administrative Borrower shall have provided the
Administrative Agent with at least ten&nbsp;(10) Business Days&#146; prior written notice of the consummation of any such Acquisition, together with summaries, prepared in reasonable detail, of all due diligence conducted by or on behalf of
Borrowers or the applicable Subsidiary prior to such Acquisition; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-26- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) the Acquisition shall have been approved by the Board or other
governing body or controlling Person of the Person acquired or the Person from whom such assets or division is acquired; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii) on a <I>pro forma</I> basis after giving effect to such Acquisition, Intermediate Holdings and its Subsidiaries shall
be in compliance with the covenants set forth in Section&nbsp;8.15. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Permitted Cash Equivalent
Investments&#148;</I> means (a)&nbsp;marketable direct obligations issued or unconditionally guaranteed by the United States or any agency or any State thereof having maturities of not more than two (2)&nbsp;years from the date of acquisition,
(b)&nbsp;commercial paper with an average maturity of no more than one (1)&nbsp;year and having the highest rating from either Standard&nbsp;&amp; Poor&#146;s Ratings Group or Moody&#146;s Investors Service, Inc., (c) any money market funds or other
investment vehicles whose principal investments are in investments described in clauses&nbsp;(a) or (b)&nbsp;above, and (d)&nbsp;certificates of deposit maturing no more than one (1)&nbsp;year after issue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Permitted Indebtedness&#148;</I> means any Indebtedness permitted under Section&nbsp;9.01. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Permitted IPO Reorganization&#148;</I> means any transactions or actions taken in connection with and reasonably
related to consummating an initial public offering of a Borrower or any direct or indirect parent thereof, so long as (a)&nbsp;such transaction does not result in a Change of Control, (b)&nbsp;after giving effect thereto, the security interest of
the Administrative Agent, on behalf of the Lenders in the Collateral, taken as a whole, is not materially impaired (as reasonably determined by Borrowers and the Administrative Agent in good faith) and (c)&nbsp;such offering is not a result of a
&#147;reverse merger&#148;, special purpose acquisition company transaction or similar transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Permitted
Licenses&#148;</I> means (a)&nbsp;licenses of off the shelf software that is commercially available to the public, <FONT STYLE="white-space:nowrap">(b)&nbsp;non-exclusive</FONT> licenses or sublicenses of Intellectual Property entered into in the
Ordinary Course of Business, (c)&nbsp;licenses permitted pursuant to Section&nbsp;9.09(k) and (d)&nbsp;licenses for the use of Obligor Intellectual Property, in each case, entered into in the Ordinary Course of Business or as otherwise may be
approved by the applicable Obligor&#146;s Board and so long as (i)&nbsp;no Event of Default has occurred and is continuing at the time such license is entered into and (ii)&nbsp;such license does not materially impair the Lenders from exercising
their rights under any of the Loan Documents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Permitted Liens&#148;</I> means any Liens permitted under
Section&nbsp;9.02. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-27- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;</I><I>Permitted Refinancing</I><I>&#148;</I> means, with respect
to any Indebtedness permitted to be refinanced, extended, renewed or replaced hereunder, any refinancings, extensions, renewals and replacements of such Indebtedness; <I>provided</I> that such refinancing, extension, renewal or replacement shall not
(a)&nbsp;increase the outstanding principal amount of the Indebtedness being refinanced, extended, renewed or replaced other than by an amount equal to the amount of fees, expenses, premium incurred in connection with such refinancings, extensions,
renewals and replacements, (b)&nbsp;contain terms relating to outstanding principal amount, amortization, interest rate or equivalent yield, maturity, collateral security (if any) or subordination (if any), or other material terms that, taken as a
whole, are less favorable in any material respect to any Obligor or the Lenders than the terms of any agreement or instrument governing the Indebtedness being refinanced, (c)&nbsp;contain any new requirement to grant any Lien or to give any
Guarantee that was not an existing requirement of the Indebtedness being refinanced and (d)&nbsp;after giving effect to such refinancing, extension, renewal or replacement, no Default shall have occurred (or could reasonably be expected to occur) as
a result thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Person&#148;</I> means any individual, corporation, exempted company, exempted limited
partnership, company, voluntary association, partnership, limited liability company, joint venture, trust, unincorporated organization or Governmental Authority or other entity of whatever nature. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;PFIC&#148;</I> has the meaning set forth in Section&nbsp;8.01(j). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;PIK</I><I></I><I>&nbsp;Interest&#148; </I>shall mean
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">payment-in-kind</FONT></FONT> of interest in respect of the Term Loans by increasing the outstanding principal amount of each Term Loan to which such interest relates by an amount
equal to such portion of interest, rather than paying such portion of interest in cash. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Prepayment
Premium&#148;</I> has the meaning set forth in Section&nbsp;3.03(a). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Prior Covenants&#148;</I> has the meaning
set forth in Section&nbsp;8.15(b). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Pro Rata Share&#148;</I> has the meaning set forth in Section&nbsp;11.08.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Product&#148;</I> means (a)&nbsp;those Devices set forth (and described in reasonable detail) on Schedule&nbsp;3
attached hereto, and (b)&nbsp;any current or future Device subject to any Product Development and Commercialization Activities by any Obligor, including any such Device currently in development. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Product Agreement&#148;</I> means, with respect to any Product, any Contract, license, document, instrument, interest
(equity or otherwise) or the like under which one or more Persons grants or receives (a)&nbsp;any right, title or interest with respect to any Product Development and Commercialization Activities of such Product, or (b)&nbsp;any right to exclude any
other Person from engaging in, or otherwise restricting any right, title or interest as to, any Product Development and Commercialization Activities with respect to such Product, including any Contract with suppliers, manufacturers, distributors,
clinical research organizations, hospitals, group purchasing organizations, wholesalers, pharmacies or any other Person related to such entity. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-28- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Product Assets&#148;</I> means, with respect to any Product,
(a)&nbsp;any and all rights, title and interest of a Borrower or any of its Subsidiaries in any assets relating to such Product or any Product Development and Commercialization Activities with respect to such Product, (b)&nbsp;all Product Related
Information with respect to such Product or any related Product Development and Commercialization Activities, (c)&nbsp;any Product Agreement related to such Product or any such Product Development and Commercialization Activities, (d)&nbsp;any
Intellectual Property, Regulatory Approvals and similar assets with respect to such Product or any such Product Development and Commercialization Activities, and (e)&nbsp;all rights, title and interests in any other property, tangible or intangible,
manifesting or otherwise in respect of such Product or any such Product Development and Commercialization Activities, including, without limitation, inventory, accounts receivable or similar rights to receive money or payment pertaining thereto and
all proceeds of the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Product Authorizations&#148;</I> means any and all Governmental Approvals
(including all applicable IDEs, Device Clearance Applications, supplements, amendments, governmental price and reimbursement approvals and approvals of applications for regulatory exclusivity), safety or quality specifications and standards, or any
other authorizations of any applicable Regulatory Authority in each case necessary for the manufacturing, development, distribution, ownership, use, storage, import, export, transport, promotion, marketing, sale or other commercialization of any
Product or for any Product Development and Commercialization Activities with respect thereto in any country or jurisdiction, whether U.S. or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Product Development and Commercialization Activities&#148;</I> means, with respect to any Product, any combination of
research, development, manufacture, import, use, sale, licensing, importation, storage, design, labeling, marketing, promotion, supply, distribution, testing, packaging, purchasing or other commercialization activities, receipt of payment in respect
of any of the foregoing (including, without limitation, in respect of licensing, royalty or similar payments), or any similar or other activities the purpose of which is to commercially exploit such Product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Product Related Information&#148; </I>means, with respect to any Product, all books, records, lists, ledgers, files,
manuals, Contracts, correspondence, reports, plans, drawings and data (in any form or medium), and all techniques and other <FONT STYLE="white-space:nowrap">know-how,</FONT> owned or possessed by a Borrower or any of its Subsidiaries that is
necessary or required for any Product Development and Commercialization Activities relating to such Product, including (a)&nbsp;brand materials, packaging and other trade dress, customer targeting and other marketing, promotion and sales materials
and information, referral, customer, supplier and other contact lists and information, product, business, marketing and sales plans, research, studies and reports, sales, maintenance and production records, training materials and other marketing,
sales and promotional information, (b)&nbsp;clinical data, information included or supporting any Product Authorization or other Regulatory Approval, any regulatory filings, updates, notices and correspondence (including adverse event and other
pharmacovigilance and other <FONT STYLE="white-space:nowrap">post-marketing</FONT> reports and information, etc.), technical information, product development and operational data and records, and all other documents, records, files, data
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-29- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">
and other information relating to product development, manufacture and use, (c)&nbsp;litigation and dispute records, and accounting records, (d)&nbsp;all documents, records and files relating to
Intellectual Property, including all correspondence from and to third parties (including Intellectual Property counsel and patent, trademark and other Intellectual Property registries, including the United States Patent and Trademark Office), and
(e)&nbsp;all other information, techniques and <FONT STYLE="white-space:nowrap">know-how</FONT> necessary or required in connection with the Product Development and Commercialization Activities for any Product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Prohibited Payment&#148;</I> means any bribe, rebate, payoff, influence payment, kickback or other payment or gift of
money or anything of value (including meals or entertainment) to any officer, employee or ceremonial office holder of any government or instrumentality thereof, political party or <FONT STYLE="white-space:nowrap">supra-national</FONT> organization
(such as the United Nations), any political candidate, any royal family member or any other person who is connected or associated personally with any of the foregoing that is prohibited under any Requirement of Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Projections&#148;</I> has the meaning set forth in Section&nbsp;7.04(b). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Property&#148;</I> of any Person means any property or assets, or interest therein, of such Person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Proportionate Share&#148;</I> means, with respect to any Lender, the percentage obtained by dividing (a)&nbsp;the
Loan Exposure of such Lender then in effect by (b)&nbsp;the aggregate Loan Exposure of all Lenders then in effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Proposal Letter&#148;</I> means the letter agreement, dated May&nbsp;22, 2023, among Administrative Borrower and
Perceptive Advisors LLC, regarding the transactions contemplated hereby and the outline of proposed terms and conditions attached thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Publicly Reporting Company&#148;</I> means an issuer generally subject to the public reporting requirements of the
Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Qualified Equity Interest&#148;</I> means, with respect to any Person, any Equity Interest of such
Person that is not a Disqualified Equity Interest. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Qualified Public Offering&#148;</I> shall mean the initial
underwritten public offering of common Equity Interests of Bermuda Parent pursuant to an effective registration statement filed with the United States Securities and Exchange Commission in accordance with the Securities Act of 1933 or similar laws
of other jurisdictions, raising net cash proceeds of at least $50,000,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Recipient&#148;</I> means any Lender
or the Administrative Agent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Redemption Date&#148;</I> has the meaning set forth in Section&nbsp;3.03(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Redemption Price&#148;</I> has the meaning set forth in Section&nbsp;3.03(a). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-30- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Referral Source&#148; </I>has the meaning set forth in
Section&nbsp;7.07(b). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Register&#148;</I> has the meaning set forth in Section&nbsp;13.05(d). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Regulation</I><I></I><I>&nbsp;T&#148;</I> means Regulation&nbsp;T of the Board of Governors of the Federal Reserve
System, as amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Regulation</I><I></I><I>&nbsp;U&#148;</I> means Regulation&nbsp;U of the Board of Governors
of the Federal Reserve System, as amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Regulation</I><I></I><I>&nbsp;X&#148;</I> means Regulation&nbsp;X of
the Board of Governors of the Federal Reserve System, as amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Regulatory Approvals&#148;</I> means any
Governmental Approval relating to any Product or any Product Development and Commercialization Activities related to such Product, including any Product Authorizations with respect thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Regulatory Authority&#148;</I> means any Governmental Authority that is concerned with or has regulatory or
supervisory oversight with respect to any Product or any Product Development and Commercialization Activities relating to any Product, including the FDA and all equivalent Governmental Authorities, whether U.S. or
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Relevant Governmental Body</I>&#148; shall mean the FRB or the
Federal Reserve Bank of New York, or a committee officially endorsed or convened by the FRB or the Federal Reserve Bank of New York, or any successor thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Representatives&#148;</I> has the meaning set forth in Section&nbsp;13.17. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Requirement of Law&#148;</I> means, as to any Person, any Law applicable to or binding upon such Person or any of its
Properties or revenues. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Resignation Effective Date&#148;</I> has the meaning set forth in Section&nbsp;12.06(a).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Resolution Authority&#148;</I> means an EEA&nbsp;Resolution Authority or, with respect to any UK&nbsp;Financial
Institution, a UK&nbsp;Resolution Authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Responsible Officer&#148;</I> of any Person means each of the
president, chief executive officer and chief financial officer of such Person or, in the case of an Obligor incorporated in Ireland, a director or the secretary of such Obligor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Restricted Payment&#148;</I> means any dividend or other distribution (whether in cash, securities or other Property)
with respect to any Equity Interest of the Obligors, or any payment (whether in cash, securities or other Property), including any sinking fund or similar deposit, on account of the purchase, redemption, retirement, acquisition, cancellation or
termination of any such shares of capital stock of the Obligors or any option, warrant or other right to acquire any such shares of capital stock of an Obligor. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-31- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Restrictive Agreement&#148;</I> means any indenture, agreement,
instrument or other binding arrangement that prohibits, restricts or imposes any condition upon (a)&nbsp;the ability of any Obligor to create, incur or permit to exist any Lien upon any of its Property (other than (i)&nbsp;customary provisions in
Contracts (including without limitation leases and <FONT STYLE="white-space:nowrap">in-bound</FONT> licenses of Intellectual Property) restricting the assignment thereof, (ii)&nbsp;restrictions or conditions imposed by any agreement governing
secured Permitted Indebtedness permitted under Section&nbsp;9.01(g), to the extent that such restrictions or conditions apply only to the Property securing such Indebtedness and (iii)&nbsp;software and other Intellectual Property licenses pursuant
to which an Obligor is the licensee of the relevant software or Intellectual Property, as the case may be (in which case, any prohibition or limitation shall relate only to the assets or rights subject to the applicable license and/or the license
itself)), or (b)&nbsp;the ability of any Obligor to pay dividends or other distributions with respect to any shares of its Equity Interests or to make or repay loans or advances to any Obligor or to Guarantee Indebtedness of any Obligor, in each
case of clauses (a)&nbsp;and (b), other than (i)&nbsp;agreements that are binding on an Obligor at the time such Obligor first becomes a wholly-owned Subsidiary of any Borrower, so long as such agreement were not entered into solely in contemplation
of such Person becoming a wholly-owned Subsidiary of any Borrower, (ii)&nbsp;agreements which are customary in joint venture or similar arrangements applicable to joint ventures permitted under Section&nbsp;9.05(l) and applicable solely to such
joint venture entered into in the Ordinary Course of Business, (iii)&nbsp;leases, subleases, licenses or asset sale agreement otherwise permitted hereby so long as such restrictions relate to the assets subject thereto, (iv)&nbsp;restrictions which
are customary provisions restricting subletting or assignment of any lease governing a leasehold interest of the Borrowers or any Obligors or the assignment of any license or sublicense agreement, (v)&nbsp;customary provisions restricting assignment
of any agreement entered into in the Ordinary Course of Business or consistent with past practice, (vi)&nbsp;restrictions on cash or deposits imposed by customers under contracts entered into in the Ordinary Course of Business or consistent with
past practice and (vii)&nbsp;customary restrictions contained in any Permitted Refinancing thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Rights&#148;
</I>has the meaning set forth in Section&nbsp;12.10(i). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Sanctions&#148;</I> means economic or financial
sanctions, requirements or trade embargoes imposed, administered or enforced from time to time by any Governmental Authority (including, but not limited to, OFAC, the U.S.&nbsp;Department of State, the U.S.&nbsp;Department of Commerce or OFSI). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Sanctions Laws&#148;</I> means all laws, rules, regulations and requirements of any jurisdiction applicable to the
Lender, any Obligor (as applicable) or any other Loan Documents concerning or relating to Sanctions, terrorism or money laundering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;SEC&#148;</I> means United States Securities and Exchange Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Second Amendment&#148;</I> means that certain Second Amendment, dated as of February&nbsp;25, 2025, by and among
OpCo, West Affum Corp. Intermediate Holdings, Kestra Medical Technology Services, Inc., the Irish Obligor, the Lenders and the Administrative Agent. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-32- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Second Amendment Effective Date&#148;</I> has the meaning set forth
in the Second Amendment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Second Amendment Warrant Certificate&#148;</I> means the warrant to be delivered to the
Administrative Agent pursuant to Section&nbsp;5(B) of the Second Amendment with an aggregate value equivalent of 10% of the aggregate amount of Term Loans funded under Section&nbsp;2.01, which replaces the Closing Date Warrant Certificate and shall
go immediately into effect upon the occurrence of a Qualified Public Offering pursuant to the terms thereof, as the Second Amendment Warrant Certificate may be amended, replaced or otherwise modified pursuant to the terms thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Securities Account&#148;</I> has the meaning set forth in the Security Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Security Agreement&#148;</I> means the Security Agreement, dated as of the date hereof, in substantially the form of
Exhibit&nbsp;G, among the Obligors, the Lenders and the Administrative Agent, granting a security interest in the personal Property constituting Collateral thereunder in favor of the Administrative Agent for the benefit of the Lenders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Security Documents&#148;</I> means, collectively, the Security Agreement, each
<FONT STYLE="white-space:nowrap">Short-Form</FONT> IP Security Agreement, the Cayman Security Documents, the Irish Security Documents, and each other security document, control agreement or financing statement executed to perfect Liens in favor of
the Administrative Agent for the benefit of the Lenders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Segregated Health Care Account&#148;</I> means a
deposit account of an Obligor in the name of such Obligor and under the sole dominion and control of such Obligor maintained in accordance with the requirements of Section&nbsp;8.17(b) hereof, the only funds on deposit in which constitute the direct
proceeds of payments made by Federal Health Care Programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Short</I><I><FONT STYLE="white-space:nowrap">-Form</FONT> IP Security Agreements&#148;</I> means <FONT
STYLE="white-space:nowrap">short-form</FONT> copyright, patent or trademark (as the case may be) security agreements, dated as of the date hereof, in substantially the form of <FONT STYLE="white-space:nowrap">Exhibits&nbsp;H-1</FONT> and <FONT
STYLE="white-space:nowrap">H-2,</FONT> entered into by one or more Obligors in favor of the Administrative Agent for the benefit of the Lenders, each in form and substance satisfactory to the Administrative Agent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;SOFR&#148;</I> means a rate equal to the secured overnight financing rate as administered by the
SOFR&nbsp;Administrator. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;SOFR</I><I></I><I>&nbsp;Administrator&#148;</I> means the Federal Reserve Bank of
New&nbsp;York (or a successor administrator of the secured overnight financing rate). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-33- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Solvent&#148;</I> means, with respect to any Person, that
(a)&nbsp;the present fair saleable value of the Property of such Person is greater than the total amount of liabilities (including contingent liabilities) of such Person, (b)&nbsp;the present fair saleable value of the Property of such Person is not
less than the amount that will be required to pay the probable liability of such Person on its debts as they become absolute and matured, and (c)&nbsp;such Person: (i) (where such is not the Irish Obligor) has not incurred and does not intend to,
and does not believe that it will, incur debts or liabilities beyond such Person&#146;s ability to pay as such debts and liabilities mature; and (ii) (where such Person is the Irish Obligor) is not &#147;unable to pay its debts&#148; (within the
meaning of Section&nbsp;509 or 570 of the Companies Act 2014 of Ireland (as amended)). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Sponsor&#148; </I>means
Bain Capital Private Equity, LP and its Affiliates (other than any portfolio operating companies). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Sponsor
Equity Commitment Letter&#148;</I> means a commitment letter provided by Bain Charger Holdings, LP to contribute equity to West Affum Holdings, L.P. (which may be in the form of either preferred equity or Sponsor Convertible Notes) for gross
proceeds of no less than $25,000,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Sponsor Convertible Notes&#148;</I> means unsecured subordinated
convertible notes issued to Sponsor by Borrowers in an aggregate principal amount not to exceed $25,000,000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Standard Bodies&#148;</I> means any of the organizations that create, sponsor or maintain safety, quality or other
standards, including ISO, ANSI, CEN and SCC and the like. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Stated Maturity Date&#148;</I> means the fifth (5th)
anniversary of the Closing Date; <I>provided</I> that if any such date shall occur on a day that is not a Business Day, then the Stated Maturity Date shall be the immediately succeeding Business Day. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Subsidiary&#148;</I> means, with respect to any Person (the <I>&#147;parent&#148;</I>) at any time of determination,
any other Person of which more than 50% of the outstanding capital stock or similar equity interests of such other Person having ordinary voting powers, determined on a fully diluted basis, is at the time directly or indirectly owned or controlled
by the parent and in relation to the Irish Obligor includes a &#147;subsidiary&#148; as defined in section 7 of the Companies Act 2014 of Ireland (as amended). Unless the context otherwise specifically requires, the term &#147;Subsidiary&#148; shall
be a reference to a Subsidiary of Intermediate Holdings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Sweep Agreement&#148;</I> means an agreement, in form
and substance reasonably satisfactory to the Administrative Agent, between an Obligor maintaining a Segregated Health Care Account, the Administrative Agent and applicable bank or other financial institution at which such Segregated Health Care
Account is maintained, pursuant to which such bank or financial institution (a)&nbsp;agrees to automatically sweep amounts deposited in such Segregated Health Care Account to another account of such Obligor subject to a <FONT
STYLE="white-space:nowrap">tri-party</FONT> springing account control agreement in favor of the Administrative Agent satisfying the requirements set forth in Section&nbsp;8.17(b) hereof, as and when funds clear and become available in accordance
with such bank&#146;s or financial institution&#146;s standard practices and procedures, and (b)&nbsp;agrees not to change such standing sweep instructions until the date at least five (5)&nbsp;days (or such lesser period as the Administrative Agent
may agree in its sole </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-34- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">
discretion or as may be required by applicable Federal Health Care Program laws, rules, regulations, orders, guidelines, requirements, manual provisions or policies) after receipt of notice from
the applicable Obligor maintaining such Segregated Health Care Account by Administrative Agent and such bank or financial institution of the termination of such standing sweep instruction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Taxes&#148;</I> means all present or future taxes, levies, imposts, duties, deductions, withholdings (including
backup withholding), assessments, fees or other charges imposed by any Governmental Authority, including any interest, additions to tax or penalties applicable thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Technical Information&#148;</I> means all trade secrets and other proprietary or confidential information, which may
include any information of a scientific, technical, or business nature in any form or medium, standards and specifications, conceptions, ideas, innovations, discoveries, Invention disclosures, all documented research, developmental, demonstration or
engineering work, data, plans, specifications, reports, summaries, experimental data, manuals, models, samples, <FONT STYLE="white-space:nowrap">know-how,</FONT> technical information, systems, methodologies, computer programs or information
technology. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Term Loans&#148;</I> means the Tranche&nbsp;A Term Loan, the Tranche&nbsp;B Term Loan and the
Tranche C Term Loan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Term SOFR&#148;</I> means the Term SOFR&nbsp;Reference Rate for a tenor comparable to the
applicable Interest Period on the day (such day, the <I>&#147;Periodic Term SOFR</I><I></I><I>&nbsp;Determination Day&#148;</I>) that is two (2)&nbsp;U.S.&nbsp;Government Securities Business Days prior to the first day of such Interest Period, as
such rate is published by the Term SOFR&nbsp;Administrator; <I>provided, however,</I> that if as of 5:00&nbsp;p.m. (New&nbsp;York City time) on any Periodic Term SOFR&nbsp;Determination Day the Term SOFR&nbsp;Reference Rate for the applicable tenor
has not been published by the Term SOFR&nbsp;Administrator and a Benchmark Replacement Date with respect to the Term SOFR&nbsp;Reference Rate has not occurred, then Term SOFR will be the Term SOFR&nbsp;Reference Rate for such tenor as published by
the Term SOFR&nbsp;Administrator on the first preceding U.S.&nbsp;Government Securities Business Day for which such Term SOFR&nbsp;Reference Rate for such tenor was published by the Term SOFR&nbsp;Administrator so long as such first preceding
U.S.&nbsp;Government Securities Business Day is not more than three (3)&nbsp;U.S.&nbsp;Government Securities Business Days prior to such Periodic Term SOFR&nbsp;Determination Day; <I>provided, further,</I> Term SOFR shall be rounded upwards to the
next 1/100% (if necessary); <I>provided</I>, <I>further, however,</I> if Term SOFR as so determined shall ever be less than the Floor, then Term SOFR shall be deemed to be the Floor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Term SOFR</I><I></I><I>&nbsp;Administrator&#148;</I> means CME Group Benchmark Administration Limited (CBA) (or a
successor administrator of the Term SOFR&nbsp;Reference Rate selected by the Administrative Agent in its reasonable discretion). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Term SOFR</I><I></I><I>&nbsp;Reference Rate&#148;</I> means the
<FONT STYLE="white-space:nowrap">forward-looking</FONT> term rate based on SOFR. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-35- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Third-Party Payor Authorizations&#148;</I><B> </B>means all
participation agreements, provider or supplier agreements, enrollments, accreditations, and billing numbers required to participate in and receive reimbursement from a Third-Party Payor Program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Third</I><I><FONT STYLE="white-space:nowrap">-Party</FONT> Payor Program&#148;</I> means any Federal Health Care
Program, or any other health care payment or reimbursement program in which an Obligor or Subsidiary participates, including programs sponsored by private insurers or managed care plans. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Title</I><I></I><I>&nbsp;IV Plan&#148;</I> means an &#147;employee pension benefit plan&#148; (as defined in
Section&nbsp;3(2) of ERISA) other than a Multiemployer Plan (a)&nbsp;that is maintained or sponsored by any Obligor or any ERISA Affiliate thereof or to which any Obligor or any ERISA Affiliate thereof makes contributions&nbsp;or (b)&nbsp;with
respect to which any Obligor has any liability, contingent of otherwise, including on account of an ERISA Affiliate, and (iii)&nbsp;that is subject to Section&nbsp;412 of the Code, Section&nbsp;302 of ERISA or Title&nbsp;IV of ERISA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Trademarks&#148;</I> has the meaning set forth in the Security Documents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Tranche</I><I></I><I>&nbsp;A Term Loan&#148; </I>means each loan advanced by a Lender pursuant to
Section&nbsp;2.01(a). For purposes of clarification, any calculation of the aggregate outstanding principal amount of the Tranche&nbsp;A Term Loan on any date of determination shall mean the aggregate principal amount of the Tranche&nbsp;A Term Loan
made pursuant to Section&nbsp;2.01(a) that has not yet been repaid as of such date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Tranche</I><I></I><I>&nbsp;A
Term Loan Commitment&#148;</I> means the commitment of a Lender to make or otherwise fund a Tranche&nbsp;A Term Loan and <I>&#147;Tranche</I><I></I><I>&nbsp;A Term Loan Commitments&#148;</I> means such commitments of all Lenders in the aggregate.
The aggregate amount of the Tranche&nbsp;A Term Loan Commitments as of the Closing Date is $45,000,000. As of the Second Amendment Effective Date, the aggregate amount of the Tranche A Term Loan Commitments is $0. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Tranche</I><I></I><I>&nbsp;B Term Loan&#148;</I> means each loan advanced by a Lender pursuant to
Section&nbsp;2.01(b). For purposes of clarification, any calculation of the aggregate outstanding principal amount of the Tranche&nbsp;B Term Loan on any date of determination shall mean the aggregate principal amount of the Tranche&nbsp;B Term Loan
made pursuant to Section&nbsp;2.01(b) that has not yet been repaid as of such date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Tranche</I><I></I><I>&nbsp;B
Term Loan Borrowing Date&#148;</I> means with respect to the Tranche&nbsp;B Term Loan, the Business Day on which all conditions set forth in Section&nbsp;6.02 have been satisfied or waived by the Lenders and the Tranche&nbsp;B Term Loan is made
hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Tranche</I><I></I><I>&nbsp;B Term Loan Commitment&#148;</I> means the commitment of a Lender to make
or otherwise fund a Tranche&nbsp;B Term Loan and <I>&#147;Tranche</I><I></I><I>&nbsp;B Term Loan Commitments&#148;</I> means such commitments of all Lenders in the aggregate. The aggregate amount of the Tranche&nbsp;B Term Loan Commitments as of the
Closing Date is $7,500,000. As of the Second Amendment Effective Date, the aggregate amount of the Tranche B Term Loan Commitments is $0. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-36- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Tranche</I><I></I><I>&nbsp;B Term Loan Commitment Termination
Date&#148;</I> means November&nbsp;1, 2024. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Tranche</I><I></I><I>&nbsp;C Term Loan&#148;</I> means each loan
advanced by a Lender pursuant to Section&nbsp;2.01(c). For purposes of clarification, any calculation of the aggregate outstanding principal amount of the Tranche&nbsp;C Term Loan on any date of determination shall mean the aggregate principal
amount of the Tranche&nbsp;C Term Loan made pursuant to Section&nbsp;2.01(c) that has not yet been repaid as of such date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Tranche</I><I></I><I>&nbsp;C Term Loan Borrowing Date&#148;</I> means with respect to the Tranche&nbsp;C Term Loan,
the Business Day on which all conditions set forth in Section&nbsp;6.03 have been satisfied or waived by the Lenders and the Tranche&nbsp;C Term Loan is made hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Tranche</I><I></I><I>&nbsp;C Term Loan Commitment&#148;</I> means the commitment of a Lender to make or otherwise
fund a Tranche&nbsp;C Term Loan and <I>&#147;Tranche</I><I></I><I>&nbsp;C Term Loan Commitments&#148;</I> means such commitments of all Lenders in the aggregate. The amount of each Lender&#146;s Tranche&nbsp;C Term Loan Commitment, if any, is set
forth on Schedule&nbsp;1. The aggregate amount of the Tranche&nbsp;C Term Loan Commitments as of the Second Amendment Effective Date is $15,000,000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Tranche</I><I></I><I>&nbsp;C Term Loan Commitment Termination Date&#148;</I> means July&nbsp;31, 2026. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Transactions&#148;</I> means the execution, delivery and performance by each Obligor of this Agreement and the other
Loan Documents to which such Obligor is a party and the other transactions contemplated hereby and thereby, including disbursement and application of the proceeds of the Term Loans. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;UK</I><I></I><I>&nbsp;Financial Institution&#148;</I> means any BRRD&nbsp;Undertaking (as such term is defined under
the PRA&nbsp;Rulebook (as amended from time to time) promulgated by the United Kingdom Prudential Regulation Authority) or any person falling within IFPRU&nbsp;11.6 of the FCA&nbsp;Handbook (as amended from time to time) promulgated by the United
Kingdom Financial Conduct Authority, which includes certain credit institutions and investment firms, and certain affiliates of such credit institutions or investment firms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;UK</I><I></I><I>&nbsp;Resolution Authority&#148;</I> means the Bank of England or any other public administrative
authority having responsibility for the resolution of any UK&nbsp;Financial Institution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Unadjusted Benchmark
Replacement&#148;</I> means the applicable Benchmark Replacement excluding the related Benchmark Replacement Adjustment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Unrestricted Cash&#148;</I> means the balance of unencumbered cash (other than cash encumbered by the Liens permitted
pursuant to Sections 9.02(a) and (h)) and Permitted Cash Equivalent Investments (which for greater certainty shall not include any undrawn credit lines), in each case, to the extent held in a Deposit Account subject to a springing account control
agreement reasonably satisfactory to the Administrative Agent. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-37- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;U.S.</I><I></I><I>&nbsp;Government Securities Business
Day&#148;</I> means any day except for (a)&nbsp;a Saturday, (b)&nbsp;a Sunday or (c)&nbsp;a day on which the Securities Industry and Financial Markets Association recommends that the fixed income departments of its members be closed for the entire
day for purposes of trading in United States government securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;U.S.</I><I></I><I>&nbsp;Person&#148;</I>
means a &#147;United States person&#148; within the meaning of Section&nbsp;7701(a)(30) of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;U.S.</I><I></I><I>&nbsp;Tax Compliance Certificate&#148;</I> has the meaning set forth in
Section&nbsp;5.03(f)(ii)(B)(3). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Warrant Certificate&#148;</I> means (a)&nbsp;prior to a Qualified Public
Offering, the Closing Date Warrant Certificate and (b)&nbsp;immediately upon the occurrence of a Qualified Public Offering, the Second Amendment Warrant Certificate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;West Affum Corp.&#148;</I> has the meaning set forth in the introduction hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;West Affum Corp. Account Charge&#148; </I>means a Cayman Islands law governed account charge issued by West Affum
Corp., dated as of the Closing Date, in favor of the Administrative Agent over certain accounts described therein and located in the Cayman Islands. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;West Affum Corp. Fixed and Floating Charge&#148;</I> means a Cayman Islands law governed Debenture, dated as of the
Closing Date, issued by West Affum Corp. in favor of the Administrative Agent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Write</I><I><FONT
STYLE="white-space:nowrap">-Down</FONT> and Conversion Powers&#148;</I> means, (a)&nbsp;with respect to any EEA&nbsp;Resolution Authority, the <FONT STYLE="white-space:nowrap">write-down</FONT> and conversion powers of such EEA&nbsp;Resolution
Authority from time to time under the <FONT STYLE="white-space:nowrap">Bail-In</FONT> Legislation for the applicable EEA&nbsp;Member Country, which <FONT STYLE="white-space:nowrap">write-down</FONT> and conversion powers are described in the <FONT
STYLE="white-space:nowrap">EU&nbsp;Bail-In</FONT> Legislation Schedule, and (b)&nbsp;with respect to the United Kingdom, any powers of the applicable Resolution Authority under the <FONT STYLE="white-space:nowrap">Bail-In</FONT> Legislation to
cancel, reduce, modify or change the form of a liability of any UK&nbsp;Financial Institution or any contract or instrument under which that liability arises, to convert all or part of that liability into shares, securities or obligations of that
person or any other person, to provide that any such Contract or instrument is to have effect as if a right had been exercised under it or to suspend any obligation in respect of that liability or any of the powers under that <FONT
STYLE="white-space:nowrap">Bail-In</FONT> Legislation that are related to or ancillary to any of those powers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;1.02.</I> <I>Accounting Terms and Principles</I>. All accounting determinations required to be made pursuant
hereto shall, unless expressly otherwise provided herein, be made substantially in accordance with GAAP. If, after the date hereof, any change occurs in GAAP or in the application thereof (an <I>&#147;</I><I>Accounting Change</I><I>&#148;</I>) and
such change would cause any amount required to be determined for the purposes of the covenants to be maintained or calculated pursuant to Article&nbsp;8 or 9 to be materially different than the amount that would be determined prior to such change,
then Administrative Borrower will provide a detailed notice of such change (an </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-38- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<I>&#147;</I><I>Accounting Change Notice</I><I>&#148;</I>) to the Administrative Agent in conjunction with the next required delivery of financial statements pursuant to Section&nbsp;8.01. If
Administrative Borrower requests an amendment to any provision hereof to eliminate the effect of any Accounting Change occurring after the Closing Date or in the application thereof on the operation of such provision, regardless of whether any
Accounting Change Notice is given before or after such Accounting Change or in the application thereof, then the Administrative Agent and Administrative Borrower agree that they will negotiate in good faith amendments to the provisions of this
Agreement that are directly affected by such Accounting Change with the intent of having the respective positions of the Administrative Agent and Borrowers after such Accounting Change conform as nearly as possible to their respective positions as
of the date of this Agreement and, until any such amendments have been agreed upon, (a)&nbsp;the provisions in this Agreement shall be calculated as if no such Accounting Change had occurred and (b)&nbsp;Administrative Borrower shall provide to the
Administrative Agent a written reconciliation in form and substance reasonably satisfactory to the Administrative Agent, between calculations of any baskets and other requirements hereunder before and after giving effect to such Accounting Change.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">All components of financial calculations made to determine compliance with this Agreement shall be adjusted to include or exclude, as the
case may be, without duplication, such components of such calculations attributable to any Acquisition or disposition of assets consummated after the first day of the applicable period of determination and prior to the end of such period, as
determined in good faith by Borrowers based on assumptions expressed therein and that were reasonable based on the information available to Borrowers at the time of preparation of the Compliance Certificate setting forth such calculations. Anything
in this Agreement to the contrary notwithstanding, for purposes of calculations made pursuant to the terms of this Agreement, any lease (or similar arrangement conveying the right to use) that is treated as an operating lease for purposes of GAAP
prior to the issuance by the Financial Accounting Standards Board on February&nbsp;25, 2016 of an Accounting Standards Update (<I>&#147;</I><I>ASU</I><I>&#148;</I>) shall not be treated as Indebtedness or as a finance lease, and shall continue to be
treated as an operating lease (and any future lease or similar arrangement conveying the right to use that would be treated as an operating lease for purposes of GAAP without giving effect to the implementation of ASC&nbsp;842 shall be treated as an
operating lease), in each case for purposes of Indebtedness under this Agreement, notwithstanding such change in GAAP after the issuance of such ASU. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;1.03.</I> <I>Interpretation</I>. For all purposes of this Agreement, except as otherwise expressly provided
herein or unless the context otherwise requires, (a)&nbsp;the terms defined in this Agreement include the plural as well as the singular and vice versa; (b)&nbsp;words importing gender include all genders; (c)&nbsp;any reference to a Section,
Article, Annex, Schedule or Exhibit refers to a Section or Article of, or Annex, Schedule or Exhibit to, this Agreement; (d)&nbsp;any reference to &#147;this Agreement&#148; refers to this Agreement, including all Annexes, Schedules and Exhibits
hereto, and the words herein, hereof, hereto and hereunder and words of similar import refer to this Agreement and its Annexes, Schedules and Exhibits as a whole and not to any particular Section, Article, Annex, Schedule, Exhibit or any other
subdivision; (e)&nbsp;references to days, months and years refer to calendar days, months and years, respectively; (f)&nbsp;all references herein to &#147;include&#148; or &#147;including&#148; shall be deemed to be followed by the words
&#147;without limitation&#148;; (g)&nbsp;the word &#147;from&#148; when used in connection with a period of time means &#147;from and including&#148; and the word &#147;until&#148; means &#147;to but not including&#148;; and (h)&nbsp;accounting
terms not specifically defined herein shall be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-39- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
construed substantially in accordance with GAAP (except for the term &#147;property,&#148; which shall be interpreted as broadly as possible, including, in any case, cash, securities, other
assets, rights under contractual obligations and permits and any right or interest in any property, except where otherwise noted). Unless otherwise expressly provided herein, references to Organizational Documents, agreements (including the Loan
Documents) and other contractual instruments shall be deemed to include all subsequent amendments, restatements, extensions, supplements and other modifications thereto permitted by the Loan Documents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;1.04.</I> <I>Divisions</I>. For all purposes under the Loan Documents, in connection with any division or plan
of division under Delaware law (or any comparable event under a different jurisdiction&#146;s laws): (a)&nbsp;if any asset, right, obligation or liability of any Person becomes the asset, right, obligation or liability of a different Person, then it
shall be deemed to have been transferred from the original Person to the subsequent Person; and (b)&nbsp;if any new Person comes into existence, such new Person shall be deemed to have been organized on the first date of its existence by the holders
of its Equity Interests at such time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;1.05.</I> <I>Interest Rates</I>. The Administrative Agent does not
warrant or accept responsibility for, and shall not have any liability with respect to (a)&nbsp;the continuation of, administration of, submission of, calculation of or any other matter related to the Term SOFR&nbsp;Reference Rate, Term SOFR, or any
component definition thereof or rates referred to in the definition thereof, or any alternative, successor or replacement rate thereto (including any Benchmark Replacement), including whether the composition or characteristics of any such
alternative, successor or replacement rate (including any Benchmark Replacement) will be similar to, or produce the same value or economic equivalence of, or have the same volume or liquidity as, the Term SOFR&nbsp;Reference Rate, Term SOFR or any
other Benchmark prior to its discontinuance or unavailability, or (b)&nbsp;the effect, implementation or composition of any Conforming Changes. The Administrative Agent and its affiliates or other related entities may engage in transactions that
affect the calculation of the Term SOFR&nbsp;Reference Rate, Term SOFR, any alternative, successor or replacement rate (including any Benchmark Replacement) or any relevant adjustments thereto, in each case, in a manner adverse to the Obligors. The
Administrative Agent may select information sources or services in its reasonable discretion to ascertain the Term SOFR&nbsp;Reference Rate, Term SOFR or any other Benchmark, in each case pursuant to the terms of this Agreement, and shall have no
liability to the Obligors, any Lender or any other person or entity for damages of any kind, including direct or indirect, special, punitive, incidental or consequential damages, costs, losses or expenses (whether in tort, contract or otherwise and
whether at law or in equity), for any error or calculation of any such rate (or component thereof) provided by any such information source or service. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-40- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>RTICLE</SMALL>&nbsp;2. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>T<SMALL>HE</SMALL> C<SMALL>OMMITMENTS</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;2.01.</I> <I>Term Loans</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Tranche</I><I></I><I>&nbsp;A Term Loan</I>. (i)&nbsp;Subject to the terms and conditions of this Agreement and relying on the
representations and warranties set forth herein, each Lender, severally and not jointly, agrees to provide its share of the Tranche&nbsp;A Term Loan to Borrowers on the Closing Date in Dollars in a principal amount equal to such Lender&#146;s
Tranche&nbsp;A Term Loan Commitment. No Lender shall have an obligation to make a Tranche&nbsp;A Term Loan in excess of such Lender&#146;s Tranche&nbsp;A Term Loan Commitment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) Subject to the terms and conditions of this Agreement (including Section&nbsp;6.01), Administrative Borrower shall deliver to the
Administrative Agent a fully executed Borrowing Notice no later than 5&nbsp;p.m. (Eastern time) at least one (1)&nbsp;Business Day in advance of the Closing Date (or such shorter period to which the Administrative Agent may agree). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) Borrowers may make one borrowing under the Tranche&nbsp;A Term Loan Commitment which shall be on the Closing Date. Subject to
Sections&nbsp;3.01 and 3.03, all amounts owed hereunder with respect to the Tranche&nbsp;A Term Loan shall be paid in full no later than the Maturity Date. Each Lender&#146;s Tranche&nbsp;A Term Loan Commitment shall terminate immediately and
without further action on the Closing Date after giving effect to the funding of such Lender&#146;s Tranche&nbsp;A Term Loan Commitment on such date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Tranche</I><I></I><I>&nbsp;B Term Loan</I>. (i)&nbsp;Subject to the terms and conditions of this Agreement and relying on the
representations and warranties set forth herein, each Lender, severally and not jointly, agrees to provide its share of the Tranche&nbsp;B Term Loan to Borrowers, at the request of Administrative Borrower on the Tranche&nbsp;B Term Loan Borrowing
Date in Dollars in a principal amount equal to such Lender&#146;s Tranche&nbsp;B Term Loan Commitment. No Lender shall have an obligation to make a Tranche&nbsp;B Term Loan in excess of such Lender&#146;s Tranche&nbsp;B Term Loan Commitment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) Subject to the terms and conditions of this Agreement (including Section&nbsp;6.02), Administrative Borrower shall deliver to the
Administrative Agent a fully executed Borrowing Notice no later than 5&nbsp;p.m. (Eastern time) at least three (3)&nbsp;Business Days in advance of the proposed Tranche&nbsp;B Term Loan Borrowing Date (or such shorter period to which the
Administrative Agent may agree). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) Borrowers may make one borrowing under the Tranche&nbsp;B Term Loan Commitment which shall be on
the Tranche&nbsp;B Term Loan Borrowing Date. Subject to Sections&nbsp;3.01 and 3.03, all amounts owed hereunder with respect to the Tranche&nbsp;B Term Loan shall be paid in full no later than the Maturity Date. Each Lender&#146;s Tranche&nbsp;B
Term Loan Commitment shall terminate immediately and without further action (A)&nbsp;on the Tranche&nbsp;B Term Loan Borrowing Date after giving effect to the funding of such Lender&#146;s Tranche&nbsp;B Term Loan Commitment on such date and
(B)&nbsp;automatically on the Tranche&nbsp;B Term Loan Commitment Termination Date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-41- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Tranche</I><I></I><I>&nbsp;C Term Loan</I>. (i)&nbsp;Subject to the terms and
conditions of this Agreement and relying on the representations and warranties set forth herein, each Lender, severally and not jointly, agrees, at the request of Administrative Borrower, to provide its share of the Tranche&nbsp;C Term Loan to
Borrowers on the Tranche&nbsp;C Term Loan Borrowing Date in Dollars in a principal amount equal to such Lender&#146;s Tranche&nbsp;C Term Loan Commitment. No Lender shall have an obligation to make a Tranche&nbsp;C Term Loan in excess of such
Lender&#146;s Tranche&nbsp;C Term Loan Commitment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) Subject to the terms and conditions of this Agreement (including
Section&nbsp;6.03), Administrative Borrower shall deliver to the Administrative Agent a fully executed Borrowing Notice no later than 5&nbsp;p.m. (Eastern time) at least three (3)&nbsp;Business Days (or such shorter period to which the
Administrative Agent may agree) in advance of the proposed Tranche&nbsp;C Term Loan Borrowing Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) Borrowers may make one
borrowing under the Tranche&nbsp;C Term Loan Commitment which shall be on the Tranche&nbsp;C Term Loan Borrowing Date. Subject to Sections&nbsp;3.01 and 3.03, all amounts owed hereunder with respect to the Tranche&nbsp;C Term Loan shall be paid in
full no later than the Maturity Date. Each Lender&#146;s Tranche&nbsp;C Term Loan Commitment shall terminate immediately and without further action (A)&nbsp;on the Tranche&nbsp;C Term Loan Borrowing Date after giving effect to the funding of such
Lender&#146;s Tranche&nbsp;C Term Loan Commitment on such date and (B)&nbsp;automatically on the Tranche&nbsp;C Term Loan Commitment Termination Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any principal amount of the Term Loans borrowed under Sections&nbsp;2.01(a), 2.01(b) and 2.01(c) hereof and subsequently repaid or prepaid may
not be reborrowed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;2.02.</I><I> Proportionate Shares</I>. Each Term Loan shall be made, and all
participations purchased, by the Lenders simultaneously and proportionately to their respective Proportionate Shares, it being understood that no Lender shall be responsible for any default by any other Lender in such other Lender&#146;s obligation
to make a Term Loan hereunder or purchase a participation required hereby nor shall the Commitment of any Lender be increased or decreased as a result of a default by any other Lender in such other Lender&#146;s obligation to make a Term Loan
requested hereunder or purchase a participation required hereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;2.03.</I> <I>Fees</I>. On the Closing
Date, Borrowers shall pay to the Administrative Agent (out of the proceeds of the Tranche&nbsp;A Term Loan advanced by such Lenders on the Closing Date) for distribution to each Lender in accordance with its Pro Rata Share of the Tranche&nbsp;A Term
Loan, a <FONT STYLE="white-space:nowrap">non-refundable</FONT> fee (the <I>&#147;</I><I>Closing Fee</I><I>&#148;</I>) in the amount of $600,000. Such payments shall be in addition to such fees, costs and expenses due and payable pursuant to
Section&nbsp;12.03. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;2.04.</I> <I>Notes</I>. Upon the request of any Lender, Borrowers shall prepare,
execute and deliver to such Lender one or more Notes evidencing the Term Loan payable to such Lender (or if requested by it, to it and its registered assigns). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;2.05.</I> <I>Use of Proceeds</I>. Borrowers shall use the proceeds of the Term Loans (a)&nbsp;for general
working capital purposes and corporate purposes permitted hereunder, (b)&nbsp;to refinance certain existing Indebtedness on the Closing Date and (c)&nbsp;to pay, in accordance with the funds flow attached to the Borrowing Notice, fees, costs and
expenses incurred in connection with the Transactions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-42- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>RTICLE</SMALL>&nbsp;3. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>P<SMALL>AYMENTS</SMALL> <SMALL>OF</SMALL> P<SMALL>RINCIPAL</SMALL> <SMALL>AND</SMALL> I<SMALL>NTEREST</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;3.01.</I> <I>Repayment</I>. There will be no scheduled repayments of principal on the Term Loans prior to the
Maturity Date. The entire outstanding principal amount of the Term Loans, together with all accrued and unpaid interest thereon (including accrued and uncapitalized PIK&nbsp;Interest on the Term Loans), will be due and payable on the Maturity Date.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;3.02.</I> <I>Interest</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <I>Interest Generally.</I> Each Borrower agrees to pay to the Lenders interest in cash on the outstanding principal amount of the Term
Loans for each Interest Period at a rate per annum equal to the sum of (i)&nbsp;Term SOFR plus (ii)&nbsp;the Applicable Margin; <I>provided, however,</I> that during period commencing on the Closing Date and ending on March&nbsp;31, 2025,
Administrative Borrower may elect by providing written notice to the Administrative Agent to have up to 2.00% of the Applicable Margin on the Term Loans paid as PIK&nbsp;Interest. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <I>Term SOFR Conforming Changes</I>. In connection with the use or administration of Term SOFR, the Administrative Agent will have the
right in consultation with the Administrative Borrower to make Conforming Changes from time to time and, notwithstanding anything to the contrary herein or in any other Loan Document, any amendments implementing such Conforming Changes will become
effective without any further action or consent of any other party to this Agreement or any other Loan Document. The Administrative Agent will promptly notify Administrative Borrower and the Lenders of the effectiveness of any Conforming Changes in
connection with the use or administration of Term SOFR. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <I>Effect of Benchmark Transition Event</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <I>Benchmark Replacement</I>. Notwithstanding anything to the contrary herein or in any other Loan Document, if a
Benchmark Transition Event and its related Benchmark Replacement Date have occurred prior to any setting of the <FONT STYLE="white-space:nowrap">then-current</FONT> Benchmark, then (A)&nbsp;if a Benchmark Replacement is determined in accordance with
clause&nbsp;(a) of the definition of &#147;Benchmark Replacement&#148; for such Benchmark Replacement Date, such Benchmark Replacement will replace such Benchmark for all purposes hereunder and under any Loan Document in respect of such Benchmark
setting and subsequent Benchmark settings without any amendment to, or further action or consent of any other party to, this Agreement or any other Loan Document and (B)&nbsp;if a Benchmark Replacement is determined in accordance with
clause&nbsp;(b) of the definition of &#147;Benchmark Replacement&#148; for such Benchmark Replacement Date, such Benchmark Replacement will replace such Benchmark for all purposes hereunder and under any Loan Document in respect of any Benchmark
setting at or after 5:00&nbsp;p.m. (New&nbsp;York City time) on the fifth (5<SUP STYLE="font-size:75%; vertical-align:top">th</SUP>) Business Day after the date notice of such Benchmark Replacement is provided to the Lenders without any amendment
to, or further action or consent of any other party to, this Agreement or any other Loan Document so long as the Administrative Agent has not received, by such time, written notice of objection to such Benchmark Replacement from Lenders comprising
the Majority Lenders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-43- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) <I>Conforming Changes</I>. In connection with the implementation of a
Benchmark Replacement, the Administrative Agent will have the right to make Conforming Changes from time to time and, notwithstanding anything to the contrary herein or in any other Loan Document, any amendments implementing such Conforming Changes
will become effective without any further action or consent of any other party to the Loan Documents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) <I>Notices;
Standards for Decisions and Determinations</I>. The Administrative Agent will promptly notify Administrative Borrower and the Lenders of (A)&nbsp;the implementation of any Benchmark Replacement and (B)&nbsp;the effectiveness of any Conforming
Changes in connection with the use, administration, adoption or implementation of a Benchmark Replacement. Any determination, decision or election that may be made by the Administrative Agent or the Lenders pursuant to this Section&nbsp;3.02(c)
including any determination with respect to a tenor, rate or adjustment or of the occurrence or <FONT STYLE="white-space:nowrap">non-occurrence</FONT> of an event, circumstance or date and any decision to take or refrain from taking any action, will
be conclusive and binding absent manifest error and may be made in its or their sole discretion and without consent from any other party hereto, except, in each case, as expressly required pursuant to this Section&nbsp;3.02(c). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) <I>Unavailability of Tenor of Benchmark</I>. Notwithstanding anything to the contrary herein or in any other Loan
Document, at any time (including in connection with the implementation of a Benchmark Replacement), (A)&nbsp;if the <FONT STYLE="white-space:nowrap">then-current</FONT> Benchmark is a term rate (including the Term SOFR&nbsp;Reference Rate) and
either (x)&nbsp;any tenor for such Benchmark is not displayed on a screen or other information service that publishes such rate from time to time as selected by the Administrative Agent in its reasonable discretion or (y)&nbsp;the regulatory
supervisor for the administrator of such Benchmark has provided a public statement or publication of information announcing that any tenor for such Benchmark is not or will not be representative, then the Administrative Agent may modify the
definition of &#147;Interest Period&#148; (or any similar or analogous definition) for any Benchmark settings at or after such time to remove such unavailable or <FONT STYLE="white-space:nowrap">non-representative</FONT> tenor and (B)&nbsp;if a
tenor that was removed pursuant to clause&nbsp;(A) above either (x)&nbsp;is subsequently displayed on a screen or information service for a Benchmark (including a Benchmark Replacement) or (y)&nbsp;is not, or is no longer, subject to an announcement
that it is not or will not be representative for a Benchmark (including a Benchmark Replacement), then the Administrative Agent may modify the definition of &#147;Interest Period&#148; (or any similar or analogous definition) for all Benchmark
settings at or after such time to reinstate such previously removed tenor. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-44- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <I>Default Interest.</I> Notwithstanding the foregoing, upon the occurrence and during
the continuance of any Event of Default, all overdue Obligations shall bear interest (including post-petition interest in any proceeding under any Insolvency Proceeding) payable on demand in cash at a rate that is equal to 4.00% per annum (the
interest rate, as increased pursuant to this Section&nbsp;3.02(d), being the <I>&#147;Default Rate&#148;</I>). If any Obligation is not paid when due under any applicable Loan Document, the amount thereof shall accrue interest at the Default Rate.
Payment or acceptance of the increased rates of interest provided for in this Section&nbsp;3.02(d) is not a permitted alternative to timely payment and shall not constitute a waiver of any Default or otherwise prejudice or limit any rights or
remedies of the Administrative Agent or any Lender. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <I>Payment Dates.</I> Accrued interest on the Term Loans shall be payable in
arrears on each Payment Date with respect to the most recently completed Interest Period in cash (other than PIK&nbsp;Interest), and upon the payment or prepayment of the Term Loans (on the principal amount being so paid or prepaid); <I>provided</I>
that interest payable at the Default Rate shall be payable from time to time on demand by the Majority Lenders. PIK&nbsp;Interest on the Term&nbsp;Loans shall be capitalized and added to the outstanding principal amount of the Term&nbsp;Loans on
each Payment Date with respect to the most recently completed Interest Period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <I>Maximum Rate.</I> Notwithstanding any other
provision of this Agreement, in no event will any interest or rates referred to herein exceed the maximum interest rate permitted by applicable Law. If such maximum interest rate would be exceeded by the terms hereof, the rates of interest payable
hereunder will be reduced to the extent necessary so that such rates (together with any fees or other amounts which are construed by a court of competent jurisdiction to be interest or in the nature of interest) equal the maximum interest rate
permitted by applicable Law, and any overpayment of interest received by the Lenders before such rates are so construed will be applied, forthwith after determination of such overpayment, to pay all then outstanding interest, and thereafter to pay
outstanding principal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;3.03.</I> <I>Prepayments</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <I>Optional Prepayments</I>. (i)&nbsp;Borrowers shall have the right to optionally prepay in whole or in part (in a minimum amount of
$500,000 and integral multiples of $100,000 in excess of that amount for each partial prepayment, or, if less, the entire outstanding principal amount of the Term Loans) the outstanding principal amount of the Term Loans on any Business Day (a
<I>&#147;Redemption Date&#148;</I>) for an amount equal to the sum of (i)&nbsp;the aggregate principal amount of the Term Loans being prepaid, (ii)&nbsp;the applicable Prepayment Premium in respect of the aggregate principal amount of the Term Loans
being prepaid and (iii)&nbsp;any accrued but unpaid interest in respect of the aggregate principal amount of the Term Loans being prepaid (such aggregate amount, the <I>&#147;Redemption Price&#148;</I>). The applicable &#147;Prepayment Premium&#148;
shall be an amount calculated pursuant to Section&nbsp;3.03(a)(ii). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) If the Redemption Date occurs: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A) on or prior to the first anniversary of the Closing Date, the Prepayment Premium shall be an amount equal to ten percent
(10%) of the aggregate outstanding principal amount of the Term Loans being prepaid on such Redemption Date; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-45- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B) after the first anniversary of the Closing Date and on or prior to the
second anniversary of the Closing Date, the Prepayment Premium shall be an amount equal to nine percent (9%) of the aggregate outstanding principal amount of the Term Loans being prepaid on such Redemption Date; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(C) after the second anniversary of the Closing Date and on or prior to the third anniversary of the Closing Date, the
Prepayment Premium shall be an amount equal to eight percent (8%) of the aggregate outstanding principal amount of the Term Loans being prepaid on such Redemption Date; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(D) after the third anniversary of the Closing Date and on or prior to the fourth anniversary of the Closing Date, the
Prepayment Premium shall be an amount equal to six percent (6%) of the aggregate outstanding principal amount of the Term Loan being prepaid on such Redemption Date; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(E) after the fourth anniversary of the Closing Date and prior to the Stated Maturity Date, the Prepayment Premium shall be an
amount equal to four percent (4%) of the aggregate outstanding principal amount of the Term Loan being prepaid on such Redemption Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No Prepayment
Premium shall be due with respect to repayment of the Term Loans on the Stated Maturity Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <I>Mandatory Prepayments</I>. Borrowers
shall promptly prepay the Term Loans in amounts as provided below, plus a Prepayment Premium on the principal amount of the Term Loans being prepaid pursuant to clauses&nbsp;(ii) and (iii)&nbsp;below (calculated in accordance with
Section&nbsp;3.03(a)(ii), it being agreed that the relevant payment date shall be deemed to be the &#147;Redemption Date&#148; for purposes of such calculation), plus any accrued but unpaid interest and fees then due and owing, as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) In the event of any Casualty Event, an amount equal to 100% of the Net Cash Proceeds received by any Obligor with respect
thereto; <I>provided, however,</I> so long as no Default has occurred and is continuing, within one hundred eighty (180)&nbsp;days after receipt of such Net Cash Proceeds (or if such Obligor enters into a bona fide commitment to reinvest such Net
Cash Proceeds within one hundred eighty (180)&nbsp;days following receipt thereof, within the later of (x)&nbsp;one hundred eighty (180)&nbsp;days following receipt thereof and (y)&nbsp;ninety (90) days of the date of such commitment), the Obligors
may use such Net Cash Proceeds not exceeding $2,500,000 in the aggregate for all losses under all casualty policies during the term of this Agreement, toward the replacement or repair of destroyed or damaged property; <I>provided, further,</I> that
any such replaced or repaired property shall be Collateral in which the Administrative Agent for the benefit of the Lenders has been granted a security interest under the Security Documents. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-46- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) In the event any Obligor incurs Indebtedness other than Indebtedness
that is permitted by Section&nbsp;9.01 hereof, 100% of the Net Cash Proceeds thereof received by such Obligor. For the avoidance of doubt, any prepayment made pursuant to this Section&nbsp;3.03(b)(ii) shall not be deemed to be a consent to any such
incurrence of Indebtedness or a cure or waiver of any Event of Default which occurs in connection therewith, it being understood that any such Event of Default may only be waived with the express consent of the Majority Lenders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) In the event any Obligor consummates an Asset Sale other than an Asset Sale that is permitted by Section&nbsp;9.09
hereof (other than Section&nbsp;9.09(j)), 100% of the Net Cash Proceeds received by such Obligor in connection with such Asset Sale; <I>provided, however,</I> so long as no Default has occurred and is continuing, within one hundred eighty
(180)&nbsp;days after receipt of such Net Cash Proceeds (or if such Obligor enters into a bona fide commitment to reinvest such Net Cash Proceeds within one hundred eighty (180)&nbsp;days following receipt thereof, within the later of (x)&nbsp;one
hundred eighty (180)&nbsp;days following receipt thereof and (y)&nbsp;ninety (90) days of the date of such commitment), the Obligors may use such Net Cash Proceeds not exceeding $2,500,000 in the aggregate for all Asset Sales during the term of this
Agreement, to purchase, replace, repair or restore properties or assets used in the Obligors&#146; businesses; <I>provided, further,</I> that any such purchased, replaced, repaired or restored property shall be Collateral in which the Administrative
Agent for the benefit of the Lenders has been granted a security interest under the Security Documents. For the avoidance of doubt, any prepayment made pursuant to this Section&nbsp;3.03(b)(iii) shall not be deemed to be a consent to any Asset Sale
or a cure or waiver of any Event of Default which occurs in connection therewith, it being understood that any such Event of Default may only be waived with the express consent of the Majority Lenders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <I>Prepayment Premium</I>. Payment of any Prepayment Premium under this Section&nbsp;3.03 constitutes liquidated damages, not unmatured
interest or a penalty, as the actual amount of damages to the Lenders as a result of the relevant triggering event, prepayment or repayment would be impracticable and extremely difficult to ascertain. Accordingly, any Prepayment Premium hereunder is
provided by mutual agreement of the Obligors and the Lenders as a reasonable estimation and calculation of such actual lost profits and other actual damages of the Lenders. Without limiting the generality of the foregoing, it is understood and
agreed that upon the occurrence of any prepayment event, any Prepayment Premium shall be automatically and immediately due and payable as though any prepaid or repaid portion of the Term Loans were voluntarily prepaid as of such date and shall
constitute part of the Obligations secured by the Collateral. Any Prepayment Premium shall also be automatically and immediately due and payable if the Term Loans are satisfied or released by foreclosure (whether by power of judicial proceeding or
otherwise), deed in lieu of foreclosure or by any other means. E<SMALL>ACH</SMALL> O<SMALL>BLIGOR</SMALL> <SMALL>HEREBY</SMALL> <SMALL>EXPRESSLY</SMALL> <SMALL>WAIVES</SMALL> (<SMALL>TO</SMALL> <SMALL>THE</SMALL> <SMALL>FULLEST</SMALL>
<SMALL>EXTENT</SMALL> <SMALL>IT</SMALL> <SMALL>MAY</SMALL> <SMALL>LAWFULLY</SMALL> <SMALL>DO</SMALL> <SMALL>SO</SMALL>) <SMALL>THE</SMALL> <SMALL>PROVISIONS</SMALL> <SMALL>OF</SMALL> <SMALL>ANY</SMALL> <SMALL>PRESENT</SMALL> <SMALL>OR</SMALL>
<SMALL>FUTURE</SMALL> <SMALL>STATUTE</SMALL> <SMALL>OR</SMALL> <SMALL>OTHER</SMALL> <SMALL>LAW</SMALL> <SMALL>THAT</SMALL> <SMALL>PROHIBITS</SMALL> <SMALL>OR</SMALL> <SMALL>MAY</SMALL> <SMALL>PROHIBIT</SMALL> <SMALL>THE</SMALL>
<SMALL>COLLECTION</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL> <SMALL>FOREGOING</SMALL> <SMALL>PREPAYMENT</SMALL> <SMALL>PREMIUM</SMALL> <SMALL>IN</SMALL> <SMALL>CONNECTION</SMALL> <SMALL>WITH</SMALL> <SMALL>ANY</SMALL> <SMALL>SUCH</SMALL>
<SMALL>EVENTS</SMALL>. Borrowers and the other Obligors expressly agree (to the fullest extent it and they may lawfully do so) that with respect to any Prepayment Premium payable under the terms of this Agreement: (i)&nbsp;such Prepayment Premium is
reasonable and is the product of an arm&#146;s length transaction between sophisticated business parties, ably represented by counsel; (ii)&nbsp;such Prepayment Premium shall be payable notwithstanding the
<FONT STYLE="white-space:nowrap">then-prevailing</FONT> market rates at the time payment is made; (iii)&nbsp;there has been a course of conduct between the Lenders and the Obligors giving specific consideration in this transaction for such agreement
to pay such Prepayment Premium; and (iv)&nbsp;the Obligors shall be estopped hereafter from claiming differently than as agreed to in this paragraph. The Obligors expressly acknowledge that their agreement to pay such Prepayment Premium as herein
described is a material inducement to the Lenders to provide the Commitments and to make the Term Loans. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-47- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>RTICLE</SMALL>&nbsp;4. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>P<SMALL>AYMENTS</SMALL>, E<SMALL>TC</SMALL>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;4.01.</I> <I>Payments</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <I>Payments Generally</I>. Each payment of principal, interest and other amounts to be made by the Obligors under this Agreement or any
other Loan Document shall be made in Dollars, in immediately available funds, without deduction, set off or counterclaim, to the deposit account of the Administrative Agent specified to Borrowers from time to time, not later than 2:00&nbsp;p.m.
(Eastern time) on the date on which such payment shall become due (each such payment made after such time on such due date to be deemed to have been made on the next succeeding Business Day). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <I>Application of Payments Prior to a Default</I>. Prior to the occurrence of a Default, each payment under this Agreement or any other
Loan Document shall be applied in the following order of priority, with proceeds being applied to a succeeding level of priority only if amounts owing pursuant to the immediately preceding level of priority have been paid in full in cash: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <I>first</I>, in reduction of Borrowers&#146; obligation to pay any unpaid interest and any fees then due and owing
including, without limitation, any Prepayment Premium, if applicable; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) <I>second</I>, to the payment of unpaid
principal of the Term Loans on a pro rata basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <I>Application of Payments Following a Default</I>. Following the occurrence of a
Default, each payment under this Agreement or any other Loan Document shall be applied in the following order of priority, with proceeds being applied to a succeeding level of priority only if amounts owing pursuant to the immediately preceding
level of priority have been paid in full in cash: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <I>first</I>, to the payment of any unpaid costs and expenses
referred to in Section&nbsp;13.03(a) then due and owing; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) <I>second</I>, in reduction of Borrowers&#146; obligation
to pay any unpaid interest and any fees then due and owing including, without limitation, (A)&nbsp;interest payable pursuant to Section&nbsp;3.02(d) and (B)&nbsp;any Prepayment Premium, if applicable; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-48- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) <I>third</I>, to the payment of unpaid principal of the Term Loans on
a pro rata basis; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) <I>fourth, </I>in reduction of Borrowers&#146; obligation to pay any Claims or Losses referred to
in Section&nbsp;13.03(b) then due and owing; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) <I>fifth</I>, in reduction of any other Obligation then due and owing;
and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) <I>sixth</I>, to Borrowers or such other Persons as may lawfully be entitled to or directed by Borrowers to
receive the remainder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Unless otherwise directed by the Majority Lenders, all payments of principal, interest and fees under this
Agreement and the other Loan Documents shall be made by the Obligors to the Lenders pro rata in accordance with the Lenders&#146; respective Proportionate Shares of such payments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <I>Non</I><I><FONT STYLE="white-space:nowrap">-Business</FONT> Days</I>. If the due date of any payment under this Agreement (whether in
respect of principal, interest, fees, costs or otherwise) would otherwise fall on a day that is not a Business Day, such date shall be extended to the next succeeding Business Day, and, in the case of any payment accruing interest, interest thereon
shall be payable for the period of such extension. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;4.02.</I> <I>Computations</I><I>.</I> All computations
of interest and fees hereunder shall be computed on the basis of a year of 360&nbsp;days and actual days elapsed during the period for which payable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;4.03.</I> <I>Notices</I><I>.</I> Each notice of optional prepayment shall be effective only if received by the
Lenders not later than 2:00&nbsp;p.m. (Eastern time) on the date three (3)&nbsp;Business Days prior to the date of prepayment. Each notice of optional prepayment shall specify the amount to be prepaid and the date of prepayment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;4.04.</I> <I>Set</I><I><FONT STYLE="white-space:nowrap">-Off</FONT></I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <I>Set</I><I><FONT STYLE="white-space:nowrap">-Off</FONT> Generally</I>. Upon the occurrence and during the continuance of any Event of
Default, the Administrative Agent, the Lenders and each of their respective Affiliates are hereby authorized at any time and from time to time, to the fullest extent permitted by Law, to set off and apply any and all deposits (general or special,
time or demand, provisional or final, other than deposits held in any account set forth in clause (d)&nbsp;of the definition of &#147;Excluded Accounts&#148;) at any time held and other Indebtedness at any time owing by the Lenders or such
Affiliates to or for the credit or the account of any Obligor against any and all of the Obligations, whether or not the Lenders shall have made any demand and although such Obligations may be unmatured. Any Person exercising rights of <FONT
STYLE="white-space:nowrap">set-off</FONT> hereunder agrees to promptly notify Administrative Borrower after any such <FONT STYLE="white-space:nowrap">set-off</FONT> and application, <I>provided</I> that the failure to give such notice shall not
affect the validity of such <FONT STYLE="white-space:nowrap">set-off</FONT> and application. The rights of the Lenders and their respective Affiliates under this Section&nbsp;4.04 are in addition to other rights and remedies (including other rights
of <FONT STYLE="white-space:nowrap">set-off)</FONT> that the Lenders and their respective Affiliates may have. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-49- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <I>Exercise of Rights Not Required</I>. Nothing contained herein shall require the
Administrative Agent, the Lenders or any of their respective Affiliates to exercise any such right or shall affect the right of such Persons to exercise, and retain the benefits of exercising, any such right with respect to any other Indebtedness or
obligation of any Obligor. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>RTICLE</SMALL>&nbsp;5. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Y<SMALL>IELD</SMALL> P<SMALL>ROTECTION</SMALL>, E<SMALL>TC</SMALL>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;5.01.</I> <I>Additional Costs</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <I>Change in Requirements of Law Generally</I>. If, on or after the date hereof, the adoption of any Requirement of Law, or any change in
any Requirement of Law, or any change in the interpretation or administration thereof by any court or other Governmental Authority charged with the interpretation or administration thereof, or compliance by any Lender (or its lending office) with
any request or directive (whether or not having the force of law) of any such Governmental Authority, shall impose, modify or deem applicable any reserve (including any such requirement imposed by the Board of Governors of the Federal Reserve
System), special deposit, contribution, insurance assessment or similar requirement, in each case that becomes effective after the date hereof, against assets of, deposits with or for the account of, or credit extended by, a Lender (or its lending
office) or shall impose on a Lender (or its lending office) any other condition affecting the Term Loans or the Commitments, not as a result of any action or inaction on the part of such Lender, and the result of any of the foregoing is to increase
the cost to any Lender of making or maintaining its portion of the Term Loans, or to reduce the amount of any sum received or receivable by any Lender under this Agreement or any other Loan Document, by an amount reasonably deemed by such Lender in
good faith to be material (other than (i)&nbsp;Indemnified Taxes, (ii)&nbsp;Taxes described in clauses&nbsp;(b) through (d)&nbsp;of the definition of <I>&#147;Excluded Taxes&#148;</I> and (iii)&nbsp;Connection Income Taxes), then Borrowers shall pay
to such Lender on demand therefor such additional amount or amounts as will compensate such Lender for such increased cost or reduction. Notwithstanding anything herein to the contrary, (i)&nbsp;the <FONT STYLE="white-space:nowrap">Dodd-Frank</FONT>
Wall Street Reform and Consumer Protection Act and all requests, rules, guidelines or directives thereunder or issued in connection therewith and (ii)&nbsp;all requests, rules, guidelines or directives promulgated by the Bank for International
Settlements, the Basel Committee on Banking Supervision (or any successor or similar authority) or the United States or foreign regulatory authorities, in each case pursuant to Basel&nbsp;III, shall in each case be deemed to constitute a change in
Requirements of Law for all purposes of this Section&nbsp;5.01, regardless of the date enacted, adopted or issued. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <I>Change in
Capital Requirements</I>. If a Lender shall have determined that, on or after the date hereof, the adoption of any Requirement of Law regarding capital adequacy, or any change therein, or any change in the interpretation or administration thereof by
any Governmental Authority charged with the interpretation or administration thereof, or any request or directive regarding capital adequacy (whether or not having the force of law) of any such Governmental Authority, in each case that becomes
effective after the date hereof, has or would have the effect of reducing the rate of return on capital of a Lender (or its parent) as a consequence of a Lender&#146;s obligations hereunder or the Term Loans to a level below that which a Lender (or
its parent) could have achieved but for such adoption, change, request or directive by an amount reasonably deemed by it to be material, then Borrowers shall pay to such Lender on demand therefor such additional amount or amounts as will compensate
such Lender (or its parent) for such reduction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-50- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <I>Notification by Lender</I>. The Lenders will promptly notify Administrative Borrower
of any event of which it has knowledge, occurring after the date hereof, which will entitle a Lender to compensation pursuant to this Section&nbsp;5.01. Before giving any such notice pursuant to this Section&nbsp;5.01(c) such Lender shall designate
a different lending office if such designation (i)&nbsp;will, in the reasonable judgment of such Lender, avoid the need for, or reduce the amount of, such compensation and (ii)&nbsp;will not, in the reasonable judgment of such Lender, be materially
disadvantageous to such Lender. A certificate of the Lender claiming compensation under this Section&nbsp;5.01, setting forth the amount or amounts to be paid to it hereunder, shall be conclusive and binding on Borrowers in the absence of manifest
error. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;5.02.</I> <I>Illegality</I><I>.</I> Notwithstanding any other provision of this Agreement, in the
event that on or after the date hereof the adoption of or any change in any Requirement of Law or in the interpretation or application thereof by any competent Governmental Authority shall make it unlawful for a Lender or its lending office to make
or maintain the Term Loans (and, in the opinion of such Lender, the designation of a different lending office would either not avoid such unlawfulness or would be disadvantageous to such Lender), then such Lender shall promptly notify Administrative
Borrower thereof following which (a)&nbsp;the Lender&#146;s Commitment shall be suspended until such time as such Lender may again make and maintain the Term Loans hereunder and (b)&nbsp;if such Requirement of Law shall so mandate, the Term Loans
shall be prepaid by Borrowers on or before such date as shall be mandated by such Requirement of Law in an amount equal to the Redemption Price applicable on the date of such prepayment in accordance with Section&nbsp;3.03(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;5.03.</I> <I>Taxes</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <I>Payments Free of Taxes</I>. Any and all payments by or on account of any Obligation shall be made without deduction or withholding for
any Taxes, except as required by applicable Law. If any applicable Law (as determined in the good faith discretion of the Administrative Agent) requires the deduction or withholding of any Tax from any such payment by an Obligor, then such Obligor
shall be entitled to make such deduction or withholding and shall timely pay the full amount deducted or withheld to the relevant Governmental Authority in accordance with applicable Law and, if such Tax is an Indemnified Tax, then the sum payable
by such Obligor shall be increased as necessary so that after such deduction or withholding for Indemnified Taxes has been made (including such deductions and withholdings for Indemnified Taxes applicable to additional sums payable under this
Section&nbsp;5.03) the applicable Recipient receives an amount equal to the sum it would have received had no such deduction or withholding for Indemnified Taxes been made. For purposes of this Section, the term &#147;applicable Law&#148; includes
FATCA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <I>Payment of Other Taxes by Borrowers</I>. Borrowers shall timely pay to the relevant Governmental Authority in accordance
with applicable Law, or at the option of the Administrative Agent, timely reimburse it for, Other Taxes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-51- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <I>Evidence of Payments</I>. As soon as practicable after any payment of Taxes by
Borrowers to a Governmental Authority, as a withholding Tax pursuant to this Section&nbsp;5.03, Borrowers shall deliver to the Administrative Agent the original or a certified copy of a receipt issued by such Governmental Authority evidencing such
payment, or a copy of the return reporting such payment or other evidence of such payment reasonably satisfactory to the Administrative Agent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <I>Indemnification</I>. Borrowers shall reimburse and indemnify each Recipient, within ten (10)&nbsp;days after demand therefor, for the
full amount of any Indemnified Taxes (including Indemnified Taxes imposed or asserted on or attributable to amounts payable under this Section&nbsp;5.03) payable or paid by such Recipient or required to be withheld or deducted from a payment to such
Recipient and any reasonable expenses arising therefrom or with respect thereto, whether or not such Indemnified Taxes were correctly or legally imposed or asserted by the relevant Governmental Authority. A certificate as to the amount of such
payment or liability delivered to Administrative Borrower by a Lender (with a copy to the Administrative Agent), or by the Administrative Agent on its own behalf or on behalf of a Lender shall be conclusive absent manifest error. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <I>Indemnification by the Lender</I>. Each Lender shall severally indemnify the Administrative Agent, within ten (10)&nbsp;days after
demand therefor, for (i)&nbsp;any Indemnified Taxes attributable to such Lender (but only to the extent that Borrowers have not already indemnified the Administrative Agent for such Indemnified Taxes and without limiting the obligation of Borrowers
to do so), and (ii)&nbsp;any Taxes attributable to such Lender, in each case, that are payable or paid by the Administrative Agent in connection with any Loan Document, and any reasonable expenses arising therefrom or with respect thereto, whether
or not such Taxes were correctly or legally imposed or asserted by the relevant Governmental Authority. A certificate as to the amount of such payment or liability delivered to any Lender by the Administrative Agent shall be conclusive absent
manifest error. Each Lender hereby authorizes the Administrative Agent to set off and apply any and all amounts at any time owing to such Lender under any Loan Document or otherwise payable by the Administrative Agent to such Lender from any other
source against any amount due to the Administrative Agent under this paragraph&nbsp;(e). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <I>Status of Lenders</I>. (i)&nbsp;Any
Lender that is entitled to an exemption from, or reduction of withholding Tax with respect to payments made under any Loan Document shall deliver to Administrative Borrower and the Administrative Agent at the time or times reasonably requested by
Administrative Borrower or the Administrative Agent such properly completed and executed documentation reasonably requested by Administrative Borrower or the Administrative Agent as will permit such payments to be made without withholding or at a
reduced rate of withholding. In addition, any Lender, if reasonably requested by Administrative Borrower or the Administrative Agent, shall deliver such other documentation prescribed by applicable Law or as reasonably requested by Administrative
Borrower or the Administrative Agent as will enable Administrative Borrower or the Administrative Agent to determine whether or not such Lender is subject to backup withholding or information reporting requirements. Notwithstanding anything to the
contrary in the preceding two sentences, the completion, execution and submission of such documentation (other than such documentation set forth in Section&nbsp;5.03(f)(ii)(A), (B) and (D)) shall not be required if in the Lender&#146;s reasonable
judgment such completion, execution or submission would subject such Lender to any material unreimbursed cost or expense or would materially prejudice the legal or commercial position of such Lender. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-52- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) Without limiting the generality of the foregoing: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A) any Lender that is a U.S.&nbsp;Person shall deliver to Administrative Borrower and the Administrative Agent on or prior
to the date on which such Lender becomes a Lender under this Agreement (and from time to time thereafter upon the reasonable request of Administrative Borrower or the Administrative Agent), duly completed, valid, executed copies of IRS <FONT
STYLE="white-space:nowrap">Form&nbsp;W-9</FONT> (or successor form) certifying that such Lender is exempt from U.S.&nbsp;Federal backup withholding Tax; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B) any Foreign Lender shall, to the extent it is legally entitled to do so, deliver to Administrative Borrower and the
Administrative Agent (in such number of copies as shall be requested by the Recipient) on or prior to the date on which such Foreign Lender becomes a Lender under this Agreement (and from time to time thereafter upon the reasonable request of
Administrative Borrower or the Administrative Agent), whichever of the following is applicable: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:18%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(1) in the case of a
Foreign Lender claiming the benefits of an income Tax treaty to which the United States is a party (x)&nbsp;with respect to payments of interest under any Loan Document, duly completed, valid executed copies of IRS
<FONT STYLE="white-space:nowrap">Form&nbsp;W-8BEN</FONT> (or successor form) or IRS <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Form&nbsp;W-8BEN-E</FONT></FONT> (or successor form) establishing an exemption from, or reduction
of, U.S. Federal withholding Tax pursuant to the &#147;interest&#148; article of such Tax treaty and (y)&nbsp;with respect to any other applicable payments under any Loan Document, duly completed, valid, executed originals of IRS <FONT
STYLE="white-space:nowrap">Form&nbsp;W-8BEN</FONT> (or successor form) or IRS <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Form&nbsp;W-8BEN-E</FONT></FONT> (or successor form) establishing an exemption from, or reduction of,
U.S.&nbsp;Federal withholding Tax pursuant to the &#147;business profits&#148; or &#147;other income&#148; article of such Tax treaty; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:18%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(2) duly completed, valid, executed copies of IRS Form <FONT STYLE="white-space:nowrap">W-8ECI</FONT> (or successor form);
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:18%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(3) in the case of a Foreign Lender claiming the benefits of the exemption for portfolio interest under
Section&nbsp;881(c) of the Code, (x)&nbsp;a certificate substantially in the form of Exhibit&nbsp;D to the effect that such Foreign Lender is not a &#147;bank&#148; within the meaning of Section&nbsp;881(c)(3)(A) of the Code, a &#147;10&nbsp;percent
shareholder&#148; of a Borrower within the meaning of Section&nbsp;881(c)(3)(B) of the Code, or a &#147;controlled foreign corporation&#148; related to the Administrative Borrower as described in Section&nbsp;881(c)(3)(C) of the Code (a
<I>&#147;U.S.</I><I></I><I>&nbsp;Tax Compliance Certificate&#148;</I>) and (y)&nbsp;executed copies of IRS <FONT STYLE="white-space:nowrap">Form&nbsp;W-8BEN</FONT> (or successor form) or IRS <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Form&nbsp;W-8BEN-E</FONT></FONT> (or successor form); or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-53- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:18%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(4) to the extent a Foreign Lender is not the beneficial owner, duly
completed, valid, executed copies of IRS <FONT STYLE="white-space:nowrap">Form&nbsp;W-8IMY</FONT> (or successor form), accompanied by IRS <FONT STYLE="white-space:nowrap">Form&nbsp;W-8ECI</FONT> (or successor form), IRS <FONT
STYLE="white-space:nowrap">Form&nbsp;W-8BEN</FONT> (or successor form), IRS <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Form&nbsp;W-8BEN-E</FONT></FONT> (or successor form), a U.S.&nbsp;Tax Compliance Certificate, IRS <FONT
STYLE="white-space:nowrap">Form&nbsp;W-9</FONT> (or successor form), and/or other certification documents from each beneficial owner, as applicable; <I>provided</I> that if the Foreign Lender is a partnership and one or more direct or indirect
partners of such Foreign Lender are claiming the portfolio interest exemption, such Foreign Lender may provide a U.S.&nbsp;Tax Compliance Certificate on behalf of each such direct and indirect partner; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(C) any Foreign Lender shall, to the extent it is legally entitled to do so, deliver to Administrative Borrower and the
Administrative Agent (in such number of copies as shall be requested by the Recipient) on or prior to the date on which such Foreign Lender becomes a Lender under this Agreement (and from time to time thereafter upon the reasonable request of
Administrative Borrower or the Administrative Agent), executed copies of any other form prescribed by applicable Law as a basis for claiming exemption from or a reduction in U.S.&nbsp;Federal withholding Tax, duly completed, together with such
supplementary documentation as may be prescribed by applicable Law to permit Administrative Borrower or the Administrative Agent to determine the withholding or deduction required to be made; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(D) if a payment made to a Lender under any Loan Document would be subject to U.S.&nbsp;federal withholding Tax imposed by
FATCA if such Lender were to fail to comply with the applicable reporting requirements of FATCA (including those contained in Section&nbsp;1471(b) or 1472(b) of the Code, as applicable), such Lender shall deliver to Administrative Borrower and the
Administrative Agent at the time or times prescribed by Law and at such time or times reasonably requested by Administrative Borrower or the Administrative Agent such documentation prescribed by applicable Law (including as prescribed by
Section&nbsp;1471(b)(3)(C)(i) of the Code) and such additional documentation reasonably requested by Administrative Borrower or the Administrative Agent as may be necessary for Administrative Borrower or the Administrative Agent to comply with its
obligations under FATCA and to determine that such Lender has complied with such Lender&#146;s obligations under FATCA or to determine the amount, if any, to deduct and withhold from such payment. Solely for purposes of this clause&nbsp;(D),
&#147;FATCA&#148; shall include any amendments made to FATCA after the date of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Each Recipient agrees that if any form or
certification it previously delivered expires or becomes obsolete or inaccurate in any respect, it shall promptly update such form or certification or promptly notify Administrative Borrower and the Administrative Agent in writing of its legal
inability to do so. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) <I>Treatment of Certain Refunds</I>. If any party to this Agreement determines, in its sole discretion exercised
in good faith, that it has received a refund of any Taxes as to which it has been indemnified pursuant to this Section&nbsp;5.03 (including by the payment of additional amounts pursuant to this Section&nbsp;5.03), it shall pay to the indemnifying
party an amount equal to such refund (but only to the extent of indemnity payments made under this Section with respect to the Taxes giving rise to such refund), net of all
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses (including Taxes) of such indemnified </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-54- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
party and without interest (other than any interest paid by the relevant Governmental Authority with respect to such refund). Such indemnifying party, upon the written request of such indemnified
party, shall repay to such indemnified party the amount paid over pursuant to this paragraph (plus any penalties, interest or other charges imposed by the relevant Governmental Authority) in the event that such indemnified party is required to repay
such refund to such Governmental Authority. Notwithstanding anything to the contrary in this Section&nbsp;5.03(g), in no event will the indemnified party be required to pay any amount to an indemnifying party pursuant to this Section&nbsp;5.03(g)
the payment of which would place the indemnified party in a less favorable net <FONT STYLE="white-space:nowrap">after-Tax</FONT> position than the indemnified party would have been in if the Tax subject to indemnification and giving rise to such
refund had not been deducted, withheld or otherwise imposed and the indemnification payments or additional amounts giving rise to such refund had never been paid. This Section&nbsp;5.03(g) shall not be construed to require any indemnified party to
make available its Tax returns (or any other information relating to its Taxes that it deems confidential) to the indemnifying party or any other Person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) <I>Mitigation Obligations.</I> If Borrowers are required to pay any Indemnified Taxes or additional amounts to any Lender or to any
Governmental Authority for the account of any Lender pursuant to Section&nbsp;5.01 or this Section&nbsp;5.03, then such Lender shall (at the request of Administrative Borrower) use commercially reasonable efforts to designate a different lending
office for funding or booking the Term Loans hereunder or to assign and delegate its rights and obligations hereunder to another of its offices, branches or Affiliates if, in the sole reasonable judgment of such Lender, such designation or
assignment and delegation would (i)&nbsp;eliminate or reduce amounts payable pursuant to Section&nbsp;5.01 or this Section&nbsp;5.03, as the case may be, in the future, (ii)&nbsp;not subject such Lender to any unreimbursed cost or expense and
(iii)&nbsp;not otherwise be disadvantageous to such Lender. Each Borrower hereby agrees to pay all reasonable costs and expenses incurred by any Lender in connection with any such designation or assignment and delegation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) <I>Survival</I>. Each party&#146;s obligations under this Article&nbsp;5 shall survive the resignation or replacement of the
Administrative Agent or any assignment of rights by, or the replacement of, a Lender, the termination of the Commitments and the repayment, satisfaction or discharge of all Obligations under any Loan Document. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;5.04.</I> <I>Delay in Requests</I>. Failure or delay on the part of any Lender to demand compensation pursuant
to this Article&nbsp;5 shall not constitute a waiver of such Lender&#146;s right to demand such compensation; <I>provided</I> that Borrowers shall not be required to compensate a Lender pursuant to this Article for any increased costs incurred or
reductions suffered more than nine (9)&nbsp;months prior to the date that such Lender notifies Administrative Borrower of the change in Law giving rise to such increased costs or reductions, and of such Lender&#146;s intention to Claim compensation
therefor (except that, if the change in Law giving rise to such increased costs or reductions is retroactive, then the nine (9)&nbsp;month period referred to above shall be extended to include the period of retroactive effect thereof). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-55- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>RTICLE</SMALL>&nbsp;6. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>C<SMALL>ONDITIONS</SMALL> P<SMALL>RECEDENT</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;6.01.</I> <I>Conditions to Tranche</I><I></I><I>&nbsp;A Term Loan; Closing Date</I><I>.</I> The obligation of
each Lender to make the Tranche&nbsp;A Term Loan on the Closing Date shall not become effective until the following conditions precedent shall have been reasonably satisfied or waived in writing by the Administrative Agent (which satisfaction or
waiver may be made simultaneously with the making of the Tranche&nbsp;A Term Loan hereunder): </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Organization and
Capitalization</I>. The organizational structure and <FONT STYLE="white-space:nowrap">pro-forma</FONT> capitalization of the Obligors, after giving effect to the Transactions, as set forth on Schedule&nbsp;7.20 shall be satisfactory to the
Administrative Agent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Terms of Material Agreements</I>. The Administrative Agent shall be satisfied in its sole
discretion with the terms and conditions of all of the Obligors&#146; Material Agreements, including without limitation, the Material Agreements that are directly or indirectly associated with Product manufacturing, distribution and payment of
royalties by any Obligor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>No Law Restraining Transactions</I>. No applicable Law or regulation shall restrain,
prevent or, in the reasonable judgment of the Administrative Agent, impose materially adverse conditions upon the Transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>Searches</I>. The Administrative Agent shall be satisfied with: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Lien searches regarding the Obligors made prior to the Closing Date; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) In respect of the Irish Obligor, (A)&nbsp;a search of the judgments office of the central office of the High Court of
Ireland, (B)&nbsp;a search of the index of petitions and winding up notices at the central office of the High Court of Ireland and (C)&nbsp;a search of the Companies Registration Office in Ireland to determine if an examiner or liquidator has been
appointed to the Irish Obligor and if the Irish Obligor has been dissolved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <I>Documentary Deliveries</I>. The
Administrative Agent shall have received the following documents, each of which shall be in form and substance satisfactory to the Administrative Agent: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <I>Agreement</I>. This Agreement duly executed and delivered by the Obligors and each of the other parties hereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-56- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) <I>Security Documents</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:18%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A) Except as set forth in Section&nbsp;8.20, the Security Documents, including, without limitation, financing statements,
each in form and substance satisfactory to the Administrative Agent and duly executed and delivered by each of the Obligors and the other parties thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:18%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B) The Collateral Questionnaire, duly executed and delivered by a Responsible Officer of Administrative Borrower,
substantially in the form of Exhibit&nbsp;I hereto and otherwise in form and substance satisfactory to the Administrative Agent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:18%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(C) Without limitation, all other documents and instruments reasonably required to perfect the Administrative Agent&#146;s
Lien on, and security interest in, the Collateral required to be delivered on or prior to the Closing Date shall have been duly executed and delivered and be in proper form for filing, and shall create in favor of the Administrative Agent, a
perfected Lien on, and security interest in, the Collateral, subject to no Liens other than Permitted Liens. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:18%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(D) All
documents required to be delivered to the Administrative Agent pursuant to the Irish Share Charge shall have been duly delivered and a copy of all notices required to be sent pursuant to the Irish Debenture executed by the relevant Obligor to be
duly delivered to the Administrative Agent on or prior to the Closing Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:18%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(E) The Administrative Agent shall have
received written authorization from the Irish Obligor authorizing each solicitor in Matheson LLP or any other legal advisor appointed by the Administrative Agent as to Irish law to sign on behalf of such Irish Obligor all required security related
registration forms and notifications required to be delivered to the Companies Registration Office in Ireland or to the Revenue Commissioners of Ireland or the Property Registration Authority in Ireland in connection with any of the Irish Security
Documents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) <I>Note</I>. Any Notes requested in accordance with Section&nbsp;2.04. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) <I>Approvals</I>. Administrative Borrower shall certify to the Administrative Agent that all Regulatory Approvals have
been made or obtained, and all material licenses, consents, authorizations and approvals of, and notices to and filings and registrations with, any Governmental Authority (including all foreign exchange approvals) in connection with the Transactions
have been made or obtained, and all material <FONT STYLE="white-space:nowrap">third-party</FONT> consents and approvals, necessary in connection with the execution, delivery and performance by the Obligors of the Loan Documents and the Transactions
have been obtained. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-57- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) <I>Organizational Documents</I>. (A)(x)&nbsp;Certified copies of the
Organizational Documents (as amended or restated to the satisfaction of the Administrative Agent, if required by the Administrative Agent in connection with the Liens created pursuant to the Security Documents) of each Obligor and of resolutions of
the Board of each Obligor approving and authorizing the execution, delivery and performance of this Agreement and each of the other Loan Documents to which it is a party, certified as of the Closing Date by the secretary or a Responsible Officer of
such Obligor as being in full force and effect without modification or amendment; (y)&nbsp;a good standing certificate and/or compliance certificate from the applicable Governmental Authority of each Obligor&#146;s jurisdiction of incorporation or
registration (other than in the case of the Irish Obligor) and in each jurisdiction in which it is qualified as a foreign corporation or other entity to do business, each dated a recent date prior to the Closing Date; and (z)&nbsp;such other
documents as the Administrative Agent may reasonably request. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:18%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B) Certified copies of the Organizational Documents of
the general partner of Parent and Parent and of resolutions of the general partner of Parent approving and authorizing the execution, delivery and performance of the Warrant Certificate, certified as of the Closing Date by the secretary or a
Responsible Officer of the general partner of Parent as being in full force and effect without modification or amendment; (y)&nbsp;a good standing certificate and/or compliance certificate from the applicable Governmental Authority of the general
partner of Parent&#146;s jurisdiction of incorporation and Parent&#146;s jurisdiction of registration and in each jurisdiction in which it is qualified as a foreign corporation or other entity to do business, each dated a recent date prior to the
Closing Date; and (z)&nbsp;such other documents as the Administrative Agent may reasonably request. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) <I>Incumbency
Certificate</I>. A certificate of each Obligor as to the authority, incumbency and specimen signatures of the persons who have executed the Loan Documents and any other documents in connection herewith on behalf of the Obligors. A certificate of the
general partner of Parent as to the authority, incumbency and specimen signatures of the persons who have executed the Warrant Certificate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii) <I>Officer&#146;s Certificate</I>. (A)&nbsp;a certificate, in form and substance satisfactory to the Administrative
Agent, dated as of the Closing Date and signed by a Responsible Officer of Administrative Borrower, confirming compliance with the conditions set forth in this Section&nbsp;6.01 and (B)&nbsp;a certificate, in form and substance satisfactory to the
Administrative Agent, dated as of the Closing Date and signed by a Responsible Officer of the Irish Obligor. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-58- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(viii) <I>Opinion of Counsel</I>. A favorable opinion or opinions, dated as
of the Closing Date, of (A)&nbsp;Kirkland and Ellis, LLP, U.S. counsel to the Obligors, (B)&nbsp;Maples and Calder (Cayman) LLP, special Cayman Islands counsel to the Obligors and (C)&nbsp;Matheson LLP, as special Irish counsel to the Administrative
Agent, each in form reasonably acceptable to the Administrative Agent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ix) <I>Evidence of Insurance</I>. Certificates
from each Obligor&#146;s insurance broker or other evidence satisfactory to the Administrative Agent that all insurance required to be maintained pursuant to Section&nbsp;8.05 is in full force and effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x) <I>Warrant Certificate</I>. Perceptive shall have received the executed Warrant Certificate dated as of the Closing Date.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xi) <I>Borrowing Notice</I>. The Administrative Agent shall have received a Borrowing Notice in accordance with
Section&nbsp;2.01(a)(ii) duly executed and delivered by a Responsible Officer of Administrative Borrower, in form and substance satisfactory to the Administrative Agent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <I>Due Diligence.</I> The Administrative Agent shall have received and be satisfied with all due diligence regarding
Parent and the Obligors (including without limitation historical financial statements, Projections, technical, operational, legal, Intellectual Property, commercial market forecasts, clinical and regulatory assessments, supply chain, securities,
labor, Tax, litigation, environmental, reimbursement and regulatory authority matters) in its sole discretion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g)
<I>Indebtedness</I>. As of the Closing Date, after giving effect to the Transactions, the Obligors shall have (A)&nbsp;repaid in full all Existing Indebtedness, (B)&nbsp;terminated any commitments to lend or make other extensions of credit
thereunder, (C)&nbsp;delivered to the Administrative Agent all documents or instruments necessary to release (including updated statutory registers, if applicable) all Liens securing Existing Indebtedness or other obligations of the Obligors
thereunder being repaid on the Closing Date, and (D)&nbsp;made arrangements satisfactory to Administrative Agent with respect to the cancellation of any letters of credit outstanding thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <I>Equity Raise. </I>Parent shall have completed a $50,000,000 equity raise on terms and provisions reasonably
satisfactory to the Administrative Agent and shall have contributed the net proceeds from such equity raise to OpCo. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)
<I>Sponsor Equity Commitment Letter</I>. The Administrative Agent shall have received the Sponsor Equity Commitment Letter which shall be pledged to the Administrative Agent as Collateral for the benefit of itself and on behalf of the Lenders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) <I>Closing Fees, Expenses, Etc.</I> The Lenders and their Affiliates shall have received for their own account, the
Closing Fee and all fees, costs and expenses due (including applicable attorney costs and the reasonable and documented <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> fees and expenses of any other
advisors to the Lenders) and payable pursuant to Section&nbsp;13.03, after deducting therefrom the Expense Deposit. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-59- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) <I>Representations and Warranties</I>. The representations and
warranties of the Obligors contained in Article&nbsp;7 or any other Loan Document shall be true and correct in all material respects on and as of the Closing Date; <I>provided</I> that to the extent that such representations and warranties
specifically refer to an earlier date, they shall be true and correct in all material respects as of such earlier date; <I>provided, further,</I> that any representation and warranty that is qualified as to &#147;materiality&#148;, &#147;Material
Adverse Effect&#148; or similar language shall be true and correct (after giving effect to any qualification therein) in all respects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) <I>No Default</I>. No Default shall exist, or would result from such proposed Borrowing or from the application of the
proceeds therefrom. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) <I>Miscellaneous</I>. Such other opinions, instruments, certificates and documents as the
Administrative Agent or any Lender shall have reasonably requested with prior notice to Administrative Borrower. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;6.02.</I> <I>Conditions to Tranche</I><I></I><I>&nbsp;B Term Loan; Tranche</I><I></I><I>&nbsp;B Term Loan
Borrowing Date.</I> The obligation of each Lender to make the Tranche&nbsp;B Term Loan on the Tranche&nbsp;B Term Loan Borrowing Date shall not become effective until the following conditions precedent shall have been reasonably satisfied or waived
in writing by the Administrative Agent (which satisfaction or waiver may be made simultaneously with the making of the Tranche&nbsp;B Term Loan hereunder): </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Tranche</I><I></I><I>&nbsp;B Loan Commitment Termination Date</I>. The Tranche&nbsp;B Term Loan Commitment Termination
Date shall not have occurred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Borrowing Notice</I>. The Administrative Agent shall have received a Borrowing
Notice in accordance with Section&nbsp;2.01(b)(ii) duly executed and delivered by a Responsible Officer of Administrative Borrower. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Representations and Warranties</I>. The representations and warranties of the Obligors contained in Article&nbsp;7 or
any other Loan Document shall be true and correct in all material respects on and as of the Tranche&nbsp;B Term Loan Borrowing Date; <I>provided</I> that to the extent that such representations and warranties specifically refer to an earlier date,
they shall be true and correct in all material respects as of such earlier date; <I>provided, further,</I> that any representation and warranty that is qualified as to &#147;materiality&#148;, &#147;Material Adverse Effect&#148; or similar language
shall be true and correct (after giving effect to any qualification therein) in all respects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>No Default</I>. No
Default or Event of Default shall exist, or would result from such proposed Borrowing or from the application of the proceeds therefrom. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <I>Milestone</I>. The Administrative Agent shall have received evidence satisfactory to the Administrative Agent that
Intermediate Holdings and its Subsidiaries have achieved Net Revenue of at least $50,000,000 for any twelve (12)&nbsp;consecutive month period prior to the Tranche&nbsp;B Term Loan Borrowing Date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-60- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <I>Expenses, Etc.</I> The Lenders and their Affiliates shall have
received for their own account, all fees, costs and expenses due (including applicable attorney costs and the reasonable and documented <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> fees and expenses
of any other advisors to the Lenders) and payable pursuant to Section&nbsp;13.03. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;6.03.</I> <I>Conditions
to Tranche</I><I></I><I>&nbsp;C Term Loan; Tranche</I><I></I><I>&nbsp;C Term Loan Borrowing Date.</I> The obligation of each Lender to make the Tranche&nbsp;C Term Loan on the Tranche&nbsp;C Term Loan Borrowing Date shall not become effective until
the following conditions precedent shall have been reasonably satisfied or waived in writing by the Administrative Agent (which satisfaction or waiver may be made simultaneously with the making of the Tranche&nbsp;C Term Loan hereunder): </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Qualified Public Offering</I>. A Qualified Public Offering shall have occurred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Tranche</I><I></I><I>&nbsp;C Term Loan Commitment Termination Date</I>. The Tranche&nbsp;C Term Loan Commitment
Termination Date shall not have occurred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Borrowing Notice</I>. The Administrative Agent shall have received a
Borrowing Notice in accordance with Section&nbsp;2.01(c)(ii) duly executed and delivered by a Responsible Officer of Administrative Borrower. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>Representations and Warranties</I>. The representations and warranties of the Obligors contained in Article&nbsp;7 or
any other Loan Document shall be true and correct in all material respects on and as of the Tranche&nbsp;C Term Loan Borrowing Date; <I>provided</I> that to the extent that such representations and warranties specifically refer to an earlier date,
they shall be true and correct in all material respects as of such earlier date; <I>provided, further,</I> that any representation and warranty that is qualified as to &#147;materiality&#148;, &#147;Material Adverse Effect&#148; or similar language
shall be true and correct (after giving effect to any qualification therein) in all respects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <I>No Default</I>. No
Default or Event of Default shall exist, or would result from such proposed Borrowing or from the application of the proceeds therefrom. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <I>Milestones</I>. The Administrative Agent shall have received evidence satisfactory to the Administrative Agent that
Intermediate Holdings and its Subsidiaries have achieved Net Revenue of at least $60,000,000 for any twelve (12)&nbsp;consecutive month period prior to the Tranche&nbsp;C Term Loan Borrowing Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <I>Expenses, Etc.</I> The Lenders and their Affiliates shall have received for their own account, all fees, costs and
expenses due (including applicable attorney costs and the reasonable and documented <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> fees and expenses of any other advisors to the Lenders) and payable
pursuant to Section&nbsp;13.03. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The borrowing of the Term Loans shall constitute a certification by Borrowers to the effect that the conditions set forth
in Sections&nbsp;6.01, 6.02 and 6.03 as applicable, have been fulfilled as of the Closing Date, the Tranche&nbsp;B Term Loan Borrowing Date, or the Tranche&nbsp;C Term Loan Borrowing Date, as applicable. For the avoidance of doubt, the
Tranche&nbsp;C Term Loans shall be available and may be borrowed (subject to the conditions in Section&nbsp;6.03) regardless of whether or not the Tranche&nbsp;B Term Loan Borrowing Date shall have occurred. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-61- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>RTICLE</SMALL>&nbsp;7. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>R<SMALL>EPRESENTATIONS</SMALL> <SMALL>AND</SMALL> W<SMALL>ARRANTIES</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">In order to induce the Lenders to enter into this Agreement and to extend the Term Loans hereunder, each Obligor represents and warrants to
the Administrative Agent and the Lenders, on the Closing Date and on each of the Tranche B Term Loan Borrowing Date and the Tranche C Term Loan Borrowing Date, that the following statements are true and correct: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;7.01.</I> <I>Power and Authority</I><I>.</I> Each Obligor and its Subsidiaries (a)&nbsp;is duly organized,
incorporated, validly existing and in good standing (to the extent such concept is applicable in its jurisdiction of organization or incorporation) under the Laws of its jurisdiction of organization or incorporation, as applicable, (b)&nbsp;has all
requisite corporate (or equivalent) power, and has all material governmental licenses, authorizations, consents and approvals necessary to own its assets and carry on its business as now being or as proposed to be conducted except to the extent that
failure to have the same would not reasonably be expected to have a Material Adverse Effect, (c)&nbsp;is qualified to do business and is in good standing in all jurisdictions in which the nature of the business conducted by it makes such
qualification necessary except where failure to so qualify would not (either individually or in the aggregate) reasonably be expected to have a Material Adverse Effect, and (d)&nbsp;has full power, authority and legal right to make and perform each
of the Loan Documents to which it is a party and, in the case of Borrowers, to borrow the Term Loans hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;7.02.</I> <I>Authorization; Enforceability</I><I>.</I> The Transactions are within each Obligor&#146;s corporate
(or equivalent) powers and have been duly authorized by all necessary corporate (or equivalent) action and, if required, by all necessary shareholder or other equity holder action. The Loan Documents have been duly executed and delivered by each
Obligor party thereto and constitutes, and each of the other Loan Documents to which it is a party when executed and delivered by such Obligor will constitute, a legal, valid and binding obligation of such Obligor, enforceable against such Obligor
in accordance with its terms, except as such enforceability may be limited by (a)&nbsp;bankruptcy, insolvency, reorganization, moratorium or similar Laws of general applicability affecting the enforcement of creditors&#146; rights and (b)&nbsp;the
application of general principles of equity (regardless of whether such enforceability is considered in a proceeding in equity or at law). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;7.03.</I> <I>Governmental and Other Approvals; No Conflicts</I><I>.</I> The Transactions (a)&nbsp;do not require
any consent or approval of, registration or filing with, or any other action by, any Governmental Authority or any other Person, except for (i)&nbsp;such as have been obtained or made and are in full force and effect and (ii)&nbsp;filings and
recordings in respect of perfecting or recording the Liens created pursuant to the Security Documents, (b)&nbsp;will not violate any Requirement of Law or the Organizational Documents of any Obligor or any order of any Governmental Authority, other
than any such violations that, individually or in the aggregate, would not reasonably be expected to have a Material Adverse Effect, (c)&nbsp;will not violate or result in a default under any Material Agreement, or give rise to a right thereunder to
require any payment to be made by any such Person, and (d)&nbsp;will not result in the creation or imposition of any Lien (other than Permitted Liens) on any asset of any Obligor or any of its Subsidiaries. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-62- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;7.04.</I> <I>Financial Statements; Projections; Material
Adverse Change</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <I>Financial Statements</I>. Borrowers have heretofore furnished to the Administrative Agent certain financial
statements as provided for in Section&nbsp;8.01. Such financial statements present fairly, in all material respects, the financial position and results of operations and cash flows of the Obligors as of such dates and for such periods substantially
in accordance with GAAP, subject to quarterly or <FONT STYLE="white-space:nowrap">year-end</FONT> adjustments and the absence of footnotes. No Obligor has any material contingent liabilities or liabilities for taxes,
<FONT STYLE="white-space:nowrap">long-term</FONT> lease or unusual forward or <FONT STYLE="white-space:nowrap">long-term</FONT> commitments not disclosed in the aforementioned financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <I>Projections</I>. On and as of the Closing Date, the projections of the Obligors (collectively, the <I>&#147;Projections&#148;</I>) are
based on good faith estimates and assumptions made by the management of the Obligors; <I>provided,</I> the Projections are not to be viewed as facts and that actual results during the period or periods covered by the Projections may differ from such
Projections and that the differences may be material; <I>provided, further,</I> as of the Closing Date, the management of the Obligors believe that the Projections are reasonable and attainable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <I>No Material Adverse Change</I>. Since December&nbsp;31, 2022, no event, circumstance or change has occurred that has caused or
evidences, either in individually or in the aggregate, a Material Adverse Change. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;7.05.</I>
<I>Properties</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <I>Property Generally</I>. Each Obligor has good and marketable fee simple title to, or valid leasehold interests
in, all its real and personal Property material to its business, including all Product Assets, subject only to Permitted Liens and except as would not reasonably be expected to interfere with its ability to conduct its business as currently
conducted or to utilize such properties for their intended purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <I>Intellectual Property</I>.
(i)&nbsp;Schedule&nbsp;7.05(b)&nbsp;(A) lists, with respect to each Obligor, all United States and foreign registrations of and applications for Patents, Trademarks, Copyrights, and industrial designs that are Obligor Intellectual Property,
including the applicable jurisdiction, registration or application number and date, as applicable thereto and (B)&nbsp;identifies which Obligor Intellectual Property is Material Intellectual Property on the Closing Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) Each Obligor owns or possesses all legal and beneficial rights, title and interest in and to its Material Intellectual Property with good
and marketable title, free and clear of any Liens or Claims of any kind, other than Permitted Liens. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) To each Obligor&#146;s
knowledge, the Material Intellectual Property does not violate any license or infringe any valid and enforceable Intellectual Property right of another. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-63- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv) Other than with respect to the Material Agreements, or as permitted by this Agreement,
the Obligors have not assigned or otherwise transferred ownership of, or agreed to assign or otherwise transfer ownership of, any Material Intellectual Property, in whole or in part, to any Person who is not an Obligor, in each case, other than
Permitted Liens. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(v) Other than as set forth on Schedule&nbsp;7.05(b), the Obligors have not received any written communications, nor is
there any pending or, to each Obligor&#146;s knowledge, threatened action in writing, suit, proceeding or Claim in writing by another, alleging that any of the Obligors has violated, infringed, diluted or misappropriated any Intellectual Property of
another in a manner that would be material to the operation of the business of such Obligor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(vi) There is no pending or, to any
Obligor&#146;s knowledge, threatened action in writing, suit, proceeding or Claim in writing by another: (A)&nbsp;challenging an Obligor&#146;s rights in or to any Material Intellectual Property owned by such Obligor; or (B)&nbsp;challenging the
validity, enforceability or scope of any Material Intellectual Property. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(vii) To each Obligor&#146;s knowledge, the Patents within
Material Intellectual Property have not ever been finally adjudicated to be invalid, unpatentable or unenforceable for any reason in any administrative, arbitration, judicial or other proceeding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(viii) To each Obligor&#146;s knowledge, no Obligor has received any written notice asserting that the issued Patents within the Material
Intellectual Property are invalid, unpatentable or unenforceable and, to each Obligor&#146;s knowledge, no Obligor has engaged in any conduct, or omitted to perform any necessary act, the result of which would invalidate or render unpatentable or
unenforceable any such Patent within the Material Intellectual Property. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ix) To the knowledge of each Obligor, no third party is
infringing upon or misappropriating, or violating any Material Intellectual Property in a manner that would be material to an Obligor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(x) Each Obligor has taken commercially reasonable precautions to protect the Material Intellectual Property (including without limitation, by
requiring that all current and former employees, contractors and consultants of the Obligors that have developed Material Intellectual Property execute written confidentiality and Invention assignment Contracts). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xi) Each Obligor has complied with the terms of each Material Agreement pursuant to which Intellectual Property has been licensed to the
Obligors, except as would not reasonably be expected to result in a Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xii) All maintenance fees, annuities, and
the like due or payable on the Patents within the Material Intellectual Property have been timely paid or the failure to so pay was the result of an intentional decision by the applicable Obligor, which would not reasonably be expected to result in
a Material Adverse Change. All documents and instruments necessary to register or apply for or renew registration of all Patents, Trademarks and Copyrights within the Material Intellectual Property have been validly executed, delivered and filed in
a timely manner with the United States Patent and Trademark Office or the United States Copyright Office, as applicable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-64- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;7.06.</I> <I>No Actions or Proceedings</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <I>Litigation</I>. There is no litigation, investigation or enforcement proceeding pending or, threatened in writing with respect to any
Obligor by or before any Governmental Authority or arbitrator&nbsp;that either individually or in the aggregate would reasonably be expected to have a Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <I>Environmental Matters</I>. The operations and the real Property of the Obligors comply with all applicable Environmental Laws, except
to the extent the failure to so comply, either individually or in the aggregate, would not reasonably be expected to have a Material Adverse Effect. To each Obligor&#146;s knowledge, there have been no conditions, occurrences or release of Hazardous
Materials which would reasonably be expected to have a Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <I>Labor Matters</I>. No Obligor has engaged in
unfair labor practices and there are no pending or, to any Obligor&#146;s knowledge, threatened in writing labor actions, disputes, grievance or arbitration proceedings involving the employees of any Obligor, in each case that would reasonably be
expected to have a Material Adverse Effect. There is no material strike or work stoppage in existence or threatened in writing against any Obligor and to the knowledge of such Obligor, no union organization activity is taking place. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;7.07.</I> <I>Compliance with Laws and Agreements</I>. (a)&nbsp;Each Obligor is in compliance with all
Requirements of Law (including Health Care Laws and Environmental Laws) and all Contracts binding upon it or its Property, except where the failure to do so, individually or in the aggregate, would not reasonably be expected to result in a Material
Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Without limiting the generality of the foregoing: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) To the best of each Obligor&#146;s knowledge, any financial relationships between or among any Obligor, on the one hand,
and any Person who is in a position to refer patients or other business to an Obligor (collectively a <I>&#147;Referral Source&#148;</I>), on the other hand, (A)&nbsp;comply in all material respects with all applicable Health Care Laws;
(B)&nbsp;reflect fair market value, have commercially reasonable terms and were negotiated at arm&#146;s length; and (C)&nbsp;do not obligate the Referral Source to purchase, use, recommend or arrange for the use of any products or services of an
Obligor. No Obligor, directly or indirectly, has guaranteed a loan, made a payment toward a loan or otherwise subsidized a loan for any Referral Source including, without limitation, any loans related to financing the Referral Source&#146;s
ownership, investment or financial interest in any Obligor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) All Products have been developed, tested, manufactured,
distributed, marketed and sold in compliance in all material respects with all applicable FDA&nbsp;Laws, including, without limitation, good manufacturing practices/quality system regulations (21&nbsp;CFR Part&nbsp;820), labeling, advertising, <FONT
STYLE="white-space:nowrap">record-keeping,</FONT> and adverse event reporting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) Each Obligor is in compliance in all
material respects with the Physician Payments Sunshine Act (Section&nbsp;6002 of the Affordable Care Act of 2010) and its implementing regulations and any applicable state disclosure and transparency laws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-65- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Each Obligor holds all Third-Party Payor Authorizations in full force and effect that
are necessary to participate in and be reimbursed by all Third-Party Payor Programs in which it participates, if any. To the knowledge of any Obligor, there is no investigation, audit, claim review, or other action pending or threatened in writing,
which could result in a suspension, revocation, termination, restriction, limitation, modification or nonrenewal of any Third-Party Payor Authorization or in the exclusion of an Obligor from participation in any Third-Party Payor Program, except to
the extent that such investigation, audit, claim review or other action, or such suspension, revocation, termination, restriction, limitation, modification or nonrenewal, individually or in the aggregate, could not reasonably be expected to result
in a Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) No Obligor, nor any owner, officer, director, partner, agent or managing employee or Person with a
&#147;direct or indirect ownership interest&#148; (as that phrase is defined in 42 C.F.R. &#167; 420.201) in any Obligor has been (i)&nbsp;excluded from any Federal Health Care Program, (ii) &#147;suspended&#148; or &#147;debarred&#148; from selling
products to the U.S. government or its agencies pursuant to the Federal Acquisition Regulation, relating to debarment and suspension applicable to federal government agencies generally (42 C.F.R. Subpart 9.4), (iii) debarred, disqualified, suspended
or excluded from participation in any Third-Party Payor Program or is listed on the General Services Administration list of excluded parties, nor, to the knowledge of the Obligors, is any such debarment, disqualification, suspension or exclusion
threatened or pending, or (iv)&nbsp;made a party to any other action by any Governmental Authority that may prohibit it from selling products or providing services to any governmental or other purchaser pursuant to any federal, state or local laws
or regulations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) No Obligor is subject to any pending audit, claim review, investigation, proceeding, or other action (in each case,
whether civil, criminal, administrative or investigative) relating to any actual or alleged noncompliance with any applicable Health Care Law, which could result in, the repayment of any material monies received, or the imposition of any material
penalties, from any Third-Party Payor Program or Governmental Authority. No Obligor, nor any owner, officer, director, partner, agent or managing employee of any Obligor is a party to or bound by any individual integrity agreement, corporate
integrity agreement, corporate compliance agreement, deferred prosecution agreement, or other formal or informal agreement with any Governmental Authority concerning compliance with any Requirements of Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Each Obligor is in compliance in all material respects with HIPAA and state health information privacy and security laws except to the
extent that any noncompliance, individually or in the aggregate, could not reasonably be expected to have a Material Adverse Effect. In each contractual arrangement that is subject to HIPAA, each Obligor has: (i)&nbsp;entered into a written business
associate agreement (as such term is defined under the HIPAA regulations) that substantially meets the requirements of HIPAA; (ii)&nbsp;at all times complied with such business associate agreements in respect of the HIPAA privacy or security
standards; and (iii)&nbsp;at no time experienced or had an unauthorized use or disclosure of Protected Health Information (as defined in the HIPAA regulations) or privacy or security breach or other privacy or security incident within the meaning of
HIPAA that has affected more than five hundred (500)&nbsp;individuals, except to the extent failure to comply with clauses (i)&nbsp;or (ii) could not be reasonably excepted to have a Material Adverse Effect. Each Obligor has created and maintains
written policies and procedures to protect the privacy of all patient protected health information in accordance with HIPAA and applicable state health information privacy and security laws, and has implemented appropriate security procedures
including, without limitation, administrative, physical and technical safeguards, to protect the confidentiality, integrity and availability of all electronic protected health information that it creates, receives, maintains or transmits. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-66- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) Each Obligor will maintain and adhere to, in all material respects, a reasonable
compliance program designed to promote compliance with and to detect, prevent and address violations of all material Health Care Laws (a <I>&#147;Health Care Compliance Program&#148;</I>). No Obligor is aware of any complaints from any employees,
independent contractors, vendors, physicians, customers, patients or other persons that could reasonably be considered to indicate a violation of Health Care Laws which would be reasonably expected to result individually or in the aggregate in a
Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;7.08.</I> <I>Taxes</I><I>.</I> Each Obligor has timely filed or caused to be filed
all federal income and other material Tax returns and reports required to have been filed and has paid or caused to be paid all federal income and other material Taxes required to have been paid by it, except Taxes that are being contested in good
faith by appropriate proceedings and for which such Obligor has set aside on its books adequate reserves with respect thereto substantially in accordance with GAAP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;7.09.</I> <I>Full Disclosure</I><I>.</I> The Obligors have disclosed to the Lenders all Material Agreements to
which any Obligor is party, and all other matters to its knowledge, that, individually or in the aggregate, would reasonably be expected to result in a Material Adverse Effect. None of the reports, financial statements, certificates or other
information furnished by or on behalf of the Obligors to the Lenders in connection with the negotiation of this Agreement and the other Loan Documents or delivered hereunder or thereunder (as modified or supplemented by other information so
furnished) (other than information of a general economic or industry specific nature) contains any material misstatement of material fact or omits to state any material fact necessary to make the statements therein, in the light of the circumstances
under which they were made, not misleading; <I>provided</I> that, with respect to projected financial information, the Obligors represent only that such information was prepared in good faith based upon assumptions believed to be reasonable at the
time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;7.10.</I> <I>Regulation</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <I>Investment Company Act</I>. No Obligor is an &#147;investment company&#148; as defined in, or subject to regulation under, the
Investment Company Act of 1940 or the Companies Act 2014 of Ireland (as amended) respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <I>Margin Stock</I>. No Obligor is
engaged principally, or as one of its important activities, in the business of extending credit for the purpose, whether immediate, incidental or ultimate, of buying or carrying Margin Stock, and no part of the proceeds of the Term Loans will be
used to buy or carry any Margin Stock in violation of Regulation&nbsp;T, U or X. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-67- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;7.11.</I> <I>Solvency</I><I>.</I> The Obligors, on a
consolidated basis, are and, immediately after giving effect to the Borrowings, the use of proceeds thereof, and the consummation of the Transactions, will be, Solvent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;7.12.</I> <I>[Reserved]</I><I>.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;7.13.</I> <I>Indebtedness and Liens</I><I>.</I> Set forth on Schedule&nbsp;7.13A is a complete and correct list
of all Permitted Indebtedness of each Obligor described in Section&nbsp;9.01(b) as of the date hereof. Set forth on Schedule&nbsp;7.13B is a complete and correct list of all Permitted Liens described in Section&nbsp;9.02(b) granted by an Obligor
with respect to its respective Property and outstanding as of the date hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;7.14.</I> <I>Material
Agreements</I><I>.</I> Set forth on Schedule&nbsp;7.14 (as such Schedule may be updated by Borrowers from time to time) is a complete and correct list of (a)&nbsp;each Material Agreement and (b)&nbsp;each Contract creating or evidencing any Material
Indebtedness, together with a summary reference to the product or purpose of each such Material Agreement and such Contract, to which an Obligor is a party. Accurate and complete copies of each such Contract listed on such schedule has been made
available to the Lenders. Except as disclosed to the Administrative Agent in writing, no Obligor is in default in any material respect under any such Material Agreement or such Contract creating or evidencing any Material Indebtedness listed on such
schedule, and no Obligor has knowledge of any default in any material respect by any counterparty to such Material Agreement or such Contract. Except as otherwise disclosed on Schedule&nbsp;7.14 (as such Schedule may be updated by Borrowers from
time to time), all material vendor purchase agreements and provider Contracts of the Obligors, and all Material Agreements including a grant of rights under any Intellectual Property to an Obligor, are in full force and effect without material
modification from the form in which the same were disclosed to the Lenders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;7.15.</I> <I>Restrictive
Agreements</I><I>.</I> None of the Obligors is party to any Restrictive Agreement, except (a)&nbsp;those listed on Schedule&nbsp;7.15 or otherwise permitted under Section&nbsp;9.11, (b)&nbsp;restrictions and conditions imposed by Law or by the Loan
Documents and (c)&nbsp;limitations associated with Permitted Liens. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;7.16.</I> <I>Real Property</I><I>.</I>
No Obligor or any of its Subsidiaries owns or leases (as tenant thereof) any real Property on the Closing Date, except as described on Schedule&nbsp;7.16. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;7.17.</I> <I>Pension and Other Plans</I>. Except as would not have a Material Adverse Effect, each Benefit Plan,
and each trust thereunder, intended to qualify for Tax exempt status under Section&nbsp;401 or 501 of the Code or other Requirements of Law so qualifies. Except for those that would not, in the aggregate, have a Material Adverse Effect,
(a)&nbsp;each Benefit Plan is in compliance with applicable provisions of ERISA, the Code and other Requirements of Law, (b)&nbsp;there are no existing or pending (or to the knowledge of any Obligor threatened) Claims (other than routine Claims for
benefits in the normal course), sanctions, actions, lawsuits or other proceedings or investigation involving any Benefit Plan to which any Obligor has an obligation or any liability or Claim and (c)&nbsp;no ERISA Event is reasonably expected to
occur. Except as would not have a Material Adverse Effect: (i)&nbsp;each Borrower and each of their ERISA Affiliates has met all applicable requirements under the ERISA Funding Rules with respect to each Title&nbsp;IV Plan,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-68- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and no waiver of the minimum funding standards under the ERISA Funding Rules has been applied for or obtained;(ii) as of the most recent valuation date for any Title&nbsp;IV Plan, the funding
target attainment percentage (as defined in Section&nbsp;430(d)(2) of the Code) is at least 60%, and neither a Borrower nor any of their ERISA Affiliates knows of any facts or circumstances that would reasonably be expected to cause the funding
target attainment percentage to fall below 60% as of the most recent valuation date; and (iii)&nbsp;as of the date hereof, no ERISA Event has occurred in connection with which obligations and liabilities (contingent or otherwise) remain outstanding.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;7.18.</I> <I>Collateral; Security Interest</I><I>.</I> Each Security Document is effective to create in
favor of the Administrative Agent for the benefit of the Lenders a legal, valid and enforceable security interest in the Collateral subject thereto and each such security interest is perfected to the extent required by (and has the priority required
by) the applicable Security Document, subject to Permitted Liens. The Security Documents collectively are effective to create in favor of the Administrative Agent for the benefit of the Lenders a legal, valid and enforceable security interest in the
Collateral, which (if applicable) upon the filing of financing statements and other similar statements filed in the appropriate offices, such security interests are perfected security interests (subject only to Permitted Liens) to the extent that
such perfection may be obtained by such filing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;7.19.</I> <I>Regulatory Approvals</I>. (a)&nbsp;With
respect to the Products, each Obligor and each of its Subsidiaries holds either directly or through licensees and agents, all Regulatory Approvals and Permits necessary or required for each Obligor and its Subsidiaries to conduct all Product
Development and Commercialization Activities with respect to the Products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Set forth on Schedule&nbsp;7.19(b) is a complete and
accurate list as of the date hereof of all Regulatory Approvals referred to in clause&nbsp;(a) above, setting forth (on a per Product basis) the Obligor that holds such Regulatory Approval and identifying the Product related to such Regulatory
Approval. All such Regulatory Approvals are (i)&nbsp;legally and beneficially owned exclusively by the Obligor identified on the Schedule, free and clear of all Liens other than Permitted Liens, (ii)&nbsp;validly registered and on file with the
applicable Regulatory Authority, in material compliance with all registration, filing and maintenance requirements (including any fee requirements) thereof, and (iii)&nbsp;in good standing, valid and enforceable with the applicable Regulatory
Authority. All required and material notices, registrations and listings, supplemental applications or notifications, reports (including annual reports, field alerts, Device reports or other reports of adverse experiences) and all other required and
material filings with respect to the Products or any related Product Development and Commercialization Activities have been filed with the FDA and all other applicable Governmental Authorities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) (i)&nbsp;All material regulatory filings required by any Regulatory Authority or in respect of any Product Authorization or other
Regulatory Approval with respect to any Product or any Product Development and Commercialization Activities have been made, and all such filings are complete and correct in all material respects and have complied in all material respects with all
applicable Requirements of Law, (ii)&nbsp;all clinical and <FONT STYLE="white-space:nowrap">pre-clinical</FONT> trials, if any, of investigational Products have been and are being conducted by each Obligor according to all applicable Requirements of
Law in all material respects along with appropriate monitoring of clinical investigator trial sites for their compliance, and (iii)&nbsp;each Obligor has disclosed to the Lenders all such material regulatory filings and all material communications
between representatives of each Obligor and any Regulatory Authority. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-69- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Each Obligor and, to each Obligor&#146;s knowledge, each of its agents are in compliance
in all material respects with all applicable statutes, rules and regulations (including all Product Authorizations and other Regulatory Approvals) of all applicable Governmental Authorities, including the FDA and all other Regulatory Authorities,
with respect to each Product and all Product Development and Commercialization Activities related thereto. Each Obligor has and maintains in full force and effect all the necessary and requisite Product Authorizations and other Regulatory Approvals.
Each Obligor is in compliance in all material respects with all applicable registration and listing requirements set forth in all applicable FDA&nbsp;Laws or equivalent regulation of each other Governmental Authority having jurisdiction over such
Person. Each Obligor adheres in all material respects to all applicable regulations of all Regulatory Authorities with respect to the Products and all Product Development and Commercialization Activities related thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Except as set forth on Schedule&nbsp;7.19(e), (i)&nbsp;no Obligor has received from any Regulatory Authority any notice of adverse
findings with respect to any Product or any Product Development and Commercialization Activities related thereto, including any FDA Form&nbsp;483 inspectional observations, notices of violations, warning letters, criminal proceeding notices under
Section&nbsp;305 of the FD&amp;C&nbsp;Act, or any other similar communication from any Regulatory Authority, (ii)&nbsp;there have been no seizures conducted or, to each Obligor&#146;s knowledge, threatened by any Regulatory Authority with respect to
any Product, and no recalls, market withdrawals, field notifications, notifications of misbranding or adulteration or safety alerts conducted, requested or, to each Obligor&#146;s knowledge, threatened by any Regulatory Authority with respect to any
Product, and no recalls, market withdrawals, field notifications, notifications of misbranding or adulteration or safety alerts have been conducted, requested or, to each Obligor&#146;s knowledge, threatened by any Regulatory Authority relating to
any Products and (iii)&nbsp;no Obligor has received any written notification that remains unresolved from the FDA or any other Regulatory Authority indicating any breach or violation of any applicable Product Authorization or other Regulatory
Approval, including that any of the Products are misbranded or adulterated as defined in the FD&amp;C&nbsp;Act or the rules and regulations promulgated thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Neither any Obligor nor, to any Obligor&#146;s knowledge, any officer, employee or agent thereof, has made an untrue statement of a
material fact or fraudulent statements to the FDA or any other Regulatory Authority, failed to disclose a material fact required to be disclosed to the FDA or any other Regulatory Authority, or committed an act, made a statement, or failed to make a
statement that, at the time such disclosure was made (or was not made), would reasonably be expected to provide a basis for the FDA or any other Regulatory Authority to invoke its policy respecting Fraud, Untrue Statements of Material Facts, Bribery
and Illegal Gratuities, set forth in 56&nbsp;Fed. Reg.&nbsp;46191 (September&nbsp;10, 1991) or any similar policy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) No Obligor has
received any written notice that the FDA or any other applicable Regulatory Authority has commenced or initiated, or, to the knowledge of any such Obligor, threatened to commence or initiate, any action to withdraw any Product Authorization and
other Regulatory Approval or requested the recall of any Products or commenced or initiated or, to the knowledge of such Obligor, threatened to commence or initiate, any action to enjoin any Product Development and Commercialization Activities of
such Obligor. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-70- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) The clinical, preclinical, safety and other studies and tests conducted by or on behalf
of or sponsored by each Obligor, or in respect of which any Products or Product candidates under development have participated, were (and if still pending, are) being conducted materially in accordance with reasonable medical and scientific research
procedures and all applicable Product Authorizations. Each Obligor has operated within, and currently is in compliance in all material respects with, all applicable Laws, Product Authorizations and other Regulatory Approvals, as well as the rules
and regulations of the FDA and each other Regulatory Authority. No Obligor has received any notices or other correspondence from the FDA or any other Regulatory Authority requiring the termination or suspension of any clinical, preclinical, safety
or other studies or tests used to support regulatory clearance of, or any Product Authorization or other Regulatory Approval for, any Product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) No material debarment or exclusionary Claims, actions, proceedings or investigations in respect of any Obligor&#146;s business is pending,
or to such Obligor&#146;s knowledge, threatened in writing against such Obligor or its officers, employees or agents. No Obligor or, to such Obligor&#146;s knowledge, any officer, employee or agent of such Obligor, has been convicted of any crime or
engaged in any conduct that would reasonably be expected to result in a debarment or exclusion under (i)&nbsp;Section&nbsp;335a of the FD&amp;C&nbsp;Act or (ii)&nbsp;any similar applicable Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;7.20.</I> <I>Capitalization</I><I>.</I> All of the issued and outstanding securities of each Obligor have been
duly authorized, are validly issued, fully paid, and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> There are no: (a)&nbsp;outstanding or authorized options, warrants, purchase rights, subscription rights, conversion rights, exchange
rights, or other contracts or commitments that could require the Obligors to issue, sell, or otherwise cause to become outstanding any of their ownership interests; (b)&nbsp;outstanding or authorized stock appreciation, phantom stock, profit
participation, or similar rights with respect to the Obligors; and (c)&nbsp;voting trusts, proxies, or other agreements or understandings with respect to the voting of the ownership interests of the Obligors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;7.21.</I> <I>Insurance</I><I>.</I> Each Obligor has obtained (and is maintaining), insurance for its assets
(including the Collateral) and business as required under the Loan Documents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;7.22.</I> <I>Certain
Fees</I><I>.</I> Except as described on Schedule&nbsp;7.22, no broker&#146;s or finder&#146;s fee will be payable in connection with the execution and delivery of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;7.23.</I> <I>Sanctions Laws</I><I>.</I> Obligors and, to the knowledge of the Obligors, any director, officer or
employee of an Obligor acting on behalf of the Obligors, are in compliance with the Sanctions Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;7.24.</I> <I>Anti</I><I><FONT STYLE="white-space:nowrap">-Corruption</FONT> Laws</I><I>.</I> No Obligor nor any
of its Subsidiaries, nor, to the knowledge of any Responsible Officer of any Obligor, any director, officer, agent or employee of any Obligor acting on behalf of such Obligor has in the past five (5)&nbsp;years (a)&nbsp;taken any action, directly or
indirectly, that would result in a violation by such Persons of the <FONT STYLE="white-space:nowrap">Anti-Corruption</FONT> Laws or Irish Anti-Corruption Laws, (b)&nbsp;made, offered to make, promised to make or authorized the payment or giving of,
directly or indirectly, any Prohibited Payment or (c)&nbsp;been subject to any investigation by any Governmental Authority with regard to any actual or alleged Prohibited Payment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-71- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;7.25.</I>
<I>Anti</I><I><FONT STYLE="white-space:nowrap">-Terrorism</FONT> Laws</I><I>.</I> The Obligors (a)&nbsp;have taken reasonable measures to ensure compliance with applicable Sanctions Laws, Economic Sanctions Laws and
<FONT STYLE="white-space:nowrap">Anti-Terrorism</FONT> Laws and Irish Anti-Terrorism Laws, (b)&nbsp;are not Designated Persons and (c)&nbsp;have not in the past five (5)&nbsp;years used any part of the proceeds from any advance on behalf of any
Designated Person or used, directly by it or indirectly through any Subsidiary, such proceeds in connection with any investment in, or any transactions or dealings with, any Designated Person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;7.26.</I> <I>Royalty and Other Payments</I>. Except as set forth on Schedule&nbsp;7.26, no Obligor, nor any of
its Subsidiaries, is obligated to pay any royalty, milestone payment, deferred payment or any other contingent payment in respect of any Product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;7.27.</I> <I>Irish Representations</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) No Obligor (other than the Irish Obligor) is a relevant external company as that term is defined in section 1301 of the Companies Act 2014
of Ireland (as amended). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Irish Obligor, to the extent applicable, has done all that is necessary to comply with section 82 of the
Companies Act 2014 of Ireland (as amended) in order to enable it to enter into the Loan Documents to which it is a party and perform its obligations under such Loan Documents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The Irish Obligor, together with each other Obligor whose obligations are guaranteed by it or the subject of security granted by it under
the Loan Documents, together comprise a &#147;group&#148; for the purposes of section 243 of the Companies Act 2014 of Ireland (as amended). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>RTICLE</SMALL>&nbsp;8. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>FFIRMATIVE</SMALL> C<SMALL>OVENANTS</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Each Obligor covenants and agrees with the Lenders that, until the Commitments have expired or been terminated and all Obligations (other than
inchoate indemnity obligations) have been paid in full in cash: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;8.01.</I> <I>Financial Statements and Other
Information</I><I>.</I> It will furnish to the Administrative Agent for distribution to the Lenders: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) as soon as
available and in any event within thirty (30)&nbsp;days after the end of each month (other than the last month of each fiscal quarter) prior to a Qualified Public Offering, the consolidated balance sheets of Intermediate Holdings and its
Subsidiaries as of the end of each such month, and the related consolidated statements of income and cash flows of Intermediate Holdings and its Subsidiaries for such month and the portion of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-72- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">
fiscal year through the end of such month, all in reasonable detail and setting forth in comparative form the figures for the corresponding period in the preceding fiscal year, together with a
certificate of a Responsible Officer of Administrative Borrower stating that such financial statements fairly present in all material respects the financial condition of Intermediate Holdings and its Subsidiaries as at such date and the results of
operations of Intermediate Holdings and its Subsidiaries for the period ended on such date and have been prepared substantially in accordance with GAAP consistently applied, subject to changes resulting from normal, quarterly or <FONT
STYLE="white-space:nowrap">year-end</FONT> adjustments and except for the absence of notes; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) as soon as available and
in any event within forty (40)&nbsp;days after the end of each fiscal quarter prior to a Qualified Public Offering, the consolidated balance sheets of Intermediate Holdings and its Subsidiaries as of the end of such quarter, and the related
consolidated statements of income and cash flows of Intermediate Holdings and its Subsidiaries for such quarter and the portion of the fiscal year through the end of such quarter, all in reasonable detail and setting forth in comparative form the
figures for the corresponding period in the preceding fiscal year, together with a certificate of a Responsible Officer of Administrative Borrower stating that such financial statements fairly present in all material respects the financial condition
of Intermediate Holdings and its Subsidiaries as at such date and the results of operations of Intermediate Holdings and its Subsidiaries for the period ended on such date and have been prepared substantially in accordance with GAAP consistently
applied, subject to changes resulting from normal quarterly or <FONT STYLE="white-space:nowrap">year-end</FONT> adjustments and except for the absence of footnotes; <I>provided</I> that, if Intermediate Holdings or a parent thereof becomes a
Publicly Reporting Company, such Person&#146;s (or such parent&#146;s) filing of a Quarterly Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-Q</FONT> with the SEC shall be deemed to satisfy the requirements of this Section&nbsp;8.01(b) on
the date on which such report is first available via the SEC&#146;s EDGAR system or a successor system related thereto; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) as soon as available and in any event within one hundred twenty (120)&nbsp;days after the end of each fiscal year prior to
a Qualified Public Offering, the consolidated balance sheets of Intermediate Holdings and its Subsidiaries as of the end of such fiscal year, and the related consolidated statements of income, shareholders&#146; equity and cash flows of Intermediate
Holdings and its Subsidiaries for such fiscal year, prepared substantially in accordance with GAAP consistently applied, all in reasonable detail and setting forth in comparative form the figures for the previous fiscal year, accompanied by a report
and opinion thereon of PricewaterhouseCoopers&nbsp;or another independent certified public accountant of national or international reputation, which report and opinion shall be prepared in accordance with generally accepted auditing standards and
shall not be subject to any &#147;going concern&#148; or like qualification or exception or any qualification or exception as to the scope of such audit (other than impending maturity of Obligations); <I>provided</I> that, if Intermediate Holdings
or a parent becomes a Publicly Reporting Company, Intermediate Holdings&#146; (or such parent&#146;s) filing of a Quarterly Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> with the SEC shall be deemed to satisfy the requirements of
this Section&nbsp;8.01(b) on the date on which such report is first available via the SEC&#146;s EDGAR system or a successor system related thereto; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-73- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) within thirty (30)&nbsp;days after the end of each month (forty
(40)&nbsp;days with respect to a month that corresponds with the last day of a fiscal quarter), a compliance certificate of a Responsible Officer of Administrative Borrower as of the end of the applicable accounting period (which delivery may,
unless a Lender requests executed originals, be by electronic communication including email and shall be deemed to be an original authentic counterpart thereof for all purposes) in the form of Exhibit&nbsp;E (a <I>&#147;Compliance
Certificate&#148;</I>) which, for purposes of clarification, shall (i)&nbsp;demonstrate the Obligors&#146; compliance with Section&nbsp;8.15(a) in respect of the last day of such month, (ii)&nbsp;for each month end that coincides with the end of a
fiscal quarter, demonstrate compliance with Section&nbsp;8.15(b) in respect of such fiscal quarter and (iii)&nbsp;for each month end that coincides with the end of a fiscal year, (A)&nbsp;provide Obligors&#146; updated Schedules to Loan Documents
(if any), (B) include details of any issues that are material that are raised by auditors and (C)&nbsp;confirm that all of the requirements set forth in Section&nbsp;8.05 are satisfied; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) promptly, and in any event within five (5)&nbsp;Business Days after receipt thereof by an Obligor, copies of each notice
or other correspondence received from any securities regulator or exchange to the authority of which an Obligor is subject concerning any investigation or possible investigation or other inquiry by such agency regarding financial or other
operational results of such Obligor; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) [reserved]; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) promptly following the Lenders&#146; written request at any time, proof of the Obligors compliance with
Section&nbsp;8.15(a); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) within ten (10)&nbsp;days of delivery, copies of all periodic reports distributed by
Intermediate Holdings to its shareholders generally (or by Parent or any other parent entity); <I>provided</I> that (i)&nbsp;any such material may be redacted to exclude information relating to the Loan Documents or the Lenders and (ii)&nbsp;the
Lenders shall not be entitled to receive statements, reports and notices relating to topics that (A)&nbsp;are subject to <FONT STYLE="white-space:nowrap">attorney-client</FONT> privilege, (B)&nbsp;present a conflict of interest for the Lenders or
(C)&nbsp;constitute a trade secret, <FONT STYLE="white-space:nowrap">know-how</FONT> or commercially sensitive information; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) a financial forecast for Intermediate Holdings and its Subsidiaries for each fiscal year, including forecasted balance
sheets, statements of income and cash flows of Intermediate Holdings and its Subsidiaries, all of which shall be prepared on a consolidated basis and delivered not later than June&nbsp;29 of such year; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) promptly following any Lender&#146;s written request, certification that such Obligor is not a passive foreign investment
company (<I>&#147;PFIC&#148;</I>) within the meaning of Sections&nbsp;1291 through 1297 of the Code, or, if such Obligor determines that it is a PFIC, such information as would allow the Lender to make a qualified electing fund election with respect
to the stock of the Obligor; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-74- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) after Bermuda Parent becomes a Publicly Reporting Company, within five
(5)&nbsp;Business Days of filing, provide access (via posting and/or links on OpCo&#146;s web site) to all reports on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> and <FONT STYLE="white-space:nowrap">Form&nbsp;10-Q</FONT> filed with the
SEC, any Governmental Authority succeeding to any or all of the functions of the SEC or with any national securities exchange; and within five (5)&nbsp;Business Days of filing, provide notice and access (via posting and/or links on OpCo&#146;s web
site) to all reports on <FONT STYLE="white-space:nowrap">Form&nbsp;8-K</FONT> filed with the SEC, and copies of (or access to, via posting and/or links on OpCo&#146;s web site) all other reports, proxy statements and other materials filed by such
Public Reporting Company with the SEC, any Governmental Authority succeeding to any of the functions of the SEC or with any national securities exchange; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) promptly after the receipt thereof, a copy of any &#147;management letter&#148; received from its certified public
accounts and the management&#146;s response thereto (other than draft versions thereof); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) such other information
respecting the operations, properties, business or condition (financial or otherwise) of the Obligors (including with respect to the Collateral) as the Lenders may from time to time reasonably request. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;8.02.</I> <I>Notices of Material Events</I><I>.</I> It will furnish to the Administrative Agent for distribution
to the Lenders written notice of the following promptly after a Responsible Officer of an Obligor first learns of the existence of: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) the occurrence of any Default or Event of Default; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) the occurrence of any event with respect to any Obligor&#146;s Property resulting in a Loss (other than the Loss of
Inventory or Equipment in the Ordinary Course of Business), to the extent not covered by insurance, aggregating $1,500,000 or more; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) (i)&nbsp;any proposed Acquisition by any Obligor that would reasonably be expected to result in environmental liability
under Environmental Laws in excess of $1,500,000, and (ii)&nbsp;in each case, to the extent that any of the following would reasonably be expected to result in liability in excess of $1,500,000: (A)&nbsp;spillage, leakage, discharge, disposal,
leaching, migration or release of any Hazardous Material required to be reported to any Governmental Authority under applicable Environmental Laws, and (B)&nbsp;all actions, suits, Claims, notices of violation, hearings, investigations or
proceedings pending, or threatened in writing against or affecting any Obligor or any of its Subsidiaries or with respect to the ownership, use, maintenance and operation of their respective businesses, operations or properties, relating to
Environmental Laws or Hazardous Material; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) the assertion of any environmental matter by any Person in writing against,
or with respect to the activities of, any Obligor or any of its Subsidiaries and any alleged violation of or <FONT STYLE="white-space:nowrap">non-compliance</FONT> with any Environmental Laws or any permits, licenses or authorizations, in each case,
which would reasonably be expected to involve damages in excess of $1,500,000 other than any environmental matter or alleged violation that, if adversely determined, would not (either individually or in the aggregate) have a Material Adverse Effect;
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-75- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) the filing or commencement of any action, suit or proceeding by or
before any arbitrator or Governmental Authority against or directly affecting any Obligor or any of its Subsidiaries, in each case, that would reasonably be expected to result in a Material Adverse Effect; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) if a Material Adverse Effect would result: (i)&nbsp;on or prior to any filing by any Obligor&nbsp;or an ERISA Affiliate
thereof&nbsp;of any notice of intent to terminate any Title&nbsp;IV Plan, a copy of such notice and (ii)&nbsp;promptly, and in any event within ten (10)&nbsp;days, after any Responsible Officer of the Obligor knows&nbsp;or has reason to
know&nbsp;that a request for a minimum funding waiver under Section&nbsp;412 of the Code has been filed with respect to any Title&nbsp;IV Plan or Multiemployer Plan, a notice (which may be made by telephone if promptly confirmed in writing)
describing such waiver request and any action that the Obligor&nbsp;or an ERISA Affiliate thereof&nbsp;proposes to take with respect thereto, together with a copy of any notice filed with the PBGC or the IRS pertaining thereto; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) within five (5)&nbsp;Business Days of obtaining written notice or knowledge thereof, (i)&nbsp;the termination of any
Material Agreement; (ii)&nbsp;the receipt by any Obligor or any of its Subsidiaries of a written notice under any Material Agreement (and a copy thereof) asserting a default by such Obligor or any of its Subsidiaries where such alleged default would
permit such counterparty to terminate such Material Agreement; (iii)&nbsp;the entering into any new Material Agreement by an Obligor (and a copy thereof); or (iv)&nbsp;any amendment to a Material Agreement that would be materially adverse to the
Lenders (and a copy thereof) (which includes, but is not limited to, any amendments to provisions relating to pricing and term), <I>provided</I> that notices required under this subsection&nbsp;(g) may be delivered with the monthly Compliance
Certificate unless any of the foregoing events would reasonably be expected to have a Material Adverse Effect; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) any
product recalls, safety alerts, corrections, withdrawals, marketing suspensions, removals or the like conducted, to be undertaken or issued by any Obligor or any of its Subsidiaries, whether or not at the request, demand or order of any Governmental
Authority; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) within five (5)&nbsp;Business Days of obtaining written notice or knowledge thereof, any infringement or
other violation by any Person of any Obligor Intellectual Property that would reasonably be expected to result in a Material Adverse Effect; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) within five (5)&nbsp;Business Days of obtaining written notice or knowledge thereof, a material licensing agreement or
arrangement entered into by any Obligor or any of its Subsidiaries in connection with any material infringement or alleged material infringement of the Intellectual Property of another Person; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) within five (5)&nbsp;Business Days of obtaining written notice or knowledge thereof, any written Claim by any Person that
the conduct of any Obligor&#146;s (or any Subsidiary thereof) business, including the development, manufacture, use, sale or other commercialization of any Product, infringes any Intellectual Property of such Person, except to the extent any such
Claim would not reasonably be expected to result in a Material Adverse Effect; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-76- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) the reports and notices as and when required by the Security Documents;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) concurrently with the delivery of any Compliance Certificate, notice of any material change in accounting policies or
financial reporting practices by the Obligors; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) promptly after the occurrence thereof, notice of any labor controversy
resulting in or threatening to result in any strike, work stoppage, boycott, shutdown or other material labor disruption against or involving an Obligor (or any Subsidiary thereof); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) any other development that results in, or would reasonably be expected to result in, a Material Adverse Effect; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) concurrently with the delivery of any Compliance Certificate, the creation or other acquisition of any Intellectual
Property by any Obligor or any Subsidiary after the date hereof and during such prior fiscal year which is registered or becomes registered or the subject of an application for registration with the United States Copyright Office or the United
States Patent and Trademark Office, as applicable, or with any other equivalent registration offices in the Cayman Islands, the European Union or Ireland, as applicable; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q) within five (5)&nbsp;Business Days of any change to any Obligor&#146;s ownership of Deposit Accounts, Securities Accounts
and Commodity Accounts, by delivering to the Lenders an updated Schedule&nbsp;7 to the Security Agreement setting forth a complete and correct list of all such accounts; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(r) (i) receipt of any subpoena, civil investigative demand letter, or other notice from any Governmental Authority of any
investigation or audit, or pending or threatened (in writing) proceedings relating to any material violation of any Health Care Law, (ii)&nbsp;receipt of notice from any Governmental Authority or Third-Party Payor Program of any payment suspension,
material overpayment demand, or prepayment review, validation review, program integrity review, relating to a Federal Health Care Program or any material Third-Party Payor Program, (iii)&nbsp;loss, suspension or relinquishment of any material
accreditation, approval or qualification for participation in a Federal Health Care Program or any material Third-Party Payor Program and (iv)&nbsp;voluntary disclosure to a Governmental Authority of an overpayment amount greater than $250,000
related to an actual or potential violation of Health Care Laws; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(s) within ten (10)&nbsp;Business Days following the
departure of a Key Person, provide written notice to the Administrative Agent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Each notice delivered under this Section&nbsp;8.02 shall
be accompanied by a statement of a Responsible Officer of Administrative Borrower setting forth in reasonable detail the event or development requiring such notice and any action taken or proposed to be taken with respect thereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-77- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Notwithstanding any contrary provision of this Agreement or any other Loan Document
(including, without limitation, Sections&nbsp;8.01 and 8.02), until such time as the Administrative Agent provides written notice to Administrative Borrower that it no longer desires to receive information that constitutes material <FONT
STYLE="white-space:nowrap">non-public</FONT> information, Borrowers shall provide any information required pursuant to the terms hereof, including any information that may be material <FONT STYLE="white-space:nowrap">non-public</FONT> information,
to the Administrative Agent; <I>provided, </I>that notwithstanding the foregoing, Borrowers shall at all times comply with Section&nbsp;8.01(d), 8.01(k) and 8.02(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;8.03.</I> <I>Existence; Maintenance of Properties, Etc.</I> (a)&nbsp;It will, and will cause each of its
Subsidiaries to, do or cause to be done all things necessary to preserve, renew and keep in full force and effect its legal existence; <I>provided</I> that the foregoing shall not prohibit any merger, amalgamation, consolidation, liquidation or
dissolution permitted under Section&nbsp;9.03. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) It shall, and shall cause each of its Subsidiaries to, maintain and preserve all
rights, licenses, permits, privileges and franchises necessary to the conduct of its business, and maintain and preserve all of its assets and properties, including all Product Assets, necessary to the conduct of its business in good working order
and condition, ordinary wear and tear and damage from casualty or condemnation excepted, except where failure to do so would not reasonably be expected to result in a Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;8.04.</I> <I>Payment of Obligations</I><I>.</I> It will, and will cause each of its Subsidiaries to, pay and
discharge (a)&nbsp;all federal income and other material Taxes, fees, assessments and governmental charges or levies imposed upon it or upon its properties or assets prior to the date on which penalties attach thereto, and all lawful Claims for
labor, materials and supplies which, if unpaid, might become a Lien (other than a Permitted Lien) upon any properties or assets of any Obligor, except to the extent such Taxes, fees, assessments or governmental charges or levies, or such Claims, are
being contested in good faith by appropriate proceedings and are adequately reserved against substantially in accordance with GAAP, (b)&nbsp;all lawful Claims which, if unpaid, would by Law become a Lien upon its Property not constituting a
Permitted Lien and (c)&nbsp;all other obligations if the failure to discharge such obligation would reasonably be expected to result in a Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;8.05.</I> <I>Insurance</I><I>.</I> At its own cost and expense, it will, and will cause each of its
Subsidiaries, to obtain and maintain, with financially sound and reputable insurers, insurance of the kinds, and in the amounts, as are consistent with customary practices and standards of its industry in the same or similar locations, it being
understood and agreed that the insurance held by the Obligors on the Closing Date is deemed to fulfill this requirement on the date hereof. All of the insurance policies required pursuant to this Section&nbsp;8.05 will name the Administrative Agent
as a &#147;lender&#146;s loss payee,&#148; &#147;additional insured&#148; or &#147;mortgagee,&#148; as applicable and as its interests may appear. Borrowers will use their commercially reasonable efforts to ensure, or to cause others to ensure, that
all insurance policies required pursuant to this Section&nbsp;8.05 shall provide that they shall not be terminated or cancelled nor shall any policy be materially changed in a manner adverse to the insured Person without at least thirty
(30)&nbsp;days&#146; written notice to insured Person and the Administrative Agent. Receipt of notice of termination or cancellation of any such insurance policies shall entitle the Administrative Agent to renew any such policies, all in accordance
with the first sentence of this Section&nbsp;8.05 or otherwise to obtain similar insurance in place of such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-78- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
policies, in each case at the expense of Borrowers (payable within three (3)&nbsp;Business Days of Administrative Borrower&#146;s receipt of written demand therefor) and, unless an Event of
Default has occurred and is continuing, with the prior written consent of Administrative Borrower (such consent not to be unreasonably withheld). The amount of any such expenses shall accrue interest at the Default Rate if not paid when due and
shall constitute &#147;Obligations&#148;. All of the insurance policies required hereby will be evidenced by one or more certificates of insurance, together with appropriate lender&#146;s loss payee or additional insured clauses or endorsements in
favor of the Administrative Agent as required by this Section, delivered to the Administrative Agent on or before the Closing Date and at such other times as the Administrative Agent may request from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;8.06.</I> <I>Books and Records; Inspection Rights</I><I>.</I> It will, and will cause each of its Subsidiaries
to, keep proper books of record and account in which full, true and correct entries are made of all dealings and transactions in relation to its business and activities in all material respect. It will, and will cause each of its Subsidiaries to,
permit any representatives designated by the Administrative Agent, upon reasonable prior notice and at reasonable times, to visit and inspect its properties, to examine and make extracts from its books and records, and to discuss its affairs,
finances and condition with its officers and independent accountants, all at such reasonable times during normal business hours and with reasonable advance notice as the Administrative Agent may request. It will, and will cause each of its
Subsidiaries to, pay all reasonable and documented <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred by the Administrative Agent (a)&nbsp;so long as no Default has occurred and is
continuing, two (2)&nbsp;such inspections each calendar year and (b)&nbsp;upon the occurrence and&nbsp;during the continuance of a Default, all such inspections. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;8.07.</I> <I>Compliance with Laws</I>. (a)&nbsp;It will, and will cause each of its Subsidiaries to,
(i)&nbsp;comply in all material respects with all Requirements of Law (including Health Care Laws and Environmental Laws) and (ii)&nbsp;comply in all material respects with all terms of outstanding Indebtedness and all Material Agreements, except
where the failure to do so, individually or in the aggregate, would not reasonably be expected to result in a Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Each Obligor will maintain, and will cause each of its Subsidiaries to maintain, all records required to be maintained by a Governmental
Authority or otherwise under any applicable Health Care Law, except where failure to do so, individually or in the aggregate, would not reasonably be expected to have a Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Each Obligor will maintain, and will cause each of its Subsidiaries to maintain, a Health Care Compliance Program, which will be reviewed
and updated annually, as necessary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;8.08.</I> <I>Licenses</I><I>.</I> It will, and will cause each of its
Subsidiaries to, obtain and maintain all licenses, authorizations, consents, filings, exemptions, registrations and other Governmental Approvals necessary in connection with the execution, delivery and performance of the Loan Documents, the
consummation of the Transactions or the operation and conduct of its business and ownership of its properties, except where failure to do so would not reasonably be expected to have a Material Adverse Effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-79- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;8.09.</I> <I>Action under Environmental Laws</I><I>.</I> It
will, and will cause each of its Subsidiaries to, upon a Responsible Officer becoming aware of the release of any Hazardous Materials or the existence of any environmental liability under applicable Environmental Laws with respect to their
respective businesses, operations or properties, take all actions, at their cost and expense, as shall be required by applicable Law to investigate and clean up the condition of their respective businesses, operations or properties, including all
required removal, containment and remedial actions, and restore their respective businesses, operations or properties to a condition, in each case in material compliance with applicable Environmental Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;8.10.</I> <I>Use of Proceeds</I><I>.</I> The proceeds of the Term Loans will be used only as provided in
Section&nbsp;2.05. No part of the proceeds of the Term Loans will be used, whether directly or indirectly, for any purpose that violates any of the regulations of the Board of Governors of the Federal Reserve System, including Regulations&nbsp;T, U
and X. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;8.11.</I> <I>Certain Obligations Respecting Subsidiaries; Further Assurances; Intellectual
Property</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <I>Subsidiaries</I>. It will take such action, and will cause each of its Subsidiaries to take such action, from time
to time as shall be necessary to ensure that all Subsidiaries are &#147;Guarantors&#148; hereunder (other than an Excluded Subsidiary). Without limiting the generality of the foregoing, in the event that any Obligor shall form or acquire any new
Subsidiary, it and its Subsidiaries will promptly and in any event within forty-five (45)&nbsp;days (or such longer time as consented to by the Administrative Agent in writing) of the formation or Acquisition of such Subsidiary: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) cause such new Subsidiary to become a &#147;Guarantor&#148; hereunder, and a &#147;Grantor&#148; under the Security
Documents, pursuant to a Guarantee Assumption Agreement (or, to the extent the new Subsidiary is a Foreign Subsidiary, the equivalent form of document in such Foreign Subsidiary&#146;s jurisdiction); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) take such action or cause such Subsidiary to take such action (including delivering such Equity Interests together with
undated transfer powers executed in blank and any intercompany notes with undated endorsements executed in blank) as shall be necessary to create and perfect valid and enforceable first priority (subject to Permitted Liens) Liens on substantially
all of the personal Property of such new Subsidiary as collateral security for the obligations of such new Subsidiary hereunder (or, to the extent such new Subsidiary is a Foreign Subsidiary, as is customary in such Foreign Subsidiary&#146;s
jurisdiction); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) to the extent that the parent of such Subsidiary is not a party to the Security Documents or has not
otherwise pledged Equity Interests in its Subsidiaries in accordance with the terms of the Security Documents and this Agreement, cause the parent of such Subsidiary to execute and deliver a pledge agreement in favor of the Lenders, in respect of
all outstanding issued shares of such Subsidiary; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-80- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) deliver such proof of corporate action, incumbency of officers,
opinions of counsel and other documents as is consistent with those delivered by each Obligor pursuant to Section&nbsp;6.01 or as the Majority Lenders shall have requested; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>provided</I> that, solely with respect to any Subsidiary that is an Excluded Subsidiary, no such actions shall be required other than a pledge by the owner
of such Excluded Subsidiary (to the extent such owner is an Obligor) of 100% of the Equity Interests of such Excluded Subsidiary, which pledge shall not be required to be perfected under the Law of such Excluded Subsidiary&#146;s jurisdiction of
formation. In the event one or more Subsidiaries that were previously Excluded Subsidiaries no longer qualify as an Excluded Subsidiary, such Subsidiary shall be treated as a Guarantor hereunder and shall be required to take such actions set forth
in this Section&nbsp;8.11(a) and Section&nbsp;8.11(b). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <I>Further Assurances</I>. It will, and will cause each of its Subsidiaries
(other than an Excluded Subsidiary) to, take such action from time to time as shall reasonably be requested in writing by the Majority Lenders to effectuate the purposes and objectives of this Agreement. Without limiting the generality of the
foregoing, it will, and will cause each Person that is required to be a Guarantor to, take such action from time to time (including executing and delivering such assignments, security agreements, control agreements and other instruments) as shall be
reasonably requested in writing by the Majority Lenders to create, in favor of the Lenders, perfected security interests and Liens (subject to Permitted Liens) in substantially all of the personal Property of such Obligor as collateral security for
the Obligations; <I>provided</I> that any such security interest or Lien shall be subject to the relevant requirements of the Security Documents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <I>Intellectual Property</I>. In the event that any Obligor creates, develops or acquires Obligor Intellectual Property during the term of
this Agreement, then the provisions of this Agreement shall automatically apply thereto and any such Obligor Intellectual Property shall automatically constitute part of the Collateral under the Security Documents, without further action by any
party, in each case from and after the date of such creation, development or acquisition (except that any representations or warranties of any Obligor shall apply to any such Obligor Intellectual Property only from and after the date, if any,
subsequent to such acquisition that such representations and warranties are brought down or made anew as provided herein). In the event that any Obligor holds or acquires Obligor Intellectual Property during the term of this Agreement, then, upon
the request of the Administrative Agent, such Obligor shall take any action as shall be reasonably necessary and reasonably requested by the Administrative Agent to ensure that the provisions of this Agreement and the Security Agreement shall apply
thereto and any such Obligor Intellectual Property shall constitute part of the Collateral under the Security Documents; <I>provided</I> that no Obligor shall be required (i)&nbsp;to register Intellectual Property, (ii)&nbsp;to file Security
Documents other than short-form security interest filings in the United States Patent and Trademark Office and the United States Copyright Office, or (iii)&nbsp;to take any action that the cost, burden, difficulty or consequence of outweighs the
benefit to the Lenders of the security afforded thereby as reasonably determined by the Administrative Agent in consultation with the Administrative Borrower. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-81- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;8.12.</I> <I>Termination of Non</I><I><FONT
STYLE="white-space:nowrap">-Permitted</FONT> Liens</I><I>.</I> In the event that any Responsible Officer of an Obligor shall become aware or be notified by the Lenders of the existence of any outstanding Lien against any Property of any Obligor,
which Lien is not a Permitted Lien, such Obligor shall use its best efforts to promptly terminate or cause the termination of such Lien. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;8.13.</I> <I>Non</I><I><FONT STYLE="white-space:nowrap">-Consolidation</FONT></I><I>.</I> It will, and will
cause each of its Subsidiaries to, (a)&nbsp;maintain entity records and books of account separate from those of any other entity which is an Affiliate of such entity; and (b)&nbsp;not commingle its funds or assets with those of any other entity
which is an Affiliate of such entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;8.14.</I>
<I>Anti</I><I><FONT STYLE="white-space:nowrap">-Terrorism</FONT> and Anti</I><I><FONT STYLE="white-space:nowrap">-Corruption</FONT> Laws</I>. No Obligor shall engage in any transaction that violates any of the applicable prohibitions set forth in
any Sanctions Laws, Economic Sanctions Law, Irish Economic Sanctions Laws, <FONT STYLE="white-space:nowrap">Anti-Terrorism</FONT> Law, Irish Anti-Terrorism Laws, or the <I>US</I><I></I><I>&nbsp;Foreign Corrupt Practices Act of 1977</I> (15&nbsp;USC.
<FONT STYLE="white-space:nowrap">&#167;&#167;&nbsp;78dd-1</FONT> <I>et</I><I></I><I>&nbsp;seq.</I>). None of the funds or assets of such Obligor or any Subsidiary that are used to repay the Term Loans shall constitute property of, or shall be owned
by, any Designated Person or, to such Obligor&#146;s knowledge, be the direct proceeds derived from any transactions that violate the prohibitions set forth in any applicable Sanctions Laws, Economic Sanctions Law or Irish Economic Sanctions Laws,
and no Designated Person shall have any direct or indirect interest in such Obligor insofar as such interest would violate any Sanctions Laws, Economic Sanctions Laws or Irish Economic Sanctions Law applicable to such Obligor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;8.15.</I> <I>Financial Covenants</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <I>Minimum Liquidity</I>. Borrowers shall ensure that the Obligors shall have aggregate Unrestricted Cash of not less than $3,000,000 at
all times. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-82- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <I>Minimum Net Revenue</I>. As of the end of the fiscal quarter ended April&nbsp;30,
2024 and each fiscal quarter thereafter, Intermediate Holdings and its Subsidiaries shall maintain, on a consolidated basis, Net Revenue for the twelve (12)&nbsp;month period most recently ended on such date of not less than the amount set forth in
the table below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP>
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">T<SMALL>WELVE</SMALL><FONT STYLE="white-space:nowrap">-M</FONT><SMALL>ONTH</SMALL>
P<SMALL>ERIOD</SMALL> E<SMALL>NDING</SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">M<SMALL>INIMUM</SMALL>&nbsp;N<SMALL>ET</SMALL>&nbsp;R<SMALL>EVENUE</SMALL></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">April&nbsp;30, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">July&nbsp;31, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">October&nbsp;31, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">January&nbsp;31, 2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">April&nbsp;30, 2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">July&nbsp;31, 2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">October&nbsp;31, 2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">January&nbsp;31, 2026</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">April&nbsp;30, 2026</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">July&nbsp;31, 2026</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">63,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">October&nbsp;31, 2026</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">68,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">January&nbsp;31, 2027</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">76,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">April&nbsp;30, 2027</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">83,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">July&nbsp;31, 2027</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">88,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">October&nbsp;31, 2027</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">93,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">January&nbsp;31, 2028</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">95,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">April&nbsp;30, 2028</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">; <I>provided</I> that in the event that a Qualified Public Offering shall not occur on or prior to July&nbsp;31, 2025, then
Intermediate Holdings and its Subsidiaries shall maintain, on a consolidated basis, Net Revenue for the twelve (12)&nbsp;month period most recently ended on the dates set forth in Section&nbsp;8.15(b) of this Agreement prior to giving effect to the
Second Amendment (the <I>&#147;Prior Covenants&#148;</I>) and, in such case, the Administrative Agent is hereby authorized to unilaterally make changes to this Section&nbsp;8.15(b) as may be necessary to give effect to the Prior Covenants with such
changes being binding upon the Obligors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">With respect to any fiscal quarter for which either financial covenant above could be breached,
Intermediate Holdings shall have the right (the <I>&#147;Cure Right&#148;</I>) to issue equity (which shall be common equity or other equity (such other equity to be on terms reasonably acceptable to the Administrative Agent)) during such fiscal
quarter or thereafter until the date that is ten (10)&nbsp;Business Days after the date that financial statements delivered pursuant to Section&nbsp;8.01(b) are required to be delivered for cash or otherwise receive cash contributions in respect of
such equity (the <I>&#147;Cure Amount&#148;</I>) deposited in a Controlled Account, and thereupon Borrowers&#146; compliance with the applicable financial covenant shall be recalculated giving effect to the following pro forma adjustment:
(a)&nbsp;with respect to the Minimum Liquidity covenant, Borrowers&#146; Unrestricted Cash balance shall be increased or (b)&nbsp;with respect to the Net Revenue covenant, Borrowers&#146; Net Revenue shall be increased, in each case solely for the
purposes of determining compliance with the applicable financial covenant, including, with respect to the Net Revenue covenant, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-83- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
determining compliance with the such financial covenant as of the end of such fiscal quarter and applicable subsequent periods that include such fiscal quarter, by an amount equal to the Cure
Amount; <I>provided</I> that with respect to the Net Revenue covenant, Borrowers&#146; Net Revenue shall be increased with respect to such applicable fiscal quarter only. If, after giving effect to the foregoing recalculations, the requirements of
the applicable financial covenant shall be satisfied, then the requirements of the applicable financial covenant shall be deemed satisfied with the same effect as though there had been no failure to comply therewith at such date, and the applicable
Event of Default with respect to the applicable financial covenant that had occurred shall be deemed cured for the purposes of this Agreement. Notwithstanding anything herein to the contrary, (a)&nbsp;in each four consecutive fiscal quarter period
there shall be at least two fiscal quarters in which the Cure Right is not exercised, (b)&nbsp;the Cure Right may not be exercised in two consecutive fiscal quarters, (c)&nbsp;during the term of this Agreement, the Cure Right shall not be exercised
more than two times with respect to each financial covenant, (d)&nbsp;the Cure Amount shall be in an amount equal to two times the amount required for purposes of complying with the applicable financial covenant (it being understood that only the
amount required to comply with the applicable financial covenant shall be included in the calculation of the Cure Amount), (e)&nbsp;upon the Lender&#146;s receipt of a written notice from Administrative Borrower that it intends to exercise the Cure
Right (a <I>&#147;Notice of Intent to Cure&#148;</I>), until the tenth (10<SUP STYLE="font-size:75%; vertical-align:top">th</SUP>) Business Day following the date that financial statements for the fiscal quarter to which such Notice of Intent to
Cure relates are required to be delivered, neither the Administrative Agent nor the Lenders shall exercise the right to accelerate the Obligations or terminate any unused Commitments, and the Lender shall not exercise any right to foreclose on or
take possession of the Collateral or any other right or remedy under this Agreement solely on the basis of such Event of Default having occurred and being continuing under the applicable financial covenant and (f)&nbsp;the Cure Amount shall be
disregarded for any other purpose. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;8.16.</I> <I>Maintenance of Regulatory Approvals, Contracts,
Intellectual Property, Etc.</I> With respect to each Product, such Obligor will, and will cause each of its Subsidiaries (to the extent applicable) to: (a)&nbsp;maintain in full force and effect all material Regulatory Approvals (including the
Product Authorizations), Material Agreements, or other material rights necessary for the current operations of such Obligor&#146;s or such Subsidiary&#146;s business, as the case may be, including in respect of all related Product Development and
Commercialization Activities, (b)&nbsp;maintain in full force and effect all Material Intellectual Property that is necessary for related Product Development and Commercialization Activities and (c)&nbsp;use commercially reasonable efforts to pursue
and maintain in full force and effect legal protection for all new, Material Intellectual Property developed or controlled by such Obligor or any of its Subsidiaries, as the case may be, that is necessary for Product Development and
Commercialization Activities relating to any Product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;8.17.</I> <I>Cash Management</I>. (a)&nbsp;It will:
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) maintain all Deposit Accounts, Securities Accounts, Commodity Accounts and lockboxes (other than Excluded Accounts)
with a bank or financial institution that has executed and delivered to the Administrative Agent a springing account control agreement, in form and substance reasonably acceptable to the Administrative Agent (each such Deposit Account, Securities
Account, Commodity Account and lockbox, a <I>&#147;Controlled Account&#148;</I>); </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-84- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) deposit promptly, and in any event no later than five (5)&nbsp;Business
Days after the date of receipt thereof, all cash, checks, drafts or other similar items of payment relating to or constituting payments made in respect of any and all accounts and other rights and interests into Controlled Accounts; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) deposit promptly, and in any event no later than five (5)&nbsp;Business Days after the date of receipt thereof, all
proceeds received by an Obligor pursuant to the Sponsor Equity Commitment Letter into a Controlled Account in the name of OpCo. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) In
order to segregate and to facilitate perfection of the security interest in any funds an Obligor receives from Third-Party Payor Programs, to the extent any Obligor receives payments from a Federal Health Care Program as of the Closing Date, such
Obligor shall, within sixty (60)&nbsp;days after the Closing Date (or such later date as may be agreed to by the Administrative Agent) (or, with respect to future participation in any Federal Health Care Program, prior to such Obligor&#146;s receipt
of payments from such Federal Health Care Program) notify all Governmental Authorities making any payments under any Federal Health Care Program to make any such payments only to one or more Segregated Health Care Accounts. No Obligor shall deposit
any funds to a Segregated Health Care Account or direct or permit any other Person to deposit any funds to a Segregated Health Care Account, other than payments received from Federal Health Care Program. The Obligors shall have until the date that
is one hundred fifty (150)&nbsp;days following (i)&nbsp;the Closing Date, or (ii)&nbsp;the date the applicable Obligor begins receiving payments from any Federal Health Care Program, to cause all amounts deposited into the Segregated Health Care
Accounts to be automatically swept on a daily basis to a Controlled Account pursuant to a Sweep Agreement; <I>provided</I> that, in each case, the Obligors shall have the option to extend the foregoing requirement by an additional thirty
(30)&nbsp;days by written notice to the Administrative Agent if the Obligors are working in good faith to enter into such Sweep Agreement (as determined by the Administrative Agent in its reasonable discretion). Any such Sweep Agreement will require
such depository bank to waive all of its existing and future rights of recoupment and <FONT STYLE="white-space:nowrap">set-off</FONT> and banker&#146;s lien against any Segregated Health Care Accounts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;8.18.</I> <I>Observer Rights</I>. Until the Obligations have been paid in full in cash, the Obligors shall
permit the Administrative Agent on behalf of all of the Lenders (the<I> </I><I>&#147;</I><I>Observer</I><I>&#148;</I>) to attend and observe (but not vote) at all meetings of OpCo&#146;s Board, whether in person, by telephone or otherwise as
requested by such Obligor; <I>provided</I> that the Observer shall not be permitted to attend any committee meetings or executive sessions. OpCo shall notify the Observer in writing at the same time as furnished to members or the applicable
committee of (a)&nbsp;the date and time for each general or special meeting of OpCo&#146;s Board and (b)&nbsp;the adoption of any resolutions or actions by the Board by written consent (describing, in reasonable detail, the nature and substance of
such action). OpCo shall concurrently deliver to the Observer all notices and any materials delivered by OpCo to its Board in connection with a meeting or action to be taken by written consent, including a draft of any material resolutions or
actions proposed to be adopted by written consent. The Observer shall be free prior to such meeting or adoption by written consent to contact members of the Board and discuss the pending actions to be taken. Notwithstanding the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-85- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
foregoing, the Observer shall not be entitled to receive materials relating to, or be in attendance for, any discussions relating to topics which (a)&nbsp;are subject to attorney client
privilege, (b)&nbsp;present a conflict of interest for the Observer or (c)&nbsp;are trade secrets, <FONT STYLE="white-space:nowrap">know-how</FONT> or other commercially sensitive information. All such discussions and materials shall be subject to
the confidentiality provisions set forth in Section&nbsp;13.17. If at any time the functions of the Board of Opco is performed by any direct or indirect parent of Opco and Opco ceases to have a Board attended by representative of the Sponsor, Opco
shall cause any such parent entity to provide the rights set forth above to the Observer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;8.19.</I>
<I>COMI</I>. The Irish Obligor will maintain its COMI in Ireland and not have an establishment (within the meaning of the EU Insolvency Regulation) outside Ireland. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;8.20.</I> <I>Post</I><I><FONT STYLE="white-space:nowrap">-Closing</FONT> Obligations</I>. Within the time
periods specified on Schedule&nbsp;8.20 (as each may be extended by the Administrative Agent in its sole discretion), complete such undertakings as are set forth on Schedule&nbsp;8.20. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;8.21.</I> <I>Second Amendment Warrant Certificate</I>. Immediately upon the occurrence of a Qualified Public
Offering, deliver to Perceptive (a)&nbsp;the executed Second Amendment Warrant Certificate, substantially in the form attached to the Second Amendment as Annex B, (b)&nbsp;certified copies of the Organizational Documents of Bermuda Parent and of
resolutions of Bermuda Parent approving and authorizing the execution, delivery and performance of the Second Amendment Warrant Certificate, certified by the secretary or a Responsible Officer of Bermuda Parent as being in full force and effect
without modification or amendment, (c)&nbsp;a good standing certificate and/or compliance certificate from the applicable Governmental Authority of Bermuda Parent&#146;s jurisdiction of incorporation and Bermuda Parent&#146;s jurisdiction of
registration, dated a recent date prior to the date of the Qualified Public Offering, (d)&nbsp;a certificate of Bermuda Parent as to the authority, incumbency and specimen signatures of the persons who have executed the Second Amendment Warrant
Certificate and (e)&nbsp;an executed favorable opinion or opinions of Walkers (Bermuda) Limited, special Bermuda counsel to Bermuda Parent, in form and substance substantially similar to the form attached to the Second Amendment as Annex C. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>RTICLE</SMALL>&nbsp;9. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N<SMALL>EGATIVE</SMALL> C<SMALL>OVENANTS</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each Obligor covenants and agrees with the Administrative Agent and the Lenders that, until the Commitments have expired or been terminated
and all Obligations (other than inchoate indemnity obligations) have been paid in full in cash: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;9.01.</I>
<I>Indebtedness</I><I>.</I> It will not, and will not permit any of its Subsidiaries to, create, incur, assume or permit to exist any Indebtedness, whether directly or indirectly, except: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) the Obligations; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-86- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Indebtedness existing on the date hereof and set forth in
Schedule&nbsp;7.13A and Permitted Refinancings thereof; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) intercompany Indebtedness: (i)&nbsp;among&nbsp;Obligors;<I>
provided</I> such Indebtedness is pledged to the Administrative Agent for the benefit of the Lenders under the Security Agreement and otherwise subordinate in right of payment to the Obligations pursuant to an Intercompany Subordinated Demand
Promissory Note; (ii)&nbsp;among Subsidiaries that are not Obligors; and (iii)&nbsp;so long as no Default or Event of Default shall occurred and is continuing, (i)&nbsp;Indebtedness owed by a Foreign Subsidiary to an Obligor in an aggregate amount
not to exceed, together with Investments made in Foreign Subsidiaries pursuant to Section&nbsp;9.05(m) and transfers of property to Foreign Subsidiaries made pursuant to Section&nbsp;9.09(f)(iii), $250,000 in any fiscal year and
(ii)&nbsp;Indebtedness owed by a Subsidiary which is not an Obligor to an Obligor in an aggregate amount not to exceed, together with Investments made in Subsidiaries which are not Obligors pursuant to Section&nbsp;9.05(m) and transfers of property
to Subsidiaries which are not Obligors made pursuant to Section&nbsp;9.09(f)(iii), $100,000 in any fiscal year; <I>provided</I> that the amount of any intercompany Indebtedness owed by the payor to the payee and the corresponding amount of
intercompany Investment made by the payee in such payor arising out of such intercompany Indebtedness shall only be counted once for purpose of determining the cap set forth above; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) accounts payable to trade creditors for goods and services and current operating liabilities (not the result of the
borrowing of money) incurred in the Ordinary Course of Business; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) Indebtedness consisting of Guarantees resulting from
endorsement of negotiable instruments for collection by it or any of its Subsidiaries in the Ordinary Course of Business; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) (i) Guarantees by any Obligor of Indebtedness of any other Obligor or (ii)&nbsp;Guarantees by any Obligor of Indebtedness
of a Subsidiary not constituting an Obligor, to the extent permitted pursuant to Section&nbsp;9.05(n); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) Purchase money
Indebtedness and Capital Lease Obligations; <I>provided</I> that (i)&nbsp;if secured, the collateral therefor consists solely of the assets being financed, the products and proceeds thereof and books and records related thereto; (ii)&nbsp;in the
case of purchase money Indebtedness, such Indebtedness shall not constitute less than 75% of the aggregate consideration paid with respect to such asset; and (iii)&nbsp;the aggregate outstanding principal amount of such Indebtedness does not exceed
$1,000,000 at any time; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) workers&#146; compensation Claims, payment obligations in connection with health, disability
or other types of social security benefits, unemployment or other insurance obligations, reclamation and statutory obligations, in each case incurred in the Ordinary Course of Business; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-87- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Indebtedness under Hedging Agreements permitted pursuant to
Section&nbsp;9.05(f); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) Indebtedness of Intermediate Holdings and its Subsidiaries with respect to corporate credit
cards not to exceed $650,000 at any time outstanding; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) the Existing Letters of Credit; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) reimbursement obligations in connection with letters of credit that are secured by cash or cash equivalents and issued on
behalf of an Obligor, not to exceed $500,000 at any time outstanding; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) Indebtedness consisting of financing of
insurance premiums incurred in the ordinary course of business not to exceed at any time the amount of such insurance premiums; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) Indebtedness with respect to performance bonds, appeal bonds and other similar obligations not to exceed $500,000 in the
aggregate; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) so long as no Default shall have occurred and is continuing at the time of such Indebtedness is incurred,
or after giving effect thereto, other unsecured Indebtedness in an aggregate principal amount not to exceed $500,000 at any time outstanding; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) Sponsor Convertible Notes on terms and provisions (including a subordination agreement) satisfactory to the Administrative
Agent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;9.02.</I> <I>Liens</I><I>.</I> It will not, and will not permit any of its Subsidiaries to, create,
incur, assume or permit to exist any Lien on any Property now owned by it, except: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Liens securing the Obligations;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) any Lien on any Property of any Obligor existing on the date hereof and set forth in Schedule&nbsp;7.13B;
<I>provided</I> that (i)&nbsp;no such Lien shall extend to any other Property of such Obligor and (ii)&nbsp;any such Lien shall secure only those obligations which it secures on the date hereof and extensions, renewals and replacements thereof that
do not increase the outstanding principal amount thereof; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Liens securing Indebtedness permitted under
Section&nbsp;9.01(g); <I>provided</I> that such Liens are restricted solely to the collateral described in Section&nbsp;9.01(g); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Liens imposed by Law which were incurred in the Ordinary Course of Business, including (but not limited to)
carriers&#146;, warehousemen&#146;s, landlords&#146; and mechanics&#146; Liens, Liens relating to leasehold improvements and other similar liens arising in the Ordinary Course of Business and which (i)&nbsp;do not in the aggregate materially detract
from the value of the Property subject thereto or materially impair the use thereof in the operations of the business of such Person or (ii)&nbsp;are being contested in good faith by appropriate proceedings, which proceedings have the effect of
preventing the forfeiture or sale of the Property subject to such Liens and for which adequate reserves have been made if required substantially in accordance with GAAP; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-88- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) Liens, pledges or deposits made in the Ordinary Course of Business in
connection with bids, Contracts, leases, appeal bonds, workers&#146; compensation, unemployment insurance or other similar social security legislation; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) Liens securing Taxes, assessments and other governmental charges, the payment of which is not yet due or is being
contested in good faith by appropriate proceedings promptly initiated and diligently conducted and for which such reserve or other appropriate provisions, if any, as shall be required by GAAP shall have been made; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) servitudes, easements, rights of way, restrictions and other similar encumbrances on real Property imposed by applicable
Laws and encumbrances consisting of zoning or building restrictions, easements, licenses, restrictions on the use of Property or minor imperfections in title thereto which, in the aggregate, are not material, and which do not in any case materially
detract from the value of the Property subject thereto or interfere with the ordinary conduct of the business of any of the Obligors; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) bankers&#146; Liens, rights of setoff and similar Liens incurred in the Ordinary Course of Business and arising in
connection with the Obligors&#146; deposit accounts or securities accounts held at financial institutions solely to secure payment of fees and similar costs and expenses of such financial institutions with respect to such accounts; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Liens in connection with transfers permitted under Section&nbsp;9.09; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) any judgment Lien or Lien arising from decrees or attachments not constituting an Event of Default; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) leases or subleases of real property granted in the Ordinary Course of Business, and leases, subleases, nonexclusive
licenses or sublicenses of personal property (other than Intellectual Property) granted in the Ordinary Course of Business; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) Liens in favor of customs and revenue authorities arising as a matter of law to secure the payment of custom duties in
connection with the importation of goods, not securing an amount in the aggregate in excess of $100,000 at any given time; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) Liens on a deposit account of the Obligors and the cash and cash equivalents therein, in each case, securing Indebtedness
described in Section&nbsp;9.01(j); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) Permitted Licenses solely to the extent that such Permitted License would
constitute a Lien; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-89- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) Liens on cash collateral securing reimbursement obligations of the
applicable Person under letters of credit to the extent permitted pursuant to Section&nbsp;9.01(k) or (l); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) deposits
as security for contested taxes or contested import or customs duties in an aggregate amount not to exceed $1,000,000; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q) other Liens securing obligations (other than Indebtedness for borrowed money) in an aggregate amount not to exceed
$500,000; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><I>provided</I> that no Lien otherwise permitted under any of the foregoing Sections 9.02 (excluding Sections 9.02(a) and
9.02(n)) shall apply to any Material Intellectual Property to secure any Indebtedness. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;9.03.</I>
<I>Fundamental Changes and Acquisitions</I><I>.</I> It will not, and will not permit any of its Subsidiaries to, (a)&nbsp;enter into or consummate any transaction of merger, amalgamation or consolidation, including without limitation, a <FONT
STYLE="white-space:nowrap">reverse-triangular</FONT> merger, or other similar transaction or series of related transactions, (b)&nbsp;liquidate, wind up or dissolve itself (or suffer any liquidation or dissolution) (including in connection with any
division or plan of division under Delaware law or any comparable event under a different jurisdiction&#146;s laws), (c)&nbsp;make or consummate any Acquisition, (d)&nbsp;make any public offering or (e)&nbsp;sell or issue any Disqualified Equity
Interests, except: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Investments permitted under Section&nbsp;9.05; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) Permitted Acquisitions for aggregate consideration for all such acquisitions not to exceed $10,000,000 in the aggregate
during for the course of this Agreement (which may include net proceeds of a substantially concurrent issuance of Qualified Equity Interests issued specifically for the purpose of funding such Permitted Acquisitions in an aggregate amount not to
exceed $5,000,000 during the course of this Agreement); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) the merger, amalgamation or consolidation of any Obligor
with or into any other Obligor, <I>provided</I> that if a Borrower is a party to such merger, amalgamation or consolidation, such Borrower shall be the surviving entity; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) a Qualified Public Offering and a Permitted IPO Reorganization in connection therewith. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;9.04.</I> <I>Lines of Business</I><I>.</I> It will not, and will not permit any of its Subsidiaries to, engage
to any material extent in any business other than the business engaged in on the date hereof by such Obligor, or a business reasonably related, incidental or complementary thereto or reasonable extensions thereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-90- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;9.05.</I> <I>Investments</I><I>.</I> It will not, and will not
permit any of its Subsidiaries to, make, directly or indirectly, or permit to remain outstanding any Investments except: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Investments outstanding on the date hereof and identified in Schedule&nbsp;9.05 and any modification, replacement, renewal
or extension thereof to the extent not involving new or additional Investments; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) operating deposit accounts with
banks; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) extensions of credit in the nature of accounts receivable or notes receivable arising from the sales of goods
or services in the Ordinary Course of Business; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Permitted Cash Equivalent Investments (or were Permitted Cash
Equivalents at the time acquired); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) (i)&nbsp;Investments consisting of 100% of the ownership of the Equity Interests
of its Subsidiaries and (ii)&nbsp;intercompany Investments by a Borrower or a Subsidiary in any Subsidiary Guarantor; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f)
Hedging Agreements entered into in the ordinary course of any Obligor&#146;s financial planning solely to hedge interest rate risks (and not for speculative purposes) in respect of Permitted Indebtedness and in aggregate amount for all such Hedging
Agreements not in excess of $500,000; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) Investments consisting of prepaid expenses, negotiable instruments held for
collection or deposit, security deposits with utilities, landlords and other like Persons, and deposits in connection with workers&#146; compensation and similar deposits, in each case made in the Ordinary Course of Business; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) Investments received in connection with any Insolvency Proceedings in respect of any customers, suppliers or clients and
in settlement of delinquent obligations of, and other disputes with, customers, suppliers or clients; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Investments
permitted under Section&nbsp;9.01(c) and Section&nbsp;9.03; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) Investments consisting of notes receivable of, or prepaid
royalties and other credit extensions, to customers and suppliers who are not Affiliates, in the Ordinary Course of Business; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) Investments consisting of (i)&nbsp;travel advances and employee relocation loans and other employee loans and advances in
the Ordinary Course of Business, and (ii)&nbsp;loans to employees, officers or managers relating to the purchase of equity securities of Intermediate Holdings or its Subsidiaries pursuant to employee stock purchase plans or agreements in an
aggregate amount not to exceed $250,000 for subclauses&nbsp;(i) and (ii)&nbsp;in any fiscal year; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-91- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) <FONT STYLE="white-space:nowrap">non-cash</FONT> Investments in joint
ventures or strategic alliances in the Ordinary Course of Business consisting of the <FONT STYLE="white-space:nowrap">non-exclusive</FONT> licensing of technology, the development of technology or the providing of technical support; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) Investments consisting of loans not involving the net transfer on a substantially contemporaneous basis of cash proceeds
to employees, officers or directors relating to the purchase of capital stock of the Administrative Borrower pursuant to employee stock purchase plans or other similar agreements, as approved by Administrative Borrower&#146;s board of directors and
not to exceed $500,000 in the aggregate; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) so long as no Default or Event of Default shall occurred and is continuing,
Investments (i)&nbsp;in Foreign Subsidiaries in an aggregate amount not to exceed, together with Indebtedness of Foreign Subsidiaries pursuant to Section&nbsp;9.01(c) and transfers of property to Foreign Subsidiaries made pursuant to
Section&nbsp;9.09(f)(iii), $250,000 in any fiscal year and (ii)&nbsp;in Subsidiaries which are not Obligors, in an aggregate amount not to exceed, together with Indebtedness of Subsidiaries which are not Obligors pursuant to Section&nbsp;9.01(c) and
transfers of property to Subsidiaries which are not Obligors made pursuant to Section&nbsp;9.09(f)(iii), $100,000 in any fiscal year; <I>provided</I> that the amount of any intercompany Indebtedness owed by the payor to the payee and the
corresponding amount of intercompany Investment made by the payee in such payor arising out of such intercompany Indebtedness shall only be counted once for purpose of determining the cap set forth above; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) so long as no Default shall have occurred and is continuing at the time of such Investment, or after giving effect
thereto, other Investments in an amount not to exceed $500,000 in any fiscal year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;9.06.</I> <I>Restricted
Payments</I><I>.</I> It will not, and will not permit any of its Subsidiaries to, declare or make, or agree to pay or make, directly or indirectly, any Restricted Payment, other than: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) dividends or distributions with respect to any Equity Interests of a Borrower or any of its Subsidiaries payable solely in
additional units of its Qualified Equity Interests; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) any Restricted Payment by a Subsidiary to a Borrower; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) any purchase, redemption, retirement, or other Acquisition by Intermediate Holdings or any of its Subsidiaries of units of
its Equity Interests with the proceeds received from a substantially concurrent issue of a new units of its Equity Interests; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) dividends or distributions paid by any Guarantor to any other Obligor (or, with respect to the Irish Obligor, solely to
the holders of Equity Interest in the Irish Obligor that are owned by a Borrower); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) cashless exercises of options and
warrants; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-92- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) repurchases pursuant to the terms of employee incentive plans, manager
or consultant incentive plans, or similar plans in an aggregate amount not to exceed $500,000 in any fiscal year; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) any
dividends, distributions or payment in respect of or the redemption, retirement or purchase of any capital stock constituting any part of a Permitted IPO Reorganization, so long as, in each case, the assets or other property (including for the
avoidance of doubt, cash and Intellectual Property) transferred in connection with such Permitted IPO Reorganization remains the assets or property of the Obligors (e.g., no dividend, distribution or payment of any assets or property is permitted to
any entity that is not an Obligor); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) any purchase of shares of capital stock from minority shareholders in an amount
not to exceed $100,000 in the aggregate; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) (x) cash payments made directly or indirectly to Parent or any other
parent company of Intermediate Holdings, the proceeds which shall be used to pay operating costs and documented expenses of such parent entities incurred in the ordinary course of business and other corporate overhead costs and documented expenses
(including administrative, legal, accounting and similar documented expenses provided by third parties), which are attributable to the ownership and operations of Intermediate Holdings and its Subsidiaries, in an aggregate amount not to exceed
$500,000 in any fiscal year and (y)&nbsp;cash payments in respect of transaction expenses in connection with equity issuances by Intermediate Holdings or any direct or indirect parent thereof, to the extent the cash proceeds of such equity issuances
have been contributed to the Administrative Borrower (and in an amount not to exceed such cash proceeds so contributed); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>provided</I>, in no event
shall Irish Obligor make any Restricted Payments until 100% of its Equity Interests are owned by Intermediate Holdings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;9.07.</I> <I>Payments of Indebtedness</I><I>.</I> It will not, and will not permit any of its Subsidiaries to,
make any payments in respect of any Material Indebtedness incurred under Section&nbsp;9.01(o) other than, so long as no Event of Default shall have occurred and is continuing, payment of regularly scheduled interest payments or principal payments at
maturity, any Permitted Refinancing thereof or the conversion of such Material Indebtedness into Qualified Equity Interests. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;9.08.</I> <I>Change in Fiscal Year</I><I>.</I> It will not, and will not permit any of its Subsidiaries to,
change the last day of its fiscal year from that in effect on the date hereof, without prior written notice to the Administrative Agent, except to change the fiscal year of a Subsidiary acquired in connection with a Permitted Acquisition to conform
its fiscal year to that of Borrowers. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-93- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;9.09.</I> <I>Sales of Assets, Etc</I><I>.</I> It will not, and
will not permit any of its Subsidiaries to, sell, lease, exclusively license (in terms of geography or field of use), as a licensor, transfer (including in connection with any division or plan of division under Delaware law or any comparable event
under a different jurisdiction&#146;s laws) or otherwise dispose of any of its Property (including accounts receivable and Equity Interests of Subsidiaries), or forgive, release or compromise any amount owed to any Obligor or any of its
Subsidiaries, in each case, in one transaction or series of transactions (any thereof, an <I>&#147;Asset Sale&#148;</I>), except: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) transfers of cash in the Ordinary Course of Business for equivalent value; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) sales or leases of inventory in the Ordinary Course of Business on ordinary business terms; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) the forgiveness, release or compromise of any amount owed to any Obligor in the Ordinary Course of Business; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) entering into, or becoming bound, by a Permitted License to the extent not otherwise prohibited by this Agreement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) development and other collaborative arrangements where such arrangements provide for the license or disclosure of Patents,
Trademarks, Copyrights or other Intellectual Property rights of any Obligor in the Ordinary Course of Business; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f)
transfers of Property (i)&nbsp;among Obligors, (ii)&nbsp;among Subsidiaries that are not Obligors and (iii)&nbsp;by an Obligor to a Subsidiary that is not an Obligor, in an aggregate amount not to exceed for this clause (iii), (x) with respect to
transfers to Foreign Subsidiaries, together with Indebtedness of Foreign Subsidiaries pursuant to Section&nbsp;9.01(c) and investments in Foreign Subsidiaries made pursuant to Section&nbsp;9.05(m), $250,000 in any fiscal year and (y)&nbsp;with
respect to transfers to Subsidiaries which are not Obligors, together with Indebtedness of Subsidiaries which are not Obligors pursuant to Section&nbsp;9.01(c) and investments in Subsidiaries which are not Obligors made pursuant to
Section&nbsp;9.05(m), $100,000 in any fiscal year; <I>provided</I> that the amount of any intercompany Indebtedness owed by the payor to the payee and the corresponding amount of intercompany Investment made by the payee in such payor arising out of
such intercompany Indebtedness shall only be counted once for purpose of determining the cap set forth above; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) a sale,
lease, exclusive license, transfer or other disposition (including by way of abandonment, cancellation or <FONT STYLE="white-space:nowrap">trade-in)</FONT> of any Property that is obsolete, worn out, surplus or no longer used or useful in connection
with the business of the Obligors or with respect to which a newer and improved version is available; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) dispositions
resulting from Casualty Events; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) any transaction permitted under Section&nbsp;9.02, 9.03, 9.05 and 9.20; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) so long as no Default shall have occurred and is continuing at the time of such Asset Sale or after giving effect thereto,
Asset Sales of other property not to exceed $500,000 in the aggregate per fiscal year; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-94- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) cross-licenses (including by way of exclusive licenses) of Intellectual
Property subject to cross-license with Medtronic, Inc. and Stryker in existence of the Closing Date (including pursuant to litigation settlements) so long as any license so granted to third parties is of equivalent value to the license so received
by the Administrative Borrower or any Subsidiary, as determined by the Administrative Borrower in good faith. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;9.10.</I> <I>Transactions with Affiliates</I><I>.</I> It will not, and will not permit any of its Subsidiaries
to, sell, lease, license or otherwise transfer any assets to, or purchase, lease, license or otherwise acquire any assets from, or otherwise engage in any other transactions with, any of its Affiliates, except: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) transactions between or among the Obligors; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) any transaction permitted under Section&nbsp;9.01, 9.05, 9.06 or 9.09; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) customary compensation and indemnification of, and other employment arrangements with, directors, officers and employees
of any Obligor in the Ordinary Course of Business; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) transactions upon fair and reasonable terms that are no less
favorable to any Obligor than would be obtained in a comparable <FONT STYLE="white-space:nowrap">arm&#146;s-length</FONT> transaction with a Person not an Affiliate; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) the transactions set forth on Schedule&nbsp;9.10; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) transactions constituting any part of a Permitted IPO Reorganization and otherwise permitted herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;9.11.</I> <I>Restrictive Agreements</I><I>.</I> It will not, and will not permit any of its Subsidiaries to,
directly or indirectly, enter into, incur or permit to exist any Restrictive Agreement other than (a)&nbsp;restrictions and conditions imposed by Law or by the Loan Documents, (b)&nbsp;Restrictive Agreements listed on Schedule&nbsp;7.15,
(c)&nbsp;Organizational Documents of an Obligor as in effect on the date hereof or (d)&nbsp;limitations associated with Permitted Liens or with any transaction permitted under Sections&nbsp;9.01, 9.03, 9.05, 9.06 or 9.09. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;9.12.</I> <I>Organizational Documents, Material Agreements</I>. (a)&nbsp;Except in connection with a Permitted
IPO Reorganization, it will not, and will not permit any of its Subsidiaries to, enter into any amendment to or modification of any Organizational Document without the prior written consent of the Administrative Agent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) It will not, and will not permit any of its Subsidiaries to (i)&nbsp;enter into any material waiver, amendment or modification of any
Material Agreement (including, but not limited to, any amendments to provisions relating to pricing and term) that would be reasonably expected to adversely affect the Lenders in any material respect or (ii)&nbsp;take or omit to take any action that
results in the termination of, or permits any other Person to terminate, any Material Agreement or Material Intellectual Property that would be reasonably expected to adversely affect the Lenders in any material respect, without, in each case, the
prior written consent of the Administrative Agent. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-95- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;9.13.</I> <I>Holding Company</I>. Intermediate Holdings shall
not: (a)&nbsp;incur, directly or indirectly, any Indebtedness or any other obligation or liability whatsoever other than the Obligations; (b)&nbsp;create or suffer to exist any Lien upon any property or assets now owned or hereafter acquired by it
other than the Liens created under the Security Documents to which it is a party or permitted pursuant to Section&nbsp;9.02; (c)&nbsp;engage in any business or activity or own any assets other than: (i)&nbsp;holding 100% of the Equity Interests of
West Affum Corp.; (ii)&nbsp;performing its obligations and activities incidental thereto under the Loan Documents; and (iii)&nbsp;making Restricted Junior Payments and Investments to the extent permitted by this Agreement; (d)&nbsp;consolidate with
or merge with or into, or convey, transfer or lease all or substantially all its assets to, any Person; (e)&nbsp;sell or otherwise dispose of any Equity Interests of any of its Subsidiaries; (f)&nbsp;create or acquire any Subsidiary or make or own
any Investment in any Person other than West Affum Corp.; or (g)&nbsp;fail to hold itself out to the public as a legal entity separate and distinct from all other Persons. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;9.14.</I> <I>Sales and Leasebacks</I><I>.</I> Except as permitted by Section&nbsp;9.01(g), it will not, and will
not permit any of its Subsidiaries to, become liable, directly or indirectly, with respect to any lease, whether an operating lease or a Capital Lease Obligation, of any Property (whether real, personal, or mixed), whether now owned or hereafter
acquired, which (a)&nbsp;any Obligor has sold or transferred or is to sell or transfer to any other Person and (b)&nbsp;any Obligor intends to use for substantially the same purposes as Property which has been or is to be sold or transferred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;9.15.</I> <I>Hazardous Material</I><I>.</I> It will not, and will not permit any of its Subsidiaries to, use,
generate, manufacture, install, treat, release, store or dispose of any Hazardous Material, except in compliance with all applicable Environmental Laws or where the failure to comply would not reasonably be expected to result in a Material Adverse
Change. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;9.16.</I> <I>Accounting Changes</I><I>.</I> It will not, and will not permit any of its
Subsidiaries to, make any significant change in accounting treatment, except as required or permitted by GAAP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;9.17.</I> <I>Compliance with ERISA</I><I>.</I> No Obligor shall cause or permit to exist&nbsp;any event that
would result in the imposition of a Lien with respect to any Title&nbsp;IV Plan or Multiemployer Plan or&nbsp;any other ERISA Event that would, in the aggregate, have a Material Adverse Effect. No Obligor shall cause or permit to exist any event
that would result in the imposition of a Lien with respect to any Benefit Plan that would have a Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;9.18.</I> <I>Outbound Licenses.</I> It will not, and will not permit any of its Subsidiaries to, enter into or
become bound by any outbound license or agreement unless such outbound license or agreement is a Permitted License. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-96- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;9.19.</I> <I>Inbound Licenses</I><I>.</I> It will not, and
will not permit any of its Subsidiaries to, enter into or become bound by any inbound license or agreement (other than Permitted Licenses) unless (a)&nbsp;no Default has occurred and is continuing, (b)&nbsp;such Obligor has provided written notice
to the Administrative Agent of the material terms of such license or agreement with a description of its anticipated and projected impact on such Obligor&#146;s business or financial condition, and (c)&nbsp;such Obligor has taken such commercially
reasonable actions as the Administrative Agent may reasonably request to obtain the consent of, or waiver by, any Person whose consent or waiver is necessary for the Administrative Agent to be granted a valid and perfected security interest in such
license or agreement allowing the Administrative Agent to fully exercise its rights under any of the Loan Documents in the event of a disposition or liquidation of the rights, assets or property that is the subject of such license or agreement;
<I>provided</I> that the aggregate consideration paid for all such inbound licenses pursuant to this Section&nbsp;9.19 shall not exceed an amount equal to $2,500,000 per fiscal year. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>RTICLE</SMALL>&nbsp;10. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>E<SMALL>VENTS</SMALL> <SMALL>OF</SMALL> D<SMALL>EFAULT</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;10.01.</I> <I>Events of Default</I><I>.</I> Each of the following events shall constitute an
<I>&#147;</I><I>Event of Default</I><I>&#148;</I>: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Borrowers shall fail to pay any principal of the Term Loans when
and as the same shall become due and payable, whether at the due date thereof or at a date fixed for prepayment thereof or otherwise; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) any Obligor shall fail to pay any Obligation (other than an amount referred to in Section&nbsp;10.01(a)) when and as the
same shall become due and payable, and such failure shall continue unremedied for a period of three (3)&nbsp;Business Days; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) any representation or warranty made by or on behalf of an Obligor or any of its Subsidiaries in or in connection with this
Agreement or any other Loan Document or any amendment or modification hereof or thereof, or in any report, certificate, financial statement or other document furnished pursuant to or in connection with this Agreement or any other Loan Document or
any amendment or modification hereof or thereof, shall: (i)&nbsp;prove to have been incorrect when made or deemed made to the extent that such representation or warranty contains any materiality or Material Adverse Effect qualifier; or
(ii)&nbsp;prove to have been incorrect in any material respect when made or deemed made to the extent that such representation or warranty does not otherwise contain any materiality or Material Adverse Effect qualifier; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) any Obligor shall fail to observe or perform any covenant, condition or agreement contained in Sections&nbsp;8.01, 8.02,
8.03(a) (with respect to a Borrower&#146;s existence), 8.10, 8.11(a), 8.13, 8.15 (subject to the last paragraph of Section&nbsp;8.15), 8.17, 8.18 (solely with respect to any act of denying the right of the Observer&#146;s attendance and observation
of a meeting of OpCo&#146;s Board (or any direct or indirect parent entity of OpCo, if applicable) and the Observer&#146;s access to such Board or preventing such attendance or observation), 8.20, 8.21 or Article&nbsp;9; or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-97- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) any Obligor shall fail to observe or perform any covenant, condition or
agreement contained in this Agreement (other than those specified in Section&nbsp;10.01(a), (b) or (d)) or any other Loan Document, and, in the case of any failure that is capable of cure, such failure shall continue unremedied for a period of
thirty (30)&nbsp;or more days after the occurrence thereof; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) any Obligor shall fail to make any payment in respect
of any Material Indebtedness, when and as the same shall become due and payable after giving effect to any applicable grace or cure period as originally provided by the terms of such Indebtedness; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) [reserved]; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) (i)&nbsp;any &#147;event of default&#148; or similar event under, the Contract governing any Material Indebtedness shall
occur and such &#147;event of default&#148; or similar event shall continue unremedied, uncured or unwaived after a period of five (5)&nbsp;Business Days after the expiration of any cure period thereunder, or (ii)&nbsp;any event or condition occurs
(A)&nbsp;that results in any Material Indebtedness becoming due prior to its scheduled maturity or (B)&nbsp;that enables or permits (with or without the giving of notice, the lapse of time or both) the holder or holders of such Material Indebtedness
or any trustee or agent on its or their behalf to cause such Material Indebtedness to become due, or to require the prepayment, repurchase, redemption or defeasance thereof, prior to its scheduled maturity; <I>provided</I> that this
Section&nbsp;10.01(h) shall not apply to secured Indebtedness that becomes due as a result of the voluntary sale or transfer of the Property securing such Material Indebtedness; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) any Obligor or any of its Subsidiaries: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) ceases to be Solvent, or generally does not or becomes unable to pay its debts or meet its liabilities as the same become
due, or admits in writing its inability to pay its debts generally, or declares any general moratorium on its Indebtedness, or proposes a compromise or arrangement or deed of company arrangement between it and any class of its creditors; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) shall (A)&nbsp;voluntarily commence any proceeding or file any petition seeking liquidation, <FONT
STYLE="white-space:nowrap">winding-up,</FONT> dissolution, <FONT STYLE="white-space:nowrap">strike-off</FONT> reorganization or other relief under any Federal, state or foreign bankruptcy, insolvency, receivership or similar law now or hereafter in
effect, (B)&nbsp;consent to the institution of, or fail to contest in a timely and appropriate manner, any proceeding or petition described in Section&nbsp;10.01(j), (C)&nbsp;apply for or consent to the appointment of a restructuring officer,
receiver, liquidator, trustee, custodian, sequestrator, conservator or similar official for an Obligor or for a substantial part of its assets, (D)&nbsp;file an answer admitting the material allegations of a petition filed against it in any such
proceeding, (E)&nbsp;make a general assignment for the benefit of creditors or (F)&nbsp;take any action for the purpose of effecting any of the foregoing; or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-98- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) an involuntary proceeding shall be commenced or an involuntary petition
shall be filed seeking (i)&nbsp;liquidation, winding-up, reorganization or other relief in respect of an Obligor or any Subsidiary of an Obligor or its debts, or of a substantial part of its assets, under any Federal, state or foreign bankruptcy,
insolvency, receivership or similar law now or hereafter in effect or (ii)&nbsp;the appointment of a receiver, liquidator, restructuring officer, trustee, custodian, sequestrator, conservator, examiner, process adviser or similar official for an
Obligor or any Subsidiary of an Obligor or for a substantial part of its assets, and, in any such case, such proceeding or petition shall continue undismissed for sixty (60) days or an order or decree approving or ordering any of the foregoing shall
be entered; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) one or more judgments for the payment of money in an aggregate amount in excess of $500,000 (excluding
any amounts covered by insurance as to which the applicable carrier has accepted coverage) shall be rendered against any Obligor or any combination thereof and the same shall remain undischarged for a period of sixty (60)&nbsp;consecutive days
during which execution shall not be effectively stayed, or any action shall be legally taken by a judgment creditor to attach or levy upon any assets of any Obligor to enforce any such judgment; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) an ERISA Event shall have occurred that when taken together with all other ERISA Events that have occurred, would
reasonably be expected to result in a Material Adverse Effect; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) a Change of Control shall have occurred; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) a Material Adverse Change shall have occurred; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) (i)&nbsp;any Lien created by any of the Security Documents shall at any time not constitute a valid and perfected Lien in
favor of the Administrative Agent on Collateral with an aggregate value in excess of $250,000, free and clear of all other Liens (other than Permitted Liens) except due to the action or inaction of the Administrative Agent or any Lender(s),
(ii)&nbsp;the Security Documents or any Guarantee of any of the Obligations shall for whatever reason cease to be in full force and effect, or (iii)&nbsp;any of the Security Documents or any Guarantee of any of the Obligations, or the enforceability
thereof, shall be repudiated or contested by any Obligor; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) any injunction, whether temporary or permanent, shall be
rendered against any Obligor that prevents the Obligors from selling or manufacturing the Product in the United States for more than one hundred twenty (120) consecutive calendar days; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q) (i)&nbsp;the FDA or any other Governmental Authority (A)&nbsp;issues a letter or other communication asserting that any
Product lacks a required Product Authorization, including in respect of CE marks, PMAs or 510(k)s, or (B)&nbsp;initiates enforcement action against, or issues a warning letter with respect to, any Obligor, or any of their Products or the
manufacturing facilities therefor, that causes any Obligor or Subsidiary thereof to discontinue marketing or withdraw any of its material Products, or causes a delay in the manufacture of any of its material Products, which discontinuance,
withdrawal or delay </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-99- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">
would reasonably be expected to last for more than ninety (90)&nbsp;days, (ii)&nbsp;there is a recall of any Product that has generated or is expected to generate an aggregate amount of revenue
equal to at least $500,000 over any consecutive twelve&nbsp;(12)&nbsp;month period, or (iii)&nbsp;any Obligor or Subsidiary thereof enters into a settlement agreement, consent decree or similar agreement with the FDA or any other Governmental
Authority that results in aggregate liability as to any single or related series of transactions, incidents or conditions, in excess of $500,000; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(r) any material Permit relating to any Product (including all Product Authorizations and other Regulatory Approvals), or any
of the Obligors&#146; or their Subsidiaries&#146; material rights or interests thereunder, is terminated, adversely amended or otherwise determined to be ineffective in any manner adverse to any of the Products or Obligors or Subsidiaries, in each
case, for more than ninety (90)&nbsp;days; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(s) (i) any Obligor is required to pay a fine, penalty, damages, judgment,
settlement amount or other payment (whether imposed by judicial order or settlement) which, individually or in the aggregate, is in excess of $250,000 for any violation or alleged violation of any Health Care Law or (ii)&nbsp;any Obligor receives
notice that it will be debarred or excluded from participation in a Federal Health Care Program; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(t) Borrowers shall
fail to receive gross proceeds from the issuance of equity or unsecured convertible promissory notes of at least $25,000,000 on or prior to April&nbsp;30, 2024. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;10.02.</I> <I>Remedies</I>. (a)&nbsp;Upon the occurrence of any Event of Default, then, and in every such event
(other than an Event of Default described in Section&nbsp;10.01(i) or (j)), and at any time thereafter during the continuance of such event, the Majority Lenders may, by notice to Administrative Borrower, take either or both of the following
actions, at the same or different times: (i)&nbsp;terminate the Commitments, and thereupon the Commitments shall terminate immediately, and (ii)&nbsp;declare the Term Loans then outstanding to be due and payable in whole (or in part, in which case
any principal not so declared to be due and payable may thereafter be declared to be due and payable), and thereupon the principal of the Term Loans so declared to be due and payable, together with accrued interest thereon and all fees and other
Obligations, shall become due and payable immediately (in the case of the Term Loans, at the Redemption Price therefor), without presentment, demand, protest or other notice of any kind, all of which are hereby waived by each Obligor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Upon the occurrence of any Event of Default described in Section&nbsp;10.01(i) or (j), the Commitments shall automatically terminate and
the principal amount of the Term Loans then outstanding, together with accrued interest thereon and all fees and other Obligations, shall automatically become due and payable immediately (in the case of the Term Loans, at the Redemption Price
therefor), without presentment, demand, protest or other notice of any kind, all of which are hereby waived by each Obligor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) If any
Lender collects any money or property pursuant to this Article&nbsp;10, they shall pay out the money or property in the order set forth in Section&nbsp;4.01(c). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-100- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;10.03.</I> <I>Prepayment Premium and Redemption
Price</I><I>.</I> For the avoidance of doubt, any Prepayment Premium (as a component of the Redemption Price) shall be due and payable at any time the Term Loans become due and payable prior to the Stated Maturity Date for any reason other than
pursuant to Section&nbsp;3.03(b)(i), whether due to acceleration pursuant to the terms of this Agreement (in which case it shall be due immediately, upon the giving of notice to Administrative Borrower in accordance with Section&nbsp;10.02(a), or
automatically, in accordance with Section&nbsp;10.02(b)), by operation of law or otherwise (including, without limitation, on account of any bankruptcy filing). In view of the impracticability and extreme difficulty of ascertaining the actual amount
of damages to the Lenders or profits lost by the Lenders as a result of such acceleration, and by mutual agreement of the parties as to a reasonable estimation and calculation of the lost profits or damages of the Lenders, any Prepayment Premium
shall be due and payable upon such date. Each Obligor hereby waives any defense to payment, whether such defense may be based in public policy, ambiguity, or otherwise. The Obligors and the Lenders acknowledge and agree that the Prepayment Premium
due and payable in accordance with this Agreement shall not constitute unmatured interest, whether under Section&nbsp;502(b)(2) of the Bankruptcy Code or otherwise. Each Obligor further acknowledges and agrees, and waives any argument to the
contrary, that payment of such amount does not constitute a penalty or an otherwise unenforceable or invalid obligation. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>RTICLE</SMALL>&nbsp;11. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>G<SMALL>UARANTEE</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;11.01.</I> <I>The Guarantee</I><I>.</I> The Guarantors hereby jointly and severally guarantee to the
Administrative Agent and each Lender, and its successors and assigns, the prompt payment in full when due (whether at stated maturity, by acceleration or otherwise) of the principal of and interest on the Term Loans, all fees and other amounts and
Obligations from time to time owing to the Administrative Agent and any Lender by Borrowers under this Agreement or under any other Loan Document and by any other Obligor under any of the Loan Documents, in each case strictly in accordance with the
terms thereof (such obligations being herein collectively called the <I>&#147;</I><I>Guaranteed Obligations</I><I>&#148;</I>). The Guarantors hereby further jointly and severally agree that if Borrowers shall fail to pay in full when due (whether at
stated maturity, by acceleration or otherwise) any of the Guaranteed Obligations, the Guarantors will promptly pay the same, without any demand or notice whatsoever, and that in the case of any extension of time of payment or renewal of any of the
Guaranteed Obligations, the same will be promptly paid in full when due (whether at extended maturity, by acceleration or otherwise) in accordance with the terms of such extension or renewal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;11.02.</I> <I>Obligations Unconditional</I><I>.</I> The obligations of the Guarantors under Section&nbsp;11.01
are absolute and unconditional, joint and several, irrespective of the value, genuineness, validity, regularity or enforceability of the obligations of Borrowers under this Agreement or any other agreement or instrument referred to herein, or any
substitution, release or exchange of any other guarantee of or security for any of the Guaranteed Obligations, and, to the fullest extent permitted by applicable Law, irrespective of any other circumstance whatsoever that might otherwise constitute
a legal or equitable discharge or defense of a surety or Guarantor (other than the payment in full in cash of the Obligations (other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-101- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
than inchoate indemnity obligations)), it being the intent of this Section&nbsp;11.02 that the obligations of the Guarantors hereunder shall be absolute and unconditional, joint and several,
under any and all circumstances. Without limiting the generality of the foregoing, it is agreed that the occurrence of any one or more of the following shall not alter or impair the liability of the Guarantors hereunder, which shall remain absolute
and unconditional as described above: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) at any time or from time to time, without notice to the Guarantors, the time
for any performance of or compliance with any of the Guaranteed Obligations shall be extended, or such performance or compliance shall be waived; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) any of the acts mentioned in any of the provisions of this Agreement or any other agreement or instrument referred to
herein shall be done or omitted; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) the maturity of any of the Guaranteed Obligations shall be accelerated, or any of
the Guaranteed Obligations shall be modified, supplemented or amended in any respect, or any right under this Agreement or any other agreement or instrument referred to herein shall be waived or any other Guarantee of any of the Guaranteed
Obligations or any security therefor shall be released or exchanged in whole or in part or otherwise dealt with; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)
any Lien or security interest granted to, or in favor of, any Lender as security for any of the Guaranteed Obligations shall fail to be perfected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Guarantors hereby expressly waive diligence, presentment, demand of payment, protest and all notices whatsoever, and any requirement that
the Administrative Agent or any Lender exhaust any right, power or remedy or proceed against any Borrower under this Agreement or any other agreement or instrument referred to herein, or against any other Person under any other Guarantee of, or
security for, any of the Guaranteed Obligations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;11.03.</I> <I>Reinstatement</I><I>.</I> The obligations of
the Guarantors under this Article&nbsp;11 shall be automatically reinstated if and to the extent that for any reason any payment by or on behalf of Borrowers in respect of the Guaranteed Obligations is rescinded or must be otherwise restored by any
holder of any of the Guaranteed Obligations, whether as a result of any proceedings in bankruptcy or reorganization or otherwise, and the Guarantors jointly and severally agree that they will indemnify the Administrative Agent and each Lender on
demand for all reasonable costs and expenses (including reasonable fees of counsel) incurred by such Persons in connection with such rescission or restoration, including any such reasonable costs and expenses incurred in defending against any Claim
alleging that such payment constituted a preference, fraudulent transfer or similar payment under any bankruptcy, insolvency or similar Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;11.04.</I> <I>Subrogation</I><I>.</I> The Guarantors hereby jointly and severally agree that, until the payment
and satisfaction in full of all Guaranteed Obligations and the expiration and termination of the Commitments, they shall not exercise any right or remedy arising by reason of any performance by them of their Guarantee in Section&nbsp;11.01, whether
by subrogation or otherwise, against Borrowers or any other guarantor of any of the Guaranteed Obligations or any security for any of the Guaranteed Obligations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-102- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;11.05.</I> <I>Remedies</I><I>.</I> The Guarantors jointly and
severally agree that, as between the Guarantors, on one hand, and the Lenders, on the other hand, the obligations of Borrowers under this Agreement and under the other Loan Documents may be declared to be forthwith due and payable as provided in
Article&nbsp;10 (and shall be deemed to have become automatically due and payable in the circumstances provided in Article&nbsp;10) for purposes of Section&nbsp;11.01 notwithstanding any stay, injunction or other prohibition preventing such
declaration (or such obligations from becoming automatically due and payable) as against Borrowers and that, in the event of such declaration (or such obligations being deemed to have become automatically due and payable), such obligations (whether
or not due and payable by Borrowers) shall forthwith become due and payable by the Guarantors for purposes of Section&nbsp;11.01. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;11.06.</I> <I>Instrument for the Payment of Money</I><I>.</I> Each Guarantor hereby acknowledges that the
Guarantee in this Article&nbsp;11 constitutes an instrument for the payment of money, and consents and agrees that each Lender, at its sole option, in the event of a dispute by such Guarantor in the payment of any moneys due hereunder, shall have
the right to proceed by motion for summary judgment in lieu of complaint pursuant to N.Y.&nbsp;Civ. Prac. L&amp;R &#167;&nbsp;3213. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;11.07.</I> <I>Continuing Guarantee</I><I>.</I> The Guarantee in this Article&nbsp;11 is a continuing guarantee,
and shall apply to all Guaranteed Obligations whenever arising. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;11.08.</I> <I>Rights of
Contribution</I><I>.</I> The Guarantors hereby agree, as between themselves, that if any Guarantor shall become an Excess Funding Guarantor (as defined below) by reason of the payment by such Guarantor of any Guaranteed Obligations, each other
Guarantor shall, on demand of such Excess Funding Guarantor (but subject to the next sentence), pay to such Excess Funding Guarantor an amount equal to such Guarantor&#146;s Pro Rata Share (as defined below and determined, for this purpose, without
reference to the properties, debts and liabilities of such Excess Funding Guarantor) of the Excess Payment (as defined below) in respect of such Guaranteed Obligations. The payment obligation of a Guarantor to any Excess Funding Guarantor under this
Section&nbsp;11.08 shall be subordinate and subject in right of payment to the prior payment in full of the obligations of such Guarantor under the other provisions of this Article&nbsp;11 and such Excess Funding Guarantor shall not exercise any
right or remedy with respect to such excess until payment and satisfaction in full of all of such obligations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">For purposes of this
Section&nbsp;11.08, (i)<I>&nbsp;&#147;Excess Funding Guarantor&#148;</I> means, in respect of any Guaranteed Obligations, a Guarantor that has paid an amount in excess of its Pro Rata Share of such Guaranteed Obligations, (ii)<I>&nbsp;&#147;Excess
Payment&#148;</I> means, in respect of any Guaranteed Obligations, the amount paid by an Excess Funding Guarantor in excess of its Pro Rata Share of such Guaranteed Obligations and (iii)<I>&nbsp;&#147;Pro Rata Share&#148;</I> means, as of the date
of determination, for any Guarantor, the ratio (expressed as a percentage) of (x)&nbsp;the amount by which the aggregate present fair saleable value of all properties of such Guarantor (excluding any shares of stock of any other Guarantor) exceeds
the amount of all the debts and liabilities of such Guarantor (including contingent, subordinated, unmatured and unliquidated liabilities, but excluding the obligations of such Guarantor hereunder and any obligations of any other Guarantor that have
been </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-103- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
guaranteed by such Guarantor) to (y)&nbsp;the amount by which the aggregate fair saleable value of all properties of all of the Guarantors exceeds the amount of all the debts and liabilities
(including contingent, subordinated, unmatured and unliquidated liabilities, but excluding the obligations of Borrowers and the Guarantors hereunder and under the other Loan Documents) of all of the Guarantors, determined (A)&nbsp;with respect to
any Guarantor that is a party hereto on the Closing Date, as of such date, and (B)&nbsp;with respect to any other Guarantor, as of the date such Guarantor becomes a Guarantor hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;11.09.</I> <I>General Limitation on Guarantee Obligations</I><I>.</I> In any action or proceeding involving any
provincial, territorial or state corporate law, or any national, state or federal bankruptcy, insolvency, reorganization or other Law affecting the rights of creditors generally, if the obligations of any Guarantor under Section&nbsp;11.01 would
otherwise, taking into account the provisions of Section&nbsp;11.08, be held or determined to be void, invalid or unenforceable, or subordinated to the Claims of any other creditors, on account of the amount of its liability under
Section&nbsp;11.01, then, notwithstanding any other provision hereof to the contrary, the amount of such liability shall, without any further action by such Guarantor, the Administrative Agent, the Lenders or any other Person, be automatically
limited and reduced to the highest amount that is valid and enforceable and not subordinated to the Claims of other creditors as determined in such action or proceeding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;11.10.</I> <I>Irish Limitation on Guarantee Obligations</I>. The obligations of the Irish Obligor under
Section&nbsp;11.01 shall be deemed not to be undertaken or incurred to the extent the same would: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) constitute unlawful
financial assistance prohibited by section 82 of the Companies Act 2014 of Ireland (as amended); or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) constitute a
breach of section 239 of the Companies Act 2014 of Ireland (as amended); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>provided </I>that (in the case of both (a)&nbsp;and (b) above), for the
avoidance of doubt, to the extent that any such obligations under Section&nbsp;11.01 have been validated by a summary approval procedure in accordance with the Companies Act 2014 of Ireland (as amended), they shall not constitute unlawful financial
assistance under the said section 82 or a breach of the said section 239 (as applicable). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>RTICLE</SMALL>&nbsp;12. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>DMINISTRATIVE</SMALL> A<SMALL>GENT</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;12.01.</I> <I>Appointment</I>. Each of the Lenders hereby irrevocably appoints Perceptive to act on its behalf
as the Administrative Agent hereunder and under the other Loan Documents and authorizes the Administrative Agent to take such actions on its behalf and to exercise such powers as are delegated to the Administrative Agent by the terms hereof or
thereof, together with such actions and powers as are reasonably incidental thereto. Other than as set forth in Section&nbsp;12.06 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-104- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and Section&nbsp;12.09, the provisions of this Article&nbsp;12 are solely for the benefit of the Administrative Agent and the Lenders, and neither Borrowers nor any other Obligor will have rights
as a <FONT STYLE="white-space:nowrap">third-party</FONT> beneficiary of any of such provisions. It is understood and agreed that the use of the term &#147;agent&#148; herein or in any other Loan Documents (or any other similar term) with reference
to the Administrative Agent is not intended to connote any fiduciary or other implied (or express) obligations arising under agency doctrine of any applicable Law. Instead, such term is used as a matter of market custom, and is intended to create or
reflect only an administrative relationship between contracting parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;12.02.</I> <I>Rights as a
Lender</I>. The Person serving as the Administrative Agent hereunder will have the same rights and powers in its capacity as a Lender as any other Lender and may exercise the same as though it were not the Administrative Agent, and the term
&#147;Lender&#148; or &#147;Lenders&#148; will, unless otherwise expressly indicated or unless the context otherwise requires, include the Person serving as the Administrative Agent hereunder in its individual capacity to the extent such Person is a
Lender. The Lenders acknowledge and agree that such Person and its Affiliates may accept deposits from, lend money to, own securities of, act as the financial advisor or in any other advisory capacity for, and generally engage in any kind of
business with, Borrowers, the other Obligors or any other Subsidiaries or Affiliates of the Obligors as if such Person were not the Administrative Agent hereunder and without any duty to account therefor to the Lenders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;12.03.</I> <I>Exculpatory Provisions</I>. (a)&nbsp;The Administrative Agent will not have any duties or
obligations except those expressly set forth herein and in the other Loan Documents, and its duties hereunder are administrative in nature. Without limiting the generality of the foregoing, the Administrative Agent: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) will not be subject to any fiduciary or other implied duties, regardless of whether a Default has occurred and is
continuing; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) will not have any duty to take any discretionary action or exercise any discretionary powers, except
discretionary rights and powers expressly contemplated hereby or by the other Loan Documents that the Administrative Agent is required to exercise as directed in writing by the Majority Lenders (or such other number or percentage of the Lenders as
will be expressly provided for herein or in the other Loan Documents); <I>provided</I> that the Administrative Agent will not be required to take any action that, in its opinion or the opinion of its counsel, may expose the Administrative Agent to
liability or that is contrary to any Loan Document or applicable Law, including any action that may be in violation of the automatic stay under any Insolvency Proceeding; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) will not, except as expressly set forth herein and in the other Loan Documents, have any duty to disclose, and will not
be liable for the failure to disclose, any information relating to the Obligors or any of its Subsidiaries or Affiliates that is communicated to or obtained by the Person serving as the Administrative Agent or any of its Affiliates in any capacity.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-105- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Administrative Agent will not be liable for any action taken or not taken by it
(i)&nbsp;with the consent or at the request of the Majority Lenders (or such other number or percentage of the Lenders as will be necessary, or as the Administrative Agent believes in good faith will be necessary, under the circumstances), or
(ii)&nbsp;in the absence of its own gross negligence or willful misconduct as determined by a court of competent jurisdiction by final and <FONT STYLE="white-space:nowrap">non-appealable</FONT> judgment. The Administrative Agent will be deemed not
to have knowledge of any Default unless and until notice describing such Default is given to the Administrative Agent in writing by Borrowers or a Lender. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The Administrative Agent will not be responsible for or have any duty to ascertain or inquire into (i)&nbsp;any statement, warranty or
representation made in or in connection with this Agreement or any other Loan Document, (ii)&nbsp;the contents of any certificate, report or other document delivered hereunder or thereunder or in connection herewith or therewith, (iii)&nbsp;the
performance or observance of any of the covenants, agreements or other terms or conditions set forth herein or therein or the occurrence of any Default, (iv)&nbsp;the validity, enforceability, effectiveness or genuineness of this Agreement, any
other Loan Document or any other agreement, instrument or document or (v)&nbsp;the satisfaction of any condition set forth in Article&nbsp;6 or elsewhere herein, other than to confirm receipt of items expressly required to be delivered to the
Administrative Agent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;12.04.</I> <I>Reliance by Administrative Agent</I>. The Administrative Agent will be
entitled to rely upon, and will not incur any liability for relying upon, any notice, request, certificate, consent, statement, instrument, document or other writing (including any electronic message, Internet or intranet website posting or other
distribution) believed by it to be genuine and to have been signed, sent or otherwise authenticated by the proper Person. The Administrative Agent also may rely upon any statement made to it orally or by telephone and believed by it to have been
made by the proper Person, and will not incur any liability for relying thereon. In determining compliance with any condition hereunder to the making of the Term Loans that by its terms must be fulfilled to the satisfaction of a Lender, the
Administrative Agent may presume that such condition is satisfactory to such Lender unless the Administrative Agent has received notice to the contrary from such Lender prior to the making of such Term Loan. The Administrative Agent may consult with
legal counsel (who may be counsel for Borrowers), independent accountants and other experts selected by it, and will not be liable for any action taken or not taken by it in accordance with the advice of any such counsel, accountants or experts.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;12.05.</I> <I>Delegation of Duties</I>. The Administrative Agent may perform any and all of its duties and
exercise its rights and powers hereunder or under any other Loan Document by or through any one or more <FONT STYLE="white-space:nowrap">sub-agents</FONT> appointed by the Administrative Agent. The Administrative Agent and any such <FONT
STYLE="white-space:nowrap">sub-agent</FONT> may perform any and all of its duties and exercise its rights and powers by or through their respective Affiliates. The exculpatory provisions of this Section&nbsp;will apply to any such <FONT
STYLE="white-space:nowrap">sub-agent</FONT> and to the Affiliates of the Administrative Agent and any such <FONT STYLE="white-space:nowrap">sub-agent,</FONT> and will apply to their respective activities in connection with the syndication of the
facility as well as activities as Administrative Agent. The Administrative Agent will not be responsible for the negligence or misconduct of any <FONT STYLE="white-space:nowrap">sub-agents</FONT> except to the extent that a court of competent
jurisdiction determines in a final and <FONT STYLE="white-space:nowrap">non-appealable</FONT> judgment that the Administrative Agent acted with gross negligence or willful misconduct in the selection of such
<FONT STYLE="white-space:nowrap">sub-agents.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-106- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;12.06.</I> <I>Resignation of Agent</I>. (a)&nbsp;The
Administrative Agent may at any time give notice of its resignation to the Lenders and Administrative Borrower, which notice shall set forth the effective date of such resignation (the <I>&#147;</I><I>Resignation Effective Date</I><I>&#148;</I>),
such date not to be earlier than the thirtieth (30th) day following the date of such notice. The Majority Lenders and Borrowers shall mutually agree upon a successor to the Administrative Agent. If the Majority Lenders and Borrowers are unable to so
mutually agree and no successor shall have been appointed within <FONT STYLE="white-space:nowrap">twenty-five&nbsp;(25)</FONT> days after the retiring Administrative Agent gives notice of its resignation, then the retiring Administrative Agent may
(but will not be obligated to), on behalf of the Lenders, appoint a successor Administrative Agent it shall designate (in its reasonable discretion after consultation with Borrowers and the Majority Lenders). Whether or not a successor has been
appointed, such resignation will become effective in accordance with such notice on the Resignation Effective Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) With effect from
the Resignation Effective Date (i)&nbsp;the retiring Administrative Agent will be discharged from its duties and obligations hereunder and under the other Loan Documents (except that in the case of any Collateral held by the Administrative Agent on
behalf of the Lenders under any of the Loan Documents, the retiring Administrative Agent will continue to hold such Collateral until such time as a successor Administrative Agent is appointed) and (ii)&nbsp;except for any indemnity payments owed to
the retiring Administrative Agent, all payments, communications and determinations provided to be made by, to or through the Administrative Agent will instead be made by or to each Lender directly, until such time, if any, as the Majority Lenders
appoint a successor Administrative Agent as provided for above. Upon the acceptance of a successor&#146;s appointment as Administrative Agent hereunder, such successor will succeed to and become vested with all of the rights, powers, privileges and
duties of the retiring Administrative Agent (other than any rights to indemnity payments owed to the retiring Administrative Agent), and the retiring Administrative Agent will be discharged from all of its duties and obligations hereunder or under
the other Loan Documents. The fees payable by Borrowers to a successor Administrative Agent will be the same as those payable to its predecessor unless otherwise agreed between Borrowers and such successor. After the retiring Administrative
Agent&#146;s resignation hereunder and under the other Loan Documents, the provisions of this Article&nbsp;12 and Sections&nbsp;13.03 and 13.06 will continue in effect for the benefit of such retiring Administrative Agent, its <FONT
STYLE="white-space:nowrap">sub-agents</FONT> and their respective Affiliates in respect of any actions taken or omitted to be taken by any of them while the retiring Administrative Agent was acting as Administrative Agent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;12.07.</I> <I>Non</I><I><FONT STYLE="white-space:nowrap">-Reliance</FONT> on Administrative Agent and Other
Lenders</I>. Each Lender acknowledges that it has, independently and without reliance upon the Administrative Agent or any other Lender or any of their Affiliates and based on such documents and information as it has deemed appropriate, made its own
credit analysis and decision to enter into this Agreement. Each Lender also acknowledges that it will, independently and without reliance upon the Administrative Agent or any other Lender or any of their Affiliates and based on such documents and
information as it will from time to time deem appropriate, continue to make its own decisions in taking or not taking action under or based upon this Agreement, any other Loan Document or any related agreement or any document furnished hereunder or
thereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-107- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;12.08.</I> <I>Administrative Agent May File Proofs of
Claim</I>. In case of the pendency of any Insolvency Proceeding or any other judicial proceeding relative to an Obligor, the Administrative Agent (irrespective of whether the principal of the Term Loans will then be due and payable as herein
expressed or by declaration or otherwise and irrespective of whether the Administrative Agent has made any demand on an Obligor) will be entitled and empowered (but not obligated), by intervention in such proceeding or otherwise: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) to file and prove a Claim for the whole amount of the principal and interest owing and unpaid in respect of the Term Loans
and all other Obligations that are owing and unpaid hereunder or under any other Loan Document and to file such other documents as may be necessary or advisable in order to have the Claims of the Lenders and the Administrative Agent (including any
claim for the reasonable compensation, expenses, disbursements and advances of the Lenders and the Administrative Agent and their respective agents and counsel and all other amounts due the Lenders and the Administrative Agent under this Agreement
or any other Loan Document) allowed in such judicial proceeding; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) to collect and receive any monies or other
property payable or deliverable on any such Claims and to distribute the same. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Any custodian, receiver, assignee, trustee, liquidator,
sequestrator or other similar official in any such judicial proceeding is hereby authorized by each Lender to make any payments of the type described above in this Section&nbsp;12.08 to the Administrative Agent and, in the event that the
Administrative Agent consents to the making of such payments directly to the Lenders, to pay to the Administrative Agent any amount due for the reasonable compensation, expenses, disbursements and advances of the Administrative Agent and its agents
and counsel, and any other amounts due the Administrative Agent under this Agreement or any other Loan Document. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;12.09.</I> <I>Collateral and Guaranty Matters; Appointment of Administrative Agent</I>. (a)&nbsp;Without
limiting the provisions of Section&nbsp;12.08, the Lenders irrevocably agree as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) the Administrative Agent is
authorized, at its option and in its discretion, to release any Lien on any property granted to or held by the Administrative Agent under any Loan Document (A)&nbsp;on the date when all Obligations have been satisfied in full in cash (other than
contingent obligations as to which no Claims have been asserted), (B)&nbsp;that is sold or otherwise disposed of or to be sold or otherwise disposed of as part of or in connection with any sale or other disposition permitted under the Loan
Documents, or (C)&nbsp;subject to Sections&nbsp;13.01 and 13.04, if approved, authorized or ratified in writing by the Majority Lenders; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) the Administrative Agent is authorized, at its option and discretion, to release any Guarantor from its obligations
hereunder if such Person ceases to be a Subsidiary as a result of a transaction permitted under the Loan Documents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon request by the Administrative
Agent at any time, each Lender will confirm in writing the Administrative Agent&#146;s authority to release or subordinate its interest in particular types or items of Collateral, or to release any Guarantor from its obligations under its guaranty
pursuant to this Section&nbsp;12.09. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-108- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Administrative Agent will not be responsible for or have a duty to ascertain or
inquire into any representation or warranty regarding the existence, value or collectability of the Collateral, the existence, priority or perfection of the Administrative Agent&#146;s Lien thereon, or any certificate prepared by any Obligor in
connection therewith, nor will the Administrative Agent be responsible or liable to the Lenders for any failure to monitor or maintain any portion of the Collateral. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Each Lender hereby appoints the Administrative Agent as its collateral agent under each of the Security Documents and agrees that, in so
acting, the Administrative Agent will have all of the rights, protections, exculpations, indemnities and other benefits provided to the Administrative Agent under this Agreement, and hereby authorizes and directs the Administrative Agent, on behalf
of such Lender and all Lenders, without the necessity of any notice to or further consent from any of the Lenders, from time to time to (i)&nbsp;take any action with respect to any Collateral or any Security Document which may be necessary to
perfect and maintain perfected the Liens on the Collateral granted pursuant to any such Security Document or protect and preserve the Administrative Agent&#146;s ability to enforce the Liens or realize upon the Collateral, (ii)&nbsp;act as
collateral agent for each Lender for purposes of acquiring, holding, enforcing and perfecting all Liens created by the Loan Documents and all other purposes stated therein, (iii)&nbsp;enter into intercreditor or subordination agreements, as the case
may be, in connection with Indebtedness permitted pursuant to Sections&nbsp;9.01(c) and 9.01(k), as applicable, (iv)&nbsp;enter into <FONT STYLE="white-space:nowrap">non-disturbance</FONT> or similar agreements in connection with licensing
agreements and arrangements permitted by this Agreement and the other Loan Documents and (v)&nbsp;otherwise to take or refrain from taking any and all action that the Administrative Agent shall deem necessary or advisable in fulfilling its role as
collateral agent under any of the Security Documents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;12.10.</I> <I>Irish Security Matters.</I>
(a)&nbsp;the Lenders appoint the Administrative Agent to hold the security interests constituted by the Irish Security Documents on trust for the Lenders on the terms of the Loan Documents and the Administrative Agent accepts that appointment. The
Administrative Agent declares that it shall hold the Charged Property on trust for the Lenders on the terms of the Loan Documents<I>.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) The Administrative Agent, its subsidiaries and associated companies may each retain for its own account and benefit any fee, remuneration
and profits paid to it in connection with (i)&nbsp;its activities under the Loan Documents and (ii)&nbsp;its engagement in any kind of banking or other business with any Obligor<I>.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) Nothing in this Agreement constitutes the Administrative Agent<B><I> </I></B>as a trustee or fiduciary of, nor shall the Administrative
Agent have any duty or responsibility to, any Obligor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) The Administrative Agent shall have no duties or obligations to any other
Person except for those which are expressly specified in the Loan Documents or mandatorily required by applicable law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) The
Administrative Agent may appoint one or more Delegates on such terms (which may include the power to <FONT STYLE="white-space:nowrap">sub-delegate)</FONT> and subject to such conditions as it thinks fit, to exercise and perform all or any of the
duties, rights, powers and discretions vested in it by the Irish Security Documents and shall not be obliged to supervise any Delegate or be responsible to any person for any loss incurred by reason of any act, omission, misconduct or default on the
part of any Delegate<I>.</I><B><I> </I></B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-109- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) The Administrative Agent may (whether for the purpose of complying with any law or
regulation of any overseas jurisdiction, or for any other reason) appoint (and subsequently remove) any person to act jointly with the Administrative Agent either as a separate trustee or as a <FONT STYLE="white-space:nowrap">co-trustee</FONT> on
such terms and subject to such conditions as the Administrative Agent thinks fit and with such of the duties, rights, powers and discretions vested in the Administrative Agent by the Irish Security Documents<B><I> </I></B>as may be conferred by the
instrument of appointment of that person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(g) The Administrative Agent shall notify the Lenders of the appointment of each Appointee
(other than a Delegate). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(h) The Administrative Agent may pay reasonable remuneration to any Delegate or Appointee, together with any
costs and expenses (including legal fees) reasonably incurred by the Delegate or Appointee in connection with its appointment. All such remuneration, costs and expenses shall be treated, for the purposes of this Agreement, as paid or incurred by the
Administrative Agent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) Each Delegate and each Appointee shall have every benefit, right, power and discretion and the benefit of
every exculpation (together, <I>&#147;Rights&#148;</I>) of the Administrative Agent (in its capacity as security trustee) under the Irish Security Documents, and each reference to the Administrative Agent<B><I> </I></B>(where the context requires
that such reference is to the Administrative Agent in its capacity as security trustee) in the provisions of the Irish Security Documents<B><I> </I></B>which confer Rights shall be deemed to include a reference to each Delegate and each Appointee.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(j) Each Lender confirms its approval of the Irish Security Documents and authorizes and instructs the Administrative Agent (i)&nbsp;to
execute and deliver the Irish Security Documents, (ii)&nbsp;to exercise the rights, powers and discretions given to the Administrative Agent (in its capacity as security trustee) under or in connection with the Irish Security Documents together with
any other incidental rights, powers and discretions and (iii)&nbsp;to give any authorizations and confirmations to be given by the Administrative Agent<B><I> </I></B>(in its capacity as security trustee) on behalf of the Lenders under the Irish
Security Documents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(k) The Administrative Agent<B><I> </I></B>may accept without inquiry the title (if any) which any person may have
to the Charged Property. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(l) Each Lender confirms that it does not wish to be registered as a joint proprietor of any security interest
constituted by an Irish Security Document and accordingly authorizes (i)&nbsp;the Administrative Agent to hold such security interest in its sole name (or in the name of any Delegate) as trustee for the Lenders and (ii)&nbsp;the Property
Registration Authority of Ireland, the Companies Registration Office of Ireland (or other relevant registry) to register the Administrative Agent (or any Delegate or Appointee) as a sole proprietor of such security interest. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-110- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(m) Except to the extent that an Irish Security Document otherwise requires, any moneys
which the Administrative Agent receives under or pursuant to an Irish Security Document may be (i)&nbsp;invested in any investments which the Administrative Agent selects and which are authorized by applicable law or (ii)&nbsp;placed on deposit at
any bank or institution (including the Administrative Agent) on terms that the Administrative Agent thinks fit, in each case in the name or under the control of the Administrative Agent, and the Administrative Agent shall hold those moneys, together
with any accrued income (net of any applicable Taxes) to the order of the Lenders, and shall pay them to the Lenders on demand. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(n) On a
disposal of any of the Charged Property which is permitted under the Loan Documents, the Administrative Agent shall (at the cost of the Obligors) execute any release of the Irish Security Documents or other claim over that Charged Property and issue
any certificates of <FONT STYLE="white-space:nowrap">non-crystallization</FONT> of floating charges that may be required or take any other action that the Administrative Agent considers desirable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(o) The Administrative Agent shall not be liable for (i)&nbsp;any defect in or failure of the title (if any) which any person may have to any
assets over which security is intended to be created by an Irish Security Document, (ii)&nbsp;any loss resulting from the investment or deposit at any bank of moneys which it invests or deposits in a manner permitted by an Irish Security Document,
(iii)&nbsp;the exercise of, or the failure to exercise, any right, power or discretion given to it by or in connection with any Loan Document or any other agreement, arrangement or document entered into, or executed in anticipation of, under or in
connection with, any Loan Document or (iv)&nbsp;any shortfall which arises on enforcing an Irish Security Document. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(p) The
Administrative Agent shall not be obligated to (i)&nbsp;obtain any authorization or environmental permit in respect of any of the Charged Property or an Irish Security Document, (ii)&nbsp;hold in its own possession an Irish Security Document, title
deed or other document relating to the Charged Property or an Irish Security Document, (iii)&nbsp;perfect, protect, register, make any filing or give any notice in respect of an Irish Security Document (or the order of ranking of an Irish Security
Document), unless that failure arises directly from its own gross negligence or willful misconduct or (iv)&nbsp;require any further assurances in relation to an Irish Security Document. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(q) In respect of any Irish Security Document, the Administrative Agent shall not be obligated to (i)&nbsp;insure, or require any other
person to insure, the Charged Property or (ii)&nbsp;make any enquiry or conduct any investigation into the legality, validity, effectiveness, adequacy or enforceability of any insurance existing over such Charged Property. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(r) In respect of any Irish Security Document, the Administrative Agent shall not have any obligation or duty to any person for any loss
suffered as a result of (i)&nbsp;the lack or inadequacy of any insurance or (ii)&nbsp;the failure of the Administrative Agent to notify the insurers of any material fact relating to the risk assumed by them, or of any other information of any kind,
unless Majority Lenders have requested it to do so in writing and the Administrative Agent has failed to do so within fourteen (14)&nbsp;days after receipt of that request. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-111- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(s) Every appointment of a successor Administrative Agent under an Irish Security
Document<B><I> </I></B>shall be by deed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(t) The rights, powers and discretions conferred on the Administrative Agent by this Agreement
shall be supplemental to the Trustee Acts of Ireland 1888 to 1989 and in addition to any other rights, powers and discretions which may be vested in the Administrative Agent by the Loan Documents, law or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(u) The duties, rights, powers and discretions conferred on the Administrative Agent by this Section&nbsp;12.10 shall be supplemental to
those conferred on the Administrative Agent pursuant to other provisions of this Agreement. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>RTICLE</SMALL>&nbsp;13. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>M<SMALL>ISCELLANEOUS</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;13.01.</I> <I>No Waiver</I><I>.</I> No failure on the part of the Administrative Agent or the Lenders to
exercise and no delay in exercising, and no course of dealing with respect to, any right, power or privilege under any Loan Document shall operate as a waiver thereof, nor shall any single or partial exercise of any right, power or privilege under
any Loan Document preclude any other or further exercise thereof or the exercise of any other right, power or privilege. The remedies provided herein are cumulative and not exclusive of any remedies provided by Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;13.02.</I> <I>Notices</I><I>.</I> All notices, requests, instructions, directions and other communications
provided for herein (including any modifications of, or waivers, requests or consents under, the Loan Documents) shall be given or made in writing (including by telecopy or electronic mail) delivered, if to Administrative Borrower, another Obligor,
the Administrative Agent or the Lenders, to its address specified on Schedule&nbsp;2 hereto or its Guarantee Assumption Agreement, as the case may be, or at such other address as shall be designated by such party in a notice to the other parties.
Except as otherwise provided in this Agreement, all such communications shall be deemed to have been duly given upon receipt of a legible copy thereof, in each case given or addressed as aforesaid. All such communications provided for herein by
telecopy or electronic mail shall be confirmed in writing promptly after the delivery of such communication (it being understood that <FONT STYLE="white-space:nowrap">non-receipt</FONT> of written confirmation of such communication shall not
invalidate such communication). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-112- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;13.03.</I> <I>Expenses, Indemnification, Etc.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <I>Expenses</I>. Each Borrower agrees to pay or reimburse (i)&nbsp;the Lenders for all of their reasonable and documented out of pocket
costs and expenses (limited, in the case of legal fees and expenses, to the reasonable and documented out of pocket costs and expenses of one counsel to the Lenders, taken as a whole (and, if reasonably necessary, of one local counsel in any
relevant jurisdiction to all such persons, taken as a whole under the Loan Documents)), in connection with (A)&nbsp;the negotiation, preparation, execution and delivery of this Agreement and the other Loan Documents and the making of the Term Loans
(exclusive of <FONT STYLE="white-space:nowrap">post-closing</FONT> costs); <I>provided</I> that, so long as the Tranche&nbsp;A Term Loan is made, such fees shall be credited against the Expense Deposit paid by Administrative Borrower, <FONT
STYLE="white-space:nowrap">(B)&nbsp;post-closing</FONT> costs and (C)&nbsp;the negotiation or preparation of any amendment, modification, supplement or waiver of any of the terms of this Agreement or any of the other Loan Documents (whether or not
consummated) and (ii)&nbsp;the Administrative Agent and the Lenders for all of their reasonable and documented out of pocket costs and expenses (including the reasonable fees and expenses of legal counsel) in connection with any enforcement or
collection proceedings resulting from the occurrence of an Event of Default. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <I>Indemnification</I>. Each Obligor hereby indemnifies
the Administrative Agent, the Lenders, their respective Affiliates, and their respective directors, officers, employees, attorneys, agents and advisors (each, an <I>&#147;Indemnified Party&#148;</I>) from and against, and agrees to hold them
harmless against, any and all Claims and Losses of any kind (limited, in the case of legal fees and expenses, to the reasonable and documented out of pocket costs and expenses of one counsel to the Lenders, taken as a whole (and, if reasonably
necessary, of one local counsel in any relevant jurisdiction to all such persons, taken as a whole under the Loan Documents) and solely to the extent any conflict exists, one conflict counsel for all similarly situated Indemnified Parties, taken as
a whole), joint or several, that is incurred by or asserted or awarded against any Indemnified Party, in each case arising out of or in connection with or relating to any investigation, litigation or proceeding or the preparation of any defense with
respect thereto arising out of or in connection with or relating to this Agreement or any of the other Loan Documents or the Transactions or any use made or proposed to be made with the proceeds of the Term Loans, whether or not such investigation,
litigation or proceeding is brought by an Obligor, any of its shareholders or creditors, an Indemnified Party or any other Person, or an Indemnified Party is otherwise a party thereto, and whether or not any of the conditions precedent set forth in
Article&nbsp;6 are satisfied or the other Transactions contemplated by this Agreement are consummated, except to the extent such Claim or Loss is found in a final, <FONT STYLE="white-space:nowrap">non-appealable</FONT> judgment by a court of
competent jurisdiction to have resulted from (i)&nbsp;any Indemnified Party&#146;s (or its Affiliate&#146;s) gross negligence or willful misconduct or material breach of the Loan Documents or (ii)&nbsp;disputes solely among the Indemnified Parties
(other than against the Administrative Agent in its capacity as such). No Obligor shall assert any Claim against any Indemnified Party, on any theory of liability, for consequential, indirect, special or punitive damages arising out of or otherwise
relating to this Agreement or any of the other Loan Documents or any of the Transactions or the actual or proposed use of the proceeds of the Term Loans. To the extent permitted by applicable law and except to the extent expressly provided for in
Section&nbsp;3.02(d), Section&nbsp;5.01 and Section&nbsp;5.02, neither Administrative Agent nor any Lender shall assert, and Administrative Agent and each Lender hereby waives, any claim against an Obligor, on any theory of liability, for special,
indirect, consequential or punitive damages (as opposed to direct or actual damages) arising out of, in connection with, or as a result of, this Agreement or any agreement or instrument contemplated hereby, the Transactions, any Term Loan or the use
of the proceeds thereof; <I>provided</I> that this shall in no manner limit any Indemnified Party&#146;s rights pursuant to this Section&nbsp;13.03(b) with respect to special, indirect, consequential or punitive damages payable by such Indemnified
Party to another Person. This Section shall not apply to Taxes other than Taxes relating to a <FONT STYLE="white-space:nowrap">non-Tax</FONT> Claim or Loss governed by this Section&nbsp;13.03(b). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-113- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;13.04.</I> <I>Amendments, Etc.</I> Except as otherwise
expressly provided in this Agreement, any provision of this Agreement or any other Loan Document may be amended, modified, waived or supplemented only by an instrument in writing signed by Borrowers, the Administrative Agent and the Majority
Lenders; <I>provided</I> that: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) no amendment, waiver or consent shall, unless in writing and signed by all of the
Lenders, do any of the following at any time: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) change the number of Lenders or the percentage of (A)&nbsp;the
Commitments or (B)&nbsp;the aggregate unpaid principal amount of the Term Loans that, in each case, shall be required for the Lenders or any of them to take any action hereunder (including pursuant to any change to the definition of
<I>&#147;Majority Lenders&#148;</I>); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) release one or more Guarantors (or otherwise limit such Guarantors&#146;
liability with respect to the Obligations owing to the Lenders under the Guarantees) if such release or limitation is in respect of all or substantially all of the value represented by the Guarantees to the Lenders; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) release, or subordinate the Lenders&#146; Liens in, all or substantially all of the Collateral in any transaction or
series of related transactions (other than in connection with any sale of Collateral permitted herein); or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) amend
any provision of this Section&nbsp;13.04; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) no amendment, waiver or consent shall, unless in writing and signed by each
Lender specified below for such amendment, waiver or consent: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) increase the Commitments of a Lender without the
consent of such Lender; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) reduce the principal of, or stated rate of interest on, or any Prepayment Premium payable
on, the Term Loans owed to a Lender or any fees or other amounts stated to be payable hereunder or under the other Loan Documents to such Lender without the consent of such Lender; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) postpone any date scheduled for any payment of principal of, or interest on, the Term Loans, any date scheduled for
payment or for any date fixed for any payment of fees hereunder (excluding the due date of any mandatory prepayment of the Term Loans), in each case payable to a Lender without the consent of such Lender; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) change the order of application of prepayment of the Term Loans from the application thereof set forth in the applicable
provisions of Sections&nbsp;4.01(b) and (c)&nbsp;in any manner that adversely affects the Lenders without the consent of holders of a majority of the Commitments or Term Loans outstanding or otherwise change any provision requiring the pro rata
distributions hereunder among the Lenders without all Lenders&#146; consent; or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-114- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) modify Section&nbsp;2.02 without the consent of each Lender directly
and adversely affected thereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing to the contrary, this Agreement may be amended by the Administrative Agent
without the consent of Borrowers to implement the Prior Covenants pursuant to the terms of Section&nbsp;8.15(b). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;13.05.</I> <I>Successors and Assigns</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <I>General</I>. The provisions of this Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective
successors and assigns permitted hereby, except that (i)&nbsp;except to the extent permitted under Section&nbsp;9.03, no Obligor may assign or otherwise transfer any of its rights or obligations hereunder without the prior written consent of the
Administrative Agent and each Lender (and any attempted assignment or transfer by such Obligor without such consent shall be null and void) and (ii)&nbsp;no Lender may assign or otherwise transfer its rights or obligations hereunder except in
accordance with this Section (and any attempted assignment or transfer by such Lender without such consent shall be null and void). Nothing in this Agreement, expressed or implied, shall be construed to confer upon any Person (other than the parties
hereto, their respective successors and assigns permitted hereby, Participants (to the extent provided in paragraph&nbsp;(e) of this Section) and, to the extent expressly contemplated hereby, the Indemnified Parties of the Lenders) any legal or
equitable right, remedy or Claim under or by reason of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <I>Amendments to Loan Documents; Majority Lender Vote</I>.
Each of the Lenders and the Obligors agrees to enter into such amendments to the Loan Documents, and such additional Security Documents and other instruments and agreements, in each case in form and substance reasonably acceptable to the Lenders and
the Obligors, as shall reasonably be necessary to implement and give effect to any assignment made by any Lender (or any direct or indirect assignee thereof) from time to time under this Section&nbsp;13.05. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <I>Assignments by Lenders</I>. (i)&nbsp;Subject to the conditions set forth in paragraph&nbsp;(c)(ii) below, any Lender may assign to one
or more Persons (other than an Ineligible Assignee) all or a portion of its rights and obligations under the Loan Documents (including all or a portion of its Commitment and the Term Loan at the time owing to it) with the prior written consent (such
consent not to be unreasonably withheld) of the Administrative Agent, <I>provided</I> that no consent of the Administrative Agent shall be required for an assignment of any Commitment or of all or any portion of the Term Loan to a Lender, an
Affiliate of a Lender or an Approved Fund. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) Assignments shall be subject to the following additional conditions: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A) except in the case of an assignment to a Lender or an Affiliate of a Lender or an assignment of the entire remaining
amount of the assigning Lender&#146;s Commitment or Term Loan, the amount of the Commitment or Term Loan of the assigning Lender subject to each such assignment (determined as of the date the Assignment Agreement with respect to such assignment is
delivered to the Administrative Agent) shall not be less than $500,000, unless the Administrative Agent otherwise consents; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-115- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B) each partial assignment shall be made as an assignment of a
proportionate part of all the assigning Lender&#146;s rights and obligations under this Agreement and the other Loan Documents; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(C) the parties to each assignment shall execute and deliver to the Administrative Agent an Assignment Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) Subject to acceptance and recording thereof pursuant to paragraph&nbsp;(d) of this Section, from and after the effective date specified
in each Assignment Agreement, the assignee thereunder shall be a party hereto and, to the extent of the interest assigned by such Assignment Agreement, have the rights and obligations of a Lender under the Loan Documents, and the assigning Lender
thereunder shall, to the extent of the interest assigned by such Assignment Agreement, be released from its obligations under the Loan Documents (and, in the case of an Assignment Agreement covering all of the assigning Lender&#146;s rights and
obligations under the Loan Documents, such Lender shall cease to be a party hereto). Any assignment or transfer by a Lender of rights or obligations under the Loan Documents that does not comply with this Section&nbsp;13.05 shall be treated for
purposes of the Loan Documents as a sale by such Lender of a participation in such rights and obligations in accordance with paragraph&nbsp;(e) of this Section. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <I>Register</I>. The Administrative Agent, acting for this purpose as a <FONT STYLE="white-space:nowrap">non-fiduciary</FONT> agent of
Borrowers, shall maintain at one of its offices a copy of each Assignment Agreement delivered to it and a register for the recordation of the names and addresses of the Lenders, and the Commitment of, and principal amount (and stated interest) of
the Term Loans owing to, each Lender pursuant to the terms hereof from time to time (the <I>&#147;Register&#148;</I>). The entries in the Register shall be conclusive absent manifest error, and Borrowers, the Administrative Agent, and the Lenders
shall treat each Person whose name is recorded in the Register pursuant to the terms hereof as a Lender hereunder for all purposes of this Agreement, notwithstanding notice to the contrary. The Register shall be available for inspection by Borrowers
and any Lender, at any reasonable time and from time to time upon reasonable prior notice. No assignment shall be effective for purposes of this Agreement unless (i)&nbsp;it has been recorded in the Register as provided in this paragraph and
(ii)&nbsp;any written consent to such assignment required by paragraph&nbsp;(b) of this Section has been obtained. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)
<I>Participations</I>. Any Lender may at any time, without the consent of, or notice to, Borrowers, sell participations to any Person (a <I>&#147;Participant&#148;</I>), other than an Ineligible Assignee, in all or a portion of such Lender&#146;s
rights and obligations under the Loan Documents (including all or a portion of its Commitment and the Term Loans owing to it); <I>provided</I> that (i)&nbsp;such Lender&#146;s obligations under the Loan Documents shall remain unchanged,
(ii)&nbsp;such Lender shall remain solely responsible to the other parties hereto for the performance of such obligations and (iii)&nbsp;Borrowers shall continue to deal solely and directly with such Lender in connection therewith. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-116- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Any agreement or instrument pursuant to which a Lender sells such a participation shall
provide that such Lender shall retain the sole right to enforce this Agreement and to approve any amendment, modification or waiver of any provision of this Agreement; <I>provided</I> that such agreement or instrument may provide that such Lender
will not, without the consent of the Participant, agree to any amendment, modification or waiver that would (i)&nbsp;increase or extend the term of such Lender&#146;s Commitment, (ii)&nbsp;extend the date fixed for the payment of principal of or
interest on the Term Loan or any portion of any fee hereunder payable to the Participant, (iii)&nbsp;reduce the amount of any such payment of principal, or (iv)&nbsp;reduce the rate at which interest is payable thereon to a level below the rate at
which the Participant is entitled to receive such interest. Each Borrower agrees that each Participant shall be entitled to the benefits of Section&nbsp;5.03 (subject to the requirements and limitations therein, including the requirements under
Section&nbsp;5.03(f) (it being understood that the documentation required under Section&nbsp;5.03(f) shall be delivered to Administrative Borrower and the participating Lender)) to the same extent as if it were a Lender and had acquired its interest
by assignment pursuant to Section&nbsp;13.05(a), <I>provided</I> that such Participant (A)&nbsp;agrees to be subject to the provisions of Section&nbsp;5.03(h) as if it were an assignee under Section&nbsp;13.05(a); and (B)&nbsp;shall not be entitled
to receive any greater payment under Section&nbsp;5.03, with respect to any participation, than its participating Lender would have been entitled to receive, unless the sale of the participation to such Participant is made with Borrowers&#146; prior
written consent. To the extent permitted by Law, each Participant also shall be entitled to the benefits of Section&nbsp;4.04(a) as though it were a Lender. Each Lender that sells a participation shall, acting solely for this purpose as a <FONT
STYLE="white-space:nowrap">non-fiduciary</FONT> agent of Borrowers, maintain a register on which it enters the name and address of each Participant and the principal amounts (and stated interest) of each Participant&#146;s interest in the Term Loans
or other obligations under the Loan Documents (the <I>&#147;Participant Register&#148;</I>); <I>provided</I> that no Lender shall have any obligation to disclose all or any portion of the Participant Register (including the identity of any
Participant or any information relating to a Participant&#146;s interest in any commitments, loans, letters of credit or its other obligations under any Loan Document) to any Person except to the extent that such disclosure is necessary to establish
that such commitment, loan, letter of credit or other obligation is in registered form under <FONT STYLE="white-space:nowrap">Section&nbsp;5f.103-1(c)</FONT> of the United States Treasury Regulations. The entries in the Participant Register shall be
conclusive absent manifest error, and such Lender shall treat each Person whose name is recorded in the Participant Register as the owner of such participation for all purposes of this Agreement notwithstanding any notice to the contrary. The
parties hereto intend that all commitments, loans, letters of credit or other obligations under any Loan Document are at all times maintained in &#147;registered form&#148; within the meaning of Section&nbsp;163(f), 871(h)(2) and 881(c)(2) of the
Code and any related United States Treasury Regulations (or any other relevant or successor provisions of the Code or of such United States Treasury Regulations), and the Register and Participant Register shall be maintained in accordance with such
intention. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) <I>Certain Pledges</I>. Subject to Section&nbsp;13.05(d), the Lenders may at any time pledge or assign a security interest
in all or any portion of its rights under this Agreement and any other Loan Document to secure obligations of the Lenders, including any pledge or assignment to secure obligations to a Federal Reserve Bank or another central bank; <I>provided</I>
that no such pledge or assignment shall release the Lenders from any of their obligations hereunder or substitute any such pledgee or assignee for the Lenders as a party hereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-117- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;13.06.</I> <I>Survival</I><I>.</I> The obligations of each
Obligor under Sections&nbsp;5.01, 5.02, 5.03, 13.03, 13.05, 13.09, 13.10, 13.11, 13.12, 13.13, 13.14 and Article&nbsp;11 (solely to the extent guaranteeing any of the obligations under the foregoing Sections) shall survive the repayment of the
Obligations and the termination of the Commitments and, in the case of any Lender&#146;s assignment of any interest in the Commitments or the Term Loans hereunder, shall survive, in the case of any event or circumstance that occurred prior to the
effective date of such assignment, the making of such assignment, notwithstanding that such Lenders may cease to be a &#147;Lender&#148; hereunder. In addition, each representation and warranty made, or deemed to be made by a notice of the Term
Loans, herein or pursuant hereto shall survive the making of such representation and warranty. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;13.07.</I>
<I>Captions</I><I>.</I> The table of contents and captions and section headings appearing herein are included solely for convenience of reference and are not intended to affect the interpretation of any provision of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;13.08.</I> <I>Counterparts</I><I>.</I> This Agreement may be executed in any number of counterparts, all of
which taken together shall constitute one and the same instrument and any of the parties hereto may execute this Agreement by signing any such counterpart. Delivery of an executed signature page of this Agreement by facsimile transmission,
electronic transmission (in PDF format) or DocuSign shall be effective as delivery of a manually executed counterpart hereof. The words &#147;execution,&#148; &#147;signed,&#148; &#147;signature,&#148; and words of like import in any Assignment
Agreement shall be deemed to include electronic signatures or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature or the use of a <FONT
STYLE="white-space:nowrap">paper-based</FONT> recordkeeping system, as the case may be, to the extent and as provided for in any applicable Law, including the Federal Electronic Signatures in Global and National Commerce Act, the New&nbsp;York State
Electronic Signatures and Records Act, or any other similar state laws based on the Uniform&nbsp;Electronic Transactions Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;13.09.</I> <I>Governing Law</I><I>.</I> T<SMALL>HIS</SMALL> A<SMALL>GREEMENT</SMALL> <SMALL>AND</SMALL>
<SMALL>THE</SMALL> <SMALL>OTHER</SMALL> L<SMALL>OAN</SMALL> D<SMALL>OCUMENTS</SMALL> (<SMALL>OTHER</SMALL> <SMALL>THAN</SMALL> <SMALL>ANY</SMALL> L<SMALL>OAN</SMALL> D<SMALL>OCUMENT</SMALL> <SMALL>WHICH</SMALL> <SMALL>IS</SMALL>
<SMALL>SPECIFICALLY</SMALL> <SMALL>GOVERNED</SMALL> <SMALL>BY</SMALL> <SMALL>THE</SMALL> <SMALL>LAWS</SMALL> <SMALL>OF</SMALL> <SMALL>ANOTHER</SMALL> <SMALL>JURISDICTION</SMALL>), <SMALL>THE</SMALL> <SMALL>RIGHTS</SMALL> <SMALL>AND</SMALL>
<SMALL>OBLIGATIONS</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL> <SMALL>PARTIES</SMALL> <SMALL>HEREUNDER</SMALL> <SMALL>AND</SMALL> <SMALL>THEREUNDER</SMALL>, <SMALL>AND</SMALL> <SMALL>ALL</SMALL> <SMALL>CLAIMS</SMALL>, <SMALL>DISPUTES</SMALL>
<SMALL>AND</SMALL> <SMALL>MATTERS</SMALL> <SMALL>ARISING</SMALL> <SMALL>HEREUNDER</SMALL> <SMALL>OR</SMALL> <SMALL>THEREUNDER</SMALL> <SMALL>OR</SMALL> <SMALL>RELATED</SMALL> <SMALL>HERETO</SMALL> <SMALL>OR</SMALL> <SMALL>THERETO</SMALL>,
<SMALL>SHALL</SMALL> <SMALL>BE</SMALL> <SMALL>GOVERNED</SMALL> <SMALL>BY</SMALL>, <SMALL>AND</SMALL> <SMALL>CONSTRUED</SMALL> <SMALL>IN</SMALL> <SMALL>ACCORDANCE</SMALL> <SMALL>WITH</SMALL>, <SMALL>THE</SMALL> <SMALL>LAWS</SMALL> <SMALL>OF</SMALL>
<SMALL>THE</SMALL> S<SMALL>TATE</SMALL> <SMALL>OF</SMALL> N<SMALL>EW</SMALL>&nbsp;Y<SMALL>ORK</SMALL> <SMALL>APPLICABLE</SMALL> <SMALL>TO</SMALL> <SMALL>CONTRACTS</SMALL> <SMALL>EXECUTED</SMALL> <SMALL>IN</SMALL> <SMALL>AND</SMALL> <SMALL>TO</SMALL>
<SMALL>BE</SMALL> <SMALL>PERFORMED</SMALL> <SMALL>ENTIRELY</SMALL> <SMALL>WITHIN</SMALL> <SMALL>THAT</SMALL> S<SMALL>TATE</SMALL>, <SMALL>WITHOUT</SMALL> <SMALL>REFERENCE</SMALL> <SMALL>TO</SMALL> <SMALL>CONFLICTS</SMALL> <SMALL>OF</SMALL>
<SMALL>LAWS</SMALL> <SMALL>PROVISIONS</SMALL> (<SMALL>OTHER</SMALL> <SMALL>THAN</SMALL> S<SMALL>ECTION</SMALL><FONT STYLE="white-space:nowrap">&nbsp;5-1401</FONT> <SMALL>OF</SMALL> <SMALL>THE</SMALL> N<SMALL>EW</SMALL>&nbsp;Y<SMALL>ORK</SMALL>
G<SMALL>ENERAL</SMALL> O<SMALL>BLIGATIONS</SMALL> L<SMALL>AW</SMALL>). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;13.10.</I> <I>Jurisdiction, Service
of Process and Venue</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <I>Submission to Jurisdiction</I>. E<SMALL>ACH</SMALL> <SMALL>PARTY</SMALL> <SMALL>HERETO</SMALL>
<SMALL>AGREES</SMALL> <SMALL>THAT</SMALL> <SMALL>ANY</SMALL> <SMALL>SUIT</SMALL>, <SMALL>ACTION</SMALL> <SMALL>OR</SMALL> <SMALL>PROCEEDING</SMALL> <SMALL>WITH</SMALL> <SMALL>RESPECT</SMALL> <SMALL>TO</SMALL> <SMALL>THIS</SMALL>
A<SMALL>GREEMENT</SMALL> <SMALL>OR</SMALL> <SMALL>ANY</SMALL> <SMALL>OTHER</SMALL> L<SMALL>OAN</SMALL> D<SMALL>OCUMENT</SMALL> (<SMALL>EXCEPT</SMALL>, <SMALL>WITH</SMALL> <SMALL>RESPECT</SMALL> <SMALL>TO</SMALL> <SMALL>ANY</SMALL>
<SMALL>OTHER</SMALL> L<SMALL>OAN</SMALL> D<SMALL>OCUMENT</SMALL> <SMALL>THAT</SMALL> <SMALL>EXPRESSLY</SMALL> <SMALL>PROVIDES</SMALL> <SMALL>FOR</SMALL> <SMALL>A</SMALL> <SMALL>DIFFERENT</SMALL> <SMALL>JURISDICTION</SMALL> <SMALL>AS</SMALL>
<SMALL>SET</SMALL> <SMALL>FORTH</SMALL> <SMALL>THEREIN</SMALL>) <SMALL>TO</SMALL> <SMALL>WHICH</SMALL> <SMALL>IT</SMALL> <SMALL>IS</SMALL> <SMALL>A</SMALL> <SMALL>PARTY</SMALL> <SMALL>OR</SMALL> <SMALL>ANY</SMALL> <SMALL>JUDGMENT</SMALL>
<SMALL>ENTERED</SMALL> <SMALL>BY</SMALL> <SMALL>ANY</SMALL> <SMALL>COURT</SMALL> <SMALL>IN</SMALL> <SMALL>RESPECT</SMALL> <SMALL>THEREOF</SMALL> <SMALL>SHALL</SMALL> <SMALL>BE</SMALL> <SMALL>BROUGHT</SMALL> <SMALL>IN</SMALL> <SMALL>THE</SMALL>
S<SMALL>UPREME</SMALL> C<SMALL>OURT</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL> S<SMALL>TATE</SMALL> <SMALL>OF</SMALL> N<SMALL>EW</SMALL>&nbsp;Y<SMALL>ORK</SMALL> <SMALL>SITTING</SMALL> <SMALL>IN</SMALL> N<SMALL>EW</SMALL>&nbsp;Y<SMALL>ORK</SMALL>
C<SMALL>OUNTY</SMALL> <SMALL>OR</SMALL> <SMALL>IN</SMALL> <SMALL>THE</SMALL> U<SMALL>NITED</SMALL> S<SMALL>TATES</SMALL> D<SMALL>ISTRICT</SMALL> C<SMALL>OURT</SMALL> <SMALL>FOR</SMALL> <SMALL>THE</SMALL> S<SMALL>OUTHERN</SMALL>
D<SMALL>ISTRICT</SMALL> <SMALL>OF</SMALL> N<SMALL>EW</SMALL>&nbsp;Y<SMALL>ORK</SMALL> <SMALL>AND</SMALL> <SMALL>IRREVOCABLY</SMALL> <SMALL>SUBMITS</SMALL> <SMALL>TO</SMALL> <SMALL>THE</SMALL> <SMALL>EXCLUSIVE</SMALL> <SMALL>JURISDICTION</SMALL>
<SMALL>OF</SMALL> <SMALL>EACH</SMALL> <SMALL>SUCH</SMALL> <SMALL>COURT</SMALL> <SMALL>FOR</SMALL> <SMALL>THE</SMALL> <SMALL>PURPOSE</SMALL> <SMALL>OF</SMALL> <SMALL>ANY</SMALL> <SMALL>SUCH</SMALL> <SMALL>SUIT</SMALL>, <SMALL>ACTION</SMALL>,
<SMALL>PROCEEDING</SMALL> <SMALL>OR</SMALL> <SMALL>JUDGMENT</SMALL>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-118- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <I>Alternative Process</I>. Nothing herein shall in any way be deemed to limit the
ability of any party to serve any such process or summonses in any other manner permitted by applicable Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <I>Waiver of Venue,
Etc.</I> E<SMALL>ACH</SMALL> <SMALL>PARTY</SMALL> <SMALL>HERETO</SMALL> <SMALL>IRREVOCABLY</SMALL> <SMALL>WAIVES</SMALL> <SMALL>TO</SMALL> <SMALL>THE</SMALL> <SMALL>FULLEST</SMALL> <SMALL>EXTENT</SMALL> <SMALL>PERMITTED</SMALL> <SMALL>BY</SMALL>
<SMALL>LAW</SMALL> <SMALL>ANY</SMALL> <SMALL>OBJECTION</SMALL> <SMALL>THAT</SMALL> <SMALL>IT</SMALL> <SMALL>MAY</SMALL> <SMALL>NOW</SMALL> <SMALL>OR</SMALL> <SMALL>HEREAFTER</SMALL> <SMALL>HAVE</SMALL> <SMALL>TO</SMALL> <SMALL>THE</SMALL>
<SMALL>LAYING</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL> <SMALL>VENUE</SMALL> <SMALL>OF</SMALL> <SMALL>ANY</SMALL> <SMALL>SUIT</SMALL>, <SMALL>ACTION</SMALL> <SMALL>OR</SMALL> <SMALL>PROCEEDING</SMALL> <SMALL>ARISING</SMALL> <SMALL>OUT</SMALL>
<SMALL>OF</SMALL> <SMALL>OR</SMALL> <SMALL>RELATING</SMALL> <SMALL>TO</SMALL> <SMALL>THIS</SMALL> A<SMALL>GREEMENT</SMALL> <SMALL>OR</SMALL> <SMALL>ANY</SMALL> <SMALL>OTHER</SMALL> L<SMALL>OAN</SMALL> D<SMALL>OCUMENT</SMALL> <SMALL>AND</SMALL>
<SMALL>HEREBY</SMALL> <SMALL>FURTHER</SMALL> <SMALL>IRREVOCABLY</SMALL> <SMALL>WAIVES</SMALL> <SMALL>TO</SMALL> <SMALL>THE</SMALL> <SMALL>FULLEST</SMALL> <SMALL>EXTENT</SMALL> <SMALL>PERMITTED</SMALL> <SMALL>BY</SMALL> <SMALL>LAW</SMALL>
<SMALL>ANY</SMALL> <SMALL>CLAIM</SMALL> <SMALL>THAT</SMALL> <SMALL>ANY</SMALL> <SMALL>SUCH</SMALL> <SMALL>SUIT</SMALL>, <SMALL>ACTION</SMALL> <SMALL>OR</SMALL> <SMALL>PROCEEDING</SMALL> <SMALL>BROUGHT</SMALL> <SMALL>IN</SMALL> <SMALL>ANY</SMALL>
<SMALL>SUCH</SMALL> <SMALL>COURT</SMALL> <SMALL>HAS</SMALL> <SMALL>BEEN</SMALL> <SMALL>BROUGHT</SMALL> <SMALL>IN</SMALL> <SMALL>AN</SMALL> <SMALL>INCONVENIENT</SMALL> <SMALL>FORUM</SMALL>. A <SMALL>FINAL</SMALL> <SMALL>JUDGMENT</SMALL>
(<SMALL>IN</SMALL> <SMALL>RESPECT</SMALL> <SMALL>OF</SMALL> <SMALL>WHICH</SMALL> <SMALL>TIME</SMALL> <SMALL>FOR</SMALL> <SMALL>ALL</SMALL> <SMALL>APPEALS</SMALL> <SMALL>HAS</SMALL> <SMALL>ELAPSED</SMALL>) <SMALL>IN</SMALL> <SMALL>ANY</SMALL>
<SMALL>SUCH</SMALL> <SMALL>SUIT</SMALL>, <SMALL>ACTION</SMALL> <SMALL>OR</SMALL> <SMALL>PROCEEDING</SMALL> <SMALL>SHALL</SMALL> <SMALL>BE</SMALL> <SMALL>CONCLUSIVE</SMALL> <SMALL>AND</SMALL> <SMALL>MAY</SMALL> <SMALL>BE</SMALL>
<SMALL>ENFORCED</SMALL> <SMALL>IN</SMALL> <SMALL>ANY</SMALL> <SMALL>COURT</SMALL> <SMALL>TO</SMALL> <SMALL>THE</SMALL> <SMALL>JURISDICTION</SMALL> <SMALL>OF</SMALL> <SMALL>WHICH</SMALL> <SMALL>SUCH</SMALL> O<SMALL>BLIGOR</SMALL> <SMALL>IS</SMALL>
<SMALL>OR</SMALL> <SMALL>MAY</SMALL> <SMALL>BE</SMALL> <SMALL>SUBJECT</SMALL>, <SMALL>BY</SMALL> <SMALL>SUIT</SMALL> <SMALL>UPON</SMALL> <SMALL>JUDGMENT</SMALL>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;13.11.</I> <I>Waiver of Jury Trial</I>. E<SMALL>ACH</SMALL> <SMALL>PARTY</SMALL> <SMALL>HERETO</SMALL>
<SMALL>HEREBY</SMALL> <SMALL>IRREVOCABLY</SMALL> <SMALL>WAIVES</SMALL>, <SMALL>TO</SMALL> <SMALL>THE</SMALL> <SMALL>FULLEST</SMALL> <SMALL>EXTENT</SMALL> <SMALL>PERMITTED</SMALL> <SMALL>BY</SMALL> <SMALL>APPLICABLE</SMALL> <SMALL>LAW</SMALL>,
<SMALL>ANY</SMALL> <SMALL>AND</SMALL> <SMALL>ALL</SMALL> <SMALL>RIGHT</SMALL> <SMALL>TO</SMALL> <SMALL>TRIAL</SMALL> <SMALL>BY</SMALL> <SMALL>JURY</SMALL> <SMALL>IN</SMALL> <SMALL>ANY</SMALL> <SMALL>SUIT</SMALL>, <SMALL>ACTION</SMALL>
<SMALL>OR</SMALL> <SMALL>PROCEEDING</SMALL> <SMALL>ARISING</SMALL> <SMALL>OUT</SMALL> <SMALL>OF</SMALL> <SMALL>OR</SMALL> <SMALL>RELATING</SMALL> <SMALL>TO</SMALL> <SMALL>THIS</SMALL> A<SMALL>GREEMENT</SMALL>, <SMALL>THE</SMALL> <SMALL>OTHER</SMALL>
<SMALL>LOAN</SMALL> <SMALL>DOCUMENTS</SMALL> <SMALL>OR</SMALL> <SMALL>THE</SMALL> <SMALL>TRANSACTIONS</SMALL> <SMALL>CONTEMPLATED</SMALL> <SMALL>HEREBY</SMALL> <SMALL>OR</SMALL> <SMALL>THEREBY</SMALL>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;13.12.</I> <I>Waiver of Immunity</I>. T<SMALL>O</SMALL> <SMALL>THE</SMALL> <SMALL>EXTENT</SMALL>
<SMALL>THAT</SMALL> <SMALL>ANY</SMALL> O<SMALL>BLIGOR</SMALL> <SMALL>MAY</SMALL> <SMALL>BE</SMALL> <SMALL>OR</SMALL> <SMALL>BECOME</SMALL> <SMALL>ENTITLED</SMALL> <SMALL>TO</SMALL> <SMALL>CLAIM</SMALL> <SMALL>FOR</SMALL> <SMALL>ITSELF</SMALL>
<SMALL>OR</SMALL> <SMALL>ITS</SMALL> <SMALL>PROPERTY</SMALL> <SMALL>OR</SMALL> <SMALL>REVENUES</SMALL> <SMALL>ANY</SMALL> <SMALL>IMMUNITY</SMALL> <SMALL>ON</SMALL> <SMALL>THE</SMALL> <SMALL>GROUND</SMALL> <SMALL>OF</SMALL> <SMALL>SOVEREIGNTY</SMALL>
<SMALL>OR</SMALL> <SMALL>THE</SMALL> <SMALL>LIKE</SMALL> <SMALL>FROM</SMALL> <SMALL>SUIT</SMALL>, <SMALL>COURT</SMALL> <SMALL>JURISDICTION</SMALL>, <SMALL>ATTACHMENT</SMALL> <SMALL>PRIOR</SMALL> <SMALL>TO</SMALL> <SMALL>JUDGMENT</SMALL>,
<SMALL>ATTACHMENT</SMALL> <SMALL>IN</SMALL> <SMALL>AID</SMALL> <SMALL>OF</SMALL> <SMALL>EXECUTION</SMALL> <SMALL>OF</SMALL> <SMALL>A</SMALL> <SMALL>JUDGMENT</SMALL> <SMALL>OR</SMALL> <SMALL>EXECUTION</SMALL> <SMALL>OF</SMALL> <SMALL>A</SMALL>
<SMALL>JUDGMENT</SMALL>, <SMALL>AND</SMALL> <SMALL>TO</SMALL> <SMALL>THE</SMALL> <SMALL>EXTENT</SMALL> <SMALL>THAT</SMALL> <SMALL>IN</SMALL> <SMALL>ANY</SMALL> <SMALL>SUCH</SMALL> <SMALL>JURISDICTION</SMALL> <SMALL>THERE</SMALL> <SMALL>MAY</SMALL>
<SMALL>BE</SMALL> <SMALL>ATTRIBUTED</SMALL> <SMALL>SUCH</SMALL> <SMALL>AN</SMALL> <SMALL>IMMUNITY</SMALL> (<SMALL>WHETHER</SMALL> <SMALL>OR</SMALL> <SMALL>NOT</SMALL> <SMALL>CLAIMED</SMALL>), <SMALL>SUCH</SMALL> O<SMALL>BLIGOR</SMALL>
<SMALL>HEREBY</SMALL> <SMALL>IRREVOCABLY</SMALL> <SMALL>AGREES</SMALL> <SMALL>NOT</SMALL> <SMALL>TO</SMALL> <SMALL>CLAIM</SMALL> <SMALL>AND</SMALL> <SMALL>HEREBY</SMALL> <SMALL>IRREVOCABLY</SMALL> <SMALL>WAIVES</SMALL> <SMALL>SUCH</SMALL>
<SMALL>IMMUNITY</SMALL> <SMALL>WITH</SMALL> <SMALL>RESPECT</SMALL> <SMALL>TO</SMALL> <SMALL>ITS</SMALL> <SMALL>OBLIGATIONS</SMALL> <SMALL>UNDER</SMALL> <SMALL>THIS</SMALL> A<SMALL>GREEMENT</SMALL> <SMALL>AND</SMALL> <SMALL>THE</SMALL>
<SMALL>OTHER</SMALL> <SMALL>LOAN</SMALL> <SMALL>DOCUMENTS</SMALL>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;13.13.</I> <I>Entire
Agreement</I><I>.</I> This Agreement and the other Loan Documents constitute the entire agreement among the parties with respect to the subject matter hereof and thereof and supersede any and all previous agreements and understandings, oral or
written, relating to the subject matter hereof. Each Obligor acknowledges, represents and warrants that in deciding to enter into this Agreement and the other Loan Documents or in taking or not taking any action hereunder or thereunder, it has not
relied, and will not rely, on any statement, representation, warranty, covenant, agreement or understanding, whether written or oral, of or with the Lenders other than those expressly set forth in this Agreement and the other Loan Documents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;13.14.</I> <I>Severability</I><I>.</I> If any provision hereof is found by a court to be invalid or
unenforceable, to the fullest extent permitted by applicable Law the parties agree that such invalidity or unenforceability shall not impair the validity or enforceability of any other provision hereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-119- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;13.15.</I> <I>No Fiduciary Relationship</I><I>.</I> The
Administrative Agent, each Lender and their Affiliates (collectively, solely for purposes of this paragraph, the <I>&#147;</I><I>Lenders</I><I>&#148;</I>), may have economic interests that conflict with those of the Obligors, their members or equity
holders and/or their Affiliates (collectively, solely for purposes of this paragraph, the <I>&#147;</I><I>Obligors</I><I>&#148;</I>). The Obligors acknowledge that the Lenders have no fiduciary relationship with, or fiduciary duty to, any Obligor
arising out of or in connection with this Agreement or the other Loan Documents, and the relationship between each Lender and each Obligor are solely that of creditors and debtors. This Agreement and the other Loan Documents do not create a joint
venture among the parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;13.16.</I> <I>USA</I><I></I><I>&nbsp;Patriot Act</I><I>.</I> The Administrative
Agent and the Lenders hereby notify the Obligors that pursuant to the requirements of the USA&nbsp;PATRIOT Act (Title&nbsp;III of Pub. L. <FONT STYLE="white-space:nowrap">107-56</FONT> (signed into law October&nbsp;26, 2001)) (the
<I>&#147;</I><I>Act</I><I>&#148;</I>) and 31&nbsp;C.F.R. &#167;&nbsp;1010.230 (the <I>&#147;</I><I>Beneficial Ownership Regulation</I><I>&#148;</I>), they are required to obtain, verify and record information that identifies the Obligors, which
information includes the name and address of each Obligor and other information that will allow the Administrative Agent and such Lender to identify each Obligor in accordance with the Act and Beneficial Ownership Regulation, including a beneficial
ownership certification in form and substance acceptable to the Administrative Agent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;13.17.</I>
<I>Treatment of Certain Information; Confidentiality</I><I>.</I> The Lenders agree to maintain the confidentiality of the Information (as defined below), except that Information may be disclosed to (a)&nbsp;its Affiliates and to its and its
Affiliates&#146; respective partners, directors, officers, employees, agents, trustees, advisors and representatives (collectively, <I>&#147;</I><I>Representatives</I><I>&#148;</I>) (it being understood that the Persons to whom such disclosure is
made will be informed of the confidential nature of such information and instructed to keep such Information confidential), (b)&nbsp;to the extent requested by any regulatory authority purporting to have jurisdiction over it (including any <FONT
STYLE="white-space:nowrap">self-regulatory</FONT> authority, such as FINRA or the National Association of Insurance Commissioners) or any exchange, (c)&nbsp;to the extent required by the applicable Laws or by any subpoena or similar legal process,
(d)&nbsp;to any other party hereto, (e)&nbsp;in connection with the exercise of any remedies hereunder or under any other Loan Document or any action or proceeding relating to this Agreement or any other Loan Document or the enforcement of rights
hereunder or thereunder, (f)&nbsp;subject to an agreement containing provisions substantially the same as those in this Section, to (i)&nbsp;any assignee of or Participant in, or any prospective assignee of or Participant in, any of its rights or
obligations under this Agreement or (ii)&nbsp;any actual or prospective counterparty (or its advisors) to any swap or derivative transaction relating to Borrowers or any Obligor and its obligation, (g)&nbsp;with the consent of Borrowers or
(h)&nbsp;to the extent such Information (x)&nbsp;becomes publicly available other than as a result of a breach of this Section or (y)&nbsp;becomes available to the Lender, or any of its respective Representatives on a nonconfidential basis from a
source other than Borrowers or any other Obligor. For purposes of this Section, <I>&#147;</I><I>Information</I><I>&#148;</I> means all information received from an Obligor relating such Obligor or its Subsidiary or any of their respective
businesses, except that the term &#147;Information&#148; shall not include, and the Lenders shall not be subject to any confidentiality obligation with respect to any information that (i)&nbsp;is or becomes available to the Lender or any of its
Representatives on a nonconfidential basis prior to disclosure by an Obligor or its Subsidiary, (ii)&nbsp;becomes available to a Lender or any of its Representatives after disclosure by Parent, Borrowers or any other Obligor from a source that, to
the knowledge of such Lender, is not subject to a confidentiality obligation to Parent, Borrowers or such other Obligor, (iii)&nbsp;is or becomes publicly available other than as a result of a breach by such Lender, or (iv)&nbsp;is developed by a
Lender or any of its Representatives. Any Person required to maintain the confidentiality of Information as provided in this Section shall be considered to have complied with its obligation to do so if such Person has exercised the same degree of
care to maintain the confidentiality of such Information as such Person would accord to its own confidential information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-120- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">In the case of any Lender that has elected to receive material <FONT
STYLE="white-space:nowrap">non-public</FONT> information pursuant to the last paragraph of Section&nbsp;8.02, such Lender acknowledges that (a)&nbsp;the Information may include material <FONT STYLE="white-space:nowrap">non-public</FONT> information
concerning an Obligor or its Subsidiary, as the case may be, (b)&nbsp;it has developed compliance procedures regarding the use of material <FONT STYLE="white-space:nowrap">non-public</FONT> information and (c)&nbsp;it will handle such material <FONT
STYLE="white-space:nowrap">non-public</FONT> information in accordance with applicable Law, including United States federal and state securities Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;13.18.</I> <I>R</I><I>eleases of Guarantees and Liens</I>. Notwithstanding anything to the contrary contained
herein or in any other Loan Document, each Lender agrees, and the Administrative Agent is hereby irrevocably authorized by each Lender and given a limited power of attorney by each Lender to perform the actions described hereafter in this
Section&nbsp;13.18 (without requirement of notice to or consent of any Lender except as expressly required by Section&nbsp;13.04) to take any action reasonably requested by Borrowers having the effect of releasing any Collateral or Obligations
(i)&nbsp;to the extent necessary to permit consummation of any transaction not prohibited by any Loan Document or that has been consented to by the Lenders or (ii)&nbsp;under the circumstances described in Section&nbsp;12.09(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;13.19.</I> <I>Acknowledgement and Consent to Bail</I><I><FONT STYLE="white-space:nowrap">-In</FONT> of Affected
Financial Institutions</I><I>.</I> Notwithstanding anything to the contrary in any Loan Document or in any other agreement, arrangement or understanding among any such parties, each party hereto acknowledges that any liability of any Affected
Financial Institution arising under any Loan Document, to the extent such liability is unsecured, may be subject to the <FONT STYLE="white-space:nowrap">write-down</FONT> and conversion powers of the applicable Resolution Authority and agrees and
consents to, and acknowledges and agrees to be bound by: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) the application of any
<FONT STYLE="white-space:nowrap">Write-Down</FONT> and Conversion Powers by the applicable Resolution Authority to any such liabilities arising hereunder which may be payable to it by any party hereto that is an Affected Financial Institution; and
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) the effects of any <FONT STYLE="white-space:nowrap">Bail-In</FONT> Action on any such liability, including, if
applicable: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) a reduction in full or in part or cancellation of any such liability; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) a conversion of all, or a portion of, such liability into shares or other instruments of ownership in such Affected
Financial Institution, its parent undertaking, or a bridge institution that may be issued to it or otherwise conferred on it, and that such shares or other instruments of ownership will be accepted by it in lieu of any rights with respect to any
such liability under this Agreement or any other Loan Document; or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-121- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) the variation of the terms of such liability in connection with the
exercise of the <FONT STYLE="white-space:nowrap">write-down</FONT> and conversion powers of the applicable Resolution Authority. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;13.20</I> <I>Administrative Borrower. </I>Each Borrower hereby designates OpCo as the administrative Borrower
(in such capacity, the <I>&#147;Administrative Borrower&#148;</I>) to act as its representative and agent on its behalf, for the purposes of giving instructions with respect to the disbursement of the proceeds of the Term Loans, giving and receiving
all notices and consents hereunder or under any of the other Loan Documents and taking all other actions on behalf of each Borrower under the Loan Documents. The Administrative Agent and each Lender may regard any notice or other communication
pursuant to any Loan Document from OpCo in its capacity as Administrative Borrower as a notice or communication from each Borrower. Each warranty, covenant, agreement and undertaking made on behalf of each Borrower by OpCo in its capacity as
Administrative Borrower for the Borrowers shall be deemed for all purposes to have been made by each Borrower and shall be binding upon and enforceable against each Borrower to the same extent as it if the same had been made directly by each
Borrower. Such appointment shall remain in full force and effect unless and until the Administrative Agent shall have received written notice signed by each Borrower terminating such appointment. Borrowers shall have the right, to appoint another
Borrower as Administrative Borrower with the prior written consent of the Administrative Agent (such consent not to be unreasonably withheld or delayed). It is understood that the handling of the loan account and Collateral of the Borrowers in a
combined fashion, as more fully set forth herein, is done solely as an accommodation to the Borrowers in order to utilize the collective borrowing powers of the Borrowers in the most efficient and economical manner and at their request, and that
neither the Administrative Agent nor the Lenders shall incur liability to the Borrowers as a result hereof. Each Borrower expects to derive benefit, directly or indirectly, from the handling of the loan account and the Collateral in a combined
fashion since the successful operation of each Borrower is dependent on the continued successful performance of the integrated group. To induce the Administrative Agent and the Lenders to do so, and in consideration thereof, each Borrower hereby
jointly and severally agrees to indemnify the Administrative Agent and hold each Indemnified Party harmless against any and all liability, expense, loss or claim of damage or injury, made against such Indemnified Party by any Borrower or by any
third party whosoever, arising from or incurred by reason of (a)&nbsp;the handling of the loan account and Collateral of the Borrowers as herein provided, (b)&nbsp;the Administrative Agent and the Lenders relying on any instructions of
Administrative Borrower, or (c)&nbsp;any other action taken by the Administrative Agent or any Lender hereunder or under the other Loan Documents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section&nbsp;13.21. Joint and Several Liability of Borrowers. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Each Borrower is accepting joint and several liability hereunder and under the other Loan Documents in consideration of
the financial accommodations to be provided by the Administrative Agent and the Lenders under the Loan Documents, for the mutual benefit, directly and indirectly, of each Borrower and in consideration of the undertakings of the Borrowers to accept
joint and several liability for the Obligations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-122- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Each Borrower, jointly and severally, hereby irrevocably and
conditionally accepts, not merely as a surety but also as a <FONT STYLE="white-space:nowrap">co-debtor,</FONT> joint and several liability with the other Borrower, with respect to the payment and performance of all of the Obligations (including any
Obligations arising under this Section&nbsp;13.21), it being the intention of the parties hereto that all the Obligations shall be the joint and several obligations of each Borrower without preferences or distinction among them. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) If and to the extent that any Borrower shall fail to make any payment with respect to any of the Obligations as and when
due or to perform any of the Obligations in accordance with the terms thereof, then in each such event the other Borrower will make such payment with respect to, or perform, such Obligation until such time as all of the Obligations are paid in full.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) The Obligations of each Borrower under the provisions of this Section&nbsp;13.21 constitute the absolute and
unconditional, full recourse Obligations of each Borrower enforceable against each Borrower to the full extent of its properties and assets, irrespective of the validity, regularity or enforceability of the provisions of this Agreement (other than
this Section&nbsp;13.21(d)) or any other circumstances whatsoever. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) Except as otherwise expressly provided in this
Agreement, each Borrower hereby waives notice of acceptance of its joint and several liability, notice of any Term Loans, notice of the occurrence of any Default, Event of Default, or of any demand for any payment under this Agreement, notice of any
action at any time taken or omitted by the Administrative Agent or the Lenders under or in respect of any of the Obligations, any requirement of diligence or to mitigate damages and, generally, to the extent permitted by applicable law, all demands,
notices and other formalities of every kind in connection with this Agreement (except as otherwise provided in this Agreement). Each Borrower hereby assents to, and waives notice of, any extension or postponement of the time for the payment of any
of the Obligations, the acceptance of any payment of any of the Obligations, the acceptance of any partial payment thereon, any waiver, consent or other action or acquiescence by the Administrative Agent or the Lenders at any time or times in
respect of any default by any Borrower in the performance or satisfaction of any term, covenant, condition or provision of this Agreement, any and all other indulgences whatsoever by the Administrative Agent or the Lenders in respect of any of the
Obligations, and the taking, addition, substitution or release, in whole or in part, at any time or times, of any security for any of the Obligations or the addition, substitution or release, in whole or in part, of any Borrower. Without limiting
the generality of the foregoing, each Borrower assents to any other action or delay in acting or failure to act on the part of the Administrative Agent or a Lender with respect to the failure by any Borrower to comply with any of its respective
Obligations, including, without limitation, any failure strictly or diligently to assert any right or to pursue any remedy or to comply fully with applicable laws or regulations thereunder, which would, but for the provisions of this
Section&nbsp;13.21 afford grounds for terminating, discharging or relieving any Borrower, in whole or in part, from any of its Obligations under this Section&nbsp;13.21, it being the intention of each Borrower that, so long as any of the Obligations
hereunder remain unsatisfied, the Obligations of each Borrower under this Section&nbsp;13.21 shall not be discharged except by performance and then only to the extent of such performance. The Obligations of each Borrower under this
Section&nbsp;13.21 shall not be diminished or rendered unenforceable by any winding up, reorganization, arrangement, liquidation, reconstruction or similar proceeding with respect to any other Borrower or the Administrative Agent or a Lender. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-123- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) Each Borrower represents and warrants to the Administrative Agent and
the Lenders that such Borrower is currently informed of the financial condition of the Borrowers and of all other circumstances which a diligent inquiry would reveal and which bear upon the risk of nonpayment of the Obligations. Each Borrower
further represents and warrants to the Administrative Agent and the Lenders that such Borrower has read and understands the terms and conditions of the Loan Documents. Each Borrower hereby covenants that such Borrower will continue to keep informed
of the other Borrower&#146;s financial condition and of all other circumstances which bear upon the risk of nonpayment or nonperformance of the Obligations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) The provisions of this Section&nbsp;13.21 are made for the benefit of the Administrative Agent and each Lender, and their
successors and assigns, and may be enforced by it or them from time to time against any or all of the Borrowers as often as occasion therefor may arise and without requirement on the part of the Administrative Agent or each Lender, or any of their
successors or assigns first to marshal any of its or their claims or to exercise any of its or their rights against any Borrower or to exhaust any remedies available to it or them against any Borrower or to resort to any other source or means of
obtaining payment of any of the Obligations hereunder or to elect any other remedy. The provisions of this Section&nbsp;13.21 shall remain in effect until all of the Obligations shall have been paid in full or otherwise fully satisfied. If at any
time, any payment, or any part thereof, made in respect of any of the Obligations, is rescinded or must otherwise be restored or returned by the Administrative Agent or any Lender upon the insolvency, bankruptcy or reorganization of any Borrower, or
otherwise, the provisions of this Section&nbsp;13.21 will forthwith be reinstated in effect, as though such payment had not been made. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) Each Borrower hereby agrees that it will not enforce any of its rights of contribution or subrogation against the other
Borrower with respect to any liability incurred by it hereunder or under any of the other Loan Documents, any payments made by it to the Administrative Agent or the Lenders with respect to any of the Obligations or any collateral security therefor
until such time as all of the Obligations have been paid in full in cash. Any claim which the Administrative Agent or a Lender may have against any Borrower with respect to any payments to the Administrative Agent or any Lender hereunder are hereby
expressly made subordinate and junior in right of payment, without limitation as to any increases in the Obligations arising hereunder or thereunder, to the prior payment in full in cash of the Obligations and, in the event of any insolvency,
bankruptcy, receivership, liquidation, reorganization or other similar proceeding under the laws of any jurisdiction relating to any Borrower, its debts or its assets, whether voluntary or involuntary, all such Obligations shall be paid in full in
cash before any payment or distribution of any character, whether in cash, securities or other property, shall be made to any Borrower therefor. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-124- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Each Borrower hereby agrees that after the occurrence and during the
continuance of any Default or Event of Default, such Borrower will not demand, sue for or otherwise attempt to collect any Indebtedness of any other Borrower owing to such Borrower until the Obligations shall have been paid in full in cash. If,
notwithstanding the foregoing sentence, such Borrower shall collect, enforce or receive any amounts in respect of such Indebtedness, such amounts shall be collected, enforced and received by such Borrower as trustee for the Administrative Agent, and
such Borrower shall deliver any such amounts to the Administrative Agent for application to the Obligations in accordance with this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Section&nbsp;13.22. Judgment Currency. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The obligations of any Obligor under this Agreement and the other Loan Documents to make payments in Dollars shall not be
discharged or satisfied by any tender or recovery pursuant to any judgment expressed in or converted into any currency other than Dollars, except to the extent that such tender or recovery results in the effective receipt by the Administrative Agent
or a Lender of the full amount of Dollars expressed to be payable to the Administrative Agent or such Lender under this Agreement or the other Loan Documents. If, for the purpose of obtaining or enforcing a judgment against any Obligor in any court
or in any jurisdiction, it becomes necessary to convert into or from any currency other than Dollars (such other currency, the &#147;<I>Judgment Currency</I>&#148;) an amount due in Dollars, the conversion shall be made at the rate of exchange
quoted by the Administrative Agent, determined, in each case, as of the Business Day immediately preceding the day on which the judgment is given (such Business Day, the &#147;<I>Judgment Currency Conversion Date</I>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) If there is a change in the rate of exchange prevailing between the Judgment Currency Conversion Date and the date of
actual payment of the amount due, each Obligor covenants and agrees to pay, or cause to be paid, such additional amounts, if any (but in any event not a lesser amount), as may be necessary to ensure that the amount paid in the Judgment Currency,
when converted at the rate of exchange prevailing on the actual date of payment, will produce the amount of Dollars that could have been purchased with the amount of the Judgment Currency stipulated in the judgment or judicial award at the rate of
exchange prevailing on the Judgment Currency Conversion Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) For purposes of determining any rate of exchange for
this Section&nbsp;13.22, such amounts shall include any premium and costs payable in connection with the purchase of Dollars. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Remainder of the Page Intentionally Left Blank; Signature Pages Follow] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-125- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL>, the parties hereto have
caused this Agreement to be duly executed and delivered as of the day and year first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">B<SMALL>ORROWERS</SMALL>:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">K<SMALL>ESTRA</SMALL> M<SMALL>EDICAL</SMALL> T<SMALL>ECHNOLOGIES</SMALL>, I<SMALL>NC</SMALL>.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Brian Webster</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Brian Webster</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: President and Chief Executive Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">W<SMALL>EST</SMALL> A<SMALL>FFUM</SMALL> H<SMALL>OLDINGS</SMALL> C<SMALL>ORP</SMALL>.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Brian Webster</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Brian Webster</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">G<SMALL>UARANTORS</SMALL>:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">K<SMALL>ESTRA</SMALL> M<SMALL>EDICAL</SMALL> T<SMALL>ECHNOLOGY</SMALL> S<SMALL>ERVICES</SMALL>, I<SMALL>NC</SMALL>.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Brian Webster</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Brian Webster</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: President and Chief Executive Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">W<SMALL>EST</SMALL> A<SMALL>FFUM</SMALL> I<SMALL>NTERMEDIATE</SMALL> H<SMALL>OLDINGS</SMALL> C<SMALL>ORP</SMALL>.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Brian Webster</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Brian Webster</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">W<SMALL>EST</SMALL> A<SMALL>FFUM</SMALL> H<SMALL>OLDINGS</SMALL> D<SMALL>ESIGNATED</SMALL> A<SMALL>CTIVITY</SMALL> C<SMALL>OMPANY</SMALL></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Brian Webster</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Brian Webster</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Director</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">P<SMALL>ERCEPTIVE</SMALL> C<SMALL>REDIT</SMALL> H<SMALL>OLDINGS</SMALL>&nbsp;IV, LP, </TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">as Administrative Agent and a Lender</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Perceptive Credit Opportunities GP, LLC, its general partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Sandeep Dixit</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Sandeep Dixit</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Chief Credit Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Sam Chawla</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Sam Chawla</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Portfolio Manager</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-127- </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>15
<FILENAME>d744414dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We hereby consent to the use in this Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> of Kestra Medical Technologies, Ltd. of our
report dated August&nbsp;28, 2024, except with respect to the matters that raise substantial doubt about the Company&#146;s ability to continue as a going concern discussed in Note 1, as to which the date is December&nbsp;11, 2024,<SUP
STYLE="font-size:75%; vertical-align:top"> </SUP>relating to the financial statements of West Affum Intermediate Holdings Corp., which appears in this Registration Statement. We also consent to the reference to us under the heading
&#147;Experts&#148;<SUP STYLE="font-size:75%; vertical-align:top"> </SUP>in such Registration Statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ PricewaterhouseCoopers LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Irvine, California<B> </B> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">February&nbsp;26, 2025 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>16
<FILENAME>d744414dex232.htm
<DESCRIPTION>EX-23.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We hereby consent to the use in this Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> of Kestra Medical Technologies, Ltd. of our
report dated August&nbsp;28, 2024<SUP STYLE="font-size:75%; vertical-align:top"> </SUP>relating to the financial statements of Kestra Medical Technologies, Ltd., which appears in this Registration Statement. We also consent to the reference to us
under the heading &#147;Experts&#148;<SUP STYLE="font-size:75%; vertical-align:top"> </SUP>in such Registration Statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ PricewaterhouseCoopers LLP
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Irvine, California<B> </B> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">February&nbsp;26, 2025 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>17
<FILENAME>d744414dexfilingfees.htm
<DESCRIPTION>EX-FILING FEES
<TEXT>
<HTML><HEAD>
<TITLE>EX-FILING FEES</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 107 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Calculation of Filing Fee Tables </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Form <FONT STYLE="white-space:nowrap">S-1</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Form Type) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Kestra Medical
Technologies, Ltd. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Exact Name of Registrant as Specified in its Articles of Association) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Table 1: Newly Registered and Carry Forward Securities </U></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="99%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="8%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Security<BR>Type</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Security<BR>Class<BR>Title</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Fee<BR>Calculation<BR>or Carry<BR>Forward<BR>Rule</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Amount<BR>Registered</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Proposed<BR>Maximum<BR>Offering<BR>Price Per<BR>Unit</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Maximum Aggregate<BR>Offering<BR>Price<SUP STYLE="font-size:75%; vertical-align:top">(1) </SUP></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Fee<BR>Rate</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Amount of<BR>Registration<BR>Fee</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Carry<BR>Forward<BR>Form<BR>Type</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Carry<BR>Forward<BR>File<BR>Number</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Carry<BR>Forward<BR>Initial<BR>Effective<BR>Date</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt">Filing Fee<BR>Previously<BR>Paid in<BR>Connection<BR>with<BR>Unsold<BR>Securities<BR>to be<BR>Carried<BR>Forward</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="1" COLSPAN="25" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="25" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt; padding-right:2pt">Newly Registered Securities</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-LEFT:1px solid #000000; padding-left:8pt">Fees to Be<BR>Paid</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Equity</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Common Shares, $1.00 par value</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Rule 457(a)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">11,500,000</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">$16.00</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">$184,000,000<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">0.00015310</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">$28,170</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-LEFT:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Fees<BR>Previously Paid</P></TD>

<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Equity</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Common Shares, $1.00 par value</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Rule 457(o) </TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">N/A </TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">N/A </TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">$100,000,000<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">0.00015310</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">$15,310</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">&#8195;&#8195;&#8195;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">&#8195;&#8195;&#8195;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" COLSPAN="25" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="25" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt; padding-right:2pt">Carry Forward Securities</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-LEFT:1px solid #000000; padding-left:8pt">Carry<BR>Forward<BR>Securities</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">N/A</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">N/A</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">N/A</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">N/A</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">N/A</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">N/A</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">N/A</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">N/A</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt">N/A</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" ALIGN="right" STYLE="padding-bottom:1pt ;">Total Offering Amounts&#8201;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">$184,000,000</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">$28,170</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" ALIGN="right" STYLE="padding-bottom:1pt ;">Total Fees Previously Paid&#8201;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">$15,310</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" ALIGN="right" STYLE="padding-bottom:1pt ;">Total Fee Offsets&#8201;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">$0</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" ALIGN="right" STYLE="padding-bottom:1pt ;BORDER-BOTTOM:1px solid #000000">Net Fee Due&#8201;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-BOTTOM:1px solid #000000">$12,860</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes offering price of additional common shares that the underwriters have the option to purchase.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(a) under the
Securities Act of 1933, as amended. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(o) under the
Securities Act of 1933, as amended. </P></TD></TR></TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g744414dsp384.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g744414dsp384.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1"  U +$# 2(  A$! Q$!_\0
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MO!NNV6O>&=.N+&[MKR">UCDCD@E$BR*5&&!!Y'O7Y??\%]^/VAO O_8N2_\
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M<?\ !13X@Z5\;_#OA>YM[!].\3R^#;>UU&*QS'#<7Z0S7T#_ #<&2%Y'C/\
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D^'[K66WWLMC:K$T_);!P.%W,QVC R2<<UV-%%,04444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g744414g10t05.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g744414g10t05.jpg
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MH1=$4E5B@C="0U2SP<+2\'-U)CBTX20EHL/1&$5VA/'_Q  : 0$!  ,! 0
M             00%!@,"_\0 ,!$!  $"! 4"!@(" P$       $"$00%,G$#
M$C$T42%2$Q0506&1,]&QP2*!H>'_V@ , P$  A$#$0 _ .J0
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MX3[*H[&Y]I])VT=T\E&EZUCQDU>+&R)[S=X_9%-7#F]G$2RY@
M
M
M
M                          ,;4<##U+%KQM1Q;&7CU_*M7[<5TS[)ZF2
MU!NSN?MGZUSW=-HOZ-DU=?'&JYK?'TT5?E3,-,;L[GO=NC\]W29Q]9QHZX[Q
M5WN[P]-%7Y1,NQ@6[A71M_;]V#EQA_#=0Q>]^/"U"W-5,1]D4U]=,>KP;=VE
MW3&/7R6MUZ-7:J\4Y&!5S4]LVZIXQ[*I[&_M9T;3=;Q)QM8P,7.QY_U,BU%<
M1Z8X^*6H]V=SKM?5.>[H=_*T;(GKBFB>_6>/JU=?X5>P&Q-J;^VQNJFF-#UG
M%R+U4?,55<EWW*N%7\EG<7;KZ!]Z:!55>PL:WJV/1/&+F#5QKC_)/"KCZO%'
M;>Z5M][,R/@E>?DW*;4\*L/4Z)N<OH^-PKI[(F L[B'/VT^Z6TK*Y+6Z-*OX
M-R>J;^+/?;?;-,\*HCLYFY-L[OV_N>U%>@ZOB9O5QFBBOA<I[:)X51[8$3H
M
M
M
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MFX\_[3'NQ7'\IZA&<
M
M
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MLY-FB]C7;=ZS7'&FNW5%5-4?;$P(]
M
M
M
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MTK;.W1R4:?K-FUDU?U;+_<W./V1%755/JS*\1UQU"
M
M
M
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M>$Q'9-06=#BO;6WMMS=-N*M!UC$RZYCCWJ*^6[';1/"J/P6$0
M
M
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M.)G6/[>/=BOAZ)X3U3Z)2(@
M
M
M   Y7W3])M7^^7OUU.J'*^Z?I-J_WR]^NIBXKI#>Y'KKV18#"=&
M         -[]!7T2ROOE?Z*&B&]^@KZ)97WRO]%#WPVMJ\X[:=X;% ;!R8
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M-:BJ/'&/J%/"?XE,?]/M:GU+:F_>CK+JRYQ=4TWD\>7AUS-N8]-=$\.'HG\
M=W#D+:7=%[HTODM:Y8Q=9QXZIJJCO-[AZU/Q?QI]K<^T^GG9FN\EO+R[FD95
M75R9M/"CCZ+D<:>';P"S:P\<3*Q\S'HOX=^UD6*XXTW+5<54U1Z)CJ>P@
M
M
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M$LK[Y7^BAHAO?H*^B65]\K_10]\-K:O..VG>&Q0&P<F
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M-+=&TNEW9FYN2C#U>UBY-7]7S?W-?'[(X_%F>R9$LOH1,3$3$\8GZP
M
M
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M;75-4TU153,Q5$\8F'K7Q+1%,,##X.:JZN+7>(F+1?K;S+=_3S]'-/\ O?\
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MJII\!ZSB9%V8X]XFKDNQ_DJX5?R$68
M
M                                                     !RONGZ3
M:O\ ?+WZZG5#E?=/TFU?[Y>_74Q<5TAO<CUU[(L!A.C
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MO'\];]Y^T9-FNJ*:;M$U3XHB579.G>6V?6!9 $4
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M?O[7XQ'-'NSVMP:!N'1]P8WPC1-3Q,ZUPXS-B[%4T]L>./:(E
M
M
M       '*^Z?I-J_WR]^NIU0Y7W3])M7^^7OUU,7%=(;W(]=>R+ 83HP
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MNR8ZA'N
M
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M,]DRV%15373%5%454S'&)B>,2(_0
M
M                                 '*^Z?I-J_WR]^NIU0Y7W3])M7^^
M7OUU,7%=(;W(]=>R+ 83HP                 !O?H*^B65]\K_ $4-$-[]
M!7T2ROOE?Z*'OAM;5YQVT[PV*B]>^:M=LI1%Z]\U:[9;!R:& 5
M        !DZ=Y;9]9C,G3O+;/K L@"*
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MDA5-J=(>U=U13&BZUBW;]7]7N5=[N^Y5PF?9QA:Q
M
M                                        !RONGZ3:O]\O?KJ=4.5]
MT_2;5_OE[]=3%Q72&]R/77LBP&$Z,                  ;WZ"OHEE??*_T
M4-$-[]!7T2ROOE?Z*'OAM;5YQVT[PV*B]>^:M=LI1%Z]\U:[9;!R:& 5
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MJI]:GQQ[82X@
M
M      Y7W3])M7^^7OUU.J'*^Z?I-J_WR]^NIBXKI#>Y'KKV18#"=&
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ME,^V)X,H0
M                                                         <K[
MI^DVK_?+WZZG5#E?=/TFU?[Y>_74Q<5TAO<CUU[(L!A.C
M   &]^@KZ)97WRO]%#1#>_05]$LK[Y7^BA[X;6U><=M.\-BHO7OFK7;*41>O
M?-6NV6P<FA@%0                  9.G>6V?68S)T[RVSZP+( BJI<^<K[
M9?+ZN?.5]LOE4                    6#1O(:>V6:PM&\AI[99J*
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M?0
M                                            #E?=/TFU?[Y>_74Z
MH<K[I^DVK_?+WZZF+BND-[D>NO9%@,)T8                  WOT%?1+*^
M^5_HH:(;WZ"OHEE??*_T4/?#:VKSCMIWAL5%Z]\U:[92B+U[YJUVRV#DT, J
M                  #)T[RVSZS&9.G>6V?6!9 $55+GSE?;+Y?5SYROME\J
M@                   "P:-Y#3VRS6%HWD-/;+-10
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M4Y&!5PG^'5/_ %>QN?:?25M+=7)1I&M8TY%7BQ[T]ZN\?LBFKAQ]G$1<
M
M                                  '*^Z?I-J_WR]^NIU0Y7W3])M7^
M^7OUU,7%=(;W(]=>R+ 83HP                 !O?H*^B65]\K_10T0WOT
M%?1+*^^5_HH>^&UM7G';3O#8J+U[YJUVRE$7KWS5KMEL')H8!4
M        &3IWEMGUF,R=.\ML^L"R (JJ7/G*^V7R^KGSE?;+Y5
M          %@T;R&GMEFL+1O(:>V6:B@\,K*MXT4S<YOC>+A#'\*X_\ C_ &
M>,#PKC_X_P #PKC_ ./\ 9XP/"N/_C_ \*X_^/\  &>,#PKC_P"/\#PKC_X_
MP!GC \*X_P#C_ \*X_\ C_ &>,#PKC_X_P #PKC_ ./\ 9XP/"N/_C_ \*X_
M^/\  &>,#PKC_P"/\#PKC_X_P!GC \*X_P#C_ \*X_\ C_ &>,#PKC_X_P #
MPKC_ ./\ 9XP/"N/_C_ \*X_^/\  &>,.SJ-B[=IMT<_-5/".,,P
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M2KA5_)97%>ZN@O>NWJJKV'B4ZK8HGC%W JFJN/\ )/"KCV1+"VYTM[[VA?\
M@MS4+]^BU/"K$U.B;G+Z.-7"NGLB8"SN$:!VEW2ND9?):W/I>1I]R>J;^-/?
MK7;,=54>SF;CVUNS0=S6>^:#JV'FQPXS1;N1ST^M1/QH]L")L
M
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M_5\6G)TK.QLW'GQ7,>[%RG\8D1F
M                                                     .5]T_2;
M5_OE[]=3JARONGZ3:O\ ?+WZZF+BND-[D>NO9%@,)T8
M WOT%?1+*^^5_HH:(;WZ"OHEE??*_P!%#WPVMJ\X[:=X;%1>O?-6NV4HB]>^
M:M=LM@Y-# *@                  R=.\ML^LQF3IWEMGU@60!%52Y\Y7VR
M^7U<^<K[9?*H                    L&C>0T]LLUA:-Y#3VRS45%Z]\W9[
M90R9U[YNSVRAEA                    &3IOEUGUED5O3?+K/K+(BP
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M2\JKJ[UGT][CCZ_&:?YPV78O6[]FB[8N47;5<<::Z*HJBJ/MB8$?8
M
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MT9-7BQLF>\W./V1%7RI]69740
M                                       <K[I^DVK_ 'R]^NIU0Y7W
M3])M7^^7OUU,7%=(;W(]=>R+ 83HP                 !O?H*^B65]\K_1
M0T0WOT%?1+*^^5_HH>^&UM7G';3O#8J+U[YJUVRE$7KWS5KMEL')H8!4
M              &3IWEMGUF,R=.\ML^L"R (JJ7/G*^V7R^KGSE?;+Y5
M                %@T;R&GMEFL+1O(:>V6:BHO7OF[/;*&3.O?-V>V4,L(
M                   R=-\NL^LLBMZ;Y=9]99$6
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M$GOMOMFF>%41V34%G0@@-L;SV[NBW%6@ZQB9E7#C-NFOA<CMHGA5'MA/B
M
M     #E?=/TFU?[Y>_74ZH<K[I^DVK_?+WZZF+BND-[D>NO9%@,)T8
M            WOT%?1+*^^5_HH:(;WZ"OHEE??*_T4/?#:VKSCMIWAL5%Z]\
MU:[92B+U[YJUVRV#DT, J                  #)T[RVSZS&9.G>6V?6!9
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MO>=N>]+R >OPB]YVY[TI_3*IJPK<U3,S/'KGME6UCTKR"U[?SD(90"*
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M0SQ
M     !RONGZ3:O\ ?+WZZG5#E?=/TFU?[Y>_74Q<5TAO<CUU[(L!A.C
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M&FY;JBJFJ/1,=4O40
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MRJOZOF?N;G'[(YNJJ?5F1++V$3$QQCK@
M                       <K[I^DVK_ 'R]^NIU0Y7W3])M7^^7OUU,7%=(
M;W(]=>R+ 83HP                 !O?H*^B65]\K_10T0WOT%?1+*^^5_H
MH>^&UM7G';3O#8J+U[YJUVRE$7KWS5KMEL')H8!4                  &3
MIWEMGUF,R=.\ML^L"R (JJ7/G*^V7R^KGSE?;+Y5
M%@T;R&GMEFL+1O(:>V6:BHO7OF[/;*&3.O?-V>V4,L(
M   R=-\NL^LLBMZ;Y=9]99$6'Y5\F>Q4ULJ^3/8J:P@
M   L>E>06O;^<JXL>E>06O;^<A#* 10
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MIXQ'9,MR[5WSMK=5%,Z%K.)E7)CCWGFY+L=M%7"K^0BR
M                              .5]T_2;5_OE[]=3JARONGZ3:O]\O?K
MJ8N*Z0WN1ZZ]D6 PG1@                 #>_05]$LK[Y7^BAHAO?H*^B6
M5]\K_10]\-K:O..VG>&Q47KWS5KME*(O7OFK7;+8.30P"H
M    ,G3O+;/K,9DZ=Y;9]8%D 154N?.5]LOE]7/G*^V7RJ
M      +!HWD-/;+-86C>0T]LLU%1>O?-V>V4,F=>^;L]LH980
M        !DZ;Y=9]99%;TWRZSZRR(L/RKY,]BIK95\F>Q4UA
M        !8]*\@M>W\Y5Q8]*\@M>W\Y"&4Q,[-C$FB)HFKFX^*>#+1&O?*L]
MDHKZ\,4^9GWCPQ3YF?>0XJ)CPQ3YF?>/#%/F9]Y#@)CPQ3YF?>/#%/F9]Y#@
M)CPQ3YF?>/#%/F9]Y#@)CPQ3YF?>/#%/F9]Y#@)CPQ3YF?>/#%/F9]Y#@)CP
MQ3YF?>/#%/F9]Y#@)CPQ3YF?>/#%/F9]Y#@)CPQ3YF?>/#%/F9]Y#@)CPQ3Y
MF?>/#%/F9]Y#@)CPQ3YF?>>V)J5.1?IMQ;FGCQZ^*!9FD>7V_;^4@L("*
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M*_T4-$-[]!7T2ROOE?Z*'OAM;5YQVT[PV*B]>^:M=LI1%Z]\U:[9;!R:& 5
M                 !DZ=Y;9]9C,G3O+;/K L@"*JESYROME\OJY\Y7VR^50
M                   !8-&\AI[99K"T;R&GMEFHJ+U[YNSVRADSKWS=GME#
M+"                    ,G3?+K/K+(K>F^76?661%A^5?)GL5-;*ODSV*F
ML(                    +'I7D%KV_G*N+'I7D%KV_G(0RD1KWRK/9*71&O
M?*L]DI"HD!4                  &9I'E]OV_E+#9FD>7V_;^4@L("*
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MJNKDS*?B<?1<CC'#TU<&TL++QL[&HR,+(LY%BN.--RU7%=-79,=0CV
M                            <K[I^DVK_?+WZZG5#E?=/TFU?[Y>_74Q
M<5TAO<CUU[(L!A.C                  &]^@KZ)97WRO\ 10T0WOT%?1+*
M^^5_HH>^&UM7G';3O#8J+U[YJUVRE$7KWS5KMEL')H8!4
M   &3IWEMGUF,R=.\ML^L"R (JJ7/G*^V7R^KGSE?;+Y5
M     %@T;R&GMEFL+1O(:>V6:BHO7OF[/;*&3.O?-V>V4,L(
M        R=-\NL^LLBMZ;Y=9]99$6'Y5\F>Q4ULJ^3/8J:P@
M        L>E>06O;^<JXL>E>06O;^<A#*1&O?*L]DI=$:]\JSV2D*B0%0
M               9FD>7V_;^4L-F:1Y?;]OY2"P@(H
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MC7^TNF#9FY>2C&U>WAY-7]7SOW-?'[(F9Y9GLF6P*9BJF)IF)B>N)CZQ
M                        !RONGZ3:O]\O?KJ=4.5]T_2;5_OE[]=3%Q72
M&]R/77LBP&$Z,                  ;WZ"OHEE??*_T4-$-[]!7T2ROOE?Z
M*'OAM;5YQVT[PV*B]>^:M=LI1%Z]\U:[9;!R:& 5                  !D
MZ=Y;9]9C,G3O+;/K L@"*JESYROME\OJY\Y7VR^50
M!8-&\AI[99K"T;R&GMEFHJ+U[YNSVRADSKWS=GME#+"
M   ,G3?+K/K+(K>F^76?661%A^5?)GL5-;*ODSV*FL(
M   +'I7D%KV_G*N+'I7D%KV_G(0RD1KWRK/9*71&O?*L]DI"HD!4
M          &9I'E]OV_E+#9FD>7V_;^4@L("*
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M[;=4\8]E4]@6='BK[4Z0-K[JIIC1-:Q;]ZK_ &%57>[ON5<)_"%H$
M               '*^Z?I-J_WR]^NIU0Y7W3])M7^^7OUU,7%=(;W(]=>R+
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MO;^<JXL>E>06O;^<A#*1&O?*L]DI=$:]\JSV2D*B0%0
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MOE?Z*'OAM;5YQVT[PV*B]>^:M=LI1%Z]\U:[9;!R:& 5
M  !DZ=Y;9]9C,G3O+;/K L@"*JESYROME\OJY\Y7VR^50
M    !8-&\AI[99K"T;R&GMEFHJ+U[YNSVRADSKWS=GME#+"
M       ,G3?+K/K+(K>F^76?661%A^5?)GL5-;*ODSV*FL(
M       +'I7D%KV_G*N+'I7D%KV_G(0RD1KWRK/9*71&O?*L]DI"HD!4
M              &9I'E]OV_E+#9FD>7V_;^4@L+SR/)[OJS^3T>>1Y/=]6?R
M156 5                    %FP/(K/JP]WA@>16?5A[HH
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M1+*^^5_HH>^&UM7G';3O#8J+U[YJUVRE$7KWS5KMEL')H8!4
M      &3IWEMGUF,R=.\ML^L"R (JJ7/G*^V7R^KGSE?;+Y5
M        %@T;R&GMEFL+1O(:>V6:BHO7OF[/;*&3.O?-V>V4,L(
M           R=-\NL^LLBMZ;Y=9]99$6'Y5\F>Q4ULJ^3/8J:P@
M           L>E>06O;^<JXL>E>06O;^<A#*1&O?*L]DI=$:]\JSV2D*B0%0
M                  9FD>7V_;^4L-F:1Y?;]OY2"PO/(\GN^K/Y/1YY'D]W
MU9_)%58!4                    6; \BL^K#W>&!Y%9]6'NB@
M                          *7NSHOVANGGKU/1K%.35X\G&CO-SC]LS3\
MKV\6F-V=S/D6^>[M36:;U/CC'SZ>6K^)3'"?=ATV X/S]O[\Z-LNK)KQ]4TG
MA/"<G&KF;57V<:Z)FF>R5,S,F]FY=_*RKE5W(OUU7+ERKQU53/&9GMF76'=9
M[C\'[-PM#LU\+VJ7^:Y$3_LK?"9_&J:/PERYI^@:QJ7#P=I.H9?'Q=XQJ[G'
M\(D?4+MT,=*&;L#5>]7^?)T')KCX3C<>NB?%WRC[*H^N/KCJ^R8[4T?4\+6=
M,Q]1TO)MY.%D417;NT3QBJ/^4^CZG#>G=$N^\_AWC;.?1Q\_$6?US#>?0/L[
MI%V5GS8U*SAQH&1/&]C7,N*JK57]NWRQ,<?MCCPG\)$EOT 0      <K[I^D
MVK_?+WZZG5#E?=/TFU?[Y>_74Q<5TAO<CUU[(L!A.C
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M7T2ROOE?Z*'OAM;5YQVT[PV*B]>^:M=LI1%Z]\U:[9;!R:& 5
M       !DZ=Y;9]9C,G3O+;/K L@"*JESYROME\OJY\Y7VR^50
M         !8-&\AI[99K"T;R&GMEFHJ+U[YNSVRADSKWS=GME#+"
M            ,G3?+K/K+(K>F^76?661%A^5?)GL5-;*ODSV*FL(
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M05]$LK[Y7^BA[X;6U><=M.\-BHO7OFK7;*41>O?-6NV6P<FA@%0
M         9.G>6V?68S)T[RVSZP+( BJI<^<K[9?+ZN?.5]LOE4
M           6#1O(:>V6:PM&\AI[99J*B]>^;L]LH9,Z]\W9[90RP@
M             #)TWRZSZRR*WIOEUGUED18?E7R9[%36RKY,]BIK"
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M\K_10]\-K:O..VG>&Q47KWS5KME*(O7OFK7;+8.30P"H
M  ,G3O+;/K,9DZ=Y;9]8%D 154N?.5]LOE]7/G*^V7RJ
M    +!HWD-/;+-86C>0T]LLU%1>O?-V>V4,F=>^;L]LH980
M      !DZ;Y=9]99%;TWRZSZRR(L/RKY,]BIK95\F>Q4UA
M      !8]*\@M>W\Y5Q8]*\@M>W\Y"&4B->^59[)2Z(U[Y5GLE(5$@*@
M              S-(\OM^W\I8;,TCR^W[?RD%A>>1Y/=]6?R>CSR/)[OJS^2
M*JP"H                    LV!Y%9]6'N\,#R*SZL/=%0FN^46_4_YRC4E
MKOE%OU/^<HU80                   !GZ)Y;_EE/('1/+?\LIY%@
M                    <K[I^DVK_?+WZZG5#E?=/TFU?[Y>_74Q<5TAO<CU
MU[(L!A.C                  &]^@KZ)97WRO\ 10T0WOT%?1+*^^5_HH>^
M&UM7G';3O#8J+U[YJUVRE$7KWS5KMEL')H8!4                  &3IWE
MMGUF,R=.\ML^L"R (JJ7/G*^V7R^KGSE?;+Y5                    %@T
M;R&GMEFL+1O(:>V6:BHO7OF[/;*&3.O?-V>V4,L(
MR=-\NL^LLBMZ;Y=9]99$6'Y5\F>Q4ULJ^3/8J:P@
ML>E>06O;^<JXL>E>06O;^<A#*1&O?*L]DI=$:]\JSV2D*B0%0
M       9FD>7V_;^4L-F:1Y?;]OY2"PO/(\GN^K/Y/1YY'D]WU9_)%58!4
M                  6; \BL^K#W>&!Y%9]6'NBH37?*+?J?\Y1J2UWRBWZG
M_.4:L(                    S]$\M_RRGD#HGEO^64\BP
M             .5]T_2;5_OE[]=3JARONGZ3:O\ ?+WZZF+BND-[D>NO9%@,
M)T8                  WOT%?1+*^^5_HH:(;WZ"OHEE??*_P!%#WPVMJ\X
M[:=X;%1>O?-6NV4HB]>^:M=LM@Y-# *@                  R=.\ML^LQF
M3IWEMGU@60!%52Y\Y7VR^7U<^<K[9?*H                    L&C>0T]L
MLUA:-Y#3VRS45%Z]\W9[90R9U[YNSVRAEA                    &3IOEU
MGUED5O3?+K/K+(BP_*ODSV*FME7R9[%36$                    %CTKR"
MU[?SE7%CTKR"U[?SD(92(U[Y5GLE+HC7OE6>R4A42 J
M #,TCR^W[?REALS2/+[?M_*06%YY'D]WU9_)Z//(\GN^K/Y(JK *@
M            "S8'D5GU8>[PP/(K/JP]T5":[Y1;]3_G*-26N^46_4_YRC5A
M                    &?HGEO\ EE/('1/+?\LIY%@'GDW[6-CW+^173;LV
MZ9KKKJ\5,1US,H/]M-N?WSA_Q$FJ(ZONGAUUZ8F5@%?_ &TVY_?.'_$/VTVY
M_?.'_$3GI\OOY?B^V?U*P"O_ +:;<_OG#_B'[:;<_OG#_B'/3Y/E^+[9_4K
M*_\ MIMS^^</^(?MIMS^^</^(<]/D^7XOMG]2L K_P"VFW/[YP_XA^VFW/[Y
MP_XAST^3Y?B^V?U*P"O_ +:;<_OG#_B'[:;<_OG#_B'/3Y/E^+[9_4K *_\
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MW\Y5Q8]*\@M>W\Y"&4B->^59[)2Z(U[Y5GLE(5$@*@
MS-(\OM^W\I8;,TCR^W[?RD%A>>1Y/=]6?R>CSR/)[OJS^2*JP"H
M           LV!Y%9]6'N\,#R*SZL/=%0FN^46_4_P"<HU):[Y1;]3_G*-6$
M                    9^B>6_Y93R!T3RW_ "RGD6$/O+Z):U]SN_HERVZD
MWE]$M:^YW?T2Y;86*ZPZ3(_XZ]P!BMX                  .I=G?1'0_N-
MC_ATN6G4NSOHCH?W&Q_PZ65A>LM'GG\=&Z7 9KFQRONGZ3:O]\O?KJ=4.5]T
M_2;5_OE[]=3%Q72&]R/77LBP&$Z,                  ;WZ"OHEE??*_T4
M-$-[]!7T2ROOE?Z*'OAM;5YQVT[PV*B]>^:M=LI1%Z]\U:[9;!R:& 5
M             !DZ=Y;9]9C,G3O+;/K L@"*JESYROME\OJY\Y7VR^50
M               !8-&\AI[99K"T;R&GMEFHJ+U[YNSVRADSKWS=GME#+"
M                  ,G3?+K/K+(K>F^76?661%A^5?)GL5-;*ODSV*FL(
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M&C>0T]LLUA:-Y#3VRS45%Z]\W9[90R9U[YNSVRAEA
M &3IOEUGUED5O3?+K/K+(BP_*ODSV*FME7R9[%36$
M %CTKR"U[?SE7%CTKR"U[?SD(92(U[Y5GLE+HC7OE6>R4A42 J
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MQZ5Y!:]OYRKBQZ5Y!:]OYR$,I$:]\JSV2ET1KWRK/9*0J) 5
M      !F:1Y?;]OY2PV9I'E]OV_E(+"\\CR>[ZL_D]'GD>3W?5G\D55@%0
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M$F BO ]/GI]T\#T^>GW4J BO ]/GI]T\#T^>GW4J BO ]/GI]T\#T^>GW4J
MBO ]/GI]T\#T^>GW4J BO ]/GI]T\#T^>GW4J BO ]/GI]T\#T^>GW4J BO
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M^>GW3P/3YZ?=2H"*\#T^>GW3P/3YZ?=2H"-C2IB.$9-<1V?_ '/!<_[S<_\
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M444T47ZZ::8X1$1PB(28J3,SU1T:;/\ O-?_ )[1(@@
M
M
M
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M9C'J]-,S,554^F(GT<0;5'S:N47K5%VU737;KIBJFJF>,51/BF)?0
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M.V0;&%8Z/M\:/OO1Z]0T.Y<Y;=?>[UF]3RW+57#CPF(F8ZX\4Q,Q^$K.
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M<>6F>$^+CQ]G6L^Q]W:5O30J-6T.[77CS5-NNBY3RUVJX\=-4?5/7$^T$^
M        #SR+DVL>[<BGFFBF:HB/KX1X@5/5=ZS.Y+NWMM:?.KZQCT1<RHF]
M%FQBTSXN^7.$_&GZJ8B9[&%IO2%-G=MG;.[-+JT75<FGFPZXOQ>Q\J/LHN<*
M9BKT3$?SCC0>Y-SIU/!W;G95??-1R<^F]?KGQSS1,Q_/G97=9XD4[-T?5K-4
MV\W!U&F+5RGJJIBJFJ9X3VT4S[!6\7AG7,BUBW*\/'IR+\?)M57.2*NO^UPG
M@P-HZG5K6U=&U2N(BO-P[.15$?5-=$53^:6$:CQ>FW"IW[:VIK.B9>F9M61&
M-7<N7J*Z**YCXOB\<3,T]?I;<<K=,FU*]9USI%UK"IJ^':+DX-[C3XYLU6/C
M_APIJ[(EO;H@W;3O/8>G:G77$YE-/>,N/LO4=54^WJJ[*A5S:DT[IKQ=9WO>
MVSM_0LK4,FB[<MTWXOT46ZXHX\U?&?%3U3V]2T=+&MY.E;6G$TF?_P ZU:[3
MIV#$3UQ<N=4U^B*:>:KCZ(:-Z+=%Q]N]TIE:1A?,8>/79IF?'5PLT\:I],SQ
MGV@Z*W#J>I:=M+.U'#TR<K5+./5<HPK=?/S5Q'R8F(XS[(XS]3$Z-]<U7<6T
M</4M?TNK2M0NS5%>/--5/5%4Q%7+5UQ$QU\)9&[]W:-M' G+UW+[Q;X3----
M%5=57U=44Q/US$<9ZNMX;5WII>XMH6]R6)NXNFUS7'')B*:HY:YHZXB9\<QU
M1Z1%E&N])Z8MI:IGZM8Q\J_1CZ;9[[>RKUJ:**OC13RTQ/QYJXS$<.7K^ICZ
M!TS[=U;=-G0;N+JNFY>15%./5GX\6J;LSXHCKF8X_5QCK[0;,
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M>7KCK],-F]&NLZ=K&R]'N:9FX^3%K#LT78M7(JFW5%$<::HCQ3U3U2(LX
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M?V8%7NG1,G2>@G=.5JL?_G6K8.5J.?,QUQ<N6YGD]'+3PIX>B6+W)G^C"_\
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M/5/7U-3]RSK^ETZMNW%NYMBSD9V7;NXUN[7%-5Z.-SY,3XYZXZH^T'1P @
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MGA5PG[$;W3NTLO+L:-NG0:+GA73[]NQ5-J/CS%5?[NJ/33<F(CU_0*MVC_\
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MI6IX.K85&7I>9CYF+7\F[8N173/MAEB
M                               ##S-*T_-NQ=S,#$R+M/BKNV::YCVS
M#, ?E%%-NBFBW3%-%,<(IICA$0_0
M              !B9FFX.;<HN9F%C9%RCY-5VU37-/9,QU,NF(IB(IB(B.J(
M@                       &+E:;@Y=ZB]E86->NT?)KN6J:JJ>R9CJ90
M                     \LO%L9EBJQEV+5^S5PYK=VB*J9X=?7$]3U (B(B
M(B(B(ZHB                        8=W2]/NY495W!Q:\F.N+M5FF:X]O
M#BS                       !C8>!AX7-\"Q,?'Y^NKO5N*./;PAD@
-              #_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g744414g16a16.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g744414g16a16.jpg
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M                $0$A,?_:  P# 0 "$0,1 #\ U2
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M1[6J+C1:OWD3J9=:AO[E;@>UO;S;N--<ZBJQ_P#QT,GVBFG@"LP>V7;Q:O\
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MF5?_  =_<E^H[#OW$E"
M
M
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MB9?'G=DC_68O%/X> (D
M
M
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M@@
M
M
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M>I? J<E3J4]P0
M
M
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M
M
M                                                     4KV6E:Z
MGV:TU.U<=M7"-CD\*(Q[OXM0FNQ6A;;]E6F(6IA'4;)E\\F7K^]Q ^RZIG2;
M/;;,U%5(;DS>\B+'(G\<%A[(:EM7LPTO*Q45$M\,:^=K4:O[T4*EP "
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M=FBNE8B>ST+\JY/>[S>/FXH?O;'-%'M#V7I)(QJ^R<BX5<=3$_B!;0 "
M    */[+BA;/L]M]7C\)37!B9_HN8]%_>C2P=C]:ZOV8:8G>N7=HQQJOAW$W
M/_:07LLZIL.S.GA54WI[A$U$\B->Y?X(3/8E3+2;*=,1N145:-LG'^FJN_Y@
M38
M
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M(J;L;$_48F?.C?":C"@ "
M
M
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M?N)U3[/K7[9:>_76IN%XN=*F*:2NE:YL'E8QC6M1?+C(5,  $    "KA,KR
M&7MM^M*O:'JFDT'HU>V*9)T;-(Q>]GE3R_\ ELXJJ\LHJ]2'5VU;7)[I5NT=
ML_<^JJ:EW:]154_%7JO!8XE3][OH\).]ANRV#0=J6KN"1S:@JF(D\B<4A;SZ
M-B_Q7K7R(@5+MGNDZ/1>E**S4.'=$W>FEQA995]\]?.O+P(B)U$C "
M
M
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M
M
M
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M'U+Y8WJBI]9?,6[IC:3I'4R,2TWVC=,[E!,[HI<^#==A5^;(1+@
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M%M;.MB&FM)+%5UC/9>ZLPJ3U+4Z-B_T(^2>=<KY4+51$1$1$PB=0!0 !
M
M
M
M           </4FDK!J6)67VT4=;PPCY(TWVIY'IWR?,I4FINQLT_6J^2P7*
MLM<B\HY$Z>-/(F<._P RE[@#+B;/=L&A^.F;P^NI&<6QT]3O-1/DI>'S)D_<
M.W37>F)&P:RTRV1$7&]+"^E>[Y\*U?F0U ?F6-DL;HY6->QR85KDRBIY4"J2
ML?9(Z4K$:VZT5RMTB\UW$FC3YVKO?Y2?6;:?HJ\(WM+4EN1R\F3R="[Z'X4_
M-[V7:*O2N6NTY0(]W-\#.@<OERS! [QV-NE*I7.MM==*!Z\F[[96)\SDS_F
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M-8B^?"<3W@(
M
M
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M;_!#U
M
M
M
M *2[+G\6M!^U(OLI2>;&OQ6:7_J$?\"!]ES^+6@_:D7V4I/-C7XK-+_U"/\
M@!,0
M
M
M
M   4EV7/XM:#]J1?92D\V-?BLTO_ %"/^! ^RY_%K0?M2+[*4GFQK\5FE_ZA
M'_ "8@
M
M
M
M     I+LN?Q:T'[4B^RE)YL:_%9I?^H1_P "!]ES^+6@_:D7V4I/-C7XK-+_
M -0C_@!,0
M
M
M
M        4EV7/XM:#]J1?92D\V-?BLTO_4(_X$#[+G\6M!^U(OLI2>;&OQ6:
M7_J$?\ )B
M
M
M
M        "DNRY_%K0?M2+[*4GFQK\5FE_P"H1_P('V7/XM:#]J1?92D\V-?B
MLTO_ %"/^ $Q
M
M
M
M           !279<_BUH/VI%]E*3S8U^*S2_]0C_ ($#[+G\6M!^U(OLI2>;
M&OQ6:7_J$?\  "8@
M
M
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M4GFQK\5FE_ZA'_ @?9<_BUH/VI%]E*3S8U^*S2_]0C_@!,0
M
M
M
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MC_@!,0
M
M
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MY'(J*BN;C"\43GX#K@#CVK3%DM-0V>VVJCIIF-5C'QQHBL:O-K?BIY$PAV
M*2[+G\6M!^U(OLI2>;&OQ6:7_J$?\"!]ES^+6@_:D7V4I/-C7XK-+_U"/^ $
MQ
M
M
M
M!279<_BUH/VI%]E*3S8U^*S2_P#4(_X$#[+G\6M!^U(OLI2>;&OQ6:7_ *A'
M_ "8@
M
M
M
M    I+LN?Q:T'[4B^RE)YL:_%9I?^H1_P('V7/XM:#]J1?92D\V-?BLTO_4(
M_P" $Q
M
M
M
M     !279<_BUH/VI%]E*3S8U^*S2_\ 4(_X$#[+G\6M!^U(OLI2>;&OQ6:7
M_J$?\ )B
M
M
M
M       "DNRY_%K0?M2+[*4GFQK\5FE_ZA'_  ('V7/XM:#]J1?92D\V-?BL
MTO\ U"/^ $Q
M
M
M
M          !279<_BUH/VI%]E*3S8U^*S2_]0C_@0/LN?Q:T'[4B^RE)YL:_
M%9I?^H1_P F(
M
M
M
M           *2[+G\6M!^U(OLI2>;&OQ6:7_ *A'_ @?9<_BUH/VI%]E*3S8
MU^*S2_\ 4(_X 3$
M
M
M
M              %)=ES^+6@_:D7V4I/-C7XK-+_U"/\ @0/LN?Q:T'[4B^RE
M)YL:_%9I?^H1_P  )B
M                         /E-4P0)F>>*-/"]Z)_$YE1JBP4V>V;[:H<?
M^95QM_BH'8!%IMHFC8<[^JK'P^+71N_@IXI=J^A8E[[4]N7]5ZN_@@$V!7[]
MLN@&<]24Z^:*5?X-/.[;?L];_P#O"U?-2S^H!9 *T=MTV?(N/9U5\U)-Z@;M
MSV>JO_?RIYZ2;U ++!7#-M^SUW_[Q,3STLZ?^P]$>V30$GO=2TR?K12)_%H$
M_!"H=JVAI?>ZGMJ?K2;O\3VP[0M'3<(]56//@6NB;_%P$H!R:;4MBJ<=K7JV
M39Y='51N_@ITH9X9DS#+'(GA8Y% ^@
M
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M6VN1>'_:8%<W/ZS-[Z5P638]1V6_1[]ENM#7-QE4@F:]4\Z(N4^<(ZH
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M7Q_YL*W]Y/+3>[7>(NDM-RHZYGQJ>=LB?N4(Z
M                         *'[,#_@BS?M%/LGEI;+_P 6^EOV93?9M*M[
M,#_@BS?M%/LGEI;+_P 6^EOV93?9M"I,  @
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M:"EA;%2PQPQ-Y,C:C6I\R'U
M     'GKJ&DKX%AKJ6"IA7G'-&CVK\RGH %=W_8OH6\HY7V.*CE=_P")0N6'
M'F:G>_N*UOG8T)%(L^E]1RPR-7+(ZR/BB_*,QCZIHX K+?:^V[07^R?57BAC
MZD5*UJHGD7\(B>;!U]/=DFZ";M76&GI:>9BX?)1JJ*B^6)_%/K&C3CZATO8]
M10]'?+51US<819HD5S?,[FGS*%<;2>TS2.J58RTWJF6I=RIYUZ&7/@1KL9^;
M),2B=6=C=I^OWY=.5U3:IEXI%)^'B\W%=Y/I4ABVK;#LO[Z@FFN]IC_)B5:N
M+=3JW%[]B>;'G U2"@M'=DA:ZM[:;5UNEMD^=UU1!F6+/7EOOF_YB[+%>[7?
MJ)*NRU]-74R_EP2(Y$7P+CDOD4(Z(                   $0UOM(TQHQCD
MO5R9VVB92D@_"3._LIR\[L(!+SQ7:[6^STCJJ[5U-14[><E1*V-OTJIFV[;;
M]9:RK7VW9W8Y:=%X=*V/IYD3PJN-QB>?/G/W:-@FJ=3U;;AM!U ^-[N*QI(M
M3-CP;R]ZWYMY L3?579#Z2M*OBM+:J\SMX(L+>CBS^N[C\Z(I 7;7-IVM7NC
MT98%I:=5PDM/3K,K?/*_O$^A"XM*;'=%Z;1CZ>T1UM2W_P >N7IG9\.%[U%\
MR(6!&QL;&LC:UK&IA&M3"(@&7F;'-I6KG))K#4?:\3N*Q3U3IU;YF-[Q/F5"
M66/L:=-TJ-==[I<;A(G-(]V!B_-A5_S%[ )4&L^R30MJ1O:^FZ&5R?E52+.J
M_754)A0V^BH(TCH:2GIF)^3#$UB?0B'I               5$5,*B*G@4X5V
MT=IN[HOLG8;75.7\N2E8KOK8RAW0!55ZV!Z$N6\L-!4V]Z_E4E0Y/W/WD_<0
M*[]C3/32]L:7U,Z.5O%C:J)6JG_Y&+_[320!66^T]N&AN,$M5>*-G4UZ5K53
MP(COPB)YD0Z=B[)*IHY^U-9:<?%,Q</?2*K'-\\3_6-(G+ONGK/?Z=8;W;*.
MNCQA$GB1RIYE7BGS!4=TGM3T?JC<9;;U RI=P2FJ5Z&3/@1'>^7]55)L4;JW
ML<=.7%'RZ>JZFT3KQ2-R]/#]#EWD^M\Q!W6S:]LJ[^BFENUGB_)C5:J%&^5B
M]^Q/-A/*!JH%%Z'[(NR7-S*;5-+)9ZI>'3LS) J^7\IOT*GE+LMU=27*CCJ[
M=4PU5+(F62PO1[7)Y%3@$>@
M  %#]F!_P19OVBGV3RTME_XM]+?LRF^S:5;V8'_!%F_:*?9/+2V7_BWTM^S*
M;[-H5)@ $
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MM=Q:[H^V]U6PN=RP]%XQK^[S%\1R,EC;)$]KXW(CFN:N45%Y*BA'Z
M    CVL]96/1MN6LO]='3M5%Z.).^DE7P-:G%?/R3K5"LMK>W.CT_++9](I'
M<KUGHWS)WT,#N6$Q[]_D3@B\_ 1'1&Q>^ZSN/MBVG5M6Q)E1Z4KG?AY$ZD=_
MY;?Z*<?U0KS7O:OK?:5<7V?9Y;JBAI%X.EB7\-NKUOD][&GF7/E4DNA>QUHX
M9$K]<US[E5N7?=30/<D>>O??[Y_S8^<O"PV2VV"W1T%EHH**DCY1Q-PGG7K5
M?*O$Z *\5GM-OLM"RCM-%3T5*SE%!&C&^?"=?E/: $
M              0;76RS2NLDDDN5O;!7._\ VREQ'+GPJN,._M(I1]SV<[0=
ME57+<]$W&:XVU%WI&0-RY43_ ,R!<H[SMROF-4@"D-FW9 6B^/CH-5QLL]R7
MO>FRO:\CO.O%B_K</*7<Q[9&->QR.8Y,HY%RBIX2M]IFQ[3VMV25/1I;;PJ9
M2LIV)WZ__4;R?Y^"^4I:UZAUSL-NL=LO\#KCIU[L1IO*Z)R=:PO7WJ]>XOT<
M<A6L@<#16K[-K.T-N%AJVS1\$DC7A)"[XKV]2_N7JR=\(
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M6)*&\;OX.NA;WRKU(]/RT\_'P*4C8]4:RV'7N.S:G@DK]//<O1HCMYBMSQ=
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MP!?6IP1/9EK>@UYIF*YT.(YV_@ZJF5<NADQQ3RHO-%ZT\N426!
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M1<L_M)E//A>HB'8JZO=>-(U%AK)%=5VER=%O+Q6!WO4_LKE/,K0J[P $
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MV7U8L>BK/2(O">OWU\NY&[UBTMF%$VW[.M-4S4QN6^!7?K*Q%7]ZJ!)@ $
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M[$3S/W4^8U*9@[)9/8K:[I*\1\')'"Y?/'.JY^A4^@+C3X "
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MM(6FIL6G*&VU]SJ+K4T[%:^LJ/?RKE5X\57AG'%5X(!V
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M/J#FRW^SPUR44MUH&5BNW.@=4,1^]X-W.<^0Z+'M>F6.1R>1<@?T
M        S!V5N*G7FE**/C*L/).??2X3^"FGS+NL7>W#LIK70Q+OP6Z:&-53
MBF(469Z?6WD"XU$  @                             H?LP/^"+-^T4^
MR>6ELO\ Q;Z6_9E-]FTJWLP/^"+-^T4^R>6ELO\ Q;Z6_9E-]FT*DP "
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MQTB\5:CFJF<83+D5>',\,FRZV2:%@TDZZWCV'A>CVM1\._P?OHBNZ/DCN/\
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MR45JMD214=)&D4;?(G6OA55XJOA4Z  1XKY;8+S9JZVU:9IZR!\#_,YJHO\
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M/34Z5#U<E.Q'+CHTY-7C[[GR3.$1$^.B84O_ &.=N@O5_6UT,%0K)ZA_?=)
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MBV;;==/:I2*DN[FV:ZKA-R=_X&1?Z#UY>9V/ F2W45%1%1<HH0
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M],6]VH+_ !+[.US.\9)Q=3Q+QPO]-W-? G#PET@!
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MLC6U-946N9?R*R%43/ZS=Y/I5"Q+/?K3>HTDM%SHJYN,YIYVR8\^%X!'2
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MY]T'^9UOI;@<=3W;-GOC''Z--Z@]VS9[XQQ^C3>H<ON?=!_F=;Z6X=S[H/\
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MTU#"D-%3PT\*<F1,1C4^9#[@
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M-?F3+O\ ,7D E1?3NS_2FG=U;18:&"5O*5T?22)_;=EW[R4
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MH1_P F(
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MJ\4\*<?.J=6IU+4SZAK[-8:""MJK='%)5K/5= UG2(JL:W#'*JJC<\D1,IQ
MDX./I*\RWZRLKJBADH)NFFA?32.1SF.CD=&N53AS;G@=@
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M*BIQ14547PGWKKQ!27:@MJ,DFK*S><UD:(O1QM3OI'Y7@U%5J>%5<B(!T@
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MM2+[*4GFQK\5FE_ZA'_ @?9<_BUH/VI%]E*3S8U^*S2_]0C_ ( 3$
M                                                           9
M@T!\*V^?+5?\%-/F8- ?"MOGRU7_  4T^      >=];2)6MH7U-.E6]G2)3K
M(F^K?C;O/'E*O9IZEINR#IJ[3\3(&MM<C[LV!NZS><[$>]CAO.QG'6C,^4FN
MH]#Z<U'<(*^\VJ*HK8&HR.='N8]J(JJB;S51<95?I.K:+306:E6GM=)#2Q*[
M><D;<;SO"Y>:KY5X@5=LZ@6Q[;]?4%;WLUT;#<*1SN'2QY=O;OAPK\?,I]K?
M;G2=DE<Z^W)BGALT;*][>2S.<FXU?+NM:OF0L6]:?M=Z?3R7*D;+-3*KH9FN
M='+$J\]U[51S<]>%XGWM%IH;13N@MM,R!CWK(]4RKGN7FYSEXN7RJJJ!SZO4
M--4V2]U&G:BFN5;;XY6K##(C\3-:JI&[')<HB8*TLFB+/M V/T57<Y6R7JKC
M?6ONJJG2QU*JN]EWQ6X1N[R1&IC&$+3L6G;38'5KK/00TCJV9:BH6-%_"/7K
M7[DX'BDT3IY\U0_V.:UM0]7SPQRO9#*Y>:OB148Y5Z\HN>L#E[%KE<KMLRL=
M7?'.DK7Q.:LC^<K&O<UCU\.6HBYZ^?6?:^(FH[Q[6Z9$2UTV[+=7-X(Y%XLI
MD_6]\[^CA/RR71QLBC;'$QK(V(C6M:F$1$Y(B'FMMNI+;%+'10I$V65\\G%7
M*][ERYRJN55?_P!"<D KNX(M;M]H:"XQMDMU/89)J2*1N6=*Z5&O<B+PWMWA
MYCZ[ 9JA^CJ^&57.HZ6ZU5/0JJY_ -?WJ)Y$57(GFQU$WO%BMUX?3ON%-OS4
M^]T4K'NCDCWDPY&O:J.1%3FF<+UGJMM!2VRA@HK?3QTU)"W<CBC;NM:GD0"J
M.R&=/02:)OCFN=;+7>(YJO"91J9;AR^1,.3SN3PG4[(3H:[9)<88<5$U9)3,
MHVQ]\LLCI6*U&>%53/+J+&K:2GKJ26EK8(JBFE:K)(I6HYKT7J5%YG%M&C+!
M:)H):"W-8ZGST"/D?(V#//HVN549_91 (!MTI9:#L?9Z.J?O5$$%%#([/OG-
MDC15^E%+5M*YM5&J<4Z%G^E#QZ@TW:-0Q,BO=#%6PM7*1S95N?#NYQGRGLME
MOI;71LI*"+H:>-,,C155&IX$SR3R 5)V2-CK9*+3VJK9 ZHET]5]L2Q,3*K$
MKFN5WF18TSX$55ZBT]-WRWZCL]-<[/4LJ*2=J.:YJY5%ZVN3J5.2IU'25$5%
M14RB]1$G[.-)K6R5<=FBIYI%R_M662!KU\K6.1%^= .A>:OV2IKQ:;6Y7UB4
M<C5E8O>PR.:J,:J_&7.<=2)E<93,([&JNCEV8TUM<G1UUKJ)J:JA<F'QOZ1S
MN*=7!W[E\!9=MH*2V4C*6W4T--3,]['$Q&M3P\$ZSCU^B]/UUSFN$]N8VMF;
MNS2PR/B69/!)N*B/_M9 JW9[0/BT_M<N<**EKKJNM[47\E[6-DWGM\BJY$S_
M $3K:!^#,G['K/X2EF5-DMM3:$M4M'#[&HSH^UF)N1[N,;N$QP\G(\4&C[#3
MV62T06V*.UR+EU*U7)&O/*;N<87*Y3K @6EU3N8W+E,>P%3]G(<"_JG<DP_L
M^F^V86Y%I"PQ65]GBML3+6]<NI6JY(UYY3=SC'%>'(^3]$:;?9VVE]I@=;&N
MWFTJJ[HD7.?>YQSX@07;/\'.K_JE#]K"?K;VJ+L%K%14PL5)C^\C)[6:0L-;
M:8;75VV*>W0_[.FD5SHV^#AGJQP\'4*[2%AK[5!;*VVQ5%O@_P!G3R*YS&^#
M@J]75X.H"LKI.^S]D!I2NN#MVW7&S]HT\KO>-E[Y=W/A5=WZR'2VT4#[KK+9
MQ24**MP9=%J<MYL@9NND<O@3@GSE@5VEK+7V1EHK;=!46Z/"LAE17(Q4Y*U5
MXM5.I47@?NS:=M5FE?-;Z7=G>U&.FDD=+(K4Y-WWJKMWR9P!7ER^$U:?_M]_
MVKS]0*G=.5'_ -M)]NTG4ND;%+>TO$ENB==47*52J[I$\B+G@G%>'(-TC8FW
MOV82VQ)=<Y[:R[I/-O9Y>3D!W2'6JIL.TC351#<Z6CKF13R4U33O3>6*1CU;
MYVJJ)E%3CA28D9GT%IF5RO;:(8)ERKIJ9SX)'Y7*[SV*CG<57FJ@5ILIL,NC
MMLNH].6.KFJ--MHFU3XGNWDIYG.;NM5?C8WO*K<9S@[&R'\96U/]H0?PD+&L
ME@M=CHI*2T445)#(JND2/.\]R\W.=S<OE5<GDMFD+#:ZRIJ[=;8J:IJ45)Y8
MW.1TN<YWESQ7BO%?"!4VD[[!INEVQW:HI4K(J:[RJM.O*3*JU&KY%5>/DR>#
M:[(M1LJL5TN=XCFJJVII9H:6G>D5-$Q>*MCC3BY&IA-YRN7S<BY*+1.G*)*U
M*6T4T;:YKFU34152=%SG?15P[FO/PGAAV9Z.AM%1;(]/TB44[FND9WRJY47*
M=]G>1$7J1<!42VT313:IV9/BD8]GL\QN\UR*F4<U%3YEX'[[(*9+=%I*\UE.
MZHL]!=6NKF(BKACFJW>QY./SJGA)Q7:(TW7-HVU=GI9&T34;3-5JHV%$Y;B)
MP;R3D=BHMU)4VY]!54\=11O9T;X9DZ1KF^!<YS\X1!)&[/*E+944D-HN=3-/
M'VC'"]LLBO54[YJ954W??*O4B+GD<[5^C6:DU;<[MHV_5%CU=;NCIZES5S'.
MBQM>SI&^!45$SQ3O5X+@F&F=!Z8TQ625=ALM+1U,B*U96HKG(B\T17*N$\B8
M/O7:/L=;=)KE-0[EPF1&RU,$TD,CT1$1$5S'(JIA$X<@.-L>U'<]1Z6GDOM-
M%!<Z*MFH:AT*89*]BIEZ>=57..&44G!YK;04EKHHJ.W4\5-2Q)AD4;=UJ=?\
M>)Z0                   ^=3_N\OZB_P #-'8=?]Y:K^3I_P#5(:7J?]WE
M_47^!FCL.O\ O+5?R=/_ *I K39YJ:AIZ>LJZJ*-$J*I6K*]>*KNM1J)YDQR
M\*JO6IZ2NMHFT6T66Y1Z>]FJ:W7"=N]453UWNTX_"B87,B_DHO!/?+P1$4CP
MZ/M+*C;CK"_V]J,H(J:.WRN;[V:I[QS\>%6HU$7RKYSY]DVB+LQ=E.5=3X^L
M=O1&L=&22T.G-(US*Q^Z]VY USMUJ(KG22.5.:JO%5RJN=YU.#V3TL<6S%>D
M>UJNKH,97GARJO[D4*MHKCLAKI-:MDM\?3.5DDZ,IMY.IKWHUWTMWD^<L1)8
MUA25KVK$K=Y'HN45.><^ K?6[[?M5V37N/2E4VNSE(5:US<S1.1^YAR(N5PB
M?VD"/=<+5!'L-GMJL3H8[ K,8ZT@SGSY3)7>F%N-VTGLGU5*R>JI[/+-3UB1
MM61S8US$V56IE51NXF5\N?"2RZZI@FV!NJXG*ZLJ;:EN;3HF9%JG,Z)8MWGO
M([/#GP)7LLT]+I;9_9+14HB5,$&9D1<XD<JO<GS*Y4^8"+Z27V*U+M"UG<&3
M4UGK9*=M,CXU:^9(8]Q7-8O%=YRX;\;JYH=VT5E'8G2W75M=2T=[NC>E?%+*
MG_9X&^]B3^BQ%[YW+><Y>M#[4_\ \UZD[97OK%9YE; GY-55MRCG^5L?%$\+
M]Y?R4(Q1JD6V;72WM42F?9H'4RR<NUD:O2XSU;^<@6I%(R6-DD3VOC>B.:YJ
MY147DJ*1S6>J6V"2UT-+ E7>+K/VO14[G[C55$RY[W87#&IQ7"*O)#A[ 65T
M>R33[;DCTEZ)ZQH_GT2R.6/YMW&/)@CVV;IK'M!T)JZ=KEL]#.^EJY$3*4Z2
M=ZCW>3"KQ_HIX4 []ZUK==(7RU0:OIZ%]HN<O:\=PHM]B03+R;(QRKP7XR+U
M+P(YV2<EU;9+,V%M'['NN]*C55[ND63OU1%3&-WASSGR'MV_4K-4Z<L5@M<C
M*BON=QB?!T3D=NQ-1V_-P_)1%Y^4^79+3Q0Z5T\V65C%]G*9W?+C@C7Y7S)P
M"K0LZW)U*JWF.C94[RX2E>YS-WACBY$7/,I[;95NO>T[0VC)G+[&U$S:VKBZ
MID1RX:ODPQ_UB[VJCD16JBHO%%0IO;K8Z^CU!IK7EHI9*QUDE1*R"),O=!O9
MWD3R9>B_K(O)%"8N1J(U$1J(B)P1$ZCD/H[?9:V\7^5S:=LU.QU6]4PW$*/7
M?7R[KL>9J'RL.K;#?K6RX6NZTDU,YN\J]*B*SR.15RU?(IQ=7K)K/0^I:"QM
MZ2*:C?%35*.[VHDPN6L\+>")O<E55\ 'DI]4:HN^F%U)8;7;W4#F.GIJ&I<]
M*BHB3.%WT[UCG(F4;AW-.)\ZK:8VJV6RZRT[0,K&11N=-3SS]&L+FKAR+A%R
MJ9SCAE.OB?/8MJ:@EV6T"5E1'2S6:#M6OCF7<=3K%EO?HO+*(BD"L=GGLG8V
MZMGK8W4S;FZ>MABD[U61OW&L3"\LHU%QY4"I9>MH&K:/0U#JVFL%M=:DI8:F
MJ9-4.;,]'HW>6-J(J-:BNX*Y57''!Z-6Z_U+:].QZJMUAHGZ:8R*61M34.2K
MDC>J=^UJ)NM3ODYJJ]>$Y'@U/-'W+['=(S=6QTS47/!5W6)CSYX'[U[/$O8S
MJ])&*QUHI&M7/!5_!I@#M[3M?UFE=*V^]VFVPUM+6/B:DDTRM5G2)EJ[B)EW
M#RISZSQ:RUYJ72E9;KA=+#1MTW5U;*1494.?61J[.'.:B;O4O>HJ^#)&MLT\
M*["=+N25FZ^2@5J[R87\'G@=OLDYXH]%V9SY6-:MYIG(JNYHF^JK] 'MU)KG
M4NFKO:*B]V2@AT[<:QE$BQU+GU4#GYW7/X;G4JJC<\L9)#>-43NU9'IBP14\
MUU[76KJ9JA5Z*EBSA,HWBYRJO!N4X<<^&(]D?/%'IC3BR2,:GL]2NRKL<$1^
M5\QY(I5TMV1=?4W9W16[4="R.CJ'KAG2L1B='O<D7O5X?TF^$"4V;6M9!KE=
M(ZJI:>GN,T/;%#54KG=#5L3.4W7<6N3=7AE>2\>6>?%KW4%3M!O.EJ73](M3
M1TK)HGNJEW%WMU4?(_=[UN'>]1JKGR<4\NKK>M_VXZ0[0P_V$@FJJ^1O%(D?
MPC8J^%51>'/&5/CIF6->R2U<Q)&*[V*@3"+QRG1Y D&SK65SO=[U!8-24-+1
MWJSOCWUI'N=%+&],M<W>X_3X4)U*S?B>S>5N\BIE.:>4J?0LT3MOVT-K9&*Y
M:>DX(O'A&U%^A2V)G*V)[DYHU50(SQHS6M=L=<W2&N[;.EICE>M%=:=BN8YK
MG*Y55/RDRJKP[Y,X5%+KTG[$5;:Z]6"J@JJ6ZR-G=)"J*U7M8UB_/AJ91>.3
MA:/U+I[:/H>G?7NH*SI(&I74DVZO1R(G?9:O),Y5%\&%0B&P:S,L^L=<Q:?G
M?-I%L\;*1ZOWV.E1%5Z,=U[N=U5Z\-YA7@V15FH8K=K2'2UNHZBJ]GZI[IJZ
M98X6^]PU-U%<YRX\B)UKU$OLNU!*O936ZNJ;7+VW0N=!/0PKG,R.1N$7'!.^
M:JKQPF>>#F=CK-$^AUHK)&.3VP5+^#D7O51N%\W AVB]75&E-B6I[O:&Q35+
M+Y-&UZIOMBWW,1)'(G-,+P\*J@%CW365^T[=M*QW^DM\U'?:AE'_ -E1[)*6
M9^-U%WE5'IE<*N&\EX'ZUEKR[V+7MBT_2V.&JBNC95BE2H7?>K6KPQC#$WMW
M+E5W#*XX%?;2*S3\-PV>UE/?676I9>Z6>KN$E1TB-CRBJJJG>1(N,[J;J<%7
M'!5))K>OI)]MVS*>*HC=#)#5.8[.$5'1JC5^?J\('?I=9:AHJ2FI-3VB@HM0
M5U;)3T4+:M.@?$QJ.=,YW%4:B9X<U7"83/#XTNT"MMVO[?IG43+9,RYQJZBK
MK<]V[OIG,;V.551>'!47K3P\./MOG]K^K=&ZJKZ/MRQ43YJ6N:L?2)&V5$1'
MX7S*OG:B=9([)JC1MVNM#3:3BMMPKI')(YU-3HG:T:<5D>[=[WJ1$YJJIY<$
M>FFU/<KY>K]1:<6UM6S3)3R15:O62=^ZCE7O53HVY7=1V'95%X$ATK7U5TT[
M;ZZX4R4E9/$CY8$7/1NZV_,5?J'25EUE>+U>M-7>73VK[7,^"IG@FW4<K/>N
ME;\56HG?)Y47>P2K99J*]WW0-GN5WHE?6SQ.5\B88DF'N:U^/Z341>'#CPX
M3H           "$[9=3U>D= 5]TMR(E6CHX62N;O)%ON1N^J=>$Y)X< 38$
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MTS8JZHZ>MLMLJ)\J[I):5CG95<JN53//B=9K4:U&M1$:B81$Y(?T
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MTX(7P5[?M)7S5UOM=MU2MI2GI*J.IEJJ1SUDF5G4UCFHD>]UKO.X9P6$$
M
M                 9@T!\*V^?+5?\%-/F8- ?"MOGRU7_!33X
M
M
M
M                                                  &8- ?"MOGR
MU7_!33YF#0'PK;Y\M5_P4T^
M
M
M                                                   !C5+9JC6N
MU_5-DLM_J*1\5;62MZ:JE;&UC9E3=3=SCWR<,$K]PW:/XX0>G5'JC8Q\)76'
MREP_F$-/A68/<-VC^.$'IU1ZH]PW:/XX0>G5'JFGP"LP>X;M'\<(/3JCU1[A
MNT?QP@].J/5-/@%9@]PW:/XX0>G5'JCW#=H_CA!Z=4>J:? *S![ANT?QP@].
MJ/5'N&[1_'"#TZH]4T^ 5F#W#=H_CA!Z=4>J/<-VC^.$'IU1ZII\ K,'N&[1
M_'"#TZH]4>X;M'\<(/3JCU33X!68/<-VC^.$'IU1ZH]PW:/XX0>G5'JFGP"L
MP>X;M'\<(/3JCU1[ANT?QP@].J/5-/@%9@]PW:/XX0>G5'JCW#=H_CA!Z=4>
MJ:? *S![ANT?QP@].J/5'N&[1_'"#TZH]4T^ 5F#W#=H_CA!Z=4>J/<-VC^.
M$'IU1ZII\ K*D78\ZWBK75D6HK<RK=E73MJ)D>N>>7;F3V>X;M'\<(/3JCU3
M3X!68/<-VC^.$'IU1ZH]PW:/XX0>G5'JFGP"LP>X;M'\<(/3JCU1[ANT?QP@
M].J/5-/@%9@]PW:/XX0>G5'JCW#=H_CA!Z=4>J:? *S![ANT?QP@].J/5'N&
M[1_'"#TZH]4T^ 5F#W#=H_CA!Z=4>J/<-VC^.$'IU1ZII\ K,'N&[1_'"#TZ
MH]4>X;M'\<(/3JCU33X!68/<-VC^.$'IU1ZH]PW:/XX0>G5'JFGP"LP>X;M'
M\<(/3JCU1[ANT?QP@].J/5-/@%9@]PW:/XX0>G5'JCW#=H_CA!Z=4>J:? *S
M![ANT?QP@].J/5'N&[1_'"#TZH]4T^ 5F#W#=H_CA!Z=4>J/<-VC^.$'IU1Z
MII\ K)FR-E^LFW^DT]>;Q4UCJ59V2IVQ(^-Z] YR<'<^KFAK,S!8/A?57RT_
M\JXT^   0
M
M
M  9@V,?"5UA\I</YA#3YF#8Q\)76'REP_F$-/A=  $
M                                        !F"P?"^JOEI_Y5QI\S!8
M/A?57RT_\JXT^
M
M
M         !F#8Q\)76'REP_F$-/F8-C'PE=8?*7#^80T^%T  0
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MGS,%@^%]5?+3_P JXT^
M
M
M               !F#8Q\)76'REP_F$-/F8-C'PE=8?*7#^80T^%T  0
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MQI\
M
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M^6G_ )5QI\
M
M
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M\+ZJ^6G_ )5QI\
M
M
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M "KC3YF"P?"^JOEI_P"5<:?
M
M
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MT^9@L'POJKY:?^5<:?
M
M
M               S!L8^$KK#Y2X?S"&GS,&QCX2NL/E+A_,(:?"Z  (
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M,I&;N&4[7>^5$ZWJG!7>#@B)E<AZ+%;V6FR6^VQ+F.CIXZ=J^%&-1J?P/<
M                  &8+!\+ZJ^6G_E7&GS,%@^%]5?+3_RKC3X
M
M
M                                               &8-C'PE=8?*7#
M^80T^9@V,?"5UA\I</YA#3X70 !
M                          9@L'POJKY:?^5<:?,P6#X7U5\M/_*N-/@
M
M
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MC3YE31%SH[SV5CKA;*AM11SR3NBE;G#D[6<F>/F-5@
M
M
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M %.]SIHCPW7TE/5'<Z:(\-U])3U2X@!3O<Z:(\-U])3U1W.FB/#=?24]4N(
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MF]\U6KE-U.I5+(
M
M
M                                            S!H#X5M\^6J_X*:?
M,P: ^%;?/EJO^"FGP
M
M
M
M                 ,P: ^%;?/EJO^"FGS,&@/A6WSY:K_@II\
M
M
M
M                                                  #,&@/A6WSY
M:K_@II\S!H#X5M\^6J_X*:?
M
M
M
M                        S!H#X5M\^6J_X*:?,P: ^%;?/EJO^"FGP
M
M
M
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M4T%)V6T\%+#'! R6=&1QM1K6IVL[DB<$-2!
M
M
M                               &8-C'PE=8?*7#^80T^9@V,?"5UA\I
M</YA#3X70 !
M          9@L'POJKY:?^5<:?,P6#X7U5\M/_*N-/@
M
M
M                                       9@V,?"5UA\I</YA#3YF#8
MQ\)76'REP_F$-/A=  $
M                 !F"P?"^JOEI_P"5<:?,P6#X7U5\M/\ RKC3X
M
M
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MF"P?"^JOEI_Y5QI\
M
M
M            #,&QCX2NL/E+A_,(:?,P;&/A*ZP^4N'\PAI\+H  @
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MIX";                    ,P6#X7U5\M/_ "KC3YF"P?"^JOEI_P"5<:?
M
M
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MEI_Y5QI\S!8/A?57RT_\JXT^
M
M
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M   &8+!\+ZJ^6G_E7&GS,%@^%]5?+3_RKC3X
M
M
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MI\
M
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MM+>U/33:.>1L]PJ)7U==.U.$D[URY4\B<$3R(@$I
M 9@L'POJKY:?^5<:?,P6#X7U5\M/_*N-/@
M
M
M                              9@V,?"5UA\I</YA#3YF#8Q\)76'REP
M_F$-/A=  $                  !_&M1J8:B(F<\#^@   !\YH(9E8LT4<B
MQKO,5S47=7PIX%/H         !_-U-Y'83>1,(I_0
M   #,%@^%]5?+3_RKC3YF"P?"^JOEI_Y5QI\
M
M
M                                #,&QCX2NL/E+A_,(:?,P;&/A*ZP^
M4N'\PAI\+H  @
M           ,P6#X7U5\M/\ RKC3YF"P?"^JOEI_Y5QI\
M
M
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M?/S&I]"I_N'L]M\_,:GT*G^XT^ 5F#V>V^?F-3Z%3_</9[;Y^8U/H5/]QI\
MK+^R?2FN7;::/4NK+151=)TSJBI>QC6[RPN:G!O!..$X(:@ "
M
M
M
M                 ,P: ^%;?/EJO^"FGS,&@/A6WSY:K_@II\
M
M
M
M                                                  #,&@/A6WSY
M:K_@II\S!H#X5M\^6J_X*:?
M
M
M
M                        S!H#X5M\^6J_X*:?,P: ^%;?/EJO^"FGP
M
M
M
M                                                         ,P:
M ^%;?/EJO^"FGS,&@/A6WSY:K_@II\
M
M
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MQ*GT:B]4$:?!D^FVA[5+/KVPV35=Q?3+5U5/OP/I:;+XGR[J\6LX9PY.>36
M0
M
M                                                        !F#6
M?PL[5\M2_9H:?,P:S^%G:OEJ7[-#3X4  0
M                                &8-NWPB-'>:A_F7FGS,&W;X1&CO-
M0_S+S3X4  0
M
M
M    9@UG\+.U?+4OV:&GS,&L_A9VKY:E^S0T^%  $
M                                       !F#;M\(C1WFH?YEYI\S!M
MV^$1H[S4/\R\T^%  $
M
M
M           &8-9_"SM7RU+]FAI\S!K/X6=J^6I?LT-/A0 !
M  /XYS6)ESD:GE7!_3F:DLE#J*RU=LN<$<U/41N8J/:B[JJBIO)GDJ9X*!T4
MEC5%5'M5$YKGD&R,<N&O:J^!%*5['""D]JVH-*72AI75MJKGT]6QT35Z9BJN
MZKLIWW%'HF>I$.=L%CM6G]IVN-,4K('K'.LU'-N]\D;7*UT:.7CWN\U/.C@+
M[61C5PKVHO@53]$"K+);+_M5953T%+,MCHLOD=$BJZ>94W45<<58R-53/+I$
M)#>M4VVT5#Z>=:JHJF1I+)!1TLE0^-BYPYR,:NZBX7&<9PN .X#BVC55DN^G
MWWRWW*"6U1M<Z2H5=U(T:F7;R+A6JG@4\U/K2T37"AHG=O05%>Y6TJ5%%-$D
MV&JY=U7-1.2*O'B!(P5E6;3J>+:BFG^AKV4-+12RSO2AE>Z67?8C=UK6JY6(
MF_WV,*J\^'&S&JCFHJ9PJ9XI@#^GY8]CU<C'-<K5W7(BYPN,X7Z4/'?;G3V6
MS5USK7;M/20NF?CFJ-3.$\J\D*<V176\V/:7>].ZM?BJOD3;S3IU)(YO?QIY
MD16__B4"\3FW2_V>TS1PW6[6^BEE]XRIJ61N?YD<J9/1<Z^&VT4E75),L,>-
M[H87RNXKC@UB*Y>?4A2NRNXV?6-DU73:FIJFLFNUTJ5D5:*9R=$UC=QO2(W#
M5:B+A,HJ+CK7B%SW.[VVU4K:FZ7"CHJ=W!):B9L;%\RN5$/O15=-74L=30U$
M-33R)EDL+T>QR>%%3@I1>B[Y9J;:C>;>^*X36>UVNFM]OCEH*B5[&*UKG[S%
M8KFY5>;D3*(G5@L+9P_25K==[#I-T\<E+,M554DD4S70N?R1$>B*B8:F$3_F
M!. <&S:NLEXJ+I!0UBK-:\=NLFB?"L&=[&]OHGQ7?0<I-IVDGTE;4PW5)HZ6
M;H'I%#(]SGXRJ,:B9=A.:HBHGA F8(:W:9I233\-YANB34DSG,8V*%[Y5<W&
M\G1HF]PRF>&$RGA0[NF-0VS4]GBNECJFU5%(JHCT16JBIS147BB^10.J
M              ,P;=OA$:.\U#_,O-/F8-NWPB-'>:A_F7FGPH  @
M
M
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MWMPQ,+Y.7D/WH71$&CY;FZCNEPJV7"H=5SLJNC5.E=[YR;K&JF<<N01+0
M              !F#;M\(C1WFH?YEYI\S!MV^$1H[S4/\R\T^%  $
M
M
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MB-'>:A_F7FGS,&W;X1&CO-0_S+S3X4  0
M
M
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M?"(T=YJ'^9>:?"@ "
M
M
M          #,&L_A9VKY:E^S0T^9@UG\+.U?+4OV:&GPH  @
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M7FGPH  @
M
M
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M  @
M
M                                                        S!K/
MX6=J^6I?LT-/F8-9_"SM7RU+]FAI\*  (                '-U)9*/4-FJ
M+9<F*ZGF1.^:N',<BY:]J]3D5$5%\AT@!X;,E?'2)#=%CDGBPSMB/@DZ?'W?
MR57K3BF>2J>Y41>:9    #@:WFU%3V%\FC::AJ;JDC<15CE:Q69[[&%3CYU3
MK/AHNTW.G=67;4KJ9;W7[C9&4V5BIXF(NY$U5XKA7/<J]:N7JP28
M >>X/J64KUH8F2U"\&)([=:B^%R\\)Y.)SM+6""P4<[&/6>LJIG5-74N3#IY
M7<W8ZDY(B=2(B'9                      !F#;M\(C1WFH?YEYI\S!MV^
M$1H[S4/\R\T^%  $
M
M
M         &8-9_"SM7RU+]FAI\S!K/X6=J^6I?LT-/A0 !
M                                             9@V[?"(T=YJ'^9>
M:?,P;=OA$:.\U#_,O-/A0 !
M
M
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M.Y>?XUM] _Z@[EY_C6WT#_J :/[>I/SJ#^\3[QV]2?G4']XGWF<.Y>?XUM]
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MJ8JCH^TMW?W'H[&=_AG!H<   @
M
M
M                                                   S!M5^%!IC
MY:A^T-/F8-JOPH-,?+4/VAI\*  (
M
M
M
M                         ,P;5?A0:8^6H?M#3YF#:K\*#3'RU#]H:?"@
M "
M
M
M                                                           #
M,&U7X4&F/EJ'[0T^9@VJ_"@TQ\M0_:&GPH  @
M
M
M
M                                  S!M5^%!ICY:A^T-/F8-JOPH-,?
M+4/VAI\*  (
M
M
M
M        ,P;5?A0:8^6H?M#3YF#:K\*#3'RU#]H:?"@ "
M
M
M
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MRZ<IH6UE5%3J_MARJU'O1N<;OE-(&8-NWPB-'>:A_F7FGP  "
M
M
M                                          #,&L_A9VKY:E^S0T^9
M@UG\+.U?+4OV:&GPH  @              'BNMVMUHA;+=KA24,3EW6OJ9FQ
M-5? BN5 /:#E1ZDL<EN?<([S;7T#';KZEM4Q8FKX%=G"+\Y^[3?[/>'O9:;M
M;ZYS$RY*:I9*K4\NZJX Z0.7)J*RQW)+=)>+<RX.<C4IG5+$E5?!N9SGYCJ
M       ^-)5T]9&]])-',QDCHG*QV41[55KFKY45%10/L 1N\ZYTW9:E8+G=
MH8'MD2)[E:Y61O7BC7O1%:U<<<.5 )(#B7W5=DL<:/N=P9&BQ]-AC72JD?QU
M1B*J-_I+P\IT+1<Z*\6Z&OM=5%5T<R;T<T3MYKD\X'K
M      !F#;M\(C1WFH?YEYI\S!MV^$1H[S4/\R\T^%  $
M
M
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M\U#_ #+S3X4  0
M
M
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M:.\U#_,O-/A0 !
M
M
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MRN%3"*Y$X=>#^Z;LC[EMKOFIX:-6V;M"*F;--"K>V*A%:N^Q')E4:C<;WT9
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MS,&W;X1&CO-0_P R\T^%  $
M
M
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M/TYHAM!I*6P7NYU%[I'TR4>)F-C:R%$5&M:UO7A??*JKP3CP0BUAV15UH_\
MAS-;7A^F$<O_ ,,1J-56*O%BRHN4:O6C43.5Y%L@"%;0MGU'JZGMLD%7+:KI
M:WI)0UM,U%6'EPW>&6\$X93EY\\JY[-KI>KAI^OO>L*N>MM,RS,D@HXHD5>&
M-UO%$7AQ5=[/4B==E #\QM5D;6J]SU1$17.QE?*N.!^@         ,P;=OA$
M:.\U#_,O-/F8-NWPB-'>:A_F7FGPH  @
M
M
M                         S!K/X6=J^6I?LT-/F8-9_"SM7RU+]FAI\*
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M #+S3X4  0
M
M
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M #+S3YF#;M\(C1WFH?YEYI\*  (
M
M
M                    ,P:S^%G:OEJ7[-#3YF#6?PL[5\M2_9H:?"@ "
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M<T4[I4==5.M/9+V^&%52*\V56S-ZG.C=(YKE\J(S'SEN!
M      !F#;M\(C1WFH?YEYI\S!MV^$1H[S4/\R\T^%  $
M
M
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M!MV^$1H[S4/\R\T^%  $
M
M
M             &8-9_"SM7RU+]FAI\S!K/X6=J^6I?LT-/A0 !
M                                                 9@V[?"(T=YJ
M'^9>:?,P;=OA$:.\U#_,O-/A0 !
M
M
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MS2UD;G-B9(CE1./5Q7'E-5 !
M
M
M                                                    &8-JOPH-
M,?+4/VAI\S!M5^%!ICY:A^T-/A0 !
M
M
M
M                          !F#:K\*#3'RU#]H:?,P;5?A0:8^6H?M#3X
M4  0
M
M
M
M 9@VJ_"@TQ\M0_:&GS,&U7X4&F/EJ'[0T^%  $
M
M
M
M                                   &8-JOPH-,?+4/VAI\S!M5^%!I
MCY:A^T-/A0 !
M
M
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MN"+D!4MIV^Z.NETH[?2MNG3U<S((]ZG1$WG.1J97>Y94MH
M
M
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M9>:?"@ "
M
M
M #,&L_A9VKY:E^S0T^9@UG\+.U?+4OV:&GPH  @
M                                     ,P;=OA$:.\U#_,O-/F8-NWP
MB-'>:A_F7FGPH  @
M
M
M         S!K/X6=J^6I?LT-/F8-9_"SM7RU+]FAI\*  (            0_
M:GJ.Y:1TG67VW0T=3'1HU9()]Y%<CGHW*.1>K*<, 3 $5LE_JI="0ZAO<UOH
M6S4;*S*-<L<+7-1R(Y57+N:<L'RV?W75%[H([AJ*VT-KIY4WHJ=JO=,K5Y.<
MB\&>''%?#@"7@   >+V3I/9GV*25%KD@[96-/R8][=15\ZYQYE ]H   'SJ$
ME6%Z4[F-EQWJO:KFHOE1%3^('T!5FA-I]5>-H=VTE?J&FI*JF61M-- YRMJ%
MC>K78WO(F4\REIKP3*\@ *JT'M,K]::[O-HMU'206JWITC:F7?=)/&KD1JHW
M*(F\G?(O@5.9:H  X>M[C<+1I6YW&T14LM524\DZ-J5<C%1C5<OO>*KP\*><
M#N AVCKU>=1;+Z*[P=J)?*NB=)%OM5L/2\=W*)QW<X)!ISV4]@Z+VP=K>RO1
M)VSVMGH]_KW<@=$   ?B=9$A>L",=+NKN(]51JKU95$7@079/JJ[:G74[+VR
MDCFMEUDH&MIFJC<,1$7BJJJ\<\0)Z               #,&W;X1&CO-0_P R
M\T^9@V[?"(T=YJ'^9>:?"@ "
M
M
M                 #,&L_A9VKY:E^S0T^9@UG\+.U?+4OV:&GPH  @
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M3WJKEJ8QCK7!Z-B<%;17+6B7&V7"B]D+S/7TRU%,]C7Q/7@N53"+Y%XA5J
M(             ,P;=OA$:.\U#_,O-/F8-NWPB-'>:A_F7FGPH  @
M
M
M                                              S!K/X6=J^6I?LT
M-/F8-9_"SM7RU+]FAI\*  (         $.EUVBW.X4=#IO4-?VC,L$D]-!%T
M2O1$54:YTB9QGP 3$%<V':O2:@MDMPLNF-35M'&]T;I(J>%<.:B*J8Z7*KQ3
MD3;3UV@OMDHKI2,FC@JXDE8R9J->U%ZG(BKA?G Z    X>M=1-TMIVKN\M!5
M5L-,Q9)&4^[EK4ZUWE3AYLKY#TZ6NS;]IRV79D*P-KJ:.H2)7;RLWFHN,]?,
M#I@     (A3:W9-M&?I%UKJX)VT;JSMB9S$:]B.1J*U$555%X\5PO#D2\
M /Q,]8X9'M8Z1S6JJ,;S=Y$.1HZ\U5_L$%PKK15V>>17(M)5>_;ARHBKP3GC
M/) .T      \-ZN#K9;IJMM%4UB1-5[HZ;<W]U$555-]S47ERSDX>@-;TFN+
M:MPM-ON,-!O.8V>J;&U'.3&41&O5W7SQ@"5                  #,&W;X1
M&CO-0_S+S3YF#;M\(C1WFH?YEYI\*  (
M
M
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M"(T=YJ'^9>:?"@ "
M
M
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MWPB-'>:A_F7FGPH  @
M
M
M           S!K/X6=J^6I?LT-/F8-9_"SM7RU+]FAI\*  (
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MWFH?YEYI\*  (
M
M
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MCCWXZ*E:JJKE6225RKE55>;WN<OG55.T?*6GAFDBDEB8]\2JZ-SFY5BXQE/
MN (;LJTW4V6W7.Y7:-([Q?*Q]PJH\YZ'>5=R+/7NHOTJI-P
M       S!MV^$1H[S4/\R\T^9@V[?"(T=YJ'^9>:?"@ "
M
M
M                                      #,&L_A9VKY:E^S0T^9@UG\
M+.U?+4OV:&GPH  @
M              ,P;=OA$:.\U#_,O-/F8-NWPB-'>:A_F7FGPH  @
M
M
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M+S3YC2KN>K-;[5-,WJ]Z>J*1\%32PKT%'*R-&-FWMY=[/QEXY-E@  $
M
M
M
M                    &8-JOPH-,?+4/VAI\S!M5^%!ICY:A^T-/A0 !
M
M
M
M                                                      !F#:K\
M*#3'RU#]H:?,P;5?A0:8^6H?M#3X4  0
M
M
M
M                             9@VJ_"@TQ\M0_:&GS,&U7X4&F/EJ'[0
MT^%  $
M
M
M
M   &8-JOPH-,?+4/VAI\S!M5^%!ICY:A^T-/A0 !
M
M
M
M                                     !F#:K\*#3'RU#]H:?,P;5?A
M0:8^6H?M#3X4  0
M
M
M                                        <6YZKT]:JMU)<[[:Z.J:
MB*Z&HJF1O1%XIE%7)Y?;[I'QHL?I\7K&;MK]CAU)V2$5FJI9(H*U::)[X\;S
M46-.*9X$[[F73OZ;NWT1^J%6M[?=(^-%C]/B]8>WW2/C18_3XO6*I[F73OZ;
MNWT1^J.YET[^F[M]$?J@6M[?=(^-%C]/B]8>WW2/C18_3XO6*I[F73OZ;NWT
M1^J.YET[^F[M]$?J@6M[?=(^-%C]/B]8>WW2/C18_3XO6*I[F73OZ;NWT1^J
M.YET[^F[M]$?J@6M[?=(^-%C]/B]8>WW2/C18_3XO6*I[F73OZ;NWT1^J.YE
MT[^F[M]$?J@6M[?=(^-%C]/B]8>WW2/C18_3XO6*I[F73OZ;NWT1^J.YET[^
MF[M]$?J@6M[?=(^-%C]/B]8>WW2/C18_3XO6*I[F73OZ;NWT1^J.YET[^F[M
M]$?J@6M[?=(^-%C]/B]8>WW2/C18_3XO6*I[F73OZ;NWT1^J.YET[^F[M]$?
MJ@6M[?=(^-%C]/B]8>WW2/C18_3XO6*I[F73OZ;NWT1^J.YET[^F[M]$?J@6
MM[?=(^-%C]/B]8>WW2/C18_3XO6*I[F73OZ;NWT1^J.YET[^F[M]$?J@6M[?
M=(^-%C]/B]8>WW2/C18_3XO6*I[F73OZ;NWT1^J.YET[^F[M]$?J@6M[?=(^
M-%C]/B]8>WW2/C18_3XO6*I[F73OZ;NWT1^J.YET[^F[M]$?J@0G:5?+55]D
M9IVY4ESHI[=%+1+)51SM=$Q&R9=ER+A,=9HSV^Z1\:+'Z?%ZQ5/<RZ=_3=V^
MB/U1W,NG?TW=OHC]4"UO;[I'QHL?I\7K#V^Z1\:+'Z?%ZQ5/<RZ=_3=V^B/U
M1W,NG?TW=OHC]4"UO;[I'QHL?I\7K#V^Z1\:+'Z?%ZQ5/<RZ=_3=V^B/U1W,
MNG?TW=OHC]4"UO;[I'QHL?I\7K#V^Z1\:+'Z?%ZQ5/<RZ=_3=V^B/U1W,NG?
MTW=OHC]4"UO;[I'QHL?I\7K#V^Z1\:+'Z?%ZQ5/<RZ=_3=V^B/U1W,NG?TW=
MOHC]4"UO;[I'QHL?I\7K#V^Z1\:+'Z?%ZQ5/<RZ=_3=V^B/U1W,NG?TW=OHC
M]4"UO;[I'QHL?I\7K#V^Z1\:+'Z?%ZQ5/<RZ=_3=V^B/U1W,NG?TW=OHC]4"
MUO;[I'QHL?I\7K#V^Z1\:+'Z?%ZQ5/<RZ=_3=V^B/U1W,NG?TW=OHC]4"UO;
M[I'QHL?I\7K#V^Z1\:+'Z?%ZQ5/<RZ=_3=V^B/U1W,NG?TW=OHC]4"UO;[I'
MQHL?I\7K#V^Z1\:+'Z?%ZQ5/<RZ=_3=V^B/U1W,NG?TW=OHC]4"UO;[I'QHL
M?I\7K#V^Z1\:+'Z?%ZQ5/<RZ=_3=V^B/U1W,NG?TW=OHC]4"UO;[I'QHL?I\
M7K#V^Z1\:+'Z?%ZQ5/<RZ=_3=V^B/U1W,NG?TW=OHC]4"VJ?6VEJF>."GU)9
MI9I7(QD;*V-7.<JX1$1'<5520&--5Z'H] [:=)VFW5514PR3T=0KY]W>15J%
M;C@B<.]0V6$
M
M
M       9@UG\+.U?+4OV:&GS,&L_A9VKY:E^S0T^%  $
M                                          !F#;M\(C1WFH?YEYI\
MS!MV^$1H[S4/\R\T^%  $
M
M
M              &8-9_"SM7RU+]FAI\S!K/X6=J^6I?LT-/A0 !
M                                                  9@V[?"(T=Y
MJ'^9>:?,P;=OA$:.\U#_ #+S3X4  0
M
M
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M>W6VEH[JM(ZCG;*^GG@5V\C)&+A<+UIR(GV/'_<VK?\ [BJ_X, M8
M        &8-NWPB-'>:A_F7FGS,&W;X1&CO-0_S+S3X4  0
M
M
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MT^9@V[?"(T=YJ'^9>:?"@ "
M
M
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M<KX,<0.^"-Z*UE;M6LN#:)D]/66^=:>LI*AJ))!(BJF%PJHJ91>**O)22
M   &8-NWPB-'>:A_F7FGS,&W;X1&CO-0_P R\T^%  $
M
M
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MJ@=D    !F#;M\(C1WFH?YEYI\S!MV^$1H[S4/\ ,O-/A0 !
M
M
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MV^$1H[S4/\R\T^9@V[?"(T=YJ'^9>:?"@ "
M
M
M                            #,&L_A9VKY:E^S0T^9@UG\+.U?+4OV:&
MGPH  @               "H-NLSY=5[,[8Y?^RU-Z;-(G4JL<Q&Y^NXMBO\
M]QJ?DW?P4K[;C9:BKLUHOU!"Z:KT[7QW'HV)ETD353I&HGAPB+_94FEQGJ:Z
MQ++84I*E]3%F%\TSHXU:YO!V6M<J\TX8 K;L6?Q3P?UN;^*'+[+=T<FB+-1M
M;OUT]S8L#&^^<B1R(N/G<U/G0[>S#2NM-"Z62RQPZ=K6-E?*V9U9,Q45WA3H
M5S]*'2M^SZJN6KJ?4VM[C#<JZC_W&BIHU92TBYSO(CE57NSQRN../ F"N575
M-=>-J$>GYJ2@N,=JM$=1VK73N9&^9[L.EPC'HY43")E.&\J\U/?HK1-XT_M
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M7FGPH  @
M
M
M S!K/X6=J^6I?LT-/F8-9_"SM7RU+]FAI\*  (                'AM5K@
MM;98J)7QTSG;S:?/>1+Q5=Q.:(N>6<)U(G$]P                 'BNUMA
MND"4]8KW4JK^$@1<-F3XK^M6^%,X7DN4RA[0 :B-:C6HB(B81$Z@
M            &8-NWPB-'>:A_F7FGS,&W;X1&CO-0_S+S3X4  0
M
M
M                                            9@UG\+.U?+4OV:&G
MS,&L_A9VKY:E^S0T^%  $
M                   !F#;M\(C1WFH?YEYI\S!MV^$1H[S4/\R\T^%  $
M
M
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M;R5"NSWJJF.^0V4?YZ[/O^/--_M.F^U:?Z%!-  $
M
1                  !__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g744414g34h43.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g744414g34h43.jpg
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M#@\,$!<4&!@7%!86&ATE'QH;(QP6%B L(",F)RDJ*1D?+3 M*# E*"DH_]L
M0P$'!P<*" H3"@H3*!H6&B@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H_\  $0@&M 75 P$B  (1 0,1 ?_$ !T
M 0 " P$! 0$            &" 0%!P," 0G_Q !C$  ! P,!! ,'#P@&" 0$
M @L  0(#! 41!@<2(3$305$(%")687'1%187&#(X<X&1DY25L[32-C="4E15
M=:$C,V)R@K$U=)*BLL'#XR0T0\)38X/A\"4F)T1DA*/3149VI/_$ !8! 0$!
M                   ! O_$ !@1 0$! 0$                1 3$A_]H
M# ,!  (1 Q$ /P"U(              8%UO-LM$72W:XT=#'^M4S-C3_ 'E0
M#/!S2];<=!VO>:EX6MD3]"DA=)G_ !81O\R#W;NG+5'O):-/5M2O4M3,V%/D
M;O@BP8*P>SIM!O:[NF])1JUW)8J2:I=\J*B?R'JEM\O?]32U-&QW5T$%/C_;
M\(+%GP5A]CS;5=?_ #VI9J5%YM==7M3Y(\H/:_:TK?\ 2NKJ=V>?]---_P 2
M(!9B:KIX459IXHT3GO/1#"EU!9HOZV[6]G]ZI8G_ #*]0]S!.]<U.K6)_<H%
M=_G(AFQ=R_1)_6ZHJ'?W:-K?_>H'<':MTXW.]J"T)CGFMC_$?C=8::<N&ZBL
MRKY*V+\1QAO<Q6A/=:BKU\T#$/I>YBLV.&H;AGX%@':H]3V&7^KOEK?_ ':N
M-?\ F9<-TM\Z_P!#74LG]R9J_P"2G!7]S#;53^CU+6-7^U3-7_FAAS=R\S&8
M-6.1>I'V_/\ E(!9%KFN3+51R=J+D_2L3NYLOE*N];M60([J58GQ?Y.4_/8>
MVJVWC;-7HJ)R2*YU$:_(K< 6>!6#U)V]V?C!65-6UO\ ^\03Y^)_$>R1MEL?
M&ZZ;DJHV^Z?+;'JW_:C5$!%GP5IH>Z8K*:3HK[I5$>GNEAJ'1JG^%S5_S)C9
MNZ+T96JC:YERMSNM9H$>WY6*J_R"1V4$7L>T+25\5K;7J&W2R.Y1NF2-Z_X'
M8=_(E"*BHBHJ*B]:                                *J(BJJX1  (K
M?MHFD;#O)=-0V^*1O.)DJ22)_@9EW\CGMZ[I#25'O-MM+<KB].3FQI$Q?C<N
M?]T#M@*QU'=&:CNLJQ:9TG$KUX(CEDJ7?(Q&GGZX=N^H/_)VVIH&.ZN\XZ?'
MQR\?YA8M ?,DC(VJZ1[6-3K<N$*Q>QOMFO7^D]2R4K'<V271Z)_LQHJ'W'W-
MM]K7;UXU9!O+S5L4DZ_[SF@6&JM36*DSWW>[9!CGTE5&W_-353[2-&09Z35-
MFRG4VK8[_)3D=)W,%N;COO4U7+V]%2MC_P W.-K3]S3I1G]==+U(ODDB:G_
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M:_HJN-$2IHWN\.%W_-J]3NOR+E B8
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M2:BC;X4?)E2B<W,\O:WJZN'(KK  "
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MM%P=PZ"L5&M<O]F3W*_'A?($CJ("*BHBHJ*B\45
M^)YHJ>%\T\C(H8T5SWO<C6M1.:JJ\D(_KO6EFT39W7"^5.XBY2*%G&29WZK6
M]?GY)UJ5NJ:_76WF[/IJ%BVW3,4F')E4AC_ONYR/Y<.2=B<P)UM%[H.BH9GV
MW1%.EUKU7HTJG(JPH[EX")QD7Y$\Y%+-LFUSM(KH[MM"NE10TKO";'-QEQV,
MBX-C3SX7R*=GV;;*M.Z%A9)1P)673'AUU0U%?GKW$Y,3S<>U5)\%0[1&S72^
MC8V+9[9&M6B<:RH1))E_Q+[GS-PA,0 @
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M=?7VIH-C.V2>"L;I3:$Y]-<(7=!#65";JJY.'1S9Y.['+SZ^/%2K"@ (
M                     &-<JZEME#/6W"HBIJ2!JODEE=NM:G:J@9)S':9M
MFT]HKI:2)WJI>&\.]('IB-?_ )C^3?-Q7R'+]=;7-0:^N[M,[,J:I;3RY8ZI
MC3=FF;R5<_\ IL\JX7M5.1,ME^P6U6#HKCJI8[O=O==$Y,T\+O,ONU\J\/)U
MA7.XJ':9MLE26KD6V:<<[*;R+%3XS^BWW4J^5<IGK0Z]H/8?I32R1SU-/ZL7
M%O'IZQJ*QJ_V8_<I\>5\IU%K4:U&M1$:B81$Y(?H1^-:C6HUJ(C43"(G4?H
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M1%=A.65XX,D #42:@HF:J@T^U^_7R4KZQS6K_5QM<UJ9\ZN7']U3;@
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MC(XV)AK&HF$1$ZD"\>=LH*2UT$%%;J>*FI(6[D<43=UK4\B&2 $
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MD1,++(O%SU\Z_P L)U%>]D;/7CW1=]OM1B2*B=//$J\4X.Z*/Y&KGXBT84
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M'R1\/TV)OM_FU#FO<B7=U5HNZVR1V>\:M'L3L9(W./\ ::Y?C"N[  (
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M$:HJJK<HK4\N45/.:K1U[EU%8(+E46NMM4DCG(M+6-W9&X<J95.Q<9 W0
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MXHVHQC&IA&HG!$1.P^S!O5Q]2K=-6+25-6R)JO>RG1JN1J(JJN'.3/+DG'R
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MO/B$;?3-BH].6IMNMRU"TS'N>U)YG2N3>555-YRJN.)M B81$557RKU@
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MQ7TVXW>7&\JN1$1#&V6:MT[!LWTU#47ZU0S16^&.2.2KC:YCD:B*BHJY145
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MC<JK\9Q'N;]#5EQN<^T#5&_+55+WNH^E3PGN=[J9?E5&_&O86+"@ "
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M=BE6&!QG8EMD@U8V.RZC<REU"Q-UKE\%E7CL3J?VMZ^KL3LP0
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MV4;C*(BJO+B$X!K]/UU3<+6RHKZ):&IZ22-\&_O[JLD<S*.PF47=RBXY*;
M      &NU%>Z#3MFJKK=YVP4=,S?>]?Y(B=:JO!$ZU YMW2NL6:;T%-;J>1$
MN-WS31HB\6Q?^H[Y/!_Q>0]^YOTH_3.SJGFJHU9771W?DB+S:Q4Q&W_9X^=R
MG(M'VZOVX;5)K]>87,T]0.;F)>+48BJK($[57F[SKRRA;!J(UJ(U$1$X(B=0
M4  0     ?SWVB?E]J7^)5/VK@-HGY?:E_B53]JX!I_0@@NUO9S0;0;%WO,K
M:>YTZ*ZDJ\<6+^J[M:O6GQDZ 95:V9[1[OLOO+M'[0()VVZ)V[%*[+G4R+R5
MJ_IQ+SX<NKL+/T-73U])#544\=133-1\<L3D<UZ+UHJ<R,;1= V77EI[TN\2
MMGC1>]ZN-,20KY%ZT[6KP7S\2O$%3KG8)=NAJ&>J6F9I.'%5@D\K5YQ/\G7_
M &N85;0$.V>[1M/:ZI$?:*I&5C6YEHIL-FC^+])/*F4)B$%1%145,HO4:[U!
MM'[JH/H[/0;$ 8$-FM<,K9(;;11R,7+7L@:BHO:BX/I;1;5J%G6WT:SJ[?Z1
M86[V]SSG&<^4S0!@MM%M;.D[;?1I,CM])$@;O;V<YSC.?*?E=9;77U45576V
MBJ:F+^KEF@:][/,JIE#/ 'A2T=-2+*M+3PPK*]9)%C8C=]R\W+CFJ]IC/LEJ
MDN3;A);*%U>WE4K Q94_Q8S_ #-@ ,2YVR@ND"0W.BIJR%KMY&5$39&HO;A4
M7B$ME E7!5)14O?4$?113=$W?C9^JUV,HGD0RP!YSP15$2Q5$;)8UQECVHY%
MPN4X+Y3T  UU?8K1<:EE3<+70550SW,L].Q[F^953*&Q1$1$1$PB=0 &MAL%
MG@CJHX;501QU7_F&LIV(DW]],>%\9D5%MH:F...HHJ:5D288V2)KD8GD14X<
MC* 'C2TM/21=%20101YSN1,1J9[<(*NDIJR-(ZNGAGC1=Y&RL1R9[<*>P UW
MJ#:/W50?1V>@]8;7;X8I8H:&ECBE3$C&0M1'IY4QQ,P 8,=GMD;9&QVZC8V1
M-UZ-@:B.3.<+PX\4/2CMU%1.<ZCHZ:G<Y,.6*)K,IY<(90 Q&6N@9324[*&E
M;3R.WWQ)"U&N=VJF,*I]4=OHZ)7+14E/3J[W2Q1M9GSX0R0!AMM=O;!+ VAI
M4AE=OR1I"U&O=VJF,*OE/NCH*.B5W>5)3T^_[KHHT9GSX0R0!KX;):H;BZX0
MVRACKW9WJEL#$D7//+L9/NXVBW7),7&WTE6F$3^GA;)P3ES3RK\IF@#QHJ2F
MH:9E/14\-/3L]S'$Q&-;YD3@>P   \*^MIK?1RU5?414U-$W>DEE>C6M3M55
M ]SF6V#:U;-!T;Z6F6.MO\C?Z*E1W"+/)\F.2>3FOD3B0#:-MXJ+E5>H.S2G
MFJ:J9W1)7)$KG.7LA9S_ ,2I\769VR;8:M/5MU!M =W]='NZ9M&]_2-8Y>.]
M*[]-V>KEVYZBM)L@V9W/6E\]>^T)9)HI7I-!3SIQJ%_1<Y.J-.&&]?#JYV91
M$1,)P0(F$PG! $     $/VH:"MVOM/.H*[$57'E]+5(W+H7_ /-J]:=?G1%.
M![/==WO8_J"32>N()G6='YC>F7= BK_61K^E&O-4ZN...46UA&-H&A[-KFSK
M07J#+FY6"HCX20.[6K_FB\% WUMKJ6YT,-;;ZB*II)FH^.6)R.:Y.U%,DJ4U
M=<; [PJ8]4M,SR>7H)?^<4F/E_M(A8/9WM(T_KND1UIJ>CK6MS+138;*SXOT
MD\J93S 3(     ,.JM=OJY>EJJ&EGDQC?DA:Y<>=4,P 8S+?1LI'4K*2G;3.
MXNA2)J,7SMQ@\J>T6VGE;+3VZCBE;[E[(&M5/,J(9P P+G9+7=71NNEMHJUT
M?N%J(&R*WS;R+@RGTT#Z;O9\$3J?=W>B5B*W'9CE@]0!BT=NH:)[GT='34[G
M)A5BB:Q53LX(>'J%:>_Y*[U+H>_9$5'U'>[.D<BIA45V,J;$ 8:VJWK1QTBT
M-+WK%[B'H6[C?,W&$/CU&M?1)%ZFT71([>1G0-QGMQCF9X P76>V.B9$ZW4:
MQ,55:Q8&X:J\U1,>1" [0J:\4%]LD]MTW'>M*TS)%J;=2HQKTF=P23HUX/1$
M5<)VJJ]BG3 !R2>TT&L:&:W46SE]G2=NX^X7&B@IUI\\WQHQ5>YZ<TY)G&5.
ME5UBM5PQZHVVBK%3'A5$#9%X<.:H;$ :^X4$3K-)14]OHIX58C&TDR(V%4SR
M5-U4PG/&#PTI8XM/V6.AB5CEZ22:1S&(QJR2/5[MUJ>Y;ERX3J3"&W &-66^
MCK5:M924]0K?<]+&U^/-E#']0;1^ZJ#Z.ST&Q &/#0TL%,^GAI8(Z=^4=$R-
M$:[//*<N)Y):;<E#%1)04B4<7]7!T+>C9YFXPG-3- &)26RAHY%DHZ*E@D5-
MU711-8JIV91#WJ:>&JIY(*F*.:"1JM?'(U'-<B\T5%X*AZ #XIX8J:".&GC9
M%#&U&LC8U&M:B<D1$Y(?8       !\R/9'&Y\CFL8U,N<Y<(B=JJ<)VH;?*.
MWNDM.AFMN=T<O1]]HW>AC<O##$_]1W\O/R G^U/:3:- 6M9*MR5%SE:JTU"Q
MWAO7]9WZK?+\F3B&SC0UZVMZG=J_73Y/4C?S'$J*U)T1>$<:?HQIUKU\>M55
M-OLTV+7&_P!S74^TZ2:::9R2MHI79DE7J65?T4_L)YEQC!8Z&*."%D4+&QQ,
M:C6,8F$:B<D1.I I#%'!"R*%C8XF-1K&-3"-1."(B=2'V $       U^H+U;
M]/VFHN=XJHZ6B@;O/D>OR(B<U5>I$XJ!D7"MIK=13UE?/'3TL#5?)+([=:QJ
M=:J5=U[KR_;7]0)I/0L,S+.KOZ1ZY8LS47C)*OZ,:=3>OAG*X1,;4%_U/MXU
M1ZC:?BDHM.4[T<[?X-:W/"294YN[&)Z5+%;/-#VC0MD;;[1%F1V'5%2]$Z2=
MW:Y>SL3DGRY+QKME6S:U;/[3T=*B5-TF:G?-:YN'/7]5OZK?)\I.@ @
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MY>MR]O\ R"\-'Z:MVDK!36BSP]'30IQ5?=2.7F]R]:K_ /C@;D (
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M-8^T53N'1US=UN?)(F6X\ZH$CJ@/*DJ8*RG9/23Q3P/3+9(GHYKO,J<#U
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M-/'Q<[F^1W6YZ]:K_P#9.!N@ @
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M,U*C&171M!5._P#V>O3H5SV(Y5W5^)0D=%!^,<U[$<QR.:J9147**A^@
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M.2'V $          !_/?:)^7VI?XE4_:N VB?E]J7^)5/VK@&G]"  &0
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M6C"HBHJ*F44+7"+!W2NG:I&MO5KN%OD7FZ+=G8GQ\'?R.AV3:EHF\HWO+4E
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M:?U.KO[U)_U@KM4>SW1T?N-*V-%[>\8U_P#:9<&C]-0?U.GK/'_=HHT_]IO
M$8E/:Z"F_P#+4-+#\'$UO^2&6G!.
M                /F6*.5N[*QKV]CDRA] #3U6E[!5Y[[L=KGSSZ2DC=_FA
MJI]FVBY\])I:S)G]2D8S_)$): ()+LAT')G>TS1)_=5[?\E,9VQ79\[.=.1<
M>RHF3_WG1 !4#N==&V#5>I]04NH+>VL@I8D="Q9'LW5WU3]%4SP[3OT>QG9_
M&N6Z;IU_O32N_P W'(>Y+_+/5?P+?M%+/A4)AV4:%A7+-,6Y?[[%=_FJFQIM
M Z1IE18-+V1BIU]Y1Y^7=)* C"I+1;:/'>EOHX,?_"A:W_)#-
M                                          5@V"^^#UAYJW[RPL^5
M@V"^^#UAYJW[RP+BSX "
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M(4D_XLF^H=.62@QWC9[=38Y=#3,9CY$-H "(B(B(F$3J0
M             !_/?:)^7VI?XE4_:N VB?E]J7^)5/VK@&G]"  &0
M                &%?/]"W#_5Y/^%2O?<:?U.KO[U)_UBPE\_T+</\ 5Y/^
M%2O?<:?U.KO[U)_U@JR( "
M                  *P=R7^6>J_@6_:*6?*P=R7^6>J_@6_:*6?
M                                                 %8-@OO@]8>:
MM^\L+/E8-@OO@]8>:M^\L"XL^  @
M                          *P:<]]U6_#3_=U+/E8-.>^ZK?AI_NZEGP
M                                  _GOM$_+[4O\2J?M7 ;1/R^U+_$
MJG[5P#3^A  #(                       #"OG^A;A_J\G_"I7ON-/ZG5W
M]ZD_ZQ82^?Z%N'^KR?\ "I7ON-/ZG5W]ZD_ZP59$ !
M                                      %8.Y+_ "SU7\"W[12SY6#N
M2_RSU7\"W[12SX
M           K!L%]\'K#S5OWEA9\K!L%]\'K#S5OWE@7%GP $
M                                               !6#3GONJWX:?[
MNI9\K!ISWW5;\-/]W4L^                                   '\]]H
MGY?:E_B53]JX#:)^7VI?XE4_:N :?T(  9                        85
M\_T+</\ 5Y/^%2O?<:?U.KO[U)_UBPE\_P!"W#_5Y/\ A4KWW&G]3J[^]2?]
M8*LB  @
M  "L'<E_EGJOX%OVBEGRL'<E_EGJOX%OVBEGP
M                                 !6#8+[X/6'FK?O+"SY6#8+[X/6'
MFK?O+ N+/@ (
M          "L&G/?=5OPT_W=2SY6#3GONJWX:?[NI9\
M                  /Y[[1/R^U+_$JG[5P&T3\OM2_Q*I^U< T_H0  R
M                     PKY_H6X?ZO)_P *E>^XT_J=7?WJ3_K%A+Y_H6X?
MZO)_PJ5[[C3^IU=_>I/^L%61  0
M                      !6#N2_RSU7\"W[12SY6#N2_P L]5_ M^T4L^
M                                                       *P;!?
M?!ZP\U;]Y86?*P;!??!ZP\U;]Y8%Q9\ !
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MZG5W]ZD_ZP59$ !
M           %8.Y+_+/5?P+?M%+/E8.Y+_+/5?P+?M%+/@
M                                          "L&P7WP>L/-6_>6%GR
ML&P7WP>L/-6_>6!<6?  0
M                   %8-.>^ZK?AI_NZEGRL&G/?=5OPT_W=2SX
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MJ3_K%A+Y_H6X?ZO)_P *E>^XT_J=7?WJ3_K!5D0 $
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M9ZK^!;]HI9\
M        5@V"^^#UAYJW[RPL^5@V"^^#UAYJW[RP+BSX "
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M#ZBO<^L=0Z9U*ZBGJ;?'#40U5)$Z)LD<B+P5JN=A47RD@UYQT/J+/[NJ/LG
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M]8[K')73:)62\1QQ7)U JU+(T\%LFXN\B>3.3A7<:?U.KO[U)_U@JR( "
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M"^^#UAYJW[RPL^5@V"^^#UAYJW[RP+BSX "
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MAI_NZEGP                                   _GOM$_+[4O\2J?M7
M;1/R^U+_ !*I^U< T_H0<SU?I>[6O:!3:XTI3-KIW0=Z7*WK(D;JB+AAS'+P
MWDPW@O/=0Z8 RC--J2NN471V_3]TIJEW#>N$388XE[7+O*KL=C<Y[4YI&;I9
M+KI[:A!JRBII[I;ZV@2@N+($19HW-5%;,C.&\B[J(J)Q3CP.F " 6RSU-3M
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M9O*!UH  5@[DO\L]5_ M^T4L^5@[DO\ +/5?P+?M%+/@
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MB97@A)@    %8-@OO@]8>:M^\L+/E8-@OO@]8>:M^\L"XL^  @
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M4Z\<>OATH(     !6#8+[X/6'FK?O+"SY6#8+[X/6'FK?O+ N+/@ (
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M5[[C3^IU=_>I/^L6$OG^A;A_J\G_  J5[[C3^IU=_>I/^L%61  0
M               !S[;EJVKTCH:2>UJC;G6S,HJ9^,[CWY57>=$:N/+@WVE]
M(6NQV6.B[UAJ9G,3OJHG8DDE3(ONGO<O%RJN>?F(YMZTI6ZJT*Z.T,Z2Y4%0
MRM@B3G(K45%:GEPY<=JHB&YTIK^PW^SQU2W&EI*IK42JI*F5(I:=Z>Z:YKE1
M4PN>/)0/FW6VT[/J+4-P?,RDLTLR5BLXJD*[C6*UJ=BJU,-3MPB<A/KF&WUM
MMAOUJN%II[C(D--4U/1K&LB^Y8_<<JL<O5GAY2,[:EK-1[.*NIL-/+4P455!
M5)N9_P#%QQNR]6)UM3@J+U[JJG#"KY;7*VAUQL\H*'3U3%65MVJJ=:)L3D<Y
MN'(YSU1.+4:W>WE7EU@2JXZ^HJ+5TFG/4ZZ3W%M(M6QL4"*DJ(Y&HC,JF>.>
M*X:F%XF%;-I4%RBN$-)8+T^]4$O15%K2)G2LX91RNWMQ&JG)=[CU(IJ7U5.W
MNC::-:F)9$TXL6%>F5?WQG'GQQP-G%=2NVK;3MVIA7,U&Y,/3BC87(Y?B7@O
M8!O6;2;2_0,NK&4MP?10[S9H&PHLT3FKAS7)G"87KSUF/6;3[?1.M$U;:KK!
M:;DZ...Y/B:D#9'IE&KX6]C^UC"XX*J<3FELKZ1VP;:&C:J!=ZX5NZB2)QWG
MMW<>?J-_M,KZ1-EFAGK50;BUUM<B](F%1J<5^+K"IS0Z\II]64MAK;3=+=-6
ML?)0S5<36,J48F7(B(Y7-7''#D1>W!G5FJ6I<ZVWVBW5=VJJ%K5JFTSHVMB5
MR91BN>YJ*]4XX3EPSC*$/VCUM(W:MLRWJF!%2:L<N7IP1T*(U?C7@G:>.S*K
M;I[6^N[+?IF4U557)]TI7SN1J5$$G6U5X+NX1%[/B").NT6RNT55:FIV5M11
MTJN9401P_P!-"]ONF/:JINJG7E<<3%7:90,FL;JBU76&VW=\4,%P?$U(4ED3
M+6+X6]Y-[&.Q53B<]FI$IMGNUN\J]L5MO%5.^AWEPDR(BITC>U'N5<=N#/VA
MUU(FRG9\Y:J#=[^MCL](G)K?"7XNL#MYQ[1E%2L[HG7*LIH6JRCI7-PQ$W55
MC%54[,G8&.:]J.8J.:J9147**AR-D\.E-OEXK;W*VDM]^H(FTM5,N[$LL:-:
ML:N7@CL-5<+Y.T"7[4*.FJ]/4O?5/%-NW2W[O2,1V,U<2+S[454^,_+UKJWV
M75%'IZ2@N,E740OEAZ&#+'HU/<MXY5>KEA.:JB&/JR[T-\J+78;15PUM;)7T
MU3,VG>DG00PRME<]ZIP:B[B-3/-7)CK-)J>KIV;?='QOJ(FO2W535:KT1454
MX)\>% E&E-:TVH)[Q2.M]?;[E:7-2IHJEC5D1'(KF.;NJJ.141<84T%NUA;:
M;0&I+[I+3LL;:*IJ.FI59' KIF(BR2/3>Y=O-W#D8NCJVE7;EM 1*F'*TU#C
MPTX[L:[WR93/81_0LL=;LCVE0T<C)Y75MT5K(U1RJCF>"J(G;U!4WTIK*5-
MV.Y7NBK4JZN*EAB5RQ9K9I6IA68?P15X^%NX0D5FOKZ^[5UNJ;95T-32113.
MZ96.9(V17HBL<URY_JUSG!S*AKM)Z@V.Z5M=YKD[T='1T;JJ&7<6CJ4B56KO
M\FN1S,8ZMY,\%-ULVFOULUE==-72ZMO]NIJ..II[FYJ=+'O.5$AE<G-V-YR9
M7../7A".F@    *P=R7^6>J_@6_:*6?*P=R7^6>J_@6_:*6?
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MURW*815SA% E(-59;_17BIK*>D[X;44>XD\4\#XG,5R*K>#D3.43.4RAM0
M   "L&G/?=5OPT_W=2SY6#3GONJWX:?[NI9\
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M%2O?<:?U.KO[U)_UBPE\_P!"W#_5Y/\ A4KWW&G]3J[^]2?]8*LB  @
M                   8=1:K=4U+:FHH*26H;RE?"USD^-4R9@ &-34%'2S2
M2TM)3PRR\7OCC1KG^=43B9( \>]:?I>DZ"+I,YW]Q,Y[<GXVCI6JJMIH454P
MN&)Q0]P!C]XTF,=ZP8[.C0_5HJ56M:M- K6\D6-,(>X \'4=*Y45U-"JHB(F
M6)P0_*R@I*Y&)6TL%0C%RU)8T?NKVIE.!D #SE@BE8C)8F/8G)KFHJ(?"T5*
MK4:M- K4Y)T:<#W 'XUK6-1K$1K43"(B81#SJJ:"KA=#50QS1.YLD:CFK\2G
MJ ,>AH:2@C6.AI8*:-5RK88T8B_$A]/I:=\G2/@B=)G.\K$5?E/8 >"4=*CE
M<E-"CESE=Q..>9]0TT$"JL,,<:KSW&HF3U '@M'3+!T*T\/0Y5>CW$W>//A\
M:G[1TE-10]%1T\-/%G.Y$Q&-SYD/8      %8.Y+_+/5?P+?M%+/E8.Y+_+/
M5?P+?M%+/@
M      "L&P7WP>L/-6_>6%GRL&P7WP>L/-6_>6!<6?  0
M         .5=T?9*VZ:&IZVV0NGGM%;'7.A:F5>QJ.1V$\F47S(IU4 :W3=\
MH-166ENEIJ&3TE0Q'M<U<X7K:O8J<E0YSM\N#JK9]42VY'ST5%<:=:Y8TRU\
M;7Y>U.W#MS/4BY3J7$S?H/3#JV6J2RTD<TJ[TG1(L;9%[7-:J([XT-\VCIFT
M7>;:>%*3<Z/H48FYN8QN[O+&.H#F>WJ-MXT%:W6E[9:^:Y4C[9)&N5=(YW!S
M5_NJY?,A[6MK5[H>\JY&JYM@APN.*?TI,K1I2QVB:.6VVV"!\>4BPBJD6>:,
M1>#$7^S@]8]-V:.\276.W4[;G(BH^J1O](Y.Q7<\>0"$;)6,36&TE4:U'+>,
M*J)QQN?_ '4YY%A.Y/O#4QNMGE1$ZD3OQ#N]#I:R4$E6^BME-3OK,]\.C;NK
M-G]94YKY5,=NB-,MMC[<VQT*6][M]U,D2=&KNU6\L@0K:W%%WGLV8L;.C345
M W=PF,8=PQV&5JS";=-!JG!RT=>B^5-Q,$QK=*6*NAI(JRU4L\='CO=LC-Y(
ML<E;GE\1Z5.F;-4W."XU%MIY:^!$;%4.;F2-$3&&NYH!!-A=3(DFM;?<EQ>(
M;[/-4-=[I6/1NX[^ZJ-7'D0@4M')2;#-IG192U27BH6WI^BL*3L;EO\ 9RBX
M\RG=KII>RW2O2NKK=#)6(SHUG3+'N9^JY6JBN;Y%RA[7#3]HN-KCMM;;:6:W
M1HB-IG1IT2(G)-WEA .<[3V,CH=F",:UJ-OU"UN$QA-QW!/Y'6325>D[#60T
M<57:J6:*CQWNV1F\D..6[GE\1NF-1C&M:F&M3" <FT*J6S;MK^CK%2.:XQ4M
M52H[ATL;6JCE;VX5<?$I+M;SLFN>FK9$]KJR6Y1U/1(N7)%$CGO>J=2)A$SV
MN1.LVU^TW9[_ -#ZL6ZGJWPKF*1[?#C7^RY.*?$HLFG+18WRR6JWPT\TJ(DD
MJ)O2/1.2.>N7*GG4"$5S6N[HNVJYK55NG9%:JIR7I\93XE4_=FV$VI;3VMPB
M=\T2X3RPJ39^G+.^]-N[[=3K=&IA*I6_TB)V;W/'DY'Q2:6L='4U5126RFAJ
M*I,5$L;=UTO]Y>:_&!QG3W'N9-38X\:[E\*XF%UM]'J/0^CZ&FO;K9>&-IIK
M?50JC]R=M.JHCFYXHK-_AU_YSBV::LMKH*BAMUKI*>BJ$5)J>.-$CD14PN6\
MERB\3'31FG&VN"VLLM"RA@EZ>*%D2-1DG+?3')WEY@1O9M>;Y+J2^6+5U)1K
M>J&&!ZW"C14CJH7*_<54ZG(N]PX<UX<./0S!M5IH;4V5*"G;$Z9R.E?E7/D5
M$PBN<N5=PX<5,X      K!ISWW5;\-/]W4L^5@TY[[JM^&G^[J6?
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M@*]^V=M7BY7?/L] ]L[:O%RN^?9Z 180%>_;.VKQ<KOGV>@>V=M7BY7?/L]
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M?:E_B53]JX!I_0@ !D
M
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M1:>LU!4MJ*&T6ZFJ&YW98:9C')E,+A43)LP
M           _GOM$_+[4O\2J?M7 ;1/R^U+_ !*I^U< T_H0  R
M
M
M               %6=@GO@]4>:M^W:6F*L[!/?!ZH\U;]NT+BTP "
M
M                             /Y[[1/R^U+_ !*I^U<!M$_+[4O\2J?M
M7 -/Z$  ,@
M
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M,3/'S%I@@
M                  _GOM$_+[4O\2J?M7 ;1/R^U+_$JG[5P#3^A  #(
M
M                                                      K!LL]]
M%J?X:N^T+/E8-EGOHM3_  U=]H6?
M                      *P=S1^>#5_P,_WAI9\K!W-'YX-7_ S_>&EGPN@
M "
M         _GOM$_+[4O\2J?M7 ;1/R^U+_$JG[5P#3^A  #(
M
M                                             K!LL]]%J?X:N^T+
M/E8-EGOHM3_#5WVA9\
M            K!W-'YX-7_ S_>&EGRL'<T?G@U?\#/\ >&EGPN@ "
M
M_GOM$_+[4O\ $JG[5P&T3\OM2_Q*I^U< T_H0  R
M
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M0ZT3ZZSUE73UDR4\,E.]G&14RC51RHJ=?R$J[YK/4[I^\'=]8SWMTK<^;>Y
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M1 .F TFCM4VG5]ECNEBJ>GI7*K'(J;KHW)S:Y.I>*?*;L"L'<T?G@U?\#/\
M>&EGRL'<T?G@U?\  S_>&EGPN@ "
M                                   _GOM$_+[4O\2J?M7 ;1/R^U+_
M !*I^U< T_H0  R
M
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M7&DL?2-W787M0(KCW-'YX-7_  ,_WAI9\K!W-'YX-7_ S_>&EGPN@ "
M
M  _GOM$_+[4O\2J?M7 ;1/R^U+_$JG[5P#3^A  #(
M
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M:O\ @9_O#2SY6#N:/SP:O^!G^\-+/A=  $
M                                        !_/?:)^7VI?XE4_:N VB
M?E]J7^)5/VK@&G]"  &0
M
M                !6#99[Z+4_PU=]H6?*P;+/?1:G^&KOM"SX
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M  0
M         '\]]HGY?:E_B53]JX#:)^7VI?XE4_:N :?T(  9
M
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ML^5@[FC\\&K_ (&?[PTL^%T  0
M                                '\]]HGY?:E_B53]JX#:)^7VI?XE4
M_:N :?T(  9
M
M        %8-EGOHM3_#5WVA9\K!LL]]%J?X:N^T+/@
M                                   %8.YH_/!J_P"!G^\-+/E8.YH_
M/!J_X&?[PTL^%T  0
M                       '\]]HGY?:E_B53]JX#:)^7VI?XE4_:N :?T(
M 9
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MHL$ZHJ=?_B&EGPN@ "
M                         _GOM$_+[4O\2J?M7 ;1/R^U+_$JG[5P#3^A
M  #(
M
M X!JON=4O^IKK=_7,L'?U5)4]%WCO;F^Y78STB9QGG@U7M7D\;%^K_\ N%E
M%JM?M7D\;%^K_P#N#VKR>-B_5_\ W"R@!5:_:O)XV+]7_P#<'M7D\;%^K_\
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M!5:_:O)XV+]7_P#<'M7D\;%^K_\ N%E "JU^U>3QL7ZO_P"X/:O)XV+]7_\
M<+* %5K]J\GC8OU?_P!P>U>3QL7ZO_[A90 JM?M7D\;%^K_^X/:O)XV+]7_]
MPLH 56OVKR>-B_5__<'M7D\;%^K_ /N%E "JU^U>3QL7ZO\ ^X/:O)XV+]7_
M /<+* %5K]J\GC8OU?\ ]P>U>3QL7ZO_ .X64 *K7[5Y/&Q?J_\ [@]J\GC8
MOU?_ -PLH 5R;9!L>39W?:RX^K7JAWQ3+3]'WMT6[X379SO+^K_,ZR $
M
M     '\]]HGY?:E_B53]JX#:)^7VI?XE4_:N :?T(  9
M
M
M        "K>P3WP6J_[M;]X:6D*M[!/?!:K_ +M;]X:%Q:0 !
M
M                         '\]]HGY?:E_B53]JX#:)^7VI?XE4_:N :?T
M(  9
M
M                            "DEEM^K*_:SJ>'0L[X+JVHJG/<R9L:]%
MTV%3*\.:M+ME8-@OO@]8>:M^\L"X_?6OMX_>M3]81>D>M?;Q^]:GZPB])9X
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M>JR98W2-J*=TR/8J] YZ<4X+^BI:4K!1^_#?\,_[FI9\(
M                 _GOM$_+[4O\2J?M7 ;1/R^U+_$JG[5P#3^A  #(
M
M
M                    5@V"^^#UAYJW[RPL^5@V"^^#UAYJW[RP+BSX "
M                                                           "
ML%'[\-_PS_N:EGRL%'[\-_PS_N:EGP
M  /Y[[1/R^U+_$JG[5P&T3\OM2_Q*I^U< T_H0  R
M
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MI_0@ !D
M
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M#\-#]T:%Q9\ !
M    "L&B_?97;X:J^S4L^5@T7[[*[?#57V:@Q9\    !_/?:)^7VI?XE4_:N
M VB?E]J7^)5/VK@&G]"  &0
M
M                   !6#99[Z+4_P -7?:%GRL&RSWT6I_AJ[[0L^
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M%ZB6A             !6#N:/SP:O^!G^\-+/E8.YH_/!J_X&?[PTL^%T  0
M  K!>/?A0_#0_=&EGRL%X]^%#\-#]T:%Q9\ !          C&O-9TFBK8MQN
MM#<):!'-:^>F;&Y&.<N$145Z.^/&.* 2<&GH[ZE3IU;PMNK88>B2=L4RQ-D<
MS"+O>[W4X=JHO P=$:PAU?0MKK?:KK34#TS'45D3(VR?W4WU<J>7&/*!)@
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M:)^7VI?XE4_:N VB?E]J7^)5/VK@&G]"  &0
M
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M:O\ @9_O#2SX70 !   "L%X]^%#\-#]T:6?*P7CWX4/PT/W1H7%GP $
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MM$_+[4O\2J?M7 ;1/R^U+_$JG[5P#3^A  #(
M
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M5_P,_P!X:6?"Z  (   5@O'OPH?AH?NC2SY6"\>_"A^&A^Z-"XL^  @
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M]E=OAJK[-08L^     _GOM$_+[4O\2J?M7 ;1/R^U+_$JG[5P#3^A  #(
M
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M[E5X)Q5,DD       *P=S1^>#5_P,_WAI9\K!W-'YX-7_ S_ 'AI9\+H  @
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MZ2R)%$DB/<W#5<O)5:JHGH)NUR.:CFJCFJF45.**@')NZC1%V2U>4Y54&/\
M:.GVA$2TT2(F$2!F$_PH<P[J-439+697G50?\1T^T*BVFB5%146!BHJ?W4 @
M^W;4MUTQL_N%79J17R/9T3ZKI&M2F1ZHW>1,Y<[PN&$X<UY87;T.IVVK1;KO
MJ6EEM5+20,572R,D61-U,*W<5>*JN$3GE2'[>[K3W;8]JE:)R2PTU1#3K*U<
MM>YLL>]A?(J[J^5%3J-9M\JG1[-]-5,+DFI*.NHJBMCC7*]%N.W5<G8JX^/
M5\]T#?;E4[)ZYM?IZHHZ:L=!T4KIF/?$J2-<B2L3W&41>2NX\%QD[1;/]&TG
MP+/\D.9=T16TM;L1NE52SQ2P5/>SX9&N14D19F*BM[>&5.A07.@H;?:TK:VF
MIUJ6QQ0)+*UG2O5J8:W*^$OD0(V@       !6#1?OLKM\-5?9J6?*P:+]]E=
MOAJK[-08L^     _GOM$_+[4O\2J?M7 ;1/R^U+_ !*I^U< T_H0  R
M
M                                                    *P;+/?1:
MG^&KOM"SY6#99[Z+4_PU=]H6?                    <LVZ:JN%LCL6FM/
MSK37;4-4E,VH;[J"/>:USD[%57(F>S/6=3.%]T'"^TZUT%JR9KEMM#6MBJGH
MF4C3?:Y%^-$?\@,=8T]I.RV&U,H*"@@Z)&XD?(Q'/F7K<]R\7*O6JFNTQHZF
MTWJR\U]JC;#;[C!"BT[5\&*1CI,[B?HM5'HN$X(N>TE<4C)HF21/:^-Z(YKF
MKE'(O)44C^M[A+#IC4$-LD5;M%;9IXF,RKFKN.1J^1<IP[<+CDH&+7Z^M%(R
MLFCBN%9143W,JJNDI72PPJWW2*Y.>[U[N<=9EW'6E@H-,,U#-<&/M#V;[)X6
M.D1R>9J*O/AQY+S(YL EIJG9!8$@1KF)%)'(WGX?2.WL^=>/QG,]*4\M)L3V
MHTK%<MLIZVLBH\\MU$1%QY.7QY"NJ0;6-*37"AHTJZA):RF[ZC=WL]6[NYO[
MJJB+X2)S1,XY<^!C3[9=(1V>.Y1U57/3O<Y$2&E>YS6M=NJ]R?HMRBX5V,X7
M')3=;*Z>&/9OI7<B8W%M@<F&IP5T:*Y?C5552%]R_2P.V31HZ&->GJ9TERU/
MZ1,X\+MX< CIVGKW;]0VBGNEFJ655#.F62-X>145%XHJ+P5%-B<C[G&C6@M6
MK*6#/J;#?:B*DSRW&X3AY."'7                      "L'<T?G@U?\#/
M]X:6?*P=S1^>#5_P,_WAI9\+H  @  !6"\>_"A^&A^Z-+/E8+Q[\*'X:'[HT
M+BSX "      :74NEK/J:!L%]I75E.F%Z%TTC8\IR56HY$5>//&3= #!LUJI
M+-0LH[<R2.FC1&LC=*^1&(B81&[RKA/(G T^L-"::U@L+M16J*KDA3#)-YT;
MVIV;S51<>3."3 #7:?L=LT]:X[=9:*&CHH\XBC3AE>:JJ\57RKQ(U3;*M$TU
M]2\0Z>I6UR/Z1JY=T;7<\I'G<1?B)L -#?\ 2-DU!64M5>*-U3/2N1\#EGD;
MT3N>\U$<B-7@G%./!#XN^C+%>*ZCK;G22U%51X[WE?4R[T*ICBU=[@O!,JG%
M<94D)\OD8Q[&O>UKGKAB*N%<N,X3MX(J_$!H)M&6*:^Q7J6DE?=8DW8ZI:J7
MI&-X^"B[W!.*\.7%>T_7:-L;M0I?5I)/5=."57?,N^B?J^Z]S_9Y>0D  C]V
MT=9+I=FW2HI9(KFUG1]]TE1+32N;^JYT;FJY/(N386^RT%NMCJ"@I^]J9RN5
MR1/<USG+S<KT7>5R];LY\IL !H]-:3LNF73K8Z-:1)W*^5K9I'->[]96JY4W
MN'/F8<V@M.R5U95LHI:>2L7-4RFJIH(ZA>V2-CD:[/7E./62@ 0':ZZ2U[/G
M4ELLCJVWODBI:FGIH$>L%+GPW,CY*J(F$[%5%ZCG5)9]B=U5&6RT5E37.]S2
MTS*WID=V;N<(OE7AY2P8 A5IT125^B+;9M5P35S($<O0SU+W;K=]58UZM5$>
MYC5:W/'EP-[6Z8L]?8/42OHFU=LPC4AJ'NDPB<L.<JN3'5QX=1N !&-'Z"TS
MH]\TFG;3%22S)NOE5[I'JG9O/551/(G ^I=#6%];6U;*>IIYZUROJG4U;/"D
MZKSWT8]$=\?5P)(YR-:KG*B-1,JJ]1Y4E53UE.V>CGBJ('9W9(GH]JX7"X5.
M'-%0"*ZVTC:+MI:GLSK%'6T].Y.\Z5CEABA>C51KG*U4PQ$5<\\]BJ2#3EM]
M1M/VRV=*Z;O*EBI^D=S?N-1N?CP; ^62,>Y[6/:YS%W7(BY5JXSA>S@J?*!I
M=3:3LNIXVQWZC=6PM5%2)\TB1HJ9PNXCD3/%>.,FI39EI%(TC2T8C1-U&I4S
M8QV8WR9 #2P:5LD&F7:>BML"65S',6D5%5BHJ[R\^/-<YYY/FVZ2L-NT_+9*
M.UTS+5*BI)3JW?;)G@N]O95>2<5[$[#> "#0;)M%0V^:A;9&NI9515CDJ)7H
MW#D=X.7+NIE$SC&>2Y0V]?HC3E=!:8:BT4W0VJ9)Z..-%C;$],<41JIGDG!<
MHN"1          5@T7[[*[?#57V:EGRL&B_?97;X:J^S4&+/@    /Y[[1/R
M^U+_ !*I^U<!M$_+[4O\2J?M7 -/Z$  ,@
M
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MQ(B+Q5V\N<N5<JJKG.5R;'3EHAL-BH+52RS2P4<+86/G=O/<B)C*J;$
M                 %8.YH_/!J_X&?[PTL^5@[FC\\&K_@9_O#2SX70 !
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M
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M]]HGY?:E_B53]JX#:)^7VI?XE4_:N :?T(  9
M
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M%T  0   K!>/?A0_#0_=&EGRL%X]^%#\-#]T:%Q9\ !
M                                  "L&B_?97;X:J^S4L^5@T7[[*[?
M#57V:@Q9\    !_/?:)^7VI?XE4_:N VB?E]J7^)5/VK@&G]"  &0
M
M                                                 !6+4FQS7[M?
M7R_:<KZ:A[\JYI8I8JU\4G1O>JX56IPX8RF3Y]C3;/XV3_7$WH+/@+58/8TV
MS^-D_P!<3>@>QIMG\;)_KB;T%GP"JP>QIMG\;)_KB;T#V--L_C9/]<3>@L^
M56#V--L_C9/]<3>@>QIMG\;)_KB;T%GP"JP>QIMG\;)_KB;T#V--L_C9/]<3
M>@L^ 56#V--L_C9/]<3>@>QIMG\;)_KB;T%GP"JP>QIMG\;)_KB;T#V--L_C
M9/\ 7$WH+/@%5@]C3;/XV3_7$WH'L:;9_&R?ZXF]!9\ JL'L:;9_&R?ZXF]
M]C3;/XV3_7$WH+/@%5@]C3;/XV3_ %Q-Z![&FV?QLG^N)O06? *K![&FV?QL
MG^N)O00K2WLE:EU9<-.VW5=S]4*'I.EZ6YRM9X#T8["YX\53J+J%8-@OO@]8
M>:M^\L >QIMG\;)_KB;T#V--L_C9/]<3>@L^ 56#V--L_C9/]<3>@>QIMG\;
M)_KB;T%GP"JP>QIMG\;)_KB;T#V--L_C9/\ 7$WH+/@%5@]C3;/XV3_7$WH'
ML:;9_&R?ZXF]!9\ JL'L:;9_&R?ZXF] ]C3;/XV3_7$WH+/@%5@]C3;/XV3_
M %Q-Z![&FV?QLG^N)O06? *K![&FV?QLG^N)O0/8TVS^-D_UQ-Z"SX!58/8T
MVS^-D_UQ-Z![&FV?QLG^N)O06? *K![&FV?QLG^N)O0/8TVS^-D_UQ-Z"SX!
M58/8TVS^-D_UQ-Z![&FV?QLG^N)O06? *X7L%V8:DT5JRYW344E)(RJI71;T
M4RR.<]9&NRN43L7B=T "      5TVH[)=9WO:?<-2Z9JJ6E;)T2P3)5.BE8K
M86L5>"<.*+U\BQ8 K![&FV?QLG^N)O0/8TVS^-D_UQ-Z"SX"U6#V--L_C9/]
M<3>@>QIMG\;)_KB;T%GP"JP>QIMG\;)_KB;T#V--L_C9/]<3>@L^ 56#V--L
M_C9/]<3>@>QIMG\;)_KB;T%GP"JP>QIMG\;)_KB;T#V--L_C9/\ 7$WH+/@%
M5@]C3;/XV3_7$WH'L:;9_&R?ZXF]!9\ JL'L:;9_&R?ZXF] ]C3;/XV3_7$W
MH+/@%5@]C3;/XV3_ %Q-Z![&FV?QLG^N)O06? *K![&FV?QLG^N)O0/8TVS^
M-D_UQ-Z"SX!58/8TVS^-D_UQ-Z![&FV?QLG^N)O06? *K![&FV?QLG^N)O0/
M8TVS^-D_UQ-Z"SX!58/8TVS^-D_UQ-Z![&FV?QLG^N)O06? *K![&FV?QLG^
MN)O0/8TVS^-D_P!<3>@L^ 56#V--L_C9/]<3>@>QIMG\;)_KB;T%GP"JP>QI
MMG\;)_KB;T#V--L_C9/]<3>@L^ 56#V--L_C9/\ 7$WH'L:;9_&R?ZXF]!9\
M JL'L:;9_&R?ZXF] ]C3;/XV3_7$WH+/@%5@]C3;/XV3_7$WH'L:;9_&R?ZX
MF]!9\ JL'L:;9_&R?ZXF] ]C3;/XV3_7$WH+/@%5@]C3;/XV3_7$WH'L:;9_
M&R?ZXF]!9\ JL'L:;9_&R?ZXF]!N=DFR?6&GMI,&HM2U-+4MW)>FE2I=+*]S
MF*B*N4X\?*6& 2@    #^>^T3\OM2_Q*I^U<!M$_+[4O\2J?M7 -/Z$  ,@
M
M
M                      !6#8+[X/6'FK?O+"SY6#8+[X/6'FK?O+ N+/@
M(
M                                     _GOM$_+[4O\2J?M7 ;1/R^U
M+_$JG[5P#3^A  #(
M
M                                        5@V"^^#UAYJW[RPL^5@V
M"^^#UAYJW[RP+BSX "
M                                                      /Y[[1/
MR^U+_$JG[5P&T3\OM2_Q*I^U< T_H0  R
M
M                                                         %8-
M@OO@]8>:M^\L+/E8-@OO@]8>:M^\L"XL^  @
M
M           #^>^T3\OM2_Q*I^U<!M$_+[4O\2J?M7 -/Z$  ,@
M
M
M              !6#8+[X/6'FK?O+"SY6#8+[X/6'FK?O+ N+/@ (
M
M                             _GOM$_+[4O\2J?M7 ;1/R^U+_$JG[5P
M#3^A  #(
M
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M>VEHWIT<]0Z1K7ME8U53*^?B61*P=S1^>#5_P,_WAI9\&@ "
M                                                       _GOM$
M_+[4O\2J?M7 ;1/R^U+_ !*I^U< T_H0  R
M
M                                *P;+/?1:G^&KOM"SY6#99[Z+4_PU
M=]H6?                                                      *
MP=S1^>#5_P #/]X:6?*P=S1^>#5_P,_WAI9\+H  @
M                                               /Y[[1/R^U+_$J
MG[5P&T3\OM2_Q*I^U< T_H0  R
M
M                       *P;+/?1:G^&KOM"SY6#99[Z+4_P -7?:%GP
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M?G@U?\#/]X:6?"Z  (
M                        #^>^T3\OM2_Q*I^U<!M$_+[4O\2J?M7 -/Z$
M  ,@
M
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M:;WA<.KDGQH=4EI*>5ZOEIX7O7FYS$53]DIH)*=U/)#&^!R;JQN:BM5.S'+
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MO^!G^\-+/A=  $
M                    !_/?:)^7VI?XE4_:N VB?E]J7^)5/VK@&G]"  &0
M
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M !
M         ?SWVB?E]J7^)5/VK@-HGY?:E_B53]JX!I_0@ !D
M
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M#2SX70 !
M               ?SWVB?E]J7^)5/VK@-HGY?:E_B53]JX!I_0@ !D
M
M                                                   5@V6>^BU/
M\-7?:%GRL&RSWT6I_AJ[[0L^                 /ECVR-WHW-<F53*+GBB
MX5/E0A&K[Y+5:QLVC;=*^*6LC?65\T:X?%2LRFZU4Y*]W@Y3BB9QQPIJ]L>J
MZC2-FL]DTPR*"\WF=M%18:F[ F4:KD3EE%<U$\^>H#I;I&-<B.>U%7DBKS/K
M*9QE,]A$;1L\T[1T+(Z^W4]VK5:G3UMPC2HFF=UN5S\JG'J3@A\:8TJ_3VL+
MM4TL]3)::VEA;#%-,Z1*9S'/RQF\JJC%W\HG5Q\@$Q!%9]H.F(%1TMT1M.LW
M>_?70R+3=)G&[TV[T><_VC-U%JZQ:<EIX[Y<8Z-U1_5=(UV)/(BHF%7R<P-Z
MJ(Y%1R(J+U*?C6M8F&HC4[$3!KKM?;=:+3ZIW*H6FH>"K*^-R(W/+>3&6_'@
MP)-:Z<BN=-;I+O2LKZACI&0.54>UJ,5ZJ]/T$W45?"P!(016R[0]*7JJK*>W
M7REDEI(UEF1RK&C6)S>BN1$5J=J90]M,:YTWJ>NJ:.Q76&KJJ=-Z2)&N:[=S
MC>1'(F4XIQ3*<4[0)(#07?6%DM554TU75O=/3,26H93T\DZP,7BCI.C:NXF$
MSX6.![OU18X[!'>Y+M1,M,C=YE4Z5$8[GP1>M>"\.?!0-P?BO:CT8KFH]R*J
M-SQ5$QE?YI\I#JW:=HZAIZ&:JOM/''6L22%5:]<M5<(YR(F6HN%XNP;^]VZ.
M\VQ6Q3+%/N])2U<2^%"_'@O:O_+DJ91<HJ@;,*B*BHJ91>HBFS+5+M5Z:2IJ
MHVQ7.EF?1UT3>3)XUP['D7@J>?'42L#Y;&QJY:QJ+VHA]
M%8.YH_/!J_X&?[PTL^5@[FC\\&K_ (&?[PTL^%T  0
M                                                '\]]HGY?:E_B
M53]JX#:)^7VI?XE4_:N :?T(  9
M
M                        %8-EGOHM3_#5WVA9\K!LL]]%J?X:N^T+/@
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MPTL^5@[FC\\&K_@9_O#2SX70 !
M                                 ?SWVB?E]J7^)5/VK@-HGY?:E_B5
M3]JX!I_0@ !D
M
M         5@V6>^BU/\ #5WVA9\K!LL]]%J?X:N^T+/@
M'(CD5'(BHO!47K/*DIH:.G9!2QMBA9P:QO)J9SA$ZD\G4>H    :746E+%J2
M2D??K72U[J5RNA69F]N9QGSHN$X+PX&Z 'XQC8V-8QJ-8U,(U$PB)V(?H
M    /&:E@FG@FFB:^2!56-SDSN*O!53RXX9\J]JGL
M K!W-'YX-7_ S_>&EGRL'<T?G@U?\#/]X:6?"Z  (
M                                               #^>^T3\OM2_Q*
MI^U<!M$_+[4O\2J?M7 -/Z$  ,@
M
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M_>&EGSB.PO91J#0FJ+C<[[66ZI954JPIWM+(]ZO5[797>8W]5>L[<   0
M
M   '\]]HGY?:E_B53]JX#:)^7VI?XE4_:N :?T(  9
M
M
M      "L&P7WP>L/-6_>6%GRL&P7WP>L/-6_>6!<6?  0
M
M                    !_/?:)^7VI?XE4_:N VB?E]J7^)5/VK@&G]"  &0
M
M
M                        K!L%]\'K#S5OWEA9\K!L%]\'K#S5OWE@7%GP
M $
M                                      ?SWVB?E]J7^)5/VK@-HGY?
M:E_B53]JX!I_0@ !D
M
M                                         *P;!??!ZP\U;]Y86?*P
M;!??!ZP\U;]Y8%Q9\ !
M                                                       '\]]H
MGY?:E_B53]JX#:)^7VI?XE4_:N :?T(  9
M
M                                                          "L
M&P7WP>L/-6_>6%GRL&P7WP>L/-6_>6!<6?  0
M
M            !_/?:)^7VI?XE4_:N VB?E]J7^)5/VK@&G]"  &0
M
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M#?K??+S<*]*6C>W<J*I\K$>V5C55$<OGX^4LN$
M                                               '\]]HGY?:E_B5
M3]JX#:)^7VI?XE4_:N :?T(  9
M
M                       %8-EGOHM3_#5WVA9\K!LL]]%J?X:N^T+/@
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MB/4              K!W-'YX-7_ S_>&EGRL'<T?G@U?\#/]X:6?"Z  (
M
M   #^>^T3\OM2_Q*I^U<!M$_+[4O\2J?M7 -/Z$  ,@
M
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M9              %8.YH_/!J_P"!G^\-+/E8.YH_/!J_X&?[PTL^%T  0
M
M   '\]]HGY?:E_B53]JX#:)^7VI?XE4_:N :?T(  9
M
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MLO<+.EI:NG:K8ZR/&<[J\G8RO#AP<G#''I=140T[$=42QQ-5<(KW(U,_&!Z
M(J*B*BY1>L\HJF";^IFBD\+=\%Z+Q[/.!Z@T#++*S6S[RM[K5ADH^@2UJ_\
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MP     "L'<T?G@U?\#/]X:6?*P=S1^>#5_P,_P!X:6?"Z  (
M                                                      #^>^T3
M\OM2_P 2J?M7 ;1/R^U+_$JG[5P#3^A  #(
M
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MGS.A@     %8.YH_/!J_X&?[PTL^5@[FC\\&K_@9_O#2SX70 !
M                                                         ?SW
MVB?E]J7^)5/VK@-HGY?:E_B53]JX!I_0@ !D
M
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MNR:S;;$LKELJTG3+<^F3"2[V.CW.?+CDW'?,/??>W2L[XW.DZ//A;N<9QV9
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MHW<MEFT2Y7"JKJS3M9)4U,KII7_T:;SW*JJN$7"<57D"\@!0 !
M
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M[/K?44>G65%Q9N7.XR.KZM/U9)..Y_@;NL\S4)($        5<[F7\\.J_\
M5I_O#"T95[N9V(FV'5WD@G3_ /Z&>@M"
M
M
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M:6?"Z  (
M
M
M                 *P;+/?1:G^&KOM"SY6#99[Z+4_PU=]H6?
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M70 !
M
M
M             !6#99[Z+4_PU=]H6?*P;+/?1:G^&KOM"SX
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M^%T  0
M
M
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ME32K B0H_>WE>UV5RG]E3LX 0
M
M
M
M    K!L%]\'K#S5OWEA9\K!L%]\'K#S5OWE@7%GP $
M
M
M
M                                                K!L%]\'K#S5O
MWEA9\K!L%]\'K#S5OWE@7%GP $
M
M
M
M                                K!L%]\'K#S5OWEA9\K!L%]\'K#S5
MOWE@7%GP $
M
M
M
M                K!L%]\'K#S5OWEA9\K!L%]\'K#S5OWE@7%GP $
M
M
M
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MWT^I_ 6? *K![!NTCQQIOI]3^ >P;M(\<:;Z?4_@+/@%5@]@W:1XXTWT^I_
M/8-VD>.--]/J?P%GP"JP>P;M(\<:;Z?4_@'L&[2/'&F^GU/X"SX!58/8-VD>
M.--]/J?P#V#=I'CC3?3ZG\!9\ JL'L&[2/'&F^GU/X![!NTCQQIOI]3^ L^
M56#V#=I'CC3?3ZG\ ]@W:1XXTWT^I_ 6? *K%W+U;=7;1+_072Y557WM1O8J
M23OD;O-F8W*;R^<LZ5@[FC\\&K_@9_O#2SX-  $
M
M
M                                                %8-EGOHM3_#5
MWVA9\K!LL]]%J?X:N^T+/@
M               %8.YH_/!J_P"!G^\-+/E8.YH_/!J_X&?[PTL^%T  0
M
M
M
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M7G00           K!W-'YX-7_ S_ 'AI9\K!W-'YX-7_  ,_WAI9\+H  @
M
M
M
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M=  $
M
M
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M\#/]X:6?"Z  (
M
M
M                      *P;+/?1:G^&KOM"SY6#99[Z+4_PU=]H6?
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M3J=ST?8+E<G7"LMD#JU[=Q\[,QOD;V/5JIO)Y%R8.T!EQM>SVXP:.MD4U7'
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M.YH_/!J_X&?[PTL^5@[FC\\&K_@9_O#2SX70 !
M
M
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M-+/E8.YH_/!J_P"!G^\-+/A=  $
M
M
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M6#N:/SP:O^!G^\-+/A=  $
M
M
M                               %8-EGOHM3_#5WVA9\K!LL]]%J?X:N
M^T+/@                ?$,,4._T,;(]]RO=NM1-YR\U7RGV
M      !\=#%T_3]&SIMW<Z3=3>W<YQGLR?8                 %8.YH_/!
MJ_X&?[PTL^5@[FC\\&K_ (&?[PTL^%T  0
M
M
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M]'?^(>UGN_C53_1W_B LYO-[4^4;S>U/E*Q^UGN_C53_ $=_XA[6>[^-5/\
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MJKO!7-J*5:=&1PJQ47?:[.55?U3L(0
M
M
M
M         K!L%]\'K#S5OWEA9\K!L%]\'K#S5OWE@7%GP $
M
M
M
M                                                     K!L%]\'
MK#S5OWEA9\K!L%]\'K#S5OWE@7%GP $
M
M
M
M                                     K!L%]\'K#S5OWEA9\K!L%]\
M'K#S5OWE@7%GP $
M
M
M
M                     K!L%]\'K#S5OWEA9\K!L%]\'K#S5OWE@7%GP $
M
M
M
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M
M
M
M            5@V6>^BU/\-7?:%GRL&RSWT6I_AJ[[0L^
M                                       5@[FC\\&K_@9_O#2SY6#N
M:/SP:O\ @9_O#2SX70 !
M
M
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M*JO)$),           %8.YH_/!J_X&?[PTL^5@[FC\\&K_@9_O#2SX70 !
M
M
M
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M'<T?G@U?\#/]X:6?*P=S1^>#5_P,_P!X:6?"Z  (
M
M
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MUIE3<;A%WE=G&/"3CGK0"8@       K!W-'YX-7_  ,_WAI9\K!W-'YX-7_
MS_>&EGPN@ "
M
M
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M.:Y,HJ>=%/8"L'<T?G@U?\#/]X:6?*P=S1^>#5_P,_WAI9\+H  @
M
M
M
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MS1^>#5_P,_WAI9\+H  @
M
M
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M@ "
M
M
M            "L&RSWT6I_AJ[[0L^5@V6>^BU/\ #5WVA9\
M $+VAZ=GK:VQZBM,2RW:QU"RMB3"+40.3=EB3^TK>*9ZTQUDT $=O=IMFM[
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MTS3Z0TG;K)2.WVTT>'R8QTCU7+G?&JJ;[<;OJ_=3?5,*['''9_-3]
M          K!W-'YX-7_  ,_WAI9\K!W-'YX-7_ S_>&EGPN@ "
M
M
M
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M0#W!X=^TO[3#\X@[]I?VF'YQ /<'AW[2_M,/SB#OVE_:8?G$ K/W-'YX-7_
MS_>&EGRL'<SJB[7]7JBY189_O#2SX70 !
M
M
M                                          !0#:O^<W5?\3J/M'$5
M #6                                                     #N_<
M@?EU>/X:OVL9;( )H  @
8                             __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g744414g34r82.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g744414g34r82.jpg
M_]C_X  02D9)1@ !  $ 8 !@  #__@ ?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$  @&!@<&!0@'!P<*"0@*#18.#0P,#1L3%! 6(!PB(1\<
M'QXC*#,K(R8P)AX?+#TM,#4V.3HY(BL_0SXX0S,X.3<!"0H*#0L-&@X.&C<D
M'R0W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W
M-S<W-S<W-__$ :(   $% 0$! 0$!           ! @,$!08'" D*"P$  P$!
M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1  (! @0$ P0'!00$  $"=P ! @,1
M! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_  !$( "@ EP,!$0 "$0$#$0'_V@ ,
M P$  A$#$0 _ /?Z "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * .
M"^+6H7NF^%;6:QO)[64WJJ7AD*,1L<XR.W _*O3RR$9UFIJ^GZHY<5)QA=/J
M1^#]1OKGX575Y<7D\MTL5P1,\A9P0#CYB<\5&*A&.+Y4M-"J3;I79@?"/6=4
MU+7;^._U*[ND6WW*L\[. =PY )KLS2E3IPCR12]$8X:<I-W92^*6NZOI_C#R
M++5;RVA^SH=D-PR+GGG -7EM&G.@W**;OV)Q$Y1G9,]EL69["W9B2QC4DD\G
MBO!>YWK8RO%_B1/"/AJYUN6TEN8K<KO2(C=@L%SS[D4AE_1]4AUG1+'5+<$0
MW<"3(#U 8 X/OS0!S?A#XB:=XPUS6=+M+>6*33)-I9R,2C<R[EQV^4?F* +G
MB+QE;>'M?T'1WMI9[G5YC''Y9&(P"H+'/;YOT- '34 4=9U)-%T+4-4DC:2.
MRMY+AD7JP12Q _*@#DM5^)UCI7A30M?DL)WAU=T2.-2-R;@3SS[4 =W0 4 %
M !0 4 % !0!YU\9_^1/M/^OY/_1<E>ME/\=^GZHY,7\"]2+P3_R1Z\_ZXW/\
MFK/%_P"^?-#I?PCG/@M_R,.H_P#7K_[,*[LW^"!CA/B9G_%[_D=_^W9/ZU>5
M?P'ZDXG^(>Z:?_R#;7_KDO\ (5\Z]ST8[%7Q'I$>O>&]1TJ3&V[MWB!/8D<'
M\#@_A2&>:_#OQ7_9OP1O;BX8K=Z"L\#JW4.N2@_\>4?A0!SW@+2&\"^+?!MU
M*"J>)-,DCG9CG,Q;S1GT."B_G[T =.Y'B#]H%I,%[?PWIW('.97!_7#_ /CM
M #5'Q5\4&ZU&SU&W\-VR2,MM936ZN[ ="Y(/7VX]J )]-\57OBSX*^*KC4XD
M34+*UO+.X,?W6=(B<C\&'XYH XGQC_R1CX=_]?$'_H#4 >@^+?&&LZAX@3PC
MX(9#J:D->WS*'CLUSTP<@M[?UZ %?7O$?BBX\20>!_"]VAU*WMUFO]4NHU/E
M@XQA0-N3D'&.XZ<F@".PUSQAX,\6:7I/BW48=6TW5G\BWO(X1&T<W92 .AZ?
MCUXQ0!DWOBWQ_?\ Q,\1>%_#LT#K$$,+W"*$M%VJ6;(7+$D@<Y^E &CK/B#Q
MK8S>&O!L>IV4?B2_B>2ZU%T!10I.-B[0"2 >-O8?4 &CHP^)&@Z[;VFJSV_B
M'2YT8FX1%@D@8#@'&,@GZ_AB@#T>@#SKXS_\B?:?]?R?^BY*];*?X[]/U1R8
MOX%ZD7@G_DCUY_UQN?Y-6>+_ -\^:'2_A'.?!;_D8=1_Z]?_ &85W9O\$#'"
M?$S/^+W_ ".__;LG]:O*OX#]2<3_ !#W33_^0;:_]<E_D*^=>YZ,=BR>E(9\
MR>*X+VR\=^(_ ]L'6+Q'J5K,I' "L2['_OIA_P!\T >G?&&Q-EX1TK6;./#:
M!?07"A>H0$+@?B5_*@#'^&-[<1^$O&GCDP&6XO9Y[F.-NK+&I95_-B/PH J>
M$M%T[QIX87Q/XR\2W%TTQ=I+8W7E0PA6(QM!&.F?QH K_#^XLG^"_P 08K-@
M(C)?O%&3\PC-NNTX_"@#+\<(\GP0\ )&Y1VEA"L.Q\ML&@#;&GS_  6\5V=]
MY\UWX>U94@OI'Y:.8?\ +0_7D_B1Z4 5]4T'1+SXY:M;^(+J>&#5;>*>QG2X
M,:OA I7<.OW3CZ>] &I>>$/ .D>*]"L/M%_>:G/<*]O''=-)Y94Y#MSP.* +
MO@O_ )+OXZ_ZY0_^@K0!J^-8O!?B7Q);>&=>D:#5(X?.MIPQC*9.,*_<G'3I
MQZT <'K=UK/PM\1Z9;Z!KUSK\%XDF=/N)/,9=HX/'3KGC'W30![_ $ <I\0?
M#%[XKT&"QL98(Y8[E9B9F(7 5AV!Y^85W8'$1P]1SGVZ&%>FZD;(9X=\+7VD
M> I]"N)8&NI(YE#(Q*9?..2 >_I45Z\:F(]JMM!PIN,.5F3\/? 6J>$]5NKJ
M_N+21)H?+40.Q(.0><J/2NG'8RGB8Q4$].YG0HRIMME7QW\.=7\3^(O[0LKF
MSCA\E8\3.P;(SZ*?6JP6-IX>DX23N*M0E.5T>D6L306D,3$%D0*<=.!7DLZD
MK(FH&8MUX4T:]\2VOB&>S5]3M4V12YZ#GM_P(T 7]3TVUU?3+C3KZ(2VMPAC
MD0]P: (M'T6PT'2(=*TZW$5G""%CZ]22?U)H YU_A7X.>]:Z.D("S;VC#$1D
M^Z]* +D7@#PW!=ZE<P:<L3ZC;O;7(0D*Z/C=QTR<=: )+SP/H%_HVG:3<6>^
MRT]E:WCW'Y"!@?SH U-7TBQUW3)M.U&W6>UF&'1J ,J\\"^'M0T6VTJ\L%GM
MK5=L)<DO&,]FZB@!GAWP#X=\+W!N=,L<7)&WSI6+N!Z;CSB@#0LO#>EZ?KU]
MK5M;[+^^ $\F?O 8Q_*@"+Q!X2T3Q/&BZM81SM']Q^C)]#U% %/P_P##_P .
7>&9S<:=8XN"-OG2L9' ] 30!T] '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g744414g62z73.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g744414g62z73.jpg
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M45,T5.,I(6@T(W.:Y8!I>V7*]]+(^F1R[U:W)6^1%1.H#?  0
M
M
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M5U4F:4\4<2<J]TOX&)J;G6U.?#5,KD7B1<D\B'C!K,NLSY?/>6;33XL?EJ
MQGL     /=8ZEU+=*>1JY(KT:[G1=BDD$7T/Z[3_ $C?22@=+P*TSCO7XM-Q
M.(YJR  WK5@     0AV2O?X?Z)_N$WD(=DKW^'^B?[@@0D "@  !9'L>_ 23
MQV3U6%;BR/8]^ DGCLGJL DL $
M                                          #A/-'3POFGD9%$Q-9S
MWN1&M3E55W <P1=B;3-9;<]\-H@DN<S=FNB\'%G\Y4S7J3+G-&K--N(I7KVM
M2VZ!G$G!N<OE5WV 6*!7.ETUXDC>BS4]MF;QHL3FKY4<;EAS39:ZQ[8KW1RV
M]R[.%C7A8^E=B*GD4"6@=%!64UPI(ZJAGCJ*>1,V21N1S53I.\
M                                                    CL !\@
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MH'1\"\M_HT_$^]0 &_:H     "$.R5[_  _T3_<)O(0[)7O\/]$_W! A( %
M  "R/8]^ DGCLGJL*W%D>Q[\!)/'9/58!)8 (
M                                                    %;]-6,JJ
M[7^IL]-*YELHG\&YC5RX61.^5W+DN:(G-GQED"G6+O"N]>.S?6.$#$  H  #
M>=$N+JG#F(Z:G=*YULK)6Q3Q*NQJJN2/3D5/.G46C*66SW1I/I6>DNF  !
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M)7O\/]$_W! A( %   "R/8]^ DGCLGJL*W%D>Q[\!)/'9/58!)8 (
M
M        %.<7>%=Z\=F^L<7&*<XN\*[UX[-]8X0,2 "@  /3;/=&E^E9Z2Z9
M2RV>Z-+]*STETP  (
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M]CWX"2>.R>JPK<61['OP$D\=D]5@$E@ @
M                                                4YQ=X5WKQV;Z
MQQ<8ISB[PKO7CLWUCA Q( *   ]-L]T:7Z5GI+IE++9[HTOTK/273   @
M
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MY"'9*]_A_HG^X($)  H   61['OP$D\=D]5A6XLCV/?@))X[)ZK )+ !
M
M            ISB[PKO7CLWUCBXQ3G%WA7>O'9OK'"!B0 4  !Z;9[HTOTK/
M273*66SW1I?I6>DNF  !
M                                      8FZ66*JUI(<HIO,[I-6J:>
M6FE6.9BM>G*;^>>NHX:R+4F;GR.3>G0$V:&#VW*W2T,F3TUHU[UZ;E_W/$$
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MM.S<U2DL*JG$Z6JR\R-^T@\ 3!)ITN:^UV>B;\Z1R_@<$TYW;/;::!4YG/\
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MIDGCW=M4[=5Z<[F[EZLNA2:+-=J"]4+*RUU4=33NW.8NY>14WHO,I![@
M'BN5RAH&)KYND7<Q-YA'8CJ5=W,,*-Y%S7[3%5U0ZJJY97+GK+LYDXCH#YW;
M!'B1Z>V4S5^:[(]<6(:5WMC)&=6:&J &[>8+C23^UU#,^15R7SGKW[B.ST4]
M944WM,SVIR9[/(%W;X#6:3$4C<DJHD>GQF;%\AFZ.XTM7DD,J:_Q7;%"[O6
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M*7B3Y*=>9A=(F-ZW%]R5SE=#;8G+VO39[OE.Y7+YMR<^H%
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M/$N[B>G&UR<:*6OP=B.DQ18H+E1+EK=S+$JYK$]-[5_\VID09L  1V  ^0
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M$S-543:V!J_!1>->5>I.?TZ,]'M)A*E2HJ=2HO$C?9)LMD:?%9S<J[U\QO9
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MT#W,EC<CV/:N2M5%S14 NP#!8'OS,287H;DW)))&:LK4^#(FQR>7;T*AG2
M !$G9"8A6BLM-9:=^4M:O"39+M2-J[$ZW>JI+95?3#=%NF/[FNMG'3.2E9S(
MS8O]6MY1 TL %    93#EAN&(KFRAM4"S3.VJNYK&_&<O$A..&M"MHI(F/OM
M1+7U'''&JQQ)S;.Z7IS3H KT"W-)@;"]*U&Q6&W*B?XD*2+Y79G?+A##DJ9/
ML%JZJ1B+YD I^"U%?HOPE6(N=I;"Y?A02.9EU(N7F-.O>@VD>CGV6ZS0NXHZ
MIB/1?]3<E3R*!! -OQ#HYQ-8]9T]N?4P-_YU+[*W+ER3:G6B&HJBM54<BHJ;
MT4#X=U%335M7#2TS%DGF>D;&)O<Y5R1#I)PT&X$FAF;B*[PK&J-_X.)Z9+MW
MR*G1L3ISY )9PS:H['8*"V1*BMIH6L5R?"=\)>M<UZS)@$   "G.+O"N]>.S
M?6.+C%.<7>%=Z\=F^L<(&) !0   '=21)-5PQ.54:][6JJ;]JY%@OT'X>_;[
MM_$C_L KN"Q'Z#\/?M]V_B1_V#]!^'OV^[?Q(_[ *[@L1^@_#W[?=OXD?]@_
M0?A[]ONW\2/^P"NY._8\X;DIZ:KO]5&K5G;P%-FF]B+FYW0JHB=2F<M>AK#-
M%4MFF=6UJ-7-(YY4U%Z4:U,R1H8HX(610L;'$Q$:UC$R1J)N1$X@.8 (   K
M-IX]\*I^@B]4CPD/3Q[X53]!%ZI'A0   ]5MKI[;6-JJ1^I.UKFM=QMUFJU5
M3GR4\H     =E/!+4S-AIHI)97+DUD;5<Y5YD0#K!NMKT88LN#&O;:G4[%XZ
ME[8U_=5=;S&630OBA4S5UN3F6=?[0(T!)GZ%L4?XEN_CN_M-MP?H6AI*EE5B
M6JCJ]1<TI8$7@U7Y3ER54YLD ZNQ_P )20-EQ%71JU96K%2-<FW57OG]>62=
M9-!\C8V-C61M:QC4R:UJ9(B<B'T@  "F>(*%ULOMQH7HJ.IZA\7D<J&/)9[(
M##3Z*^1WRGC7M6M1&3*B;&RHF6WI1$ZT4B8H &1LEDN5\JTIK31S54W&D;=C
M>=5W(G.H&.!,N'=!]3*ULF(+BVG1=\%,FN[K<NQ%Z$4WZV:*L)T+4UK>ZJ>G
MPZB5SL^I,D\P%7 7 AP?AR%N4=AM?72L5?*J'R?!^&YFJV2PVO)>-*5B+Y40
M"H +-7S1%ABXL<M+!+;IEW/@>JIGSM=FF71D0QCO1[=L)*LTR)5VY5R;51)L
M3D1R?!7S<X&F     !O6B'%KL,XE9'4296VM5(IT5=C%^"_J5=O,JFB@"[@-
M)T/8@6_X+I5F?K5=&O:TRKO75[U>MJIUY@@\(.<K%CD>QVQS55%. ?(
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MIEVPU/@K\KD7JZ*V*F2Y+O+ME5M+]G99L>7".%J-@J,JF-$XM??_ %(XL#3
M    $V=CA>%X2ZV:1VQ42JB3DW-?]PG JSH9KEHM(=KVY,G5\#N?6:N7GR+3
M$   "EUUJ%K+I65+ES=-,^15Z7*OVET2DCD5KE1=Z+DI8'P    !:S19AF##
M>%*5J1IV[5,;-4R9;5<J9HWH1%R\J\9N!@\$7J"_X7M]=3/1VM$ULC4^ ]$R
M<U>O[#.$      ,/>L+V2]9K=+72U#U_YCF(C_WDV^<S  U6U:/,*VNI2HH[
M/!PS5S:Z5SI=5>9'JJ(;4       "G.+O"N]>.S?6.+C%.<7>%=Z\=F^L<(&
M) !0  'IMGNC2_2L])=,I9;/=&E^E9Z2Z8  $           5FT\>^%4_01>
MJ1X2'IX]\*I^@B]4CPH      !O>BG [\6W5TM6CF6FF5%F>FQ9%XF(OI7B3
MI0#YHYT=UV+9$J97+26ECLG3JG=2<J,3CZ=R<^XL1AG"UHPU2I#::..)<LG2
MJFM(_I=OZMQE:6GAI*:*GIHF101-1C&,3)&HFY$0[2           /'=[;27
M>W3T%QA;-2S-U7L=Z4Y%YR#\0:$;C%4O=8JZGGIE7-K*E59(WFS1%1>G9T$^
M "%L*:$HXW-FQ-6I+EM[6I55&KTO5,_(B=)+MIM=#:*-M+;*6&EIV[F1MR3I
M7E7G4]@      !U55/#5TTM/4Q,E@E:K'L>F:.1=Z*AV@"JNE+"#L)8A6.!'
M+;JE%DIG+MR3C8J\J>A4--+4:7K V^X)K4:S.JHT[:A7CS:BZR=;<^O(JN4
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M3B,NVQ)!96U.HB5:IKR+EMU>).K?UJ8H[S3VO;%6V3OLY;-%8O,4[  /9Y
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M5W?RN^,Y?_,C7=#%SM=?@RGBM<$=-+3=Q50MW\)\=>-=;?GU<1O9
M (\T\5*P:/:B-%R[8GBB7][6^Z2&1=V1*K^95(G$M<SU) *Z  H   3GV-2)
MVMB!>/7@]#R#"2M$&.;7@^&Z,ND57(M4Z-6< QKLM76SSS<G*@%D@1A^FS#7
M[-=?X+/[Q^FS#7[-=?X+/[R"3P1A^FS#7[-=?X+/[Q^FS#7[-=?X+/[P)/!&
M'Z;,-?LUU_@L_O'Z;,-?LUU_@L_O D\KOV13F+C*B1N6LE"W6_??D;=7Z<;,
MR)W:%MN$TN6Q)=2-N?2CG+YB%,57ZKQ)?*BYU^JDLJHB,;WK&IL1J%@8@
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MWKQV;ZQQ<8ISB[PKO7CLWUCA Q( *   ]-L]T:7Z5GI+IE++9[HTOTK/273
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MYIFFU#Z:;HXOG;] M!4/SJ:9.X5=[F<7DW>0W(X?48+:?)..WN=+BRQEI%X
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M]''J4T38V\>2;5Z5XSO!U.FT6'31[$=?7WM'FU.3-/M3T]  &6\
M     (0[)7O\/]$_W";R$.R5[_#_ $3_ '! A( %             !LNC[%,
M^$\0PUL>L^F?['4Q)\-B_:F]"V%!5P5]%!5TDC9:>9B21O;N<U=RE*B8M!&-
M.U*E,.7*7_AYG9TCW+WCUWLZ%XN?I GH $      (M[(GP+H_'F>I(2D1;V1
M/@71^/,]20"NH *                     #=-#E M?I#M299L@<Z=W-JM5
M4\^1:@ACL=L/204]=?JABM2=.UZ?--[47-[NC-$3J4F<@   8+&V'*?%.'JF
MVU"HU[N[AERSX.1-SOL7F53.@"F%YME79KG44%QA=%4P.U7-7TIRHN]%/$6K
MTC8$HL84**JMI[G$WV&HR_I=RM]'%QHM:,16&XX>N#Z*[4SX)4[U=[7IRM7<
MJ%&+        /K55KD5JJBIM14XCX -XPQI/Q)8E9&M7V_2MV<#5YOV<SN^3
MRY<Q,6$=*]AOJL@K'K;*QVS4G<FHY>9^[RY%90!=Q%14145%1=RH"L6CS25<
M<+RQTM8Y];:,\EA<N;HDY6*OJ[NC>61L]SI+Q;H*ZW3-GI9FZS'M]"\BIR$'
ML     "G.+O"N]>.S?6.+C%.<7>%=Z\=F^L<(&) !0  'IMGNC2_2L])=,I9
M;/=&E^E9Z2Z8  $           5FT\>^%4_01>J1X2'IX]\*I^@B]4CPH
M  +)Z +>E+@7ME4[NLJ'R9\S<F)ZJ^4DDU717 E/H^L;$3+.G1_[RJ[[3:B
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M[?5_QG?B>1[W2/<^1RN>Y<U<Y<U53B      #E%[8WI0"+VQO2@ NT "
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MZ0                (0[)7O\/\ 1/\ <)O(0[)7O\/]$_W! A( %
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MWPJGZ"+U2/"@     MYH\3+ M@\1A]1#8#7]'O@-8/$8?40V @
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MQJQ(B[4VFEWJB[3K7-:GL3^Z9T<@26/(_P!,-9P=JHJ-%VS2K(O0U/Q<GD)
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M2I.&E;_Q$J9KG\%O$AFP#N,&&N#'&.G:'-9,DY+3>WO  >KS
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MJ1X2'IX]\*I^@B]4CPH     +>:/? :P>(P^HAL!K^CWP&L'B,/J(; 0
M      !TUM3'1T=14S+E%#&Z1Z\B(BJOH*:7:NEN=SJZZH7.:IE=*[I5<RTV
ME6J6CT>WR1JY*Z#@OWW(W[2IQ8     !D\-V>HO]\H[92>VU#T;K*FQJ;U<O
M,B(J]1;+"V'K?AJU1T-LA1C&IF]ZIW4KN-SEXU(.['6E9+B^MJ'HBK!1NU>9
M7.:F?DS\I8@@     !37$M4VNQ%=:N-<V3U4LC5YE>JH6<TJ8C9AS"%7,U^5
M74-6GITX]9R+MZDS7R<I5$L      Y1>V-Z4 B]L;TH +M  @
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M^E[<NL$:IFQJZ[NA"1C1\#P>;-/RC]VRXEE[8X^8 #H6I
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M.BBS930K\%O*OREWKU)Q&J@%     !RB]L;TH!%[8WI0 7: !
M   :9I$3M6AJ:Q-F5-(J]+452JQ:O2YW.!+G*F]D:IU.35^TJH6      <HW
MK'(U[5R<U45.E"VFC]4ELJU+=TSD<G1JHOVE22UVB9_"8 M$G&Z+)>I=7[#&
MR8N;-2_IO]]GM2^V.U?79MP ,AX@  &GZ39NT[#/5IL=%!+ETZNSSFX&@:<I
M."T?U;DWND8Q.MVT"L0 *   ')CE:Y')O1<T.( M=H_B26&:LR[YK6M7IVK]
MAMQK6C9O_P E6J7CFA;(OD1/L-E,/0X?!P5H]]3D\3+-@ &6\
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MOI:>:JQ_BJJ:J2WVM1%_PW\'ZN1K  [ZNKJ:R59:RHFGD7X<KU<OE4Z
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MU',<BM<U4S147B4"DH-OTG81EPGB&2)C7+;JA5DI9/D\;57E;NZ,EXS4"@
M        !8?0)BJ2ZV>:S5LBOJ:!$6%SEVNA79E_I79T*A7@D#054N@TB4<;
M5R;/%+&[G345WI:@%G  0  !6;3Q[X53]!%ZI'A(>GCWPJGZ"+U2/"@
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MM1-ZJU=;+S%2"[A!.D71%5]O37#"S&S02JKWT>LC71JN_4SV*G-O3G$"&0;
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M9DGQ47:J\>67+D L4 "
M                             Q=_P_:[_2]KWBBBJF)WJN3)S?FN3:G4
MI&]TT'6J:1SK;<ZNE1?@2,25$Z-RDN "$H] Z:WLF(<V_)H\E]<V2Q:',.6Z
M1LE:M1<9$VY3.U6?NMR\ZJ22 .JEIH:2G9!2PQPPL3)L<;4:UJ<R(=H
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MBS#-ED;*M*^OJ&[4?5JCT1>9J(C?*BF](B(B(B(B)L1$
M  &MXMP39,4Q_P#Q.E1*E$R;4Q=S(WKXTYES-D %?;_H2NU,YS[+64];%Q,E
M]BDZ/BKY4-+KL!XHHG*D]BKG9<<4?"IY6YEM@!3=</WEKLEM%Q1>1:9_X'LH
M\&8EJW(D%BN*Y\;X',3RN1$+> HK=9=#6)*US5KUIK='Q\(_7?U(W-/*J$G8
M6T2X?LKF35C'7.J;MUJA/8T7F9N\N9(8(/C&M8U&L1&M1,D1$R1$/H    8;
M$N&+1B2G2*\44<^JF3).]>SH<FU.C<1M<=!=#)(JVZ\U$#%W-FA27+K16DQ
M"%(-!#$>G#X@<YG(RDU5\[U-OPYHJPU99&S/IWW"H;M1]6J.1%YFHB-\J*;X
M #41K41J(B)L1$X@
M
M
M
M
M                             JHF]4  ^:S>5/*-9O*GE ^@^:R<J'T
M ?-9.5/*!]!\UF\J>4^@                 #A++'"F<LC&)RN<B <P?&.:
M]J.8J.:NY47-#Z             9@ ,TY1FG*  S3E&8  *N6\ #YK-Y4\HU
MF\J>4#Z#YK-Y4\I]3;N                  !51-X
M                          %5$WJA\UF\J>4#Z#YK-Y4\HUDY4\H'T
M#IFJJ>%<IIXHUY'O1 .X'&.1DK<XWM>G*U<SD
M
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M">L<Q8HFPYJUC57:N:HFU<LMW+R@2< "
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M3E(-^
M                            A#LE>_P_T3_<)O(0[)7O\/\ 1/\ <$"%
MJ;]8B^<GI+:X_P -1XIPO4V]=5*C+A*=[O@R)NZEVHO,I4JF_6(OG)Z2[#=R
M%%8L.:+<0UU\AIKE02T=&UZ</.]4R1J+MU=NU5XLB7],5/%2:*[C3TT;8X(D
M@8QC=S6I*Q$0WXT;3;[VMVZ8?KF$%7"U>A_WN++]&_ZQQ50M7H?][BR_1O\
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MN+?L0\6C*@DN&/+)%$BKJ5+9G+R-8NLOH*+:@ @
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M<ZEC-$^ $PE2R5=P<R2[5#=5RMVMB9OU47C7=FO,G7E-%W@M#TFVD
(      !__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g744414g89x91.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g744414g89x91.jpg
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M)U?B\:-&A)6DI?_$ !H! 0$! 0$! 0             ! @,$!0;_Q !%$0$
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MV'0@KDD9&TND<&M'25135#*AKG1WL#:Y%KJF:EBFE;)*"ZPL&D[>97P
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M,CC-0(]&NJJ)M,=@X$C0--R=]+M]S<=31!J>60ZLS=F&LDGJ'MIC#0Q,>3I
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MW0RPQ4;VL,\ND1R7:'7:;\!>QO;=/8_^XQ/>_D=;_8I\F)_WE_Y7]Q/]Y?\
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M56[32S'J8?L5%<98X:XRT@](Z54H^'#310C^S=2%(W B(J"(B B(@(B("(B
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M5K:&=KL-R=[F[CNE9EF.LK(*FHKJITM,YTE.YNEKH7.AYHZ2!< @EUN&K?H
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M,QJB;5X3GZ:KIB2WG(F:A<<1W7%3O]GVM_\ F59]$?YD2[Z"&)T! M74IO\
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MPX]=^FZ_0!$(A^>WM S9_P#'<3_9W(S(&; X:LN8I;]7<OT)1%<*^YBRSCV
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M>QCOTH\R>QCOTH\R*E=FT_Z4>8IV;3_I1YBHOL8[]*/,GL8[]*/,B)?9M/\
MI1YBG9M/^E'F*B>QCOTH\R>QCOTH\R"5V;3_ *4>8IV=3VOSHMUV*B^Q;K;R
MCS+%')],7N=S\MW$GCMOX$&>[/I;?AFJ_#-',S5$X.;UA:W+E&"1D;9*B0B,
M6:; =/B69P7#V891"FB<7,!)!/A*":Q[7@EA! -MEZHM%2"FDJ'ZRYTS]9'
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M.A Z']L^WCOQ06Y-$8897!FLAH!/$GH^I>E^@$!)(Z>!A,H!-]5W]LXGHXJ
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M2O59KOQ.?Y!5D76D.:"T@@\"%ZK-'^*0_('V*\D B(@P^*8_3X?5&"2*5[P
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M&ZFJ1*/F;[K_ /&<+_5_\Y7=\@3Q>TC+<?.-U^QM,+7W_!-7!_NO_P :PO\
M5_\ .5W;(%-#[2<N2<VWG/8ZF.KP\TU4;#-*R&)TDK@UC1<D]"K:0X @W!W"
MQV8_R)6?-E3*7\5A^0/L5ML2^VRJ&5DS2Z)P< 2TD=87HD:9"P.&L"Y'2L5E
MC\2F^?D_>*\I/SIKOF&?:4LS%6R)[7M75EM1I,FDDZ6B_%3Z28OI]3SW.Q*U
MO&3_ .J4?SQ^PK.TOXE+Y59AFF=LIZ\:X.%VFX1O<CQ*U2?@C\H_:LNBZ' N
M(ON%ZK3/QF3Q!745\W_=C?@<J_.3_P"1=>Y&_P"K7 _FW_XCER'[L;\#E7YR
M?_(NN\C?]6N!_-O_ ,1R#DO+Y_7!DS]9H_\ &<N_XM1&MA:UK@US3<77S_R^
M?UQ9,_6*/_&<OHY!K/L?B%.?<B2/[+E6)\5 MH?X[+8T5NEFJOHL0JWZI6N)
M_M+)87A'8\HEG(<\< .A9A$N66YH(IPP31LDT.#FZA>Q' A7$116O8MBSS*Z
M&G=I:W8N'2HM%AU17CG'.LP^^=TK*OP.!SW.+WW)NLA1P"FIVQ-)+6\+K5[;
MDL@4^"4\=C(2\_4LE%#'$VT;&M'@"K19NKYI^ZY_+F4/'+]K%W_)_P":>"?J
M4/\ AA< ^ZX_+F4/'+]K%W_)_P":>"?J4/[@09=.A$Z$%#N!4:7B5)=P*C2\
M2@@S<5#DXJ9-Q4.3BJCX2SE^<V,?K4G[Q6V8>SG(Z:.X;J#&W/1=:GG+\YL8
M_6I/WBMPPBJEHA3STY:)6,%BYH<.'45O#XI7P2,3HS05\]*YX>Z)VDN M=3Z
M'+.+5U&RKIJ353O%Q(7@"WE6/KJR:MFYVH+2^UKM:&_8K;)Y6MTMD>&]0*ZN
M;-.R?C@+0*$N+MVAKVG4.L>!1,8P'$L%$?LG3&G,ALT%P)47L^K[YF],JW/4
M33@":5[P.&HDV3:+2WWD/_K"I/FG_P %H*WWD/\ ZPJ/YI_\%*MTD;WT\B\7
MJ\SLO0<"KBMP<"KBHC5\$U1&UL%0Z!P=<EHO<=22P\Y&62.)&U[;+VNAFGC:
MV"<PD&Y<!>XZEY4R-I:9TLA>X "^D7)1&.GR[AE1)+)+21.DD;NXMO;P@'8*
M%49+P6H>'=C.B.C2!#*Y@'AL"!=;%3N;-"V1NMH<+V<+'S*L,MTE;C$JCBQJ
MJ)X-4@R)@D1CTP2Z0"',,S]+_"1=5LR/@;#>.E(N_4=;S)Y!J)L/$MH#+6W.
MRA55?#33<U(V8G;=K+A-97VK&'3&Z&-.5L,$)CBC?%'KU.:R1P:X7X$7M97I
MLN88]KM%)#"^P&N)H8X = (X+,-;J;>[A?>Q7NC^T4UE7::JCL8*IRSAT\CI
MGT[))PS2Q\]Y= \&HE(LL8;%'IIH>QWEA&N$EAN>G;CY5G=/A*H+@V5D?;W<
M#8VV365=J:JCL:P<F4C&1BBJ:JE=JU2/CE=JD\>]OJ5FHR+0.I(XJ2IJZ>1K
MB3)SADUG^T'7!6X:.&Y31MQ*NMK[34T=C5*;).'12/EF?-4REP),I[6PZ T6
M !\2GU>5\)J8G,DH8+7%BV,-<!U @7LLYHX[G=68YFOJ980) Y@!)(V/B4UE
M7::JCL:Z<E86WG74_/Q2%H$;A/(>:/6WME(ILL4D.'/IR7/FE86R5#G.<]QO
M<$W)X+8-/A*:/"4UE7:NKIC99JKLGQQ0T\>'8A64#1;G702$&0^(W OX+*>_
M+X9A78N&U<U#-SHE-1& YSG ^^U7!OPW6;+0!Q.RLT50RIC>Z-KP&NT]L+)-
M<SO(HB-R!)@TCY'O&)UK=6Y:'BP\0LI]!3NI:<1OGEG=>^N0W*D(LW;LCR]V
M52JI/PA5*R(>+_DJM^9?^Z5^>V'&V(4WSK?M"_0G%_R56_,O_=*_/;#_ ,H4
MOSK/M"L+#[RH/Q:'Y#?L6K<K?YL0?K;?W'K::#\6A^0W[%JW*W^;$'ZVW]QZ
M3N<Z_HROY!_-6@\3OWRM"^Z2P 5V5J?%H6WGH9+.(^ [8_79;]D+\U*#Q._?
M*RN,4$.*8754-2T.BGC+"#X5(:HW0^4L$K&OHHZFE;)V8PLE9(T_@RWC<>.Q
M7UEES$V8S@5#B$=K5$37D#H=TCR&Z^.L.BJ,"S!7X1.Y\4D4CHW$&QL#8^<;
MKOW(-BS74V)X-SO.-@DY^ VXL.Q^NWG72WY-S=-F_P"8)JMDM%!2TQECG>6R
MO ),8Z^KIOOU)@-%74F'/CQ"H;+.YY<#J+K#QGRGRK+RO;%&^20V:P:B0+[!
M68W]DQO(9)&W;27;%WAMT+-]EEMMNMM$<0+G&Y&]W< K;ZMLS *0&21I[=QV
M:WJ\?D7@IA-*UTSB]H-PRUF^;UJ<UK&.>W;<; **A04SGNO4NYX@]SP:/(I$
MS8Q"08Q)HW#1L+A1:NN;#V@&J0\&-5J.FGJY :@Z&=#&\?\ S@H)#97S N8[
MA8AO000O#2":2-\I+WMOXO,JHXFT;;2O&D7:T#B1?:Z-EDGE?&!S3  1UD+,
MS$3M6(NO/E9%LZ[G]#6JF5KZAA$Y#(NEC3;SE6)9!2Q_T:(2OU .[:UA?<DG
MJXV7,L[<K>#Y;ADHZ"3V3Q*/M0QM^;8?[3O5<^):A'0*)\>&8C7OD<(J QME
MYU[K,9;8[E<1Y7>4C!\3S'@$V7S+45>#U?.]DM'N;Q<$M;TNW W^U:348GG#
ME1Q'F&F2:!AOS;/<X(@>D]?EN5V;DWY.\-RQ!'/51Q56*6N^H<+M:;\& \/'
MQ5C;+/!VJDF94TT4\1NR1@>WQ$75Y82DG(:"QRR$-2'"SC8KI9BZ6O"J6E5!
M95Y9++U$'EEZ$1!YP7A0E>*H+GG+01["4(OOV1_E*Z#(]L;'/>;- N2N$\H6
M:F8YC3J.E=JIJ;?5UNX%2J-DI5NEVGDZ_,G"/F?XE;$M=Y.OS)PCYG^)6Q+,
M.E.Z&/?A4+WN<7R7)OT(H$U?4MFD:)38.(&P1<=*GL=+2SD,3(8PR,6:.A5J
M)A3W/HFN>XN-SN3?I4M=8W,"$@ D\!NBLULK8:.>5]]+&%QMXE1R')99)28K
M51 \W4XC/*TD6N-5OX+8H.*U[(KFORG0S,!#9PZ< \;.<2M@@XI"2RM,-@JJ
MR5M/3R2O/:L!)2D&RAYEVPN4#WUA]:JPU_#Y'U53-52\7G8=0Z%AI*AGLQ47
M/OK+,T T1@#9:;4/(Q6??_B)"3O=7P)H9AT?6[MED%BL,?IIXFWX-"R0=<*H
MKXHO O0%!BH_SA?\G^ 69:%AX_SB?\C^ 6:8OC]#[L?]Y7^+VYK_ "?=A[;M
M2J JP>U<%::5]=Y%?0B#@B"EXNUPZQ98&1ND@CHV6P+#5;+/<T?"183J3=@*
MON-@58HMHU<D-CY%826,Q>I[&HY)>D#;QK$9>81I+NZ==Q\:GX^W71%O6X*C
M"6AL@'4%J&9W-OC+8<,=*\VTL)^I:A0ZG1:R.V<XN\8NLYF.HYC"&Q--G26;
M98NB9IIVM/%HV6):IAZYO3;M3Q42>(@$6NWB%D7#C;@5%G( 45A:JFUW$OX,
M="83B+\+EYN0%U(X\;]PKU7)VI"@$A[2#N"JS9O+'M>QKVF[7"X/6%=8;A:S
ME:N?=]#4'N-XB3Q;U+86NL5IG<L8T_FL.G>3:S3NM,P: NIGR/%Q(3<'I"SV
M=*DBACIV=U,ZVW4H<#&PT\<3?>M 4EJ'/LP9:Q&.J!PP0RTIW D[J/P#K"WG
MD]IFTF$\V[4*DNU2@BV_@\"O2D$%6:2;L>I:]NQOOX5(5+Y1&,]JLL\ALRGG
M@G)Z@V5I)\P72XGMEB9(PW8\!P/6"N=YT:*O)&+AHN'4KG@>(7_@MQRG6MQ+
M*^$5L;2QE1212AIX@.8#;ZT&51$0$1$!6*J#GS%VVG0\.X7NKZC5D[H3#HMV
M[PTWZE)W;2$E>.(:TEQ :-R2O59KOQ.?Y!5D76D.:"T@@[@A>JS1?BD/R!]B
MO) (B(-9?^>[/D?Y"ME>YK&ESW!K6BY)-@ M:?\ GNSY'^0K9E\;H??F/WE7
MR>S-_P#S^['S<2P#$<3=V9C6$ET6(YDS&6![HM7-T-.TB[@1MVD9MP/;BR\H
M<W9AJ(,)Q"MFK9C1X368W/210"/LDZW-IXC9M]FZK^$ \;7[<K-;4Q4=)/55
M#M,,+#(]UB;- N38>!?9>-Q[$LZ8]0P8;45&/X8R+$Q(Z$ 1QM#FP"S1*\:
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M1,@C#(Q9H\*K43"7.?1-+W%QN=R;]*EKK&Y@6-S+40TF 8A/4R".&.%Q<X\
M++)+5>507Y.\P#KI7*C2\HQ\SE+!X_@TD?V+-P\5C\+8(\(H6#@V",?W0LA
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MN7<,@TU7[4,M2-JCS/L?3$QD#AS3-E1G\:@?4X74PQ"[WL( 4F!I93QL/$-
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M%[0X#2..YW6LXWF:M8RGJ,&FIZB"9NK0X6<SQJ+#,#)N7QPPJE] +WVFY?\
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M'\V__$<@Y#R]?US9/_6*+_&<OHJJI(*H-%1&U^GA<<%\Z<O/]<^3_P!8HO\
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M2K:R^/X*W"&Q_P!.AJ9'$AS8QLVWAN5APK ]6^\A_P#6%1_-/_@M"6^\A_\
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M#2U0@&B0"(OJG =,8+7 'C>^Y35T]B7GM=0YB+]$ST0L!G2-C,,B+&-:>='
M6Z"LUAD53!A]/%7U+:JK8P"6=L8C$CK;N#1POU+$9V_)<7SP^QR^7TW13&0Q
M;1P>K)3.OI^UFZ3\5A^0W[%=6KPT>/N@C+*V(,+187X#T57V#F$_^^B\_P#^
MZN>'TIB11$1EZ]W9'-:LM3>?ZRGUY-E1:U['Y@[_ (O2/\J>QV/V_*$?I'^5
M:]J8OZM7Z<TZM3XD>O)LJ+6?8S'NG$6>F?4GL7COQDWTW>I/:F/^K5^G,ZM1
MXD>K'<HLC)33T\LFF!@,L@Z^K^*YS'FC"J>MDHHXY&B( N<&["_ ]:V;.E-5
MQLGCJ)>>F :YS@2;A<VFP9M0^HJZ0N[-.G6PG9S0#P7ARN%/2M6)BYBJJG1F
MT4Q-M&W&;<9=\2J,K%--$1-XO>V]OTKA)0/JJ9IGB#.<.@CN>M:Y4XY4APFP
MRKJ:&J8+-D!#FVZB%F,%Q49;P.&KK(A(T-+3$[:X=?;^*PU!F".GQ&69N&T\
MT$@NV-P[FZ]_1&+7B8-5.)5I:%4TQ/;$;I>;.QH51-,;XB;=C9L!Y4ZVCE%-
MF>BN18": =UX>*ZOAE;#B-!!64I)AF8'M)%C8KY\&)SRMGAEIX@RH<6L:X:@
MTD&UNI=RR32S464\*IZEI9.R!NMIZ"=[+ZT/-&YFD1%H$1$!:_GS%A@^6:R9
MM^?E:880..MP('K6P+2<R,..9VPC"@":>@_IU1TBX(T ^4'SH,[DW"!@66Z'
M#[#7&R[[?#<23]9691$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!
M$1 1$0>.-FD^!1\.E?-2,?(;N-][>%22+@CK5JEA%/"(VDD#I*G$741%01$0
M$1$%#Y6,<QKG6<\V:.M5J%6@FKHR 2 XW4U2)'S%]U]^/X;^K#_$<N_Y _,3
M+?\ TVF_PFKY_P#NOORCAWZJW_$>OH#('YB9;_Z;3?X351GD1$!$1 1$0$1$
M!$1!\W_=C?@<J_.3_P"1==Y&_P"K7 _FW_XCER+[L;\#E7YR?_(NN\C?]6N!
M_-O_ ,1R#D'+S_7/E#]8HO\ &<N\YFP^:NI8Q3@.>QU[7MLN"\O']=&4?UFB
M_P 9R^DT28O%FA>U[$?T(]()[7L1_0CT@M]16[&JAH7M>Q']"/2">U[$?T(]
M(+?42YJH<UJ,ES3RF26C:YY-[ZO_ #J"D4V5ZVFB$<-.&L' :ET)$N:J&A>U
M[$?T(]()[7L1_0CT@M]1+FJAH7M>Q']"/2"JBR]B!D;JC#1?<ZEO:)<U4/F;
M[K)G-XKDUE[Z1(/K8OH/)_YIX)^HP?X87S_]US^7,H>.7]YB[_D_\T\$_4H/
M\,*.C+H45#CN4'CN"C2GBKKW;*-([B@B3%0I3NI,[MU G?N54?#6<OSFQ?\
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MJRAHH3#HHJ;MWAIO&."DX?2MMM='E5S6*LKV5><+7MFPW]))Z!3VS8;^DD]
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MFG@1944P2-FB;(V^EPN+JM1L-CDBI&LE%G-)^U25(W B(J"(B B(@(B("(B
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MK*9INYL%R\CRBREFKNSY+A['RIA4=K?T=KO.+_Q695NGA93T\4,0M'&T,:/
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M*D-@B:UK6Q, :;M :-CX$&+RS433Q5PJ:CGI(ZN:/@ 6M#R +>(!9A>!H%[
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M#8BVK<C?BLPB B(J"(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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M^Y"R[94E6VQQMX-)\9)5+B!T#S(6'FW%672BZ]UA \(6>->XGM6.*NM=+T,
M\95 D Z5Z9>I15SW0C=X'B"IYLD[N)5'/6"1R:B@USE):]N78.9TF3LZETZN
M%^>9:ZR^*-EHLY/96-C9/B=$R7W,G29(MGVO\X/,J,P,9-)@L<C0YCL3IK@]
M/NC2LERO4SX\$HL9@83-A-4RH<0-^:O:3R:;GR*-0L0/LY59F8)<NU4GOH0V
M=IZG,<' _4K!(U@M(+3N#U@K(\R*K#JBG=PEC+/.++4[F>+<X)63PQRPN#XY
M&A[7#@0=P562 "2; =*U/DMJ9)<ET--4$FHP_5027ZXG%@/E !\JS]2R6IGY
MFQ9 W=SOA> +G,V:A)DACE?&]PN6&[=]E<7C&AC UHLT"P"]5!$1 42:H?!5
M-$H',/V:[J/A4M431,FC+)!=I4D5HK;GQT\;0]P:W9HNK@WX*@B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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M3=C#W8B^F*Q<;!M]KW'@73P+ "]T1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
@1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1!_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
